FN ISI Export Format
VR 1.0
PT J
AU He, DH
   Chen, TY
   Yang, MJ
   Han, CF
   Yang, Y
   Cao, XT
   Cai, Z
AF He, Donghua
   Chen, Taoyong
   Yang, Mingjin
   Han, Chaofeng
   Yang, Yang
   Cao, Xuetao
   Cai, Zhen
TI Rab7b Promotes Megakaryocytic Differentiation of K562 Cells by
   Activating the Protein Kinase C/Extracellular Signal-Regulated Kinase
   Dependent Pathway.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [He, Donghua; Yang, Yang; Cai, Zhen] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Cao, Xuetao] Mil Med Coll 2, Inst Immunol, Shanghai, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1397
EP 1397
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804276
ER

PT J
AU Racke, FK
   Baird, ME
   Barth, R
   Huo, TY
   Yang, WL
   Weldon, M
   Gupta, N
AF Racke, Frederick Karl
   Baird, Maureen E.
   Barth, Rolf
   Huo, Tianyao
   Yang, Weilian
   Weldon, Michael
   Gupta, Nilendu
TI Unique Thrombopoietic Activity of Novel PKC Agonist Ingenol 3,20
   Dibenzoate.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Racke, Frederick Karl; Baird, Maureen E.; Barth, Rolf; Huo, Tianyao; Yang, Weilian; Weldon, Michael; Gupta, Nilendu] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1400
EP 1400
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804286
ER

PT J
AU Li, Y
   Chen, S
   He, YZ
   Li, XH
   Yang, FC
AF Li, Yan
   Chen, Shi
   He, Yongzheng
   Li, Xiaohong
   Yang, Fengchun
TI Impaired Bone Marrow Microenvironment in Fanconi Anemia Murine Model Is
   Responsible for the Defective Hematopoietic Stem Progenitor Cell
   Mobilization
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Li, Yan; Chen, Shi; He, Yongzheng; Li, Xiaohong] Indiana Univ Sch Med, Indianapolis, IN USA.
   [Yang, Fengchun] Indiana Univ, Inst Canc Res, Indianapolis, IN 46204 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1402
EP 1402
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804293
ER

PT J
AU Singh, A
   Evens, AM
   Anderson, R
   Beckstead, J
   Sankar, N
   Bhalla, S
   Yang, S
   Forte, T
   Ryan, R
   Gordon, LI
AF Singh, Amareshwar
   Evens, Andrew M.
   Anderson, Reilly
   Beckstead, Jennifer
   Sankar, Natesan
   Bhalla, Savita
   Yang, Shuo
   Forte, Trudy
   Ryan, Robert
   Gordon, Leo I.
TI All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid
   Receptor-Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell
   Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Beckstead, Jennifer; Forte, Trudy; Ryan, Robert] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.
   [Bhalla, Savita; Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA.
   [Yang, Shuo] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1433
EP 1434
PG 2
SC Hematology
GA 532DS
UT ISI:000272725804386
ER

PT J
AU Xu, L
   Patterson, CJ
   Sun, J
   Yang, G
   Zhou, YS
   Hunter, Z
   Hatjiharissi, E
   Ciccarelli, B
   Gong, P
   Liu, X
   Tseng, H
   Ioakimidis, T
   Manning, R
   Hanzis, C
   Cao, Y
   Lewicki, M
   Treon, S
AF Xu, Lian
   Patterson, Christopher J.
   Sun, Jenny
   Yang, Guang
   Zhou, Yangsheng
   Hunter, Zachary
   Hatjiharissi, Evdoxia
   Ciccarelli, Bryan
   Gong, Ping
   Liu, Xia
   Tseng, Hsiuyi
   Ioakimidis, Thea
   Manning, Robert
   Hanzis, Christina
   Cao, Yang
   Lewicki, Megan
   Treon, Steven
TI Involvement of Fatty Acid Synthase in Azacytidine-Induced Cytotoxicity
   in Waldenstrom's Macroglobulinemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroflublinemia Ctr, Boston, MA 02115 USA.
   [Sun, Jenny; Zhou, Yangsheng; Liu, Xia; Tseng, Hsiuyi] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1437
EP 1437
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804395
ER

PT J
AU Yang, G
   Gong, P
   Xu, L
   Hunter, Z
   Sun, J
   Ciccarelli, B
   Zhou, YS
   Liu, X
   Tseng, H
   Cao, Y
   Manning, R
   Lewicki, M
   Hanzis, C
   Ioakimidis, T
   Sheehy, P
   Patterson, CJ
   Treon, S
AF Yang, Guang
   Gong, Ping
   Xu, Lian
   Hunter, Zachary
   Sun, Jenny
   Ciccarelli, Bryan
   Zhou, Yangsheng
   Liu, Xia
   Tseng, Hsiuyi
   Cao, Yang
   Manning, Robert
   Lewicki, Megan
   Hanzis, Christina
   Ioakimidis, Thea
   Sheehy, Patricia
   Patterson, Christopher J.
   Treon, Steven
TI The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by
   Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces
   Apoptosis in Waldenstrom's Macroglobulinemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Xu, Lian; Hunter, Zachary; Ciccarelli, Bryan; Hanzis, Christina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1438
EP 1439
PG 2
SC Hematology
GA 532DS
UT ISI:000272725804400
ER

PT J
AU Sun, J
   Tseng, H
   Xu, L
   Hunter, Z
   Ciccarelli, B
   Fulciniti, M
   Yang, G
   Gong, P
   Zhou, YS
   Liu, X
   Munshi, NC
   Patterson, CJ
   Treon, S
AF Sun, Jenny
   Tseng, Hsiuyi
   Xu, Lian
   Hunter, Zachary
   Ciccarelli, Bryan
   Fulciniti, Mariateresa
   Yang, Guang
   Gong, Ping
   Zhou, Yangsheng
   Liu, Xia
   Munshi, Nikhil C.
   Patterson, Christopher J.
   Treon, Steven
TI Vorinostat Induced Cellular Stress Disrupts the Balance Between p38
   MAPK and Erk Pathways Leading to Apoptosis in WM Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Sun, Jenny; Tseng, Hsiuyi; Fulciniti, Mariateresa; Zhou, Yangsheng; Liu, Xia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA.
   [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1440
EP 1440
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804404
ER

PT J
AU Yang, DH
   Kim, WS
   Suh, C
   Kwak, JY
   Jung, JS
   Kim, SH
   Kim, JS
   Lee, JJ
   Kim, HJ
AF Yang, Deok-Hwan
   Kim, Won Seog
   Suh, Cheolwon
   Kwak, Jae-Yong
   Jung, Joo-Sep
   Kim, Sung Hyun
   Kim, Jin Seok
   Lee, Je-Jung
   Kim, Hyeoung-Joon
TI Phase II Trial of (90)y-Ibritumomab Tiuxetan Treatment as Consolidation
   After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky
   Diffuse Large B Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Yang, Deok-Hwan] Chonnam Natl Univ, Hwasun Hosp, Jeollanam Do, South Korea.
   [Kim, Won Seog] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   [Suh, Cheolwon] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
   [Kwak, Jae-Yong] Chonbuk Natl Univ Hosp, Dept Internal Med, Jeonju, South Korea.
   [Jung, Joo-Sep] Busan Natl Univ Hosp, Pusan, South Korea.
   [Kim, Sung Hyun] Dong A Univ, Coll Med, Dept Internal Med, Pusan, South Korea.
   [Kim, Jin Seok] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Kim, Hyeoung-Joon] Chonnam Natl Univ, Hwasun Hosp, Coll Med, Hwasun, Jellanamdo, South Korea.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1444
EP 1444
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804415
ER

PT J
AU Kim, M
   Oh, B
   Kim, SY
   Park, HK
   Hwang, SM
   Moon, HW
   She, CJ
   Yang, I
   Yoon, SS
   Yoon, JH
   Lee, DS
AF Kim, Miyoung
   Oh, Bora
   Kim, Song-yee
   Park, Hyun-Kyung
   Hwang, Sang Mee
   Moon, Hee Won
   She, Cha Ja
   Yang, Inchul
   Yoon, Sung-Soo
   Yoon, Jong Hyun
   Lee, Dong Soon
TI p15INK4b Methylation is Related to Blast Percentage, Thrombocytopenia,
   the Number of Lineages Involved in Cytopenia and Survival in
   Myelodysplastic Syndrome at the Time of Diagnosis: a Pyrosequencing
   Study
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Kim, Miyoung; Kim, Song-yee] Seoul Natl Univ Hosp, Dept Lab Med, Seoul 110744, South Korea.
   [Oh, Bora] Seoul Natl Univ, Coll Med, Dept Mol & Clin Oncol, Seoul, South Korea.
   [Park, Hyun-Kyung] Seoul Clin Lab, Seoul, South Korea.
   [Moon, Hee Won] Konkuk Univ, Coll Med, Dept Lab Med, Seoul, South Korea.
   [She, Cha Ja; Lee, Dong Soon] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea.
   [Yang, Inchul] Korea Res Inst Stand & Sci, Organ & Bioanal Grp, Taejon, South Korea.
   [Yoon, Sung-Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
   [Yoon, Jong Hyun] Seoul Natl Univ, Boramae Hosp, Dept Lab Med, Seoul, South Korea.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1458
EP 1459
PG 2
SC Hematology
GA 532DS
UT ISI:000272725804457
ER

PT J
AU Hunter, Z
   Hatjiharissi, E
   Sun, J
   Cao, Y
   Tseng, H
   Lewicki, M
   Xu, L
   Yang, G
   Zhou, YS
   Liu, X
   Gong, P
   Hanzis, C
   Ioakimidis, T
   Patterson, CJ
   Sheehy, P
   Barlogie, B
   Shaughnessy, JD
   Treon, S
AF Hunter, Zachary
   Hatjiharissi, Evdoxia
   Sun, Jenny
   Cao, Yang
   Tseng, Hsiuyi
   Lewicki, Megan
   Xu, Lian
   Yang, Guang
   Zhou, Yangsheng
   Liu, Xia
   Gong, Ping
   Hanzis, Christina
   Ioakimidis, Thea
   Patterson, Christopher J.
   Sheehy, Patricia
   Barlogie, Bart
   Shaughnessy, John D., Jr.
   Treon, Steven
TI Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia
   Patients Presenting with Familial Disease, Advanced IPSS Prognostic
   Score, and Previous Treatment with Rituximab.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Sun, Jenny; Tseng, Hsiuyi; Zhou, Yangsheng; Liu, Xia; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA.
   [Barlogie, Bart; Shaughnessy, John D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1511
EP 1511
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804594
ER

PT J
AU Zhou, YS
   Liu, X
   Gong, P
   Xu, L
   Ciccarelli, B
   Yang, G
   Patterson, CJ
   Treon, S
AF Zhou, Yangsheng
   Liu, Xia
   Gong, Ping
   Xu, Lian
   Ciccarelli, Bryan
   Yang, Guang
   Patterson, Christopher J.
   Treon, Steven
TI Metalloproteinase Inhibitors Inhibit the Release of Soluble CD27 by
   Waldenstrom's Macroglobulinemia Cells.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Zhou, Yangsheng; Liu, Xia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1516
EP 1516
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804606
ER

PT J
AU Goodwin, CB
   Yang, ZY
   Vemula, S
   Yin, FQ
   Kapur, R
   Chan, RJ
AF Goodwin, Charles B.
   Yang, Zhenyun
   Vemula, Sasidhar
   Yin, Fuqin
   Kapur, Reuben
   Chan, Rebecca J.
TI Genetic Disruption of the PI3K Regulatory Subunit, p85 alpha Partially
   Normalizes Gain-of-Function PTPN11-Induced Hypersensitivity to GM-CSF
   in Hematopoietic Progenitors
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Goodwin, Charles B.; Yang, Zhenyun; Vemula, Sasidhar; Yin, Fuqin; Kapur, Reuben; Chan, Rebecca J.] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1526
EP 1526
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804632
ER

PT J
AU Yang, JF
   Chen, Z
   Zhu, WL
   Ruan, CG
AF Yang, Jianfeng
   Chen, Zhi
   Zhu, Weiliang
   Ruan, Changgeng
TI A Novel Platelet Small-Molecule Agonist Targeting Glycoprotein Ibalpha
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Yang, Jianfeng] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Chen, Zhi; Zhu, Weiliang] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 200031, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1540
EP 1540
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804674
ER

PT J
AU Clapp, DW
   Yang, FC
   Ingram, DA
   Robertson, KA
   Hutchins, GD
   Parada, LF
AF Clapp, D. Wade
   Yang, Fengchun
   Ingram, David A., Jr.
   Robertson, Kent A.
   Hutchins, Gary D.
   Parada, Luis F.
TI Mast Cells and Tumor Progression
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Clapp, D. Wade; Yang, Fengchun; Ingram, David A., Jr.; Hutchins, Gary D.] Indiana Univ, Sch Med, Canc Res Inst, Indianapolis, IN USA.
   [Robertson, Kent A.] Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Indianapolis, IN 46223 USA.
   [Parada, Luis F.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 1582
EP 1582
PG 1
SC Hematology
GA 532DS
UT ISI:000272725804793
ER

PT J
AU Yang, D
   Zeng, Y
   Tian, C
   Liu, J
   Guo, SB
   Zheng, YH
   Li, HH
AF Yang, Dan
   Zeng, Yong
   Tian, Cui
   Liu, Jing
   Guo, Shu-Bin
   Zheng, Yue-Hong
   Li, Hui-Hua
TI Transcriptomic Analysis of Mild Hypothermia-dependent Alterations
   during Endothelial Reperfusion Injury
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Mild hypothermia; Ischemia-Reperfusion; Endothelial cells; Microarray
ID CELL-PROLIFERATION; SIGNALING PATHWAYS; THERAPEUTIC HYPOTHERMIA;
   MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; FOCAL
   ISCHEMIA; PROTEIN-KINASE; CARDIAC-ARREST; BRAIN
AB Background: Mild hypothermia (32-34 C) improves resistance to
   ischemia-reperfusion (I/R) injury. However, the mechanisms by which it
   affects human cellular function are not fully elucidated. To further
   test for hypothermic modulation of global biological processes, we used
   DNA microarray technique to detect the overall gene expression profile.
   Methods: Human umbilical endothelial cells (HUVECs) were incubated
   under control condition (37 degrees C) or mild hypothermia (33 degrees
   C) for 2 hours after stimulated ischemia. Detection of differentially
   expressed genes was performed with Affymetrix U133 plus 2.0 arrays and
   PARTEK software. We used DAVID and KEGG Pathways database to identify
   global trends in gene expression data. Results: Our analysis has
   identified numerous interesting genes and processes that are
   differentially presented in hypothermic group when compared with
   normothermic control. The cell cycle was the most prominent process;
   several genes involved in cell apoptosis and proliferation displayed
   significantly differential expression; lower transcriptional level was
   observed for genes involved in chemokine and cell adhesion processes;
   genes associated with activity of transmembrane transporter and lipase
   were also under-expressed. Conclusion: Our data indicated that mild
   hypothermia altered endothelial expression pattern under the condition
   of I/R, preferably through varying the expression of genes associated
   with cell cycle, apoptosis, proliferation, and inflammatory response.
   Copyright (C) 2010 S. Karger AG, Basel
C1 [Yang, Dan; Tian, Cui; Liu, Jing; Li, Hui-Hua] Capital Med Univ, Sch Basic Med Sci, Dept Pathol, Beijing 100069, Peoples R China.
   [Zheng, Yue-Hong] Peking Union Med Hosp, Dept Vasc Surg, Beijing 100730, Peoples R China.
   [Guo, Shu-Bin] Peking Union Med Hosp, Dept Emergency Med, Beijing 100730, Peoples R China.
   [Zeng, Yong] Peking Union Med Hosp, Dept Cardiol, Beijing 100730, Peoples R China.
RP Li, HH, Capital Med Univ, Sch Basic Med Sci, Dept Pathol, 10 Xitoutiao,
   Beijing 100069, Peoples R China.
EM yuehongzheng@yahoo.com
   hhli1935@yahoo.cn
FU China Natural Science Foundation [2006CB910306]; 111 project [B08007]
FX This work was supported by grants from China Natural Science Foundation
   (H. L., 2006CB910306) and the 111 project (H. L., B08007). We thank Dr.
   Ran Zhang (Central Laboratory, Institute of Basic Medical Sciences,
   Chinese Academy of Medical Sciences and Peking Union Medical College)
   for helpful assistance of microarray technique.
CR ARMSTRONG SC, 2004, CARDIOVASC RES, V61, P427, DOI
   10.1016/j.cardiores.2003.09.031
   BERNARD SA, 2002, NEW ENGL J MED, V346, P557
   BUTTRAM SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349
   CARDEN DL, 2000, J PATHOL, V190, P255
   CAYROL R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551
   FAN YN, 2008, FEBS LETT, V582, P4008, DOI 10.1016/j.febslet.2008.11.009
   GANTA CK, 2006, AM J PHYSIOL-REG I, V291, R558, DOI
   10.1152/ajpregu.00846.2005
   GONZALEZNICOLINI V, 2004, INVEST NEW DRUG, V22, P253
   GRESSENS P, 2008, BRAIN PATHOL, V18, P10, DOI
   10.1111/j.1750-3639.2007.00095.x
   HADDIX TL, 1996, J SURG RES, V64, P176
   HU MCT, 1998, MOL CELL BIOL, V18, P6063
   IBAYASHI S, 2000, NEUROCHEM RES, V25, P369
   ITOH F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065
   KANAGAWA T, 2006, BRAIN RES, V1111, P36, DOI
   10.1016/j.brainres.2006.06.112
   KAWAI N, 2000, STROKE, V31, P1982
   KERRIGAN CL, 1993, MICROSURG, V14, P165
   KIMURA T, 2002, EXP BRAIN RES, V145, P83
   LEE HS, 2002, NEUROSCI LETT, V329, P53
   MATSUOKA K, 2003, PANCREAS, V26, P12
   MIYAZAWA T, 2003, NEUROL RES, V25, P457
   PAN GH, 1998, FEBS LETT, V424, P41
   PARDALI K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304
   SAFAR PJ, 2002, NEW ENGL J MED, V346, P612
   SCHARPFENECKER M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   STEPHENSON A, 2004, GENOMICS, V83, P1105, DOI
   10.1016/j.ygeno.2003.12.007
   TOYODA T, 1996, NEUROSURGERY, V39, P1200
   VINCENT AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI
   10.1016/S1096-6374(02)0017-5
   WANG PH, 2001, CIRC RES, V88, P552
   YANAMOTO H, 2001, STROKE, V32, P232
   YANG D, 2009, FEBS LETT, V583, P2500, DOI 10.1016/j.febslet.2009.07.006
   ZHAO H, 2007, J CEREBR BLOOD F MET, V27, P1879
   ZHAO YM, 2007, CANCER RES, V67, P9276, DOI 10.1158/0008-5472.CAN-07-2124
NR 32
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 25
IS 6
BP 605
EP 614
DI 10.1159/000315079
PG 10
SC Cell Biology; Physiology
GA 599DI
UT ISI:000277890000005
ER

PT J
AU Rotte, A
   Pasham, V
   Bhandaru, M
   Eichenmuller, M
   Yang, W
   Qadri, SM
   Kempe, DS
   Puchchakayala, G
   Pearce, D
   Birnbaum, MJ
   Lang, F
AF Rotte, Anand
   Pasham, Venkanna
   Bhandaru, Madhuri
   Eichenmueller, Melanie
   Yang, Wenting
   Qadri, Syed M.
   Kempe, Daniela S.
   Puchchakayala, Goverdhan
   Pearce, David
   Birnbaum, Morris J.
   Lang, Florian
TI Regulation of Gastric Acid Secretion by PKB/Akt2
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE PI3 kinase; PKB/Akt2; Stomach; H+/K+ ATPase; K+ recycling; H+ secretion
ID INDUCIBLE KINASE SGK; PROTEIN-KINASE; POTASSIUM CHANNELS;
   PHOSPHOINOSITIDE 3-KINASE; SERUM; PDK1; MICE; CELL; DEXAMETHASONE;
   STIMULATION
AB Pharmacological inhibition of phosphoinositol 3 kinase (PI3K) and
   partial deficiency of phosphoinositide dependent kinase PDK1 have
   previously been shown to enhance basal gastric acid secretion.
   PI3K/PDK1 dependent signaling involves activation of protein kinase
   B/Akt, which may thus be similarly involved in the regulation of
   gastric acid secretion. To test that hypothesis, gastric acid secretion
   was determined in isolated glands from gene targeted mice lacking
   functional Akt2 (akt2(-/-)) or from their wild type littermates
   (akt2(+/+)). According to BCECF-fluorescence cytosolic pH in isolated
   gastric glands was similar in akt2(-/-) and akt2(+/+) mice.
   Na+-independent pH recovery (Delta pH/min) following an ammonium pulse,
   a measure of H+/K+ ATPase activity, was, however, significantly faster
   in akt2(-/-) than in akt2(+/+) mice. In both genotypes, Delta pH/min
   was virtually abolished by H+/K+ ATPase inhibitor omeprazole (100 mu
   M). Increase of extracellular K+ concentrations to 35 mM (replacing
   Na+) increased Delta pH/min to a significantly larger extent in
   akt2(+/+) than in akt2(-/-) mice and dissipated the differences between
   the genotypes. Similarly, treatment with 5 mu M forskolin enhanced
   Delta pH/min significantly only in akt2(+/+) mice and abolished the
   differences between the genotypes. Conversely, protein kinase A
   inhibitor H89 (50 nM) decreased Delta pH/min to similarly low values in
   both genotypes. In conclusion, Akt2 suppresses gastric acid secretion
   and contributes to or even accounts for the inhibition of gastric acid
   secretion by PI3K. Copyright (C) 2010 S. Karger AG, Basel
C1 [Rotte, Anand; Pasham, Venkanna; Bhandaru, Madhuri; Eichenmueller, Melanie; Yang, Wenting; Qadri, Syed M.; Kempe, Daniela S.; Puchchakayala, Goverdhan; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany.
   [Birnbaum, Morris J.] Univ Penn, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.
   [Pearce, David] Univ Calif San Francisco, Dept Med Nephrol, San Francisco, CA 94143 USA.
RP Lang, F, Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen,
   Germany.
EM florian.lang@uni-tuebingen.de
FU DFG [SFB 773]
FX The authors gratefully acknowledge the meticulous preparation of the
   manuscript by Tanja Loch. This work was supported by grants from the
   DFG (SFB 773).
CR ALESSI DR, 1996, EMBO J, V15, P6541
   ALESSI DR, 1998, CURR OPIN GENET DEV, V8, P55
   AMMAR DA, 2002, AM J PHYSIOL-GASTR L, V282, G23
   BOYARSKY G, 1988, AM J PHYSIOL, V255, C844
   BUSJAHN A, 2004, CELL PHYSIOL BIOCHEM, V14, P135, DOI 10.1159/000078105
   CHO H, 2001, J BIOL CHEM, V276, P38349
   CHO H, 2001, SCIENCE, V292, P1728
   DEDEK K, 2001, PFLUG ARCH EUR J PHY, V442, P896
   DIVECHA N, 1991, EMBO J, V10, P3207
   DONG MQ, 2006, J MEMBRANE BIOL, V210, P183
   EMBARK HM, 2003, PFLUG ARCH EUR J PHY, V445, P601, DOI
   10.1007/s00424-002-0982-y
   GAMPER N, 2002, PFLUG ARCH EUR J PHY, V443, P625
   GRAHAMMER F, 2001, GASTROENTEROLOGY, V120, P1363
   HEITZMANN D, 2004, J PHYSIOL-LONDON, V561, P547, DOI
   10.1113/jphysiol.2004.075168
   HEITZMANN D, 2007, CELL PHYSIOL BIOCHEM, V19, P21, DOI 10.1159/000099189
   HOFER AM, 1992, J MEMBRANE BIOL, V126, P245
   HOU W, 2006, CURR OPIN GASTROEN, V22, P593
   KOBAYASHI T, 1999, BIOCHEM J 2, V339, P319
   KOTANI K, 1994, EMBO J, V13, P2313
   KUROKAWA J, 2003, P NATL ACAD SCI USA, V100, P2122, DOI
   10.1073/pnas.0434935100
   LANG F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005
   LANG PA, 2007, CELL PHYSIOL BIOCHEM, V20, P527, DOI 10.1159/000107536
   LAWLOR MA, 2002, EMBO J, V21, P3728
   LEE HC, 1979, BIOCHIM BIOPHYS ACTA, V553, P107
   LEE MP, 2000, J CLIN INVEST, V106, P1447
   LUO JC, 2008, BIOCHEM PHARMACOL, V76, P841, DOI
   10.1016/j.bcp.2008.07.010
   MARX SO, 2002, SCIENCE, V295, P496
   METTLER SE, 2007, AM J PHYSIOL-GASTR L, V293, G532, DOI
   10.1152/ajpgi.00138.2007
   PARK J, 1999, EMBO J, V18, P3024
   PFAFFL MW, 2001, NUCLEIC ACIDS RES, V29, ARTN e45
   POTET F, 2001, AM J PHYSIOL-HEART C, V280, H2038
   ROOS A, 1981, PHYSIOL REV, V61, P296
   ROTTE A, 2008, CELL PHYSIOL BIOCHEM, V22, P725, DOI 10.1159/000185556
   ROTTE A, 2009, CELL PHYSIOL BIOCHEM, V23, P133, DOI 10.1159/000204102
   SANDU C, 2007, PFLUG ARCH EUR J PHY, V455, P493, DOI
   10.1007/s00424-007-0305-4
   SEEBOHM G, 2007, CIRC RES, V100, P686, DOI
   10.1161/01.RES.0000260250.83824.8f
   SIDANI S, 2009, PFLUG ARCH EUR J PHY, V459, P39, DOI
   10.1007/s00424-009-0698-3
   SIDANI SM, 2007, J BIOL CHEM, V282, P6068, DOI 10.1074/jbc.M608427200
   VALLON V, 2005, P NATL ACAD SCI USA, V102, P17864
   WAISBREN SJ, 1994, AM J PHYSIOL, V266, C1013
   WALLACE JL, 2007, GASTROENTEROLOGY, V132, P261, DOI
   10.1053/j.gastro.2006.11.042
   WANG GZ, 2007, CELL PHYSIOL BIOCHEM, V20, P205, DOI 10.1159/000104167
   YAO XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI
   10.1146/annurev.physiol.65.072302.114200
   YOKOTA A, 2007, DIGEST DIS SCI, V52, P1452, DOI
   10.1007/s10620-006-9273-3
NR 44
TC 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 25
IS 6
BP 695
EP 704
DI 10.1159/000315089
PG 10
SC Cell Biology; Physiology
GA 599DI
UT ISI:000277890000015
ER

PT J
AU Kuebler, WM
   Yang, Y
   Samapati, R
   Uhlig, S
AF Kuebler, Wolfgang M.
   Yang, Yang
   Samapati, Rudi
   Uhlig, Stefan
TI Vascular Barrier Regulation by PAF, Ceramide, Caveolae, and NO - an
   Intricate Signaling Network with Discrepant Effects in the Pulmonary
   and Systemic Vasculature
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Review
DE Permeability; Endothelium; aveolae; Acid sphingomyelinase; Ceramide;
   Nitric oxide
ID NITRIC-OXIDE SYNTHASE; HYDROSTATIC LUNG EDEMA; ENDOTHELIAL-CELLS;
   MICROVASCULAR PERMEABILITY; TYROSINE PHOSPHORYLATION; ACID
   SPHINGOMYELINASE; IN-VIVO; INDUCED HYPERPERMEABILITY; FILTRATION
   COEFFICIENT; DEPENDENT ACTIVATION
AB Increased endothelial permeability and vascular barrier failure are
   hallmarks of inflammatory responses in both the pulmonary and the
   systemic circulation. Platelet-activating factor (PAF) has been
   implicated as an important lipid mediator in the formation of pulmonary
   and extrapulmonary edema. Ostensibly, the PAF-induced signaling
   pathways in endothelial cells utilize similar structures and molecules
   including acid sphingomyelinase, ceramide, caveolae, endothelial nitric
   oxide synthase, and nitric oxide, in pulmonary and systemic
   microvessels. Yet, the constituents of these signaling pathways act and
   respond in distinctly different and frequently opposing ways in the
   lung versus organs of the systemic circulation. By confronting
   seemingly discrepant findings from the literature, we reconstruct the
   differential signaling pathways by which PAF regulates edema formation
   in the systemic and the pulmonary vascular bed, and trace this
   dichotomy from the level of myosin light chain kinase via the
   regulation of endothelial nitric oxide synthase and sphingomyelinase
   signaling to the level of caveolar trafficking. Here, we propose that
   PAF regulates vascular barrier function in individual organs by
   opposing signaling pathways that culminate in increased respectively
   decreased nitric oxide synthesis in the systemic and the pulmonary
   endothelium. The present review may provide a physiological explanation
   for the overall disappointing results of previous pharmacological
   strategies in conditions of generalized barrier failure such as sepsis,
   and instead advertises the development of organ-specific interventions
   by targeting the individual composition or trafficking of endothelial
   caveolae. Copyright (C) 2010 S. Karger AG, Basel
C1 [Yang, Yang; Uhlig, Stefan] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Fac Med, D-52074 Aachen, Germany.
   [Kuebler, Wolfgang M.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
   [Kuebler, Wolfgang M.; Samapati, Rudi] Charite Univ Med Berlin, Inst Physiol, Berlin, Germany.
RP Uhlig, S, Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Fac Med,
   Wendlingweg 2, D-52074 Aachen, Germany.
EM suhlig@ukaachen.de
FU Deutsche Forschungsgemeinschaft [KU 1218/5-1, UH 88/8-1]
FX This study was funded by the Deutsche Forschungsgemeinschaft within the
   SPP1267 "Sphingolipids and disease" (KU 1218/5-1, UH 88/8-1).
CR ADAMSON RH, 2003, AM J PHYSIOL-HEART C, V285, H406, DOI
   10.1152/ajpheart.00021.2003
   ALVAREZ DF, 2006, CIRC RES, V99, P988, DOI
   10.1161/01.RES.000247065.11756.19
   ARMSTRONG R, 2001, INT IMMUNOPHARMACOL, V1, P1501
   BUSSOLATI B, 2002, KIDNEY INT, V62, P1322
   CHATTERJEE S, 2003, J CELL SCI, V116, P3645, DOI 10.1242/jcs.00664
   CLAUS RA, 2005, FASEB J, V19, P1719
   CLEMENTI E, 2003, TRENDS PHARMACOL SCI, V24, P518, DOI
   10.1016/j.tips.2003.08.008
   CZARNY M, 2004, AM J PHYSIOL-HEART C, V287, H1344, DOI
   10.1152/ajpheart.00222.2004
   DEDKOVA EN, 2002, J PHYSIOL-LONDON, V539, P77
   DHILLON B, 2003, MOL CELL BIOCHEM, V247, P101
   DHILLON SS, 2005, CHEST, V128, P1706
   DIMMELER S, 1999, NATURE, V399, P601
   DIRKS WG, 1999, IN VITRO CELL DEV-AN, V35, P558
   FARHI LE, 1990, ADV EXP MED BIOL, V277, P579
   FERON O, 1996, J BIOL CHEM, V271, P22810
   FERON O, 1998, J BIOL CHEM, V273, P3125
   FERON O, 2006, CARDIOVASC RES, V69, P788, DOI
   10.1016/j.cardiores.2005.12.014
   FILEP JG, 1993, BRIT J PHARMACOL, V110, P1347
   FLEMING I, 2003, AM J PHYSIOL-REG I, V284, P1
   FLORIO T, 2003, MOL PHARMACOL, V63, P297
   GAMBLE J, 1997, J GRAVIT PHYSL, V4, P35
   GARCIACARDENA G, 1996, J BIOL CHEM, V271, P27237
   GOGGEL R, 2002, AM J RESP CRIT CARE, V166, P657, DOI
   10.1164/rccm.20011.0710C
   GOGGEL R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977
   GOGGEL R, 2005, EUR RESPIR J, V25, P849, DOI 10.1183/09031936.05.0069804
   GRATTON JP, 2004, CIRC RES, V94, P1408, DOI
   10.1161/01.RES.0000129178.56294.17
   GUYTON AC, 1959, CIRC RES, V7, P649
   HALL CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI
   10.1016/j.niox.2009.07.002
   HAMANAKA K, 2007, AM J PHYSIOL-LUNG C, V293, L923, DOI
   10.1152/ajplung.00221.2007
   HATAKEYAMA T, 2006, J PHYSIOL-LONDON, V574, P275, DOI
   10.1113/jphysiol.2006.108175
   HE PN, 2006, AM J PHYSIOL-HEART C, V291, H591, DOI
   10.1152/ajpheart.01228.2005
   HUDRYCLERGEON H, 2005, FASEB J, V19, P512, DOI 10.1096/fj.04-2202com
   IGARASHI J, 1999, P NATL ACAD SCI USA, V96, P12583
   JACOBSON JR, 2007, CURR DRUG TARGETS, V8, P509
   JIAN MY, 2008, AM J RESP CELL MOL, V38, P386, DOI
   10.1165/rcmb.2007-0192OC
   JIANG YY, 2008, AM J PHYSIOL-HEART C, V295, H898, DOI
   10.1152/ajpheart.00309.2008
   KAESTLE SM, 2007, AM J PHYSIOL-LUNG C, V293, L859, DOI
   10.1152/ajplung.00008.2007
   KIKUCHI M, 2008, PROSTAG LEUKOTR ESS, V78, P305, DOI
   10.1016/j.plefa.2008.04.002
   KIM DD, 2009, MICROCIRCULATION, V16, P323, DOI 10.1080/10739680902734876
   KLABUNDE RE, 2000, EUR J PHARMACOL, V404, P387
   KNEZEVIC II, 2009, J BIOL CHEM, V284, P5381, DOI 10.1074/jbc.M808958200
   KUBES P, 1990, AM J PHYSIOL, V259, G859
   KUEBLER WM, 2003, AM J RESP CRIT CARE, V168, P1391, DOI
   10.1164/rccm.200304-562OC
   KUEBLER WM, 2007, J APPL PHYSIOL, V102, P1255, DOI
   10.1152/japplphysiol.00786.2006
   LAUTENSCHLAGER I, 2010, AM J PHYSIOL-GASTR L, V298, G304, DOI
   10.1152/ajpgi.00313.2009
   LI S, 2009, J CLIN PHARM THER, V34, P447, DOI
   10.1111/j.1365-2710.2008.01014.x
   LI XA, 2002, J BIOL CHEM, V277, P11058
   LI XA, 2006, CARDIOVASC TOXICOL, V6, P1
   MANIATIS NA, 2006, CIRC RES, V99, P870, DOI
   10.1161/01.RES.0000245187.08026.47
   MARON MB, 1982, AM J PHYSIOL, V242, H565
   MICHEL CC, 1999, PHYSIOL REV, V79, P703
   MINSHALL RD, 2006, HANDB EXP PHARM, V176, P107
   PANI B, 2009, CELL CALCIUM, V45, P625, DOI 10.1016/j.ceca.2009.02.009
   PARIA BC, 2004, AM J PHYSIOL-LUNG C, V287, L1303, DOI
   10.1152/ajplung.00240.2004
   PARKER JC, 2008, AM J PHYSIOL-LUNG C, V295, L235, DOI
   10.1152/ajplung.00064.2008
   PEI DS, 2008, J NEUROCHEM, V106, P1952, DOI
   10.1111/j.1471-4159.2008.05531.x
   PIKE LJ, 2004, BIOCHEM J 2, V378, P281, DOI 10.1042/BJ20031672
   POISSON C, 2009, J IMMUNOL, V183, P2747, DOI 10.4049/jimmunol.0802651
   PREDESCU D, 2005, AM J PHYSIOL-LUNG C, V289, L371, DOI
   10.1152/ajplung.00175.2004
   RAMIREZ MM, 1995, MICROVASC RES, V50, P223
   ROTH AG, 2009, ANGEW CHEM INT EDIT, V48, P7560, DOI
   10.1002/anie.200903288
   SAMAPATI R, 2009, J VASC RES S3, V46, P34
   SANCHEZ FA, 2006, AM J PHYSIOL-HEART C, V291, H1058, DOI
   10.1152/ajpheart.00370.2006
   SANCHEZ FA, 2008, AM J PHYSIOL-HEART C, V295, H1642, DOI
   10.1152/ajpheart.00629.2008
   SANCHEZ FA, 2009, P NATL ACAD SCI USA, V106, P6849, DOI
   10.1073/pnas.0812694106
   SBAA E, 2005, TRENDS CARDIOVAS MED, V15, P157
   SCHLORMANN W, 2010, HISTOCHEM CELL BIOL, V133, P223, DOI
   10.1007/s00418-009-0651-8
   SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759
   SCHUBERT W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200
   SIMONI JM, 2000, WOMEN HEALTH, V31, P39
   STARLING EH, 1896, J PHYSIOL-LONDON, V19, P312
   TAN XD, 2000, BRIT J PHARMACOL, V129, P1522
   TIRUPPATHI C, 2002, CIRC RES, V91, P70
   TIRUPPATHI C, 2006, MICROCIRCULATION, V13, P693, DOI
   10.1080/10739680600930347
   UHLIG S, 1994, J APPL PHYSIOL, V77, P262
   UHLIG S, 1997, J PHARMACOL TOXICOL, V37, P119
   UHLIG S, 2005, PHARMACOL REP S, V57, P206
   UHLIG S, 2008, AM J RESP CRIT CARE, V178, P1100, DOI
   10.1164/rccm.200804-595SO
   WANG LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   WARE LB, 2000, NEW ENGL J MED, V342, P1334
   WONG ML, 2000, P NATL ACAD SCI USA, V97, P8681
   YANG Y, 2009, EUR RESP J IN PRESS
   YAO XQ, 2005, CIRC RES, V97, P853, DOI
   10.1161/01.RES.0000187473.85419.3e
   YIN J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   YIN J, 2010, CELL BIOCHEM BIOPHYS, V56, P1, DOI
   10.1007/s12013-009-9067-2
   ZHU LK, 2004, AM J PHYSIOL-HEART C, V286, H195, DOI
   10.1152/ajpheart.00667.2003
   ZHU LK, 2005, AM J PHYSIOL-HEART C, V288, H2869, DOI
   10.1152/ajpheart.01080.2004
NR 87
TC 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 26
IS 1
BP 29
EP 40
DI 10.1159/000315103
PG 12
SC Cell Biology; Physiology
GA 599DL
UT ISI:000277890300004
ER

PT J
AU Duncan, DJ
   Yang, ZK
   Hopkins, PM
   Steele, DS
   Harrison, SM
AF Duncan, David J.
   Yang, Zhaokang
   Hopkins, Philip M.
   Steele, Derek S.
   Harrison, Simon M.
TI TNF-alpha and IL-1 beta increase Ca2+ leak from the sarcoplasmic
   reticulum and susceptibility to arrhythmia in rat ventricular myocytes
SO CELL CALCIUM
LA English
DT Article
DE Sepsis; Cytokines; Sarcoplasmic reticulum; Myocardial contraction;
   Calcium; Arrhythmia
ID NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; RYANODINE RECEPTORS; CALCIUM
   SPARKS; SEPTIC SHOCK; SEPSIS; DYSFUNCTION; SKELETAL; RELEASE;
   INTERLEUKIN-1-BETA
AB Sepsis is associated with ventricular dysfunction and increased
   incidence of atrial and ventricular arrhythmia however the underlying
   pro-arrhythmic mechanisms are unknown. Serum levels of tumour necrosis
   factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) are
   elevated during sepsis and affect Ca2+ regulation. We investigated
   whether pro-inflammatory cytokines disrupt cellular Ca2+ cycling
   leading to reduced contractility, but also increase the probability of
   pro-arrhythmic spontaneous Ca2+ release from the sarcoplasmic reticulum
   (SR). Isolated rat ventricular myocytes were exposed to TNF-alpha (0.05
   ng ml(-1)) and IL-1 beta (2 ng ml(-1)) for 3 hr and then loaded with
   fura-2 or fluo-3 to record the intracellular Ca2+ concentration
   ([Ca2+](i)). Cytokine treatment decreased the amplitude of the
   spatially averaged Ca2+ transient and the associated contraction,
   induced asynchronous Ca2+ release during electrical stimulation,
   increased the frequency of localized Ca2+ release events, decreased the
   SR Ca2+ content and increased the frequency of spontaneous Ca2+ waves
   at any given cytoplasmic Ca2+. These data suggest that INF-alpha and
   IL-1 beta increase the SR Ca2+ leak from the SR, which contributes to
   the depressed Ca2+ transient and contractility. Increased
   susceptibility to spontaneous SR Ca2+ release may contribute to
   arrhythmias in sepsis as the resulting Ca2+ extrusion via NCX is
   electrogenic, leading to cell depolarisation. (C) 2010 Elsevier Ltd.
   All rights reserved.
C1 [Duncan, David J.; Yang, Zhaokang; Steele, Derek S.; Harrison, Simon M.] Univ Leeds, Inst Membrane & Syst Biol, Multidisciplinary Cardiovasc Res Ctr, Leeds LS2 9JT, W Yorkshire, England.
   [Hopkins, Philip M.] Univ Leeds, Acad Unit Anaesthesia, Leeds LS2 9JT, W Yorkshire, England.
RP Harrison, SM, Univ Leeds, Inst Membrane & Syst Biol, Multidisciplinary
   Cardiovasc Res Ctr, Garstang Bldg, Leeds LS2 9JT, W Yorkshire, England.
EM S.M.Harrison@leeds.ac.uk
FU British Heart Foundation ; White Rose Consortium 
FX This work was supported by grants from the British Heart Foundation and
   the White Rose Consortium.
CR AKAR FG, 2007, CIRC RES, V101, P968, DOI 10.1161/CIRCRESAHA.107.164426
   BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, C1313
   BAUMGARTEN G, 2000, TRENDS CARDIOVAS MED, V10, P216
   CASEY LC, 1993, ANN INTERN MED, V119, P771
   CHANDLER WK, 2003, J GEN PHYSIOL, V121, P311
   CHENG H, 1996, AM J PHYSIOL-CELL PH, V270, C148
   DETTBARN CA, 1994, J MOL CELL CARDIOL, V26, P229
   DUNCAN DJ, 2007, BRIT J PHARMACOL, V150, P720, DOI
   10.1038/sj.bjp.0707147
   EISNER DA, 1998, CARDIOVASC RES, V38, P589
   HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517
   HORTON JW, 2000, AM J PHYSIOL-HEART C, V278, H1955
   KELLER M, 2007, CARDIOVASC RES, V74, P39, DOI
   10.1016/j.cardiores.2007.02.006
   KHADOUR FH, 2002, AM J PHYSIOL-HEART C, V283, H1108, DOI
   10.1152/ajpheart.00549.2001
   KUMAR A, 1996, J EXP MED, V183, P949
   KUMAR A, 1999, AM J PHYSIOL-REG I, V276, R265
   KUMAR A, 2000, CRIT CARE CLIN, V16, P251
   LUKYANENKO V, 2001, BIOPHYS J, V81, P785
   MITCHELL JA, 2000, EUR J PHARMACOL, V389, P209
   PICHT E, 2007, AM J PHYSIOL-CELL PH, V293, C1073, DOI
   10.1152/ajpcell.00586.2006
   RUBART M, 2005, J CLIN INVEST, V115, P2305, DOI 10.1172/JCI26381
   RUDIGER A, 2007, CRIT CARE MED, V35, P1599, DOI
   10.1097/01.CCM.0000266683.64081.02
   SALAMA G, 2000, ANTIOXID REDOX SIGN, V2, P5
   SCHLOTTHAUER K, 2000, CIRC RES, V87, P774
   SCHWARTZ A, 2002, EUR J INTERN MED, V13, P434
   STAMM C, 2001, ANESTHESIOLOGY, V95, P1396
   STOYANOVSKY D, 1997, CELL CALCIUM, V21, P19
   SUN XP, 1998, J PHYSIOL-LONDON, V509, P67
   TANAKA H, 1998, J PHYSIOL-LONDON, V508, P145
   WALSH SR, 2007, ANN ROY COLL SURG, V89, P91, DOI
   10.1308/003588407X168253
   YANG ZK, 2005, CARDIOVASC RES, V65, P167, DOI
   10.1016/j.cardiores.2004.09.008
   YU XW, 2005, J PHYSIOL-LONDON, V566, P327, DOI
   10.1113/jphysiol.2005.086686
   ZHU XS, 2005, CRIT CARE MED, V33, P598, DOI
   10.1097/01.ccm.0000152223.27176.A6
NR 32
TC 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
J9 CELL CALCIUM
JI Cell Calcium
PD APR
PY 2010
VL 47
IS 4
BP 378
EP 386
DI 10.1016/j.ceca.2010.02.002
PG 9
SC Cell Biology
GA 597SI
UT ISI:000277781100008
ER

PT J
AU Tamura, D
   Arao, T
   Tanaka, K
   Kaneda, H
   Matsumoto, K
   Kudo, K
   Aomatsu, K
   Fujita, Y
   Watanabe, T
   Saijo, N
   Kotani, Y
   Nishimura, Y
   Nishio, K
AF Tamura, Daisuke
   Arao, Tokuzo
   Tanaka, Kaoru
   Kaneda, Hiroyasu
   Matsumoto, Kazuko
   Kudo, Kanae
   Aomatsu, Keiichi
   Fujita, Yoshihiko
   Watanabe, Takashi
   Saijo, Nagahiro
   Kotani, Yoshikazu
   Nishimura, Yoshihiro
   Nishio, Kazuto
TI Bortezomib potentially inhibits cellular growth of vascular endothelial
   cells through suppression of G2/M transition
SO CANCER SCIENCE
LA English
DT Article
ID MULTIPLE-MYELOMA; PROTEASOME INHIBITION; PROTEIN-DEGRADATION; UBIQUITIN
   SYSTEM; APOPTOSIS; CANCER; THERAPIES; LYMPHOMA; ARREST; LINES
AB Bortezomib, a selective 26S proteasome inhibitor, has shown clinical
   benefits against refractory multiple myeloma. The indirect
   anti-angiogenic activity of bortezomib has been widely recognized;
   however, the growth-inhibitory mechanism of bortezomib on vascular
   endothelial cells remains unclear, especially on the cell cycle. Here,
   we showed that bortezomib (2 nM of the IC50 value) potently inhibited
   the cellular growth of human umbilical vascular endothelial cells
   (HUVECs) via a vascular endothelial growth factor receptor
   (VEGFR)-independent mechanism resulting in the induction of apoptosis.
   Bortezomib significantly increased the vascular permeability of HUVECs,
   whereas a VEGFR-2 tyrosine kinase inhibitor decreased it.
   Interestingly, a cell cycle analysis using flow cytometry, the
   immunostaining of phospho-histone H3, and Giemsa staining revealed that
   bortezomib suppressed the G2/M transition of HUVECs, whereas the
   mitotic inhibitor paclitaxel induced M-phase accumulation. A further
   analysis of cell cycle-related proteins revealed that bortezomib
   increased the expression levels of cyclin B1, the cdc2/cyclin B
   complex, and the phosphorylation of all T14, Y15, and T161 residues on
   cdc2. Bortezomib also increased the ubiquitination of cyclin B1 and
   wee1, but inhibited the kinase activity of the cdc2/cyclin B complex.
   These protein modifications support the concept that bortezomib
   suppresses the G2/M transition, rather than causing M-phase arrest. In
   conclusion, we demonstrated that bortezomib potently inhibits cell
   growth by suppressing the G2/M transition, modifying G2/M-phase-related
   cycle regulators, and increasing the vascular permeability of vascular
   endothelial cells. Our findings reveal a cell cycle-related mode of
   action and strongly suggest that bortezomib exerts an additional unique
   vascular disrupting effect as a vascular targeting drug. (Cancer Sci
   2010).
C1 [Tamura, Daisuke; Arao, Tokuzo; Tanaka, Kaoru; Kaneda, Hiroyasu; Matsumoto, Kazuko; Kudo, Kanae; Aomatsu, Keiichi; Fujita, Yoshihiko; Nishio, Kazuto] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan.
   [Tamura, Daisuke; Kotani, Yoshikazu; Nishimura, Yoshihiro] Kobe Univ, Div Resp Med, Dept Internal Med, Grad Sch Med, Kobe, Hyogo 657, Japan.
   [Watanabe, Takashi; Saijo, Nagahiro] Natl Canc Ctr Hosp, Div Med Oncol, Kashiwa, Chiba, Japan.
RP Nishio, K, Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan.
EM knishio@med.kindai.ac.jp
FU Third-Term Comprehensive 10-Year Strategy for Cancer Control ; National
   Institute of Biomedical Innovation (NiBio) ; funds for Health and Labor
   Scientific Research 
FX We thank Mr Shinji Kurashimo, Mr Yoshihiro Mine, and Ms Tomoko Kitayama
   for their technical assistance. This work was supported in part by the
   Third-Term Comprehensive 10-Year Strategy for Cancer Control, the
   Program for the Promotion of Fundamental Studies in Health Sciences of
   the National Institute of Biomedical Innovation (NiBio), funds for
   Health and Labor Scientific Research Grants, and a Grant-in-Aid for
   Scientific Research (A).
CR 2003, CLIN ADV HEMATOL ONC, V1, P190
   CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139
   DESAI SD, 1997, J BIOL CHEM, V272, P24159
   GENINI D, 2008, PPAR RES, UNSP 195065
   GRIMM LM, 1996, EMBO J, V15, P3835
   HAYASHI T, 2003, BRIT J HAEMATOL, V120, P10
   HERSHKO A, 1998, ANNU REV BIOCHEM, V67, P425
   HIDESHIMA T, 2001, CANCER RES, V61, P3071
   HIDESHIMA T, 2001, SEMIN ONCOL, V28, P607
   HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215
   JENTSCH S, 1995, CELL, V82, P881
   JUNG L, 2004, ONCOLOGY WILLISTON P, V18, P4
   LEONARD JP, 2006, INT J CANCER, V119, P971, DOI 10.1002/ijc.21805
   LING YH, 2003, CLIN CANCER RES, V9, P1145
   LIPPERT JW, 2007, BIOORGAN MED CHEM, V15, P605, DOI
   10.1016/j.bmc.2006.10.020
   MANI A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   MATSUMOTO K, 2009, CANCER RES, V69, P7160, DOI
   10.1158/0008-5472.CAN-09-1289
   PHAM LV, 2003, J IMMUNOL, V171, P88
   PODAR K, 2004, CANCER RES, V64, P7500
   RAJKUMAR SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030
   RICHARDSON PG, 2005, NEW ENGL J MED, V352, P2487
   ROCCARO AM, 2006, CANCER RES, V66, P184, DOI
   10.1158/0008-5472.CAN-05-1195
   SCHWARTZ EL, 2009, CLIN CANCER RES, V15, P2594, DOI
   10.1158/1078-0432.CCR-08-2710
   SIEMANN DW, 2005, CLIN CANCER RES, V11, P416
   STRAUSS SJ, 2007, CANCER RES, V67, P2783, DOI
   10.1158/0008-5472.CAN-06-3254
   TAKEDA M, 2007, CLIN CANCER RES, V13, P3051, DOI
   10.1158/1078-0432.CCR-06-2743
   TOZER GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628
   TREIER M, 1994, CELL, V78, P787
NR 28
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD JUN
PY 2010
VL 101
IS 6
BP 1403
EP 1408
DI 10.1111/j.1349-7006.2010.01544.x
PG 6
SC Oncology
GA 599LJ
UT ISI:000277913800011
ER

PT J
AU Yang, JYK
   Williams, S
   Brandao, LR
   Chan, AKC
AF Yang, Janet Y. K.
   Williams, Suzan
   Brandao, Leonardo R.
   Chan, Anthony K. C.
TI Neonatal and childhood right atrial thrombosis: recognition and a
   risk-stratified treatment approach
SO BLOOD COAGULATION & FIBRINOLYSIS
LA English
DT Review
DE central venous catheters; children; pediatric; right atrial thrombosis;
   right atrial thrombus
ID TISSUE-PLASMINOGEN ACTIVATOR; CENTRAL VENOUS CATHETERS; TWO-DIMENSIONAL
   ECHOCARDIOGRAPHY; TOTAL PARENTERAL-NUTRITION; RIGHT HEART THROMBUS;
   VENA-CAVA; THROMBOEMBOLIC COMPLICATIONS; INTRACARDIAC THROMBOSIS;
   PULMONARY-EMBOLISM; PREMATURE-INFANTS
AB Pediatric literature and guidelines of treatment options for right
   atrial thrombosis (RAT) are lacking; thus, this review summarizes the
   available literature on RAT in infants and children. Medline search
   identified 35 publications, with 27 prospective or retrospective case
   series included for data analysis. A total of 122 cases of RAT were
   identified. The mean age of patients is 3.58 years (n=86) with a strong
   predominance in the neonatal and infancy period. Ninety-one percent of
   cases were found to be associated with central venous catheters, 40.8%
   are premature neonates, 27.2% are postcardiac surgery patients, and
   19.2% have underlying malignancies. Gut failure with total parenteral
   nutrition given via the central venous catheters occurred in 45.6% of
   patients. The most frequent presenting symptoms are respiratory
   distress and arrhythmia, and 56.8% (42 of 74) were asymptomatic. Our
   study defined high-risk features on echocardiogram as large size, more
   than 2cm in any dimension, pedunculated, mobile, or snake-shaped, and
   mobile. Our result confirmed there is significant difference in the
   mortality for the high-risk group (16.7%; three of 18) versus the low
   risk group (0%; n=32; P=0.0416). Moreover, none of the asymptomatic
   patients showed progression in disease or died. Asymptomatic and
   hemodynamically stable patients with RAT who are at low risk are
   associated with good prognosis irrespective of treatment. We
   recommended removal of central venous line if possible, with or without
   anticoagulation for this group of patients. Systemic anticoagulation
   therapy should be given to all high-risk or symptomatic RAT patients.
   Surgical thrombectomy or thrombolytic therapy carries significant risk
   and should be considered individually. Blood Coagul Fibrinolysis
   21:301-307 (C) 2010 Wolters Kluwer Health vertical bar Lippincott
   Williams & Wilkins.
C1 [Yang, Janet Y. K.; Chan, Anthony K. C.] McMaster Univ, Dept Pediat, Div Hematol & Oncol, Hamilton, ON, Canada.
   [Yang, Janet Y. K.] Tuen Mun Hosp, Dept Pediat & Adolescent Med, Hong Kong, Peoples R China.
   [Williams, Suzan; Brandao, Leonardo R.] Hosp Sick Children, Dept Hematol & Oncol, Toronto, ON M5G 1X8, Canada.
RP Chan, AKC, Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3,
   Canada.
EM achan@thrombosis.hhscr.org
FU Heart and Stroke Foundation of Canada 
FX A.C. is a career investigator funded by the Heart and Stroke Foundation
   of Canada.
CR ANDREW M, 1994, BLOOD, V83, P1251
   ASANTEKORANG A, 1992, INT J CARDIOL, V35, P317
   ATALAY S, 2002, ACTA PAEDIATR, V91, P168
   ATHALE UH, 2007, SEMIN THROMB HEMOST, V33, P416, DOI
   10.1055/s-2007-976177
   BAGNALL HA, 1989, PEDIATRICS, V83, P963
   BAGWELL CE, 1989, CRIT CARE MED, V17, P295
   BERMAN W, 1991, CHEST, V99, P963
   BILGINER Y, 2008, PEDIATR TRANSPLANT, V12, P251, DOI
   10.1111/j.1399-3046.2007.00857.x
   BOIGNER H, 2001, PAEDIATR ANAESTH, V11, P729
   CESARO S, 2002, SUPPORT CARE CANCER, V10, P253
   CROWELL RH, 1988, CHEST, V94, P1236
   DELAPLANE D, 1982, J PEDIATR, V100, P149
   DESCHEPPER J, 1993, AM J PERINAT, V10, P39
   DHANDE V, 1983, PEDIATRICS, V72, P109
   DOLLERY CM, 1994, LANCET, V344, P1043
   FYFE DA, 1991, J AM COLL CARDIOL, V18, P1733
   GIANNOULIAKARADANA A, 2000, J PEDIATR SURG, V35, P1459
   GILON D, 1998, AM HEART J, V135, P457
   GIUFFRE B, 1998, ACTA PAEDIATR, V87, P695
   GRAHAM L, 1984, PEDIATRICS, V73, P225
   HANSEUS K, 1988, PEDIATR CARDIOL, V9, P7
   HOLLINGSED MJ, 1997, PERFUSION, V12, P197
   KADAR K, 1991, PEDIATR CARDIOL, V12, P24
   KAKZANOV V, 2008, JPEN-PARENTER ENTER, V32, P88
   KINGDON EJ, 2001, AM J KIDNEY DIS, V38, P631, DOI
   10.1053/ajkd.2001.26898
   KINNEY EL, 1989, AM HEART J, V118, P569
   KORONES DN, 1996, J PEDIATR, V128, P841
   KRONIK G, 1989, EUR HEART J, V10, P1046
   MAHONY L, 1981, J PEDIATR, V98, P469
   MARSH D, 1988, CRIT CARE MED, V16, P202
   MARSH D, 1988, PEDIATRICS, V81, P284
   MOUKARZEL A, 1991, JPEN-PARENTER ENTER, V15, P551
   NESTICO PF, 1984, AM HEART J, V107, P1278
   OZIMEK W, 2000, MED SCI MONITOR, V6, P1013
   PAUT O, 1992, INTENS CARE MED, V18, P375
   REED WP, 1985, SURG GYNECOL OBSTET, V160, P417
   RIGGS T, 1981, AM J CARDIOL, V48, P961
   ROSS P, 1989, J PEDIATR SURG, V24, P253
   RUPAR DG, 1990, AM J DIS CHILD, V144, P879
   SADIQ HF, 1987, CRIT CARE MED, V15, P47
   SCHIAVETTI A, 2008, J PEDIAT HEMATOL ONC, V30, P148
   SHARRATT GP, 1986, PEDIATR CARDIOL, V7, P189
   TEITELBAUM DH, 1989, J PEDIATR SURG, V24, P1118
   TORRESVALDIVIESO MJ, 2003, AM J PERINAT, V20, P91
   VANOMMEN CH, 2001, J PEDIAT, V139, P678
NR 45
TC 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0957-5235
J9 BLOOD COAGULAT FIBRINOL
JI Blood Coagul. Fibrinolysis
PD JUN
PY 2010
VL 21
IS 4
BP 301
EP 307
DI 10.1097/MBC.0b013e3283333c7c
PG 7
SC Hematology
GA 599PO
UT ISI:000277925800001
ER

PT S
AU Watanabe, Y
   Buckingham, M
AF Watanabe, Yusuke
   Buckingham, Margaret
ED Beyar, R; Landesberg, A
TI The formation of the embryonic mouse heart Heart fields and myocardial
   cell lineages
SO ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE
SE Annals of the New York Academy of Sciences
LA English
DT Proceedings Paper
CT 6th Larry and Horti Fairberg Workshop on Analysis of Cardiac
   Development, From Embryo to Old Age
CY MAR 30-APR 01, 2009
CL Haifa, ISRAEL
SP Rambam Med Ctr
HO Tech-Israel Inst Technol
DE cardiogenesis; mouse embryos; second heart field; myocardial cell
   lineages
ID CARDIAC OUTFLOW TRACT; NEURAL CREST CELLS; FORKHEAD TRANSCRIPTION
   FACTORS; LEFT-RIGHT ASYMMETRY; ARTERIAL POLE; CARDIOVASCULAR
   DEVELOPMENT; VENTRICULAR MYOCARDIUM; SECONDARY HEART; PHARYNGEAL ARCH;
   SONIC HEDGEHOG
AB During cardiogenesis in the mouse, the second heart field (SHF) is the
   source of the myocardium of the outflow tract and it contributes to
   other regions of the heart with the exception of the primitive left
   ventricle. This contribution corresponds with that of the second
   myocardial cell lineage, identified by retrospective clonal analysis.
   Gene regulatory networks, signaling pathways, and heterogeneity within
   the SHF are discussed, together with the question of regulation of
   myocardial progenitor cells within the first heart field. The extension
   of the SHF into the mesodermal core of the arches also gives rise to
   endothelial cells of the pharyngeal arch arteries. Knowledge about the
   origin and genetic regulation of cells that contribute to the heart and
   associated vasculature is important for the diagnosis and treatment of
   congenital heart malformations.
C1 [Buckingham, Margaret] Inst Pasteur, CNRS, Dept Dev Biol, URA 2578, F-75015 Paris, France.
RP Buckingham, M, Inst Pasteur, CNRS, Dept Dev Biol, URA 2578, 25 Rue Dr
   Roux, F-75015 Paris, France.
EM margab@pasteur.fr
FU Pasteur Institute ; Centre National de la Recherche Scientifique ;
   European Union ; Integrated Project "Heart Repair" [LHSM-CT2005-018630]
FX We thank D. Rocancourt and S. Meilhac for help with illustrations.
   M.B.'s laboratory is supported by the Pasteur Institute, the Centre
   National de la Recherche Scientifique, and the European Union.
   Integrated Project "Heart Repair" (LHSM-CT2005-018630). Y.W. is a
   research fellow supported by the Heart Repair project.
CR ABUISSA R, 2002, DEVELOPMENT, V129, P4613
   BAJOLLE F, 2009, ARCH CARDIOVASC DIS, V102, P105, DOI
   10.1016/j.acvd.2008.04.010
   BUCKINGHAM M, 2005, NAT REV GENET, V6, P826, DOI 10.1038/nrg1710
   CAI CL, 2003, DEV CELL, V5, P877
   COHEN ED, 2008, DEVELOPMENT, V135, P789, DOI 10.1242/dev.016865
   DELACRUZ MV, 1977, J ANAT, V123, P661
   DELACRUZ MV, 1989, J ANAT, V165, P121
   DODOU E, 2004, DEVELOPMENT, V131, P3931, DOI 10.1242/dev.01256
   EPSTEIN JA, 2001, TRENDS GENET, V17, S13
   FRANK DU, 2002, DEVELOPMENT, V129, P4591
   GALLI D, 2008, DEVELOPMENT, V135, P1157, DOI 10.1242/dev.014563
   GARCIAMARTINEZ V, 1993, DEV BIOL, V159, P706
   GARG V, 2001, DEV BIOL, V235, P62
   GARRY DJ, 2006, CELL, V127, P1101, DOI 10.1016/j.cell.2006.11.031
   GODDEERIS MM, 2007, DEVELOPMENT, V134, P1593, DOI 10.1042/dev.02824
   HARVEY RP, 2002, NAT REV GENET, V3, P544
   HIGH FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279
   HU TH, 2004, DEVELOPMENT, V131, P5491
   HUYNH T, 2007, GENESIS, V45, P470, DOI 10.1002/dvg.20317
   JIANG XB, 2000, DEVELOPMENT, V127, P1607
   KAARTINEN V, 2004, DEVELOPMENT, V131, P3481, DOI 10.1242/dev.01214
   KATHIRIYA IS, 2000, AM J MED GENET, V97, P271
   KELLY RG, 2001, DEV CELL, V1, P435
   KIOUSSI C, 2002, CELL, V111, P673
   LIN LZ, 2006, DEV BIOL, V295, P756, DOI 10.1016/j.ydbio.2006.03.053
   LIU CY, 2001, DEVELOPMENT, V128, P2039
   LIU W, 2004, P NATL ACAD SCI USA, V101, P4489, DOI
   10.1073/pnas.0308466101
   LLOYDJONES D, 2009, CIRCULATION, V119, E21
   MCCULLEY DJ, 2008, DEV DYNAM, V237, P3200, DOI 10.1002/dvdy.21743
   MEILHAC SM, 2004, DEV CELL, V6, P685
   MEILHAC SM, 2004, J CELL BIOL, V164, P97
   MJAATVEDT CH, 2001, DEV BIOL, V238, P97
   MOORMAN AFM, 2003, PHYSIOL REV, V83, P1223, DOI
   10.1152/physrev.00006.2003
   OLSON EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292
   PARK EJ, 2006, DEVELOPMENT, V133, P2419, DOI 10.1242/dev.02367
   PARK EJ, 2008, DEVELOPMENT, V135, P3599, DOI 10.1242/dev.025437
   PRATT OW, 2007, CELL, V128, P947
   RYCKEBUSCH L, 2008, P NATL ACAD SCI USA, V105, P2913, DOI
   10.1073/pnas.0712344105
   SAGA Y, 2000, TRENDS CARDIOVAS MED, V10, P345
   SEO S, 2006, DEV BIOL, V296, P421, DOI 10.1016/j.ydbio.2006.06.012
   STOTTMANN RW, 2004, DEVELOPMENT, V131, P2205, DOI 10.1242/dev.01086
   TAKEUCHI JK, 2009, NATURE, V459, P708, DOI 10.1038/nature08039
   TZAHOR E, 2007, DEV CELL, V13, P10, DOI 10.1016/j.devcel.2007.06.006
   VANWIJK B, 2007, CARDIOVASC RES, V74, P244, DOI
   10.1016/j.cardiores.2006.11.022
   WALDO KL, 2001, DEVELOPMENT, V128, P3179
   WALDO KL, 2005, DEV BIOL, V281, P78, DOI 10.1016/j.ydbio.2005.02.012
   WEINTRAUB H, 1991, SCIENCE, V251, P761
   WU SM, 2008, CELL STEM CELL, V3, P1, DOI 10.1016/j.stem.2008.06.017
   YUTZEY KE, 1994, DEVELOPMENT, V120, P871
   ZAFFRAN S, 2004, CIRC RES, V95, P261, DOI
   10.1161/01.RES.0000136815.73623.BE
   ZAFFRAN S, 2005, BIOCHEM BIOPH RES CO, V334, P361, DOI
   10.1016/j.bbrc.2005.06.090
   ZHANG J, 2008, DEVELOPMENT, V135, P3611, DOI 10.1242/dev.025361
   ZHOU WL, 2007, NAT GENET, V39, P1225, DOI 10.1038/ng2112
NR 53
TC 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND
SN 0077-8923
BN 978-1-57331-747-4
J9 ANN N Y ACAD SCI
JI Ann.NY Acad.Sci.
PY 2010
VL 1188
BP 15
EP 24
DI 10.1111/j.1749-6632.2009.05078.x
PG 10
SC Multidisciplinary Sciences
GA BOV10
UT ISI:000277731600003
ER

PT J
AU Payne, JL
   Turchyn, AV
   Paytan, A
   DePaolo, DJ
   Lehrmann, DJ
   Yu, MY
   Wei, JY
AF Payne, Jonathan L.
   Turchyn, Alexandra V.
   Paytan, Adina
   DePaolo, Donald J.
   Lehrmann, Daniel J.
   Yu, Meiyi
   Wei, Jiayong
TI Calcium isotope constraints on the end-Permian mass extinction
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID EARLIEST TRIASSIC MICROBIALITES; MARINE CARBONATE PLATFORMS;
   PHOTIC-ZONE EUXINIA; SOUTH CHINA; NANPANJIANG BASIN; GREAT BANK;
   GUIZHOU PROVINCE; METHANE RELEASE; CA ISOTOPES; BOUNDARY
AB The end-Permian mass extinction horizon is marked by an abrupt shift in
   style of carbonate sedimentation and a negative excursion in the carbon
   isotope (delta C-13) composition of carbonate minerals. Several
   extinction scenarios consistent with these observations have been put
   forward. Secular variation in the calcium isotope (delta(44)/Ca-40)
   composition of marine sediments provides a tool for distinguishing
   among these possibilities and thereby constraining the causes of mass
   extinction. Here we report delta(44)/Ca-40 across the Permian-Triassic
   boundary from marine limestone in south China. The delta(44)/Ca-40
   exhibits a transient negative excursion of similar to 0.3 parts per
   thousand over a few hundred thousand years or less, which we interpret
   to reflect a change in the global delta(44)/Ca-40 composition of
   seawater. CO2-driven ocean acidification best explains the coincidence
   of the delta(44)/Ca-40 excursion with negative excursions in the delta
   C-13 of carbonates and organic matter and the preferential extinction
   of heavily calcified marine animals. Calcium isotope constraints on
   carbon cycle calculations suggest that the average delta C-13 of CO2
   released was heavier than -28 parts per thousand and more likely near
   -15 parts per thousand; these values indicate a source containing
   substantial amounts of mantle- or carbonate-derived carbon.
   Collectively, the results point toward Siberian Trap volcanism as the
   trigger of mass extinction.
C1 [Payne, Jonathan L.] Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA.
   [Turchyn, Alexandra V.] Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England.
   [Paytan, Adina] Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA.
   [DePaolo, Donald J.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.
   [Lehrmann, Daniel J.] Univ Wisconsin, Dept Geol, Oshkosh, WI 54901 USA.
   [Yu, Meiyi] Guizhou Univ, Coll Resource & Environm Engn, Guiyang 550003, Guizhou Prov, Peoples R China.
   [Wei, Jiayong] Guizhou Geol Survey, Guiyang 550005, Guizhou Prov, Peoples R China.
RP Payne, JL, Stanford Univ, Dept Geol & Environm Sci, 450 Serra Mall,Bldg
   320, Stanford, CA 94305 USA.
EM jlpayne@stanford.edu
FU Miller Institute for Basic Research ; Canadian Institute for Advanced
   Research ; American Chemical Society [45329-G8, 40948]; National
   Geographic Society [8102-06]; National Science Foundation
   [EAR-0807377]; National Aeronautics and Space Administration
   [NNX09AN67G]
FX We thank S. Brown, T. Owens, and A. Jost for assistance with analyses.
   This study was supported by the Miller Institute for Basic Research and
   the Canadian Institute for Advanced Research (fellowships to A. V. T.),
   the Petroleum Research Fund of the American Chemical Society [Grant
   45329-G8 (to J.L.P.); Grant 40948 (to D.J.L.), the National Geographic
   Society [Grant 8102-06 (to J.L.P.)], the National Science Foundation
   [CAREER Award (to A. P.); Grant EAR-0807377 (to J.L.P.)], and National
   Aeronautics and Space Administration [Grant NNX09AN67G (to J.L.P.)].
CR ARCHER D, 1997, GEOPHYS RES LETT, V24, P405
   BAUD A, 1989, GEOL RUNDSCH, V78, P649
   BAUD A, 1997, FACIES, V36, P238
   BAUD A, 2005, CR PALEVOL, V4, P569, DOI 10.1016/j.crpv.2005.03.001
   BERNER RA, 2002, P NATL ACAD SCI USA, V99, P4172
   BOWRING SA, 1998, SCIENCE, V280, P1039
   BURTON EA, 1987, GEOLOGY, V15, P111
   CALDEIRA K, 2005, J GEOPHYS RES-OCEANS, V110, ARTN C09S04
   CHEN J, 2009, J ASIAN EARTH SCI, V36, P442, DOI
   10.1016/j.jseaes.2008.08.002
   CORSETTI FA, 2005, CR PALEVOL, V4, P405
   DELAROCHA CL, 2000, SCIENCE, V289, P1176
   DEPAOLO DJ, 2004, REV MINERAL GEOCHEM, V55, P255
   ENOS P, 2006, GEOLOGICAL SOC AM SP, V417
   ERWIN DH, 1993, GREAT PALEOZOIC CRIS
   EZAKI Y, 2008, PALAIOS, V23, P356, DOI 10.2110/palo.2007.p07-035r
   FANTLE MS, 2005, EARTH PLANET SC LETT, V237, P102, DOI
   10.1016/j.epsl.2005.06.024
   FANTLE MS, 2007, GEOCHIM COSMOCHIM AC, V71, P2524, DOI
   10.1016/j.gca.2007.03.006
   FARKAS J, 2007, GEOCHIM COSMOCHIM AC, V71, P5117
   GRICE K, 2005, SCIENCE, V307, P706, DOI 10.1126/science.1104323
   GRIFFITH EM, 2008, P AM GEOPH UN ANN M
   GROTZINGER JP, 1995, PALAIOS, V10, P578
   GUSSONE N, 2005, GEOCHIM COSMOCHIM AC, V69, P4485, DOI
   10.1016/j.gca.2005.06.003
   HEYDARI E, 2003, SEDIMENT GEOL, V163, P147, DOI
   10.1016/j.sedgeo.2003.08.002
   HEYDARI E, 2008, PALAEOGEOGR PALAEOCL, V264, P147, DOI
   10.1016/j.palaeo.2008.04.013
   HOLMDEN C, 2009, CHEM GEOL, V268, P180, DOI
   10.1016/j.chemgeo.2009.08.009
   HOLSER WT, 1989, NATURE, V337, P39
   HOTINSKI RM, 2001, GEOLOGY, V29, P7
   ISOZAKI Y, 1997, SCIENCE, V276, P235
   KERSHAW S, 1999, PALAEOGEOGR PALAEOCL, V146, P1
   KERSHAW S, 2002, FACIES, V47, P83
   KERSHAW S, 2007, FACIES, V53, P409, DOI 10.1007/s10347-007-0105-5
   KIESSLING W, 2008, NAT GEOSCI, V1, P527, DOI 10.1038/ngeo251
   KNOLL AH, 1996, SCIENCE, V273, P452
   KNOLL AH, 2007, EARTH PLANET SC LETT, V256, P295, DOI
   10.1016/j.epsl.2007.02.018
   KORTE C, 2004, INT J EARTH SCI, V93, P565, DOI 10.1007/s00531-004-0406-7
   KRULL ES, 2000, GEOL SOC AM BULL, V112, P1459
   KRULL ES, 2004, PALAEOGEOGR PALAEOCL, V204, P297, DOI
   10.1016/S0031-0182(03)00732-6
   KUMP LR, 2005, GEOLOGY, V33, P397, DOI 10.1130/G21295.1
   LEHRMANN DJ, 1998, J SEDIMENT RES B, V68, P311
   LEHRMANN DJ, 1999, GEOLOGY, V27, P359
   LEHRMANN DJ, 2001, PALAEOGEOGR PALAEOCL, V173, P103
   LEHRMANN DJ, 2003, PALAIOS, V18, P138
   LEHRMANN DJ, 2007, AAPG BULL, V91, P287, DOI 10.1306/10160606065
   LEMARCHAND D, 2004, GEOCHIM COSMOCHIM AC, V68, P4665, DOI
   10.1016/j.gca.2004.05.029
   MARZIANO GI, 2008, CONTRIB MINERAL PETR, V155, P719, DOI
   10.1007/s00410-007-0267-8
   MEYER KM, 2008, GEOLOGY, V36, P747, DOI 10.1130/G24618A.1
   MUNDIL R, 2004, SCIENCE, V305, P1760
   MUSASHI M, 2001, EARTH PLANET SC LETT, V191, P9
   NIELSEN JK, 2004, GEOLOGY, V32, P1037, DOI 10.1130/G20987.1
   OPDYKE BN, 1993, AM J SCI, V293, P217
   PAYNE JL, 2004, SCIENCE, V305, P506
   PAYNE JL, 2006, PALAIOS, V21, P63, DOI 10.2110/palo.2005.p05-12p
   PAYNE JL, 2007, GEOL SOC AM BULL, V119, P771, DOI 10.1130/B26091.1
   RAMPINO MR, 2005, TERRA NOVA, V17, P554, DOI
   10.1111/j.1365-3121.2005.00648.x
   REICHOW MK, 2009, EARTH PLANET SC LETT, V277, P9, DOI
   10.1016/j.epsl.2008.09.030
   RETALLACK GJ, 1999, GEOL SOC AM BULL, V111, P52
   RETALLACK GJ, 2008, J GEOL, V116, P1, DOI 10.1086/524120
   SANO H, 1997, FACIES, V36, P1
   SELF S, 2005, ELEMENTS, V1, P283
   SVENSEN H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566
   SVENSEN H, 2009, EARTH PLANET SC LETT, V277, P490, DOI
   10.1016/j.epsl.2008.11.015
   TANG JW, 2008, GEOCHIM COSMOCHIM AC, V72, P3733, DOI
   10.1016/j.gca.2008.05.033
   THOMAS E, 1996, GEOLOGICAL SOC LONDO, V101, P401
   WALKER LJ, 2002, J GEOL, V110, P75
   WIGNALL PB, 2002, GEOLOGICAL SOC AM SP, V356, P395
   ZACHOS JC, 2005, SCIENCE, V308, P1611, DOI 10.1126/science.1109004
   ZHANG R, 2001, PALEOCEANOGRAPHY, V16, P317
   ZHU P, 1998, GEOCHIM COSMOCHIM AC, V62, P1691
NR 68
TC 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 PROC NAT ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 11
PY 2010
VL 107
IS 19
BP 8543
EP 8548
DI 10.1073/pnas.0914065107
PG 6
SC Multidisciplinary Sciences
GA 595DP
UT ISI:000277591200012
ER

PT J
AU Zhong, BL
   Chen, HH
   Zhang, JF
   Xu, HM
   Zhou, C
   Yang, F
   Song, J
   Tang, J
   Xu, Y
   Zhang, S
   Zhang, Y
   Zhou, L
AF Zhong, Bao-liang
   Chen, Hong-hui
   Zhang, Jian-fang
   Xu, Han-ming
   Zhou, Cong
   Yang, Fan
   Song, Jin
   Tang, Jun
   Xu, Yang
   Zhang, Sheng
   Zhang, Yan
   Zhou, Lei
TI Prevalence, correlates and recognition of depression among inpatients
   of general hospitals in Wuhan, China
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Depression; Prevalence; Correlates; Recognition; Inpatients
ID OLDER MEDICAL INPATIENTS; CORONARY-ARTERY-DISEASE; MAJOR DEPRESSION;
   EPIDEMIOLOGIC SURVEY; MINOR DEPRESSION; DISORDERS; COMORBIDITY;
   DISABILITY; MORTALITY; ANXIETY
AB Objective: To determine the prevalence, correlates and recognition of
   depression among inpatients of general hospitals in Wuhan, China.
   Method: A total of 513 patients were randomly selected from 1923
   inpatients from three general hospitals and evaluated with a Chinese
   version of the Structured Clinical Interview for Diagnostic and
   Statistical Manual-IV Axis 1 disorders by eight psychiatrists. Logistic
   regression was used to identify factors that were associated with
   depression.
   Results: The prevalence (95% confidence interval) of all current
   depressive disorders and major depressive disorder (MDD) was found to
   be 16.2% (13.0-19.4%) and 9.4% (6.8-11.9%), respectively. The
   correlates for depression include higher hospital class, divorce/being
   widowed/separation, low family income, chronic diseases, lack of
   medical insurance, dwelling in rural area, suffering from severe
   illness and multiple hospitalization history. None of the patients with
   current MDD were detected, treated or referred to psychiatric
   consultation.
   Conclusions: The prevalence of depression among inpatients of general
   hospitals in Wuhan, China, was high. None of the depressive patients
   were recognized or treated for depression, indicating a serious neglect
   of depression in general hospitals. Our studies suggest an urgent need
   to improve clinicians' ability to detect and treat depression. Crown
   Copyright (C) 2010 Published by Elsevier Inc. All rights reserved.
C1 [Zhong, Bao-liang; Chen, Hong-hui; Zhang, Jian-fang; Xu, Han-ming; Zhou, Cong; Yang, Fan; Song, Jin; Tang, Jun; Xu, Yang; Zhang, Sheng; Zhang, Yan; Zhou, Lei] Huazhong Univ Sci & Technol, Affiliated Mental Hlth Ctr, Tongji Med Coll, Wuhan Mental Hlth Ctr, Wuhan 430074, Hubei, Peoples R China.
RP Chen, HH, Huazhong Univ Sci & Technol, Affiliated Mental Hlth Ctr,
   Tongji Med Coll, Wuhan Mental Hlth Ctr, Wuhan 430074, Hubei, Peoples R
   China.
EM c_honghui@hotmail.com
FU National Natural Science Foundation of China [30770754]; Affiliated
   Mental Health Center of Tongji Medical College of the Huazhong
   University of Science and Technology 
FX Role of funding source: This study was supported by grants from
   National Natural Science Foundation of China (Grant Number 30770754)
   and the Affiliated Mental Health Center of Tongji Medical College of
   the Huazhong University of Science and Technology.
CR ANDRADE L, 2003, INT J METH PSYCH RES, V12, P3
   AROLT V, 1998, J PSYCHOSOM RES, V45, P117
   BAREFOOT JC, 1996, AM J CARDIOL, V78, P613
   BARRETT J, 1987, J AFFECT DISORDERS, V12, P167
   BEMD L, 2008, GEN HOSP PSYCHIAT, V30, P191
   COLE MG, 2006, AM J GERIAT PSYCHIAT, V14, P966
   CUI LJ, 2007, CHINESE J PSYCIAT, V40, P140
   DESU MM, 1990, SAMPLE SIZE METHODOL
   EGEDE LE, 2007, GEN HOSP PSYCHIAT, V29, P409, DOI
   10.1016/j.genhosppsych.2007.06.002
   FILIPCIC I, 2007, COLLEGIUM ANTROPOL, V31, P139
   FIRST M, 2002, STRUCTURED CLIN INTE
   FU CW, 2006, ZHONGHUA LIU XING BI, V27, P803
   GE H, 2008, ZHONGHUA WAI KE ZA Z, V46, P362
   GHOREISHIZADEH M, 2008, RES J BIOL SCI, V3, P1018
   GLASSMAN AH, 1998, AM J PSYCHIAT, V155, P4
   HAN Y, 2008, CHIN MENT HLTH J, V22, P874
   HOSAKA T, 1999, PSYCHIAT CLIN NEUROS, V53, P491
   HUANG Y, 2008, 2008 C CHIN PSYCH AS, P8
   KELLER MB, 2003, JAMA-J AM MED ASSOC, V289, P3152
   KESSLER RC, 2003, JAMA-J AM MED ASSOC, V289, P3095
   LEE S, 2007, J AFFECT DISORDERS, V98, P129, DOI
   10.1016/j.jad.2006.07.009
   LI H, 2003, ZHEJIANG DA XUE XUE, V32, P77
   LI H, 2003, ZHEJIANG DA XUE XUE, V32, P83
   LU L, 1998, CHINESE J PSYCHIAT, V31, P234
   MA X, 2007, CHIN J PSYCHIAT, V40, P100
   MARTIN GC, 2007, GEN HOSP PSYCHIAT, V29, P425
   MARTUCCI M, 1999, PSYCHOL MED, V29, P823
   MCCUSKER J, 2005, J AM GERIATR SOC, V53, P1344, DOI
   10.1111/j.1532-5415.2005.53404.x
   MCCUSKER J, 2006, J GERONTOL A-BIOL, V61, P975
   MCCUSKER J, 2007, GEN HOSP PSYCHIAT, V29, P340, DOI
   10.1016/j.genhosppsych.2007.03.007
   MHAIDAT NM, 2009, SUPPORT CARE CANCER, V17, P1403, DOI
   10.1007/s00520-009-0600-z
   MORTEN SH, 2001, J PSYCHOSOM RES, V50, P199
   NEJATISAFA AA, 2008, EUR PSYCHIAT S2, V23, S278
   PAKRIEV S, 2009, NORD J PSYCHIAT, V63, P1
   PHILLIPS MR, 2004, CHIN J NEUR PSYCHIAT, V30, P1
   PHILLIPS MR, 2009, LANCET, V373, P2041
   RENTSCH D, 2007, GEN HOSP PSYCHIAT, V29, P25, DOI
   10.1016/j.genhosppsych.2006.08.008
   RUNKEWITZ K, 2006, J PSYCHOSOM RES, V60, P445, DOI
   10.1016/j.jpsychores.2005.09.003
   RUTTLEY A, 2006, PSYCHIATRY, V5, P89
   SCOTT BP, 2005, JCE, V58, P184
   SHI S, 2000, NATL MED J CHINA, P75
   SINGLEE GDC, 1998, SHANGHAI ARCH PSYCHI, V10, P1
   TANAJURA D, 2002, BRAZIL REV BRAS PSIQ, V24, P182
   VAEROY H, 2003, NORD J PSYCHIAT, V57, P13
   WANG HI, 2005, CHIN J BEHAV MED SCI, V114, P955
   WANG Z, 2006, CHIN MENT HLTH J, V20, P176
   WEYERER S, 2008, J AFFECT DISORDERS, V111, P153, DOI
   10.1016/j.jad.2008.02.008
   WILHELM K, 2003, J AFFECT DISORDERS, V75, P155, DOI
   10.1016/S0165-0327(02)00040-X
   WITTCHEN HU, 2001, INT CLIN PSYCHOPHARM, V16, P121
   YANG LL, 1987, AM J PSYCHIAT, V144, P226
   ZHANG J, 2007, CAN J PLANT SCI, V87, P93
   ZHOU RY, 1997, CHIN J PSYCHIAT, V30, P45
NR 52
TC 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2010
VL 32
IS 3
BP 268
EP 275
DI 10.1016/j.genhosppsych.2010.01.016
PG 8
SC Psychiatry
GA 594HT
UT ISI:000277527900006
ER

PT J
AU Ku, HL
   Yang, KC
   Lee, YC
   Lee, MB
   Chou, YH
AF Ku, Hsiao-Lun
   Yang, Kai-Chun
   Lee, Ying-Chiao
   Lee, Ming-Been
   Chou, Yuan-Hwa
TI Predictors of carbon monoxide poisoning-induced delayed
   neuropsychological sequelae
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Carbon monoxide; Predictors; Poisoning; Neuropsychological sequelae
ID HYPERBARIC-OXYGEN THERAPY; TERM MORTALITY; RISK-FACTORS; INTOXICATION;
   ENCEPHALOPATHY
AB Objective: Carbon monoxide poisoning (COP) commonly results in delayed
   neuropsychological sequelae (DNS). The aim of the article is to
   demonstrate the clinical characteristics and potential predictors of
   COP-induced DNS later.
   Method: Retrospective medical record review was performed for patients
   who had COP in the past year at a National Medical Center in Taiwan.
   Sixty patients with COP were registered during a one-year period.
   Filly-six of them (93.3%) were COP because of suicide attempt. Patients
   with COP who have a complete medical record of carboxyhemoglobin (COHb)
   and Glasgow Coma Scale (GCS) and Mini-Mental Status Examination (MMSE)
   scores were recruited. Multiple regression analysis was performed to
   search for the predictive factors of DNS.
   Results: Forty-three patients were recruited. Most had attempted
   suicide (93.0%) using CO, and thirteen developed DNS later. A longer
   duration of admission, more sessions of hyperbaric oxygen therapy, and
   positive findings in brain computed tomography (CT) scans were more
   often found in patients with DNS than those without DNS. The GCS and
   MMSE scores and positive findings in brain CT scans were associated
   with the development of DNS but COHb was not.
   Conclusions: Our results identified several potential predictors of
   DNS. This finding may help clinicians understand and treat COP patients
   efficiently. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Ku, Hsiao-Lun; Lee, Ying-Chiao; Chou, Yuan-Hwa] Natl Yang Ming Univ, Dept Psychiat, Taipei Vet Gen Hosp, Taipei 112, Taiwan.
   [Ku, Hsiao-Lun; Lee, Ying-Chiao; Chou, Yuan-Hwa] Natl Yang Ming Univ, Taipei 112, Taiwan.
   [Yang, Kai-Chun] Yuanshan Vet Hosp, Dept Psychiat, Yilan 264, Taiwan.
   [Lee, Ming-Been] Taiwan Suicide Prevent Ctr, Dept Hlth, Executive Yuan 100, Taiwan.
   [Lee, Ming-Been] Natl Taiwan Univ & Hosp, Dept Psychiat, Coll Med, Taipei 100, Taiwan.
   [Chou, Yuan-Hwa] Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan.
RP Chou, YH, Natl Yang Ming Univ, Dept Psychiat, Taipei Vet Gen Hosp,
   Taipei 112, Taiwan.
EM c520608@ms64.hinet.net
FU National Science Council, Taiwan [NSC 97-2314-B-075-004]; Taipei
   Veterans General Hospital [97DHA0100009]
FX This project was supported by the National Science Council, Taiwan (NSC
   97-2314-B-075-004) and the Taipei Veterans General Hospital
   (97DHA0100009).
CR BUCKLEY NA, 2005, TOXICOL REV, V24, P75
   CEVIK AA, 2006, INT J CLIN PRACT, V60, P1558, DOI
   10.1111/j.1742-1241.2006.00962.x
   CHANG KH, 1992, RADIOLOGY, V184, P117
   CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433
   CHOI IS, 1993, J KOREAN MED SCI, V8, P78
   CHOI IS, 1999, EUR NEUROL, V42, P141
   DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9
   ERNST A, 1998, NEW ENGL J MED, V339, P1603
   GORMAN D, 2003, TOXICOLOGY, V187, P25, DOI 10.1016/S0300-483X(03)00005-2
   HAMPSON NB, 2008, CRIT CARE MED, V36, P2523, DOI
   10.1097/CCM.0b013e31818419d8
   HAMPSON NB, 2009, CRIT CARE MED, V37, P1941, DOI
   10.1097/CCM.0b013e3181a0064f
   HAY PJ, 2002, J PSYCHOSOM RES, V53, P699
   HSU LH, 1996, CHUNG HUA HSUEH TSA, V58, P407
   HURLEY RA, 2001, J NEUROPSYCH CLIN N, V13, P157
   JONES JS, 1994, AM J EMERG MED, V12, P448
   JUURLINK DN, 2005, COCHRANE DB SYST REV, V1, UNSP CD002041
   KALES SN, 1993, AM FAM PHYSICIAN, V48, P1100
   KAO CH, 1998, J NUCL MED, V39, P769
   LIMA CX, 2008, ACTA CIR BRAS, V23, P315
   LO CP, 2007, EUR J NEUROL, V14, P777, DOI
   10.1111/j.1468-1331.2007.01854.x
   MIN SK, 1986, ACTA PSYCHIAT SCAND, V73, P80
   MYERS RAM, 1989, CRIT CARE MED, V17, P139
   NORKOOL DM, 1985, ANN EMERG MED, V14, P1168
   PRACYK JB, 1995, UNDERSEA HYPERBAR M, V22, P1
   PROCKOP LD, 1999, J NEUROIMAGING, V9, P175
   ROPPER AH, 2005, ADAMS VICTORS PRINCI
   SATRAN D, 2005, J AM COLL CARDIOL, V45, P1513, DOI
   10.1016/j.jacc.2005.01.044
   STOLLER KP, 2007, NEUROL RES, V29, P146, DOI 10.1179/016164107X181770
   THOM SR, 1995, ANN EMERG MED, V25, P474
   VARON J, 1999, J EMERG MED, V17, P87
   VILA JF, 2005, UNDERSEA HYPERBAR M, V32, P151
   WEAVER LK, 1996, ANN EMERG MED, V27, P736
   WEAVER LK, 1999, CRIT CARE CLIN, V15, P297
   WEAVER LK, 2002, NEW ENGL J MED, V347, P1057
   WEAVER LK, 2007, AM J RESP CRIT CARE, V176, P491, DOI
   10.1164/rccm.200701-026OC
   WEAVER LK, 2009, NEW ENGL J MED, V360, P1217
NR 36
TC 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2010
VL 32
IS 3
BP 310
EP 314
DI 10.1016/j.genhosppsych.2009.11.005
PG 5
SC Psychiatry
GA 594HT
UT ISI:000277527900011
ER

PT J
AU Wu, RQ
   Li, ZX
   Yang, JP
   Xing, XH
   Shao, DY
   Xing, KL
AF Wu, Rui-Qin
   Li, Zhi-Xi
   Yang, Jia-Ping
   Xing, Xiao-Hui
   Shao, Dong-Yan
   Xing, Kang-Lin
TI Mutagenesis induced by high hydrostatic pressure treatment: a useful
   method to improve the bacterial cellulose yield of a Gluconoacetobacter
   xylinus strain
SO CELLULOSE
LA English
DT Article
DE Gluconoacetobacter xylinus; High hydrostatic pressure; Mutagenesis;
   Bacterial cellulose
ID ACETOBACTER-XYLINUM; LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; MUTANTS;
   GROWTH; ENZYME; TEMPERATURE; BLOOD; MILK
AB Bacterial cellulose (BC) is a new biomaterial which has wide
   application potential in various industries. BC industrialization
   requires bacterial strains with high BC productivity. The objective of
   this study is to increase the BC yield of a Gluconoacetobacter xylinus
   strain through mutagenesis induced by high hydrostatic pressure (HHP)
   treatment. In this study, the parental strain in its exponential phase
   was treated at 250 MPa and 25 degrees C for 15 min to induce
   mutagenesis using a HHP machine. The HHP-treated strains were incubated
   in glucose agar plate at 30 degrees C for 4 days. After the incubation,
   50 larger colonies in these plates were randomly selected and
   cultivated to produce BC membrane in a tailor-made glass vessel, and
   wet weights of the BC membranes were tested. Compared with the parental
   strain, 29 mutants showed higher BC yields, of which eight mutants with
   BC yield >130.00 g/L were initially screened and were then cultivated
   for five generations to test their genetic stabilities for BC
   production. Among the eight mutants, M-438, a mutant which showed the
   highest average BC yield (158.56 g/L) and lowest coefficient of
   variation (2.4%) for five generations, was finally screened as
   objective mutant. HHP treatment can serve as an effective method to
   cause mutagenesis in BC-producing bacteria. The HHP-treated strains
   with significantly higher BC yield than parental strain can be screened
   from the HHP-induced mutants.
C1 [Wu, Rui-Qin; Li, Zhi-Xi; Yang, Jia-Ping; Xing, Xiao-Hui; Shao, Dong-Yan] NW A&F Univ, Coll Food Sci & Engn, Yangling 712100, Shaanxi, Peoples R China.
   [Xing, Kang-Lin] Henan Univ Technol, Coll Mech & Elect Engn, Zhengzhou 450000, Henan, Peoples R China.
RP Li, ZX, NW A&F Univ, Coll Food Sci & Engn, Yangling 712100, Shaanxi,
   Peoples R China.
EM lzx580721@yahoo.com.cn
FU Provincial Key Project for Science and Technology Development, Shaanxi,
   China [2005K03-G03]
FX This research was financially supported by the Provincial Key Project
   for Science and Technology Development (grant number: 2005K03-G03),
   Shaanxi, China. The technical support of Dr. Xuchang Duan, associate
   professor of the College of Food Science and Engineering, Northwest A&F
   University, is also gratefully acknowledged.
CR ALONI Y, 1983, J BIOL CHEM, V258, P4419
   ANICUTA SG, 2007, NUCL INSTRUM METH B, V265, P434
   BENZIMAN M, 1972, J BACTERIOL, V111, P325
   BUDHIONO A, 1999, CARBOHYD POLYM, V40, P37
   CHE LM, 2006, FOOD TECHNOL, V27, P109
   DEWULF P, 1996, J CHEM TECHNOL BIOT, V67, P376
   GAO X, 2001, ACTA BIOCH BIOPH SIN, V33, P77
   GERVILLA R, 1997, J FOOD PROTECT, V60, P33
   GROMET Z, 1957, BIOCHEM J, V67, P679
   GUO YX, 2009, FOOD CHEM, V114, P328, DOI 10.1016/j.foodchem.2008.09.041
   HAYMAN MM, 2007, INT J FOOD MICROBIOL, V115, P220, DOI
   10.1016/j.ijfoodmicro.2006.10.019
   HOFHERR LA, 1983, J DAIRY SCI, V66, P2482
   HONG F, 2008, CARBOHYD POLYM, V72, P545, DOI
   10.1016/j.carbpol.2007.09.015
   JONAS R, 1998, POLYM DEGRAD STABIL, V59, P101
   KESHK S, 2006, ENZYME MICROB TECH, V40, P4, DOI
   10.1016/j.enzmictec.2006.07.037
   KLEMM D, 2001, PROG POLYM SCI, V26, P1561
   LAURO FM, 2008, J BACTERIOL, V190, P1699, DOI 10.1128/JB.01176-07
   LIU FZ, 2008, LIQUOR MAKING SCI TE, V3, P51
   MILES AA, 1938, J HYG-CAMBRIDGE, V38, P732
   NGUYEN VT, 2008, FOOD MICROBIOL, V25, P471, DOI 10.1016/j.fm.2008.01.004
   ODONOVAN GA, 1965, J BACTERIOL, V90, P611
   REYES DS, 2009, INNOV FOOD SCI EMERG, V10, P135
   ROSS P, 1987, NATURE, V325, P279
   VALLA S, 1989, MOL GEN GENET, V217, P26
   VANDAMME EJ, 1998, POLYM DEGRAD STABIL, V59, P93
   VEZZI A, 2005, SCIENCE, V307, P1459, DOI 10.1126/science.1103341
   WANG SL, 2006, IND MICROBIOL, V36, P31
   WANG X, 2008, T ASABE, V51, P55
   WU RQ, 2008, CHIN J BIOTECHNOL, V24, P1068
   WU RQ, 2008, CHINA BREW, V10, P37
   YU XB, 1999, J CELLUL SCI TECHNOL, V7, P63
NR 31
TC 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-0239
J9 CELLULOSE
JI Cellulose
PD APR
PY 2010
VL 17
IS 2
BP 399
EP 405
DI 10.1007/s10570-009-9388-8
PG 7
SC Materials Science, Paper & Wood; Materials Science, Textiles; Polymer
   Science
GA 595TT
UT ISI:000277636800017
ER

PT J
AU Su, W
   Sun, AJ
   Xu, DL
   Zhang, HQ
   Yang, L
   Yuan, LY
   Jia, JG
   Zou, YZ
   Wu, YL
   Wang, KQ
   Ge, JB
AF Su, Wei
   Sun, Ai-jun
   Xu, Dan-ling
   Zhang, Hong-qi
   Yang, Lin
   Yuan, Ling-yan
   Jia, Jian-guo
   Zou, Yun-zeng
   Wu, Yi-ling
   Wang, Ke-qiang
   Ge, Jun-bo
TI Inhibiting effects of total saponins of panax ginseng on immune
   maturation of dendritic cells induced by oxidized-low density
   lipoprotein
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Dendritic cells; Oxidized-LDL; Atherosclerosis; TSPG
ID PPAR-GAMMA; LYMPHOID-TISSUE; ACTIVATION; MONOCYTE; RECEPTOR; LDL
AB Total saponins of panax ginseng (TSPG) are the major active components
   in panax ginseng. Dendritic cells (DCs) play an active role in the
   immunological processes related to atherosclerosis. The purpose of this
   study was to determine the effect and possible mechanisms of TSPG on
   the maturation and immune function of DCs. Compared with those
   untreated, the DCs pre-treated with TSPG and then induced by
   oxidized-LDL exhibited a significantly lower expression of the
   maturation-associated markers of CD40, CD86, HLA-DR, and CD1a, together
   with an increased endocytosic function as well as decreased secretions
   of cytokine. However, silencing the expression of PPAR gamma in DCs,
   the inhibitory effect of TSPG on the maturation DCs was significantly
   reduced. In conclusion, TSPG could inhibit the maturation of DCs
   induced by oxidized-LDL which suggests beneficial effects on
   atherosclerosis and this effect was partly dependent on the PPAR gamma
   pathway at least. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Su, Wei; Sun, Ai-jun; Yang, Lin; Yuan, Ling-yan; Jia, Jian-guo; Zou, Yun-zeng; Wang, Ke-qiang; Ge, Jun-bo] Fudan Univ, Zhongshan Hosp, Inst Cardiovasc Dis, Shanghai 200032, Peoples R China.
   [Su, Wei] Xinxiang Med Univ, Dept Pathol, Xinxiang 453003, Henan Province, Peoples R China.
   [Xu, Dan-ling] Tongji Univ, Coll Med, Dept Anat, Shanghai 200092, Peoples R China.
   [Zhang, Hong-qi] Fudan Univ, Shanghai Med Coll, Dept Anat Histol & Embryol, Shanghai 200032, Peoples R China.
   [Wu, Yi-ling] Integrat Tradit & Western Med Res Acad Hebei Prov, Shijiazhuang 050035, Peoples R China.
RP Ge, JB, Fudan Univ, Zhongshan Hosp, Inst Cardiovasc Dis, 180 Fenglin
   Rd, Shanghai 200032, Peoples R China.
EM jbge@zs-hospital.sh.cn
FU National Basic Research Program of China [2006CB503803, 2005CB523302];
   Science and Technology Ministry [2006AA0ZA406]; National Natural
   Science Foundation of China [30725036]; Key Projects in the National
   Science 82 Technology Pillar Program in the Eleventh Five-year Plan
   Period [2006BAI 01A 04]
FX The authors thank Dr. Kai. Hu from University of Wurzburg, Germany, for
   his assistance in data analysis and article language. This study was
   funded by National Basic Research Program of China (2006CB503803 &
   2005CB523302), 863 Program of Science and Technology Ministry
   (2006AA0ZA406), Outstanding Youth Grant from National Natural Science
   Foundation of China (30725036) and Key Projects in the National Science
   82 Technology Pillar Program in the Eleventh Five-year Plan Period
   (2006BAI 01A 04).
CR ALDERMAN CJJ, 2002, CARDIOVASC RES, V55, P806
   BANCHEREAU J, 1998, NATURE, V392, P245
   BERNADETTE P, 2000, BIOCHEM PHARMACOL, V60, P1245
   BOBRYSHEV YV, 1995, ARCH HISTOL CYTOL, V58, P307
   BOBRYSHEV YV, 1998, CARDIOVASC RES, V37, P799
   DEJONG EC, 2005, SPRINGER SEMIN IMMUN, V26, P289, DOI
   10.1007/s00281-004-0167-1
   GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586
   HEATH WR, 2004, IMMUNOL REV, V199, P9
   HIRAI A, 1999, P 99 KOR JAP GINS S, P16
   JIANG CY, 1998, NATURE, V391, P82
   LANGENKAMP A, 2000, NAT IMMUNOL, V1, P311
   LIPSCOMB MF, 2002, PHYSIOL REV, V82, P97
   LOTZE MT, 2001, DENDRITIC CELLS BIOL
   LUO YK, 2004, J CARDIOVASC PHARM, V44, P381
   MOREL PA, 2003, CLIN EXP IMMUNOL, V133, P1
   NAGY L, 1998, CELL, V93, P229
   NAH JJ, 2000, NEUROPHARMACOLOGY, V39, P2180
   NAH SY, 1994, J ETHNOPHARMACOL, V42, P45
   NAH SY, 1997, KOREAN J GINSENG SCI, V21, P1
   PARK JD, 2005, PHYTOCHEM REV, V4, P159
   PASARE C, 2004, IMMUNITY, V21, P733
   PERRINCOCON L, 2001, J IMMUNOL, V167, P3785
   SCHUURHUIS DH, 2000, J EXP MED, V192, P145
   STEINMAN RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI
   10.1146/annurev.immunol.21.120601.141040
   TONTONOZ P, 1998, CELL, V93, P241
   WALTNERROMEN M, 1998, J HISTOCHEM CYTOCHEM, V46, P1347
   WEST MA, 2004, SCIENCE, V305, P1153
   WICK G, 1997, FASEB J, V11, P1199
   YURI V, 2005, J EUR HEART J, V262, P1700
NR 29
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2010
VL 263
IS 1
BP 99
EP 104
DI 10.1016/j.cellimm.2010.03.004
PG 6
SC Cell Biology; Immunology
GA 595EL
UT ISI:000277593400012
ER

PT J
AU Wen, X
   Xu, GZ
   Liu, J
   Zhu, HF
   Dai, H
   Li, L
   Hong, Y
   Yang, J
   Dai, W
   Ping, L
   Shen, GX
AF Wen, Xue
   Xu, Guozheng
   Liu, Jing
   Zhu, Huifen
   Dai, Hong
   Li, Li
   Hong, Yi
   Yang, Jing
   Dai, Wei
   Ping, Lei
   Shen, Guanxin
TI Overexpression of programmed death-1 ligand-1 on NIT cells lead to
   negative regulation of allogeneic lymphocyte activation
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE PD-L1; Alloimmune responses; Apoptosis; Cytokine; Negative regulation;
   NIT-1 cells; PD-1; Proliferation; Immune responses; Autoimmune diseases
ID B7 FAMILY; T-CELLS; PD-1; EXPRESSION; RESPONSES; TOLERANCE; MEMBER;
   B7-H1; ARTERIOSCLEROSIS; SUPERFAMILY
AB PD-L1 have been identified as the ligand for PD-1, and shown to play a
   role in the regulation of immune responses. In the present study, we
   investigated whether overexpressing PD-L1 on islet beta cells could
   induce negative regulation in primary and primed allogeneic lymphocyte
   response. pPD-L1-EGFP or pEGFPn1 were transfected in NIT-1 cells, for
   establishment of pPD-L1-EGFP or pEGFPn1 stable transfectants, namely
   NIT-PD-L1 and NIT-EGFP. In mixed cells reaction, as compared with the
   controls of NIT-I or NIT-EGFP, NIT-PD-L1-primed splenocytes showed the
   lowest proliferative response but severe apoptosis when restimulated
   with NIT-PD-L1 cells in vitro. Overexpressing PD-L1 on NIT-1 cells
   could downregulate IFN-gamma but upregulate IL-4 and IL-10 production
   by the primed lymphocytes. In addition, proliferative response of
   primary reactive lymphocytes stimulated with NIT-PD-L1 was lower than
   those lymphocytes restimulated with NIT-1 cells or NIT-EGFP cells. Our
   data demonstrated that PD-L1 has down-regulative effects on alloimmune
   responses. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Wen, Xue; Liu, Jing; Zhu, Huifen; Dai, Hong; Hong, Yi; Yang, Jing; Dai, Wei; Ping, Lei; Shen, Guanxin] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430030, Peoples R China.
   [Wen, Xue; Xu, Guozheng] Wuhan Gen Hosp, Guangzhou Command, Dept Neurosurg, Wuhan 430070, Peoples R China.
   [Li, Li] Wuhan Inst Biol Prod, Wuhan, Peoples R China.
   [Hong, Yi] Hubei Univ Chinese Med, Wuhan 430065, Peoples R China.
RP Shen, GX, Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol,
   Wuhan 430030, Peoples R China.
EM guanxin_shen@yahoo.com.cn
FU National Natural Science foundation [30972734]
FX This work was supported by Grant from the National Natural Science
   foundation (No. 30972734).
CR ANSARI MJI, 2003, J EXP MED, V198, P63, DOI 10.1084/jem.20022125
   BLANK C, 2004, CANCER RES, V64, P1140
   BROWN JA, 2003, J IMMUNOL, V170, P1257
   CARRENO BM, 2002, ANNU REV IMMUNOL, V20, P29
   COYLE AJ, 2001, NAT IMMUNOL, V2, P203
   DONG HD, 1999, NAT MED, V5, P1365
   DONG HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   DONG HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015
   EPPIHIMER MJ, 2002, MICROCIRCULATION, V9, P133
   FREEMAN GJ, 2000, J EXP MED, V192, P1027
   GRAKOUI A, 2006, J HEPATOL, V45, P468, DOI 10.1016/j.jhep.2006.07.009
   ISHIDA Y, 1992, EMBO J, V11, P3887
   KEIR ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776
   KEIR ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI
   10.1016/j.coi.2007.04.012
   KEIR ME, 2007, J IMMUNOL, V179, P5064
   KRUPNICK AS, 2005, J IMMUNOL, V175, P6265
   LATCHMAN Y, 2001, NAT IMMUNOL, V2, P261
   NAGANO H, 1997, J CLIN INVEST, V100, P550
   NISHIMURA H, 2001, TRENDS IMMUNOL, V22, P265
   REYNOSO ED, 2009, J IMMUNOL, V182, P2102, DOI 10.4049/jimmunol.0802769
   RODIG N, 2003, EUR J IMMUNOL, V33, P3117, DOI 10.1002/eji.200324270
   TELLIDES G, 2000, NATURE, V403, P207
NR 22
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2010
VL 263
IS 1
BP 122
EP 128
DI 10.1016/j.cellimm.2010.03.007
PG 7
SC Cell Biology; Immunology
GA 595EL
UT ISI:000277593400015
ER

PT J
AU Jin, HJ
   Nam, HY
   Bae, YK
   Kim, SY
   Im, IR
   Oh, W
   Yang, YS
   Choi, SJ
   Kim, SW
AF Jin, Hye Jin
   Nam, Hae Yun
   Bae, Yun Kyong
   Kim, Soo Yeon
   Im, I. Rang
   Oh, Wonil
   Yang, Yoon Sun
   Choi, Soo Jin
   Kim, Seong Who
TI GD2 expression is closely associated with neuronal differentiation of
   human umbilical cord blood-derived mesenchymal stem cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Umbilical cord blood; Mesenchymal stem cells; Ganglioside GD2;
   Multi-lineage differentiation; Neuronal differentiation; Basic
   helix-loop-helix
ID NEURAL GANGLIOSIDE GD2; HUMAN BONE-MARROW; STROMAL CELLS; IN-VITRO;
   COMPLEX GANGLIOSIDES; ADIPOSE-TISSUE; SYNTHASE; BRAIN; TRANSPLANTATION;
   ACTIVATION
AB GD2 ganglioside has been identified as a key determinant of bone
   marrow-derived mesenchymal stem cells (BM-MSCs). Here, we characterized
   GD2 ganglioside expression and its implications in umbilical cord
   blood-derived MSCs (UCB-MSCs). Using immune-selection analysis, we
   showed that both GD2-positive and GD2-negative UCB-MSCs expressed
   general stem cell markers and possessed mesodermal lineage
   differentiation potential. Although the fraction of GD2-expressing
   cells was lower in UCB-MSC than in BM-MSC populations, inhibition of
   GD2 synthesis in UCB-MSCs suppressed neuronal differentiation and
   down-regulated basic helix-loop-helix (bHLH) transcription factors,
   which are involved in early stage neuronal differentiation. In
   addition, the levels of bHLH factors in neuronally induced UCB-MSCs
   were significantly higher in GD2-positive than GD2-negative cells. Our
   data demonstrate that GD2 ganglioside expression is associated with
   regulation of bHLH factors and identify neurogenic-capable UCB-MSCs,
   providing new insights into the potential clinical applications of
   MSC-based therapy.
C1 [Jin, Hye Jin; Nam, Hae Yun; Im, I. Rang; Kim, Seong Who] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 136736, South Korea.
   [Jin, Hye Jin; Bae, Yun Kyong; Oh, Wonil; Yang, Yoon Sun; Choi, Soo Jin] Medipost Co Ltd, Biomed Res Inst, Seoul 136736, South Korea.
   [Kim, Soo Yeon] Mercersburg Acad, Mercersburg, PA 17236 USA.
RP Kim, SW, Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, 388-1 Pungnap 2
   Dong, Seoul 136736, South Korea.
EM sjchoi@medi-post.co.kr
   swhokim@amc.seoul.kr
FU Ministry of Health and Welfare, Republic of Korea [A084036]; Ministry
   of Education, Science and Technology [2009-0089589]
FX This work was supported in part by a grant from the Korea Health 21 R&D
   Project, Ministry of Health and Welfare, Republic of Korea (A084036),
   and by Basic Science Research Program through the National Research
   Foundation of Korea funded by the Ministry of Education, Science and
   Technology (2009-0089589 to SW Kim).
CR BAE S, 2008, BRIT J HAEMATOL, V142, P827, DOI
   10.1111/j.1365-2141.2008.07241.x
   BAKSH D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709
   BERTRAND N, 2002, NAT REV NEUROSCI, V3, P517
   BLONDHEIM NR, 2006, STEM CELLS DEV, V15, P141
   BRUDER SP, 1997, J CELL BIOCHEM, V64, P278
   BUHRING HJ, 2007, ANN NY ACAD SCI, V1106, P262, DOI
   10.1196/annals.1392.000
   CAPLAN AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   DENG J, 2006, STEM CELLS, V24, P1054
   DOMINICI M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FLYNN A, 2007, CYTOTHERAPY, V9, DOI 10.1080/14653240701584578
   FUKUCHI Y, 2004, STEM CELLS, V22, P649
   FURUKAWA K, 2002, BBA-GEN SUBJECTS, V1573, P356
   GANG EJ, 2007, BLOOD, V109, P1743
   GIRAUDO CG, 1999, BIOCHEM J 3, V342, P633
   GNECCHI M, 2006, FASEB J, V20, P661
   GRONTHOS S, 2000, P NATL ACAD SCI USA, V97, P13625
   HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713
   HENG BC, 2004, STEM CELLS, V22, P1152, DOI 10.1634/stemcells.2004-0062
   JIANG YH, 2002, NATURE, V418, P41
   JIN HJ, 2009, BIOCHEM BIOPH RES CO, V381, P676, DOI
   10.1016/j.bbrc.2009.02.118
   KERN S, 2006, STEM CELLS, V24, P1294
   KIM DS, 2009, STEM CELLS DEV, V18, DOI 10.1089/scd.2008.0050
   KIM SS, 2008, STEM CELLS, V26, P2217, DOI 10.1634/stemcells.2008-0108
   KIM SW, 2006, STEM CELLS, V24, P1620, DOI 10.1634/stemcells.2005-0365
   LEE DH, 2007, BIOCHEM BIOPH RES CO, V362, P313, DOI
   10.1016/j.bbrc.2007.07.142
   LEE JK, 2007, CELL TRANSPLANT, V16, P849
   LEE OK, 2004, BLOOD, V103, P1669
   LIVAK KJ, 2001, METHOD METHODS, V4, P402
   LOPEZ PHH, 2009, CURR OPIN STRUC BIOL, V19, P549, DOI
   10.1016/j.sbi.2009.06.001
   MARTINEZ C, 2007, BLOOD, V109, P4245, DOI 10.1182/blood-2006-08-039347
   OISHI K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI
   10.1073/pnas.0808400106
   OWEN ME, 1987, J CELL SCI 5, V87, P731
   PANEPUCCI RA, 2004, STEM CELLS, V22, P1263, DOI
   10.1634/stemcells.2004-0024
   PAREKKADAN B, 2007, BIOCHEM BIOPH RES CO, V363, P247, DOI
   10.1016/j.bbre.2007.05.150
   REBELATTO CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712-RM-356
   ROSS SE, 2003, NEURON, V39, P13
   SECCO M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381
   SECCO M, 2009, STEM CELL REV REP, V5, P387, DOI
   10.1007/s12015-009-9098-5
   TAKAMIYA K, 1996, P NATL ACAD SCI USA, V93, P10662
   XU J, 2009, CELL PHYSIOL BIOCHEM, V23, P415, DOI 10.1159/000218188
   YI SH, 2008, MOL THER, V16, P1873, DOI 10.1038/mt.2008.189
   YOSHIDA S, 2001, CANCER RES, V61, P4244
   YU RK, 1988, J NEUROCHEM, V50, P1825
   YU RK, 1994, PROG BRAIN RES, V101, P31
   ZHAO ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 45
TC 2
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUN
PY 2010
VL 67
IS 11
BP 1845
EP 1858
DI 10.1007/s00018-010-0292-z
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 594MN
UT ISI:000277541900007
ER

PT J
AU Drapeau, C
   Antarr, D
   Ma, HY
   Yang, ZJ
   Tang, L
   Hoffman, RM
   Schaeffer, DJ
AF Drapeau, Christian
   Antarr, Donna
   Ma, Huaiyu
   Yang, Zhijian
   Tang, Li
   Hoffman, Robert M.
   Schaeffer, David J.
TI Mobilization of bone marrow stem cells with StemEnhance (R) improves
   muscle regeneration in cardiotoxin-induced muscle injury
SO CELL CYCLE
LA English
DT Article
DE bone marrow stem cell; mobilization; cardiotoxin; green fluorescent
   protein; regeneration; tissue repair
ID ENDOTHELIAL PROGENITOR CELLS; COLONY-STIMULATING FACTOR; ACUTE
   MYOCARDIAL-INFARCTION; SKELETAL-MUSCLE; G-CSF; IN-VIVO; HEART;
   TRANSPLANTATION; STRENGTH; MICE
AB Bone marrow-derived stem cells have the ability to migrate to sites of
   tissue damage and participate in tissue regeneration. the number of
   circulating stem cells has been shown to be a key parameter in this
   process. therefore, stimulating the mobilization of bone marrow stem
   cells may accelerate tissue regeneration in various animal models of
   injury. In this study we investigated the effect of the bone marrow
   stem cells mobilizer StemEnhance (SE), a water-soluble extract of the
   cyanophyta Aphanizomenon flos-aquae (AFA), on hematopoietic recovery
   after myeloablation as well as recovery from cardiotoxin-induced injury
   of the anterior tibialis muscle in mice. Control and SE-treated female
   mice were irradiated, and then transplanted with GFP(+) bone marrow
   stem cells and allowed to recover. Immediately after transplant,
   animals were gavaged daily with 300 mg/kg of Se in PBS or a PBS
   control. After hematopoietic recovery (23 days), mice were injected
   with cardiotoxin in the anterior tibialis muscle. Five weeks later, the
   anterior tibialis muscles were analyzed for incorporation of GFP(+)
   bone marrow-derived cells using fluorescence imaging. SE significantly
   enhanced recovery from cardiotoxin-injury. However, Stemenhance did not
   affect the growth of the animal and did not affect hematopoietic
   recovery after myeloablation, when compared to control. this study
   suggests that inducing mobilization of stem cells from the bone marrow
   is a strategy for muscle regeneration.
C1 [Drapeau, Christian; Antarr, Donna] STEMTech HealthSci Inc, San Clemente, CA USA.
   [Ma, Huaiyu; Yang, Zhijian; Tang, Li; Hoffman, Robert M.] AntiCanc Inc, San Diego, CA USA.
   [Schaeffer, David J.] Univ Illinois, Dept Vet Biosci, Urbana, IL 61801 USA.
RP Drapeau, C, STEMTech HealthSci Inc, San Clemente, CA USA.
EM cdrapeau@stemtechmail.com
FU STEMTech HealthSciences, Inc. 
FX This study was supported by a grant from STEMTech HealthSciences, Inc.,
   to AntiCancer, Inc. This work was presented as a poster presentation at
   the Annual Meeting of the International Society of Stem Cell Research,
   Philadelphia, June 2008.
CR ABBOTT JD, 2004, CIRCULATION, V110, P3300, DOI
   10.1161/01.CIR.0000147780.30124.CF
   ABEDI M, 2004, BLOOD CELL MOL DIS, V32, P42, DOI
   10.1016/j.bcmd.2003.09.026
   ABEDI M, 2004, EXP HEMATOL, V32, P426, DOI 10.1016/j.exphem.2004.02.007
   BENSINGER WI, 1996, BONE MARROW TRANSPL, V17, P19
   CAMARGO FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963
   COGLE CR, 2004, LANCET, V363, P1432
   CONTRERAS JL, 2003, SURGERY, V134, P390, DOI 10.1067/msy.2003.250
   COTTLERFOX MH, 2003, HEMATOLOGY AM SOC HE, P419
   FERRARI G, 1998, SCIENCE, V279, P1528
   FOX A, 2008, BRIT J SURG, V95, P244, DOI 10.1002/bjs.5913
   FUKUHARA S, 2004, CELL TRANSPLANT, V13, P741
   HARVEY AL, 1982, TOXICON, V20, P379
   HAYAKAWA J, 2003, INT J HEMATOL, V77, P456
   HISASHI Y, 2004, JPN J THORAC CARDIOV, V52, P451
   HOEHN M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI
   10.1073/pnas.242435499
   INCE H, 2005, CIRCULATION, V112, P173
   JENSEN GS, 2007, CARDIOVASC REVASC ME, V8, P189
   KAWAKAMI N, 1999, IMMUNOL LETT, V70, P165
   KLEEBERGER W, 2003, AM J PATHOL, V162, P1487
   KRAUSE DS, 2001, CELL, V105, P369
   LAFLAMME MA, 2002, CIRC RES, V90, P634
   LAING AJ, 2007, J ORTHOP RES, V25, P44, DOI 10.1002/jor.20228
   LEE DY, 2008, BONE, V42, P932, DOI 10.1016/j.bone.2008.01.007
   LEE KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   LEONE AM, 2006, INT J CARDIOL, V111, P202, DOI
   10.1016/j.ijcard.2005.06.043
   MATZIOLIS G, 2006, TISSUE ENG, V12, P361
   OKABE M, 1997, FEBS LETT, V407, P313
   ORLIC D, 2001, NATURE, V410, P701
   ORLIC D, 2001, P NATL ACAD SCI USA, V98, P10344
   QUAINI F, 2002, NEW ENGL J MED, V346, P5
   SANCHEZRAMOS JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337
   SCHAEFFER DJ, 1999, ECOTOX ENVIRON SAFE, V44, P73
   SEEBERGER KL, 2006, LAB INVEST, V86, P141, DOI 10.1038/labinvest.3700377
   SESTI C, 2005, J AM COLL CARDIOL, V46, P1662, DOI
   10.1016/j.jacc.2005.08.012
   SHINTANI S, 2001, CIRCULATION, V103, P2776
   SHYU WC, 2004, CIRCULATION, V110, P1847, DOI
   10.1161/01.CIR.0000142616.07367.66
   STOUT CL, 2007, AM SURGEON, V73, P1106
   STRATOS I, 2007, J APPL PHYSIOL, V103, P1857, DOI
   10.1152/japplphysiol.00066.2007
   SUGIYAMA K, 2008, CANCER SCI, V99, P1021, DOI
   10.1111/j.1349-7006.2008.00761.x
   THEISE ND, 2000, HEPATOLOGY, V32, P11
   TOMITA M, 2002, STEM CELLS, V20, P279
   VASA M, 2001, CIRC RES, V89, P1
   VOLTARELLI JC, 2007, JAMA-J AM MED ASSOC, V297, P1568
   WERNER N, 2005, NEW ENGL J MED, V353, P999
NR 44
TC 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2010
VL 9
IS 9
BP 1819
EP 1823
PG 5
SC Cell Biology
GA 592TC
UT ISI:000277402200034
ER

PT J
AU Yu, HJ
   Chen, SL
   Yang, ZH
   Pan, A
   Zhang, G
   Shan, JJ
   Tang, XJ
   Zhou, WL
AF Yu, Haijie
   Chen, Siliang
   Yang, Zihuan
   Pan, Ao
   Zhang, Geng
   Shan, Jiajie
   Tang, Xiaojiang
   Zhou, Wenliang
TI Trimethyltin chloride induced chloride secretion across rat distal colon
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Cl- secretion; cystic fibrosis transmembrane conductance regulator
   (CFTR); K+ channel; rat distal colon; short circuit current;
   trimethyltin chloride
ID RYANODINE RECEPTORS; ANION SECRETION; ION-TRANSPORT; MOUSE COLON;
   CHANNEL; EPITHELIUM; CELLS; ACTIVATION; CFTR; TIN
AB TMT (trimethyltin chloride), an organotin, is ubiquitous in the
   environment. The consumption of contaminated food may cause exposure of
   the human diet to this toxic compound. The present study was to
   investigate the effects of TMT on the regulation of ion transport
   across the rat distal colon. The rat colonic mucosa was mounted in
   Ussing chambers. The effects of TMT were assessed using the I-SC
   (short-circuit current). Both apical and basolateral TMT induced,
   dose-dependently, an increase in I-SC, which was due to a stimulation
   of Cl- secretion as measured using ion substitution experiments and
   pharmacological manoeuvres. The secretion was also inhibited by several
   K+ channel blockers administrated at the basolateral side. When the
   apical side was permeabilized by nystatin, the TMT-induced K+
   conductance was effectively blocked by tetrapentylammonium, a
   Ca2+-sensitive K+ channel blocker. The response of TMT was sensitive to
   the basolateral Ca2+ and the intracellular Ca2+ store, which could be
   disclosed by applying the inhibitors of ryanodine receptors and
   inositol 1,4,5-trisphosphate receptors. In conclusion, TMT led to Cl-
   secretion, which was essentially regulated by basolateral
   Ca2+-sensitive K+ channels. These results suggest the importance of K+
   channels in the toxicity hazard of TMT.
C1 [Yu, Haijie; Chen, Siliang; Yang, Zihuan; Pan, Ao; Zhang, Geng; Shan, Jiajie; Zhou, Wenliang] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China.
   [Tang, Xiaojiang] Guangdong Prov Ctr Occupat Dis Prevent & Treatmen, Dept Toxicol, Guangzhou, Guangdong, Peoples R China.
RP Zhou, WL, Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Guangdong,
   Peoples R China.
EM lsszwl@yahoo.com.cn
FU Natural Science Foundation of China [30770817]; National 973 Project
   Foundation [2006CB504002, 2009CB5221027]
FX This work was supported by the Natural Science Foundation of China
   [grant number 30770817]; and the National 973 Project Foundation [grant
   number 2006CB504002, 2009CB5221027].
CR BARNES JM, 1958, BR J IND MED, V15, P15
   BARRETT KE, 2000, ANNU REV PHYSIOL, V62, P535
   BROWN AW, 1984, J APPL TOXICOL, V4, P12
   BUCKKOEHNTOP BA, 2005, J MOL BIOL, V354, P652, DOI
   10.1016/j.jmb.2005.09.038
   CAREW MA, 2000, EXP PHYSIOL, V85, P67
   CERMAK R, 2002, BRIT J PHARMACOL, V135, P1183
   CUTHBERT AW, 1999, IMMUNOPHARMACOLOGY, V45, P191
   CUTHBERT AW, 2003, BRIT J PHARMACOL, V138, P1528, DOI
   10.1038/sj.bjp.0705203
   DUSZYK M, 2001, BRIT J PHARMACOL, V134, P853
   FENT K, 1996, CRIT REV TOXICOL, V26, P1
   FLOREA AM, 2005, CELL CALCIUM, V37, P251, DOI 10.1016/j.ceca.2004.10.005
   FLOREA AM, 2005, TOXICOLOGY, V216, P1, DOI 10.1016/j.tox.2005.05.029
   FLORES CA, 2007, J PHYSIOL-LONDON, V583, P705, DOI
   10.1113/jphysiol.2007.134387
   GREGER R, 2000, ANNU REV PHYSIOL, V62, P467
   GUAN YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278
   HASAN Z, 1984, NEUROTOXICOLOGY, V5, P217
   HOSODA Y, 2000, AM J PHYSIOL-GASTR L, V278, G625
   JOINER WJ, 2003, AM J PHYSIOL-GASTR L, V285, G185, DOI
   10.1152/ajpgi.00337.2002
   JOSEPH SK, 2006, BIOCHEM J 2, V393, P575, DOI 10.1042/BJ20050889
   KOCKS S, 2002, PFLUG ARCH EUR J PHY, V445, P390, DOI
   10.1007/s00424-002-0947-1
   KOON HW, 2006, J IMMUNOL, V176, P5050
   KUNZELMANN K, 2001, J MEMBRANE BIOL, V179, P155
   KUNZELMANN K, 2002, PHYSIOL REV, V82, P245
   LAM RS, 2004, BBA-BIOMEMBRANES, V1667, P241, DOI
   10.1016/j.bbamem.2004.11.004
   LITTLEWOOD JM, 1992, BRIT MED BULL, V48, P847
   LIU Y, 1996, ACTA OTO-LARYNGOL, V116, P417
   MA TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112
   PRINZ G, 2008, ACTA PHYSIOL, V193, P151, DOI
   10.1111/j.1748-1716.2007.01802.x
   SAARY MJ, 2002, OCCUP MED-OXFORD, V52, P227
   SCHROEDER BC, 2000, NATURE, V403, P196
   SCHULTHEISS G, 1997, BRIT J PHARMACOL, V122, P87
   SCHULTHEISS G, 2008, BRIT J PHARMACOL, V154, P991, DOI
   10.1038/bjp.2008.162
   SCHULTZ BD, 1999, PHYSIOL REV, V79, S109
   SIEFJEDIERS A, 2007, CELL CALCIUM, V41, P303, DOI
   10.1016/j.ceca.2006.07.009
   SKARNING CRF, 2002, BIOCHEM PHARMACOL, V64, P657
   SNOEIJ NJ, 1987, ENVIRON RES, V44, P335
   STRABEL D, 1995, EUR J PHARMACOL, V274, P181
   WARTH R, 1999, PFLUG ARCH EUR J PHY, V438, P437
   WINSHIP KA, 1988, ADVERSE DRUG REACT, V7, P19
   WU DZ, 2008, J PHARMACOL EXP THER, V325, P256, DOI
   10.1124/jpet.107.131961
   XIA RH, 2000, J BIOL CHEM, V275, P36556
   YEROMIN AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108
   YONEYAMA M, 2008, NEUROCHEM INT, V52, P761, DOI
   10.1016/j.neuint.2007.09.003
   YU ZP, 2000, TOXICOL APPL PHARM, V168, P200
   ZIMA AV, 2006, CARDIOVASC RES, V71, P310, DOI
   10.1016/j.cardiores.2006.02.019
NR 45
TC 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JAN
PY 2010
VL 34
IS 1
BP 99
EP 108
DI 10.1042/CBI20090022
PG 10
SC Cell Biology
GA 592PK
UT ISI:000277391400015
ER

PT J
AU Wang, TY
   Zhang, JH
   Jing, CQ
   Yang, XJ
   Lin, JT
AF Wang, Tian-Yun
   Zhang, Jun-He
   Jing, Chang-Qin
   Yang, Xian-Jun
   Lin, Jun-Tang
TI Positional effects of the matrix attachment region on transgene
   expression in stably transfected CHO cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE gene silencing; mammalian expression system; matrix attachment region;
   positional effect
ID DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; RICE PLANTS; ARABIDOPSIS;
   STABILITY; ELEMENTS; MICE
AB Previous work has shown that the MAR (matrix attachment region) could
   increase transgene expression in stably transfected CHO
   (Chinese-hamster ovary) cells. To study the positional effect of MAR on
   transgene expression, three expression vectors were constructed which
   contained the human beta-globin MAR in different sites, including the
   vector with two MARs flanking the CAT (chloramphenicol
   acetyltransferase) expression cassette, one MAR at the 5' or 3' site.
   These vectors were transfected into CHO cells. The level of CAT gene
   expression was most effectively increased by two MARs flanking the CAT
   expression cassette. This increase was also seen when MAR was inserted
   at the 5' site upstream of the expression cassette, whereas the
   transgene expression level decreased when MAR was inserted at the 3'
   site downstream of the expression cassette. We have also shown that the
   transgene expression level is not directly proportional to the gene
   copy number, and gene copy number dependency does not exist.
EM wty@xxmu.edu.cn
FU Natural Science Foundation of Henan Province, China [511042300,
   624410041]; Science and Technology Innovation Talents in University of
   Henan Province [2008HASTIT026]
FX This work was supported by the Natural Science Foundation of Henan
   Province, China [grant numbers 511042300, 624410041]; and Science and
   Technology Innovation Talents in University of Henan Province [grant
   number 2008HASTIT026].
CR BUTAYE KMJ, 2004, PLANT J, V39, P440, DOI
   10.1111/j.1365-313X.2004.02144.x
   GIROD PA, 2007, NAT METHODS, V4, P747, DOI 10.1038/NMETH1076
   HUBER MC, 1994, NUCLEIC ACIDS RES, V22, P4195
   KALOS M, 1995, MOL CELL BIOL, V15, P198
   KIM JM, 2004, J BIOTECHNOL, V107, P95, DOI 10.1016/j.biotec.2003.09.015
   LAEMMLI UK, 1992, CURR OPIN GENE DEV, V2, P275
   LI JY, 2008, PLANT BIOTECHNOL J, V6, P887, DOI
   10.1111/j.1467-7652.2008.00369.x
   MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943
   NAMCIU SJ, 1998, MOL CELL BIOL, V18, P2382
   NAMCIU SJ, 2004, MOL CELL BIOL, V24, P10236, DOI
   10.1128/MCB.24.23.10236-10245.2004
   NEZNANOV N, 2003, J VIROL, V77, P7341
   OH SJ, 2005, PLANT CELL REP, V24, P145, DOI 10.1007/s00299-005-0915-2
   THOMPSON EM, 1994, MOL CELL BIOL, V14, P4694
   VAIN P, 1999, PLANT J, V18, P233
   VANDERGEEST AHM, 2004, PLANT BIOTECHNOL J, V2, P13, DOI
   10.1046/j.1467-7652.2003.00044.x
   WANG TY, 2007, APPL MICROBIOL BIOT, V76, P651, DOI
   10.1007/s00253-007-1040-7
   WANG TY, 2008, CELL BIOL INT, V32, P1279, DOI
   10.1016/j.cellbi.2008.07.014
   YU JH, 1994, GENE, V139, P139
   ZAHNZABAL M, 2001, J BIOTECHNOL, V87, P29
   ZHANG JD, 2009, TRANSGENIC RES, V18, P377, DOI 10.1007/s11248-008-9230-3
NR 20
TC 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD FEB
PY 2010
VL 34
IS 2
BP 141
EP 145
DI 10.1042/CBI20090017
PG 5
SC Cell Biology
GA 592PL
UT ISI:000277391500001
ER

PT J
AU Wang, TY
   Zhang, JH
   Jing, CQ
   Yang, XJ
   Lin, JT
AF Wang, Tian-Yun
   Zhang, Jun-He
   Jing, Chang-Qin
   Yang, Xian-Jun
   Lin, Jun-Tang
TI Positional effects of the matrix attachment region on transgene
   expression in stably transfected CHO cells (vol 34, pg 141, 2010)
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Correction
CR WANG TY, 2010, CELL BIOL INT, V34, P141, DOI 10.1042/CBI20090017
NR 1
TC 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD FEB
PY 2010
VL 34
IS 2
BP 235
EP 235
PG 1
SC Cell Biology
GA 592PL
UT ISI:000277391500012
ER

PT J
AU Huang, YC
   Yang, ZM
   Jiang, NG
   Chen, XH
   Li, XQ
   Tan, MY
   Zhou, KP
   Tang, L
   Xie, HQ
   Deng, L
AF Huang, Yong-Can
   Yang, Zhi-Ming
   Jiang, Neng-Gang
   Chen, Xiao-He
   Li, Xiu-Qun
   Tan, Mei-Yun
   Zhou, Kun-Peng
   Tang, Li
   Xie, Hui-Qi
   Deng, Li
TI Characterization of MSCs from human placental decidua basalis in
   hypoxia and serum deprivation
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE cytokine secretion; hypoxia; metabolic activity; phenotype;
   proliferation; serum deprivation
ID MESENCHYMAL STEM-CELLS; UMBILICAL-CORD BLOOD; BONE-MARROW; IN-VITRO;
   INDUCED APOPTOSIS; PROLIFERATION; TISSUE; NEURONS; BFGF
AB Recently, we reported that human PDB (placental decidua basalis) is an
   excellent source of MSCs (mesenchymal stem cells), meanwhile, PDB-MSCs
   could survive under hypoxia and serum deprivation. Herein, we
   investigated the proliferation, clonogentic efficiency, phenotypes,
   metabolic activity and cytokines secretion of PDB-MSCs in hypoxia and
   serum deprivation. PDB-MSCs were cultured in four groups: normoxia (20%
   O-2) and complete medium [10% FBS (foetal bovine serum)+DMEM-HG
   (Dulbecco's modified Eagle's medium-high glucose)], hypoxia and
   complete medium, normoxia and serum deprivation (0% FBS), and hypoxia
   and serum deprivation. After 96 h of culture in the above groups,
   PDB-MSCs maintain the phenotypes stably. Interestingly, hypoxia notably
   enhanced the proliferation, colony-forming potential and
   lactate/glucose ratio in complete medium, but suppressed the secretion
   of BMP-2 (bone morphogenetic protein-2) and bFGF (basic fibroblast
   growth factor), while it did not change the quantity of VEGF (vascular
   endothelial growth factor) and bFGF in serum deprivation. Although
   PDB-MSCs grew slowly and seldom formed a colony unit in hypoxia and
   serum deprivation, they possessed a moderate metabolism. In conclusion,
   our results indicate that PDB-MSCs appear to be promising seed cells
   for ischaemia-related tissue engineering.
C1 [Huang, Yong-Can; Yang, Zhi-Ming; Chen, Xiao-He; Li, Xiu-Qun; Tan, Mei-Yun; Zhou, Kun-Peng; Tang, Li; Xie, Hui-Qi; Deng, Li] Sichuan Univ, Div Stem Cell & Tissue Engn, State Key Lab Biotherapy, W China Hosp, Chengdu 610041, Peoples R China.
   [Huang, Yong-Can; Tang, Li] Sichuan Univ, W China Sch Pharm, Chengdu 610041, Peoples R China.
   [Jiang, Neng-Gang] Sichuan Univ, W China Hosp, Dept Lab Med, Chengdu 610041, Peoples R China.
RP Deng, L, Sichuan Univ, Div Stem Cell & Tissue Engn, State Key Lab
   Biotherapy, W China Hosp, Chengdu 610041, Peoples R China.
EM dengli2000@gmail.com
FU National High Technology Research and Development Program ("863") of
   China [2007AA021900]; Science and Technology Bureau of Sichuan province
   [07SG111-004, 2008SZ0035]
FX This work was supported by the National High Technology Research and
   Development Program ("863") of China [grant number 2007AA021900] and
   the Key Project of Science and Technology Bureau of Sichuan province
   [grant numbers 07SG111-004, 2008SZ0035).
CR BIALIK S, 1999, CIRC RES, V85, P403
   BIEBACK K, 2004, STEM CELLS, V22, P625
   CARGNONI A, 2009, CELL TRANSPLANT, V18, P405
   CHEN JH, 2008, STEM CELLS, V26, P135, DOI 10.1634/stemcells.2007-0098
   CHO SW, 2008, BIOCHEM BIOPH RES CO, V376, P158, DOI
   10.1016/j.bbrc.2008.08.123
   FU YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053
   GRAYSON WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   GRAYSON WL, 2007, BIOCHEM BIOPH RES CO, V358, P948, DOI
   10.1016/j.bbrc.2007.05.054
   HEPPENSTALL RB, 1975, CLIN ORTHOP RELAT R, P357
   HUANG YC, 2009, STEM CELL REV REP, V5, P247, DOI
   10.1007/s12015-009-9069-x
   INTANKER PS, 2004, STEM CELLS, V22, P1338, DOI
   10.1634/stemcells.2004-0058
   KERN S, 2006, STEM CELLS, V24, P1294
   KNIPPENBERG M, 2006, BIOCHEM BIOPH RES CO, V342, P902, DOI
   10.1016/j.bbrc.2006.02.052
   KWONG F, 2007, INJ EXTRA, V38, P162
   LANGER HF, 2009, J MOL CELL CARDIOL, V47, P315, DOI
   10.1016/j.yjmcc.2009.03.011
   LEE OK, 2004, BLOOD, V103, P1669
   LOU JR, 1999, J ORTHOPAED RES, V17, P43
   MIAO ZN, 2006, CELL BIOL INT, V30, P681, DOI
   10.1016/j.cellbi.2006.03.009
   MITCHELL KE, 2003, STEM CELLS, V21, P50
   MYLOTTE LA, 2008, STEM CELLS, V26, P1325, DOI
   10.1634/stemcells.2007-1072
   PACKER L, 1977, NATURE, V267, P423
   PITTENGER MF, 1999, SCIENCE, V284, P143
   SONG GB, 2008, MAT SCI ENG C-BIO S, V28, P1467, DOI
   10.1016/j.msec.2008.04.005
   TOMA C, 2002, CIRCULATION, V105, P93
   TROYER DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439
   WANG J, 2009, ZHONGGUO XIU FU CHON, V23, P136
   XU RX, 2008, J CELL BIOCHEM, V103, P256, DOI 10.1002/jcb.21402
   ZHAO P, 2005, TRANSPLANTATION, V79, P528, DOI
   10.1097/01.TP.0000149503.92433.39
   ZHAO YH, 2007, NEUROSCI LETT, V421, P197, DOI
   10.1016/j.neulet.2007.04.028
   ZHU WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005-0121
NR 30
TC 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD MAR
PY 2010
VL 34
IS 3
BP 237
EP 243
DI 10.1042/CBI20090044
PG 7
SC Cell Biology
GA 592PM
UT ISI:000277391600001
ER

PT J
AU Yang, TY
   Zaman, MH
AF Yang, Tianyi
   Zaman, Muhammad H.
TI Estimation of Cellular Adhesion Forces Using Mean Field Theory
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Cell matrix interactions; Adhesion force; Mean field theory
ID RED-BLOOD-CELLS; LARGE CONTACT AREAS; LEADING-EDGE; DETACHMENT;
   THERMODYNAMICS; PROTRUSION; MIGRATION; PHYSICS
AB A complete understanding of the interaction of the cell with the
   surrounding substrate requires a quantitative understanding of the
   force with which they adhere to the matrix. Using mean field theory, we
   provide a new and robust method to calculate this force of cellular
   adhesion to a ligand coated substrate in a system that contains
   receptors, ligands and solvent. Our calculations incorporate molecular
   conformations, long and short range interactions and solvent entropic
   effects that regulate adhesion in native environments. The results of
   our calculations provide a set of testable quantitative predictions
   that will guide future experimental endeavors.
C1 [Zaman, Muhammad H.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Yang, Tianyi] Univ Texas Austin, Dept Phys, Austin, TX 78712 USA.
RP Zaman, MH, Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
EM zaman@bu.edu
FU Robert A. Welch Foundation 
FX MHZ acknowledges the support of Robert A. Welch Foundation grant.
CR BERK D, 1991, BIOPHYS J, V59, P861
   BOHNET S, 2006, BIOPHYS J, V90, P1810, DOI 10.1529/biophysj.105.064600
   BORISY GG, 2000, CURR OPIN CELL BIOL, V12, P104
   EVANS E, 1991, BIOPHYS J, V59, P838
   EVANS E, 1991, BIOPHYS J, V59, P849
   GRIMM HP, 2003, EUR BIOPHYS J BIOPHY, V32, P563, DOI
   10.1007/s00249-003-0300-4
   LAUFFENBURGER DA, 1996, CELL, V84, P359
   LIANG MN, 2000, P NATL ACAD SCI USA, V97, P13092
   MOGILNER A, 2005, BIOPHYS J, V89, P782, DOI 10.1529/biophysj.104.056515
   MUNEVAR S, 2001, MOL BIOL CELL, V12, P3947
   OSTER GF, 1987, J CELL SCI, V8, P35
   PRASS M, 2006, J CELL BIOL, V174, P767
   SZLEIFER I, 1987, J CHEM PHYS, V86, P7094
   TORDEUX C, 2002, PHYS REV E 1, V65, ARTN 041912
   WEIKL TR, 2002, EUR PHYS J E, V8, P59
   YANG TY, 2007, J CHEM PHYS, V126, ARTN 045103
   YANG TY, 2008, CHEM PHYS LETT, V454, P362, DOI
   10.1016/j.cplett.2008.01.088
   ZHU BR, 2002, BIOCHEMISTRY-US, V41, P12163, DOI 10.1021/bi020296g
NR 18
TC 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1865-5025
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD JUN
PY 2010
VL 3
IS 2
BP 190
EP 194
DI 10.1007/s12195-010-0115-1
PG 5
SC Cell & Tissue Engineering; Biophysics; Cell Biology
GA 592HK
UT ISI:000277368900010
ER

PT J
AU Liu, XD
   Shin, N
   Koblish, HK
   Yang, GJ
   Wang, Q
   Wang, K
   Leffet, L
   Hansbury, MJ
   Thomas, B
   Rupar, M
   Waeltz, P
   Bowman, KJ
   Polam, P
   Sparks, RB
   Yue, EW
   Li, YL
   Wynn, R
   Fridman, JS
   Burn, TC
   Combs, AP
   Newton, RC
   Scherle, PA
AF Liu, Xiangdong
   Shin, Niu
   Koblish, Holly K.
   Yang, Gengjie
   Wang, Qian
   Wang, Kathy
   Leffet, Lynn
   Hansbury, Michael J.
   Thomas, Beth
   Rupar, Mark
   Waeltz, Paul
   Bowman, Kevin J.
   Polam, Padmaja
   Sparks, Richard B.
   Yue, Eddy W.
   Li, Yanlong
   Wynn, Richard
   Fridman, Jordan S.
   Burn, Timothy C.
   Combs, Andrew P.
   Newton, Robert C.
   Scherle, Peggy A.
TI Selective inhibition of IDO1 effectively regulates mediators of
   antitumor immunity
SO BLOOD
LA English
DT Article
ID INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; HUMAN DENDRITIC CELLS; CD8(+)
   T-CELLS; TRYPTOPHAN CATABOLISM; COLORECTAL-CANCER; POOR-PROGNOSIS;
   1-METHYL-TRYPTOPHAN; PROLIFERATION; SUPPRESSION; PROGRESSION
AB Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage
   of tryptophan, an amino acid essential for cell proliferation and
   survival. IDO1 inhibition is proposed to have therapeutic potential in
   immunodeficiency-associated abnormalities, including cancer. Here, we
   describe INCB024360, a novel IDO1 inhibitor, and investigate its roles
   in regulating various immune cells and therapeutic potential as an
   anticancer agent. In cellular assays, INCB024360 selectively inhibits
   human IDO1 with IC50 values of approximately 10nM, demonstrating little
   activity against other related enzymes such as IDO2 or tryptophan
   2,3-dioxygenase (TDO). In coculture systems of human allogeneic
   lymphocytes with dendritic cells (DCs) or tumor cells, INCB024360
   inhibition of IDO1 promotes T and natural killer (NK)-cell growth,
   increases IFN-gamma production, and reduces conversion to regulatory T
   (T-reg)-like cells. IDO1 induction triggers DC apoptosis, whereas
   INCB024360 reverses this and increases the number of CD86(high) DCs,
   potentially representing a novel mechanism by which IDO1 inhibition
   activates T cells. Further-more, IDO1 regulation differs in DCs versus
   tumor cells. Consistent with its effects in vitro, administration of
   INCB024360 to tumor-bearing mice significantly inhibits tumor growth in
   a lymphocyte-dependent manner. Analysis of plasma kynurenine/tryptophan
   levels in patients with cancer affirms that the IDO pathway is
   activated in multiple tumor types. Collectively, the data suggest that
   selective inhibition of IDO1 may represent an attractive cancer
   therapeutic strategy via up-regulation of cellular immunity. (Blood.
   2010; 115(17): 3520-3530)
C1 [Scherle, Peggy A.] Incyte Corp, Expt Stn, Wilmington, DE 19880 USA.
RP Scherle, PA, Incyte Corp, Expt Stn, Rte 141 & Henry Clay Rd,
   Wilmington, DE 19880 USA.
EM pscherle@incyte.com
CR AGAUGUE S, 2006, J IMMUNOL, V177, P2061
   ASTIGIANO S, 2005, NEOPLASIA, V7, P390, DOI 10.1593/neo.04658
   BALL HJ, 2007, GENE, V396, P203, DOI 10.1016/j.gene.2007.04.010
   BALL HJ, 2009, INT J BIOCHEM CELL B, V41, P467, DOI
   10.1016/j.biocel.2008.01.005
   BOON T, 1996, J EXP MED, V183, P725
   BRANDACHER G, 2006, CLIN CANCER RES, V12, P1144, DOI
   10.1158/1078-0432.CCR-05-1966
   CORM S, 2009, LEUKEMIA RES, V33, P490, DOI 10.1016/j.leukres.2008.06.014
   CURTI A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863
   DELLACHIESA M, 2006, BLOOD, V108, P4118, DOI
   10.1182/blood-2006-06-006700
   DESILVA DR, 1996, J EXP MED, V183, P2017
   ERCOLINI AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167
   FALLARINO F, 2006, J IMMUNOL, V176, P6752
   FOROUZANDEH F, 2008, MOL CELL BIOCHEM, V309, P1, DOI
   10.1007/s11010-007-9635-y
   FRIBERG M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645
   GALON J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   HIGUCHI K, 1967, ARCH BIOCHEM BIOPHYS, V120, P397
   HOU DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925
   HUANG A, 2002, BRIT J CANCER, V86, P1691
   HWU P, 2000, J IMMUNOL, V164, P3596
   INO K, 2006, BRIT J CANCER, V95, P1555, DOI 10.1038/sj.bjc.6603477
   JUNG ID, 2007, FEBS LETT, V581, P1449, DOI 10.1016/j.febslet.2007.02.073
   KOBLISH HK, 2010, MOL CANCER THER, V9, P489
   LAURENT S, 2007, ARTERY RES, V1, P2
   LIU XD, 2006, CANCER BIOL THER, V5, P648
   LOB S, 2008, BLOOD, V111, P2152, DOI 10.1182/blood-2007-10-116111
   LOB S, 2009, CANCER IMMUNOL IMMUN, V58, P153, DOI
   10.1007/s00262-008-0513-6
   LOB S, 2009, NAT REV CANCER, V9, P445, DOI 10.1038/nrc2639
   LOGAN GJ, 2002, IMMUNOLOGY, V105, P478
   MELLOR AL, 2003, J IMMUNOL, V171, P1652
   MELLOR AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457
   MULLER AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196
   MULLER AJ, 2008, P NATL ACAD SCI USA, V105, P17073, DOI
   10.1073/pnas.0806173105
   MUNN DH, 1998, SCIENCE, V281, P1191
   MUNN DH, 1999, J EXP MED, V189, P1363
   NAKAMURA T, 2007, CANCER SCI, V98, P874, DOI
   10.1111/j.1349-7006.2007.00470.x
   OKAMOTO A, 2005, CLIN CANCER RES, V11, P6030, DOI
   10.1158/1078-0432.CCR-04-2671
   OU XL, 2008, J CANCER RES CLIN, V134, P525, DOI
   10.1007/s00432-007-0315-9
   QIAN Y, 2001, EXPERT REV MOL MED, V3, P1
   SANSOM DM, 2003, TRENDS IMMUNOL, V24, P313
   SEYMOUR RL, 2006, J LEUKOCYTE BIOL, V80, P1320, DOI 10.1189/jlb.1205727
   SHIMIZU T, 1978, J BIOL CHEM, V253, P4700
   THOMPSON JE, 2002, BIOORG MED CHEM LETT, V12, P1219
   UYTTENHOVE C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934
   WEINLICH G, 2007, DERMATOLOGY, V214, P8, DOI 10.1159/000096906
   WITKIEWICZ A, 2008, J AM COLL SURGEONS, V206, P849, DOI
   10.1016/j.jamcollsurg.2007.12.014
   YEN MC, 2009, CLIN CANCER RES, V15, P641, DOI
   10.1158/1078-0432.CCR-08-1988
   YUE EW, 2009, J MED CHEM, V52, P7364, DOI 10.1021/jm900518f
   ZENG J, 2009, CANCER RES, V69, P3963, DOI 10.1158/0008-5472.CAN-08-2476
   ZHENG XF, 2006, J IMMUNOL, V177, P5639
   ZOU WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586
   ZOU WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806
NR 51
TC 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 29
PY 2010
VL 115
IS 17
BP 3520
EP 3530
DI 10.1182/blood-2009-09-246124
PG 11
SC Hematology
GA 591WL
UT ISI:000277335800017
ER

PT J
AU Li, J
   Sze, DMY
   Brown, RD
   Cowley, MJ
   Kaplan, W
   Mo, SL
   Yang, SH
   Aklilu, E
   Kabani, K
   Loh, YS
   Yamagishi, T
   Chen, YL
   Ho, PJ
   Joshua, DE
AF Li, Jia
   Sze, Daniel M. -Y.
   Brown, Ross D.
   Cowley, Mark J.
   Kaplan, Warren
   Mo, Sui-Lin
   Yang, Shihong
   Aklilu, Esther
   Kabani, Karieshma
   Loh, Yen S.
   Yamagishi, Tetsuo
   Chen, Yuling
   Ho, P. Joy
   Joshua, Douglas E.
TI Clonal expansions of cytotoxic T cells exist in the blood of patients
   with Waldenstrom macroglobulinemia but exhibit anergic properties and
   are eliminated by nucleoside analogue therapy
SO BLOOD
LA English
DT Article
ID CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE-PHOSPHATASE HEPTP; NF-KAPPA-B;
   MULTIPLE-MYELOMA; CYCLE PROGRESSION; REPERTOIRE USAGE; PROTEIN-KINASE;
   RECEPTOR; BETA; ARREST
AB T cells contribute to host-tumor interactions in patients with
   monoclonal gammopathies. Expansions of CD8(+)CD57(+) T-cell receptor V
   beta-positive (TCRV beta(+))-restricted cytotoxic T-cell (CTL) clones
   are found in 48% of patients with multiple myeloma and confer a
   favorable prognosis. We now report that CTL clones with varying TCRV
   beta repertoire are present in 70% of patients with Waldenstrom
   macroglobulinemia (WM; n = 20). Previous nucleoside analog (NA)
   therapy, associated with increased incidence of transformation to
   aggressive lymphoma, significantly influenced the presence of TCRV beta
   expansions (chi(2) = 11.6; P < .001), as 83% of patients without (n =
   6) and only 7% with (n = 14) TCRV beta expansions had received NA.
   Clonality of CD3(+)CD8(+)CD57(+) TCRV beta(+) restricted CTLs was
   confirmed by TCRV beta CDR3 size analysis and direct sequencing. The
   differential expression of CD3(+)CD8(+)CD57(+) TCRV beta(+) cells was
   profiled using DNA microarrays and validated at mRNA and protein level.
   By gene set enrichment analysis, CTL clones expressed not only genes
   from cytotoxic pathways (GZMB, PRF1, FGFBP2) but also genes that
   suppress apoptosis, inhibit proliferation, arrest cell-cycle G1/S
   transition, and activate T cells (RAS, CSK, and TOB pathways).
   Proliferation tracking after stimulation confirmed their anergic state.
   Our studies demonstrate the incidence, NA sensitivity, and nature of
   clonal CTLs in WM and highlight mechanisms that cause anergy in these
   cells. (Blood. 2010; 115(17): 3580-3588)
C1 [Li, Jia; Sze, Daniel M. -Y.; Mo, Sui-Lin; Loh, Yen S.; Yamagishi, Tetsuo; Chen, Yuling] Univ Sydney, Fac Pharm, Canc Immunol Grp, Sydney, NSW 2006, Australia.
   [Sze, Daniel M. -Y.; Brown, Ross D.; Yang, Shihong; Aklilu, Esther; Kabani, Karieshma; Ho, P. Joy; Joshua, Douglas E.] Royal Prince Alfred Hosp, Inst Haematol, Sydney, NSW, Australia.
   [Sze, Daniel M. -Y.] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China.
   [Cowley, Mark J.; Kaplan, Warren] Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Sydney, NSW, Australia.
   [Kaplan, Warren; Chen, Yuling] Univ New S Wales, Sydney, NSW, Australia.
   [Mo, Sui-Lin] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
RP Brown, RD, Royal Prince Alfred Hosp, Inst Haematol, Missenden Rd,
   Camperdown, NSW 2050, Australia.
EM ross.brown@sswahs.nsw.gov.au
FU Cancer Institute NSW ; Sydney Foundation for Medical Research 
FX This work was supported by grants from Cancer Institute NSW (D.M.-Y.S.
   and K. K.) and Sydney Foundation for Medical Research (E. A.).
CR *NAT CTR BIOT INF, GEN EXPR OMN GEO
   ARAKI Y, 2008, J IMMUNOL, V180, P8102
   ASSAF C, 2005, BLOOD, V105, P503, DOI 10.1182/blood-2004-06-2220
   BAUGHN LB, 2006, CANCER RES, V66, P7661, DOI
   10.1158/0008-5472.CAN-06-1098
   BOUCHARD C, 1999, EMBO J, V18, P5321
   BROWN RD, 1997, LEUKEMIA, V11, P1312
   BROWN RD, 2005, BLOOD, V106, B659
   BROWN RD, 2009, LEUKEMIA LYMPHOMA, V50, P1860, DOI
   10.3109/10428190903216804
   CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941
   CONG F, 1999, P NATL ACAD SCI USA, V96, P13819
   DEVRIES ACH, 2008, LEUKEMIA, V22, P1170, DOI 10.1038/leu.2008.23
   EPLINGBURNETTE PK, 2007, LEUKEMIA, V21, P659, DOI 10.1038/sj.leu.2404590
   FIEBIG AA, 2006, BMC CANCER, V6, ARTN 213
   FUJII S, 2000, LEUKEMIA LYMPHOMA, V38, P21
   GAUTIER L, 2004, BIOINFORMATICS, V20, P307, DOI
   10.1093/bioinformatics/btg405
   GENTLEMAN RC, 2004, GENOME BIOL, V5
   HALAPI E, 1997, EUR J IMMUNOL, V27, P2245
   IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299
   IMAKI H, 2003, CANCER RES, V63, P4607
   KAWABUCHI M, 2000, NATURE, V404, P999
   KAY N, 1999, LEUKEMIA LYMPHOMA, V33, P127
   LABRECQUE N, 1993, J EXP MED, V177, P1735
   LAZUARDI L, 2009, BIOGERONTOLOGY, V10, P191, DOI
   10.1007/s10522-008-9167-1
   LELEU X, 2009, CLIN LYMPHOMA MYELOM, V9, P71, DOI 10.3816/CLM.2009.n.018
   LELEU X, 2009, J CLIN ONCOL, V27, P250
   LI YQ, 2004, CHINESE MED J-PEKING, V117, P840
   LIM SH, 2001, CANCER, V91, P900
   MAKINO K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485
   MATEYAK MK, 1999, MOL CELL BIOL, V19, P4672
   MONOD MY, 2004, BIOINFORMATICS S1, V20, P379
   MUSTJOKI S, 2009, LEUKEMIA, V23, P1398, DOI 10.1038/leu.2009.46
   NIKA K, 2004, BIOCHEM J 2, V378, P335, DOI 10.1042/BJ20031244
   ORSINI E, 2000, BONE MARROW TRANSPL, V25, P623
   RAITAKARI M, 2000, BRIT J HAEMATOL, V110, P203
   RAITAKARI M, 2003, HEMATOL ONCOL, V21, P33, DOI 10.1002/hon.704
   ROMASHKOVA JA, 1999, NATURE, V401, P86
   ROSENKILDE MM, 2006, J BIOL CHEM, V281, P13199, DOI
   10.1074/jbc.M602245200
   SAEED AI, 2003, BIOTECHNIQUES, V34, P374
   SAXENA M, 1998, J BIOL CHEM, V273, P15340
   SMYTH GK, 2004, STAT APPL GENET MOL, V3, ARTN 3
   SMYTH GK, 2005, BIOINFORMATICS COMPU, P397
   STOREY JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI
   10.1073/pnas.1530509100
   SUBRAMANIAN A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI
   10.1073/pnas.0506580102
   SZE DMY, 2001, BLOOD, V98, P2817
   SZE DMY, 2003, LEUKEMIA LYMPHOMA, V44, P1667, DOI
   10.1080/1042819031000097438
   TAKEUCHI S, 2000, J BIOL CHEM, V275, P29183
   TZACHANIS D, 2001, NAT IMMUNOL, V2, P1174
   TZACHANIS D, 2009, CELL CYCLE, V8, P1019
   YAMANAKA R, 2006, ONCOGENE, V25, P5994, DOI 10.1038/sj.onc.1209585
   YAMATO K, 1997, MOL ENDOCRINOL, V11, P1044
NR 50
TC 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 29
PY 2010
VL 115
IS 17
BP 3580
EP 3588
DI 10.1182/blood-2009-10-246991
PG 9
SC Hematology
GA 591WL
UT ISI:000277335800023
ER

PT J
AU Han, LQ
   Yang, GY
   Zhu, HS
   Wang, YY
   Wang, LF
   Guo, YJ
   Lu, WF
   Li, HJ
   Wang, YL
AF Han, L. Q.
   Yang, G. Y.
   Zhu, H. S.
   Wang, Y. Y.
   Wang, L. F.
   Guo, Y. J.
   Lu, W. F.
   Li, H. J.
   Wang, Y. L.
TI Selection and use of reference genes in mouse mammary glands
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE geNorm; Lactation; Quantitative real-time PCR; Reference gene
ID POLYMERASE-CHAIN-REACTION; QUANTITATIVE RT-PCR; REAL-TIME PCR;
   LACTATION CYCLE; EXPRESSION; NORMALIZATION; TISSUE
AB Obtaining quantitative data concerning gene expression is important for
   understanding milk synthesis in mammary glands. Quantitative real-time
   PCR (qRT-PCR) is an efficient tool to calculate gene expression;
   however, it is necessary to find valid reference genes for
   normalization of qRT-PCR data. We applied the geNorm software to eight
   commonly used reference genes to identify the most stable and optimal
   genes for the mouse mammary gland. Based on this analysis, HPRT, RPL
   and GAPDH are the most appropriate reference genes for data
   normalization. We tested the expression of the a-lactalbumin and fatty
   acid synthase genes using these three reference genes, both normalized
   and non-normalized. The normalized mRNA expression ratio was
   significantly different from the non-normalized ratio. We recommend the
   use of these three reference genes for the normalization of qRT-PCR
   data in gene expression studies of mouse mammary glands.
C1 [Han, L. Q.; Zhu, H. S.; Wang, Y. Y.; Wang, L. F.; Guo, Y. J.; Lu, W. F.; Li, H. J.; Wang, Y. L.] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Peoples R China.
   [Han, L. Q.; Yang, G. Y.; Wang, Y. L.] Minist Agr, Key Lab Anim Growth & Dev, Zhengzhou, Peoples R China.
RP Wang, YL, Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Peoples R
   China.
EM ylwang2001@yahoo.cn
FU Chinese National Programs for Science and Technology Development
   [2006BAD04A03-10]
FX Research supported by Chinese National Programs for Science and
   Technology Development (#2006BAD04A03-10).
CR BERNARD L, 2005, J DAIRY RES, V72, P250, DOI 10.1017/S0022029905000786
   BIONAZ M, 2007, PHYSIOL GENOMICS, V29, P312, DOI
   10.1152/physiolgenomics.00223.2006
   BIONAZ M, 2008, BMC GENOMICS, V9, ARTN 366
   BUSTIN SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755
   GOOSSENS K, 2005, BMC DEV BIOL, V5, ARTN 27
   HEID CA, 1996, GENOME RES, V6, P986
   HEMBRUFF SL, 2005, ANAL BIOCHEM, V345, P237, DOI
   10.1016/j.ab.2005.07.014
   LISOWSKI P, 2008, J APPL GENET, V49, P367
   MODHA G, 2004, ENDOCR RES, V30, P127, DOI 10.1081/ERC-120029892
   PFAFFL MW, 2003, J DAIRY SCI, V86, P538
   SCHMITTGEN TD, 2000, J BIOCHEM BIOPH METH, V46, P69
   TRAMONTANA S, 2008, J DAIRY SCI, V91, P3057, DOI 10.3168/jds.2008-1164
   TRICARICO C, 2002, ANAL BIOCHEM, V309, P293
   VANDESOMPELE J, 2002, GENOME BIOL, V3, ARTN 0034.1
NR 14
TC 0
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA HUDSON 655, JARDIM CANADA, RIBEIRAO PRETO, SP, BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2010
VL 9
IS 1
BP 449
EP 456
DI 10.4238/vol9-1gmr724
PG 8
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 591TC
UT ISI:000277326200040
ER

PT J
AU Yang, XY
   Wu, ZF
   Chen, H
   Shao, JR
   Wu, Q
AF Yang, Xiao-yan
   Wu, Zhen-Fang
   Chen, Hui
   Shao, Ji-rong
   Wu, Qi
TI Karyotype and genetic relationship based on RAPD markers of six wild
   buckwheat species (Fagopyrum spp.) from southwest of China
SO GENETIC RESOURCES AND CROP EVOLUTION
LA English
DT Article
DE Cultivar buckwheat; Fagopyrum; Genetic relationship; Karyotype; RAPD
   marker; Wild buckwheat
ID PHYLOGENETIC-RELATIONSHIPS; NUCLEOTIDE-SEQUENCES; PERENNIAL BUCKWHEAT;
   POLYGONACEAE; REGION
AB Karyotypes of six wild buckwheat species from Sichuan Pan'xi Regions of
   China were investigated in present study. This study will help in
   understanding evolutionary mechanisms and relationships among the taxes
   in this section. The karyotypes of three species, F. densovillosum, F.
   gracilipes var. odontopterum and F. gracilipes are being reported for
   the first time. F. esculentum, F. cymosum, F. tataricum and F.
   densovillosum are diploid while F. gracilipes var. odontopterum and F.
   gracilipes are tetraploid, 2n = 4x = 32. At diploid level, the
   variation of the buckwheat chromosome karyotypes is bigger; however, on
   the tetraploid level, it shows a higher similarity. The karyotype
   evolutionary trend of buckwheat indicated that F. densovillosum seemed
   to be more advanced than F. gracilipes var. odontopterum and F.
   gracilipes. F. densovillosum, F. gracilipes var. odontopterum. and F.
   gracilipes were found more closely related genetically whereas F.
   tataricum clustered into a separate group. F. esculentum and F. cymosum
   clustered together in one separate group.
C1 [Yang, Xiao-yan; Wu, Zhen-Fang; Chen, Hui; Shao, Ji-rong; Wu, Qi] Sichuan Agr Univ, Coll Life Sci, Yaan 625014, Sichuan, Peoples R China.
RP Chen, H, Sichuan Agr Univ, Coll Life Sci, Yaan 625014, Sichuan, Peoples
   R China.
EM samkam@126.com
   chenhui@sicau.edu.cn
FU key scientific project of Sichuan, China [04NG001-015]
FX This work was supported by key scientific project of Sichuan, China
   (04NG001-015).
CR CHEN B, 2001, SPECTROSC SPECT ANAL, V21, P107
   HE FF, 1992, J SICHUAN AGR U, V14, P522
   HE XJ, 2001, ACTA PHYTOTAX SINICA, V39, P423
   KISHIMA Y, 1995, PLANT SCI, V108, P173
   KONG HH, 2007, ACTA PHYTOTAXON SIN, V45, P257
   LEI B, 2000, J SICHUAN U NAT SCI, V37, P142
   LI MX, 1985, J WUHAN BOT RES, V3, P297
   LIU XL, 2007, J YANGZHOU UNIV-NAT, V10, P49
   MORRIS MR, 1951, J HERED, V42, P85
   OHNISHI O, 1996, GENES GENET SYST, V71, P383
   OHNISHI O, 1998, FAGOPYRUM, V15, P18
   OHNISHI O, 1998, FAGOPYRUM, V15, P8
   SHARMA TR, 2002, THEOR APPL GENET, V105, P306, DOI
   10.1007/s00122-002-0938-9
   STEBBINS GL, 1971, CHROMOSOMAL EVOLUTIO
   STEVENS NE, 1912, BOT GAZ, V3, P277
   SUVOROVA GN, 1999, RUSS J GENET+, V35, P1428
   WANG AH, 2006, J XICHANG COLL NATUR, V20, P10
   WANG RX, 2001, ACTA PHYTOTAX SINICA, V39, P51
   YAMANE K, 2001, GENET RESOUR CROP EV, V48, P69
   YAMANE K, 2003, AM J BOT, V90, P339
   YANG K, 2006, SOLID STATE COMMUN, V139, P144, DOI
   10.1016/j.ssc.2006.05.040
   YASUI Y, 1998, AM J BOT, V85, P1134
   YASUI Y, 1998, GENES GENET SYST, V73, P201
   ZHANG H, 2000, J INNER MONGOLIA AGR, V21, P69
   ZHANG YZ, 2004, SEEDS, V23, P39
   ZHAO ZC, 2000, ACTA PHYTOTAXONOMICA, V38, P486
NR 26
TC 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-9864
J9 GENET RESOUR CROP EVOLUTION
JI Genet. Resour. Crop Evol.
PD JUN
PY 2010
VL 57
IS 5
BP 649
EP 656
DI 10.1007/s10722-009-9500-9
PG 8
SC Agronomy; Plant Sciences
GA 590QC
UT ISI:000277241100002
ER

PT J
AU Mei, J
   Li, Q
   Yang, X
   Qian, L
   Liu, L
   Yin, J
   Frauen, M
   Li, J
   Qian, W
AF Mei, J.
   Li, Q.
   Yang, X.
   Qian, L.
   Liu, L.
   Yin, J.
   Frauen, M.
   Li, J.
   Qian, W.
TI Genomic relationships between wild and cultivated Brassica oleracea L.
   with emphasis on the origination of cultivated crops
SO GENETIC RESOURCES AND CROP EVOLUTION
LA English
DT Article
DE Brassica oleracea; Cultivated form; Genomic relationships; Sicily; Wild
   taxa
ID GENETIC DIVERSITY; LEPTOSPHAERIA-MACULANS; LENGTH POLYMORPHISMS; RAPD
   MARKERS; RELATIVES 2N; DNA; POPULATION; CHLOROPLAST; RESISTANCE;
   CRUCIFERAE
AB Wild taxa in Brassica oleracea L. play an important role to improve
   cultivated crops, but the genomic relationships between wild and
   cultivated forms have not been well clarified. An overall survey of
   genomic relationships among 39 accessions covering 10 wild and 7
   cultivared types in B. oleracea was performed using amplified fragment
   length polymorphism and simple sequence repeat. The cultivated types
   were clustered together with B. oleracea ssp. oleracea, B. incana, B.
   bourgeaui, B. montana, B. cretica and B. hilarionis, while 4 wild taxa
   from Sicily, B. rupestris, B. insularis, B. macrocarpa and B. villosa
   formed the other group. It implies the low possibility that current B.
   oleracea crops originated in Sicily.
C1 [Mei, J.; Li, Q.; Yang, X.; Qian, L.; Liu, L.; Yin, J.; Li, J.; Qian, W.] Southwest Univ, Coll Agron & Biotechnol, Chongqing 400716, Peoples R China.
   [Frauen, M.] Norddeutsch Pflanzenzucht Hans Georg Lembke KG, D-24363 Hohenlieth, Germany.
RP Li, J, Southwest Univ, Coll Agron & Biotechnol, Chongqing 400716,
   Peoples R China.
EM ljn1950@swu.edu.cn
   qianwei666@hotmail.com
FU NPZ Company ; Natural Science Foundation [2007BB1362, 2006AA10ZIE6];
   Ministry of Education of China ; Ministry of Personnel of China Fund 
FX We thank CGN in Netherlands, IPK in Germany, UPM in Spain, Prof.
   Snogerup S from UL in Sweden and Prof. Quiros C from UC Davis for kind
   supports in collection of materials. It is financially supported by NPZ
   Company, Natural Science Foundation Project of CQ (2007BB1362), 863
   Project (2006AA10ZIE6) and Ministry of Education of China and Ministry
   of Personnel of China Fund to W. Qian.
CR *SAS I, 1992, SAS TECHN REP SAS ST
   ALLENDER CJ, 2007, THEOR APPL GENET, V114, P609, DOI
   10.1007/s00122-006-0461-5
   DIAS JS, 1995, GENET RESOUR CROP EV, V42, P363
   ELLIS PR, 1999, EUPHYTICA, V110, P207
   FALUSH D, 2007, MOL ECOL NOTES, V7, P574, DOI
   10.1111/j.1471-8286.2007.01758.x
   GERACI A, 2001, PLANT BREEDING, V120, P193
   GLADIS T, 2001, GENET RESOUR CROP EV, V48, P7
   GOMEZCAMPO C, 1999, BIOL BRASSICA COENOS
   HARBERD DJ, 1976, BIOL CHEM CRUCIFERAE
   KIANIAN SF, 1992, GENET RESOUR CROP EV, V39, P165
   LANNER C, 1997, GENOME, V40, P302
   LANNER C, 1998, CAN J BOT, V76, P228
   LAZARO A, 1996, SCI HORTIC-AMSTERDAM, V65, P219
   LAZARO A, 1998, ANN BOT-LONDON, V82, P821
   LAZARO A, 1998, ANN BOT-LONDON, V82, P829
   LOUARN S, 2007, GENET RESOUR CROP EV, V54, P1717, DOI
   10.1007/s10722-006-9181-6
   MEI J, 2008, ISHS BRASS S 16 CRUC, P81
   MITHEN RF, 1987, T BRIT MYCOL SOC, V88, P525
   MITHEN RF, 1992, PLANT BREEDING, V108, P60
   NEI M, 1979, P NATL ACAD SCI USA, V76, P5269
   PANDA S, 2003, THEOR APPL GENET, V106, P1122, DOI
   10.1007/s00122-002-1134-7
   PERRINO P, 1985, KULTURPFLANZE, V33, P225
   RAMSEY AD, 1994, ISHS BRASS S 9 CRUC
   ROHLF FJ, 1997, NTS YS PC 2 1 NUMERI
   SAGHAIMAROOF MA, 1984, P NATL ACAD SCI USA, V81, P8014
   SNEATH PHA, 1973, NUMERICAL TAXONOMY P
   SNOGERUP S, 1980, BRASSICA CROPS WILD, P121
   SNOGERUP S, 1990, WILLDENOWIA, V19, P271
   SONG K, 1990, THEOR APPL GENET, V79, P497
   THOMPSON KF, 1976, EVOLUTION CROP PLANT
   VONBOTHMER R, 1995, GENET RESOUR CROP EV, V42, P165
   VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407
   YAP IV, 1996, WINBOOT PROGRAM PERF
   ZHANG J, 2002, THEOR APPL GENET, V105, P1166, DOI
   10.1007/s00122-002-1100-4
NR 34
TC 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-9864
J9 GENET RESOUR CROP EVOLUTION
JI Genet. Resour. Crop Evol.
PD JUN
PY 2010
VL 57
IS 5
BP 687
EP 692
DI 10.1007/s10722-009-9504-5
PG 6
SC Agronomy; Plant Sciences
GA 590QC
UT ISI:000277241100006
ER

PT J
AU Zhang, H
   Jin, YB
   Zhang, ZX
   Yang, L
   Huang, YC
AF Zhang, Hong
   Jin, Yin-Bin
   Zhang, Zhen-Xi
   Yang, Lin
   Huang, Ye-Cho
TI Effects of electrical heterogeneity on transmural reentry during acute
   global ischemia
SO GENERAL PHYSIOLOGY AND BIOPHYSICS
LA English
DT Article
DE Arrhythmia; Acute ischemia; Computer simulation; Reentry; Transmural
   heterogeneity
ID ACTION-POTENTIAL DURATION; ACUTE MYOCARDIAL-ISCHEMIA; SUDDEN CARDIAC
   DEATH; LONG-QT SYNDROME; IONIC CURRENTS; M-CELLS; SIMULATION; MODEL;
   ARRHYTHMIAS; EPICARDIUM
AB Ventricular arrhythmias are commonly observed in patients with
   ischemia. It is reported that the electrophysiological changes evoked
   by ischemia are greater in the epicardium than in the endocardium. To
   investigate the effects of this heterogeneity on transmural reentry,
   the computer simulation method is used. A two-dimensional model which
   can reproduce the endocardial, epicardial and middle cell types,
   approximate the ischemic characteristics and distribution of the
   ischemic severity is developed by setting different ratios of the
   maximum conductance of the rapid and slow inward rectifier potassium
   currents and considering the three major component conditions of acute
   ischemia at the ionic level. The results demonstrate that action
   potentials of the ischemic cells have elevated resting potential,
   shortened duration, slowed upstroke and declined amplitude. Conduction
   velocity is much more depressed in the epicardium because of the
   ischemia-induced transmural gradient of excitability. The epicardially
   initiated activation has wider vulnerable window and more possibility
   to cause unidirectional propagation even reentry. Dispersion of the
   excitability is proposed to be the underlying mechanism.
C1 [Zhang, Hong; Jin, Yin-Bin] Xi An Jiao Tong Univ, Sch Elect Engn, Xian 710049, Shaanxi, Peoples R China.
   [Zhang, Hong; Zhang, Zhen-Xi; Huang, Ye-Cho] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ China, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.
   [Yang, Lin] Xi An Jiao Tong Univ, Hosp 1, Dept Cardiol, Xian 710061, Peoples R China.
RP Zhang, H, Xi An Jiao Tong Univ, Sch Elect Engn, 28 W Xianning Rd, Xian
   710049, Shaanxi, Peoples R China.
EM maxr@263.net
FU National Natural Science Foundation of P. R. China [30870659,
   30971221]; Health Foundation of Shaanxi Province, P. R. China [08D23]
FX This study is supported by the National Natural Science Foundation of
   P. R. China (No. 30870659 and 30971221) and the Health Foundation of
   Shaanxi Province, P. R. China (No. 08D23). We also thank Dr. Shien-Fong
   Lin (Krannert Institute of Cardiology, Indiana University School of
   Medicine, USA) for his advice and help.
CR AKAR FG, 2002, CIRCULATION, V105, P1247
   ANTZELEVITCH C, 2005, EUROPACE S2, V7, S3, DOI
   10.1016/j.eupc.2005.05.010
   ASLANIDI OV, 2007, COMPUTER CARDIOLOGY, V34, P241, DOI
   10.1109/CIC.2007.4745466
   BEELER GW, 1977, J PHYSIOL-LONDON, V268, P177
   BLANCA R, 2004, AM J PHYSIOL-HEART C, V286, H2078
   CARMELIET E, 1999, PHYSIOL REV, V79, P917
   CASCIO WE, 2001, J CARDIOVASC ELECTR, V12, P726
   CLAYTON RH, 2002, CHAOS SOLITON FRACT, V13, P1671
   CORDEIRO JM, 2008, AM J PHYSIOL-HEART C, V295, H154, DOI
   10.1152/ajpheart.01327.2007
   ELHARRAR V, 1977, AM J PHYSIOL, V233, H329
   FIGUEREDO VM, 1993, CIRC RES, V72, P1082
   FURUKAWA T, 1991, CIRC RES, V68, P1693
   GILMOUR RF, 1980, CIRC RES, V46, P814
   HENRY H, 2004, CHAOS, V14, P172, DOI 10.1063/1.1636272
   JANTUNEN E, 1989, APPL PATHOL, V7, P179
   KIMURA S, 1986, CIRCULATION, V74, P401
   LOPSHIRE JC, 2006, CIRCULATION, V114, P1134, DOI
   10.1161/CIRCULATIONAHA.106.647933
   LOWE JE, 1983, CIRCULATION, V68, P190
   LUKAS A, 1993, CIRCULATION, V88, P2903
   LUO CH, 1991, CIRC RES, V68, P1501
   LUO CH, 1994, CIRC RES, V74, P1071
   MICHAILOVA A, 2007, AM J PHYSIOL-CELL PH, V293, C542, DOI
   10.1152/ajpcell.00148.2006
   NOBLE D, 1991, ANN NY ACAD SCI, V639, P334
   NOBLE D, 1998, CAN J CARDIOL, V14, P123
   PIAO L, 2007, J MOL CELL CARDIOL, V43, P27, DOI
   10.1016/j.yjmcc.2007.04.002
   QI XY, 2000, ACTA PHYSL SINICA, V52, P360
   QU ZL, 2006, BIOPHYS J, V91, P793, DOI 10.1529/biophysj.106.080945
   RUBART M, 2005, J CLIN INVEST, V115, P2305, DOI 10.1172/JCI26381
   SHAW RM, 1997, CARDIOVASC RES, V35, P256
   TANG L, 2008, CIRCULATION S2, V118, S527
   TRENOR B, 2007, ANN BIOMED ENG, V35, P1756, DOI
   10.1007/s10439-007-9353-3
   VISWANATHAN PC, 1999, CIRCULATION, V99, P2466
   WU JS, 2002, AM J PHYSIOL-HEART C, V283, H2004, DOI
   10.1152/ajpheart.00965.2001
   XIE F, 2001, AM J PHYSIOL-HEART C, V280, H1667
   XU AX, 1998, CHAOS, V8, P157
   YANG Z, 2007, PHYSIOL MEAS, V28, P481
   ZHANG H, 2005, CHINESE J PHYSIOL, V48, P155
   ZHANG H, 2006, MATH BIOSCI, V203, P1, DOI 10.1016/j.mbs.2006.06.003
NR 38
TC 0
PU GENERAL PHYSIOL AND BIOPHYSICS
PI BRATISLAVA
PA INST OF MOLEC PHYSIOL GENETICS SLOVAK ACAD OF SCI VLARSKA 5, 83334
   BRATISLAVA, SLOVAKIA
SN 0231-5882
J9 GEN PHYSIOL BIOPHYS
JI Gen. Physiol. Biophys.
PD MAR
PY 2010
VL 29
IS 1
BP 12
EP 22
DI 10.4149/gpb_2010_01_12
PG 11
SC Biochemistry & Molecular Biology; Biophysics; Physiology
GA 589HD
UT ISI:000277136800003
ER

PT J
AU Yang, S
   Lin, G
   Tan, YQ
   Deng, LY
   Yuan, D
   Lu, GX
AF Yang, S.
   Lin, G.
   Tan, Y. -Q.
   Deng, L. -Y.
   Yuan, D.
   Lu, G. -X.
TI Differences between karyotypically normal and abnormal human embryonic
   stem cells
SO CELL PROLIFERATION
LA English
DT Article
ID HUMAN ES CELLS; CHROMOSOMAL-ABNORMALITIES; GENOMIC INSTABILITY;
   CULTURE; DIFFERENTIATION; FIBROBLASTS; PROTEINS; CANCER; P53
AB Objectives:
   To compare different biological characteristics of human embryonic stem
   cells (HESCs) between those with normal and those with abnormal
   karyotype.
   Materials and methods:
   Culture-adapted HESCs (chHES-3) with abnormal karyotype were compared
   with karyotypically normal cells, with regard to pluripotency and
   differentiation capacity, ultrastructure, growth characteristics, gene
   expression profiles and signalling pathways.
   Results:
   We found a new abnormal karyotype of HESCs. We observed that chHES-3
   cells with normal and abnormal karyotypes shared similarities in
   expression markers of pluripotency; however, karyotypically abnormal
   chHES-3 cells had a tendency for differentiation towards ectoderm
   lineages and were easily maintained in suboptimal culturing conditions.
   Abnormal chHES-3 cells displayed relatively mature cell organelles
   compared to normal cells, and karyotypically abnormal chHES-3 cells had
   increased survival and population growth. Genes related to cell
   proliferation and apoptosis were up-regulated, but genes associated
   with genetic instability (p53, Rb, BRCA1) were down-regulated in the
   karyotypically abnormal cells.
   Conclusion:
   Karyotypically abnormal chHES-3 cells had a more developed capacity for
   proliferation, resistance to apoptosis and less genetic stability
   compared to normal chHES-3 cells and may be an excellent model for
   studying and characterizing initial stages that determine transition of
   embryonic stem cells into cancer stem cells.
C1 [Lu, G. -X.] Cent S Univ, Inst Reprod & Stem Cell Engn, Changsha, Peoples R China.
   Natl Engn Res Ctr Human Stem Cells, Changsha, Peoples R China.
RP Lu, GX, Cent S Univ, Inst Reprod & Stem Cell Engn, Changsha, Peoples R
   China.
EM lugxdirector@yahoo.com.cn
FU National Natural Science Foundation Major Program of China [30030070];
   Hi-Tech Research and Development of China [2003AA205181, 2006AA02A102];
   National Basic Research Program of China [00CB 51010]
FX The authors thank Associate Prof. Jozef Lazar and Assistant Prof. Aron
   Geurts for revising and editing the manuscript. This study was
   supported by the National Natural Science Foundation Major Program of
   China (No. 30030070), the Hi-Tech Research and Development of China
   (863 program No. 2003AA205181 and 2006AA02A102) and the National Basic
   Research Program of China (973 program No. 00CB 51010).
CR ANDREWS PW, 2002, PHILOS T ROY SOC B, V357, P405
   ANDREWS PW, 2006, NAT BIOTECHNOL, V24, P325, DOI 10.1038/nbt0306-325
   BAKER DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285
   BUZZARD JJ, 2004, NAT BIOTECHNOL, V22, P381, DOI 10.1038/nbt0404-381
   DRAPER JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   ENVER T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345
   GORGOULIS VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   HERSZFELD D, 2006, NAT BIOTECHNOL, V24, P351, DOI 10.1038/nbt1197
   HOFFMAN LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
   HOUGHTON FD, 1996, MOL REPROD DEV, V44, P476
   IMREH MP, 2006, J CELL BIOCHEM, V99, P508, DOI 10.1002/jcb.20897
   INZUNZA J, 2004, MOL HUM REPROD, V10, P461, DOI 10.1093/molehr/gah051
   KEITH WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762
   LEFORT N, 2008, NAT BIOTECHNOL, V26, P1364, DOI 10.1038/nbt.1509
   LIN TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211
   LIVAK KJ, 2001, METHOD METHODS, V4, P402
   LONGO L, 1997, TRANSGENIC RES, V6, P321
   MAHENDRA R, 2004, DEV BIOL, V275, P269
   MAITRA A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631
   MARTIN KL, 2000, HUM FERTIL CAMB, V3, P247
   MITALIPOVA MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19
   NEVINS JR, 2001, HUM MOL GENET, V10, P699
   PETER M, 1994, CELL, V79, P181
   QIN H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200
   SANDBERG AA, 1996, J UROLOGY, V155, P1531
   SKOTHEIM RI, 2003, APMIS, V111, P136
   SPITS C, 2008, NAT BIOTECHNOL, V26, P1361, DOI 10.1038/nbt.1510
   THOMSON JA, 1998, SCIENCE, V282, P1147
   WERNIG M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   XIE CQ, 2004, BIOCHEM BIOPH RES CO, V315, P581, DOI
   10.1016/j.bbrc.2004.01.089
   YANG S, 2008, GENE CHROMOSOME CANC, V47, P665, DOI 10.1002/gcc.20574
NR 31
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD JUN
PY 2010
VL 43
IS 3
BP 195
EP 206
DI 10.1111/j.1365-2184.2010.00669.x
PG 12
SC Cell Biology
GA 589PL
UT ISI:000277164400001
ER

PT J
AU Pan, K
   Sun, Q
   Zhang, J
   Ge, S
   Li, S
   Zhao, Y
   Yang, P
AF Pan, K.
   Sun, Q.
   Zhang, J.
   Ge, S.
   Li, S.
   Zhao, Y.
   Yang, P.
TI Multilineage differentiation of dental follicle cells and the roles of
   Runx2 over-expression in enhancing osteoblast/cementoblast-related gene
   expression in dental follicle cells
SO CELL PROLIFERATION
LA English
DT Article
ID MARROW STROMAL CELLS; CEMENTUM ATTACHMENT PROTEIN; OSTEOBLAST
   DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; STEM-CELLS; IN-VITRO; CBFA1;
   TOOTH; CEMENTOGENESIS; BIOLOGY
AB Objectives:
   Dental follicle cells (DFCs) provide the origin of periodontal tissues,
   and Runx2 is essential for bone formation and tooth development. In
   this study, pluripotency of DFCs was evaluated and effects of Runx2 on
   them were investigated.
   Materials and methods:
   The DFCs were induced to differentiate towards osteoblasts, adipocytes
   or chondrocytes, and alizarin red staining, oil red O staining or
   alcian blue staining was performed to reveal the differentiated states.
   Bone marrow stromal cells (BMSCs) and primary mouse fibroblasts served
   as controls. DFCs were also infected with recombinant retroviruses
   encoding either full-length Runx2 or mutant Runx2 without the VWRPY
   motif. Western blot analysis, real-time real time RT-PCR and in vitro
   mineralization assay were performed to evaluate the effects of
   full-length Runx2 or mutant Runx2 on osteogenic/cementogenic
   differentiation of the cells.
   Results:
   The above-mentioned staining methods demonstrated that DFCs were
   successfully induced to differentiate towards osteoblasts, adipocytes
   or chondrocytes respectively, confirming the existence of pluripotent
   mesenchymal stem cells in dental follicle tissues. However, staining
   intensity in DFC cultures was weaker than in BMSC cultures. Real-time
   PCR analysis indicated that mutant Runx2 induced a more pronounced
   increase in expression levels of OC, OPN, Col I and CP23 than
   full-length Runx2. Mineralization assay also showed that mutant Runx2
   increased mineralization nodule formation more prominently than
   full-length Runx2.
   Conclusions:
   Multipotent DFCs can be induced to differentiate towards osteoblasts,
   adipocytes or chondrocytes in vitro. Runx2 over-expression up-regulated
   expression levels of osteoblast/cementoblast-related genes and in vitro
   enhanced osteogenic differentiation of DFCs. In addition, mutant
   Runx2-induced changes in DFCs were more prominent than those induced by
   full-length Runx2.
C1 [Pan, K.; Sun, Q.; Zhang, J.; Ge, S.; Li, S.; Yang, P.] Shandong Univ, Sch Dent, Dept Periodontol, Jinan 250012, Shandong, Peoples R China.
   [Pan, K.; Sun, Q.; Zhang, J.; Ge, S.; Li, S.; Yang, P.] Shandong Univ, Sch Dent, Inst Oral Biomed, Jinan 250012, Shandong, Peoples R China.
   [Pan, K.] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Stomatol, Qingdao 266071, Peoples R China.
   [Zhao, Y.] Tianjin Med Univ, Stomatol Hosp, Dept Orthodont, Tianjin, Peoples R China.
RP Yang, P, Shandong Univ, Sch Dent, Dept Periodontol, 44-1 Wenhuaxi Rd,
   Jinan 250012, Shandong, Peoples R China.
EM yangps@sdu.edu.cn
FU national Natural Science Foundation of China, Beijing, China
   [30772425]; Shandong Provincial Natural Science Foundation, Jinan,
   China [Y 2007C 091]
FX This study was supported by grants from the national Natural Science
   Foundation of China (No. 30772425), Beijing, China, and Shandong
   Provincial Natural Science Foundation (No. Y 2007C 091), Jinan, China.
CR ARZATE H, 2002, J DENT RES, V81, P541
   BOSSHARDT DD, 1996, ANAT RECORD, V245, P267
   BRONCKERS ALJJ, 2001, MECH DEVELOP, V101, P255
   BRUHN L, 1997, GENE DEV, V11, P640
   CHAI Y, 2000, DEVELOPMENT, V127, P1671
   CHO MI, 1988, J PERIODONTAL RES, V23, P268
   CHO MI, 2000, PERIODONTOL 2000, V24, P9
   COVELLO KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906
   DATTA N, 2005, BIOMATERIALS, V26, P971, DOI
   10.1016/j.biomaterials.2004.04.001
   DIEKWISCH TGH, 2001, INT J DEV BIOL, V45, P695
   DSOUZA RN, 1999, DEVELOPMENT, V126, P2911
   DUCY P, 1997, CELL, V89, P747
   DUCY P, 2000, DEV DYNAM, V219, P461
   FOSTER BL, 2007, CURR TOP DEV BIOL, V78, P47, DOI
   10.1016/S0070-2153(06)78003-6
   GRAYSON WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   HATA K, 2005, MOL CELL BIOL, V25, P1971, DOI
   10.1128/MCB.25.5.1971-1979.2005
   HITCHIN AD, 1975, BR DENT J, V139, P313
   HONG JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   HOU LT, 1999, ARCH ORAL BIOL, V44, P759
   JAVED A, 2000, J CELL SCI, V113, P2221
   JENSEN BL, 1990, J ORAL PATHOL, V19, P89
   KOMORI T, 1997, CELL, V89, P755
   KWON YJ, 2003, J VIROL, V77, P5712, DOI 10.1128/JVI.77.10.5715-5720.2003
   LEZOT F, 2000, J HISTOCHEM CYTOCHEM, V48, P277
   LI S, 2008, J CELL PHYSIOL, V215, P204, DOI 10.1002/jcp.21302
   LINDROOS B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI
   10.1016/j.bbrc.2008.01.081
   MACNEIL RL, 1993, J PERIODONTOL, V64, P285
   MCLARREN KW, 2001, J BIOL CHEM, V276, P1578
   MORSCZECK C, 2005, MATRIX BIOL, V24, P155, DOI
   10.1016/j.matbio.2004.12.004
   MORSCZECK C, 2006, CALCIFIED TISSUE INT, V78, P98, DOI
   10.1007/s00223-005-0146-0
   MORSCZECK C, 2008, CLIN ORAL INVEST, V12, P113, DOI
   10.1007/s00784-007-0170-8
   OTTO F, 1997, CELL, V89, P765
   PAN K, 2009, CELL PROLIFERAT, V42, P364, DOI
   10.1111/j.1365-2184.2009.00599.x
   PAYNTER KJ, 1958, ANAT REC, V131, P233
   PEREZ MAA, 2003, J STRUCT BIOL, V143, P1, DOI
   10.1016/S1047-8477(03)001160-3
   PITARU S, 1992, J PERIODONTAL RES, V27, P640
   PITARU S, 1995, J PERIODONTAL RES, V30, P360
   PITTENGER MF, 1999, SCIENCE, V284, P147
   POLIMENI G, 2006, PERIODONTOL 2000, V41, P30
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177
   SAITO M, 2001, BONE, V29, P242
   SIERRA J, 2003, MOL CELL BIOL, V23, P3339, DOI
   10.1128/MCB.23.9.3339-3351.2003
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420
   STEIN GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   TENCATE AR, 1997, PERIODONTOL 2000, V13, P9
   THIRUNAVUKKARASU K, 1998, MOL CELL BIOL, V18, P4197
   TU Q, 2008, J CELL PHYSIOL, V217, P40, DOI 10.1002/jcp.21472
   TU QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI
   10.1016/j.bbrc.2006.01.092
   VANDENBOS T, 2005, J DENT RES, V84, P1021
   VILLARREALRAMIREZ E, 2009, BIOCHEM BIOPH RES CO, V384, P49, DOI
   10.1016/j.bbrc.2009.04.072
   WEBB PP, 1996, J ANAT 3, V188, P529
   WISE GE, 1992, CELL TISSUE RES, V267, P483
   XIE Y, 2008, CHIN J STOMATOL RES, V2, P14
NR 53
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD JUN
PY 2010
VL 43
IS 3
BP 219
EP 228
DI 10.1111/j.1365-2184.2010.00670.x
PG 10
SC Cell Biology
GA 589PL
UT ISI:000277164400003
ER

PT J
AU Yen, TH
   Chen, Y
   Fu, JF
   Weng, CH
   Tian, YC
   Hung, CC
   Lin, JL
   Yang, CW
AF Yen, T. -H.
   Chen, Y.
   Fu, J. -F.
   Weng, C. -H.
   Tian, Y. -C.
   Hung, C. -C.
   Lin, J. -L.
   Yang, C. -W.
TI Proliferation of myofibroblasts in the stroma of renal oncocytoma
SO CELL PROLIFERATION
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA;
   BONE-MARROW-CELLS; CD34(+) FIBROCYTES; PROSTATE-CANCER; TUMOR INVASION;
   COLON-CANCER; FIBROBLASTS; SMOOTH; GROWTH
AB Objectives:
   Myofibroblasts are a vital component of stroma of many malignant
   neoplasms, but it is not yet established whether stromal myofibroblasts
   also exist in benign tumours such as oncocytoma of the kidney.
   Materials and methods:
   Histomorphological and immunohistochemical analysis of 16 renal
   oncocytomas diagnosed at Chang Gung Memorial Hospital, Taiwan, has been
   performed.
   Results:
   Renal oncocytomas were composed of oncocytes, large cells with granular
   eosinophilic cytoplasm, arranged mostly in sheets, in tubulocystic or
   combined pattern. Few oncocytes appeared to be undergoing proliferation
   or apoptosis. MIB-1 and active caspase 3 indices were low, but higher
   in tumour than in surrounding non-tumour parenchyma (MIB-1: 0.93 +/-
   0.09 versus 0.46 +/- 0.07, P < 0.001 and active caspase 3: 0.76 +/-
   0.08 versus 0.41 +/- 0.09, P < 0.001). Wnt/beta-catenin signalling was
   not implicated in this neoplasm, as there was no loss of E-cadherin
   membranous localization or expression of intranuclear beta-catenin in
   the cells. Clumps of oncocytes were stained with periodic acid Schiff
   and had collagen I-, collagen III- and fibronectin-positive, but
   desmin- and human caldesmon-negative stromas. Importantly, alpha-smooth
   muscle actin (SMA)-immunostaining established the myofibroblastic
   nature of many of the stromal cells. Some of the myofibroblasts were
   also positive for MIB-1, indicating a proliferative role for them in
   the stroma.
   Conclusions:
   Renal oncocytomas were composed of two independent compartments: benign
   oncocytes and pronounced fibrotic stroma, which consisted of
   proliferating myofibroblasts (SMA- and MIB-1-positive) which were
   associated with excessive deposition of extracellular matrix (periodic
   acid Schiff-component, collagen I-, collagen III- and
   fibronectin-positive, and desmin- and human caldesmon-negative).
C1 [Yen, T. -H.; Weng, C. -H.; Tian, Y. -C.; Hung, C. -C.; Lin, J. -L.; Yang, C. -W.] Chang Gung Mem Hosp, Dept Nephrol, Taipei 105, Taiwan.
   [Chen, Y.] Chang Gung Mem Hosp, Dept Urol, Taipei 105, Taiwan.
   [Fu, J. -F.] Chang Gung Mem Hosp, Dept Med Res, Taipei 105, Taiwan.
   [Yen, T. -H.; Chen, Y.; Fu, J. -F.; Weng, C. -H.; Tian, Y. -C.; Hung, C. -C.; Lin, J. -L.; Yang, C. -W.] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
RP Yen, TH, Chang Gung Mem Hosp, Dept Nephrol, 199 Tung Hwa N Rd, Taipei
   105, Taiwan.
EM m19570@adm.cgmh.org.tw
FU Chang Gung Memorial Hospital [CMRP G370601, G370602]; National Science
   Council of Taiwan [NMRP G370601]
FX Parts of this study have been presented at the annual meeting of the
   Taiwan Society of Nephrology (12-13 December 2008, Taipei, Taiwan).
   Tzung-Hai Yen was funded by research grants from the Chang Gung
   Memorial Hospital (CMRP G370601 and G370602) and National Science
   Council of Taiwan (NMRP G370601).
CR ABE R, 2001, J IMMUNOL, V166, P7556
   ALISON MR, 1995, HUM EXP TOXICOL, V14, P935
   BARSKY SH, 1984, AM J PATHOL, V115, P329
   BARTH PJ, 2002, VIRCHOWS ARCH, V440, P128
   BARTH PJ, 2002, VIRCHOWS ARCH, V440, P298
   BARTH PJ, 2002, VIRCHOWS ARCH, V441, P564, DOI 10.1007/s00428-002-0713-y
   BENTZON JF, 2007, CIRCULATION, V116, P2053, DOI
   10.1161/CIRCULATIONAHA.107.722355
   BISSELL MJ, 2001, NAT REV CANCER, V1, P46
   BRITTAN M, 2005, GASTROENTEROLOGY, V128, P1984, DOI
   10.1053/j.gastro.2005.03.028
   DEWEVER O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925
   DIREKZE NC, 2004, CANCER RES, V64, P8492
   DOUCET C, 2000, ONCOGENE, V19, P5898
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   FANG TC, 2008, CELL PROLIFERAT, V41, P575, DOI
   10.1111/j.1365-2184.2008.00545.x
   FANG TC, 2008, CELL PROLIFERAT, V41, P592, DOI
   10.1111/j.1365-2184.2008.00546.x
   GABBIANI G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   GUARINO M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI
   10.1016/j.biocel.2007.07.011
   GUARINO M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   GUPTA PB, 2007, CANCER RES, V67, P2062, DOI
   10.1158/0008-5472.CAN-06-3895
   HALL PA, 1994, BRIT J CANCER, V70, P244
   IWANO M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   KAAIJK P, 2003, BRIT J CANCER, V88, P775, DOI 10.1038/sj.bjc.6600787
   KALLURI R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   KALLURI R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   KISSELEVA T, 2006, J HEPATOL, V45, P429, DOI 10.1016/j.jhep.2006.04.014
   KLEIN MJ, 1976, CANCER, V38, P906
   KOJC N, 2005, HUM PATHOL, V36, P16, DOI 10.1016/j.humpath.2004.10.011
   LIU YH, 2004, J AM SOC NEPHROL, V15, P1, DOI
   10.1097/01.ASN.0000106015.29070.E7
   LOHR M, 2001, CANCER RES, V61, P550
   MARTIN M, 1996, PATHOL RES PRACT, V192, P712
   MIURA S, 1993, J SURG ONCOL, V53, P36
   MOLLMANN H, 2006, CARDIOVASC RES, V71, P661, DOI
   10.1016/j.cardiores.2006.06.013
   MORRA MN, 1993, J UROLOGY, V150, P295
   NEAUD V, 1997, HEPATOLOGY, V26, P1458
   PARK JE, 1999, J BIOL CHEM, V274, P36505
   RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859
   ROWLEY DR, 1998, CANCER METAST REV, V17, P411
   SAPPINO AP, 1988, INT J CANCER, V41, P707
   SAPPINO AP, 1990, LAB INVEST, V63, P144
   TUXHORN JA, 2002, CLIN CANCER RES, V8, P2912
   VANHOORDE L, 2000, PROG MOLEC, V25, P105
   XU QB, 2003, CIRC RES, V93, E76, DOI 10.1161/01.RES.0000097864.24725.60
   YEN TH, 2006, STEM CELL REV, V2, P203
   YEN TH, 2007, CELL PROLIFERAT, V40, P143
   ZIPPEL L, 1942, VIRCHOWS ARCH A, V308, P360
NR 45
TC 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD JUN
PY 2010
VL 43
IS 3
BP 287
EP 296
DI 10.1111/j.1365-2184.2010.00681.x
PG 10
SC Cell Biology
GA 589PL
UT ISI:000277164400009
ER

PT J
AU Yang, YF
   Steeg, J
   Honaramooz, A
AF Yang, Yanfei
   Steeg, Jordon
   Honaramooz, Ali
TI The effects of tissue sample size and media on short-term hypothermic
   preservation of porcine testis tissue
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Gonocytes; Testis tissue; Hypothermic; Leibovitz L15; HypoThermosol;
   Porcine (Yorkshire-cross)
ID GERM-CELL TRANSPLANTATION; TESTICULAR TISSUE; STEM-CELLS; COLD-STORAGE;
   CRYOPRESERVATION; MICE; TRANSMISSION; FERTILITY; GONOCYTES; SPERM
AB The objective of this study was to develop effective strategies for
   hypothermic preservation of immature porcine testis tissue to maintain
   structural integrity and cell viability. In Experiment 1, testes from
   1-week-old piglets were used to study the effects of tissue sample size
   (as intact testes or fragments of 100-or 30 mg) and the use of one of 9
   different media on hypothermic preservation of the testis tissue for 6
   days. The examined media included: Dulbecco's phosphate-buffered saline
   (DPBS), Dulbecco's modified Eagle's medium (DMEM), Leibovitz L15 (L15),
   L15 with fetal bovine serum (FBS, at 10%, 20% or 50%), HypoThermosol
   solution-FRS (HTS), Ham's F12, and Media 199. On days 0, 3, and 6,
   testis tissues were digested to compare the cell survival rates. Tissue
   sections were also semi-quantitatively assessed to determine the
   efficiency of different preservation strategies. There was no effect of
   testis sample size (P > 0.05), but cell survival rates of testis cells
   isolated from preserved testis tissues changed depending on the media
   and day (P < 0.05). Testis tissue within HTS did not show morphological
   changes after 6 days. In Experiment 2, two of the top performing media
   (20% FBS-L15 and HTS) were selected for immunocytochemical detection of
   gonocytes. Proportions of gonocytes (%) in isolated testis cells,
   however, did not differ between the two media on days 0, 3, or 6. These
   results show that testis tissue can be maintained for 3 days at 4A
   degrees C with high cell survival rate, and tissue morphology can be
   preserved for at least 6 days in HTS.
C1 [Yang, Yanfei; Steeg, Jordon; Honaramooz, Ali] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Biomed Sci, Saskatoon, SK S7N 5B4, Canada.
RP Honaramooz, A, Univ Saskatchewan, Western Coll Vet Med, Dept Vet Biomed
   Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.
EM ali.honaramooz@usask.ca
FU University of Saskatchewan Colleges of Graduate Studies and Veterinary
   Medicine ; Natural Sciences and Engineering Research Council (NSERC) of
   Canada 
FX We thank the University of Saskatchewan Colleges of Graduate Studies
   and Veterinary Medicine for scholarships (to Y. Yang), and the Natural
   Sciences and Engineering Research Council (NSERC) of Canada for a
   summer student scholarship (to J. Steeg) and grants (to A. Honaramooz)
   to support this project.
CR ABRISHAMI M, 2010, THERIOGENOLOGY, V73, P86, DOI
   10.1016/j.theriogenology.2009.08.004
   BAICU SC, 2002, CRYOBIOLOGY, V45, P33
   BONVENTRE JV, 1985, AM J PHYSIOL, V249, C149
   BRONK SF, 1993, AM J PHYSIOL, V264, P744
   CRABBE E, 1999, INT J ANDROL, V22, P43
   DEROOIJ DG, 1998, INT J EXP PATHOL, V79, P67
   DOBRINSKI I, 2007, REPROD FERT DEVELOP, V19, P732, DOI 10.1071/RD07036
   EHMCKE J, 2008, REPRODUCTION, V136, P717, DOI 10.1530/REP-08-0093
   FRANCA LR, 2000, BIOL REPROD, V63, P1629
   FRANKENHUIS MT, 1981, INT J ANDROL, V4, P105
   FULLER BJ, 1988, TRANSPLANTATION, V45, P239
   GOEL S, 2007, BIOL REPROD, V77, P127, DOI 10.1095/biolreprod.106.056879
   GOOSSENS E, 2008, FERTIL STERIL, V89, P725, DOI
   10.1016/j.fertnstert.2007.03.044
   HOCHACHKA PW, 1983, SCIENCE, V219, P1391
   HONARAMOOZ A, 2002, BIOL REPROD, V66, P21
   HONARAMOOZ A, 2002, NATURE, V418, P778
   HONARAMOOZ A, 2003, BIOL REPROD, V69, P1260, DOI
   10.1095/biolreprod.103.018788
   HONARAMOOZ A, 2004, BIOL REPROD, V70, P1500, DOI
   10.1095/biolreprod.103.025536
   HONARAMOOZ A, 2008, FASEB J, V22, P374
   HUGHES PE, 1980, REPROD PIG
   JAHNUKAINEN K, 2007, HUM REPROD, V22, P1060, DOI 10.1093/humrep/del471
   KEROS V, 2007, HUM REPROD, V22, P1384, DOI 10.1093/humrep/del508
   LINDELL S, 1998, TRANSPLANT INT, V11, P208
   MILAZZO JP, 2008, HUM REPROD, V23, P17, DOI 10.1093/humrep/dem355
   OATLEY JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI
   10.1146/annurev.cellbio.24.110707.175355
   RYU BY, 2004, DEV BIOL, V274, P158, DOI 10.1016/j.ydbio.2004.07.004
   SETHU P, 2004, ANAL CHEM, V76, P6247, DOI 10.1021/ac049429p
   SHINOHARA T, 2002, HUM REPROD, V17, P3039
   SMITH K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3
   SONG Y, 2007, POULTRY SCI, V86, P1390
   SOUTHARD JH, 1995, ANNU REV MED, V46, P235
   WYNS C, 2007, HUM REPROD, V22, P1603
   YANG YF, 2010, REPROD FERT DEVELOP, V22, P523, DOI 10.1071/RD09206
   ZENG W, 2009, REPROD FERT DEVELOP, V21, P489, DOI 10.1071/RD08235
NR 34
TC 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD MAY
PY 2010
VL 340
IS 2
BP 397
EP 406
DI 10.1007/s00441-010-0946-z
PG 10
SC Cell Biology
GA 589HE
UT ISI:000277136900016
ER

PT J
AU Wang, YX
   Jha, AK
   Chen, RJ
   Doonan, JH
   Yang, M
AF Wang, Yixing
   Jha, Ajay K.
   Chen, Rujin
   Doonan, John H.
   Yang, Ming
TI Polyploidy-Associated Genomic Instability in Arabidopsis thaliana
SO GENESIS
LA English
DT Article
DE cell cycle; flow cytometry; cyclin; aneuploid; generative cell; dyad
ID EVOLUTION; CELLS; MEIOSIS; SENESCENCE; PATTERNS; DIVISION; TELEOSTS
AB Formation of polyploid organisms by fertilization of unreduced gametes
   in meiotic mutants is believed to be a common phenomenon in species
   evolution. However, not well understood is how species in nature
   generally exist as haploid and diploid organisms in a long evolutionary
   time while polyploidization must have repeatedly occurred via meiotic
   mutations. Here, we show that the ploidy increased for two consecutive
   generations due to unreduced but viable gametes in the Arabidopsis
   cyclin a1;2-2 (also named tardy asynchronous meiosis-2) mutant, but the
   resultant octaploid plants produced progeny of either the same or
   reduced ploidy via genomic reductions during meiosis and pollen
   mitosis. Ploidy reductions through sexual reproduction were also
   observed in independently generated artificial octaploid and hexaploid
   Arabidopsis plants. These results demonstrate that octaploid is likely
   the maximal ploidy produced through sexual reproduction in Arabidopsis.
   The polyploidy-associated genomic instability may be a general
   phenomenon that constrains ploidy levels in species evolution. genesis
   48:254-263,2010. (C) 2010 Wiley-Liss, Inc.
C1 [Wang, Yixing; Jha, Ajay K.; Yang, Ming] Oklahoma State Univ, Dept Bot, Stillwater, OK 74078 USA.
   [Chen, Rujin] Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA.
   [Doonan, John H.] John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.
RP Yang, M, Oklahoma State Univ, Dept Bot, 104 Life Sci E, Stillwater, OK
   74078 USA.
EM ming.yang@okstate.edu
FU Underwood Fellowship ; BBSRC ; Samuel Roberts Noble Foundation ;
   Oklahoma State University 
FX Contract grant sponsors: The Underwood Fellowship, BBSRC, The Samuel
   Roberts Noble Foundation, Oklahoma State University.
CR BENNETZEN JL, 2007, CURR OPIN PLANT BIOL, V10, P176, DOI
   10.1016/j.pbi.2007.01.010
   BUGGS RJA, 2009, HEREDITY, V103, P73, DOI 10.1038/hdy.2009.24
   CHAUDHARY B, 2009, GENETICS, V182, P503
   DAVIS E, 2008, ONCOGENE, V27, P976, DOI 10.1038/sj.onc.1210701
   DERFURTH I, 2008, PLOS GENET, V4, ARTN e1000274
   DERFURTH I, 2009, PLOS BIOL, V7, ARTN e1000124
   EILAM T, 2008, GENOME, V51, P616, DOI 10.1139/G08-043
   EVANS BJ, 2004, MOL PHYLOGENET EVOL, V33, P197, DOI
   10.1016/j.ympev.2004.04.018
   FAWCETT JA, 2009, P NATL ACAD SCI USA, V106, P5737, DOI
   10.1073/pnas.0900906106
   GAFF DF, 1971, J EXP BOT, V22, P756
   JIANG LY, 2009, MOL PHYLOGENET EVOL, V52, P183, DOI
   10.1016/j.ympev.2009.03.004
   LI XC, 2009, HEREDITY, V102, P24, DOI 10.1038/hdy.2008.84
   MACQUEEN DJ, 2008, PLOS ONE, V3, ARTN e1567
   MADLUNG A, 2005, PLANT J, V41, P221, DOI
   10.1111/j.1365-313X.2004.02297.x
   MAGNARD JL, 2001, PLANT PHYSIOL, V127, P1157
   MANSILLA S, 2009, BIOCHEM PHARMACOL, V78, P123, DOI
   10.1016/j.bcp.2009.03.027
   MATZKE MA, 1999, BIOESSAYS, V21, P761
   MAYER VW, 1990, MUTAT RES, V231, P177
   MOGHADAM HK, 2009, BMC GENOMICS, V10, ARTN 278
   NGUYEN HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963
   OTTO SP, 2007, CELL, V131, P452, DOI 10.1016/j.cell.2007.10.022
   RAJARAMAN R, 2005, CELL BIOL INT, V29, P1084, DOI
   10.1016/j.cellbi.2005.10.003
   RAVI M, 2008, NATURE, V451, P1121, DOI 10.1038/nature06557
   ROH M, 2008, LOS ONE, V3, E2572
   ROUSSEAUGUEUTIN M, 2008, GENETICS, V179, P2045, DOI
   10.1534/genetics.107.083840
   SEMON M, 2007, MOL BIOL EVOL, V24, P860, DOI 10.1093/molbev/msm003
   SLIWINSKA MA, 2009, MECH AGEING DEV, V130, P24, DOI
   10.1016/j.mad.2008.04.011
   STORCHOVA Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178
   WALEN KH, 2008, CELL CYCLE, V7, P1623
   WANG YX, 2004, PLANT PHYSIOL, V136, P4127, DOI 10.1104/pp.104.051201
NR 30
TC 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD APR
PY 2010
VL 48
IS 4
BP 254
EP 263
DI 10.1002/dvg.20610
PG 10
SC Developmental Biology; Genetics & Heredity
GA 587UF
UT ISI:000277018300005
ER

PT J
AU Kwon, YS
   Oh, YH
   Yi, SI
   Kim, HY
   An, JM
   Yang, SG
   Ok, SH
   Shin, JS
AF Kwon, Yong-Sham
   Oh, You-Hwan
   Yi, Seung-In
   Kim, Hee-Yeul
   An, Jong-Moon
   Yang, Seung-Gyun
   Ok, Sung-Han
   Shin, Jeong-Sheop
TI Informative SSR markers for commercial variety discrimination in
   watermelon (Citrullus lanatus)
SO GENES & GENOMICS
LA English
DT Article
DE Genetic characterization; Molecular fingerprinting; SSR marker;
   Watermelon
ID GENIC MICROSATELLITE MARKERS; SIMPLE SEQUENCE REPEATS; GENETIC
   ASSESSMENT; L. VARIETIES; LINKAGE MAPS; IDENTIFICATION; CONSTRUCTION;
   UNIFORMITY; DIVERSITY; GERMPLASM
AB SSR markers were used for variety discrimination and genetic assessment
   in watermelon varieties. Genetic characterization of 49 watermelon
   varieties was investigated using 30 SSR markers developed from melon
   and watermelon. A total of 121 polymorphic amplified fragments were
   obtained by using 30 SSR markers. The average polymorphism information
   content (PIC) was 0.502 ranging from 0.223 to 0.800. One hundred twenty
   one SSR loci were used to calculate Jaccard's distance coefficients for
   unweighted pair group method using the arithmetic averages (UPGMA)
   cluster analysis. A clustering group of varieties, based on the results
   of SSR analysis, were categorized into 5 major groups corresponding to
   morphological traits. Inheritance mode of 2 SSR markers was
   investigated to F-1 plants and F-2 populations of 2 crosses. Parental
   alleles were transmitted from F1 plants and F2 populations. Therefore,
   these marker sets may prove to be effectively applicable to genetic
   assessment of germplasm, genome mapping, and fingerprinting of
   watermelon varieties.
C1 [Kwon, Yong-Sham; Oh, You-Hwan; Kim, Hee-Yeul] MIFAFF, Korea Seed & Variety Serv, Variety Testing Div, Suwon 443400, South Korea.
   [Yi, Seung-In] MIFAFF, Korea Seed & Variety Serv, Plant Variety Protect Div, Anyang 430016, South Korea.
   [An, Jong-Moon; Yang, Seung-Gyun] Nong Woo Bio Co, Breeding Inst, Yeoju 468885, Gyeonggi, South Korea.
   [Ok, Sung-Han; Shin, Jeong-Sheop] Korea Univ, Grad Sch Biotechnol, Div Plant Technol, Seoul 136701, South Korea.
RP Kwon, YS, MIFAFF, Korea Seed & Variety Serv, Variety Testing Div, Suwon
   443400, South Korea.
EM yskwon@seed.go.kr
FU Technology Development Program for Agriculture and Forestry, Ministry
   of Agriculture and Forestry, Republic of Korea 
FX This study was supported by the Technology Development Program for
   Agriculture and Forestry, Ministry of Agriculture and Forestry,
   Republic of Korea.
CR *UPOV BMT, 2002, 36 SESS TECHN COMM T
   AGGARWAL RK, 2007, THEOR APPL GENET, V114, P359, DOI
   10.1007/s00122-006-0440-x
   ANDERSON JA, 1993, GENOME, V36, P181
   BREDEMEIJER GMM, 2002, THEOR APPL GENET, V105, P1019, DOI
   10.1007/s00122-002-1038-6
   CHE KP, 2003, HORTSCIENCE, V38, P81
   DANINPOLEG Y, 2001, THEOR APPL GENET, V102, P61
   ESSELINK GD, 2003, THEOR APPL GENET, V106, P277, DOI
   10.1007/s00122-002-1122-y
   GONZALO MJ, 2005, THEOR APPL GENET, V110, P802, DOI
   10.1007/s00122-004-1814-6
   GUERRASANZ JM, 2002, MOL ECOL NOTES, V2, P223, DOI
   10.1046/j.1471-8286.2002.00200.x
   JACCARD P, 1908, B SOCIETE VAUDOISE S, V44, P223
   JARRET RL, 1997, GENOME, V40, P433
   JOOBEUR T, 2006, THEOR APPL GENET, V112, P1553
   KWON YS, 2005, MOL CELLS, V19, P428
   KWON YS, 2007, KOREAN J GENETIC, V29, P137
   LEE SJ, 1996, THEOR APPL GENET, V92, P719
   LEFEBVRE V, 2001, THEOR APPL GENET, V102, P741
   LEVI A, 2001, GENET RESOUR CROP EV, V48, P559
   LEVI A, 2007, HORTSCIENCE, V42, P210
   LU H, 2002, THEOR APPL GENET, V105, P622, DOI 10.1007/s00122-002-0970-9
   MILBOURNE D, 1997, MOL BREEDING, V3, P127
   RAKOCZYTROJANOWSKA M, 2004, CELL MOL BIOL LETT, V9, P221
   RITSCHEL PS, 2004, BMC PLANT BIOL, V4, P1471
   ROHLF FJ, 2000, NTSYSPC NUMERICAL TA
   SAYED H, 2002, EUPHYTICA, V225, P265
   SCOTT KD, 2001, PLANT GENOTYPING DNA, P225
   SNEATH PHA, 1973, NUMERICAL TAXONOMY P
   STAUB JE, 1996, HORTSCIENCE, V31, P729
   TOMMASINI L, 2003, THEOR APPL GENET, V106, P1091, DOI
   10.1007/s00122-002-1125-8
   VARSHNEY RK, 2005, PLANT SCI, V168, P195, DOI
   10.1016/j.plantsci.2004.08.001
   VARSHNEY RK, 2005, TRENDS BIOTECHNOL, V23, P48, DOI
   10.1016/j.tibtech.2004.11.005
   WEISING K, 2005, DNA FINGERPRINTING P, P235
NR 31
TC 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD APR
PY 2010
VL 32
IS 2
BP 115
EP 122
DI 10.1007/s13258-008-0674-x
PG 8
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 587VH
UT ISI:000277022100003
ER

PT J
AU Sang, XC
   Fang, LK
   Vanichpakorn, Y
   Ling, YH
   Du, P
   Zhao, FM
   Yang, ZL
   He, GH
AF Sang, Xian-chun
   Fang, Li-kui
   Vanichpakorn, Yuenyong
   Ling, Ying-hua
   Du, Peng
   Zhao, Fang-ming
   Yang, Zheng-lin
   He, Guang-hua
TI Physiological character and molecular mapping of leaf-color mutant wyv1
   in rice (Oryza sativa L.)
SO GENES & GENOMICS
LA English
DT Article
DE Chlorophyll deficient; Fine mapping; Rice (Oryza sativa L.);
   white-yellow-virescent 1 (wyv1)
ID CHLOROPHYLL-DEFICIENT MUTANT; CHLOROPLAST DEVELOPMENT; GENE;
   TEMPERATURE; MUTATION; IDENTIFICATION; BIOSYNTHESIS; VIRESCENT-2;
   BIOGENESIS; SUBUNITS
AB The seed of an excellent indica restorer line Jinhui10 (Oryza sativa L.
   ssp. indica) was treated by ethyl methanesulfonate (EMS); a leaf-color
   mutant displaying distinct phenotype throughout development grown in
   paddy field was identified from the progeny. The mutant leaf showed
   white-yellow at seedling stage and then turned to yellow-green at
   tillering stage, after that, virescent color appeared until to
   maturity. The mutant was thus temporarily designed as wyv1. The
   chlorophyll contents decreased significantly and the changing was
   consistent with the chlorotic level of wyv1 leaves. Chlorophyll
   fluorescence kinetic parameters measured at the seedling stage showed
   that co-efficiency of photochemical quenching (qP), actual photosystem
   II efficiency (I broken vertical bar PS II), electron transport rate
   (ETR) and initial chlorophyll fluorescence level (Fo), net
   photosynthetic rate (Pn) and maximum photochemical efficiency (Fv / Fm)
   significantly decreased in severe chlorotic leaf of the mutant compared
   with that of wild type. However, no significant differences were
   observed for Pn and Fv/Fm between virescent leaf and normal green leaf.
   Genetic analysis suggested that the mutant phenotype was controlled by
   a single recessive nuclear gene which was finally mapped between SSR
   marker Y7 and Y6 on rice chromosome 3 based on F2 population of
   Xinong1A / wyv1. Genetic distances were 0.06 cM and 0.03 cM
   respectively, and the physical distance was 84 kb according to the
   sequence of indica rice 9311. The results must facilitate map-based
   cloning and functional analysis of WYV1 gene.
C1 [Sang, Xian-chun; Fang, Li-kui; Vanichpakorn, Yuenyong; Ling, Ying-hua; Du, Peng; Zhao, Fang-ming; Yang, Zheng-lin; He, Guang-hua] Southwest Univ, Coll Agron & Biotechnol, Key Lab Biotechnol & Crop Qual Improvement, Minist Agr, Chongqing 400716, Peoples R China.
RP He, GH, Southwest Univ, Coll Agron & Biotechnol, Key Lab Biotechnol &
   Crop Qual Improvement, Minist Agr, Chongqing 400716, Peoples R China.
EM hegh1968@yahoo.com.cn
FU National Natural Sciences Foundation of P. R. China [30800598]; Special
   Capital of Southwest University basic scientific research [XDJK
   2009B019]; Excellent Youth Foundation Project of Chongqing
   [2008BA1033]; New Century Project for Excellent Innovative Human of
   Education Ministry in P. R. China 
FX This study was supported by the National Natural Sciences Foundation of
   P. R. China (30800598), the Special Capital of Southwest University
   basic scientific research (XDJK 2009B019), the Excellent Youth
   Foundation Project of Chongqing (CSTC, 2008BA1033), and the New Century
   Project for Excellent Innovative Human of Education Ministry in P. R.
   China
CR *IRGSP, 2005, NAT, V436, P793
   ARNON DI, 1949, PLANT PHYSIOL, V24, P15
   AYUMI T, 2006, CURR OPIN PLANT BIOL, V9, P248
   BAO ZF, 2006, J NUCL AGR SCI, V20, P401
   BEALE SI, 2005, TRENDS PLANT SCI, V10, P309, DOI
   10.1016/j.tplants.2005.05.005
   BEVINS MA, 1993, PLANT PHYSIOL, V103, P1123
   CHEN T, 2007, J GENET GENOMICS, V34, P331
   CHEN T, 2009, J GENET GENOMICS, V36, P117, DOI
   10.1016/S1673-8527(08)60098-3
   DU P, 2009, GENES GENOM, V31, P165
   ECKHARDT U, 2004, PLANT MOL BIOL, V56, P1
   HE B, 2006, PLANT PHYSL COMMUNIC, V42, P1
   HOEBERICHTS FA, 2008, J BIOL CHEM, V283, P5708
   HORTENSTEINER S, 2009, TRENDS PLANT SCI, V14, P155, DOI
   10.1016/j.tplants.2009.01.002
   HUANG XQ, 2007, CHINESE J RICE SCI, V21, P355
   JUNG KH, 2003, PLANT CELL PHYSIOL, V44, P463
   KURATA N, 2005, PLANT CELL PHYSIOL, V46, P48, DOI 10.1093/pcp/pci506
   LANDER ES, 1987, GENOMICS, V1, P174
   LI Q, 2005, HEREDITAS BEIJING, V27, P808
   LI ZB, 2005, COTTON SCI, V17, P189
   LIU WZ, 2007, PLANTA, V226, P785, DOI 10.1007/s00425-007-0525-z
   LIU ZL, 2008, PHOTOSYNTHETICA, V46, P73, DOI 10.1007/s11099-008-0013-0
   LOPEZJUEZ E, 2007, J EXP BOT, V58, P11, DOI 10.1093/jxb/erl196
   MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828
   MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321
   PASINI L, 2005, PHYSIOL PLANTARUM, V124, P362, DOI
   10.1111/j.1399-3054.2005.00522.x
   SANG XC, 2006, EUPHYTICA, V152, P177, DOI 10.1007/s10681-006-9196-2
   SHEN SQ, 2005, HYBRID RICE, V20, P10
   SUGIMOTO H, 2004, PLANT CELL PHYSIOL, V45, P985
   SUGIMOTO H, 2007, PLANT J, V52, P512, DOI
   10.1111/j.1365-313X.2007.03251.x
   WELLBURN AR, 1994, J PLANT PHYSIOL, V144, P307
   WU DX, 2003, FIELD CROP RES, V81, P141
   WU ZM, 2007, PLANT PHYSIOL, V145, P29, DOI 10.1104/pp.107.100321
   YOO SC, 2009, PLANT PHYSIOL, V150, P388, DOI 10.1104/pp.109.136648
   YUE B, 2009, J PLANT PHYSL, V166, P44
   ZHANG HT, 2006, PLANT MOL BIOL, V62, P325, DOI 10.1007/s11103-006-9024-z
NR 35
TC 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD APR
PY 2010
VL 32
IS 2
BP 123
EP 128
DI 10.1007/s13258-009-0794-y
PG 6
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 587VH
UT ISI:000277022100004
ER

PT J
AU Liu, SH
   Yang, CN
   Pan, HC
   Sung, YJ
   Liao, KK
   Chen, WB
   Lin, WZ
   Sheu, ML
AF Liu, Shing Hwa
   Yang, Cheng Ning
   Pan, Hung Chuan
   Sung, Yen Jen
   Liao, Ko Kaung
   Chen, Wen Bao
   Lin, Wen Zheng
   Sheu, Meei Ling
TI IL-13 downregulates PPAR-gamma/heme oxygenase-1 via ER
   stress-stimulated calpain activation: aggravation of activated
   microglia death
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Microglia; Interleukin-13; Calpain; PPAR-gamma; Heme oxygenase-1
ID ENDOPLASMIC-RETICULUM STRESS; HEME OXYGENASE-1; OXIDATIVE STRESS;
   CELL-DEATH; NEURODEGENERATIVE DISORDERS; CYCLOOXYGENASE-2 EXPRESSION;
   PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BRAIN-INJURY; MOUSE MODEL
AB Interleukin 13 (IL-13) has been shown to induce the death of activated
   microglia. We observed that IL-13, but not IL-4 or IL-10, significantly
   enhanced endoplasmic reticulum (ER) stress induction, apoptosis and
   death in microglia activated by lipopolysaccharide (LPS). IL-13
   enhanced ER stress-regulated calpain activation and calpain-II
   expression in LPS-activated microglia. Calpain-II siRNA effectively
   reversed the IL-13 + LPS-activated caspase-12 activation. Expression of
   heme oxygenase-1 (HO-1) and peroxisome proliferator-activated
   receptor-gamma (PPAR-gamma) was also increased in activated microglia,
   and this was effectively blocked by IL-13 and recombinant calpain. Both
   HO-1 inhibitor and PPAR-gamma antagonist augmented, but calpain
   inhibitor and PPAR-gamma agonists reversed, apoptosis induction in
   activated microglia. Transfection of PPAR-gamma siRNA effectively
   inhibited HO-1 protein expression in activated microglia. LPS
   stimulated transcriptional activation of HO-1 via an increase in
   PPAR-gamma DNA binding activity, which was reversed by IL-13. These
   results indicate that an ER stress-related calpain-down-regulated
   PPAR-gamma/HO-1 pathway is involved in the IL-13-enhanced activated
   death of microglia.
C1 [Pan, Hung Chuan; Chen, Wen Bao; Lin, Wen Zheng; Sheu, Meei Ling] Natl Chung Hsing Univ, Inst Med Technol, Taichung 402, Taiwan.
   [Liu, Shing Hwa] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10764, Taiwan.
   [Yang, Cheng Ning] Natl Yang Ming Univ, Sch Life Sci, Inst Neurosci, Taipei 112, Taiwan.
   [Pan, Hung Chuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Sung, Yen Jen] Natl Yang Ming Univ, Sch Life Sci, Inst Anat & Cell Biol, Taipei 112, Taiwan.
   [Liao, Ko Kaung] Chung Shan Med Univ, Dept Anat, Taichung, Taiwan.
   [Sheu, Meei Ling] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan.
RP Sheu, ML, Natl Chung Hsing Univ, Inst Med Technol, 250 Kuo Kuang Rd,
   Taichung 402, Taiwan.
EM shinghwaliu@ntu.edu.tw
   mlsheu@nchu.edu.tw
FU Taichung Veterans General Hospital, Taiwan [TCVGH-977304B]; National
   Science Council of Taiwan [NSC96-2320-B-040-003-MY3]
FX This work was supported by research grants from Taichung Veterans
   General Hospital, Taiwan (TCVGH-977304B), and the National Science
   Council of Taiwan (NSC96-2320-B-040-003-MY3).
CR BLOCK ML, 2005, PROG NEUROBIOL, V76, P77, DOI
   10.1016/j.pneurobio.2005.06.004
   CONTESTABILE A, 2009, CURR MED CHEM, V16, P350
   CROCKER SJ, 2003, J NEUROSCI, V23, P4081
   CULMSEE C, 2006, CURR ALZHEIMER RES, V3, P269
   DHEEN ST, 2007, CURR MED CHEM, V14, P1189
   FRANCO SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175
   GLYNN P, 2000, PROG NEUROBIOL, V61, P61
   HABICHT GS, 1991, J INFECT DIS, V164, P568
   INNAMORATO NG, 2008, J IMMUNOL, V181, P680
   KAPADIA R, 2008, FRONT BIOSCI, V13, P1813, DOI 10.2741/2802
   KELLYWELCH AE, 2003, SCIENCE, V300, P1527
   KIELIAN T, 2008, J IMMUNOL, V180, P5004
   KIM I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   KRONKE G, 2007, ARTERIOSCL THROM VAS, V27, P1276, DOI
   10.1161/ATVBAHA.107.142638
   KYUHOU S, 2006, NEUROSCI LETT, V396, P91, DOI
   10.1016/j.neulet.2005.11.023
   LAPORTE SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030
   LEE GH, 2007, J BIOL CHEM, V282, P21618, DOI 10.1074/jbc.M700053200
   LEE SR, 2009, BIOCHEM BIOPH RES CO, V380, P17, DOI
   10.1016/j.bbrc.2008.12.181
   LIN TN, 2006, ARTERIOSCL THROM VAS, V26, P481, DOI
   10.1161/01.ATV.0000201933.53964.5b
   LIN Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI
   10.1038/sj.jcbfm.9600412
   LINDHOLM D, 2006, CELL DEATH DIFFER, V13, P385, DOI
   10.1038/sj.cdd.4401778
   LIU XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200
   MALHOTRA JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI
   10.1089/ars.2007.1782
   MARKESBERY WR, 1997, FREE RADICAL BIO MED, V23, P134
   MINGHETTI L, 2005, BRAIN RES REV, V48, P251, DOI
   10.1016/j.brainresrev.2004.12.015
   MURPHY GM, 1998, J BIOL CHEM, V273, P20967
   NAKAGAWA T, 2000, J CELL BIOL, V150, P887
   NAKAGAWA T, 2000, NATURE, V403, P98
   NAKANISHI H, 2003, MOL NEUROBIOL, V27, P163
   NETEA MG, 2001, EUR J IMMUNOL, V31, P2529
   RAY SK, 2003, CURR DRUG TARGETS CN, V2, P173
   ROSA AO, 2008, EXP NEUROL, V212, P93, DOI
   10.1016/j.expneurol.2008.03.008
   SCHINTU N, 2009, EUR J NEUROSCI, V29, P954, DOI
   10.1111/j.1460-9568.2009.06657.x
   SCHIPPER HM, 2000, EXP GERONTOL, V35, P821
   SCHIPPER HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI
   10.1016/j.freeradbiomed.2004.09.015
   SHEU ML, 2004, MOL PHARMACOL, V66, P187
   SHEU ML, 2005, ARTERIOSCL THROM VAS, V25, P539, DOI
   10.1161/01.ATV.0000155462.24263.e4
   SHEU ML, 2007, PLOS ONE, V2, ARTN e1096
   SHIN WH, 2004, GLIA, V46, P142, DOI 10.1002/glia.10357
   SIMAN R, 2001, J BIOL CHEM, V276, P44736
   SOBRADO M, 2009, J NEUROSCI, V29, P3875, DOI
   10.1523/JNEUROSCI.5529-08.2009
   SYAPIN PJ, 2008, BRIT J PHARMACOL, V155, P623, DOI 10.1038/bjp.2008.342
   SZCZEPANIK AM, 2001, J NEUROIMMUNOL, V113, P49
   TAKEDA A, 2004, ANTIOXID REDOX SIGN, V6, P888
   TAN YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200
   UEHARA T, 2007, ANTIOXID REDOX SIGN, V9, P597, DOI 10.1089/ars.2006.1517
   WANG JA, 2007, BRAIN 6, V130, P1643, DOI 10.1093/brain/awm095
   WHITNEY NP, 2009, J NEUROCHEM, V108, P1343, DOI
   10.1111/j.1471-4159.2009.05886.x
   YANG MS, 2002, GLIA, V38, P273
   YANG MS, 2006, J IMMUNOL, V177, P1323
   YOSHIDA H, 2007, FEBS J, V274, P630, DOI
   10.1111/j.1742-4658.2004.05639.x
   YU X, 2008, BRAIN RES, V1200, P146, DOI 10.1016/j.brainres.2008.01.047
   ZHAO LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI
   10.1016/j.ceb.2006.06.006
NR 53
TC 0
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2010
VL 67
IS 9
BP 1465
EP 1476
DI 10.1007/s00018-009-0255-4
PG 12
SC Biochemistry & Molecular Biology; Cell Biology
GA 585ZJ
UT ISI:000276869600006
ER

PT J
AU Yang, Q
   Gong, ZJ
   Zhou, Y
   Yuan, JQ
   Cheng, JA
   Tian, L
   Li, S
   Lin, XD
   Xu, RJ
   Zhu, ZR
   Mao, CG
AF Yang, Qiong
   Gong, Zhong-Jun
   Zhou, Ying
   Yuan, Jing-Qun
   Cheng, Jiaan
   Tian, Lin
   Li, Sheng
   Lin, Xin-Da
   Xu, Ruijuan
   Zhu, Zeng-Rong
   Mao, Cungui
TI Role of Drosophila alkaline ceramidase (Dacer) in Drosophila
   development and longevity
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Alkaline ceramidase; Drosophila; Development; Lifespan
ID KEY REGULATORY ENZYME; MOLECULAR-CLONING; LIFE-SPAN;
   SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; NEUTRAL CERAMIDASE;
   MASS-SPECTROMETRY; C-ELEGANS; MELANOGASTER; SPHINGOSINE
AB Ceramidases catalyze the hydrolysis of ceramides to generate
   sphingosine (SPH) and fatty acids, and ceramide metabolism is
   implicated in various biological responses in Drosophila melanogaster.
   Here we report the cloning, biochemical characterization, and
   functional analysis of a Drosophila alkaline ceramidase (Dacer). Dacer,
   a membrane-bound protein of 284 amino acids, shares homology with yeast
   and mammalian alkaline ceramidases. Overexpression of Dacer in High
   Five insect cells increases ceramidase activity in the alkaline pH
   range, indicating that Dacer is a bona fide alkaline ceramidase. Dacer
   mRNA is highly expressed in the midgut and at the pupal stage. An
   inactivation of Dacer by insertional mutagenesis increases the levels
   of ceramides in both Drosophila pupae and adult flies. Dacer
   inactivation increases Drosophila pre-adult development time, lifespan,
   and anti-oxidative stress capacity. Collectively, these results suggest
   that Dacer plays an important role in the Drosophila development and
   longevity by controlling the metabolism of ceramides.
C1 [Yang, Qiong; Gong, Zhong-Jun; Zhou, Ying; Cheng, Jiaan; Zhu, Zeng-Rong] Zhejiang Univ, Inst Insect Sci, Hangzhou 310029, Zhejiang, Peoples R China.
   [Yang, Qiong; Gong, Zhong-Jun; Zhou, Ying; Cheng, Jiaan; Zhu, Zeng-Rong] Minist Agr China, Key Lab Mol Biol Crop Pathogens & Insects, State Key Lab Rice Biol, Hangzhou 310029, Zhejiang, Peoples R China.
   [Yuan, Jing-Qun] Zhejiang Univ, Ctr Chem Anal & Detect, Hangzhou 310029, Zhejiang, Peoples R China.
   [Tian, Lin; Li, Sheng] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China.
   [Lin, Xin-Da] China Jiliang Univ, Coll Life Sci, Hangzhou 310018, Zhejiang, Peoples R China.
   [Xu, Ruijuan; Mao, Cungui] Med Univ S Carolina, Dept Med & Mol Biol, Charleston, SC 29425 USA.
   [Xu, Ruijuan; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Zhu, ZR, Zhejiang Univ, Inst Insect Sci, Hangzhou 310029, Zhejiang,
   Peoples R China.
EM zrzhu@zju.edu.cn
   maoc@musc.edu
FU China's National Basic Research 973 Program [2009CB119203]; NSFC
   [30528024]; MOE ; United States National Institutes of Health
   [R01CA104834]
FX This work was supported by China's National Basic Research 973 Program
   2009CB119203 (ZZ), NSFC grants 30528024 (CM), and MOE project 111 (CM),
   and the United States National Institutes of Health grant R01CA104834
   (CM). We thank Qiang Li, Dongdong Niu, Weihua Wang, and Wenjuan Jiao
   for their technical assistance in fly colony maintenance. We also thank
   Dr. Jennifer Schnellmann for English proof reading and editing of the
   manuscript.
CR ACHARYA U, 2005, CELL MOL LIFE SCI, V62, P128, DOI
   10.1007/s00018-004-4254-1
   AERTS AM, 2008, CELL MOL LIFE SCI, V65, P1933, DOI
   10.1007/s00018-008-8129-8
   BIELAWSKI J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004
   BOQUET I, 2000, J NEUROBIOL, V42, P33
   CHANG KT, 2005, NAT NEUROSCI, V8, P1577, DOI 10.1038/nn1564
   DUBESSAY P, 2007, BIOCHIMIE, V89, P988, DOI 10.1016/j.biochi.2007.03.018
   FYRST H, 2008, J LIPID RES, V49, P597, DOI 10.1194/jlr.M700414-JLR200
   GILBERT LI, 2000, INSECT BIOCHEM MOLEC, V30, P617
   KANGOSINGH M, 2004, GENOME BIOL, V5
   KINJOH T, 2007, INSECT BIOCHEM MOLEC, V37, P808, DOI
   10.1016/j.ibmb.2007.03.008
   KLOWDEN MJ, 2007, PHYSL SYSTEMS INSECT
   KRISHNAN KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI
   10.1196/annals.1395.024
   LEE HS, 2008, PESTIC BIOCHEM PHYS, V92, P19, DOI
   10.1016/j.pestbp.2008.05.002
   LIN YJ, 1998, SCIENCE, V282, P943
   LIU Y, 2009, DEVELOPMENT, V136, P2015, DOI 10.1242/dev.033712
   MANDAL S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006
   MAO CG, 2000, J BIOL CHEM, V275, P31369
   MAO CG, 2000, J BIOL CHEM, V275, P6876
   MAO CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200
   MAO CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI
   10.1016/j.bbalip.2008.06.002
   MENUZ V, 2009, SCIENCE, V324, P381, DOI 10.1126/science.1168532
   NIJHOUT HF, 1998, INSECT HORMONES
   OKINO N, 1998, J BIOL CHEM, V273, P14368
   OKINO N, 1999, J BIOL CHEM, V274, P36616
   OLSSON M, 2004, AM J PHYSIOL-GASTR L, V287, G929, DOI
   10.1152/ajpgi.00155.2004
   OSAWA Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200
   POWERS RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406
   QIU J, 1996, J BIOL RHYTHM, V11, P75
   RAO RP, 2007, P NATL ACAD SCI USA, V104, P11364, DOI
   10.1073/pnas.0705049104
   SARETZKI G, 2009, EXP GERONTOL, V44, P485, DOI
   10.1016/j.exger.2009.05.004
   SEDENSKY MM, 2006, EXP GERONTOL, V41, P957, DOI
   10.1016/j.exger.2006.06.056
   SEGUI B, 2000, FASEB J, V14, P36
   SENKAL CE, 2010, FASEB J, V24
   SHENG ZT, 2008, ARCH INSECT BIOCHEM, V69, P143, DOI 10.1002/arch.20268
   SHINODA T, 2003, P NATL ACAD SCI USA, V100, P11986, DOI
   10.1073/pnas.2134232100
   SUN W, 2008, J INVEST DERMATOL, V128, P389, DOI 10.1038/sj.jid.5701025
   USTA J, 2001, BIOCHEMISTRY-US, V40, P9657
   VANREMMEN H, 2001, EXP GERONTOL, V36, P957
   VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185
   XU RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com
   YOSHIMURA Y, 2002, J BIOCHEM, V132, P229
   YOSHIMURA Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200
NR 42
TC 2
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2010
VL 67
IS 9
BP 1477
EP 1490
DI 10.1007/s00018-010-0260-7
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 585ZJ
UT ISI:000276869600007
ER

PT J
AU Liu, YS
   Teng, XH
   Yang, XX
   Song, Q
   Lu, R
   Xiong, JX
   Liu, B
   Zeng, NJ
   Zeng, Y
   Long, J
   Cao, R
   Lin, Y
   He, QZ
   Chen, P
   Lu, M
   Liang, SP
AF Liu, Yisong
   Teng, Xiaohua
   Yang, Xiaoxu
   Song, Qing
   Lu, Rong
   Xiong, Jixian
   Liu, Bo
   Zeng, Nianju
   Zeng, Yu
   Long, Jia
   Cao, Rui
   Lin, Yong
   He, Quanze
   Chen, Ping
   Lu, Ming
   Liang, Songping
TI Shotgun Proteomics and Network Analysis Between Plasma Membrane and
   Extracellular Matrix Proteins From Rat Olfactory Ensheathing Cells
SO CELL TRANSPLANTATION
LA English
DT Article
DE Olfactory ensheathing cells; Neural repair; 1D-shotgun proteomics;
   Plasma membrane; Extracellular matrix
ID CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E-GENOTYPE; SPINAL-CORD
   INJURIES; GROWTH-FACTOR; BINDING PROTEIN-2; SIGNAL PEPTIDES; GENE
   ONTOLOGY; SCHWANN-CELLS; STEM-CELLS; IN-VITRO
AB Olfactory ensheathing cells (OECs) are a special type of dial cells
   that have characteristics of both astrocytes and Schwann cells.
   Evidence suggests that the regenerative capacity of OECs is induced by
   soluble, secreted factors that influence their microenvironment These
   factors may regulate OECs self-renewal and/or induce their capacity to
   augment spinal cord regeneration Profiling of plasma membrane and
   extracellular matrix through a high-throughput expression proteomics
   approach was undertaken to identify plasma membrane and extracellular
   matrix proteins of OECs under serum-free conditions 1D-shotgun
   proteomics followed with gene ontology (GO) analysis was used to screen
   proteins from primary culture rat OECs Four hundred and seventy
   nonredundant plasma membrane proteins and 168 extracellular matrix
   proteins were identified, the majority of which were never before
   reported to be produced by OECs Furthermore. plasma membrane and
   extracellular proteins were classified based on their protein protein
   interaction predicted by STRING quantitatively integrates interaction
   data The proteomic profiling of the OECs plasma membrane proteins and
   their connection with the secretome in serum-free culture conditions
   provides new insights into the nature of their in vivo
   microenvironmental niche Proteomic analysis for the discovery of
   clinical biomarkers of OECs mechanism warrants further study
C1 [Liu, Yisong; Yang, Xiaoxu; Song, Qing; Lu, Rong; Xiong, Jixian; Long, Jia; Cao, Rui; Lin, Yong; He, Quanze; Chen, Ping; Liang, Songping] Hunan Normal Univ, Key Lab Prot Chem & Dev Biol, Minist Educ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China.
   [Teng, Xiaohua; Liu, Bo; Zeng, Nianju; Zeng, Yu; Lu, Ming] Hunan Normal Univ, Hosp PLA 163, Affiliated Hosp 2, Dept Neurosurg, Changsha 410081, Hunan, Peoples R China.
RP Chen, P, Hunan Normal Univ, Key Lab Prot Chem & Dev Biol, Minist Educ,
   Coll Life Sci, Changsha 410081, Hunan, Peoples R China.
FU National 973 Project of China [2007CB516809, 200703914203]; National
   Natural Science Foundation of China [30770437]
FX The authors thank all the members of our group for kindly help and
   suggestions This work was supported by a grant from National 973
   Project of China (2007CB516809, 200703914203), and National Natural
   Science Foundation of China (30770437)
CR AIGELSREITER A, 2009, HISTOPATHOLOGY, V54, P561, DOI
   10.1111/j.1365-2559.2009.03258.x
   AO Q, 2007, MED HYPOTHESES, V69, P1234, DOI 10.1016/j.mehy.2007.04.011
   ASHBURNER M, 2000, NAT GENET, V25, P25
   AU E, 2002, METH MOL B, V198, P49
   AU E, 2003, GLIA, V41, P224, DOI 10.1002/glia.10160
   AU E, 2007, J NEUROSCI, V27, P7208, DOI 10.1523/JNEUROSCI.0509-07.2007
   BADER HI, 2003, J MASS DENT SOC, V51, P20
   BENDTSEN JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028
   BLANDINI F, 2010, CELL TRANSPLANT, V19, P203, DOI
   10.3727/096368909X479839
   BOYD JG, 2006, GLIA, V53, P434, DOI 10.1002/glia.20299
   BREESE CR, 1996, J COMP NEUROL, V369, P388
   BUNGE MB, 2003, J REHABIL RES DEV S1, V40, P55
   CAO R, 2006, J PROTEOME RES, V5, P634, DOI 10.1021/pr050387a
   CHEN P, 2006, J NEUROCHEM, V98, P1126, DOI
   10.1111/j.1471-4159.2006.03934.x
   CHESIK D, 2004, J NEUROSCI RES, V77, P354, DOI 10.1002/jnr.20172
   CHUAH MI, 1993, BRAIN RES, V601, P213
   CHUAH MI, 1999, NEUROSCIENCE, V88, P1043
   CLAUSER KR, 1999, ANAL CHEM, V71, P2871
   CRAWFORD F, 2009, NEUROSCIENCE, V159, P1349, DOI
   10.1016/j.neuroscience.2009.01.033
   ESPOSITO C, 2009, GROWTH FACTORS, V27, P173, DOI
   10.1080/08977190902834077
   FAIRLESS R, 2005, INT J BIOCHEM CELL B, V37, P693, DOI
   10.1016/j.biocel.2004.10.010
   FAWCETT JW, 1999, BRAIN RES BULL, V49, P377
   FERNANDES AM, 2010, CELL TRANSPLANT
   FORNER F, 2006, MOL CELL PROTEOMICS, V5, P608, DOI
   10.1074/mcp.M500298-MCP200
   GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713
   GUIZZETTI M, 1996, J NEUROCHEM, V67, P2236
   HUANG HY, 2003, CHINESE MED J-PEKING, V116, P1488
   JENSEN LJ, 2009, NUCLEIC ACIDS RES, V37, D412, DOI 10.1093/nar/gkn760
   KAMADA H, 2005, MOL BRAIN RES, V134, P181, DOI
   10.1016/j.molbrainres.2004.10.037
   KEYVANFOULADI N, 2002, BRAIN RES REV, V40, P325
   KIM H, 2002, J NEUROCHEM, V83, P1389
   KYTE J, 1982, J MOL BIOL, V157, P105
   LEAVER SG, 2006, GLIA, V53, P467, DOI 10.1002/glia.20311
   LEITAO CB, 2010, CELL TRANSPLANT, V19, P119, DOI
   10.3727/096368909X478641
   LIMA C, 2006, J SPINAL CORD MED, V29, P191
   LIPSON AC, 2003, EXP NEUROL, V180, P167, DOI
   10.1016/S0014-4486(02)00058-4
   LOPEZVALES R, 2007, GLIA, V55, P303, DOI 10.1002/glia.20457
   MACKAYSIM A, 2005, KEIO J MED, V54, P8
   MCMICHAEL GL, 2008, HUM GENET, V124, P411, DOI 10.1007/s00439-008-0564-y
   MUTO Y, 2003, BRAIN RES MOL BRAIN, V111, P111
   NAKADATE K, 2008, J COMP NEUROL, V508, P94, DOI 10.1002/cne.21662
   NIE QH, 2004, WORLD J GASTROENTERO, V10, P86
   NIELSEN H, 1997, PROTEIN ENG, V10, P1
   PATRAKITKOMJORN S, 2008, J BIOL CHEM, V283, P9399, DOI
   10.1074/jbc.M708206200
   RAMONCUETO A, 1998, BRAIN RES BULL, V46, P175
   RICHARDSON RR, 1980, SPINE, V5, P42
   RIDDELL JS, 2004, GLIA, V47, P150, DOI 10.1002/glia.20041
   RIJKELIJKHUIZEN JK, 2010, CELL TRANSPLANT
   RUITENBERG MJ, 2005, BRAIN 4, V128, P839, DOI 10.1093/brain/awh424
   SANAGI T, 2008, J NEUROCHEM, V106, P1841, DOI
   10.1111/j.1471-4159.2008.05529.x
   SANTOSBENITO FF, 2003, ANAT REC B, V271, P77
   SEIFERT JL, 2009, NEUROSCI LETT, V450, P176, DOI
   10.1016/j.neulet.2008.11.025
   SONG BK, 2003, NEUROSCI LETT, V338, P29, DOI
   10.1016/S0304-3940(02)01364-2
   SOTTILE J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048
   SRIVASTAVA N, 2009, INT J DEV NEUROSCI, V27, P103, DOI
   10.1016/j.ijdevneu.2008.08.002
   WIGGINS AK, 2003, BRAIN RES MOL BRAIN, V114, P20
   WOODHALL E, 2001, BRAIN RES MOL BRAIN, V88, P203
   YABE T, 2005, GLIA, V50, P223, DOI 10.1002/glia.20171
   YUKAWA H, 2009, CELL TRANSPLANT, V18, P611
   ZHANG B, 2004, BMC BIOINFORMATICS, V5, ARTN 16
   ZHANG LJ, 2007, J PROTEOME RES, V6, P34, DOI 10.1021/pr060069r
   ZHAO XZ, 2006, INT J NEUROPSYCHOPH, V9, P705, DOI
   10.1017/S1461145705006267
NR 62
TC 4
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2010
VL 19
IS 2
BP 133
EP 146
DI 10.3727/096368910X492607
PG 14
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 587BI
UT ISI:000276961300002
ER

PT J
AU Wu, MM
   Fan, DG
   Tadmori, I
   Yang, H
   Furman, M
   Jiao, XY
   Young, W
   Sun, DM
   You, SW
AF Wu, Ming-Mei
   Fan, De-Gang
   Tadmori, Iman
   Yang, Hao
   Furman, Maya
   Jiao, Xi-Ying
   Young, Wise
   Sun, Dongming
   You, Si-Wei
TI Death of Axotomized Retinal Ganglion Cells Delayed After Intraoptic
   Nerve Transplantation of Olfactory Ensheathing Cells in Adult Rats
SO CELL TRANSPLANTATION
LA English
DT Article
DE Olfactory ensheathing cell transplantation; Optic nerve transection;
   Retinal ganglion cells; Neuroprotection
ID NEUROTROPHIC FACTOR; OPTIC-NERVE; SPINAL-CORD; AXONAL REGENERATION;
   GLIA TRANSPLANTS; PC12 CELLS; IN-VIVO; SURVIVAL; TRANSECTION; GDNF
AB Intraorbital transection of the optic nerve (ON) always induces
   ultimate apoptosis of retinal ganglion cells (RGCs) and consequently
   irreversible defects of vision function It was demonstrated that
   transplanted olfactory ensheathing cells (OECs) in partially injured
   spinal cord have a distant in vivo neuroprotective effect on descending
   cortical and brain stein neurons However, this study gave no answers to
   the question whether OECs can protect the central sensitive neurons
   with a closer axonal injury because different neurons respond variously
   to similar axonal injury and the distance between the neuronal soma and
   axonal injury site has a definite effect on the severity of neuronal
   response and apoptosis In the present study, we investigated the effect
   of transplanted OECs on RGCs after intraorbital ON transection in adult
   rats Green fluorescent protein (GFP)-OECs were injected into the ocular
   stumps of transected ON and a significantly higher number of surviving
   RGCs was found together with a consistent marked increase in the mRNA
   and protein levels of BDNF in the ON stump and retina in the
   OEC-treated group at 7 days, but not 2 and 14 days, time point when
   complied to the control group Our findings suggest that OEC
   transplantation induces the expression of BDNF in the ocular ON stump
   and retina and delays the death of axotomized RGCs at a certain
   survival period.
C1 [Wu, Ming-Mei; Yang, Hao; Jiao, Xi-Ying; You, Si-Wei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.
   [Fan, De-Gang] Fourth Mil Med Univ, Inst Orthoped Oncol, Tangdu Hosp, Xian 710032, Peoples R China.
   [Tadmori, Iman; Furman, Maya; Young, Wise; Sun, Dongming] Rutgers State Univ, Dept Cell Biol & Neurosci, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ USA.
RP You, SW, Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R
   China.
FU Natural Science Foundations of China [30872829, 30571998, 30901049];
   Army Medical Research Foundation of China [06H039]
FX Supported by Natural Science Foundations of China (Grant numbers
   30872829, 30571998, and 30901049) and Army Medical Research Foundation
   of China (Grant number 06H039)
CR BARAKAT DJ, 2005, CELL TRANSPLANT, V14, P225
   BATISTATOU A, 1991, J CELL BIOL, V115, P461
   BERKELAAR M, 1994, J NEUROSCI, V14, P4368
   BORUCH AV, 2001, GLIA, V33, P225
   CASTANHEIRA P, 2009, CELL TRANSPLANT, V18, P423
   CHEUNG ZH, 2002, J NEUROTRAUM, V19, P369
   CHUN MH, 2000, BRAIN RES, V868, P358
   COHEN A, 1994, J NEUROBIOL, V25, P953
   DREHER B, 1985, BRAIN BEHAV EVOLUT, V26, P10
   HOU B, 2004, INVEST OPHTH VIS SCI, V45, P662, DOI 10.1167/iovs.03-0281
   IMAIZUMI T, 2000, BRAIN RES, V854, P70
   JOHNSON JE, 1986, J NEUROSCI, V6, P3031
   JU WK, 2000, NEUROREPORT, V11, P3893
   KLOCKER N, 1997, NEUROREPORT, V8, P3439
   KOEBERLE PD, 1998, VISION RES, V38, P1505
   LI Y, 2003, J NEUROSCI, V23, P7783
   LIPSON AC, 2003, EXP NEUROL, V180, P167, DOI
   10.1016/S0014-4486(02)00058-4
   PEINADORAMON P, 1996, INVEST OPHTH VIS SCI, V37, P489
   PERRY VH, 1983, J COMP NEUROL, V219, P356
   PLANT GW, 2003, J NEUROTRAUM, V20, P11
   POLENTES J, 2004, NEUROBIOL DIS, V16, P638, DOI
   10.1016/j.nbd.2004.04.009
   RAMONCUETO A, 1994, EXP NEUROL, V127, P232
   RAMONCUETO A, 1998, J NEUROSCI, V18, P3803
   ROSKAMS AJI, 1996, J NEUROSCI, V16, P1294
   SASAKI M, 2006, GLIA, V53, P352
   SIEVERS J, 1987, NEUROSCI LETT, V76, P157
   TAKAHASHI JB, 1993, NEUROSCI LETT, V149, P83
   THANOS S, 1989, EUR J NEUROSCI, V1, P19
   VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23
   WANG YZ, 2003, NEUROSCI LETT, V346, P9, DOI
   10.1016/S0304-3940(03)00412-9
   WOODHALL E, 2001, BRAIN RES MOL BRAIN, V88, P203
   YAN Q, 1999, J NEUROBIOL, V38, P382
   YIP HK, 2000, PROG RETIN EYE RES, V19, P559
NR 33
TC 10
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2010
VL 19
IS 2
BP 159
EP 166
DI 10.3727/096368910X492625
PG 8
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 587BI
UT ISI:000276961300004
ER

PT J
AU Kawase, T
   Matsuo, K
   Suzuki, T
   Hirose, K
   Hosono, S
   Watanabe, M
   Inagaki, M
   Iwata, H
   Tanaka, H
   Tajima, K
AF Kawase, Takakazu
   Matsuo, Keitaro
   Suzuki, Takeshi
   Hirose, Kaoru
   Hosono, Satoyo
   Watanabe, Miki
   Inagaki, Masaki
   Iwata, Hiroji
   Tanaka, Hideo
   Tajima, Kazuo
TI Association between vitamin D and calcium intake and breast cancer risk
   according to menopausal status and receptor status in Japan
SO CANCER SCIENCE
LA English
DT Article
ID FOOD FREQUENCY QUESTIONNAIRE; DIETARY CALCIUM; GENERAL-POPULATION;
   ESTROGEN-RECEPTOR; NUTRIENT INTAKE; DAIRY-PRODUCTS; CHINESE WOMEN;
   CELL-GROWTH; IN-VITRO; MICRONUTRIENTS
AB (Cancer Sci 2010; 101: 1234-1240).
C1 [Kawase, Takakazu; Matsuo, Keitaro; Hosono, Satoyo; Watanabe, Miki; Tanaka, Hideo; Tajima, Kazuo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
   [Matsuo, Keitaro; Tanaka, Hideo] Nagoya Univ, Grad Sch Med, Dept Epidemiol, Nagoya, Aichi 4648601, Japan.
   [Suzuki, Takeshi] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan.
   [Inagaki, Masaki] Aichi Canc Ctr, Res Inst, Div Biochem, Nagoya, Aichi 464, Japan.
   [Iwata, Hiroji] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan.
RP Matsuo, K, Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya,
   Aichi 464, Japan.
EM kmatsuo@aichi-cc.jp
FU Ministry of Education, Science, Sports, Culture and Technology of Japan
   ; Ministry of Health, Labour and Welfare of Japan 
FX This study was supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Science, Sports, Culture and Technology of
   Japan, by a Grant-in-Aid for Cancer Research from the Ministry of
   Health, Labour and Welfare of Japan, and by a Grant-in-Aid for the
   Third Term Comprehensive 10-Year Strategy for Cancer Control from the
   Ministry of Health. The authors are grateful to all of the doctors,
   nurses, technical staff, and hospital business staff of Aichi Cancer
   Center Hospital for daily administration of the HERPACC study.
CR *IARC, 2007, BREAST FOOD NUTR PHY, P289
   ADZERSEN KH, 2003, NUTR CANCER, V46, P131
   BELL NH, 1998, J BONE MINER RES, V13, P350
   BOYAPATI SM, 2003, NUTR CANCER, V46, P38
   CAREY LA, 2006, JAMA-J AM MED ASSOC, V295, P2492
   CARLOMAGNO C, 1996, J CLIN ONCOL, V14, P2702
   CHLEBOWSKI RT, 2008, J NATL CANCER I, V100, P1581, DOI
   10.1093/jnci/djn360
   COLSTON KW, 1989, LANCET, V1, P188
   COLSTON KW, 2002, ENDOCR-RELAT CANCER, V9, P45
   CUI Y, 2006, CANCER EPIDEM BIOMAR, V15, P1427, DOI
   10.1158/1055-9965.EPI-06-0075
   HAMAJIMA N, 1995, J EPIDEMIOL, V5, P99
   HAMAJIMA N, 2001, ASIAN PACIFIC J CANC, V2, P99
   HEANEY RP, 2003, AM J CLIN NUTR, V77, P204
   IMAEDA N, 2007, J EPIDEMIOL, V17, P100
   INOUE M, 1997, J CLIN EPIDEMIOL, V50, P69
   JOHN EM, 1999, CANCER EPIDEM BIOMAR, V8, P399
   KATSOUYANNI K, 1988, CANCER, V61, P181
   KESSEGUYOT E, 2007, ANN NUTR METAB, V51, P139, DOI 10.1159/000103274
   LANDA MC, 1994, EUR J CANCER PREV, V3, P313
   LARSSON SC, 2009, AM J CLIN NUTR, V89, P277
   LEVI F, 2001, INT J CANCER, V91, P260
   LIN J, 2007, ARCH INTERN MED, V167, P1050
   MANTELL DJ, 2000, CIRC RES, V87, P214
   MATSUO K, 2006, CANCER EPIDEM BIOMAR, V15, P1009, DOI
   10.1158/1055-9965.EPI-05-0911
   MCCULLOUGH ML, 2005, CANCER EPIDEM BIOMAR, V14, P2898, DOI
   10.1158/1055-9995.EPI-05-0611
   MCGRATH CM, 1984, IN VITRO CELL DEV B, V20, P652
   MEZZETTI G, 1988, ENDOCRINOLOGY, V122, P389
   MILNE RL, 2009, J NATL CANCER I, V101, P1012, DOI 10.1093/jnci/djp167
   NEGRI E, 1996, INT J CANCER, V65, P140
   NEWMARK HL, 1994, ADV EXP MED BIOL, V364, P109
   NICHOLS HB, 2005, CANCER EPIDEM BIOMAR, V14, P41
   PEROU CM, 2000, NATURE, V406, P747
   PIETRAS RJ, 1995, ONCOGENE, V10, P2435
   ROBIEN K, 2007, CANCER CAUSE CONTROL, V18, P775, DOI
   10.1007/s10552-007-9020-x
   RUSSO J, 2001, RADIAT RES 2, V155, P151
   SAEZ S, 1993, BREAST CANCER RES TR, V27, P69
   SAHOTA H, 2008, CANCER EPIDEM BIOMAR, V17, P232, DOI
   10.1158/1055-9965.EPI-07-0632
   SHIN MH, 2002, J NATL CANCER I, V94, P1301
   SIMARD A, 1991, CAN J PUBLIC HEALTH, V82, P300
   SIMPSON ER, 2003, J STEROID BIOCHEM, V86, P225, DOI
   10.1016/S0960-0760(03)00360-1
   TAJIMA K, 2000, ASIAN PACIFIC J CANC, V1, P35
   TOKUDOME Y, 2005, J EPIDEMIOL, V15, P135
   VANTVEER P, 1991, INT J CANCER, V47, P649
   WELSH J, 2004, AM J CLIN NUTR, V80, P1721
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17
   WITTE JS, 1997, BREAST CANCER RES TR, V42, P243
   XUE LX, 1999, J NATL CANCER I, V91, P176
   YANG XR, 2007, CANCER EPIDEM BIOMAR, V16, P439, DOI
   10.1158/1055-9965.EPI-06-0806
   ZARIDZE D, 1991, INT J CANCER, V48, P493
NR 49
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2010
VL 101
IS 5
BP 1234
EP 1240
DI 10.1111/j.1349-7006.2010.01496.x
PG 7
SC Oncology
GA 585UD
UT ISI:000276853900024
ER

PT J
AU Yang, XY
AF Yang, Xiaoyong
TI A wheel of time: the circadian clock, nuclear receptors, and physiology
SO GENES & DEVELOPMENT
LA English
DT Article
DE Circadian oscillator; transcription; protein-protein interaction
ID REV-ERB-ALPHA; ARNT-LIKE PROTEIN-1; SUPRACHIASMATIC NUCLEUS; RECIPROCAL
   REGULATION; PERIPHERAL-TISSUES; MAMMALIAN CLOCK; BLOOD-PRESSURE;
   PPAR-GAMMA; IN-VIVO; EXPRESSION
AB It is a long-standing view that the circadian clock functions to
   proactively align internal physiology with the 24-h rotation of the
   earth. Recent studies, including one by Schmutz and colleagues (pp.
   345-357) in the February 15, 2010, issue of Genes & Development,
   delineate strikingly complex connections between molecular clocks and
   nuclear receptor signaling pathways, implying the existence of a
   large-scale circadian regulatory network coordinating a diverse array
   of physiological processes to maintain dynamic homeostasis.
C1 Yale Univ, Sch Med, Program Integrat Cell Signaling & Neurobiol Metab, Dept Cellular & Mol Physiol,Sect Comparat Med, New Haven, CT 06519 USA.
RP Yang, XY, Yale Univ, Sch Med, Program Integrat Cell Signaling &
   Neurobiol Metab, Dept Cellular & Mol Physiol,Sect Comparat Med, 333
   Cedar St, New Haven, CT 06519 USA.
EM xiaoyong.yang@yale.edu
FU Yale start-up package ; American Diabetes Association [1-10-JF-56]
FX I thank Hai-Bin Ruan for preparation of the artwork, and Mindian Li for
   inspiring discussions. Research in my laboratory is supported by the
   Yale start-up package and American Diabetes Association Junior Faculty
   Award (1-10-JF-56).
CR ABIZAID A, 2005, EUR J NEUROSCI, V21, P1536, DOI
   10.1111/j.1460-9568.2005.03964.x
   ALVAREZ JD, 2008, J BIOL RHYTHM, V23, P26, DOI 10.1177/0748730407311254
   ARJONA A, 2006, BRAIN BEHAV IMMUN, V20, P469, DOI
   10.1016/j.bbi.2005.10.002
   ASHER G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050
   BOOKOUT AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   BROWN SA, 2002, CURR BIOL, V12, P1574
   CANAPLE L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052
   CAVADINI G, 2007, P NATL ACAD SCI USA, V104, P12843, DOI
   10.1073/pnas.0701466104
   CHAWLA A, 2001, SCIENCE, V294, P1866
   CHO Y, 2009, MOL PHARMACOL, V76, P1360, DOI 10.1124/mol.109.057000
   COOGAN AN, 2008, BRAIN RES, V1232, P104, DOI
   10.1016/j.brainres.2008.07.087
   CURTIS AM, 2007, P NATL ACAD SCI USA, V104, P3450, DOI
   10.1073/pnas.0611680104
   DAMIOLA F, 2000, GENE DEV, V14, P2950
   DOI M, 2010, NAT MED, V16, P67, DOI 10.1038/nm.2061
   ESTALL JL, 2009, P NATL ACAD SCI USA, V106, P22510, DOI
   10.1073/pnas.0912533106
   EVANS RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   FU LN, 2002, CELL, V111, P41
   GACHON F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015
   HALBERG F, 1960, P SOC EXP BIOL MED, V103, P142
   HASTINGS MH, 2008, J NEUROENDOCRINOL, V20, P812, DOI
   10.1111/j.1365-2826.2008.01715.x
   HUNT T, 2007, CELL, V129, P461, DOI 10.1016/j.cell.2007.04.015
   KAASIK K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724
   KARATSOREOS IN, 2007, ENDOCRINOLOGY, V148, P5487, DOI
   10.1210/en.2007-0775
   KELLER M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI
   10.1073/pnas.0906361106
   KEMPER JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009
   KO CH, 2006, HUM MOL GENET, V15, P271
   KONDRATOV RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206
   KOVAC J, 2009, MOL CELLS, V28, P75, DOI 10.1007/s10059-009-0113-0
   LAMIA KA, 2008, P NATL ACAD SCI USA, V105, P15172
   LEMARTELOT G, 2009, PLOS BIOL, V7, ARTN e1000181
   LEMINH N, 2001, EMBO J, V20, P7128
   LI SM, 2009, J APPL PHYSIOL, V107, P1959, DOI
   10.1152/japplphysiol.00467.2009
   LI X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032
   LIU AC, 2008, PLOS GENET, V4, ARTN e1000023
   LIU C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767
   MARPEGAN L, 2005, J NEUROIMMUNOL, V160, P102, DOI
   10.1016/j.jneuroim.2004.11.003
   MATSUO T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   MCNAMARA P, 2001, CELL, V105, P877
   MILLER BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI
   10.1073/pnas.0611724104
   MORIN LP, 1977, SCIENCE, V196, P305
   NAKAHATA Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002
   NAKAHATA Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803
   NAKAMURA TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677
   OGAWA S, 2003, ENDOCRINOLOGY, V144, P230, DOI 10.1210/en.2002-220519
   OHDO S, 2001, NAT MED, V7, P356
   OISHI K, 2005, BIOCHEM J 3, V386, P575, DOI 10.1042/BJ20041150
   OSTER H, 2006, J BIOL RHYTHM, V21, P350, DOI 10.1177/0748730406293053
   POTTHOFF MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI
   10.1073/pnas.0904187106
   PREITNER N, 2002, CELL, V110, P251
   QATANANI M, 2005, CURR DRUG METAB, V6, P329
   RAGHURAM S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344
   RAMSEY KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641
   ROYBAL K, 2007, P NATL ACAD SCI USA, V104, P6406, DOI
   10.1073/pnas.0609625104
   RUSSELL W, 2008, J CLIN ENDOCR METAB, V93, P2300
   SCHMUTZ I, 2010, GENE DEV, V24, P345, DOI 10.1101/gad.564110
   SHECHTER A, 2010, INT J ENDOCRINOL, DOI 10.1155/2010/259345
   SHIMBA S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI
   10.1073/pnas.0502383102
   SO AYL, 2009, P NATL ACAD SCI USA, V106, P17582, DOI
   10.1073/pnas.0909733106
   SON GH, 2008, P NATL ACAD SCI USA, V105, P20970, DOI
   10.1073/pnas.0806962106
   STRICKER J, 2008, NATURE, V456, P516, DOI 10.1038/nature07389
   TAKAHASHI S, 2010, J ATHEROSCLER THROMB, V17, P73
   TEBOUL M, 2008, MOL ENDOCRINOL, V22, P2573, DOI 10.1210/me.2007-0521
   TIGGES M, 2009, NATURE, V457, P309, DOI 10.1038/nature07616
   TUREK FW, 1984, RECENT PROG HORM RES, V40, P143
   TUREK FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750
   WANG NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009
   WEITZMAN ED, 1976, ANNU REV MED, V27, P225
   WILLIAMS GH, 1972, J CLIN INVEST, V51, P1731
   WU N, 2009, GENE DEV, V23, P2201, DOI 10.1101/gad.1825809
   YAMAMOTO T, 2005, J BIOL CHEM, V280, P42036, DOI 10.1074/jbc.M509600200
   YANG X, 2007, COLD SPRING HARB SYM, V72, P387
   YANG XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050
   YIN L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179
   YOUNG MW, 2000, SCI AM, V282, P64
NR 74
TC 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD APR 15
PY 2010
VL 24
IS 8
BP 741
EP 747
DI 10.1101/gad.1920710
PG 7
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 584DK
UT ISI:000276730300003
ER

PT J
AU de la Torre-Ubieta, L
   Gaudilliere, B
   Yang, Y
   Ikeuchi, Y
   Yamada, T
   DiBacco, S
   Stegmuller, J
   Schuller, U
   Salih, DA
   Rowitch, D
   Brunet, A
   Bonni, A
AF de la Torre-Ubieta, Luis
   Gaudilliere, Brice
   Yang, Yue
   Ikeuchi, Yoshiho
   Yamada, Tomoko
   DiBacco, Sara
   Stegmueller, Judith
   Schueller, Ulrich
   Salih, Dervis A.
   Rowitch, David
   Brunet, Anne
   Bonni, Azad
TI A FOXO-Pak1 transcriptional pathway controls neuronal polarity
SO GENES & DEVELOPMENT
LA English
DT Article
DE FOXO; neuronal polarity; Pak1; transcription; axons; dendrites
ID P21-ACTIVATED KINASE; POSTMITOTIC NEURONS; SAD KINASES; CELL-CYCLE;
   FOXO; AXON; MORPHOLOGY; CDH1-APC; PHOSPHORYLATION; POLARIZATION
AB Neuronal polarity is essential for normal brain development and
   function. However, cell-intrinsic mechanisms that govern the
   establishment of neuronal polarity remain to be identified. Here, we
   report that knockdown of endogenous FOXO proteins in hippocampal and
   cerebellar granule neurons, including in the rat cerebellar cortex in
   vivo, reveals a requirement for the FOXO transcription factors in the
   establishment of neuronal polarity. The FOXO transcription factors,
   including the brain-enriched protein FOXO6, play a critical role in
   axo-dendritic polarization of undifferentiated neurites, and hence in a
   switch from unpolarized to polarized neuronal morphology. We also
   identify the gene encoding the protein kinase Pak1, which acts locally
   in neuronal processes to induce polarity, as a critical direct target
   gene of the FOXO transcription factors. Knockdown of endogenous Pak1
   phenocopies the effect of FOXO knockdown on neuronal polarity.
   Importantly, exogenous expression of Pak1 in the background of FOXO
   knockdown in both primary neurons and postnatal rat pups in vivo
   restores the polarized morphology of neurons. These findings define the
   FOXO proteins and Pak1 as components of a cell-intrinsic
   transcriptional pathway that orchestrates neuronal polarity, thus
   identifying a novel function for the FOXO transcription factors in a
   unique aspect of neural development.
C1 [de la Torre-Ubieta, Luis; Gaudilliere, Brice; Yang, Yue; Ikeuchi, Yoshiho; Yamada, Tomoko; DiBacco, Sara; Stegmueller, Judith; Bonni, Azad] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [de la Torre-Ubieta, Luis; Yang, Yue; Bonni, Azad] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
   [Schueller, Ulrich; Rowitch, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
   [Salih, Dervis A.; Brunet, Anne] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
RP Bonni, A, Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM azad_bonni@hms.harvard.edu
FU NIH [NS041021, NS051255]; A. Brunet [AG026648]; National Science
   Foundation ; Albert J. Ryan Foundation ; Edward and Anne Lefler
   Fellowship ; Human Frontier Science Program Long-term Fellowship ;
   Japan Society for the Promotion of Science Fellowship ; Deutsche
   Forschungsgemeinschaft 
FX We thank Constance Cepko, Gabriel Corfas, and David van Vactor for
   helpful discussions; Marten P. Smidt for the FOXO1-GFP, FOXO3-GFP, and
   FOXO6-GFP plasmids; Jonathan Chernoff for the Pak1 plasmid; Margareta
   Nikolic for the Pak1 shRNA; and members of the Bonni laboratory for
   helpful discussions and critical reading of the manuscript. This work
   was supported by NIH grants to A. Bonni (NS041021 and NS051255), A.
   Brunet (AG026648), the National Science Foundation (L. T. U. and Y.
   Y.), the Albert J. Ryan Foundation (L. T. U. and Y. Y.) the Edward and
   Anne Lefler Fellowship (Y. Y.), the Human Frontier Science Program
   Long-term Fellowship (Y. I.), the Japan Society for the Promotion of
   Science Fellowship (T. Y.), and the Deutsche Forschungsgemeinschaft (J.
   S.).
CR ACCILI D, 2004, CELL, V117, P421
   AIZAWA H, 2004, SCIENCE, V303, P197
   ALTMAN J, 1997, DEV CEREBELLAR SYSTE
   ALVAREZ B, 2001, NATURE, V413, P744
   ARDEN KC, 2004, MOL CELL, V14, P416
   ARIASROMERO LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109
   ARIMURA N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056
   BARNES AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025
   BARTHEL A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI
   10.1016/j.tem.2005.03.010
   BOKOCH GM, 2003, ANNU REV BIOCHEM, V72, P743
   BREWER GJ, 1993, J NEUROSCI RES, V35, P567
   BRUNET A, 1999, CELL, V96, P857
   BURGERING BMT, 2002, TRENDS BIOCHEM SCI, V27, P352
   CAJAL SRY, 1995, HISTOLOGY NERVOUS SY
   CARTER ME, 2007, CURR BIOL, V17, R113
   CAUSERET F, 2009, CEREB CORTEX, V19, P861, DOI 10.1093/cercor/bhn133
   COFFER PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488
   CRAIG AM, 1994, ANNU REV NEUROSCI, V267, P310
   DEANDA FC, 2005, NATURE, V436, P704, DOI 10.1038/nature03811
   EDWARDS DC, 1999, NAT CELL BIOL, V1, P253
   GAUDILLIERE B, 2002, J BIOL CHEM, V277, P46442, DOI
   10.1074/jbc.M206653200
   GAUDILLIERE B, 2004, NEURON, V41, P229
   GOLDBERG JL, 2004, CURR OPIN NEUROBIOL, V14, P551, DOI
   10.1016/j.conb.2004.08.012
   GRUEBER WB, 2003, CELL, V112, P805
   HAND R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032
   HAYASHI ML, 2004, NEURON, V42, P773
   HAYASHI ML, 2007, P NATL ACAD SCI USA, V104, P11489, DOI
   10.1073/pnas.0705003104
   HOEKMAN MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI
   10.1016/j.modgep.2005.07.003
   JACOBS FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200
   JACOBS T, 2007, J NEUROSCI, V27, P8604, DOI
   10.1523/JNEUROSCI.0765-07.2007
   JACOBSON C, 2006, NEURON, V49, P797, DOI 10.1016/j.neuron.2006.02.005
   JAN YN, 2003, NEURON, V40, P229
   JIANG H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033
   KANDEL ER, 2000, PRINCIPLES NEURAL SC
   KIM AH, 2007, MOL CELL NEUROSCI, V34, P281, DOI
   10.1016/j.mcn.2006.11.019
   KISHI M, 2005, SCIENCE, V307, P929, DOI 10.1126/science.1107403
   KONISHI Y, 2002, MOL CELL, V9, P1005
   KONISHI Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712
   KUMAR R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892
   LEHTINEN MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046
   NIKOLIC M, 2008, MOL NEUROBIOL, V37, P187, DOI 10.1007/s12035-008-8032-1
   PAIK JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.13.029
   POLLEUX F, 2007, NAT REV NEUROSCI, V8, P331, DOI 10.1038/nrn2118
   POWELL SK, 1997, J NEUROBIOL, V32, P223
   RAMOS B, 2007, P NATL ACAD SCI USA, V104, P9882, DOI
   10.1073/pnas.0701946104
   SCHWAMBORN JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295
   SHALIZI A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513
   SHELLY M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012
   SHI SH, 2003, CELL, V112, P63
   STEGMULLER J, 2005, TRENDS NEUROSCI, V28, P596, DOI
   10.1016/j.tins.2005.09.003
   STEGMULLER J, 2006, NEURON, V50, P389
   TRAN H, 2003, SCI STKE, RE5
   VANDERHEIDE LP, 2004, BIOCHEM J 2, V380, P297
   VANDERHEIDE LP, 2005, BIOCHEM J 3, V391, P623, DOI 10.1042/BJ20050525
   WITTMANN T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200
   YOSHIMURA T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012
   YUAN ZQ, 2008, SCIENCE, V319, P1665, DOI 10.1126/science.1152337
   ZHOU FQ, 2004, NEURON, V42, P897
NR 58
TC 2
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD APR 15
PY 2010
VL 24
IS 8
BP 799
EP 813
DI 10.1101/gad.1880510
PG 15
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 584DK
UT ISI:000276730300008
ER

PT J
AU Barbon, CM
   Yang, M
   Wands, GD
   Ramesh, R
   Slusher, BS
   Hedley, ML
   Luby, TM
AF Barbon, Christine M.
   Yang, Min
   Wands, Gregory D.
   Ramesh, Radha
   Slusher, Barbara S.
   Hedley, Mary Lynne
   Luby, Thomas M.
TI Consecutive low doses of cyclophosphamide preferentially target T-regs
   and potentiate T cell responses induced by DNA PLG microparticle
   immunization
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Poly(lactide-co-glycolide); PLG; Regulatory T cell; Avidity;
   Epitope-spreading; CYP1B1; Cyclophosphamide; Vaccine; Immunization; Treg
ID IMMUNOLOGICAL SELF-TOLERANCE; CO-GLYCOLIDE MICROPARTICLES; ANTIGEN
   CYTOCHROME P4501B1; MURINE MELANOMA MODEL; GROWTH-FACTOR-BETA;
   REGULATORY-CELLS; IMMUNE-RESPONSE; IN-VIVO; TUMOR-IMMUNITY;
   CANCER-IMMUNOTHERAPY
AB Cyclophosphamide in combination with immunotherapeutic approaches
   preferentially impinges on T-reg activity and allows for robust
   generation of T cell effectors. Reduced dosages of cyclophosphamide are
   necessary to restrict its cytotoxic effects to the negative regulatory
   cell populations while sparing effector lymphocytes. We investigated
   cyclophosphamide dosing in combination with ZYC300, a PLG-encapsulated
   plasmid DNA vaccine which encodes the cytochrome P450 family member,
   CYP1B1, a known human tumor-associated antigen. In mice, three
   consecutive, low doses of cyclophosphamide comprised a superior regimen
   in enhancing the magnitude, diversity of epitopes, and avidity to
   individual epitopes of specific T cell responses when compared to
   regimens that used either a single low or a single high dose.
   Consecutive low doses of cyclophosphamide predominantly targeted T-regs
   while sparing overall T lymphocyte counts. Thus, we report the
   synergistic activity of pharmacologic T-reg depletion with
   cyclophosphamide on quantitatively and qualitatively increasing T cell
   responses to a known human tumor-associated antigen. (C) 2010 Elsevier
   Inc. All rights reserved.
C1 [Barbon, Christine M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Yang, Min; Wands, Gregory D.; Ramesh, Radha; Slusher, Barbara S.; Hedley, Mary Lynne; Luby, Thomas M.] Eisai Res Inst Inc, Andover, MA USA.
RP Barbon, CM, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM ChristineM_Barbon@DFCI.harvard.edu
CR AKBAR AN, 2003, IMMUNOLOGY, V109, P319
   BENNETT CL, 2001, NAT GENET, V27, P20
   BERD D, 1982, CANCER RES, V42, P4862
   BERRAONDO P, 2007, CANCER RES, V67, P8847, DOI
   10.1158/0008-5472.CAN-07-0321
   BILLIARD F, 2006, J IMMUNOL, V177, P2167
   BRACCI L, 2007, CLIN CANCER RES 1, V13, P644, DOI
   10.1158/1078-0432.CCR-06-1209
   BROCK N, 1958, DEUT MED WOCHENSCHR, V83, P453
   BRODE S, 2008, CRIT REV IMMUNOL, V28, P109
   BROOKE D, 1973, AM J HOSP PHARM, V30, P134
   BRUNKOW ME, 2001, NAT GENET, V27, P68
   BUBENIK J, 2004, INT J ONCOL, V25, P487
   COLOMBO MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250
   CURIEL TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   CURTI A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863
   DERBY MA, 2001, J IMMUNOL, V166, P1690
   DEVISSER KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
   DRAKE CG, 2006, ADV IMMUNOL, V90, P51, DOI 10.1016/S0065-2776(06)90002-9
   EDDAHRI F, 2006, EUR J IMMUNOL, V36, P855, DOI 10.1002/eji.200535500
   EMENS LA, 2005, CANCER RES, V65, P8059, DOI
   10.1158/0008-5472.CAN-05-1797
   EMENS LA, 2005, ENDOCR-RELAT CANCER, V12, P1, DOI 10.1677/erc.1.00671
   ERCOLINI AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167
   GALLELLI JF, 1967, AM J HOSP PHARM, V24, P425
   GARCIALORA A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290
   GHIRINGHELLI F, 2004, EUR J IMMUNOL, V34, P336
   GHIRINGHELLI F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI
   10.1007/s00262-006-0225-8
   GRAUER OM, 2007, INT J CANCER, V121, P95, DOI 10.1002/ijc.22607
   GRIBBEN JG, 2005, CLIN CANCER RES, V11, P4430
   GROSSMAN WJ, 2004, IMMUNITY, V21, P589
   HEDLEY ML, 1998, HUM GENE THER, V9, P325
   HERMANS IF, 2003, CANCER RES, V63, P8408
   JORDAN MS, 2001, NAT IMMUNOL, V2, P301
   LEVINGS MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI
   10.1159/000067596
   LIYANAGE UK, 2002, J IMMUNOL, V169, P2756
   LU Z, 2008, 50 ANN AM SOC HEM
   LUBY TM, 2004, CLIN IMMUNOL, V112, P45, DOI 10.1016/j.clim.2004.04.002
   LUBY TM, 2008, EXPERT REV VACCINES, V7, P995, DOI
   10.1586/14760584.7.7.995
   LUTSIAK MEC, 2005, BLOOD, V105, P2862
   MAECKER B, 2003, BLOOD, V102, P3287, DOI 10.1182/blood-2003-05-1374
   MAGUIRE HC, 1967, J INVEST DERMATOL, V48, P29
   MAGUIRE HC, 1976, INT ARCH ALLER A IMM, V50, P651
   MATSUSHITA N, 2008, J IMMUNOL METHODS, V333, P167, DOI
   10.1016/j.jim.2008.01.012
   MCFADYEN MCE, 1999, J HISTOCHEM CYTOCHEM, V47, P1457
   MCKEEVER U, 2002, VACCINE, V20, P1524
   MCMAHAN RH, 2007, SEMIN CANCER BIOL, V17, P317, DOI
   10.1016/j.semcancer.2007.06.006
   MIYARA M, 2007, TRENDS MOL MED, V13, P108, DOI
   10.1016/j.molmed.2007.01.003
   MOTOYOSHI Y, 2006, ONCOL REP, V16, P141
   MURRAY GI, 1997, CANCER RES, V57, P3026
   NADLER LM, 2008, 99 AACR ANN M
   NAVAPARADA P, 2007, CANCER RES, V67, P1326, DOI
   10.1158/0008-5472.CAN-06-3290
   POLAK L, 1974, NATURE, V249, P654
   PROIETTI E, 1998, J CLIN INVEST, V101, P429
   RONCAROLO MG, 2006, IMMUNOL REV, V212, P28
   RUTER J, 2009, FRONT BIOSCI, V14, P1761, DOI 10.2741/3338
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   SAKAGUCHI S, 2001, IMMUNOL REV, V182, P18
   SAKAGUCHI S, 2005, INT REV IMMUNOL, V24, P211
   SCHWARTZ A, 1978, J IMMUNOL, V121, P1573
   SHAKED Y, 2005, CANCER RES, V65, P7045, DOI
   10.1158/0008-5742.CAN-05-0765
   SHEVACH EM, 2001, J EXP MED, V193, F41
   SHEVACH EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010
   SHIMIZU J, 1999, J IMMUNOL, V163, P5211
   TAIEB J, 2006, J IMMUNOL, V176, P2722
   TAKAHASHI T, 1998, INT IMMUNOL, V10, P1969
   TAYLOR A, 2006, IMMUNOLOGY, V117, P433, DOI
   10.1111/j.1365-2567.2006.02321.x
   VALZASINA B, 2006, CANCER RES, V66, P4488, DOI
   10.1158/0008-5472.CAN-05-4217
   VIGUIER M, 2004, J IMMUNOL, V173, P1444
   WADA S, 2009, CANCER RES, V69, P4309, DOI 10.1158/0008-5472.CAN-08-4102
   WALKER LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701
   WALKER LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315
   YEE C, 1999, J IMMUNOL, V162, P2227
   YOU S, 2006, IMMUNOL REV, V212, P185
   ZEH HJ, 1999, J IMMUNOL, V162, P989
   ZHAO Y, 2006, MED HYPOTHESES, V67, P1384, DOI 10.1016/j.mehy.2006.05.052
NR 73
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2010
VL 262
IS 2
BP 150
EP 161
DI 10.1016/j.cellimm.2010.02.007
PG 12
SC Cell Biology; Immunology
GA 582LO
UT ISI:000276599100012
ER

PT J
AU Shen, FJ
   Zhang, C
   Zheng, HY
   Xiong, YH
   Wang, X
   Liao, WB
   Du, XJ
   Yang, SX
   Wang, LL
AF Shen, Fujin
   Zhang, Ci
   Zheng, Hongyun
   Xiong, Yunhe
   Wang, Xi
   Liao, Wenbiao
   Du, Xianjin
   Yang, Sixing
   Wang, Linglong
TI Long-Term Culture and Transplantation of Spermatogonial Stem Cells from
   BALB/c Mice
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Spermatogonial stem cells; Cell culture; Transplantation mouse
ID IN-VITRO; SELF-RENEWAL; MOUSE TESTES; LINE; PLURIPOTENCY; SOX2
AB Development of a culture system that supports self-renewal and
   proliferation of spermatogonial stem cells (SSCs) is enormously
   valuable for experimental research and potential treatment for male
   infertility. Although several research groups had reported their
   successes in SSC isolation and culture, the two current accepted
   culture systems are different in cell enrichment methods, serum and
   growth factors. Previous researches also indicated SSCs from different
   mouse strains required different culture conditions. Here we report for
   the first time that SSCs from BALB/c mice could be cultured in an
   improved culture system for 3 months. The modified culture system
   consisted of an improved enzymatic procedure, the enrichment of
   undifferentiated spermatogonia by differential adherence selection of
   isolated SSCs, mouse embryonic fibroblast feeder cells, StemPro-34 SFM
   medium supplemented with glial cell line-derived neurotrophic factor
   (GDNF), basic fibroblast growth factor and GDNF-family receptor alpha 1
   (GFR alpha 1). The improved digestion method increased the viability
   and enrichment efficiency of isolated testis cells. Furthermore, basal
   culture medium with 10% fetal bovine serum as selected medium could
   increase the number of germ cell colonies in the initiation stage of
   culture. Cultured SSCs were characterized morphologically and formed
   typical colonies. Immunocytochemical staining and RT-PCR showed that
   cultured SSCs expressed Oct-4, GFR alpha 1, Sox2 and several other
   special genes resembling undifferentiated spermatogonia. Spermatogonia
   transplantation further confirmed that cultured SSCs were functionally
   normal and could restore complete spermatogenesis. The culture methods
   described here could serve as a paradigm to establish conditions for
   the culture of SSCs from other species, allowing identification of
   universal factors necessary for proliferation of SSCs. Copyright (c)
   2010 S. Karger AG, Basel
C1 [Shen, Fujin; Zhang, Ci; Xiong, Yunhe; Liao, Wenbiao; Du, Xianjin; Yang, Sixing; Wang, Linglong] Wuhan Univ, Dept Urol, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Zheng, Hongyun] Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Wang, Xi] Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan 430072, Peoples R China.
RP Zhang, C, Wuhan Univ, Dept Urol, Renmin Hosp, 238 Jiefang Rd, Wuhan
   430060, Peoples R China.
EM urology@163.com
FU National Natural Science Foundation of China [30400160]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 30400160). We thank Min Peng, Ping Hu (Renmin Hospital
   of Wuhan University, Wuhan, China), Lu Wang and Pu Yang (Tongji Medical
   College, Huazhong University of Science and Technology, Wuhan, China)
   for great assistance.
CR APONTE PM, 2005, APMIS, V113, P727
   AVILION AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   BRINSTER RL, 2007, SCIENCE, V316, P404, DOI 10.1126/science.1137741
   FENG LX, 2002, SCIENCE, V297, P392
   GUAN K, 2009, NAT PROTOC, V4, P143, DOI 10.1038/nprot.2008.242
   IZADYAR F, 2002, REPRODUCTION, V124, P85
   JEONG DK, 2003, J ANDROL, V24, P661
   KANATSUSHINOHARA M, 2003, BIOL REPROD, V69, P612, DOI
   10.1095/biloreprod.103.017012
   KANATSUSHINOHARA M, 2005, BIOL REPROD, V72, P985, DOI
   10.1095/biolreprod.104.036400
   KANATSUSHINOHARA M, 2007, BIOL REPROD, V76, P55, DOI
   10.1095/biolreprod.106.055863
   KANATSUSHINOHARA M, 2008, BIOL REPROD, V78, P611, DOI
   10.1095/biolreprod.107.065615
   KO K, 2009, CELL STEM CELL, V5, P87, DOI 10.1016/j.stem.2009.05.025
   KUBOTA H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI
   10.1073/pnas.0407063101
   KUBOTA H, 2006, NAT CLIN PRACT ENDOC, V2, P99, DOI 10.1038/ncpendmet0098
   KUBOTA H, 2008, METHOD CELL BIOL, V86, P59, DOI
   10.1016/S0091-679X(08)00004-6
   LEE J, 2007, DEVELOPMENT, V134, P1853, DOI 10.1242/dev.003004
   MASUI S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589
   NAGANO M, 2002, FERTIL STERIL, V78, P1225
   NAGANO M, 2003, BIOL REPROD, V68, P2207, DOI
   10.1095/biolreprod.102.014050
   NAUGHTON CK, 2006, BIOL REPROD, V74, P314, DOI
   10.1095/biolreprod.105.047365
   OATLEY JM, 2006, METHOD ENZYMOL, V419, P259, DOI
   10.1016/S0076-6879(06)19011-4
   OGAWA T, 2004, ARCH HISTOL CYTOL, V67, P297
   RYU BY, 2005, P NATL ACAD SCI USA, V102, P14302, DOI
   10.1073/pnas.0506970102
   SHARIATMADARI R, 2001, BIOTECHNIQUES, V30, P1282
   SHI YQ, 2006, FRONT BIOSCI, V11, P2614
NR 25
TC 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1422-6405
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2010
VL 191
IS 5
BP 372
EP 381
DI 10.1159/000276586
PG 10
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 584JT
UT ISI:000276748700004
ER

PT J
AU Zhang, JH
   Yang, Y
   Wu, JR
AF Zhang, Jianhua
   Yang, Ying
   Wu, Jiarui
TI Palmitate impairs cytokinesis associated with RhoA inhibition
SO CELL RESEARCH
LA English
DT Letter
ID CLEAVAGE; ZONE
C1 [Zhang, Jianhua; Yang, Ying; Wu, Jiarui] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol, State Key Lab Mol Biol,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
   [Wu, Jiarui] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.
   [Wu, Jiarui] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
RP Wu, JR, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol,
   State Key Lab Mol Biol,Inst Biochem & Cell Biol, 320 Yue Yang Rd,
   Shanghai 200031, Peoples R China.
EM wujr@sibs.ac.cn
CR BARR FA, 2007, CELL, V131, P847, DOI 10.1016/j.cell.2007.11.011
   BEMENT WM, 2005, J CELL BIOL, V170, P91, DOI 10.1083/jcb.200501131
   BROOKHEART RT, 2009, CELL METAB, V10, P9, DOI 10.1016/j.cmet.2009.03.011
   FIELD SJ, 2005, CURR BIOL, V15, P1407, DOI 10.1016/j.cub.2005.06.059
   GLOTZER M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896
   KANAZAWA T, 2000, J CELL BIOL, V149, P943
   PIEKNY A, 2005, TRENDS CELL BIOL, V15, P651, DOI
   10.1016/j.tcb.2005.10.006
   SAUL D, 2004, J CELL SCI, V117, P3887, DOI 10.1242/jcs.01236
   UNGER RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI
   10.1016/j.tem.2003.09.008
   YONEMURA S, 2004, EXP CELL RES, V295, P300, DOI
   10.1016/j.yexcr.2004.01.005
NR 10
TC 0
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2010
VL 20
IS 4
BP 492
EP 494
DI 10.1038/cr.2010.33
PG 3
SC Cell Biology
GA 585PG
UT ISI:000276838100012
ER

PT J
AU Wang, YJ
   Huang, CX
   Yang, SN
   Jin, LJ
   Hu, XJ
   Wu, G
   Xie, Q
AF Wang Yujing
   Huang Congxin
   Yang Shaning
   Jin Lijun
   Hu Xiaojun
   Wu Gang
   Xie Qiang
TI Digitalis Does not Improve Left Atrial Mechanical Dysfunction After
   Successful Electrical Cardioversion of Chronic Atrial Fibrillation
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Digitalis; Atrial fibrillation; Cardioversion; Myocardial stunning
ID APPENDAGE FUNCTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CONTRACTILE
   DYSFUNCTION; THROMBOEMBOLIC EVENTS; TIME-COURSE; PREDICTORS;
   PERSISTENT; DOFETILIDE; FLUTTER; FLOW
AB This study was designed to investigate whether administration of
   digitalis could improve mechanical function of left atrial appendage
   (LAA) and left atrium prospectively in patients with atrial stunning.
   Fifty-four consecutive patients in whom atrial stunning was observed
   immediately after cardioversion of chronic atrial fibrillation (AF)
   were randomized into digitalis or control group for 1 week following
   cardioversion. Transthoracic echocardiography (TTE) and transesophageal
   echocardiography (TEE) were performed prior to, immediately following,
   1 day after and 1 week after cardioversion to measure transmitral flow
   velocity and LAA flow velocity. Electrical cardioversion of AF elicited
   significantly slower left atrial appendage peak emptying velocity
   (LAA-PEV) and peak filling velocity (LAA-PFV) immediately following
   cardioversion in both groups. 1 day post cardioversion, there were no
   significant differences in transmitral E wave, A wave, E/A ratio,
   LAA-PEV, LAA-PFV or left atrial appendage ejection fraction (LAA-EF)
   between digitalis and control groups. 1 week post cardioversion, no
   significant differences were found in transmitral E wave, A wave, E/A
   ratio, LAA-PEV, LAA-PFV or LAA-EF between the two groups. The
   occurrence rates of spontaneous echo contrast were not significantly
   different between digitalis and control groups one day and one week
   post cardioversion. In conclusion, digitalis did not improve left
   atrial and appendage mechanical dysfunction following cardioversion of
   chronic AF. Digitalis did not prevent the development of spontaneous
   echo contrast in left atrial chamber and appendage. This may be due to
   the fact that digitalis aggravates intracellular calcium overload
   induced by chronic AF and has a negative effect on ventricular rate.
C1 [Yang Shaning; Jin Lijun] Changjiang Univ, Affiliated Hosp 1, Peoples Hosp Jingzhou 1, Cardiovasc Dept, Jinzhou 434000, Hubei Province, Peoples R China.
   [Wang Yujing; Huang Congxin; Hu Xiaojun; Wu Gang; Xie Qiang] Wuhan Univ, Renmins Hosp, Div Cardiol, Wuhan 430060, Hubei Province, Peoples R China.
RP Yang, SN, Changjiang Univ, Affiliated Hosp 1, Peoples Hosp Jingzhou 1,
   Cardiovasc Dept, Hangkong Rd 8, Jinzhou 434000, Hubei Province, Peoples
   R China.
EM yang_sn130@sina.com
FU Department of Education of Hubei Province, China [Q20081208]
FX This study was supported in part by Grant Q20081208 from the Department
   of Education of Hubei Province, China. We are indebted to the
   participants in the Ultrasound Department in First People's Hospital of
   Jingzhou for their outstanding commitment and cooperation.
CR ANTONIELLI E, 1999, AM J CARDIOL, V84, P1092
   AUSMA J, 2001, J MOL CELL CARDIOL, V33, P2083
   BASKIN EP, 1991, J CARDIOVASC PHARM, V18, P406
   BLACK IW, 1994, CIRCULATION, V89, P2509
   BRUNDEL BJJM, 1999, CARDIOVASC RES, V42, P443
   CHANG CM, 2001, CIRCULATION, V103, P22
   DAOUD EG, 1999, CIRCULATION, V99, P3024
   DATE T, 2002, INT J CARDIOL, V84, P59
   DECARA JM, 2000, AM J CARDIOL, V86, P685
   DETHY M, 1988, AM J CARDIOL 1, V62, P723
   FRIEDMAN HS, 2000, CHEST, V118, P1116
   GOETTE A, 1996, CIRCULATION, V94, P2968
   GOETTE A, 2002, AM J PHYSIOL-HEART C, V283, H264
   GRIMM RA, 1993, J AM COLL CARDIOL, V22, P1359
   GRIMM RA, 1997, J AM COLL CARDIOL, V29, P582
   HARJAI KJ, 1997, J AM COLL CARDIOL, V30, P481
   KAMP O, 1999, EUR HEART J, V20, P979
   KHAN IA, 2003, INT J CARDIOL, V92, P113, DOI
   10.1016/S0167-5273(03)00107-4
   KNELLER J, 2002, CARDIOVASC RES, V54, P416
   LEISTAD E, 1996, CIRCULATION, V93, P1747
   LEUNG DY, 1996, PROG CARDIOVASC DIS, V39, P21
   LEVY S, 1997, CIRCULATION, V96, P253
   MANNING WJ, 1994, J AM COLL CARDIOL, V23, P1535
   MIHM MJ, 2001, CIRCULATION, V104, P174
   NISHINO M, 2000, AM J CARDIOL, V85, P1451
   OMRAN H, 1999, ECHOCARDIOGR-J CARD, V16, P245
   ROSS J, 1995, CIRCULATION, V92, P2327
   SAHN DJ, 1978, CIRCULATION, V58, P1072
   TABATA T, 1997, AM J CARDIOL, V79, P615
   TAKAGI M, 2005, HEART, V91, P58, DOI 10.1136/hrt.2003.032334
   THIJSSEN VLJL, 2001, CARDIOVASC RES, V52, P14
   TORPPEDERSEN C, 2000, EUR HEART J, V21, P1204
   VANWAGONER DR, 1999, CIRC RES, V85, P428
   VERHORST PMJ, 1997, AM J CARDIOL, V79, P1355
   WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954
   YANG SN, 2003, CHINESE MED J-PEKING, V116, P1445
   ZABALGOITIA M, 1998, J AM COLL CARDIOL, V31, P1622
   ZAPOLSKI T, 2005, KARDIOL POL, V63, P254
NR 38
TC 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD MAY
PY 2010
VL 57
IS 1
BP 27
EP 34
DI 10.1007/s12013-010-9080-5
PG 8
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 584GT
UT ISI:000276740100004
ER

PT J
AU Gong, GC
   Roach, ML
   Jiang, L
   Yang, XZ
   Tian, XC
AF Gong, Guochun
   Roach, Marsha L.
   Jiang, Le
   Yang, Xiangzhong
   Tian, Xiuchun Cindy
TI Culture Conditions and Enzymatic Passaging of Bovine ESC-Like Cells
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; IN-VITRO; NUCLEAR
   TRANSFER; FACTOR LIF; BLASTOCYSTS; LINES; ESTABLISHMENT; MASS;
   DIFFERENTIATION
AB The goals of the current study were to (1) improve culture conditions
   and (2) chemical passaging of bovine embryonic stem cell-like
   (bESC-like) cells. Specifically, the effects of human leukemia
   inhibitory factor (hLIF), two types of feeders, mouse embryonic
   fibroblast (MEF) and bovine embryonic fibroblast (BEF), as well as
   three different enzymatic treatments including Trypsin-EDTA, TrypLE,
   and Liberase Blendzymes 3 were investigated. The addition of hLIF at
   1000 U/mL to the culture medium (41.2 and 36.9%), and the use of either
   MEF or BEF feeders (40.3 and 38.1%) had no significant effect on the
   ability of inner cell masses (ICMs) to form primary cell colonies
   compared to controls. All bESC-like cells were first dissociated
   mechanically for three passages followed by enzymatic dissociation. The
   ability to maintain ESC morphology to passage 10 was compared among the
   three enzymes above. More bESC-like cell lines survived beyond passage
   10 when treated with TrypLE compared to Trypson-EDTA (28.8 and 12.6%; p
   < 0.05), and bESC-like cells differentiated quickly when treated with
   Liberase Blendzyme 3. The bESC-like cells generated in our study
   displayed typical stem cell morphology and expressed specific markers
   such as SSEA-1, AP, OCT-4, and Nanog. When removed from feeders, these
   bESC-like cells formed embryoid bodies (EBs) in a suspension culture.
   When EBs were cultured on tissue culture plates, they differentiated
   into various cell types. In summary, we were able to culture bESC-like
   cells more than 10 passages by enzymatic dissociation, which is
   important in gene targeting, maintenance, and banking of bESC lines.
C1 [Gong, Guochun; Jiang, Le; Yang, Xiangzhong; Tian, Xiuchun Cindy] Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA.
   [Gong, Guochun; Jiang, Le; Yang, Xiangzhong; Tian, Xiuchun Cindy] Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA.
   [Roach, Marsha L.] Zenith Biotech LLC, Guilford, CT USA.
RP Tian, XC, Univ Connecticut, Dept Anim Sci, 1392 Storrs Rd, Storrs, CT
   06269 USA.
EM xiuchun.tian@uconn.edu
CR BRACKETT BG, 1975, BIOL REPROD, V12, P260
   CIBELLI JB, 1998, NAT BIOTECHNOL, V16, P642
   DOETSCHMAN T, 1988, DEV BIOL, V127, P224
   EVANS MJ, 1981, NATURE, V292, P154
   GONG GC, 2004, SCI CHINA SER C, V47, P183
   GRAVES KH, 1993, MOL REPROD DEV, V36, P424
   HATOYA S, 2006, MOL REPROD DEV, V73, P298, DOI 10.1002/mrd.20392
   IANNACCONE PM, 1994, DEV BIOL, V163, P288
   IWASAKI S, 2000, BIOL REPROD, V62, P470
   KIM H, 2009, ORG LETT, V11, P89, DOI 10.1021/ol8024617
   LI M, 2003, MOL REPROD DEV, V65, P429, DOI 10.1002/mrd.10301
   LI M, 2004, J REPROD DEVELOP, V50, P237
   LI P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006
   LUDWIG TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177
   MALI P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008-0346
   MEINECKETILLMANN S, 1996, J ANIM BREED GENET, V113, P413
   MITALIPOVA M, 2001, CLONING, V3, P59
   MOORE K, 1997, IN VITRO CELL DEV-AN, V33, P62
   PANT D, 2006, REPROD FERT DEVELOP, V18, P110
   PANT D, 2009, CLONING STEM CELLS, V11, P355, DOI 10.1089/clo.2008.0078
   PEASE S, 1990, DEV BIOL, V141, P344
   PIEDRAHITA JA, 1990, THERIOGENOLOGY, V34, P865
   RENARD JP, 2007, THERIOGENOLOGY S1, V68, S196, DOI
   10.1016/j.theriogenology.2007.05.060
   RODRIGUEZ A, 2007, THERIOGENOLOGY, V67, P1092, DOI
   10.1016/j.theriogenology.2006.11.015
   ROSENKRANS CF, 1994, J ANIM SCI, V72, P434
   SAITO S, 2002, FEBS LETT, V531, P389
   SAITO S, 2003, BIOCHEM BIOPH RES CO, V309, P104, DOI
   10.1016/S0006-291X(03)01536-5
   STICE SL, 1996, BIOL REPROD, V54, P100
   STRELCHENKO N, 1996, THERIOGENOLOGY, V45, P131
   SUEMORI H, 2001, DEV DYNAM, V222, P273
   SUKOYAN MA, 1993, MOL REPROD DEV, V36, P148
   TALBOT NC, 1993, IN VITRO CELL DEV-AN, V29, P543
   TALBOT NC, 1995, MOL REPROD DEV, V42, P35
   THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844
   THOMSON JA, 1998, SCIENCE, V282, P1147
   TIAN HB, 2006, CELL BIOL INT, V30, P452, DOI
   10.1016/j.cellbi.2006.02.006
   VANSTEKELENBURGHAMERS AEP, 1995, MOL REPROD DEV, V40, P444
   VEJLSTED M, 2005, MOL REPROD DEV, V70, P445, DOI 10.1002/mrd.20221
   WANG L, 2005, BIOL REPROD, V73, P149, DOI 10.1095/biolreprod.104.037150
   WELLS DN, 1997, BIOL REPROD, V57, P385
   XU CH, 2001, NAT BIOTECHNOL, V19, P971
   XU RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744
   YAMANAKA M, 1999, ANIM SCI J, V70, P444
NR 43
TC 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
J9 CELL REPROGRAMM
JI Cell. Reprogramm.
PY 2010
VL 12
IS 2
BP 151
EP 160
DI 10.1089/cell.2009.0049
PG 10
SC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 584DL
UT ISI:000276730400005
ER

PT J
AU Sung, LY
   Chang, CC
   Amano, T
   Lin, CJ
   Amano, M
   Treaster, SB
   Xu, J
   Chang, WF
   Nagy, ZP
   Yang, XZ
   Tian, XC
AF Sung, Li-Ying
   Chang, Ching-Chien
   Amano, Tomokazu
   Lin, Chih-Jen
   Amano, Misa
   Treaster, Stephen B.
   Xu, Jie
   Chang, Wei-Fang
   Nagy, Zsolt Peter
   Yang, Xiangzhong
   Tian, X. Cindy
TI Efficient Derivation of Embryonic Stem Cells from Nuclear Transfer and
   Parthenogenetic Embryos Derived from Cryopreserved Oocytes
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID IN-VITRO; THERAPEUTIC CLONING; SOMATIC-CELLS; MOUSE OOCYTES;
   PARKINSONIAN MICE; ES CELLS; 1,2-PROPANEDIOL; VITRIFICATION; PREGNANCY;
   DISEASE
AB Deriving histocompatible embryonic stem (ES) cells by somatic cell
   nuclear transfer (SCNT) and parthenogenetic activation (PA) requires
   fresh oocytes, which prevents their applications in humans. Here, we
   evaluated the efficiency of deriving ES cells from mature metaphase II
   (MII) and immature metaphase I (MI) vitrified oocytes, by PA or SCNT,
   in a mouse model. We successfully generated ES cell lines from PA (MII
   and MI) and SCNT (MII and MI) blastocysts. These cell lines expressed
   genes and antigens characteristic of pluripotent ES cells and produced
   full-term pups upon tetraploid embryo complementation. This study
   established an animal model for efficient generation of
   patient-specific ES cell lines using cryopreserved oocytes. This is a
   major step forward in the application of therapeutic cloning and
   parthenogenetic technology in human regenerative medicine and will
   serve as an important alternative to the iPS cell technology in
   countries/regions where these technologies are permitted.
C1 [Tian, X. Cindy] Univ Connecticut, Dept Anim Sci, Ctr Regenerat Biol, Storrs, CT 06269 USA.
   [Sung, Li-Ying; Chang, Wei-Fang] Natl Taiwan Univ, Inst Biotechnol, Taipei 106, Taiwan.
   [Chang, Ching-Chien; Nagy, Zsolt Peter] Reprod Biol Associates, Atlanta, GA USA.
   [Xu, Jie] Evergen Biotechnol Inc, Storrs, CT USA.
RP Tian, XC, Univ Connecticut, Dept Anim Sci, Ctr Regenerat Biol, 1392
   Storrs Rd,U 4243, Storrs, CT 06269 USA.
EM xiuchun.tian@uconn.edu
FU National Taiwan University ; National Science Council [NSC
   96-2321-B002-033]
FX We appreciate the technical assistance provide by Tuz-An Lin. This
   research was supported by funds from USDA-ARS to X.C.T. and X.Y. and to
   L.Y.S. from National Taiwan University and National Science Council
   (NSC 96-2321-B002-033).
CR AMANO T, 2009, CLONING STEM CELLS, V11, P77, DOI 10.1089/clo.2008.0059
   ANTINORI M, 2007, REPROD BIOMED ONLINE, V14, P72
   BARBERI T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   BARRITT J, 2007, FERTIL STERIL, V87, UNSP 189E13-189E7
   BORINI A, 2006, REPROD BIOMED ONLINE, V12, P481
   BRAMBRINK T, 2006, P NATL ACAD SCI USA, V103, P933
   CHA KY, 1998, HUM REPROD UPDATE, V4, P103
   CHEN C, 1986, LANCET, V1, P884
   COVINGTON SN, 2007, FERTIL STERIL, V87, P1001, DOI
   10.1016/j.fertnstert.2006.12.037
   COWAN CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447
   DALEY GQ, 2007, SCIENCE, V315, P603, DOI 10.1126/science.1139337
   ECKARDT S, 2007, GENE DEV, V21, P409, DOI 10.1101/gad.1524207
   EGGAN K, 2004, NATURE, V428, P44
   EGLI D, 2007, NATURE, V447, P679, DOI 10.1038/nature05879
   ENDOH K, 2007, J REPROD DEVELOP, V53, P1199
   EROGLU A, 2009, BIOL REPROD, V80, P70, DOI 10.1095/biolreprod.108.070383
   FABBRI R, 2000, MOL CELL ENDOCRINOL, V169, P39
   GARDNER DK, 2007, THERIOGENOLOGY, V67, P64, DOI
   10.1016/j.theriogenology.2006.09.012
   HALL VJ, 2006, STEM CELLS, V24, P1628, DOI 10.1634/stemcells.2005-0592
   HANSIS C, 2004, CURR BIOL, V14, P1475, DOI 10.1016/j.cub.2004.08.031
   HOCHEDLINGER K, 2003, NEW ENGL J MED, V349, P275
   KIKYO N, 2000, SCIENCE, V289, P2360
   KIM K, 2007, CELL STEM CELL, V1, P346, DOI 10.1016/j.stem.2007.07.001
   KIM K, 2007, SCIENCE, V315, P482, DOI 10.1126/science.1133542
   KISHIGAMI S, 2006, BIOCHEM BIOPH RES CO, V340, P183, DOI
   10.1016/j.bbrc.2005.11
   KUWAYAMA M, 2005, REPROD BIOMED ONLINE, V11, P300
   LARMAN MG, 2006, REPRODUCTION, V131, P53, DOI 10.1530/rep.1.00878
   LARMAN MG, 2007, HUM REPROD, V22, P250, DOI 10.1093/humrep/del319
   OGURA A, 2000, MOL REPROD DEV, V57, P55
   OKITA K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   OKTAY K, 2006, FERTIL STERIL, V86, P70, DOI
   10.1016/j.fertnstert.2006.03.017
   PORCU E, 1999, AM J OBSTET GYNECOL, V180, P1044
   RIDEOUT WM, 2002, CELL, V109, P17
   SHAW JM, 1989, GAMETE RES, V24, P269
   SMITZ JEJ, 2004, GYNECOL OBSTET INVES, V57, P18
   SPAR D, 2007, NEW ENGL J MED, V356, P1289
   STOJKOVIC M, 2005, REPROD BIOMED ONLINE, V11, P226
   TABAR V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732
   TADA M, 2001, CURR BIOL, V11, P1553
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAMADA H, 2006, MOL CELL BIOL, V26, P1259
   TARANGER CK, 2005, MOL BIOL CELL, V16, P5719
   TUCKER MJ, 1998, HUM REPROD, V13, P3156
   VANDERELST J, 1988, HUM REPROD, V3, P960
   VOGEL G, 2006, SCIENCE, V313, P155
   WAKAYAMA T, 1998, NATURE, V394, P369
   WAKAYAMA T, 2001, SCIENCE, V292, P740
   WERNIG M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   WILMUT I, 1997, NATURE, V385, P813
   YANG XZ, 2007, NAT GENET, V39, P295
NR 50
TC 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
J9 CELL REPROGRAMM
JI Cell. Reprogramm.
PY 2010
VL 12
IS 2
BP 203
EP 211
DI 10.1089/cell.2009.0072
PG 9
SC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 584DL
UT ISI:000276730400010
ER

PT J
AU Wei, YC
   Zhu, J
   Huan, YJ
   Liu, ZF
   Yang, CR
   Zhang, XM
   Mu, YS
   Xia, P
   Liu, ZH
AF Wei, Yanchang
   Zhu, Jiang
   Huan, Yanjun
   Liu, Zhongfeng
   Yang, Cairong
   Zhang, Xinmiao
   Mu, Yanshuang
   Xia, Ping
   Liu, Zhouhua
TI Aberrant Expression and Methylation Status of Putatively Imprinted
   Genes in Placenta of Cloned Piglets
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID EMBRYONIC STEM-CELLS; NUCLEAR TRANSFER; FETAL-DEVELOPMENT; DNA
   METHYLATION; PREIMPLANTATION EMBRYOS; BOVINE CLONES; MOUSE EMBRYOS;
   BLASTOCYSTS; REGIONS; CALVES
AB Unlike embryos derived from fertilization, most cloned embryos die
   during postimplantation development, and those that survive to term are
   frequently defective. Many of the observed defects involve placenta.
   Abnormal placentation has been described in several cloned species.
   Imprinted genes are important regulators of placenta growth, and may be
   subjected to faulty reprogramming during somatic cell nuclear transfer.
   We aimed to determine the expression levels and methylation patterns of
   imprinted genes in placentas of live cloned piglets and dead ones.
   Quantitative real-time reverse transcriptase-polymerase chain reaction
   (RT-PCR) analysis showed that the expression of all four imprinted
   genes (IGF2, H19, PEG3, and GRB10) was significantly reduced in
   placentas of dead clones compared with placentas of live cloned piglets
   and controls (p < 0.05). In contrast, both live and dead cloned piglets
   exhibited steady-state mRNA levels for these genes within the control
   range (p > 0.05). Transcript levels for these genes in live clones
   rarely differed from those of controls in both piglets and placentas.
   Examination of the methylation status of DMR2 of IGF2 and CTCF3 of H19
   genes revealed that both genes exhibited significant high methylation
   levels in placentas of dead clones compared with placentas of live
   clones and controls. In contrast, both genes showed a normal
   differential methylation pattern in live cloned piglets and their
   placentas compared with controls. Importantly, dead cloned piglets also
   showed a normal pattern. Our results suggest that abnormal expression
   of imprinted genes in placenta may contribute to the development
   failure in pig somatic cell nuclear transfer (SCNT), which may be
   caused by abnormal methylation patterns in differentially methylated
   regions (DMRs) of imprinted genes as a result of incomplete
   reprogramming during SCNT.
C1 [Wei, Yanchang; Zhu, Jiang; Huan, Yanjun; Liu, Zhongfeng; Yang, Cairong; Zhang, Xinmiao; Mu, Yanshuang; Liu, Zhouhua] NE Agr Univ, Coll Life Sci, Harbin, Heilongjiang, Peoples R China.
   [Xia, Ping] NE Agr Univ, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China.
RP Liu, ZH, NE Agr Univ, Coll Life Sci, 59 Mucai Steet, Harbin,
   Heilongjiang, Peoples R China.
EM liu086@yahoo.com
FU National Natural Science Foundation of China, NSFC [30871431]; National
   High Technology Research and Development Program (863 Program) of China
   [2008AA101006]; New Century Talent Foundation of Heilongjiang Province
   [1153-NCET-007]
FX The authors are thankful to Dr. Yongjun Shu for his generous
   consultation on statistical analysis. The authors are also thankful to
   colleagues in the "Lab of Embryo Biotechnology'' for their helpful
   discussions. This work was supported by National Natural Science
   Foundation of China, NSFC (30871431), the National High Technology
   Research and Development Program (863 Program) of China (2008AA101006),
   and the New Century Talent Foundation of Heilongjiang Province
   (1153-NCET-007).
CR ANGIOLINI E, 2006, PLACENTA A, V27, S98, DOI
   10.1016/j.placenta.2005.12.008
   BISCHOFF SR, 2009, BIOL REPROD, V81, P906, DOI
   10.1095/biolreprod.109.078139
   CASPARY T, 1998, MOL CELL BIOL, V18, P3466
   CHAE JI, 2008, PROTEOMICS, V8, P2724, DOI 10.1002/pmic.200701134
   CHAE JI, 2009, THERIOGENOLOGY, V71, P323, DOI
   10.1016/j.theriogenology.2008.07.025
   CHAVATTEPALMER P, 2002, BIOL REPROD, V66, P1596
   CIBELLI JB, 2002, NAT BIOTECHNOL, V20, P13
   COAN PM, 2005, PLACENTA A, V26, S10, DOI 10.1016/j.placenta.2004.12.009
   EAKIN GS, 2003, DEV DYNAM, V228, P751, DOI 10.1002/dvdy.10363
   FERGUSONSMITH AC, 2001, SCIENCE, V293, P1086
   HAN DW, 2008, MOL REPROD DEV, V75, P777
   HILL JR, 2000, BIOL REPROD, V63, P1787
   HOCHEDLINGER K, 2003, NEW ENGL J MED, V349, P275
   INOUE K, 2002, SCIENCE, V295, P297
   JIANG L, 2007, CLONING STEM CELLS, V9, P97, DOI 10.1089/clo.2006.0041
   KHOSLA S, 2001, BIOL REPROD, V64, P918
   KOHDA T, 2005, BIOL REPROD, V73, P1302, DOI
   10.1095/biolreprod.105.044958
   KOO DB, 2002, BIOL REPROD, V67, P487
   KOO DB, 2004, THERIOGENOLOGY, V62, P779, DOI
   10.1016/j.theriogenology.2003.12.027
   LEE SY, 2007, PROTEOMICS, V7, P1303, DOI 10.1002/pmic.200601045
   LI E, 1993, NATURE, V366, P362
   LI SJ, 2005, BIOL REPROD, V72, P258, DOI 10.1095/biolreprod.104.029462
   LIU JH, 2008, MOL REPROD DEV, V75, P598, DOI 10.1002/mrd.20803
   LIU Z, 2007, SCI CHINA SER C, V37, P634
   MANN MRW, 2003, BIOL REPROD, V69, P902, DOI
   10.1095/biolreprod.103.017293
   MIYOSHI N, 2006, CYTOGENET GENOME RES, V113, P6, DOI 10.1159/000090808
   NAGY A, 1990, DEVELOPMENT, V110, P815
   OGAWA H, 2003, REPRODUCTION, V126, P549
   PARK CH, 2009, GENOMICS, V93, P179, DOI 10.1016/j.ygeno.2008.10.002
   REIK W, 2003, J PHYSIOL-LONDON, V547, P35, DOI
   10.1113/jphysiol.2002.033274
   RIDEOUT WM, 2001, SCIENCE, V293, P1093
   ROSSANT J, 2001, NAT REV GENET, V2, P538
   SUEMIZU H, 2003, DEV BIOL, V253, P36, DOI 10.1006/dbio.2002.0870
   TREMBLAY KD, 1995, NAT GENET, V9, P407
   WAKAYAMA S, 2006, STEM CELLS, V24, P2023, DOI
   10.1634/stemcells.2005-0537
   WARNECKE PM, 1998, GENOMICS, V51, P182
   WEBER M, 2001, MECH DEVELOP, V101, P133
   WELLS DN, 1999, BIOL REPROD, V60, P996
   WILMUT I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079
   YANG L, 2005, MOL REPROD DEV, V71, P431, DOI 10.1002/mrd.20311
   YANG XZ, 2007, NAT GENET, V39, P295
   YOUNG LE, 2001, NAT GENET, V27, P153
NR 42
TC 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
J9 CELL REPROGRAMM
JI Cell. Reprogramm.
PY 2010
VL 12
IS 2
BP 213
EP 222
DI 10.1089/cell.2009.0090
PG 10
SC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 584DL
UT ISI:000276730400011
ER

PT J
AU Delaloy, C
   Liu, L
   Lee, JA
   Su, H
   Shen, FX
   Yang, GY
   Young, WL
   Ivey, KN
   Gao, FB
AF Delaloy, Celine
   Liu, Lei
   Lee, Jin-A
   Su, Hua
   Shen, Fanxia
   Yang, Guo-Yuan
   Young, William L.
   Ivey, Kathy N.
   Gao, Fen-Biao
TI MicroRNA-9 Coordinates Proliferation and Migration of Human Embryonic
   Stem Cell-Derived Neural Progenitors
SO CELL STEM CELL
LA English
DT Article
ID IN-VITRO DIFFERENTIATION; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTION
   FACTORS; ADULT NEUROGENESIS; EXPRESSION; STATHMIN; MECHANISMS;
   PRECURSORS; IDENTIFICATION; REPRESSION
AB Human pluripotent stem cells offer promise for use in cell-based
   therapies for brain injury and diseases. However, their cellular
   behavior is poorly understood. Here we show that the expression of the
   brain-specific microRNA-9 (miR-9) is turned on in human neural
   progenitor cells (hNPCs) derived from human embryonic stem cells. Loss
   of miR-9 suppressed proliferation but promoted migration of hNPCs
   cultured in vitro. hNPCs without miR-9 activity also showed enhanced
   migration when transplanted into mouse embryonic brains or adult brains
   of a mouse model of stroke. These effects were not due to precocious
   differentiation of hNPCs. One of the key targets directly regulated by
   miR-9 encodes stathmin, which increases microtubule instability and
   whose expression in hNPCs correlates inversely with that of miR-9.
   Partial inhibition of stathmin activity suppressed the effects of miR-9
   loss on proliferation and migration of human or embryonic rat neural
   progenitors. These results identify miR-9 as a novel regulator that
   coordinates the proliferation and migration of hNPCs.
C1 [Delaloy, Celine; Liu, Lei; Lee, Jin-A; Gao, Fen-Biao] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.
   [Delaloy, Celine; Liu, Lei; Lee, Jin-A; Gao, Fen-Biao] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA.
   [Su, Hua; Shen, Fanxia; Yang, Guo-Yuan; Young, William L.] Univ Calif San Francisco, Cerebrovasc Res Ctr, Dept Anesthesia, San Francisco, CA 94110 USA.
   [Su, Hua; Shen, Fanxia; Yang, Guo-Yuan; Young, William L.] Univ Calif San Francisco, Cerebrovasc Res Ctr, Dept Perioperat Care, San Francisco, CA 94110 USA.
   [Su, Hua; Shen, Fanxia; Yang, Guo-Yuan; Young, William L.] Univ Calif San Francisco, Cerebrovasc Res Ctr, Dept Neurol & Neurosurg, San Francisco, CA 94110 USA.
   [Ivey, Kathy N.] Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA.
   [Gao, Fen-Biao] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA.
   [Gao, Fen-Biao] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.
RP Gao, FB, Univ Calif San Francisco, Gladstone Inst Neurol Dis, San
   Francisco, CA 94158 USA.
FU California Institute for Regenerative Medicine (CIRM) ; NIH 
FX We thank J Rubenstein, D Srivastava. and our lab members for
   discussions and comments, G Howard and S Ordway for editorial
   assistance, and S Mitchell for administrative assistance C D would like
   to thank Bettencourt Schueller Foundation for help with relocation to
   San Francisco C D and J -A L are supported by fellowships from the
   California Institute for Regenerative Medicine (CIRM) This work is
   supported by grants from the CIRM (F -B G) and the NIH (F -B G and W L
   Y)
CR AMBROS V, 2001, CELL, V107, P823
   AMBROS V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006
   AYALA R, 2007, CELL, V128, P29
   BALDASSARRE G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025
   BARTEL DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   BELLETTI B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894
   BELMONT LD, 1996, CELL, V84, P623
   BIRYUKOVA I, 2009, DEV BIOL, V327, P487, DOI 10.1016/j.ydbio.2008.12.036
   BUSHATI N, 2007, ANNU REV CELL DEV BI, V23, P175
   COBOS I, 2007, NEURON, V54, P873, DOI 10.1016/j.neuron.2007.05.024
   DELALOY C, 2008, NAT NEUROSCI, V11, P625, DOI 10.1038/nn0608-625
   DEO M, 2006, DEV DYNAM, V235, P2538, DOI 10.1002/dvdy.20847
   DUAN X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI
   10.1016/j.conb.2008.04.001
   ELKABETZ Y, 2008, GENE DEV, V22, P152, DOI 10.1101/gad.1616208
   FILIPOWICZ W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   FISH JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   GADEA G, 2007, J CELL BIOL, V178, P23
   GAO FB, 2008, TRENDS NEUROSCI, V31, P20, DOI 10.1016/j.tins.2007.10.004
   GIAMPIETRO C, 2005, ENDOCRINOLOGY, V146, P1825, DOI 10.1210/en.2004-0972
   HOBERT O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   HOCHEDLINGER K, 2003, NEW ENGL J MED, V349, P275
   JIN KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com
   KOSIK KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037
   LAGOSQUINTANA M, 2002, CURR BIOL, V12, P735
   LEUCHT C, 2008, NAT NEUROSCI, V11, P641, DOI 10.1038/nn.2115
   LI XJ, 2006, METH MOL B, V331, P169
   LI Y, 2006, GENE DEV, V20, P2793, DOI 10.1101/gad.1466306
   MAO YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044
   PIETRZYKOWSKI AZ, 2008, NEURON, V59, P274, DOI
   10.1016/j.neuron.2008.05.032
   POLITZ JCR, 2006, P NATL ACAD SCI USA, V103, P18957, DOI
   10.1073/pnas.0609466103
   ROSENFELD N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   RUBIN CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187
   SHIBATA M, 2008, J NEUROSCI, V28, P10415, DOI
   10.1523/JNEUROSCI.3219-08.2008
   SUH MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019
   TAY Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   VASUDEVAN S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   WICHTERLE H, 1999, NAT NEUROSCI, V2, P461
   YAMANAKA S, 2007, CELL STEM CELL, V1, P39
   YU JY, 2008, GENE DEV, V22, P1987, DOI 10.1101/gad.1689808
   ZHANG SC, 2001, NAT BIOTECHNOL, V19, P1129
   ZHAO C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576
   ZHAO CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033
   ZHAO Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI
   10.1016/j.tibs.2007.02.006
   ZHU W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801
NR 44
TC 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD APR 2
PY 2010
VL 6
IS 4
BP 323
EP 335
DI 10.1016/j.stem.2010.02.015
PG 13
SC Cell & Tissue Engineering; Cell Biology
GA 585KD
UT ISI:000276823300011
ER

PT J
AU Be'er, A
   Ariel, G
   Kalisman, O
   Helman, Y
   Sirota-Madi, A
   Zhang, HP
   Florin, EL
   Payne, SM
   Ben-Jacob, E
   Swinney, HL
AF Be'er, Avraham
   Ariel, Gil
   Kalisman, Oren
   Helman, Yael
   Sirota-Madi, Alexandra
   Zhang, H. P.
   Florin, E. -L.
   Payne, Shelley M.
   Ben-Jacob, Eshel
   Swinney, Harry L.
TI Lethal protein produced in response to competition between sibling
   bacterial colonies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bacterial competition; bacterial growth inhibition; growth regulation;
   Paenibacillus dendritiformis; subtilisin
ID COOPERATIVE ORGANIZATION; SELF-ORGANIZATION; BACILLUS-SUBTILIS;
   CANNIBALISM; FRATRICIDE; MECHANISMS; IMMUNITY; GROWTH
AB Sibling Paenibacillus dendritiformis bacterial colonies grown on
   low-nutrient agar medium mutually inhibit growth through secretion of a
   lethal factor. Analysis of secretions reveals the presence of
   subtilisin (a protease) and a 12 kDa protein, termed sibling lethal
   factor (Slf). Purified subtilisin promotes the growth and expansion of
   P. dendritiformis colonies, whereas Slf is lethal and lyses P.
   dendritiformis cells in culture. Slf is encoded by a gene belonging to
   a large family of bacterial genes of unknown function, and the gene is
   predicted to encode a protein of approximately 20 kDa, termed
   dendritiformis sibling bacteriocin. The 20 kDa recombinant protein was
   produced and found to be inactive, but exposure to subtilisin resulted
   in cleavage to the active, 12 kDa form. The experimental results,
   combined with mathematical modeling, show that subtilisin serves to
   regulate growth of the colony. Below a threshold concentration,
   subtilisin promotes colony growth and expansion. However, once it
   exceeds a threshold, as occurs at the interface between competing
   colonies, Slf is then secreted into the medium to rapidly reduce cell
   density by lysis of the bacterial cells. The presence of genes encoding
   homologs of dendritiformis sibling bacteriocin in other bacterial
   species suggests that this mechanism for self-regulation of colony
   growth might not be limited to P. dendritiformis.
C1 [Be'er, Avraham; Zhang, H. P.; Florin, E. -L.; Swinney, Harry L.] Univ Texas Austin, Ctr Nonlinear Dynam, Austin, TX 78712 USA.
   [Be'er, Avraham; Zhang, H. P.; Florin, E. -L.; Swinney, Harry L.] Univ Texas Austin, Dept Phys, Austin, TX 78712 USA.
   [Ariel, Gil] Univ Texas Austin, Dept Math, Austin, TX 78712 USA.
   [Kalisman, Oren; Helman, Yael; Sirota-Madi, Alexandra; Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel.
   [Helman, Yael; Sirota-Madi, Alexandra] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   [Payne, Shelley M.] Univ Texas Austin, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.
   [Ben-Jacob, Eshel] Univ Calif San Diego, Ctr Theoret & Biol Phys, La Jolla, CA 92093 USA.
RP Be'er, A, Univ Texas Austin, Ctr Nonlinear Dynam, Austin, TX 78712 USA.
EM beerav@gmail.com
   eshelbj@gmail.com
   swinney@chaos.utexas.edu
FU Welch Foundation [F-1573]; National Institutes of Health [AI50669];
   National Science Foundation-sponsored Center for Theoretical Biological
   Physics [PHY-0216576, 0225630]; University of California at San Diego ;
   Sid W. Richardson Foundation 
FX We thank I. Brainis (Tel Aviv University) for providing the bacterial
   strain and the growth protocol; S. A. Craig and E. R. Murphy
   (University of Texas, Austin) for helping us with electrophoresis
   gel-runs and protein precipitation; K.D. Linse (University of Texas,
   Austin) for advice and for help with Edman protein sequence and HPLC;
   and B. Engquist and R. Tsai (University of Texas, Austin) for valuable
   suggestions on modeling and numerical algorithms. The sequencing effort
   was supported by the Tauber Family Foundation and was conducted under
   the Tauber Initiative (Tel Aviv University) in collaboration with
   GeneBee group at Moscow State University and the Genome center at the
   Weizmann Institute and DYN-GS Israel. This work was supported by R.A.
   Welch Foundation Grant F-1573 (E.L.F.), National Institutes of Health
   Grant AI50669 (S.M.P.), National Science Foundation-sponsored Center
   for Theoretical Biological Physics Grants PHY-0216576 and 0225630
   (E.B.J.), the University of California at San Diego (E.B.J.), and the
   Sid W. Richardson Foundation (H.L.S.).
CR ALVARO D, 2007, PLOS GENET, V3, P2439, ARTN e228
   BEER A, 2009, J BACTERIOL, V191, P5758, DOI 10.1128/JB.00660-09
   BEER A, 2009, P NATL ACAD SCI USA, V106, P428, DOI
   10.1073/pnas.0811816106
   BENJACOB E, 1995, PHYS REV LETT, V75, P2899
   BENJACOB E, 1997, BACTERIA MULTICELLUL, P394
   BENJACOB E, 1998, ANNU REV MICROBIOL, V52, P779
   BENJACOB E, 2000, ADV PHYS, V49, P395
   BENJACOB E, 2000, PHYSICA A, V282, P247
   BENJACOB E, 2003, PHILOS T ROY SOC A, V361, P1283, DOI
   10.1098/rsta.2003.1199
   CLAVERYS JP, 2007, NAT REV MICROBIOL, V5, P219, DOI 10.1038/nrmicro1613
   ELLERMEIER CD, 2006, CELL, V124, P549
   ERRINGTON J, 2003, NAT REV MICROBIOL, V1, P117
   FINN RD, 2008, NUCLEIC ACIDS RES, V36, P281
   GIBBS KA, 2008, SCIENCE, V321, P256, DOI 10.1126/science.1160033
   GONZALEZPASTOR JE, 2003, SCIENCE, V301, P510, DOI
   10.1126/science.1086462
   GUIRAL S, 2005, P NATL ACAD SCI USA, V102, P8710
   HAVARSTEIN LS, 2006, MOL MICROBIOL, V59, P1297, DOI
   10.1111/j.1365-2005.05021.x
   HENG NCK, 2006, INT C SERIES, V1289, P351
   KIM JH, 2001, BIOTECHNOL LETT, V23, P999
   SWE PM, 2009, J ANTIMICROB CHEMOTH, V63, P679, DOI 10.1093/jac/dkn552
NR 20
TC 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 PROC NAT ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 6
PY 2010
VL 107
IS 14
BP 6258
EP 6263
DI 10.1073/pnas.1001062107
PG 6
SC Multidisciplinary Sciences
GA 579MH
UT ISI:000276374400026
ER

PT J
AU Yang, J
   Wray, NR
   Visscher, PM
AF Yang, Jian
   Wray, Naomi R.
   Visscher, Peter M.
TI Comparing Apples and Oranges: Equating the Power of Case-Control and
   Quantitative Trait Association Studies
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE association; case-control study; quantitative trait
ID GENOME-WIDE ASSOCIATION; COMPLEX TRAITS; SCHIZOPHRENIA; LINKAGE
AB Genome-wide association studies have achieved unprecedented success in
   the identification of novel genes and pathways implicated in complex
   traits. Typically, studies for disease use a case-control (CC) design
   and studies for quantitative traits (QT) are population based. The
   question that we address is what is the equivalence between CC and QT
   association studies in terms of detection power and sample size? We
   compare the binary and continuous traits by assuming a threshold model
   for disease and assuming that the effect size on disease liability has
   similar feature as on QT. We derive the approximate ratio of the
   non-centrality parameter (NCP) between CC and QT association studies,
   which is determined by sample size, disease prevalence (K) and the
   proportion of cases (v) in the CC study. For disease with prevalence
   <0.1, CC association study with equal numbers of cases and controls (v
   = 0.5) needs smaller sample size than QT association study to achieve
   equivalent power, e.g. a CC association study of schizophrenia (K =
   0.01) needs only similar to 55% sample size required for association
   study of height. So a planned meta-analysis for height on 120,000
   individuals has power equivalent to a CC study on 33,100 schizophrenia
   cases and 33,100 controls, a size not yet achievable for this disease.
   With equal sample size, when v = K, the power of CC association study
   is much less than that of QT association study because of the
   information lost by transforming a quantitative continuous trait to a
   binary trait. Genet. Epidemiol. 34:254-257, 2010. (C) 2009 Wiley-Liss,
   Inc.
C1 [Yang, Jian; Wray, Naomi R.; Visscher, Peter M.] Queensland Inst Med Res, Brisbane, Qld 4029, Australia.
RP Yang, J, Queensland Inst Med Res, 300 Herston Rd, Brisbane, Qld 4029,
   Australia.
EM jian.yang@qimr.edu.au
FU Australian National and Medical Research Council [496688, 389892];
   Australian Research Council [DP0770096]
FX Contract grant sponsor: Australian National and Medical Research
   Council; Contract grant numbers: 496688; 389892; Contract grant
   sponsor: Australian Research Council; Contract grant number: DP0770096.
CR BURTON PR, 2007, NATURE, V447, P661
   CICHON S, 2009, AM J PSYCHIAT, V166, P540, DOI
   10.1176/appi.ajp.2008.08091354
   DEMPSTER ER, 1950, GENETICS, V35, P212
   FALCONER DS, 1996, INTRO QUANTITATIVE G
   GOLDSTEIN DB, 2009, NEW ENGL J MED, V360, P1696, DOI
   10.1056/NEJMp0806284
   GOTTESMAN II, 1967, P NATIONAL ACADEMY S, V58, P199
   LYNCH M, 1998, GENETICS ANAL QUANTI
   MCCARTHY MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   PURCELL S, 2003, BIOINFORMATICS, V19, P149
   RISCH N, 1990, AM J HUM GENET, V46, P222
   SULLIVAN PF, 2003, ARCH GEN PSYCHIAT, V60, P1187
   VISSCHER PM, 2008, NAT GENET, V40, P489
   WRAY NR, 2007, GENOME RES, V17, P1520, DOI 10.1101/gr.6665407
NR 13
TC 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD APR
PY 2010
VL 34
IS 3
BP 254
EP 257
DI 10.1002/gepi.20456
PG 4
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 580KW
UT ISI:000276448100007
ER

PT J
AU Lu, Y
   Zhang, HY
   Hou, J
   Wang, HQ
   Hu, XB
   Ma, YJ
   Ge, XY
   Huang, L
   Yang, YA
   Cao, RY
   Fan, H
   Liu, JJ
   Wu, J
AF Lu Yong
   Zhang Huiyong
   Hou Jing
   Wang Huaqian
   Hu Xiangbing
   Ma Yanjun
   Ge Xiaoyu
   Huang Li
   Yang Yanan
   Cao Rongyue
   Fan Hao
   Liu Jingjing
   Wu Jie
TI Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP
   induces prophylactic and therapeutic antitumor activity in vivo
SO GENE THERAPY
LA English
DT Article
DE gastrin-releasing peptide; immunotherapy; prostate carcinoma;
   neutralizing antibody
ID GASTRIN-RELEASING-PEPTIDE; RECEPTOR ANTAGONISTS INHIBIT; ENHANCE
   IMMUNOGENICITY; TANDEM REPEATS; CANCER CELLS; LUNG-CANCER; BOMBESIN;
   MICE; PROTEINS; KINASE
AB Gastrin-releasing peptide (GRP), a bombesin-like peptide, is an
   autocrine or paracrine growth factor that can stimulate the growth of
   various cancer cells, making it an ideal target antigen to develop
   vaccines against cancer. In this study, we developed a novel DNA
   vaccine that encodes six tandem repeats of B-cell epitope GRP(18-27)
   (GRP6) flanked by HSP65 as carrier and four tandem repeats of
   mycobacterial HSP70(407-426) (M4) as helper T-cell epitopes for
   enhancement of immunogenicity. When intramuscularly immunized to mice,
   this anti-GRP DNA vaccine-induced GRP-specific antibody ( Ab) responses
   that were at least 10-fold higher in magnitude compared with HSP65-GRP6
   protein vaccine. Both prophylactic and therapeutic antitumor immunities
   induced by vaccination significantly suppressed the growth of
   GRP-dependent prostate carcinoma RM-1 in vivo and prolonged the
   survival of tumor-inoculated mice. Out results also showed that the
   immune sera with high titer of GRP-specific Abs effectively inhibited
   the growth of tumor in mice and dose dependently inhibited
   proliferation of cultured RM-1 cells in vitro, suggesting that the GRP
   neutralizing Ab is responsible for the protective and therapeutic
   antitumor activity of vaccination. These findings may be of great
   importance in the further exploration of the applications of growth
   factors identified in human in cancer therapy. Gene Therapy (2010) 17,
   459-468; doi: 10.1038/gt.2009.165; published online 4 February 2010
C1 [Lu Yong; Zhang Huiyong; Hou Jing; Wang Huaqian; Hu Xiangbing; Ma Yanjun; Ge Xiaoyu; Huang Li; Yang Yanan; Cao Rongyue; Liu Jingjing; Wu Jie] China Pharmaceut Univ, Minigene Pharm Lab, Biopharmaceut Coll, Nanjing 210009, Peoples R China.
   [Zhang Huiyong] Xinxiang Med Univ, Dept Life Sci & Technol, Xinxiang, Peoples R China.
   [Lu Yong; Fan Hao] Shanghai Yijiu Biomed Cooperat Ltd, Shanghai, Peoples R China.
RP Wu, J, China Pharmaceut Univ, Minigene Pharm Lab, Biopharmaceut Coll,
   24 TongjiaXiang, Nanjing 210009, Peoples R China.
EM Minigene@21cn.com
FU China National Natural Science Fund Committee [30500458, 30701023,
   30672464, 30572272, 30872393, 30772570]; Natural Science Foundation of
   Jiangsu Province [BK 2007170, BK2007169]
FX This work was supported by the China National Natural Science Fund
   Committee (grant nos. 30500458, 30701023, 30672464, 30572272, 30872393
   and 30772570); the Natural Science Foundation of Jiangsu Province (no.
   BK 2007170 and BK2007169).
CR ANAND SB, 2008, ACTA TROP, V107, P106, DOI
   10.1016/j.actatropica.2008.04.018
   APRIKIAN AG, 1997, INT J CANCER, V72, P498
   CHAUDHRY A, 1999, CLIN CANCER RES, V5, P3385
   DUPUIS M, 2000, J IMMUNOL, V165, P2850
   GONZALEZ G, 2007, CURR CANCER DRUG TAR, V7, P229
   GUOJUN W, 2008, ENDOCR-RELAT CANCER, V15, P149
   HELLMICH MR, 1999, J BIOL CHEM, V274, P23901
   JIN L, 2007, VACCINE, V25, P2043, DOI 10.1016/j.vaccine.2006.11.052
   JIN L, 2008, J IMMUNOL, V180, P58
   KJERRULF M, 1997, MOL IMMUNOL, V34, P599
   KROOG GS, 1995, J BIOL CHEM, V270, P8217
   LU Y, 2009, VACCINE, V27, P5411, DOI 10.1016/j.vaccine.2009.06.089
   MIYAZAKI M, 1998, EUR J CANCER, V34, P710
   MOODY TW, 2000, EUR J PHARMACOL, V409, P133
   MOODY TW, 2003, EUR J PHARMACOL, V474, P21, DOI
   10.1016/S0014-2999(03)01996-4
   MOODY TW, 2004, J BIOL CHEM, V279, P23580, DOI 10.1074/jbc.M401938200
   NIMAL S, 2006, VACCINE, V24, P3298, DOI 10.1016/j.vaccine.2006.01.020
   PAPAC DI, 1994, PROTEIN SCI, V3, P1485
   PATEL O, 2006, BBA-REV CANCER, V1766, P23, DOI
   10.1016/j.bbcan.2006.01.003
   PERRAUT R, 1993, CLIN EXP IMMUNOL, V93, P382
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83
   SZEPESHAZI K, 2003, CANCER, V98, P1401, DOI 10.1002/cncr.11649
   WANG Y, 2005, J IMMUNOL, V174, P3306
   XIAO DM, 2002, REGUL PEPTIDES, V109, P141
   YANKAI Z, 2006, BIOCHEM BIOPH RES CO, V345, P1365, DOI
   10.1016/j.bbrc.2006.05.022
NR 25
TC 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD APR
PY 2010
VL 17
IS 4
BP 459
EP 468
DI 10.1038/gt.2009.165
PG 10
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 580CZ
UT ISI:000276425800003
ER

PT J
AU Yang, N
   Nijhuis, ER
   Volders, HH
   Eijsink, JJH
   Lendvai, A
   Zhang, B
   Hollema, H
   Schuuring, E
   Wisman, GBA
   van der Zee, AGJ
AF Yang, Nan
   Nijhuis, Esther R.
   Volders, Haukeline H.
   Eijsink, Jasper J. H.
   Lendvai, Agnes
   Zhang, Bo
   Hollema, Harry
   Schuuring, Ed
   Wisman, G. Bea A.
   van der Zee, Ate G. J.
TI Gene promoter methylation patterns throughout the process of cervical
   carcinogenesis
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Methylation; cervical (intraepithelial) neoplasia; DAPK; CCNA1; CADM1
ID ABERRANT DNA METHYLATION; HUMAN-PAPILLOMAVIRUS DNA; SQUAMOUS-CELL
   CARCINOMA; UTERINE CERVIX; CANCER; HYPERMETHYLATION; NEOPLASIA; PCR;
   PREVALENCE; EXPRESSION
AB Objectives: To determine methylation status of nine genes, previously
   described to be frequently methylated in cervical cancer, in squamous
   intraepithelial lesions (SIL).
   Methods: QMSP was performed in normal cervix, low-grade ( L) SIL,
   high-grade (H) SIL, adenocarcinomas and squamous cell cervical cancers,
   and in corresponding cervical scrapings.
   Results: Only CCNA1 was never methylated in normal cervices and rarely
   in LSILs. All other genes showed methylation in normal cervices, with
   CALCA, SPARC and RAR-beta(2) at high levels. Methylation frequency of 6
   genes (DAPK, APC, TFPI2, SPARC, CCNA1 and CADM1) increased with
   severity of the underlying cervical lesion. DAPK showed the highest
   increase in methylation frequency between LSIL and HSIL (10% vs. 40%, p
   < 0.05), while CCNA1 and TFPI2 were most prominently methylated in
   cervical cancers compared to HSILs (25% vs. 52%, p < 0.05, 30% vs. 58%,
   p < 0.05). CADM1 methylation in cervical cancers was related to depth
   of invasion ( p < 0.05) and lymph vascular space involvement ( p <
   0.01), suggesting a role in invasive potential of cervical cancers.
   Methylation ratios in scrapings reflected methylation status of the
   underlying lesions ( p < 0.05).
   Conclusion: Methylation of previously reported cervical cancer specific
   genes frequently occurs in normal epithelium. However, frequency of
   methylation increases during cervical carcinogenesis, with CCNA1 and
   DAPK as the best markers to distinguish normal/LSIL from HSIL/cancer
   lesions.
C1 [Yang, Nan; Nijhuis, Esther R.; Volders, Haukeline H.; Eijsink, Jasper J. H.; Lendvai, Agnes; Wisman, G. Bea A.; van der Zee, Ate G. J.] Univ Groningen, Dept Gynecol Oncol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
   [Yang, Nan; Zhang, Bo] Peking Univ, Dept Pathol, Sch Basic Med Sci, Hlth Sci Ctr, Beijing 100871, Peoples R China.
   [Hollema, Harry; Schuuring, Ed] Univ Groningen, Dept Pathol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
RP Wisman, GBA, Univ Groningen, Dept Gynecol Oncol, Univ Med Ctr
   Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands.
EM g.b.a.wisman@og.umcg.nl
FU Dutch Cancer Society (NKB) [RUG 2004-3161]
FX This study was supported by OncoMethylome Sciences S. A., Liege,
   Belgium and by the Dutch Cancer Society (NKB) (project-number RUG
   2004-3161). Nan Yang is a recipient of Bernoulli Bursary.
CR AHUJA N, 2000, HISTOL HISTOPATHOL, V15, P835
   BAAY MFD, 1996, J CLIN MICROBIOL, V34, P745
   BAYLIN SB, 2001, HUM MOL GENET, V10, P687
   BURGERS WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950
   DEWILDE J, 2008, CELL ONCOL, V30, P77
   DONG SM, 2001, CLIN CANCER RES, V7, P1982
   EADS CA, 2000, NUCLEIC ACIDS RES, V28, P32
   FENG QH, 2005, J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118
   GUSTAFSON KS, 2004, CANCER CYTOPATHOL, V102, P259, DOI
   10.1002/cncr.20425
   HENKEN FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   INSINGA RP, 2008, CANCER EPIDEM BIOMAR, V17, P1611, DOI
   10.1158/1055-9965.EPI-07-2922
   IVANOVA T, 2002, BMC CANCER, V2, ARTN 4
   JONES PA, 1997, P NATL ACAD SCI USA, V94, P2103
   KAHN SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258
   KAMANGAR F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   KANG S, 2006, INT J CANCER, V118, P2168, DOI 10.1002/ijc.21609
   KITKUMTHORN N, 2006, BMC CANCER, V6, ARTN 55
   LAI HC, 2007, GYNECOL ONCOL, V104, P629, DOI 10.1016/j.ygyno.2006.10.003
   LUNG HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590
   MCCREDIE MRE, 2008, LANCET ONCOL, V9, P425, DOI
   10.1016/S1470-2045(08)70103-7
   MITCHELL MF, 1996, J NATL CANC I MONOGR, V21, P17
   MULLER HM, 2004, CANCER LETT, V209, P231, DOI
   10.1016/j.canlet.2003.12.016
   NARAYAN G, 2003, MOL CANCER, V2, P24
   PARKIN DM, 1990, INT J CANCER, V80, P827
   PETO J, 2004, LANCET, V364, P249
   REESINKPETERS N, 2004, MOL CANCER RES, V2, P289
   SAWADA M, 2007, CANCER LETT, V251, P211, DOI
   10.1016/j.canlet.2006.11.023
   SCHIFFMAN M, 2005, J NATL CANCER I, V97, P147, DOI 10.1093/jnci/dji014
   SHIVAPURKAR N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   SHIVAPURKAR N, 2007, GYNECOL ONCOL, V107, P549, DOI
   10.1016/j.ygyno.2007.08.057
   SNIJDERS PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866
   SOVA P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI
   10.1158/1055-9965.EPI-05-0323
   STEENBERGEN RDM, 2004, J NATL CANCER I, V96, P294, DOI
   10.1093/jnci/djh031
   VANDONGEN JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202
   VIRMANI AK, 2001, CLIN CANCER RES, V7, P584
   VISSER J, 2006, INT J CANCER, V118, P2529, DOI 10.1002/ijc.21673
   WENTZENSEN N, 2008, GYNECOL ONCOL, V112, P293
   WIDSCHWENDTER A, 2004, CLIN CANCER RES, V10, P3396
   WISMAN GBA, 1998, J CLIN ONCOL, V16, P2238
   WISMAN GBA, 2006, INT J CANCER, V119, P1908, DOI 10.1002/ijc.22060
NR 41
TC 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1570-5870
J9 CELL ONCOL
JI Cell. Oncol.
PY 2010
VL 32
IS 1-2
BP 131
EP 143
DI 10.3233/CLO-2009-0510
PG 13
SC Oncology; Cell Biology; Pathology
GA 580PQ
UT ISI:000276461800012
ER

PT J
AU Yang, H
   Qian, XH
   Cong, R
   Li, JW
   Yao, Q
   Jiao, XY
   Ju, G
   You, SW
AF Yang, Hao
   Qian, Xin-Hong
   Cong, Rui
   Li, Jing-wen
   Yao, Qin
   Jiao, Xi-Ying
   Ju, Gong
   You, Si-Wei
TI Evidence for Heterogeneity of Astrocyte De-Differentiation in vitro:
   Astrocytes Transform into Intermediate Precursor Cells Following
   Induction of ACM from Scratch-Insulted Astrocytes
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Astrocytes; De-differentiation; Intermediate precursor cell; A2B5; NG2;
   Neural stem cell; Cell culture
ID CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; RAT SPINAL-CORD;
   NG2-EXPRESSING CELLS; NG2-POSITIVE CELLS; NG2 PROTEOGLYCAN; PROGENITOR
   CELLS; OLIGODENDROGLIAL PROGENITORS; SUBVENTRICULAR ZONE; DEMYELINATION
AB Our previous study definitely demonstrated that the mature astrocytes
   could undergo a de-differentiation process and further transform into
   pluripotential neural stem cells (NSCs), which might well arise from
   the effect of diffusible factors released from scratch-insulted
   astrocytes. However, these neurospheres passaged from one
   neurosphere-derived from de-differentiated astrocytes possessed a
   completely distinct characteristic in the differentiation behavior,
   namely heterogeneity of differentiation. The heterogeneity in cell
   differentiation has become a crucial but elusive issue. In this study,
   we show that purified astrocytes could de-differentiate into
   intermediate precursor cells (IPCs) with addition of scratch-insulted
   astrocyte-conditioned medium (ACM) to the culture, which can express
   NG2 and A2B5, the IPCs markers. Apart from the number of NG2(+) and
   A2B5(+) cells, the percentage of proliferative cells as labeled with
   BrdU progressively increased with prolonged culture period ranging from
   1 to 10 days. Meanwhile, the protein level of A2B5 in cells also
   increased significantly. These results revealed that not all astrocytes
   could de-differentiate fully into NSCs directly when induced by ACM,
   rather they generated intermediate or more restricted precursor cells
   that might undergo progressive de-differentiation to generate NSCs.
C1 [Yang, Hao; Li, Jing-wen; Yao, Qin; Jiao, Xi-Ying; Ju, Gong; You, Si-Wei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.
   [Qian, Xin-Hong] Fourth Mil Med Univ, Xijing Hosp, Dept Pediat, Xian 710032, Peoples R China.
   [Cong, Rui] Fourth Mil Med Univ, Xijing Hosp, Dept Inst Orthopaed, Xian 710032, Peoples R China.
RP Ju, G, Fourth Mil Med Univ, Inst Neurosci, 17 W Chang Le Rd, Xian
   710032, Peoples R China.
EM yanghao71_99@yahoo.com
   jugong@fmmu.edu.cn
   yonsiwei@fmmu.edu.cn
FU Natural Science Foundation of China [30973088, 30872829, 30571998];
   Chinese PLA [06G089, 08Z028]
FX This work was supported by the Natural Science Foundation of China
   (Grant Nos. 30973088, 30872829, and 30571998), Chinese PLA national
   scientific technological project (06G089), and the 11th Five-year
   Special-purpose Programme for PLA (08Z028).
CR ABNEY ER, 1983, DEV BIOL, V100, P166
   AGUIRRE A, 2004, J NEUROSCI, V24, P10530, DOI
   10.1523/JNEUROSCI.3572-04.2004
   AGUIRRE AA, 2004, J CELL BIOL, V165, P575, DOI 10.1083/jcb.200311141
   BARACSKAY KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519
   BELACHEW S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110
   CAI S, 2007, BIOSCIENCE, V57, P655, DOI 10.1641/B570805
   CHATTERJEE N, 2008, J BIOL CHEM, V283, P8310, DOI 10.1074/jbc.M706074200
   CHITTAJALLU R, 2004, J PHYSIOL-LONDON, V561, P109, DOI
   10.1113/jphysiol.2004.074252
   DAWSON MRL, 2000, J NEUROSCI RES, V61, P471
   DIBELLO IC, 1999, J NEUROCYTOL, V28, P365
   DIERSFENGER M, 2001, GLIA, V34, P213
   DROMARD C, 2007, STEM CELLS, V25, P340, DOI 10.1634/stemcells.2005-0556
   GANAT YM, 2006, J NEUROSCI, V26, P8609, DOI
   10.1523/JNEUROSCI.2532-06.2006
   GRINSPAN J, 2002, J NEUROPATH EXP NEUR, V61, P297
   HARRISINGH MC, 2004, EMBO J, V23, P3061, DOI 10.1038/sj.emboj.7600309
   KEIRSTEAD HS, 1998, GLIA, V22, P161
   LANG B, 2004, NEUROSCIENCE, V128, P775, DOI
   10.1016/j.neuroscience.2004.06.033
   LEVINE JM, 1999, EXP NEUROL, V160, P333
   LEVINE JM, 2001, TRENDS NEUROSCI, V24, P39
   LIU Y, 2002, GLIA, V40, P25, DOI 10.1002/glia.10111
   LIU Y, 2004, BIOL CELL, V96, P279, DOI 10.1016/j.biolcel.2004.02.001
   MALLON BS, 2002, J NEUROSCI, V22, P876
   NISHIYAMA A, 1997, J NEUROSCI RES, V48, P299
   POLITO A, 2005, J ANAT, V207, P707
   RAO MS, 1998, P NATL ACAD SCI USA, V95, P3996
   RUFFINI F, 2004, AM J PATHOL, V165, P2167
   STALLCUP WB, 2002, J NEUROCYTOL, V31, P423
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   WALDER S, 2003, DEV GENES EVOL, V213, P625, DOI
   10.1007/s00427-003-0364-2
   YANG H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4
   YANG H, 2008, NEUROCHEM RES, V33, P1169
   YANG H, 2009, CELL MOL NEUROBIOL, V29, P455, DOI
   10.1007/s10571-008-9337-3
NR 32
TC 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD APR
PY 2010
VL 30
IS 3
BP 483
EP 491
DI 10.1007/s10571-009-9474-3
PG 9
SC Cell Biology; Neurosciences
GA 580XQ
UT ISI:000276484500018
ER

PT J
AU Gan, L
   Liu, P
   Lu, H
   Chen, S
   Yang, J
   McCarthy, JB
   Knudsen, KE
   Huang, H
AF Gan, L.
   Liu, P.
   Lu, H.
   Chen, S.
   Yang, J.
   McCarthy, J. B.
   Knudsen, K. E.
   Huang, H.
TI Cyclin D1 promotes anchorage-independent cell survival by inhibiting
   FOXO-mediated anoikis (vol 16, pg 1408, 2009)
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Correction
CR GAN L, 2009, CELL DEATH DIFFER, V16, P1408, DOI 10.1038/cdd.2009.86
NR 1
TC 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD MAY
PY 2010
VL 17
IS 5
BP 900
EP 900
DI 10.1038/cdd.2010.15
PG 1
SC Biochemistry & Molecular Biology; Cell Biology
GA 581HU
UT ISI:000276513600018
ER

PT J
AU Yang, J
   Darley, RL
   Hallett, M
   Evans, WH
AF Yang, Jian
   Darley, Richard L.
   Hallett, Maurice
   Evans, W. Howard
TI Low Connexin Channel-Dependent Intercellular Communication in Human
   Adult Hematopoietic Progenitor/Stem Cells: Probing Mechanisms of
   Autologous Stem Cell Therapy
SO CELL COMMUNICATION AND ADHESION
LA English
DT Article
ID GAP JUNCTIONAL COMMUNICATION; MESENCHYMAL STROMAL CELLS;
   MYOCARDIAL-INFARCTION; EXPRESSION; TRANSPLANTATION; CARDIOMYOCYTES;
   HEMICHANNELS; REPAIR; HEART; MOUSE
AB Human bone marrow is a clinical source of autologous progenitor stem
   cells showing promise for cardiac repair following ischemic insult.
   Functional improvements following delivery of adult bone marrow
   CD34<SU+</SU cells into heart tissue may require metabolic/electrical
   communication between participating cells. Since connexin43 (Cx43)
   channels are implicated in cardiogenesis and provide intercellular
   connectivity in the heart, the authors analyzed the expression of 20
   connexins (Cx) in CD34<SU+</SU cells and in monocytes and granulocytes
   in bone marrow and spinal cord. Reverse transcriptase-polymerase chain
   reaction (RT-PCR) detected only low expression of Cx43 and Cx37. Very
   low level dye coupling was detected by flow cytometry between
   CD34<SU+</SU cells and other Cx43 expressing cells, including HL-1
   cardiac cells, and was not inhibited by specific gap junction
   inhibitors. The results indicate that CD34<SU+</SU cells are unlikely
   to communicate via gap junctions and the authors conclude that use of
   CD34<SU+</SU cells to repair damaged hearts is unlikely to involve gap
   junctions. The results concur with the hypothesis that bone marrow
   cells elicit improved cardiac function through release of undefined
   paracrine mediators.
C1 [Evans, W. Howard] Cardiff Univ, Sch Med, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales.
   [Darley, Richard L.] Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales.
   [Hallett, Maurice] Cardiff Univ, Sch Med, Dept Surg, Cardiff CF14 4XN, S Glam, Wales.
   [Yang, Jian; Evans, W. Howard] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales.
RP Evans, WH, Cardiff Univ, Sch Med, Wales Heart Res Inst, Cardiff CF14
   4XN, S Glam, Wales.
EM whewmb@cardiff.ac.uk
FU British Heart Foundation [PG/05/051]
FX This work was supported by grant PG/05/051 from the British Heart
   Foundation.
CR BALSAM LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   BREITBACH M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood-2006-12-063412
   CHEN Z, 2006, STEM CELLS, V24, P1265
   COTRINA ML, 2008, GLIA, V56, P1791, DOI 10.1002/glia.20728
   DREXLER H, 2009, NAT REV CARDIOL, V6, P615, DOI
   10.1038/nrcardio.2009.158
   ELTZSCHIG HK, 2006, CIRC RES, V99, P1100
   EVANS WH, 2006, BIOCHEM J 1, V397, P1, DOI 10.1042/BJ20060175
   EVANS WH, 2007, CELL COMMUN ADHES, V14, P265, DOI
   10.1080/15419060801891034
   GALLO MP, 2007, J CELL BIOCHEM, V100, P86, DOI 10.1002/jcb.21012
   HIRABAYASHI Y, 2007, J MEMBRANE BIOL, V217, P105, DOI
   10.1007/s00232-007-9042-z
   HUETTNER JE, 2006, STEM CELLS, V24, P1654, DOI
   10.1634/stemcells.2005-0003
   JONES DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319
   KANNO S, 2003, J AM COLL CARDIOL, V41, P681, DOI
   10.1016/S0735-1097(02)02893-0
   KAWAMOTO A, 2006, CIRCULATION, V114, P2163, DOI
   10.1161/CIRCULATIONAHA.106.644518
   KOYANAGI M, 2008, J NEUROSCI RES, V86, P270, DOI 10.1002/jnr.21502
   LEOBON B, 2003, P NATL ACAD SCI USA, V100, P7808
   MARTIN PEM, 2001, J CELL SCI, V114, P3845
   MARTINRENDON E, 2008, EUR HEART J, V29, P1807, DOI
   10.1093/eurheartj/ehn220
   MATIC M, 2002, J INVEST DERMATOL, V118, P110
   MOORE JC, 2008, BIOCHEM BIOPH RES CO, V377, P46, DOI
   10.1016/j.bbrc.2008.09.076
   MURRY CE, 2005, CIRCULATION, V112, P3174, DOI
   10.1161/CIRCULATIONAHA.105.546218
   NAHRENDORF M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   OVIEDOORTA E, 2000, IMMUNOLOGY, V99, P578
   PAEMELEIRE K, 2000, MOL BIOL CELL, V11, P1815
   PASSIER R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040
   PSALTIS PJ, 2008, STEM CELLS, V26, P2201, DOI
   10.1634/stemcells.2008-0428
   RAFF M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI
   10.1146/annurev.cellbio.19.111301.143037
   ROELL W, 2007, NATURE, V450, P819, DOI 10.1038/nature06321
   ROSE RA, 2008, STEM CELLS, V26, P2884
   SEGERS VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800
   SITNICKA E, 2003, BLOOD, V102, P881, DOI 10.1182/blood-2002-06-1694
   VEITCH GI, 2004, J CELL SCI, V117, P2699, DOI 10.1242/jcs.01124
   VERMA V, 2008, EUR J CELL BIOL, V88, P79
   WATKINS SC, 2005, IMMUNITY, V23, P309
   WHITE SM, 2004, AM J PHYSIOL-HEART C, V286, H823, DOI
   10.1152/ajpheart.00986.2003
   WILLECKE K, 2002, BIOL CHEM, V383, P725
   WONG CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441
   WONG RCB, 2008, STEM CELL REV, V4, P283, DOI 10.1007/s12015-008-9038-9
   WORSDORFER P, 2008, STEM CELLS, V26, P431, DOI
   10.1634/stemcells.2007-0482
   YIP HK, 2008, CIRC J, V72, P1336
   ZHANG SH, 2007, STEM CELLS, V25, P1195, DOI 10.1634/stemcells.2006-0605
   ZHANG WJ, 1998, SCI CHINA SER C, V41, P419
NR 42
TC 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1541-9061
J9 CELL COMMUN ADHES
JI Cell Commun. Adhes.
PD DEC
PY 2009
VL 16
IS 5-6
BP 138
EP 145
DI 10.3109/15419061003653763
PG 8
SC Biochemistry & Molecular Biology; Cell Biology
GA 581VZ
UT ISI:000276554700003
ER

PT J
AU Lee, MW
   Chanda, D
   Yang, JQ
   Oh, H
   Kim, SS
   Yoon, YS
   Hong, S
   Park, KG
   Lee, IK
   Choi, CS
   Hanson, RW
   Choi, HS
   Koo, SH
AF Lee, Min-Woo
   Chanda, Dipanjan
   Yang, Jianqi
   Oh, Hyunhee
   Kim, Su Sung
   Yoon, Young-Sil
   Hong, Sungpyo
   Park, Keun-Gyu
   Lee, In-Kyu
   Choi, Cheol Soo
   Hanson, Richard W.
   Choi, Hueng-Sik
   Koo, Seung-Hoi
TI Regulation of Hepatic Gluconeogenesis by an ER-Bound Transcription
   Factor, CREBH
SO CELL METABOLISM
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; INSULIN-RESISTANCE; INTRAMEMBRANE
   PROTEOLYSIS; COACTIVATOR PGC-1; CREB/ATF-FAMILY; LIVER; ATF6; CLEAVAGE;
   METABOLISM; PROTEIN
AB Endoplasmic reticulum (ER)-bound transcription factor families are
   shown to be involved in the control of various metabolic pathways.
   Here, we report a critical function of ER-bound transcription factor,
   CREBH, in the regulation of hepatic gluconeogenesis. Expression of
   CREBH is markedly induced by fasting or in the insulin-resistant state
   in rodents in a dexamethasone- and PGC-1 alpha-dependent manner, which
   results in the accumulation of active nuclear form of CREBH (CREBH-N).
   Overexpression of constitutively active CREBH activates transcription
   of PEPCK-C or G6Pase by binding to its enhancer site that is distinct
   from the well-characterized CREB/CRTC2 regulatory sequences in vivo. Of
   interest, knockdown of CREBH in liver significantly reduces blood
   glucose levels without altering expression of genes involved in the ER
   stress signaling cascades in mice. These data suggest a crucial role
   for CREBH in the regulation of hepatic glucose metabolism in mammals.
C1 [Chanda, Dipanjan; Choi, Hueng-Sik] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.
   [Lee, Min-Woo; Yoon, Young-Sil; Hong, Sungpyo; Koo, Seung-Hoi] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 440746, Gyeonggi Do, South Korea.
   [Choi, Hueng-Sik] Chonnam Natl Univ, Sch Med, Dept Biomed Sci, Res Inst Med Sci, Kwangju 501746, South Korea.
   [Yang, Jianqi; Hanson, Richard W.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.
   [Oh, Hyunhee; Kim, Su Sung; Choi, Cheol Soo] Gachon Univ Med & Sci, Gil Med Ctr, Lee Gil Ya Canc & Diabet Inst, Inchon 405760, South Korea.
   [Choi, Cheol Soo] Gachon Univ Med & Sci, Gil Med Ctr, Div Endocrinol, Inchon 405760, South Korea.
   [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Res Inst Aging & Metab, Dept Internal Med, Taegu 700422, South Korea.
   [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Res Inst Aging & Metab, Dept Biochem, Taegu 700422, South Korea.
   [Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Res Inst Aging & Metab, World Class Univ Program, Taegu 700422, South Korea.
   [Park, Keun-Gyu] Keimyung Univ, Sch Med, Dept Internal Med, Taegu, South Korea.
RP Choi, HS, Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr,
   Kwangju 500757, South Korea.
EM hsc@chonnam.ac.kr
   shkoo@med.skku.ac.kr
FU Ministry for Health, Welfare, and Family Affairs, Republic of Korea
   [A080150]; NRF [NRL-ROA-2005-000-10047-0]
FX We would like to thank Sun Myung Park and Yo-Na Kim for technical
   assistance. We would also like to thank Dr. Seok-Yong Choi for critical
   reading. This work was supported by a grant of the Korea Healthcare
   technology R&D Project, Ministry for Health, Welfare, and Family
   Affairs, Republic of Korea (A080150) (S.-H.K.) and by the NRF through
   the National Research Laboratory program (NRL-ROA-2005-000-10047-0)
   (H.-S.C.).
CR ANDREWS RC, 1999, CLIN SCI, V96, P513
   BROU C, 2000, MOL CELL, V5, P207
   BROWN MS, 2000, CELL, V100, P391
   CHANDA D, 2008, ENDOCR J, V55, P253
   CHEN X, 2002, J BIOL CHEM, V277, P13045
   CHIN KT, 2005, NUCLEIC ACIDS RES, V33, P1859, DOI 10.1093/nar/gki332
   HALL RK, 1999, J BASIC CLIN PHYSL P, V10, P119
   HANSON RW, 1997, ANNU REV BIOCHEM, V66, P581
   HAZE K, 1999, MOL BIOL CELL, V10, P3787
   HERZIG S, 2001, NATURE, V413, P179
   KONDO S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213
   KOO SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044
   KOO SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967
   LEONE TC, 2005, PLOS BIOL, V3, P672, ARTN e101
   LIN JD, 2004, CELL, V119, P121
   OMORI Y, 2001, NUCLEIC ACIDS RES, V29, P2154
   PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175
   PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755
   PUIGSERVER P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667
   RAGGO C, 2002, MOL CELL BIOL, V22, P5639
   RHEE J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI
   10.1073/pnas.0730870100
   ROSS EJ, 1982, LANCET, V2, P646
   SHEN JS, 2002, DEV CELL, V3, P99
   VANSCHAFTINGEN E, 2002, BIOCHEM J 3, V362, P513
   WANG YG, 2009, NATURE, V460, P534, DOI 10.1038/nature08111
   YE J, 2000, MOL CELL, V6, P1355
   YOON JC, 2001, NATURE, V413, P131
   ZHANG KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040
   ZINKER B, 2007, METABOLISM, V56, P380, DOI 10.1016/j.metabol.2006.10.021
NR 29
TC 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD APR 7
PY 2010
VL 11
IS 4
BP 331
EP 339
DI 10.1016/j.cmet.2010.02.016
PG 9
SC Cell Biology; Endocrinology & Metabolism
GA 581TE
UT ISI:000276546700015
ER

PT J
AU Huang, Y
   Lin, M
   Wu, JR
   Yang, LY
   Xiang, Z
AF Huang, Yue
   Lin, Min
   Wu, Jiao-Ren
   Yang, Li-Ye
   Xiang, Zu
TI Hb CS-H disease combined with beta-thalassemia-a case report
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Letter
C1 [Huang, Yue; Lin, Min; Wu, Jiao-Ren; Yang, Li-Ye] Chaozhou Cent Hosp, Chaozhou 521021, Guangdong, Peoples R China.
   [Xiang, Zu] Decipher Biosci LTD, Shenzhen 518034, Guangdong, Peoples R China.
RP Yang, LY, Chaozhou Cent Hosp, Chaozhou 521021, Guangdong, Peoples R
   China.
EM yangleeyee@sina.com
CR CHUI DHK, 2003, BLOOD, V101, P791, DOI 10.1182/blood-2002-07-1975
   LIN M, 2008, BLOOD CELL MOL DIS, V22, P5259
   QIN W, 1979, CHIN MED J, V92, P787
   SCHRIER SL, 1997, BLOOD, V89, P1762
   TAN JAMA, 2009, GENES GENET SYST, V84, P67
NR 5
TC 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD APR 15
PY 2010
VL 44
IS 4
BP 215
EP 216
DI 10.1016/j.bcmd.2010.01.003
PG 2
SC Hematology
GA 581RC
UT ISI:000276541000004
ER

PT J
AU Zhang, L
   Lin, M
   Yang, LY
   Zheng, L
   Wang, Q
AF Zhang, Ling
   Lin, Min
   Yang, Li-Ye
   Zheng, Lei
   Wang, Qian
TI First detection of Hb Hornchurch (beta 43(CD2) Glu-Lys) in a Chinese
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Letter
ID GLOBIN GENE; HEMOGLOBIN; VARIANTS
C1 [Lin, Min; Zheng, Lei; Wang, Qian] So Med Univ, Nangfang Hosp, Lab Med Ctr, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhang, Ling] Guangzhou Kingmed Ctr Clin Lab, Guangzhou 510330, Guangdong, Peoples R China.
   [Lin, Min; Yang, Li-Ye] Chaozhou Cent Hosp, Cent Lab, Chaozhou 521021, Guangdong, Peoples R China.
RP Wang, Q, So Med Univ, Nangfang Hosp, Lab Med Ctr, Guangzhou 510515,
   Guangdong, Peoples R China.
EM nflab@163.com
CR HARDISON RC, 2002, HUM MUTAT, V19, P225
   HOYER J, 2005, COMMUNICATION
   HOYER JD, 2008, HEMOGLOBIN, V32, P471, DOI 10.1080/03630260802341901
   SACK JS, 1978, HEMOGLOBIN, V2, P153
   WILD B, 2002, COMMUNICATION
NR 5
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD APR 15
PY 2010
VL 44
IS 4
BP 217
EP 218
DI 10.1016/j.bcmd.2010.01.008
PG 2
SC Hematology
GA 581RC
UT ISI:000276541000005
ER

PT J
AU Srinivasan, RS
   Geng, X
   Yang, Y
   Wang, YD
   Mukatira, S
   Studer, M
   Porto, MPR
   Lagutin, O
   Oliver, G
AF Srinivasan, R. Sathish
   Geng, Xin
   Yang, Ying
   Wang, Yingdi
   Mukatira, Suraj
   Studer, Michele
   Porto, Marianna P. R.
   Lagutin, Oleg
   Oliver, Guillermo
TI The nuclear hormone receptor Coup-TFII is required for the initiation
   and early maintenance of Prox1 expression in lymphatic endothelial cells
SO GENES & DEVELOPMENT
LA English
DT Article
DE Lymphatics; Prox1; Coup-TFII; mouse; endothelial cell
ID TRANSGENIC MICE; IN-VIVO; RBP-J; VASCULATURE; FOREBRAIN;
   HAPLOINSUFFICIENCY; TRANSCRIPTION; IDENTITY; DEFECTS; SYSTEM
AB The homeobox gene Prox1 is crucial for mammalian lymphatic vascular
   development. In the absence of Prox1, lymphatic endothelial cells
   (LECs) are not specified. The maintenance of LEC identity also requires
   the constant expression of Prox1. However, the mechanisms controlling
   the expression of this gene in LECs remain poorly understood. The
   SRY-related gene Sox18 is required to induce Prox1 expression in venous
   LEC progenitors. Although Sox18 is also expressed in embryonic
   arteries, these vessels do not express Prox1, nor do they give rise to
   LECs. This finding suggests that some venous endothelial cell-specific
   factor is required for the activation of Prox1. Here we demonstrate
   that the nuclear hormone receptor Coup-TFII is necessary for the
   activation of Prox1 in embryonic veins by directly binding a conserved
   DNA domain in the regulatory region of Prox1. In addition, we show that
   the direct interaction between nuclear hormone receptors and Prox1 is
   also necessary for the maintenance of Prox1 expression during early
   stages of LEC specification and differentiation.
C1 [Srinivasan, R. Sathish; Geng, Xin; Yang, Ying; Wang, Yingdi; Porto, Marianna P. R.; Lagutin, Oleg; Oliver, Guillermo] St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA.
   [Mukatira, Suraj] St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA.
   [Studer, Michele] Telethon Inst Genet & Med, Dev Disorders Program, I-80131 Naples, Italy.
RP Oliver, G, St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N
   Lauderdale St, Memphis, TN 38105 USA.
EM guillermo.oliver@stjude.org
FU NIH [R01-HL073402]; American Lebanese Syrian Associated Charities
   (ALSAC) 
FX We thank Drs. S. Tsai and M.-J. Tsai for providing the Coup-TFII floxed
   mouse strain; Dr. J. Westmoreland for the Prox1<SUP>+/flox</SUP>; R26R
   mouse strain; Dr. J. Johnson for the Rbpj floxed mouse strain; Dr. Y.
   Lee for help with the design of primers and probes for real-time PCR;
   Drs. J. Downing, S. Baker, and R. Endersby for providing the GFPCre
   cDNA cassette; Drs. F. Mathias and P. Koopmann for the Sox18 in situ
   probe; Dr. M. Yanagisawa for the Tie2-Cre strain; Dr. E. Dejana for the
   H5V cells; Mr. S. Connell, Dr. L. Zhao, Dr. Y. Ouyang and Dr. J.
   Peterson for help with confocal imaging; and Dr. A. McArthur for
   editing of this manuscript. We thank all of the members of our
   laboratory for their helpful suggestions and discussions. This work was
   supported by NIH grant R01-HL073402 ( to G.O) and the American Lebanese
   Syrian Associated Charities (ALSAC).
CR BULL LN, 2000, AM J HUM GENET, V67, P994
   DEBOER J, 2003, EUR J IMMUNOL, V33, P314
   DELORME B, 1997, CIRC RES, V81, P423
   FRANCOIS M, 2008, NATURE, V456, P643, DOI 10.1038/nature07391
   FRUHWIRTH M, 2003, J PEDIATR, V142, P441, DOI 10.1067/mpd.2003.148
   GENG X, 2008, DEV CELL, V15, P236, DOI 10.1016/j.devcel.2008.07.003
   HARVEY NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642
   JEONG Y, 2008, NAT GENET, V40, P1348, DOI 10.1038/ng.230
   JOHNSON NC, 2008, GENE DEV, V22, P3282, DOI 10.1101/gad.1727208
   KATO H, 1997, DEVELOPMENT, V124, P4133
   KISANUKI YY, 2001, DEV BIOL, V230, P230
   KREBS LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204
   LEE S, 2009, BLOOD, V113, P1856, DOI 10.1182/blood-2008-03-145789
   LI LP, 2009, CELL METAB, V9, P77, DOI 10.1016/j.cmet.2008.12.002
   LIU YW, 2003, MOL CELL BIOL, V23, P7243, DOI
   10.1128/MCB.23.20.7243-7255.2003
   MATYS V, 2006, NUCLEIC ACIDS RES, V34, P108
   OLIVER G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI
   10.1146/annurev.cellbio.21.012704.132338
   OLIVER G, 2008, ANN NY ACAD SCI, V1131, P75, DOI 10.1196/annals.1413.006
   PENNISI D, 2000, NAT GENET, V24, P434
   QIN J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009
   SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138
   SCHOLLE MD, 2004, PROTEIN EXPRES PURIF, V37, P243, DOI
   10.1016/j.pep.2004.05.012
   SORIANO P, 1999, NAT GENET, V21, P71
   SRINIVASAN RS, 2007, GENE DEV, V21, P2422, DOI 10.1101/gad.1588407
   STEFFENSEN KR, 2004, EMBO REP, V5, P613, DOI 10.1038/sj.embor.7400147
   TAKAMOTO N, 2005, DEVELOPMENT, V132, P2179
   TANIGAKIK K, 2002, NAT IMMUNOL, V3, P443
   THOMASCHOLLIER M, 2008, NUCLEIC ACIDS RES S, V36, W119, DOI
   10.1093/nar/gkn304
   TRIPODI M, 2004, DEVELOPMENT, V131, P6119, DOI 10.1242/dev.01530
   WANG LF, 2008, CELL RES, V18, P911, DOI 10.1038/cr.2008.275
   WIGLE JT, 1999, CELL, V98, P769
   WIGLE JT, 2002, EMBO J, V21, P1505
   YAMAZAKI T, 2009, GENES CELLS, V14, P425, DOI
   10.1111/j.1365-2443.2008.01279.x
   YOU LR, 2005, NATURE, V435, P98, DOI 10.1038/nature03511
NR 34
TC 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD APR 1
PY 2010
VL 24
IS 7
BP 696
EP 707
DI 10.1101/gad.1859310
PG 12
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 577PD
UT ISI:000276235400008
ER

PT J
AU Bian, SY
   Gai, LY
   Ye, P
   Guo, ZK
   Li, QF
   Yang, YF
   Wang, H
   Wang, LS
AF Bian Su Yan
   Gai Lu Yue
   Ye Ping
   Guo Zi Kuan
   Li Qing Fang
   Yang Yue Feng
   Wang Hua
   Wang Li-Sheng
TI Sphingosine kinase-1 protects transplanted mesenchymal stem cells and
   improves the performance of the infarcted heart Research Article
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE infracted; myocardiocyte; hypoxia
ID LEFT-VENTRICULAR FUNCTION; HEPATOCYTE GROWTH-FACTOR;
   MYOCARDIAL-INFARCTION; OVEREXPRESSING AKT; RAT; ACTIVATION; INJURY;
   SPHINGOSINE-1-PHOSPHATE; REPAIR; DIFFERENTIATION
AB In this study we investigated whether sphingosine kinase-1 (SPK1)
   modification could offer cytoprotective effects on mesenchymal stem
   cells (MSCs) in vitro and in vivo in a myocardial infarction rat model.
   MSCs carrying green fluorescent protein (MSCs/GFP), SPK1 (MSCs/SPK1) or
   with firefly luciferase genes (MSCs/GFP/luc and MSCs/SPK1/luc) were
   obtained and functionally identified. The in vitro protective effects
   of SPK1 on MSCs were evaluated after exposure to serum-deprivation and
   hypoxia stimuli. Cells (1 x 106) were injected intramyocardially around
   the infarcted zone and the fate of the transplanted cells was traced by
   SPK1 and luciferase assessment in the ischemic myocardium. The survival
   of the remaining myocardiocytes was evaluated by in situ TUNEL assay
   72hours after cell transplantation. The morphological and functional
   features of the injured heart were observed with echocardiography,
   hemodynamic and histological examinations. The results showed that SPK1
   protected MSCs both in vitro and in vivo. MSCs/SPK1/luc implantation
   elevated SPK1 activities in the ischemic myocardium, which peaked on
   day 3 and reduced to the baseline on day 7. Compared with MSCs/GFP/luc,
   luciferase activity was significantly higher in MSCs/SPK1/luc-injected
   myocardium (p<0.01 on days 3 and 5 post-injection). The percentage of
   TUNEL-positive cells in the ischemic area was significantly lower in
   MSCs/SPK1 (%, 15.5 +/- 2.3 vs. MSCs/GFP 23.1 +/- 4.9, p<0.05).
   Concordantly, the parameters including fractional shortening (%, 29.33
   +/- 2.94 vs. MSCs/GFP 23.29 +/- 2.86, p<0.05), ejection fraction (%,
   60.35 +/- 4.96 vs. 51.99 +/- 5.16, p<0.05), left ventricular
   end-diastolic pressure (15.3 +/- 3.6 vs. 18.2 +/- 3.3 mmHg, p<0.05) and
   blood vessel density (number per field: 33.82 +/- 5.45 vs. 23.06 +/-
   4.01, p<0.01) were greatly improved in MSCs/SPK1, though those of the
   infarct size, collagen deposition in non-infracted area and the
   spherical indexes of the hearts were comparable between two cell
   treatment groups. In conclusion, MSCs/SPK1 improve the performance of
   the infarcted hearts by providing prosurvival signals to the
   transplanted MSCs and myocardiocytes.
C1 [Guo Zi Kuan; Li Qing Fang; Yang Yue Feng; Wang Hua; Wang Li-Sheng] Beijing Inst Radiat Med, Dept Expt Hematol, Beijing 100850, Peoples R China.
   [Bian Su Yan; Gai Lu Yue; Ye Ping] Gen Hosp PLA, Dept Geriatr Cardiol, Beijing 100853, Peoples R China.
RP Wang, LS, Beijing Inst Radiat Med, Dept Expt Hematol, 27 Taiping Rd,
   Beijing 100850, Peoples R China.
EM wanghualjh@gmail.com
   wangls@nic.bmi.ac.cn
FU Chinese National Science Foundation [30871018]; Chinese National Basic
   Research and Development [2006CB504105]; Chinese High-Tech Program
   '863' [2007AA021007, 2007AA02Z454]
FX We thank Prof. Jia-Xi Wang for his critical reviewing on this
   manuscript. This work was supported by Chinese National Science
   Foundation (No. 30871018), Chinese National Basic Research and
   Development Grants '973' (No. 2006CB504105), and Chinese High-Tech
   Program '863' (No. 2007AA021007 and No. 2007AA02Z454).
CR BENZHI C, 2009, J MOL CELL CARDIOL, V47, P41
   DAVANI S, 2003, CIRCULATION S, V108, P253, DOI
   10.1161/01.cir.0000089186.09692.fa
   DUAN HF, 2003, MOL THER, V8, P467, DOI 10.1016/S1525-0016(03)00186-2
   DUAN HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049
   DUAN HF, 2007, HUM GENE THER, V18, P1119, DOI 10.1089/hum.2007.036
   FUJIMOTO KL, 2009, CELL TRANSPLANT, V18, P477
   GNECCHI M, 2006, FASEB J, V20, P661
   GNECCHI M, 2009, STEM CELLS, V27, P971, DOI 10.1002/stem.12
   GUO J, 2007, INFLAMMATION, V30, P97, DOI 10.1007/s10753-007-9025-3
   GUO WN, 1996, CARDIOVASC RES, V32, P524
   HAIDER HK, 2008, CIRC RES, V103, P1300, DOI
   10.1161/CIRCRESAHA.108.186742
   HANNUN YA, 2008, NAT REV MOL CELL BIO, V9, P135
   JIN HK, 2004, CURR PHARM DESIGN, V10, P2525
   JIN ZQ, 2007, CARDIOVASC RES, V76, P41, DOI
   10.1016/j.cardiores.2007.05.029
   JIN ZQ, 2008, CARDIOVASC RES, V79, P134, DOI 10.1093/cvr/cvn065
   JUGDUTT BI, 2003, CIRCULATION, V108, P1395, DOI
   10.1161/01.CIR.0000085658.98621.49
   KARLINER JS, 2001, J MOL CELL CARDIOL, V33, P1713
   MANGI AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   MEANS CK, 2007, AM J PHYSIOL-HEART C, V292, H2944, DOI
   10.1152/ajpheart.01331.2006
   MEANS CK, 2009, CARDIOVASC RES, V82, P193, DOI 10.1093/cvr/cvp086
   NOISEUX N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016
   PACARY E, 2006, J CELL SCI, V119, P2667, DOI 10.1242/jcs.03004
   PANTOS C, 2007, EUR J CARDIO-THORAC, V32, P333, DOI
   10.1016/j.ejcts.2007.05.004
   PCHEJETSKI D, 2007, CIRC RES, V100, P41, DOI
   10.1161/01.RES.0000253900.66640.34
   RAMOS GA, 2007, CELL TRANSPLANT, V16, P951
   SCORSIN M, 2000, J THORAC CARDIOV SUR, V119, P1169
   SHUJIA J, 2008, CARDIOVASC RES, V77, P525, DOI 10.1093/cvr/cvm077
   SIA YT, 2002, J CARDIOVASC PHARM, V39, P73
   TAKUWA Y, 2008, BBA-MOL CELL BIOL L, V1781, P483, DOI
   10.1016/j.bbalip.2008.04.003
   TAMER A, 2004, GENE THER MOL BIOL, V8, P351
   TIMMERMANS F, 2003, CARDIOLOGY, V100, P176, DOI 10.1159/000074811
   YANG JF, 2007, CARDIOLOGY, V107, P17, DOI 10.1159/000093609
   YEH CC, 2009, AM J PHYSIOL-HEART C, V296, H1193, DOI
   10.1152/ajpheart.01032.2008
   ZENG B, 2008, J MOL CELL CARDIOL, V44, P281
   ZHANG D, 2008, EUR J CARDIO-THORAC, V34, P850
NR 35
TC 0
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2009
VL 13B
BP 274
EP 283
PG 10
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
GA 575QR
UT ISI:000276083000003
ER

PT J
AU Sun, B
   Yang, ZS
   Zhou, ZY
   Jin, MF
AF Sun, B.
   Yang, Z. S.
   Zhou, Z. Y.
   Jin, M. F.
TI Antagonism of radiation damage in mice by expression of high levels of
   VEGF Research Article
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Gene therapy; VEGF; radiation damage; mice
ID ENDOTHELIAL GROWTH-FACTOR; COLON-CANCER CELLS; CELLULAR PROLIFERATION;
   FACTOR RECEPTOR; MUSCLE
AB The study was designed to study the effect of intramuscular injections
   of a vascular endothelial growth factor (VEGF) expression plasmid in
   preventing radiation damage in the mouse and the molecular mechanism of
   this protection. The recombinant pcDNA3.1-VEGF(165) plasmid was
   successfully constructed and intramuscular injection of this plasmid
   can remarkably decrease the mortality of mice after severe radiation
   damage, decrease the apoptosis rates of cells in the thymus and spleen,
   and improve the pathologic change of organs of the immune system. Our
   work indicates that VEGF injection can be one of the effective methods
   for preventing severe radiation injury. These studies provide the
   experimental basis for further clinical usage of VEGF.
C1 [Yang, Z. S.; Zhou, Z. Y.] Soochow Univ, Inst Radiat Med & Publ Hlth, Coll Med, Suzhou 215123, Peoples R China.
   [Sun, B.; Jin, M. F.] Soochow Univ, Childrens Hosp, Suzhou 215003, Peoples R China.
RP Yang, ZS, Soochow Univ, Inst Radiat Med & Publ Hlth, Coll Med, Suzhou
   215123, Peoples R China.
EM fd@suda.edu.cn
FU National Natural Science Foundation of China [30570549]; National
   Defense Basic Science and Technology Foundation [A3820060138]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30570549), and the National Defense Basic Science and
   Technology Foundation (No. A3820060138).
CR CUI YF, 2004, XI BAO YU FEN ZI MIA, V20, P750
   CUNEO KC, 2007, ANTI-CANCER DRUG, V18, P349
   GYONGYOSI M, 2005, CIRCULATION, V112, P157
   HOVINGA KE, 2005, J NEURO-ONCOL, V74, P99, DOI 10.1007/s11060-004-4204-7
   KOUKOURAKIS MI, 2007, AM J CLIN ONCOL-CANC, V30, P315, DOI
   10.1097/01.coc.0000258119.90805.ca
   LEONGPOI H, 2007, CIRC RES, V101, P295, DOI
   10.1161/CIRCRESAHA.107.148676
   LIU SZ, 2005, CHIN J RADIOL MED PR, V25, P193
   LU Z, 2001, CHIN J RADIOL MED PR, V21, P276
   MAES C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   MITSIADES CS, 2006, J CLIN ENDOCR METAB, V91, P3662, DOI
   10.1210/jc.2006-0055
   MULKEEN AL, 2006, ARCH SURG-CHICAGO, V141, P367
   SHEARD MA, 2001, INT J CANCER, V96, P213
   SHINTANI S, 2006, NAT CLIN PRACT CA S1, V3, S123
   TAKESHITA S, 1994, J CLIN INVEST, V93, P662
   VANWEEL V, 2007, ARTERIOSCL THROM VAS, V27, P1426, DOI
   10.1161/ATVBAHA.107.139642
   WHANG E, 2006, ARCH SURG-CHICAGO, V141, P374
NR 16
TC 0
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2009
VL 13B
BP 308
EP 315
PG 8
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
GA 575QR
UT ISI:000276083000006
ER

PT J
AU Sall, A
   Zhang, HFM
   Qiu, DX
   Liu, ZB
   Yuan, J
   Liu, Z
   Lim, T
   Ye, X
   Marchant, D
   McManus, B
   Yang, DC
AF Sall, Alhousseynou
   Zhang, Huifang M.
   Qiu, Dexin
   Liu, Zhongbin
   Yuan, Ji
   Liu, Zhen
   Lim, Travis
   Ye, Xin
   Marchant, David
   McManus, Bruce
   Yang, Decheng
TI Pro-apoptotic activity of mBNIP-21 depends on its BNIP-2 and Cdc42GAP
   homology (BCH) domain and is enhanced by coxsackievirus B3 infection
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID CYTOCHROME-C RELEASE; CELL-DEATH; BCL-2 FAMILY; GENE-EXPRESSION; RHO
   GTPASES; BH3 DOMAIN; PROTEIN; MITOCHONDRIAL; ACTIVATION; PATHWAY
AB P>Our previous study reported that mouse BNIP-21 (mBNIP-21) induces
   apoptosis through a mitochondria-dependent pathway. To map the
   functional domains of mBNIP-21, we performed mutational analyses and
   demonstrated that the BNIP-2 and Cdc42GAP homology (BCH) domain is
   required for apoptosis induction by mBNIP-21 targeting the mitochondria
   and inducing cytochrome c release. This pro-apoptotic activity was
   enhanced by coxsackievirus infection. However, deletion of the Bcl-2
   homology 3 (BH3)-like domain, a well-known cell 'death domain' in
   proapoptotic Bcl-2 family proteins, did not affect the activity of
   mBNIP-21. These data were further supported by transfection of a mouse
   Bax (mBax) mutant, whose BH3 was replaced by the mBNIP-21 BH3-like
   domain. This replacement significantly reduced the pro-apoptotic
   activity of mBax. We also found that the predicted calcium binding
   domain has no contribution to the mBNIP-21-induced apoptosis. Further
   mapping of the motifs of BCH domain demonstrated that deletion of the
   hydrophobic motif proximal to the C-terminal of the BCH significantly
   reduced its proapoptotic activity. These findings suggest that
   mBNIP-21, as a member of the BNIP subgroup of the Bcl-2-related
   proteins, functions without need of BH3 but its BCH domain is critical
   for its activity in inducing cell elongation, membrane protrusions and
   apoptotic cell death.
C1 [Yang, Decheng] Univ British Columbia, St Pauls Hosp, Providence Heart & Lung Inst,Dept Pathol, iCapture Ctr, Vancouver, BC, Canada.
   Univ British Columbia, St Pauls Hosp, Providence Heart & Lung Inst,Lab Med, iCapture Ctr, Vancouver, BC, Canada.
RP Yang, DC, Univ British Columbia, St Pauls Hosp, Providence Heart & Lung
   Inst,Dept Pathol, iCapture Ctr, Vancouver, BC, Canada.
EM dyang@mrl.ubc.ca
FU Canadian Institutes of Health Research ; Heart and Stroke Foundation ;
   IMPACT/CIHR ; Michael Smith Foundation of Health Research 
FX We thank Dr Boon Chuan Low, The National University of Singapore for
   providing us with the human BNIP-2 antibody and Dr John C. Reed,
   Burnham Institute for Medical Research, CA, USA for the plasmid
   expressing Bax protein. We also thank Brian Wong for his assistance in
   the manuscript preparation. This work was supported by grants from the
   Canadian Institutes of Health Research and the Heart and Stroke
   Foundation of BC and Yukon. Dr Alhousseynou Sall is supported in part
   by the IMPACT/CIHR postdoctoral fellowship. Ji Yuan is supported by a
   Doctoral Research Award from the Canadian Institutes of Health Research
   and Michael Smith Foundation of Health Research. Zhen Liu is supported
   by a Doctoral Research Award from the Heart and Stroke Foundation of
   Canada.
CR ADAMS JM, 1998, SCIENCE, V281, P1322
   ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295
   AOUACHERIA A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234
   BELCREDITO S, 2001, BRAIN RES REV, V37, P335
   BLANC C, 2000, CANCER RES, V60, P4386
   BOKOCH GM, 1993, FASEB J, V7, P750
   BOYD JM, 1994, CELL, V79, P341
   CABADO AG, 2004, ARCH TOXICOL, V78, P74, DOI 10.1007/s00204-003-0505-4
   CARTHY CM, 1998, J VIROL, V72, P7669
   CHAO DT, 1998, ANNU REV IMMUNOL, V16, P395
   CHEN G, 1999, J BIOL CHEM, V274, P7
   CIZEAU J, 2000, ONCOGENE, V19, P5453
   COSULICH SC, 1997, CURR BIOL, V7, P913
   GRZANKA A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI
   10.1016/S0006-2952(03)00532-X
   HERNANDEZPERERA O, 2000, CIRC RES, V87, P616
   HOCKENBERY D, 1990, NATURE, V348, P334
   JIANG XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI
   10.1146/annurev.biochem.73.011303.073706
   JURGENSMEIER JM, 1998, P NATL ACAD SCI USA, V95, P4997
   KELEKAR A, 1998, TRENDS CELL BIOL, V8, P324
   LI HL, 1998, CELL, V94, P491
   LOW BC, 1999, J BIOL CHEM, V274, P33123
   LOW BC, 2000, J BIOL CHEM, V275, P37742
   LUO X, 1998, CELL, V94, P481
   MACHIDA T, 2006, ONCOGENE, V25, P1931, DOI 10.1038/sj.onc.1209225
   MATSUSHIMA M, 1998, GENE CHROMOSOME CANC, V21, P230
   PUTHALAKATH H, 1999, MOL CELL, V3, P287
   RAY R, 2000, J BIOL CHEM, V275, P1439
   REGULA KM, 2002, CIRC RES, V91, P226, DOI
   10.1161/01.RES.0000029232.42227.16
   SCORRANO L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI
   10.1016/S0006-291X(03)00615-6
   SHANG X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200
   SOH UJK, 2008, J CELL SCI, V121, P1739, DOI 10.1242/jcs.021774
   TAPON N, 1997, CURR OPIN CELL BIOL, V9, P86
   TUSNADY GE, 1998, J MOL BIOL, V283, P489
   VILLALONGA P, 2006, GROWTH FACTORS, V24, P159, DOI
   10.1080/08977190600560651
   WOLTER KG, 1997, J CELL BIOL, V139, P1281
   YANG DC, 1999, CIRC RES, V84, P704
   ZHANG HFM, 2005, MOL CELL BIOL, V25, P6247, DOI
   10.1128/MCB.25.14.6247-6258.2005
   ZHANG HM, 2002, CIRC RES, V90, P1251
   ZHANG HM, 2003, APOPTOSIS, V8, P229
   ZHOU YT, 2005, EXP CELL RES, V303, P263
   ZHOU YT, 2006, ONCOGENE, V25, P2393, DOI 10.1038/sj.onc.1209274
NR 41
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-5814
J9 CELL MICROBIOL
JI Cell Microbiol.
PD MAY
PY 2010
VL 12
IS 5
BP 599
EP 614
DI 10.1111/j.1462-5822.2009.01416.x
PG 16
SC Cell Biology; Microbiology
GA 577LA
UT ISI:000276223400004
ER

PT J
AU Bao, XX
   Wang, B
   Zhang, JB
   Yan, T
   Yang, WP
   Jiao, FC
   Liu, J
   Wang, S
AF Bao, Xuexiang
   Wang, Bin
   Zhang, Jinbei
   Yan, Ting
   Yang, Weiping
   Jiao, Fangchao
   Liu, Jing
   Wang, Shun
TI Localization of serotonin/tryptophan-hydroxylase-immunoreactive cells
   in the brain and suboesophageal ganglion of Drosophila melanogaster
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Brain; Immunohistochemistry; Serotonin; Tryptophan hydroxylase;
   Drosophila melanogaster (Insecta)
ID SEROTONIN-CONTAINING NEURONS; TRYPTOPHAN-HYDROXYLASE; SYSTEM; INSECTS;
   DOPAMINE; ISOFORM
AB We previously demonstrated that tryptophan hydroxylase (TPH), the
   rate-limiting enzyme of serotonin (5-HT) synthesis, was commonly
   present in the brains of some insects. The current study was aimed at
   determining the number of serotonergic neurons in the brain and
   suboesophageal ganglion of adult Drosophila melanogaster and to
   investigate further the differences in immunoreactivity between 5-HT
   and TPH. Brain sections of Drosophila were immunostaind with sheep
   anti-TPH polyclonal antibody and rabbit anti-5-HT antiserum. The
   5-HT-like immunoreactive neurons were also immunoreactive for TPH and
   bilaterally symmetrical; 83 neurons were found in each hemisphere of
   the brain and suboesophageal ganglion of adult Drosophila. This
   technique of colocalizing 5-HT and TPH revealed a larger number of
   serotonergic neurons in the brain and suboesophageal ganglion than that
   previous reported, thus updating our knowledge of the 5-HT neuronal
   system of Drosophila.
C1 [Bao, Xuexiang; Wang, Bin; Zhang, Jinbei; Yan, Ting; Yang, Weiping; Jiao, Fangchao; Liu, Jing; Wang, Shun] NE Normal Univ, Sch Life Sci, Lab Insect Brain Neurobiol, Changchun 130024, Jilin, Peoples R China.
RP Bao, XX, NE Normal Univ, Sch Life Sci, Lab Insect Brain Neurobiol,
   Changchun 130024, Jilin, Peoples R China.
EM xuexiangb@yahoo.com.cn
FU National Natural Science Foundation of China [30470546]; Natural
   Science Foundation of Jilin Province [20030550-7]
FX This work was supported by grants from the National Natural Science
   Foundation of China (grant no. 30470546) and the Natural Science
   Foundation of Jilin Province (grant no. 20030550-7).
CR ALI DW, 1993, J INSECT PHYSIOL, V39, P623
   BAO XX, 1999, CHINESE SCI BULL, V44, P1021
   BAO XX, 2006, BRAIN RES, V1073, P202, DOI 10.1016/j.brainres.2005.12.041
   BAO XX, 2008, CELL TISSUE RES, V332, P555, DOI 10.1007/s00441-008-0596-6
   BENDER DA, 1987, P ISTRY 86 5 M INT S
   COLEMAN CM, 2004, INVERTEBR NEUROSCI, V5, P85
   COLEMAN CM, 2005, ARCH INSECT BIOCHEM, V59, P12, DOI 10.1002/arch.20050
   DACKS AM, 2006, J COMP NEUROL, V498, P727, DOI 10.1002/cne.21076
   DAVIS NT, 1987, J COMP NEUROL, V259, P604
   HAMASAKA Y, 2006, J COMP NEUROL, V494, P314, DOI 10.1002/cne.20807
   HOMBERG U, 1989, CELL TISSUE RES, V258, P1
   HOMBERG U, 1994, PROG ZOOL, V40, P301
   KLEMM N, 1984, J COMP NEUROL, V225, P387
   LANGE AB, 2004, ARCH INSECT BIOCHEM, V56, P179, DOI 10.1002/arch.20010
   LEITINGER G, 1999, BRAIN RES, V823, P11
   NASSEL DR, 1988, PROG NEUROBIOL, V30, P1
   NECKAMEYER WS, 2007, GENES BRAIN BEHAV, V6, P756, DOI
   10.1111/j.1601-183X.2007.00307.x
   SEVERSON CA, 2003, NAT NEUROSCI, V6, P1139, DOI 10.1038/nn1130
   SIJU KP, 2008, ARTHROPOD STRUCT DEV, V37, P248, DOI
   10.1016/j.asd.2007.12.001
   VALLES AM, 1988, J COMP NEUROL, V268, P414
   WALTHER DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI
   10.1016/S0006-2952(03)00556-2
   WALTHER DJ, 2003, SCIENCE, V299, P76
NR 22
TC 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD APR
PY 2010
VL 340
IS 1
BP 51
EP 59
DI 10.1007/s00441-010-0932-5
PG 9
SC Cell Biology
GA 576QF
UT ISI:000276160000005
ER

PT J
AU Bais, C
   Wu, XM
   Yao, J
   Yang, SY
   Crawford, Y
   McCutcheon, K
   Tan, C
   Kolumam, G
   Vernes, JM
   Eastham-Anderson, J
   Haughney, P
   Kowanetz, M
   Hagenbeek, T
   Kasman, I
   Reslan, HB
   Ross, J
   Van Bruggen, N
   Carano, RAD
   Meng, YJG
   Hongo, JA
   Stephan, JP
   Shibuya, M
   Ferrara, N
AF Bais, Carlos
   Wu, Xiumin
   Yao, Jenny
   Yang, Suya
   Crawford, Yongping
   McCutcheon, Krista
   Tan, Christine
   Kolumam, Ganesh
   Vernes, Jean-Michel
   Eastham-Anderson, Jeffrey
   Haughney, Peter
   Kowanetz, Marcin
   Hagenbeek, Thijs
   Kasman, Ian
   Reslan, Hani Bou
   Ross, Jed
   Van Bruggen, Nick
   Carano, Richard A. D.
   Meng, Yu-Ju Gloria
   Hongo, Jo-Anne
   Stephan, Jean-Philippe
   Shibuya, Masabumi
   Ferrara, Napoleone
TI PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
SO CELL
LA English
DT Article
ID VEGFR1-ACTIVITY-INDEPENDENT METASTASIS FORMATION; HIGH-AFFINITY
   BINDING; FACTOR RECEPTOR-1; TYROSINE KINASE; IN-VIVO; VEGF; FLT-1;
   ANTIBODY; TARGETS; CANCER
AB It has been recently reported that treatment with an anti-placenta
   growth factor (PlGF) antibody inhibits metastasis and primary tumor
   growth. Here we show that, although anti-PlGF treatment inhibited wound
   healing, extravasation of B16F10 cells, and growth of a tumor
   engineered to overexpress the PlGF receptor (VEGFR-1), neutralization
   of PlGF using four novel blocking antibodies had no significant effect
   on tumor angiogenesis in 15 models. Also, genetic ablation of the
   tyrosine kinase domain of VEGFR-1 in the host did not result in growth
   inhibition of the anti-VEGF-A sensitive or resistant tumors tested.
   Furthermore, combination of anti-PlGF with anti-VEGF-A antibodies did
   not result in greater antitumor efficacy than anti-VEGF-A monotherapy.
   In conclusion, our data argue against an important role of PlGF during
   primary tumor growth in most models and suggest that clinical
   evaluation of anti-PlGF antibodies may be challenging.
C1 [Bais, Carlos; Wu, Xiumin; Yao, Jenny; Yang, Suya; Crawford, Yongping; McCutcheon, Krista; Tan, Christine; Kolumam, Ganesh; Vernes, Jean-Michel; Eastham-Anderson, Jeffrey; Haughney, Peter; Kowanetz, Marcin; Hagenbeek, Thijs; Kasman, Ian; Reslan, Hani Bou; Ross, Jed; Van Bruggen, Nick; Carano, Richard A. D.; Meng, Yu-Ju Gloria; Hongo, Jo-Anne; Stephan, Jean-Philippe; Shibuya, Masabumi; Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
   [Shibuya, Masabumi] Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Tokyo 1138510, Japan.
RP Bais, C, Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM bais@gene.com
   nf@gene.com
CR AUTIERO M, 2003, J THROMB HAEMOST, V1, P1356
   AVECILLA ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973
   CAO YH, 1996, J BIOL CHEM, V271, P3154
   CARMELIET P, 1996, NATURE, V380, P435
   CARMELIET P, 2001, NAT MED, V7, P575
   CASANOVAS O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   CIANFARANI F, 2006, AM J PATHOL, V169, P1167, DOI
   10.2353/ajpath.2006.051314
   CLYNES RA, 2000, NAT MED, V6, P443
   DAVISSMYTH T, 1996, EMBO J, V15, P4919
   DAWSON MR, 2009, NATURE, V461, E4, DOI 10.1038/nature08254
   DAWSON MR, 2009, PLOS ONE, V4, ARTN e6525
   ELLIS LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   ERIKSSON A, 2002, CANCER CELL, V1, P99
   FERRARA N, 1996, NATURE, V380, P439
   FERRARA N, 1998, NAT MED, V4, P336
   FERRARA N, 2003, NAT MED, V9, P669
   FERRARA N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRARA N, 2010, CYTOKINE GROWTH F R, V21, P21
   FISCHER C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   FISCHER C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   FONG GH, 1995, NATURE, V376, P66
   GERBER HP, 2000, CANCER RES, V60, P6253
   GLUZMANPOLTORAK Z, 2000, J BIOL CHEM, V275, P29922
   HATTORI K, 2002, NAT MED, V1, P1
   HIRATSUKA S, 1998, P NATL ACAD SCI USA, V95, P9349
   HIRATSUKA S, 2001, CANCER RES, V61, P1207
   HIRATSUKA S, 2002, CANCER CELL, V2, P289
   HOLASH J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI
   10.1073/pnas.172398299
   KAPLAN RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   KAPLAN RN, 2009, NATURE, V461, E5, DOI 10.1038/nature08261
   KERBEL RS, 2008, NEW ENGL J MED, V358, P2039
   KERBER M, 2008, CANCER RES, V68, P7342, DOI
   10.1158/0008-5472.CAN-07-6241
   KIM KJ, 1993, NATURE, V362, P841
   LIANG WC, 2006, J BIOL CHEM, V281, P951
   LUTTUN A, 2002, NAT MED, V1, P1
   LYDEN D, 2001, NAT MED, V7, P1194
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267
   MARCELLINI M, 2006, AM J PATHOL, V169, P643, DOI
   10.2353/ajpath.2006.051041
   MURAKAMI M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   ODORISIO T, 2002, J CELL SCI, V115, P2559
   OFLAZOGLU E, 2007, BLOOD, V110, P4370, DOI 10.1182/blood-2007-06-097014
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   SAMUELSSON A, 2001, SCIENCE, V291, P484
   SCHOMBER T, 2007, CANCER RES, V67, P10840, DOI
   10.1158/0008-5472CAN-07-1034
   SHIBUYA M, 2001, CELL STRUCT FUNCT, V26, P25
   SHOJAEI F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   WU Y, 2006, CLIN CANCER RES, V12, P6573, DOI
   10.1158/1078-0432.CCR-06-0831
   WU Y, 2006, INT J CANCER, V119, P1519, DOI 10.1002/ijc.21865
   ZICHE M, 1997, LAB INVEST, V76, P517
NR 49
TC 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 1
PY 2010
VL 141
IS 1
BP 166
EP 177
DI 10.1016/j.cell.2010.01.033
PG 12
SC Biochemistry & Molecular Biology; Cell Biology
GA 577GS
UT ISI:000276211100021
ER

PT J
AU Zhao, JJ
   Lin, JH
   Lwin, T
   Yang, H
   Guo, JP
   Kong, W
   Dessureault, S
   Moscinski, LC
   Rezania, D
   Dalton, WS
   Sotomayor, E
   Tao, JG
   Cheng, JQ
AF Zhao, Jian-Jun
   Lin, Jianhong
   Lwin, Tint
   Yang, Hua
   Guo, Jianping
   Kong, William
   Dessureault, Sophie
   Moscinski, Lynn C.
   Rezania, Dorna
   Dalton, William S.
   Sotomayor, Eduardo
   Tao, Jianguo
   Cheng, Jin Q.
TI microRNA expression profile and identification of miR-29 as a
   prognostic marker and pathogenetic factor by targeting CDK6 in mantle
   cell lymphoma
SO BLOOD
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN SOLID TUMORS; DOWN-REGULATION;
   POOR-PROGNOSIS; MESSENGER-RNA; BREAST-CANCER; LUNG-CANCER; STEM-CELLS;
   SIGNATURE; SURVIVAL
AB Mantle cell lymphoma (MCL) is one of the most aggressive B-cell
   lymphomas. Although several protein-coding genes are altered,
   expression signature and importance of microRNA (miRNA) have not been
   well documented in this malignancy. Here, we performed miRNA-expression
   profile in 30 patients with MCL using a platform containing 515 human
   miRNAs. Eighteen miRNAs were down-regulated and 21 were up-regulated in
   MCL compared with normal B lymphocytes. The most frequently altered
   miRNAs are decrease of miR-29a/b/c, miR-142-3p/5p, and miR-150 and
   increase of miR-124a and miR-155. Notably, expression levels of miR-29
   family are associated with prognosis. The patients with significant
   downregulated miR-29 had short survival compared with those who express
   relatively high levels of miR-29. The prognostic value of miR-29 is
   comparable with the Mantle Cell Lymphoma International Prognostic
   Index. Furthermore, we demonstrate miR-29 inhibition of CDK6 protein
   and mRNA levels by direct binding to 3'-untranslated region. Inverse
   correlation between miR-29 and CDK6 was observed in MCL. Because cyclin
   D1 overexpression is a primary event and exerts its function through
   activation of CDK4/CDK6, our results in primary MCL cells indicate that
   down-regulation of miR-29 could cooperate with cyclin D1 in MCL
   pathogenesis. Thus, our findings provide not only miRNA expression
   signature but also a novel prognostic marker and pathogenetic factor
   for this malignancy. (Blood. 2010;115(13):2630-2639)
C1 [Zhao, Jian-Jun; Lin, Jianhong; Lwin, Tint; Yang, Hua; Guo, Jianping; Kong, William; Dessureault, Sophie; Moscinski, Lynn C.; Rezania, Dorna; Dalton, William S.; Sotomayor, Eduardo; Tao, Jianguo; Cheng, Jin Q.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
RP Tao, JG, Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst,
   12902 Magnolia Dr, Tampa, FL 33612 USA.
EM jianguo.tao@moffitt.org
   jin.cheng@moffitt.org
FU National Institutes of Health [CA137041, CA107078]; Department of
   Defense [W81XWH-08-1-0444, W81XWH-08-2-0101, W81XWH-08-1-0116];
   Bankhead-Coley [09BB-05]; Leukemia Research Foundation ; Lymphoma
   Research Foundation 
FX This work was supported by the National Institutes of Health (CA137041
   and CA107078), the Department of Defense (W81XWH-08-1-0444,
   W81XWH-08-2-0101, and W81XWH-08-1-0116), Bankhead-Coley (grant 09BB-05)
   (J. Q. C.), Leukemia Research Foundation (J. T.), and Lymphoma Research
   Foundation (S. D.).
CR ARGATOFF LH, 1997, BLOOD, V89, P2067
   BANKS PM, 1992, AM J SURG PATHOL, V16, P637
   CALIN GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI
   10.1073/pnas.0404432101
   CALIN GA, 2005, NEW ENGL J MED, V353, P1793
   CALIN GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   CERVO PRD, 2009, BLOOD, V113, P6498, DOI 10.1182/blood-2009-02-203174
   CHAN JA, 2005, CANCER RES, V65, P6029
   CHEN RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182
   CHENG LC, 2005, NEURON, V46, P363, DOI 10.1016/j.neuron.2005.04.027
   FABBRI M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI
   10.1073/pnas.0707628104
   GAUR A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   GREINER TC, 1996, BLOOD, V87, P4302
   GRIFFITHSJONES S, 2006, NUCLEIC ACIDS RES, V34, D140
   HARRIS NL, 2000, MODERN PATHOL, V13, P193
   HOSTER E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331
   IORIO MV, 2005, CANCER RES, V65, P7065, DOI
   10.1158/0008-5472.CAN-05-1783
   KAWAMATA N, 2009, EXP HEMATOL, V37, P937, DOI
   10.1016/j.exphem.2009.04.012
   KREK A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   LEE EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   LEWIS BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   LOUIE DC, 1995, BLOOD, V86, P2892
   LU J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   LWIN T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood-2006-11-060350
   MIRANDA KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   MOTT JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   MRAZ M, 2009, LEUKEMIA, V23, P1159, DOI 10.1038/leu.2008.377
   NAVARRO A, 2009, CANCER RES, V69, P7071, DOI
   10.1158/0008-5472.CAN-09-1095
   PARK SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533
   PEKARSKY Y, 2006, CANCER RES, V66, P11590, DOI
   10.1158/0008-5472.CAN-06-3613
   PINYOL M, 1997, BLOOD, V89, P272
   RINALDI A, 2007, LEUKEMIA LYMPHOMA, V48, P410, DOI
   10.1080/10428190601059738
   ROSENWALD A, 2003, CANCER CELL, V3, P185
   SETHUPATHY P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606
   SILBER J, 2008, BMC MED, V6, ARTN 14
   STAMATOPOULOS B, 2009, BLOOD, V113, P5237, DOI
   10.1182/blood-2008-11-189407
   TAKAMIZAWA J, 2004, CANCER RES, V64, P3753
   TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5116
   VELDERS GA, 1996, J CLIN ONCOL, V14, P1269
   VOLINIA S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI
   10.1073/pnas.0510565103
   WANG H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   XU H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517
   YANAIHARA N, 2006, CANCER CELL, V9, P189
   YANG H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   YEKTA S, 2004, SCIENCE, V304, P594
   ZHANG L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI
   10.1073/pnas.0508889103
   ZHAO JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 46
TC 13
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 1
PY 2010
VL 115
IS 13
BP 2630
EP 2639
DI 10.1182/blood-2009-09-243147
PG 10
SC Hematology
GA 577DI
UT ISI:000276201000012
ER

PT J
AU Terhzaz, S
   Finlayson, AJ
   Stirrat, L
   Yang, JL
   Tricoire, H
   Woods, DJ
   Dow, JAT
   Davies, SA
AF Terhzaz, Selim
   Finlayson, Andrew J.
   Stirrat, Laura
   Yang, JingLi
   Tricoire, Herve
   Woods, Debra J.
   Dow, Julian A. T.
   Davies, Shireen-A
TI Cell-specific inositol 1,4,5 trisphosphate 3-kinase mediates epithelial
   cell apoptosis in response to oxidative stress in Drosophila
SO CELLULAR SIGNALLING
LA English
DT Article
DE H2O2; Stress; Mitochondria; Inositol phosphates; bcl-2
ID 1,4,5-TRISPHOSPHATE 3-KINASES; REDOX REGULATION; MELANOGASTER; CALCIUM;
   MITOCHONDRIA; PATHWAY; GENE; EXPRESSION; OXIDASE; MECHANISMS
AB Organismal stress responses to oxidative stress are relevant to ageing
   and disease and involve key cell-/tissue-specific signal transduction
   mechanisms. Using Drosophila, an established in vivo model for stress
   studies, we show that cell-specific inositol phosphate signalling
   specifically via inositol 1,4,5 trisphosphate 3-kinase (InsP(3) 3-K,
   IP3K), negatively regulates organismal responses to oxidative stress.
   We demonstrate that the Drosophila Malpighian tubule (equivalent to
   vertebrate kidney and liver) is a key epithelial sensor for organismal
   oxidative stress responses: precise targeting of either
   gain-of-function constructs of Drosophila IP(3)Ks (IP3K-1 and IP3K-2),
   or loss-of-function (RNAi) constructs to only one cell type in tubule
   reversibly modulates survival of stress-challenged adult flies. In
   vivo, targeted IP3K-1 directly increases H2O2 production, pro-apoptotic
   caspase-9 activity and mitochondrial membrane potential. The
   mitochondrial calcium load in tubule principal cells-assessed by
   luminescent and fluorescent genetically-encoded mitochondrial calcium
   reporters-is significantly increased by IP3K-1 under oxidative stress
   conditions, leading to apoptosis.
   The Drosophila orthologues of human apoptotic bcl-2 genes include debcl
   and buffy. Oxidative stress challenge does not modulate gene expression
   of either debcl or buffy in tubules; and altered debcl expression does
   not influence survival rates under oxidative stress challenge. Finally,
   targeted over-expression of either debcl or buffy to tubule principal
   cells does not impact on tubule caspase-9 activity. Thus, IP3K-1
   modulates epithelial cell apoptosis without involvement of bcl-2-type
   proteins. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Terhzaz, Selim; Finlayson, Andrew J.; Stirrat, Laura; Yang, JingLi; Dow, Julian A. T.; Davies, Shireen-A] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.
   [Tricoire, Herve] Univ Paris 07, CNRS, Lab Genet Stress & Vieillissement, F-75205 Paris 13, France.
   [Woods, Debra J.] Pfizer Anim Hlth, Vet Med Res & Dev, Kalamazoo, MI USA.
RP Davies, SA, Univ Glasgow, Fac Biomed & Life Sci, Glasgow G11 6NU,
   Lanark, Scotland.
EM s.a.davies@bio.gla.ac.uk
FU UK Biotechnology and Biological Sciences Research Council (BBSRC) ;
   Pfizer, Inc. USA 
FX This work was funded by grants from the UK Biotechnology and Biological
   Sciences Research Council (BBSRC) and Pfizer, Inc. USA, to JATD and SD.
   We are very grateful to Dr L Quinn, Melbourne for UAS-debcl and -buffy
   lines; and we thank P. Cabrero and V. R. Chintapalli (Glasgow), for
   experimental support.
CR AGARWAL R, 2009, MOL CELL BIOCHEM, V328, P155, DOI
   10.1007/s11010-009-0085-6
   ALLAN AK, 2005, PHYSL GENOMICS
   BAGGALEY EM, 2008, AM J PHYSL CELL PHYS
   BAROLO S, 2000, BIOTECHNIQUES, V29, P726
   BAROLO S, 2000, BIOTECHNIQUES, V29, P728
   BAROLO S, 2000, BIOTECHNIQUES, V29, P730
   BAROLO S, 2000, BIOTECHNIQUES, V29, P732
   BAUMGARTNER HK, 2009, J BIOL CHEM, V284, P20796, DOI
   10.1074/jbc.M109.025353
   BRAND AH, 1993, DEVELOPMENT, V118, P401
   BRODERICK KE, 2004, J BIOL CHEM, V279, P8159, DOI 10.1074/jbc.M304679200
   CHEN MZ, 2009, J BIOL CHEM, V284, P23743, DOI 10.1074/jbc.M109.036509
   CHINTAPALLI VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049
   COLUSSI PA, 2000, J CELL BIOL, V148, P703
   CURTIS C, 2007, GENOME BIOL, V8, ARTN R262
   DAVIES SA, 2008, GEN COMP ENDOCRINOL
   DAVIES SA, 2009, J EXP BIOL, V212, P387, DOI 10.1242/jeb.024513
   DOW JAT, 2009, J EXP BIOL, V212, P435, DOI 10.1242/jeb.024224
   FERRY S, 2002, CARCINOGENESIS, V23, P2031
   FORD D, 2007, EXP GERONTOL, V42, P483, DOI 10.1016/j.exger.2007.01.004
   GU M, 2009, MOL CARCINOG
   HA EM, 2005, SCIENCE, V310, P847, DOI 10.1126/science.1117311
   HALESTRAP AP, 2009, J MOL CELL CARDIOL
   HILLIKER AJ, 1992, P NATL ACAD SCI USA, V89, P4343
   IMAI Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   IRVINE RF, 2006, ADV ENZYME REGUL, V46, P314, DOI
   10.1016/j.advenzreg.2006.01.009
   JACOBSON J, 2004, MOL CELL BIOCHEM, V256, P209
   KAMATA H, 1999, CELL SIGNAL, V11, P1
   KEAN L, 2002, AM J PHYSIOL-REG I, V282, R1297
   KONDO N, 2006, ANTIOXID REDOX SIGN, V8, P1881
   LEE YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3
   LLOYDBURTON SM, 2007, J BIOL CHEM, V282, P9526, DOI
   10.1074/jbc.M610253200
   MARTELLI AM, 2007, EUR J HISTOCHEM S1, V51, P125
   MCGETTIGAN J, 2005, INSECT BIOCHEM MOLEC, V35, P741, DOI
   10.1016/j.ibmb.2005.02.017
   MILLER AT, 2008, CELL CYCLE, V7, P463
   MIWA S, 2003, FREE RADICAL BIO MED, V35, P938, DOI
   10.1016/S0891-5849(03)00464-7
   MOHANTY JG, 1997, J IMMUNOL METHODS, V202, P133
   MOLINACRUZ A, 2008, J BIOL CHEM, V283, P3217, DOI 10.1074/jbc.M705873200
   MONNIER V, 2002, GENESIS, V34, P76, DOI 10.1002/gene.10130
   MULLER FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI
   10.1016/j.freeradbiomed.2007.03.034
   MURPHY MP, 2009, BIOCHEM J 1, V417, P1, DOI 10.1042/BJ20081386
   NAGAI T, 2001, P NATL ACAD SCI USA, V98, P3197
   NALASKOWSKI MM, 2003, J BIOL CHEM, V278, P19765, DOI
   10.1074/jbc.M211059200
   NARAYAN P, 2001, AM J PHYSIOL-HEART C, V281, H1931
   NIKI E, 2005, BIOCHEM BIOPH RES CO, V338, P668, DOI
   10.1016/j.bbrc.2005.08.072
   ONNEBO SMN, 2009, BIOCHEM J 1, V423, P109, DOI 10.1042/BJ20090241
   PICCOLO E, 2004, ONCOGENE, V23, P1754, DOI 10.1038/sj.onc.1207296
   QUINN L, 2003, EMBO J, V22, P3568
   ROSAY P, 1997, J CELL SCI 15, V110, P1683
   ROY S, 2009, CANCER RES, V69, P1166, DOI 10.1158/0008-5472.CAN-08-3115
   SCHELL MJ, 2001, J BIOL CHEM, V276, P37537
   SEEDS AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200
   SOUTHALL TD, 2006, PHYSIOL GENOMICS, V26, P35, DOI
   10.1152/physiolgenomics.00038.2006
   STERGIOPOULOS K, 2009, PHYSIOL GENOMICS, V37, P1, DOI
   10.1152/physiolgenomics.90360.2008
   TERHZAZ S, 2006, J BIOL CHEM, V281, P18849, DOI 10.1074/jbc.M603002200
   WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114
   YANG J, 2007, PHYSIOL GENOMICS, V30, P223
   ZHOU MJ, 1997, ANAL BIOCHEM, V253, P162
NR 57
TC 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD MAY
PY 2010
VL 22
IS 5
BP 737
EP 748
DI 10.1016/j.cellsig.2009.12.009
PG 12
SC Cell Biology
GA 574JG
UT ISI:000275984600004
ER

PT J
AU Zhao, Y
   Shen, HY
   Chen, XY
   Xiong, RP
   Li, P
   Liu, P
   Yang, N
   Zhou, YG
AF Zhao, Yan
   Shen, Hai-Ying
   Chen, Xing-Yun
   Xiong, Ren-Ping
   Li, Ping
   Liu, Ping
   Yang, Nan
   Zhou, Yuan-Guo
TI Genetic Variations of Heat Shock Protein 84 in Mice Mediate Cellular
   Glucocorticoid Response
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Heat shock protein 90; Glucocorticoid receptor; Heat stress;
   Dexamethasone; Geldanamycin
ID HSP90/HSP70-BASED CHAPERONE MACHINERY; ACUTE LYMPHOBLASTIC-LEUKEMIA;
   MOLECULAR-MECHANISMS; ATPASE ACTIVITY; RECEPTOR ISOFORMS; HUMAN HSP90;
   RESISTANCE; BINDING; HEAT-SHOCK-PROTEIN-90; EXPRESSION
AB Heat shock protein 90 (Hsp90), encoded by hsp84 and hsp86 in mice, has
   been confirmed to modulate glucocorticoid receptor (GR) function;
   however, the contribution of Hsp90 in glucocorticoid (GC)
   sensibility/resistance has received less attention. Previously, we
   found that genetic variations of Hsp84 are related to differences in
   the in vivo GC-GR responses between BALB/c and C57BL/6 mice suffering
   from traumatic injury. To evaluate the modulation of Hsp84
   polymorphisms on the GC response, we used a cellular heat-stress injury
   (HSI) model combined with a transgene-plasmid infection approach and
   assessed HSI-induced cellular damage and GR nuclear translocation, with
   or without dexamethasone pretreatment. We demonstrated that after HSI,
   fibroblasts from the C57BL/6 line exhibit higher cellular survival,
   higher nuclear GR levels and lower lactate dehydrogenase activity
   compared to those from the BALB/c line. We showed that
   dexamethasone-rescued HSI-induced damage is accompanied by increasing
   nuclear GR levels in both lines. Importantly, this protection against
   HSI was greater in C57BL/6 fibroblasts and was resistant to
   geldanamycin, a selective inhibitor of Hsp90. Importantly, transfection
   of the hsp84-transgene from C57BL/6 mice increased the nuclear GR
   levels and lessened HSI-induced damage in BALB/c fibroblasts. Our data
   thereby demonstrate that Hsp84 from C57BL/6 mice modulates higher
   cellular GC-GR responsiveness. Copyright (C) 2010 S. Karger AG, Basel
C1 [Zhao, Yan; Shen, Hai-Ying; Chen, Xing-Yun; Xiong, Ren-Ping; Li, Ping; Liu, Ping; Yang, Nan; Zhou, Yuan-Guo] Third Mil Med Univ, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Inst Surg Res, Chongqing 400042, Peoples R China.
   [Zhao, Yan; Shen, Hai-Ying; Chen, Xing-Yun; Xiong, Ren-Ping; Li, Ping; Liu, Ping; Yang, Nan; Zhou, Yuan-Guo] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China.
RP Zhou, YG, Third Mil Med Univ, Ctr Mol Biol, State Key Lab Trauma Burn &
   Combined Injury, Inst Surg Res, Chongqing 400042, Peoples R China.
EM ygzhou@cta.cq.cn
FU National Basic Research Program of China [2005CB522602]; National
   Natural Science Foundation of China [30470988, 30871170]
FX This work was supported by the National Basic Research Program of China
   (No. 2005CB522602) and the National Natural Science Foundation of China
   (No. 30470988 and No. 30871170)
CR ADCOCK IM, 1995, J IMMUNOL, V154, P3500
   BEESLEY AH, 2009, BRIT J CANCER, V100, P1926, DOI 10.1038/sj.bjc.6605072
   BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424
   BRAY PJ, 2003, HUM MUTAT, V21, P557, DOI 10.1002/humu.10213
   CHARMANDARI E, 2004, ANN NY ACAD SCI, V1024, P168, DOI
   10.1196/annals.1321.014
   CHARMANDARI E, 2008, J CLIN ENDOCR METAB, V93, P1563, DOI
   10.1210/jc.2008-0040
   CHARMANDARI E, 2008, J CLIN ENDOCR METAB, V93, P4963, DOI
   10.1210/jc.2008-0892
   CHO YJ, 2003, ALLERGY ASTHMA PROC, V24, P353
   CUNNINGHAM CN, 2008, J BIOL CHEM, V283, P21170, DOI
   10.1074/jbc.M800046200
   DELIA M, 2009, AM J PHYSIOL-ENDOC M, V296, E97, DOI
   10.1152/ajpendo.90582.2008
   DUMA D, 2006, J STEROID BIOCHEM, V102, P11, DOI
   10.1016/j.jsbmb.2006.09.009
   GROSS KL, 2009, MOL CELL ENDOCRINOL, V300, P7
   ITO K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI
   10.1016/j.jaci.2006.01.032
   KANELAKIS KC, 2003, METHOD ENZYMOL, V364, P159
   KOPER JW, 1997, HUM GENET, V99, P663
   KOZACI DL, 2007, RHEUMATOLOGY, V46, P579, DOI
   10.1093/rheumatology/kel276
   LIU JM, 1999, MOL ENDOCRINOL, V13, P355
   MACLEAN MJ, 2005, BIOCHEM BIOPH RES CO, V337, P133, DOI
   10.1016/j.bbrc.2005.09.025
   MCLAUGHLIN SH, 2002, J MOL BIOL, V315, P787
   MCLAUGHLIN SH, 2004, J MOL BIOL, V344, P813, DOI
   10.1016/j.jmb.2004.09.055
   MERKULOV VM, 2009, J STEROID BIOCHEM, V115, P1, DOI
   10.1016/j.jsbmb.2009.02.003
   OUYANG J, 2006, CLIN VACCINE IMMUNOL, V13, P496, DOI
   10.1128/CVI.13.4.496-500.2006
   OWEN BAL, 2002, J BIOL CHEM, V277, P7086
   PEARL LH, 2000, CURR OPIN STRUC BIOL, V10, P46
   PEARL LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI
   10.1146/annurev.biochem.75.103004.142738
   PEETERS RP, 2008, CLIN ENDOCRINOL OXF
   PIETERS R, 1998, LEUKEMIA, V12, P1344
   PRATT WB, 2003, EXP BIOL MED, V228, P111
   RAISON CL, 2003, AM J PSYCHIAT, V160, P1554
   RICHTER K, 2008, J BIOL CHEM, V283, P17757, DOI 10.1074/jbc.M800540200
   RUTHERFORD S, 2007, ADV EXP MED BIOL, V594, P190
   RUTHERFORD S, 2007, CRIT REV BIOCHEM MOL, V42, P355, DOI
   10.1080/10409230701597782
   SCHONEVELD OJLM, 2004, BBA-GENE STRUCT EXPR, V1680, P114, DOI
   10.1016/j.bbaexp.2004.09.004
   SHEN HY, 2005, J BIOL CHEM, V280, P39962, DOI 10.1074/jbc.M505524200
   SHEN HY, 2010, J NEUROTRAU IN PRESS
   TAGO K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI
   10.1016/j.ce.2003.10.057
   VANDENAKKER ELT, 2009, INTENS CARE MED, V35, P1247, DOI
   10.1007/s00134-009-1468-6
   VAUGHAN CK, 2009, FEBS J, V276, P199, DOI
   10.1111/j.1742-4658.2008.06773.x
   WHITESELL L, 1996, MOL ENDOCRINOL, V10, P705
   ZARGAROVA T, 2004, CLIN EXP IMMUNOL, V137, P313, DOI
   10.1111/j.1365-2249.2004.02539.x
NR 40
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 25
IS 4-5
BP 359
EP 366
DI 10.1159/000303039
PG 8
SC Cell Biology; Physiology
GA 574DK
UT ISI:000275968600001
ER

PT J
AU Huo, R
   Li, Z
   Lu, CC
   Xie, Y
   Wang, B
   Tu, YJ
   Hu, JT
   Xu, CQ
   Yang, BF
   Dong, DL
AF Huo, Rong
   Li, Zhe
   Lu, Cui-Cui
   Xie, Yan
   Wang, Bin
   Tu, Yu-Jie
   Hu, Jun-Tao
   Xu, Chang-Qing
   Yang, Bao-Feng
   Dong, De-Li
TI Inhibition of 2-Aminoethoxydiphenyl Borate-induced Rat Atrial Ectopic
   Activity by Anti-arrhythmic Drugs
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE 2-aminoethoxydiphenyl borate; Anti-arrhythmic drugs; Ectopic activity;
   Atria
ID CALCIUM-ENTRY CHANNELS; OPERATED CA2+ ENTRY; VENTRICULAR MYOCYTES;
   RECEPTOR FUNCTION; PACEMAKER CELLS; K+ CURRENTS; RELEASE; 2-APB; MOUSE;
   STIMULATION
AB Background/Aims: 2-aminoethoxydiphenyl borate (2-APB) provokes
   spontaneous mechanical activity in isolated rat left atria. The present
   study is to characterize 2-APB-induced ectopic activity in rat atria
   and to investigate the inhibition of 2-APB-induced ectopic activity by
   anti-arrhythmic drugs. Methods: 2-APB-induced ectopic activity was
   measured through an isometric force transducer connected to a
   multichannel acquisition and analysis system. Intracellular [Ca2+](i)
   was measured with fluorescence laser scanning confocal microscopy.
   Voltage-dependent L-type Ca2+ currents were recorded by using
   patch-clamp technique. Results: 2-APB dose-dependently increased the
   ectopic activity of left atria at 1, 5, 10, 20, 50 mu M.
   Anti-arrhythmic drugs, quinidine (10 mu M), lidocaine (10 mu M),
   verapamil (5 mu M), and amiodarone (50 mu M, 100 mu M) inhibited
   2-APB-induced ectopic activity. 2-APB-induced ectopic activity was
   inhibited by Ca2+-free bath, Na+/Ca2+ exchanger blockers, 3',
   4'-dichlorobenzamil hydrochloride (DHC) and Ni2+, not by non-selective
   cation channel blocker Gd3+. 2-APB also induced ectopic contractions in
   ventricular tissue straps and the ectopic contractions were inhibited
   by quinidine, verapamil and DHC. Lidocaine, verapamil and DHC inhibited
   2-APB-induced increase of intracellular Ca2+ concentration in
   cardiomyocytes. Low molecular weight heparin inhibited phenylephrine
   (PE)-induced but not 2-APB - induced atria ectopic activity, and the
   pattern of 2-APB-induced ectopic activity was continuous, distinct from
   the discontinuous activity induced by PE. Conclusion: 2-APB-induced
   atria ectopic activity was inhibited by classic anti-arrhythmic drugs
   quinidine, lidocaine, verapamil, amiodarone, and Na+/Ca2+ exchanger
   blockers. It can be used for testing agents able to affect any of Na+,
   Ca2+ channel, Na+/Ca2+ exchanger without selectivity. Copyright (C)
   2010 S. Karger AG, Basel
C1 [Huo, Rong; Li, Zhe; Lu, Cui-Cui; Xie, Yan; Wang, Bin; Tu, Yu-Jie; Hu, Jun-Tao; Yang, Bao-Feng; Dong, De-Li] Harbin Med Coll, Dept Pharmacol, Harbin 150081, Peoples R China.
   [Xu, Chang-Qing] Harbin Med Coll, Dept Pathophysiol, Harbin 150081, Peoples R China.
   Biopharmaceut Key Lab Heilongjiang Prov, Harbin, Peoples R China.
RP Dong, DL, Harbin Med Coll, Dept Pharmacol, Baojian Rd 157, Harbin
   150081, Peoples R China.
EM delidong2004@yahoo.com.cn
FU National Natural Science Foundation of China [30873064]; National
   Excellent Doctoral Dissertation of PR China [2007B72]; Program for New
   Century Excellent Talents in University 
FX This work was supported by National Natural Science Foundation of China
   (30873064), A Foundation for the Author of National Excellent Doctoral
   Dissertation of PR China (2007B72), and Program for New Century
   Excellent Talents in University.
CR BOOTMAN MD, 2002, FASEB J, V16, P1145
   BOYLE WA, 1992, J GEN PHYSIOL, V100, P1041
   CHU WF, 2006, BASIC CLIN PHARMACOL, V98, P104
   CHUNG MK, 2004, J NEUROSCI, V24, P5177, DOI
   10.1523/JNEUROSCI.0934-04.2004
   DOBRYNDEVA Y, 2001, MOL PHARMACOL, V60, P541
   DONG D, 2003, CARDIOVASC RES, V57, P320
   DONG DL, 2004, ACTA PHARMACOL SIN, V25, P751
   DONG DL, 2006, EUR J PHARMACOL, V545, P161, DOI
   10.1016/j.ejphar.2006.06.063
   DUKES ID, 1991, J PHYSIOL-LONDON, V435, P395
   GOEL M, 2007, AM J PHYSIOL-HEART C, V292, H874, DOI
   10.1152/ajpheart.00785.2006
   GORDIENKO DV, 2008, CELL CALCIUM, V43, P122, DOI
   10.1016/j.ceca.2007.04.012
   GYSEMBERGH A, 1999, AM J PHYSIOL-HEART C, V277, H2458
   HASHIMOTO K, 2007, J PHARMACOL SCI, V103, P333, DOI
   10.1254/jphs.CRJ06013X
   HUSER J, 2000, J PHYSIOL-LONDON, V524, P415
   JONAS S, 1997, ANN NY ACAD SCI, V825, P389
   KAPUR N, 2007, J PHYSIOL-LONDON, V581, P1113, DOI
   10.1113/jphysiol.2007.125955
   KODAMA I, 1999, AM J CARDIOL, V84, P20
   LUCCHESI BR, 1993, AM J CARDIOL, V72, F25
   MA HT, 2002, J BIOL CHEM, V277, P6915
   MA HT, 2003, BIOCHEM J 3, V376, P667
   PADAR S, 2005, BIOCHEM PHARMACOL, V69, P1177, DOI
   10.1016/j.bcp.2005.01.011
   PEPPIATT CM, 2003, CELL CALCIUM, V34, P97, DOI
   10.1016/S0143-4160(03)00026-3
   RYCHKOV G, 2007, HANDB EXP PHARM, V179, P23
   SCHLOTTHAUER K, 2000, CIRC RES, V87, P774
   SERGEANT GP, 2001, AM J PHYSIOL-CELL PH, V280, C1349
   SIPIDO KR, 2006, HANDB EXP PHARM, V171, P159
   SIPIDO KR, 2007, ANN NY ACAD SCI, V1099, P339, DOI
   10.1196/annals.1387.066
   SOULSBY MD, 2002, CELL CALCIUM, V32, P175, DOI
   10.1016/S0143-4160(02)00152-5
   WANG JP, 2005, TOXICOL APPL PHARM, V209, P134, DOI
   10.1016/j.taap.2005.04.002
   WANG Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143-4160(02)00156-2
   WINSLOW E, 1980, BRIT J PHARMACOL, V71, P615
   WOLKOWICZ PE, 2007, EUR J PHARMACOL, V576, P122, DOI
   10.1016/j.ejphar.2007.08.004
   WOLKOWICZ PE, 2007, J CARDIOVASC PHARM, V49, P325
   WU J, 2000, MOL PHARMACOL, V58, P1368
   XU SZ, 2005, BRIT J PHARMACOL, V145, P405
   ZHAINAZAROV AB, 2003, J MEMBRANE BIOL, V193, P91, DOI
   10.1007/s00232-002-2010-8
   ZHANG YH, 2005, CIRCULATION, V112, P2904, DOI
   10.1161/CIRCULATIONAHA.105.568832
   ZIMA AV, 2004, J PHYSIOL-LONDON, V555, P607, DOI
   10.1113/jphysiol.2003.058529
   ZIMMERMANN K, 2005, NEUROSCIENCE, V135, P1277, DOI
   10.1016/j.neuroscience.2005.07.018
NR 39
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 25
IS 4-5
BP 425
EP 432
DI 10.1159/000303047
PG 8
SC Cell Biology; Physiology
GA 574DK
UT ISI:000275968600008
ER

PT J
AU Du, J
   Zhang, LJ
   Yang, Y
   Li, WX
   Chen, L
   Ge, YB
   Sun, CQ
   Zhu, YC
   Gu, L
AF Du, Jun
   Zhang, Lijia
   Yang, Yu
   Li, Weixing
   Chen, Ling
   Ge, Yingbin
   Sun, Chongqi
   Zhu, Yichao
   Gu, Luo
TI ATP Depletion-induced Actin Rearrangement Reduces Cell Adhesion via p38
   MAPK-HSP27 Signaling in Renal Proximal Tubule Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Actin cytoskeleton; ATP depletion; Cell adhesion; Tubular epithelial
   cells; p38MAPK; HSP27
ID EPITHELIAL-CELLS; PROTEIN-KINASE; ISCHEMIA; CYTOSKELETON; ACTIVATION;
   INJURY; FAILURE; HSP27; DEATH; PHOSPHORYLATION
AB Ischemia causes desquamation of proximal tubular epithelial cells
   leading to acute renal failure. However, the molecular mechanisms
   underlying the detachment of proximal tubule cells remain unknown. In
   this study, we reported that ATP depletion resulted in actin
   polymerization, a shift of filamentous actin from weblike structure to
   fragmented parallel stress fibers, followed by a reduction of cellular
   adhesion ability. The pre-treatment with Jasplakinolide, an actin
   stabilizer, prevented ATP depletion-induced actin polymerization and
   reduction of cell adhesion, indicating that the cytoskeleton
   reorganization decreased the cellular adhesion ability. Furthermore,
   the ATP depletion markedly increased the levels of p38MAPK and HSP27
   phosphorylation with enhanced translocation of phosphorylated HSP27
   from cytoskeleton to cytoplasm. The inhibition of p38MAPK by SB203580
   blocked the ATP depletion to induce HSP27 phosphorylation and actin
   polymerization. These findings suggest that ischemia remodels
   filamentous actin leading to desquamation of proximal tubular
   epithelial cells through p38 MAPK-HSP27 signaling. Copyright (C) 2010
   S. Karger AG, Basel
C1 [Zhu, Yichao; Gu, Luo] Nanjing Med Univ, Ctr Canc, Nanjing 210029, Peoples R China.
   [Du, Jun; Zhang, Lijia; Yang, Yu; Chen, Ling; Ge, Yingbin] Nanjing Med Univ, Dept Physiol, Nanjing 210029, Peoples R China.
   [Li, Weixing] Taizhou Polytech Coll, Dept Med, Taizhou, Peoples R China.
   [Sun, Chongqi] Nanjing Med Univ, Kangda Coll, Nanjing 210029, Peoples R China.
RP Gu, L, Nanjing Med Univ, Ctr Canc, 140 HanZhong Rd, Nanjing 210029,
   Peoples R China.
EM lgu@njmu.edu.cn
FU National Natural Science Foundation of China [30872926]; China Ministry
   of Health [WKJ2005-2-02]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No 30872926) and from China Ministry of Health
   Grant (WKJ2005-2-02) to Dr. L Gu. J Du and L. J. Zhang contributed
   equally to this work.
CR AOTO M, 2009, FEBS LETT, V583, P1611, DOI 10.1016/j.febslet.2009.04.028
   BARRETTI P, 1997, RENAL FAILURE, V19, P253
   BERKOWITZ P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200
   DAI T, 2006, KIDNEY INT, V69, P806, DOI 10.1038/sj.ki.5000033
   DESILVA H, 1998, BIOCHEM BIOPH RES CO, V250, P647
   DI KJ, 2007, EXP CELL RES, V313, P3983, DOI 10.1016/j.yexcr.2007.08.023
   DOUCET C, 2008, AM J PHYSIOL-RENAL, V295, F179, DOI
   10.1152/ajprenal.00252.2007
   GEIGER B, 2001, NAT REV MOL CELL BIO, V2, P793
   HIRANO S, 2004, CELL BIOL TOXICOL, V20, P1
   KELLER M, 2005, WORLD J GASTROENTERO, V11, P7418
   KIM WH, 2005, NEUROCHEM RES, V30, P969, DOI 10.1007/s11064-005-6223-y
   KIMURA H, 2006, LIFE SCI, V78, P1901, DOI 10.1016/j.lfs.2005.08.040
   KROSHIAN VM, 1994, AM J PHYSIOL 2, V266, F21
   KWON O, 2002, AM J PHYSIOL-RENAL, V282, F1012
   LEE SH, 2001, J BIOL CHEM, V276, P25066
   LIEBERTHAL W, 1998, AM J PHYSIOL, V275, F623
   MCMULLEN ME, 2005, J BIOL CHEM, V280, P20995
   MOLITORIS BA, 1997, PEDIATR NEPHROL, V11, P761
   MOLITORIS BA, 2002, CRIT CARE MED S, V30, S240
   MOLITORIS BA, 2004, KIDNEY INT, V66, P871
   MOUNIER N, 2002, CELL STRESS CHAPERON, V7, P167
   MUKHOPADHYAY NK, 2005, J CELL MOL MED, V9, P387
   MURAYAMA T, 2006, TRANSPLANTATION, V81, P1325, DOI
   10.1097/01.tp.0000209167.48030.6b
   OKADA T, 2005, AM J PHYSIOL-HEART C, V289, H2310, DOI
   10.1152/ajpheart.00462.2005
   ONO K, 2000, CELL SIGNAL, V12, P1
   PRAHALAD P, 2004, AM J PHYSIOL-CELL PH, V286, C693, DOI
   10.1152/ajpcell.00124.2003
   SAENZMORALES D, 2006, EXP CELL RES, V312, P3711, DOI
   10.1016/j.yexcr.2006.05.024
   SAKAMOTO K, 2000, BIOCHEM BIOPH RES CO, V269, P137
   SAURIN AT, 2000, FASEB J, V14, P2237
   SCHWARTZ N, 1999, AM J PHYSIOL-RENAL, V276, F544
   SHERIDAN AM, 1993, AM J PHYSIOL, V265, F342
   SUTTON TA, 2003, AM J PHYSIOL-RENAL, V285, F191, DOI
   10.1152/ajprenal.00042.2003
   SUURNA MV, 2006, AM J PHYSIOL-RENAL, V290, F1398, DOI
   10.1152/ajprenal.00194.2005
   THADHANI R, 1996, NEW ENGL J MED, V334, P1448
   TURCOTTE S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427
   VANDE WB, 1994, AM J PHYSIOL, V267, F888
   VASIOUKHIN V, 2000, CELL, V100, P209
   WELSH DJ, 2006, PULM PHARMACOL THER, V19, P128, DOI
   10.1016/j.pupt.2005.04.008
   WHITE MY, 2006, J MOL CELL CARDIOL, V40, P761, DOI
   10.1016/j.yjmcc.2006.02.007
NR 39
TC 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2010
VL 25
IS 4-5
BP 501
EP 510
DI 10.1159/000303055
PG 10
SC Cell Biology; Physiology
GA 574DK
UT ISI:000275968600016
ER

PT J
AU Yang, Z
   Jiang, J
   Stewart, DM
   Qi, SK
   Yamane, K
   Li, JW
   Zhang, Y
   Wong, JM
AF Yang, Ze
   Jiang, Jun
   Stewart, David M.
   Qi, Shankang
   Yamane, Kenichi
   Li, Jiwen
   Zhang, Yi
   Wong, Jiemin
TI AOF1 is a histone H3K4 demethylase possessing demethylase
   activity-independent repression function
SO CELL RESEARCH
LA English
DT Article
DE AOF1; histone H3K4 demethylase; chromatin; repression; Zf-CW
ID DOMAIN-CONTAINING PROTEINS; NONHISTONE PROTEINS; ANDROGEN-RECEPTOR;
   CRYSTAL-STRUCTURE; XENOPUS-OOCYTES; LSD1; METHYLATION; TRANSCRIPTION;
   DEACETYLASE; INTERPLAY
AB LSD1 (KDM1 under the new nomenclature) was the first identified
   lysine-specific histone demethylase belonging to the flavin-dependent
   amine oxidase family. Here, we report that AOF1 (KDM1B under the new
   nomenclature), a mammalian protein related to LSD1, also possesses
   histone demethylase activity with specificity for H3K4me1 and H3K4me2.
   Like LSD1, the highly conserved SWIRM domain is required for its
   enzymatic activity. However, AOF1 differs from LSD1 in several aspects.
   First, AOF1 does not appear to form stable protein complexes containing
   histone deacetylases. Second, AOF1 is found to localize to chromosomes
   during the mitotic phase of the cell cycle, whereas LSD1 does not.
   Third, AOF1 represses transcription when tethered to DNA and this
   repression activity is independent of its demethylase activity.
   Structural and functional analyses identified its unique N-terminal
   Zf-CW domain as essential for the demethylase activity-independent
   repression function. Collectively, our study identifies AOF1 as the
   second histone demethylase in the family of flavin-dependent amine
   oxidases and reveals a demethylase-independent repression function of
   AOF1.
C1 [Yang, Ze; Qi, Shankang; Li, Jiwen; Wong, Jiemin] E China Normal Univ, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Yang, Ze; Qi, Shankang; Li, Jiwen; Wong, Jiemin] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Jiang, Jun] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Urol, Chongqing 400042, Peoples R China.
   [Stewart, David M.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA.
   [Yamane, Kenichi; Zhang, Yi] Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.
   [Yamane, Kenichi; Zhang, Yi] Univ N Carolina, Chapel Hill, NC 27599 USA.
RP Wong, JM, E China Normal Univ, Inst Biomed Sci, Shanghai 200241,
   Peoples R China.
EM jmweng@bio.ecnu.edu.cn
FU National Natural Science Foundation of China [90919025, 30871381];
   Ministry of Science and Technology of China [2009CB918402,
   2009CB825601]; Research Platform for Cell Signaling Networks from the
   Science and Technology Commission of Shanghai Municipality [06DZ22923]
FX We thank Dr Ramin Shiekhattar (Wistar Institute, USA) for the
   baculoviruses expressing Flag-LSD1 and Drs Jianguo Song and Degui Chen
   (Shanghai Institute of Biochemistry and Cell Biology, China) for
   anti-HDAC1 antibody and H3K36me2 antibody, respectively. This study was
   partially supported by grants from the National Natural Science
   Foundation of China (90919025, 30871381), the Ministry of Science and
   Technology of China (2009CB918402, 2009CB825601) and the Research
   Platform for Cell Signaling Networks from the Science and Technology
   Commission of Shanghai Municipality (06DZ22923).
CR ALMOUZNI G, 1993, GENE DEV, V7, P2033
   ARAVIND L, 2002, GENOME BIOL, V3, UNSP RESEARCH0039
   CHEN Y, 2006, P NATL ACAD SCI USA, V103, P13956, DOI
   10.1073/pnas.0606381103
   CICCONE DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   CULHANE JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI
   10.1016/j.cbpa.2007.07.014
   DA GP, 2006, P NATL ACAD SCI USA, V103, P2057, DOI
   10.1073/pnas.0510949103
   DEROBERTIS EM, 1977, BIOCHEMISTRY CELL NU, V42, P181
   FORNERIS F, 2005, FEBS LETT, V579, P2203, DOI
   10.1016/j.febslet.2005.03.015
   HUANG J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   IWASE S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   KARYTINOS A, 2009, J BIOL CHEM, V284, P17775, DOI
   10.1074/jbc.M109.003087
   KLOSE RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   LAN F, 2009, SCI CHINA SER C, V52, P311, DOI 10.1007/s11427-009-0054-z
   LEE MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   LEE MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   MARTIN C, 2005, NAT REV MOL CELL BIO, V6, P838
   METZGER E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   NICHOLSON TB, 2009, EPIGENETICS, V4, P129
   PERRY J, 2003, TRENDS BIOCHEM SCI, V28, P576, DOI
   10.1016/j.tibs.2003.09.007
   SHI YJ, 2004, CELL, V119, P941
   SHI YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   STAVROPOULOS P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI
   10.1038/nsmb1113
   STEWART MD, 2005, MOL CELL BIOL, V25, P2525, DOI
   10.1128/MCB.25.7.2525-2538.2005
   STEWART MD, 2006, MOL CELL BIOL, V26, P6890, DOI 10.1128/MCB.00948-06
   TREWICK SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379
   TSUKADA Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   WANG J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   WANG Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   WEGENER D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8
   WHETSTINE JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   WONG JM, 1998, EMBO J, V17, P520
   WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167
   XIANG Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83
   YAMANE K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   ZHANG Y, 2001, GENE DEV, V15, P2343
NR 35
TC 5
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD MAR
PY 2010
VL 20
IS 3
BP 276
EP 287
DI 10.1038/cr.2010.12
PG 12
SC Cell Biology
GA 572GS
UT ISI:000275816300005
ER

PT J
AU Staron, M
   Yang, Y
   Liu, B
   Li, J
   Shen, YK
   Zuniga-Pflucker, JC
   Aguila, HL
   Goldschneider, I
   Li, ZH
AF Staron, Matthew
   Yang, Yi
   Liu, Bei
   Li, Janet
   Shen, Yuankai
   Zuniga-Pflucker, Juan Carlos
   Aguila, Hector L.
   Goldschneider, Irving
   Li, Zihai
TI gp96, an endoplasmic reticulum master chaperone for integrins and
   Toll-like receptors, selectively regulates early T and B lymphopoiesis
SO BLOOD
LA English
DT Article
ID TRANSCRIPTION FACTOR XBP-1; UNFOLDED PROTEIN RESPONSE; PLASMA-CELL
   DIFFERENTIATION; BONE-MARROW; LYMPHOID PROGENITOR; ALPHA-4 INTEGRINS;
   STEM-CELLS; MICE; EXPRESSION; PRECURSOR
AB Integrins contribute to lymphopoiesis, whereas Toll-like receptors
   (TLRs) facilitate the myeloid replenishment during inflammation. The
   combined role of TLRs and integrin on hematopoiesis remains unclear.
   gp96 (grp94, HSP90b1) is an endoplasmic reticulum master chaperone for
   multiple TLRs. We report herein that gp96 is also essential for
   expression of 14 hematopoietic system-specific integrins. Genetic
   deletion of gp96 thus enables us to determine the collective roles of
   gp96, integrins, and TLRs in hematopoiesis. We found that gp96-null
   hematopoietic stem cells could support long-term myelopoiesis. B-and
   T-cell development, however, was severely compromised with transitional
   block from pro-B to preB cells and the inability of thymocytes to
   develop beyond the CD4(-)CD8-stage. These defects were cell-intrinsic
   and could be recapitulated on bone marrow stromal cell culture.
   Furthermore, defective lymphopoiesis correlated strongly with failure
   of hematopoietic progenitors to form close contact with stromal cell
   niche and was not the result of the defect in the assembly of antigen
   receptor or interleukin-7 signaling. These findings define gp96 as the
   only known molecular chaperone to specifically regulate T- and B-cell
   development. (Blood. 2010;115:2380-2390)
C1 [Staron, Matthew; Yang, Yi; Liu, Bei; Li, Janet; Shen, Yuankai; Aguila, Hector L.; Goldschneider, Irving; Li, Zihai] Univ Connecticut, Sch Med, Dept Immunol, Farmington, CT 06030 USA.
   [Zuniga-Pflucker, Juan Carlos] Univ Toronto, Dept Immunol, Sunnybrook Res Inst, Toronto, ON, Canada.
RP Li, ZH, Univ Connecticut, Sch Med, Dept Immunol, MC 1601,263 Farmington
   Ave, Farmington, CT 06030 USA.
EM zihai@uchc.edu
FU National Institutes of Health [AI070603, AI077283, 5T32AI007080];
   [RC1HL100556]
FX This work was supported by the National Institutes of Health (grants
   AI070603, AI077283, and RC1HL100556; Z.L.). M.S. is supported in part
   by the National Institutes of Health (training grant 5T32AI007080).
CR ADOLFSSON J, 2001, IMMUNITY, V15, P659
   ARROYO AG, 1996, CELL, V85, P997
   ARROYO AG, 1999, IMMUNITY, V11, P555
   BANERJEE ER, 2008, EXP HEMATOL, V36, P1004, DOI
   10.1016/j.exphem.2008.03.008
   BENZ C, 2005, J EXP MED, V202, P21, DOI 10.1084/jem.20050146
   BENZ C, 2008, J EXP MED, V205, P1187, DOI 10.1084/jem.20072168
   BHANDOOLA A, 2007, IMMUNITY, V26, P678, DOI 10.1016/j.immuni.2007.05.009
   BUNGARTZ G, 2006, BLOOD, V108, P1857, DOI 10.1182/blood-2005-10-007658
   CEREDIG R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937
   CHRISTENSEN JL, 2001, P NATL ACAD SCI USA, V98, P14541
   CHRISTIANSON JC, 2008, NAT CELL BIOL, V10, P272, DOI 10.1038/ncb1689
   CRISA L, 1996, J EXP MED, V184, P215
   DENZEL A, 2002, MOL CELL BIOL, V22, P7398
   DEPOOTER R, 2007, CURR OPIN IMMUNOL, V19, P163, DOI
   10.1016/j.coi.2007.02.011
   GAVIN AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299
   GRIBI R, 2006, BLOOD, V108, P501, DOI 10.1182/blood-2005-10-4209
   HAAS IG, 1994, EXPERIENTIA, V50, P1012
   HESS J, 2001, P NATL ACAD SCI USA, V98, P1745
   HORWITZ BH, 2001, BLOOD, V97, P1578
   IWAKOSHI NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   IWAKOSHI NN, 2007, J EXP MED, V204, P2267, DOI 10.1084/jem.20070525
   KARASUYAMA H, 1994, CELL, V77, P133
   KITAMURA D, 1992, CELL, V69, P823
   LAMMERMANN T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887
   LIND EF, 2001, J EXP MED, V194, P127
   LIU B, 2008, BLOOD, V112, P1223, DOI 10.1182/blood-2008-03-143107
   LU TT, 2002, SCIENCE, V297, P409
   LUO BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI
   10.1146/annurev.immunol.25.022106.141618
   LUO SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06
   MALHOTRA JD, 2007, SEMIN CELL DEV BIOL, V18, P716
   MASSBERG S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047
   MEDZHITOV R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   MIRANTI CK, 2002, NAT CELL BIOL, V4, E83
   MIYAKE K, 1991, J EXP MED, V173, P599
   NAGAI Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008
   PAPAYANNOPOULOU T, 2001, BLOOD, V98, P2403
   PORCELLINI S, 2006, J EXP MED, V203, P461, DOI 10.1084/jem.20051519
   PORRITT HE, 2004, IMMUNITY, V20, P735
   RANDOW F, 2001, NAT CELL BIOL, V3, P891
   REIMOLD AM, 2001, NATURE, V412, P300
   ROLINK A, 1994, INT IMMUNOL, V6, P1257
   RYAN DH, 1991, J CLIN INVEST, V88, P995
   SCIMONE ML, 2006, P NATL ACAD SCI USA, V103, P7006, DOI
   10.1073/pnas.0602024103
   SCOTT LM, 2003, MOL CELL BIOL, V23, P9349, DOI
   10.1128/MCB.23.24.9349-9360.2003
   SITNICKA E, 2002, IMMUNITY, V17, P463
   UEDA Y, 2005, J EXP MED, V201, P1771, DOI 10.1084/jem.20041419
   ULYANOVA T, 2007, EXP HEMATOL, V35, P1256, DOI
   10.1016/j.exphem.2007.04.015
   VANMOLLE W, 2002, IMMUNITY, V16, P685
   WANDERLING S, 2007, MOL BIOL CELL, V18, P3764, DOI
   10.1091/mbc.E07-03-0275
   WASKOW C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615
   WU L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006
   XIAO XZ, 1999, EMBO J, V18, P5943
   YANG Y, 2005, MOL CELLS, V20, P173
   YANG Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005
   ZHANG KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848
   ZHENG H, 2004, J IMMUNOL, V173, P5929
NR 56
TC 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 25
PY 2010
VL 115
IS 12
BP 2380
EP 2390
DI 10.1182/blood-2009-07-233031
PG 11
SC Hematology
GA 574IF
UT ISI:000275981900011
ER

PT J
AU Kuang, SQ
   Bai, H
   Fang, ZH
   Lopez, G
   Yang, H
   Tong, WG
   Wang, ZZ
   Garcia-Manero, G
AF Kuang, Shao-Qing
   Bai, Hao
   Fang, Zhi-Hong
   Lopez, Gonzalo
   Yang, Hui
   Tong, Weigang
   Wang, Zack Z.
   Garcia-Manero, Guillermo
TI Aberrant DNA methylation and epigenetic inactivation of Eph receptor
   tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia
SO BLOOD
LA English
DT Article
ID COLORECTAL-CANCER; DOWN-REGULATION; CELLS; PROMOTER; TUMORIGENESIS;
   ACTIVATION; MECHANISMS; EXPRESSION; GENOME; TUMORS
AB Eph receptors and their ephrin ligands are involved in normal
   hematopoietic development and tumorigenesis. Using methylated CpG
   island amplification/DNA promoter microarray, we identified several EPH
   receptor and EPHRIN genes as potential hypermethylation targets in
   acute lymphoblastic leukemia (ALL). We subsequently studied the DNA
   methylation status of the Eph/ephrin family by bisulfite
   pyrosequencing. Hypermethylation of EPHA2, -A4, -A5, -A6, -A7, -A10,
   EPHB1, -B2, -B3, -B4, EFNA1, -A3, -A5, and EFNB1 and -B2 genes was
   detected in leukemia cell lines and primary ALL bone marrow samples.
   Expression analysis of EPHB4, EFNB2, and EFNA5 genes demonstrated that
   DNA methylation was associated with gene silencing. We cloned the
   promoter region of EPHB4 and demonstrated that promoter
   hypermethylation can result in EPHB4 transcriptional silencing.
   Restoration of EPHB4 expression by lentiviral transduction resulted in
   reduced proliferation and apoptotic cell death in Raji cells in which
   EPHB4 is methylated and silenced. Finally, we demonstrated that
   phosphorylated Akt is down-regulated in Raji cells transduced with
   EPHB4. These results suggest that epigenetic silencing by
   hypermethylation of EPH/EPHRIN family genes contributes to ALL
   pathogenesis and that EPHB4 can function as a tumor suppressor in ALL.
   (Blood. 2010;115:2412-2419)
C1 [Kuang, Shao-Qing; Fang, Zhi-Hong; Yang, Hui; Tong, Weigang; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Bai, Hao; Wang, Zack Z.] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA.
   [Lopez, Gonzalo] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.
RP Garcia-Manero, G, Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Box
   428,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ggarciam@mdanderson.org
FU Leukemia SPORE [P50 CA100632]; National Cancer Institute [CA100067,
   CA105771]; Leukemia & Lymphoma Society of America ; M. D. Anderson
   Cancer Center Physician-Scientist Award ; Commonwealth Cancer
   Foundation for Research 
FX This work was supported by a Leukemia SPORE (P50 CA100632) Career
   Development Award to S.-Q.K. and by National Cancer Institute grants
   CA100067 and CA105771, the Leukemia & Lymphoma Society of America, and
   an M. D. Anderson Cancer Center Physician-Scientist Award from the
   Commonwealth Cancer Foundation for Research (all to G.G.-M.).
CR 1997, CELL, V90, P403
   ALAZZOUZI H, 2005, CANCER RES, V65, P10170, DOI
   10.1158/0008-5472.CAN-05-2580
   BATLLE E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626
   BRUCKNER K, 1998, CURR OPIN NEUROBIOL, V8, P375
   DAVALOS V, 2006, CANCER RES, V66, P8943, DOI
   10.1158/0008-5472.CAN-05-4640
   FOUBERT P, 2007, J CLIN INVEST, V117, P1527, DOI 10.1172/JCI28338
   FOX BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI
   10.1016/j.bbrc.2005.11.174
   FOX BP, 2006, BIOCHEM BIOPH RES CO, V342, P1263, DOI
   10.1016/j.bbrc.2006.02.099
   GUO H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004
   HAFNER C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849
   HAFNER C, 2006, MODERN PATHOL, V19, P1369, DOI 10.1038/modpathol.3800660
   HIMANEN JP, 2003, INT J BIOCHEM CELL B, V35, P130
   HUUSKO P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408
   KUANG SQ, 2007, ONCOGENE, V26, P1439, DOI 10.1038/sj.onc.1209907
   KUANG SQ, 2008, LEUKEMIA, V22, P1529, DOI 10.1038/leu.2008.130
   KULLANDER K, 2002, NAT REV MOL CELL BIO, V3, P475
   MANNING G, 2002, SCIENCE, V298, P1912
   NAKADA M, 2006, CANCER RES, V66, P8492, DOI
   10.1158/0008-5472.CAN-05-4211
   NOREN NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438
   NOSHO K, 2007, CARCINOGENESIS, V28, P1364, DOI 10.1093/carcin/bgl246
   PASQUALE EB, 2004, NAT NEUROSCI, V7, P417, DOI 10.1038/nn0504-417
   SHU JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629
   SUN XP, 2007, MODERN PATHOL, V20, P811
   SURAWSKA H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI
   10.1016/j.cytofr.2004.09.002
   TANG XX, 2000, P NATL ACAD SCI USA, V97, P10936
   WANG JD, 2005, ONCOGENE, V24, P5637, DOI 10.1038/sj.onc.1208720
   WANG ZY, 2002, BLOOD, V99, P2740
   YENDAMURI S, 2007, CANCER RES, V67, P7738, DOI
   10.1158/0008-5472.CAN-07-1481
   ZELINSKI DP, 2001, CANCER RES, V61, P2301
NR 29
TC 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 25
PY 2010
VL 115
IS 12
BP 2412
EP 2419
DI 10.1182/blood-2009-05-222208
PG 8
SC Hematology
GA 574IF
UT ISI:000275981900015
ER

PT J
AU Yang, CPH
   Liu, LL
   Ikui, AE
   Horwitz, SB
AF Yang, Chia-Ping Huang
   Liu, Lingling
   Ikui, Amy E.
   Horwitz, Susan Band
TI The interaction between mitotic checkpoint proteins, CENP-E and BubR1,
   is diminished in epothilone B-resistant A549 cells
SO CELL CYCLE
LA English
DT Article
DE taxol; epothilone B; CENP-E; BubR1; drug resistance; kinetochore;
   mitotic checkpoint
ID MICROTUBULE-STABILIZING AGENTS; BETA-TUBULIN; KINETOCHORE LOCALIZATION;
   SPINDLE CHECKPOINT; TAXOL; PACLITAXEL; ANEUPLOIDY; DYNAMICS;
   ASSOCIATION; IXABEPILONE
AB Centromere associated protein-E (CENP-E), a mitotic checkpoint protein,
   is required for efficient, stable microtubule capture at kinetochores
   during mitosis. Absence of CENP-E results in misaligned chromosomes
   leading to metaphase arrest. Microtubule-interacting agents such as
   Taxol and epothilone B (EpoB), at concentrations that induce mitotic
   arrest, transiently increase expression of CENP-E in a variety of
   cancer cell lines. The CENP-E level in an EpoB-resistant A549 cell
   line, EpoB40, is similar to 2-fold higher than in A549 cells. CENP-E
   overexpression, after transfection with CENP-E cDNA into drug sensitive
   cells, does not alter Taxol or EpoB sensitivity. However, suppression
   of CENP-E expression by CENP-E siRNA results in a moderate increase in
   drug sensitivity, suggesting that a minimal quantity of CENP-E is
   required for maintaining its function. It is known that CENP-E binds to
   BubR1 and enhances its recruitment to each unattached kinetochore.
   Suppression of CENP-E results in a decrease in BubR1 levels in EpoB40
   cells. During metaphase, both targeting of CENP-E and BubR1 to the
   kinetochores and the interaction between CENP-E and BubR1 are
   significantly reduced in EpoB40 cells, compared to A549 cells. In
   addition, the distance between the two centrosomes during metaphase is
   shorter in EpoB40 than in A549 cells, suggesting that defects in the
   spindle-assembly checkpoint have occurred in EpoB40 cells during the
   development of drug resistance. These results indicate that defects in
   the mitotic checkpoint may have a role in, or be the result of, the
   development of EpoB resistance.
C1 [Yang, Chia-Ping Huang; Liu, Lingling; Ikui, Amy E.; Horwitz, Susan Band] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.
RP Yang, CPH, Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY
   10467 USA.
EM chia-ping.h.yang@einstein.yu.edu
FU NIH [CA077263, CA124898]; National Foundation for Cancer Research ;
   Breast Cancer Research Foundation ; Department of Defense
   [W81XWH-04-1-0754]
FX This work was supported by NIH CA077263, CA124898, the National
   Foundation for Cancer Research, the Breast Cancer Research Foundation
   (S. B. H.) and Department of Defense W81XWH-04-1-0754 (C. P. H. Y.).
CR ASHAR HR, 2000, J BIOL CHEM, V275, P30451
   BLAGOSKLONNY MV, 1999, INT J CANCER, V83, P151
   BOLLAG DM, 1995, CANCER RES, V55, P2325
   CAI S, 2008, MOL BIOL CELL
   CHAN GKT, 1998, J CELL BIOL, V143, P49
   CHEN JG, 2003, CANCER RES, V63, P7891
   DREWES G, 1998, TRENDS BIOCHEM SCI, V23, P307
   FORNIER MN, 2007, CLIN BREAST CANCER, V7, P757
   GOODIN S, 2008, AM J HEALTH-SYST PH, V65, P2017, DOI 10.2146/ajhp070628
   HE LF, 2001, MOL CANCER THER, V1, P3
   IKUI AE, 2005, CELL CYCLE, V4, P1385
   KOWALSKI RJ, 1997, J BIOL CHEM, V272, P2534
   LIAO H, 1994, SCIENCE, V265, P394
   LIU D, 2007, J BIOL CHEM, V282, P21415, DOI 10.1074/jbc.M609026200
   MAO YH, 2003, CELL, V114, P87
   MARTELLO LA, 2003, CANCER RES, V63, P1207
   MITCHISON TJ, 2005, MOL BIOL CELL, V16, P3064
   OHI R, 2007, CURR BIOL, V17, P953, DOI 10.1016/j.cub.2007.04.057
   ORR GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934
   PUTKEY FR, 2002, DEV CELL, V3, P351
   SCHAFERHALES K, 2007, MOL CANCER THER, V6, P1317, DOI
   10.1158/1535-7163.MCT-06-0703
   SCHIFF PB, 1979, NATURE, V277, P665
   SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561
   SHARPBAKER H, 2001, J CELL BIOL, V153, P1239
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107
   SPILIOTIS ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823
   SUDO T, 2004, CANCER RES, V64, P2502
   TANUDJI M, 2004, MOL BIOL CELL, V15, P3771, DOI 10.1091/mbc.E03-07-0482
   WEAVER BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167
   WEAVER BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003
   WIESEN KM, 2007, CANCER LETT, V257, P227
   XIA SJ, 2006, BIOCHEMISTRY-US, V45, P11762, DOI 10.1021/bi060497a
   YANG CPH, 2000, CANCER RES, V60, P5171
   YAO XB, 2000, NAT CELL BIOL, V2, P484
   YEN TJ, 1991, EMBO J, V10, P1245
   YEN TJ, 1992, NATURE, V359, P536
   YVON AMC, 1999, MOL BIOL CELL, V10, P947
   ZHANG XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013
   ZHU M, 2008, J BIOL CHEM, V283, P18916, DOI 10.1074/jbc.M710591200
NR 39
TC 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAR 15
PY 2010
VL 9
IS 6
BP 1207
EP 1213
PG 7
SC Cell Biology
GA 569XT
UT ISI:000275636900026
ER

PT J
AU Inami, K
   Abe, M
   Takeda, K
   Hagiwara, Y
   Maeda, M
   Segawa, T
   Suyama, M
   Watanabe, S
   Hino, O
AF Inami, Koichi
   Abe, Masaaki
   Takeda, Kazuyoshi
   Hagiwara, Yoshiaki
   Maeda, Masahiro
   Segawa, Tatsuya
   Suyama, Masafumi
   Watanabe, Sumio
   Hino, Okio
TI Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo
SO CANCER SCIENCE
LA English
DT Article
ID ASBESTOS-RELATED MESOTHELIOMA; EXPRESSING TUMOR XENOGRAFTS;
   PANCREATIC-CANCER; N-ERC/MESOTHELIN; OVARIAN-CANCER; MOLECULAR-CLONING;
   IMMUNOTOXIN SS1P; EKER RAT; T-CELLS; MARKER
AB Mesothelioma is an aggressive cancer often caused by chronic asbestos
   exposure, and its prognosis is very poor despite the therapies
   currently used. Due to the long latency period between asbestos
   exposure and tumor development, the worldwide incidence will increase
   substantially in the next decades. Thus, novel effective therapies are
   warranted to improve the prognosis. The ERC/mesothelin gene (MSLN) is
   expressed in wide variety of human cancers, including mesotheliomas,
   and encodes a precursor protein cleaved by proteases to generate
   C-ERC/mesothelin and N-ERC/mesothelin. In this study, we investigated
   the antitumor activity of C-ERC/mesothelin-specific mouse monoclonal
   antibody, 22A31, against tumors derived from a human mesothelioma cell
   line, ACC-MESO-4, in a xenograft experimental model using female BALB/c
   athymic nude mice. Treatment with 22A31 did not inhibit cell
   proliferation of ACC-MESO-4 in vitro; however, therapeutic treatment
   with 22A31 drastically inhibited tumor growth in vivo. 22A31 induced
   antibody-dependent cell-mediated cytotoxicity by natural killer (NK)
   cells, but not macrophages, in vitro. Consistently, the F(ab')(2)
   fragment of 22A31 did not inhibit tumor growth in vivo, nor did it
   induce antibody-dependent cell mediated cytotoxicity (ADCC) in vitro.
   Moreover, NK cell depletion diminished the antitumor effect of 22A31.
   Thus, 22A31 induced NK cell-mediated ADCC and exerted antitumor
   activity in vivo. 22A31 could have potential as a therapeutic tool to
   treat C-ERC/mesothelin-expressing cancers including mesothelioma.
   (Cancer Sci 2010; 101: 969-974)
C1 [Inami, Koichi; Abe, Masaaki; Hagiwara, Yoshiaki; Hino, Okio] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan.
   [Inami, Koichi; Suyama, Masafumi; Watanabe, Sumio] Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 113, Japan.
   [Takeda, Kazuyoshi] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.
   [Hagiwara, Yoshiaki; Maeda, Masahiro; Segawa, Tatsuya] Immunobiol Labs Co Ltd, Gunma, Japan.
RP Hino, O, Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan.
EM ohino@juntendo.ac.jp
FU Ministry of Education, Culture, Sport, and Science and Technology,
   Government of Japan 
FX We would like to thank Masumi Maruo, Hidehiro Okura, Sun Guo Dong, Wang
   Lu, Piao Xiang Hua, Kazu Shiomi, Danqing Zhang, Shuji Matsuoka,
   Toshiyuki Kobayashi, and members of the Department of Gastroenterology,
   Juntendo Hospital, for their help in the preparation of this study.
   This work was supported by a Grant-in-Aid for Cancer Research and
   Grants-in-Aid for Scientific Research from the Ministry of Education,
   Culture, Sports and Science and Technology of Japan and the Ministry of
   Health, Labor and Welfare of Japan. This study was partially supported
   by a consignment expense for the molecular imaging program on 'Research
   Base for PET Diagnosis' from the Ministry of Education, Culture, Sport,
   and Science and Technology, Government of Japan.
CR ARGANI P, 2001, CLIN CANCER RES, V7, P3862
   BARUCH AC, 2007, DIAGN CYTOPATHOL, V35, P143
   BERA TK, 2000, MOL CELL BIOL, V20, P2902
   BRITTON M, 2002, SEMIN ONCOL, V29, P18
   CHANG K, 1996, P NATL ACAD SCI USA, V93, P136
   CONNELLY RR, 1987, J NATL CANCER I, V78, P1053
   DHODAPKAR KM, 2002, J EXP MED, V195, P125
   HASSAN R, 2006, CLIN CANCER RES, V12, P447, DOI
   10.1158/1078-0432.CCR-05-1477
   HASSAN R, 2006, CLIN CANCER RES, V12, P4983, DOI
   10.1158/1078-0432.CCR-06-0441
   HASSAN R, 2007, CANC IMMUN, V7, P20
   HASSAN R, 2007, CLIN CANCER RES, V13, P5144, DOI
   10.1158/1078-0432.CCR-07-0869
   HASSAN R, 2007, CLIN CANCER RES, V13, P7166, DOI
   10.1158/1078-0432.CCR-07-1592
   HINO O, 1995, J CANCER RES CLIN, V121, P602
   HINO O, 2007, CANCER SCI, V98, P1147
   HUNG CF, 2007, GENE THER, V14, P921, DOI 10.1038/sj.gt.3302913
   INAMI K, 2008, ONCOL REP, V20, P1375, DOI 10.3892/or_00000155
   ISHIKAWA K, 2009, PATHOL INT, V59, P161, DOI
   10.1111/j.1440-1827.2009.02344.x
   ISMAILKHAN R, 2006, CANC CONTROL, V13, P255
   ITO M, 2008, CURR TOP MICROBIOL, V324, P53
   KANAZAWA N, 2006, JPN J CLIN ONCOL, V36, P254, DOI 10.1093/jjco/hyl018
   KOJIMA T, 1995, J BIOL CHEM, V270, P21984
   LI DH, 2004, LANCET, V363, P1049
   LI M, 2008, MOL CANCER THER, V7, P286, DOI 10.1158/1535-7163.MCT-07-0483
   MAEDA M, 2006, ONCOLOGY-BASEL, V71, P26, DOI 10.1159/000100446
   MAEDA M, 2006, PATHOL INT, V56, P649, DOI
   10.1111/j.1440-1827.2006.02024.x
   ONDA M, 2006, CLIN CANCER RES 1, V12, P4225, DOI
   10.1158/1078-0432.CCR-06-0472
   PASS H, 2001, CLIN LUNG CANCER, V3, P102
   PEGRAM MD, 1998, J CLIN ONCOL, V16, P2659
   RAFFIT H, 2004, CLIN CANCER RES, V10, P3937
   ROBINSON BW, 2003, LANCET, V15, P1612
   ROBINSON BWS, 2005, LUNG CANCER-J IAS S1, V49, S109, DOI
   10.1016/j.lungcan.2005.03.020
   ROUARD H, 1997, INT REV IMMUNOL, V16, P147
   SATO N, 2005, J NUCL MED, V46, P1201
   SCHOLLER N, 1999, P NATL ACAD SCI USA, V96, P11531
   SHIOMI K, 2006, CANCER SCI, V97, P928, DOI
   10.1111/j.1349-7006.2006.00246.x
   SHIOMI K, 2008, CLIN CANCER RES, V14, P1431, DOI
   10.1158/1078-0432.CCR-07-1613
   SINGH AP, 2008, LANCET ONCOL, V9, P1076
   TAKEDA K, 1993, J EXP MED, V177, P155
   TAKEDA K, 2001, NAT MED, V7, P94
   TAKEDA K, 2007, CANCER SCI, V98, P1297, DOI
   10.1111/j.1349-7006.2007.00529.x
   THOMAS AM, 2004, J EXP MED, V200, P297, DOI 10.1084/jem.20031435
   UEHARA N, 2008, MOL CANCER RES, V6, P186, DOI
   10.1158/1541-7786.MCR-07-0254
   USAMI N, 2006, CANCER SCI, V97, P387, DOI
   10.1111/j.1349-7006.2006.00184.x
   WILSON DS, 2002, J IMMUNOL METHODS, V260, P29
   WRAY CJ, 2005, GASTROENTEROLOGY, V128, P1626
   YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805
   YAMASHITA Y, 2000, BIOCHEM BIOPH RES CO, V275, P134
   YAZIJI H, 2006, MODERN PATHOL, V19, P514, DOI 10.1038/modpathol.3800534
   ZUMBUSCHENFELDE CM, 2002, CANCER RES, V62, P2244
NR 49
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2010
VL 101
IS 4
BP 969
EP 974
DI 10.1111/j.1349-7006.2009.01463.x
PG 6
SC Oncology
GA 571CK
UT ISI:000275728200021
ER

PT J
AU Paudyal, P
   Paudyal, B
   Hanaoka, H
   Oriuchi, N
   Iida, Y
   Yoshioka, H
   Tominaga, H
   Watanabe, S
   Watanabe, S
   Ishioka, NS
   Endo, K
AF Paudyal, Pramila
   Paudyal, Bishnuhari
   Hanaoka, Hirofumi
   Oriuchi, Noboru
   Iida, Yashuhiko
   Yoshioka, Hiroki
   Tominaga, Hideyuki
   Watanabe, Satoshi
   Watanabe, Shigeki
   Ishioka, Noriko S.
   Endo, Keigo
TI Imaging and biodistribution of Her2/neu expression in non-small cell
   lung cancer xenografts with 64Cu-labeled trastuzumab PET
SO CANCER SCIENCE
LA English
DT Article
ID METASTATIC BREAST-CANCER; IN-SITU HYBRIDIZATION; PHASE-II TRIAL;
   MONOCLONAL-ANTIBODY; HER-2/NEU; LINES; IMMUNOHISTOCHEMISTRY;
   GEMCITABINE; CARCINOMAS; CYCLOTRON
AB Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in
   approximately 59% of cases. Trastuzumab, a humanized monoclonal
   antibody, interferes with Her2 signaling and is approved for the
   treatment of Her2/neu overexpressing breast cancer. However, its
   therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The
   present study aimed to determine the role of 64 Cu-labeled trastuzumab
   positron emission tomography (PET) for non-invasive imaging of Her2/neu
   expression in NSCLC. Trastuzumab was conjugated with the bifunctional
   chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid
   (DOTA) and radiolabeled with Cu-64. The molecular specificity of
   DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu
   overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging
   of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice
   with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies
   revealed specific binding of DOTA-trastuzumab in the Her2/neu positive
   NCI-H2170 cells, while no binding was seen in the Her2/neu negative
   NCI-H520 cell line. Biodistribution and PET studies revealed a
   significantly high accumulation of 64 CuDOTA-trastuzumab in the
   Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection
   (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g),
   respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed
   much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170
   tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than
   that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a
   very clear image of a Her2/neu positive tumor and appeared to be
   effective as a PET tracer for imaging of Her2/neu gene expression in
   NSCLC, suggesting its potential clinical use for identifying patients
   that might benefit from trastuzumab-based therapy. (Cancer Sci 2010;
   101: 1045-1050)
C1 [Paudyal, Pramila; Paudyal, Bishnuhari; Oriuchi, Noboru; Yoshioka, Hiroki; Tominaga, Hideyuki; Endo, Keigo] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan.
   [Paudyal, Pramila; Paudyal, Bishnuhari; Oriuchi, Noboru; Yoshioka, Hiroki; Tominaga, Hideyuki; Endo, Keigo] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan.
   [Watanabe, Satoshi; Watanabe, Shigeki; Ishioka, Noriko S.] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gumma, Japan.
RP Paudyal, P, Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi,
   Gunma, Japan.
EM pramila@med.gunma-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan 
FX This work was supported by the 21st century COE program from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan.
CR ANDERSON CJ, 1992, J NUCL MED, V33, P1685
   ASAMURA H, 1996, J THORAC CARDIOV SUR, V111, P1125
   BASELGA J, 1998, CANCER RES, V58, P2825
   BEHR TM, 2001, NEW ENGL J MED, V345, P995
   BUNN PA, 2001, CLIN CANCER RES, V7, P3239
   CAI WB, 2006, J NUCL MED, V47, P2048
   EIBLMAIER M, 2008, J NUCL MED, V49, P1472, DOI 10.2967/jnumed.108.052316
   GARRETT TPJ, 2003, MOL CELL, V11, P495
   GATZEMEIER U, 2004, ANN ONCOL, V15, P19, DOI 10.1093/annonc/mdh031
   HIRSCH FR, 2002, BRIT J CANCER, V86, P1449
   HIRSCH FR, 2002, SEMIN ONCOL S4, V29, P51
   KERN JA, 1994, J CLIN INVEST, V93, P516
   LINE BR, 2004, CURR TREAT OPTIONS O, V5, P63
   LUBDEHOOGE MN, 2004, BRIT J PHARMACOL, V143, P99, DOI
   10.1038/sj.bjp.0705915
   MCCARTHY DW, 1997, NUCL MED BIOL, V24, P35
   MICHELI A, 2002, ANN ONCOL, V13, P840
   NAGENGAST WB, 2007, J NUCL MED, V48, P1313, DOI
   10.2967/jnumed.107.041301
   OBATA A, 2003, NUCL MED BIOL, V30, P535, DOI
   10.1016/S0969-8051(03)00024-6
   PEGRAM MD, 2000, SEMIN ONCOL S11, V27, P21
   PELLEGRINI C, 2003, CLIN CANCER RES 1, V9, P3645
   PENTLOW KS, 1991, MED PHYS, V18, P357
   PERIK PJ, 2006, J CLIN ONCOL, V24, P2276, DOI 10.1200/JCO.2005.03.8448
   PERK LR, 2005, J NUCL MED, V46, P1898
   PHILPOTT GW, 1995, J NUCL MED, V36, P1818
   RAHMIM A, 2008, NUCL MED COMMUN, V29, P193
   ROHREN EM, 2004, RADIOLOGY, V231, P305, DOI 10.1148/radiol.2312021185
   ROSELL R, 2004, J CLIN ONCOL, V22, P1171, DOI 10.1200/JCO.2004.01.904
   SAMPATH L, 2007, J NUCL MED, V48, P1501, DOI 10.2967/jnumed.107.042234
   SLAMON DJ, 2001, NEW ENGL J MED, V344, P783
   TANG Y, 2005, NUCL MED BIOL, V32, P51, DOI
   10.1016/j.nucmedbio.204.08.003
   TATEISHI M, 1991, BRIT J CANCER, V63, P130
   TOKUNAGA E, 2006, INT J CLIN ONCOL, V11, P199
   TSAI CM, 1993, J NATL CANCER I, V85, P897
   TUBBS RR, 2001, J CLIN ONCOL, V19, P2714
   ZINNER RG, 2004, LUNG CANCER-J IASLC, V44, P99, DOI
   10.1016/j.lungcan.2003.09.026
NR 35
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2010
VL 101
IS 4
BP 1045
EP 1050
PG 6
SC Oncology
GA 571CK
UT ISI:000275728200031
ER

PT J
AU Tamaki, K
   Sasano, H
   Maruo, Y
   Takahashi, Y
   Miyashita, M
   Moriya, T
   Sato, Y
   Hirakawa, H
   Tamaki, N
   Watanabe, M
   Ishida, T
   Ohuchi, N
AF Tamaki, Kentaro
   Sasano, Hironobu
   Maruo, Yohei
   Takahashi, Yayoi
   Miyashita, Minoru
   Moriya, Takuya
   Sato, Yasufumi
   Hirakawa, Hisashi
   Tamaki, Nobumitsu
   Watanabe, Mika
   Ishida, Takanori
   Ohuchi, Noriaki
TI Vasohibin-1 as a potential predictor of aggressive behavior of ductal
   carcinoma in situ of the breast
SO CANCER SCIENCE
LA English
DT Article
ID NEGATIVE FEEDBACK REGULATOR; ANGIOGENESIS INHIBITOR; TUMOR
   ANGIOGENESIS; ENDOTHELIAL-CELLS; GROWTH-FACTOR; CANCER; EXPRESSION;
   BEVACIZUMAB; PATTERNS; GRADE
AB Vasohibin-1 is a recently identified negative feedback regulator of
   angiogenesis induced by VEGF-A and bFGF. In this study, we first
   evaluated mRNA expression of vasohibin-1 and CD31 in 39 Japanese female
   breast carcinoma specimens including 22 invasive ductal carcinoma (IDC)
   and 17 ductal carcinoma in situ (DCIS) using a real-time quantitative
   RT-PCR (QRT-PCR) with LightCycler system. In addition, we also
   immunolocalized vasohibin-1 and CD31 and compared their
   immunoreactivity to nuclear grades and histological grades of 100
   carcinoma cases (50 IDC and 50 DCIS). There were no statistically
   significant differences of CD31 mRNA expression and the number of CD31
   positive vessels between DCIS and IDC (P = 0.250 and P = 0.191,
   respectively), whereas there was a statistically significant difference
   in vasohibin-1 mRNA expression and the number of vasohibin-1 positive
   vessels in DCIS and IDC (P = 0.022 and P <= 0.001, respectively). There
   was a significant positive correlation between vasohibin-1 mRNA level
   and Ki-67 labeling index in DCIS (r(2) = 0.293, P <= 0.001). In
   addition, vasohibin-1 mRNA expression was correlated with high nuclear
   and histological grades in DCIS cases and a significant positive
   correlation was detected between the number of vasohibin-1 positive
   vessels and Ki-67 labeling index or nuclear grade or Van Nuys
   classification of carcinoma cells (P <= 0.001, respectively). These
   results all indicate the possible correlation between aggressive
   biological features in DCIS including increased tumor cell
   proliferation and the status of neovascularization determined by
   vasohibin-1 immunoreactivity. (Cancer Sci 2010; 101: 1051-1058) (Cancer
   Sci 2010; 101: 1051-1058).
C1 [Moriya, Takuya] Kawasaki Med Univ, Dept Pathol 2, Okayama, Japan.
   [Tamaki, Nobumitsu] Dept Breast Surg, Nahanishi Clin, Okinawa, Japan.
   [Tamaki, Kentaro; Miyashita, Minoru; Ishida, Takanori; Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Surg Oncol, Sendai, Miyagi 980, Japan.
   [Sasano, Hironobu; Maruo, Yohei; Takahashi, Yayoi; Miyashita, Minoru; Watanabe, Mika] Tohoku Univ Hosp, Dept Pathol, Tohoku, Miyagi, Japan.
   [Moriya, Takuya] Kawasaki Med Univ, Dept Pathol 2, Okayama, Japan.
   [Sato, Yasufumi] Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 980, Japan.
   [Hirakawa, Hisashi] Tohoku Kosai Hosp, Dept Surg, Tohoku, Miyagi, Japan.
   [Tamaki, Nobumitsu] Nahanishi Clin, Dept Breast Surg, Okinawa, Japan.
RP Tamaki, K, Tohoku Univ, Grad Sch Med, Dept Surg Oncol, Sendai, Miyagi
   980, Japan.
EM nahanisikenta@yahoo.co.jp
FU Japanese Ministry of Health, Labour and Welfare for Researches on
   Intractable Diseases ; Risk Analysis Research on Food and
   Pharmaceuticals ; Development of Multidisciplinary Treatment Algorithm
   with Biomarkers and Modeling of the Decision-making Process with
   Artificial Intelligence for Primary Breast Cancer ; Japanese Ministry
   of Education, Culture, Sports, Science and Technology [18390109];
   Yasuda Medical Foundation 
FX We appreciate Katsuhiko Ono, MT, for his excellent technical
   assistance. This work was partly supported by the grants from the
   Japanese Ministry of Health, Labour and Welfare for Researches on
   Intractable Diseases, Risk Analysis Research on Food and
   Pharmaceuticals, and Development of Multidisciplinary Treatment
   Algorithm with Biomarkers and Modeling of the Decision-making Process
   with Artificial Intelligence for Primary Breast Cancer. This work was
   also partly supported by Grant-in-Aid for Scientific Research
   (18390109) from the Japanese Ministry of Education, Culture, Sports,
   Science and Technology, and the Yasuda Medical Foundation.
CR BERNARD PS, 2002, CLIN CHEM, V48, P1178
   BLUFF JE, 2009, BRIT J CANCER, V101, P666, DOI 10.1038/sj.bjc.6605196
   BUERGER H, 1999, J PATHOL, V189, P521
   CAO Y, 2004, ARCH PATHOL LAB MED, V128, P893
   CHAPMAN JAW, 2007, BMC CANCER, V7, ARTN 174
   ENGELS K, 1997, J PATHOL, V181, P207
   FERRARA N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FOLKMAN J, 1995, NAT MED, V1, P27
   FOX SB, 2007, BREAST CANCER RES, V9, ARTN 216
   GUIDI AJ, 1994, J NATL CANCER I, V86, P614
   HIDA K, 2004, CANCER RES, V64, P8249
   HOSKIN PJ, 2004, RADIOTHER ONCOL, V72, P159, DOI
   10.1016/j.radonc.2004.03.017
   KAMANGAR F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   KERBEL RS, 2004, J CLIN INVEST, V114, P884, DOI 10.1172/JC1200423153
   KERLIKOWSKE K, 2003, J NATL CANCER I, V95, P1692, DOI
   10.1093/jnci/djg097
   LIGHTFOOT HM, 2004, BREAST CANCER RES TR, V88, P109
   MILLER KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   MOMMERS ECM, 2001, J PATHOL, V194, P327
   NAKAMURA Y, 2006, AM J PATHOL, V169, P362, DOI
   10.2353/ajpath.2006.051351
   NIJSTEN T, 2004, BRIT J DERMATOL, V151, P837, DOI
   10.1111/j.1365-2133.2004.06214.x
   OHTANI S, 2004, MOL CANCER THER, V3, P93
   PAGE DL, 1982, CANCER, V49, P751
   PAVLAKIS K, 2008, BMC CANCER, V8, ARTN 88
   RELF M, 1997, CANCER RES, V57, P963
   RUGO HS, 2004, ONCOLOGIST S1, V9, P43
   SATO Y, 2006, ENDOTHELIUM-J ENDOTH, V13, P147, DOI
   10.1080/1062332060069110
   SATO Y, 2007, ARTERIOSCL THROM VAS, V27, P37, DOI
   10.1161/01.ATV.0000252062.48280.61
   SCHWARTZ GF, 1997, CANCER, V80, P1798
   SHEN KL, 1998, CANCER, V82, P2373
   SHIMIZU K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI
   10.1016/j.bbrc.2004.12.073
   SONODA H, 2006, BIOCHEM BIOPH RES CO, V342, P640, DOI
   10.1016/j.bbrc.2006.01.185
   SUZUKI T, 2004, CANCER RES, V64, P4670
   TAMAKI K, 2009, CANCER SCI, V100, P88, DOI
   10.1111/j.1349-7006.2008.01015.x
   TEO NB, 2003, EUR J CANCER, V39, P38
   WATANABE K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   WEDAM SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645
   WEIDNER N, 1991, NEW ENGL J MED, V324, P1
   WEIDNER N, 1992, J NATL CANCER I, V84, P1875
   WILLIAMS NS, 2003, CLIN CANCER RES, V9, P931
   WITTWER CT, 1997, BIOTECHNIQUES, V22, P176
   WULFING P, 2005, BRIT J CANCER, V92, P1720, DOI 10.1038/sj.bjc.6602567
   YOSHINAGA K, 2008, CANCER SCI, V99, P914, DOI
   10.1111/j.1349-7006.2008.00777.x
NR 42
TC 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2010
VL 101
IS 4
BP 1051
EP 1058
PG 8
SC Oncology
GA 571CK
UT ISI:000275728200032
ER

PT J
AU Zhao, JX
   Ji, WQ
   Wu, J
   Chen, XH
   Cheng, XN
   Wang, JW
   Pang, YH
   Liu, SH
   Yang, QH
AF Zhao, Ji-Xin
   Ji, Wan-Quan
   Wu, Jun
   Chen, Xin-Hong
   Cheng, Xue-Ni
   Wang, Jian-Wei
   Pang, Yu-Hui
   Liu, Shu-Hui
   Yang, Qun-Hui
TI Development and identification of a wheat-Psathyrostachys huashanica
   addition line carrying HMW-GS, LMW-GS and gliadin genes
SO GENETIC RESOURCES AND CROP EVOLUTION
LA English
DT Article
DE Disomic addition line; GISH; PAGE; Psathyrostachys huashanica; Triticum
   aestivum
ID GLUTENIN SUBUNIT GENES; STORAGE PROTEINS; CHROMOSOMAL LOCATION; ALLELIC
   VARIATION; AGROPYRON-ELONGATUM; TRITICUM-AESTIVUM; COMMON WHEAT; BREAD
   WHEAT; STRIPE-RUST; SDS-PAGE
AB Psathyrostachys huashanica Keng, in the family Poaceae, subtribe
   Triticeae is an endangered and endemic species of China. It is
   characterized as Shaanxi, drought tolerant and fungus and disease
   resistant. In this paper, a wheat (Triticum aestivum L.)-P. huashanica
   disomic addition line "H9021-28-5" was developed using cytogenetics
   methods including SDS-PAGE, A-PAGE, and GISH. These investigations
   revealed that the chromosome number and configuration of "H9021-28-5"
   were 2n = 44 = 22 II. The mitotic and meiotic GISH analysis indicated
   that "H9021-28-5" contained 42 wheat chromosomes and a pair of P.
   huashanica chromosomes. The SDS-PAGE and A-PAGE analysis showed that
   "H9021-28-5" carried the HMW-GS, LMW-GS and gliadin genes of P.
   huashanica. The results suggest that these storage protein genes of P.
   huashanica had been transferred into common wheat. Development of this
   new germplasm is significant for enriching and improving wheat
   resources of storage proteins genes, and for continuing to exploit the
   advantageous genes of P. huashanica.
C1 [Zhao, Ji-Xin; Ji, Wan-Quan; Wu, Jun; Chen, Xin-Hong; Wang, Jian-Wei; Pang, Yu-Hui; Liu, Shu-Hui; Yang, Qun-Hui] NW A & F Univ, Coll Agron, Yangling 712100, Shaanxi, Peoples R China.
   [Cheng, Xue-Ni] NW A & F Univ, Coll Life Sci, Yangling 712100, Shaanxi, Peoples R China.
RP Chen, XH, NW A & F Univ, Coll Agron, Yangling 712100, Shaanxi, Peoples
   R China.
EM cxh2089@126.com
FU National Natural Science Foundation of China ; Ministry of Education
   [NCET-06-0862]; Major Innovation Project for Science and Technology of
   Shaanxi Province [2008ZDKG-07, 2008ZDGC-02]
FX The authors thank Prof. Song Wei-ning and Dr. Zhang Xiao-ke at
   Northwest A & F University for critically reviewing the manuscript.
   This research was supported by the National Natural Science Foundation
   of China (No. 30771345), 'New Century Talents Support Scheme' project
   from Ministry of Education (No. NCET-06-0862), and '13115' Major
   Innovation Project for Science and Technology of Shaanxi Province (No.
   2008ZDKG-07, 2008ZDGC-02).
CR *CHIN NAT FOR BUR, 1999, LIST CHIN URG PROT W
   *I BOT BOR OCC AC, 1976, FLOR TSINL, V1, P99
   AHMAD M, 2000, THEOR APPL GENET, V101, P892
   ALKHIMOVA AG, 1999, CHROMOSOME RES, V7, P205
   AMIOUR N, 2002, J CEREAL SCI, V35, P149
   BRANLARD G, 2001, EUPHYTICA, V119, P59
   CAO ZJ, 2008, PLANT SCI, V174, P544, DOI 10.1016/j.plantsci.2008.02.007
   CHEN SY, 1991, ACTA GENET SIN, V18, P508
   CHEN SY, 1996, ACTA GENET SINICA, V23, P447
   DEPACE C, 2001, EUPHYTICA, V117, P67
   DEWEY DR, 1984, GENE MANIPULATION PL, P209
   DRISCOLL CS, 1971, AGR ABSTR, V6
   FENG DS, 2004, THEOR APPL GENET, V110, P136, DOI
   10.1007/s00122-004-1810-x
   GUPTA RB, 1994, J CEREAL SCI, V19, P19
   HE MY, 1988, SCI CHINA SER B, V11, P1161
   ISLAM AKMR, 2000, EUPHYTICA, V111, P145
   KANG HY, 2009, PLANT BREEDING, V128, P36, DOI
   10.1111/j.1439-0523.2008.01542.x
   KHAN K, 1985, CEREAL CHEM, V62, P310
   LI WJ, 1996, PLANT SYST EVOL, V202, P265
   LUO Z, 2005, THEOR APPL GENET, V111, P272, DOI 10.1007/s00122-005-2021-9
   MCINTOSH RA, 1996, EUPHYTICA, V89, P395
   MONTEBOVE L, 1987, THEOR APPL GENET, V73, P836
   PAYNE PI, 1984, PHILOS T R SOC B, V304, P359
   PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141
   PAYNE PI, 1987, BIOCHEM GENET, V25, P53
   SHANG HY, 2005, RUSS J GENET+, V41, P1372
   SHARMA HC, 1983, EUPHYTICA, V32, P17
   SHEWRY PR, 1983, HEREDITY, V50, P179
   SHEWRY PR, 2002, J EXP BOT, V53, P947
   SINGH NK, 1991, J CEREAL SCI, V14, P203
   SUN GL, 1992, ACTA GENET SIN, V19, P322
   SUN X, 2006, THEOR APPL GENET, V113, P631, DOI 10.1007/s00122-006-0327-x
   WANG L, 2006, BIOCHEM SYST ECOL, V34, P310, DOI
   10.1016/j.bse.2005.09.009
   WANG RRC, 1987, GENOME, V29, P811
   WANG RRC, 1994, P 2 INT TRIT S LOG U, P29
   WU J, 2007, J AGR U HEBEI, V30, P9
   WU J, 2007, J NW A F U NAT SCI E, V35, P45
   XU H, 2004, ACTA BOT SIN, V46, P595
   YAN YM, 2003, EUPHYTICA, V130, P377
   YAN ZH, 2006, GENETICA, V127, P267, DOI 10.1007/s10709-005-4824-7
   ZHANG HB, 1991, AM J BOT, V78, P871
   ZHAO JX, 2003, J NW SCI TECH U AGR, V31, P1
   ZHAO JX, 2004, J NW SCI TECH U AGR, V32, P105
   ZHENG Q, 2006, EUPHYTICA, V152, P51, DOI 10.1007/s10681-006-9176-6
NR 44
TC 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-9864
J9 GENET RESOUR CROP EVOLUTION
JI Genet. Resour. Crop Evol.
PD MAR
PY 2010
VL 57
IS 3
BP 387
EP 394
DI 10.1007/s10722-009-9477-4
PG 8
SC Agronomy; Plant Sciences
GA 567QC
UT ISI:000275460700010
ER

PT J
AU Zhang, C
   Wang, YS
   Wu, H
   Zhang, ZX
   Cai, Y
   Hou, HY
   Zhao, W
   Yang, XM
   Ma, JX
AF Zhang, C.
   Wang, Y-S
   Wu, H.
   Zhang, Z-X
   Cai, Y.
   Hou, H-Y
   Zhao, W.
   Yang, X-M
   Ma, J-X
TI Inhibitory efficacy of hypoxia-inducible factor 1 alpha short hairpin
   RNA plasmid DNA-loaded poly (D, L-lactide-co-glycolide) nanoparticles
   on choroidal neovascularization in a laser-induced rat model
SO GENE THERAPY
LA English
DT Article
DE poly (D, L-lactic/glycolic acid) nanoparticles; plasmid DNA; RNA
   interference; hypoxia-inducible factor 1 alpha
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR;
   SHORT-INTERFERING RNAS; HUMAN RPE CELLS; MACULAR DEGENERATION;
   MAMMALIAN-CELLS; GENE DELIVERY; TARGETING HIF-1-ALPHA; DRUG-DELIVERY;
   BLOOD-FLOW
AB The aim of this study was to evaluate the possibility of poly (D,
   L-lactide-co-glycolide) nanoparticle (NPs) as a gene vector for
   functional plasmid DNA (pDNA) and to investigate its inhibitory
   efficacy on experimental choroidal neovascularization (CNV). We
   developed intravitreal administered, hypoxia-inducible factor 1 alpha
   (HIF-1 alpha) short hairpin RNA and green fluorescent protein (GFP)
   co-expressed pDNA-loaded NPs (pshHIF-1 alpha NPs). CNV was induced by
   laser photocoagulation in 112 rats. The rats were then randomly
   assigned to be injected intravitreally with phosphate-buffered saline
   (PBS), blank NPs, naked pDNA, control pDNA NPs and pshHIF-1 alpha NPs,
   respectively, and non-injection group was set as the control.
   Immunofluorescence staining, fluorescein fundus angiography and
   histologic analysis were performed to evaluate the inhibitory efficacy
   on CNV. The results showed that the expression of GFP preferentially
   localized in the retinal pigment epithelium cell layer and lasted for 4
   weeks. The fluorescein leakage areas of CNV were significantly larger
   in the PBS, blank NPs, control pDNA NPs, non-injection group and naked
   pDNA group than in pshHIF-1 alpha NPs group (P<0.01). The mean
   thickness of the CNV lesions in the intravitreally pshHIF-1 alpha
   NPs-treated group was significantly smaller than other groups (P<0.01).
   No signs of functional or ultrastructural destruction in retina were
   detected. Therefore, pshHIF-1a NPs may act as a novel therapeutic
   option to transfer specific pDNA and inhibit the formation of
   experimental CNV. Gene Therapy (2010) 17, 338-351;
   doi:10.1038/gt.2009.158; published online 24 December 2009
C1 [Zhang, C.; Wang, Y-S; Wu, H.; Zhang, Z-X; Cai, Y.; Hou, H-Y; Zhao, W.; Yang, X-M; Ma, J-X] Fourth Mil Med Univ, Xijing Hosp, Inst Ophthalmol Chinese PLA, Dept Ophthalmol, Xian 710032, Peoples R China.
RP Wang, YS, Fourth Mil Med Univ, Xijing Hosp, Inst Ophthalmol Chinese
   PLA, Dept Ophthalmol, Xian 710032, Peoples R China.
EM wangys@fmmu.edu.cn
   wuhxa@yahoo.com.cn
FU National Natural Science Foundation of China [30371516, 30672291];
   Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry, China ; Alexander Von Humboldt
   Foundation in Germany [V8151/02085]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 30371516, No. 30672291) and the Scientific
   Research Foundation for the Returned Overseas Chinese Scholars, State
   Education Ministry, China (2004). The project was sponsored partly by
   the equipment donation from the Alexander Von Humboldt Foundation in
   Germany (to YSW, V8151/02085).
CR AIELLO LP, 2005, NEW ENGL J MED, V353, P839
   ARJAMAA O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   AUKUNURU JV, 2003, J PHARM PHARMACOL, V55, P1199, DOI
   10.1211/0022357021701
   BARTLETT DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   BEJJANI R, 2005, MOL VIS, V11, P124
   BIRCH DG, 2007, INT J NANOMED, V2, P65
   BOURGES JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI
   10.1167/iovs.02-1068
   BRESSLER NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRUMMELKAMP TR, 2002, SCIENCE, V296, P550
   CAMPA C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI
   10.1167/iovs.07-1194
   CAMPOCHIARO PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   CAPLEN NJ, 2001, P NATL ACAD SCI USA, V98, P9742
   CERADINI DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   CHECK E, 2005, NAT MED, V11, P243, DOI 10.1038/nm0305-243
   CHENG TL, 2007, METH MOL B, V408, P223
   COHEN H, 2000, GENE THER, V7, P1896
   DAS A, 2003, PROG RETIN EYE RES, V22, P721, DOI
   10.1016/j.perteyeres.2003.08.001
   DUNNE M, 2003, J CONTROL RELEASE, V92, P209, DOI
   10.1016/S0168-3659(03)00304-3
   DUVVURI S, 2005, J CONTROL RELEASE, V108, P282, DOI
   10.1016/j.jconrel.2005.09.002
   ELBASHIR SM, 2001, NATURE, V411, P494
   FERRARA N, 2006, RETINA-J RET VIT DIS, V26, P859
   GIORDANO GG, 1997, J BIOMED MATER RES, V34, P87
   GROSSNIKLAUS HE, 2002, MOL VIS, V8, P119
   GRUNWALD JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   GRUNWALD JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI
   10.1167/iovs.04-1050
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385
   HANNON GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HEDLEY ML, 1998, NAT MED, V4, P365
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213
   HYON SH, 2000, YONSEI MED J, V41, P720
   INOUE Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI
   10.1136/bjo.2006.111583
   JAIN RA, 2000, EUR J PHARM BIOPHARM, V50, P257
   KENT D, 2003, MOL VIS, V9, P747
   KIMURA H, 1994, CURR EYE RES, V13, P353
   KINOSE F, 2005, MOL VIS, V11, P366
   KVANTA A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   KWAK N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LOPEZ PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MALIYEKKEL A, 2006, CELL CYCLE, V5, P2390
   MARTIN G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI
   10.1007/s00417-003-0838-y
   MCANUFF MA, 2007, J PHARM SCI-US, V96, P2922, DOI 10.1002/jps.20968
   MURATA N, 2008, J CONTROL RELEASE, V126, P246, DOI
   10.1016/j.jconrel.2007.11.017
   OGURA Y, 1995, SURV OPHTHALMOL, V39, S17
   OTANI A, 2002, MICROVASC RES, V64, P162
   PANYAM J, 2002, FASEB J, V16, P1217
   PANYAM J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI
   10.1016/S0169-409X(02)00228-4
   RAO DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI
   10.1016/j.addr.2009.04.004
   REICH S, 2003, MOL VIS, V9, P210
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   SAKURAI E, 2001, OPHTHALMIC RES, V33, P31
   SARKS JP, 1997, EYE 4, V11, P515
   SCHLINGEMANN RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI
   10.1007/s00417-003-0828-0
   SCHWESINGER C, 2001, AM J PATHOL, V158, P1161
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447
   SHEN J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHERIDAN CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI
   10.1167/iovs.05-0779
   SHERIDAN CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI
   10.1007/s00417-009-1133-3
   SINGH SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   SONG SJ, 2008, OPHTHAL RES, V40, P35, DOI 10.1159/000111157
   STRAUSS O, 2005, PHYSIOL REV, V85, P845
   SUI GC, 2002, P NATL ACAD SCI USA, V99, P5515
   TOLENTINO MJ, 2004, RETINA-J RET VIT DIS, V24, P132
   TUSCHL T, 1999, GENE DEV, V13, P3191
   VINORES SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   WATTIAUX R, 2000, ADV DRUG DELIVER REV, V41, P201
   WENGER RH, 2002, FASEB J, V16, P1151
   WU L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI
   10.1007/s00417-007-0660-z
   WU MT, 2005, BIOCHEM BIOPH RES CO, V330, P53, DOI
   10.1016/j.bbrc.2005.02.129
   XIA XB, 2008, CURR EYE RES, V33, P892, DOI 10.1080/02713680802416670
   XU JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   YANG XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI
   10.1167/iovs.08-2591
   YASUKAWA T, 2004, CURR EYE RES, V28, P359
   YOSHIDA D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0
   YU JY, 2002, P NATL ACAD SCI USA, V99, P6047
   ZHANG P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   ZHANG P, 2009, GRAEF ARCH CLIN EXP, V247, P633, DOI
   10.1007/s00417-008-1031-0
   ZHAO W, 2008, GRAEF ARCH CLIN EXP, V246, P1413, DOI
   10.1007/s00417-008-0858-8
   ZHU J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
NR 79
TC 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD MAR
PY 2010
VL 17
IS 3
BP 338
EP 351
DI 10.1038/gt.2009.158
PG 14
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 566SE
UT ISI:000275392600005
ER

PT J
AU Krykbaev, R
   Fitz, LJ
   Reddy, PS
   Winkler, A
   Xuan, DJ
   Yang, XK
   Fleming, M
   Wolf, SF
AF Krykbaev, Rustem
   Fitz, Lori J.
   Reddy, Padmalatha S.
   Winkler, Aaron
   Xuan, Dejun
   Yang, Xiaoke
   Fleming, Margaret
   Wolf, Stanley F.
TI Evolutionary and biochemical differences between human and monkey
   acidic mammalian chitinases
SO GENE
LA English
DT Article
DE Acidic Mammalian Chitinase; Ortholog; Pseudoortholog; Pseudogene;
   Macaca gene; Enzyme
ID GLYCOSYL HYDROLASES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE;
   CHITOTRIOSIDASE; INSIGHTS; FAMILY; SITE; RESIDUES; PROTEIN; ASTHMA
AB Acidic mammalian chitinase (AMCase), an enzyme implicated in the
   pathology of asthma, is capable of chitin cleavage at a low pH optimum.
   The corresponding gene (CHIA) can be found in genome databases of a
   variety of mammals, but the enzyme properties of only the human and
   mouse proteins were extensively studied. We wanted to compare enzymes
   of closely related species, such as humans and macaques. In our attempt
   to study macaque AMCase, we searched for CHIA-like genes in human and
   macaque genomes. We found that both genomes contain several additional
   CHIA-like sequences. In humans, CHIA-L1 (hCHIA-L1) is an apparent
   pseudogene and has the highest homology to CHIA. To determine which of
   the two genes is functional in monkeys, we assessed their tissue
   expression levels. In our experiments, CHIA-L1 expression was not
   detected in human stomach tissue, while CHIA was expressed at high
   levels. However in the, cynomolgus macaque stomach tissue, the
   expression pattern of these two genes was reversed: CHIA-L1 was
   expressed at high levels and CHIA was undetectable. We hypothesized
   that in macaques CHIA-L1 (mCHIAL1), and not CHIA, is a gene encoding an
   acidic chitinase, and cloned it, using the sequence of human CHIA-Ll as
   a guide for the primer design. We named the new enzyme MACase (Macaca
   Acidic Chitinase) to emphasize its differences from AMCase. MACase
   shares a similar tissue expression pattern and pH optimum with human
   AMCase, but is 50 times more active in our enzymatic activity assay.
   DNA sequence of the mCHIA-L1 has higher percentage identity to the
   human pseudogene hCHIA-L1 (91.7%) than to hCHIA (84%). Our results
   suggest alternate evolutionary paths for human and monkey acidic
   chitinases. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Krykbaev, Rustem; Fitz, Lori J.; Winkler, Aaron; Xuan, Dejun; Yang, Xiaoke; Fleming, Margaret; Wolf, Stanley F.] Pfizer Biotherapeut Res & Dev, Dept Inflammat & Immunol, Cambridge, MA 02140 USA.
   [Reddy, Padmalatha S.] Pfizer Biotherapeut Res & Dev, Dept Global Biotherapeut Technol, Cambridge, MA 02140 USA.
RP Krykbaev, R, Pfizer Biotherapeut Res & Dev, Dept Inflammat & Immunol,
   200 CambridgePk Dr, Cambridge, MA 02140 USA.
EM rkrykbaev@wyeth.com
   lfitz@wyeth.com
   preddy@wyeth.com
   awinkler@wyeth.com
   dxuan@wyeth.com
   xyang@wyeth.com
   mfleming@wyeth.com
   swolf@wyeth.com
CR BOOT RG, 1995, J BIOL CHEM, V270, P26252
   BOOT RG, 2001, J BIOL CHEM, V276, P6770
   BUSSINK AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846
   CHOU YT, 2006, BIOCHEMISTRY-US, V45, P4444, DOI 10.1021/bi0525977
   COFFMAN RL, 2005, J EXP MED, V201, P1875, DOI 10.1084/jem.20050901
   COULSON AFW, 1994, FEBS LETT, V354, P41
   FOLLETTIE MT, 2006, PHARMACOGENOMICS J, V6, P141, DOI
   10.1038/sj.tpj.6500357
   FUNKHOUSER JD, 2007, BMC EVOL BIOL, V7, ARTN 96
   FUSETTI F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200
   GE LM, 1997, BIOTECHNIQUES, V22, P28
   GIBBS RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247
   HENRISSAT B, 1993, BIOCHEM J, V293, P781
   HERRERAESTRELLA A, 1999, EXS, V87, P171
   HO SN, 1989, GENE, V77, P51
   HOUSTON DR, 2003, J BIOL CHEM, V278, P30206, DOI 10.1074/jbc.M303371200
   KOGA D, 1999, EXS, V87, P111
   KOONIN EV, 2005, ANNU REV GENET, V39, P309, DOI
   10.1146/annurev.genet.39.073003.114725
   OLLAND AM, 2009, PROTEIN SCI, V18, P569, DOI 10.1002/pro.63
   OSHIMA H, 2002, ZOOL SCI, V19, P293
   PALLI SR, 1999, EXS, V87, P85
   REESE TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746
   RENKEMA GH, 1995, J BIOL CHEM, V270, P2198
   SAITO A, 1999, GENE, V239, P325
   SEIBOLD MA, 2009, J BIOL CHEM, V284, P19650, DOI 10.1074/jbc.M109.012443
   SUN YJ, 2001, J BIOL CHEM, V276, P17507
   SYNSTAD B, 2004, EUR J BIOCHEM, V271, P253, DOI
   10.1046/j.1432-1033.2003.03923.x
   TJOELKER LW, 2000, J BIOL CHEM, V275, P514
   VANAALTEN DMF, 2001, P NATL ACAD SCI USA, V98, P8979
   WIRTH SJ, 1992, SOIL BIOL BIOCHEM, V24, P511
   ZHENG T, 2005, GENE, V357, P37, DOI 10.1016/j.gene.2005.05.006
   ZHU Z, 2004, SCIENCE, V304, P1678
NR 31
TC 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAR 1
PY 2010
VL 452
IS 2
BP 63
EP 71
DI 10.1016/j.gene.2009.12.005
PG 9
SC Genetics & Heredity
GA 566GY
UT ISI:000275359300003
ER

PT J
AU Wang, ZT
   Li, XY
   Li, ZY
   Yang, L
   Sasaki, Y
   Wang, S
   Zhou, LM
   Araki, S
   Mezawa, M
   Takai, H
   Ogata, Y
AF Wang, Zhitao
   Li, Xinyue
   Li, Zhengyang
   Yang, Li
   Sasaki, Yoko
   Wang, Shuang
   Zhou, Liming
   Araki, Shouta
   Mezawa, Masaru
   Takai, Hideki
   Ogata, Yorimasa
TI Effects of inorganic polyphosphate on bone sialoprotein gene expression
SO GENE
LA English
DT Article
DE Bone sialoprotein; Inorganic polyphosphate; Osteoblasts; Transcription
ID RAT BSP GENE; CELL-FREE SYSTEM; RESPONSE ELEMENT; PHOSPHATIDYLINOSITOL
   3-KINASE; OSTEOBLAST DIFFERENTIATION; PROXIMAL PROMOTER;
   GROWTH-FACTORS; MESSENGER-RNA; HUMAN BREAST; IN-VITRO
AB Inorganic polyphosphate (poly(P)) is a biopolymer existing in almost
   all cells and tissues. The biological functions of poly(P) in
   micro-organisms have been extensively investigated in studies of
   poly(P) in eukaryotic cells, especially osteoblasts, and are
   increasing. Bone sialoprotein (BSP) is thought to function in bone
   mineralization, and is selectively expressed by differentiated
   osteoblasts. In this study, application of sodium phosphate glass type
   25 (SPG25, 12.5 and 125 mu M) increased BSP mRNA levels at 12 h in
   osteoblast-like ROS 17/2.8 cells. In transient transfection assay, 12.5
   and 125 mu M SPG25 increased luciferase activities of the constructs
   pLUC3 (-116 to +60), pLUC4 (-425 to +60), pLUC5 (-801 to +60) and pLUC6
   (-938 to +60). Introduction of 2 bp mutations to the luciferase
   constructs showed that the effects of SPG25 were mediated by a FGF2
   response element (FRE) and a homeodomain protein binding site (HOX).
   Luciferase activities induced by SPG25 were blocked by tyrosine kinase
   inhibitor herbimycine A. MAP kinase kinase inhibitor U0126,
   PI3-kinase/Akt inhibitor LY249002 and inorganic phosphate transport
   inhibitor foscarnet. Gel shift analyses showed that both 12.5 and 125
   mu M SPG25 increased nuclear protein binding to FRE and HOX elements.
   These studies demonstrate that SPG25 stimulates BSP transcription by
   targeting FRE and HOX elements in the proximal promoter of the rat BSP
   gene. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Wang, Zhitao; Li, Xinyue; Li, Zhengyang; Yang, Li; Sasaki, Yoko; Wang, Shuang; Zhou, Liming; Araki, Shouta; Mezawa, Masaru; Takai, Hideki; Ogata, Yorimasa] Nihon Univ, Sch Dent Matsudo, Dept Periodontol, Chiba 2718587, Japan.
   [Wang, Zhitao; Li, Xinyue; Li, Zhengyang; Yang, Li] Tianjin Stomatol Hosp, Tianjin, Peoples R China.
   [Wang, Shuang] Tianjin Med Univ, Stomatol Coll, Tianjin, Peoples R China.
   [Takai, Hideki; Ogata, Yorimasa] Nihon Univ, Sch Dent Matsudo, Res Inst Oral Sci, Chiba 2718587, Japan.
RP Ogata, Y, Nihon Univ, Sch Dent Matsudo, Dept Periodontol, Chiba
   2718587, Japan.
EM ogata.yorimasa@nihon-u.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology (MEXT)
   [20082012]; Nihon University Multidisciplinary Research [2009-2010]
FX This work was supported in part by a Grant from the Supporting Project
   for Strategic Research in Private Universities by the Ministry of
   Education, Culture, Sports, Science, and Technology (MEXT), 20082012,
   and Nihon University Multidisciplinary Research Grant for 2009-2010.
CR BELLAHCENE A, 1994, CANCER RES, V54, P2823
   BELLAHCENE A, 1997, CALCIFIED TISSUE INT, V61, P183
   BELLAHCENE A, 1998, THYROID, V8, P641
   BENSON MD, 1999, J BONE MINER RES, V14, P396
   BENSON MD, 2000, J BIOL CHEM, V275, P13907
   BROWN MRW, 2004, P NATL ACAD SCI USA, V101, P16085, DOI
   10.1073/pnas.0406909101
   FATHERAZI S, 2009, J DENT RES, V88, P39, DOI 10.1177/0022034508328072
   FLEISCH H, 1995, BISPHOSPHONATES BONE, P176
   FOSTER BL, 2006, CALCIFIED TISSUE INT, V78, P103, DOI
   10.1007/s00223-005-0184-7
   FUJITA T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   GANSS B, 1999, CRIT REV ORAL BIOL M, V10, P79
   GHOSHCHOUDHURY N, 2002, J BIOL CHEM, V277, P33361, DOI
   10.1074/jbc.M205053200
   HACCHOU Y, 2007, J DENT RES, V86, P893
   HAN KY, 2007, BIOCHEM J 1, V406, P49, DOI 10.1042/BJ20061542
   HASSAN MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074//jbc.M604508200
   ITOH H, 2006, J MICROBIOL METH, V64, P241, DOI
   10.1016/j.mimet.2005.05.003
   KALIMAN P, 1996, J BIOL CHEM, V271, P19146
   KAWAZOE Y, 2004, J DENT RES, V83, P613
   KAWAZOE Y, 2008, INT J BIOL SCI, V4, P37
   KERR JM, 1993, GENOMICS, V17, P408
   KIM RH, 1994, MATRIX BIOL, V14, P31
   KIM RH, 1999, CANCER RES, V59, P565
   KITAOKA Y, 1996, J BIOTECHNOL, V48, P1
   KIYOSHIMA T, 2002, GENE, V299, P205
   KOMORI T, 1997, CELL, V89, P755
   KORNBERG A, 1995, J BACTERIOL, V177, P491
   KULAEV I, 1999, J BIOSCI BIOENG, V88, P111
   LEYHAUSEN G, 1998, J BONE MINER RES, V13, P803
   LI JJ, 1993, BIOCHEM J, V289, P625
   LI JJ, 1995, BIOCHEM J 1, V310, P33
   LIEBERMAN JR, 2002, J BONE JOINT SURG  A, V84, P1032
   MCINERNEY P, 2006, MOL MICROBIOL, V60, P438, DOI
   10.1111/j.1365-2958.2006.05103.x
   NAKASHIMA K, 2002, CELL, V108, P17
   NAKAYAMA Y, 2006, J CELL PHYSIOL, V208, P326, DOI 10.1002/jcp.20664
   NEWBERRY EP, 1998, BIOCHEMISTRY-US, V37, P16360
   OGATA Y, 1995, EUR J BIOCHEM, V230, P183
   OGATA Y, 1997, J CELL BIOCHEM, V65, P501
   OGATA Y, 2000, MATRIX BIOL, V19, P395
   OGATA Y, 2008, J PERIODONTAL RES, V43, P127, DOI
   10.1111/j.1600-0765.2007.01014.x
   PENG XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   SAKAUE H, 1998, J BIOL CHEM, V273, P28945
   SAMEE N, 2007, CRIT REV EUKAR GENE, V17, P173
   SAMOTO H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200
   SCHRODER HC, 1999, PROG MOL SUBCELL BIO, V23, P45
   SCHRODER HC, 2000, BIOCHEMISTRY-MOSCOW, V65, P353
   SHIBA T, 2000, BIOCHEMISTRY-MOSCOW+, V65, P315
   SHIBA T, 2003, J BIOL CHEM, V278, P26788, DOI 10.1074/jbc.M303468200
   SHIBA T, 2004, KEY ENG MAT, V254, P1119
   SHIMIZU E, 2006, BONE, V39, P42, DOI 10.1016/j.bone.2005.12.011
   SHIMIZUSASAKI E, 2001, J BIOL CHEM, V276, P5459
   SHIRAKABE K, 2001, GENES CELLS, V6, P851
   TYE CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200
   UEDA T, 1991, NUCLEIC ACIDS RES, V19, P547
   WALTREGNY D, 1998, J NATL CANCER I, V90, P1000
   WALTREGNY D, 2000, J BONE MINER RES, V15, P834
   WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235
   YAMAOKA M, 2008, GERODONTOLOGY, V25, P10
   YAMAUCHI M, 1996, MATRIX BIOL, V15, P119
   YUAN Q, 2009, ACTA BIOMATER, V5, P1716, DOI 10.1016/j.actbio.2009.01.034
   YUMI K, 2008, INT J BIOL SCI, V4, P37
NR 60
TC 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAR 1
PY 2010
VL 452
IS 2
BP 79
EP 86
DI 10.1016/j.gene.2009.12.010
PG 8
SC Genetics & Heredity
GA 566GY
UT ISI:000275359300005
ER

PT J
AU Shen, L
   Liu, XW
   Hou, WG
   Yang, GD
   Wu, YS
   Zhang, R
   Li, X
   Che, HL
   Lu, ZF
   Zhang, YQ
   Liu, XP
   Yao, LB
AF Shen, Lan
   Liu, Xuewu
   Hou, Wugang
   Yang, Guodong
   Wu, Yousheng
   Zhang, Rui
   Li, Xia
   Che, Honglei
   Lu, Zifan
   Zhang, Yuanqiang
   Liu, Xinping
   Yao, Libo
TI NDRG2 is highly expressed in pancreatic beta cells and involved in
   protection against lipotoxicity
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE NDRG2; Pancreatic beta cell; Protein kinase Akt; Free fatty acid;
   Apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; DOWNSTREAM-REGULATED GENE-2; NITRIC-OXIDE
   SYNTHASE; FREE FATTY-ACIDS; INDUCED APOPTOSIS; ER STRESS; PROTEIN; AKT;
   TISSUES; CANCER
AB The N-myc downstream-regulated gene 2 (NDRG2) is involved in cell
   differentiation and apoptosis, but its function in the pancreas remains
   to be established. Herein we examine the expression and function of
   NDRG2 in the endocrine pancreas. NDRG2 immunoreactivity was localized
   mainly in the cytoplasm of pancreatic beta cells. When beta-TC3 cells
   were exposed chronically to high levels of free fatty acid (FFA), cell
   viability was impaired, and Akt and NDRG2 phosphorylation were reduced.
   NDRG2 is a potential substrate of protein kinase Akt. Overexpression of
   constitutively active Akt enhanced NDRG2 phosphorylation and abolished
   the apoptosis induced by FFA in beta-TC3 cells, whereas NDRG2
   knock-down attenuated Akt-mediated protection of beta cells against
   fatty acid-triggered apoptosis. Collectively, these data indicate that
   NDRG2 acts as a key molecule in pancreatic beta cells and is involved
   in the Akt-mediated protection of beta cells against lipotoxicity.
C1 [Shen, Lan; Liu, Xuewu; Yang, Guodong; Wu, Yousheng; Zhang, Rui; Li, Xia; Che, Honglei; Lu, Zifan; Liu, Xinping; Yao, Libo] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem & Mol Biol, Xian 710032, Peoples R China.
   [Hou, Wugang; Zhang, Yuanqiang] Fourth Mil Med Univ, Dept Histol & Embryol, Xian 710032, Peoples R China.
   [Hou, Wugang] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol, Xian 710032, Peoples R China.
RP Yao, LB, Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem &
   Mol Biol, 17 Chang Le W Rd, Xian 710032, Peoples R China.
EM lanshen@fmmu.edu.cn
   bioyao@fmmu.edu.cn
FU National Natural Science Foundation of China [30600314, 30670303,
   30830054, 30801309, 30170465]
FX This work was supported by grants from the National Natural Science
   Foundation of China (nos. 30600314, 30670303, 30830054, 30801309 and
   30170465). We thank members of our laboratory for helpful discussions.
CR AIKIN R, 2006, DIABETOLOGIA, V49, P2900, DOI 10.1007/s00125-006-0476-0
   BURCHFIELD JG, 2004, J BIOL CHEM, V279, P18623, DOI
   10.1074/jbc.M401504200
   BUTEAU J, 2004, DIABETOLOGIA, V47, P806, DOI 10.1007/s00125-004-1379-6
   CHEN B, 2006, J BIOL CHEM, V281, P2764, DOI 10.1074/jbc.M507330200
   CHOI SC, 2007, EXP MOL MED, V39, P705
   DAI FHF, 2006, J BIOL CHEM, V281, P21942, DOI 10.1074/jbc.M512921200
   DENG YC, 2001, PROG BIOCHEM BIOPHYS, V28, P72
   DENG YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228
   FOLETTA VC, 2009, J PHYSIOL-LONDON, V587, P1619, DOI
   10.1113/jphysiol.2008.167882
   HAN Z, 2007, J EXP CLIN CANC RES, V26, P261
   HU XL, 2006, ACTA PHYSIOL SIN, V58, P331
   HU XL, 2006, CELL TISSUE RES, V325, P67, DOI 10.1007/s00441-005-0137-5
   JEFFREY KD, 2008, P NATL ACAD SCI USA, V105, P8452, DOI
   10.1073/pnas.0711232105
   KHARROUBI I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478
   LACHAT P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI
   10.1007/s00418-002-0460-9
   LAYBUTT DR, 2007, DIABETOLOGIA, V50, P752, DOI 10.1007/s00125-006-0590-z
   LIU N, 2008, NUCLEIC ACIDS RES, V36, P5335, DOI 10.1093/nar/gkn504
   LIU XP, 2009, APPL BIOCHEM BIOTECH, V152, P306, DOI
   10.1007/s12010-008-8267-3
   MASUOKA HC, 2009, J BIOL CHEM, V284, P30039, DOI 10.1074/jbc.M109.039545
   MELLOUL D, 2002, DIABETOLOGIA, V45, P309
   MITCHELMORE C, 2004, NEUROBIOL DIS, V16, P48, DOI
   10.1016/j.nbd.2004.01.003
   OBRIEN J, 2000, EUR J BIOCHEM, V267, P5421
   OHKI T, 2002, BRAIN RES DEV BRAIN, V135, P55
   PINHASHAMIEL O, 2007, LANCET, V369, P1823
   POITOUT V, 2002, ENDOCRINOLOGY, V143, P339
   QADER SS, 2005, REGUL PEPTIDES, V131, P82, DOI
   10.1016/j.regpep.2005.07.002
   QADER SS, 2007, AM J PHYSIOL-ENDOC M, V292, E1447, DOI
   10.1152/ajpendo.00172.2006
   SHEN L, 2008, NEUROREPORT, V19, P927
   SRINIVASAN S, 2005, DIABETES, V54, P968
   TAKAHASHI K, 2005, NEUROSCI LETT, V388, P157, DOI
   10.1016/j.neulet.2005.06.055
   WANG HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513
   WANG LF, 2008, CELL PHYSIOL BIOCHEM, V21, P239
   WANG XL, 2006, DIABETES, V55, P2301, DOI 10.2337/db05-1574
   WIELPUTZ MO, 2007, J BIOL CHEM, V282, P28264, DOI 10.1074/jbc.M702168200
   YAO LB, 2008, ACTA BIOCH BIOPH SIN, V40, P625, DOI
   10.1111/j.1745-7270.2008.00434.x
   ZHANG N, 2006, DIABETOLOGIA, V49, P506, DOI 10.1007/s00125-005-0095-1
   ZHANG Y, 2007, J MOL ENDOCRINOL, V38, P651, DOI 10.1677/JME-06-0048
   ZHOUT PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200
NR 38
TC 0
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD APR
PY 2010
VL 67
IS 8
BP 1371
EP 1381
DI 10.1007/s00018-010-0258-1
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 569VZ
UT ISI:000275632100013
ER

PT J
AU Yang, PH
   Xing, L
   Tang, C
   Jia, WH
   Zhao, ZP
   Liu, K
   Gao, X
   Wang, XL
AF Yang, Penghui
   Xing, Li
   Tang, Chong
   Jia, Weihong
   Zhao, Zhongpeng
   Liu, Kun
   Gao, Xiao
   Wang, Xiliang
TI Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split
   vaccine
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE BALB/c mice; influenza; influenza A (H1N1); split vaccine
ID ANIMAL-MODELS; A/H5N1 VACCINE; VIRUS-VACCINE; H5N1 VACCINE;
   IMMUNOGENICITY; SAFETY; ANTIGENS; ANTIBODY; IMMUNITY; FERRETS
AB The novel influenza A (H1N1) 2009 virus has emerged to cause the first
   pandemic of the twenty-first century. Disease outbreaks caused by the
   influenza A (H1N1) virus have prompted concerns about the potential for
   a pandemic and have driven the development of vaccines against this
   subtype of influenza A. In this study, we developed a monovalent
   influenza A (H1N1) split vaccine and evaluated its effects in BALB/c
   mice. Mice were immunized subcutaneously with 2 doses of the vaccine
   containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide
   (Al(OH)(3)) adjuvant. Immunization with varying doses of HA (3.75, 7.5,
   15, 30, 45 or 60 mu g) was performed to induce the production of
   neutralizing antibodies. The vaccine elicited strong hemagglutination
   inhibition (HI) and microneutralization, and addition of the adjuvant
   augmented the antibody response. A preliminary safety evaluation showed
   that the vaccine was not toxic at large doses (0.5 ml containing 60 mu
   g HA+600 pg Al(OH)(3) or 60 mu g HA). Moreover, the vaccine was found
   to be safe at a dose of 120 mu g HA+ 1200 pg Al(OH)(3) or 120 mu g HA
   in 1.0 ml in rats. In conclusion;, the present study provides support
   for the clinical evaluation of influenza A (H1N1) vaccination as a
   public health intervention to mitigate a possible pandemic.
   Additionally, our findings support the further evaluation of the
   vaccine used in this study in primates or humans. Cellular & Molecular
   Immunology (2010) 7, 116-122; doi: 10.1038/cmi.2009.116; published
   online 1 February 2010
C1 [Wang, Xiliang] Beijing Inst Microbiol & Epidemiol, Dept Immunol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
RP Wang, XL, Beijing Inst Microbiol & Epidemiol, Dept Immunol, State Key
   Lab Pathogen & Biosecur, 20 Dongdajie St, Beijing 100071, Peoples R
   China.
EM xiliangw@yahoo.com
FU National Scientific and Technical Supporting Program of China
   [2009CB522102]; National Programs for High Technology Research and
   Development of China [2006AA02Z450]
FX We thank Hualan Vaccine Inc. (Xinxiang, Henan, China) for providing the
   influenza A (H1N1) split vaccine. We are grateful to Dr H. Fen-Tian for
   his critical reading of the manuscript. This work was carried out in
   part with funding from the National Scientific and Technical Supporting
   Program of China (2009CB522102) and National Programs for High
   Technology Research and Development of China (2006AA02Z450). No other
   potential conflict of interest relevant to this article exists.
CR *WHO, 2009, SIT UPD INFL H1N1
   BARNARD DL, 2009, ANTIVIR RES, V82, A110, DOI
   10.1016/j.antiviral.2008.12.014
   BEIGEL JH, 2009, J INFECT DIS, V200, P501, DOI 10.1086/599992
   BRADY RC, 2009, VACCINE, V27, P5091, DOI 10.1016/j.vaccine.2009.06.057
   BUTLER D, 2009, NATURE, V459, P144, DOI 10.1038/459144a
   CHEN ZY, 2009, J VIROL, V83, P65, DOI 10.1128/JVI.01775-08
   CLARK TW, 2009, N ENGL J MED
   COLLIN N, 2009, VACCINE IN PRESS
   COX RJ, 2009, VACCINE, V27, P1889, DOI 10.1016/j.vaccine.2009.01.116
   DAWOOD FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810
   DU N, 2008, VACCINE, V26, P2912, DOI 10.1016/j.vaccine.2008.03.048
   ENSERINK M, 2009, SCIENCE, V324, P702
   GALLI G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI
   10.1073/pnas.0903181106
   HAUGE S, 2009, SCAND J IMMUNOL, V69, P576, DOI
   10.1111/j.1365-3083.2009.02254.x
   HOVDEN AO, 2009, INFLUENZA OTHER RESP, V3, P21
   HUBER VC, 2009, VACCINE, V27, P1192, DOI 10.1016/j.vaccine.2008.12.023
   JIN RZ, 2008, PLOS ONE, V3, ARTN e3933
   KATZ J, 2009, MMWR-MORBID MORTAL W, V58, P521
   MACDONALD N, 2009, VACCINE IN PRESS
   MATSUOKA Y, 2009, CURR PROTOC MICROBIO, CH15
   MICHAELIS M, 2009, MED MICROBIOL IMMUN, V198, P175, DOI
   10.1007/s00430-009-0118-5
   MURAKAMI S, 2008, VACCINE, V26, P6398, DOI 10.1016/j.vaccine.2008.08.053
   NAFFAKH N, 2009, MICROBES INFECT, V11, P725, DOI
   10.1016/j.micinf.2009.05.002
   ROMANOVA J, 2009, PLOS ONE, V4, ARTN e5984
   SHETTY P, 2009, LANCET INFECT DIS, V9, P339
   SMITH GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   SUGUITAN AL, 2006, PLOS MED, V3, P1541, ARTN e360
   TADA Y, 2008, INFLUENZA OTHER RESP, V2, P261, DOI
   10.1111/j.1750-2659.2008.00066.x
   TREANOR JJ, 2006, NEW ENGL J MED, V354, P1343
   TRIPP RA, 2009, CURR TOP MICROBIOL, V333, P397, DOI
   10.1007/978-3-540-92165-3_19
   VAJDY M, 2007, CLIN IMMUNOL, V123, P166, DOI 10.1016/j.clim.2007.01.009
   VANDERLAAN JW, 2008, EXPERT REV VACCINES, V7, P783, DOI
   10.1586/14760584.7.6.783
   WEBSTER RG, 1991, VACCINE, V9, P303
   XIAO WJ, 2008, VACCINE, V26, P5022, DOI 10.1016/j.vaccine.2008.07.028
NR 34
TC 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD MAR
PY 2010
VL 7
IS 2
BP 116
EP 122
DI 10.1038/cmi.2009.116
PG 7
SC Immunology
GA 567AK
UT ISI:000275414400007
ER

PT J
AU Gao, LR
   Xu, RY
   Zhang, NK
   Chen, Y
   Wang, ZG
   Zhu, ZM
   Fei, YX
   Cao, Y
   Xu, HT
   Yang, Y
AF Gao, Lian Ru
   Xu, Ru Yi
   Zhang, Ning Kun
   Chen, Yu
   Wang, Zhi Guo
   Zhu, Zhi Ming
   Fei, Yu Xing
   Cao, Yi
   Xu, Hong Tao
   Yang, Ye
TI Increased Apelin Following Bone Marrow Mononuclear Cell Transplantation
   Contributes to the Improvement of Cardiac Function in Patients With
   Severe Heart Failure
SO CELL TRANSPLANTATION
LA English
DT Article
DE Cell transplantation; Apelin; Heart failure; Paracrine
ID MESENCHYMAL STEM-CELLS; ORPHAN RECEPTOR APJ; MYOCARDIAL-INFARCTION;
   PROGENITOR CELLS; LIGAND; TRANSDIFFERENTIATION; CARDIOMYOCYTES;
   REGENERATION; SECRETION; TRIAL
AB We previously reported that intracoronary implantation of bone marrow
   mononuclear cells (BMMC) into ischemic hearts improved cardiac function
   after myocardial infarction. However, the mechanisms have not been
   elucidated. The present study investigates whether apelin, a newly
   described inotropic peptide with important cardiovascular regulatory
   properties, contributes to the functional improvement in patients with
   severe heart failure after cell transplantation. Forty consecutive
   patients with severe heart failure secondary to myocardial infarction
   were assigned to the BMMC therapy group or the standard medication
   group according to each patient's decision on a signed consent
   document. In 20 patients intracoronary cell infusion was performed, and
   another 20 patients were matched to receive standard medication as
   therapeutic Controls. An additional 20 healthy subjects were designated
   as normal controls. Clinical manifestations, echocardiograms, and
   biochemical assays were recorded. Plasma apelin and brain natriuretic
   protein (BNP) levels were determined by enzyme immunoassay. Baseline
   levels of plasma apelin were significantly lower in all heart failure
   patients compared to normal Subjects. In patients who underwent cell
   transplantation, apelin increased significantly front 3 to 21 days
   after operation, followed by significant improvement in cardiac
   function. In parallel, BNP varied inversely with the increase of
   apelin. In patients receiving standard medical treatment, apelin
   remained at a lower level. Our findings indicated that increased apelin
   levels following cell therapy may act as a paracrine mediator produced
   front BMMCs and play an important role in the treatment of heart
   failure through autocrine and paracrine mechanisms.
C1 [Gao, Lian Ru; Zhang, Ning Kun; Chen, Yu; Wang, Zhi Guo; Zhu, Zhi Ming; Fei, Yu Xing; Cao, Yi; Xu, Hong Tao; Yang, Ye] Navy Gen Hosp, Dept Cardiol, Beijing 100037, Peoples R China.
   [Xu, Ru Yi] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Cardiol, Beijing, Peoples R China.
RP Gao, LR, Navy Gen Hosp, Dept Cardiol, 6 Fucheng Rd, Beijing 100037,
   Peoples R China.
EM lianru@yahoo.com.cn
FU National Advanced Technology Development the Plan of China
   [2006AA02Z469]
FX This study was supported by a grant of the National Advanced Technology
   Development the Plan of China (863 plan) (2006AA02Z469). We thank Dr.
   Joel S. Karliner, Professor of Medicine, University of California San
   Francisco, and Associate Chief of Medicine for Research, Department of
   Veterans Affairs Medical Center, University of California San
   Francisco, USA for valuable comments and helpful suggestions in writing
   and revising this manuscript.
CR ANVERSA P, 2002, NATURE, V415, P240
   BERRY MF, 2004, CIRCULATION, V110, P11187
   CAPLAN AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   CHONG KS, 2006, EUR J HEART FAIL, V8, P355, DOI
   10.1016/j.ejheart.2005.10.007
   DAIA T, 2006, EUR J PHARMACOL, V553, P222
   FOLDES G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI
   10.1016/S0006-291X(03)01424-4
   GAO LR, 2006, AM J CARDIOL, V98, P597, DOI 10.1016/j.amjcard.2006.03.034
   GRUH I, 2006, CIRCULATION, V113, P1326, DOI
   10.1161/CIRCULATIONAHA.105.559005
   JACKSON KA, 2001, J CLIN INVEST, V107, P1395
   JANSSENS S, 2006, LANCET, V367, P113
   JIA YX, 2006, REGUL PEPTIDES, V133, P147, DOI
   10.1016/j.regpep.2005.09.033
   KEVIN JPA, 2007, CELL MOL BIOL, V12, P127
   KLEINZ MJ, 2005, PHARMACOL THERAPEUT, V107, P198
   KOCHER AA, 2001, NAT MED, V7, P430
   MEYER GP, 2006, CIRCULATION, V113, P1287, DOI
   10.1161/CIRCULATIONAHA.105.575118
   NYGREN JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040
   ORLIC D, 2001, NATURE, V410, P701
   RAMOS GA, 2007, CELL TRANSPLANT, V16, P951
   ROLAND E, 2007, DEV BIOL, V305, P599
   RONKAINEN VP, 2007, FASEB J, V21, P1821, DOI 10.1096/fj.06-7294com
   SCHACHINGER V, 2006, NEW ENGL J MED, V355, P1210
   SCOTT IC, 2007, DEV CELL, V12, P403, DOI 10.1016/j.devcel.2007.01.012
   SOLOMON SD, 2005, NEW ENGL J MED, V352, P2581
   SZE SK, 2007, MOL CELL PROTEOMICS, V6, P1680, DOI
   10.1074/mcp.M600393-MCP200
   SZOKODI I, 2002, CIRC RES, V91, P434, DOI
   10.1161/01.RES.0000033522.37861.69
   TATEMOTO K, 1998, BIOCHEM BIOPH RES CO, V251, P471
   XU MF, 2007, J MOL CELL CARDIOL, V42, P441, DOI
   10.1016/j.yjmcc.2006.10.009
   ZENG XXI, 2007, DEV CELL, V12, P391, DOI 10.1016/j.devcel.2007.01.011
   ZIEGELHOEFFER T, 2004, CIRC RES, V94, P230, DOI
   10.1161/01.RES.0000110419.50982.1C
NR 29
TC 4
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2009
VL 18
IS 12
BP 1311
EP 1318
DI 10.3727/096368909X474843
PG 8
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 563PY
UT ISI:000275146400005
ER

PT J
AU Goldberg, AD
   Banaszynski, LA
   Noh, KM
   Lewis, PW
   Elsaesser, SJ
   Stadler, S
   Dewell, S
   Law, M
   Guo, XY
   Li, X
   Wen, DC
   Chapgier, A
   DeKelver, RC
   Miller, JC
   Lee, YL
   Boydston, EA
   Holmes, MC
   Gregory, PD
   Greally, JM
   Rafii, S
   Yang, CW
   Scambler, PJ
   Garrick, D
   Gibbons, RJ
   Higgs, DR
   Cristea, IM
   Urnov, FD
   Zheng, DY
   Allis, CD
AF Goldberg, Aaron D.
   Banaszynski, Laura A.
   Noh, Kyung-Min
   Lewis, Peter W.
   Elsaesser, Simon J.
   Stadler, Sonja
   Dewell, Scott
   Law, Martin
   Guo, Xingyi
   Li, Xuan
   Wen, Duancheng
   Chapgier, Ariane
   DeKelver, Russell C.
   Miller, Jeffrey C.
   Lee, Ya-Li
   Boydston, Elizabeth A.
   Holmes, Michael C.
   Gregory, Philip D.
   Greally, John M.
   Rafii, Shahin
   Yang, Chingwen
   Scambler, Peter J.
   Garrick, David
   Gibbons, Richard J.
   Higgs, Douglas R.
   Cristea, Ileana M.
   Urnov, Fyodor D.
   Zheng, Deyou
   Allis, C. David
TI Distinct Factors Control Histone Variant H3.3 Localization at Specific
   Genomic Regions
SO CELL
LA English
DT Article
ID ZINC-FINGER NUCLEASES; EMBRYONIC STEM-CELLS; REPEAT-CONTAINING RNA;
   ATR-X SYNDROME; MAMMALIAN TELOMERES; SYNDROME PROTEIN; GENE-EXPRESSION;
   POLYMERASE-II; DNA-SYNTHESIS; ES CELLS
AB The incorporation of histone H3 variants has been implicated in the
   epigenetic memory of cellular state. Using genome editing with
   zinc-finger nucleases to tag endogenous H3.3, we report genome-wide
   profiles of H3 variants in mammalian embryonic stem cells and neuronal
   precursor cells. Genome-wide patterns of H3.3 are dependent on amino
   acid sequence and change with cellular differentiation at
   developmentally regulated loci. The H3.3 chaperone Hira is required for
   H3.3 enrichment at active and repressed genes. Strikingly, Hira is not
   essential for localization of H3.3 at telomeres and many transcription
   factor binding sites. Immunoaffinity purification and mass spectrometry
   reveal that the proteins Atrx and Daxx associate with H3.3 in a
   Hira-independent manner. Atrx is required for Hira-independent
   localization of H3.3 at telomeres and for the repression of telomeric
   RNA. Our data demonstrate that multiple and distinct factors are
   responsible for H3.3 localization at specific genomic locations in
   mammalian cells.
C1 [Guo, Xingyi; Zheng, Deyou] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA.
   [Greally, John M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   [Greally, John M.; Zheng, Deyou] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
   [Zheng, Deyou] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA.
   [Goldberg, Aaron D.; Banaszynski, Laura A.; Noh, Kyung-Min; Lewis, Peter W.; Elsaesser, Simon J.; Stadler, Sonja; Allis, C. David] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA.
   [Dewell, Scott] Rockefeller Univ, Genom Resource Ctr, New York, NY 10065 USA.
   [Li, Xuan; Yang, Chingwen] Rockefeller Univ, Gene Targeting Resource Ctr, New York, NY 10065 USA.
   [Law, Martin; Garrick, David; Gibbons, Richard J.; Higgs, Douglas R.] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford OX3 9DS, England.
   [Wen, Duancheng; Rafii, Shahin] Weill Cornell Med Coll, Howard Hughes Med Inst, New York, NY 10065 USA.
   [Wen, Duancheng; Rafii, Shahin] Weill Cornell Med Coll, Ansary Stem Cell Inst, New York, NY 10065 USA.
   [Wen, Duancheng; Rafii, Shahin] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA.
   [Chapgier, Ariane; Scambler, Peter J.] Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England.
   [DeKelver, Russell C.; Miller, Jeffrey C.; Lee, Ya-Li; Boydston, Elizabeth A.; Holmes, Michael C.; Gregory, Philip D.; Urnov, Fyodor D.] Sangamo BioSci, Point Richmond Tech Ctr, Richmond, CA 94804 USA.
   [Cristea, Ileana M.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
RP Zheng, DY, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA.
EM deyou.zheng@einstein.yu.edu
   alliscd@rockefeller.edu
FU National Institutes of Health (NIH) [GM07739, RR00862, RR022220,
   DP1DA026192, GM53122, GM53512]; Damon Runyon Cancer Research Foundation
   ; Rockefeller University ; Starr Foundation ; New York State Department
   of Health [C023046]; Howard Hughes Medical Institute ; Biotechnology
   and Biological Sciences Research Council UK ; British Heart Foundation
   ; Albert Einstein College of Medicine of Yeshiva University 
FX We thank L. Baker, E.M. Duncan, G.G. Wang for critical reading of the
   manuscript, P. Wu, A. Sfeir, and T. de Lange for telomere reagents and
   helpful discussion, P.D. Adams for Hira antibodies, R. Jaenisch for F1
   hybrid male 129SVJae x M. m. castaneus ESCs, G. Almouzni for H3.1 and
   H3.3-FLAG-HA HeLa cells, K. Zhao for sharing his native ChIP-seq
   protocol, E. Moehle for drawing the gene editing schemes, N. Jina of
   the University College London Genomics Core, K.R. Molloy for assistance
   with mass spectrometric analysis, and S. Mazel and A. North of the
   Rockefeller University Flow Cytometry and Bio-Imaging Resource Centers.
   A. D. G. is supported by National Institutes of Health (NIH) Medical
   Scientist Training Program grant GM07739. L. A. B. is a Damon Runyon
   Cancer Research Foundation fellow. This work was funded by
   institutional support from The Rockefeller University and grants from
   the Tri-Institutional Stem Cell Initiative (funded by the Starr
   Foundation), Empire State Stem Cell fund through New York State
   Department of Health contract #C023046, the Howard Hughes Medical
   Institute (S.R.), Biotechnology and Biological Sciences Research
   Council UK and the British Heart Foundation (P.J.S.), startup funds
   from the Albert Einstein College of Medicine of Yeshiva University
   (D.Z.), and NIH grants RR00862, RR022220, DP1DA026192 (I.M.C.),
   GM53122, and GM53512 (C.D.A.). J.C.M., M.C.H., Y.L.L., P.D.G., and
   F.D.U. are full-time employees of Sangamo BioSciences, Inc.
CR AHMAD K, 2002, MOL CELL, V9, P1191
   AZZALIN CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182
   BARSKI A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   BERNSTEIN BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   BERNSTEIN BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   BONNEFOY E, 2007, PLOS GENET, V3, P1991, DOI
   10.1371/journal.pgen.0030182
   BURDON T, 2002, TRENDS CELL BIOL, V12, P432
   CARROLL D, 2008, GENE THER, V15, P1463, DOI 10.1038/gt.2008.145
   CHEN X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   CLOONAN N, 2008, NAT METHODS, V5, P613, DOI 10.1038/nmeth.1223
   CONTI L, 2005, PLOS BIOL, V3, P1594, ARTN e283
   CREYGHTON MP, 2008, CELL, V135, P649, DOI 10.1016/j.cell.2008.09.056
   CRISTEA IM, 2005, MOL CELL PROTEOMICS, V4, P1933, DOI
   10.1074/mcp.M500227-MCP200
   DAURY L, 2006, EMBO REP, V7, P66, DOI 10.1038/sj.embor.7400561
   DEKONING L, 2007, NAT STRUCT MOL BIOL, V14, P997, DOI 10.1038/nsmb1318
   DOYON Y, 2008, NAT BIOTECHNOL, V26, P702, DOI 10.1038/nbt1409
   GARRICK D, 2006, PLOS GENET, V2, P438, ARTN e58
   GASPARMAIA A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212
   GIBBONS RJ, 2008, HUM MUTAT, V29, P796, DOI 10.1002/humu.20734
   GOLDBERG AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   GUENTHER MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   GUTTMAN M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   HAKE SB, 2006, J BIOL CHEM, V281, P559
   HAKE SB, 2006, P NATL ACAD SCI USA, V103, P6428, DOI
   10.1073/pnas.0600803103
   HEINTZMAN ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   HENIKOFF S, 2008, NAT REV GENET, V9, P15, DOI 10.1038/nrg2206
   HENIKOFF S, 2009, GENOME RES, V19, P460, DOI 10.1101/gr.087619.108
   HODL M, 2009, CURR BIOL, V19, P1221, DOI 10.1016/j.cub.2009.05.048
   JANICKI SM, 2004, CELL, V116, P683
   JIN C, 2006, P NATL ACAD SCI USA, V103, P574, DOI
   10.1073/pnas.0509974103
   JIN CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409
   KONEV AY, 2007, SCIENCE, V317, P1087, DOI 10.1126/science.1145339
   LEE TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot2006.98
   LOPPIN B, 2005, NATURE, V437, P1386, DOI 10.1038/nature04059
   LOYOLA A, 2007, TRENDS BIOCHEM SCI, V32, P425, DOI
   10.1016/j.tibs.2007.08.004
   LUKE B, 2009, EMBO J, V28, P2503, DOI 10.1038/emboj.2009.166
   LUO Y, 2009, J AM SOC MASS SPECTR, V21, P34
   MARION RM, 2009, CELL STEM CELL, V4, P141, DOI
   10.1016/j.stem.2008.12.010
   MCSTAY B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI
   10.1146/annurev.cellbio.24.110707.175259
   MESHORER E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017
   MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049
   MIKKELSEN TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   MITO Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637
   MITO Y, 2007, SCIENCE, V315, P1408, DOI 10.1126/science.1134004
   MOEHLE EA, 2007, P NATL ACAD SCI USA, V104, P3055, DOI
   10.1073/pnas.0611478104
   NAKAYAMA T, 2007, GENE DEV, V21, P552, DOI 10.1101/gad.1503407
   PICKETTS DJ, 1996, HUM MOL GENET, V5, P1899
   RAMIREZCARROZZI VR, 2009, CELL, V138, P114, DOI
   10.1016/j.cell.2009.04.020
   RAYGALLET D, 2002, MOL CELL, V9, P1091
   ROBERTS C, 2002, MOL CELL BIOL, V22, P2318
   SAKAI A, 2009, CURR BIOL, V19, P1816, DOI 10.1016/j.cub.2009.09.021
   SAXONOV S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI
   10.1073/pnas.0510310103
   SCHNEIDERMAN JI, 2009, P NATL ACAD SCI USA, V106, P14472, DOI
   10.1073/pnas.0905816106
   SCHOEFTNER S, 2008, NAT CELL BIOL, V10, P228
   SCHONES DE, 2008, CELL, V132, P887
   SCHWARTZ BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805
   SFEIR A, 2009, CELL, V138, P90, DOI 10.1016/j.cell.2009.06.021
   SIEGEL TN, 2009, GENE DEV, V23, P1063, DOI 10.1101/gad.1790409
   SMITH S, 1989, CELL, V58, P15
   STOCK JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663
   SUTCLIFFE EL, 2009, MOL CELL BIOL, V29, P1972, DOI 10.1128/MCB.01590-08
   TAGAMI H, 2004, CELL, V116, P51
   TALBERT PB, 2009, GENE DEV, V23, P1037, DOI 10.1101/gad.1806409
   TAMURA T, 2009, J BIOL CHEM, V284, P12217, DOI 10.1074/jbc.M805651200
   TANG J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200
   URNOV FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556
   WANG ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   WONG LH, 2009, GENOME RES, V19, P404, DOI 10.1101/gr.084947.108
   XUE YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI
   10.1073/pnas.1937626100
NR 69
TC 57
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAR 5
PY 2010
VL 140
IS 5
BP 678
EP 691
DI 10.1016/j.cell.2010.01.003
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 564EZ
UT ISI:000275197400017
ER

PT J
AU Yang, XY
   Lu, X
   Lombes, M
   Rha, GB
   Chi, YI
   Guerin, TM
   Smart, EJ
   Liu, J
AF Yang, Xingyuan
   Lu, Xin
   Lombes, Marc
   Rha, Geun Bae
   Chi, Young-In
   Guerin, Theresa M.
   Smart, Eric J.
   Liu, Jun
TI The G(0)/G(1) Switch Gene 2 Regulates Adipose Lipolysis through
   Association with Adipose Triglyceride Lipase
SO CELL METABOLISM
LA English
DT Article
ID HORMONE-SENSITIVE LIPASE; CHANARIN-DORFMAN-SYNDROME; EPITHELIUM-DERIVED
   FACTOR; LIPID STORAGE DISEASE; INSULIN-RESISTANCE; TRIACYLGLYCEROL
   LIPASE; STIMULATED LIPOLYSIS; ENERGY-METABOLISM; CRYSTAL-STRUCTURE;
   PERILIPIN-A
AB Adipose triglyceride lipase (ATGL) is the rate-limiting enzyme for
   triacylglycerol (TAG) hydrolysis in adipocytes. The precise mechanisms
   whereby ATGL is regulated remain uncertain. Here, we demonstrate that a
   protein encoded by G(0)/G(1) switch gene 2 (G0S2) is a selective
   regulator of ATGL. G0S2 is highly expressed in adipose tissue and
   differentiated adipocytes. When overexpressed in HeLa cells, G0S2
   localizes to lipid droplets and prevents their degradation mediated by
   ATGL. Moreover, G0S2 specifically interacts with ATGL through the
   hydrophobic domain of G0S2 and the patatin-like domain of ATGL. More
   importantly, interaction with G0S2 inhibits ATGL TAG hydrolase
   activity. Knockdown of endogenous G0S2 accelerates basal and stimulated
   lipolysis in adipocytes, whereas overexpression of G0S2 diminishes the
   rate of lipolysis in both adipocytes and adipose tissue explants. Thus
   G0S2 functions to attenuate ATGL action both in vitro and in vivo and
   by this mechanism regulates TAG hydrolysis.
C1 [Yang, Xingyuan; Lu, Xin; Guerin, Theresa M.; Smart, Eric J.; Liu, Jun] Univ Kentucky, Dept Pediat, Lexington, KY 40536 USA.
   [Yang, Xingyuan; Lu, Xin; Guerin, Theresa M.; Smart, Eric J.; Liu, Jun] Univ Kentucky, Kentucky Pediat Res Inst, Lexington, KY USA.
   [Rha, Geun Bae; Chi, Young-In] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
   [Rha, Geun Bae; Chi, Young-In] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
   [Lombes, Marc] Fac Med Paris Sud, INSERM, U693, Le Kremlin Bicetre, France.
RP Liu, J, Univ Kentucky, Dept Pediat, Lexington, KY 40536 USA.
EM jun.liu@uky.edu
CR AHMADIAN M, 2009, DIABETES, V58, P855, DOI 10.2337/db08-1644
   BELLER M, 2008, PLOS BIOL, V6, P2530, ARTN e292
   BEZAIRE V, 2009, J BIOL CHEM, V284, P18282, DOI 10.1074/jbc.M109.008631
   BODEN G, 2002, EUR J CLIN INVEST S3, V32, P14
   BRASAEMLE DL, 2006, CURR PROTOC CELL BIO, V3, P15
   CHEN XW, 2007, DEV CELL, V13, P391, DOI 10.1016/i.devcel.2007.07.007
   CHUNG C, 2008, J HEPATOL, V48, P471, DOI 10.1016/j.jhep.2007.10.012
   DESSEN A, 1999, CELL, V97, P349
   DUNCAN RE, 2007, ANNU REV NUTR, V27, P79, DOI
   10.1146/annurev.nutr.27.061406.093734
   EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537
   FISCHER J, 2007, NAT GENET, V39, P28, DOI 10.1038/ng1951
   GRANNEMAN JG, 2007, J BIOL CHEM, V282, P5726, DOI 10.1074/jbc.M610580200
   GREENBERG CC, 2003, J BIOL CHEM, V278, P30835, DOI
   10.1074/jbc.M303846200
   GUILHERME A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391
   HAEMMERLE G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965
   HUIJSMAN E, 2009, AM J PHYSIOL-ENDOC M, V297, E505, DOI
   10.1152/ajpendo.00190.2009
   JENKINS CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200
   KERSHAW EE, 2006, DIABETES, V55, P148
   KOBAYASHI K, 2008, J CLIN ENDOCR METAB, V93, P2877, DOI
   10.1210/jc.2007-2247
   LANGIN D, 2005, DIABETES, V54, P3190
   LASS A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005
   LEFEVRE C, 2001, AM J HUM GENET, V69, P1002
   LU P, 2008, J BIOL CHEM, V283, P33685, DOI 10.1074/jbc.M806213200
   MA L, 2006, J BIOL CHEM, V281, P28721, DOI 10.1074/jbc.M601576200
   MARTIN S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   MIYOSHI H, 2007, J BIOL CHEM, V282, P996, DOI 10.1074/jbc.M605770200
   NOTARI L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200
   PARIKH H, 2007, PLOS MED, V4, P868, ARTN e158
   RABEN DM, 2005, TRENDS ENDOCRIN MET, V16, P35
   RUSSELL L, 1991, DNA CELL BIOL, V10, P581
   RYDEL TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r
   RYDEN M, 2007, AM J PHYSIOL-ENDOC M, V292, E1847, DOI
   10.1152/ajpendo.00040.2007
   SCHWEIGER M, 2008, J BIOL CHEM, V283, P17211, DOI 10.1074/jbc.M710566200
   SMIMOVA E, 2006, EMBO REP, V7, P106
   SONI KG, 2009, J CELL SCI, V122, P1834, DOI 10.1242/jcs.045849
   SZTALRYD C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169
   VILLENA JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200
   WATT MJ, 2007, FUTURE LIPIDOL, V2, P659, DOI 10.2217/17460875.2.6.659
   WATT MJ, 2008, BIOCHEM J 3, V414, P313, DOI 10.1042/BJ20080305
   ZANDBERGEN F, 2005, BIOCHEM J 2, V392, P313, DOI 10.1042/BJ20050636
   ZECHNER R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200
   ZIMMERMANN R, 2004, SCIENCE, V306, P1383
   ZIMMERMANN R, 2009, BBA-MOL CELL BIOL L, V1791, P494, DOI
   10.1016/j.bbalip.2008.10.005
NR 43
TC 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD MAR 3
PY 2010
VL 11
IS 3
BP 194
EP 205
DI 10.1016/j.cmet.2010.02.003
PG 12
SC Cell Biology; Endocrinology & Metabolism
GA 565WE
UT ISI:000275325400006
ER

PT J
AU Lorenzo, VF
   Yang, Y
   Simonson, TS
   Nussenzveig, R
   Jorde, LB
   Prchal, JT
   Ge, RL
AF Lorenzo, V. F.
   Yang, Y.
   Simonson, T. S.
   Nussenzveig, R.
   Jorde, L. B.
   Prchal, J. T.
   Ge, R. L.
TI Genetic adaptation to extreme hypoxia: Study of high-altitude pulmonary
   edema in a three-generation Han Chinese family (vol 43, pg 221, 2009)
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Correction
C1 [Lorenzo, V. F.; Yang, Y.; Simonson, T. S.; Nussenzveig, R.; Jorde, L. B.; Prchal, J. T.; Ge, R. L.] Univ Utah, Salt Lake City, UT 84132 USA.
RP Prchal, JT, Univ Utah, SOM 5C210,30 N 1900 E, Salt Lake City, UT 84132
   USA.
EM josef.prchal@hsc.utah.edu
CR LORENZO VF, 2009, BLOOD CELL MOL DIS, V43, P221, DOI
   10.1016/j.bcmd.2009.04.006
NR 1
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD MAR 15
PY 2010
VL 44
IS 3
BP 198
EP 198
DI 10.1016/j.bcmd.2009.12.008
PG 1
SC Hematology
GA 564MC
UT ISI:000275217800014
ER

PT J
AU Huang, JG
   Yang, M
   Liu, P
   Yang, GD
   Wu, CA
   Zheng, CC
AF Huang, Jin-Guang
   Yang, Mei
   Liu, Pei
   Yang, Guo-Dong
   Wu, Chang-Ai
   Zheng, Cheng-Chao
TI Genome-wide profiling of developmental, hormonal or environmental
   responsiveness of the nucleocytoplasmic transport receptors in
   Arabidopsis
SO GENE
LA English
DT Article
DE Importin; Exportin; Nuclear pore complex; Signaling pathway; Abiotic
   stress
ID NUCLEAR-LOCALIZATION SEQUENCES; PORE-TARGETING COMPLEX; IMPORTIN-ALPHA;
   SIGNAL-TRANSDUCTION; BETA; EXPRESSION; PROTEIN; PLANTS; EXPORT; LIGHT
AB Being poilkilothermic and sessile organisms, plants have to respond
   quickly to changing environmental cues, and a higher order of gene
   regulation is required The significance of nucleocytoplasmic transport
   via importin alpha and importin beta (alpha/beta) has been exhibited in
   a wide spectrum of biological processes However, most of these
   receptors have not been characterized as to which cellular or
   development processes are required and how their expression is
   regulated by environmental stimuli Here we pursued a phylogenetic
   analysis and investigated the expression patterns of all 8 IMP alpha s
   and 18 IMP beta s in Arabidopsis The IMP alpha isoforms could be
   tracked back to a common ancestor, while the IMP beta s derived from
   different ones The majority of transport receptor genes were
   constitutively expressed Intriguingly, AtIMP alpha 5, 7, 8 and AtIMP
   beta 5 were specifically expressed in different tissues AtIMP beta 3
   was the sole receptor that was obviously modulated by exogenous
   phytohormones, whereas three IMP alpha s and five IMP beta s exhibited
   responses to environmental stimuli Furthermore, our RT-PCR data
   provided direct evidence that AtIMP alpha 5, 8 and AtIMP beta 5 are not
   pseudogenes and we also corrected the open reading frame annotation of
   AtIMP alpha 8 These genome-wide profilin g results not only widen our
   understanding of these transport receptors, but also provide strong
   evidence supporting the role of transport receptors in multiple
   signaling pathways and give us an insight into the further analysis of
   nucleocytoplasmic trafficking in Arabidopsis (C) 2009 Elsevier B V All
   rights reserved
C1 [Huang, Jin-Guang; Yang, Mei; Liu, Pei; Yang, Guo-Dong; Wu, Chang-Ai; Zheng, Cheng-Chao] Shandong Agr Univ, State Key Lab Crop Biol, Coll Life Sci, Tai An 271018, Shandong, Peoples R China.
   [Liu, Pei] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou 310028, Zhejiang, Peoples R China.
RP Zheng, CC, Shandong Agr Univ, State Key Lab Crop Biol, Coll Life Sci,
   Tai An 271018, Shandong, Peoples R China.
FU National Basic Research Program [2006CB1001006]; Changjiang Scholars
   and Innovative Research Team in University [IRT0635]; National Special
   Program for Research and Industrialization of Transgenic Plants in
   China [2009ZX08009-092B]
FX This work was supported by the National Basic Research Program (Grant
   No. 2006CB1001006), the Program for Changjiang Scholars and Innovative
   Research Team in University (Grant No. IRT0635) and the National
   Special Program for Research and Industrialization of Transgenic Plants
   (Grant No. 2009ZX08009-092B) in China.
CR BHATTACHARJEE S, 2008, PLANT CELL, V20, P2661, DOI
   10.1105/tpc.108.060467
   BLANC G, 2003, GENOME RES, V13, P137, DOI 10.1101/gr.751803
   BLANVILLAIN R, 2008, GENETICS, V180, P1493, DOI
   10.1534/genetics.108.094896
   BOLLMAN KM, 2003, DEVELOPMENT, V130, P1493, DOI 10.1242/dev.00362
   CHINNUSAMY V, 2008, CURR TOP MICROBIOL, V326, P235
   DENG XW, 1991, GENE DEV, V5, P1172
   GAO Y, 2008, J INTEGR PLANT BIOL, V50, P906, DOI
   10.1111/j.1744-7909.2008.00695.x
   GOLDFARB DS, 2004, TRENDS CELL BIOL, V14, P505, DOI
   10.1016/j.tcb.2004.07.016
   GREBER UF, 2002, EMBO REP, V3, P410
   GRUSS OJ, 2001, CELL, V104, P83
   HICKS GR, 1996, PLANT CELL, V8, P1337
   HOGARTH CA, 2007, DEV DYNAM, V236, P2311, DOI 10.1002/dvdy.21238
   HUBNER S, 1999, J BIOL CHEM, V274, P22610
   HUNTER CA, 2003, PLANT PHYSIOL, V132, P2135, DOI 10.1104/pp.103.023309
   HWANG I, 2001, NATURE, V413, P383
   KAFFMAN A, 1999, ANNU REV CELL DEV BI, V15, P291
   KAMEI Y, 1999, J HISTOCHEM CYTOCHEM, V47, P363
   KIRCHER S, 2002, PLANT CELL, V14, P1541
   LEE HJ, 2001, GENE DEV, V15, P912
   LEE Y, 2008, J EXP BOT, V59, P3229, DOI 10.1093/jxb/ern200
   MALIK HS, 1997, P NATL ACAD SCI USA, V94, P13738
   MATSUKI R, 1998, PLANT CELL PHYSIOL, V39, P879
   MATTAJ IW, 1998, ANNU REV BIOCHEM, V67, P265
   MERKLE T, 2003, CURR GENET, V44, P231, DOI 10.1007/s00294-003-0444-x
   MOSAMMAPARAST N, 2004, TRENDS CELL BIOL, V14, P547
   NACHURY MV, 2001, CELL, V104, P95
   NADLER SG, 1997, J BIOL CHEM, V272, P4310
   PALMA K, 2005, CURR BIOL, V15, P1129
   PARK MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI
   10.1073/pnas.0405570102
   PEMBERTON LF, 1998, CURR OPIN CELL BIOL, V10, P392
   RIBBECK K, 2001, EMBO J, V20, P1320
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   SHAN DP, 2007, NEW PHYTOL, V176, P70, DOI
   10.1111/j.1469-8137.2007.02160.x
   SONNHAMMER ELL, 1997, PROTEINS, V28, P405
   SOROKIN AV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1439, DOI
   10.1134/S0006297907130032
   STROM AC, 2001, GENOME BIOL, V2, UNSP REVIEWS3008.1-3008.9
   THOMPSON JD, 1997, NUCLEIC ACIDS RES, V25, P4876
   TSUJI L, 1997, FEBS LETT, V416, P30
   VERSLUES PE, 2006, PLANT J, V47, P776, DOI
   10.1111/j.1365-313X.2006.02833.x
   YASUHARA N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521
   YI R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   YOSHIDA Y, 2009, DEVELOPMENT, V136, P1039, DOI 10.1242/dev.030585
   ZHANG CM, 2002, CURR BIOL, V12, P498
   ZHAO JF, 2007, PLANT CELL, V19, P3805, DOI 10.1105/tpc.106.048900
NR 44
TC 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD FEB 1
PY 2010
VL 451
IS 1-2
BP 38
EP 44
DI 10.1016/j.gene.2009.11.009
PG 7
SC Genetics & Heredity
GA 561YA
UT ISI:000275014800006
ER

PT J
AU Huang, Y
   Yang, X
   Wu, Y
   Jing, W
   Cai, X
   Tang, W
   Liu, L
   Liu, Y
   Grottkau, BE
   Lin, Y
AF Huang, Y.
   Yang, X.
   Wu, Y.
   Jing, W.
   Cai, X.
   Tang, W.
   Liu, L.
   Liu, Y.
   Grottkau, B. E.
   Lin, Y.
TI gamma-secretase inhibitor induces adipogenesis of adipose-derived stem
   cells by regulation of Notch and PPAR-gamma
SO CELL PROLIFERATION
LA English
DT Article
ID ACTIVATED-RECEPTOR-GAMMA; SIGNALING PATHWAY; TRANSCRIPTION FACTOR;
   DIFFERENTIATION; EXPRESSION; PREF-1; PROLIFERATION; PREADIPOCYTES;
   SPECIFICATION; TARGET
AB Objective:
   To determine the inhibitory effect and mechanism of Notch signalling on
   adipogenesis of mouse adipose-derived stem cells (mASCs).
   Materials and methods:
   Varied concentrations of
   N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butylester
   (DAPT) were added to mASCs 3 days before adipogenic induction with
   insulin-containing differentiation medium. The process of adipogenesis
   and ability of lipid droplet accumulation were analysed using oil red-O
   staining. The Notch signalling pathway (Notch-1, -2, -3, -4, Hes-1 and
   Hey-1) and adipogenesis-related factors (PPAR-gamma, DLK-1/Pref-1 and
   Acrp) were tested using real-time PCR, Western blot analysis and
   immunofluorescence staining assays.
   Results:
   We demonstrated that Notch-2-Hes-1 signalling pathway was inhibited
   dose-dependently by DAPT in mASCs. In addition, transcription of
   PPAR-gamma was promoted by DAPT before adipogenic induction, while
   inhibitor of adipogenesis DLK-1/Pref-1 was further depressed. At early
   stages of differentiation (2-4 days), adipogenesis in mASCs was
   advanced and significantly enhanced in 5 and 10 mu m DAPT pre-treated
   cases. On day 4, in differentiated mASCs cases with DAPT pre-treatment,
   we also found promotion of activation of de-PPAR-gamma and depression
   of HES-1, DLK-1/Pref-1 mRNA and protein expression.
   Conclusions:
   We conclude that blocking Notch signalling with DAPT enhances
   adipogenesis of differentiated mASCs at an early stage. It may be due
   to depression of DLK-1/Pref-1 and promotion of de-PPAR-gamma
   activation, which work through inhibition of Notch-2-Hes-1 pathway by
   DAPT.
C1 [Grottkau, B. E.; Lin, Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Children & Pediat Orthopaed L, Boston, MA USA.
   [Huang, Y.; Yang, X.; Wu, Y.; Jing, W.; Cai, X.; Tang, W.; Liu, L.; Liu, Y.; Lin, Y.] Sichuan Univ, State Key Lab Oral Dis, W China Coll Stomatol, Chengdu 610064, Peoples R China.
   [Huang, Y.] Capital Med Univ, Beijing Friendship Hosp, Dept Oral & Maxillofacial Surg, Beijing, Peoples R China.
RP Grottkau, BE, Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept
   Orthopaed,Children & Pediat Orthopaed Lab Ti, Boston, MA 02115 USA.
EM bgrottkau@partners.org
   yunfenglin@scu.edu.cn
FU National Natural Science Foundation of China [30801304]; Anthony and
   Constance Franchi Fund for Pediatric Orthopaedics at the MassGeneral
   Hospital for Children ; Specialized Research Fund for the Doctoral
   Program of Higher Education [20070610062]; State Key Laboratory of Oral
   Diseases, Sichuan University [SKLOD011]; Applied Fundamental Project of
   Sichuan Province [2008JY0028-2]
FX This study was funded by the National Natural Science Foundation of
   China (30801304), the Anthony and Constance Franchi Fund for Pediatric
   Orthopaedics at the MassGeneral Hospital for Children, Specialized
   Research Fund for the Doctoral Program of Higher Education
   (20070610062), Opening Funding of the State Key Laboratory of Oral
   Diseases, Sichuan University (SKLOD011) and Applied Fundamental Project
   of Sichuan Province (2008JY0028-2).
CR ADAMS M, 1997, J BIOL CHEM, V272, P5128
   AKERBLAD P, 2005, PHYSIOL GENOMICS, V23, P206, DOI
   10.1152/physiolgenomics.00015.2005
   ASTUDILLO P, 2008, J CELL BIOCHEM, V103, P1054, DOI 10.1002/jcb.21516
   BAN A, 2008, J VET MED SCI, V70, P761
   BARON M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI
   10.1016/S1084-9521(02)00179-9
   BIDDINGER SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI
   10.1146/annurev.physiol.68.040104.124723
   BURGERMEISTER E, 2006, MOL ENDOCRINOL, V20, P809, DOI
   10.1210/me.2005-0171
   CHENG HT, 2005, KIDNEY INT, V68, P1951
   FINK T, 2004, STEM CELLS, V22, P1346, DOI 10.1634/stemcells.2004-0038
   GARCES C, 1997, J BIOL CHEM, V272, P29729
   GE K, 2002, NATURE, V417, P563
   GROTTKAU BE, 2009, INT J ORAL SCI, V1, P81
   ISO T, 2002, J BIOL CHEM, V277, P6598
   ISO T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   JING W, 2007, CELL TISSUE RES, V330, P567, DOI 10.1007/s00441-007-0493-4
   KADESCH T, 2004, CURR OPIN GENET DEV, V14, P506, DOI
   10.1016/j.gde.2004.07.007
   KAMON J, 2002, NIPPON RINSHO S7, V60, P593
   KIM KA, 2007, MOL CELL BIOL, V27, P2294, DOI 10.1128/MCB.02207-06
   LATHIA JD, 2008, J NEUROCHEM, V107, P1471, DOI
   10.1111/j.1471-4159.2008.05715.x
   LEBLANC K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   LEONG KG, 2008, DIFFERENTIATION, V76, P699, DOI
   10.1111/j.1432-0436.2008.00288.x
   LI J, 2008, AI ZHENG, V27, P471
   LIN YF, 2006, CELL PROLIFERAT, V39, P79
   LIN YF, 2008, CELL PROLIFERAT, V41, P803, DOI
   10.1111/j.1365-2184.2008.00542.x
   LOHRKE B, 1998, J ENDOCRINOL, V159, P429
   LOVSCHALL H, 2005, EUR J ORAL SCI, V113, P312
   MIELE L, 2006, CLIN CANCER RES, V12, P1074, DOI
   10.1158/1078-0432.CCR-05-2570
   MIELE L, 2006, CURR MOL MED, V6, P905
   MOERMAN EJ, 2004, AGING CELL, V3, P379, DOI
   10.1111/j.1474-9728.2004.00127.x
   NICHOLS AM, 2004, GENESIS, V40, P40, DOI 10.1002/gene.20061
   NICHOLSON AC, 2007, BRIT J PHARMACOL, V151, P807, DOI
   10.1038/sj.bjp.0707250
   NICKOLOFF BJ, 2002, CELL DEATH DIFFER, V9, P842
   NUEDA ML, 2007, J MOL BIOL, V367, P1281, DOI 10.1016/j.jmb.2006.10.043
   OHAZAMA A, 2004, DEV CELL, V6, P219
   PORRAS A, 2002, FEBS LETT, V520, P58
   RAYA A, 2003, P NATL ACAD SCI U S1, V100, P11889, DOI
   10.1073/pnas.1834204100
   ROSS DA, 2004, MOL CELL BIOL, V24, P3505, DOI
   10.1128/MCB.24.8.3505-3513.2004
   ROSS DA, 2006, MOL ENDOCRINOL, V20, P698
   SARMENTO LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559
   SCHADINGER SE, 2005, AM J PHYSIOL-ENDOC M, V288, P1195
   SPIEGELMAN BM, 1997, BIOCHIMIE, V79, P111
   TURKSEN K, 2004, DEV CELL, V6, P454
   VATS A, 2002, CLIN OTOLARYNGOL, V27, P227
   VUJOVIC S, 2007, CELL PROLIFERAT, V40, P185
   WANG Q, 2004, YI CHUAN, V26, P653
   WANG YH, 2006, J NUTR, V136, P2953
   WERMTER AK, 2008, EUR J HUM GENET, V16, P1126, DOI 10.1038/ejhg.2008.64
   WU L, 2009, J CELL MOL MED
   WU LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI
   10.1016/j.semcancer.2004.04.014
NR 49
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD APR
PY 2010
VL 43
IS 2
BP 147
EP 156
DI 10.1111/j.1365-2184.2009.00661.x
PG 10
SC Cell Biology
GA 560VR
UT ISI:000274932500006
ER

PT J
AU Shimizu, S
   Hong, P
   Arumugam, B
   Pokomo, L
   Boyer, J
   Koizumi, N
   Kittipongdaja, P
   Chen, A
   Bristol, G
   Galic, Z
   Zack, JA
   Yang, O
   Chen, ISY
   Lee, B
   An, DS
AF Shimizu, Saki
   Hong, Patrick
   Arumugam, Balamurugan
   Pokomo, Lauren
   Boyer, Joshua
   Koizumi, Naoya
   Kittipongdaja, Panyamol
   Chen, Angela
   Bristol, Greg
   Galic, Zoran
   Zack, Jerome A.
   Yang, Otto
   Chen, Irvin S. Y.
   Lee, Benhur
   An, Dong Sung
TI A highly efficient short hairpin RNA potently down-regulates CCR5
   expression in systemic lymphoid organs in the hu-BLT mouse model
SO BLOOD
LA English
DT Article
ID SHORT-INTERFERING RNAS; HUMAN IMMUNE-SYSTEM; HIV-1 INFECTION; T-CELLS;
   DISEASE PROGRESSION; LENTIVIRAL VECTOR; HUMANIZED MICE;
   MAMMALIAN-CELLS; CO-RECEPTORS; REV SIRNA
AB Inhibiting the expression of the HIV-1 coreceptor CCR5 holds great
   promise for controlling HIV-1 infection in patients. Here we report
   stable knockdown of human CCR5 by a short hairpin RNA(shRNA) in a
   humanized bone marrow/liver/thymus (BLT) mouse model. We delivered a
   potent shRNA against CCR5 into human fetal liver-derived CD34(+)
   hematopoietic progenitor/stem cells (HPSCs) by lentiviral vector
   transduction. We transplanted vector-transduced HPSCs solidified with
   Matrigel and a thymus segment under the mouse kidney capsule.
   Vector-transduced autologous CD34(+) cells were subsequently injected
   in the irradiated mouse, intended to create systemic reconstitution.
   CCR5 expression was down-regulated in human T cells and
   monocytes/macrophages in systemic lymphoid tissues, including
   gut-associated lymphoid tissue, the major site of HIV-1 replication.
   The shRNA-mediated CCR5 knockdown had no apparent adverse effects on
   T-cell development as assessed by polyclonal T-cell receptor V beta
   family development and naive/memory T-cell differentiation. CCR5
   knockdown in the secondary transplanted mice suggested the potential of
   long-term hematopoietic reconstitution by the shRNA-transduced HPSCs.
   CCR5 tropic HIV-1 infection was effectively inhibited in mouse-derived
   human splenocytes ex vivo. These results demonstrate that lentiviral
   vector delivery of shRNA into human HPSCs could stably down-regulate
   CCR5 in systemic lymphoid organs in vivo. (Blood. 2010;115:1534-1544)
C1 [An, Dong Sung] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, AIDS Inst, Los Angeles, CA 90095 USA.
   [Shimizu, Saki; Pokomo, Lauren; Boyer, Joshua; Koizumi, Naoya; Kittipongdaja, Panyamol; Bristol, Greg; Galic, Zoran; Zack, Jerome A.; Chen, Irvin S. Y.; An, Dong Sung] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Hong, Patrick; Arumugam, Balamurugan; Zack, Jerome A.; Yang, Otto; Chen, Irvin S. Y.; Lee, Benhur] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol, Los Angeles, CA 90095 USA.
   [Hong, Patrick; Arumugam, Balamurugan; Zack, Jerome A.; Yang, Otto; Chen, Irvin S. Y.; Lee, Benhur] Univ Calif Los Angeles, David Geffen Sch Med, Dept Immunol, Los Angeles, CA 90095 USA.
   [Hong, Patrick; Arumugam, Balamurugan; Zack, Jerome A.; Yang, Otto; Chen, Irvin S. Y.; Lee, Benhur] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Genet, Los Angeles, CA 90095 USA.
   [Chen, Angela] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
RP An, DS, Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol
   Oncol, AIDS Inst, 188 BSRB,615 Charles E Young Dr S, Los Angeles, CA
   90095 USA.
EM an@ucla.edu
FU Rheumatology Fellowship Training Grant [T32 AR053463]; UCLA AIDS
   Institute ; UCLA Center for AIDS Research (CFAR) ; National Institute
   of Allergy and Infectious Diseases [AI028697]; National Heart, Lung,
   and Blood Institute [1R01HL086409]; National Cancer Institute [CA086306]
FX The authors thank Victor Garcia for valuable information and Jennifer
   Fulcher, Alvin Welch, Ana Beatriz Ruiz, Stephanie Matyas, Min Zhou,
   Patrick Kim, Ruth Cortado, Encarnacion Montecino-Rodriguez, Eun Mi Hur,
   Sonal Patel, Parvataneni Ram, and Broad Stem Cell Research Center flow
   core facility at UCLA for their reagents and technical support.
   This work was supported by the Rheumatology Fellowship Training Grant
   T32 AR053463, UCLA AIDS Institute, UCLA Center for AIDS Research
   (CFAR), National Institute of Allergy and Infectious Diseases
   (AI028697), National Heart, Lung, and Blood Institute (1R01HL086409),
   and the National Cancer Institute (CA086306).
CR ADACHI A, 1986, J VIROL, V59, P284
   AN DS, 2006, MOL THER, V14, P494, DOI 10.1016/j.ymthe.2006.05.015
   AN DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI
   10.1073/pnas.0705474104
   ANDERSON J, 2007, GENE THER, V14, P1287, DOI 10.1038/sj.gt.3302958
   ANDERSON J, 2007, MOL THER, V15, P1182, DOI 10.1038/sj.mt.6300157
   ANTON PA, 2000, AIDS, V14, P1761
   ARTEAGA HJ, 2003, NAT BIOTECHNOL, V21, P230, DOI 10.1038/nbt0303-230
   BERGER EA, 1999, ANNU REV IMMUNOL, V17, P657
   BRIDGE AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173
   DENTON PW, 2008, PLOS MED, V5, P79, ARTN e16
   DIROSA F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011
   FIRE A, 1998, NATURE, V391, P806
   FISH RJ, 2004, BMC MOL BIOL, V5, ARTN 9
   GRIMM D, 2006, NATURE, V441, P537
   HUANG YX, 1996, NAT MED, V2, P1240
   HUTTER G, 2009, NEW ENGL J MED, V360, P692
   IOANNIDIS JPA, 2001, ANN INTERN MED, V135, P782
   JACKSON AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   JACQUE JM, 2002, NATURE, V418, P435
   KILLIAN MS, 2002, CLIN DIAGN LAB IMMUN, V9, P858
   KUMAR P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   LAN P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388
   LEE MTM, 2003, J VIROL, V77, P11964, DOI
   10.1128/JVI.77.22.11964-11972.2003
   LO HL, 2007, GENE THER, V14, P1503, DOI 10.1038/sj.gt.3303011
   MARTINEZ MA, 2002, AIDS, V16, P2385
   MELKUS MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431
   MOORE JP, 1997, CURR OPIN IMMUNOL, V9, P551
   MOSIER DE, 2000, IMMUNOL RES, V21, P253
   NOVINA CD, 2002, NAT MED, V8, P681
   OBRIEN SJ, 2004, NAT GENET, V36, P565
   OBRIEN WA, 1990, NATURE, V348, P69
   PERSENGIEV SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904
   POLURI A, 2008, MOL THER, V16, P378, DOI 10.1038/sj.mt.6300370
   QIN XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI
   10.1073/pnas.232688199
   SCACHERI PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI
   10.1073/pnas.0308698100
   SHIMIZU S, 2009, GENET VACCINES THER, V7, P8, DOI 10.1186/1479-0556-7-8
   SHIRANE D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290
   SIMMONS G, 2000, IMMUNOL REV, V177, P112
   SLEDZ CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   SMITH MW, 1997, SCIENCE, V277, P959
   STEINBERGER P, 2000, P NATL ACAD SCI USA, V97, P805
   SUN ZF, 2007, J EXP MED, V204, P705
   TAMHANE M, 2008, AIDS RES THER, V5, P16
   TERBRAKE O, 2008, MOL THER, V16, P557, DOI 10.1038/sj.mt.6300382
   TERBRAKE O, 2009, GENE THER, V16, P148, DOI 10.1038/gt.2008.124
   WU LJ, 1997, J EXP MED, V185, P1681
NR 46
TC 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 25
PY 2010
VL 115
IS 8
BP 1534
EP 1544
DI 10.1182/blood-2009-04-215855
PG 11
SC Hematology
GA 561KB
UT ISI:000274974200011
ER

PT J
AU Guan, CM
   Ye, C
   Yang, XM
   Gao, JG
AF Guan, Chunmei
   Ye, Chao
   Yang, Xiaomei
   Gao, Jiangang
TI A Review of Current Large-Scale Mouse Knockout Efforts
SO GENESIS
LA English
DT Review
DE knockout mouse; gene trapping; gene targeting; transposon; ES cells
ID EMBRYONIC STEM-CELLS; HUMAN-GENOME-PROJECT; GENE-TRAP MUTAGENESIS;
   FUNCTIONAL GENOMICS; INSERTIONAL MUTAGENESIS; CRE RECOMBINASE;
   CHROMOSOMAL REARRANGEMENTS; HOMOLOGOUS RECOMBINATION; MULTIPURPOSE
   ALLELES; SOMATIC INTEGRATION
AB After the successful completion of the human genome project (HGP),
   biological research in the post-genome era urgently needs an efficient
   approach for functional analysis of genes. Utilization of knockout
   mouse models has been powerful for elucidating the function of genes as
   well as finding new therapeutic interventions for human diseases. Gene
   trapping and gene targeting are two independent techniques for making
   knockout mice from embryonic stem (ES) cells. Gene trapping is
   high-throughput, random, and sequence-tagged while gene targeting
   enables the knockout of specific genes. It has been about 20 years
   since the first gene targeting and gene trapping mice were generated.
   In recent years, new tools have emerged for both gene targeting and
   gene trapping, and organizations have been formed to knock out genes in
   the mouse genome using either of the two methods. The knockout mouse
   project (KOMP) and the international gene trap consortium (IGTC) were
   initiated to create convenient resources for scientific research
   worldwide and knock out all the mouse genes. Organizers of KOMP regard
   it as important as the HGP. Gene targeting methods have changed from
   conventional gene targeting to high-throughput conditional gene
   targeting. The combined advantages of trapping and targeting elements
   are improving the gene trapping spectrum and gene targeting efficiency.
   As a newly-developed insertional mutation system, transposons have some
   advantages over retrovirus in trapping genes. Emergence of the
   international knockout mouse consortium (IKMP) is the beginning of a
   global collaboration to systematically knock out all the genes in the
   mouse genome for functional genomic research. genesis 48:73-85, 2010.
   (C) 2010 Wiley-Liss, Inc.
C1 [Guan, Chunmei; Ye, Chao; Yang, Xiaomei; Gao, Jiangang] Shandong Univ, Coll Life Sci, Jinan 250100, Shandong, Peoples R China.
RP Yang, XM, Shandong Univ, Coll Life Sci, South Bldg,Room 117, Jinan
   250100, Shandong, Peoples R China.
EM yxm411@sdu.edu.cn
   jggao@sdu.edu.cn
FU National Natural Sciences Foundation of China [30871436, 30973297]; 973
   Program [2010CB945002]; Ministry of Education of China [200804220011];
   Shandong Province Science and Technology Key Program [2009GG10003039]
FX This work is supported by the National Natural Sciences Foundation of
   China (30871436, 30973297), the 973 Program (2010CB945002), grant from
   Ministry of Education of China (200804220011), grant for returned
   Chinese scholars, and Shandong Province Science and Technology Key
   Program (2009GG10003039).
CR ABRAMOWICZ M, 2003, ADV GENET, V50, P231
   ABUIN A, 2007, HDB EXP PHARM, V178, P129
   ADAMS DJ, 2004, NAT GENET, V36, P867, DOI 10.1038/ng1388
   ALTMAN JK, 2008, J BIOL CHEM, V283, P1992, DOI 10.1074/jbc.M705227200
   AMSTERDAM A, 1997, COLD SPRING HARB SYM, V62, P437
   AMSTERDAM A, 2003, DEV DYNAM, V228, P523, DOI 10.1002/dvdy.10381
   ARAKI K, 1999, CELL MOL BIOL, V45, P737
   ARAKI M, 2009, CURR PHARM BIOTECHNO, V10, P221
   AUSTIN CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921
   BARBARIC I, 2007, BRIEF FUNCT GENOMICS, V6, P91, DOI 10.1093/bfgp/elm008
   BESTOR TH, 2005, CELL, V122, P322, DOI 10.1016/j.cell.2005.07.024
   BOOMINATHAN L, 2007, MOL CANCER, V6, ARTN 27
   BROWN SDM, 2006, GENOME DYN, V2, P33
   BURTON H, 2003, NURS EDUC TODAY, V23, P380, DOI
   10.1016/S0260-6917(03)00061-3
   BUSS RR, 2006, J NEUROSCI, V26, P13413, DOI
   10.1523/JNEUROSCI.3528-06.2006
   CAPECCHI MR, 1989, SCIENCE, V244, P1288
   CAPECCHI MR, 2001, NAT MED, V7, P1086
   CARLSON CM, 2005, P NATL ACAD SCI USA, V102, P17059, DOI
   10.1073/pnas.0502974102
   CHAN W, 2007, NUCLEIC ACIDS RES, V35, ARTN e64
   CHECK E, 2002, NATURE, V417, P106
   COLLBERG C, 2007, COMM COM INF SC, V1, P1
   COLLINS FS, 2001, CANCER S, V91, P221
   COLLINS FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018
   COPELAND NG, 2001, NAT REV GENET, V2, P769
   DING S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013
   DINNYES A, 2005, ACTA BIOCHIM POL, V52, P585
   DUPUY AJ, 2001, GENESIS, V30, P82
   EISENBERG D, 2000, NATURE, V405, P823
   EVANS MJ, 1981, NATURE, V292, P154
   FRIEDEL RH, 2005, P NATL ACAD SCI USA, V102, P13188, DOI
   10.1073/pnas.0505474102
   FRIEDEL RH, 2007, BRIEF FUNCT GENOMICS, V6, P180, DOI
   10.1093/bfgp/elm022
   GAO JG, 2004, MOL BRAIN RES, V132, P192, DOI
   10.1016/j.molbrainres.2004.06.035
   GERITS N, 2007, TRANSGENIC RES, V16, P281, DOI 10.1007/s11248-006-9052-0
   GLASER S, 2005, NAT GENET, V37, P1187, DOI 10.1038/ng1668
   GONDO Y, 2008, NAT REV GENET, V9, P803, DOI 10.1038/nrg2431
   GOSSLER A, 1989, SCIENCE, V244, P463
   GOTTESMAN MM, 1994, PREV MED, V23, P591
   GREGORY SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957
   GRIMM D, 2006, SCIENCE, V312, P1862
   HACKING DF, 2008, EARLY HUM DEV, V84, P821, DOI
   10.1016/j.earlhumdev.2008.09.011
   HANSEN GM, 2008, GENOME RES, V18, P1670, DOI 10.1101/gr.078352.108
   HARRIS S, 2000, PHARMACOGENOMICS, V1, P433
   HENIKOFF S, 2004, PLANT PHYSIOL, V135, P630, DOI 10.1104/pp.104.041061
   HICKS GG, 1997, NAT GENET, V16, P338
   HOGAN B, 1988, NATURE, V336, P304
   ISHIDA Y, 1999, NUCLEIC ACIDS RES, V27, E35
   IVICS Z, 2004, METH MOL B, V260, P255
   JOHNSON KD, 1987, J ORTHOP TRAUMA, V1, P1
   KONDO A, 2006, BBA-PROTEINS PROTEOM, V1764, P1881, DOI
   10.1016/j.bbapap.2006.10.011
   KOTHARY R, 1988, NATURE, V335, P435
   KUHN R, 1997, CURR OPIN IMMUNOL, V9, P183
   LEE EC, 2001, GENOMICS, V73, P56
   LEE T, 2007, MOL HUM REPROD, V13, P771, DOI 10.1093/molehr/gam069
   LIU PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203
   MAK TW, 2007, CELL, V131, P1027, DOI 10.1016/j.cell.2007.11.033
   MANSOUR SL, 1988, NATURE, V336, P347
   MARSHALL E, 2002, SCIENCE, V296, P1005
   MARTIN GR, 1981, P NATL ACAD SCI USA, V78, P7634
   MATSUDA E, 2004, P NATL ACAD SCI USA, V101, P4170, DOI
   10.1073/pnas.0400604101
   MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183
   MICHAEL SK, 1999, MECH DEVELOP, V85, P35
   MOENS CB, 2008, BRIEF FUNCT GENOMICS, V7, P454, DOI 10.1093/bfgp/eln046
   MOREADITH RW, 1997, J MOL MED-JMM, V75, P208
   NAGY A, 2000, METH MOL B, V158, P95
   NAGY A, 2009, METHOD MOL BIOL, V530, P1
   NIWA H, 1993, J BIOCHEM, V113, P343
   OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123
   OLEYKOWSKI CA, 1998, NUCLEIC ACIDS RES, V26, P4597
   QI F, 2004, YI CHUAN XUE BAO, V31, P750
   ROMA G, 2007, GENOME RES, V17, P1051, DOI 10.1101/gr.5720807
   ROMA G, 2008, NUCLEIC ACIDS RES, V36, D741, DOI 10.1093/nar/gkm825
   RUSSELL VA, 2007, J NEUROSCI METH, V161, P185, DOI
   10.1016/j.jneumeth.2006.12.005
   SALMINEN M, 1998, DEV DYNAM, V212, P326
   SCHNUETGEN F, 2008, NUCLEIC ACIDS RES, V36, ARTN e133
   SCHNUTGEN F, 2005, P NATL ACAD SCI USA, V102, P7221, DOI
   10.1073/pnas.050227310
   SCHNUTGEN F, 2006, BRIEF FUNCT GENOMICS, V5, P15, DOI
   10.1093/bfgp/ell009
   SCHNUTGEN F, 2007, TRANSGENIC RES, V16, P405, DOI
   10.1007/s11248-007-9089-8
   SHIGEOKA T, 2005, NUCLEIC ACIDS RES, V33, ARTN e20
   SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592
   SMITHIES O, 1985, NATURE, V317, P230
   STANFORD WL, 2001, NAT REV GENET, V2, P756
   STRYKE D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064
   SUN LV, 2008, NUCLEIC ACIDS RES, V36, D729, DOI 10.1093/nar/gkm790
   SZYBALSKI W, 1992, BIOESSAYS, V14, P495
   TAKEUCHI T, 1997, DEV GROWTH DIFFER, V39, P127
   TANIWAKI T, 2005, DEV GROWTH DIFFER, V47, P163
   TESTA G, 2004, GENESIS, V38, P151, DOI 10.1002/gene.20012
   THOMAS KR, 1987, CELL, V51, P503
   VALENZUELA DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822
   VIVIAN JL, 2002, P NATL ACAD SCI USA, V99, P15542, DOI
   10.1073/pnas.242474199
   WALZ A, 2002, J NEUROSCI, V22, P4025
   WANG HS, 2007, J BIOL CHEM, V282, P1507, DOI 10.1074/jbc.M607291200
   WANG SY, 2006, J BIOL CHEM, V281, P34810, DOI 10.1074/jbc.M607484200
   WANG W, 2009, GENOME RES, V19, P667, DOI 10.1101/gr.085621.108
   WATSON JD, 1991, FASEB J, V5, P8
   WU S, 2007, NAT GENET, V39, P922, DOI 10.1038/ng2060
   WU Y, 2008, J GENET GENOMICS, V35, P431
   YAGI T, 1993, ANAL BIOCHEM, V214, P77
   YANT SR, 2000, NAT GENET, V25, P35
   YEN PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI
   10.1016/j.mce.2005.11.030
   YU YJ, 2001, NAT REV GENET, V2, P780
   ZAMBROWICZ BP, 1998, INT J DEV BIOL, V42, P1025
   ZAMBROWICZ BP, 1998, NATURE, V392, P608
   ZAMBROWICZ BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI
   10.1073/pnas.2336103100
   ZHENG BH, 1999, NUCLEIC ACIDS RES, V27, P2354
NR 105
TC 8
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD FEB
PY 2010
VL 48
IS 2
BP 73
EP 85
DI 10.1002/dvg.20594
PG 13
SC Developmental Biology; Genetics & Heredity
GA 558CZ
UT ISI:000274719500001
ER

PT J
AU Yang, Q
   Wu, SB
AF Yang, Qing
   Wu, Shubin
TI WHEAT STRAW PYROLYSIS ANALYSIS BY THERMOGRAVIMETRY AND GAS
   CHROMATOGRAPHY-MASS SPECTROMETRY
SO CELLULOSE CHEMISTRY AND TECHNOLOGY
LA English
DT Article
DE wheat straw; thermogravimetry; kinetics; Py-GC-MS; catalyst; pyrolysis
ID BIOMASS
AB The effect of the heating rates and the existence of a Ni-catalyst on
   the thermogravimetric characteristics of wheat straw were investigated
   by thermogravimetry and gas chromatography-mass spectrometry. The
   weight loss of wheat straw was not markedly by the heating rates, over
   a temperature range from 220.6 and 391.2 degrees C, although to obtain
   the same weight loss, the corresponding temperature was increased and
   the heating rates was enhanced. The thermogravimetric kinetic
   parameters of wheat straw were calculated both without catalyst and
   with 0.5% Ni-catalyst, by the method of Kissinger; the apparent
   activation energy values of wheat straw were of 93.92 and 119.80
   KJ.mol(-1) and the frequency factors lnA were 17.82 and 23.02 min(-1)
   respectively. The weight loss of wheat straw wasnot markedly influenced
   by the Ni-catalyst while pyrolysis-gas chromatography-mass spectrometry
   (Py-GC-MS) evidenced that at 800 degrees C, the presence of the
   catalyst influecned the peak intensities derived form cellulose,
   hemicellulose and lignin. It was concluded tat the Ni-catalyst favors a
   more analytic effect on wheat straw lignin that is the total value of
   the peak area from phenolic compounds and vanillin was higher than Mal
   from furfural and levoglucosan.
C1 [Yang, Qing; Wu, Shubin] S China Univ Technol, State Key Lab Pulp Paper Engn, Guangzhou 510640, Guangdong, Peoples R China.
RP Yang, Q, S China Univ Technol, State Key Lab Pulp Paper Engn, Guangzhou
   510640, Guangdong, Peoples R China.
CR ANTAL MJ, 2000, IND ENG CHEM RES, V39, P4024
   BRADBURY AGW, 1979, J APPL POLYM SCI, V23, P3271
   BRIDGWATER AV, 2002, FAST PYROLYSIS BIOMA, V2
   BRIDGWATER AV, 2005, FAST PYROLYSIS BIOMA, V2
   FAHMI R, 2007, FUEL, V86, P1560, DOI 10.1016/j.fuel.2006.11.030
   HSISHENG T, 1998, IND ENG CHEM RES, V37, P3806
   KISSINGER HE, 1957, ANAL CHEM, V29, P1702
   RAVEENDRAN K, 1995, FUEL, V74, P1812
   SONG CC, 2003, COAL CONVERSION, V26, P91
   YANG HP, 2006, ENERGY FUEL, V20, P383
NR 10
TC 1
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 0576-9787
J9 CELL CHEM TECHNOL
JI Cell Chem. Technol.
PD APR-JUN
PY 2009
VL 43
IS 4-6
BP 123
EP 131
PG 9
SC Materials Science, Paper & Wood
GA 556SR
UT ISI:000274612700002
ER

PT J
AU Yang, Q
   Wu, SB
AF Yang, Qing
   Wu, Shubin
TI THERMOGRAVIMETRIC CHARACTERISTICS OF WHEAT STRAW LIGNIN
SO CELLULOSE CHEMISTRY AND TECHNOLOGY
LA English
DT Article
DE wheat straw; thermogravimetry; dynamics; lignin
ID THERMAL-ANALYSIS; PYROLYSIS; CELLULOSE; KINETICS; BIOMASS; WOOD; TG
AB The thermogravimetric characteristics of wheat straw EMAL (Enzymatic
   Acidolysis Lignin) were analyzed. The effect of the heating rates on
   the thermogravimetric characteristics of wheat straw and the wheat
   straw influence on pyrolysis were investigated. The influence of
   various heating rates on wheat straw was significant, the pyrolysis
   rate of wheat straw EMAL increased at temperatures between 200 and 500
   degrees C. At a temperature above 200 degrees C the pyrolysis rate of
   wheat straw EMAL was clearly accelerated. since all DTG curves and the
   maximum temperature corresponding to pyrolysis shigted to high
   temperature areas, two maxima being also recorded on the DTG curves.
   The thermogravimetric dynamics parameters of wheat straw were
   calculated by the methods of Kissinger and Ozawa, respectively; the
   activation energy of wheat straw EMAL was of 103.92 and 107.69 KJ
   mol(-1), respectively; and the frequency factor, InA of 19.21 and 20.60
   min(-1). The fitting degree of the Kissinger method was better than
   that of the Ozawa one. At a pyrolysis temperature over 400 degrees C,
   the influence of the lignin present in wheat straw on wheat straw
   thermal behaviour was very clear, lignin pyrolysis dominating over that
   of wheat straw.
C1 [Yang, Qing; Wu, Shubin] S China Univ Technol, State Key Lab Pulp & Paper Engn, Guangzhou 510640, Guangdong, Peoples R China.
RP Yang, Q, S China Univ Technol, State Key Lab Pulp & Paper Engn,
   Guangzhou 510640, Guangdong, Peoples R China.
FU Major State Basic Research Development Program of China [2007CB210201];
   National High Technology Research and Development Program of China
   [2007AA05Z456]; National Natural Science Foundation of China [20576043]
FX Investigations were supported by a grant from the Major State Basic
   Research Development Program of China (973 Program) No. 2007CB210201)
   the National High Technology Research and Development Program of China
   (863 Program) (No. 2007AA05Z456) and the National Natural Science
   Foundation of China (No. 20576043).
CR BALL R, 2004, COMBUST THEOR MODEL, V8, P281, DOI
   10.1088/1364-7830/8/2/005
   CHEN JX, 1989, STUDY METHODS CHEM S, P43
   DOMINGUEZ JC, 2008, IND CROP PROD, V27, P150, DOI
   10.1016/j.indcrop.2007.07.006
   GARCIAPEREZ M, 2007, J ANAL APPL PYROL, V78, P104, DOI
   10.1016/j.jaap.2006.05.003
   KISSINGER HE, 1957, ANAL CHEM, V29, P1702
   LIU Q, 2008, J ANAL APPL PYROL, V82, P170, DOI
   10.1016/j.jaap.2008.03.007
   MULLERHAGEDORN A, 2007, J ANAL APPL PYROL, V79, P136, DOI
   10.1016/j.jaap.2006.12.008
   OZAWA T, 2000, THERMOCHIM ACTA, V355, P35
   SHI SL, 2003, ANAL PULP PAPERMAKIN, P25
   WANG G, 2008, FUEL, V87, P552, DOI 10.1016/j.fuel.2007.02.032
   YANG HP, 2006, ENERGY FUEL, V20, P383
   YANG HP, 2007, FUEL, V86, P1781, DOI 10.1016/j.fuel.2007.12.013
NR 12
TC 1
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 0576-9787
J9 CELL CHEM TECHNOL
JI Cell Chem. Technol.
PD APR-JUN
PY 2009
VL 43
IS 4-6
BP 133
EP 139
PG 7
SC Materials Science, Paper & Wood
GA 556SR
UT ISI:000274612700003
ER

PT J
AU Dong, GG
   Yang, Q
   Wang, Q
   Kim, YI
   Wood, TL
   Osteryoung, KW
   van Oudenaarden, A
   Golden, SS
AF Dong, Guogang
   Yang, Qiong
   Wang, Qiang
   Kim, Yong-Ick
   Wood, Thammajun L.
   Osteryoung, Katherine W.
   van Oudenaarden, Alexander
   Golden, Susan S.
TI Elevated ATPase Activity of KaiC Applies a Circadian Checkpoint on Cell
   Division in Synechococcus elongatus
SO CELL
LA English
DT Article
ID GENE-EXPRESSION; BACILLUS-SUBTILIS; CLOCK SYSTEM; CYANOBACTERIA;
   PHOSPHORYLATION; PROTEIN; IDENTIFICATION; OSCILLATION; DOMAIN; FTSZ
AB A circadian clock coordinates physiology and behavior in diverse groups
   of living organisms. Another major cyclic cellular event, the cell
   cycle, is regulated by the circadian clock in the few cases where
   linkage of these cycles has been studied. In the cyanobacterium
   Synechococcus elongatus, the circadian clock gates cell division by an
   unknown mechanism. Using timelapse microscopy, we confirm the gating of
   cell division in the wild-type and demonstrate the regulation of
   cytokinesis by key clock components. Specifically, a state of the
   oscillator protein KaiC that is associated with elevated ATPase
   activity closes the gate by acting through a known clock output pathway
   to inhibit FtsZ ring formation at the division site. An activity that
   stimulates KaiC phosphorylation independently of the KaiA protein was
   also uncovered. We propose a model that separates the functions of KaiC
   ATPase and phosphorylation in cell division gating and other circadian
   behaviors.
C1 [Dong, Guogang; Wood, Thammajun L.; Golden, Susan S.] Texas A&M Univ, Dept Biol, Ctr Biol Clocks Res, College Stn, TX 77843 USA.
   [Dong, Guogang; Kim, Yong-Ick; Golden, Susan S.] Univ Calif San Diego, Div Biol Sci, Ctr Chronobiol, La Jolla, CA 92093 USA.
   [Wang, Qiang; Osteryoung, Katherine W.] Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.
   [Yang, Qiong; van Oudenaarden, Alexander] MIT, Dept Phys, Cambridge, MA 02139 USA.
   [van Oudenaarden, Alexander] MIT, Dept Biol, Cambridge, MA 02139 USA.
RP Golden, SS, Texas A&M Univ, Dept Biol, Ctr Biol Clocks Res, College
   Stn, TX 77843 USA.
EM sgolden@ucsd.edu
FU NIH [R01 GM62419, P01 NS39546, R01 GM068957]; American Recovery and
   Reinvestment Act ; NSF [PHY-0548484]; DOE [DE-FG-02-06ER15808]
FX We thank P. Luitel for helpful discussions, A. LiWang for sharing
   instrumentation and unpublished data, C.-C. Zhang for providing the
   FtsZ antiserum, and A. Suescun for technical assistance. We are
   grateful to J. Xiao, T. Liu, and I. M. Axmann for constructive
   suggestions on the ATPase assays. This work was supported by grants
   from the NIH (R01 GM62419 and P01 NS39546 to S. S. G., R01 GM068957 to
   A.v.O.), the American Recovery and Reinvestment Act (S. S. G.), NSF
   (PHY-0548484 to A.v.O.), and DOE (DE-FG-02-06ER15808 to K.W.O.). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   General Medical Sciences or the National Institutes of Health.
CR BELLPEDERSEN D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633
   CHABOT JR, 2007, NATURE, V450, P1249, DOI 10.1038/nature06395
   CHEN Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958
   CLERICO EM, 2007, METHOD MOL BIOL, V362, P155
   DONG GG, 2008, CURR OPIN MICROBIOL, V11, P541, DOI
   10.1016/j.mib.2008.10.003
   GREGORY JA, 2008, GENE DEV, V22, P3475, DOI 10.1101/gad.1732408
   HAYASHI F, 2003, GENES CELLS, V8, P287
   HAYASHI F, 2004, J BIOL CHEM, V279, P52331, DOI 10.1074/jbc.M406604200
   HAYASHI F, 2006, BIOCHEM BIOPH RES CO, V348, P864, DOI
   10.1016/j.bbrc.2006.07.143
   ISHIURA M, 1998, SCIENCE, V281, P1519
   IVLEVA NB, 2005, EMBO J, V24, P1202, DOI 10.1038/sj.emboj.7600606
   IVLEVA NB, 2006, P NATL ACAD SCI USA, V103, P17468, DOI
   10.1073/pnas.0606639103
   IWASAKI H, 2000, CELL, V101, P223
   IWASAKI H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI
   10.1073/pnas.222467299
   KAWAI Y, 2003, MOL MICROBIOL, V47, P1113
   KIM YI, 2008, P NATL ACAD SCI USA, V105, P12825, DOI
   10.1073/pnas.0800526105
   KITAYAMA Y, 2003, EMBO J, V22, P2127
   KITAYAMA Y, 2008, GENE DEV, V22, P1513, DOI 10.1101/gad.1661808
   KUTSUNA S, 2007, J BACTERIOL, V189, P7690, DOI 10.1128/JB.00835-07
   LIU Y, 1995, GENE DEV, V9, P1469
   LUTKENHAUS J, 2007, ANNU REV BIOCHEM, V76, P539, DOI
   10.1146/annurev.biochem.75.103004.142652
   MACKEY SR, 2007, METHOD MOL BIOL, V362, P115
   MACKEY SR, 2007, TRENDS MICROBIOL, V15, P381, DOI
   10.1016/j.tim.2007.08.005
   MARGOLIN W, 2005, NAT REV MOL CELL BIO, V6, P862, DOI 10.1038//nrm1745
   MATSUO T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   MAZOUNI K, 2004, MOL MICROBIOL, V52, P1145, DOI
   10.1111/j.1365-2958.2004.04042.x
   MIHALCESCU I, 2004, NATURE, V430, P81, DOI 10.1038/nature02533
   MIYAGISHIMA SY, 2005, MOL MICROBIOL, V56, P126, DOI
   10.1111/j.1365-2958.2005.04548.x
   MORI T, 1996, P NATL ACAD SCI USA, V93, P10183
   MORI T, 2001, J BACTERIOL, V183, P2439
   MORI T, 2009, BACT CIRC PROGR, P183
   NAGOSHI E, 2004, CELL, V119, P693
   NAKAJIMA M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451
   NISHIWAKI T, 2000, P NATL ACAD SCI USA, V97, P495
   NISHIWAKI T, 2004, P NATL ACAD SCI USA, V101, P13927, DOI
   10.1073/pnas.0403906101
   NISHIWAKI T, 2007, EMBO J, V26, P4029, DOI 10.1038/sj.emboj.7601832
   RUST MJ, 2007, SCIENCE, V318, P809, DOI 10.1126/science.1148596
   SCHMITZ O, 2000, SCIENCE, V289, P765
   SMITH RM, 2006, P NATL ACAD SCI USA, V103, P8564, DOI
   10.1073/pnas.0508696103
   TAKAI N, 2006, J BIOL RHYTHM, V21, P235, DOI 10.1177/0748730406289400
   TAKAI N, 2006, P NATL ACAD SCI USA, V103, P12109, DOI
   10.1073/pnas.0602955103
   TERAUCHI K, 2007, P NATL ACAD SCI USA, V104, P16377, DOI
   10.1073/pnas.0706292104
   TOMITA J, 2005, SCIENCE, V307, P251, DOI 10.1126/science.1102540
   WANG JM, 2004, J STRUCT BIOL, V148, P259, DOI 10.1016/j.jsb.2004.07.003
   WEART RB, 2007, CELL, V130, P335, DOI 10.1016/j.cell.2007.05.043
   WILLIAMS SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI
   10.1073/pnas.232517099
   XU Y, 2004, P NATL ACAD SCI USA, V101, P13933, DOI
   10.1073/pnas.0404768101
   YE JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI
   10.1016/j.bbabio.2004.06.003
   ZHANG XF, 2006, MOL MICROBIOL, V60, P658, DOI
   10.1111/j.1365-2958.2006.05138.x
NR 49
TC 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 19
PY 2010
VL 140
IS 4
BP 529
EP 539
DI 10.1016/j.cell.2009.12.042
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 557KQ
UT ISI:000274668400016
ER

PT J
AU Kokubo, T
   Kakinuma, S
   Kobayashi, T
   Watanabe, F
   Iritani, R
   Tateno, K
   Nishimura, M
   Nishikawa, T
   Hino, O
   Shimada, Y
AF Kokubo, Toshiaki
   Kakinuma, Shizuko
   Kobayashi, Toshiyuki
   Watanabe, Fumiko
   Iritani, Riichirou
   Tateno, Kaori
   Nishimura, Mayumi
   Nishikawa, Tetsu
   Hino, Okio
   Shimada, Yoshiya
TI Age dependence of radiation-induced renal cell carcinomas in an Eker
   rat model
SO CANCER SCIENCE
LA English
DT Article
ID TUBEROUS SCLEROSIS COMPLEX; POSTNATAL-DEVELOPMENT; N-NITROSOETHYLUREA;
   SOMATIC MUTATIONS; GROWTH-FACTOR; IN-UTERO; 2ND HIT; KIDNEY; CANCER;
   TUMORS
AB Exposure to carcinogens early in life may contribute to cancer
   development later in life. The amount of radiation exposure children
   experience during medical procedures has been increasing, so it is
   important to evaluate the radiation risk of cancer in developing
   organs. Toward this goal, we assessed the risk of developing renal cell
   carcinoma using Eker rats as a kidney tumor model. F1 hybrids of male
   Eker (Tsc2 mutant) and female F344 rats were irradiated with 0.5 or 2
   Gy gamma radiation on gestation days 15 and 19, and on postnatal days
   5, 20, and 49. At 27 weeks of age, kidneys were examined for
   proliferative lesions. Preneoplastic lesions such as phenotypically
   altered tubules increased after postnatal irradiation as a function of
   age-at-irradiation, and hyperplasia were greatly increased after
   perinatal and postnatal irradiation. In contrast, development of
   adenoma and adenocarcinoma were evident in animals irradiated at
   perinatal ages, being maximal at gestational day 19. The frequency of
   LOH at the Tsc2 locus was unexpectedly low - 0% (0 of 4) for the
   unirradiated control, and 17% (6 of 35) for the irradiated group.
   Irrespective of LOH, the mTOR (mammalian target of rapamycin) pathway,
   which is negatively regulated by the Tsc1/2 complex, was activated in
   both benign and malignant lesions, as evidenced by phosphorylation of
   S6 ribosomal protein and 4E-BP1. This suggests that the wild-type Tsc2
   allele may be functionally inactivated. In conclusion, actively growing
   kidneys in perinatal-aged (F344 x Eker) F1 rats (Tsc2(+/-)) are at risk
   for radiation-induced malignant transformation of the renal epithelium
   associated with mTOR activation. (Cancer Sci 2010; 101: 616-623)
C1 [Kokubo, Toshiaki; Kakinuma, Shizuko; Watanabe, Fumiko; Nishimura, Mayumi; Shimada, Yoshiya] Natl Inst Radiol Sci, Res Ctr Radiat Protect, Expt Radiobiol Childrens Hlth Res Grp, Chiba 260, Japan.
   [Kokubo, Toshiaki; Kobayashi, Toshiyuki; Hino, Okio] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan.
   [Kokubo, Toshiaki; Nishikawa, Tetsu] Natl Inst Radiol Sci, Fundamental Technol Ctr, Dept Tech Support & Dev, Lab Anim Sci Sect, Chiba 260, Japan.
   [Iritani, Riichirou; Tateno, Kaori] Sci Serv Co, Chiba, Japan.
RP Shimada, Y, Natl Inst Radiol Sci, Res Ctr Radiat Protect, Expt
   Radiobiol Childrens Hlth Res Grp, Chiba 260, Japan.
EM y_shimad@nirs.go.jp
FU National Institute of Radiological Sciences ; Japan Chemical Industry
   Association ; Ministry of Health, Labor and Welfare of Japan 
FX We thank Mr S. Tateno, Ms E. Kubo and all members of the Laboratory
   Animal Sciences Section of our institute for animal care. This work was
   supported by institute funds from the National Institute of
   Radiological Sciences, the LRI program of the Japan Chemical Industry
   Association, and a Grant-in-Aid for Cancer Research from the Ministry
   of Health, Labor and Welfare of Japan.
CR ALSALEEM T, 1998, CANCER, V83, P2208
   ANDERSON LM, 2000, ENVIRON HEALTH PE S3, V108, P573
   BERTRAM JF, 2000, ANAT REC, V258, P128
   BITHELL JF, 1975, BRIT J CANCER, V31, P271
   CHOYKE PL, 2003, RADIOLOGY, V226, P33, DOI 10.1148/radiol.2261011296
   CICHOWSKI K, 2001, CELL, V104, P593
   COLES HSR, 1993, DEVELOPMENT, V118, P777
   DAVIES JA, 1999, INT J DEV BIOL, V43, P473
   DIWAN BA, 1995, CARCINOGENESIS, V16, P2023
   DRESSLER GR, 2006, ANNU REV CELL DEV BI, V22, P509
   ELLENDER M, 2006, INT J RADIAT BIOL, V82, P141, DOI
   10.1080/09553000600632253
   FUKUDA T, 1998, JPN J CANCER RES, V89, P1104
   GNARRA JR, 1997, P NATL ACAD SCI USA, V94, P9102
   GOBE GC, 1988, INT J RADIAT BIOL, V54, P567
   HENSKE EP, 1996, AM J HUM GENET, V59, P400
   HINO O, 1993, CANCER RES, V53, P5856
   HINO O, 1993, P NATL ACAD SCI USA, V90, P327
   HINO O, 2002, INT CONGR SER, V1236, P163
   HONG DP, 2002, J RADIAT RES, V43, P175
   INGRAM DA, 2000, J EXP MED, V191, P181
   INOKI K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   KENERSON H, 2005, PEDIATR RES, V57, P67, DOI
   10.1203/01.PDR.0000147727.878571.07
   KOBAYASHI T, 1997, JPN J CANCER RES, V88, P254
   KUBO Y, 1995, CANCER RES, V55, P989
   LAPING NJ, 2007, CLIN CANCER RES, V13, P3087, DOI
   10.1158/1078-0432.CCR-06-1811
   MARIC C, 1997, ANAT EMBRYOL, V195, P503
   MARQUEZ MG, 2002, ANAT EMBRYOL, V205, P431, DOI
   10.1007/s00429-002-0262-9
   MARSH DJ, 1998, GENE CHROMOSOME CANC, V21, P61
   MCDORMAN KS, 2002, TOXICOL PATHOL, V30, P675, DOI
   10.1080/01926230290168542
   MORITZ KM, 2008, ADV ANAT EMBRYOL CEL, V196, P1
   NIIDA Y, 2001, AM J HUM GENET, V69, P493
   OHAKI Y, 1989, PEDIATR PATHOL, V9, P19
   PASCUAL D, 2008, ADV UROL, DOI 10.1155/2008/782381
   PRESTON DL, 2007, RADIAT RES, V168, P1
   SHIONO M, 2008, ONCOGENE, V27, DOI 10.1038/onc.2008.283
   TAKANO K, 2007, TOHOKU J EXP MED, V212, P81
   TUCKER T, 2002, CLIN GENET, V62, P345
   TURUSOV VS, 1980, NEOPLASMA, V27, P229
   VANOORDT CWV, 1997, CARCINOGENESIS, V18, P2197
   VENKATACHALAM S, 1998, EMBO J, V17, P4657
   WAKEFORD R, 2008, RADIAT PROT DOSIM, V132, P166, DOI 10.1093/rpd/ncn272
   WOLF DC, 1998, CARCINOGENESIS, V19, P2043
   YOSHIMOTO Y, 1988, LANCET, V2, P665
NR 43
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAR
PY 2010
VL 101
IS 3
BP 616
EP 623
DI 10.1111/j.1349-7006.2009.01456.x
PG 8
SC Oncology
GA 556VQ
UT ISI:000274621800007
ER

PT J
AU Wang, XF
   Nagase, H
   Watanabe, T
   Nobusue, H
   Suzuki, T
   Asami, Y
   Shinojima, Y
   Kawashima, H
   Takagi, K
   Mishra, R
   Igarashi, J
   Kimura, M
   Takayama, T
   Fukuda, N
   Sugiyama, H
AF Wang, Xiaofei
   Nagase, Hiroki
   Watanabe, Takayoshi
   Nobusue, Hiroyuki
   Suzuki, Tsukasa
   Asami, Yukihiro
   Shinojima, Yui
   Kawashima, Hiroyuki
   Takagi, Keiko
   Mishra, Rajeev
   Igarashi, Jun
   Kimura, Makoto
   Takayama, Tadatoshi
   Fukuda, Noboru
   Sugiyama, Hiroshi
TI Inhibition of MMP-9 transcription and suppression of tumor metastasis
   by pyrrole-imidazole polyamide
SO CANCER SCIENCE
LA English
DT Article
ID MATRIX-METALLOPROTEINASE INHIBITORS; CELL-LINES; KAPPA-B; CANCER;
   EXPRESSION; INVASION; DNA; RECOGNITION; PROGRESSION; INDUCTION
AB Matrix metalloproteinase (MMP)-9, the 92-kDa type IV collagenase,
   contributes to tumor invasion and metastases, and strategies to
   down-regulate its expression could ultimately be of clinical utility. A
   pyrrole-imidazole (PI) polyamide that targets the activator protein-1
   (AP-1)-binding site of the MMP-9 promoter was designed and synthesized
   as a gene-silencing agent for tumor metastases. The synthesized product
   showed selective DNA binding ability. The MMP-9 PI polyamide
   significantly inhibited MMP-9's mRNA expression, protein level, and
   enzymatic activity in human breast adenocarcinoma cells (MDA-MB-231).
   Furthermore, the MMP-9 PI polyamide inhibited migration and invasion by
   in vitro wound-healing and matrigel-invasion assay. The FITC-labeled PI
   polyamide was localized in nuclei in 45 min of incubation with an
   MDA-MB-231 cell and remained in the nuclei for up to 96 h after
   incubation in vitro. It was also quickly localized in the mouse
   cellular nuclei of many tissues, including liver, kidney, and spleen,
   after intravenous injection without using any drug-delivery system.
   Moreover, the polyamide treatment significantly decreased metastasis in
   a mouse model of liver metastasis. Our results suggest that this PI
   polyamide, which targets the MMP-9 gene promoter, can be a novel MMP-9
   downregulating molecule for antimetastasis. (Cancer Sci 2010; 101:
   759-766)
C1 [Wang, Xiaofei; Nagase, Hiroki; Igarashi, Jun; Fukuda, Noboru] Nihon Univ, Adv Res Inst Sci & Humanities, Tokyo, Japan.
   [Nagase, Hiroki; Watanabe, Takayoshi; Nobusue, Hiroyuki; Suzuki, Tsukasa; Asami, Yukihiro; Shinojima, Yui; Kawashima, Hiroyuki; Mishra, Rajeev; Kimura, Makoto] Nihon Univ, Sch Med, Dept Adv Med Sci, Div Canc Genet, Tokyo, Japan.
   [Takagi, Keiko; Takayama, Tadatoshi] Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan.
   [Sugiyama, Hiroshi] Kyoto Univ, Grad Sch Sci, Dept Chem, Kyoto, Japan.
   [Nagase, Hiroki] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
RP Nagase, H, Nihon Univ, Adv Res Inst Sci & Humanities, Tokyo, Japan.
EM nagase.hiroki@nihon-u.ac.jp
FU MEXT ; National Institute of Environmental Health Services [ES012249-01]
FX We thank Mr Motoaki Kataba, Mr Shigeki Nakai, and Ms Yuki Yamada for
   their technical support. This work was supported by the Nihon
   University Multidisciplinary Research Grant for 2007; the Academic
   Frontier Project for 2006 for Private Universities: Matching fund
   subsidy from MEXT to H. N.; and a grant from the National Institute of
   Environmental Health Services to H. N. (no. ES012249-01).
CR ARCAMONE F, 1964, NATURE, V203, P1064
   BANDO T, 2006, ACCOUNTS CHEM RES, V39, P935, DOI 10.1021/ar030287f
   BAXTER AD, 2001, BIOORG MED CHEM LETT, V11, P1465
   BERTRAND V, 1999, CANCER GENET CYTOGEN, V113, P36
   BEST TP, 2003, P NATL ACAD SCI USA, V100, P12063, DOI
   10.1073/pnas.2035074100
   BISWAS S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740
   BROWN PD, 2000, EXPERT OPIN INV DRUG, V9, P2167
   CHAKRABORTI S, 2003, MOL CELL BIOCHEM, V253, P269
   CHEN PN, 2006, CHEM-BIOL INTERACT, V163, P218, DOI
   10.1016/j.cbi.2006.08.003
   DERVAN PB, 2001, BIOORGAN MED CHEM, V9, P2215
   DERVAN PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI
   10.1016/S0959-440X(03)00081-2
   DRUMMOND AH, 1999, ANN NY ACAD SCI, V878, P228
   HIMELSTEIN BP, 1994, J CELL SCI 2, V107, P477
   HUANG Q, 2004, BIOCHEM PHARMACOL, V68, P361, DOI
   10.1016/j.bcp.2004.03.032
   ITOH T, 1999, CLIN EXP METASTAS, V17, P177
   JEMAL A, 2003, CA-CANCER J CLIN, V53, P5
   KATORI H, 2006, J SURG ONCOL, V93, P80, DOI 10.1002/jso.20386
   LAKKA SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200
   MCCAWLEY LJ, 2000, MOL MED TODAY, V6, P149
   MILDELANGOSCH K, 2005, EUR J CANCER, V41, P2449, DOI
   10.1016/j.ejca.2005.08.008
   MORINI M, 2000, INT J CANCER, V87, P336
   MOSES MA, 1997, STEM CELLS, V15, P180
   POSTE G, 1980, NATURE, V283, P139
   ROOMI MW, 2006, INT J GYNECOL CANCER, V16, P1241
   RUCKER VC, 2003, J AM CHEM SOC, V125, P1195, DOI 10.1021/ja021011q
   TAKAHRA T, 2004, INT J BIOCHEM CELL B, V36, P353, DOI
   10.1016/S1357-2725(03)00260-7
   VU TH, 1998, GELATINASE B
   WANG XF, 2004, AM J PATHOL, V165, P1375
   WURTZ NR, 2001, ORG LETT, V3, P1201
   YOSHIDA Y, 2006, EXP MOL PATHOL, V81, P77, DOI
   10.1016/j.yexmp.2005.10.005
NR 30
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAR
PY 2010
VL 101
IS 3
BP 759
EP 766
DI 10.1111/j.1349-7006.2009.01435.x
PG 8
SC Oncology
GA 556VQ
UT ISI:000274621800027
ER

PT J
AU Tajima, N
   Fukui, K
   Uesato, N
   Maruhashi, J
   Yoshida, T
   Watanabe, Y
   Tojo, A
AF Tajima, Nobuyuki
   Fukui, Kenji
   Uesato, Naofumi
   Maruhashi, Junji
   Yoshida, Takayuki
   Watanabe, Yoshihiro
   Tojo, Arinobu
TI JTE-607, a multiple cytokine production inhibitor, induces apoptosis
   accompanied by an increase in p21(waf1/cip1) in acute myelogenous
   leukemia cells
SO CANCER SCIENCE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; ENDOTHELIAL
   GROWTH-FACTOR; BLAST CELLS; BONE-MARROW; MYELODYSPLASTIC SYNDROMES;
   AUTOCRINE GROWTH; KAPPA-B; GM-CSF; EXPRESSION
AB Proinflammatory cytokines and growth factors have been thought to play
   crucial roles in the pathology of acute myelogenous leukemia (AML) by
   supporting the proliferation and survival of AML cells in an autocrine
   and paracrine manner, although further elucidation is required. JTE-607
   was originally identified as a multiple cytokine inhibitor that
   suppresses production of proinflammatory cytokines from
   lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells.
   Herein, we report that JTE-607 exhibits inhibitory activity on the
   growth of AML cell lines accompanying reduction of the proinflammatory
   cytokine and growth factor production. In in vitro studies, JTE-607
   suppressed expression and production of cytokines, which are
   spontaneously up-regulated in AML cell lines. JTE-607 also abrogated
   proliferation of AML cells in a concentration range in which colony
   formation of normal bone marrow cells was not affected. The growth
   inhibition by JTE-607 was characterized by induction of cell-cycle
   arrest at the S-phase and apoptosis, accompanied by a decrease in c-Myc
   and increase in p21(waf1/cip1). In a leukemia model engrafted with
   U-937 cells, JTE-607 significantly prolonged survival in mice and
   reduced human cytokine mRNA levels in the bone marrow. These results
   suggest the usefulness of JTE-607 in therapeutic applications for
   patients with hypercytokinemia and aggressive AML cell proliferation.
   (Cancer Sci 2010; 101: 774-781)
C1 [Tajima, Nobuyuki; Fukui, Kenji; Uesato, Naofumi; Maruhashi, Junji] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol & Pharmacol Labs, Osaka, Japan.
   [Yoshida, Takayuki; Watanabe, Yoshihiro] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Pharmaceut Frontier Res Labs, Kanagawa, Japan.
   [Tojo, Arinobu] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Mol Therapy, Tokyo, Japan.
RP Tajima, N, Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol &
   Pharmacol Labs, Osaka, Japan.
EM nobuyuki.tajima@jt.com
CR AGUAYO A, 2000, BLOOD, V96, P2240, UNSP 10979972
   AGUAYO A, 2002, CANCER, V95, P1923
   ASOU H, 1996, JPN J CANCER RES, V87, P269
   BARTEK J, 2004, NAT REV MOL CELL BIO, V5, P793
   BIRKENKAMP KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145
   BUBICI C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936
   COLLER HA, 2000, P NATL ACAD SCI USA, V97, P3260
   DEBONT ESJM, 2001, MED PEDIATR ONCOL, V37, P511
   DIAS S, 2001, P NATL ACAD SCI USA, V98, P10857
   DUNBAR CE, 1989, SCIENCE, V245, P1493
   FREEMERMAN AJ, 1997, LEUKEMIA, V11, P504
   GARTEL AL, 2002, MOL CANCER THER, V1, P639
   GOTTIFREDI V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200
   HATFIELD K, 2006, INT J CANCER, V119, P2313, DOI 10.1002/ijc.22180
   HATFIELD KJ, 2005, CURR CANCER DRUG TAR, V5, P229
   HOFFMAN B, 2002, ONCOGENE, V21, P3414
   HSU HC, 2002, ONCOLOGY-BASEL, V63, P64
   IWAMURA H, 2004, J PHARMACOL EXP THER, V311, P1256, DOI
   10.1124/jpet.104.072421
   KAKUTANI M, 1999, INFLAMM RES, V48, P461
   KAN QM, 2008, J BIOL CHEM, V283, P17864, DOI 10.1074/jbc.M802055200
   KISS C, 2004, PEDIATR BLOOD CANCER, V42, P113, DOI 10.1002/pbc.10436
   LICHT JD, 2005, HEMATOLOGY AM SOC HE, P137
   LIU SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI
   10.1016/S1368-7646(03)00044-X
   LOWENBERG B, 1999, NEW ENGL J MED, V341, P1051
   MILELLA M, 2005, CURR PHARM DESIGN, V11, P2779
   MIYAUCHI J, 1988, LEUKEMIA, V2, P382
   MUROHASHI I, 1989, BLOOD, V74, P35
   MUROHASHI I, 1993, EXP HEMATOL, V21, P846
   NEGAARD HFS, 2009, LEUKEMIA, V23, P162
   OGRYZKO VV, 1997, MOL CELL BIOL, V17, P4877
   PADRO T, 2000, BLOOD, V95, P2637
   PADRO T, 2002, LEUKEMIA, V16, P1302
   RADOSEVIC N, 2001, LEUKEMIA, V15, P559
   RENNEVILLE A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19
   RODRIGUEZCIMADE.JC, 1990, BLOOD, V76, P1481
   ROSATO RR, 2003, CANCER RES, V63, P3637
   RYNINGEN A, 2005, LEUKEMIA RES, V29, P185, DOI
   10.1016/j.leukres.2004.06.008
   SAILY M, 1998, EUR J HAEMATOL, V61, P190
   SASAKI J, 2003, AM J PHYSIOL-LUNG C, V284, L270, DOI
   10.1152/ajplung.00108.2002
   SEOANE J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119
   SUGIYAMA H, 1996, LEUKEMIA LYMPHOMA, V21, P49
   TALLMAN MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178
   TOBLER A, 1993, BLOOD, V82, P2517
   UESATO N, 2006, EXP HEMATOL, V34, P1385, DOI
   10.1016/j.exphem.2006.05.016
   WANG ZL, 1999, CANCER RES, V59, P1259
   WANG ZL, 2000, DIFFERENTIATION, V66, P1
   WEIGIEL B, 2009, LEUKEMIA, V23, P251
   WU Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200
   WU SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145
   YOUNG DC, 1986, BLOOD, V68, P1178
NR 50
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAR
PY 2010
VL 101
IS 3
BP 774
EP 781
DI 10.1111/j.1349-7006.2009.01446.x
PG 8
SC Oncology
GA 556VQ
UT ISI:000274621800029
ER

PT J
AU Watanabe, T
   Miura, T
   Degawa, Y
   Fujita, Y
   Inoue, M
   Kawaguchi, M
   Furihata, C
AF Watanabe, Takashi
   Miura, Tomohiro
   Degawa, Yusuke
   Fujita, Yuna
   Inoue, Masaaki
   Kawaguchi, Makoto
   Furihata, Chie
TI Comparison of lung cancer cell lines representing four
   histopathological subtypes with gene expression profiling using
   quantitative real-time PCR
SO CANCER CELL INTERNATIONAL
LA English
DT Article
ID COLON-CARCINOMA CELLS; FAMILY-MEMBERS; E-CADHERIN; ADENOCARCINOMA;
   CLASSIFICATION; BIOINFORMATICS; SENSITIVITY; METASTASIS; SUBCLASSES;
   BIOMARKERS
AB Background: Lung cancers are the most common type of human malignancy
   and are intractable. Lung cancers are generally classified into four
   histopathological subtypes: adenocarcinoma (AD), squamous cell
   carcinoma (SQ), large cell carcinoma (LC), and small cell carcinoma
   (SC). Molecular biological characterization of these subtypes has been
   performed mainly using DNA microarrays. In this study, we compared the
   gene expression profiles of these four subtypes using twelve human lung
   cancer cell lines and the more reliable quantitative real-time PCR
   (qPCR).
   Results: We selected 100 genes from public DNA microarray data and
   examined them by DNA microarray analysis in eight test cell lines
   (A549, ABC-1, EBC-1, LK-2, LU65, LU99, STC 1, RERF-LC-MA) and a normal
   control lung cell line (MRC-9). From this, we extracted 19 candidate
   genes. We quantified the expression of the 19 genes and a housekeeping
   gene, GAPDH, with qPCR, using the same eight cell lines plus four
   additional validation lung cancer cell lines (RERF-LC-MS, LC-1/sq,
   86-2, and MS-1-L). Finally, we characterized the four subtypes of lung
   cancer cell lines using principal component analysis (PCA) of gene
   expression profiling for 12 of the 19 genes (AMY2A, CDH1, FOXG1, IGSF3,
   ISL1, MALL, PLAU, RAB25, S100P, SLCO4A1, STMN1, and TGM2). The combined
   PCA and gene pathway analyses suggested that these genes were related
   to cell adhesion, growth, and invasion. S100P in AD cells and CDH1 in
   AD and SQ cells were identified as candidate markers of these lung
   cancer subtypes based on their upregulation and the results of PCA
   analysis. Immunohistochemistry for S100P and RAB25 was closely
   correlated to gene expression.
   Conclusions: These results show that the four subtypes, represented by
   12 lung cancer cell lines, were well characterized using qPCR and PCA
   for the 12 genes examined. Certain genes, in particular S100P and CDH1,
   may be especially important for distinguishing the different subtypes.
   Our results confirm that qPCR and PCA analysis provide a useful tool
   for characterizing cancer cell subtypes, and we discuss the possible
   clinical applications of this approach.
C1 [Watanabe, Takashi; Miura, Tomohiro; Degawa, Yusuke; Fujita, Yuna; Furihata, Chie] Aoyama Gakuin Univ, Sch Sci & Engn, Dept Chem & Biol Sci, Kanagawa 2298558, Japan.
   [Inoue, Masaaki] Japan Labor Hlth & Welf Org, Niigata Rosai Hosp, Dept Chest Surg, Niigata 9428502, Japan.
   [Kawaguchi, Makoto] Japan Labor Hlth & Welf Org, Niigata Rosai Hosp, Dept Pathol, Niigata 9428502, Japan.
RP Furihata, C, Aoyama Gakuin Univ, Sch Sci & Engn, Dept Chem & Biol Sci,
   Kanagawa 2298558, Japan.
EM chiefurihata@gmail.com
FU Regional New Consortium RD Projects ; Ministry of Economy, Trade and
   Industry, Japan ; Ministry of Education, Culture, Sports, Science, and
   Technology, Japan 
FX This work was supported in part by Regional New Consortium R&D
   Projects, The Ministry of Economy, Trade and Industry, Japan (C.
   Furihata), and a Grant-in-Aid from the Private School High-tech
   Research Center Program of the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan (C. Furihata). We thank Dr. Takayuki
   Negishi, School of Science and Engineering, Aoyama Gakuin University,
   for collaboration with the Bioanalyzer experiment, and Dr. Kazuhiko
   Matsumoto, Torii Pharmaceutical Co. Ltd. for his advice on Dunnett's
   test.
CR AI LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280
   BARTLING B, 2007, EUR J CANCER, V43, P1935, DOI
   10.1016/j.ejca.2007.06.010
   BASU GD, 2008, INT J CANCER, V123, P330, DOI 10.1002/ijc.23447
   BEER DG, 2002, NAT MED, V8, P816
   BHATTACHARJEE A, 2001, P NATL ACAD SCI USA, V98, P13790
   BRAAKHUIS BJM, 2003, CANCER RES, V63, P1727
   BRAAKHUIS BJM, 2004, J PATHOL, V203, P620, DOI 10.1002/path.1549
   CASWELL PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012
   DIEDERICHS S, 2004, CANCER RES, V64, P5564
   ENDOH H, 2004, J CLIN ONCOL, V22, P811, DOI 10.1200/JCO.2004.04.109
   FAN X, 2009, BMC P S2, V3, S4
   GARBER ME, 2001, P NATL ACAD SCI USA, V98, P13784
   GIORDANO TJ, 2001, AM J PATHOL, V159, P1231
   INAMURA K, 2005, ONCOGENE, V24, P7105, DOI 10.1038/sj.onc.1208858
   JU Z, 2005, MOL GENET GENOMICS, V274, P141, DOI
   10.1007/s00438-005-0014-7
   KIM B, 2007, CANCER RES, V67, P7431, DOI 10.1158/0008-5472.CAN-07-0003
   KUNER R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033
   MANGALA LS, 2005, MOL CANCER, V4, ARTN 33
   MCDONIELSSILVERS AL, 2002, CLIN CANCER RES, V8, P1127
   MULLER N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766
   NACHT M, 2001, P NATL ACAD SCI USA, V98, P15203
   NARDON E, 2009, EXP MOL PATHOL, V87, P146
   NIKOLOVA DA, 2009, CANCER RES, V69, P2461, DOI
   10.1158/0008-5472.CAN-08-3236
   OFFERSEN BV, 2007, LUNG CANCER, V56, P43, DOI
   10.1016/j.lungcan.2006.11.018
   PROVENANO M, 2007, ADV EXP MED BIOL, V593, P66
   QIN LX, 2006, BMC BIOINFORMATICS, V7, ARTN 23
   RANA S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI
   10.1586/14737140.8.9.1461
   SCHWARTEWALDHOFF I, 1999, ONCOGENE, V18, P3152
   SINGER S, 2009, CANCER RES, V69, P2234, DOI
   10.1158/0008-5472.CAN-08-3338
   VIRTANEN C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI
   10.1073/pnas.192240599
   WAAGMEESTER AS, 2008, GENES NUTR, V3, P139, DOI
   10.1007/s12263-008-0098-x
   WATANABE T, 2009, MUTAT RES-GEN TOX EN, V673, P9, DOI
   10.1016/j.mrgentox.2008.11.004
   YAUK CL, 2007, ENVIRON MOL MUTAGEN, V48, P380, DOI 10.1002/em.20290
NR 33
TC 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD JAN 21
PY 2010
VL 10
AR 2
DI 10.1186/1475-2867-10-2
PG 12
SC Oncology
GA 557SS
UT ISI:000274691000001
ER

PT J
AU Trojani, A
   Montillo, M
   Nichelatti, M
   Tedeschi, A
   Colombo, C
   Veronese, S
   Mura, MA
   Ricci, F
   Scarpati, B
   Colosimo, A
   Lodola, M
   Morra, E
AF Trojani, Alessandra
   Montillo, Marco
   Nichelatti, Michele
   Tedeschi, Alessandra
   Colombo, Chiara
   Veronese, Silvio
   Mura, Maria Angela
   Ricci, Francesca
   Scarpati, Barbara
   Colosimo, Anna
   Lodola, Milena
   Morra, Enrica
TI ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic
   lymphocytic leukemia
SO CANCER BIOMARKERS
LA English
DT Article
DE CLL; biomarkers; ZAP-70; IgVh; cytogenetics
ID MUTATION STATUS; GENOMIC ABERRATIONS; DISEASE PROGRESSION; 11Q
   DELETION; P53 GENE; IMMUNOGLOBULIN; EXPRESSION; SURVIVAL; DIAGNOSIS;
   PREDICTS
AB Background: New prognostic factors such as IgVh mutational status,
   ZAP-70 protein expression and cytogenetic abnormalities have shown to
   offer important prognostic information for patients with chronic
   lymphocytic leukemia (CLL). Our aim was to evaluate the optimal cut-off
   for IgVh mutational status, ZAP-70 expression and cytogenetic
   abnormalities in association with disease progression defined as the
   need for treatment within 3 years from diagnosis in 170 patients with
   B-CLL.
   Design and methods: Receiver operating characteristics (ROC) analysis
   and multivariate general linear models (GLMs) were used to investigate
   the most significant cut-off values of these biomarkers and their
   prognostic impact.
   Results: Our findings estimated that the optimal cut-off for IgVh
   mutation status and for ZAP-70 protein expression was 97% and 16.5%
   respectively and a high concordance between the two was demonstrated.
   We identified 30% as being the best-cut-off for 17p-, 11q- and 6q-. In
   univariate analysis 17p- was found to be a significant predictor of the
   event only for the whole population. Multivariate analysis including
   all biological parameters, identified 11q deletion as the only
   significant regressor.
   Conclusions: We assessed that IgVh mutational status, ZAP-70 protein
   and 6q- are powerful prognostic markers. Analyses of all these factors
   revealed that 11q deletion was the strongest predictor of disease
   progression in B-CLL.
C1 [Trojani, Alessandra; Montillo, Marco; Tedeschi, Alessandra; Colombo, Chiara; Ricci, Francesca; Lodola, Milena; Morra, Enrica] Osped Niguarda Ca Granda, Div Hematol, I-20162 Milan, Italy.
   [Nichelatti, Michele] Osped Niguarda Ca Granda, Serv Biostat, I-20162 Milan, Italy.
   [Veronese, Silvio; Colosimo, Anna] Osped Niguarda Ca Granda, Mol Pathol Unit, Dept Lab Med, I-20162 Milan, Italy.
   [Scarpati, Barbara] Osped Niguarda Ca Granda, Dept Trasfus Med, I-20162 Milan, Italy.
   [Scarpati, Barbara] Osped Niguarda Ca Granda, Div Hematol, I-20162 Milan, Italy.
RP Trojani, A, Osped Niguarda Ca Granda, Div Hematol, Piazza Osped
   Maggiore 3, I-20162 Milan, Italy.
EM alessandra.trojani@ospedaleniguarda.it
FU Associazione Malattie del Sangue (AMS, Milan, Italy) 
FX This study was supported by Associazione Malattie del Sangue (AMS,
   Milan, Italy). The authors would like to thank Dr. Silvia Soriani who
   participated to the cytogenetic studies.
CR 1978, BR J HAEMATOL, V39, P311
   AUSTEN B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649
   BINET JL, 1977, CANCER, V40, P855
   BINET JL, 2006, BLOOD, V107, P859, DOI 10.1182/blood-2005-04-1677
   BYRD JC, 2003, CANCER RES, V63, P36
   CHESON BD, 1996, BLOOD, V87, P4990
   CRESPO M, 2003, NEW ENGL J MED, V348, P1764
   CUNEO A, 2004, LEUKEMIA, V18, P476, DOI 10.1038/sj.leu.2403242
   DICKER F, 2009, LEUKEMIA, V23, P117
   DICKINSON JD, 2006, LEUKEMIA LYMPHOMA, V47, P231, DOI
   10.1080/10428190500254141
   DIGHIERO G, 2008, LANCET, V371, P1017
   DOHNER H, 1995, BLOOD, V85, P1580
   DOHNER H, 2000, NEW ENGL J MED, V343, P1910
   FINK SR, 2006, CANCER GENET CYTOGEN, V167, P177, DOI
   10.1016/j.cancergencyto.2006.01.005
   GACHARD N, 2008, HAEMATOL-HEMATOL J, V93, P215, DOI
   10.3324/haematol.11622
   GOWDA A, 2006, CURR OPIN HEMATOL, V13, P266
   HALLEK M, 2008, ANN ONCOL S4, V19, P51, DOI 10.1093/annonc/mdn196
   HAMBLIN TJ, 2008, BRIT J HAEMATOL, V140, P320, DOI
   10.1111/j.1365-2141.2007.06928.x
   KAY NE, 2007, CURR HEMATOL MALIGN, V2, P49
   KHARTANDABAJA MA, 2008, CANCER, V113, P897, DOI 10.1002/cncr.23671
   KROBER A, 2002, BLOOD, V100, P1410
   KROBER A, 2006, J CLIN ONCOL, V24, P969, DOI 10.1200/JCO.2005.03.7184
   LAU LC, 2008, CANCER GENET CYTOGEN, V185, P95, DOI
   10.1016/j.cancergencyto.2008.04.017
   MITELMAN F, 1995, ISCN 1995 INT SYSTEM
   MORENO C, 2008, BLOOD REV, V22, P211, DOI 10.1016/j.blre.2008.03.003
   ORCHARD JA, 2004, LANCET, V363, P105
   OSCIER DG, 2002, BLOOD, V100, P1177
   PASSAM F, 2006, ANN HEMATOL, V85, P795, DOI 10.1007/s00277-006-0159-4
   RASSENTI LZ, 2004, NEW ENGL J MED, V351, P893
   RASSENTI LZ, 2008, BLOOD, V112, P1923
   REDDY KS, 2006, BRIT J HAEMATOL, V132, P705, DOI
   10.1111/j.1365-2141.2005.05919.x
   ROZMAN C, 1995, NEW ENGL J MED, V333, P1052
   SCHWARZ G, 1978, ANN STAT, V6, P461
   SHAFFER LG, 2005, INT SYSTEM HUMAN CYT
   STILGENBAUER S, 1999, LEUKEMIA, V13, P1331
   STILGENBAUER S, 2007, HAEMATOL-HEMATOL J, V92, P1242, DOI
   10.3324/haematol.10720
   VANDONGEN JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202
NR 37
TC 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2010
VL 6
IS 1
BP 1
EP 9
DI 10.3233/CBM-2009-0114
PG 9
SC Oncology
GA 556PQ
UT ISI:000274603900001
ER

PT J
AU Halperin, MH
   Tertrais, B
   Payne, KB
   Subrahmanyam, K
   Sagan, SD
AF Halperin, Morton H.
   Tertrais, Bruno
   Payne, Keith B.
   Subrahmanyam, K.
   Sagan, Scott D.
TI The Case for No First Use: An Exchange
SO SURVIVAL
LA English
DT Editorial Material
ID WEAPONS
AB In the June-July 2009 issue of Survival, Scott D. Sagan argued the
   current case for the United States to adopt a declaratory policy of no
   nuclear first use. Survival invited four experts from Europe, Asia and
   North America to comment on Sagan's argument. The author concludes the
   debate with his own final thoughts.
C1 [Payne, Keith B.] Missouri State Univ, Grad Dept Def & Strateg Studies, Springfield, MO USA.
   [Sagan, Scott D.] Stanford Univ, Stanford, CA 94305 USA.
   [Sagan, Scott D.] Stanfords Ctr Int Secur & Cooperat, Stanford, CA USA.
CR ARKIN WM, 1996, WASH QUART, V19, P3
   BAKER JA, 1995, POLITICS DIPLOMACY R, P359
   BUSH G, 1998, WORLD TRANSFORMED, P463
   BUSH GHW, 2000, ALL BEST G BUSH MY L, P500
   COHEN A, 1998, ISRAEL BOMB, P259
   FITCHETT J, 1995, NY TIMES        0912
   FOUILLAND P, 2009, DET S OM NEBR 30 JUL
   FUKUYAMA S, 2009, JAPAN TIMES     0825
   GROSSMAN E, 2009, GLOBAL SECURITY 0728
   HALPERIN MH, 1961, PROPOSAL BAN USE NUC
   HUSSEIN S, 2004, COMMUNICATION   0311
   HUSSEIN S, 2004, COMMUNICATION   0513
   KRISTENSEN HM, 2007, WHITE HOUSE GUIDANCE
   MCCARTHY TV, 2000, PLANNING UNTHINKABLE, P47
   MCNAMARA RS, 2005, FOREIGN POLICY   MAY, P28
   MEHTA AK, 2008, PIONEER         0115
   OKADA K, 2009, SEKAI            JUL
   PAYNE KB, 1996, DETERRENCE 2 NUCL AG, P81
   PAYNE KB, 2005, WASH QUART, V28, P135
   PAYNE KB, 2008, GREAT AM GAMBLE DETE, P414
   PERRY WJ, 2009, AM STRATEGIC POSTURE, P36
   RICE C, 2005, WASHINGTON POST 1211
   SAGAN SD, 2000, INT SECURITY, V24, P85
   SAGAN SD, 2009, INSIDE NUCL S ASIA, P219
NR 24
TC 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0039-6338
J9 SURVIVAL
JI Survival
PY 2009
VL 51
IS 5
BP 17
EP 46
DI 10.1080/00396330903309840
PG 30
SC International Relations; Political Science
GA 552KN
UT ISI:000274288800002
ER

PT J
AU Lee, SH
   Kim, KY
   Ryu, SY
   Yoon, Y
   Hahm, DH
   Kang, SA
   Cho, SH
   Lim, JS
   Moon, EY
   Yoon, SR
   Lee, HG
   Yoon, DY
   Yang, Y
AF Lee, S. H.
   Kim, K-Y
   Ryu, S. Y.
   Yoon, Y.
   Hahm, D-H
   Kang, S. A.
   Cho, S. H.
   Lim, J-S
   Moon, E-Y
   Yoon, S. R.
   Lee, H. G.
   Yoon, D. Y.
   Yang, Y.
TI ASARONE INHIBITS ADIPOGENESIS AND STIMULATES LIPOLYSIS IN 3T3-L1
   ADIPOCYTES
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE C/EBP alpha; PPAR gamma; Adiponectin; Asarone; Hormone-sensitive lipase
ID HORMONE-SENSITIVE LIPASE; ADIPOSE TRIGLYCERIDE LIPASE; ACTIVATED
   PROTEIN-KINASE; FATTY-ACID OXIDATION; RESVERATROL; APOPTOSIS; ALPHA;
   CELLS
AB Asarone is a molecule found in certain plants such as Acorus calamus,
   the root of which is used in traditional medicine to treat diabetes. We
   determined the molecular mechanism underlying the anti-diabetic
   activity of asarone. Treatment of asarone significantly inhibited the
   differentiation of 3T3-L1 preadipocytes through suppression of
   expression of the transcription factors, CCAAT/enhancer binding
   protein-alpha and peroxisome proliferator activated receptor-gamma,
   which activate adipogenesis. Intracellular triglyceride levels were
   reduced by asarone in a dose-dependent manner and asarone treatment
   stimulated the phosphorylation of hormone-sensitive lipase. Together,
   the present findings indicate that asarone inhibits adipogenesis by
   down-regulation of PPAR gamma and C/EBP alpha and reduces lipid
   accumulation by stimulation of lipolysis through an increase in
   hormone-sensitive lipase activity.
C1 [Lee, S. H.; Kim, K-Y; Lim, J-S; Yang, Y.] Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea.
   [Ryu, S. Y.] Korea Res Inst Chem Technol, Taejon 305343, South Korea.
   [Yoon, Y.] Chung Ang Univ, Dept Microbiol, Coll Med, Seoul 140757, South Korea.
   [Hahm, D-H] Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea.
   [Kang, S. A.] Seoul Univ Venture & Informat, Dept Fermented Food Sci, Seoul 135731, South Korea.
   [Cho, S. H.] Chung Ang Univ, Dept Family Med, Yongsan Hosp, Seoul 140757, South Korea.
   [Moon, E-Y] Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea.
   [Yoon, S. R.; Lee, H. G.] Korea Res Inst Biosci & Biotechnol, Taejon 305343, South Korea.
   [Yoon, D. Y.] Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea.
RP Yang, Y, Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South
   Korea.
EM yyang@sookmyung.ac.kr
FU Rural Development Administration [20070301034031]; Korea Research
   Foundation [KRF-2008-313-C00708]; Korea government (MEST)
   [R01-2008-000-20127-0]
FX This work was supported by the Biogreen 21 project (20070301034031) of
   Rural Development Administration, and a Korea Research Foundation Grant
   KRF-2008-313-C00708 and the Korea Science and Engineering Foundation
   (KOSEF) grant funded by the Korea government (MEST)
   (R01-2008-000-20127-0).
CR ACUNA UM, 2002, PHYTOTHER RES, V16, P63
   ANTUNEZSOLIS J, 2009, J ENZYM INHIB MED CH, V24, P903, DOI
   10.1080/14756360802318902
   ARDEVOL A, 2000, INT J OBESITY, V24, P319
   BERG AH, 2001, NAT MED, V7, P947
   DENNEHY CE, 2005, ANN PHARMACOTHER, V39, P1634, DOI 10.1345/aph.1G0185
   GREENBERG AS, 2001, J BIOL CHEM, V276, P45456
   HOLM C, 2003, BIOCHEM SOC T 6, V31, P1120
   HU E, 1996, J BIOL CHEM, V271, P10697
   KIM JH, 2008, CANCER LETT, V261, P253, DOI 10.1016/j.canlet.2007.11.020
   MIYOSHI H, 2008, J CELL BIOCHEM, V105, P1430, DOI 10.1002/jcb.21964
   PIERRE SV, 2008, CELL MOL BIOL S, V54, P1032, DOI 10.1170/118
   RAYALAM S, 2008, PHYTOTHER RES, V22, P1367, DOI 10.1002/ptr.2503
   RYDEN M, 2007, AM J PHYSIOL-ENDOC M, V292, E1847, DOI
   10.1152/ajpendo.00040.2007
   SZKUDELSKA K, 2000, J STEROID BIOCHEM, V75, P265
   TANG QQ, 2003, P NATL ACAD SCI USA, V100, P44
   VISAVADIYA NP, 2009, CELL MOL BIOL, V55, P1083
   YAMAUCHI T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   YANG JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003
   YEH WC, 1995, GENE DEV, V9, P168
   YOON MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322
NR 20
TC 0
PU C M B  ASSOC
PI POITIERS
PA 40 AVENUE  RECTEUR PINEAU,  BAT MECANIQUE, 86022 POITIERS, FRANCE
SN 0145-5680
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2010
VL 56
SU Suppl. S
BP OL1215
EP OL1222
DI 10.1170/138
PG 8
SC Biochemistry & Molecular Biology; Cell Biology
GA 556DY
UT ISI:000274570400001
ER

PT J
AU Qiao, G
   Li, Z
   Minto, AW
   Shia, J
   Yang, L
   Bao, L
   Tschopp, J
   Gao, JX
   Wang, J
   Quigg, RJ
   Zhang, J
AF Qiao, G.
   Li, Z.
   Minto, A. W.
   Shia, J.
   Yang, L.
   Bao, L.
   Tschopp, J.
   Gao, J-X
   Wang, J.
   Quigg, R. J.
   Zhang, J.
TI Altered thymic selection by overexpressing cellular FLICE inhibitory
   protein in T cells causes lupus-like syndrome in a BALB/c but not
   C57BL/6 strain
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE signal transduction; autoimmunity; T-cell activation; apoptosis
ID NF-KAPPA-B; C-FLIP; NEGATIVE SELECTION; POSITIVE SELECTION; ANTIGEN
   RECEPTOR; IN-VIVO; ACTIVATION; LYMPHOCYTES; CASPASE-8; AUTOIMMUNITY
AB The cellular FLICE inhibitory protein (c-FLIP) is an endogenous
   inhibitor of the caspase-8 proapoptotic signaling pathway downstream of
   death receptors. Recent evidence indicates that the long form of c-FLIP
   (c-FLIPL) is required for proliferation and effector T-cell
   development. However, the role of c-FLIPL in triggering autoimmunity
   has not been carefully analyzed. We now report that c-FLIPL transgenic
   (Tg) mice develop splenomegaly, lymphadenopathy, multiorgan
   infiltration, high titers of autoantibodies, and proliferative
   glomerulonephritis with immune complex deposition in a strain-dependent
   manner. The development of autoimmunity requires CD4(+) T cells and may
   result from impaired thymic selection. At the molecular level, c-FLIPL
   overexpression inhibits the zeta chain-associated protein tyrosine
   kinase of 70 kDa (ZAP-70) activation, thus impairing the signaling
   pathway derived from ZAP-70 required for thymic selection. Therefore,
   we have identified c-FLIPL as a susceptibility factor under the
   influence of epistatic modifiers for the development of autoimmunity.
   Cell Death and Differentiation (2010) 17, 522-533; doi:
   10.1038/cdd.2009.143; published online 9 October 2009
C1 [Qiao, G.; Li, Z.; Minto, A. W.; Yang, L.; Bao, L.; Quigg, R. J.; Zhang, J.] Univ Chicago, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
   [Qiao, G.; Yang, L.; Zhang, J.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.
   [Shia, J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Tschopp, J.] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
   [Gao, J-X] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Wang, J.] Invitrogen Corp, BioSource Cytokines & Signaling, Camarillo, CA USA.
   [Zhang, J.] Univ Chicago, Comm Mol Med, Chicago, IL 60637 USA.
RP Zhang, J, Univ Chicago, Dept Med, Nephrol Sect, 5841 S Maryland Ave,
   Chicago, IL 60637 USA.
EM jzhang@medicine.bsd.uchicago.edu
FU National Institutes of Health (NIH) [R01 AR049775, DK055357]; American
   Heart Association [09GRNT2010084]; NIH independent scientist award [K02
   AR 049047]; American Lung Association Career Investigator 
FX We thank Drs. Marcus Peter and Yang-Xin Fu for critical reading of the
   paper and discussion. This work is in part supported by a novel
   research grant from the Lupus Research Institute (to JZ) and a start-up
   fund from the University of Chicago. Additional support was provided by
   grants from the National Institutes of Health (NIH) (R01 AR049775 to JZ
   and DK055357 to RJQ) and from the American Heart Association
   (09GRNT2010084 to JZ). JZ was supported by a NIH independent scientist
   award (K02 AR 049047), and is an American Lung Association Career
   Investigator.
CR AZZAM HS, 1998, J EXP MED, V188, P2301
   BOLLAND S, 2000, IMMUNITY, V13, P277
   BOUILLET P, 2002, NATURE, V415, P922
   BUDD RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787
   CANNONS JL, 2004, IMMUNITY, V21, P693
   CHAU H, 2005, J EXP MED, V202, P405, DOI 10.1084/jem.20050118
   GAO JX, 2002, J EXP MED, V195, P959
   HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745
   HOGQUIST KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707
   HUTCHESON J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015
   KATAOKA T, 2000, CURR BIOL, V10, P640
   KORETZKY GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750
   KRETZROMMEL A, 2000, NAT MED, V6, P298
   LAYER K, 2003, IMMUNITY, V19, P243
   LENS SMA, 2002, MOL CELL BIOL, V22, P5419
   LISTON A, 2008, NAT REV IMMUNOL, V8, P545, DOI 10.1038/nri2336
   MARIATHASAN S, 2000, EUR J IMMUNOL, V30, P1060
   MCNEIL LK, 2005, P NATL ACAD SCI USA, V102, P13574, DOI
   10.1073/pnas.0505110102
   MICHEAU O, 2001, MOL CELL BIOL, V21, P5299
   MISRA RS, 2007, J BIOL CHEM, V282, P19365, DOI 10.1074/jbc.M610610200
   MORA AL, 2001, J IMMUNOL, V167, P5628
   MURPHY KM, 1990, SCIENCE, V250, P1720
   PALMER E, 2009, NAT REV IMMUNOL, V9, P206, DOI 10.1038/nri2469
   ROBERTSON JM, 2000, J IMMUNOL, V164, P4706
   SAKAGUCHI N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   SALMENA L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703
   SALOJIN K, 1997, J EXP MED, V186, P887
   SALOJIN KV, 2000, J BIOL CHEM, V275, P5966
   SOMMERS CL, 2002, SCIENCE, V296, P2040
   STARR TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI
   10.1146/annurev.immunol.21.120601.141107
   SU H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765
   SUGAWARA T, 1998, IMMUNITY, V9, P565
   THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269
   THOME M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352
   TOYAMA H, 2002, IMMUNITY, V17, P329
   TSEVELEKI V, 2004, J IMMUNOL, V173, P6619
   VANPARIJS L, 1999, IMMUNITY, V11, P763
   WERLEN G, 2003, SCIENCE, V299, P1859
   WU WF, 2004, J IMMUNOL, V172, P4724
   XU LT, 2004, NAT MED, V10, P411, DOI 10.1038/nm1005
   ZHANG J, 2004, CELL MOL IMMUNOL, V1, P186
   ZHANG JA, 2003, J IMMUNOL, V170, P3495
   ZHANG N, 2005, J EXP MED, V202, P395, DOI 10.1084/jem.20050117
NR 43
TC 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD MAR
PY 2010
VL 17
IS 3
BP 522
EP 533
DI 10.1038/cdd.2009.143
PG 12
SC Biochemistry & Molecular Biology; Cell Biology
GA 556CL
UT ISI:000274565300015
ER

PT J
AU Heng, JCD
   Feng, B
   Han, JY
   Jiang, JM
   Kraus, P
   Ng, JH
   Orlov, YL
   Huss, M
   Yang, L
   Lufkin, T
   Lim, B
   Ng, HH
AF Heng, Jian-Chien Dominic
   Feng, Bo
   Han, Jianyong
   Jiang, Jianming
   Kraus, Petra
   Ng, Jia-Hui
   Orlov, Yuriy L.
   Huss, Mikael
   Yang, Lin
   Lufkin, Thomas
   Lim, Bing
   Ng, Huck-Hui
TI The Nuclear Receptor Nr5a2 Can Replace Oct4 in the Reprogramming of
   Murine Somatic Cells to Pluripotent Cells
SO CELL STEM CELL
LA English
DT Article
ID STEM-CELLS; FIBROBLASTS; LRH-1; DOMAIN; MOUSE; MYC
AB Somatic cells can be reprogrammed to induced pluripotent stem cells
   (iPSGs) with the introduction of Oct4, Sox2, Klf4, and c-Myc. Among
   these four factors, Oct4 is critical in inducing pluripotency because
   no transcription factor can substitute for Oct4, whereas Sox2, Klf4,
   and c-Myc can be replaced by other factors. Here we show that the
   orphan nuclear receptor Nr5a2 (also known as Lrh-1) can replace Oct4 in
   the derivation of iPSCs from mouse somatic cells, and it can also
   enhance reprogramming efficiency. Sumoylation mutants of Nr5a2 with
   enhanced transcriptional activity can further increase reprogramming
   efficiency. Genome-wide location analysis reveals that Nr5a2 shares
   many common gene targets with Sox2 and Klf4, which suggests that the
   transcription factor trio works in concert to mediate reprogramming. We
   also show that Nr5a2 works in part through activating Nanog. Together,
   we show that unrelated transcription factors can replace Oct4 and
   uncovers an exogenous Oct4-free reprogramming code.
C1 [Heng, Jian-Chien Dominic; Feng, Bo; Jiang, Jianming; Ng, Jia-Hui; Yang, Lin; Ng, Huck-Hui] Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore.
   [Orlov, Yuriy L.; Huss, Mikael] Genome Inst Singapore, Computat & Syst Biol Grp, Singapore 138672, Singapore.
   [Heng, Jian-Chien Dominic; Ng, Jia-Hui; Ng, Huck-Hui] NUS, Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore.
   [Lufkin, Thomas; Ng, Huck-Hui] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.
   [Lim, Bing] Harvard Univ, Sch Med, Ctr Life Sci, Boston, MA 02115 USA.
RP Ng, HH, Genome Inst Singapore, Gene Regulat Lab, Singapore 138672,
   Singapore.
EM nghh@gis.a-star.edu.sg
FU Biomedical Research Council, Agency for Science, Technology and
   Research and Singapore Stem Cell Consortium ; NUS Graduate School for
   Integrative Sciences and Engineering ; A STAR 
FX We are grateful to the Biomedical Research Council, Agency for Science,
   Technology and Research and Singapore Stem Cell Consortium for funding.
   J.H. is supported by the NUS Graduate School for Integrative Sciences
   and Engineering Scholarship. J.-H.N. is supported by the A STAR
   graduate scholarship. We thank Xiangling Ng and Kuee-Theng Kuay for
   technical support and Meng-Chun Hu for plasmids. We acknowledge Valere
   Cacheux-Rataboul for karyotype analysis and GTB group for sequencing.
   We thank Andrew Hutchins and Felicia Huimei Hong for comments to the
   manuscript.
CR CHEN X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   FENG B, 2009, CELL STEM CELL, V4, P301, DOI 10.1016/j.stem.2009.03.005
   FENG B, 2009, NAT CELL BIOL, V11, P197, DOI 10.1038/ncb1827
   GU PL, 2005, MOL CELL BIOL, V25, P3492
   ICHIDA JK, 2009, CELL STEM CELL, V5, P491, DOI
   10.1016/j.stem.2009.09.012
   KIM JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436
   LEWITZKY M, 2007, CURR OPIN BIOTECH, V18, P467, DOI
   10.1016/j.copbio.2007.09.007
   MAHERALI N, 2009, CURR BIOL, V19, P1718, DOI 10.1016/j.cub.2009.08.025
   NAKAGAWA M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   NICHOLS J, 1998, CELL, V95, P379
   PARE JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200
   SABLIN EP, 2003, MOL CELL, V11, P1575
   SCHOLER HR, 1990, NATURE, V344, P435
   SILVA J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039
   SOLOMON IH, 2005, J MOL BIOL, V354, P1091, DOI 10.1016/j.jmb.2005.10.009
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   WERNIG M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001
   YANG FM, 2009, FEBS J, V276, P425, DOI 10.1111/j.1742-4658.2008.06785.x
   YU JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 19
TC 29
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD FEB 5
PY 2010
VL 6
IS 2
BP 167
EP 174
DI 10.1016/j.stem.2009.12.009
PG 8
SC Cell & Tissue Engineering; Cell Biology
GA 555OC
UT ISI:000274520800011
ER

PT J
AU Guo, J
   Liu, ML
   Yang, DH
   Bouxsein, ML
   Saito, H
   Galvin, RJS
   Kuhstoss, SA
   Thomas, CC
   Schipani, E
   Baron, R
   Bringhurst, FR
   Kronenberg, HM
AF Guo, Jun
   Liu, Minlin
   Yang, Dehong
   Bouxsein, Mary L.
   Saito, Hiroaki
   Galvin, R. J. Sells
   Kuhstoss, Stuart A.
   Thomas, Clare C.
   Schipani, Ernestina
   Baron, Roland
   Bringhurst, F. Richard
   Kronenberg, Henry M.
TI Suppression of Wnt Signaling by Dkk1 Attenuates PTH-Mediated Stromal
   Cell Response and New Bone Formation
SO CELL METABOLISM
LA English
DT Article
ID RECEPTOR-RELATED PROTEIN-5; PARATHYROID-HORMONE; BETA-CATENIN; IN-VIVO;
   OSTEOBLASTIC CELLS; HEAD INDUCTION; INHIBITION; DIFFERENTIATION;
   PHOSPHORYLATION; KINASE
AB Parathyroid hormone (PTH) suppresses Dickkopf 1 (Dkk1) expression in
   osteoblasts. To determine whether this suppression is essential for
   PTH-mediated Wnt signaling and bone formation, we examined mice that
   overexpress Dkk1 in osteoblasts (Dkk1 mice). Dkk1 mice were osteopenic
   due to abnormal osteoblast and osteoclast activity. When fed a
   low-calcium diet, and in two other models of hyperparathyroidism, these
   mice failed to develop the peritrabecular stromal cell response
   ("osteitis fibrosis") and new bone formation seen in wild-type mice.
   Despite these effects of Dkk1 overexpression, PTH still activated Wnt
   signaling in Dkk1 mice and in osteoblastic cells cultured from these
   mice. In cultured MC3T3E1 preosteoblastic cells, PTH dramatically
   suppressed Dkk1 expression, induced PKA-mediated phosphorylation of
   beta-catenin, and significantly enhanced Lef1 expression. Our findings
   indicate that the full actions of PTH require intact Wnt signaling but
   that PTH can activate the Wnt pathway despite overexpression of Dkk1.
C1 [Guo, Jun; Liu, Minlin; Yang, Dehong; Thomas, Clare C.; Schipani, Ernestina; Bringhurst, F. Richard; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Orthopaed Biomech Lab, Boston, MA 02215 USA.
   [Galvin, R. J. Sells; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med, Boston, MA 02115 USA.
   [Galvin, R. J. Sells; Kuhstoss, Stuart A.] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.
RP Kronenberg, HM, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA
   02114 USA.
EM kronenberg.henry@mgh.harvard.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [HL081030]
FX We thank Venkatesh Krishnan for useful discussion regarding the
   anti-Dkk1 study. This work was supported by a grant to H.M.K. from the
   National Heart, Lung, and Blood Institute (NHLBI) Specialized Center
   for Cell-Based Therapy (HL081030).
CR BABIJ P, 2003, J BONE MINER RES, V18, P960
   BELLIDO T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005-0239
   BELLIDO T, 2006, J MUSCULOSKELET  NEU, V6, P358
   BOYDEN LM, 2002, NEW ENGL J MED, V346, P1513
   CALVI LM, 2001, J CLIN INVEST, V107, P277
   CASTELLONE MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   DASGUPTA R, 1999, DEVELOPMENT, V126, P4557
   DAY TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   FLEMING HE, 2008, CELL STEM CELL, V2, P274, DOI
   10.1016/j.stem.2008.01.003
   GLASS DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GLINKA A, 1998, NATURE, V391, P357
   GOESSLING W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   GONG YQ, 2001, CELL, V107, P513
   GUO J, 2002, DEV CELL, V3, P183
   HE X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   HILL TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   HINO S, 2005, MOL CELL BIOL, V25, P9063, DOI
   10.1128/MCB.25.20.9063-9072.2005
   HODSMAN AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004-0006
   HOLMEN SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   JILKA RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   KULKARNI NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   LEUPIN O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   LI J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   LIU ZY, 2008, J BIOL CHEM, V283, P8723, DOI 10.1074/jbc.M706105200
   LOTINUN S, 2005, ENDOCRINOLOGY, V146, P4074, DOI 10.1210/en.2005-0480
   MARVIN MJ, 2001, GENE DEV, V15, P316
   MIAO DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   MORVAN F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   MUKHOPADHYAY M, 2001, DEV CELL, V1, P423
   RODDA SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   SUZUKI A, 2008, J CELL BIOCHEM, V104, P304, DOI 10.1002/jcb.21626
   TAURIN S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   TAURIN S, 2007, J BIOL CHEM, V282, P19518, DOI 10.1074/jbc.M702655200
   TAURIN S, 2008, AM J PHYSIOL-CELL PH, V294, C1169, DOI
   10.1152/ajpcell.00096.2008
   TOBIMATSU T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005-1627
   WAN M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   WANG FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   YACCOBY S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood-2006-09-047712
   YADAV VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   YANG D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
NR 40
TC 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD FEB 3
PY 2010
VL 11
IS 2
BP 161
EP 171
DI 10.1016/j.cmet.2009.12.007
PG 11
SC Cell Biology; Endocrinology & Metabolism
GA 555ON
UT ISI:000274521900008
ER

PT J
AU Takai, H
   Ashihara, M
   Ishiguro, T
   Terashima, H
   Watanabe, T
   Kato, A
   Suzuki, M
AF Takai, Hirotake
   Ashihara, Motohki
   Ishiguro, Takahiro
   Terashima, Hiromichi
   Watanabe, Takeshi
   Kato, Atsuhiko
   Suzuki, Masami
TI Involvement of glypican-3 in the recruitment of M2-polarized
   tumor-associated macrophages in hepatocellular carcinoma
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE GPC3; HCC; xenograft models; TAM; M2 macrophage; microarray analysis
ID HEPARAN-SULFATE PROTEOGLYCANS; COLONY-STIMULATING FACTOR; BREAST-CANCER
   MODEL; XENOGRAFTS IN-VIVO; GENE-EXPRESSION; MICROARRAY ANALYSIS;
   T-CELLS; PROGRESSION; RANTES; LUNG
AB Previously, we demonstrated that membrane expression of glypican-3
   (GPC3) stimulates the recruitment of macrophages into human
   hepatocellular carcinoma (HCC) tissues. however, functional
   polarization of the macrophages and the chemoattractant factors related
   to the recruitment has yet to be determined. In this study, to clarify
   the polarization (M1 or M2) of the macrophages and provide a clue as to
   the factors involved in the recruitment, we used xenograft models of
   SK-HEP-1 and SK03 cell lines with undetectable and high-level membrane
   expression of GPC3, respectively and analyzed the expression profiles
   of the relevant genes in both xenografts mainly using microarray
   techniques. Clustering analyses with mouse genome arrays revealed that
   the SK-HEP-1 and SK03 xenografts showed different expression profiles
   for M2 macrophage-related genes but not for M1 macrophage-related
   genes. Many of the M2 macrophage-related genes were upregulated in the
   SK03 xenografts compared to the SK-HEP-1 xenografts. additionally, most
   of the macrophages infiltrating into the SK03 xenografts were positive
   for M2 macrophage-specific markers. Regarding the chemoattractant
   factors, the microarray and quantitative real-time PCR analyses
   revealed that, of the genes reportedly related to macrophage
   recruitment, CCL5, CCL3 and CSF1 were significantly upregulated in the
   SK03 xenograft. These findings suggest that the macrophages recruited
   into GPC3-overexpressing (with membrane expression) HCC are
   M2-polarized ones and, more specifically, M2 tumor-associated
   macrophages which are known to promote tumor progression and
   metastasis, and CCL5, CCL3 and CSF1 are possible candidate genes for
   the recruitment of macrophages.
C1 [Takai, Hirotake; Watanabe, Takeshi; Kato, Atsuhiko; Suzuki, Masami] Chugai Pharmaceut Co Ltd, Dept Safety Assessment, Shizuoka, Japan.
   [Ashihara, Motohki; Terashima, Hiromichi] Chugai Pharmaceut Co Ltd, Dept Pharmaceut Technol, Kanagawa, Japan.
   [Ishiguro, Takahiro] Chugai Pharmaceut Co Ltd, Pharmaceut Res Dept 2, Kanagawa, Japan.
RP Takai, H, Chugai Pharmaceut Co Ltd, Dept Safety Assessment, Shizuoka,
   Japan.
EM takaihrt@chugai-pharm.co.jp
CR ACUFF HB, 2006, CANCER RES, V66, P7968, DOI
   10.1158/0008-5472.CAN-05-4279
   ALLAVENA P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI
   10.1016/j.critrevonc.2007.07.004
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805
   AZENSHTEIN E, 2002, CANCER RES, V62, P1093
   BALKWILL F, 2001, LANCET, V357, P539
   BALKWILL F, 2005, CANCER CELL, V7, P211
   BANDAPALLI OR, 2006, INT J CANCER, V118, P74, DOI 10.1002/ijc.21307
   BERNFIELD M, 1999, ANNU REV BIOCHEM, V68, P729
   BINGLE L, 2002, J PATHOL, V196, P254
   BLACKHALL FH, 2001, BRIT J CANCER, V85, P1094
   CAPURRO M, 2003, GASTROENTEROLOGY, V125, P89, DOI
   10.1016/S0016-5085(03)00689-9
   CAPURRO MI, 2005, CANCER RES, V65, P6245
   CHENG W, 2008, CARCINOGENESIS, V29, P1319, DOI 10.1093/carcin/bgn091
   COFFELT SB, 2009, BBA-REV CANCER, V1796, P11, DOI
   10.1016/j.bbcan.2009.02.004
   CONDEELIS J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   COUSSENS LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   CREIGHTON CJ, 2005, MOL CANCER RES, V3, P119
   DENADAI P, 2006, J INVEST DERMATOL, V126, P2057, DOI
   10.1038/sj.jid.5700369
   DORNER BG, 2002, P NATL ACAD SCI USA, V99, P6181
   DOUGLASS TG, 2008, INT IMMUNOPHARMACOL, V8, P1354, DOI
   10.1016/j.intimp.2008.04.016
   FILMUS J, 1995, BIOCHEM J 2, V311, P561
   FILMUS J, 2001, GLYCOBIOLOGY, V11, P19
   FISCHER FR, 2001, J IMMUNOL, V167, P1637
   GERSCH C, 2002, HISTOCHEM CELL BIOL, V118, P41
   IRIZARRY RA, 2003, BIOSTATISTICS, V4, P249
   JIA HL, 2007, CLIN CANCER RES, V13, P1133, DOI
   10.1158/1078-0432.CCR-06-1025
   JONES JO, 2003, J VIROL, V77, P1268, DOI 10.1128/JVI.77.2.1268-1280.2003
   KLUGER HM, 2004, LAB INVEST, V84, P320, DOI 10.1038/labinvest.3700044
   KOMOHARA Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370
   KWACK MH, 2006, MOL CELLS, V21, P224
   LIBBRECHT L, 2006, AM J SURG PATHOL, V30, P1405
   LIN EY, 2001, J EXP MED, V193, P727
   LIN XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522
   LIOVET JM, 2006, GASTROENTEROLOGY, V131, P1758
   LIVAK KJ, 2001, METHOD METHODS, V4, P402
   LUCAS T, 2008, FRONT BIOSCI, V13, P5580
   MARTIN L, 2001, BIOCHEMISTRY-US, V40, P6303
   MARTINEZ FO, 2006, J IMMUNOL, V177, P7303
   MAURER M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI
   10.1016/j.biocel.2003.10.019
   MAYANIL CSK, 2001, J BIOL CHEM, V276, P49299
   MIDORIKAWA Y, 2003, INT J CANCER, V103, P455, DOI 10.1002/ijc.10856
   MONTEL V, 2005, AM J PATHOL, V166, P1565
   MONTEL V, 2006, INT J CANCER, V119, P251, DOI 10.1002/ijc.21757
   MURDOCH C, 2004, BLOOD, V104, P2224
   POLLARD JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   SAKATA T, 1992, J IMMUNOL, V149, P4002
   SAKTHIVEL SK, 2008, BMC MICROBIOL, V8, ARTN 136
   SCHALL TJ, 1990, NATURE, V347, P669
   SCHALL TJ, 1991, CYTOKINE, V3, P165
   SCOTTON CJ, 2005, J IMMUNOL, V174, P834
   SERODY JS, 2000, BLOOD, V96, P2973
   SHIRAKAWA H, 2009, CANCER SCI, V100, P1403, DOI
   10.1111/j.1349-7006.2009.01206.x
   SICA A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   SICA A, 2008, SEMIN CANCER BIOL, V18, P349, DOI
   10.1016/j.semcancer.2008.03.004
   SUNG YK, 2003, CANCER SCI, V94, P259
   SUTTON A, 2007, MOL CANCER THER, V6, P2948, DOI
   10.1158/1535-7163.MCT-07-0114
   SUZUKI M, 2000, J TOXICOL PATHOL, V13, P109
   TAKAI H, 2009, ACTA HISTOCHEMICA
   TAKAI H, 2009, CANCER BIOL THER, V8, P930
   TAKAI H, 2009, LIVER INT, V29, P1056, DOI
   10.1111/j.1478-3231.2008.01968.x
   TANAKA Y, 1998, TRENDS GLYCOSCI GLYC, V10, P153
   TOMOKIYO R, 2002, ATHEROSCLEROSIS, V161, P123
   TSUTSUI S, 2005, ONCOL REP, V14, P425
   VANDENBERG TK, 2005, TRENDS IMMUNOL, V26, P506, DOI
   10.1016/j.it.2005.07.008
   WU Y, 2008, J IMMUNOL, V181, P6384
   WU ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683
   YAMAUCHI N, 2005, MODERN PATHOL, V18, P1591, DOI
   10.1038/modpathol.3800436
   YANO S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005-0065
   ZHU ZW, 2001, GUT, V48, P558
NR 69
TC 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD DEC 15
PY 2009
VL 8
IS 24
BP 2329
EP 2338
PG 10
SC Oncology
GA 551RI
UT ISI:000274226300010
ER

PT J
AU Yang, FC
   Tso, AC
   Chen, CW
   Peng, GS
AF Yang, Fu-Chi
   Tso, An-Chen
   Chen, Chun-Wen
   Peng, Giia-Sheun
TI Cerebral venous thrombosis initially presenting with left occipital
   hemorrhage and headache
SO BLOOD COAGULATION & FIBRINOLYSIS
LA English
DT Article
DE anticoagulation; cerebral hemorrhage; cerebral venous thrombosis;
   headache
ID DURAL SINUS THROMBOSIS
AB Cerebral venous thrombosis (CVT) can be difficult to diagnose because
   of its wide spectrum of clinical manifestations. In the present
   article, we report a 58-year-old man coming to our emergency department
   presenting with left temporal throbbing headache and right hemianopia.
   Computed tomography of the brain revealed acute hemorrhages over the
   left occipital area. Due to the unusual location of hemorrhage,
   magnetic resonance venography was performed, revealing absence of
   venous flow over the superior sagittal and transverse sinuses
   suggestive of CVT. He received anticoagulant therapy for 6 months and
   the headache subsided. We feel that a high index of clinical suspicion
   is needed to diagnose an intracerebral hemorrhage in an uncommon site
   caused by CVT, even if risk factors of CVT are not present, so that
   appropriate treatment can be initiated as promptly as possible. Failure
   to recognize the signs of CVT could result in inappropriate management
   and suboptimal secondary prophylaxis strategies, which could affect the
   patient's clinical outcome. Blood Coagul Fibrinolysis 21:182-184 (C)
   2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Yang, Fu-Chi; Tso, An-Chen; Peng, Giia-Sheun] Triserv Gen Hosp, Dept Neurol, Natl Def Med Ctr, Taipei 114, Taiwan.
   [Chen, Chun-Wen] Triserv Gen Hosp, Dept Radiol, Natl Def Med Ctr, Taipei 114, Taiwan.
RP Peng, GS, Triserv Gen Hosp, Dept Neurol, Natl Def Med Ctr, 325,Sect
   2,Cheng Kung Rd, Taipei 114, Taiwan.
EM fuji-yang@yahoo.com.tw
   penggs@mail.ndmctsgh.edu.tw
CR AGOSTONI E, 2004, NEUROL SCI S3, V25, S206, DOI
   10.1007/s10072-004-0287-3
   BOUSSER MG, 1985, STROKE, V16, P199
   BRETEAU G, 2003, J NEUROL, V250, P29, DOI 10.1007/s00415-003-0932-4
   CONNOR SEJ, 2002, CLIN RADIOL, V57, P449
   EINHAUPL K, 2006, EUR J NEUROL, V13, P553, DOI
   10.1111/j.1468-1331.2006.01398.x
   EINHAUPL KM, 1991, LANCET, V338, P597
   FINK JN, 2001, INTERN MED J, V31, P384
   HINMAN JM, 2002, EUR J RADIOL, V41, P147
   MAK W, 2001, CEREBROVASC DIS, V11, P282
   PRETER M, 1996, STROKE, V27, P243
   RENOWDEN S, 2004, EUR RADIOL, V14, P215, DOI 10.1007/s00330-003-2021-6
   SAW VPJ, 1999, J CLIN NEUROSCI, V6, P480
   TERAZZI E, 2005, NEUROL SCI, V25, P311, DOI 10.1007/s10072-004-0363-8
NR 13
TC 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0957-5235
J9 BLOOD COAGULAT FIBRINOL
JI Blood Coagul. Fibrinolysis
PD MAR
PY 2010
VL 21
IS 2
BP 182
EP 184
DI 10.1097/MBC.0b013e328333782c
PG 3
SC Hematology
GA 555LZ
UT ISI:000274513600014
ER

PT J
AU Yang, HC
   Chen, JW
   Liu, CM
   Wen, CC
   Liu, YL
   Chen, CH
   Hwu, HG
AF Yang, Hsin-Chou
   Chen, Jia-Wei
   Liu, Chih-Min
   Wen, Chun-Chiang
   Liu, Yu-Li
   Chen, Chun-Houh
   Hwu, Hai-Gwo
TI The Taiwan Schizophrenia Genetic Interaction Study
SO GENETIC EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the International-Genetic-Epidemiology-Society
CY OCT 10-20, 2009
CL Honolulu, HI
SP Int Genet Epidemiol Soc
C1 [Yang, Hsin-Chou; Chen, Jia-Wei; Chen, Chun-Houh] Acad Sinica, Inst Stat Sci, Taipei, Taiwan.
   [Liu, Chih-Min; Wen, Chun-Chiang; Hwu, Hai-Gwo] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan.
NR 0
TC 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD DEC
PY 2009
VL 33
IS 8
BP 67         
PG 1
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 529TK
UT ISI:000272540600077
ER

PT J
AU Levin, AM
   Datta, I
   Yang, J
   Iannuzzi, MC
   McKeigue, PM
   Rybicki, BA
   Gray-McGuire, CL
AF Levin, Albert M.
   Datta, Indrani
   Yang, James
   Iannuzzi, Micheal C.
   McKeigue, Paul M.
   Rybicki, Benjamin A.
   Gray-McGuire, Courtney L.
TI Ancestry Informative Markers and Family-Based Association
SO GENETIC EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the International-Genetic-Epidemiology-Society
CY OCT 10-20, 2009
CL Honolulu, HI
SP Int Genet Epidemiol Soc
C1 [Levin, Albert M.; Datta, Indrani; Yang, James; Rybicki, Benjamin A.] Henry Ford Hlth Syst, Detroit, MI USA.
   [Iannuzzi, Micheal C.] SUNY Upstate Med Univ, Syracuse, NY USA.
   [McKeigue, Paul M.] Univ Edinburgh, Western Gen Hosp, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Gray-McGuire, Courtney L.] Oklahoma Med Res Fdn, Oklahoma City, OK USA.
NR 0
TC 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD DEC
PY 2009
VL 33
IS 8
BP 107        
PG 1
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 529TK
UT ISI:000272540600117
ER

PT J
AU Yang, W
   Gu, CC
AF Yang, Wei
   Gu, Chi C.
TI A Whole-genome Simulator Capable of Modeling High-order Epistasis for
   GWAS Studies of Complex Disease
SO GENETIC EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the International-Genetic-Epidemiology-Society
CY OCT 10-20, 2009
CL Honolulu, HI
SP Int Genet Epidemiol Soc
C1 [Gu, Chi C.] Washington Univ, Div Biostat, Dept Genet, St Louis, MO USA.
NR 0
TC 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD DEC
PY 2009
VL 33
IS 8
BP 148        
PG 1
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 529TK
UT ISI:000272540600157
ER

PT J
AU Chen, L
   Yang, G
AF Chen, Lian
   Yang, Guang
TI A genomic scanning using AFLP to detect candidate loci under selection
   in the finless porpoise (Neophocaena phocaenoides)
SO GENES & GENETIC SYSTEMS
LA English
DT Article
DE AFLP; finless porpoise; outlier loci; population genomics; selection
ID BACKGROUND SELECTION; POPULATION-STRUCTURE; FUNCTIONAL GENOMICS;
   NATURAL-POPULATIONS; GENETIC-STRUCTURE; MARKERS; DIFFERENTIATION;
   POLYMORPHISM; ADAPTATION; DIVERGENCE
AB Identifying loci under natural selection from genomic surveys is of
   great interest in different research areas, stimulated by the
   increasing ease with large numbers of markers to gain a genome-wide
   perspective on differentiation. In this study, we searched for the
   genetic signatures of selection by screening 114 amplified fragment
   length polymorphism (AFLP) markers in three finless porpoise
   populations inhabiting contrasting natural environments (freshwater and
   marine habitat). Comparing among three populations, four AFLP loci
   exhibited F-ST values higher than 0.975 quantile which might be
   inferred to be under divergent selection and two loci fell below the
   0.025 quantile which might be affected by balancing selection. Although
   these loci were not supported with statistical significance in false
   discovery rate (FDR) analysis, the present study illustrated the
   potential of genome-wide surveys to identify specific genome regions or
   genes associated with freshwater adaptation of the finless porpoise.
C1 [Chen, Lian; Yang, Guang] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Biodivers & Biotechnol, Nanjing 210046, Peoples R China.
RP Yang, G, Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Biodivers
   & Biotechnol, Nanjing 210046, Peoples R China.
EM gyang@njnu.edu.cn
FU National Natural Science Foundation of China (NSFC) [30830016,
   30670294, 30470253]; Program for New Century Excellent Talents in
   University [NCET-07-0445]; Ministry of Education of China ; Specialized
   Research Fund for the Doctoral Program of Higher Education [SRFDP
   20060319002]; Natural Science Foundation of the Jiangsu Higher
   Education Institutions of China [07KJA18016]
FX We thank Dr. Aurelie Bonin for her valuable advice and kind assistance
   on analytical issues. This research was financially supported by the
   National Natural Science Foundation of China (NSFC) key project grant
   no. 30830016, NSFC grant nos 30670294 and 30470253, the Program for New
   Century Excellent Talents in University (NCET-07-0445), the Ministry of
   Education of China, the Specialized Research Fund for the Doctoral
   Program of Higher Education (SRFDP 20060319002), the Ministry of
   Education of China, and the major project of the Natural Science
   Foundation of the Jiangsu Higher Education Institutions of China
   (07KJA18016).
CR BEAUMONT MA, 1996, P R SOC B, V263, P1619
   BEAUMONT MA, 2004, MOL ECOL, V13, P969, DOI
   10.1111/j.1365-294X.2004.02125.x
   BEAUMONT MA, 2005, TRENDS ECOL EVOL, V20, P435, DOI
   10.1016/j.tree.2005.05.017
   BONIN A, 2005, METHOD ENZYMOL, V395, P145
   BONIN A, 2006, MOL BIOL EVOL, V23, P773, DOI 10.1093/molbev/msj087
   CAMPBELL D, 2004, MOL BIOL EVOL, V21, P945, DOI 10.1093/molbev/msh101
   CHARLESWORTH B, 1997, GENET RES, V70, P155
   CHARLESWORTH D, 2006, PLOS GENET, V2, P379, ARTN e64
   EGAN SP, 2008, EVOLUTION, V62, P1162, DOI
   10.1111/j.1558-5646.2008.00352.x
   EXCOFFIER L, 2005, EVOL BIOINFORM, V1, P47
   FEDER ME, 2003, NAT REV GENET, V4, P651, DOI 10.1038/nrg1128
   GALLAVOTTI A, 2004, NATURE, V432, P630, DOI 10.1038/nature03148
   GAO A, 1995, ACTA THERIOLOGICA SI, V15, P161
   GAO A, 1995, ACTA THERIOLOGICA SI, V15, P246
   GAO A, 1995, ACTA THERIOLOGICA SI, V15, P81
   KASUYA T, 1999, HDB MARINE MAMMALS, V6, P411
   KINGSTON SE, 2004, J HERED, V95, P1, DOI 10.1093/jhered/esh010
   LUIKART G, 2003, NAT REV GENET, V4, P981, DOI 10.1038/nrg1226
   MACKAY TFC, 2001, ANNU REV GENET, V35, P303
   MCVEAN G, 2005, PLOS GENET, V1, P413, ARTN e54
   NAMROUD MC, 2008, MOL ECOL, V17, P3599, DOI
   10.1111/j.1365-294X.2008.03840.x
   NIELSEN R, 2005, ANNU REV GENET, V39, P197, DOI
   10.1146/annurev.genet.39.073003.112420
   ORR HA, 2005, NAT REV GENET, V6, P119, DOI 10.1038/nrg1523
   PRZEWORSKI M, 2005, EVOLUTION, V59, P2312
   REEVES RR, 1997, ASIAN MAR BIOL, V14, P111
   SCHLOTTERER C, 2003, TRENDS GENET, V19, P32
   SMITH JM, 1974, GENET RES, V23, P23
   STEPHAN W, 1998, P NATL ACAD SCI USA, V95, P5649
   STINCHCOMBE JR, 2008, HEREDITY, V100, P158, DOI 10.1038/sj.hdy.6800937
   STOREY JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI
   10.1073/pnas.1530509100
   STORZ JF, 2005, MOL ECOL, V14, P671, DOI
   10.1111/j.1365-294X.2004.02437.x
   TESHIMA KM, 2006, GENOME RES, V16, P702, DOI 10.1101/gr.5105206
   TSUMURA Y, 2007, GENETICS, V176, P2393, DOI 10.1534/genetics.107.072652
   WANG ZS, 2003, EVOLUTION, V57, P2852
   WILDING CS, 2001, J EVOLUTION BIOL, V14, P611
   WILLIAMS LM, 2008, BMC EVOL BIOL, V8, ARTN 282
   WRIGHT S, 1951, ANN EUGEN, V15, P323
   YANG G, 2002, MAR MAMMAL SCI, V18, P336
   YANG G, 2003, ACTA THERIOL, V48, P469
   YANG G, 2008, BIOL J LINN SOC, V95, P193
   ZHIVOTOVSKY LA, 1999, MOL ECOL, V8, P907
NR 41
TC 1
PU GENETICS SOC JAPAN
PI SHIZUOKA
PA NATL INST GENETICS, YATA, MISHIMA,, SHIZUOKA, 411, JAPAN
SN 1341-7568
J9 GENES GENET SYST
JI Genes Genet. Syst.
PD AUG
PY 2009
VL 84
IS 4
BP 307
EP 313
PG 7
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 553OL
UT ISI:000274376600006
ER

PT J
AU Li, Z
   Zhao, B
   Wang, P
   Chen, F
   Dong, ZH
   Yang, HR
   Guan, KL
   Xu, YH
AF Li, Ze
   Zhao, Bin
   Wang, Ping
   Chen, Fei
   Dong, Zhenghong
   Yang, Huirong
   Guan, Kun-Liang
   Xu, Yanhui
TI Structural insights into the YAP and TEAD complex
SO GENES & DEVELOPMENT
LA English
DT Article
DE YAP; TEAD; structure; Hippo
ID YES-ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR; ONCOGENIC TRANSFORMATION;
   CELL-PROLIFERATION; CONTACT INHIBITION; GROWTH-CONTROL; SIZE-CONTROL;
   ORGAN SIZE; DOMAIN; COACTIVATOR
AB The Yes-associated protein (YAP) transcriptional coactivator is a key
   regulator of organ size and a candidate human oncogene inhibited by the
   Hippo tumor suppressor pathway. The TEAD family of transcription
   factors binds directly to and mediates YAP-induced gene expression.
   Here we report the three-dimensional structure of the YAP (residues
   50-171)-TEAD1 (residues 194-411) complex, in which YAP wraps around the
   globular structure of TEAD1 and forms extensive interactions via three
   highly conserved interfaces. Interface 3, including YAP residues
   86-100, is most critical for complex formation. Our study reveals the
   biochemical nature of the YAP-TEAD interaction, and provides a basis
   for pharmacological intervention of YAP-TEAD hyperactivation in human
   diseases.
C1 [Li, Ze; Wang, Ping; Chen, Fei; Dong, Zhenghong; Yang, Huirong; Xu, Yanhui] Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.
   [Li, Ze; Xu, Yanhui] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Zhao, Bin; Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Zhao, Bin; Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Xu, Yanhui] Fudan Univ, Dept Pathol, Canc Hosp, Shanghai 200032, Peoples R China.
RP Xu, YH, Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.
EM kuguan@ucsd.edu
   xuyh@fudan.edu.cn
FU National Natural Science Foundation of China [30870493]; National Basic
   Research Program of China [2009CB918600]; Shanghai Pujiang Program
   [08PJ14010]; Shanghai Leading Academic Discipline Project [B111]; NIH 
FX We thank all of the staff at the beamline BL17U at Shanghai Synchrotron
   Radiation Facility (China) and BL17A at Photon Factory (Japan) for
   assistance in data collection, and Karen Tumaneng for critical reading
   of the manuscript. This work was supported by grants from the National
   Natural Science Foundation of China (30870493), National Basic Research
   Program of China (2009CB918600), Shanghai Pujiang Program (08PJ14010),
   and Shanghai Leading Academic Discipline Project (B111) to Y.X., and
   grants from the NIH to K.L.G.
CR ADAMS PD, 2002, ACTA CRYSTALLOGR  11, V58, P1948, DOI
   10.1107/S0907444902016657
   ANBANANDAM A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI
   10.1073/pnas.0607171103
   CAMARGO FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039
   CAO XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608
   CHAN SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200
   DARIMONT BD, 1998, GENE DEV, V12, P3343
   DONG JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019
   EMSLEY P, 2004, ACTA CRYSTALLOGR  12, V60, P2126, DOI
   10.1107/S0907444904019158
   FOSSDAL R, 2004, HUM MOL GENET, V13, P975, DOI 10.1093/hmg/ddh106
   GOULEV Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034
   HALDER G, 1998, GENE DEV, V12, P3900
   HANZALBAYER M, 2002, EMBO J, V21, P2095
   HOLM L, 2008, BIOINFORMATICS, V24, P2780, DOI
   10.1093/bioinformatics/btn507
   KITAGAWA M, 2007, BIOCHEM BIOPH RES CO, V361, P1022, DOI
   10.1016/j.bbrc.2007.07.129
   KOMURO A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200
   LANDAU M, 2005, NUCLEIC ACIDS RES S2, V33, W299, DOI 10.1093/nar/gki370
   MAHONEY WM, 2005, BIOCHEM J 1, V388, P217, DOI 10.1042/BJ20041434
   MORINKENSICKI EM, 2006, MOL CELL BIOL, V26, P77, DOI
   10.1128/MCB.26.1.77-87.2006
   NISHIOKA N, 2008, MECH DEVELOP, V125, P270, DOI
   10.1016/j.mod.2007.11.002
   NISHIOKA N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003
   NOLTE RT, 1998, NATURE, V395, P137
   OTA M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   OVERHOLTZER M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI
   10.1073/pnas.0605579103
   SAWADA A, 2008, MOL CELL BIOL, V28, P3177, DOI 10.1128/MCB.01759-07
   SIMMONDS AJ, 1998, GENE DEV, V12, P3815
   STEINHARDT AA, 2008, HUM PATHOL, V39, P1582, DOI
   10.1016/j.humpath.2008.04.012
   STRANO S, 2001, J BIOL CHEM, V276, P15164
   VASSILEV A, 2001, GENE DEV, V15, P1229
   WESTIN S, 1998, NATURE, V395, P199
   WU S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007
   YAGI R, 1999, EMBO J, V18, P2551
   YAGI R, 2007, DEVELOPMENT, V134, P3827, DOI 10.1242/dev.010223
   ZENDER L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030
   ZHANG H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200
   ZHANG L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006
   ZHAO B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   ZHAO B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
   ZHAO B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997
NR 38
TC 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD FEB 1
PY 2010
VL 24
IS 3
BP 235
EP 240
DI 10.1101/gad.1865810
PG 6
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 550UZ
UT ISI:000274157300003
ER

PT J
AU Yang, H
   Cui, GB
   Jiao, XY
   Wang, J
   Ju, G
   You, SW
AF Yang, Hao
   Cui, Guang-Bin
   Jiao, Xi-Ying
   Wang, Jian
   Ju, Gong
   You, Si-Wei
TI Thymosin-beta 4 Attenuates Ethanol-induced Neurotoxicity in Cultured
   Cerebral Cortical Astrocytes by Inhibiting Apoptosis
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Thymosin-beta 4; Ethanol; Astrocyte; Cell culture; Apoptosis
ID RAT HIPPOCAMPAL ASTROCYTES; CENTRAL-NERVOUS-SYSTEM; FETAL ALCOHOL
   SYNDROME; BETA(4) MESSENGER-RNA; INDUCED CELL-DEATH;
   ALZHEIMERS-DISEASE; IN-VITRO; CA2+ MOBILIZATION; OXIDATIVE DAMAGE;
   EPITHELIAL-CELLS
AB Thymosin-beta 4 (T beta 4) is a major actin monomer-binding peptide in
   mammalian tissues and plays a crucial role in the nervous system in
   synaptogenesis, neuronal survival and migration, axonal growth, and
   plastic changes of dendritic spines. However, it is unknown whether T
   beta 4 is also involved in challenges with external stress such as
   ethanol-induced neurotoxicity. In the present study, we investigated
   the effects of T beta 4 on ethanol-induced neurotoxicity in cultured
   cerebral cortical astrocytes and the underlying mechanisms. Primarily
   cultured astrocytes were treated with 1 mu g/ml T beta 4 2 h prior to
   administration of 100 mM ethanol for 0.5, 1, 3 and 6 days,
   respectively. The results showed that ethanol caused neurotoxicity in
   cultured astrocytes, as shown by declined cell viability, distinct
   astroglial apoptosis and increased intracellular peroxidation. T beta 4
   markedly promoted cell viability, ameliorated the injury of
   intracellular glial fibrillary acidic protein-immunopositive
   cytoskeletal structures, reduced the percentage of apoptotic astrocyte
   and cellular DNA fragmentation, suppressed caspase-3 activity and
   upregulated Bcl-2 expression, inhibited the accumulation of reactive
   oxygen species and production of malondialdehyde in ethanol-treated
   astrocytes in a time-dependent manner. These data indicated that T beta
   4 attenuates ethanol-induced neurotoxicity in cultured cortical
   astrocytes through inhibition of apoptosis signaling, and one of the
   mechanisms underlying the capacity of T beta 4 to suppress apoptosis
   may in part be due to its effect of anti-peroxidation.
C1 [Yang, Hao; Jiao, Xi-Ying; Wang, Jian; Ju, Gong; You, Si-Wei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.
   [Cui, Guang-Bin] Fourth Mil Med Univ, Tangdu Hosp, Dept Radiol, Xian 710038, Peoples R China.
RP Ju, G, Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.
EM yanghao71_99@yahoo.com
   jugong@fmmu.edu.cn
   yousiwei@fmmu.edu.cn
FU Natural Science Foundation of China [30872829, 30571998]; Chinese PLA
   national scientific technological project [06G089]
FX This work was supported by the Natural Science Foundation of China
   (30872829, 30571998) and Chinese PLA national scientific technological
   project (06G089).
CR AMSTAD PA, 2001, REDOX REP, V6, P351
   BACHIS A, 2003, J NEUROSCI, V23, P5715
   BARNHAM KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330
   BEDNAREK R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200
   BORDER BG, 1993, J NEUROCHEM, V61, P2104
   BRIEGER A, 2007, BIOCHEM BIOPH RES CO, V364, P731, DOI
   10.1016/j.bbrc.2007.10.010
   BUTTERFIELD DA, 1997, J NEUROCHEM, V68, P2451
   CARO AA, 2002, ARCH BIOCHEM BIOPHYS, V408, P162
   CARPINTERO P, 1999, NEUROSCIENCE, V90, P1433
   CONDON MR, 1992, J MOL NEUROSCI, V3, P165
   DRINGEN R, 2000, PROG NEUROBIOL, V62, P649
   ELLERBY LM, 1996, J NEUROCHEM, V67, P1259
   FIFKOVA E, 1985, BRAIN RES, V356, P187
   GONZALEZ A, 2007, BRAIN RES, V1178, P28, DOI
   10.1016/j.brainres.2007.08.040
   GOODLETT CR, 2001, ALCOHOL RES HEALTH, V25, P175
   GRESSENS P, 1992, ALCOHOL ALCOHOLISM, V27, P219
   GUERRI C, 1994, ADV EXP MED BIOL, V366, P291
   GUERRI C, 2001, NEUROTOXICOLOGY, V22, P593
   HATTEN ME, 1999, ANNU REV NEUROSCI, V22, P511
   HEATON MB, 2000, ALCOHOL CLIN EXP RES, V24, P512
   HIRATA H, 2006, NEUROSCI LETT, V393, P136, DOI
   10.1016/j.neulet.2005.09.066
   HO JHC, 2007, INVEST OPHTH VIS SCI, V48, P27, DOI 10.1167/iovs.06-0826
   HO JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747
   HOLOWNIA A, 1997, NEUROTOXICOL TERATOL, V19, P141
   HUFF T, 2001, INT J BIOCHEM CELL B, V33, P205
   JACOBSON JL, 1993, ALCOHOL CLIN EXP RES, V17, P174
   KAMIGUCHI H, 1998, J NEUROSCI, V18, P5311
   KANE CJM, 1996, BRAIN RES, V731, P39
   KANE DJ, 1993, SCIENCE, V262, P1274
   LEE WT, 2002, NEUROSCIENCE, V112, P707
   MARKUS GG, 2000, CURR OPIN STRUC BIOL, V10, P649
   MATSUOKA Y, 1998, J CELL BIOL, V142, P485
   MECOCCI P, 1994, ANN NEUROL, V36, P747
   MILLER MW, 1992, DEV CENTRAL NERVOUS, P47
   MONTOLIU C, 1995, J NEUROCHEM, V65, P2561
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55
   NIU M, 2000, CELL ADHES COMMUN, V7, P311
   NUNOMURA A, 1999, J NEUROSCI, V19, P1959
   OTERO A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P59
   POPOLI P, 2007, ANN NY ACAD SCI, V1112, P219, DOI
   10.1196/annals.1415.033
   RAMANATHAN R, 1996, J CELL BIOL, V133, P381
   RENAUPIQUERAS J, 1989, J HISTOCHEM CYTOCHEM, V37, P229
   REYES E, 1993, ALCOHOL CLIN EXP RES, V17, P877
   RINTALA J, 2001, ALCOHOL, V23, P1
   ROTH LWA, 1999, DEVELOPMENT, V126, P1365
   ROTH LWA, 1999, EUR J NEUROSCI, V11, P3488
   SALAZAR M, 2008, NEUROCHEM INT, V52, P1061, DOI
   10.1016/j.neuint.2007.11.001
   SHIMIZU S, 1999, NATURE, V399, P483
   SIGNORINIALLIBE N, 2005, ALCOHOL ALCOHOLISM, V40, P163
   SOSNE G, 2001, EXP EYE RES, V72, P605
   SOSNE G, 2002, CURR EYE RES, V24, P268
   SOSNE G, 2002, EXP EYE RES, V74, P293
   SOSNE G, 2004, EXP CELL RES, V293, P175, DOI 10.1016/j.yexcr.2003.09.022
   SOSNE G, 2004, INVEST OPHTH VIS SCI, V45, P1095, DOI
   10.1167/iovs.03-1002
   STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315
   TAKUMA K, 2004, PROG NEUROBIOL, V72, P111, DOI
   10.1016/j.pneurobio.2004.02.001
   TIJERINA M, 1997, NEUROIMMUNOMODULAT, V4, P163
   TOMAS M, 2002, J NEUROCHEM, V83, P601
   TURRINI P, 1998, J NEUROIMMUNOL, V82, P64
   VALLES S, 1996, J NEUROCHEM, V67, P2425
   VALLES S, 1997, J NEUROCHEM, V69, P2484
   VARTIAINEN N, 1996, NEUROREPORT, V7, P1613
   WEINBERG J, 1985, ALCOHOL CLIN EXP RES, V9, P49
   WEST JR, 1987, ALCOHOL DRUG RES, V7, P423
   YANG H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4
   YANG H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y
NR 66
TC 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JAN
PY 2010
VL 30
IS 1
BP 149
EP 160
DI 10.1007/s10571-009-9439-6
PG 12
SC Cell Biology; Neurosciences
GA 549XI
UT ISI:000274087400015
ER

PT J
AU Yang, WL
   Wu, CY
   Wu, J
   Lin, HK
AF Yang, Wei-Lei
   Wu, Ching-Yuan
   Wu, Juan
   Lin, Hui-Kuan
TI Regulation of Akt signaling activation by ubiquitination
SO CELL CYCLE
LA English
DT Review
DE Akt; kinase; ubiquitination; phosphorylation; TRAF6; E3 ligase; PDK1;
   mTORC2; NF kappa B; tumorigenesis
ID NF-KAPPA-B; PLECKSTRIN HOMOLOGY DOMAIN; PROSTATE INTRAEPITHELIAL
   NEOPLASIA; PHOSPHOINOSITIDE 3-KINASE PATHWAY; SERINE-THREONINE KINASE;
   PROTEIN-KINASE; MOLECULAR-CLONING; TUMOR SUPPRESSION; CELL-MIGRATION;
   E17K MUTATION
AB Akt (also known as PKB) signaling orchestrates many aspects of
   biological functions and, importantly, its deregulation is linked to
   cancer development. Akt activity is well-known regulated through its
   phosphorylation at T308 and S473 by PDK1 and mTORC2, respectively.
   Although in the last decade the research has been primarily focused on
   Akt phosphorylation and its role in Akt activation and functions, other
   posttranslational modifications on Akt have never been reported. Until
   very recently, a novel posttranslational modification on Akt termed
   ubiquitination was identified and shown to play an important role in
   Akt activation. The cancer-associated Akt mutant recently identified in
   a subset of human cancers displays enhanced Akt ubiquitination, in turn
   contributing to Akt hyperactivation, suggesting a potential role of Akt
   ubiquitination in cancers. Thus, this novel posttranslational
   modification on Akt reveals an exciting avenue that has advanced our
   current understandings of how Akt signaling activation is regulated.
C1 [Yang, Wei-Lei; Wu, Ching-Yuan; Wu, Juan; Lin, Hui-Kuan] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Yang, Wei-Lei; Lin, Hui-Kuan] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.
   [Wu, Ching-Yuan] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Chinese Med, Kaohsiung, Taiwan.
   [Wu, Juan] Sun Yat Sen Univ, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China.
   [Wu, Juan] Sun Yat Sen Univ, Dept Expt Res, Guangzhou 510275, Guangdong, Peoples R China.
RP Lin, HK, Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol,
   Houston, TX 77030 USA.
EM hklin@mdanderson.org
FU National Science Council fund [NSC-97-2911-I-182-004-2]; China
   Scholarship Council fund 
FX We thank the members of the Lin's lab for their critical reading and
   comments on our manuscript. We apologize to many investigators whose
   important works were not cited here due to space limitations. This work
   is supported by M. D. Anderson Research Trust Scholar Fund to H. K.
   Lin, a National Science Council fund (NSC-97-2911-I-182-004-2) from
   Taiwan to C.Y. Wu, and a China Scholarship Council fund to J. Wu.
CR ADHIKARI A, 2009, DEV CELL, V16, P485, DOI 10.1016/j.devcel.2009.04.001
   ADHIKARY S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016
   ARROYO JD, 2005, ONCOGENE, V24, P7746
   ASKHAM JM, 2009, ONCOGENE
   BAUD V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   BAYASCAS JR, 2008, CELL CYCLE, V7, P2978
   BEAULIEU JM, 2005, CELL, V122, P261
   BELLACOSA A, 1991, SCIENCE, V254, P274
   BELLACOSA A, 1995, INT J CANCER, V64, P280
   BELLACOSA A, 1998, ONCOGENE, V17, P313
   BERG LJ, 2005, ANNU REV IMMUNOL, V23, P549
   BERTRAND MJM, 2008, MOL CELL, V30, P689, DOI
   10.1016/j.molcel.2008.05.014
   BHOJ VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959
   BONDY CA, 2004, EUR J PHARMACOL, V490, P25, DOI
   10.1016/j.ejphar.2004.02.042
   BRAZIL DP, 2002, CELL, V111, P293
   BROGNARD J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   CANTLEY LC, 2002, SCIENCE, V296, P1655
   CARPTEN JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
   CHEN ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006
   CHEN RY, 2001, J BIOL CHEM, V276, P31858
   CHEN ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758
   CHEN ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014
   CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267
   CHENG JQ, 1996, P NATL ACAD SCI USA, V93, P3636
   COFFER PJ, 1991, EUR J BIOCHEM, V201, P475
   COMPAGNO M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968
   CRISTOFANO AD, 2000, CELL, V100, P387
   DARNAY BG, 2007, ADV EXP MED BIOL, V597, P152
   DATTA K, 1996, J BIOL CHEM, V271, P30835
   DATTA SR, 1999, GENE DEV, V13, P2905
   DEY A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098
   DICRISTOFANO A, 2001, NAT GENET, V27, P222
   DUMMLER B, 2007, BIOCHEM SOC T 2, V35, P231
   DURAN A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   ECKER K, 2009, NAT CELL BIOL, V11, P377, DOI 10.1038/ncb1859
   ENOMOTO A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001
   GAO DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847
   GAO TY, 2005, MOL CELL, V18, P13
   GIASSON BI, 2003, CELL, V114, P1
   GONZALEZ E, 2009, CELL CYCLE, V8, P2502
   GUERTIN DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   HELDIN CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI
   10.1016/j.ceb.2009.01.021
   HENNESSY BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   HIGUCHI M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795
   HOELLER D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
   HUEN MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041
   IRIE HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087
   JIANG TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200
   JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171
   KATO M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969
   KIM AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200
   KIM MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212
   KORCHNAK AC, 2009, CELL SIGNAL, V21, P1620, DOI
   10.1016/j.cellsig.2009.06.008
   KUMAR R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892
   LI J, 2005, DEV CELL, V9, P663, DOI 10.1016/j.devcel.2005.09.012
   LI Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007
   LIN HK, 2002, EMBO J, V21, P4037
   LIN HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849
   LIU PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   LOMAGA MA, 1999, GENE DEV, V13, P1015
   LUAN B, 2009, NATURE, V457, P1146, DOI 10.1038/nature07617
   MAILAND N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040
   MAJUMDER PK, 2003, P NATL ACAD SCI USA, V100, P7841
   MAJUMDER PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   MALANGA D, 2008, CELL CYCLE, V7, P665
   MANNING BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI
   10.1016/j.tibs.2003.09.003
   MANNING BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   MAYO LD, 2001, P NATL ACAD SCI USA, V98, P11598
   MCKENNA LB, 2007, CELL MOL LIFE SCI, V64, P2723, DOI
   10.1007/s00018-007-7247-z
   MENDOZA MC, 2007, MOL CELL, V25, P798, DOI 10.1016/j.molcel.2007.03.007
   MILLWARD TA, 1999, TRENDS BIOCHEM SCI, V24, P186
   MIYAKE H, 2000, ENDOCRINOLOGY, V141, P2257
   MOHAMEDALI A, 2008, TECHNOL CANCER RES T, V7, P407
   MORA A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI
   10.1016/j.semcdb.2003.12.022
   MOSCAT J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI
   10.1016/j.tibs.2006.12.002
   NAKATANI K, 1999, J BIOL CHEM, V274, P21528
   NEUMANN D, 2002, EUR J IMMUNOL, V32, P3689
   NOGUCHI M, 2007, FASEB J, V21, P2273, DOI 10.1096/fj.06-7684rev
   NOVAK U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110
   OZES ON, 1999, NATURE, V401, P82
   PEI HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   PICKART CM, 2001, ANNU REV BIOCHEM, V70, P503
   QIU Y, 2000, ONCOGENE, V19, P5651
   RAIBORG C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961
   RESTUCCIA DF, 2009, SCIENCE, V325, P1083, DOI 10.1126/science.1179972
   SABATINI DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   SALMENA L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   SEHAT B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364
   SHOJI K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109
   SORRENTINO A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034
   STAHL JM, 2004, CANCER RES, V64, P7002
   SUN SC, 2008, NAT REV IMMUNOL, V8, P501, DOI 10.1038/nri2337
   SUN SC, 2009, CELL DEATH DIFFER
   TROTMAN LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809
   TROTMAN LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   VARGHESE B, 2008, MOL CELL BIOL, V28, P5275, DOI 10.1128/MCB.00350-08
   VARNAI P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606
   VIVARELLI MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446
   WALSH MC, 2008, PLOS ONE, V3, P4064
   WANG B, 2007, P NATL ACAD SCI USA, V104, P20759
   WANG Y, 2007, PRION, V1, P128
   WONG BR, 1999, MOL CELL, V4, P1041
   WONG F, 2004, BLOOD, V103, P4520, DOI 10.1182/blood-2003-06-2118
   WU XY, 1998, P NATL ACAD SCI USA, V95, P15587
   XIA ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247
   YAMASHITA M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   YAMAZAKI K, 2009, SCI SIGNAL, V2, P66
   YANG WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   YAO RJ, 1995, SCIENCE, V267, P2003
   YE H, 2002, NATURE, V418, P443
   ZHOU BHP, 2001, NAT CELL BIOL, V3, P973
   ZHOU GL, 2003, MOL CELL BIOL, V23, P8058, DOI
   10.1128/MCB.23.22.8058-8069.2003
   ZILBERMAN DE, 2009, CANCER GENET CYTOGEN, V191, P34, DOI
   10.1016/j.cancergencyto.2009.01.009
NR 114
TC 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD FEB 1
PY 2010
VL 9
IS 3
BP 486
EP 497
PG 12
SC Cell Biology
GA 550PI
UT ISI:000274140000027
ER

PT J
AU Tang, XF
   Bu, XK
   Hang, NH
   Li, XX
   Huang, HJ
   Bai, H
   Yang, X
AF Tang, Xiaofei
   Bu, Xiaokun
   Zhang, Naihong
   Li, Xiaoxia
   Huang, Huanjun
   Bai, Hong
   Yang, Xi
TI Inefficiency of C3H/HeN Mice to Control Chlamydial Lung Infection
   Correlates with Downregulation of Neutrophil Activation during the Late
   Stage of Infection
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Chlamydia trachomatis; neutrophils; selectins; ICAM-1; CD11b
ID CD11B/CD18 EXPRESSION; CROSS-LINKING; HOST-DEFENSE; P-SELECTIN;
   TRACHOMATIS; INFLAMMATION; INTEGRINS; HISTOPATHOLOGY; SEQUESTRATION;
   PHAGOCYTOSIS
AB We previously reported that massive infiltration of neutrophils in
   C3H/HeN (C3H) mice could not efficiently control Chlamydia muridarum
   (Cm) infection and might contribute to the high susceptibility of these
   mice to lung infection. To further define the nature of neutrophil
   responses in C3H mice during chlamydial infection, we examine the
   expression of adhesion molecules and CD11b related to neutrophils
   infiltration and activation, respectively, following intranasal Cm
   infection. The results showed that the expression of selectins
   (E-selectin, P-selectin and L-selectin), and intercellular cell
   adhesion molecule-1 (ICAM-1) in the lung of C3H mice increased more
   significantly than in C57BL/6 (116) mice, the more resistant strain.
   These results correlated well with the massive neutrophils infiltration
   in C3H mice. In contrast, CD11b expression on peripheral blood and lung
   neutrophils in C3H mice exhibited a significant reduction compared with
   B6 mice during the late phage of infection (day 14). These findings
   suggest that the high-level expression of adhesion molecules in C3H
   mice may enhance neutrophils recruitment to the lung, but the decline
   of CD11b expression on neutrophils may attenuate neutrophil function.
   Therefore, CD11b down-regulation on neutrophils may contribute to the
   failure of C3H mice to control chlamydial lung infection. Cellular &
   Molecular Immunology. 2009;6(4):253-260.
C1 [Tang, Xiaofei; Bu, Xiaokun; Zhang, Naihong; Li, Xiaoxia; Huang, Huanjun; Bai, Hong; Yang, Xi] Tianjin Med Univ, Dept Immunol, Tianjin Key Lab Cellular & Mol Immunol, Key Lab Educ Minist China, Tianjin 300070, Peoples R China.
   [Yang, Xi] Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Infect & Immun, Winnipeg, MB, Canada.
   [Yang, Xi] Univ Manitoba, Fac Med, Dept Immunol, Lab Infect & Immun, Winnipeg, MB R3E 0W3, Canada.
RP Bai, H, Tianjin Med Univ, Dept Immunol, Tianjin Key Lab Cellular & Mol
   Immunol, Key Lab Educ Minist China, 22 Qixiangtai Rd, Tianjin 300070,
   Peoples R China.
EM hongbai25@163.com
   yangxi@cc.umanitoba.ca
FU Tianjin Municipal Science and Technology Commission [07JCYBJC 10600]
FX This work was supported by fund from Tianjin Municipal Science and
   Technology Commission (07JCYBJC 10600).
CR BAI H, 2005, IMMUNOLOGY, V114, P246, DOI
   10.1111/j.1365-2567.2004.02088.x
   BARNETT CC, 1998, AM J PHYSIOL, V274, P1634
   BARTENEVA N, 1996, INFECT IMMUN, V64, P4830
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BUENDIA AJ, 1999, INFECT IMMUN, V67, P2110
   CONLAN JW, 1997, INFECT IMMUN, V65, P630
   COXON A, 1996, IMMUNITY, V5, P653
   DARVILLE T, 2001, INFECT IMMUN, V69, P3556
   GAO XP, 2001, J IMMUNOL, V167, P2895
   GREEN CE, 2004, J IMMUNOL, V172, P7780
   KIVIAT NB, 1990, HUM PATHOL, V21, P831
   KUBO H, 1999, AM J RESP CRIT CARE, V159, P267
   LAUFS H, 2002, INFECT IMMUN, V70, P826
   LECABEC V, 2002, J IMMUNOL, V169, P2003
   MAYADAS TN, 2005, TRENDS IMMUNOL, V26, P388, DOI
   10.1016/j.it.2005.05.002
   MAZZONE A, 1995, HAEMATOLOGICA, V80, P161
   MIYAIRI I, 2007, J IMMUNOL, V179, P1814
   MOBBERLEYSCHUMAN PS, 2005, INFECT IMMUN, V73, P7317, DOI
   10.1128/IAI.73.11.7317-7323.2005
   PATEL KD, 2002, SEMIN IMMUNOL, V14, P73
   PATTON DL, 1989, J REPROD FERTIL, V85, P647
   QIU HY, 2004, IMMUNOLOGY, V111, P453, DOI
   10.1111/j.1365-2567.2004.01835.x
   RUPP J, 2009, PLOS ONE, V4, ARTN e6020
   SANDILANDS GP, 2005, IMMUNOLOGY, V114, P354, DOI
   10.1111/j.1365-2567.2004.02114.x
   SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179
   SIMON SI, 1995, J IMMUNOL, V155, P1502
   SJOSTEDT A, 1994, INFECT IMMUN, V62, P2779
   SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76
   SOLBACH W, 2000, ADV IMMUNOL, V74, P275
   YANG X, 1996, J IMMUNOL, V156, P4338
   ZARBOCK A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502
   ZHOU XM, 2005, AM J PHYSIOL-LUNG C, V288, L655, DOI
   10.1152/ajplung.00327.2004
NR 31
TC 0
PU CHINESE SOC IMMUNOLOGY
PI BEIJING
PA 5 SANTIAO DONGDAN, BEIJING, 10005, PEOPLES R CHINA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD AUG
PY 2009
VL 6
IS 4
BP 253
EP 260
PG 8
SC Immunology
GA 552WH
UT ISI:000274324000003
ER

PT J
AU Lo, CKC
   Lam, QLK
   Yang, M
   Ko, KH
   Sun, L
   Ma, R
   Wang, SJ
   Xu, HX
   Tam, S
   Wu, CY
   Zheng, BJ
   Lu, LW
AF Lo, Cherry Kam Chun
   Lam, Queenie Lai Kwan
   Yang, Min
   Ko, King-Hung
   Sun, Lingyun
   Ma, Rui
   Wang, Shengjun
   Xu, Huaxi
   Tam, Sidney
   Wu, Chang-You
   Zheng, Bo-Jiang
   Lu, Liwei
TI Leptin Signaling Protects NK Cells from Apoptosis During Development in
   Mouse Bone Marrow
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE NK cell; bone marrow; lymphocyte development
ID NATURAL-KILLER-CELLS; TRANSCRIPTION FACTOR; DENDRITIC CELLS; B
   LYMPHOPOIESIS; MICE; RECEPTOR; ACTIVATION; IMMUNITY; HEMATOPOIESIS;
   DEFICIENCY
AB Increasing evidence indicates a role of leptin in immune response, but
   it remains largely unclear whether leptin signaling is involved in
   regulating NK cell development in the bone marrow (BM). In this study,
   we have characterized NK cell differentiation and maturation in the BM
   of leptin-receptor deficient db/db mice at a prediabetic stage.
   Although the BM cellularity was similar to the control value, the total
   number of NK cells was severely reduced in mutant mice. Flow cytometric
   analysis of db/db BM cells revealed significantly decreased frequencies
   of developing NK cells at various stages of differentiation. BM db/db
   NK cells displayed markedly increased apoptosis but maintained normal
   cell cycling status and proliferative capacity. Moreover, recombinant
   leptin could significantly enhance the survival of NK cells from
   wild-type mice in cultures. Further examination on NK cell functional
   activity showed that db/db NK cells exhibited normal intrinsic
   cytotoxicity with significantly increased IL-10 production. Taken
   together, our findings suggest that leptin signaling regulates NK cell
   development via enhancing the survival of immature NK cells in mouse
   BM. Cellular & Molecular Immunology. 2009;6(5):353-360.
C1 [Lo, Cherry Kam Chun; Lam, Queenie Lai Kwan; Yang, Min; Ko, King-Hung; Zheng, Bo-Jiang; Lu, Liwei] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Lo, Cherry Kam Chun; Lam, Queenie Lai Kwan; Yang, Min; Ko, King-Hung; Zheng, Bo-Jiang; Lu, Liwei] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Lo, Cherry Kam Chun; Lam, Queenie Lai Kwan; Yang, Min; Ko, King-Hung; Zheng, Bo-Jiang; Lu, Liwei] Univ Hong Kong, Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Sun, Lingyun] Nanjing Univ, Dept Rheumatol, Drum Tower Hosp, Sch Med, Nanjing 210008, Peoples R China.
   [Ma, Rui; Wang, Shengjun; Xu, Huaxi] Jiangsu Univ, Dept Immunol, Sch Med Sci & Lab Med, Zhenjiang, Peoples R China.
   [Tam, Sidney] Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Wu, Chang-You] Sun Yat Sen Univ, Dept Immunol, Guangzhou 510275, Guangdong, Peoples R China.
RP Lu, LW, Univ Hong Kong, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong,
   Peoples R China.
EM liweilu@hkucc.hku.hk
FU Research Grants Council of Hong Kong 
FX This work was supported by a grant to L Lu from the Research Grants
   Council of Hong Kong.
CR ARJONA A, 2004, J IMMUNOL, V172, P2811
   BARTON K, 1998, IMMUNITY, V9, P555
   BENNETT BD, 1996, CURR BIOL, V6, P1170
   BRUNO A, 2005, J IMMUNOL, V174, P8090
   DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377
   FANTUZZI G, 2000, J LEUKOCYTE BIOL, V68, P437
   FUJITA Y, 2002, CLIN EXP IMMUNOL, V128, P21
   HAMERMAN JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI
   10.1016/j.coi.2004.11.001
   HARIZI H, 2006, CELL MOL IMMUNOL, V3, P271
   HOWARD JK, 1999, J CLIN INVEST, V104, P1051
   KENNEDY MK, 2000, J EXP MED, V191, P771
   KIM S, 2002, NAT IMMUNOL, V3, P523
   LAM QLK, 2006, EUR J IMMUNOL, V36, P3118, DOI 10.1002/eji.200636602
   LAM QLK, 2007, CELL MOL IMMUNOL, V4, P1
   LAM QLK, 2007, J BIOL CHEM, V282, P27587, DOI 10.1074/jbc.M704579200
   LI ZP, 2002, GASTROENTEROLOGY, V123, P1304, DOI 10.1053/gast.2002.35997
   LOHOFF M, 2000, J EXP MED, V192, P325
   LORD GM, 1998, NATURE, V394, P897
   LU LW, 1997, J IMMUNOL, V158, P5136
   LU LW, 2000, IMMUNOL REV, V175, P158
   MATTIOLI B, 2005, J IMMUNOL, V174, P6820
   MEHROTRA PT, 1998, J IMMUNOL, V160, P2637
   OGASAWARA K, 1998, NATURE, V391, P700
   RONCAROLO MG, 2006, IMMUNOL REV, V212, P28
   ROSMARAKI EE, 2001, EUR J IMMUNOL, V31, P1900
   TIAN ZG, 2002, BIOCHEM BIOPH RES CO, V298, P297
   WU Q, 2001, J IMMUNOL, V166, P1684
   YOKOTA Y, 1999, NATURE, V397, P702
   ZHANG C, 2006, CELL MOL IMMUNOL, V3, P241
   ZHAO YR, 2003, BIOCHEM BIOPH RES CO, V300, P247
NR 30
TC 5
PU CHINESE SOC IMMUNOLOGY
PI BEIJING
PA 5 SANTIAO DONGDAN, BEIJING, 10005, PEOPLES R CHINA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD OCT
PY 2009
VL 6
IS 5
BP 353
EP 360
PG 8
SC Immunology
GA 552WI
UT ISI:000274324100005
ER

PT J
AU Cai, ZJ
   Zhang, W
   Li, M
   Yue, YP
   Yang, F
   Yu, L
   Cao, XT
   Wang, JL
AF Cai, Zhijian
   Zhang, Wei
   Li, Min
   Yue, Yinpu
   Yang, Fei
   Yu, Lei
   Cao, Xuetao
   Wang, Jianli
TI TGF-beta 1 gene-modified, immature dendritic cells delay the
   development of inflammatory bowel disease by inducing CD4(+)Foxp3(+)
   regulatory T cells
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE DCs; IBD; TGF-beta 1; Treg
ID EXPRESSION; TOLERANCE; IMMUNITY
AB Inflammatory bowel disease (IBD) is caused by an uncontrolled immune
   response in the intestinal lumen, leading to inflammation in
   genetically predisposed individuals. Immunotherapy may be a promising
   approach to the treatment of IBD. Here, we show that transforming
   growth factor-beta 1 (TGF-beta 1) gene-modified immature dendritic
   cells (imDCs) could enhance the inhibitory function of imDCs and delay
   the progress of IBD induced by dextran sodium sulfate in mice. The
   results of fluorescence-activated cell sorter (FACS) demonstrated that
   this protective effect is mediated partially by inducing CD4(+)Foxp3(+)
   regulatory T cells (Tregs) in mesentery lymph nodes to control
   inflammation. In vitro experiments also supported this hypothesis. In
   conclusion, we provide evidence that TGF-beta 1-modified bone
   marrow-derived imDCs may have a therapeutic effect to IBD. Cellular &
   Molecular Immunology (2010) 7, 35-43; doi:10.1038/cmi.2009.107
C1 [Cai, Zhijian; Zhang, Wei; Li, Min; Yue, Yinpu; Yang, Fei; Yu, Lei; Cao, Xuetao; Wang, Jianli] Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058, Zhejiang, Peoples R China.
   [Cao, Xuetao] Mil Med Coll 2, Inst Immunol, Shanghai, Peoples R China.
   [Cao, Xuetao] Mil Med Coll 2, Natl Key Lab Med Immunol, Shanghai, Peoples R China.
RP Wang, JL, Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058,
   Zhejiang, Peoples R China.
EM jlwang@zju.edu.cn
FU National Key Basic Research Program of China [2007CB512400]; National
   High Technology Research and Development Program of China
   [2006AA02A239, 2007AA021102]; National Natural Science Foundation of
   China [30671909, 30972725]; Natural Science Foundation of Zhejiang
   Province [Z2090042]
FX We thank Professor Lin-Rong Lu for his critical review of the
   manuscript. This work was supported by the National Key Basic Research
   Program of China (Grant 2007CB512400), the National High Technology
   Research and Development Program of China (Grants 2006AA02A239 and
   2007AA021102), the National Natural Science Foundation of China (Grant
   30671909 and 30972725) and Natural Science Foundation of Zhejiang
   Province (Z2090042).
CR AHARONI R, 2006, J PHARMACOL EXP THER, V318, P68, DOI
   10.1124/jpet.106.103192
   BANCHEREAU J, 1998, NATURE, V392, P245
   BLOBE GC, 2000, NEW ENGL J MED, V342, P1350
   COOPER HS, 1993, LAB INVEST, V69, P238
   JONG EC, 2005, SPRINGER SEMIN IMMUN, V26, P289
   KUHBACHER T, 2007, WORLD J GASTROENTERO, V13, P1149
   LAWRANCE IC, 2001, INFLAMM BOWEL DIS, V7, P16
   LEEHLER R, 2001, IMMUNITY, V14, P357
   LOFTUS EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI
   10.1053/j.gastro.2004.01.063
   PAPADAKIS KA, 2000, ANNU REV MED, V51, P289
   PEPPER MS, 1997, CYTOKINE GROWTH F R, V8, P21
   PLACEK K, 2009, IMMUNOLOGY, V127, P155, DOI
   10.1111/j.1365-2567.2009.03059.x
   PODOLSKY DK, 2002, NEW ENGL J MED, V347, P417
   SAUER S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI
   10.1073/pnas.0800928105
   STEINBRINK K, 1997, J IMMUNOL, V159, P4772
   STEINMAN RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI
   10.1146/annurev.immunol.21.120601.141040
   SUN WJ, 2002, J MOL MED-JMM, V80, P514, DOI 10.1007/s00109-002-0346-2
   THOMSON AW, 1995, STEM CELLS, V13, P622
   TRINCHIERI G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   WALLET MA, 2005, CLIN MED RES, V3, P166
   WING K, 2006, INT IMMUNOL, V18, P991, DOI 10.1093/intimm/dxl044
   YU YM, 2004, IMMUNOL RES, V29, P55
   ZHANG MH, 2004, NAT IMMUNOL, V5, P1124, DOI 10.1038/ni1130
NR 23
TC 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD JAN
PY 2010
VL 7
IS 1
BP 35
EP 43
DI 10.1038/cmi.2009.107
PG 9
SC Immunology
GA 552WG
UT ISI:000274323900005
ER

PT J
AU Sun, JT
   Zhang, Y
   Yang, MX
   Zhang, Y
   Xie, Q
   Li, ZW
   Dong, ZG
   Yang, YM
   Deng, BP
   Feng, A
   Hu, WX
   Mao, HT
   Qu, X
AF Sun, Jintang
   Zhang, Yan
   Yang, Meixiang
   Zhang, Yun
   Xie, Qi
   Li, Zewu
   Dong, Zhaogang
   Yang, Yongmei
   Deng, Biping
   Feng, Alei
   Hu, Weixu
   Mao, Haiting
   Qu, Xun
TI Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7
   expression: the role of adenosine receptor A(2)
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE adenosine receptor; apoptosis; CCR7; T cells
ID DENDRITIC CELLS; EFFECTOR FUNCTIONS; DEAMINASE DEFICIENCY; LYMPHOCYTES;
   PROLIFERATION; SUPPRESSES; ACTIVATION; MECHANISMS; PROTECTION; SUBSETS
AB Hypoxia is a major characteristic of the tumor microenvironment, and
   its effects on immune cells are proposed to be important factors for
   the process of tumor immune escape. It has been reported that hypoxia
   affects the function of dendritic cells and the antitumor function of T
   cells. Here we discuss the effects of hypoxia on T-cell survival. Our
   results showed that hypoxia induced apoptosis of T cells. Adenosine and
   adenosine receptors (AR) are important to the hypoxia-related signaling
   pathway. Using AR agonists and antagonists, we demonstrated that
   hypoxia-induced apoptosis of T cells was mediated by A(2a) and A(2b)
   receptors. Furthermore, we are the first, to our knowledge, to report
   that hypoxia significantly inhibited the expression of chemokine C
   receptor 7 (CCR7) of T cells via the A(2)R signal pathway, perhaps
   representing a mechanism of hypoxia-induced apoptosis of T cells.
   Collectively, our research demonstrated that hypoxia induces T-cell
   apoptosis by the A(2)R signaling pathway partly by suppressing CCR7.
   Blocking the A(2)R signaling pathway and/or activation of CCR7 can
   increase the anti-apoptosis function of T cells and may become a new
   strategy to improve antitumor potential. Cellular & Molecular
   Immunology (2010) 7, 77-82; doi:10.1038/cmi.2009.105; published online
   23 December 2009
C1 [Sun, Jintang; Zhang, Yan; Yang, Meixiang; Zhang, Yun; Xie, Qi; Li, Zewu; Dong, Zhaogang; Yang, Yongmei; Deng, Biping; Feng, Alei; Hu, Weixu; Mao, Haiting; Qu, Xun] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Jinan 250012, Peoples R China.
   [Zhang, Yan] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China.
RP Qu, X, Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Jinan 250012,
   Peoples R China.
EM quxun@sdu.edu.cn
FU National Natural Science Foundation of China [30671902, 30872321];
   Natural Science Foundation of Shandong Province [Y2008C02, Y2006C122]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 30671902 and No. 30872321) and the Natural
   Science Foundation of Shandong Province (No. Y2008C02 and No.
   Y2006C122).
CR APASOV SG, 2001, J CLIN INVEST, V108, P131
   BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373
   CALDWELL CC, 2001, J IMMUNOL, V167, P6140
   CHAMBERS CA, 2001, ANNU REV IMMUNOL, V19, P565
   ELTZSCHIG HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066
   ESCRIBANO C, 2009, J IMMUNOL, V183, P6282, DOI 10.4049/jimmunol.0804093
   FREDHOLM BB, 2001, PHARMACOL REV, V53, P527
   GORLACH A, 2005, CIRC RES, V97, P1, DOI
   10.1161/01.RES.0000174112.36064.77
   HASKO G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003
   HELMLINGER G, 1997, NAT MED, V3, P177
   HOSKIN DW, 2008, INT J ONCOL, V32, P527
   HUANG S, 1997, BLOOD, V90, P1600
   KIANG JG, 2008, MOL PHARMACOL, V73, P738, DOI 10.1124/mol.107.041079
   KIM JW, 2005, CLIN CANCER RES, V11, P7901, DOI
   10.1158/1078-0432.CCR-05-1346
   KOSHIBA M, 1999, MOL PHARMACOL, V55, P614
   LINDEN J, 2001, ANNU REV PHARMACOL, V41, P775
   LOEFFLER DA, 1992, BRIT J CANCER, V66, P619
   MAKINO Y, 2003, J IMMUNOL, V171, P6534
   MANCINO A, 2008, BLOOD, V112, P3723, DOI 10.1182/blood-2008-02-142091
   NALDINI A, 1999, J CELL PHYSIOL, V181, P448
   PARMIANI G, 2005, CLIN CANCER RES, V11, P7587, DOI
   10.1158/1078-0432.CCR-05-1965
   QU X, 2005, IMMUNOL CELL BIOL, V83, P668, DOI
   10.1111/j.1440-1711.2005.01383.x
   SALLUSTO F, 1999, NATURE, V401, P708
   SALLUSTO F, 2000, IMMUNOL REV, V177, P134
   SANCHEZSANCHEZ N, 2004, BLOOD, V104, P619, DOI
   10.1182/blood-2003-11-3943
   SITKOVSKY M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685
   SITKOVSKY MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI
   10.1146/annurev.immunol.22.012703.104731
   SUGIYAMA H, 1992, J BIOL CHEM, V267, P25256
   ZHAO P, 2008, MOL IMMUNOL, V45, P2187, DOI 10.1016/j.molimm.2007.12.002
   ZHAO WL, 2005, EUR J IMMUNOL, V35, P3468, DOI 10.1002/eji.200526262
   ZUCKERBERG AL, 1994, CRIT CARE MED, V22, P197
NR 31
TC 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD JAN
PY 2010
VL 7
IS 1
BP 77
EP 82
DI 10.1038/cmi.2009.105
PG 6
SC Immunology
GA 552WG
UT ISI:000274323900010
ER

PT J
AU Yoshida, C
   Hishiyama, K
   Miyazaki, K
   Watanabe, M
   Kanbe, M
   Yamada, Y
   Matsuzaki, K
   Miyashita, K
   Kitanaka, S
   Miyata, S
AF Yoshida, Chisato
   Hishiyama, Kazsuyoshi
   Miyazaki, Khosuke
   Watanabe, Manami
   Kanbe, Masahiro
   Yamada, Yuta
   Matsuzaki, Keiithi
   Miyashita, Kiichi
   Kitanaka, Susumu
   Miyata, Shohei
TI Analysis of inhibition of topoisomerase II alpha and cancer cell
   proliferation by ingenolEZ
SO CANCER SCIENCE
LA English
DT Article
ID DNA TOPOISOMERASE; EUPHORBIA-KANSUI; INDUCE APOPTOSIS; DECATENATION;
   CHECKPOINT; ENZYME; ESTERS; CYTOTOXICITY; DERIVATIVES; DITERPENES
AB We previously reported that many ingenol compounds derived from
   Euphorbia kansui exhibit topoisomerase inhibitory activity and/or
   inhibitory activity of cell proliferation. The inhibitory effects of
   20-O-(2'E,4'Z-decadienoyl) ingenol and
   3-O-(2'E,4'Z-decadienoyl)-ingenol among these compounds on
   topoisomerase II activity and on the cell proliferative activity and
   arrest phase of the cell cycle were studied using a mouse breast cancer
   (MMT) cell line. Although 20-O-ingenolEZ exerted inhibitory effects on
   both topoisomerase II activity and cell proliferative activity,
   3-O-ingenolEZ exerted inhibitory activity on neither. The
   20-O-ingenolEZ-induced cell arrest of MMT-cell proliferation led to a
   cell cycle arrest in the G2/M phase. Topoisomerase II inhibition can be
   divided into the poison and catalytic inhibitor types. A checkpoint
   mechanism is activated when cells are treated with these topoisomerase
   II inhibitors. Poison-type inhibition occurs via induction of the DNA
   damage checkpoint and the catalytic-type inhibition occurs via
   induction of the DNA-decatenation checkpoint, suggestive of distinct
   checkpoint reactions. 20-O-ingenolEZ inhibited topoisomerase II alpha
   activity through inhibition of ATPase, and induced DNA-decatenation
   checkpoint without signaling for phosphorylation of H2AX. (Cancer Sci
   2010; 101: 374-378).
C1 [Yoshida, Chisato; Miyazaki, Khosuke; Watanabe, Manami; Kanbe, Masahiro; Yamada, Yuta; Miyata, Shohei] Nihon Univ, Coll Humanities & Sci, Dept Chem, Tokyo, Japan.
   [Hishiyama, Kazsuyoshi; Matsuzaki, Keiithi; Kitanaka, Susumu] Nihon Univ, Coll Pharm, Chiba, Japan.
   [Miyashita, Kiichi] Keio Univ, Sch Med, Inst Adv Med Res, Tokyo, Japan.
RP Miyata, S, Nihon Univ, Coll Humanities & Sci, Dept Chem, Tokyo, Japan.
EM miyata@chs.nihon-u.ac.jp
FU Nihon University 
FX This investigation was supported in part by a grant from Nihon
   University to S. Miyata.
CR ANDOH T, 1998, BBA-GENE STRUCT EXPR, V1400, P155
   BLANCOMOLINA M, 2001, CHEM BIOL, V8, P767
   BURDEN DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139
   COGAN EB, 1999, ANAL BIOCHEM, V271, P29
   DEMING PB, 2001, P NATL ACAD SCI USA, V98, P12044
   DOWNES CS, 1994, NATURE, V372, P467
   FORTUNE JM, 1998, J BIOL CHEM, V273, P17643
   FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429
   HAMMONDS TR, 1997, J BIOL CHEM, V272, P32696
   ISHIMI Y, 1995, J MOL BIOL, V247, P835
   ITOKAWA H, 1989, PLANTA MED, V55, P271
   JENSEN PB, 1991, CANCER RES, V51, P5093
   KUPCHAN SM, 1976, SCIENCE, V191, P571
   MILLER KG, 1981, J BIOL CHEM, V256, P9334
   MIYATA S, 2004, CELL BIOL INT, V28, P179, DOI
   10.1016/j.cellbi.2003.11.017
   MIYATA S, 2006, BIOORGAN MED CHEM, V14, P2048, DOI
   10.1016/j.bmc.2005.10.059
   NAKAGAWA T, 2004, CANCER RES, V64, P4826
   ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781
   ROGAKOU EP, 1998, J BIOL CHEM, V273, P5858
   SKOUFIAS DA, 2004, MOL CELL, V15, P977
   VIGONE A, 2005, EUR J GYNAECOL ONCOL, V26, P526
   WHELAN LC, 2003, PHYTOMEDICINE, V10, P53
   WU TS, 1991, J NAT PRODUCTS, V54, P823
   YU FR, 2003, J LANZHOU U, V39, P453
   YU FR, 2005, J PHARM PHARM SCI, V8, P528
   ZHENG WF, 1998, PLANTA MED, V64, P754
NR 26
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2010
VL 101
IS 2
BP 374
EP 378
DI 10.1111/j.1349-7006.2009.01408.x
PG 5
SC Oncology
GA 550UR
UT ISI:000274156400013
ER

PT J
AU Tatsuwaki, H
   Tanigawa, T
   Watanabe, T
   Machida, H
   Okazaki, H
   Yamagami, H
   Shiba, M
   Watanabe, K
   Tominaga, K
   Fujiwara, Y
   Oshitani, N
   Muguruma, K
   Sawada, T
   Hirakawa, K
   Higuchi, K
   Arakawa, T
AF Tatsuwaki, Hiroshi
   Tanigawa, Tetsuya
   Watanabe, Toshio
   Machida, Hirohisa
   Okazaki, Hirotoshi
   Yamagami, Hirokazu
   Shiba, Masatsugu
   Watanabe, Kenji
   Tominaga, Kazunari
   Fujiwara, Yasuhiro
   Oshitani, Nobuhide
   Muguruma, Kazuya
   Sawada, Tetsuji
   Hirakawa, Kosei
   Higuchi, Kazuhide
   Arakawa, Tetsuo
TI Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an
   independent predictor of poor survival associated with enhanced cell
   proliferation in gastric adenocarcinoma
SO CANCER SCIENCE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EPIDERMAL-GROWTH-FACTOR;
   COLORECTAL-CANCER; CYCLOOXYGENASE-2 EXPRESSION; TUMOR-SUPPRESSOR;
   PROSTAGLANDIN E-2; PROSTATE-CANCER; LUNG-CANCER; CARCINOMAS;
   OVEREXPRESSION
AB Prostaglandin (PG) E-2 promotes gastrointestinal carcinogenesis and
   tumor progression. We determined the correlations between pattern of
   expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a
   catabolic enzyme for biological inactivation of PGE(2), in gastric
   adenocarcinoma and various clinicopathological factors and patient
   outcome in an attempt to elucidate its biological significance. In 35
   of 71 cases of gastric adenocarcinoma, expression of 15-PGDH protein
   was reduced in tumor tissues. Multivariate analysis revealed reduction
   of 15-PGDH expression to be an independent predictor of poor survival.
   The proportion of Ki67-positive cells in 15-PGDH-negative
   adenocarcinoma was higher than that in 15-PGDH-positive adenocarcinoma.
   No differences were found in clinicopathological parameters between
   patients with cyclooxygenase-2 (COX-2)-positive tumors and those with
   COX-2 negative tumors. In an in vitro study, use of specific siRNA to
   silence 15-PGDH or a specific inhibitor of 15-PGDH enhanced cell
   proliferation in the gastric cancer cell line AGS, which expresses
   15-PGDH. These findings suggest that reduction of 15-PGDH is an
   independent predictor of poor survival associated with enhancement of
   cell proliferation in gastric adenocarcinoma. (Cancer Sci 2010; 101:
   550-558)
C1 [Tatsuwaki, Hiroshi; Tanigawa, Tetsuya; Watanabe, Toshio; Machida, Hirohisa; Okazaki, Hirotoshi; Yamagami, Hirokazu; Shiba, Masatsugu; Watanabe, Kenji; Tominaga, Kazunari; Fujiwara, Yasuhiro; Oshitani, Nobuhide; Arakawa, Tetsuo] Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Osaka 558, Japan.
   [Muguruma, Kazuya; Sawada, Tetsuji; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan.
   [Shiba, Masatsugu] Osaka City Gen Hosp, Dept Gastroenterol, Osaka, Japan.
   [Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Takatsuki, Osaka 569, Japan.
RP Tanigawa, T, Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Osaka
   558, Japan.
EM ttanigawa@med.osaka-cu.ac.jp
FU Ministry of Education, Science, and Culture of Japan 
FX This study was supported by a Grant-in-Aid from the Ministry of
   Education, Science, and Culture of Japan.
CR BACKLUND MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M41122100
   CHEN CN, 2001, ANN SURG, V233, P183
   CHEN L, 2008, TUMORI, V94, P531
   DING YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277
   ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313
   FARROW DC, 1998, CANCER EPIDEM BIOMAR, V7, P97
   FERNANDEZCEBRIAN JM, 2007, CLIN TRANSL ONCOL, V9, P663, DOI
   10.1007/s12094-007-0119-z
   FUJIMOTO Y, 2003, GASTRIC CANCER, V6, P39
   GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609
   HANSENPETRIK MB, 2002, CANCER RES, V62, P403
   ISHIDA H, 2004, CANCER LETT, V207, P109, DOI
   10.1016/j.canlet.2003.10.032
   ITO Y, 1999, BRIT J CANCER, V81, P747
   JANG TJ, 2008, YONSEI MED J, V49, P917, DOI 10.3349/ymj.2008.49.6.917
   JOO YE, 2002, DIGESTION, V66, P222, DOI 10.1159/000068366
   LEE TL, 2001, CANCER LETT, V168, P133
   LEUNG WK, 2001, BRIT J CANCER, V84, P335
   LIM HY, 2000, CLIN CANCER RES, V6, P519
   LIU ZX, 2008, CARCINOGENESIS, V29, P1219, DOI 10.1093/carcin/bgm297
   LODYGIN D, 2005, CANCER RES, V65, P4218
   MANN JR, 2006, CANCER RES, V66, P6649, DOI 10.1158/0008-5472.CAN-06-1787
   MULLER W, 1996, BRIT J CANCER, V74, P759
   MURATA H, 1999, AM J GASTROENTEROL, V94, P451
   MYUNG SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI
   10.1073/pnas.0603235103
   NARUMIYA S, 1999, PHYSIOL REV, V79, P1193
   OKANO H, 2004, CLIN CANCER RES, V10, P6938
   PUGH S, 1994, GUT, V35, P675
   QUIDVILLE V, 2006, PROSTAG OTH LIPID M, V81, P14, DOI
   10.1016/j.prostaglandins.2006.06.004
   RIGAS B, 1993, J LAB CLIN MED, V122, P518
   SAUKKONEN K, 2003, APMIS, V111, P915
   SKALOVA A, 1994, HUM PATHOL, V25, P929
   SMALLEY WE, 1997, ADV PHARMACOL, V39, P1
   SPYRATOS F, 2002, CANCER, V94, P2151
   SUNG JJY, 2000, AM J PATHOL, V157, P729
   SWAMI S, 2007, J NUTR S, V137, S205
   TANIGAWA T, 2004, AM J PHYSIOL-GASTR L, V286, G148, DOI
   10.1152/ajpgi.00137.2003
   TANIGAWA T, 2007, DIGEST DIS SCI, V52, P240, DOI
   10.1007/s10620-006-9226-x
   THIEL A, 2009, CLIN CANCER RES, V15, P4572, DOI
   10.1158/1078-0432.CCR-08-2518
   THUN MJ, 1994, CANCER METAST REV, V13, P269
   WAKIMOTO N, 2008, CANCER RES, V68, P6978, DOI
   10.1158/0008-5472.CAN-07-5675
   WANG D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100
   WATANABE T, 2008, GUT, V57, P181, DOI 10.1136/gut.2007.125963
   WILLIAMS C, 1999, ANN NY ACAD SCI, V889, P72
   WOLF I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   YANG L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287
   YOO NJ, 2007, PATHOLOGY, V39, P174, DOI 10.1080/00313020601123946
NR 45
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2010
VL 101
IS 2
BP 550
EP 558
DI 10.1111/j.1349-7006.2009.01390.x
PG 9
SC Oncology
GA 550UR
UT ISI:000274156400038
ER

PT J
AU Lorbeck, MT
   Singh, N
   Zervos, A
   Dhatta, M
   Lapchenko, M
   Yang, C
   Elefant, F
AF Lorbeck, Meridith T.
   Singh, Neetu
   Zervos, Ashley
   Dhatta, Madhusmita
   Lapchenko, Maria
   Yang, Chen
   Elefant, Felice
TI The histone demethylase Dmel\Kdm4A controls genes required for life
   span and male-specific sex determination in Drosophila
SO GENE
LA English
DT Article
DE Chromatin; Histone demethylase; Epigenetics; Drosophila; Gene control;
   Life span; Male-specific sex determination; Kdm4A
ID DOMAIN-CONTAINING PROTEINS; ANDROGEN-RECEPTOR; FRUITLESS GENE;
   METHYLATION; DISEASE; H3; MUTANTS; FAMILY; MODEL; PHOSPHORYLATION
AB Histone methylation plays an important role in regulating
   chromatin-mediated gene control and epigenetic-based memory systems
   that direct cell fate. Enzymes termed histone demethylases directly
   remove the methyl marks from histones, thus contributing to a
   dynamically regulated histone methylated genome; however. the
   biological functions of these newly identified enzymes remain unclear.
   The JMJD2-AD family belongs to the JmjC domain-containing family of
   histone demethylases (JHDMs). Here, we report the cloning and
   functional characterization of the Drosophila HDM gene Dmel\Kdm4A that
   is a homolog of the human JMJD2 family. We show that homologs for three
   human JHDM families, JHDM1, JHDM2, and JMJD2, are present in Drosophila
   and that each is expressed during the Drosophila lifecycle. Disruption
   of Dmel/Kdm4A results in a reduction of the male life span and a
   male-specific wing extension/twitching phenotype that occurs in
   response to other males and is reminiscent of an inter-male courtship
   phenotype involving the courtship song. Remarkably, certain genes
   associated with each of these phenotypes are significantly
   downregulated in response to Dmel\Kdm4A loss, most notably the
   longevity associated Hsp22 gene and the male sex-determination
   fruitless gene. Our results have implications for the role of the
   epigenetic regulator Dmel\Kdm4A in the control of genes involved in
   life span and male-specific sex determination in the fly. (C) 2009
   Elsevier B.V. All rights reserved.
C1 [Lorbeck, Meridith T.; Singh, Neetu; Zervos, Ashley; Dhatta, Madhusmita; Lapchenko, Maria; Yang, Chen; Elefant, Felice] Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA.
RP Elefant, F, Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA.
EM fe22@drexel.edu
FU National Institute of Health [1R01HD057939]
FX The authors gratefully acknowledge Dr. Daniel Marenda and Dr. Xianmin
   Zhu for their invaluable advice and technical support. This work was
   supported by a National Institute of Health grant 1R01HD057939 to F.E.
CR 1999, NUCL ACIDS RES, V27, P85
   AGRAWAL N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI
   10.1073/pnas.0500055102
   AIGAKI T, 1984, EXP GERONTOL, V19, P267
   BERGER SL, 2002, CURR OPIN GENET DEV, V12, P142
   BILLETER JC, 2006, CURR BIOL, V16, R766, DOI 10.1016/j.cub.2006.08.025
   BOTTOMLEY MJ, 2004, EMBO REP, V5, P464, DOI 10.1038/sj.embor.7400146
   CERTEL SJ, 2007, P NATL ACAD SCI USA, V104, P4706, DOI
   10.1073/pnas.0700328104
   CHAI A, 2008, HUM MOL GENET, V17, P266, DOI 10.1093/hmg/ddm303
   CHAN HYE, 2000, CELL DEATH DIFFER, V7, P1075
   CHAN YB, 2003, HUM MOL GENET, V12, P1367, DOI 10.1093/hmg/ddg157
   CHANG BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801
   CHEN L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443
   CIRELLI C, 2005, NATURE, V434, P1087, DOI 10.1038/nature03486
   CLYNE JD, 2008, CELL, V133, P354, DOI 10.1016/j.cell.2008.01.050
   CROWTHER DC, 2004, CURR OPIN PHARMACOL, V4, P513, DOI
   10.1016/j.coph.2004.07.001
   DICKSON BJ, 2002, SCIENCE, V298, P1959
   DICKSON BJ, 2008, SCIENCE, V322, P904, DOI 10.1126/science.1159276
   DISTEFANO L, 2007, CURR BIOL, V17, P808, DOI 10.1016/j.cub.2007.03.068
   FEANY MB, 2000, NATURE, V404, P394
   FEINBERG AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI
   10.1016/S1044-579X(02)00059-7
   FELSENFELD G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411
   FISCHLE W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI
   10.1016/S0955-0674(03)00013-9
   FREEMAN MR, 1999, DEVELOPMENT, V126, P4591
   GREENE JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI
   10.1073/pnas.0737556100
   KIMURA K, 2008, NEURON, V59, P759, DOI 10.1016/j.neuron.2008.06.007
   KLOSE RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   LACHNER M, 2001, NATURE, V410, P116
   LIN CH, 2008, MOL CELL, V32, P696, DOI 10.1016/j.molcel.2008.11.008
   LIVAK KJ, 2001, METHODS, V25, P402
   LLORETLLINARES M, 2008, NUCLEIC ACIDS RES, V36, P2852, DOI
   10.1093/nar/gkn098
   LUGER K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1
   MARGUERON R, 2005, CURR OPIN GENET DEV, V15, P163
   MARTIN C, 2005, NAT REV MOL CELL BIO, V6, P838
   METZGER E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   MORROW G, 2004, J BIOL CHEM, V279, P43382, DOI 10.1074/jbc.C400357200
   MOURIKIS P, 2006, P NATL ACAD SCI USA, V103, P1307, DOI
   10.1073/pnas.0510564103
   NOWAK SJ, 2000, GENE DEV, V14, P3003
   REDOWICZ MJ, 2002, ACTA BIOCHIM POL, V49, P789
   RICE JC, 2001, CURR OPIN CELL BIOL, V13, P263
   ROGINA B, 2000, SCIENCE, V290, P2137
   ROGINA B, 2002, SCIENCE, V298, P1745
   ROGINA B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI
   10.1073/pnas.0404184101
   SANTOSROSA H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   SHI Y, 2007, NAT REV GENET, V8, P829
   SHI YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   SHIN S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI
   10.1016/j.bbrc.2006.12.147
   SHIN S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI
   10.1016/j.bbrc.2007.05.179
   SONG HJ, 2002, GENETICS, V162, P1703
   TAN JM, 2006, NEURON, V50, P527
   TSUKADA Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   TZSCHACH A, 2006, HUM MUTAT, V27, P389
   UEDA A, 2008, J NEUROGENET, V22, P1
   VILLELLA A, 1997, GENETICS, V147, P1107
   WALLRATH LL, 2008, MOL CELL, V32, P601, DOI 10.1016/j.molcel.2008.11.015
   WANG JW, 2000, J NEUROSCI, V20, P5958
   WANG Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400
   WHETSTINE JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   YAMAMOTO D, 2008, J NEUROGENET, V15, P1
   YUAN JS, 2006, BMC BIOINFORMATICS, V7, ARTN 85
   ZHANG Y, 2001, GENE DEV, V15, P2343
   ZHONG Y, 1993, J NEUROSCI, V13, P4669
NR 61
TC 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JAN 15
PY 2010
VL 450
IS 1-2
BP 8
EP 17
DI 10.1016/j.gene.2009.09.007
PG 10
SC Genetics & Heredity
GA 547YF
UT ISI:000273925100002
ER

PT J
AU Lin, Q
   Zhu, FC
   Yang, WN
AF Lin, Qiong
   Zhu, Fengchang
   Yang, Wannian
TI Coupling cellular mitogenesis to apoptosis by designed biomolecules
SO CELLULAR SIGNALLING
LA English
DT Article
DE Signaling rewiring; Ras; Raf; Caspase 3; Mitogenesis; Apoptosis
ID GENE-THERAPY; RETROVIRAL VECTORS; CASPASE ACTIVATION; CYSTEINE
   PROTEASE; MECHANISMS; PATHWAYS; CANCER; CPP32; KINASES; DOMAINS
AB Cellular signal transduction pathways transduce input signals to
   produce corresponding output effects, ensuring correct response to
   extracellular signals. Manipulation of components in signaling pathways
   will alter correlation of input signals to output effects. Here we
   report that by reconstructing the components in mitogenic and apoptotic
   signaling pathways, Ras, Raf, and caspase-3, we manipulated the cells
   to couple mitogenic signal input to apoptotic output. The reconstructed
   biomolecules that couple mitogenesis to apoptosis are designated as
   "mitogenesis coupled-apoptosis molecular device" (MCAMD). As
   mitogenesis in cancer cells is constitutively active, MCAMD may have
   potential applications for cancer gene therapy. (C) 2009 Elsevier B.V.
   All rights reserved.
C1 [Lin, Qiong; Zhu, Fengchang; Yang, Wannian] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA.
RP Yang, WN, Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA
   17822 USA.
EM wyang1@geisinger.edu
FU Congress-directed Medical Research Programs-Prostate Cancer Research
   Program [W81XWH-05-1-0178, W81XWH-07-1-0084]
FX This work was supported by research grants (W81XWH-05-1-0178 and
   W81XWH-07-1-0084; to W.Y.) from Congress-directed Medical Research
   Programs-Prostate Cancer Research Program.
CR BAKIN RE, 2003, CANCER RES, V63, P1981
   BHATTACHARYYA RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI
   10.1146/annurev.biochem.75.103004.142710
   BOATRIGHT KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI
   10.1016/j.ceb.2003.10.009
   BUDIHARDJO I, 1999, ANNU REV CELL DEV BI, V15, P269
   CHANG LJ, 2001, CURR OPIN MOL THER, V3, P468
   DUEBER JE, 2004, CURR OPIN STRUC BIOL, V14, P690, DOI
   10.1016/j.sbi.2004.10.004
   ENARI M, 1996, NATURE, V380, P723
   FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761
   FERNANDESALNEMRI T, 1996, P NATL ACAD SCI USA, V93, P7464
   HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506
   HOWARD PL, 2003, P NATL ACAD SCI USA, V100, P11267, DOI
   10.1073/pnas.1934711100
   HUBBARD SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI
   10.1016/j.ceb.2007.02.010
   JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230
   JONESON T, 1997, J MOL MED-JMM, V75, P587
   KUMAR S, 1997, INT J BIOCHEM CELL B, V29, P393
   MARUTA H, 1994, BIOESSAYS, V16, P489
   MCKAY MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394
   NASSAR N, 1995, NATURE, V375, P554
   NI CZ, 2003, J MOL RECOGNIT, V16, P121, DOI 10.1002/jmr.615
   NICHOLSON DW, 1995, NATURE, V376, P37
   PARK SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979
   PORTER AG, 1999, CELL DEATH DIFFER, V6, P99
   RIEDL SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   ROBBINS PD, 1994, ANN NY ACAD SCI, V716, P72
   SEGER R, 1995, FASEB J, V9, P726
   STENNICKE HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17
   YANG WN, 2001, J BIOL CHEM, V276, P17468
   YANG WN, 2001, J BIOL CHEM, V276, P43987
   YEH BJ, 2007, NATURE, V447, P596, DOI 10.1038/nature05851
   YOUNG LS, 2006, J PATHOL, V208, P299, DOI 10.1002/path.1896
NR 30
TC 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2010
VL 22
IS 2
BP 190
EP 196
DI 10.1016/j.cellsig.2009.09.005
PG 7
SC Cell Biology
GA 548LR
UT ISI:000273964800003
ER

PT J
AU Tung, WH
   Hsieh, HL
   Yang, CM
AF Tung, Wei-Hsuan
   Hsieh, Hsi-Lung
   Yang, Chuen-Mao
TI Enterovirus 71 induces COX-2 expression via MAPKs, NF-kappa B, and AP-1
   in SK-N-SH cells: Role of PGE(2) in viral replication
SO CELLULAR SIGNALLING
LA English
DT Article
DE Viral infection; COX-2; PGE(2); Neurons; MAPKs; Transcription factors
ID SMOOTH-MUSCLE-CELLS; HEPATITIS-C VIRUS; PROSTAGLANDIN E-2;
   EPITHELIAL-CELLS; P42/P44 MAPK; REGULATING CYCLOOXYGENASE-2; SIGNALING
   PATHWAY; MESSENGER-RNA; T-CELLS; ACTIVATION
AB The enterovirus 71 (EV71) causes severe neurological diseases that were
   mediated through cyclooxygenase-2 (COX-2) expression in brain. However,
   the mechanisms underlying EV71-initiated intracellular signaling
   pathways leading to COX-2 expression remain unknown in neurons. Here we
   report that exposure of SK-N-SH cells to EV71 increased COX-2
   expression and PGE(2) generation in a time- and virus titer-dependent
   manner, revealed by Western blots real-time PCR, and PGE(2) analyses.
   These EV71-induced responses were mediated through activation of
   p42/p44 MAPK, p38 MAPK, JNK, NF-kappa B, and AP-1, revealed by using
   selective pharmacological inhibitors or transfection with respective
   siRNAs. Consistently, EV71-stimulated translocation of NF-kappa B into
   the nucleus and degradation of I kappa B alpha in the cytosol was
   blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126)
   and NF-kappa B (Bay11-7085), respectively, suggesting that
   MEK1/2-p42/p44 MAPK cascade linking to NF-kappa B was involved in COX-2
   expression. In addition, EV71-induced AP-1 subunits (c-jun and c-fos
   mRNA) expression was also attenuated by pretreatment with a selective
   JNK inhibitor SP600125, suggesting that JNK cascade linking to AP-1 was
   involved in COX-2 expression induced by EV71. These findings suggested
   that up-regulation of COX-2 associated with the release of PGE2 from
   EV71-infected SK-N-SH cells which was mediated through activation of
   p38 MAPK, JNK, p42/p44 MAPK NF-kappa B. and AP-1 pathways. (C) 2009
   Elsevier Inc. All rights reserved.
C1 [Tung, Wei-Hsuan; Yang, Chuen-Mao] Chang Gung Univ, Dept Physiol & Pharmacol, Tao Yuan, Taiwan.
   [Hsieh, Hsi-Lung] Chang Gung Inst Technol, Dept Nursing, Div Basic Med Sci, Tao Yuan, Taiwan.
RP Yang, CM, Chang Gung Univ, Dept Pharmacol, 259 Wen Hwa 1st Rd, Tao
   Yuan, Taiwan.
EM chuenmao@mail.cgu.edu.tw
FU Chang Gung Medical Research Foundation [CMRPD150253, CMRPD150313,
   CMRPD170491]; National Science Council, Taiwan [NSC96-2320-B-182-003,
   NSC96-2320-B-182-047-MY3, NSC972321-B-182-007]
FX This work was supported by grants CMRPD150253, CMRPD150313, and
   CMRPD170491 from Chang Gung Medical Research Foundation and
   NSC96-2320-B-182-003, NSC96-2320-B-182-047-MY3, and NSC972321-B-182-007
   from National Science Council, Taiwan.
CR BALASUBRAMANIAN A, 2003, J BIOL CHEM, V278, P35755, DOI
   10.1074/jbc.M302889200
   BRUDER JT, 1997, J VIROL, V71, P398
   CHEN CS, 2007, J VIROL, V81, P8996, DOI 10.1128/JVI.00236-07
   CHEN N, 2000, VIROLOGY, V276, P44
   CHEN N, 2002, VIRAL IMMUNOL, V15, P133
   CHU WM, 1999, IMMUNITY, V11, P721
   CHUN KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI
   10.1016/j.bcp.2004.05.031
   DUMAIS N, 1998, J BIOL CHEM, V273, P27306
   FLORY E, 2000, J BIOL CHEM, V275, P8307
   GRIFFIN DE, 1999, TRENDS MICROBIOL, V7, P155
   HINSON VK, 2001, CURR OPIN NEUROL, V14, P369
   HISCOTT J, 2001, J CLIN INVEST, V107, P143
   HOOKS JJ, 2006, MICROBES INFECT, V8, P2236, DOI
   10.1016/j.micinf.2006.04.010
   HSIEH HL, 2006, J CELL PHYSIOL, V207, P757, DOI 10.1002/jcp.20621
   HSIEH HL, 2007, CELL SIGNAL, V19, P330, DOI
   10.1016/j.cellsig.2006.07.006
   INIGUEZ MA, 2000, J BIOL CHEM, V275, P23627
   KARAMOUZIS MV, 2007, MOL CANCER RES, V5, P109, DOI
   10.1158/1541-7786.MCR-06-0311
   KLINE JN, 1998, EXP LUNG RES, V24, P3
   KUJIME K, 2000, J IMMUNOL, V164, P3222
   LEWIS P, 2005, PEDIATR REV, V26, P353
   LIU CC, 2007, VACCINE, V25, P19, DOI 10.1016/j.vaccine.2006.06.083
   LUDWIG S, 2003, TRENDS MOL MED, V9, P46
   MORIUCHI M, 2001, J VIROL, V75, P192
   NARUMIYA S, 2001, J CLIN INVEST, V108, P25
   ONGRADI J, 1990, ACTA VIROL, V34, P380
   PALACIOS G, 2005, J NEUROVIROL, V11, P424, DOI 10.1080/13550280591002531
   PARK SA, 2007, ANN NY ACAD SCI, V1095, P545, DOI 10.1196/annals.1397.059
   PYEON D, 2000, J VIROL, V74, P5740
   RIDLEY SH, 1998, FEBS LETT, V439, P75
   SAVARD M, 2000, J IMMUNOL, V164, P6467
   SCHERLE PA, 2000, J BIOL CHEM, V275, P37086
   SCHMITZ KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018
   SHAULIAN E, 2002, NAT CELL BIOL, V4, E131
   SHIH SR, 2004, ANTIMICROB AGENTS CH, V48, P3523, DOI
   10.1128/AAC.48.9.3523-3529.2004
   SIROIS J, 2004, HUM REPROD UPDATE, V10, P373, DOI 10.1093/humupd/dmh032
   SLOAN DD, 2007, J VIROL, V81, P12504, DOI 10.1128/JVI.01111-07
   STEER SA, 2003, VIRAL IMMUNOL, V16, P447
   TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190
   TSATSANIS C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI
   10.1016/j.biocel.2006.03.021
   WANG CC, 2005, AM J PHYSIOL-LUNG C, V288, L227, DOI
   10.1152/ajplung.00224.2004
   WARNER TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI
   10.1073/pnas.222543099
   WILLIAMS CS, 1996, AM J PHYSIOL-GASTR L, V270, G393
   ZHU H, 2002, P NATL ACAD SCI USA, V99, P3932
NR 43
TC 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2010
VL 22
IS 2
BP 234
EP 246
DI 10.1016/j.cellsig.2009.09.018
PG 13
SC Cell Biology
GA 548LR
UT ISI:000273964800007
ER

PT J
AU Sun, WJ
   Tan, XJ
   Shi, Y
   Xu, GF
   Mao, RF
   Gu, X
   Fan, YH
   Yu, Y
   Burlingame, S
   Zhang, H
   Rednam, SP
   Lu, XB
   Zhang, T
   Fu, SB
   Cao, GW
   Qin, J
   Yang, JH
AF Sun, Wenjing
   Tan, Xiaojie
   Shi, Yi
   Xu, Gufeng
   Mao, Renfang
   Gu, Xue
   Fan, Yihui
   Yu, Yang
   Burlingame, Susan
   Zhang, Hong
   Rednam, Surya P.
   Lu, Xiongbin
   Zhang, Ting
   Fu, Songbin
   Cao, Guangwen
   Qin, Jun
   Yang, Jianhua
TI USP11 negatively regulates TNF alpha-induced NF-kappa B activation by
   targeting on I kappa B alpha
SO CELLULAR SIGNALLING
LA English
DT Article
DE I kappa B alpha; NF-kappa B; USP11; IKK beta; TNF alpha
ID IKK-BETA; DEUBIQUITINATING ENZYME; TRANSCRIPTION FACTOR; KINASE
   COMPLEX; SIGNAL-TRANSDUCTION; INTERLEUKIN-6 GENE; DNA-DAMAGE;
   PHOSPHORYLATION; INTERACTS; PROTEINS
AB I kappa B alpha serves as a central anchoring molecule in the
   sequestration of NF-kappa B transcription factor in the cytoplasm.
   Ubiquitination-mediated I kappa B alpha degradation immediately
   precedes and is required for NF-kappa B nuclear translocation and
   activation. However, the precise mechanism for the deubiquitination Of
   I kappa B alpha is still not fully understood. Using a proteomic
   approach, we have identified Ubiquitin Specific Pepticlase 11 (USP11)
   as an I kappa B alpha associated deubiquitinase. Overexpression of
   USP11 inhibits I kappa B alpha ubiquitination. Recombinant USP11
   catalyzes deubiquitination Of I kappa B alpha in vitro. Moreover,
   knockdown of USP11 expression enhances TNF alpha-induced I kappa B
   alpha ubiquitination and NF-kappa B activation. These data demonstrate
   that USP11 plays an important role in the downregulation of TNF
   alpha-mediated NF-kappa B activation through modulating I kappa B alpha
   stability. In addition, overexpression of a catalytically inactive
   USP11 mutant partially inhibits TNF alpha- and IKK beta-induced
   NF-kappa B activation, suggesting that USP11 also exerts a
   non-catalytic function in its negative regulation of TNF alpha-mediated
   NF-kappa B activation. Thus. I kappa B alpha ubiquitination and
   deubiquitination processes function as a Yin-Yang regulatory mechanism
   on TNF alpha-induced NF-kappa B activation. (C) 2009 Elsevier Inc. All
   rights reserved.
C1 [Sun, Wenjing; Tan, Xiaojie; Xu, Gufeng; Gu, Xue; Fan, Yihui; Yu, Yang; Burlingame, Susan; Rednam, Surya P.; Yang, Jianhua] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA.
   [Shi, Yi; Qin, Jun] Baylor Coll Med, Dept Mol & Cellular Biol, Verna & Marrs Mclean Dept Biochem & Mol Biol, Ctr Mol Discovery, Houston, TX 77030 USA.
   [Mao, Renfang; Zhang, Hong] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Lu, Xiongbin] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
   [Tan, Xiaojie; Cao, Guangwen] Mil Med Coll 2, Dept Epidemiol, Shanghai 200433, Peoples R China.
   [Sun, Wenjing; Fu, Songbin] Harbin Med Coll, Med Genet Lab, Harbin 150081, Peoples R China.
   [Gu, Xue; Zhang, Ting] Capital Inst Pediat, Beijing 100020, Peoples R China.
RP Yang, JH, Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr,
   Houston, TX 77030 USA.
EM jianhuay@bcm.edu
FU Diabetes Endocrinology Research Center (DERC) [DK079638]; NIH/NCI
   [IR21CA106513-OIA2]; American Cancer Society [RSG-06-070-01-TBE];
   Fleming and Davenport Award ; National Basic Research Program
   [2007CB511900]
FX We thank the proteomics core of Diabetes Endocrinology Research Center
   (DERC) supported by DK079638 for protein identification. We are very
   grateful to Dr. Paul Chiao for providing Flag-IKBot expression
   construct, Dr. Xinhua Feng for HA-ubiquitin expression plasmid, and Dr.
   Zhijian Chen for GST-Control and GST-IKBOt plasmids. This work was
   supported by thegrants; from the NIH/NCI IR21CA106513-OIA2 (toj.Y.),
   the American Cancer Society grant RSG-06-070-01-TBE (to j.Y.), the
   Fleming and Davenport Award (to HZ), and the National Basic Research
   Program (973 Program) of China grant 2007CB511900 (to TZ).
CR BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P649
   BEG AA, 1993, GENE DEV, V7, P2064
   BOUWMEESTER T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086
   DIDONATO JA, 1997, NATURE, V388, P548
   GHOSH S, 2002, CELL S, V109, S81
   HAYDEN MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   IDEGUCHI H, 2002, BIOCHEM J 1, V367, P87, DOI 10.1042/BJ20011851
   LI ZW, 1999, J EXP MED, V189, P1839
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327
   LIN CH, 2008, J BIOL CHEM, V283, P15681, DOI 10.1074/jbc.M708278200
   MAY MJ, 1998, IMMUNOL TODAY, V19, P80
   MERCURIO F, 1997, SCIENCE, V278, P860
   MU JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200
   NIJMAN SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   REGNIER CH, 1997, CELL, V90, P373
   ROTHWARF DM, 1998, NATURE, V395, P297
   ROTHWARF DM, 1999, SCI STKE, RE1
   SCHOENFELD AR, 2004, MOL CELL BIOL, V24, P7444, DOI
   10.1128/MCB.24.17.7444-7455.2004
   SCHWEITZER K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600
   SHIMIZU H, 1990, MOL CELL BIOL, V10, P561
   SUN WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012
   TANAKA M, 1999, IMMUNITY, V10, P421
   VERMA IM, 1995, GENE DEV, V9, P2723
   WORONICZ JD, 1997, SCIENCE, V278, P866
   YAMAGUCHI T, 2007, J BIOL CHEM, V282, P33943, DOI 10.1074/jbc.M706282200
   YAMAOKA S, 1998, CELL, V93, P1231
   YU Y, 2008, J BIOL CHEM, V283, P24497
   ZANDI E, 1997, CELL, V91, P243
   ZANDI E, 1998, SCIENCE, V281, P1360
   ZHANG Y, 1990, MOL CELL BIOL, V10, P3818
NR 30
TC 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD MAR
PY 2010
VL 22
IS 3
BP 386
EP 394
DI 10.1016/j.cellsig.2009.10.008
PG 9
SC Cell Biology
GA 548CD
UT ISI:000273935700006
ER

PT J
AU Esteban, MA
   Wang, T
   Qin, BM
   Yang, JY
   Qin, DJ
   Cai, JL
   Li, W
   Weng, ZH
   Chen, JK
   Ni, S
   Chen, KS
   Li, Y
   Liu, XP
   Xu, JY
   Zhang, SQ
   Li, F
   He, WZ
   Labuda, K
   Song, YC
   Peterbauer, A
   Wolbank, S
   Redl, H
   Zhong, M
   Cai, DZ
   Zeng, LW
   Pei, DQ
AF Esteban, Miguel Angel
   Wang, Tao
   Qin, Baoming
   Yang, Jiayin
   Qin, Dajiang
   Cai, Jinglei
   Li, Wen
   Weng, Zhihui
   Chen, Jiekai
   Ni, Su
   Chen, Keshi
   Li, Yuan
   Liu, Xiaopeng
   Xu, Jianyong
   Zhang, Shiqiang
   Li, Feng
   He, Wenzhi
   Labuda, Krystyna
   Song, Yancheng
   Peterbauer, Anja
   Wolbank, Susanne
   Redl, Heinz
   Zhong, Mei
   Cai, Daozhang
   Zeng, Lingwen
   Pei, Duanqing
TI Vitamin C Enhances the Generation of Mouse and Human Induced
   Pluripotent Stem Cells
SO CELL STEM CELL
LA English
DT Article
ID IPS CELLS; HUMAN FIBROBLASTS; DEFINED FACTORS; DISEASE; DEMETHYLASES;
   EFFICIENCY; INDUCTION; PATHWAY; LIMITS; LINES
AB Somatic cells can be reprogrammed into induced pluripotent stem cells
   (iPSCs) by defined factors. However, the low efficiency and slow
   kinetics of the reprogramming process have hampered progress with this
   technology. Here we report that a natural compound, vitamin C (Vc),
   enhances iPSC: generation from both mouse and human somatic cells. Vc
   acts at least in part by alleviating cell senescence, a recently
   identified roadblock for reprogramming. In addition, Vc accelerates
   gene expression changes and promotes the transition of pre-iPSC
   colonies to a fully reprogrammed state. Our results therefore highlight
   a straightforward method for improving the speed and efficiency of iPSC
   generation and provide additional insights into the mechanistic basis
   of the reprogramming process.
C1 [Esteban, Miguel Angel; Wang, Tao; Qin, Baoming; Yang, Jiayin; Qin, Dajiang; Cai, Jinglei; Li, Wen; Weng, Zhihui; Chen, Jiekai; Ni, Su; Chen, Keshi; Li, Yuan; Liu, Xiaopeng; Xu, Jianyong; Zhang, Shiqiang; Li, Feng; He, Wenzhi; Zeng, Lingwen; Pei, Duanqing] Chinese Acad Sci, Guangzhou Inst Biomed, S China Inst Stem Cell Biol & Regenerat Med, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, Guangzhou 510663, Guangdong, Peoples R China.
   [Esteban, Miguel Angel; Wang, Tao; Qin, Baoming; Yang, Jiayin; Qin, Dajiang; Cai, Jinglei; Li, Wen; Weng, Zhihui; Chen, Jiekai; Ni, Su; Chen, Keshi; Li, Yuan; Liu, Xiaopeng; Xu, Jianyong; Zhang, Shiqiang; Li, Feng; He, Wenzhi; Zeng, Lingwen; Pei, Duanqing] Chinese Acad Sci, Guangzhou Inst Hlth, Guangzhou 510663, Guangdong, Peoples R China.
   [Labuda, Krystyna; Wolbank, Susanne; Redl, Heinz] Ludwig Boltzmann Inst Clin & Expt Traumatol, A-1200 Vienna, Austria.
   [Song, Yancheng; Cai, Daozhang] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
   [Peterbauer, Anja] Red Cross Blood Transfus Serv Upper Austria, A-4020 Linz, Austria.
   [Zhong, Mei] Nanfang Hosp, Ctr Prenatal & Hereditary Dis Diag, Guangzhou 510515, Guangdong, Peoples R China.
RP Pei, DQ, Chinese Acad Sci, Guangzhou Inst Biomed, S China Inst Stem
   Cell Biol & Regenerat Med, Stem Cell & Canc Biol Grp,Key Lab Regenerat
   Biol, Guangzhou 510663, Guangdong, Peoples R China.
EM pei_duanqing@gibh.ac.cn
FU National Natural Science Foundation of China [30630039, 90813033];
   National Science Fund for Distinguished Young Scholars [30725012];
   Knowledge Innovation Project of The Chinese Academy of Sciences
   [KSCX2-YW-R-48, KSCX1-YW-02-1]; Bureau of Science and Technology of
   Guangzhou Municipality, China [2008A1-E4011]; Key Technologies R&D
   Program, 973 Program of China [2006CB701504, 2006CB943600,
   2007CB948002, 2009CB941102, 2009CB940902]; EFBIC RED travel grant ;
   Chinese Academy of Sciences/SAFEA International Partnership [230725012]
FX Supported by National Natural Science Foundation of China (grant
   numbers 30630039 and 90813033), National Science Fund for Distinguished
   Young Scholars (30725012), Knowledge Innovation Project of The Chinese
   Academy of Sciences (grant numbers KSCX2-YW-R-48, KSCX1-YW-02-1),
   Bureau of Science and Technology of Guangzhou Municipality, China
   (grant 2008A1-E4011), Key Technologies R&D Program, 973 Program of
   China (grant numbers 2006CB701504, 2006CB943600, 2007CB948002,
   2009CB941102, 2009CB940902), an EFBIC RED travel grant, and the Chinese
   Academy of Sciences/SAFEA International Partnership Program for
   Creative Research Teams (grant number 230725012). We wish to thank
   members of our laboratories for their support.
CR ARRIGONI O, 2002, BBA-GEN SUBJECTS, V1569, P1
   CLOOS PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   ESTEBAN MA, 2009, J BIOL CHEM, V284, P17634, DOI 10.1074/jbc.M109.008938
   GARCIAGONZALO FR, 2008, PLOS ONE, V3, ARTN e1384
   HARMAN D, 1956, J GERONTOL, V11, P298
   HONG H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   HUANGFU DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   KANG L, 2008, CELL STEM CELL, V5, P135
   KAWAMURA T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
   KIM D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   LI H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290
   MARION RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   MASSIP L, 2009, FASEB J
   NAKAGAWA M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   OKITA K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   PARK IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   PARRINELLO S, 2003, NAT CELL BIOL, V5, P741
   QIN DJ, 2008, J BIOL CHEM, V283, P33730, DOI 10.1074/jbc.M806788200
   SHI Y, 2007, NAT REV GENET, V8, P829
   SILVA J, 2008, PLOS BIOL, V6, P2237, ARTN e253
   SUN N, 2009, P NATL ACAD SCI USA, V106, P15720, DOI
   10.1073/pnas.0908450106
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAKAHASHI K, 2007, CELL, V131, P861
   UTIKAL J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285
   WERNIG M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   WERNIG M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001
   WILMUT I, 1997, NATURE, V385, P813
   YAMANAKA S, 2009, CELL, V137, P13, DOI 10.1016/j.cell.2009.03.034
   YU JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   YU JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   ZHAO XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267
   ZHAO Y, 2008, CELL STEM CELL, V3, P475, DOI 10.1016/j.stem.2008.10.002
NR 32
TC 50
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD JAN 8
PY 2010
VL 6
IS 1
BP 71
EP 79
DI 10.1016/j.stem.2009.12.001
PG 9
SC Cell & Tissue Engineering; Cell Biology
GA 549EW
UT ISI:000274029700013
ER

PT J
AU Huang, YW
   Liao, YT
   Chen, W
   Chen, CL
   Hu, JT
   Liu, CJ
   Lai, MY
   Chen, PJ
   Chen, DS
   Yang, SS
   Kao, JH
AF Huang, Y-W
   Liao, Y-T
   Chen, W.
   Chen, C-L
   Hu, J-T
   Liu, C-J
   Lai, M-Y
   Chen, P-J
   Chen, D-S
   Yang, S-S
   Kao, J-H
TI Vitamin D receptor gene polymorphisms and distinct clinical phenotypes
   of hepatitis B carriers in Taiwan
SO GENES AND IMMUNITY
LA English
DT Article
DE vitamin D receptor; polymorphism; hepatitis B virus; chronic carrier;
   hepatocellular carcinoma
ID VIRUS-INFECTION; 1,25-DIHYDROXYVITAMIN D-3; HEPATOCELLULAR-CARCINOMA;
   AMINOTRANSFERASE LEVELS; VIRAL-HEPATITIS; NATURAL-HISTORY;
   LIVER-DISEASE; HBV INFECTION; E-ANTIGEN; CIRRHOSIS
AB Vitamin D exhibits immunomodulatory and antiproliferative effects
   through vitamin D receptor (VDR) in chronic infections and cancers. We
   genotyped the BsmI (rs1544410), ApaI (rs7975232) and TaqI (rs731236)
   polymorphisms of VDR gene in 250 Taiwanese chronic hepatitis B virus
   (HBV) carriers who were categorized into six phenotypes. After
   adjustment for age and sex, the frequencies of the VDR B/b, B/a, B/T,
   B/a/T in patients with hepatitis flare(s) were lower than those without
   (7 vs 20%, P = 0.009; 1 vs 9%, P = 0.004; 3 vs 10%, P = 0.007; 1 vs 9%,
   P = 0.005, respectively); in contrast, T/t, A/T, A/t, b/A/t were higher
   in flare(s) (8 vs 3%, P = 0.003; 49 vs 34%, P = 0.027; 2 vs 1%, P =
   0.004; 0.5 vs 0%, P = 0.001, respectively). In addition, B/b, B/B, T/t,
   b/A, B/a, B/A, B/T, B/t, A/t, b/A/T, B/a/T, B/A/T, B/A/t, b/A/t were
   higher in patients positive for HBeAg. The distribution of VDR
   genotypes was comparable between patients with and without
   hepatocellular carcinoma (HCC). VDR gene polymorphisms are associated
   with distinct clinical phenotypes in Taiwanese HBV carriers but not
   with HCC development. Genes and Immunity (2010) 11, 87-93;
   doi:10.1038/gene.2009.65; published online 20 August 2009
C1 [Kao, J-H] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Dept Internal Med, Div Gastroenterol, Taipei 10002, Taiwan.
   [Huang, Y-W; Liu, C-J; Lai, M-Y; Chen, P-J; Chen, D-S; Kao, J-H] Natl Taiwan Univ, Coll Med, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan.
   [Huang, Y-W; Hu, J-T; Yang, S-S] Cathay Gen Hosp, Med Ctr, Liver Unit, Taipei, Taiwan.
   [Liao, Y-T] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10764, Taiwan.
   [Chen, W.; Chen, D-S; Kao, J-H] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan.
   [Chen, C-L; Liu, C-J; Lai, M-Y; Chen, P-J; Chen, D-S; Kao, J-H] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan.
   [Hu, J-T; Yang, S-S] Fu Jen Catholic Univ, Coll Med, Sch Med, Taipei, Taiwan.
   [Lai, M-Y; Chen, P-J; Kao, J-H] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan.
RP Kao, JH, Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Dept Internal Med,
   Div Gastroenterol, 1 Chang Te St, Taipei 10002, Taiwan.
EM kaojh@ntu.edu.tw
FU National Taiwan University Hospital ; Cathay General Hospital
   [97-CGN01]; Department of Health ; National Science Council, Taiwan ;
   National Health Research Institutes, Taiwan ; Liver Disease Prevention
   and Treatment Research Foundation 
FX This study was supported by grants from the National Taiwan University
   Hospital; Cathay General Hospital (97-CGN01), Department of Health and
   the National Science Council, Executive Yuan, Taiwan; National Health
   Research Institutes, Taiwan; and Liver Disease Prevention and Treatment
   Research Foundation.
CR *CDC, 1991, MMWR, V40
   BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI
   10.1093/bioinformatics/bth457
   BELLAMY R, 1999, J INFECT DIS, V179, P721
   BRUIX J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933
   CHEN DS, 1993, SCIENCE, V262, P369
   CHISARI FV, 1997, J CLIN INVEST, V99, P1472
   CHU CM, 2000, J GASTROEN HEPATOL S, V15, E25
   CHU CM, 2004, AM J MED, V116, P829, DOI 10.1016/j.amjmed.2003.12.040
   CHU CM, 2007, GASTROENTEROLOGY, V133, P1458, DOI
   10.1053/j.gastro.2007.08.039
   CHU CM, 2007, HEPATOLOGY, V45, P1187, DOI 10.1002/hep.21612
   DALHOFF K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104
   FORZANI B, 1984, HEPATOLOGY, V4, P1107
   HANN HWL, 2007, AM J GASTROENTEROL, V102, P767, DOI
   10.1111/j.1572-0241.2007.01060.x
   HATTUM JV, 1987, HEPATOLOGY, V7, P11
   HAUSSLER MR, 1998, J BONE MINER RES, V13, P325
   HUANG YW, 2009, J MED VIROL, V81, P588, DOI 10.1002/jmv.21448
   HUO TI, 2000, EUR J GASTROEN HEPAT, V12, P687
   KAO JH, 2000, INFEC DIS S, P313
   KAO JH, 2001, HEPATOLOGY 1, V34, P817
   KAO JH, 2002, J CLIN MICROBIOL, V40, P1207
   LEE WM, 1997, NEW ENGL J MED, V337, P1733
   LI JH, 2006, CHINESE J MED GENET, V23, P402
   LI JH, 2006, ZHONGHUA YI XUE ZHI, V86, P1952
   LIN KW, 2004, AM FAM PHYSICIAN, V69, P75
   LOK ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   MCQUILLAN GM, 1989, AM J MED S3A, V87, P5
   POTTER DM, 2005, STAT MED, V24, P693, DOI 10.1002/sim.1931
   POURGHOLAMI MH, 2000, CANCER LETT, V151, P97
   POURGHOLAMI MH, 2004, J STEROID BIOCHEM, V89, P513, DOI
   10.1016/j.jsbmb.2004.03.065
   REALDI G, 1994, J HEPATOL, V21, P656
   RIGGS BL, 1995, J BONE MINER RES, V10, P991
   SHIFFMAN ML, 2000, J INFECT DIS, V182, P1595
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771
   SUNEETHA PV, 2006, J HEPATOL, V44, P856, DOI 10.1016/j.jhep.2006.01.028
   UITTERLINDEN AG, 2004, GENE, V338, P143, DOI 10.1016/j.gene.2004.05.014
   VALDIVIELSO JM, 2006, CLIN CHIM ACTA, V371, P1, DOI
   10.1016/j.cca.2006.02.016
   VELDMAN CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334
   WASLEY A, 2005, MMWR SURVEILL SUMM, V56, P1
   YEH SH, 2004, J HEPATOL, V41, P659, DOI 10.1016/j.jhep.2004.06.031
NR 39
TC 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JAN
PY 2010
VL 11
IS 1
BP 87
EP 93
DI 10.1038/gene.2009.65
PG 7
SC Genetics & Heredity; Immunology
GA 546CE
UT ISI:000273785200009
ER

PT J
AU Cho, DY
   Lin, SZ
   Yang, WK
   Hsu, DM
   Lee, HC
   Lee, WY
   Liu, SP
AF Cho, Der-Yang
   Lin, Shinn-Zong
   Yang, Wen-Kuang
   Hsu, Den-Mei
   Lee, Han-Chung
   Lee, Wen-Yeun
   Liu, Shih-Ping
TI Recent Advances of Dendritic Cells (DCs)-Based Immunotherapy for
   Malignant Gliomas
SO CELL TRANSPLANTATION
LA English
DT Proceedings Paper
CT 1st Pan Pacific Sympsoium of Cell Stem Research
CY JUN, 2008
CL Taichung, TAIWAN
HO China Med Univ & Hosp
DE Anaplastic astrocytoma; Cancer stem cells; Cytotoxic T lymphocytes
   (CTLs); Dendritic cells (DCs); Glioblastoma multiforme (GBM);
   Immunotherapy; Malignant gliomas; Tumor vaccine
ID CYTOTOXIC T-CELLS; GROWTH-FACTOR RECEPTOR; CANCER STEM-CELLS;
   PHASE-I/II TRIAL; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME;
   IMMUNE-RESPONSES; MURINE GLIOMA; INTRACRANIAL GLIOMAS;
   MONOCLONAL-ANTIBODY
AB Immunotherapy is a new light of hope for the treatment of malignant
   gliomas. The brain is no longer believed to be an immunologically
   privileged organ. The major advantage of immunotherapy is the
   tumor-specific cytotoxic effect on the tumor cells with minimal side
   effects. Autologous dendritic cells (DCs)-based immunotherapy is a
   promising and feasible method. DCs are the most potent
   antigen-presenting cells (APCs). DCs prime T lymphocytes by epitopic
   major histocompatibility (MHC) class I and II for CD8(+) cytotoxic T
   lymphocytes (CTLs) and CD4(+) T helper cells, respectively. From the
   tissue specimen examination after DCs-based immunotherapy, CD8(+) CTLs
   have replaced T regulatory cells (Tregs) as the major dominant tissue
   infiltrating lymphocytes (TILs). CD8(+) CTLs play a key role in the
   tumor response, which may also be effective against cancer stem cells.
   DCs themselves also produce many cytokines including interferon-gamma
   and interleukin (IL-2) to kill the tumor cells. From the preliminary
   better outcomes in the literature for malignant gliomas, DC-based
   immunotherapy may improve tumor response by increasing the survival
   rate and time. It is recommended that DC-based immunotherapy is applied
   as soon as possible with conjunctive radiotherapy and chemotherapy.
   Malignant gliomas have heterogeneity of tissue-associated antigens
   (TAAs). To find universal common antigens through different kinds of
   tumor culture may be the essential issue for tumor vaccine development
   in the future.
C1 [Cho, Der-Yang; Lin, Shinn-Zong; Yang, Wen-Kuang; Hsu, Den-Mei; Lee, Han-Chung; Lee, Wen-Yeun; Liu, Shih-Ping] China Med Univ & Hosp, Dept Neurosurg, Ctr Neuropsychiat, Cell Gene Therapy Res Lab, Taichung, Taiwan.
   [Cho, Der-Yang; Lin, Shinn-Zong] China Med Univ, Grad Inst Immunol, Taichung, Taiwan.
RP Yang, WK, China Med Univ Hosp, Cell Gene Therapy Res Lab, 2 Yu Der Rd,
   Taichung, Taiwan.
EM d5057@mail.cmuh.org.tw
CR AKASAKI Y, 2004, J IMMUNOL, V173, P4352
   AKASAKI Y, 2005, EXPERT REV NEUROTHER, V5, P497
   BAO SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   BARBA D, 1989, J NEUROSURG, V70, P175
   BROOKS WH, 1978, ANN NEUROL, V4, P219
   BUCKLAND M, 2009, HDB EXP PHARM, V188, P197
   CARPENTIER AE, 2006, CURR OPIN ONCOL, V18, P631
   CONSTAM DB, 1992, J IMMUNOL, V148, P1404
   DAVIS FG, 1998, J NEUROSURG, V88, P1
   DEVLEESCHOUWER S, 2004, J NEUROSURG S, V100, P492
   DEVLEESCHOUWER S, 2005, CHILD NERV SYST, V21, P7, DOI
   10.1007/s00381-004-0994-3
   DEVLEESCHOUWER S, 2006, NEUROSURGERY, V59, P988, DOI
   10.1227/01.NEU.0000245595.38957.3E
   DEVLEESCHOUWER S, 2008, CLIN CANCER RES, V14, P3098, DOI
   10.1158/1078-0432.CCR-07-4875
   DHODAPKAR KM, 2004, INT J CANCER, V109, P893, DOI 10.1002/ijc.20050
   DONSON AM, 2007, PEDIATR BLOOD CANCER, V48, P403, DOI 10.1002/pbc.20803
   FECCI PE, 2006, CLIN CANCER RES 1, V12, P4294, DOI
   10.1158/1078-0432.CCR-06-0053
   FENSTERMAKER RA, 2004, CANC CONTROL, V11, P181
   FONTANA A, 1982, J IMMUNOL, V129, P2413
   FONTENOT JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   HALL WA, 2004, SURG NEUROL, V61, P145, DOI 10.1016/j.surneu.2003.07.005
   HEIMBERGER AB, 2000, J NEUROIMMUNOL, V103, P16
   KANG MK, 2008, BMC NEUROSCI, V9, ARTN 15
   KELLY KA, 1984, CANCER TREAT REV, V11, P1
   KIKUCHI T, 2001, CANCER IMMUNOL IMMUN, V50, P337
   KIKUCHI T, 2004, J IMMUNOTHER, V27, P452
   KIM CH, 2006, CANCER IMMUNOL IMMUN, V55, P1309, DOI
   10.1007/s00262-006-0134-x
   KIM CH, 2007, IMMUNOLOGY, V122, P615, DOI
   10.1111/j.1365-2567.2007.02680.x
   KJAERGAARD J, 2005, J NEUROSURG, V103, P156
   KOBAYASHI T, 2003, CANCER IMMUNOL IMMUN, V52, P632, DOI
   10.1007/s00262-003-0408-5
   KURPAD SN, 1995, GLIA, V15, P244
   KUWASHIMA N, 2005, J IMMUNOL, V175, P2730
   LEGLER JM, 1999, J NATL CANCER I, V91, P1382
   LIAU LM, 1999, J NEUROSURG, V90, P1115
   LIAU LM, 2005, CLIN CANCER RES, V11, P5515
   MCLENDON RE, 2000, J HISTOCHEM CYTOCHEM, V48, P1103
   NAKAHARA N, 2003, CANCER GENE THER, V10, P549, DOI
   10.1038/sj.cgt.7700598
   NOURISHIRAZI M, 2000, J IMMUNOL, V165, P3797
   PARAJULI P, 2004, CANCER INVEST, V22, P405, DOI 10.1081/CNV-200034909
   PARAJULI P, 2004, NEUROSURGERY, V55, P1194, DOI
   10.1227/01.NEU.0000141082.20865.48
   PEREZCASTILLO A, 2008, CLIN TRANSL ONCOL, V10, P262, DOI
   10.1007/s12094-008-0195-8
   PESHWA MV, 1998, CELL TRANSPLANT, V7, P1
   ROUABHIA M, 1994, CELL TRANSPLANT, V3, P529
   RUTKOWSKI S, 2004, BRIT J CANCER, V91, P1656, DOI 10.1038/sj.bjc.6602195
   SAKARIASSEN PO, 2007, NEOPLASIA, V9, P882, DOI 10.1593/neo.07658
   SHAPERO MH, 2000, CELL TRANSPLANT, V9, P307
   SURAWICZ TS, 1998, J NEURO-ONCOL, V40, P151
   TANG J, 2005, CLIN CANCER RES, V11, P5292
   VICHCHATORN P, 2005, J NEURO-ONCOL, V75, P111, DOI
   10.1007/s11060-005-2317-2
   WEN PY, 2008, NEW ENGL J MED, V359, P492
   WERSALL P, 1997, CANCER IMMUNOL IMMUN, V44, P157
   WHEELER CJ, 2004, CLIN CANCER RES, V10, P5316
   YAMADA Y, 2003, J NEUROSURG, V99, P738
   YAMANAKA R, 2003, BRIT J CANCER, V89, P1172, DOI 10.1038/sj.bjc.6601268
   YAMANAKA R, 2003, J NEUROSURG, V99, P746
   YAMANAKA R, 2005, CLIN CANCER RES, V11, P4160
   YAMANAKA R, 2005, DNA CELL BIOL, V24, P317
   YAMANAKA R, 2005, J NEURO-ONCOL, V72, P107, DOI
   10.1007/s11060-004-3550-9
   YU JS, 2001, CANCER RES, V61, P842
   YU JS, 2004, CANCER RES, V64, P4973
   YU JS, 2006, CLIN NEUROSURG, V53, P345
   ZELTZER PM, 1999, CHILD NERV SYST, V15, P514
   ZHU XM, 2005, J NEURO-ONCOL, V74, P9, DOI 10.1007/s11060-004-3339-x
NR 62
TC 6
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2009
VL 18
IS 9
BP 977
EP 983
DI 10.3727/096368909X12483162196962
PG 7
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 544ZA
UT ISI:000273699100003
ER

PT J
AU Hong, Z
   Yang, YR
   Zhang, C
   Niu, Y
   Li, K
   Zhao, X
   Liu, JJ
AF Hong, Zhi
   Yang, Yanrui
   Zhang, Cheng
   Niu, Yang
   Li, Ke
   Zhao, Xi
   Liu, Jia-Jia
TI The retromer component SNX6 interacts with dynactin p150(Glued) and
   mediates endosome-to-TGN transport
SO CELL RESEARCH
LA English
DT Article
DE sorting nexin; retromer; p150(Glued); retrograde transport;
   dynein/dynactin; CI-MPR
ID BETA-III-SPECTRIN; SORTING NEXIN-1; MAMMALIAN RETROMER; PX-DOMAIN;
   COMPLEX; RECEPTOR; SUBUNIT; MOTOR; MICROTUBULES; ASSOCIATION
AB The retromer is a protein complex that mediates retrograde transport of
   transmembrane cargoes from endosomes to the trans-Golgi network (TGN).
   It is comprised of a cargo-selection subcomplex of Vps26, Vps29 and
   Vps35 and a membrane-binding coat subcomplex of sorting nexins (SNXs).
   Previous studies identified SNX1/2 as one of the components of the SNX
   subcomplex, and SNX5/6 as candidates for the second SNX. How the
   retromer-associated cargoes are recognized and transported by molecular
   motors are largely unknown. In this study, we found that one of
   SNX1/2's dimerization partners, SNX6, interacts with the p150(Glued)
   subunit of the dynein/dynactin motor complex. We present evidence that
   SNX6 is a component of the retromer, and that recruitment of the motor
   complex to the membrane-associated retromer requires the
   SNX6-p150(Glued) interaction. Disruption of the SNX6-p150Glued
   interaction causes failure in formation and detachment of the
   tubulovesicular sorting structures from endosomes and results in block
   of CI-MPR retrieval from endosomes to the TGN. These observations
   indicate that in addition to SNX1/2, SNX6 in association with the
   dynein/dynactin complex drives the formation and movement of tubular
   retrograde intermediates.
C1 [Hong, Zhi; Yang, Yanrui; Zhang, Cheng; Niu, Yang; Li, Ke; Zhao, Xi; Liu, Jia-Jia] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100101, Peoples R China.
   [Hong, Zhi; Niu, Yang; Li, Ke; Zhao, Xi] Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China.
RP Liu, JJ, Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev
   Biol, Beijing 100101, Peoples R China.
EM jjliu@genetics.ac.cn
FU National Natural Science Foundation of China [30770675]; Chinese
   Academy of Sciences [KSCX1-YW-R-37]; CAS 
FX We thank Yingfang Liu (Institute of Biophysics, Chinese Academy of
   Sciences) for advice on PX domain structure and SNX6 mutations. We are
   particularly grateful to Yanmin Yang (Stanford University, USA) for
   insightful discussions and the Flag-MAP1B LC construct. We also thank
   Juan S Bonifacino (NIH, USA) for the rabbit anti- CI- MPR antibody,
   Hiroyoshi Ariga (Hokkaido University, Japan) for Flag- and HA-tagged
   human SNX6 overexpression constructs, and Li Yu (Tsinghua University,
   China) for the YFP- EEA1 expression construct. We thank Chonglin Yang
   (Institute of Genetics and Developmental Biology, Chinese Academy of
   Sciences), Dahua Chen (Institute of Zoology, Chinese Academy of
   Sciences) and Li Yu for critical reading of the manuscript. This work
   was supported by grants from the National Natural Science Foundation of
   China (30770675) and Chinese Academy of Sciences (KSCX1-YW-R-37). J-J
   Liu is supported by the CAS 100-Talents Program.
CR ARIGHI CN, 2004, J CELL BIOL, V165, P123
   BONIFACINO JS, 2008, CURR OPIN CELL BIOL, V20, P427, DOI
   10.1016/j.ceb.2008.03.009
   BRAVO J, 2001, MOL CELL, V8, P829
   CARLTON J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077
   CARLTON JG, 2005, J CELL SCI, V118, P4527, DOI 10.1242/jcs.02568
   COZIER GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200
   CULLEN PJ, 2008, NAT REV MOL CELL BIO, V9, P574, DOI 10.1038/nrm2427
   DING JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055
   DUNCAN JE, 2006, PLOS GENET, V2, P1275, ARTN e124
   ECHEVERRI CJ, 1996, J CELL BIOL, V132, P617
   ENGELENDER S, 1997, HUM MOL GENET, V6, P2205
   GAUTHIER LR, 2004, CELL, V118, P127
   GRIFFIN CT, 2005, P NATL ACAD SCI USA, V102, P15173, DOI
   10.1073/pnas.0409558102
   GRUENBERG J, 2001, NAT REV MOL CELL BIO, V2, P721
   HOLLERAN EA, 2001, J BIOL CHEM, V276, P36598
   HOOGENRAAD CC, 2001, EMBO J, V20, P4041
   HOOGENRAAD CC, 2003, EMBO J, V22, P6004
   HORAZDOVSKY BF, 1997, MOL BIOL CELL, V8, P1529
   HUNYADY L, 2002, J CELL BIOL, V157, P1211
   ISHIBASHI Y, 2001, FEBS LETT, V506, P33
   JOHANSSON M, 2007, J CELL BIOL, V176, P459, DOI 10.1083/jcb.200606077
   JORDENS I, 2001, CURR BIOL, V11, P1680
   KING SJ, 2000, NAT CELL BIOL, V2, P20
   LIU JJ, 2003, J CELL BIOL, V163, P223, DOI 10.1083/jcb.200306075
   MATANIS T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891
   MELKONIAN KA, 2007, J BIOL CHEM, V282, P19355, DOI
   10.1074/jbc.M700003200
   PONS V, 2008, PLOS BIOL, V6, P1942, ARTN e214
   REINSCH S, 1997, CURR BIOL, V7, P211
   ROJAS R, 2007, MOL CELL BIOL, V27, P1112, DOI 10.1128/MCB.00156-06
   ROJAS R, 2008, J CELL BIOL, V183, P513, DOI 10.1083/jcb.200804048
   SCHROER TA, 2004, ANNU REV CELL DEV BI, V20, P759
   SEAMAN MNJ, 1998, J CELL BIOL, V142, P665
   SEAMAN MNJ, 2004, J CELL BIOL, V165, P111
   TRAER CJ, 2007, NAT CELL BIOL, V9, P1370, DOI 10.1038/ncb1656
   VALE RD, 2003, CELL, V112, P467
   WASSMER T, 2007, J CELL SCI, V120, P45, DOI 10.1242/jcs.03302
   WASSMER T, 2009, DEV CELL, V17, P110, DOI 10.1016/j.devcel.2009.04.016
   XU Y, 2001, NAT CELL BIOL, V3, P658
   YARAR D, 2007, DEV CELL, V13, P43, DOI 10.1016/j.devcel.2007.04.014
   ZERIAL M, 2001, NAT REV MOL CELL BIO, V2, P107
   ZHONG Q, 2002, P NATL ACAD SCI USA, V99, P6767
NR 41
TC 2
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD DEC
PY 2009
VL 19
IS 12
BP 1334
EP 1349
DI 10.1038/cr.2009.130
PG 16
SC Cell Biology
GA 546CD
UT ISI:000273785100006
ER

PT J
AU Chen, RQ
   Sun, SL
   Wang, C
   Li, YS
   Liang, Y
   An, FY
   Li, C
   Dong, HL
   Yang, XH
   Zhang, J
   Zuo, JR
AF Chen, Ruiqiang
   Sun, Shulan
   Wang, Chun
   Li, Yansha
   Liang, Yan
   An, Fengying
   Li, Chao
   Dong, Haili
   Yang, Xiaohui
   Zhang, Jian
   Zuo, Jianru
TI The Arabidopsis PARAQUAT RESISTANT2 gene encodes an
   S-nitrosoglutathione reductase that is a key regulator of cell death
SO CELL RESEARCH
LA English
DT Article
DE GSNOR1/HOT5/PAR2; nitric oxide; paraquat; cell death; superoxide
ID DEPENDENT FORMALDEHYDE DEHYDROGENASE; DISEASE RESISTANCE RESPONSE;
   PLANT-PATHOGEN INTERACTIONS; NITRIC-OXIDE; ARABIDOPSIS-THALIANA;
   SUPEROXIDE-DISMUTASE; METHYL VIOLOGEN; HYPERSENSITIVE RESPONSE;
   NITROSYLATED PROTEINS; ASCORBATE PEROXIDASE
AB Metabolism of S-nitrosoglutathione (GSNO), a major biologically active
   nitric oxide (NO) species, is catalyzed by the evolutionally conserved
   GSNO reductase (GSNOR). Previous studies showed that the Arabidopsis
   GSNOR1/HOT5 gene regulates salicylic acid signaling and thermotolerance
   by modulating the intracellular S-nitrosothiol level. Here, we report
   the characterization of the Arabidopsis paraquat resistant2-1 (par2-1)
   mutant that shows an anti-cell death phenotype. The production of
   superoxide in par2-1 is comparable to that of wild-type plants when
   treated by paraquat (1,1'-dimethyl-4,4'-bipyridinium dichloride),
   suggesting that PAR2 acts downstream of superoxide to regulate cell
   death. PAR2, identified by positional cloning, is shown to be identical
   to GSNOR1/HOT5. The par2-1 mutant carries a missense mutation in a
   highly conserved glycine, which renders the mutant protein unstable.
   Compared to wild type, par2-1 mutant has a higher NO level, as revealed
   by staining with 4,5-diaminofluorescein diacetate. Consistent with this
   result, wild-type plants treated with an NO donor display resistance to
   paraquat. Interestingly, the GSNOR1/HOT5/PAR2 protein level, other than
   its steady-state mRNA level, is induced by paraquat, but is reduced by
   NO donors. Taken together, these results suggest that GSNOR1/HOT5/PAR2
   plays an important role in regulating cell death in plant cells through
   modulating intracellular NO level.
C1 [Chen, Ruiqiang; Sun, Shulan; Wang, Chun; Li, Yansha; Liang, Yan; An, Fengying; Li, Chao; Dong, Haili; Yang, Xiaohui; Zhang, Jian; Zuo, Jianru] Chinese Acad Sci, State Key Lab Plant Genom, Beijing 100101, Peoples R China.
   [Chen, Ruiqiang; Sun, Shulan; Wang, Chun; Li, Yansha; Liang, Yan; An, Fengying; Li, Chao; Dong, Haili; Yang, Xiaohui; Zhang, Jian; Zuo, Jianru] Chinese Acad Sci, Inst Genet & Dev Biol, Natl Plant Gene Res Ctr Beijing, Beijing 100101, Peoples R China.
   [Chen, Ruiqiang; Sun, Shulan; Wang, Chun; Li, Yansha; An, Fengying; Li, Chao; Dong, Haili] Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China.
RP Zuo, JR, Chinese Acad Sci, State Key Lab Plant Genom, Beijing 100101,
   Peoples R China.
EM jrzuo@genetics.ac.cn
FU National Natural Science Foundation of China [30330360]; Ministry of
   Science and Technology of China [2006AA10A112]; Chinese Academy of
   Sciences [KSCX2-YW-N-015]
FX We thank Dr Gary Loake (University of Edinburgh, UK) for providing
   gsnor1-3 seeds. We are grateful to Drs Chuanyou Li, Shuhua Yang and
   Yiqin Wang for critically reading the manuscript. This study was
   supported by grants from the National Natural Science Foundation of
   China (30330360), the Ministry of Science and Technology of China
   (2006AA10A112) and the Chinese Academy of Sciences (KSCX2-YW-N-015).
CR ACHKOR H, 2003, PLANT PHYSIOL, V132, P2248
   ARISI ACM, 1998, PLANT PHYSIOL, V117, P565
   ASAI T, 2000, PLANT CELL, V12, P1823
   BABBS CF, 1989, PLANT PHYSIOL, V90, P1267
   BELENGHI B, 2007, J BIOL CHEM, V282, P1352, DOI 10.1074/jbc.M608931200
   BELIGNI MV, 1999, NITRIC OXIDE-BIOL CH, V3, P199
   BELIGNI MV, 2002, PLANT PHYSIOL, V129, P1642, DOI 10.1104/pp.002337
   BOWLER C, 1991, EMBO J, V10, P1723
   BRADFORD MA, 1976, ANAL BIOCHEM, V72, P254
   CLARK D, 2000, MOL PLANT MICROBE IN, V13, P1380
   CLOUGH SJ, 1998, PLANT J, V16, P735
   CRAWFORD NM, 2005, TRENDS PLANT SCI, V10, P195, DOI
   10.1016/j.tplants.2005.02.008
   DANGL JL, 2001, NATURE, V411, P826
   DELLEDONNE M, 1998, NATURE, V394, P585
   DELLEDONNE M, 2001, P NATL ACAD SCI USA, V98, P13454
   DELLEDONNE M, 2005, CURR OPIN PLANT BIOL, V8, P390, DOI
   10.1016/j.pbi.2005.05.002
   DIAZ M, 2003, FEBS LETT, V543, P136, DOI 10.1016/S0014-5793(03)00426-5
   DODGE AD, 1971, ENDEAVOUR, V30, P130
   FEECHAN A, 2005, P NATL ACAD SCI USA, V102, P8054, DOI
   10.1043/pnas.0501456102
   FENG HZ, 2007, PLANT PHYSIOL, V144, P1531, DOI 10.1104/pp.107.098079
   FOISSNER I, 2000, PLANT J, V23, P817
   FUJIBE T, 2004, PLANT PHYSIOL, V134, P275, DOI 10.1104/pp.103.033480
   FUJII T, 1990, BIOCHIM BIOPHYS ACTA, V1015, P41
   GECHEV TS, 2005, J CELL BIOL, V168, P17
   GREENBERG JT, 1993, PLANT J, V4, P327
   GREENBERG JT, 2004, CELL MICROBIOL, V6, P201, DOI
   10.1111/j.1462-5822.2004.00361.x
   GUO FQ, 2005, PLANT CELL, V17, P3436, DOI 10.1105/tpc.105.037770
   GUPTA AS, 1993, P NATL ACAD SCI USA, V90, P1629
   HARA MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268
   HE YK, 2004, SCIENCE, V305, P1968
   JABS T, 1996, SCIENCE, V273, P1853
   JENSEN DE, 1998, BIOCHEM J 2, V331, P659
   LAM E, 2001, NATURE, V411, P848
   LAM E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358
   LEE U, 2008, PLANT CELL, V20, P786, DOI 10.1105/tpc.107.052647
   LINDERMAYR C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719
   LINDERMAYR C, 2006, J BIOL CHEM, V281, P4285, DOI 10.1074/jbc.M511635200
   LIU LM, 2001, NATURE, V410, P490
   MANNICK JB, 2007, AMINO ACIDS, V32, P523, DOI 10.1007/s00726-006-0427-6
   MARTINEZ MC, 1996, EUR J BIOCHEM, V241, P849
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473
   MURGIA I, 2004, PLANT J, V38, P940, DOI 10.1111/j.1365-313X.2004.02092.x
   NEILL S, 2008, J EXP BOT, V59, P165, DOI 10.1093/jxb/erm293
   PENNELL RI, 1997, PLANT CELL, V9, P1157
   ROMEROPUERTAS MC, 2004, CELL MICROBIOL, V6, P795, DOI
   10.1111/j.1462-5822.2004.00428.x
   ROMEROPUERTAS MC, 2007, PLANT CELL, V19, P4120, DOI
   10.1105/tpc.107.055061
   ROMEROPUERTAS MC, 2008, PROTEOMICS, V8, P1459, DOI
   10.1002/pmic.200700536
   RUSTERUCCI C, 2007, PLANT PHYSIOL, V143, P1282, DOI
   10.1104/pp.106.091686
   SAKAMOTO A, 2002, FEBS LETT, V515, P20
   SAMBROOK J, 2001, MOL CLONING LAB MANU
   SAWA A, 1997, P NATL ACAD SCI USA, V94, P11669
   SHI LH, 2007, CELL RES, V17, P1030, DOI 10.1038/cr.2007.100
   STAMLER JS, 1994, CELL, V78, P931
   STONE JM, 2000, PLANT CELL, V12, P1811
   STONE JM, 2005, PLANT J, V41, P744, DOI 10.1111/j.1365-313X.2005.02334.x
   SUNTRES ZE, 2002, TOXICOLOGY, V180, P65
   TADA Y, 2008, SCIENCE, V321, P952, DOI 10.1126/science.1156970
   TENG C, 2008, PLANT PHYSIOL, V146, P1322, DOI 10.1104/pp.107.113506
   WANG YQ, 2006, J EXP BOT, V57, P1777, DOI 10.1093/jxb/erj211
   WANG YQ, 2009, J BIOL CHEM, V284, P2131, DOI 10.1074/jbc.M806782200
   WENDEHENNE D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI
   10.1016/j.pbi.2004.04.002
   ZANINOTTO F, 2006, PLANT PHYSIOL, V141, P379, DOI 10.1104/pp.106.078857
NR 62
TC 3
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD DEC
PY 2009
VL 19
IS 12
BP 1377
EP 1387
DI 10.1038/cr.2009.117
PG 11
SC Cell Biology
GA 546CD
UT ISI:000273785100009
ER

PT J
AU Wang, HZ
   Gao, XL
   Huang, Y
   Yang, JN
   Liu, ZR
AF Wang, Haizhen
   Gao, Xueliang
   Huang, Yun
   Yang, Jenny
   Liu, Zhi-Ren
TI P68 RNA helicase is a nucleocytoplasmic shuttling protein
SO CELL RESEARCH
LA English
DT Article
DE P68 RNA helicase; nucleocytoplasm shuttle; NLS; NES; DEAD box
ID ESTROGEN-RECEPTOR-ALPHA; STRUCTURE PREDICTION SERVER; NUCLEAR EXPORT;
   MESSENGER-RNA; CELL-PROLIFERATION; TRANSCRIPTIONAL COACTIVATOR;
   IMPORTIN-ALPHA; SMAD PROTEINS; T-ANTIGEN; TRANSPORT
AB P68 RNA helicase is a prototypical DEAD box RNA helicase. The protein
   plays a very important role in early organ development and maturation.
   Consistent with the function of the protein in transcriptional
   regulation and pre-mRNA splicing, p68 was found to predominately
   localize in the cell nucleus. However, recent experiments demonstrate a
   transient cytoplasmic localization of the protein. We report here that
   p68 shuttles between the nucleus and the cytoplasm. The
   nucleocytoplasmic shuttling of p68 is mediated by two nuclear
   localization signal and two nuclear exporting signal sequence elements.
   Our experiments reveal that p68 shuttles via a classical
   RanGTPase-dependent pathway.
C1 [Wang, Haizhen; Gao, Xueliang; Liu, Zhi-Ren] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.
   [Huang, Yun; Yang, Jenny] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
RP Liu, ZR, Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.
EM biozrl@langate.gsu.edu
FU National Institutes of Health [GM063874, CA118113]; Georgia Cancer
   Coalition ; MBD fellowship ; GSU 
FX We thank Drs Joan A Steitz (Yale University School of Medicine),
   Melissa J Moore (University of Massachusetts medical school) and
   Hung-Ying Kao (Case Western Reserve University) for providing the
   vectors for expression of MS2-DEK and human CRM1. We are grateful to
   Professor Peter Stockley (University of Leeds) for providing antibody
   against MS2-DEK. We also thank Birgit Neuhaus (Georgia State
   University) for assistance in confocal imaging. This manuscript is
   greatly improved by comments from Christie Carter, Michael Kirberger
   and Heena Dey (Georgia State University). This work is supported in
   part by research grants from National Institutes of Health (GM063874
   and CA118113) and Georgia Cancer Coalition to ZR Liu. X Gao is
   supported by an MBD fellowship, GSU.
CR ARATANI S, 2006, BIOCHEM BIOPH RES CO, V340, P125
   ASKJAER P, 1999, MOL CELL BIOL, V19, P6276
   BATES GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550
   BUSZCZAK M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306
   CARTWRIGHT P, 2000, CELL MOL LIFE SCI, V57, P1193
   CRAWFORD L, 1982, J VIROL, V42, P612
   CUFF JA, 1998, BIOINFORMATICS, V14, P892
   DAVIS BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   ENDOH H, 1999, MOL CELL BIOL, V19, P5363
   FAN XHC, 1998, EMBO J, V17, P3448
   FORD MJ, 1988, NATURE, V332, P736
   FORNEROD M, 1997, CELL, V90, P1051
   FRIED H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI
   10.1007/s00018-003-3070-3
   FUJITA T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200
   FUKUDA T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577
   GOH PY, 2004, J VIROL, V78, P5288, DOI 10.1128/JVI.78.10.5288-5298.2004
   GOLDFARB DS, 1986, NATURE, V322, P641
   GOLDFARB DS, 2004, TRENDS CELL BIOL, V14, P505, DOI
   10.1016/j.tcb.2004.07.016
   GORLICH D, 1999, ANNU REV CELL DEV BI, V15, P607
   HARRIS D, 2006, MOL CELL PROTEOMICS, V5, P1006, DOI
   10.1074/mcp.M500429-MCP200
   HILL CS, 2009, CELL RES, V19, P36, DOI 10.1038/cr.2008.325
   HIRLING H, 1989, NATURE, V339, P562
   HUANG YL, 2002, J BIOL CHEM, V277, P12810
   IGGO RD, 1989, EMBO J, V8, P1827
   JOST JP, 1999, NUCLEIC ACIDS RES, V27, P3245
   KAHLINA K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200
   KALDERON D, 1984, CELL, V39, P499
   KAU TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274
   LANE DP, 1980, NATURE, V288, P167
   LIN CR, 2005, MOL CELL BIOL, V25, P7484, DOI
   10.1128/MCB.25.17.7484-7493.2005
   LINDSAY ME, 2002, CELL, V110, P349
   LIU ZR, 2002, MOL CELL BIOL, V22, P5443
   LOYOLA A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI
   10.1016/j.bbaexp.2003.09.012
   LUSK CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165
   MCGUFFIN LJ, 2000, BIOINFORMATICS, V16, P404
   NAKIELNY S, 1999, CELL, V99, P677
   NEUMANN G, 2000, EMBO J, V19, P6751
   NICOL SM, 2000, EXP CELL RES, V257, P272
   NIU Y, 2006, MOL CELL BIOL, V26, P4288, DOI 10.1128/MCB.01817-05
   OKAMURA H, 2000, MOL CELL, V6, P539
   ROBBINS J, 1991, CELL, V64, P615
   ROSSOW KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067
   SCHNEIDER J, 1988, CELL, V54, P117
   SENGOKU T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054
   SHENG Y, 2006, J BIOL CHEM, V281, P35048, DOI 10.1074/jbc.M605086200
   SHIBUYA T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750
   STEVENSON RJ, 1998, J PATHOL, V184, P351
   WANG HZ, 2007, CANCER LETT, V247, P150, DOI 10.1016/j.canlet.2006.04.002
   WARNER DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI
   10.1016/j.bbrc.2004.09.017
   WATANABE M, 1999, GENES CELLS, V4, P291
   WATANABE M, 2001, EMBO J, V20, P1341
   WEI Y, 2001, YI CHUAN XUE BAO, V28, P991
   WEN W, 1995, CELL, V82, P463
   WILSON BJ, 2004, BMC MOL BIOL, V5, ARTN 11
   WRIGHTON KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327
   XU L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331
   YANG LQ, 2004, PROTEIN EXPRES PURIF, V35, P327, DOI
   10.1016/j.pep.2004.02.004
   YANG LQ, 2005, CELL SIGNAL, V17, P1495, DOI
   10.1016/j.cellsig.2005.03.008
   YANG LQ, 2005, MOL CANCER RES, V3, P355
   YANG LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036
   YANG LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200
   ZHU J, 2000, CELL MOL LIFE SCI, V57, P411
NR 62
TC 3
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD DEC
PY 2009
VL 19
IS 12
BP 1388
EP 1400
DI 10.1038/cr.2009.113
PG 13
SC Cell Biology
GA 546CD
UT ISI:000273785100010
ER

PT J
AU Peng, J
   Yang, XO
   Chang, SH
   Yang, J
   Dong, C
AF Peng, Juan
   Yang, Xuexian O.
   Chang, Seon Hee
   Yang, Jiong
   Dong, Chen
TI IL-23 signaling enhances Th2 polarization and regulates allergic airway
   inflammation
SO CELL RESEARCH
LA English
DT Article
DE cytokines; helper T cells; T cell differentiation; allergic airway
   inflammation
ID CD4 T-CELLS; AUTOIMMUNE INFLAMMATION; TH17 CELLS; ASTHMA;
   INTERLEUKIN-17; INNATE; IL-17; CYTOKINE; DISTINCT; MICE
AB IL-23/IL-17 axis is an important regulator in various inflammatory
   diseases. However, the role of IL-23 in allergic airway inflammation is
   not well understood. In this study, we show that in an allergen-induced
   asthma model, mice with transgenic overexpression of IL-23R exhibited
   increased airway infiltration of eosinophils and Th2 cytokine
   production, whereas those deficient in IL-23 displayed reduced airway
   inflammation. In vitro, IL-23-IL-23R signaling promoted GATA-3
   expression and enhanced Th2 cytokine expression. Conversely, in the
   absence of this signal, Th2 cell differentiation was partially
   inhibited. Therefore, IL-23 signaling may regulate allergic asthma
   through modulation of Th2 cell differentiation.
C1 [Peng, Juan; Yang, Xuexian O.; Chang, Seon Hee; Dong, Chen] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.
   [Peng, Juan; Yang, Jiong] Wuhan Univ, Renmin Hosp, Dept Resp Dis, Wuhan 430060, Peoples R China.
   [Peng, Juan; Yang, Jiong] Wuhan Univ, Zhongnan Hosp, Dept Resp Dis, Wuhan 430071, Peoples R China.
RP Dong, C, Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol,
   Houston, TX 77030 USA.
EM xoyang@mdanderson.org
   cdong@mdanderson.org
FU NIH ; MD Anderson Center for Targeted Therapy ; American Heart
   Association ; Ministry of Education of China 
FX We thank Dr Jan Parker-Thornburg (MD Anderson Cancer Center, USA) for
   her help in the generation of IL-23R transgenic animals and the Dong
   lab members for their help and discussion. The work was supported by
   research grants from the NIH, and the MD Anderson Center for Targeted
   Therapy (to CD) and from the American Heart Association (to XOY). JP
   receives a fellowship from the Ministry of Education of China, and CD
   is a Trust Fellow of the MD Anderson Cancer Center and a Leukemia and
   Lymphoma Society Scholar.
CR BARCZYK A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507
   BUSSE WW, 2001, NEW ENGL J MED, V344, P350
   COHN L, 2004, ANNU REV IMMUNOL, V22, P789, DOI
   10.1146/annurev.immunol.22.012703.104716
   CUA DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   DUERR RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   HARRINGTON LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   HERRICK CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084
   HOFSTETTER HH, 2005, CELL IMMUNOL, V237, P123, DOI
   10.1016/j.cellimm.2005.11.002
   HUE S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099
   IZCUE A, 2008, IMMUNITY, V28, P559, DOI 10.1016/j.immuni.2008.02.019
   KOLLS JK, 2003, AM J RESP CELL MOL, V28, P9, DOI
   10.1165/rcmb.2002-0255PS
   LANGRISH CL, 2004, IMMUNOL REV, V202, P96
   LANGRISH CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257
   LARCHE M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI
   10.1067/mai.2003.169
   LOCKHART E, 2006, J IMMUNOL, V177, P4662
   MARTINEZ GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI
   10.1196/annals.1443.021
   MISEOMATA S, 2007, J IMMUNOL, V179, P6596
   MOLET S, 2001, J ALLERGY CLIN IMMUN, V108, P430
   MURPHY CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   NAKAE S, 2003, J IMMUNOL, V171, P6173
   OPPMANN B, 2000, IMMUNITY, V13, P715
   PARHAM C, 2002, J IMMUNOL, V168, P5699
   PARK H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   SCHNYDERCANDRIAN S, 2006, J EXP MED, V203, P2715, DOI
   10.1084/jem.20061401
   SHINKAI K, 2002, NATURE, V420, P825, DOI 10.1038/nature01202
   SMITH RL, 2008, J INVEST DERMATOL, V128, P1325, DOI
   10.1038/sj.jid.5701140
   UHLIG HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017
   WAKASHIN H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI
   10.1164/rccm.200801-086OC
   YANG XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978
   YEN D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404
   ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133
NR 31
TC 8
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD JAN
PY 2010
VL 20
IS 1
BP 62
EP 71
DI 10.1038/cr.2009.128
PG 10
SC Cell Biology
GA 546DT
UT ISI:000273790500008
ER

PT J
AU Ohsumi, S
   Shimozuma, K
   Ohashi, Y
   Takeuchi, A
   Nomura, Y
   Suemasu, K
   Kuranami, M
   Ohno, S
   Watanabe, T
AF Ohsumi, S.
   Shimozuma, K.
   Ohashi, Y.
   Takeuchi, A.
   Nomura, Y.
   Suemasu, K.
   Kuranami, M.
   Ohno, S.
   Watanabe, T.
TI Objective and Subjective Assessment of Edema during Adjuvant
   Chemotherapy Using Taxane-Containing Regimens in a Randomized
   Controlled Trial: National Surgical Adjuvant Study of Breast Cancer
   (NSAS-BC) 02
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual San Antonio Breast Cancer Symposium
CY DEC 09-13, 2009
CL San Antonio, TX
C1 NHO Shikoku Canc Ctr, Matsuyama, Ehime, Japan.
   Ritsumeikan Univ, Shiga, Japan.
   Univ Tokyo, Tokyo, Japan.
   Comprehens Support Project Orcol Res, Tokyo, Japan.
   Arche Clin, Saitama, Japan.
   Kitasato Univ, Kanagawa, Japan.
   NHO Kyushu Canc Ctr, Fukuoka, Japan.
   Hamamatsu Oncol Ctr, Shizuoka, Japan.
NR 0
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2009
VL 69
IS 24
SU Suppl. 3
BP 622S
EP 622S
PG 1
SC Oncology
GA 534TR
UT ISI:000272920701123
ER

PT J
AU Peng, C
   Chen, YY
   Yang, ZF
   Zhang, HJ
   Osterby, L
   Rosmarin, AG
   Li, SG
AF Peng, Cong
   Chen, Yaoyu
   Yang, Zhongfa
   Zhang, Haojian
   Osterby, Lori
   Rosmarin, Alan G.
   Li, Shaoguang
TI PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced
   leukemias in mice
SO BLOOD
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; KINASE INHIBITOR STI571; TYROSINE KINASE;
   CHRONIC PHASE; PROTEIN; MUTATION; CANCER; GENE; EXPRESSION; RESISTANCE
AB The tumor suppressor gene phosphatase and tensin homolog (PTEN) is
   inactivated in many human cancers. However, it is unknown whether PTEN
   functions as a tumor suppressor in human Philadelphia
   chromosome-positive leukemia that includes chronic myeloid leukemia
   (CML) and B-cell acute lymphoblastic leukemia (B-ALL) and is induced by
   the BCR-ABL oncogene. By using our mouse model of BCR-ABL-induced
   leukemias, we show that Pten is down-regulated by BCR-ABL in leukemia
   stem cells in CML and that PTEN deletion causes acceleration of CML
   development. In addition, overexpression of PTEN delays the development
   of CML and B-ALL and prolongs survival of leukemia mice. PTEN
   suppresses leukemia stem cells and induces cell-cycle arrest of
   leukemia cells. Moreover, PTEN suppresses B-ALL development through
   regulating its downstream gene Akt1. These results demonstrate a
   critical role of PTEN in BCR-ABL-induced leukemias and suggest a
   potential strategy for the treatment of Philadelphia chromosome
   positive leukemia. (Blood. 2010; 115: 626-635)
C1 [Peng, Cong; Chen, Yaoyu; Yang, Zhongfa; Zhang, Haojian; Osterby, Lori; Rosmarin, Alan G.; Li, Shaoguang] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA USA.
RP Li, SG, 364 Plantat St,LRB 315, Worcester, MA 01604 USA.
EM Shaoguang.Li@umassmed.edu
FU Leukemia & Lymphoma Society ; National Institutes of Health
   [R01CA122142, R01-CA114199]; Scholar of the Leukemia & Lymphoma Society 
FX This work was supported by the grants from the Leukemia & Lymphoma
   Society and the National Institutes of Health (R01-CA122142,
   R01-CA114199) to S. L. S. L. is a Scholar of the Leukemia & Lymphoma
   Society.
CR BECK Z, 2000, LEUKEMIA LYMPHOMA, V38, P587
   BRUNS I, 2009, LEUKEMIA, V23, P892, DOI 10.1038/leu.2008.392
   CARNERO A, 2008, CURR CANCER DRUG TAR, V8, P187
   CARPTEN JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
   CHEN ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006
   CHOW JYC, 2007, CARCINOGENESIS, V28, P2321, DOI 10.1093/carcin/bgm159
   DICRISTOFANO A, 1998, NAT GENET, V19, P348
   DICRISTOFANO A, 1999, SCIENCE, V285, P2122
   DRUKER BJ, 2001, NEW ENGL J MED, V344, P1031
   GEORGESCU MM, 1999, P NATL ACAD SCI USA, V96, P10182
   GORRE ME, 2001, SCIENCE, V293, P876
   GRAHAM SM, 2002, BLOOD, V99, P319
   GRONBAEK K, 1998, BLOOD, V91, P4388
   HAO SX, 2000, MOL CELL BIOL, V20, P1149
   HU YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI
   10.1073/pnas.0606509103
   LESCHE R, 2002, GENESIS, V32, P148
   LI J, 1997, SCIENCE, V275, P1943
   LI L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593
   LI SG, 1999, J EXP MED, V189, P1399
   LIU TC, 2000, AM J HEMATOL, V63, P170
   MACCARIO H, 2007, BIOCHEM J 3, V405, P439, DOI 10.1042/BJ20061837
   MAEHAMA T, 1998, J BIOL CHEM, V273, P13375
   MAHIMAINATHAN L, 2006, DIABETES, V55, P2115, DOI 10.2337/db05-1326
   MARLEY SB, 2000, EXP HEMATOL, V28, P551
   NEVIANI P, 2005, CANCER CELL, V8, P355
   PEIFFER SL, 1995, CANCER RES, V55, P1922
   PENG C, 2007, BLOOD, V110, P678, DOI 10.1182/blood-2006-10-054098
   PODSYPANINA K, 1999, P NATL ACAD SCI USA, V96, P1563
   RAMEH LE, 1999, J BIOL CHEM, V274, P8347
   SAVONA M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368
   SHAH NP, 2002, CANCER CELL, V2, UNSP ST1571)
   SILVA A, 2008, J CLIN INVEST
   STAMBOLIC V, 1998, CELL, V95, P29
   STAMBOLIC V, 2001, MOL CELL, V8, P317
   SUZUKI A, 1998, CURR BIOL, V8, P1169
   SUZUKI A, 2001, IMMUNITY, V14, P523
   TORRES J, 2001, J BIOL CHEM, V276, P993
   TROTMAN LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   TROTTA R, 2003, CANCER CELL, V3, P145
   VARNAI P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606
   VAZQUEZ F, 2000, MOL CELL BIOL, V20, P5010
   VIROLLE T, 2001, NAT CELL BIOL, V3, P1124
   WANG J, 2005, CANCER RES, V65, P6601
   WEISBERG E, 2000, BLOOD, V95, P3498
   WONG S, 2004, ANNU REV IMMUNOL, V22, P247, DOI
   10.1146/annurev.immunol.22.012703.104753
   WU WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200
   XIA DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200
   YILMAZ OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   ZHANG JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747
NR 49
TC 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JAN 21
PY 2010
VL 115
IS 3
BP 626
EP 635
DI 10.1182/blood-2009-06-228130
PG 10
SC Hematology
GA 546OR
UT ISI:000273820600024
ER

PT J
AU Yang, LP
   Meng, ZN
   Liu, Y
   Zhang, Y
   Liu, XC
   Lu, DQ
   Huang, JH
   Lin, HR
AF Yang, Liping
   Meng, Zining
   Liu, Yun
   Zhang, Yong
   Liu, Xiaochun
   Lu, Danqi
   Huang, Junhai
   Lin, Haoran
TI Growth hormone and prolactin in Andrias davidianus: cDNA cloning,
   tissue distribution and phylogenetic analysis
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article
DE Growth hormone; Prolactin; Andrias davidianus; Phylogeny
ID MESSENGER-RNA EXPRESSION; SEQUENCE ALIGNMENT; MOLECULAR EVOLUTION;
   GENES; FISHES; SALAMANDERS; AMPHIBIA; CAUDATA; DNA
AB The Chinese giant salamander (Andrias davidianus) is one of the largest
   and 'living fossil' species of amphibian. To obtain genetic information
   for this species, the cDNAs encoding growth hormone (adGH) and
   prolactin (adPRL) were cloned from a pituitary cDNA library. The
   isolated adGH cDNA consisted of 864 bp and encoded a propeptide of 215
   amino acids, while the cDNA of adPRL was 1106 bp in length and encoded
   a putative peptide of 229 amino acids. Expression of the GH and PRL
   mRNA was only detected in the pituitary. Phylogenetic analyses were
   performed based on the isolated pituitary hormone sequences using
   maximum parsimony and neighbor-joining algorithms. The clustering
   results are similar to that based on the morphological characteristics
   or the rRNA genes, which indicate that the two orders (Anura and
   Caudata) of amphibian were monophyletic, and that A. davidianus was
   diverged early in the Caudate clade. These results indicated that both
   the GH and PRL sequence might be useful to study the phylogenies of
   relatively moderate evolved groups. Crown Copyright (C) 2009 Published
   by Elsevier Inc. All rights reserved.
C1 [Yang, Liping; Meng, Zining; Liu, Yun; Zhang, Yong; Liu, Xiaochun; Lu, Danqi; Lin, Haoran] Sun Yat Sen Univ, Sch Life Sci, Inst Aquat Econ Anim, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.
   [Yang, Liping; Meng, Zining; Liu, Yun; Zhang, Yong; Liu, Xiaochun; Lu, Danqi; Lin, Haoran] Sun Yat Sen Univ, Sch Life Sci, Guangdong Prov Key Lab Aquat Econ Anim, Guangzhou 510275, Guangdong, Peoples R China.
   [Yang, Liping] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Guangzhou 510380, Guangdong, Peoples R China.
   [Huang, Junhai] Zhuhai Doumen Jinni Fishery Sci & Technol Co LTD, Doumen 519100, Peoples R China.
   [Lin, Haoran] Hainan Univ, Coll Ocean, Haikou 570228, Peoples R China.
RP Lin, HR, Sun Yat Sen Univ, Sch Life Sci, Inst Aquat Econ Anim, State
   Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.
EM lsslhr@mail.sysu.edu.cn
FU Ministry of Education, Guangdong [2006D90204002]; Guangdong Provincial
   Scientific and Technical Program [20041326001183]
FX This work was supported by Combination Projects on Production,
   Education and Research, Ministry of Education, Guangdong (No.
   2006D90204002), the grants from Guangdong Provincial Scientific and
   Technical Program (No. 20041326001183) and the priming scientific
   research foundation for the junior teachers in Sun Yat-Sen University.
   Thanks to Pei Zhu Ph.D. for improvements on an earlier draft of this
   paper.
CR BERNARDI G, 1993, J MOL EVOL, V37, P644
   CANNATELLA DC, 1993, HERPETOL MONOGR, V7, P1
   DONG H, 2008, FISH PHYSIOL BIOCHEM, V103, DOI 10.1007/S10695-008-9231-4
   DORES RM, 1996, GEN COMP ENDOCR, V103, P1
   EDWARDS JL, 1976, J MORPHOL, V148, P305
   FORSYTH IA, 2002, J MAMMARY GLAND BIOL, V7, P291
   GAO KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491
   GRAYBEAL A, 1994, SYST BIOL, V43, P174
   HAY JM, 1995, MOL BIOL EVOL, V12, P928
   KAWAUCHI H, 1988, PROLACTIN GENE FAMIL, P61
   KUMAR S, 2004, BRIEF BIOINFORM, V5, P150
   LAW MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P19
   LI WS, 2005, GEN COMP ENDOCR, V144, P78, DOI 10.1016/j.ygcen.2005.04.018
   MARINS LF, 2003, GENET MOL BIOL, V26, P295
   MATSUI M, 2007, MOL PHYLOGENET EVOL, V44, P204, DOI
   10.1016/j.ympev.2006.11.031
   REGAL PJ, 1966, EVOLUTION, V20, P392
   RUBIN DA, 1994, GEN COMP ENDOCR, V95, P71
   RUBIN DA, 1995, MOL PHYLOGENET EVOL, V4, P129
   SANTOS CRA, 1999, GEN COMP ENDOCR, V114, P57
   STOCK DW, 1991, J FISH BIOL A, V39, P225
   SWOFFORD DL, 2001, PAUP PHYLOGENETIC AN
   TAKAHASHI N, 2001, GEN COMP ENDOCR, V121, P188
   THOMPSON JD, 1997, NUCLEIC ACIDS RES, V25, P4876
   WALLIS M, 1996, J MOL EVOL, V43, P93
   WALLIS M, 2000, J MOL EVOL, V50, P465
   WEISROCK DW, 2006, MOL PHYLOGENET EVOL, V41, P368, DOI
   10.1016/j.ympev.2006.05.008
   YAMAMOTO K, 2000, GEN COMP ENDOCR, V117, P103
   YANG BY, 1999, MOL REPROD DEV, V53, P127
   ZHANG P, 2005, SYST BIOL, V54, P391, DOI 10.1080/10635150590945278
NR 29
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
J9 GEN COMP ENDOCRINOL
JI Gen. Comp. Endocrinol.
PD JAN 15
PY 2010
VL 165
IS 2
BP 177
EP 180
DI 10.1016/j.ygcen.2009.07.010
PG 4
SC Endocrinology & Metabolism
GA 542TD
UT ISI:000273517500001
ER

PT J
AU Ke, XY
   Wang, J
   Gao, ZF
   Zhao, LZ
   Li, M
   Jing, HM
   Wang, JJ
   Zhao, W
   Gilbert, H
   Yang, XF
AF Ke, Xiaoyan
   Wang, Jing
   Gao, Zifen
   Zhao, Lingzhi
   Li, Min
   Jing, Hongmei
   Wang, Jijun
   Zhao, Wei
   Gilbert, Heather
   Yang, Xiao-Feng
TI Clinical characteristics and prognostic analysis of Chinese patients
   with diffuse large B-cell lymphoma
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE Diffuse large B-cell lymphoma; Prognostic analysis; Cell origin of
   tumor; Lactate dehydrogenase; International prognostic index
ID GERMINAL CENTER; EXPRESSION PATTERNS; GENE REARRANGEMENT; HLA ALLELES;
   CHOP; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY; PREDICTOR; RITUXIMAB; DISEASE
AB Diffuse large B-cell lymphoma (DLBCL) is the most common type of
   lymphoma in adults. As it is a highly heterogenous disease, many
   studies have focused on finding useful prognostic factors to help guide
   therapy. In this report, we examine several biological markers in 83
   patients with DLBCL enrolled in our hospital, including cell origin,
   serum lactate dehydrogenase (LDH) levels, and international prognostic
   index (IPI), in order to find the best combination of prognostic
   factors. We also examined whether DLBCL has a significant geographic
   difference. since several studies have suggested that the prevalence
   and potential etiological factors of lymphomas in China may be
   different from those in other countries. Our results demonstrate that:
   (1) patients in China have higher extranodal tissue involvement and
   different extranodal organ distribution than patients reported from
   other countries; (2) Chinese patients have higher rates of germinal
   center (GC) cell origin: and (3) among nine prognostic variables, lower
   IPI scores, GC cell origin determined by immunohistochemical staining,
   and no more than 1.5 times of normal levels of LDH are statistically
   significant good prognostic factors in Chinese patients with DLBCL,
   whereas age at the time of diagnosis, clinical stage,
   beta(2)-microglobulin levels, extranodal tissue involvement, and
   expression levels of Bcl-6 protein were not useful in determining
   prognosis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Ke, Xiaoyan; Wang, Jing; Zhao, Lingzhi; Jing, Hongmei; Wang, Jijun; Zhao, Wei] Peking Univ, Hosp 3, Dept Hematol, Beijing 100191, Peoples R China.
   [Ke, Xiaoyan; Wang, Jing; Zhao, Lingzhi; Jing, Hongmei; Wang, Jijun; Zhao, Wei] Peking Univ, Hosp 3, Lymphoma Res Ctr, Beijing 100191, Peoples R China.
   [Gao, Zifen; Li, Min] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Gilbert, Heather] Univ Utah, Special Genet Lab, ARUP Labs, Sect Hematol,Dept Internal Med,Sch Med, Salt Lake City, UT 84132 USA.
   [Yang, Xiao-Feng] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA.
RP Ke, XY, Peking Univ, Hosp 3, Dept Hematol, Beijing 100191, Peoples R
   China.
EM xiaoyank@yahoo.com
CR ALIZADEH AA, 2000, NATURE, V403, P503
   BARRANS SL, 2002, BLOOD, V99, P1136
   CHANG CC, 2004, AM J SURG PATHOL, V28, P464
   CHOI HB, 2008, INT J HEMATOL, V87, P203, DOI 10.1007/s12185-008-0040-4
   CLEARY ML, 1984, P NATL ACAD SCI USA, V81, P593
   COIFFIER B, 2002, NEW ENGL J MED, V346, P235
   COLOMO L, 2003, BLOOD, V101, P78, DOI 10.1182/bllod-2002-04-1286
   CONCONI A, 2000, HEMATOL ONCOL, V18, P61
   HABERMANN TM, 2006, J CLIN ONCOL, V24, P3121, DOI
   10.1200/JCO.2005.05.1003
   HANS CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   JAFFE E, 2001, WHO CLASSIFICATION T
   JERKEMAN M, 2002, INT J ONCOL, V20, P161
   JERKEMAN M, 2004, ANN HEMATOL, V83, P414, DOI 10.1007/s00277-004-0855-x
   KE XY, 2007, LEUKEMIA LYMPHOMA, V48, P2157, DOI
   10.1080/10428190701606818
   KIM S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI
   10.1073/pnas.0712229105
   KUPPERS R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589
   LI S, 2007, BIOL DIRECT, V2, P8
   REE HJ, 2001, HUM PATHOL, V32, P954
   ROSENWALD A, 2002, NEW ENGL J MED, V346, P1937
   SAEZ AI, 2004, AM J PATHOL, V164, P613
   SEHN LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257
   SHIPP MA, 2002, NAT MED, V8, P68
   SHIPP MA, 2007, AM SOC HEMATOL ED PR, P265
   TRAINOR KJ, 1991, BLOOD, V78, P192
   UCHIYAMA M, 2003, J CLIN PATHOL, V56, P778
   WANG LL, 2006, CHINESE J CATAL, V27, P656
   XU Y, 2002, MODERN PATHOL, V15, P413
   ZHANG AM, 1999, PATHOL INT, V49, P1043
   ZHANG W, 2007, BMC GENOMICS, V8, ARTN 332
NR 29
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD JAN 15
PY 2010
VL 44
IS 1
BP 55
EP 61
DI 10.1016/j.bcmd.2009.09.002
PG 7
SC Hematology
GA 544XY
UT ISI:000273695100010
ER

PT J
AU Degenhardt, Y
   Huang, J
   Greshock, J
   Horiates, G
   Nathanson, K
   Yang, XL
   Herlyn, M
   Weber, B
AF Degenhardt, Yan
   Huang, Jia
   Greshock, Joel
   Horiates, Galene
   Nathanson, Katherine
   Yang, Xiaolu
   Herlyn, Meenhard
   Weber, Barbara
TI Distinct MHC Gene Expression Patterns During Progression of Melanoma
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ANTIGEN-PROCESSING MACHINERY; CLASS-II GENES;
   T-CELLS; DOWN-REGULATION; BRAF MUTATIONS; TUMOR-CELLS; CANCER; LINES;
   ASSOCIATION
AB Abnormal expression of major histocompatibility complex l molecules in
   melanoma has been reported previously. However, the MHC molecule
   expression patterns in different growth phases of melanoma and the
   underlying mechanisms are not well understood. Here, we demonstrate
   that in vertical growth phase (VGP) melanomas, MHC genes are subject to
   increased rates of DNA copy number gains, accompanied by increased
   expression, in comparison to normal melanocytes. In contrast, MHC
   expression in metastatic melanomas drastically decreased compared to
   VGP melanomas, despite still prevalent DNA copy number gains.
   Subsequent investigations found that the master transactivator of MHC
   genes, CIITA, was also significantly downregulated in metastatic
   melanomas when compared to VGP melanomas. This could be one of the
   mechanisms accounting for the discrepancy between DNA copy number and
   expression level in metastatic melanomas, a potentially separate
   mechanism of gene regulation. These results infer a dynamic role of MHC
   function in melanoma progression. We propose potential mechanisms for
   the overexpression of MHC molecules in earlier stages of melanoma as
   well as for its downregulation in metastatic melanomas. (C) 2009
   Wiley-Liss, Inc.
C1 [Degenhardt, Yan; Greshock, Joel; Horiates, Galene] GlaxoSmithKline Inc, Canc Metab DPU, King Of Prussia, PA 19406 USA.
   [Huang, Jia] Univ Miami, Miami Inst Human Genom, Miami, FL USA.
   [Nathanson, Katherine; Yang, Xiaolu] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA.
   [Nathanson, Katherine; Yang, Xiaolu] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Herlyn, Meenhard] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
   [Weber, Barbara] Novartis Inst Biomed Res, Boston, MA USA.
RP Degenhardt, Y, GlaxoSmithKline Inc, Canc Metab DPU, Mail Stop
   UW2109,709 Swedeland Rd, King Of Prussia, PA 19406 USA.
EM yan.y.degenhardt@gsk.com
FU National Cancer Institute Melanoma [P50CA093372]
FX Supported by: National Cancer Institute Melanoma Specialized Program of
   Research Excellence (SPORE), Grant number: P50CA093372.
CR ALTOMONTE M, 2003, ONCOGENE, V22, P6564, DOI 10.1038/sj.onc.1206960
   ANICHINI A, 2006, CANCER RES, V66, P6405, DOI
   10.1158/0008-5472.CAN-06-0854
   AOUDJIT F, 2004, EXP CELL RES, V299, P79, DOI
   10.1016/j.yexcr.2004.05.011
   BALAZS M, 2001, CYTOMETRY, V46, P222
   BYERS HR, 1998, HEMATOL ONCOL CLIN N, V12, P717
   CHANG CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI
   10.1007/s00262-006-0183-1
   CURTIN JA, 2005, NEW ENGL J MED, V353, P2135
   DEFFRENNES V, 2001, J IMMUNOL, V167, P98
   DROZINA G, 2005, CURR TOP MICROBIOL, V290, P147
   FERRONE S, 1995, IMMUNOL TODAY, V16, P487
   GARRIDO F, 1997, IMMUNOL TODAY, V18, P89
   GENTLEMAN RC, 2004, GENOME BIOL, V5, ARTN R80
   GOODWIN BL, 2001, CELL GROWTH DIFFER, V12, P327
   GRESHOCK J, 2009, GENE CHROMOSOME CANC, V48, P419, DOI 10.1002/gcc.20651
   HOEK KS, 2006, PIGM CELL RES, V19, P290, DOI
   10.1111/j.1600-0749.2006.00322.x
   HOLLING TM, 2006, BIOCHEM PHARMACOL, V72, P1570, DOI
   10.1016/j.bcp.2006.06.034
   HYNES NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI
   10.1016/j.ceb.2008.12.010
   KIM ES, 2009, J THORAC ONCOL, V4, P444
   KOOPMAN LA, 2000, J EXP MED, V191, P961
   MACH B, 1996, ANNU REV IMMUNOL, V14, P301
   MARGOLIN AA, 2005, BIOINFORMATICS, V21, P3308, DOI
   10.1093/bioinformatics/bti500
   MARINCOLA FM, 2000, ADV IMMUNOL, V74, P181
   MARTIN BK, 1997, IMMUNITY, V6, P591
   MATSUSHITA K, 2006, CANCER SCI, V97, P57, DOI
   10.1111/j.1349-7006.2006.00137.x
   MEISSNER M, 2005, CLIN CANCER RES, V11, P2552
   MENDEZ R, 2008, CANCER IMMUNOL IMMUN, V57, P719, DOI
   10.1007/s00262-007-0411-3
   MENDEZ R, 2009, CANCER IMMUNOL IMMUN, V58, P1507, DOI
   10.1007/s00262-009-0701-z
   MORTARINI R, 2003, CANCER RES, V63, P2535
   MU D, 2003, CANCER CELL, V3, P297
   NAYLOR TL, 2005, BREAST CANCER RES, V7, R1186, DOI 10.1186/bcr1356
   NORELL H, 2006, CANCER RES, V66, P6387, DOI
   10.1158/0008-5472.CAN-06-0029
   OGINO T, 2003, CLIN CANCER RES, V9, P4043
   OGINO T, 2006, CANCER RES, V66, P9281, DOI 10.1158/0008-5472.CAN-06-0488
   PRINS J, 1993, ANTICANCER RES, V13, P1373
   RENKVIST N, 2001, CANCER IMMUNOL IMMUN, V50, P3
   RIMSZA LM, 2004, BLOOD, V103, P4251, DOI 10.1182/blood-2003-07-2365
   RODRIGUEZ T, 2005, CANCER IMMUNOL IMMUN, V54, P141, DOI
   10.1007/s00262-004-0561-5
   RODRIGUEZ T, 2007, IMMUNOGENETICS, V59, P123, DOI
   10.1007/s00251-006-0171-9
   SANTOS GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389
   SATYAMOORTHY K, 2003, CANCER RES, V63, P756
   TATSUMI T, 2003, CLIN CANCER RES, V9, P947
   TSAVACHIDOU D, 2004, CANCER RES, V64, P5556
   VANDENELSEN PJ, 2003, CLIN IMMUNOL, V109, P46, DOI
   10.1016/S1521-6616(03)00200-6
   VANDENELSEN PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI
   10.1016/j.coi.2003.11.015
   VANDUINEN SG, 1988, CANCER RES, V48, P1019
   WANG HY, 2005, J IMMUNOL, V174, P2661
   WRIGHT KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007
NR 47
TC 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1045-2257
J9 GENE CHROMOSOME CANCER
JI Gene Chromosomes Cancer
PD FEB
PY 2010
VL 49
IS 2
BP 144
EP 154
DI 10.1002/gcc.20728
PG 11
SC Oncology; Genetics & Heredity
GA 539XX
UT ISI:000273293700006
ER

PT J
AU Yang, B
   Jiang, Q
   Chan, T
   Ko, WKW
   Wong, AOL
AF Yang, Bo
   Jiang, Quan
   Chan, Ting
   Ko, Wendy K. W.
   Wong, Anderson O. L.
TI Goldfish kisspeptin: Molecular cloning, tissue distribution of
   transcript expression, and stimulatory effects on prolactin, growth
   hormone and luteinizing hormone secretion and gene expression via
   direct actions at the pituitary level
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article
DE Kisspeptin-10; Kisspeptin receptor; Growth hormone; Prolactin;
   Gonadotropin; Laser capture microdissection; Pituitary cells; Goldfish
ID GONADOTROPIN-RELEASING-HORMONE; METASTASIS-SUPPRESSOR GENE;
   PROTEIN-COUPLED-RECEPTOR; CARASSIUS-AURATUS; KISS-1 PEPTIDE; NATURAL
   LIGAND; IN-VIVO; CELLS; GPR54; RAT
AB Kisspeptin, the product of Kiss1 gene, is a novel regulator of the
   gonadotropic axis. In mammals, its stimulatory effect on gonadotropin
   secretion is well documented and mediated mainly by hypothalamic
   release of gonadotropin-releasing hormone. Although the pituitary
   actions of kisspeptin have been reported, the effects of kisspeptin on
   gonadotropin release via direct action on pituitary cells are still
   controversial. Using goldfish as a model, here we examined the direct
   actions of kisspeptin on pituitary functions in modern-day bony fish.
   As a first step, the structural identity of goldfish Kiss1 was
   established by T/TRACE and Kiss1 transcript was shown to be widely
   expressed in various tissues in goldfish. At the pituitary level, Kiss1
   receptor (Kissi1r) expression was detected in immuno-identified
   gonadotrophs, lactotrophs, and somatotrophs. Kiss1 transcript was also
   located in goldfish somatotrophs but not in lactotrophs or
   gonadotrophs. In parallel studies, goldfish kisspeptin-10 was
   synthesized and used to test the pituitary actions of kisspeptin in
   vitro. In goldfish pituitary cell cultures, 30-min incubation with
   kisspeptin-10 increased basal release of luteinizing hormone (LH),
   prolactin (PRL), and growth hormone (GH). Transcript expression of LH,
   PRL, and GH were also elevated by prolonging kisspeptin-10 treatment to
   24 h. These results taken together suggest that kisspeptin via Kiss1r
   activation can act directly at the pituitary level to trigger LH, PRL,
   and GH secretion and gene expression in goldfish. Our finding of Kiss1
   expression in somatotrophs also rises the possibility that kisspeptin
   may be produced locally in the fish pituitary and serve as an
   autocrine/paracrine regulator. (C) 2009 Elsevier Inc. All rights
   reserved.
C1 [Yang, Bo; Jiang, Quan; Chan, Ting; Ko, Wendy K. W.; Wong, Anderson O. L.] Univ Hong Kong, Div Endocrinol, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China.
RP Wong, AOL, Univ Hong Kong, Div Endocrinol, Sch Biol Sci, 4S-12 Kadoorie
   Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM olwong@hkucc.hku.hk
FU Research Grant Council (Hong Kong) ; National 973 Program (China) ;
   University Research Committee (University of Hong Kong) ; School of
   Biological Sciences (University of Hong Kong) 
FX The project was supported by grants (to A.O.L.W.) from Research Grant
   Council (Hong Kong), National 973 Program (China), and University
   Research Committee (University of Hong Kong). Financial support from
   the School of Biological Sciences (University of Hong Kong) in the form
   of postgraduate studentship is also acknowledged (to BY., Q.J., and
   T.Q. Special thanks are given to Dr. R.E. Peter (University of Alberta,
   Canada) for the supply of antisera used in GH, PRL, and LH measurement.
CR ADACHI S, 2007, J REPROD DEVELOP, V53, P367
   BILBAN M, 2004, J CELL SCI, V117, P1319, DOI 10.1242/jcs.00971
   BIRAN J, 2008, BIOL REPROD, V79, P776, DOI 10.1095/biolreprod.107.066266
   CASTELLANO JM, 2006, ENDOCRINOLOGY, V147, P4852, DOI
   10.1210/en.2006-0117
   CASTELLANO JM, 2009, PEPTIDES, V30, P139, DOI
   10.1016/j.peptides.2008.06.007
   CHANG JP, 2001, J NEUROENDOCRINOL, V13, P540
   CHANG JP, 2003, MOL CELL ENDOCRINOL, V206, P63, DOI
   10.1016/S0303-7207(03)00234-X
   COLLEDGE WH, 2004, TRENDS ENDOCRIN MET, V15, P448, DOI
   10.1016/j.tem.2004.09.008
   COLLEDGE WH, 2008, RES PRO CEL, V46, P117, DOI 10.1007/400_2007_050
   COLLEDGE WH, 2009, TRENDS ENDOCRIN MET, V20, P115, DOI
   10.1016/j.tem.2008.10.005
   FELIP A, 2008, MOL CELL ENDOCRINOL, DOI 10.1016/J.MCE.2008.11.1017
   FILBY AL, 2008, BIOL REPROD, V78, P278, DOI
   10.1095/biolreprod.107.063420
   GOTTSCH ML, 2004, ENDOCRINOLOGY, V145, P4073, DOI 10.1210/en.2004-0431
   GREIVES TJ, 2007, ENDOCRINOLOGY, V148, P1158, DOI 10.1210/en.2006-1249
   GUTIERREZPASCUAL E, 2007, J NEUROENDOCRINOL, V19, P521, DOI
   10.1111/j.1365-2826.2007.01558.x
   HUO LF, 2004, ENDOCRINOLOGY, V145, P5056, DOI 10.1210/en.2004-0584
   JIANG Q, 2008, AM J PHYSIOL-ENDOC M, V295, E463, DOI
   10.1152/ajpendo.90385.2008
   KADOKAWA H, 2008, ANIM REPROD SCI, V105, P404
   KANDA S, 2008, ENDOCRINOLOGY, V149, P2467, DOI 10.1210/en.2007-1503
   KITAHASHI T, 2009, ENDOCRINOLOGY, V150, P821, DOI 10.1210/en.2008-0940
   KOTANI M, 2001, J BIOL CHEM, V276, P34631
   LEE JH, 1996, J NATL CANCER I, V88, P1731
   LI SS, 2009, J ENDOCRINOL, V201, P407, DOI 10.1677/JOE-09-0016
   MATSUI H, 2004, BIOCHEM BIOPH RES CO, V320, P383, DOI
   10.1016/j.bbrc.2004.05.185
   MESSAGER S, 2005, P NATL ACAD SCI USA, V102, P1761, DOI
   10.1073/pnas.0409330102
   MIKKELSEN JD, 2009, PEPTIDES, V30, P26, DOI
   10.1016/j.peptides.2008.09.004
   NAVARRO VM, 2005, ENDOCRINOLOGY, V146, P156, DOI 10.1210/en.2004-0836
   NAVARRO VM, 2005, ENDOCRINOLOGY, V146, P1689, DOI 10.1210/en.2004-1353
   NAZIAN SJ, 2006, J ANDROL, V27, P444, DOI 10.2164/jandrol.05144
   OHTAKI T, 2001, NATURE, V411, P613
   POPESKU JT, 2008, MOL CELL ENDOCRINOL, V293, P43, DOI
   10.1016/j.mce.2008.06.017
   QUAYNOR S, 2007, MOL ENDOCRINOL, V21, P3062, DOI 10.1210/me.2007-0207
   RICHARD N, 2008, J NEUROENDOCRINOL, V20, P381, DOI
   10.1111/j.1365-2826.2008.01653.x
   RICHARD N, 2009, PEPTIDES, V30, P123, DOI 10.1016/j.peptides.2008.09.015
   ROA J, 2008, AM J PHYSIOL-ENDOC M, V294, E1088, DOI
   10.1152/ajpendo.90240.2008
   ROA J, 2008, FRONT NEUROENDOCRIN, V29, P48, DOI
   10.1016/j.yfrne.2007.07.002
   ROA J, 2009, PEPTIDES, V30, P57, DOI 10.1016/j.peptides.2008.08.009
   ROSEWEIR AK, 2009, HUM REPROD UPDATE, V15, P203, DOI
   10.1093/humupd/dmn058
   SEMINARA SB, 2006, ENDOCRINOLOGY, V147, P2122, DOI 10.1210/en.2005-1550
   SMITH JT, 2008, ENDOCRINOLOGY, V149, P1951, DOI 10.1210/en.2007-1425
   SUZUKI S, 2008, ANIM REPROD SCI, V103, P360, DOI
   10.1016/j.anireprosci.2007.05.016
   THOMPSON EL, 2004, J NEUROENDOCRINOL, V16, P850, DOI
   10.1111/j.1365-2826.2004.01240.x
   VANAERLE R, 2008, PEPTIDES, V29, P57, DOI 10.1016/j.peptides.2007.10.018
   WHITLOCK BK, 2008, NEUROENDOCRINOLOGY, V88, P212
   WONG AO, 1994, GEN COMP ENDOCR, V64, P316
   WONG AOL, 1994, ENDOCRINOLOGY, V135, P1593
   WONG AOL, 2007, AM J PHYSIOL-ENDOC M, V292, E203, DOI
   10.1152/ajpendo.00337.2006
   ZHAO E, 2009, ENDOCRINOLOGY, V1501, P2273
   ZHOU H, 2004, ENDOCRINOLOGY, V145, P4615, DOI 10.1210/en.2004-0163
   ZHOU H, 2004, ENDOCRINOLOGY, V145, P5548, DOI 10.1210/en.2004-0362
NR 50
TC 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
J9 GEN COMP ENDOCRINOL
JI Gen. Comp. Endocrinol.
PD JAN 1
PY 2010
VL 165
IS 1
BP 60
EP 71
DI 10.1016/j.ygcen.2009.06.001
PG 12
SC Endocrinology & Metabolism
GA 542HP
UT ISI:000273483900009
ER

PT J
AU Zheng, CL
   Yang, SG
   Guo, ZX
   Liao, WB
   Zhang, L
   Yang, RC
   Han, ZC
AF Zheng, Cuiling
   Yang, Shaoguang
   Guo, Zhenxing
   Liao, Wenbin
   Zhang, Lei
   Yang, Renchi
   Han, Zhong Chao
TI Human Multipotent Mesenchymal Stromal Cells From Fetal Lung Expressing
   Pluripotent Markers and Differentiating Into Cell Types of Three Germ
   Layers
SO CELL TRANSPLANTATION
LA English
DT Article
DE Multipotent mesenchymal stromal cells; Fetal lung; Pluripotent markers;
   Differentiation capacity
ID HUMAN BONE-MARROW; UMBILICAL-CORD BLOOD; STEM-CELLS; ADIPOSE-TISSUE;
   IN-VITRO; THERAPY; IDENTIFICATION; EXPANSION; MSC; TRANSPLANTATION
AB Multipotent mesenchymal stromal cells (MSCs) are a promising cell type
   for cell transplantation; however, their utilization remains limited
   until the availability of adequate alternative sources of MSCs and the
   thorough understanding of the biology of MSCs isolated from various
   sources are realized. Fetal lung has been identified as a rich source
   of MSCs. To explore the therapeutic potential of passaged fetal lung
   MSCs (FLMSCs), the present study evaluated their growth kinetics,
   telomere length, karyotype, immunophenotype, and the differentiation
   potential during in vitro expansion. FLMSCs could be easily amplified
   in vitro with no significant shorting of telomere length and had a
   normal karyotype. No significant differences between passage 5 or
   passage 25 were observed in the immunophenotype analysis using flow
   cytometry. Moreover, flow cytometry results provided the first
   demonstration, to our knowledge, that FLMSCs stably expressed
   pluripotent markers including Oct4, Nanog, Sox2, TRA-1-60, c-Myc, and
   SSEA-4 through 25 passages. In vitro differentiation studies as
   identified by confocal microscopy, flow cytometry, RT-PCR, and
   immunohistochemistry showed that FLMSCs had extended capacity of
   differentiating into mesodermal, ectodermal, and endodermal lineages,
   and that their potential for adipogenic, osteogenic, and chondrogenic
   differentiation may be maintained over 25 passages. Furthermore,
   osteogenic and chondrogenic differentiation was used as an indicator of
   their differentiation capability in vivo, as evidenced by ectopic bone
   and cartilage formation. In summary, these results suggest that FLMSCs
   are a primitive population and that their extensive in vitro expansion
   does not involve significant functional modification of the cells,
   including morphology, growth, karyotype, immunophenotype, and
   mesodermal differentiation potential. Hence, FLMSCs might constitute an
   attractive cell resource for cell transplantation to induce
   regeneration of damaged tissues/organs.
C1 [Zheng, Cuiling; Yang, Shaoguang; Guo, Zhenxing; Liao, Wenbin; Zhang, Lei; Yang, Renchi; Han, Zhong Chao] Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Zheng, Cuiling; Yang, Shaoguang; Guo, Zhenxing; Liao, Wenbin; Zhang, Lei; Yang, Renchi; Han, Zhong Chao] Peking Union Med Coll, Tianjin 300020, Peoples R China.
   [Guo, Zhenxing] Tsinghua Univ, Hosp 1, Dept Hematol Oncol, Beijing 100084, Peoples R China.
RP Han, ZC, Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, State Key
   Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
EM tihzchan@public.tpt.tj.cn
FU Ministry Science & Technology of China [2006AA02A110]; National Natural
   Science Foundation of China [30600238]; Tianjin Municipal Science and
   Technology Commission [07JCYBJC11200, 08ZCKFSF03200]
FX The authors would like to thank HUES Cell Facility/Melton Laboratory
   (Harvard Universityl HHMI, Cambridge, MA, USA) for kindly providing
   Human ES cell line. The authors would like to thank Dr. Shihong Lu,
   Qian ren, and Qinjun Zhao for their discussion and help with the
   writing of the manuscript. This study was supported by 863 projects
   from Ministry Science & Technology of China (2006AA02A110), National
   Natural Science Foundation of China (30600238), and Tianjin Municipal
   Science and Technology Commission (07JCYBJC11200 and 08ZCKFSF03200).
CR ABDALLAH BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI
   10.1016/j.bbrc.2004.11.059
   ABDALLAH BM, 2009, J CELL PHYSIOL, V218, P9, DOI 10.1002/jcp.21572
   ARTHUR A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   BANFI A, 2000, EXP HEMATOL, V28, P707
   BATTULA VL, 2007, DIFFERENTIATION, V75, P279, DOI
   10.1111/j.1432-0436.2006.00139.x
   BELTRAMI AR, 2007, BLOOD, V110, P3438, DOI 10.1182/blood-2006-11-055566
   BIEBACK K, 2004, STEM CELLS, V22, P625
   BILIC G, 2008, CELL TRANSPLANT, V17, P955
   CAI XX, 2007, CELL BIOL INT, V31, P776, DOI 10.1016/j.cellbi.2007.01.011
   CAMPAGNOLI C, 2001, BLOOD, V98, P2396
   COVAS DT, 2008, EXP HEMATOL, V36, P642, DOI 10.1016/j.exphem.2007.12.015
   DE CP, 2007, NAT BIOTECHNOL, V25, P100
   DIPPOLITO G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103
   DOMINICI M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FAN CG, 2005, CELL TRANSPLANT, V14, P311
   FERRERO I, 2008, CELL TRANSPLANT, V17, P255
   FOX JM, 2007, BRIT J HAEMATOL, V137, P491, DOI
   10.1111/j.1365-2141.2007.06610.x
   GANG EJ, 2007, BLOOD, V109, P1743
   GONZALEZ R, 2007, BIOCHEM BIOPH RES CO, V362, P491, DOI
   10.1016/j.bbrc.2007.08.033
   GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P298
   GRONTHOS S, 2002, J DENT RES, V81, P531
   GUILLOT PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   GUO H, 2003, EXP HEMATOL, V31, P650, DOI 10.1016/S0301-472X(03)00087-0
   HO AD, 2008, CYTOTHERAPY, V10, P320, DOI 10.1080/14653240802217011
   INTANKER PS, 2003, HAEMATOLOGICA, V88, P845
   JETHVA R, 2009, CYTOTHERAPY, V11, P3, DOI 10.1080/14653240902753477
   JIANG YH, 2002, NATURE, V418, P41
   KISHI Y, 2008, CELL TRANSPLANT, V17, P1095
   KOGLER G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440
   LEBLANC K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   LEE JK, 2007, CELL TRANSPLANT, V16, P849
   MARTINEZ C, 2007, BLOOD, V109, P4245, DOI 10.1182/blood-2006-08-039347
   MITCHELL KE, 2003, STEM CELLS, V21, P50
   NAUTA AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
   NEUSS S, 2008, CELL TRANSPLANT, V17, P977
   ODONOGHUE K, 2004, BEST PRACT RES CL OB, V18, P853, DOI
   10.1016/j.bpobgyn.2004.06.010
   PENG LY, 2008, STEM CELLS DEV, V17, P761
   PRUSA AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279
   RAMOS GA, 2007, CELL TRANSPLANT, V16, P951
   REYES M, 2001, BLOOD, V98, P2615
   ROOBROUCK VD, 2008, EXP CELL RES, V314, P1937, DOI
   10.1016/j.yexcr.2008.03.006
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TATEISHI K, 2008, CELL TRANSPLANT, V17, P549
   TORRENTE Y, 2008, CELL TRANSPLANT, V17, P1103
   VALTIERI M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521
   WAGNER W, 2005, EXP HEMATOL, V33, P1402, DOI
   10.1016/j.exphem.2005.07.003
   WANG XY, 2008, BLOOD, V111, P2436, DOI 10.1182/blood-2007-07-099333
   YEN BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098
   YEN ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006-0295
NR 49
TC 3
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2009
VL 18
IS 10-11
BP 1093
EP 1109
DI 10.3727/096368909X12483162197042
PG 17
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 541QU
UT ISI:000273434500004
ER

PT J
AU Yang, J
   Liu, X
   Nyland, SB
   Zhang, RR
   Ryland, LK
   Broeg, K
   Baab, KT
   Jarbadan, NR
   Irby, R
   Loughran, TP
AF Yang, Jun
   Liu, Xin
   Nyland, Susan B.
   Zhang, Ranran
   Ryland, Lindsay K.
   Broeg, Kathleen
   Baab, Kendall Thomas
   Jarbadan, Nancy Ruth
   Irby, Rosalyn
   Loughran, Thomas P., Jr.
TI Platelet-derived growth factor mediates survival of leukemic large
   granular lymphocytes via an autocrine regulatory pathway
SO BLOOD
LA English
DT Article
ID KILLER-CELL-ACTIVITY; PDGF BETA-RECEPTOR; LYMPHOPROLIFERATIVE DISEASE;
   SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; LGL LEUKEMIA; T-CELLS;
   EXPRESSION; INHIBITION; ALPHA
AB Large granular lymphocyte (LGL) leukemia results from chronic expansion
   of cytotoxic T cells or natural killer (NK) cells. Apoptotic resistance
   resulting from constitutive activation of survival signaling pathways
   is a fundamental pathogenic mechanism. Recent network modeling analyses
   identified platelet-derived growth factor (PDGF) as a key master switch
   in controlling these survival pathways in T-cell LGL leukemia. Here we
   show that an autocrine PDGF regulatory loop mediates survival of
   leukemic LGLs of both T- and NK-cell origin. We found high levels of
   circulating PDGF-BB in platelet-poor plasma samples from LGL leukemia
   patients. Production of PDGF-BB by leukemic LGLs was demonstrated by
   immunocytochemical staining. Leukemic cells expressed much higher
   levels of PDGFR-beta transcripts than purified normal CD8(+) T cells or
   NK cells. We observed that phosphatidylinositol-3-kinase (PI3 kinase),
   Src family kinase (SFK), and downstream protein kinase B (PKB)/AKT
   pathways were constitutively activated in both T- and NKLGL leukemia.
   Pharmacologic blockade of these pathways led to apoptosis of leukemic
   LGLs. Neutralizing antibody to PDGF-BB inhibited PKB/AKT
   phosphorylation induced by LGL leukemia sera. These results suggest
   that targeting of PDGF-BB, a pivotal regulator for the long-term
   survival of leukemic LGLs, may be an important therapeutic strategy.
   (Blood. 2010;115:51-60)
C1 [Yang, Jun; Liu, Xin; Nyland, Susan B.; Zhang, Ranran; Ryland, Lindsay K.; Broeg, Kathleen; Baab, Kendall Thomas; Jarbadan, Nancy Ruth; Irby, Rosalyn; Loughran, Thomas P., Jr.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Med, Hershey, PA 17033 USA.
RP Yang, J, Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept
   Med, CH74,500 Univ Dr, Hershey, PA 17033 USA.
EM jyang@psu.edu
FU National Institutes of Health [R01 CA112112]
FX This work was supported by National Institutes of Health grant R01
   CA112112.
CR CHOUDHURY GG, 2006, CELL SIGNAL, V18, P1854, DOI
   10.1016/j.cellsig.2006.02.003
   DAYNES RA, 1991, J EXP MED, V174, P1323
   EPLINGBURNETT PK, 2004, ONCOGENE, V23, P9220, DOI 10.1038/sj.onc.1208122
   EPLINGBURNETTE PK, 2001, J CLIN INVEST, V107, P351
   EPLINGBURNETTE PK, 2004, BLOOD, V103, P3431
   GERSUK GM, 1988, J IMMUNOL, V141, P4031
   GERSUK GM, 1991, SCAND J IMMUNOL, V33, P521
   GOUSTIN AS, 1990, GROWTH FACTORS, V2, P189
   HARSH GR, 1990, J NEURO-ONCOL, V8, P1
   HELDIN CH, 1996, ROLE PLATELET DERIVE
   HELDIN CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79
   HELDIN CH, 1999, PHYSIOL REV, V79, P1283
   KIRWAN RP, 2005, GLIA, V52, P309, DOI 10.1002/glia.20247
   KOEHLER NKU, 2008, J NEUROSCI RES, V86, P392, DOI 10.1002/jnr.21497
   LAMY T, 2003, SEMIN HEMATOL, V40, P185, DOI
   10.1016/S0037-1963(03)00133-1
   LAZARO E, 2007, PRESSE MED 2, V36, P1694, DOI 10.1016/j.lpm.2007.06.002
   LIVAK KJ, 2001, METHOD METHODS, V4, P402
   LOUGHRAN TP, 1997, BLOOD, V90, P1977
   LOUGHRAN TP, 1998, BRIT J HAEMATOL, V101, P318
   MORI S, 1993, EMBO J, V12, P2257
   PANTAZIS P, 1987, ONCOGENE, V1, P285
   PAWSON T, 1994, PRINCESS TAKAMATSU S, V24, P303
   POZO D, 2004, J PINEAL RES, V37, P48
   ROBERTSON MJ, 1996, EXP HEMATOL, V24, P406
   RODRIGUEZCABALLERO A, 2008, BLOOD, V112, P4609, DOI
   10.1182/blood-2008-03-146241
   ROLNY C, 2002, J BIOL CHEM, V277, P19315
   ROSS R, 1990, PHILOS T R SOC B, V327, P155
   SCHADE AE, 2006, BLOOD, V107, P4834, DOI 10.1182/blood-2005-08-3076
   SCHADE AE, 2006, CELL CYCLE, V5, P2571
   SHAH MV, 2008, BLOOD, V112, P770, DOI 10.1182/blood-2007-11-121871
   TAYLOR CC, 2000, ENDOCRINOLOGY, V141, P1545
   WARREN HS, 2003, J IMMUNOL METHODS, V280, P135, DOI
   10.1016/S0022-1759(03)00106-6
   YANG J, 2008, BLOOD, V111, P1610, DOI 10.1182/blood-2007-06-093823
   ZAMBELLO R, 2003, BLOOD, V102, P1797, DOI 10.1182/blood-2002-12-3898
   ZHANG RR, 2008, P NATL ACAD SCI USA, V105, P16308, DOI
   10.1073/pnas.0806447105
NR 35
TC 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JAN 7
PY 2010
VL 115
IS 1
BP 51
EP 60
DI 10.1182/blood-2009-06-223719
PG 10
SC Hematology
GA 541CE
UT ISI:000273389600012
ER

PT J
AU Festing, MH
   Speer, MY
   Yang, HY
   Giachelli, CM
AF Festing, Maria H.
   Speer, Mei Y.
   Yang, Hsueh-Ying
   Giachelli, Cecilia M.
TI Generation of Mouse Conditional and Null Alleles of the Type III
   Sodium-Dependent Phosphate Cotransporter PiT-1
SO GENESIS
LA English
DT Article
DE PiT-1; Slc20a1; yolk sac vasculature; anemia; knockout; conditional;
   mouse; embryonic lethal; type III sodium-dependent phosphate
   cotransporter
ID INORGANIC-PHOSPHATE; TRANSPORT FUNCTION; CALCIFICATION; FAMILY
AB Accelerated vascular calcification occurs in several human diseases
   including diabetes and chronic kidney disease (CKD). In patients with
   CKD, vascular calcification is highly correlated with elevated serum
   phosphate levels. In vitro, elevated concentrations of phosphate
   induced vascular smooth muscle cell matrix mineralization, and the
   inorganic phosphate transporter-1 (PiT-1), was shown to be required. To
   determine the in vivo role of PiT-1, mouse conditional and null alleles
   were generated. Here we show that the conditional allele, PiT-1(flox),
   which has loxP sites flanking exons 3 and 4, is homozygous viable.
   Cre-mediated recombination resulted in a null allele that is homozygous
   lethal. Examination of early embryonic development revealed that the
   PiT-1(Delta e3,4/Delta e3,4) embryos displayed anemia, a defect in yolk
   sac vasculature, and arrested growth. Thus, conditional and null PiT-1
   mouse alleles have been successfully generated and PiT-1 has a
   necessary, non-redundant role in embryonic development. genesis
   47:858-863, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Festing, Maria H.; Speer, Mei Y.; Yang, Hsueh-Ying; Giachelli, Cecilia M.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Giachelli, CM, Univ Washington, Dept Bioengn, Box 355061, Seattle, WA
   98195 USA.
EM ceci@uw.edu
FU NIH [HL07828, HL62329]
FX NIH, Contract grant numbers: HL07828, HL62329
CR BOTTGER P, 2002, J BIOL CHEM, V277, P42741, DOI 10.1074/jbc.M7096200
   BOTTGER P, 2005, FEBS J, V272, P3060, DOI
   10.1111/j.1742-4658.2005.04720.x
   BOYER CJC, 1998, BBA-BIOMEMBRANES, V1368, P73
   COLLINS JF, 2004, PFLUG ARCH EUR J PHY, V447, P647, DOI
   10.1007/s00424-003-1088-x
   HONJO S, 2008, REJUV RES, V11, P809, DOI 10.1089/rej.2007.0649
   LI XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   ROZEN S, 1998, PRIMER3
   SALAUN C, 2004, J MOL BIOL, V340, P39, DOI 10.1016/j.jmb.2004.04.050
   SHIGEMATSU T, 2003, NEPHROL DIAL TRAN S3, V18, P86, DOI
   10.1093/ndt/gfg1022
   TOMIYAMA C, 2006, NEPHROL DIAL TRANSPL, V21, P2464, DOI
   10.1093/ndt/gfl291
   TRUETT GE, 2000, BIOTECHNIQUES, V29, P52
NR 11
TC 9
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD DEC
PY 2009
VL 47
IS 12
BP 858
EP 863
DI 10.1002/dvg.20577
PG 6
SC Developmental Biology; Genetics & Heredity
GA 537JG
UT ISI:000273108600009
ER

PT J
AU Gamble, MJ
   Frizzell, KM
   Yang, C
   Krishnakumar, R
   Kraus, WL
AF Gamble, Matthew J.
   Frizzell, Kristine M.
   Yang, Christine
   Krishnakumar, Raga
   Kraus, W. Lee
TI The histone variant macroH2A1 marks repressed autosomal chromatin, but
   protects a subset of its target genes from silencing
SO GENES & DEVELOPMENT
LA English
DT Article
DE MacroH2A1; histone variant; transcription; ChIP-chip
ID INACTIVE X-CHROMOSOME; HUMAN GENOME; STRUCTURAL-CHARACTERIZATION;
   MICROARRAY DATA; TRANSCRIPTION; BINDING; PROMOTERS; RECRUITMENT;
   INTERFERES; ACTIVATION
AB MacroH2A1 is a histone variant that is enriched on the inactive X
   chromosome (Xi) in mammals and is postulated to play an important, but
   unknown, role in the repression of gene expression. Here we show that,
   although macroH2A1 marks repressed autosomal chromatin, it positively
   regulates transcription when located in the transcribed regions of a
   subset of its target genes. We used chromatin immunoprecipitation
   (ChIP) coupled with tiling microarrays (ChIP-chip) to determine the
   genomic localization of macroH2A1 in IMR90 human primary lung
   fibroblasts and MCF-7 breast cancer cells. The patterns of macroH2A1
   deposition are largely similar across the autosomes of both cell lines.
   Our studies revealed a genomic localization pattern unique among
   histone variants; namely, the occupation by macroH2A1 of large
   chromatin domains (>500 kb in some cases) that contain repressive
   chromatin marks (e.g., histone H3 Lys 27 trimethylation). The
   boundaries of macroH2A1-containing domains tend to occur in
   promoter-proximal regions. Not all promoters, however, serve as
   macroH2A1 boundaries; many macroH2A1-containing chromatin domains
   invade the transcribed regions of genes whose products play key roles
   in development and cell-cell signaling. Surprisingly, the expression of
   a subset of these genes is positively regulated by macroH2A1. MacroH2A1
   also plays a role in augmenting signal-regulated transcription,
   specifically for genes responsive to serum starvation. Collectively,
   our results document an unexpected role for macroH2A1 in the escape
   from heterochromatin-associated silencing and the enhancement of
   autosomal gene transcription.
C1 [Gamble, Matthew J.; Frizzell, Kristine M.; Yang, Christine; Krishnakumar, Raga; Kraus, W. Lee] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
   [Frizzell, Kristine M.; Krishnakumar, Raga; Kraus, W. Lee] Cornell Univ, Grad Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA.
   [Kraus, W. Lee] Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA.
RP Kraus, WL, Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
EM wlk5@cornell.edu
FU NIH/NIDDK [DK069710, DK079847-01]; Cornell University Center for
   Vertebrate Genomics ; Endocrine Society ; American Heart Association
   (AHA) 
FX We thank J. Lis, A. Clark, J. Waterfall, D. Ruhl, M. Kininis, and T.
   Zhang for critical reading of this manuscript, technical advice, and
   helpful discussions. This work was supported by grants from the
   NIH/NIDDK (DK069710), the Cornell University Center for Vertebrate
   Genomics, and the Endocrine Society to W. L. K.; a post-doctoral
   fellowship from the American Heart Association (AHA) and from the
   NIH/NIDDK (DK079847-01) to M. J. G.; and a predoctoral fellowship from
   the AHA to K. M. F.
CR *R DEV COR TEAM, 2006, R LANG ENV STAT COMP
   ABBOTT DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i
   AGELOPOULOS M, 2006, EMBO J, V25, P4843, DOI 10.1038/sj.emboj.7601364
   AHEL D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321
   ANGELOV D, 2003, MOL CELL, V11, P1033
   ANGELOV D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046
   BARRETT T, 2009, NUCLEIC ACIDS RES, V37, D885, DOI 10.1093/nar/gkn764
   BERNSTEIN E, 2008, P NATL ACAD SCI USA, V105, P1533, DOI
   10.1073/pnas.0711632105
   BOYLE EI, 2004, BIOINFORMATICS, V20, P3710, DOI
   10.1093/bioinformatics/bth456
   BUSCHBECK M, 2009, NAT STRUCT MOL BIOL, V16, P1074, DOI
   10.1038/nsmb.1665
   CHAKRAVARTHY S, 2005, MOL CELL BIOL, V25, P7616, DOI
   10.1128/MCB.25.17.7616-7624.2005
   CHANG EY, 2008, BIOCHEMISTRY-US, V47, P13726, DOI 10.1021/bi8016944
   CHANGOLKAR LN, 2006, MOL CELL BIOL, V26, P4410
   CHANGOLKAR LN, 2007, MOL CELL BIOL, V27, P2758, DOI 10.1128/MCB.02334-06
   CHANGOLKAR LN, 2008, MOL CELL BIOL, V28, P2059, DOI 10.1128/MCB.01362-07
   CHOO JH, 2006, HUM MOL GENET, V15, P717, DOI 10.1093/hmg/ddi485
   CHOW J, 2009, CURR OPIN CELL BIOL, V21, P359, DOI
   10.1016/j.ceb.2009.04.012
   CORE LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   DOYEN CM, 2006, MOL CELL BIOL, V26, P1156, DOI
   10.1128/MCB.26.3.1156-1164.2006
   GOTTSCHALK AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI
   10.1073/pnas.0906920106
   HEINTZMAN ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   HERNADEZMUNOZ I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI
   10.1073/pnas.0408918102
   KAROLCHIK D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129
   KENT WJ, 2002, GENOME RES, V12, P996
   KIM TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   KRAUS WL, 2009, NAT STRUCT MOL BIOL, V16, P904, DOI 10.1038/nsmb0909-904
   KRISHNAKUMAR R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   KUSTATSCHER G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   LADURNER AG, 2003, MOL CELL, V12, P1
   MIETTON F, 2009, MOL CELL BIOL, V29, P150, DOI 10.1128/MCB.00997-08
   NUSINOW DA, 2007, J BIOL CHEM, V282, P12851, DOI 10.1074/jbc.M610502200
   OUARARHNI K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106
   PEHRSON JR, 1992, SCIENCE, V257, P1398
   PEHRSON JR, 1997, J CELL BIOCHEM, V65, P107
   PEHRSON JR, 1998, NUCLEIC ACIDS RES, V26, P2837
   PHILLIPS JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   RASMUSSEN TP, 1999, NUCLEIC ACIDS RES, V27, P3685
   SALDANHA AJ, 2004, BIOINFORMATICS, V20, P3246, DOI
   10.1093/bioinformatics/bth349
   SARMA K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567
   SIRCHIA SM, 2005, CANCER RES, V65, P2139
   SMYTH GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5
   SPORN JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26
   TIMINSZKY G, 2009, NAT STRUCT MOL BIOL, V16, P923, DOI 10.1038/nsmb.1664
   VENABLES WN, 2002, MODERN APPL STAT S
   ZHANG RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019
NR 45
TC 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD JAN 1
PY 2010
VL 24
IS 1
BP 21
EP 32
DI 10.1101/gad.1876110
PG 12
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 539JD
UT ISI:000273249300005
ER

PT J
AU Zheng, JF
   Mercado-Uribe, I
   Rosen, DG
   Chang, B
   Liu, PS
   Yang, G
   Malpica, A
   Naora, H
   Auersperg, N
   Mills, GB
   Bast, RC
   Liu, JS
AF Zheng, Jingfang
   Mercado-Uribe, Imelda
   Rosen, Daniel G.
   Chang, Bin
   Liu, Peishu
   Yang, Gong
   Malpica, Anais
   Naora, Honami
   Auersperg, Nelly
   Mills, Gordon B.
   Bast, Robert C.
   Liu, Jinsong
TI Induction of papillary carcinoma in human ovarian surface epithelial
   cells using combined genetic elements and peritoneal microenvironment
SO CELL CYCLE
LA English
DT Article
DE high grade serous carcinoma; HER2/neu; human ovarian surface epithelial
   cells; transformation
ID SEROUS CARCINOMA; HUMAN-BREAST; FALLOPIAN-TUBE; MOUSE MODEL; CANCER;
   CARCINOGENESIS; TRANSITION; EXPRESSION; BIOLOGY; TUMORS
AB Papillary differentiation is one of the most common histological
   features of ovarian cancer, although the underlying mechanism that
   leads to such differentiation is not known. We hypothesized that human
   ovarian surface epithelial cells can be transformed into carcinoma with
   papillary differentiation by overexpressing HeR2/neu in these cells.
   Mice were injected either subcutaneously or intraperitoneally with two
   immortalized human ovarian surface epithelial cell lines after enforced
   expression of HeR-2/neu. Mice subcutaneously injected with tumor cells
   from either the T29Nt or T80Nt developed undifferentiated carcinomas.
   In contrast, mice injected intraperitoneally with T29Nt cells developed
   papillary carcinoma, and those injected intraperitoneally with T80Nt
   cells developed undifferentiated carcinoma. our results demonstrate
   that ovarian surface epithelial cells can develop into papillary
   carcinoma in mice, and that the induction of papillary differentiation
   depends not only on specific genetic modifications but also on the
   tumor microenvironment and epithelial cell type from ovary from
   different patients.
C1 [Zheng, Jingfang; Mercado-Uribe, Imelda; Rosen, Daniel G.; Chang, Bin; Yang, Gong; Malpica, Anais; Liu, Jinsong] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Naora, Honami; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Zheng, Jingfang; Bast, Robert C.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Zheng, Jingfang; Liu, Peishu] Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Auersperg, Nelly] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada.
RP Liu, JS, Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX
   77030 USA.
EM jliu@mdanderson.org
CR AUERSPERG N, 1994, LAB INVEST, V71, P510
   AUERSPERG N, 1997, J CELL PHYSIOL, V173, P261
   AUERSPERG N, 2001, ENDOCR REV, V22, P255
   CHENG WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   CONNOLLY DC, 2003, CANCER RES, V63, P1389
   DINULESCU DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173
   DUBEAU L, 1999, GYNECOL ONCOL, V72, P437
   FLESKENNIKITIN A, 2003, CANCER RES, V63, P3459
   INCE TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013
   JEMAL A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   KINDELBERGER DW, 2007, AM J SURG PATHOL, V31, P161
   LEE Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091
   LIU JC, 2007, CANCER RES, V67, P8671
   LIU JS, 2004, CANCER RES, V64, P1655
   MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729
   MAINESBANDIERA SL, 2004, DIFFERENTIATION, V72, P150
   MANI SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   ORSULIC S, 2002, CANCER CELL, V1, P53
   REESE DM, 1997, STEM CELLS, V15, P1
   SLAMON DJ, 1989, SCIENCE, V244, P707
   TONE AA, 2008, CLIN CANCER RES, V14, P4067, DOI
   10.1158/1078-0432.CCR-07-4959
   VERRI E, 2005, ONCOLOGY-BASEL, V68, P154, DOI 10.1159/000086958
   WU R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016
NR 23
TC 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JAN 1
PY 2010
VL 9
IS 1
BP 140
EP 146
PG 7
SC Cell Biology
GA 539EQ
UT ISI:000273236800033
ER

PT J
AU Zhu, XY
   Yang, N
   Cai, JG
   Yang, GM
   Liang, SH
   Ren, DM
AF Zhu, Xiangying
   Yang, Nan
   Cai, Jianguo
   Yang, Guimei
   Liang, Shenghua
   Ren, Daming
TI The intrabody targeting of hTERT attenuates the immortality of cancer
   cells
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE Cancer; Intrabody; Anti-hTERT ScFv; Immortality
ID TELOMERASE CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; INTRACELLULAR
   EXPRESSION; TUMOR-CELLS; INHIBITION; CARCINOMA; PROLIFERATION;
   PROSPECTS; IMMUNITY; THERAPY
AB hTERT (human telomerase reverse transcriptase) plays a key role in the
   process of cell immortalization. Overexpression of hTERT has been
   implicated in 85% of malignant tumors and offers a specific target for
   cancer therapy. In this paper, we describe an effective approach using
   a single-chain variable fragment (scFv) intrabody derived from
   monoclonal hybridoma directed against hTERT to attenuate the
   immortalization of human uterine cervix and hepatoma cells. The scFv we
   constructed had a high affinity to hTERT, and specifically neutralized
   over 70% of telomere synthesis activity, thereby inhibiting the
   viability and proliferation of the cancer cells. Our results indicate
   that this anti-hTERT intrabody is a promising tool to target hTERT and
   intervene in the immortalization process of cancer cells.
C1 [Zhu, Xiangying; Yang, Nan; Cai, Jianguo; Yang, Guimei; Liang, Shenghua; Ren, Daming] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China.
RP Ren, DM, Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai,
   Peoples R China.
EM dmren@fudan.edu.cn
CR AHMED A, 2003, J AM GERIATR SOC, V51, P116
   BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422
   BIOCCA S, 1994, BIOTECHNOLOGY NY, V4, P396
   BLACKBURN EH, 1991, NATURE, V350, P569
   BLACKBURN EH, 2000, NATURE, V408, P53
   BONNIN E, 2004, METHODS, V34, P225, DOI 10.1016/j.ymeth.2004.04.005
   BURKE B, 1984, CELL, V4, P847
   CARDINALE A, 1998, FEBS LETT, V439, P197
   CHANG JT, 2006, BRIT J CANCER, V94, P870, DOI 10.1038/sj.bjc.6603008
   DUAN L, 1994, P NATL ACAD SCI USA, V11, P5075
   FU W, 2008, J GENE MED, V6, P690
   GRAESSMANN A, 1980, METHOD ENZYMOL, V1, P816
   HARLEY CB, 1991, MUTAT RES, V256, P271
   HARRINGTON L, 1997, GENE DEV, V11, P3109
   HOLT SE, 1997, P NATL ACAD SCI USA, V94, P10687
   HYTIROGLOU P, 2006, AM J GASTROENTEROL, V101, P839, DOI
   10.1111/j.1572-0241.2006.00521.x
   KALDERON D, 1984, CELL, V39, P499
   KELLAND LR, 2005, EUR J CANCER, V41, P971, DOI
   10.1016/j.ejca.2004.11.024
   KIM NW, 1994, SCIENCE, V266, P2011
   MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889
   MARASCO WA, 1997, GENE THER, V4, P11
   MARASCO WA, 2001, CURR TOP MICROBIOL, V260, P247
   MEEKER AK, 2002, CANCER RES, V62, P6405
   MEEKER AK, 2004, AM J PATHOL, V164, P925
   MEYERSON M, 1997, CELL, V90, P785
   MHASHILKAR AM, 1995, EMBO J, V14, P1542
   MINEV B, 2000, P NATL ACAD SCI USA, V97, P4796
   MORGAN DO, 1988, IMMUNOL TODAY, V3, P84
   MORIN GB, 1989, CELL, V59, P521
   PLUMB JA, 2001, ONCOGENE, V20, P7797
   SAVRETRAIN I, 2000, P SOC EXP BIOL MED, V223, P379
   SEAY TM, 1996, J UROLOGY, V155, P757
   STRAHL C, 1996, MOL CELL BIOL, V16, P53
   STRAZISAR M, 2009, CELL MOL BIOL LETT, V3, P442
   VALLE G, 1982, NATURE, V5887, P71
   VANHEEK NT, 2002, AM J PATHOL, V161, P1541
   VONDERHEIDE RH, 1999, IMMUNITY, V10, P673
   WEINRICH SL, 1997, NAT GENET, V17, P498
   WILLIAMS BR, 2006, CURR MED CHEM, V13, P1473
   WU P, 2005, BIOCHEM BIOPH RES CO, V335, P36, DOI
   10.1016/j.bbrc.2005.07.039
   XIONG Y, 1990, EMBO J, V9, P3353
   YANG N, 2008, CANCER BIOL THER, V1, P145
   ZHANG PH, 2006, J SURG RES, V131, P143, DOI 10.1016/j.jss.2005.09.017
NR 43
TC 0
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 1425-8153
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD MAR
PY 2010
VL 15
IS 1
BP 32
EP 45
DI 10.2478/s11658-009-0032-2
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 535LB
UT ISI:000272968600003
ER

PT J
AU Wang, F
   Yang, W
AF Wang, Feng
   Yang, Wei
TI Structural Insight into Translesion Synthesis by DNA Pol II
SO CELL
LA English
DT Article
ID ESCHERICHIA-COLI; POLYMERASE-II; SPONTANEOUS MUTAGENESIS; FAMILY
   POLYMERASES; DAMAGE TOLERANCE; GENOME STABILITY; ABASIC LESION;
   Y-FAMILY; B-FAMILY; IN-VIVO
AB E. coli DNA Pol II and eukaryotic Rev3 are B-family polymerases that
   can extend primers past a damaged or mismatched site when the
   high-fidelity replicative polymerases in the same family are
   ineffective. We report here the biochemical and structural properties
   of DNA Pol II that facilitate this translesion synthesis. DNA Pol II
   can extend primers past lesions either directly or by template
   skipping, in which small protein cavities outside of the active site
   accommodate looped-out template nucleotides 1 or 2 bp upstream. Because
   of multiple looping-out alternatives, mutation spectra of bypass
   synthesis are complicated. Moreover, translesion synthesis is enhanced
   by altered partitioning of DNA substrate between the polymerase active
   site and the proofreading exonuclease site. Compared to the replicative
   B family polymerases, DNA Pol II has subtle amino acid changes remote
   from the active site that allow it to replicate normal DNA with high
   efficiency yet conduct translesion synthesis when needed.
C1 [Wang, Feng; Yang, Wei] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Yang, W, NIDDK, Mol Biol Lab, NIH, 9000 Rockville Pike,Bldg 5,Room
   B1-03, Bethesda, MD 20892 USA.
EM wei.yang@nih.gov
FU National Institute of Diabetes and Digestive and Kidney Diseases
   intramural research program at National Institutes of Health 
FX We thank S. Doublie for purified gp43 protein and the gp43-beta- clone,
   W. Konigsberg for the gp43 exo- clone, our labmates for technical
   support, D. Leahy and R. Craigie for critical reading of the
   manuscript, and F. Dyda for maintaining the X-ray equipment. The
   research is funded by the National Institute of Diabetes and Digestive
   and Kidney Diseases intramural research program at National Institutes
   of Health.
CR *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760
   ABDULOVIC AL, 2008, NUCLEIC ACIDS RES, V36, P2082, DOI
   10.1093/nar/gkn054
   ALMAMUN AAM, 2006, MUTAT RES-FUND MOL M, V593, P164, DOI
   10.1016/j.mrfmmm.2005.07.016
   ALMAMUN AAM, 2007, MUTAT RES-FUND MOL M, V625, P29, DOI
   10.1016/j.mrfmmm.2007.05.002
   ANDERSEN PL, 2008, CELL RES, V18, P162, DOI 10.1038/cr.2007.114
   ANDERSON WF, 1994, J MOL BIOL, V238, P120
   ARANA ME, 2007, DNA REPAIR, V6, P213, DOI 10.1016/j.dnarep.2006.09.012
   BEARD WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200
   BEBENEK A, 2001, J BIOL CHEM, V276, P10387
   BEBENEK K, 2004, ADV PROTEIN CHEM, V69, P137
   BECHEREL OJ, 2001, P NATL ACAD SCI USA, V98, P8566
   BERMAN AJ, 2007, EMBO J, V26, P3494, DOI 10.1038/sj.emboj.7601780
   BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663
   BRUNGER AT, 1998, ACTA CRYSTALLOGR D 5, V54, P905
   CAI H, 1995, J BIOL CHEM, V270, P15327
   CHANG DJ, 2009, NAT CHEM BIOL, V5, P82, DOI 10.1038/nchembio.139
   CURTI E, 2009, MOL MICROBIOL, V71, P315, DOI
   10.1111/j.1365-2958.2008.06526.x
   DOUBLIE S, 1999, STRUCT FOLD DES, V7, R31
   EMSLEY P, 2004, ACTA CRYSTALLOGR  12, V60, P2126, DOI
   10.1107/S0907444904019158
   FOSTER PL, 2005, MUTAT RES-FUND MOL M, V569, P3, DOI
   10.1016/j.mrfmmm.2004.07.017
   FRANKLIN MC, 2001, CELL, V105, P657
   FREISINGER E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158
   FUCHS RP, 2007, DNA REPAIR, V6, P1032, DOI 10.1016/j.dnarep.2007.02.021
   GAN GN, 2008, CELL RES, V18, P174, DOI 10.1038/cr.2007.117
   GARCIADIAZ M, 2006, CELL, V124, P331, DOI 10.1016/j.cel.2005.10.039
   HOGG M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150
   HOGG M, 2007, J BIOL CHEM, V282, P1432, DOI 10.1074/jbc.M605675200
   IWASAKI H, 1991, MOL GEN GENET, V226, P24
   JAROSZ DF, 2006, NATURE, V439, P225, DOI 10.1038/nature04318
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110
   JOYCE CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z
   KROEGER KM, 2004, BIOCHEMISTRY-US, V43, P6723, DOI 10.1021/bi049813g
   LAWRENCE CW, 2001, PHILOS T ROY SOC B, V356, P41
   LEE HR, 2009, BIOCHEMISTRY-US, V48, P2087, DOI 10.1021/bi8016284
   LING H, 2004, MOL CELL, V13, P751
   MCKENZIE GJ, 2001, CURR OPIN MICROBIOL, V4, P586
   MOON AF, 2007, DNA REPAIR, V6, P1709, DOI 10.1016/j.dnarep.2007.05.009
   NAPOLITANO R, 2000, EMBO J, V19, P6259
   NEELEY WL, 2007, J BIOL CHEM, V282, P12741, DOI 10.1074/jbc.M700575200
   OHMORI H, 2001, MOL CELL, V8, P7
   OTWINOWSKI Z, 1997, METHOD ENZYMOL, V276, P307
   PAZELIZUR T, 1996, J BIOL CHEM, V271, P24662
   REHAKRANTZ LJ, 2009, BIOCH IN PRESS 0621
   SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762
   SCHENTEN D, 2009, J EXP MED, V206, P477, DOI 10.1084/jem.20080669
   SHARIEF FS, 1999, GENOMICS, V59, P90
   SONODA E, 2003, EMBO J, V22, P3188
   STEITZ TA, 1999, J BIOL CHEM, V274, P17395
   STRAUSS BS, 1985, CANCER SURV, V4, P493
   STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77
   WAGNER J, 2002, DNA REPAIR, V1, P159
   WILSON RC, 2008, MOL CELL, V29, P767, DOI 10.1016/j.molcel.2008.01.014
   YANG W, 2007, P NATL ACAD SCI USA, V104, P15591, DOI
   10.1073/pnas.0704219104
   YEISER B, 2002, P NATL ACAD SCI USA, V99, P8737
   ZENG G, 1998, BIOTECHNIQUES, V25, P206
   ZHONG XJ, 2006, NUCLEIC ACIDS RES, V34, P4731, DOI 10.1093/nar/gkl465
NR 56
TC 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD DEC 24
PY 2009
VL 139
IS 7
BP 1279
EP 1289
DI 10.1016/j.cell.2009.11.043
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 536MO
UT ISI:000273048700016
ER

PT J
AU Sun, J
   Yu, EY
   Yang, YT
   Confer, LA
   Sun, SH
   Wan, K
   Lue, NF
   Lei, M
AF Sun, Jia
   Yu, Eun Young
   Yang, Yuting
   Confer, Laura A.
   Sun, Steven H.
   Wan, Ke
   Lue, Neal F.
   Lei, Ming
TI Stn1-Ten1 is an Rpa2-Rpa3-like complex at telomeres
SO GENES & DEVELOPMENT
LA English
DT Article
DE Telomere; telomere-binding protein; telomerase; homologous recombination
ID SINGLE-STRANDED-DNA; REPLICATION PROTEIN-A; CHROMOSOME END-PROTECTION;
   CANDIDA-ALBICANS; BINDING-PROTEIN; CRYSTAL-STRUCTURE; LENGTH
   REGULATION; FISSION YEAST; OB-FOLD; POT1
AB In budding yeast, Cdc13, Stn1, and Ten1 form a heterotrimeric complex
   (CST) that is essential for telomere protection and maintenance.
   Previous bioinformatics analysis revealed a putative
   oligonucleotide/oligosaccharide-binding (OB) fold at the N terminus of
   Stn1 (Stn1N) that shows limited sequence similarity to the OB fold of
   Rpa2, a subunit of the eukaryotic ssDNA-binding protein complex
   replication protein A (RPA). Here we present functional and structural
   analyses of Stn1 and Ten1 from multiple budding and fission yeast. The
   crystal structure of the Candida tropicalis Stn1N complexed with Ten1
   demonstrates an Rpa2N-Rpa3-like complex. In both structures, the OB
   folds of the two components pack against each other through
   interactions between two C-terminal helices. The structure of the
   C-terminal domain of Saccharomyces cerevisiae Stn1 (Stn1C) was found to
   comprise two related winged helix-turn-helix (WH) motifs, one of which
   is most similar to the WH motif at the C terminus of Rpa2, again
   supporting the notion that Stn1 resembles Rpa2. The crystal structure
   of the fission yeast Schizosaccharomyces pombe Stn1N-Ten1 complex
   exhibits a virtually identical architecture as the C. tropicalis
   Stn1N-Ten1. Functional analyses of the Candida albicans Stn1 and Ten1
   proteins revealed critical roles for these proteins in suppressing
   aberrant telomerase and recombination activities at telomeres.
   Mutations that disrupt the Stn1-Ten1 interaction induce telomere
   uncapping and abolish the telomere localization of Ten1. Collectively,
   our structural and functional studies illustrate that, instead of being
   confined to budding yeast telomeres, the CST complex may represent an
   evolutionarily conserved RPA-like telomeric complex at the 3' overhangs
   that works in parallel with or instead of the well-characterized
   POT1-TPP1/TEBP alpha-beta complex.
C1 [Sun, Jia; Yang, Yuting; Confer, Laura A.; Wan, Ke; Lei, Ming] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.
   [Sun, Jia; Yang, Yuting; Confer, Laura A.; Sun, Steven H.; Wan, Ke; Lei, Ming] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.
   [Yu, Eun Young; Lue, Neal F.] Cornell Univ, Dept Microbiol & Immunol, WR Hearst Microbiol Res Ctr, Weill Med Coll, New York, NY 10065 USA.
RP Lei, M, Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI
   48109 USA.
EM nflue@med.cornell.edu
   leim@umich.edu
FU NIH [GM 083015-01, GM069507]; American Cancer Society Research Scholar
   ; Sidney Kimmel Scholar Award ; Michigan Economic Development
   Corporation ; Michigan Technology Tri-Corridor [085P1000817]; U. S.
   Department of Energy, Office of Science, Office of Basic Energy
   Sciences [DE-AC02-06CH11357]
FX We thank Y. Chen and F. Wang for help at various stages of the project.
   This work was supported by NIH grants (GM 083015-01 to M. L. and
   GM069507 to N. L.), an American Cancer Society Research Scholar grant,
   and a Sidney Kimmel Scholar Award (to M. L.). M. L. is a Howard Hughes
   Medical Institute Early Career Scientist. N. F. L. thanks Drs.
   Ting-Fang Wang and Chung Wang (Academia Sinica, Taiwan) for support
   during his summer 2007 visit, on which occasion some of the works
   described here were initiated. Use of Life Sciences Collaborative
   Access Team Sector 21 was supported by the Michigan Economic
   Development Corporation and the Michigan Technology Tri-Corridor (grant
   085P1000817). Use of the Advanced Photon Source was supported by the U.
   S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under contract number DE-AC02-06CH11357.
CR ANDALUZ E, 2006, MOL MICROBIOL, V59, P1452, DOI
   10.1111/j.1365-2958.2005.05038.x
   BAUMANN P, 2001, SCIENCE, V292, P1171
   BECHARD LH, 2009, MOL CELL BIOL, V29, P626, DOI 10.1128/MCB.00423-08
   BERA AK, 2003, J BACTERIOL, V185, P4099, DOI
   10.1128/JB.185.14.4099-4109.2003
   BERTUCH AA, 2006, CURR OPIN CELL BIOL, V18, P247, DOI
   10.1016/j.ceb.2006.04.005
   BIANCHI A, 2008, MOL CELL, V31, P153, DOI 10.1016/j.molcel.2008.06.013
   BISWAS K, 2003, GENE, V307, P151, DOI 10.1016/S0378-1119(03)00456-6
   BOCHKAREV A, 1999, EMBO J, V18, P4498
   BOCHKAREV A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI
   10.1016/j.sbi.2004.01.001
   BREWER BJ, 1987, CELL, V51, P463
   BRUNGER AT, 1998, ACTA CRYSTALLOGR D 5, V54, P905
   CASTEEL DE, 2009, J BIOL CHEM, V284, P5807, DOI 10.1074/jbc.M807593200
   COHEN S, 1996, MOL CELL BIOL, V16, P2002
   COOPER JP, 2006, COLD SPRING HARBOR M, V45, P495
   DELAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472
   ENLOE B, 2000, J BACTERIOL, V182, P5730
   FANNING E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gk1550
   FERREIRA MG, 2004, MOL CELL, V13, P7
   FONZI WA, 1993, GENETICS, V134, P717
   GAO H, 2007, NAT STRUCT MOL BIOL, V14, P208, DOI 10.1038/nsmb1205
   GARVIK B, 1995, MOL CELL BIOL, V15, P6128
   GOTTSCHLING DE, 1986, CELL, V47, P195
   GRANDIN N, 2001, EMBO J, V20, P1173
   GRAY JT, 1991, CELL, V67, P807
   GROSSI S, 2004, GENE DEV, V18, P992, DOI 10.1101/gad.300004
   HOFFMAN CS, 1987, GENE, V57, P267
   HOLM L, 1991, J MOL BIOL, V218, P183
   HORVATH MP, 1998, CELL, V95, P963
   HSU M, 2007, P NATL ACAD SCI USA, V104, P11682
   IYER S, 2005, MOL CELL BIOL, V25, P8064, DOI
   10.1128/MCB.25.18.8064-8073.2005
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110
   KOMORI H, 1999, EMBO J, V18, P4597
   LAMZIN VS, 2001, INT TABLES CRYSTALLO, F, P720
   LEGRAND M, 2007, EUKARYOT CELL, V6, P2194, DOI 10.1128/EC.00299-07
   LEI M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092.
   LEI M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867
   LOAYZA D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688
   MARTIN V, 2007, P NATL ACAD SCI USA, V104, P14038, DOI
   10.1073/pnas.0705497104
   MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453
   MCEACHERN MJ, 2006, ANNU REV BIOCHEM, V75, P111
   MER G, 2000, CELL, V103, P449
   MIYAKE Y, 2009, MOL CELL, V36, P193, DOI 10.1016/j.molcel.2009.08.009
   MIYOSHI T, 2008, SCIENCE, V320, P1341, DOI 10.1126/science.1154819
   MORETTI P, 1994, GENE DEV, V8, P2257
   NABETANI A, 2009, MOL CELL BIOL, V29, P703, DOI 10.1128/MCB.00603-08
   NEUMANN AA, 2006, COLD SPRING HARBOR M, V45, P163
   OTWINOWSKI Z, 1997, METHOD ENZYMOL, V276, P307
   PALM W, 2008, ANNU REV GENET, V42, P301, DOI
   10.1146/annurev.genet.41.110306.130350
   PETREACA RC, 2006, NAT CELL BIOL, V8, P748, DOI 10.1038/ncb1430
   PUGLISI A, 2008, EMBO J, V27, P2328, DOI 10.1038/emboj.2008.158
   ROST B, 2004, NUCLEIC ACIDS RES S2, V32, W321, DOI 10.1093/nar/gkh377
   SONG XY, 2008, P NATL ACAD SCI USA, V105, P19815, DOI
   10.1073/pnas.0807867105
   STEINBERGNEIFACH O, 2006, NUCLEIC ACIDS RES, V34, P2710, DOI
   10.1093/nar/gkl345
   SUROVTSEVA YV, 2009, MOL CELL, V36, P207, DOI
   10.1016/j.molcel.2009.09.017
   TEIXEIRA MT, 2005, CHROMOSOME RES, V13, P535, DOI
   10.1007/s10577-005-0999-0
   WAN M, 2009, J BIOL CHEM, V284, P26725, DOI 10.1074/jbc.M109.021105
   WANG F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454
   WILSON RB, 1999, J BACTERIOL, V181, P1868
   WOLD MS, 1997, ANNU REV BIOCHEM, V66, P61
   XIN HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469
   YU EY, 2007, MOL CELL BIOL, V27, P5639, DOI 10.1128/MCB.00418-07
   YU EY, 2008, NAT STRUCT MOL BIOL, V15, P985, DOI 10.1038/nsmb.1471
NR 62
TC 16
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD DEC 15
PY 2009
VL 23
IS 24
BP 2900
EP 2914
DI 10.1101/gad.1851909
PG 15
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 532YB
UT ISI:000272785500012
ER

PT J
AU Dou, BD
   Hou, BW
   Xu, HM
   Lou, XY
   Chi, XF
   Yang, JB
   Wang, F
   Ni, ZF
   Sun, QX
AF Dou, Bingde
   Hou, Beiwei
   Xu, Haiming
   Lou, Xiangyang
   Chi, Xiaofei
   Yang, Jinbin
   Wang, Fang
   Ni, Zhongfu
   Sun, Qixin
TI Efficient mapping of a female sterile gene in wheat (Triticum aestivum
   L.)
SO GENETICS RESEARCH
LA English
DT Article
ID HYBRID SEED PRODUCTION; LOCI; POPULATIONS; INHERITANCE; POLLENIZER;
   FERTILITY; EVOLUTION; SYSTEM; MAP
AB Studies on inheritance of fertility are of great importance in wheat
   breeding. Although Substantial progress has been achieved in molecular
   characterization or male sterility and fertility restoration recently,
   little effort has been devoted to female sterility. To identify the
   gene(s) controlling female sterility in wheat efficiently, an
   investigation was conducted for the seed setting ratio using a set of
   F-2 populations derived from the cross between a female sterile line
   XND126 and an elite cultivar Gaocheng 8901. Bulked segregation analysis
   (BSA) method and recessive class approach were adopted to screen for
   SSR markers potentially linked to female fertility gene loci in 2005.
   Out of 1080 SSRs in wheat genome, eight markers on chromosome 2D showed
   a clear difference between two disparate bulks and small recombination
   frequency values, suggesting a strong linkage signal to the sterility
   gene. Based on the candidate linked markers, partial linkage maps were
   constructed with Mapmaker 3.0 (EXP) instead of whole genome maps, and
   quantitative trait locus (QTL) mapping was implemented with software
   QTLNetwork 2.0. A major gene locus designated as taf1, was located on
   chromosome 2DS. The above result was confirmed by the analysis for 2007
   data, and taf1 was identified on the same chromosome 2DS with a
   confidence interval of 2.4 cM, which Could explain 44-99 % of
   phenotypic variation. These results provided fundamental information
   for fine mapping studies and laid the groundwork for wheat fertility
   genetic studies.
C1 [Dou, Bingde; Hou, Beiwei; Yang, Jinbin] Huaiyin Normal Univ, Inst Plant Biotechnol, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.
   [Dou, Bingde; Hou, Beiwei; Yang, Jinbin; Wang, Fang] Xinjiang Agr Univ, Agron Coll, Urumqi 830052, Peoples R China.
   [Xu, Haiming; Lou, Xiangyang; Chi, Xiaofei] Zhejiang Univ, Coll Agr & Biotechnol, Hangzhou 310029, Zhejiang, Peoples R China.
   [Ni, Zhongfu; Sun, Qixin] China Agr Univ, Dept Plant Genet & Breeding, Beijing 100094, Peoples R China.
RP Dou, BD, Huaiyin Normal Univ, Inst Plant Biotechnol, Jiangsu Key Lab
   Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.
EM doubd@163.com
FU National Natural Science Foundation of China [30771380]; Qing Lan
   Project in Jiangsu Province 
FX We are grateful to Professor Dr Zhiyong Liu, Department of Plant
   Genetics and Breeding, China Agricultural University for their
   technical support on this program. This research was sponsored by the
   National Natural Science Foundation of China (No. 30771380) and Qing
   Lan Project in Jiangsu Province.
CR AHOKAS H, 1977, BARLEY GENETICS NEWS, V7, P8
   ALLARD RW, 1956, HILGARDIA, V24, P235
   BROWN DE, 1984, CROP SCI, V24, P1207
   BUDAR F, 2003, GENETICA, V117, P3
   CAO SH, 2004, ACTA GENET SINICA, V31, P293
   CHARLESWORTH D, 2001, CURRENT OPINION GENE, V11, P6856
   CHI XF, 2009, GENETICA, V135, P267, DOI 10.1007/s10709-008-9275-5
   DASKALOV S, 1988, THEOR APPL GENET, V76, P530
   DELPH LF, 2003, EVOL DEV, V5, P34
   DOERGE RW, 1996, GENETICS, V142, P285
   DOU BD, 2001, ACTA AGRONOMICA SINI, V27, P1013
   FU DX, 2002, YI CHUAN XUE BAO, V29, P1085
   GOTZOV K, 1979, P 5 INT WHEAT GEN S, V1, P533
   GUO RX, 2006, THEOR APPL GENET, V112, P1271, DOI
   10.1007/s00122-006-0228-z
   HANNA WW, 1973, AGR ABSTR, P6
   HOISINGTON D, 1994, LAB PROTOCOLS CIMMYT
   HOU BW, 2006, YICHUAN, V28, P1567, DOI 10.1360/yc-006-1567
   JANSEN RC, 1995, THEOR APPL GENET, V91, P33
   JASSEM B, 1971, HODOWLA ROSLIN AKLIM, V15, P35
   KIHARA H, 1951, CYTOLOGIA, V16, P177
   KONG FL, 2006, PLANT QUANTITATIVE G
   KOSAMBI DD, 1944, ANN EUGEN, V12, P172
   LANDER ES, 1987, GENOMICS, V1, P174
   LI XL, 2005, PLANT BREEDING, V127, P413
   LIANG FS, 2003, HEREDITAS BEIJING, V25, P461
   LING DH, 1991, ACTA GENET SINICA, V18, P446
   LIU CG, 2002, ACTA GENET SINICA, V29, P638
   MA ZQ, 1995, MOL GEN GENET, V247, P351
   MAURICE S, 1994, HEREDITY, V73, P346
   MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828
   PLASCHKE J, 1996, EUPHYTICA, V89, P33
   RODER MS, 1998, GENETICS, V149, P2007
   RONG DF, 1999, TRITICAL CROPS, V19, P61
   SODHI YS, 2006, THEOR APPL GENET, V114, P93, DOI
   10.1007/s00122-006-0413-0
   SREIFF K, 1997, THESIS I NATL POLYTE, P160
   TAN CH, 1992, J XINAN AGR U, V4, P1
   TIMOTHY AH, 2002, MOL BREEDING, V9, P63
   VAIDYA KR, 1994, REV BRAS GENET, V17, P309
   WANG LQ, 1996, RECENT ADV CROP MALE, P136
   WANG S, 2007, WINDOWS QTL CARTOGRA
   XING QH, 2003, THEOR APPL GENET, V107, P1500, DOI
   10.1007/s00122-003-1385-y
   XING YZ, 2001, ACTA GENET SINICA, V28, P439
   XU SB, 2002, HEREDITAS, V24, P336
   YANG J, 2007, BIOINFORMATICS, V23, P1527, DOI
   10.1093/bioinformatics/btm143
   ZHANG C, 2003, ACTA GENE SIN, V30, P459
   ZHANG QF, 1994, P NATL ACAD SCI USA, V91, P8675
NR 46
TC 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0016-6723
J9 GENET RES
JI Genet. Res.
PD OCT
PY 2009
VL 91
IS 5
BP 337
EP 343
DI 10.1017/S0016672309990218
PG 7
SC Genetics & Heredity
GA 534DP
UT ISI:000272876000004
ER

PT J
AU Sharma, G
   Mirza, S
   Yang, YH
   Parshad, R
   Hazrah, P
   Gupta, SD
   Ralhan, R
AF Sharma, Gayatri
   Mirza, Sameer
   Yang, Yi-Hsin
   Parshad, Rajinder
   Hazrah, Priya
   Gupta, Siddartha Datta
   Ralhan, Ranju
TI Prognostic relevance of promoter hypermethylation of multiple genes in
   breast cancer patients
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; methylation; prognosis; RAR beta; GSTP1; BRCA1
ID METHYLATION-SPECIFIC PCR; DNA METHYLATION; CELL-LINES; CPG-ISLAND;
   ESTROGEN-RECEPTOR; OVARIAN-TUMORS; RAR-BETA; BRCA1; EXPRESSION; RASSF1A
AB Background: Methylation-mediated suppression of detoxification, DNA
   repair and tumor suppressor genes has been implicated in cancer
   development. This study was designed to investigate the impact of
   concurrent methylation of multiple genes in breast tumors on disease
   prognosis.
   Methods: Methylation specific PCR was carried out to analyze the
   methylation status of seven genes in archived breast tissues and
   determine the effect of aberrant methylation of multiple genes on
   disease prognosis and patients' survival.
   Results: Promoter hypermethylation was observed in PRB 67%, ER alpha
   64%, RASSF1A 63%, p16INK4A 51%, RAR beta 2 22%, GSTP1 25% and BRCA1 27%
   of the breast cancers, respectively. Concurrent methylation of BRCA1,
   ERa, GSTP1 and RAR beta 2, was observed in a large proportion of breast
   cancers analyzed, suggesting that these genes do not appear to be
   methylated alone. Patients with high methylation indices had poor
   prognosis (p < 0.001, Hazards ratio = 14.58). Cox regression analysis
   showed RAR beta 2 promoter methylation to be an independent important
   determinant of breast cancer prognosis.
   Conclusion: Our results suggest that methylation of multiple genes
   plays an important role in prognosis of breast cancer. Our study not
   only describes the association of methylation mediated silencing of
   multiple genes with the severity of disease, but also drives to
   speculate the molecular crosstalk between genes or genetic pathways
   regulated by them individually.
C1 [Sharma, Gayatri; Mirza, Sameer; Ralhan, Ranju] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Parshad, Rajinder; Hazrah, Priya] All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   [Gupta, Siddartha Datta] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
   [Yang, Yi-Hsin] Kaohsiung Med Univ, Dept Oral Hyg, Kaohsiung, Taiwan.
   [Yang, Yi-Hsin] Kaohsiung Med Univ Hosp, Dept Clin Res, Div Stat Anal, Kaohsiung, Taiwan.
RP Ralhan, R, Mt Sinai Hosp, Joseph & Mildred Sonshine Family Ctr Head &
   Neck, Joseph & Wolf Lebovic Hlth Complex,600 Univ Ave,R, Toronto, ON
   M5G 1X5, Canada.
EM rralhan@mtsinai.on.ca
CR AGELOPOULOS K, 2007, CELL ONCOL, V29, P443
   ALTUCCI L, 2009, EUR J CANCER, V45, P1137, DOI
   10.1016/j.ejca.2009.03.001
   BAE YK, 2004, CLIN CANCER RES 1, V10, P5998
   BAGADI SAR, 2007, BREAST CANCER RES TR, V104, P277, DOI
   10.1007/s10549-006-9422-6
   BAGADI SAR, 2008, LIFE SCI, V82, P1288, DOI 10.1016/j.lfs.2008.04.020
   BECKMANN MW, 1997, J MOL MED-JMM, V75, P429
   CLARK SJ, 2002, ONCOGENE, V21, P5380
   COSTELLO JF, 2000, NAT GENET, V24, P132
   CROWE DL, 2006, BREAST CANCER RES, V8, ARTN R1
   DAMMANN R, 2001, CANCER RES, V61, P3105
   EHRLICH M, 2002, ONCOGENE, V21, P5400
   ESTELLER M, 2000, J NATL CANCER I, V92, P564
   ESTELLER M, 2001, HUM MOL GENET, V10, P3001
   ESTELLER M, 2005, ANNU REV PHARMACOL, V45, P629, DOI
   10.1146/annurev.pharmtox.45.120403.095832
   ESTELLER M, 2008, NEW ENGL J MED, V358, P1148
   FACKLER MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   FACKLER MJ, 2004, CANCER RES, V64, P4442
   FENG QH, 2005, J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   FENG W, 2007, BREAST CANCER RES, V9, ARTN R57
   FIEGL H, 2005, CANCER RES, V65, P1141
   FRIEDRICH K, 2008, CELL ONCOL, V30, P39
   HAYES DF, 2001, J MAMMARY GLAND BIOL, V6, P375
   HERMAN JG, 1996, P NATL ACAD SCI USA, V93, P9821
   ISSA JPJ, 2003, CLIN CANCER RES, V9, P2879
   JANSSEN EAM, 2007, CELL ONCOL, V29, P25
   KARAMOUZIS MV, 2007, CELL ONCOL, V29, P183
   LAPIDUS RG, 1996, CLIN CANCER RES, V2, P805
   LEHMANN U, 2002, AM J PATHOL, V160, P605
   MA YX, 2005, ONCOGENE, V24, P1831
   MA YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488
   MANNELLO F, 2008, CELL ONCOL, V30, P51
   MIASAKI FY, 2008, J ENDOCRINOL INVEST, V31, P724
   MIKI Y, 1994, SCIENCE, V266, P66
   MIRZA S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   MONTANARO L, 2008, CELL ONCOL, V30, P483, DOI 10.3233/CLO-2008-0436
   MULLER HM, 2003, CANCER RES, V63, P7641
   NAQVI RA, 2008, DNA CELL BIOL, V27, P517, DOI 10.1089/dna.2007.0660
   PALII SS, 2007, CRIT REV EUKAR GENE, V17, P295
   PAREDES J, 2007, CELL ONCOL, V29, P467
   PERTSCHUK LP, 1990, CANCER, V66, P1663
   RHODES A, 2002, AM J CLIN PATHOL, V118, P408
   SASAKI M, 2001, CANCER RES, V61, P97
   SHARMA G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   SHUKLA S, 2006, EPIGENETICS, V1, P88
   SOILAND H, 2007, CELL ONCOL, V29, P195
   SORLIE T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI
   10.1073/pnas.0932692100
   SUNAMI E, 2008, BREAST CANCER RES, V10, ARTN R46
   TAO MH, 2009, BREAST CANCER RES TR, V114, P559, DOI
   10.1007/s10549-008-0028-z
   TISCHKOWITZ MD, 2006, CELL CYCLE, V5, P963
   TOMMASI S, 2007, CELL ONCOL, V29, P241
   TOYOTA M, 1999, P NATL ACAD SCI USA, V96, P8681
   VANDEURZEN CHM, 2007, CELL ONCOL, V29, P497
   VIRMANI AK, 2000, J NATL CANCER I, V92, P1303
   WILEY A, 2006, CANCER, V107, P299, DOI 10.1002/cncr.21992
NR 54
TC 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1570-5870
J9 CELL ONCOL
JI Cell. Oncol.
PY 2009
VL 31
IS 6
BP 487
EP 500
DI 10.3233/CLO-2009-0507
PG 14
SC Oncology; Cell Biology; Pathology
GA 533VV
UT ISI:000272854400007
ER

PT J
AU Yang, B
   Kumar, S
AF Yang, B.
   Kumar, S.
TI Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with
   distinct physiological functions
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Review
DE ubiquitylation; endocytosis; trafficking; receptor; signaling
ID EPITHELIAL NA+ CHANNEL; FACTOR-I RECEPTOR; INDUCIBLE KINASE ISOFORMS;
   YEAST METAL TRANSPORTER; GROWTH-FACTOR RECEPTOR; SODIUM-CHANNEL; WW
   DOMAINS; PROTEASOMAL DEGRADATION; MULTIVESICULAR BODIES; MEDIATED
   DEGRADATION
AB The Nedd4 (neural precursor cell-expressed developmentally
   downregulated gene 4) family of ubiquitin ligases (E3s) is
   characterized by a distinct modular domain architecture, with each
   member consisting of a C2 domain, 2-4 WW domains, and a HECT-type
   ligase domain. Of the nine mammalian members of this family, Nedd4 and
   its close relative, Nedd4-2, represent the ancestral ligases with
   strong similarity to the yeast, Rsp5. In Saccharomyces cerevisiae Rsp5
   has a key role in regulating the trafficking, sorting, and degradation
   of a large number of proteins in multiple cellular compartments.
   However, in mammals the Nedd4 family members, including Nedd4 and
   Nedd4-2, appear to have distinct functions, thereby suggesting that
   these E3s target specific proteins for ubiquitylation. In this article
   we focus on the biology and emerging functions of Nedd4 and Nedd4-2,
   and review recent in vivo studies on these E3s. Cell Death and
   Differentiation (2010) 17, 68-77; doi:10.1038/cdd.2009.84; published
   online 26 June 2009
C1 [Yang, B.] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA.
   [Kumar, S.] SA Pathol, Ctr Canc Biol, Adelaide, SA 5000, Australia.
   [Kumar, S.] Hanson Inst, Adelaide, SA 5000, Australia.
RP Yang, B, Univ Iowa, Carver Coll Med, 200 Hawkins Dr,46 MRF, Iowa City,
   IA 52242 USA.
EM baoli-yang@uiowa.edu
   Sharad.Kumar@health.sa.gov.au
FU NIH [DK52617, AR052647, DE16215]; National Health and Medical Research
   Council [508086]; Australian Research Council [DP0880571]
FX The work in the Yang laboratory is supported by the NIH (DK52617,
   AR052647, and DE16215 to BY), and in the Kumar Laboratory by the
   National Health and Medical Research Council (508086), and the
   Australian Research Council (DP0880571). We thank the members of our
   respective laboratories and Dr. Paula Oliver (Children's Hospital of
   Philadelphia) for helpful comments.
CR ALSORKHY M, 2009, J BIOL CHEM, V284, P2617, DOI 10.1074/jbc.M804847200
   ANGRAND PO, 2006, MOL CELL PROTEOMICS, V5, P2211, DOI
   10.1074/mcp.M600147-MCP200
   ANINDYA R, 2007, MOL CELL, V28, P386, DOI 10.1016/j.molcel.2007.10.008
   AOH QL, 2009, MOL BIOL CELL, V20, P1816, DOI 10.1091/mbc.E08-09-0894
   AREVALO JC, 2006, NEURON, V50, P549, DOI 10.1016/j.neuron.2006.03.044
   ASHER C, 2003, BBA-BIOMEMBRANES, V1612, P59, DOI
   10.1016/S0005-2736(03)00083-X
   BALTAEV R, 2005, PFLUG ARCH EUR J PHY, V450, P26, DOI
   10.1007/s00424-004-1369-z
   BHALLA V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193
   BOEHMER C, 2003, J NEUROCHEM, V86, P1181, DOI
   10.1046/j.1471-4159.2003.01937.x
   BOEHMER C, 2006, J NEUROCHEM, V97, P911
   BRICKLEY DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200
   BRIDGES D, 2005, SCI STKE, RE10
   BRUCE MC, 2008, BIOCHEM J 1, V415, P155, DOI 10.1042/BJ20071708
   CAO XR, 2008, SCI SIGNAL, V1, ARTN ra5
   CHAN W, 2009, J BIOL CHEM, V284, P8185, DOI 10.1074/jbc.M806877200
   CIECHANOVER A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   CONKRIGHT J, 2009, AM J RESP C IN PRESS
   DEBONNEVILLE C, 2001, EMBO J, V20, P7052
   DEPHOURE N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI
   10.1073/pnas.0805139105
   DIETER M, 2004, OBES RES, V12, P862
   DIMMOCK NJ, 2007, INTRO MODERN VIROLOG
   DINUDOM A, 1998, P NATL ACAD SCI USA, V95, P7169
   EDINGER RS, 2009, J BIOL CHEM, V284, P150, DOI 10.1074/jbc.M807358200
   EKBERG J, 2007, J BIOL CHEM, V282, P12135, DOI 10.1074/jbc.M609385200
   EMBARK HM, 2004, KIDNEY INT, V66, P1918
   FANG DY, 2002, NAT IMMUNOL, V3, P281
   FARRELL PM, 1975, AM REV RESPIR DIS, V111, P657
   FEDOROFF OY, 2004, J BIOL CHEM, V279, P34991, DOI 10.1074/jbc.M404987200
   FOOT NJ, 2008, BLOOD, V112, P4268, DOI 10.1182/blood-2008-04-150953
   FOTIA AB, 2003, FASEB J, V17, P70
   FOTIA AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200
   FOTIA AB, 2006, INT J BIOCHEM CELL B, V38, P472, DOI
   10.1016/j.biocel.2005.11.006
   FOULADKOU F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI
   10.1073/pnas.0803233105
   GIORGETTIPERALDI S, 2001, ONCOGENE, V20, P3959
   GIRNITA L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI
   10.1073/pnas.1431613100
   HARTY RN, 2000, P NATL ACAD SCI USA, V97, P13871
   HARVEY KF, 1998, J BIOL CHEM, V273, P13524
   HARVEY KF, 1999, J BIOL CHEM, V274, P12525
   HARVEY KF, 1999, TRENDS CELL BIOL, V9, P166
   HARVEY KF, 2001, J BIOL CHEM, V276, P8597
   HARVEY KF, 2002, J BIOL CHEM, V277, P9307
   HATANAKA T, 2006, J BIOL CHEM, V281, P35922, DOI 10.1074/jbc.M606577200
   HE YW, 2008, J BIOL CHEM, V283, P24000, DOI 10.1074/jbc.M803361200
   HEIN C, 1995, MOL MICROBIOL, V18, P77
   HEISSMEYER V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047
   HENKE G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430
   HERSHKO A, 1998, ANNU REV BIOCHEM, V67, P425
   HETTEMA EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137
   HRYCIW DH, 2004, J BIOL CHEM, V279, P54996, DOI 10.1074/jbc.M411491200
   HUANG L, 1999, SCIENCE, V286, P1321
   HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563
   ICHIMURA T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200
   IKEDA M, 2000, VIROLOGY, V268, P178
   INGHAM RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436
   ITANI OA, 2003, AM J PHYSIOL-RENAL, V285, F916, DOI
   10.1152/ajprenal.00203.2003
   ITANI OA, 2005, AM J PHYSIOL-RENAL, V289, F334, DOI
   10.1152/ajprenal.00394.2004
   JESPERSEN T, 2007, CARDIOVASC RES, V74, P64, DOI
   10.1016/j.cardiores.2007.01.008
   JOLLIFFE CN, 2000, BIOCHEM J 3, V351, P557
   KAMYNINA E, 2001, FASEB J, V15, P204
   KANELIS V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018
   KATZ M, 2002, TRAFFIC, V3, P740
   KONCAREVIC A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com
   KONSTAS AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200
   KOTORASHVILI A, 2009, J BIOL CHEM, V284, P16667, DOI
   10.1074/jbc.M109.002816
   KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155
   KUMAR S, 1997, GENOMICS, V40, P435
   KURATOMI G, 2005, BIOCHEM J 3, V386, P461, DOI 10.1042/BJ20040738
   LAFONT F, 2001, P NATL ACAD SCI USA, V98, P3180
   LEE IH, 2007, J BIOL CHEM, V282, P29866, DOI 10.1074/jbc.M701923200
   LEON S, 2008, MOL BIOL CELL, V19, P2379
   LEYKAUF K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149
   LIANG XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200
   LIANG XB, 2008, J BIOL CHEM, V283, P27418, DOI 10.1074/jbc.M803687200
   LIN CH, 2008, CELL, V135, P714, DOI 10.1016/j.cell.2008.09.025
   LIU XF, 1997, J BIOL CHEM, V272, P11763
   LIU Y, 2009, DEV BIOL, V330, P153, DOI 10.1016/j.ydbio.2009.03.023
   MAGNIFICO A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200
   MALAKHOVA OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200
   MATENTZOGLU K, 2008, BIOCHEM SOC T 5, V36, P797
   MOREN A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200
   MORRIONE A, 1999, J BIOL CHEM, V274, P24094
   MUELLER DL, 2004, NAT IMMUNOL, V5, P883, DOI 10.1038/ni1106
   MURDACA J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200
   NAGAKI K, 2006, BIOCHEMISTRY-US, V45, P6733, DOI 10.1021/bi052640q
   NIKKO E, 2008, EMBO REP, V9, P1216, DOI 10.1038/embor.2008.199
   NOGEE LM, 2001, NEW ENGL J MED, V344, P573
   OLIVER PM, 2006, IMMUNITY, V25, P929, DOI 10.1016/j.immuni.2006.10.012
   PALMADA M, 2004, AM J PHYSIOL-GASTR L, V287, G143, DOI
   10.1152/ajpgi.00121.2003
   PERRY WL, 1998, NAT GENET, V18, P143
   PERUZZI F, 2001, J BIOL CHEM, V276, P25990
   PLANT PJ, 2000, J CELL BIOL, V149, P1473
   PLANT PJ, 2009, BIOCHEM J 1, V419, P57, DOI 10.1042/BJ20081866
   PRADERVAND S, 1999, J AM SOC NEPHROL, V10, P2527
   PRADERVAND S, 2003, J AM SOC NEPHROL, V14, P2219, DOI
   10.1097/01.ASN.000080204.65527.E6
   PUTZ U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200
   ROST M, 2008, J BIOL CHEM, V283, P32119, DOI 10.1074/jbc.M802632200
   ROTIN D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690
   ROUGIER JS, 2005, AM J PHYSIOL-CELL PH, V288, C692, DOI
   10.1152/ajpcell.00460.2004
   SANG Q, 2006, J NEUROSCI, V26, P7234, DOI 10.1523/JNEUROSCI.1398-06.2006
   SCHEFFNER M, 1993, CELL, V75, P495
   SEHAT B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364
   SHEARWINWHYATT L, 2006, BIOESSAYS, V28, P617, DOI 10.1002/bies.20422
   SHEARWINWHYATT LM, 2004, J CELL SCI, V117, P3679, DOI 10.1242/jcs.01212
   SHENOY SK, 2008, J BIOL CHEM, V283, P22166, DOI 10.1074/jbc.M709668200
   SHI PP, 2008, AM J PHYSIOL-RENAL, V295, F462, DOI
   10.1152/ajprenal.90300.2008
   SNYDER PM, 2002, J BIOL CHEM, V277, P5
   SNYDER PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200
   SORKINA T, 2006, J NEUROSCI, V26, P8195, DOI
   10.1523/JNEUROSCI.1301-06.2006
   STAUB O, 1996, EMBO J, V15, P2371
   STIMPSON HEM, 2006, EMBO J, V25, P662, DOI 10.1038/sj.emboj.7600984
   STRACK B, 2000, P NATL ACAD SCI USA, V97, P13063
   TROTMAN LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   VANBEMMELEN MX, 2004, CIRC RES, V95, P284, DOI
   10.1161/01.RES.0000136816.05109.89
   VECCHIONE A, 2003, MOL CELL BIOL, V23, P3363, DOI
   10.1128/MCB.23.9.3363-3372.2003
   WANG XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039
   XU P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041
   YANG BL, 2008, NAT IMMUNOL, V9, P1356, DOI 10.1038/ni.1670
   ZHOU RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200
NR 118
TC 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD JAN
PY 2010
VL 17
IS 1
BP 68
EP 77
DI 10.1038/cdd.2009.84
PG 10
SC Biochemistry & Molecular Biology; Cell Biology
GA 533JC
UT ISI:000272818700009
ER

PT J
AU Watanabe, T
   Kato, H
   Kobayashi, Y
   Yamasaki, S
   Morita-Hoshi, Y
   Yokoyama, H
   Morishima, Y
   Ricker, JL
   Otsuki, T
   Miyagi-Maesima, A
   Matsuno, Y
   Tobinai, K
AF Watanabe, Takashi
   Kato, Harumi
   Kobayashi, Yukio
   Yamasaki, Satoshi
   Morita-Hoshi, Yuriko
   Yokoyama, Hiroki
   Morishima, Yasuo
   Ricker, Justin L.
   Otsuki, Tetsuya
   Miyagi-Maesima, Akiko
   Matsuno, Yoshihiro
   Tobinai, Kensei
TI Potential efficacy of the oral histone deacetylase inhibitor vorinostat
   in a phase I trial in follicular and mantle cell lymphoma
SO CANCER SCIENCE
LA English
DT Article
ID SUBEROYLANILIDE HYDROXAMIC ACID; ADVANCED CANCER; SAHA; DEPSIPEPTIDE;
   APOPTOSIS; TUMORS
AB Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a
   histone deacetylase inhibitor with clinical activity in cutaneous
   T-cell lymphoma (CTCL). A phase I trial of oral vorinostat was
   conducted in Japanese patients with malignant lymphoma. Vorinostat 100
   or 200 mg was administered twice daily for 14 consecutive days followed
   by a 1-week rest interval. Of 10 patients enrolled, four had follicular
   lymphoma (FL), two mantle cell lymphoma (MCL), two diffuse large B-cell
   lymphoma, and two CTCL (median age, 60 years; median number of prior
   regimens, 3). Vorinostat was well tolerated up to 200 mg with only one
   of six patients developing a dose-limiting toxicity (DLT; Grade 3
   anorexia/hypokalemia). Common Grade 3 events were reversible
   neutropenia (30%), thrombocytopenia, and hypermagnesemia (20% each).
   The median number of treatment cycles was five (range, 1-36); two
   patients were continuing treatment. The overall response rate was 40%,
   with two complete responses/unconfirmed (CRu) and one partial response
   among FL patients and one CRu among MCL patients. One FL patient
   maintained CRu for 18.0 months. The median time to achieve CRu among
   the three patients was 8 months. These data suggest that further
   investigations of vorinostat in non-Hodgkin lymphoma, focusing on FL
   and MCL, are warranted. (Cancer Sci 2009).
C1 [Watanabe, Takashi; Kobayashi, Yukio; Yamasaki, Satoshi; Morita-Hoshi, Yuriko; Yokoyama, Hiroki; Tobinai, Kensei] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Tokyo, Japan.
   [Kato, Harumi; Morishima, Yasuo] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi 464, Japan.
   [Ricker, Justin L.] Merck Res Labs, N Wales, PA USA.
   [Otsuki, Tetsuya] Banyu Pharmaceut Co Ltd, Tokyo, Japan.
   [Miyagi-Maesima, Akiko; Matsuno, Yoshihiro] Natl Canc Ctr, Clin Lab, Tokyo, Japan.
RP Watanabe, T, Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, 1-1
   Tsukiji 5 Chome, Tokyo, Japan.
EM takawata@ncc.go.jp
FU Merck Research Laboratories, Rahway, NJ, USA ; Banyu Pharmaceutical,
   Tokyo, Japan 
FX \We thank all of the investigators including Drs Takashi Terauchi
   (Diagnostic Division, Research Center for Cancer Prevention and
   Screening, National Cancer Center) and Teruhisa Azuma and Masakazu Mori
   (Hematology Division, National Cancer Center Hospital) for their
   response assessment by reviews of serial computed tomography performed
   every 3 months; and a clinical research coordinator, Ms Tamami Yamano,
   at National Cancer Center Hospital, for her data collection. We also
   thank Dr Shinichi Kanazu (Banyu Pharmaceutical) and Dr James S.
   Hardwick (Merck Research Laboratories) for their support in preparing
   this manuscript and thank Ms Mary Flynn (Merck Research Laboratories)
   for her assistance with the histone acetylation assays. This trial was
   supported by research funding from Merck Research Laboratories, Rahway,
   NJ, USA, and Banyu Pharmaceutical, Tokyo, Japan.
CR NATL CANC I COMMON T
   BLUMENSCHEIN GR, 2008, INVEST NEW DRUG, V26, P81, DOI
   10.1007/s10637-007-9075-2
   CHESON BD, 1999, J CLIN ONCOL, V17, P1244
   CRUMP M, 2008, ANN ONCOL, V19, P964, DOI 10.1093/annonc/mdn031
   DUVIC M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   FUJIWARA Y, 2009, CANCER SCI, V100, P1728, DOI
   10.1111/j.1349-7006.2009.01237.x
   GARCIAMANERO G, 2008, BLOOD, V111, P1060, DOI
   10.1182/blood-2007-06-098061
   HEIDER U, 2006, EUR J HAEMATOL, V76, P42, DOI
   10.1111/j.1600-0609.2005.00546.x
   KAWAMATA N, 2007, BLOOD, V110, P2667, DOI 10.1182/blood-2005-11-026344
   KELLY WK, 2002, EXPERT OPIN INV DRUG, V11, P1695
   KELLY WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   OCONNOR OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679
   OLSEN EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   PARKIN DM, 2002, CA CANC J CLIN, V55, P74
   PIEKARZ RL, 2006, CLIN CANCER RES, V12, P3762, DOI
   10.1158/1078-0432.CCR-05-2095
   RUBIN EH, 2006, CLIN CANCER RES, V12, P7039, DOI
   10.1158/1078-0432.CCR-06-1802
   SAKAJIRI S, 2005, EXP HEMATOL, V33, P53, DOI
   10.1016/j.ecphem.2004.09.008
   SHAH MH, 2006, CLIN CANCER RES, V12, P3997, DOI
   10.1158/1078-0432.CCR-05-2689
   ZHANG CL, 2005, J INVEST DERMATOL, V125, P1045, DOI
   10.1111/j.0022-202X.2005.23925.x
NR 19
TC 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2010
VL 101
IS 1
BP 196
EP 200
DI 10.1111/j.1349-7006.2009.01360.x
PG 5
SC Oncology
GA 530ZM
UT ISI:000272631500028
ER

PT J
AU Chi, HT
   Vu, HA
   Iwasaki, R
   Thao, LB
   Hara, Y
   Taguchi, T
   Watanabe, T
   Sato, Y
AF Chi, Hoang Thanh
   Vu, Hoang Anh
   Iwasaki, Reo
   Thao, Le Ba
   Hara, Yukihiko
   Taguchi, Takahiro
   Watanabe, Toshiki
   Sato, Yuko
TI Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and
   causes caspase-dependent cell death in gastrointestinal stromal tumor
   including imatinib-resistant cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE GIST-T1; GIST-T1 IR; EGCG; MAPK; AKT
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; COLON-CANCER CELLS;
   C-KIT; (-)-EPIGALLOCATECHIN GALLATE; SIGNALING PATHWAYS; MUTATIONS;
   MESYLATE; EPIGALLOCATECHIN-3-GALLATE; INACTIVATION
AB Imatinib, a selective tyrosine kinase inhibitor, has been used as a
   standard first-line therapy for gastrointestinal stromal tumor (GIST)
   patients. Unfortunately, most patients responding to imatinib will
   eventually exhibit the resistance, the cause of which is not fully
   understood. The serious clinical problems of imatinib-resistance demand
   alternative treatment strategy. (-)-Epigallocatechin- 3-gallate (EGCG),
   a main component of green tea catechin, has been demonstrated potential
   anti-tumor effects on various types of cancer cells. Here, we report
   for the first time that EGCG has shown anti-tumor effects on
   gastrointestinal stromal tumor cell line GIST-T1 by suppressing cell
   proliferation and eventually inducing cell death via caspase-dependent
   pathways. GIST-T1 and imatinib resistant GIST-T1 (GIST-T1 IR) cells
   were used to assess the effects of EGCG. In both cell types, KIT
   activity was completely inhibited after 4 h treatment with 60 mu M
   EGCG. EGCG specifically inhibited activated KIT, which was demonstrated
   by using Ba/F3 cells transfected with human wild-type KIT construct. At
   a dose of 30 mu M EGCG, the KIT activity remains but at more than 40 mu
   M EGCG, the KIT activity was abolished in these transfected-Ba/F3
   cells. Our results suggest that EGCG has a promising potential as a
   natural KIT inhibitor and therefore it could be used as a novel
   therapeutic or preventive reagent for GISTs including the
   imatinib-resistant cases.
C1 [Chi, Hoang Thanh; Vu, Hoang Anh; Iwasaki, Reo; Thao, Le Ba; Sato, Yuko] Res Inst Int Med Ctr Japan, Div Ultrafine Struct, Dept Pathol, Tokyo, Japan.
   [Chi, Hoang Thanh; Iwasaki, Reo; Thao, Le Ba; Watanabe, Toshiki] Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Tokyo, Japan.
   [Hara, Yukihiko] Hara Off Inc, Tea Solut, Sumida Ku, Tokyo, Japan.
   [Taguchi, Takahiro] Kochi Univ, Grad Sch Integrated Arts & Sci, Doctoral Course, Kochi, Japan.
RP Sato, Y, Res Inst Int Med Ctr Japan, Div Ultrafine Struct, Dept Pathol,
   Tokyo, Japan.
EM ysato@ri.imcj.go.jp
FU Japan Foundation for Promotion of International Medical Research
   Co-operation (JF-PIMRC) 
FX This work was supported by the Japan Foundation for Promotion of
   International Medical Research Co-operation (JF-PIMRC).
CR ADACHI S, 2007, CANCER RES, V67, P6493, DOI
   10.1158/0008-5472.CAN-07-0411
   ADHAMI VM, 2004, CANCER RES, V64, P8715
   BAUER S, 2005, INT J CANCER, V117, P316, DOI 10.1002/ijc.21164
   BUCHDUNGER E, 2000, J PHARMACOL EXP THER, V295, P139
   CHEN ZP, 1998, CANCER LETT, V129, P173
   DAGHER R, 2002, CLIN CANCER RES, V8, P3034
   DEBIECRYCHTER M, 2005, GASTROENTEROLOGY, V128, P270, DOI
   10.1053/j.gastro.2004.11.020
   DEGUCHI H, 2002, INT J ONCOL, V21, P1301
   DEMATTEO RP, 2000, ANN SURG, V231, P51
   DEMETRI GD, 2002, NEW ENGL J MED, V347, P472
   DEMETRI GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   GILMORE AP, 2005, CELL DEATH DIFFER S2, V12, P1473, DOI
   10.1038/sj.cdd.4401723
   HEINRICH MC, 2000, BLOOD, V96, P925
   HEINRICH MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190
   HEINRICH MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666
   HEINRICH MC, 2006, J CLIN ONCOL, V24, P4764, DOI
   10.1200/JCO.2006.06.2265
   HIROTA S, 1998, SCIENCE, V279, P577
   HOU Z, 2005, CANCER RES, V65, P8049, DOI 10.1158/0008-5472.CAN-05-0480
   KINDBLOM LG, 1998, AM J PATHOL, V152, P1259
   KOYAMA T, 2006, GASTRIC CANCER, V9, P235
   KROEMER G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   LAMBERT JD, 2008, FREE RADICAL BIO MED, V44, P1069, DOI
   10.1016/j.freeradbiomed.2007.12.016
   LASOTA J, 2008, HISTOPATHOLOGY, V53, P245, DOI
   10.1111/j.1365-2559.2008.02977.x
   LETHAO B, 2009, CANCER BIOL THER, V8, P683
   LIU Y, 2007, CANCER RES, V67, P2685, DOI 10.1158/0008-5472.CAN-06-3497
   MASUDA M, 2001, CLIN CANCER RES, V7, P4220
   NISHIDA T, 2008, CANCER SCI, V99, P799, DOI
   10.1111/j.1349-7006.2008.00727.x
   OIKONOMOU D, 2007, J CANCER RES CLIN, V133, P951, DOI
   10.1007/s00432-007-0238-5
   OKUDA K, 2001, BLOOD, V97, P2440
   SAKURAMA K, 2009, MOL CANCER THER, V8, P127, DOI
   10.1158/1535-7163.MCT-08-0884
   SHAH NP, 2004, SCIENCE, V305, P399
   SHIMIZU M, 2005, CLIN CANCER RES, V11, P2735
   TAGUCHI T, 2002, LAB INVEST, V82, P663
   TUVESON DA, 2001, ONCOGENE, V20, P5054
NR 34
TC 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD OCT 15
PY 2009
VL 8
IS 20
BP 1934
EP 1939
PG 6
SC Oncology
GA 533BB
UT ISI:000272795800009
ER

PT J
AU Yang, C
   Zhu, XY
   Yi, L
   Shi, ZY
   Wang, H
   Hu, YL
   Wang, YP
AF Yang, Chi
   Zhu, Xiangyu
   Yi, Long
   Shi, Zhiyang
   Wang, Hua
   Hu, Yali
   Wang, Yaping
TI Comparative Study of Three PCR-Based Copy Number Variant Approaches,
   CFMSA, M-PCR, and MLPA, in 22q11.2 Deletion Syndrome
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
ID SUBTELOMERIC REARRANGEMENTS; ABNORMALITIES; DISEASE
AB Small submicroscopic DNA copy number variants represent an important
   source of variation in the human genome, human phenotypic diversity,
   and disease susceptibility. Consequently, there is a pressing need for
   the development of methods allowing the efficient, accurate, and cheap
   measurement of genomic copy number polymorphisms in clinical cohorts.
   The PCR-based strategies, being cost-effective and sensitive, are
   considered important in the development of screening techniques.
   PCR-based techniques such as multiplex PCR; multiplex
   ligation-dependent probe amplification; and a new single-tube assay
   technique, the competitive fluorescent multiplex STRP assay, have been
   applied to 22q11.2 detection, a typical example of deletion syndromes.
   In this study, we compared the reliability and application of these
   three techniques in a cohort of 17 patients affected with 22q11.2
   deletion and 300 normal controls. All three techniques shared 100%
   sensitivity; however, the competitive fluorescent multiplex STRP assay
   had the lowest possibility of concurrent false-positive signals from
   two adjoining probes in a genomic region. Moreover, it is a relatively
   fast and low-cost procedure to detect the deletion of 22q11.2 in
   numerous patients with several minor symptoms of deletion syndromes.
   Multiplex PCR, a rapidly developing and cheap technique, allows
   detection of atypical deletions.
C1 [Zhu, Xiangyu; Hu, Yali] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Obstet & Gynecol, Nanjing 210008, Peoples R China.
   [Yang, Chi; Wang, Yaping] Nanjing Univ, Dept Med Genet, Nanjing 210008, Peoples R China.
   [Yang, Chi; Yi, Long] Nanjing Univ, Dept Pathol, Nanjing 210008, Peoples R China.
   [Yang, Chi; Yi, Long; Hu, Yali; Wang, Yaping] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210008, Peoples R China.
   [Shi, Zhiyang; Wang, Hua] Jiangsu Prov Ctr Dis Prevent & Control, Nanjing, Peoples R China.
RP Hu, YL, Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Obstet
   & Gynecol, Nanjing 210008, Peoples R China.
EM yali_hu@hotmail.com
   wangyap@nju.edu.cn
FU Health Foundation of Jiangsu Province [H2006]; Jiangsu Foundation for
   Development [BS2006012]; Medical Science and Technology Development
   Foundation ; Nanjing Department of Health [ZKX06018]
FX This work was supported by the Health Foundation of Jiangsu Province
   (grant number: H2006) and the Jiangsu Foundation for Development (grant
   number: BS2006012), the key project of the Medical Science and
   Technology Development Foundation, Nanjing Department of Health (grant
   number: ZKX06018), and the Foundation for the Jiangsu's Outstanding
   Fellow in Medical Science (grant number: LJ200628).
CR AHN C, 2007, J HIGH ENERGY PHYS, ARTN 021
   BUTLER JM, 2005, METH MOL B, V297, P53
   CARTER NP, 2007, NAT GENET S7, V39, S16, DOI 10.1038/ng2028
   FROHLING S, 2002, J CLIN ONCOL, V20, P2480
   JALALI GR, 2008, HUM MUTAT, V29, P433, DOI 10.1002/humu.20640
   KOBRYNSKI LJ, 2007, LANCET, V370, P1443
   LUPSKI JR, 2007, NAT GENET S7, V39, S43, DOI 10.1038/ng2084
   MONFORT S, 2006, J LAB CLIN MED, V147, P295, DOI
   10.1016/j.lab.2006.01.006
   PIERPONT ME, 2007, CIRCULATION, V115, P3015, DOI
   10.1161/CIRCULATIONAHA.106.183056
   ROOMS L, 2005, HUM MUTAT, V25, P513, DOI 10.1002/humu.20185
   SHAFFER LG, 2007, AM J MED GENET C C, V145, P87, DOI
   10.1002/ajmg.c.30114
   STENSON PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212
   VORSTMAN JAS, 2006, HUM MUTAT, V27, P814, DOI 10.1002/humu.20330
   YANG C, 2009, ELECTROPHORESIS, V30, P465, DOI 10.1002/elps.200800321
NR 14
TC 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
J9 GENET TEST MOL BIOMARK
JI Genet. Test. Mol. Biomark.
PD DEC
PY 2009
VL 13
IS 6
BP 803
EP 808
DI 10.1089/gtmb.2009.0058
PG 6
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 531AC
UT ISI:000272633800017
ER

PT J
AU Mills, DR
   Haskell, MD
   Callanan, HM
   Flanagan, DL
   Brilliant, KE
   Yang, DQ
   Hixson, DC
AF Mills, David R.
   Haskell, Michelle D.
   Callanan, Helen M.
   Flanagan, Donna L.
   Brilliant, Kate E.
   Yang, DongQin
   Hixson, Douglas C.
TI Monoclonal antibody to novel cell surface epitope on Hsc70 promotes
   morphogenesis of bile ducts in newborn rat liver
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Hsc70; Epitope mapping; Cell surface; Cholangiocyte; Bile duct
ID SHOCK COGNATE PROTEIN; NATURAL-KILLER-CELLS; HUMAN TUMOR-CELLS;
   PROGENITOR CELLS; PLASMA-MEMBRANES; UNCOATING ATPASE; EPITHELIAL-CELLS;
   HSP70; EXPRESSION; DIFFERENTIATION
AB We previously described a cell surface reactive monoclonal antibody,
   MAb OC.10, which recognizes an epitope shared by rat fetal liver ductal
   cells, hepatic progenitor cells, mature cholangiocytes, and
   hepatocellular carcinomas (HCC). Here, intrasplenic injection of MAb
   OC.10 into newborn rats was shown by immunofluorescence microscopy to
   strongly label intrahepatic bile ducts. Furthermore, the in situ
   labeling of intrahepatic cholangiocytes by injecting MAb OC.10
   increased the number of intraportal and intralobular bile ducts with
   well-defined lumens when compared to IgM-injected control animals. The
   antigen for MAb OC.10 was identified by mass spectrometry as Hsc70, a
   constitutively expressed heat shock protein belonging to the HSP70
   family. Immunoblot analysis demonstrated that MAb OC.10 reacted with
   recombinant bovine Hsc70 protein, with protein immunoprecipitated from
   rat bile duct epithelial (BDE) cell lysates with monoclonal anti-Hsc70
   antibody, and with Hsc70-FLAG protein over-expressed in human 293T
   cells. In addition, Hsc70-specific small interfering RNA reduced the
   amount of OC.10 antigen expressed in nucleofected BDE cells. Consistent
   with the specificity of MAb OC.10 for Hsc70, heat shock did not induce
   OC.10 expression in BDE cells, a characteristic of Hsp70.
   Immunofluorescence with BDE cells further suggested that MAb OC.10
   binds a novel cell surface epitope of Hsc70. This was in contrast to a
   commercially available monoclonal anti-Hsc70 antibody that showed
   strong cytosolic reactivity. These findings demonstrate that
   presentation of the OC.10 epitope differs between cytosolic and surface
   forms of Hsc70 and may suggest distinct differences in protein
   conformation or epitope availability determined in part by
   protein-protein or protein-lipid interactions. Phage display and
   pepscan analysis mapped the epitope for MAb OC.10 to the N-terminal
   340-384 amino acids of the ATPase domain of rat Hsc70. These findings
   suggest that MAb OC.10 recognizes an epitope on rat Hsc70 when
   presented on the cell surface that promotes morphogenic maturation of
   bile ducts in newborn rat liver. Furthermore, since we have shown
   previously that the OC.10 antigen is expressed on HCC subpopulations
   with oval cell characteristics, our current results indicate that Hsc70
   has the potential to be expressed on the surface of certain tumor cells.
C1 [Mills, David R.] Rhode Isl Hosp, Providence, RI 02903 USA.
   [Mills, David R.; Haskell, Michelle D.; Callanan, Helen M.; Flanagan, Donna L.; Brilliant, Kate E.; Yang, DongQin; Hixson, Douglas C.] Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol & Oncol,Warren Alpert Med Sch, Providence, RI 02903 USA.
RP Mills, DR, Rhode Isl Hosp, George Bldg Room 362,593 Eddy St,
   Providence, RI 02903 USA.
EM David_Mills@Brown.edu
   Douglas_Hixson@Brown.edu
FU National Institutes of Health [CA93840, CA42715, RRP20RR017695];
   National Center for Research Resources (NCRR) [P20RR016457]; National
   Institutes of Health (NIH) 
FX We wish to thank Laura Bangs and Sandy DeAngelis for clerical
   assistance and Dr. James G. Clifton for technical assistance with the
   QSTAR XL mass spectrometry studies. This work was supported by grants
   CA93840, CA42715, and RRP20RR017695 (to D. C. H.) from the National
   Institutes of Health and RI-INBRE Grant P20RR016457 (to D. R. M.) from
   the National Center for Research Resources (NCRR), a component of the
   National Institutes of Health (NIH). Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of NCRR or NIH.
CR ARISPE N, 2000, J BIOL CHEM, V275, P30839
   ARISPE N, 2002, CELL STRESS CHAPERON, V7, P330
   ARISPE N, 2004, FASEB J, V18, P1636, DOI 10.1096/fj.04-2088com
   BISGAARD HC, 1993, MOL CARCINOGEN, V7, P60
   BOTZLER C, 1996, CANCER IMMUNOL IMMUN, V43, P226
   BOTZLER C, 1998, CELL STRESS CHAPERON, V3, P6
   BROQUET AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200
   CLIFTON JG, 2006, J CHROMATOGR A, V1123, P205, DOI
   10.1016/j.chroma.2006.02.020
   COLEMAN WB, 1997, AM J PATHOL, V151, P353
   DABEVA MD, 1997, P NATL ACAD SCI USA, V94, P7356
   DASTOOR Z, 2000, J CELL SCI, V113, P2845
   DAUGAARD M, 2007, FEBS LETT, V581, P3702, DOI
   10.1016/j.febsiet.2007.05.039
   DELAROSA EJ, 1998, P NATL ACAD SCI USA, V95, P9950
   DEMAIO A, 1999, SHOCK, V11, P1
   DUNSFORD HA, 1989, CANCER RES, V49, P4894
   EISENBERG E, 2007, TRAFFIC, V8, P640, DOI
   10.1111/j.1600-0854.2007.00568.x
   ELEFANT F, 1999, MOL BIOL CELL, V10, P2101
   FAN GH, 2002, J BIOL CHEM, V277, P6590
   FERRARINI M, 1992, INT J CANCER, V51, P613
   FISHELSON Z, 2001, INT IMMUNOL, V13, P983
   GEHRMANN M, 2008, PLOS ONE, V3, ARTN e1925
   GORDON GJ, 2000, AM J PATHOL, V157, P771
   HANZALBAYER MF, 2007, FEBS LETT, V581, P2098, DOI
   10.1016/j.febslet.2007.03.019
   HIRAI I, 1998, CELL STRUCT FUNCT, V23, P153
   HIXSON DC, 1997, BILIARY PANCREATIC D, P1
   HIXSON DC, 2000, EXP MOL PATHOL, V68, P152
   KAMIGUCHI K, 2008, MICROBIOL IMMUNOL, V52, P94, DOI
   10.1111/j.1348-0421.2008.00017.x
   KUBOTA H, 2000, P NATL ACAD SCI USA, V97, P12132
   LAWSON EL, 2006, ELECTROPHORESIS, V27, P2747, DOI 10.1002/elps.200600059
   MAYER MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI
   10.1007/s00018-004-4464-6
   MULTHOFF G, 1995, INT J CANCER, V61, P272
   MULTHOFF G, 1997, J IMMUNOL, V158, P4341
   MULTHOFF G, 1999, EXP HEMATOL, V27, P1627
   MULTHOFF G, 2001, CELL STRESS CHAPERON, V6, P337
   NEWMYER SL, 2003, DEV CELL, V4, P929
   NOVIKOFF PM, 1996, AM J PATHOL, V148, P1473
   PATRA SK, 2008, BBA-REV CANCER, V1785, P182, DOI
   10.1016/j.bbcan.2007.11.002
   RAJAPANDI T, 2000, J BIOL CHEM, V275, P22597
   SARRIO S, 2000, MOL CELL BIOL, V20, P5164
   SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723
   SELL S, 1994, LAB INVEST, V70, P6
   SELL S, 1997, RESPONSE INJURY LIVE, P223
   SELL S, 1998, HEPATOLOGY, V27, P317
   SHIN BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200
   SHRIVASTAV A, 2008, J IMMUNOL, V180, P1019
   SIMONS K, 1997, NATURE, V387, P569
   SIMPERRONAN R, 2006, DEVELOPMENT, V133, P4269, DOI 10.1242/dev.02589
   SORGER PK, 1987, EMBO J, V6, P993
   SUZUKI A, 2002, J CELL BIOL, V156, P173
   TATENO C, 1996, AM J PATHOL, V149, P1593
   TAVARIA M, 1996, CELL STRESS CHAPERON, V1, P23
   TRIANTAFILOU K, 2001, NAT IMMUNOL, V2, P338
   TSUBOI N, 1994, HYBRIDOMA, V13, P373
   TSUKAHARA F, 2004, J BIOL CHEM, V279, P8867, DOI 10.1074/jbc.M308848200
   VEGANINEZ E, 1999, MECH DEVELOP, V82, P199
   YANG L, 1993, GASTROENTEROLOGY, V104, P840
   YANG L, 1993, HEPATOLOGY, V18, P357
   ZHOU DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009
NR 58
TC 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
J9 CELL STRESS CHAPERONES
JI Cell Stress Chaperones
PD JAN
PY 2010
VL 15
IS 1
BP 39
EP 53
DI 10.1007/s12192-009-0120-2
PG 15
SC Cell Biology
GA 530CU
UT ISI:000272567300004
ER

PT J
AU Lin, CR
   Yang, LQ
   Tanasa, B
   Hutt, K
   Ju, BG
   Ohgi, K
   Zhang, J
   Rose, DW
   Fu, XD
   Glass, CK
   Rosenfeld, MG
AF Lin, Chunru
   Yang, Liuqing
   Tanasa, Bogdan
   Hutt, Kasey
   Ju, Bong-gun
   Ohgi, Kenny
   Zhang, Jie
   Rose, David W.
   Fu, Xiang-Dong
   Glass, Christopher K.
   Rosenfeld, Michael G.
TI Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie
   Specific Translocations in Cancer
SO CELL
LA English
DT Article
ID CLASS-SWITCH RECOMBINATION; DOUBLE-STRAND BREAKS; PROSTATE-CANCER;
   REGULATED TRANSCRIPTION; L1 RETROTRANSPOSITION; HOMOLOGOUS
   RECOMBINATION; GENOME INSTABILITY; ANDROGEN RECEPTOR; HISTONE H3; GENE
AB Chromosomal translocations are a hallmark of leukemia/lymphoma and also
   appear in solid tumors, but the underlying mechanism remains elusive.
   By establishing a cellular model that mimics the relative frequency of
   authentic translocation events without proliferation selection, we
   report mechanisms of nuclear receptor-dependent tumor translocations.
   Intronic binding of liganded androgen receptor (AR) first juxtaposes
   translocation loci by triggering intra-and interchromosomal
   interactions. AR then promotes site-specific DNA double-stranded breaks
   (DSBs) at translocation loci by recruiting two types of enzymatic
   activities induced by genotoxic stress and liganded AR, including
   activation-induced cytidine deaminase and the LINE-1 repeat-encoded
   ORF2 endonuclease. These enzymes synergistically generate
   site-selective DSBs at juxtaposed translocation loci that are ligated
   by nonhomologous end joining pathway for specific translocations. Our
   data suggest that the confluence of two parallel pathways initiated by
   liganded nuclear receptor and genotoxic stress underlies nonrandom
   tumor translocations, which may function in many types of tumors and
   pathological processes.
C1 [Lin, Chunru; Yang, Liuqing; Tanasa, Bogdan; Ju, Bong-gun; Ohgi, Kenny; Zhang, Jie; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.
   [Hutt, Kasey] Univ Calif San Diego, Sch Med, Bioinformat Grad Program, La Jolla, CA 92093 USA.
   [Rose, David W.; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.
   [Fu, Xiang-Dong; Glass, Christopher K.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Ju, Bong-gun] Sogang Univ, Dept Life Sci, Seoul 121742, South Korea.
RP Rosenfeld, MG, Univ Calif San Diego, Sch Med, Howard Hughes Med Inst,
   9500 Gilman Dr, La Jolla, CA 92093 USA.
EM mrosenfeld@ucsd.edu
FU National Institutes of Health (NIH) [DK39949, DK18477, CA97134,
   NS34934]; Department of Defense (DoD) [00325108]; Prostate Cancer
   Foundation 
FX We thank C. Nelson for various cell culture assistance, J. Hightower
   for artwork, D. Benson for assistance with the manuscript, V. Lunyak
   and X. Zhu for critical comments, M. Schwartz and E. Nunez for
   assistance with fluorescence microscopy and FISH technology, Y. Zhang
   for providing the FLAG-DOT1L construct, M. B. Kastan for providing the
   HA-ER-I-PpoI construct, J. L. Goodier for providing LINE-1 ORF1, ORF2
   constructs, Ankara vaccinia virus that expresses T7 polymerase, and
   polyclonal antibody against ORF2, S. Heinz for providing PIWIL1 and
   PIWIL2 expression constructs, and AstraZeneca for providing Casodex. M.
   G. R. is a Howard Hughes Medical Institute Investigator. This study was
   funded by grants from The National Institutes of Health (NIH; DK39949,
   DK18477, CA97134, NS34934), the Department of Defense (DoD), and
   Prostate Cancer Foundation to M. G. R., and X. D. F., and NIH grants to
   X. D. F. and C. K. G. C. L. is a fellow of Susan G. Komen for the Cure
   (KG080247), and L. Yang is an awardee of Era of Hope Postdoctoral Award
   supported by the DoD (grant 00325108).
CR AGUILERA A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268
   APLAN PD, 2006, TRENDS GENET, V22, P46, DOI 10.1016/j.tig.2005.10.002
   ARAVIN AA, 2007, SCIENCE, V316, P744, DOI 10.1126/science.1142612
   BANERJEE S, 2008, J CELL BIOL, V181, P1083
   BERKOVICH E, 2008, NAT PROTOC, V3, P915, DOI 10.1038/nprot.2008.54
   BOCHKAREV A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI
   10.1016/j.sbi.2004.01.001
   CHAUDHURI J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574
   CHAUDHURI J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395
   CORRAL J, 1996, CELL, V85, P853
   CREMER T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI
   10.1016/j.ceb.2006.04.007
   CRITCHLOW SE, 1998, TRENDS BIOCHEM SCI, V23, P394
   DEININGER MWN, 1998, CANCER RES, V58, P421
   FARKASH EA, 2006, NUCLEIC ACIDS RES, V34, P1196, DOI 10.1093/nar/gkj522
   GOLDBERG AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   GOODIER JL, 2004, HUM MOL GENET, V13, P1041, DOI 10.1093/hmg/ddh118
   GREAVES MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164
   GRUMMT I, 2006, CURR OPIN GENET DEV, V16, P191, DOI
   10.1016/j.gde.2006.02.001
   HEINLEIN CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032
   HOFMANN WA, 2006, J CELL BIOL, V172, P495, PMID 16476772
   HOLZINGER A, 2001, METH MOL B, V161, P109
   HONJO T, 2002, ANNU REV IMMUNOL, V20, P165
   HU Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI
   10.1073/pnas.0810634105
   HUYEN Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   JHUNJHUNWALA S, 2008, CELL, V133, P265, DOI 10.1016/j.cell.2008.03.024
   JU BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196
   KRIVTSOV AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253
   LUCAS J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330
   MALONE CD, 2009, CELL, V137, P522, DOI 10.1016/j.cell.2009.03.040
   METIVIER R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   MUOTRI AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663
   MYUNG K, 2001, NATURE, V411, P1073
   NEVES H, 1999, BLOOD, V93, P1197
   NG HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI
   10.1073/pnas.0437846100
   NIKIFOROVA MN, 2000, SCIENCE, V290, P138
   ODONNELL KA, 2007, CELL, V129, P37, DOI 10.1016/j.cell.2007.03.028
   PENG JC, 2008, CURR OPIN GENET DEV, V18, P204, DOI
   10.1016/j.gde.2008.01.021
   PERISSI V, 2004, CELL, V116, P511
   PRAK NL, 2006, J BIOMED BIOTECHNOL, P37049
   RAI K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042
   RAJEWSKY K, 2008, CURR OPIN IMMUNOL, V20, P127, DOI
   10.1016/j.coi.2008.04.005
   RIZK RS, 2005, CURR BIOL, V15, R841
   ROBBIANI DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062
   ROIX JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177
   SANTOURLIDIS S, 1999, PROSTATE, V39, P166
   SHAFFER DR, 2006, NAT MED, V12, P14
   SHANG YF, 2000, CELL, V103, P843
   SHOGRENKNAAK M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   STAVNEZER J, 2008, ANNU REV IMMUNOL, V26, P261, DOI
   10.1146/annurev.immunol.26.021607.090248
   THOMAS BJ, 1989, CELL, V56, P619
   TOMLINS SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   TOMLINS SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024
   WANG JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966
   WANG Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709
   WANG QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   YI YW, 2000, BIOCHEM BIOPH RES CO, V272, P193
NR 55
TC 51
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD DEC 11
PY 2009
VL 139
IS 6
BP 1069
EP 1083
DI 10.1016/j.cell.2009.11.030
PG 15
SC Biochemistry & Molecular Biology; Cell Biology
GA 530WK
UT ISI:000272622800010
ER

PT J
AU Yang, IV
   Wade, CM
   Kang, HM
   Alper, S
   Rutledge, H
   Lackford, B
   Eskin, E
   Daly, MJ
   Schwartz, DA
AF Yang, Ivana V.
   Wade, Claire M.
   Kang, Hyun Min
   Alper, Scott
   Rutledge, Holly
   Lackford, Brad
   Eskin, Eleazar
   Daly, Mark J.
   Schwartz, David A.
TI Identification of Novel Genes That Mediate Innate Immunity Using Inbred
   Mice
SO GENETICS
LA English
DT Article
ID WHOLE-GENOME ASSOCIATION; TOLL-LIKE RECEPTORS; SALMONELLA-ENTERITIDIS;
   INFLAMMATORY RESPONSE; POPULATION-STRUCTURE; CONGENIC STRAINS;
   HUMAN-DISEASE; LOCI; LIPOPOLYSACCHARIDE; PERSISTENCE
AB Innate immunity is the first line of defense against microbial
   infections. Although polymorphisms in toll-like receptors (TLRs) and
   downstream signaling molecules (CD14, TLR2, TLR4, TLR5, and IRAK4)
   affect the innate immune response, these variants account for only a
   portion of the ability of the host to respond to bacteria, fungi, and
   viruses. To identify other genes involved in the innate immune
   response, we challenged 16 inbred murine strains with
   lipopolysaccharide (LPS) systemically and measured serum concentrations
   of pro-inflammatory cytokines IL-1 beta, IL-6, and TNF alpha, and the
   chemokine KC 6 hr post-treatment. Loci that segregate with strain
   phenotypes were identified by whole genome association (WGA) mapping of
   cytokine concentrations. Published gene expression profiles and
   quantitative trait loci (QTL) were then utilized to prioritize loci and
   genes that potentially regulate the host response to LPS. Sixteen loci
   were selected for further investigation by combining WGA analysis with
   previously published QTL for murine response to LPS or gram negative
   bacteria. Thirty-eight genes within these loci were then selected for
   further investigation on the basis of the significance of the
   identified locus, transcriptional response to LPS, and biological
   plausibility. RNA interference-mediated inhibition of 4 of 38 candidate
   genes was shown to block the production of IL-6 in J774A.1 macrophages.
   In summary, our analysis identified 4 genes that have not previously
   been implicated in innate immunity, namely, 1110058L19Rik,
   4933415F23Rik, Fbxo9, and Ipo7. These genes could represent potential
   sepsis biomarkers or therapeutic targets that should be further
   investigated in human populations.
C1 [Yang, Ivana V.; Schwartz, David A.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
   [Yang, Ivana V.; Alper, Scott; Schwartz, David A.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO 80206 USA.
   [Alper, Scott] Natl Jewish Hlth, Dept Immunol, Denver, CO 80206 USA.
   [Wade, Claire M.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Wade, Claire M.; Daly, Mark J.] MIT, Cambridge, MA 02142 USA.
   [Wade, Claire M.; Daly, Mark J.] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA.
   [Kang, Hyun Min] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA.
   [Rutledge, Holly; Lackford, Brad] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA.
   [Eskin, Eleazar] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90095 USA.
   [Eskin, Eleazar] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA.
RP Yang, IV, Natl Jewish Hlth, Dept Med, 1400 Jackson St,A630, Denver, CO
   80206 USA.
EM yangi@njhealth.org
FU Department of Veterans Affairs ; National Institute of Environmental
   Health Sciences [ES11375, ES011961]; National Institutes of Health,
   National Institute of the Environmental Health Sciences, and National
   Heart, Lung, and Blood Institute 
FX This study was funded by the Department of Veterans Affairs (merit
   review), the National Institute of Environmental Health Sciences
   (ES11375 and ES011961), and the Intramural Research Program of the
   National Institutes of Health, National Institute of the Environmental
   Health Sciences, and National Heart, Lung, and Blood Institute.
CR AKIRA S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   ALPER S, 2008, P NATL ACAD SCI USA, V105, P7016, DOI
   10.1073/pnas.0802405105
   BARON RM, 2006, AM J RESP CELL MOL, V34, P129, DOI 10.1165/rcmb.F308
   BURAS JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   CARON J, 2002, GENES IMMUN, V3, P196
   CARON J, 2005, GENES IMMUN, V6, P500, DOI 10.1038/sj.gene.6364234
   COOK DN, 2004, GENOMICS, V83, P961, DOI 10.1016/j.ygeno.2003.12.008
   COOK DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   DEMAIO A, 1998, SHOCK, V10, P319
   FONG A, 2002, J BIOL CHEM, V277, P22111
   FRAZER KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067
   FULTON WB, 2006, J IMMUNOL, V176, P3767
   GARANTZIOTIS S, 2008, ANNU REV MED, V59, P343, DOI
   10.1146/annurev.med.59.061206.112455
   GRUPE A, 2001, SCIENCE, V292, P1915
   KANG HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101
   LIEW FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630
   LIU PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849
   LORENZ E, 2001, AM J PHYSIOL-LUNG C, V281, L1106
   MATESIC LE, 1999, GENOMICS, V62, P34
   MATESIC LE, 2000, FASEB J, V14, P2247
   MCCLURG P, 2007, GENETICS, V176, P675, DOI 10.1534/genetics.106.066241
   MORTON DB, 1985, VET REC, V116, P431
   PAPATHANASSOGLO.ED, 2006, AACN ADV CRIT CARE, V17, P394
   PLETCHER MT, 2004, PLOS BIOL, V2, P2159, ARTN e393
   PURCELL S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   SEBASTIANI G, 1998, GENOMICS, V47, P180
   SVOBODA P, 2007, CURR OPIN MOL THER, V9, P248
   WADE CM, 2005, NAT GENET, V37, P1175, DOI 10.1038/ng1666
   WALDMANN I, 2007, J BIOL CHEM, V282, P27685, DOI 10.1074/jbc.M703301200
NR 29
TC 1
PU GENETICS SOC AM
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD DEC
PY 2009
VL 183
IS 4
BP 1535
EP 1544
DI 10.1534/genetics.109.107540
PG 10
SC Genetics & Heredity
GA 528HV
UT ISI:000272435000026
ER

PT J
AU Oyama, T
   Yasui, Y
   Sugie, S
   Koketsu, M
   Watanabe, K
   Tanaka, T
AF Oyama, Takeru
   Yasui, Yumiko
   Sugie, Shigeyuki
   Koketsu, Mamoru
   Watanabe, Kunitomo
   Tanaka, Takuji
TI Dietary Tricin Suppresses Inflammation-Related Colon Carcinogenesis in
   Male Crj: CD-1 Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID DEXTRAN SODIUM-SULFATE; BRAN CONSTITUENT TRICIN; CANCER
   CHEMOPREVENTION; RICE BRAN; COLORECTAL-CANCER; FLAVONE TRICIN;
   AZOXYMETHANE; PLASMA; PREVENTION; EXTRACTS
AB The flavone 4',5,7-trihydroxy-3',5'-dimethoxyflavone (tricin) present
   in rice, oats, barley, and wheat exhibits antigrowth activity in
   several human cancer cell lines and anti-inflammatory potential.
   However, the chemopreventive activity has not yet been elucidated in
   preclinical animal models of colorectal cancer. This study was designed
   to determine whether dietary tricin exerts inflammation-associated
   colon carcinogenesis induced by azoxymethane and dextran sulfate sodium
   in mice. Male Crj: CD-1 mice were initiated with a single i.p.
   injection of azoxymethane (10 mg/kg body weight) and followed by a
   1-week exposure to dextran sulfate sodium (1.5%, w/v) in drinking water
   to induce colonic neoplasms. They were then given the experimental diet
   containing 50 or 250 ppm tricin. The experiment was terminated at week
   18 to determine the chemopreventive efficacy of tricin. In addition,
   the effects of dietary tricin on the expression of several inflammatory
   cytokines, including tumor necrosis factor (TNF)-alpha, were assayed.
   The development of colonic adenomas and adenocarcinomas was
   significantly reduced by feeding with 50 and 250 ppm tricin,
   respectively. Dietary tricin also significantly reduced the
   proliferation of adenocarcinoma cells as well as the numbers of
   mitoses/anaphase bridging in adenocarcinoma cells. The dietary
   administration with tricin significantly inhibited the expression of
   TNF-alpha in the nonlesional cypts. Our findings that dietary tricin
   inhibits inflammation-related mouse colon carcinogenesis by suppressing
   the expression of TNF-alpha in the nonlesional cyrpts and the
   proliferation of adenocarcinomas suggest a potential use of tricin for
   clinical trials of colorectal cancer chemoprevention.
C1 [Oyama, Takeru; Yasui, Yumiko; Sugie, Shigeyuki; Tanaka, Takuji] Kanazawa Med Univ, Dept Oncol Pathol, Uchinada, Ishikawa 9200293, Japan.
   [Koketsu, Mamoru] Gifu Univ, Life Sci Res Ctr, Div Instrumental Anal, Gifu, Japan.
   [Watanabe, Kunitomo] Gifu Univ, Life Sci Res Ctr, Div Anaerobe Res, Gifu, Japan.
   [Tanaka, Takuji] Tohkai Cytopathol Inst Canc Res & Prevent, Gifu, Japan.
RP Tanaka, T, Kanazawa Med Univ, Dept Oncol Pathol, 1-1 Daigaku, Uchinada,
   Ishikawa 9200293, Japan.
EM takutt@kanazawa-med.ac.jp
FU Ministry of Health, Labour and Welfare of Japan [18592076, 17015016,
   18880030]; Ministry of Education, Culture, Sports, Science and
   Technology of Japan [H2008-12]
FX Grant-in-Aid for Cancer Research, for the Third-Term Comprehensive
   10-Year Strategy for Cancer Control from the Ministry of Health, Labour
   and Welfare of Japan; Grants-in-Aid grant nos. 18592076 (T. Tanaka),
   17015016 (T. Tanaka), and 18880030 (Y. Yasui) for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan; and grant H2008-12 (T. Tanaka) for the Project Research from
   the High-Technology Center of Kanazawa Medical University.
CR AGGARWAL BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI
   10.1016/j.bcp.2006.02.009
   AGGARWAL BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI
   10.1016/j.bcp.2006.06.029
   ALFAYEZ M, 2006, CANCER CHEMOTH PHARM, V58, P816, DOI
   10.1007/s00280-006-0228-3
   CAI H, 2003, BIOMED CHROMATOGR, V17, P435, DOI 10.1002/bmc.260
   CAI H, 2004, BRIT J CANCER, V91, P1364, DOI 10.1038/sj.bjc.6602124
   CAI H, 2005, BIOMED CHROMATOGR, V19, P518, DOI 10.1002/bmc.473
   CAI H, 2005, MOL CANCER THER, V4, P1287, DOI
   10.1158/1535-7163.MCT-05-0165
   CAI H, 2007, CANCER CHEMOTH PHARM, V60, P257, DOI
   10.1007/s00280-006-0368-5
   CAI H, 2009, BIOMED CHROMATOGR, V23, P335, DOI 10.1002/bmc.1120
   DEVI RR, 2007, FOOD CHEM TOXICOL, V45, P2014, DOI
   10.1016/j.fct.2007.04.020
   DUARTEALMEIDA JM, 2007, PHYTOCHEMISTRY, V68, P1165, DOI
   10.1016/j.phytochem.2007.01.015
   FIORENTINO A, 2008, BIOCHEM SYST ECOL, V36, P691, DOI
   10.1016/j.bse.2008.07.002
   HUDSON EA, 2000, CANCER EPIDEM BIOMAR, V9, P1163
   JANAKIRAM NB, 2008, ACTA PHARMACOL SIN, V29, P1, DOI
   10.1111/j.1745-7254.2008.00742.x
   JEMAL A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   KARIMKOS HE, 2008, EUR J CANCER, V44, P1345, DOI
   10.1016/j.ejca.2007.12.015
   KUWABARA H, 2003, J NAT PROD, V66, P1273, DOI 10.1021/np030020p
   MURTHY NS, 2009, J POSTGRAD MED, V55, P45, DOI 10.4103/0022-3859.43549
   PAN MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   PARK HS, 2007, ARCH PHARM RES, V30, P161
   RAO CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI
   10.1016/j.mrfmmm.2004.05.022
   RAO CV, 2007, ADV EXP MED BIOL, V595, P213
   REDDY BS, 2004, ENVIRON MOL MUTAGEN, V44, P26, DOI 10.1002/em.20026
   REDDY BS, 2005, CURR GASTROENTEROL R, V7, P389
   ROSENBERG DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   RUDOLPH KL, 2001, NAT GENET, V28, P155
   SAKAI A, 2008, ANTIVIR CHEM CHEMOTH, V19, P125
   SETHI G, 2008, FRONT BIOSCI, V13, P5094, DOI 10.2741/3066
   SURH YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   SUZUKI R, 2004, CANCER SCI, V95, P721
   SUZUKI R, 2005, HISTOL HISTOPATHOL, V20, P483
   TANAKA T, 1997, CRIT REV ONCOL HEMAT, V25, P73
   TANAKA T, 2003, CANCER SCI, V94, P965
   TANAKA T, 2006, CURR TOP NUTRACEUT R, V4, P127
   TANAKA T, 2006, INT J CANCER, V118, P25, DOI 10.1002/ijc.21282
   TANAKA T, 2008, CURR TOP NUTRACEUT R, V6, P165
   TANAKA T, 2008, NUTR CANCER S1, V60, P70, DOI 10.1080/01635580802381253
   TANAKA T, 2009, CHEM-BIOL INTERACT, V177, P128, DOI
   10.1016/j.cbi.2008.10.047
   TANAKA T, 2009, J CARCINOG, V8, ARTN 5
   VERSCHOYLE RE, 2006, CANCER CHEMOTH PHARM, V57, P1, DOI
   10.1007/s00280-005-0039-y
   WANG HK, 1998, ADV EXP MED BIOL, V439, P191
   YAMADA Y, 2002, CANCER RES, V62, P6367
   YASUI Y, 2009, CURR ENZYME INHIBITI, V5, P1
NR 43
TC 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD DEC
PY 2009
VL 2
IS 12
BP 1031
EP 1038
DI 10.1158/1940-6207.CAPR-09-0061
PG 8
SC Oncology
GA 528TM
UT ISI:000272469900006
ER

PT J
AU Kambe, A
   Yoshioka, H
   Kamitani, H
   Watanabe, T
   Baek, SJ
   Eling, TE
AF Kambe, Atsushi
   Yoshioka, Hiroki
   Kamitani, Hideki
   Watanabe, Takashi
   Baek, Seung Joon
   Eling, Thomas E.
TI The Cyclooxygenase Inhibitor Sulindac Sulfide Inhibits EP4 Expression
   and Suppresses the Growth of Glioblastoma Cells
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID ACTIVATING TRANSCRIPTION FACTOR-3; BETA SUPERFAMILY MEMBER;
   GENE-EXPRESSION; PROGNOSTIC-SIGNIFICANCE; SP1 PHOSPHORYLATION;
   COLORECTAL-CANCER; INDUCED APOPTOSIS; PROTEIN-KINASE; BREAST-CANCER;
   RECEPTOR
AB EP4 expression in human glioblastoma cells correlates with growth on
   soft agar. The cyclooxygenase inhibitor sulindac sulfide first altered
   specificity protein-1 (Sp-1) and early growth response gene-1
   expression, then increased the expression of nonsteroidal
   anti-inflammatory drug-activated gene 1 and activating transcription
   factor 3, and then decreased EP4 expression. EP4 suppression was
   dependent on blocking the Sp-1 binding sites in the human EP4 promoter.
   Mutation in the Sp-1 sites in EP4 altered the promoter activity and
   abolished sulindac sulfide effects. The inhibitory effect of sulindac
   sulfide on EP4 expression was reversed by PD98059, a mitogen-activated
   protein/extracellular signal-regulated kinase kinase-1/extracellular
   signal-regulated kinase inhibitor. Sp-1 phosphorylation was dependent
   on sulindac sulfide-induced Erk activation. Chromatin
   immunoprecipitation assay confirmed that Sp-1 phosphorylation decreases
   Sp-1 binding to DNA and leads to the suppression of EP4. Inhibition of
   cell growth on soft agar assay was found to be a highly complex process
   and seems to require not only the inhibition of cyclooxygenase activity
   but also increased expression of nonsteroidal anti-inflammatory
   drug-activated gene 1 and activating transcription factor 3 and
   suppression of EP4 expression. Our data suggest that the suppression of
   EP4 expression by sulindac sulfide represents a new mechanism for
   understanding the tumor suppressor activity.
C1 [Kambe, Atsushi; Yoshioka, Hiroki; Eling, Thomas E.] Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Kambe, Atsushi; Yoshioka, Hiroki; Kamitani, Hideki; Watanabe, Takashi] Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurosurg, Tottori 680, Japan.
   [Baek, Seung Joon] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37901 USA.
RP Eling, TE, Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, NIH,
   111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM Eling@niehs.nih.gov
FU NIH, National Institute of Environmental Health Sciences Intramural
   Research Program 
FX NIH, National Institute of Environmental Health Sciences Intramural
   Research Program.
CR BAE MA, 2003, MOL PHARMACOL, V63, P401
   BAEK SJ, 2001, MOL PHARMACOL, V59, P901
   BAEK SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200
   BAEK SJ, 2005, MOL PHARMACOL, V67, P356, DOI 10.1124/mol.104.005108
   BAEK SJ, 2006, PROG LIPID RES, V45, P1, DOI
   10.1016/j.plipres.2005.10.001
   BIGGS JR, 1996, J BIOL CHEM, V271, P901
   BONELLO MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   BOTTONE FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200
   BOTTONE FG, 2005, J PHARMACOL EXP THER, V315, P668, DOI
   10.1124/jpet.089607
   BOTTONE FG, 2005, MOL CANCER THER, V4, P693
   CHANG SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI
   10.1073/pnas.2535911100
   CHIEN EK, 2003, AM J OBSTET GYNECOL, V189, P1501, DOI
   10.1067/S0002-9378(03)000764-6
   CHU SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013
   ELING TE, 2006, J BIOCHEM MOL BIOL, V39, P649
   ERKINHEIMO TL, 2004, CLIN CANCER RES, V10, P538
   FAWCETT TW, 1999, BIOCHEM J 1, V339, P135
   FIEBICH BL, 2001, J NEUROCHEM, V79, P950
   FISCHER C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200
   FOORD SM, 1996, GENOMICS, V35, P182
   HAN SW, 2004, BIOCHEM BIOPH RES CO, V314, P1093, DOI
   10.1016/j.bbrc.2004.01.007
   HAN SW, 2005, J BIOL CHEM, V280, P33240, DOI 10.1074/jbc.M507617200
   HENSON JW, 2006, ARCH NEUROL-CHICAGO, V63, P337
   ISHIBASHI M, 2005, EXP CELL RES, V302, P244, DOI
   10.1016/j.yexer.2004.09.021
   KAMBE A, 2008, BBA-MOL CELL RES, V1783, P1211, DOI
   10.1016/j.bbamcr.2008.01.032
   KARLSEDER J, 1996, MOL CELL BIOL, V16, P1659
   KIM JS, 2005, MOL CANCER THER, V4, P487
   LEE HC, 2005, J CELL BIOCHEM, V94, P597, DOI 10.1002/jcb.20312
   LEE SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268
   LEE SH, 2008, MOL CANCER THER, V7, P3739, DOI
   10.1158/1535-7163.MCT-08-0548
   LEVIN VA, 2006, J NEURO-ONCOL, V78, P85, DOI 10.1007/s11060-005-9062-4
   MILANINIMONGIAT J, 2002, J BIOL CHEM, V277, P20631
   RAZA SM, 2004, CLIN CANCER RES 1, V10, P212
   RISTIMAKI A, 2002, CANCER RES, V62, P632
   SHEEHAN KM, 1999, JAMA-J AM MED ASSOC, V282, P1254
   SHONO T, 2001, CANCER RES, V61, P4375
   SONOSHITA M, 2001, NAT MED, V7, P1048
   TUCKER ON, 1999, CANCER RES, V59, P987
NR 37
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD DEC
PY 2009
VL 2
IS 12
BP 1088
EP 1099
DI 10.1158/1940-6207.CAPR-09-0140
PG 12
SC Oncology
GA 528TM
UT ISI:000272469900012
ER

PT J
AU Guo, QY
   Wang, YN
   Yang, X
   Mao, HP
   Yu, XQ
AF Guo Qunying
   Wang Yaning
   Yang Xiao
   Mao Haiping
   Yu Xueqing
TI Effects of High Glucose on the Expression of VEGF and Its Receptors in
   Rat Peritoneal Mesothelial Cells
SO BLOOD PURIFICATION
LA English
DT Meeting Abstract
C1 [Guo Qunying; Wang Yaning; Yang Xiao; Mao Haiping; Yu Xueqing] Sun Yat Sen Univ, Guangzhou 510275, Guangdong, Peoples R China.
NR 0
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
J9 BLOOD PURIFICAT
JI Blood Purif.
PY 2009
VL 28
IS 4
BP 302
EP 302
PG 1
SC Hematology; Urology & Nephrology
GA 527AP
UT ISI:000272338500021
ER

PT J
AU Wang, XF
   Jin, X
   Wang, XY
   Liu, J
   Feng, JJ
   Yang, QQ
   Mu, WL
   Shi, XJ
   Lu, ZJ
AF Wang, Xiu-Fang
   Jin, Xia
   Wang, Xiaoyan
   Liu, Jing
   Feng, Jingjing
   Yang, QinQing
   Mu, Wenli
   Shi, Xiaojuan
   Lu, Zhanjun
TI Effects of L1-ORF2 fragments on green fluorescent protein gene
   expression
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE gene expression; green fluorescent protein gene; L1-ORF2; transcription
   termination; orientation
ID X-CHROMOSOME INACTIVATION; LINE-1 RETROTRANSPOSON; HUMAN GENOME; L1
   RETROTRANSPOSON; CHAPERONE ACTIVITY; MOBILE ELEMENTS; ORF1 PROTEIN;
   EVOLUTION; MOUSE; CELLS
AB The retrotransposon known as long interspersed nuclear element-1 (L1)
   is 6 kb long, although most L1s in mammalian and other eukaryotic cells
   are truncated. L1 contains two open reading frames, ORF1 and ORF2, that
   code for an RNA-binding protein and a protein with endonuclease and
   reverse transcriptase activities, respectively. In this work, we
   examined the effects of full length L1-ORF2 and ORF2 fragments on green
   fluorescent protein gene (GFP) expression when inserted into the
   pEGFP-C1 vector downstream of GFP. All of the ORF2 fragments in sense
   orientation inhibited GFP expression more than when in antisense
   orientation, which suggests that small ORF2 fragments contribute to the
   distinct inhibitory effects of this ORF on gene expression. These
   results provide the first evidence that different 280-bp fragments have
   distinct effects on the termination of gene transcription, and that
   when inserted in the antisense direction, fragment 280-9 (the 3' end
   fragment of ORF2) induces premature termination of transcription that
   is consistent with the effect of ORF2.
C1 [Wang, Xiu-Fang; Jin, Xia; Wang, Xiaoyan; Liu, Jing; Feng, Jingjing; Yang, QinQing; Mu, Wenli; Shi, Xiaojuan; Lu, Zhanjun] Hebei Med Univ, Dept Genet, Hebei Key Lab Lab Anim, Shijiazhuang 050017, Hebei Province, Peoples R China.
RP Lu, ZJ, Hebei Med Univ, Dept Genet, Hebei Key Lab Lab Anim, 361
   Zhongshan E Rd, Shijiazhuang 050017, Hebei Province, Peoples R China.
EM lslab@hebmu.edu.cn
FU Hebei Province Natural Science Foundation of China [C2008001065]
FX This study was supported by grant C2008001065 from the Hebei Province
   Natural Science Foundation of China.
CR ABRUSAN G, 2008, GENETICS, V178, P573, DOI 10.1534/genetics.106.061861
   ALLEN E, 2003, P NATL ACAD SCI USA, V100, P9940, DOI
   10.1073/pnas.1737401100
   ATHANIKAR JN, 2004, NUCLEIC ACIDS RES, V32, P3846, DOI
   10.1093/nar/gkh698
   BAILEY JA, 2000, P NATL ACAD SCI USA, V97, P6634
   BELANCIO VP, 2006, NUCLEIC ACIDS RES, V34, P1512, DOI 10.1093/nar/gkl027
   BOISSINOT S, 2000, MOL BIOL EVOL, V17, P915
   BURWINKEL B, 1998, J MOL BIOL, V277, P513
   COST GJ, 2002, EMBO J, V21, P5899
   DEININGER PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI
   10.1016/j.gde.2003.10.013
   DEWANNIEUX M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   ERGUN S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200
   FENG QH, 1996, CELL, V87, P905
   GRAHAM T, 2006, J BIOMED BIOTECHNOL, ARTN 75327
   HACKENBERG M, 2005, J MOL EVOL, V60, P365, DOI 10.1007/s00239-004-0197-2
   HAN JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536
   HEDGES DJ, 2005, BIOESSAYS, V27, P785, DOI 10.1002/bies.20268
   KAZAZIAN HH, 1998, NAT GENET, V19, P19
   LANDER ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LYON MF, 2000, P NATL ACAD SCI USA, V97, P6248
   MARTIN SL, 1993, MOL CELL BIOL, V13, P5383
   MARTIN SL, 2001, MOL CELL BIOL, V21, P467
   MARTIN SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003
   MEDSTRAND P, 2002, GENOME RES, V12, P1483, DOI 10.1101/gr.388902
   MORAN JV, 1996, CELL, V87, P917
   MUOTRI AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663
   OKANO K, 2008, APPL ENVIRON MICROB, V74, P1117, DOI 10.1128/AEM.02012-07
   PAVLICEK A, 2001, GENE, V276, P39
   SASSAMAN DM, 1997, NAT GENET, V16, P6
   SCIAMANNA I, 2005, ONCOGENE, V24, P3923
   SHEEN FM, 2000, GENOME RES, V10, P1496
   SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457
   SMIT AFA, 1999, CURR OPIN GENET DEV, V9, P657
   SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718
   WEICHENRIEDER O, 2004, STRUCTURE, V12, P975, DOI
   10.1016/j.str.2004.04.011
   YANG S, 2004, GENOME RES, V14, P517
NR 35
TC 0
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2009
VL 32
IS 4
BP 688
EP 696
PG 9
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 524ZK
UT ISI:000272182700003
ER

PT J
AU Dai, RY
   Chen, Y
   Fu, J
   Dong, LW
   Ren, YB
   Yang, GZ
   Qian, YW
   Cao, J
   Tang, SH
   Yang, SL
   Wang, HY
AF Dai, Rong-Yang
   Chen, Yao
   Fu, Jing
   Dong, Li-Wei
   Ren, Yi-Bin
   Yang, Guang-Zhen
   Qian, You-Wen
   Cao, Jie
   Tang, Shan-Hua
   Yang, Sheng-Li
   Wang, Hong-Yang
TI p28(GANK) inhibits endoplasmic reticulum stress-induced cell death via
   enhancement of the endoplasmic reticulum adaptive capacity
SO CELL RESEARCH
LA English
DT Article
DE p28(GANK); ER stress; UPR; GRP78; apoptosis
ID UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; HUMAN HEPATOCELLULAR-CARCINOMA;
   INDUCED PHOSPHORYLATION; ONCOPROTEIN P28(GANK); REGULATOR GRP78/BIP;
   SIGNALING PATHWAY; TUMOR-DEVELOPMENT; ER CHAPERONE; KINASE
AB It has been shown that oncoprotein p28(GANK), which is consistently
   overexpressed in human hepatocellular carcinoma (HCC), plays a critical
   role in tumorigenesis of HCC. However, the underlying mechanism remains
   unclear. Here, we demonstrated that p28(GANK) inhibits apoptosis in HCC
   cells induced by the endoplasmic reticulum (ER) stress. During ER
   stress, p28(GANK) enhances the unfolded protein response, promotes ER
   recovery from translational repression, and thereby facilitates cell's
   ability to cope with the stress conditions. Furthermore, p28(GANK)
   upregulates glucose-regulated protein 78 (GRP78), a key ER chaperone
   protein, which subsequently enhances the ER folding capacity and
   promotes recovery from ER stress. We also demonstrated that p28(GANK)
   increases p38 mitogen-activated protein kinase and Akt phosphorylation,
   and inhibits nuclear factor kappa B (NF-kappa B) activation under ER
   stress, which in turn contributes to GRP78 upregulation. Taken
   together, our results indicate that p28(GANK) inhibits ER
   stress-induced apoptosis in HCC cells, at least in part, by enhancing
   the adaptive response and GRP78 expression. We propose that p28(GANK)
   has potential implications for HCC progression under the ER stress
   conditions.
C1 [Dai, Rong-Yang; Yang, Sheng-Li; Wang, Hong-Yang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China.
   [Dai, Rong-Yang; Yang, Sheng-Li; Wang, Hong-Yang] Shanghai Jiao Tong Univ, Inst Canc, Shanghai 200032, Peoples R China.
   [Dai, Rong-Yang; Chen, Yao; Fu, Jing; Dong, Li-Wei; Ren, Yi-Bin; Yang, Guang-Zhen; Qian, You-Wen; Cao, Jie; Tang, Shan-Hua; Wang, Hong-Yang] Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China.
RP Wang, HY, Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab
   Oncogenes & Related Genes, Shanghai 200032, Peoples R China.
EM hywangk@vip.sina.com
CR CHEN XX, 2002, CARCINOGENESIS, V23, P123
   CHEN Y, 2007, CELL RES, V17, P1020, DOI 10.1038/cr.2007.99
   DONG DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950
   FERNANDEZ PM, 2000, BREAST CANCER RES TR, V59, P15
   FU XY, 2002, WORLD J GASTROENTERO, V8, P638
   GETHING MJ, 1992, NATURE, V355, P33
   HARDING HP, 1999, NATURE, V397, P271
   HARDING HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI
   10.1146/annurev.cellbio.18.011402.160624
   HENDERSHOT LM, 2004, MT SINAI J MED, V71, P289
   HIGASHITSUJI H, 2005, CANCER CELL, V8, P75, DOI
   10.1016/j.ccr.2005.06.006
   HIGASHITSUJI H, 2007, BIOCHEM BIOPH RES CO, V363, P879, DOI
   10.1016/j.bbrc.2007.09.072
   HORI T, 1998, GENE, V216, P113
   HU P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200
   HU P, 2006, MOL CELL BIOL, V26, P3071, DOI
   10.1128/MCB.26.8.3071-3084.2006
   IWAI A, 2003, J GASTROENTEROL, V38, P751, DOI 10.1007/s00535-003-1141-8
   JAMORA C, 1996, P NATL ACAD SCI USA, V93, P7690
   KAUFMAN RJ, 1999, GENE DEV, V13, P1211
   KENNEDY SG, 1997, GENE DEV, V11, P701
   KIM I, 2009, J BIOL CHEM, V284, P1593, DOI 10.1074/jbc.M807308200
   KYOKANE T, 2000, NAT MED, V6, P96
   LEE AS, 2001, TRENDS BIOCHEM SCI, V26, P504
   LEE AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   LI HH, 2005, GASTROENTEROLOGY, V128, P2029, DOI
   10.1053/j.gastro.2005.03.001
   LI JZ, 2006, CURR MOL MED, V6, P45
   LIN JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   LUO S, 2002, BIOCHEM J 3, V366, P787, DOI 10.1042/BJ20011802
   MA YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   MARCINIAK SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   MORI K, 2000, CELL, V101, P451
   NISHITOH H, 2002, GENE DEV, V16, P1345
   NOVOA I, 2003, EMBO J, V22, P1180
   NOZAKI S, 2001, ONCOGENE, V20, P2178
   PYRKO P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   RANGANATHAN AC, 2006, CANCER RES, V66, P1702, DOI
   10.1158/0008-5472.CAN-05-3092
   RON D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   RUTKOWSKI DT, 2004, TRENDS CELL BIOL, V14, P20, DOI
   10.1016/j.tcb.2003.11.001
   SCHAPANSKY J, 2007, EXP NEUROL, V208, P169, DOI
   10.1016/j.expneurol.2007.04.009
   SCHRODER M, 2005, ANNU REV BIOCHEM, V74, P739, DOI
   10.1146/annurev.biochem.73.011303.074134
   SCHRODER M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI
   10.1016/j.mrfmmm.2004.06.056
   SHUDA M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1
   SONG MS, 2001, CANCER RES, V61, P8322
   SOUTHWOOD CM, 2002, NEURON, V36, P585
   URANO F, 2000, SCIENCE, V287, P664
   WANG XZ, 1996, SCIENCE, V272, P1347
   YAMAMOTO K, 2007, DEV CELL, V13, P365
   YOSHIDA H, 2001, MOL CELL BIOL, V21, P1239
   ZINSZNER H, 1998, GENE DEV, V12, P982
NR 47
TC 4
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD NOV
PY 2009
VL 19
IS 11
BP 1243
EP 1257
DI 10.1038/cr.2009.104
PG 15
SC Cell Biology
GA 524LU
UT ISI:000272145600005
ER

PT J
AU Wu, YR
   Deng, ZY
   Lai, JB
   Zhang, YY
   Yang, CP
   Yin, BJ
   Zhao, QZ
   Zhang, L
   Li, Y
   Yang, CW
   Xie, Q
AF Wu, Yaorong
   Deng, Zhiyong
   Lai, Jianbin
   Zhang, Yiyue
   Yang, Cuiping
   Yin, Bojiao
   Zhao, Qingzhen
   Zhang, Ling
   Li, Yin
   Yang, Chengwei
   Xie, Qi
TI Dual function of Arabidopsis ATAF1 in abiotic and biotic stress
   responses
SO CELL RESEARCH
LA English
DT Article
DE abiotic stress; Arabidopsis; ATAF1; biotic stress
ID NAC TRANSCRIPTION FACTORS; LATERAL ROOT DEVELOPMENT; ABSCISIC-ACID;
   DEFENSE RESPONSES; REACTIVE OXYGEN; OXIDATIVE STRESS; CELL-DEATH; E3
   LIGASE; GENE; PROTEIN
AB NAC family genes encode plant-specific transcription factors involved
   in diverse biological processes. In this study, the Arabidopsis NAC
   gene ATAF1 was found to be induced by drought, high-salinity, abscisic
   acid (ABA), methyl jasmonate, mechanical wounding, and Botrytis cinerea
   infection. Significant induction of ATAF1 was found in an ABA-deficient
   mutant aba2 subjected to drought or high salinity, revealing an
   ABA-independent mechanism of expression. Arabidopsis
   ATAF1-overexpression lines displayed many altered phenotypes, including
   dwarfism and short primary roots. Furthermore, in vivo experiments
   indicate that ATAF1 is a bona fide regulator modulating plant responses
   to many abiotic stresses and necrotrophic-pathogen infection.
   Overexpression of ATAF1 in Arabidopsis increased plant sensitivity to
   ABA, salt, and oxidative stresses. Especially, ATAF1 overexpression
   plants, but not mutant lines, showed remarkably enhanced plant
   tolerance to drought. Additionally, ATAF1 overexpression enhanced plant
   susceptibility to the necrotrophic pathogen B. cinerea, but did not
   alter disease symptoms caused by avirulent or virulent strains of P.
   syringae pv tomato DC3000. Transgenic plants overexpressing ATAF1 were
   hypersensitive to oxidative stress, suggesting that reactive oxygen
   intermediates may be related to ATAF1-mediated signaling in response to
   both pathogen and abiotic stresses.
C1 [Wu, Yaorong; Lai, Jianbin; Zhang, Yiyue; Yin, Bojiao; Zhao, Qingzhen; Xie, Qi] Chinese Acad Sci, Inst Genet & Dev Biol, Natl Ctr Plant Gene Res, State Key Lab Plant Genom, Beijing 100101, Peoples R China.
   [Deng, Zhiyong; Lai, Jianbin; Zhang, Yiyue; Yang, Cuiping; Yin, Bojiao; Zhang, Ling; Li, Yin; Yang, Chengwei; Xie, Qi] Sun Yat Sen Zhongshan Univ, Sch Life Sci, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.
RP Xie, Q, Chinese Acad Sci, Inst Genet & Dev Biol, Natl Ctr Plant Gene
   Res, State Key Lab Plant Genom, Datun Rd, Beijing 100101, Peoples R
   China.
EM qxie@genetics.ac.cn
FU National Natural Science Foundation of China
   [30530400/90717006/30670195]; Chinese Academy of Science
   [KSCX2-YW-N-010, CXTD-S2005-2]; Guangdong Natural Science Foundation,
   China [5300648]
FX We would like to thank Dr Nam-Hai Chua (Rockefeller University) for
   kindly providing the pBA002Myc vector and the Arabidopsis Biological
   Resource Center (ABRC), Ohio State University for providing T-DNA
   insertion lines. This work was supported by grants from National
   Natural Science Foundation of China (No. 30530400/90717006/30670195) to
   Q Xie and Y Wu, the Chinese Academy of Science (KSCX2-YW-N-010 and
   CXTD-S2005-2), and the Guangdong Natural Science Foundation, China (No.
   5300648) to Z Deng.
CR ABUQAMAR S, 2006, PLANT J, V48, P28, DOI
   10.1111/j.1365-313X.2006.02849.x
   APEL K, 2004, ANNU REV PLANT BIOL, V55, P373
   BU QY, 2008, CELL RES, V18, P756, DOI 10.1038/cr.2008.53
   CHEONG YH, 2002, PLANT PHYSIOL, V129, P661
   COLLINGE M, 2001, PLANT MOL BIOL, V46, P521
   DAVLETOVA S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254
   DELESSERT C, 2005, PLANT J, V43, P745, DOI
   10.1111/j.1365-313X.2005.02488.x
   DOMBRECHT B, 2007, PLANT CELL, V19, P2225, DOI 10.1105/tpc.106.048017
   FINKELSTEIN RR, 2000, PLANT CELL, V12, P599
   FUJITA M, 2004, PLANT J, V39, P863, DOI 10.1111/j.1365-313X.2004.02171.x
   FUJITA M, 2006, CURR OPIN PLANT BIOL, V9, P436, DOI
   10.1016/j.pbi.2006.05.014
   GLAZEBROOK J, 2005, ANNU REV PHYTOPATHOL, V43, P205, DOI
   10.1146/annurev.phyto.43.040204.135923
   GOVRIN EM, 2000, CURR BIOL, V10, P751
   GUO YF, 2006, PLANT J, V46, P601, DOI 10.1111/j.1365-313X.2006.02723.x
   HE XJ, 2005, PLANT J, V44, P903, DOI 10.1111/j.1365-313X.2005.02575.x
   HIBARA K, 2003, PLANT J, V36, P687, DOI 10.1046/j.1365-313X.2003.01911.x
   HU HH, 2006, P NATL ACAD SCI USA, V103, P12987, DOI
   10.1073/pnas.0604882103
   ISHIDA T, 2000, PLANT CELL PHYSIOL, V41, P60
   JENSEN MK, 2007, PLANT MOL BIOL, V65, P137, DOI
   10.1007/s11103-007-9204-5
   JENSEN MK, 2008, PLANT J, V56, P867, DOI
   10.1111/j.1365-313X.2008.03646.x
   KANG JY, 2002, PLANT CELL, V14, P343
   KAZAN K, 1998, MOL PLANT MICROBE IN, V11, P555
   LAURIEBERRY N, 2006, MOL PLANT MICROBE IN, V19, P789, DOI
   10.1094/MPMI-19-0789
   LEONKLOOSTERZIEL KM, 1996, PLANT J, V10, P655
   LORENZO O, 2004, PLANT CELL, V16, P1938, DOI 10.1105/tpc.022319
   LU PL, 2007, PLANT MOL BIOL, V63, P289, DOI 10.1007/s11103-006-9089-8
   MAUCHMANI B, 2005, CURR OPIN PLANT BIOL, V8, P409, DOI
   10.1016/j.pbi.2005.05.015
   MENGISTE T, 2003, PLANT CELL, V15, P2551, DOI 10.1105/tpc.014167
   MITTLER R, 2002, TRENDS PLANT SCI, V7, P405
   MURATA Y, 2001, PLANT CELL, V13, P2513
   NAKASHIMA K, 1997, PLANT J, V12, P851
   NAKASHIMA K, 2007, PLANT J, V51, P617, DOI
   10.1111/j.1365-313X.2007.03168.x
   NATON B, 1996, PLANT PHYSIOL, V112, P433
   OHNISHI T, 2005, GENES GENET SYST, V80, P135
   SCHENK PM, 2000, P NATL ACAD SCI USA, V97, P11655
   SEKI M, 2002, PLANT J, V31, P279
   SELTH LA, 2005, PLANT CELL, V17, P311, DOI 10.1105/tpc.104.027235
   SIMPSON SD, 2003, PLANT J, V33, P259
   TORRES MA, 2005, CURR OPIN PLANT BIOL, V8, P397, DOI
   10.1016/j.pbi.2005.05.014
   TRAN LSP, 2004, PLANT CELL, V16, P2481, DOI 10.1105/tpc.104.022699
   XIE Q, 1999, PLANT MOL BIOL, V39, P647
   XIE Q, 2000, GENE DEV, V14, P3024
   ZHANG XR, 2005, GENE DEV, V19, P1532, DOI 10.1101/gad.1318705
   ZHANG YY, 2007, PLANT CELL, V19, P1912, DOI 10.1105/tpc.106.048488
   ZHENG XN, 2009, BIOCHEM BIOPH RES CO, V379, P985, DOI
   10.1016/j.bbrc.2008.12.163
NR 45
TC 6
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD NOV
PY 2009
VL 19
IS 11
BP 1279
EP 1290
DI 10.1038/cr.2009.108
PG 12
SC Cell Biology
GA 524LU
UT ISI:000272145600008
ER

PT J
AU Cai, YQ
   Yang, YH
   Shen, MH
   Zhou, TH
AF Cai, Yuqi
   Yang, Yuehong
   Shen, Minhong
   Zhou, Tianhua
TI Inhibition of cytokinesis by overexpression of NudCL that is localized
   to the centrosome and midbody
SO CELL RESEARCH
LA English
DT Letter
ID PROTEIN; MICROTUBULES
C1 [Cai, Yuqi; Yang, Yuehong; Shen, Minhong; Zhou, Tianhua] Zhejiang Univ, Sch Med, Dept Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China.
   [Cai, Yuqi; Yang, Yuehong; Shen, Minhong; Zhou, Tianhua] Zhejiang Univ, Sch Med, Ctr Dis Modeling, Hangzhou 310058, Zhejiang, Peoples R China.
RP Zhou, TH, Zhejiang Univ, Sch Med, Dept Cell Biol, Hangzhou 310058,
   Zhejiang, Peoples R China.
EM tzhou@zju.edu.cn
CR AUMAIS JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412
   GLOTZER M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609
   GROMLEY A, 2005, CELL, V123, P75
   GUERTIN DA, 2002, MICROBIOL MOL BIOL R, V66, P155
   LIN SH, 2004, ONCOGENE, V23, P2499, DOI 10.1038/sj.onc.1207343
   PIEL M, 2001, SCIENCE, V291, P1550
   SAXTON WM, 1987, J CELL BIOL, V105, P875
   SKOP AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931
   STRAIGHT AF, 2000, CURR BIOL, V10, R760
   ZHOU T, 2003, DEV CELL, V5, P127
   ZHOU TH, 2006, P NATL ACAD SCI USA, V103, P9039, DOI
   10.1073/pnas.0602916103
NR 11
TC 1
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD NOV
PY 2009
VL 19
IS 11
BP 1305
EP 1308
DI 10.1038/cr.2009.118
PG 4
SC Cell Biology
GA 524LU
UT ISI:000272145600010
ER

PT J
AU Jasmin, JF
   Yang, M
   Iacovitti, L
   Lisanti, MP
AF Jasmin, Jean-Francois
   Yang, Ming
   Iacovitti, Lorraine
   Lisanti, Michael P.
TI Genetic ablation of caveolin-1 increases neural stem cell proliferation
   in the subventricular zone (SVZ) of the adult mouse brain
SO CELL CYCLE
LA English
DT Article
DE neural stem cells; caveolin gene family; subventricular zone;
   proliferation
ID DENTATE GYRUS; HUNTINGTONS-DISEASE; RAT HIPPOCAMPUS; GENERATED NEURONS;
   PROTEIN-COMPONENT; MEMBRANE DOMAINS; CHAIN MIGRATION; PLASMA-MEMBRANE;
   SHOW EVIDENCE; IN-VIVO
AB Adult neural stem cells are self-renewing multipotent cells that have
   the potential to replace dysfunctional and/or dying neuronal cells at
   the site of brain injury or degeneration. Caveolins are well-known
   tumor-suppressor genes that were recently found to be involved in the
   regulation of stem cell proliferation. For instance, ablation of the
   caveolin-1 (Cav-1) gene in mice markedly increases the proliferation of
   intestinal and mammary stem cells. However, the roles of caveolins in
   the proliferation of adult neural stem cells still remain unknown. In
   this study, dual-label immunofluorescence analysis of the proliferation
   marker, Ki67, and the stem cell markers, nestin and Sox2, was performed
   on brains of 8 week-old wild-type (WT) and Cav-1 knockout (KO) mice.
   Our results demonstrate an increased number of Ki67-positive nuclei in
   the subventricular zone (SVZ) of Cav-1 KO brains. Importantly, our
   dual-label immunofluorescence analyses demonstrate increased
   co-localization of Ki67 with both nestin and Sox2 in the SVZ of Cav-1
   KO brains. Remarkably similar results were also obtained with Cav-2 and
   Cav-3 KO mouse brains as well, with increased proliferation of adult
   neural stem cells. Thus, the SVZ of caveolin KO mouse brains displays
   an increased proliferation of adult neural stem cells. Caveolin
   proteins might represent new crucial regulators of adult neural stem
   cell proliferation.
C1 [Jasmin, Jean-Francois; Lisanti, Michael P.] Thomas Jefferson Univ, Dept Stem Cell Biol & Regenerat Med, Philadelphia, PA 19107 USA.
   [Jasmin, Jean-Francois; Lisanti, Michael P.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.
   [Lisanti, Michael P.] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Jasmin, Jean-Francois; Iacovitti, Lorraine; Lisanti, Michael P.] Thomas Jefferson Univ, Jefferson Stem Cell Biol & Regenerat Med Ctr, Philadelphia, PA 19107 USA.
   [Yang, Ming; Iacovitti, Lorraine] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
   [Iacovitti, Lorraine] Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA.
RP Jasmin, JF, Thomas Jefferson Univ, Dept Stem Cell Biol & Regenerat Med,
   Philadelphia, PA 19107 USA.
EM jeanfrancois.jasmin@jefferson.edu
   mlisanti@mail.jci.tju.edu
FU NIH [R01-CA098779, R01-CA120876]
FX This work was supported by NIH grants (R01-CA098779 and R01-CA120876)
   to M.P.L. and a Hassel Foundation Award to L.I.
CR ABERG MAI, 2000, J NEUROSCI, V20, P2896
   ALTMAN J, 1962, EXP NEUROL, V5, P302
   ARVIDSSON A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747
   CAMERON HA, 1993, NEUROSCIENCE, V56, P337
   CAMPOS LS, 2006, J BIOL CHEM, V281, P5300, DOI 10.1074/jbc.M511886200
   CAO L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395
   COHEN AW, 2003, AM J PHYSIOL-CELL PH, V284, P457
   COHEN AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physre.00046.2003
   CREWS FT, 2003, ALCOHOL CLIN EXP RES, V27, P324, DOI
   10.1097/01.ALC.0000042581.46630.C5
   CURTIS MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science1136281
   ENGELMAN JA, 1998, FEBS LETT, V428, P205
   ERIKSSON PS, 1998, NAT MED, V4, P1313
   GALBIATI F, 1998, P NATL ACAD SCI USA, V95, P10257
   GALBIATI F, 2001, MOL BIOL CELL, V12, P2229
   GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517
   GOULD E, 1999, NAT NEUROSCI, V2, P260
   GUZMANMARIN R, 2005, EUR J NEUROSCI, V22, P2111, DOI
   10.1111/j.1460-9568.2005.04376.x
   IKEZU T, 1998, BRAIN RES, V804, P177
   IMAMURA O, 2008, STEM CELLS, V26, P3247, DOI 10.1634/stemcells.2008-0578
   JACOBS BL, 2000, MOL PSYCHIATR, V5, P262
   JIN KL, 2001, P NATL ACAD SCI USA, V98, P4710
   JIN KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010
   JIN KL, 2005, P NATL ACAD SCI USA, V102, P18189, DOI
   10.1073/pnas.0506375102
   KEMPERMANN G, 1997, NATURE, V386, P493
   KOGA A, 2003, HYPERTENSION, V42, P213, DOI
   10.1161/01.HYP.0000082926.08268.5D
   KORNACK DR, 2001, P NATL ACAD SCI USA, V98, P4752
   KUHN HG, 1996, J NEUROSCI, V16, P2027
   KULKARNI VA, 2002, EUR J NEUROSCI, V16, P2008, DOI
   10.1046/j.1460-9568.2002.02268.x
   LI JW, 2005, CELL CYCLE, V4, P1817
   LISANTI MP, 1994, TRENDS CELL BIOL, V4, P231
   LOIS C, 1996, SCIENCE, V271, P978
   LUSKIN MB, 1993, NEURON, V11, P173
   MA DK, 2009, MOL BRAIN, V2, P16
   MALBERG JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI
   10.1038/sj.npp.1300234
   MARKAKIS EA, 1999, J COMP NEUROL, V406, P449
   MCDERMOTT KW, 1991, J ANAT, V178, P45
   MEISSNER KK, 2005, BRAIN RES, V1057, P105, DOI
   10.1016/j.brainres.2005.07.057
   MOHAPEL P, 2005, NEUROBIOL AGING, V26, P939, DOI
   10.1016/j.neurobiolaging.2004.07.015
   NIXON K, 2002, J NEUROCHEM, V83, P1087
   OKAMOTO T, 1998, J BIOL CHEM, V273, P5419
   RA SM, 2002, NEUROSCI LETT, V333, P123
   RAZANI B, 2000, J CELL SCI, V113, P2103
   RAZANI B, 2001, J BIOL CHEM, V276, P38121
   RAZANI B, 2002, MOL CELL BIOL, V22, P2329
   REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1
   ROTHBERG KG, 1992, CELL, V68, P673
   SANAI N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301
   SCHERER PE, 1996, P NATL ACAD SCI USA, V93, P131
   SCHERER PE, 1997, J BIOL CHEM, V272, P29337
   SONG KS, 1996, J BIOL CHEM, V271, P9690
   SOTGIA F, 2005, CELL CYCLE, V4, P1808
   SOTGIA F, 2009, AM J PATHOL, V174, P613, DOI 10.2353/ajpath.2009.080653
   TAKAHASHI K, 2008, BRAIN RES, V1234, P172, DOI
   10.1016/j.brainres.2008.07.086
   TANG ZL, 1996, J BIOL CHEM, V271, P2255
   TATTERSFIELD AS, 2004, NEUROSCIENCE, V127, P319, DOI
   10.1016/j.neuroscience.2004.04.061
   THORED P, 2006, STEM CELLS, V24, P739
   VANPRAAG H, 1999, NAT NEUROSCI, V2, P266
   VAZEY EM, 2006, EXP NEUROL, V199, P384, DOI
   10.1016/j.expneurol.2006.01.034
   WOODMAN SE, 2002, J BIOL CHEM, V277, P38988, DOI 10.1074/jbc.M205511200
   XUAN AG, 2008, NEUROSCI LETT, V440, P331, DOI
   10.1016/j.neulet.2008.05.107
   YOSHIMURA S, 2001, P NATL ACAD SCI USA, V98, P5874
   ZHANG RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI
   10.1097/01.WCB.000014701.97890.3B
NR 62
TC 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD DEC 1
PY 2009
VL 8
IS 23
BP 3978
EP 3983
PG 6
SC Cell Biology
GA 525MD
UT ISI:000272219200037
ER

PT J
AU Visser, S
   Yang, XL
AF Visser, Stacy
   Yang, Xiaolong
TI Identification of LATS transcriptional targets in HeLa cells using
   whole human genome oligonucleotide microarray
SO GENE
LA English
DT Article
DE LATS1; LATS2; Microarray; Tumor suppressor; Cell proliferation;
   Apoptosis; Cell migration
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; DROSOPHILA TUMOR-SUPPRESSOR;
   DOWN-REGULATION; HIPPO PATHWAY; PROMOTER HYPERMETHYLATION; HUMAN
   HOMOLOG; CONTACT INHIBITION; NEGATIVE REGULATOR; PROTEIN-KINASE;
   GROWTH-CONTROL
AB Human LATS1 and LATS2) (LATS1/2) are tumor suppressors that have been
   shown to be mutated or downregulated in several human cancers including
   leukemia, lung, prostate and breast cancers. However, the precise
   mechanisms and the proteins modulated by LATS1/2 that are responsible
   for these events remain largely unknown. To elucidate potential
   signaling pathways, the current study investigated the expression
   profile in HeLa cells with reduced expression of LATS1/2. Using
   RNA-mediated interference, both LATS1 and LATS2 were substantially
   knocked-down, and accordingly, this lead to an increase in multiple
   phenotypes associated with tumor progression, including enhanced cell
   proliferation, resistance to drug-induced cell death, and increased
   cell migration. Using whole human genome Oligo (60-met) arrays
   (Agilent), genes modulated by loss of LATS1/2 were identified and
   functionally grouped into categories including cell proliferation, cell
   death, cell adhesion and motility, as well as cell communication.
   Selected genes, including known tumor suppressor genes and oncogenes
   such as CDKN1A, WISP2, SLIT2, TP53INP1, BIRC4BP, SPRY2, SPRY4, SPRED1,
   FAT4, and CYR61 were confirmed by qRT-PCR to be significantly
   differentially expressed. Importantly, the collection of genes
   identified suggests that LATS1/2 function through diverse mechanisms
   and multiple signaling pathways including the Hippo signaling pathway,
   as well as the p53. Ras-ERK, or WNT networks, to inhibit tumor
   progression. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Visser, Stacy; Yang, Xiaolong] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.
RP Yang, XL, Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6,
   Canada.
EM yang@cliff.path.queensu.ca
FU Canadian Institute of Health Research (CIHR) [77726]; Ontario Ministry
   of Research and Innovation, Canada ; Queen's University, Canada 
FX We would like to thank Yawei Hao for technical support, Dr. Harriet
   Feilotter for microarray design, Hong Guo for performing the microarray
   experiments, Dr. David Lillicrap for use of ABI Prism 7700 Sequence
   Detection System, and Babak Rashidi for aiding with analysis of the
   microarray experiments. This work was supported by Canadian Institute
   of Health Research (CIHR #77726), a New Investigator Award from
   Canadian Institute of Health Research (CIHR), and an Early Researcher
   Award from Ontario Ministry of Research and Innovation, Canada, to
   Xiaolong Yang, as well as the Dr. Robert John Wilson Fellowship from
   Queen's University, Canada, to Stacy Visser.
CR ABE Y, 2006, FEBS LETT, V580, P782, DOI 10.1016/j.febslet.2005.12.096
   AYLON Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006
   BOTHOS J, 2005, CANCER RES, V65, P6568
   BUNDSCHU K, 2007, BIOESSAYS, V29, P897, DOI 10.1002/bies.20632
   CABRITA MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1
   CHAN SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696
   DHILLON AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   ELDEIRY WS, 1993, CELL, V75, P817
   EVAN GI, 2001, NATURE, V411, P342
   GALLETTI E, 2007, CHEMMEDCHEM, V2, P920, DOI 10.1002/cmdc.200600308
   GILES RH, 2003, BBA-REV CANCER, V1653, P1, DOI
   10.1016/S0304-419X(03)00005-2
   HANAHAN D, 2000, CELL, V100, P57
   HAO YW, 2008, J BIOL CHEM, V283, P5496
   HISAOKA M, 2002, LAB INVEST, V82, P1427, DOI
   10.1097/01.LAB.0000032381.68634.CA
   HORI T, 2000, ONCOGENE, V19, P3101
   IIDA S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623
   JIANG Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006
   JIMENEZVELASCO A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974
   JORDAN MA, 1996, CANCER RES, V56, P816
   KAMIKUBO Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200
   KASSIS J, 2001, SEMIN CANCER BIOL, V11, P105
   KAWAHARA M, 2008, BLOOD, V112, P3856, DOI 10.1182/blood-2007-09-111773
   KE HN, 2004, EXP CELL RES, V298, P329, DOI 10.1016/j.yexcr.2004.04.031
   KIM HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   LAU YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190
   LEASK A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270
   LEI QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07
   LI YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603
   LO TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032
   MCPHERSON JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371
   MIKELADZEDVALI T, 2005, CELL, V122, P775, DOI 10.1016/j.cell.2005.07.026
   OKAMURA S, 2001, MOL CELL, V8, P85
   OTA M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   OVERHOLTZER M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI
   10.1073/pnas.0605579103
   PELLOCK BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021
   POWZANIUK M, 2004, MOL ENDOCRINOL, V18, P2011, DOI 10.1210/me.2004-0065
   ROMANGOMEZ J, 2004, BLOOD, V104, P2492
   SAUCEDO LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221
   STJOHN MAR, 1999, NAT GENET, V21, P182
   STRAZISAR M, 2009, LUNG CANCER, V64, P257, DOI
   10.1016/j.lungcan.2008.09.011
   TAKAHASHI Y, 2005, CLIN CANCER RES, V11, P1380
   TAO WF, 1999, NAT GENET, V21, P177
   TOJI S, 2004, GENES CELLS, V9, P383, DOI
   10.1111/j.1365-9597.2004.00732.x
   XIA H, 2002, ONCOGENE, V21, P1233
   XU TA, 1995, DEVELOPMENT, V121, P1053
   YABUTA N, 2000, GENOMICS, V63, P263
   YABUTA N, 2007, J BIOL CHEM, V282, P19259, DOI 10.1074/jbc.M608562200
   YAMAZAKI D, 2005, CANCER SCI, V96, P379, DOI
   10.1111/j.1349-7006.2005.00062.x
   YANG XL, 2001, ONCOGENE, V20, P6516
   YANG XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140
   ZHANG JM, 2008, CANCER RES, V68, P2789, DOI
   10.1158/0008-5472.CAN-07-6205
   ZHAO B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   ZHAO B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI
   10.1016/j.ceb.2008.10.001
   ZHAO B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
NR 54
TC 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JAN 1
PY 2010
VL 449
IS 1-2
BP 22
EP 29
DI 10.1016/j.gene.2009.09.008
PG 8
SC Genetics & Heredity
GA 523JA
UT ISI:000272067900003
ER

PT J
AU Wang, N
   Sang, XC
   Li, YF
   Ling, YH
   Zhao, FM
   Yang, ZL
   He, GH
AF Wang, Nan
   Sang, Xian-Chun
   Li, Yun-Feng
   Ling, Ying-Hua
   Zhao, Fang-Ming
   Yang, Zheng-Lin
   He, Guang-Hua
TI Gene Mapping and Expression Analysis of a Novel Mutant reproduce organs
   absent (roa) in Rice
SO GENES & GENOMICS
LA English
DT Article
DE rice (Oryza sativa L.); flower mutant; gene mapping; ABCE model
ID MADS-BOX GENES; FLORAL ORGAN; FLOWER DEVELOPMENT; ORYZA-SATIVA;
   IDENTITY; ARABIDOPSIS; CONSERVATION; OSMADS1
AB Mutant plays an important role in function analysis in plant. A rice
   flower mutant reproduce organs absent (roa), showing a stable
   inheritance during several years of study, was identified in rice
   (Oryza sativa L. ssp. Indica) cultivar Jinhui10 treated with EMS and
   used in this study. This mutant showed following: elongated palea and
   pedicle; absence of inner three whorls of floral organs; multi-whorls
   glume like organs inside the lemma/palea; spikelet meristem like organ
   upon the pedicle. These phenotypes suggested that ROA is a key gene in
   rice spikelet development. Genetic analysis confirmed that the mutant
   traits were controlled by a single recessive nuclear gene. By gene
   mapping, ROA was restricted between two SSR markers RM221 and RM1342 on
   the chromosome 2. It concluded that ROA was a novel gene involving in
   flower development in rice. Besides, the mutation of ROA influenced the
   transcription level of floral homeotic genes; the expression of floral
   homeotic genes decreased in roa panicle compared with wild-type, and it
   suggested that ROA affected flower development by influencing the
   expression of floral homeotic genes.
C1 [Wang, Nan; Sang, Xian-Chun; Li, Yun-Feng; Ling, Ying-Hua; Zhao, Fang-Ming; Yang, Zheng-Lin; He, Guang-Hua] Southwest Univ, Rice Res Inst, Minist Agr, Key Lab Biotechnol & Crop Qual Improvement, Chongqing 400715, Peoples R China.
RP He, GH, Southwest Univ, Rice Res Inst, Minist Agr, Key Lab Biotechnol &
   Crop Qual Improvement, Chongqing 400715, Peoples R China.
EM hegh1968@yahoo.com.cn
FU National Natural Sciences Foundation [30800598]; Excellent Youth
   Foundation Project of Chongqing (CSTC) [2008BA1033]; Natural Sciences
   Foundation Project of Chongqing [2008BB1258]; Fine Animals and Plants
   Breeding Project of Chongqing (CSTC) [2007AA1019]
FX This research was supported by the National Natural Sciences Foundation
   (30800598), the Excellent Youth Foundation Project of Chongqing (CSTC,
   2008BA1033), the Natural Sciences Foundation Project of Chongqing
   (CSTC, 2008BB1258) and the Fine Animals and Plants Breeding Project of
   Chongqing (CSTC, 2007AA1019).
CR AGRAWAL G, 2005, PLANT MOL BIOL, V59, P125, DOI
   10.1007/s11103-005-2161-y
   CHUNG YY, 1995, PLANT SCI, V109, P45
   COEN ES, 1991, NATURE, V353, P31
   DITTA G, 2004, CURR BIOL, V14, P1935, DOI 10.1016/j.cub.2004.10.028
   FORNARA F, 2004, PLANT PHYSIOL, V135, P2207, DOI 10.1104/pp.104.045039
   GRECO R, 1997, MOL GEN GENET, V253, P615
   HONMA T, 2001, NATURE, V409, P525
   JEON JS, 2000, MOL BREEDING, V6, P581
   JEON JS, 2000, PLANT CELL, V12, P871
   KANG HG, 1997, MOL CELLS, V7, P45
   KATER MM, 2006, J EXP BOT, V57, P3433, DOI 10.1093/jxb/erl097
   KYOZUKA J, 2000, PLANT CELL PHYSIOL, V41, P710
   LUO ZK, 2007, GENOME, V50, P811, DOI 10.1139/G07-064
   NAGASAWA N, 2003, DEVELOPMENT, V130, P705, DOI 10.1242/dev.00294
   PELAZ S, 2000, NATURE, V405, P200
   PELUCCHI N, 2002, SEX PLANT REPROD, V15, P113, DOI
   10.1007/s00497-002-0151-7
   PRASAD K, 2003, GENETICS, V165, P2301
   PRASAD K, 2005, PLANT J, V43, P915, DOI 10.1111/j.1365-313X.2005.02504.x
   ROGERS SO, 1988, PLANT MOL BIOL MAN A, V6, P1
   THEISSEN G, 2001, NATURE, V409, P469
   YAMAGUCHI T, 2004, PLANT CELL, V16, P500, DOI 10.1105/tpc.018044
   YAMAGUCHI T, 2006, PLANT CELL, V18, P15, DOI 10.1105/tpc.105.037200
   YAMAGUCHI T, 2006, TSW DEV EMBRYOL, V1, P99
NR 23
TC 0
PU KOREAN SOC GENETICS
PI SEOUL
PA KOREAN SCIENCE & TECHNOLOGY CENTER, RM 1002, 635-4 YEOKSAM-DONG,
   KANGNAM, SEOUL, 135-703, SOUTH KOREA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD OCT
PY 2009
VL 31
IS 5
BP 361
EP 368
PG 8
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 521PI
UT ISI:000271933800004
ER

PT J
AU Chang, YS
   Oh, W
   Choi, SJ
   Sung, DK
   Kim, SY
   Choi, EY
   Kang, S
   Jin, HJ
   Yang, YS
   Park, WS
AF Chang, Yun Sil
   Oh, Wonil
   Choi, Soo Jin
   Sung, Dong Kyung
   Kim, Soo Yoon
   Choi, Eun Yang
   Kang, Saem
   Jin, Hye Jin
   Yang, Yoon Sun
   Park, Won Soon
TI Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Attenuate
   Hyperoxia-Induced Lung Injury in Neonatal Rats
SO CELL TRANSPLANTATION
LA English
DT Article
DE Hyperoxic lung injury; Transplantation; Animal; Newborn; Inflammation;
   Cell differentiation
ID BRONCHOPULMONARY DYSPLASIA; BONE-MARROW; PROGENITOR CELLS; RETINOIC
   ACID; STROMAL CELLS; MICE; GROWTH; TRANSPLANTATION; EXPRESSION;
   DIFFERENTIATION
AB Recent evidence suggests mesenchymal stem cells (MSCs) can downmodulate
   bleomycin-induced lung injury, and umbilical cord blood (UCB) is a
   promising source for human MSCs. This study examined whether
   intratracheal or intraperitoneal transplantation of human UCB-derived
   MSCs can attenuate hyperoxia-induced lung injury in immunocompetent
   newborn rats. Wild-type Sprague-Dawley rats were randomly exposed to
   95% oxygen or air from birth. In the transplantation groups, a single
   dose of PKH26-labeled human UCB-derived MSCs was administered either
   intratracheally (2 x 10(6) cells) or intraperitoneally (5 x 105 cells)
   at postnatal day (P) 5. At P14, the harvested lungs were examined for
   morphometric analyses of alveolarization and TUNEL staining, as well as
   the myeoloperoxidase activity, the level of tumor necrosis factor
   (TNF)-alpha, interleukin (IL)-6, and transforming growth factor
   (TGF)-beta mRNA, a-smooth muscle actin (SMA) protein, and collagen
   levels. Differentiation of MSCs to the respiratory epithelium was also
   evaluated both in vitro before transplantation and in vivo after
   transplantation. Despite one fourth dosage of MSCs, significantly more
   PKB26-labeled donor cells were recovered with intratracheal
   administration than with intraperitoneal administration both during
   normoxia and hyperoxia. The hyperoxia-induced increase in the number of
   TUNEL-positive cells, myeloperoixdase activity, and the level of IL-6
   mRNA were significantly attenuated with both intratracheal and
   intraperitoneal MSCs transplantation. However, the hyperoxia-induced
   impaired alveolarization and increased the level of TNF-alpha and
   TGF-beta mRNA, alpha-SMA protein, and collagen were significantly
   attenuated only with intratracheal MSCs transplantation. MSCs
   differentiated into respiratory epithelium in vitro and a few
   PKH26-positive donor cells were colocalized with pro surfactant protein
   C in the damaged lungs. In conclusion, intratracheal transplantation of
   human UCB-derived MSCs is more effective than intraperitoneal
   transplantation in attenuating the hyperoxia-induced lung injury in
   neonatal rats.
C1 [Chang, Yun Sil; Park, Won Soon] Samsung Med Ctr, Dept Pediat, Seoul 135710, South Korea.
   [Chang, Yun Sil; Sung, Dong Kyung; Kim, Soo Yoon; Choi, Eun Yang; Kang, Saem; Park, Won Soon] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Seoul, South Korea.
   [Oh, Wonil; Choi, Soo Jin; Jin, Hye Jin; Yang, Yoon Sun] MEDIPOST Co Ltd, Biomed Res Inst, Seoul, South Korea.
RP Park, WS, Samsung Med Ctr, Dept Pediat, 50 Irwon Dong, Seoul 135710,
   South Korea.
EM wonspark@skku.edu
FU Korea Research Foundation ; Korean Government (MOEHRD)
   [KRF-2005-041-EO0219]; Medipost Research Institute 
FX The authors wish to thank to Dr. Su Jin Cho for her advice on the
   morphometric analysis of the lung. This work was supported by the Korea
   Research Foundation Grant funded by the Korean Government (MOEHRD)
   (KRF-2005-041-EO0219) and a grant funded by Medipost Research Institute.
CR ABE S, 2003, CYTOTHERAPY, V5, P523, DOI 10.1080/14653240310003576
   AGGARWAL S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   AVERY ME, 1987, PEDIATRICS, V79, P26
   BERGER MJ, 2006, CYTOTHERAPY, V8, P480, DOI 10.1080/14653240600941549
   BHANDARI V, 2006, FREE RADICAL BIO MED, V41, P4, DOI
   10.1016/j.freeradbiomed.2006.01.027
   BREGMAN J, 1992, CLIN PERINATOL, V19, P673
   CHANG YJ, 2006, STEM CELLS, V24, P679
   CHO SJ, 2005, AM J RESP CELL MOL, V33, P622
   CHOOWING R, 2007, AM J PHYSIOL-LUNG C, V293, L142, DOI
   10.1152/ajplung.00434.2006
   COONEY TP, 1982, THORAX, V37, P580
   DELEMOS RA, 1992, CLIN PERINATOL, V19, P521
   DIEHL KH, 2001, J APPL TOXICOL, V21, P15
   EGLITIS MA, 1999, NEUROREPORT, V10, P1289
   GRAY KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010
   GROVE JE, 2002, AM J RESP CELL MOL, V27, P645, DOI
   10.1165/rcmb.2002-0056RC
   HASHIMOTO S, 2001, AM J RESP CRIT CARE, V163, P152
   HOU LL, 2003, INT J HEMATOL, V78, P256
   JANG YK, 2006, ANN HEMATOL, V85, P212, DOI 10.1007/s00277-005-0047-3
   KASPER FK, 2006, J BIOMED MATER RES A, V78, P335, DOI
   10.1002/jbm.a.30698
   KERN S, 2006, STEM CELLS, V24, P1294
   KOGLER G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440
   KWONG KY, 2006, LIFE SCI, V79, P2349, DOI 10.1016/j.lfs.2006.07.040
   LEBLANC K, 2003, EXP HEMATOL, V31, P890
   LEE JK, 2007, CELL TRANSPLANT, V16, P849
   LEE OK, 2004, BLOOD, V103, P1669
   LINDSAY L, 2000, INFLAMMATION, V24, P347
   LIU CH, 2005, CYTOKINE, V32, P270, DOI 10.1016/j.cyto.2005.11.003
   MARCHO Z, 1991, AM J RESP CELL MOL, V5, P556
   MEIER C, 2006, PEDIATR RES, V59, P244, DOI
   10.1203/01.pdr.0000197309.08852.f5
   NORTHWAY WH, 1979, J PEDIATR, V95, P815
   OHNISHI S, 2007, J MOL CELL CARDIOL, V42, P88, DOI
   10.1016/j.yjmcc.2006.10.003
   ORTIZ LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI
   10.1073/pnas.1432929100
   ORTIZ LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI
   10.1073/pnas.0704421104
   ROJAS M, 2005, AM J RESP CELL MOL, V33, P145, DOI
   10.1165/rcmb.2004-0330OC
   SCHURCH W, 1998, AM J SURG PATHOL, V22, P141
   SEMEDO P, 2007, TRANSPL P, V39, P421, DOI
   10.1016/j.transproceed.2007.01.036
   SIME PJ, 1997, J CLIN INVEST, V100, P768
   SNYDER JM, 2005, PEDIATR RES, V57, P384, DOI
   10.1203/01.PDR.0000151315.81106.D3
   TOCCI A, 2003, HEMATOL J, V4, P92
   TORRENTE Y, 2008, CELL TRANSPLANT, V17, P1103
   TSE WT, 2003, TRANSPLANTATION, V75, P389, DOI
   10.1097/01.TP.0000045055.63901.A9
   WALSH MC, 2006, PEDIATRICS S, V117, S52, DOI 10.1542/peds.2005-0620I
   WARNER BB, 1998, AM J PHYSIOL-LUNG C, V275, L110
   WU YP, 2000, AM J PATHOL, V156, P1849
   YANG SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041
NR 45
TC 11
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2009
VL 18
IS 8
BP 869
EP 886
DI 10.3727/096368909X471189
PG 18
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 521PE
UT ISI:000271933400005
ER

PT J
AU Wang, SC
   Lu, MC
   Chen, HL
   Tseng, HI
   Ke, YY
   Wu, YC
   Yang, PY
AF Wang, Shih-Chung
   Lu, Mei-Chin
   Chen, Hsiu-Lin
   Tseng, Hsing-I
   Ke, Yu-Yuan
   Wu, Yang-Chang
   Yang, Pei-Yu
TI Cytotoxicity of calotropin is through caspase activation and
   downregulation of anti-apoptotic proteins in K562 cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Apoptosis; Calotropin; Caspase; Cell cycle
ID CYCLE ARREST; G2/M ARREST; CANCER; INHIBITOR; INDUCTION; PATHWAYS; AKT
AB Calotropin is one of cardenolides isolated from milkweed used for
   medicinal purposes in many Asian countries. Whereas calotropin
   possesses cytotoxicity against several cancer cells, the mechanisms of
   action remain unclear. We set out to evaluate the cytotoxic mechanism
   of calotropin on human chronic myeloid leukemia K562 cells. Calotropin
   inhibited the growth of K562 cells in a time- and dose-dependent manner
   by G(2)/M phase arrest. It upregulated the expression of p27 leading to
   this arrest by downregulating the G2/M regulatory proteins, cyclins A
   and B, and by upregulating the cdk inhibitor, p27. Furthermore, it
   downregulated anti-apoptotic signaling (XIAP and survivin) and survival
   pathways (p-Akt and NF kappa B), leading to caspase-3 activation which
   resulted in the induction of apoptosis. In all, calotropin exerted its
   anticancer activity on K562 cells by modulating the pro-survival
   signaling that leads to induction of apoptosis. (C) 2009 International
   Federation for Cell Biology. Published by Elsevier Ltd. All rights
   reserved.
C1 [Lu, Mei-Chin; Wu, Yang-Chang; Yang, Pei-Yu] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung 807, Taiwan.
   [Wu, Yang-Chang] Kaohsiung Med Univ, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.
   [Wang, Shih-Chung; Ke, Yu-Yuan] Changhua Christian Hosp, Dept Pediat, Changhua 500, Taiwan.
   [Chen, Hsiu-Lin; Tseng, Hsing-I] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung 807, Taiwan.
   [Yang, Pei-Yu] Show Chwan Mem Hosp, Dept Med Res, Changhua, Taiwan.
RP Wu, YC, Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung 807, Taiwan.
EM yachwu@kmu.edu.tw
   yachwu@kmu.edu.tw
FU Changhua Christian Hospital [95-CCH-KMU-11, 12]; [NSC-952314-B-037-051]
FX This work was supported in part by a grant from Changhua Christian
   Hospital (95-CCH-KMU-11 and 12) and NSC-952314-B-037-051.
CR BLAGOSKLONNY MV, 2001, CANCER RES, V61, P4301
   BUNZ F, 1998, SCIENCE, V282, P1497
   CHEUNG HTA, 1989, J CHEM SOC P1, V9, P1563
   HAMED AI, 2006, J NAT PROD, V69, P1319, DOI 10.1021/np0602281
   HARTWELL LH, 1994, SCIENCE, V266, P1821
   HERMEKING H, 1997, MOL CELL, V1, P3
   HSIAO YC, 2007, J BIOMED SCI, V14, P107, DOI 10.1007/s11373-006-9117-3
   KANEKO R, 2007, J BIOL CHEM, V282, P19273, DOI 10.1074/jbc.M610350200
   LU MC, 2006, LIFE SCI, V78, P2378, DOI 10.1016/j.lfs.2005.09.048
   MURRAY AW, 2004, CELL, V116, P221
   RASSIDAKIS GZ, 2005, BLOOD, V105, P827, DOI 10.1182/blood-2004-06-2125
   ROY MC, 2005, J NAT PROD, V68, P1494, DOI 10.1021/np0501740
   SHERR CJ, 2000, CANCER RES, V60, P3689
   SINGH B, 1970, PHYTOCHEMISTRY, V9, P315
   TANG PP, 2002, CELL SIGNAL, V14, P961
   TSAI CH, 2006, CLIN EXP PHARMACOL P, V33, P177
   VAUX DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI
   10.1016/S0006-291X(03)00622-3
   WU SJ, 2005, EUR J PHARMACOL, V518, P96, DOI
   10.1016/j.ejphar.2005.06.021
   YAN X, 2008, MOL CELL BIOCHEM, V310, P227, DOI 10.1007/s11010-007-9684-2
   YANG SH, 2007, TOXICON, V49, P966, DOI 10.1016/j.toxicon.2007.01.005
NR 20
TC 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD DEC
PY 2009
VL 33
IS 12
BP 1230
EP 1236
DI 10.1016/j.cellbi.2009.08.013
PG 7
SC Cell Biology
GA 521EI
UT ISI:000271902600004
ER

PT J
AU Lin, SH
   Liu, CM
   Liu, YL
   Fann, CSJ
   Hsiao, PC
   Wu, JY
   Hung, SI
   Chen, CH
   Wu, HM
   Jou, YS
   Liu, SK
   Hwang, TJ
   Hsieh, MH
   Chang, CC
   Yang, WC
   Lin, JJ
   Chou, FHC
   Faraone, SV
   Tsuang, MT
   Hwu, HG
   Chen, WJ
AF Lin, S. -H.
   Liu, C. -M.
   Liu, Y. -L.
   Fann, C. Shen-Jang
   Hsiao, P. -C.
   Wu, J. -Y.
   Hung, S. -I.
   Chen, C. -H.
   Wu, H. -M.
   Jou, Y. -S.
   Liu, S. K.
   Hwang, T. J.
   Hsieh, M. H.
   Chang, C. -C.
   Yang, W. -C.
   Lin, J. -J.
   Chou, F. H. -C.
   Faraone, S. V.
   Tsuang, M. T.
   Hwu, H. -G.
   Chen, W. J.
TI Clustering by neurocognition for fine mapping of the schizophrenia
   susceptibility loci on chromosome 6p
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE Candidate gene; cluster analysis; endophenotype; executive dysfunction;
   schizophrenia; sustained attention deficit
ID CARD SORTING TEST; SUSTAINED ATTENTION DEFICITS; MINOR PHYSICAL
   ANOMALIES; DYSBINDIN GENE DTNBP1; BONE MORPHOGENETIC PROTEIN-6;
   CONTINUOUS PERFORMANCE-TEST; FAMILY-BASED TESTS; NONPSYCHOTIC
   RELATIVES; TAIWANESE FAMILIES; LINKAGE ANALYSIS
AB Chromosome 6p is one of the most commonly implicated regions in the
   genome-wide linkage scans of schizophrenia, whereas further association
   studies for markers in this region were inconsistent likely due to
   heterogeneity. This study aimed to identify more homogeneous subgroups
   of families for fine mapping on regions around markers D6S296 and
   D6S309 (both in 6p24.3) as well as D6S274 (in 6p22.3) by means of
   similarity in neurocognitive functioning. A total of 160 families of
   patients with schizophrenia comprising at least two affected siblings
   who had data for eight neurocognitive test variables of the continuous
   performance test (CPT) and the Wisconsin card sorting test (WCST) were
   subjected to cluster analysis with data visualization using the test
   scores of both affected siblings. Family clusters derived were then
   used separately in family-based association tests for 64 single
   nucleotide polymorphisms (SNPs) covering the region of 6p24.3 and
   6p22.3. Three clusters were derived from the family-based clustering,
   with deficit cluster 1 representing deficit on the CPT, deficit cluster
   2 representing deficit on both the CPT and the WCST, and a third
   cluster of nondeficit. After adjustment using false discovery rate for
   multiple testing, SNP rs13873 and haplotype rs1225934-rs13873 on
   BMP6-TXNDC5 genes were significantly associated with schizophrenia for
   the deficit cluster 1 but not for the deficit cluster 2 or nondeficit
   cluster. Our results provide further evidence that the BMP6-TXNDC5
   locus on 6p24.3 may play a role in the selective impairments on
   sustained attention of schizophrenia.
C1 [Lin, S. -H.; Hsiao, P. -C.; Hwu, H. -G.; Chen, W. J.] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol, Taipei 100, Taiwan.
   [Lin, S. -H.; Hsiao, P. -C.; Chen, W. J.] Natl Taiwan Univ, Genet Epidemiol Core Lab, Div Genom Med, Res Ctr Med Excellence, Taipei 100, Taiwan.
   [Liu, C. -M.; Liu, S. K.; Hwang, T. J.; Hsieh, M. H.; Hwu, H. -G.; Chen, W. J.] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan.
   [Liu, C. -M.; Liu, S. K.; Hwang, T. J.; Hsieh, M. H.; Hwu, H. -G.; Chen, W. J.] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan.
   [Liu, Y. -L.] Natl Hlth Res Inst, Div Mental Hlth & Subst Abuse Res, Zhunan, Taiwan.
   [Wu, J. -Y.; Hung, S. -I.] Acad Sinica, Inst Biomed Sci, Natl Genotyping Ctr, Taipei, Taiwan.
   [Chen, C. -H.] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan.
   [Wu, J. -Y.] Tamkang Univ, Dept Math, Taipei, Taiwan.
   [Yang, W. -C.] Acad Sinica, Taiwan Int Grad Program, Program Mol Med, Taipei 115, Taiwan.
   [Liu, S. K.] Far Eastern Mem Hosp, Taipei, Taiwan.
   [Yang, W. -C.] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Lin, J. -J.] Chimei Med Ctr, Dept Psychiat, Tainan, Taiwan.
   [Chou, F. H. -C.] Kai Suan Psychiat Hosp, Kaohsiung, Taiwan.
   [Faraone, S. V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA.
   [Faraone, S. V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA.
   [Tsuang, M. T.] Harvard Univ, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA.
   [Tsuang, M. T.] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA 02115 USA.
   [Tsuang, M. T.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
   [Tsuang, M. T.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genom, San Diego, CA 92103 USA.
   [Hwu, H. -G.] Natl Taiwan Univ, Coll Sci, Dept Psychol, Taipei 10764, Taiwan.
RP Chen, WJ, Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol, 17 Xuzhou
   Rd, Taipei 100, Taiwan.
EM wjchen@ntu.edu.tw
FU National Research Program for Genomic Medicine (NRPGM) ; National
   Science Council (NSC), Taiwan [NSC-91-3112-B-002-011,
   NSC-92-3112-B-002-019, NSC-93-3112-B-002-012, NSC-94-3112-B-002];
   National Health Research Institute (NHRI), Taiwan [NHRI-90-8825PP,
   NHRI-EX91, 92, 93, 94-9113PP, NHRI-EX98-9511PP]; Neurobiology and
   Cognitive Science Center ; National Taiwan University [96R0506];
   Department of Health, Taiwan [DOH94-TD-G-111-035]; National Institute
   of Mental Health (NIMH), USA [1R01 MH59624-01, 1R01 MH59624-02];
   Department of Medical Research ; National Taiwan University Hospital 
FX This study was supported in part by the grants from National Research
   Program for Genomic Medicine (NRPGM), National Science Council (NSC),
   Taiwan (NSC-91-3112-B-002-011; NSC-92-3112-B-002-019;
   NSC-93-3112-B-002-012; NSC-94-3112-B-002); National Health Research
   Institute (NHRI), Taiwan (NHRI-90-8825PP; NHRI-EX91, 92, 93, 94-9113PP;
   NHRI-EX98-9511PP); Neurobiology and Cognitive Science Center, National
   Taiwan University (96R0506); Department of Health, Taiwan
   (DOH94-TD-G-111-035); and National Institute of Mental Health (NIMH),
   USA (1R01 MH59624-01, 1R01 MH59624-02). We acknowledge the SNP
   genotyping work done by the National Genotyping Center (NGC), NSC,
   Taiwan and the support from the Department of Medical Research,
   National Taiwan University Hospital.
CR ALLEN NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171
   ALVAREZ JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI
   10.1007/s11065-006-9002-x
   ANOKHIN AP, 2003, NEUROREPORT, V14, P1975, DOI
   10.1097/01.wnr.0000089570.45990.a2
   ANTONARAKIS SE, 1995, NAT GENET, V11, P233
   BAILER U, 2000, NEUROPSYCHOBIOLOGY, V42, P175
   BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI
   10.1093/bioinformatics/bth457
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   CALUSERIU O, 2006, AM J MED GENET A A, V140, P1208, DOI
   10.1002/ajmg.a.31222
   CHEN CH, 2002, STAT SINICA, V12, P7
   CHEN WJ, 1998, AM J PSYCHIAT, V155, P1214
   CHEN WJ, 1998, SCHIZOPHRENIA BULL, V24, P163
   CHEN WJ, 2000, AM J MED GENET, V97, P52
   CHEN WJ, 2004, BIOL PSYCHIAT, V55, P995, DOI
   10.1016/j.biopsych.2004.01.010
   CORNBLATT BA, 1994, SCHIZOPHR B, V20, P31
   EGAN MF, 2001, P NATL ACAD SCI USA, V98, P6917
   GALTER D, 1999, EUR J NEUROSCI, V11, P2444
   GOLDBERG TE, 1987, ARCH GEN PSYCHIAT, V44, P1008
   GOTTESMAN II, 2003, AM J PSYCHIAT, V160, P636
   GREEN MF, 1994, SCHIZOPHRENIA BULL, V20, P433
   HALLMAYER JF, 2005, AM J HUM GENET, V77, P468
   HEATON RK, 1993, WISCONSIN CARD SORTI
   HOLLIDAY EG, 2006, TWIN RES HUM GENET, V9, P531
   HORVATH S, 2001, EUR J HUM GENET, V9, P301
   HORVATH S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   HOTI F, 2004, BMC PSYCHIATRY, V4, P20
   HOVATTA I, 1999, AM J HUM GENET, V65, P1114
   HWU HG, 2000, AM J MED GENET, V96, P74
   HWU HG, 2005, AM J MED GENET B B, V134, P30, DOI 10.1002/ajmg.b.30139
   ISMAIL B, 1998, AM J PSYCHIAT, V155, P1695
   JABLENSKY A, 2006, MOL PSYCHIATR, V11, P815, DOI 10.1038/sj.mp.4001857
   JOO EJ, 2006, NEUROSCI LETT, V407, P101, DOI
   10.1016/j.neulet.2006.08.011
   JORDAN J, 1997, EUR J NEUROSCI, V9, P1699
   JOYCE EM, 2007, CURR OPIN PSYCHIATR, V20, P268
   KOREN D, 1998, NEUROPSYCHOLOGY, V12, P289
   KREMEN WS, 2007, AM J MED GENET B B, V144, P403, DOI
   10.1002/ajmg.b.30527
   LAIRD NM, 2000, GENET EPIDEMIOL S1, V19, S36
   LIN CCH, 2000, J CLIN EXP NEUROPSYC, V22, P69
   LIU CM, 2007, SCHIZOPHR RES, V93, P391, DOI 10.1016/j.schres.2007.02.003
   LIU SK, 2006, J PSYCHIAT RES, V40, P613, DOI
   10.1016/j.jpsychires.2006.06.010
   LIU YL, 2006, BIOL PSYCHIAT, V60, P554, DOI
   10.1016/j.biopsych.2006.04.024
   LIU YL, 2007, MOL PSYCHIATR, V12, P966
   MARTINEZ G, 2001, BRAIN RES, V894, P1
   MOISES HW, 1995, NAT GENET, V11, P321
   MORRIS DW, 2003, SCHIZOPHR RES, V60, P167, DOI
   10.1016/S0920-9964(02)00527-3
   MUTSUDDI M, 2006, AM J HUM GENET, V79, P903
   NISSOM PM, 2006, FEBS LETT, V580, P2216, DOI
   10.1016/j.febslet.2006.03.029
   NUECHTERLEIN KH, 1992, SCHIZOPHRENIA BULL, V18, P387
   OCONNELL JR, 1998, AM J HUM GENET, V63, P259
   PETERS K, 2008, AM J MED GENET B B, V147, P1159, DOI
   10.1002/ajmg.b.30741
   POSTHUMA D, 2005, AM J HUM GENET, V77, P318
   ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605
   ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343
   SCHWAB SG, 1995, NAT GENET, V11, P325
   SCHWAB SG, 2000, MOL PSYCHIATR, V5, P638
   STRAUB RE, 1995, NAT GENET, V11, P287
   STRAUB RE, 2002, AM J HUM GENET, V71, P337
   STRAUB RE, 2002, MOL PSYCHIATR, V7, P542
   STRAUB RE, 2005, AM J MED GENET B B, V138, P136
   SULLIVAN DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200
   TAYLOR J, 2007, TWIN RES HUM GENET, V10, P829
   TRIXLER M, 2001, SCHIZOPHR RES, V52, P195
   TSUANG HC, 2006, SCHIZOPHR RES, V87, P172, DOI
   10.1016/j.schres.2006.03.045
   TURECKI G, 1997, AM J MED GENET, V74, P195
   WALL NA, 1993, J CELL BIOL, V120, P493
   WANG DT, 2005, J BIOL CHEM, V280, P3096, DOI 10.1074/jbc.M407709200
   WILLIAMS NM, 2005, SCHIZOPHRENIA BULL, V31, P800, DOI
   10.1093/schbul/sbi061
   WOLF LE, 2002, SCHIZOPHR RES, V57, P173
   WU HM, 2008, COMPUTATIONAL STAT D, DOI 10.1016/J.CSDA.2008.09.029
NR 68
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601-1848
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD NOV
PY 2009
VL 8
IS 8
BP 785
EP 794
DI 10.1111/j.1601-183X.2009.00523.x
PG 10
SC Behavioral Sciences; Neurosciences
GA 517QY
UT ISI:000271633300006
ER

PT J
AU Aravindaram, K
   Yu, HH
   Lan, CW
   Wang, PH
   Chen, YH
   Chen, HM
   Yagita, H
   Yang, NS
AF Aravindaram, K.
   Yu, H-H
   Lan, C-W
   Wang, P-H
   Chen, Y-H
   Chen, H-M
   Yagita, H.
   Yang, N-S
TI Transgenic expression of human gp100 and RANTES at specific time points
   for suppression of melanoma
SO GENE THERAPY
LA English
DT Article
DE prime-boost; melanoma; chemokine; vaccinia virus; migration; death
   receptors
ID APOPTOSIS-INDUCING LIGAND; VACCINIA VIRUS ANKARA; MURINE RENAL-CANCER;
   DENDRITIC CELLS; IN-VIVO; TUMOR REJECTION; NK CELLS; IMMUNE-RESPONSE;
   CC-CHEMOKINE; T-CELLS
AB The induction of strong cell-mediated immunity against targeted cancer
   cells is difficult, and often requires specific vaccination schema and
   the appropriate adjuvants to be effective. The chemokine RANTES has
   been studied as a vaccine adjuvant in cancer therapy, but specific
   applications remain to be determined. For gene-based vaccination
   against B16 melanoma in C57BL/6JNarl mice, initial priming with mouse
   RANTES cDNA followed 24 h later by human gp100 DNA vaccination, and
   later boosting with a viral vector expressing mRANTES and hgp100
   strongly suppressed B16/hgp100 primary tumors and lung metastasis. The
   inclusion of mRANTES in this vaccination regimen gave significantly
   better suppression of tumor growth, substantially enhanced mouse
   survival, and led to greater cytotoxic activity of splenocytes against
   B16/hgp100 cells than vaccination against hgp100 alone. B16/hgp100
   melanoma cells were resistant to the ligands TRAIL and FasL in vitro
   but sensitized to them in vivo owing to the priming effect of cytokines
   in response to vaccination. Our data demonstrate that co-vaccination
   with chemokine (mRANTES) and tumor-specific (hgp100) genes in a
   specific time sequence is more effective at suppressing tumor growth
   and metastasis than hgp100 alone, and this effect may be mediated by
   sensitization of tumor cells to death ligands. Gene Therapy (2009) 16,
   1329-1339; doi:10.1038/gt.2009.90; published online 23 July 2009
C1 [Aravindaram, K.; Yu, H-H; Lan, C-W; Wang, P-H; Chen, Y-H; Chen, H-M; Yang, N-S] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
   [Yagita, H.] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.
RP Yang, NS, Acad Sinica, Agr Biotechnol Res Ctr, 128 Sect 2,Acad Rd,
   Taipei 115, Taiwan.
EM nsyang@gate.sinica.edu.tw
FU National Science Council, Taiwan [94-2320-B-001-044]
FX This work was supported by a Grant (94-2320-B-001-044) from the
   National Science Council, Taiwan.
CR ACRES B, 2005, CANCER RES, V65, P9536
   ALBERTINI MR, 1996, CANCER GENE THER, V3, P192
   BLOOM MB, 1997, J EXP MED, V185, P453
   BRAUN SE, 2000, J IMMUNOL, V164, P4025
   CONWAY TF, 2000, J IMMUNOL METHODS, V233, P57
   COULIE PG, 1994, J EXP MED, V180, P35
   EARL PL, 1998, CURRENT PROTOCOLS MO
   FERRONE CR, 2006, CLIN CANCER RES, V12, P5511, DOI
   10.1158/1078-0432.CCR-06-0979
   HADIDA F, 1998, J EXP MED, V188, P609
   HENKART PA, 1994, CURR BIOL, V4, P923
   HERD KA, 2004, VIROLOGY, V319, P237, DOI 10.1016/j.virol.2003.10.032
   KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458
   KAYAGAKI N, 1999, J IMMUNOL, V163, P1906
   KIM CH, 1999, CELL IMMUNOL, V193, P226
   LABEUR MS, 1999, J IMMUNOL, V162, P168
   LANING J, 1994, J IMMUNOL, V153, P4625
   LANZAVECCHIA A, 1993, SCIENCE, V260, P937
   LIAN H, 2007, CANCER IMMUNOL IMMUN, V56, P181, DOI
   10.1007/s00262-006-0178-y
   LUO YP, 2005, CANCER RES, V65, P3419
   MANTOVANI A, 2004, TRENDS IMMUNOL, V25, P677, DOI
   10.1016/j.jit.2004.09.015
   MCCONKEY SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   MULE JJ, 1996, HUM GENE THER, V7, P1545
   NAGIRA M, 1998, EUR J IMMUNOL, V28, P1516
   NAKAZAKI Y, 2006, MOL THER, V14, P599, DOI 10.1016/j.ymthe.2006.04.014
   PACZESNY S, 2004, J EXP MED, V199, P1503, DOI 10.1084/jem.20032118
   PERRICONE MA, 2000, MOL THER, V1, P275
   RAKHMILEVICH AL, 1996, P NATL ACAD SCI USA, V93, P6291
   RAKHMILEVICH AL, 2001, CLIN CANCER RES, V7, P952
   ROSSI D, 2000, ANNU REV IMMUNOL, V18, P217
   RUBBERT A, 1998, J IMMUNOL, V160, P3933
   SALLUSTO F, 2000, IMMUNOL REV, V177, P134
   SAYERS TJ, 2000, J LEUKOCYTE BIOL, V68, P81
   SCHNEIDER J, 1998, NAT MED, V4, P397
   SEKI N, 2003, CANCER RES, V63, P207
   SHARMA S, 2000, J IMMUNOL, V164, P4558
   TAKEDA K, 2001, NAT MED, V7, P94
   TOMURA M, 1999, J IMMUNOL, V60, P3759
   VICARI AP, 2000, J IMMUNOL, V165, P1992
   VROON A, 2004, J LEUKOCYTE BIOL, V75, P901, DOI 10.1189/jlb.0403136
   WAGNER L, 1998, NATURE, V391, P908
   WAN YH, 1999, CELL IMMUNOL, V198, P131
   WARD SG, 1998, BIOCHEM J 3, V333, P457
   WYATT LS, 1996, VACCINE, V14, P1451
   YAMAZAKI T, 1991, FLORA JAPAN A, V3, P183
   YANG SC, 2006, CANCER RES, V66, P3205, DOI 10.1158/0008-5472.CAN-05-3619
   ZHAI YF, 1997, J IMMUNOTHER, V20, P15
   ZHANG YY, 2004, J NATL CANCER I, V96, P201, DOI 10.1093/jnci/djh024
   ZHAO LL, 2005, HUM GENE THER, V16, P845
NR 48
TC 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD NOV
PY 2009
VL 16
IS 11
BP 1329
EP 1339
DI 10.1038/gt.2009.90
PG 11
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 518CB
UT ISI:000271666600007
ER

PT J
AU Yang, K
   Sun, K
   Srinivasan, KN
   Salmon, J
   Marques, ET
   Xu, J
   August, JT
AF Yang, K.
   Sun, K.
   Srinivasan, K. N.
   Salmon, J.
   Marques, E. T.
   Xu, J.
   August, J. T.
TI Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced
   by N immunization with a chimera of lysosome-associated membrane protein
SO GENE THERAPY
LA English
DT Article
DE SARS CoV; N; LAMP; cluster of dominant T-cell epitopes; DNA vaccine;
   ELISpot
ID NEUTRALIZING ANTIBODY-RESPONSE; MHC CLASS-I; TARGETING ANTIGEN;
   DENDRITIC CELLS; DNA VACCINE; ENDOSOMAL/LYSOSOMAL COMPARTMENTS;
   GENE-PRODUCT; MEMORY; CD4(+); TRAFFICKING
AB In our previous study by Gupta et al, dominant T-cell epitopes of SARS
   CoV-N(N) protein were predicted by software. The spectrum of interferon
   (IFN)-gamma responses of Balb/c mice immunized against two different
   forms of SARS CoV-N plasmid was then analyzed. A cluster of dominant
   T-cell epitopes of SARS CoV-N protein was found in the N-terminus
   (amino acids 76-114). On the basis of this study, four different
   plasmids were constructed: (i) DNA encoding the unmodified N (p-N) or
   N70-122 (p-N70-122) as an endogenous cytoplasmic protein or (ii) DNA
   encoding a lysosome-associated membrane protein (LAMP) chimera with N
   (p-LAMP/N) or N70-122 (p-LAMP/N70-122). The immune responses of mice to
   these four constructs were evaluated. The results showed marked
   differences in the responses of the immunized mice. A single priming
   immunization with the p-LAMP/N construct was sufficient to elicit an
   antibody response. Enzyme-linked immunospot (ELISpot) assay indicated
   that p-LAMP/N70-122 and p-LAMP/N plasmids both elicited a greater
   IFN-gamma response than p-N. p-N and p-N70-122 constructs induced low
   or undetectable levels of cytokine secretion. We also found that the
   p-LAMP/N70-122 construct promoted a long-lasting T-cell memory response
   without an additional boost 6 months after three immunizations. These
   findings show that DNA vaccines, even epitope-based DNA vaccines using
   LAMP as chimera, can elicit both humoral and cellular immune responses.
   Gene Therapy (2009) 16, 1353-1362; doi:10.1038/gt.2009.92; published
   online 3 September 2009
C1 [Yang, K.] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Shaanxi Prov, Peoples R China.
   [Yang, K.; Srinivasan, K. N.; Salmon, J.; Marques, E. T.; August, J. T.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Sun, K.] Div Biomed Sci, Singapore, Singapore.
   [Srinivasan, K. N.] Hlth Sci Author, Ctr Drug Adm, Prod Evaluat & Registrat Div, Singapore, Singapore.
   [Marques, E. T.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   [Xu, J.] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710032, Shaanxi Prov, Peoples R China.
RP Yang, K, Fourth Mil Med Univ, Dept Immunol, 17 Changle W Rd, Xian
   710032, Shaanxi Prov, Peoples R China.
EM yangkunkun@fmmu.edu.cn
   taugust@jhmi.edu
FU National Institute of Allergy and Infectious Diseases ; National
   Institutes of Health ; Department of Health and Human Services of USA
   [HHSN266200400085C]; National High-tech R&D Program of China
   [2006AA02A237]
FX This study was supported by grants from the National Institute of
   Allergy and Infectious Diseases, the National Institutes of Health,
   Department of Health and Human Services, contract no. HHSN266200400085C
   of USA, and the National High-tech R&D Program (863 Program) of China
   (No. 2006AA02A237). We thank Chikhlikar PR, Paul Tan, Vladimir Perovic,
   Keun OK Jung, Garg S, Milton Maciel Jr, Betty Hart and Delores Henson
   for their excellent technical assistance. The support of the NIH AIDS
   Research and Reference Reagent Program in providing the SARS-N peptides
   and purified SARS-N protein is gratefully acknowledged.
CR ANWAR A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   ARRUDA LB, 2006, J IMMUNOL, V177, P2265
   BONINI C, 2001, J IMMUNOL, V166, UNSP 1665250-1665257
   CHEN JW, 1985, J CELL BIOL, V101, P85
   CHENG WF, 2001, HUM GENE THER, V12, P235
   CHIKHLIKAR P, 2004, VIROLOGY, V323, P220, DOI
   10.1016/j.virol.2004.02.025
   CHIKHLIKAR P, 2006, PLOS ONE, V1, ARTN e135
   DEARRUDA LB, 2004, IMMUNOLOGY, V112, P126, DOI
   10.1111/j.1365-2567.2004.01823.x
   DOBANO C, 2007, IMMUNOL LETT, V111, P92, DOI 10.1016/j.imlet.2007.05.007
   DRAKE JR, 1999, J IMMUNOL, V162, P1150
   ESKELINEN EL, 2003, TRENDS CELL BIOL, V13, P137, DOI
   10.1016/S0962-8924(03)00005-9
   ESKELINEN EL, 2006, MOL ASPECTS MED, V27, P495, DOI
   10.1016/j.mam.2006.08.005
   FASSNACHT M, 2005, CLIN CANCER RES, V11, P5566
   FUKUDA M, 1991, J BIOL CHEM, V266, P21327
   GEUZE HJ, 1998, IMMUNOL TODAY, V19, P282
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   GUPTA V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042
   HUNZIKER W, 1996, NEPHROLOGIE, V17, P347
   JANSSEN EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   JI HX, 1999, HUM GENE THER, V10, P2727
   KAECH SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   KANG TH, 2006, IMMUNOL LETT, V106, P126, DOI 10.1016/j.imlet.2006.05.004
   KESSLER PD, 1996, P NATL ACAD SCI USA, V93, P14082
   KHANOLKAR A, 2007, IMMUNOL RES, V39, P94, DOI 10.1007/s12026-007-0081-4
   KLEIJMEER MJ, 1997, J CELL BIOL, V139, P639
   KWON YJ, 2005, MOL PHARMACEUT, V2, P83, DOI 10.1021/mp0498953
   LU Y, 2003, VACCINE, V21, P2187
   MARQUES ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   NAIR SK, 1998, NAT BIOTECHNOL, V16, P364
   PENG SW, 2005, J BIOMED SCI, V12, P689, DOI 10.1007/s11373-005-9012-3
   PETERS PJ, 1991, NATURE, V349, P669
   RAVIPRAKASH K, 2001, VIROLOGY, V290, P74
   ROCHA B, 2004, CURR OPIN IMMUNOL, V16, P259, DOI
   10.1016/j.col.2004.03.004
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   RUFF AL, 1997, J BIOL CHEM, V272, P8671
   SHEDLOCK DJ, 2003, SCIENCE, V300, P337
   SU Z, 2002, CANCER RES, V62, P5041
   SUN JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   TURLEY SJ, 2000, SCIENCE, V288, P522
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671
   ZHAO JC, 2007, J VIROL, V81, P6079, DOI 10.1128/JVI.02568-06
NR 41
TC 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD NOV
PY 2009
VL 16
IS 11
BP 1353
EP 1362
DI 10.1038/gt.2009.92
PG 10
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 518CB
UT ISI:000271666600009
ER

PT J
AU Cui, J
   Le, GW
   Yang, RL
   Shi, YH
AF Cui, Jue
   Le, Guowei
   Yang, Ruili
   Shi, Yonghui
TI Lipoic acid attenuates high fat diet-induced chronic oxidative stress
   and immunosuppression in mice jejunum: A microarray analysis
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE High fat diet; Chronic oxidative stress; Lipoic acid; Jejunum; DNA
   microarray; B cell receptor signaling pathway; T cell differentiation;
   Free radical scavenger
ID TYROSINE PHOSPHORYLATION; LIPID-PEROXIDATION; MUCOSAL IMMUNITY;
   T-LYMPHOCYTES; ACTIVATION; CELLS; RESPONSES; TRANSCRIPTION;
   ANTIOXIDANTS; METABOLISM
AB A high fat diet (HFD) has long been linked to immune dysfunction,
   including diminished numbers or reactivity of lymphocytes, increased
   susceptibility to infection, inhibited lymphocytes function during
   antigen-specific responses and developed oxidative stress. Whereas the
   molecular mechanistic events associated with immune deficiency remain
   to be fully determined. Using the DNA microarray system, we analyzed
   the gene expression patterns of lymphocyte related signal transduction
   proteins in jejunum of C57BL/6 mice in order to gain insight on the
   possible molecular mechanism by which HFD induced oxidative stress
   effects on signal transduction of lymphocytes. Results of present study
   showed that HFD induced oxidative stress and immunosuppression in
   jejunum. Antioxidant lipoic acid (LA) supplement ameliorated that HFD
   induced oxidative stress and immunosuppression by recovering
   transcriptional levels of the gene involved in B cell receptor, T cell
   differentiation signaling pathway, and free radical scavengers. The
   present study indicates that a HFD can induce chronic oxidative stress,
   suppress signal transduction of gut-associated lymphocytes, and lead to
   an inhibition of mucosal immunity. (C) 2009 Published by Elsevier Inc.
C1 [Cui, Jue; Le, Guowei; Yang, Ruili; Shi, Yonghui] Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Jiangsu, Peoples R China.
RP Le, GW, Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Jiangsu,
   Peoples R China.
EM cuijue1980@hotmail.com
   lgw@jiangnan.edu.cn
FU National Natural Science Foundation of China [30571347]
FX This work was supported by the National Natural Science Foundation of
   China (Grant 30571347).
CR AMES BN, 1983, SCIENCE, V221, P1256
   AW TY, 1999, AM J CLIN NUTR, V70, P557
   BISHOP GA, 2003, CRIT REV IMMUNOL, V23, P149
   BRIGELIUS R, 1985, OXIDATIVE STRESS, P243
   CHIRICO S, 1993, FREE RADICAL RES COM, V19, P51
   CORTHESY V, 2009, IMMUNOPHARM IMMUNOTO, V31, P174
   DATTA SR, 1997, CELL, V91, P231
   DELAROSA M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274
   DONG F, 2007, DIABETES, V56, P2201, DOI 10.2337/db06-1596
   FEARON DT, 2000, ANNU REV IMMUNOL, V18, P393
   FLESCHER E, 1994, J IMMUNOL, V153, P4880
   FORCHIELLI ML, 2005, BR J NUTR S1, V93, P41
   FRUMAN DA, 1999, SCIENCE, V283, P393
   GOLOVKINA TV, 1999, SCIENCE, V286, P1965
   HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527
   HOLBROOK NJ, 1991, NEW BIOL, V3, P825
   ISHII T, 2000, J BIOL CHEM, V275, P16023
   IZCUE A, 2006, IMMUNOL REV, V212, P256
   KANG YJ, 2006, EXP BIOL MED, V231, P1459
   KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300
   KLEIN MA, 1997, NATURE, V390, P687
   KNIGHT JA, 2000, ANN CLIN LAB SCI, V30, P145
   KOLLMORGEN GM, 1979, CANCER RES, V39, P3458
   LAHDENPOHJA N, 1998, J IMMUNOL, V160, P1354
   LESLIE NR, 2006, ANTIOXID REDOX SIGN, V8, P1765
   LOWRY OH, 1951, J BIOL CHEM, V193, P275
   MA X, 2007, HEPATOLOGY, V46, P1519, DOI 10.1002/hep.21823
   MCARTHUR JG, 1993, J EXP MED, V178, P1645
   MCBURNEY MI, 1994, CAN J PHYSIOL PHARM, V72, P260
   NEURATH MF, 2002, NAT MED, V8, P567
   NIIRO H, 2002, NAT REV IMMUNOL, V2, P945
   POGUE SL, 2000, J IMMUNOL, V165, P1300
   SCOTT BC, 1994, FREE RADICAL RES, V20, P119
   SREEKUMAR R, 2002, AM J PHYSIOL-ENDOC M, V282, P1055
   TOHYAMA Y, 2004, CURR PHARM DESIGN, V10, P835
   VACA CE, 1988, MUTAT RES, V195, P137
   VERWEIJ CL, 2002, ANTIOXID REDOX SIGN, V4, P543
   WINDHAGEN A, 1995, J EXP MED, V182, P1985
   YANG RL, 2006, NUTRITION, V22, P1185, DOI 10.1016/j.nut.2006.08.018
NR 39
TC 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 260
IS 1
BP 44
EP 50
DI 10.1016/j.cellimm.2009.08.001
PG 7
SC Cell Biology; Immunology
GA 519RF
UT ISI:000271784500008
ER

PT J
AU Coutandin, D
   Lohr, F
   Niesen, FH
   Ikeya, T
   Weber, TA
   Schafer, B
   Zielonka, EM
   Bullock, AN
   Yang, A
   Guntert, P
   Knapp, S
   McKeon, F
   Ou, HD
   Dotsch, V
AF Coutandin, D.
   Loehr, F.
   Niesen, F. H.
   Ikeya, T.
   Weber, T. A.
   Schaefer, B.
   Zielonka, E. M.
   Bullock, A. N.
   Yang, A.
   Guentert, P.
   Knapp, S.
   McKeon, F.
   Ou, H. D.
   Doetsch, V.
TI Conformational stability and activity of p73 require a second helix in
   the tetramerization domain
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE p73; p63; p53 family; heterooligomerization; tetramerization;
   transcriptional activity
ID TRIPLE-RESONANCE EXPERIMENTS; SQUAMOUS-CELL CARCINOMAS; P53
   TUMOR-SUPPRESSOR; TRANSFORMING DOMAIN; LARGE PROTEINS; LI-FRAUMENI;
   DNA-BINDING; P63; FAMILY; EXPRESSION
AB p73 and p63, the two ancestral members of the p53 family, are involved
   in neurogenesis, epithelial stem cell maintenance and quality control
   of female germ cells. The highly conserved oligomerization domain ( OD)
   of tumor suppressor p53 is essential for its biological functions, and
   its structure was believed to be the prototype for all three proteins.
   However, we report that the ODs of p73 and p63 differ from the OD of
   p53 by containing an additional alpha-helix that is not present in the
   structure of the p53 OD. Deletion of this helix causes a dissociation
   of the OD into dimers; it also causes conformational instability and
   reduces the transcriptional activity of p73. Moreover, we show that ODs
   of p73 and p63 strongly interact and that a large number of different
   heterotetramers are supported by the additional helix. Detailed
   analysis shows that the heterotetramer consisting of two homodimers is
   thermodynamically more stable than the two homotetramers. No
   heterooligomerization between p53 and the p73/p63 subfamily was
   observed, supporting the notion of functional orthogonality within the
   p53 family. Cell Death and Differentiation (2009) 16, 1582-1589; doi:
   10.1038/cdd.2009.139; published online 18 September 2009
C1 [Ou, H. D.] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, Inst Biophys Chem, D-60438 Frankfurt, Hessen, Germany.
   [Coutandin, D.; Loehr, F.; Ikeya, T.; Weber, T. A.; Schaefer, B.; Zielonka, E. M.; Guentert, P.; Ou, H. D.; Doetsch, V.] Goethe Univ Frankfurt, Cluster Excellence Macromol Complexes CEF, D-60438 Frankfurt, Hessen, Germany.
   [Niesen, F. H.; Bullock, A. N.; Knapp, S.] Univ Oxford, Struct Genom Consortium, Nuffield Dept Med, Oxford OX3 7DQ, England.
   [Yang, A.; McKeon, F.] Harvard Univ, Dept Cell Biol, Sch Med, Boston, MA USA.
   [Guentert, P.] Frankfurt Inst Adv Studies, Frankfurt, Germany.
   [Knapp, S.] Univ Oxford, Struct Genom Consortium, Dept Clin Pharmacol, Oxford OX3 7DQ, England.
   [Zielonka, E. M.; McKeon, F.] Genome Inst Singapore, Singapore 138672, Singapore.
RP Ou, HD, Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, Inst
   Biophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Hessen, Germany.
EM hou@salk.edu
   vdoetsch@em.uni-frankfurt.de
FU Deutsche Forschungsgemeinschaft [DO 545/2-1]; EU [LSHB-CT-019067];
   Centre for Biomolecular Magnetic Resonance at the University of
   Frankfurt (BMRZ) ; Cluster of Excellence Frankfurt ; Volkswagen
   Foundation ; Canadian Institutes for Health Research [1097737];
   Canadian Foundation for Innovation ; Genome Canada through the Ontario
   Genomics Institute ; GlaxoSmithKline ; Karolinska Institutet ; Knut and
   Alice Wallenberg Foundation ; Ontario Innovation Trust ; Ontario
   Ministry for Research and Innovation ; Merck Co., Inc. ; Novartis
   Research Foundation ; Swedish Agency for Innovation Systems ; Swedish
   Foundation for Strategic Research ; Wellcome Trust 
FX We thank Benjamin Bardiaux (Institut Pasteur) for providing a modified
   version of ARIA2.2 capable of handling tetramers with a D2 symmetry,
   and Hongmei Mou for help with immunohistochemistry. The research was
   funded by the Deutsche Forschungsgemeinschaft (DO 545/2-1), by the
   EU-Grant EPISTEM (LSHB-CT-019067), by the Centre for Biomolecular
   Magnetic Resonance at the University of Frankfurt (BMRZ), by the
   Cluster of Excellence Frankfurt (Macromolecular Complexes) and by the
   Volkswagen Foundation (PG). The Structural Genomics Consortium is a
   registered charity (number 1097737) that receives funds from the
   Canadian Institutes for Health Research, the Canadian Foundation for
   Innovation, Genome Canada through the Ontario Genomics Institute, from
   GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg
   Foundation, the Ontario Innovation Trust, the Ontario Ministry for
   Research and Innovation, Merck & Co., Inc., the Novartis Research
   Foundation, the Swedish Agency for Innovation Systems, the Swedish
   Foundation for Strategic Research and from the Wellcome Trust.
CR BRODSKY MH, 2000, CELL, V101, P103
   BRYCE DL, 2004, J BIOMOL NMR, V28, P273
   CHENE P, 2001, ONCOGENE, V20, P2611
   CORNILESCU G, 1999, J BIOMOL NMR, V13, P289
   DAVISON TS, 1999, J BIOL CHEM, V274, P18709
   DAVISON TS, 2001, J MOL BIOL, V307, P605
   DELAURENZI V, 1998, J EXP MED, V188, P1768
   DERRY WB, 2001, SCIENCE, V294, P591
   FERNANDEZFERNANDEZ MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI
   10.1073/pnas.0501459102
   GODDARD TD, SPARKY, V3
   GONG JG, 1999, NATURE, V399, P806
   HU H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739
   JAYARAMAN J, 1995, CELL, V81, P1021
   JEFFREY PD, 1995, SCIENCE, V267, P1498
   LEE WT, 1994, NAT STRUCT BIOL, V1, P877
   LINGE JP, 2001, METHOD ENZYMOL B, V339, P71
   LOHR F, 2007, J BIOMOL NMR, V37, P205, DOI 10.1007/s10858-006-9128-4
   LOMAX ME, 1998, ONCOGENE, V17, P643
   MASSION PP, 2004, CHEST S, V125, S102
   MELACINI G, 2000, J AM CHEM SOC, V122, P9735
   MILLS AA, 1999, NATURE, V398, P708
   NYMAN U, 2009, MOL CELL BIOL, V29, P1814, DOI 10.1128/MCB.00585-08
   OLLMANN M, 2000, CELL, V101, P91
   OTTIGER M, 1998, J AM CHEM SOC, V120, P12334
   OU HD, 2007, EMBO J, V26, P3463
   RAJAGOPALAN S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI
   10.1093/nar/gkn598
   ROCCO JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013
   SALZMANN M, 1998, P NATL ACAD SCI USA, V95, P13585
   SALZMANN M, 1999, J AM CHEM SOC, V121, P844
   SERBER Z, 2002, MOL CELL BIOL, V22, P8601, DOI
   10.1128/MCB.22.24.8601-8601.2002
   SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581
   SNIEZEK JC, 2004, LARYNGOSCOPE, V114, P2063, DOI
   10.1097/01.mlg.0000149437.35855.4b
   STURZBECHER HW, 1992, ONCOGENE, V7, P1513
   SUH EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337
   VARLEY JM, 1996, ONCOGENE, V12, P2437
   WEBER A, 2002, INT J CANCER, V99, P22
   YANG A, 1999, NATURE, V398, P714
   YANG A, 2000, NATURE, V404, P99
   YANG A, 2002, TRENDS GENET, V18, P90
   YANG AN, 1998, MOL CELL, V2, P305
NR 40
TC 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD DEC
PY 2009
VL 16
IS 12
BP 1582
EP 1589
DI 10.1038/cdd.2009.139
PG 8
SC Biochemistry & Molecular Biology; Cell Biology
GA 519QY
UT ISI:000271783600003
ER

PT J
AU Yang, L
   Stephens, GJ
AF Yang, Li
   Stephens, Gary J.
TI Effects of neuropathy on high-voltage-activated Ca2+ current in sensory
   neurones
SO CELL CALCIUM
LA English
DT Article
DE Calcium channel; R-type channel; Neuropathy; DRG; SNX-482
ID DEPENDENT CALCIUM-CHANNEL; ROOT GANGLION NEURONS; SCIATIC-NERVE INJURY;
   N-TYPE; DORSAL-HORN; MICE LACKING; NEUROTRANSMITTER RELEASE;
   SYNAPTIC-TRANSMISSION; DENDRITIC SPINES; MOLECULAR-BASIS
AB Voltage-dependent Ca2+ channels (VDCCs) have emerged as targets to
   treat neuropathic pain; however, amongst VDCCs, the precise role of the
   Ca(V)2.3 subtype in nociception remains unproven. Here, we investigate
   the effects of partial sciatic nerve ligation (PSNL) on Ca2+ currents
   in small/medium diameter dorsal root ganglia (DRG) neurones isolated
   from Ca(V)2.3(-/-) knock-out and wild-type (WT) mice. DRG neurones from
   Ca(V)2.3(-/-) mice had significantly reduced sensitivity to SNX-482
   versus WT mice. DRGs from Ca(V)2.3(-/-) mice also had increased
   sensitivity to the Ca(V)2.2 VDCC blocker omega-conotoxin. In WT mice,
   PSNL caused a significant increase in omega-conotoxin-sensitivity and a
   reduction in SNX-482-sensitivity. In Ca(V)2.3(-/-) mice, PSNL caused a
   significant reduction in w-conotoxin-sensitivity and an increase in
   nifedipine sensitivity. PSNL-induced changes in Ca2+ current were not
   accompanied by effects on voltage-dependence of activation in either
   Ca(V)2.3(-/-) or WT mice. These data suggest that Ca(V)2.3 subunits
   contribute, but do not fully underlie, drug-resistant (R-type) Ca2+
   current in these cells. In WT mice, PSNL caused adaptive changes in
   Ca(V)2.2- and Ca(V)2.3-mediated Ca2+ currents, supporting roles for
   these VDCCs in nociception during neuropathy. In Ca(V)2.3(-/-) mice,
   PSNL-induced changes in Ca(V)1 and Ca(V)2.2 Ca2+ current, consistent
   with alternative adaptive mechanisms occurring in the absence of
   Ca(V)2.3 subunits. (c) 2009 Elsevier Ltd. All rights reserved.
C1 [Yang, Li; Stephens, Gary J.] Univ Reading, Sch Pharm, Reading RG6 6AJ, Berks, England.
RP Stephens, GJ, Univ Reading, Sch Pharm, POB 228, Reading RG6 6AJ, Berks,
   England.
EM g.j.stephens@reading.ac.uk
FU BBSRC 
FX We wish to thank Alomone Labs, Israel for kind gifts of SNX-482 and
   Ca<INF>V</INF>2.3 antibody, and in particular the support of Dr. Alon
   Meir. We also wish to thank Prof. Toni Schneider, University of Koln,
   Germany for original supply of breeding pairs of C57B1/6 WT and
   Ca<INF>V</INF>2.3(-/-) mice. The authors declare no conflicts of
   interest. Work funded by BBSRC.
CR ABDULLA FA, 2001, J NEUROPHYSIOL, V85, P630
   ALTIER C, 2004, TRENDS PHARMACOL SCI, V25, P465, DOI
   10.1016/j.tips.2004.07.004
   ALTIER C, 2007, J NEUROSCI, V27, P6363, DOI
   10.1523/JNEUROSCI.0307-07.2007
   BAO JP, 1998, J NEUROSCI, V18, P8740
   BLOODGOOD BL, 2007, CURR OPIN NEUROBIOL, V17, P345, DOI
   10.1016/j.conb.2007.04.003
   BLOODGOOD BL, 2007, NEURON, V53, P249, DOI 10.1016/j.neuron.2006.12.017
   BOURINET E, 1996, P NATL ACAD SCI USA, V93, P1486
   BREUSTEDT J, 2003, P NATL ACAD SCI USA, V100, P12450, DOI
   10.1073/pnas.2035117100
   BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195
   CATTERALL WA, 2000, ANNU REV CELL DEV BI, V16, P521
   CHAPLAN SR, 1994, J PHARMACOL EXP THER, V269, P1117
   CIZKOVA D, 2002, EXP BRAIN RES, V147, P456, DOI
   10.1007/s00221-002-1217-3
   DELMAS P, 2000, NAT NEUROSCI, V3, P670
   DIBIASE V, 2008, J NEUROSCI, V28, P13845, DOI
   10.1523/JNEUROSCI.3213-08.2008
   DIETRICH D, 2003, NEURON, V39, P483
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441
   DOBREMEZ E, 2005, EUR J NEUROSCI, V21, P3321, DOI
   10.1111/j.1460-9568.2005.04177.x
   ERTEL EA, 2000, NEURON, V25, P533
   FANG Z, 2007, J BIOL CHEM, V282, P4757, DOI 10.1074/jbc.M605248200
   GRIBKOFF VK, 2006, SEMIN CELL DEV BIOL, V17, P555, DOI
   10.1016/j.semcdb.2006.09.002
   HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31
   HEINKE B, 2004, EUR J NEUROSCI, V19, P103, DOI
   10.1046/j.1460-9568.2003.03083.x
   IKEDA M, 2003, LIFE SCI, V73, P1175, DOI 10.1016/S0024-3205(03)00414-4
   JUN K, 1999, P NATL ACAD SCI USA, V96, P15245
   KAJA S, 2006, J NEUROPHYSIOL, V95, P2698, DOI 10.1152/jn.01221.2005
   KAMP MA, 2005, EUR J NEUROSCI, V21, P1617, DOI
   10.1111/j.1460-9568.2005.03984.x
   KIM C, 2001, MOL CELL NEUROSCI, V18, P235
   LEE SC, 2002, P NATL ACAD SCI USA, V99, P3276
   LIGHT AR, 1979, J COMP NEUROL, V186, P117
   LOWRY OH, 1951, J BIOL CHEM, V193, P275
   LUO ZD, 2001, J NEUROSCI, V21, P1868
   MATTHEWS EA, 2001, PAIN, V92, P235
   MATTHEWS EA, 2007, EUR J NEUROSCI, V25, P3561, DOI
   10.1111/j.1460-9568.2007.05605.x
   MCCLESKEY EW, 1999, ANNU REV PHYSIOL, V61, P835
   MURAKAMI M, 2004, BRAIN RES, V1024, P122, DOI
   10.1016/j.brainres.2004.07.066
   NEWCOMB R, 1998, BIOCHEMISTRY-US, V37, P15353
   PEREVERZEV A, 2002, MOL ENDOCRINOL, V16, P884
   RYCROFT BK, 2007, J PHYSIOL-LONDON, V580, P883, DOI
   10.1113/jphysiol.2006.125880
   SAEGUSA H, 2000, P NATL ACAD SCI USA, V97, P6132
   SAEGUSA H, 2001, EMBO J, V20, P2349
   SAEGUSA H, 2002, NEUROSCI RES, V43, P1
   SCHOLZ KP, 1995, J NEUROSCI, V15, P4612
   SCHROEDER CI, 2006, MED CHEM, V2, P535
   SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639
   SELTZER Z, 1990, PAIN, V43, P205
   SOCHIVKO D, 2002, J PHYSIOL-LONDON, V542, P699, DOI
   10.1113/jphysiol.2002.020677
   STAATS PS, 2004, JAMA-J AM MED ASSOC, V291, P63
   STRIESSNIG J, 2008, CHANNELS, V2, P233
   URBANO FJ, 2003, P NATL ACAD SCI USA, V100, P3491, DOI
   10.1073/pnas.0437991100
   VANEGAS H, 2000, PAIN, V85, P9
   WESTENBROEK RE, 1998, J NEUROSCI, V18, P6319
   WILSON SM, 2000, J NEUROSCI, V20, P8566
   WOOLF CJ, 1991, PAIN, V44, P293
   WU LG, 1999, J NEUROSCI, V19, P726
   YAKSH TL, 2006, J PAIN S1, V7, S13, DOI 10.1016/j.jpain.2005.09.007
   YOKOYAMA K, 2003, ANESTHESIOLOGY, V99, P1364
   YOKOYAMA K, 2004, EUR J NEUROSCI, V20, P3516, DOI
   10.1111/j.1460-9568.2004.03810.x
   YUSAF SP, 2001, NEUROSCI LETT, V311, P137
NR 58
TC 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
J9 CELL CALCIUM
JI Cell Calcium
PD OCT
PY 2009
VL 46
IS 4
BP 248
EP 256
DI 10.1016/j.ceca.2009.08.001
PG 9
SC Cell Biology
GA 518KK
UT ISI:000271690100004
ER

PT J
AU Byeon, IJL
   Meng, X
   Jung, JW
   Zhao, GP
   Yang, RF
   Ahn, JW
   Shi, J
   Concel, J
   Aiken, C
   Zhang, PJ
   Gronenborn, AM
AF Byeon, In-Ja L.
   Meng, Xin
   Jung, Jinwon
   Zhao, Gongpu
   Yang, Ruifeng
   Ahn, Jinwoo
   Shi, Jiong
   Concel, Jason
   Aiken, Christopher
   Zhang, Peijun
   Gronenborn, Angela M.
TI Structural Convergence between Cryo-EM and NMR Reveals Intersubunit
   Interactions Critical for HIV-1 Capsid Function
SO CELL
LA English
DT Article
ID C-TERMINAL DOMAIN; DIMERIZATION DOMAIN; CRYSTAL-STRUCTURES;
   MEMBRANE-PROTEINS; TUBULAR CRYSTALS; GAG POLYPROTEIN; VIRUS;
   RESOLUTION; ALIGNMENT; RECONSTRUCTIONS
AB Mature HIV-1 particles contain conical-shaped capsids that enclose the
   viral RNA genome and perform essential functions in the virus life
   cycle. Previous structural analysis of two-and three-dimensional arrays
   of the capsid protein (CA) hexamer revealed three interfaces. Here, we
   present a cryoEM study of a tubular assembly of CA and a
   high-resolution NMR structure of the CA C-terminal domain (CTD) dimer.
   In the solution dimer structure, the monomers exhibit different
   relative orientations compared to previous X-ray structures. The
   solution structure fits well into the EM density map, suggesting that
   the dimer interface is retained in the assembled CA. We also identified
   a CTD-CTD interface at the local three-fold axis in the cryoEM map and
   confirmed its functional importance by mutagenesis. In the tubular
   assembly, CA intermolecular interfaces vary slightly, accommodating the
   asymmetry present in tubes. This provides the necessary plasticity to
   allow for controlled virus capsid dis/assembly.
C1 [Byeon, In-Ja L.; Meng, Xin; Jung, Jinwon; Zhao, Gongpu; Ahn, Jinwoo; Concel, Jason; Zhang, Peijun; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [Yang, Ruifeng; Shi, Jiong; Aiken, Christopher] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
RP Zhang, PJ, Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA
   15260 USA.
EM pez7@pitt.edu
   amg100@pitt.edu
FU National Institutes of Health [GM082251, AI076121, GM085043]
FX We thank Dr. Joanne Yeh for useful discussions and Dr. Teresa
   Brosenitsch for critical reading of the manuscript. We thank Drs. Koji
   Yonekura, Edward Egelman, and Niko Grigorieff for sharing their image
   processing software and Dr. Jing Zhou for technical assistance. This
   work is a contribution from the Pittsburgh Center for HIV Protein
   Interactions and was supported by the National Institutes of Health
   (GM082251, AI076121, and GM085043).
CR AIKEN C, 2009, METH MOL B, V485, P41, DOI 10.1007/978-1-59745-170-3_4
   ALCARAZ LA, 2007, BIOPHYS J, V93, P1264, DOI 10.1529/biophysj.106.101089
   BAX A, 1993, ACCOUNTS CHEM RES, V26, P131
   BERTHETCOLOMINAS C, 1999, EMBO J, V18, P1124
   BOSCO DA, 2004, BIOCHEMISTRY-US, V43, P6110, DOI 10.1021/bi049841z
   BRIGGS JAG, 2003, EMBO J, V22, P1707
   BRIGGS JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   BRUNGER AT, 1992, NATURE, V355, P472
   CARDONE G, 2009, NATURE, V457, P694, DOI 10.1038/nature07724
   CLORE GM, 1998, TRENDS BIOTECHNOL, V16, P22
   CORNILESCU G, 1999, J BIOMOL NMR, V13, P289
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277
   EGELMAN EH, 2007, J STRUCT BIOL, V157, P83, DOI
   10.1016/j.jsb.2006.05.015
   ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577
   FORSHEY BM, 2002, J VIROL, V76, P5667
   GALLAY P, 1997, P NATL ACAD SCI USA, V94, P9825
   GAMBLE TR, 1996, CELL, V87, P1285
   GAMBLE TR, 1997, SCIENCE, V278, P849
   GANSER BK, 1999, SCIENCE, V283, P80
   GANSERPORNILLOS BK, 2004, J VIROL, V78, P2545, DOI
   10.1128/JVI.78.5.2545-2552.2004
   GANSERPORNILLOS BK, 2007, CELL, V131, P70, DOI
   10.1016/j.cell.2007.08.018
   GODDARD TD, 2004, SPARKY 3
   HANSEN MR, 1998, NAT STRUCT BIOL, V5, P1065
   HERRMANN T, 2002, J MOL BIOL, V319, P209
   IVANOV D, 2007, P NATL ACAD SCI USA, V104, P4353, DOI
   10.1073/pnas.0609477104
   KELLY BN, 2006, BIOCHEMISTRY-US, V45, P11257, DOI 10.1021/bi060927x
   KORADI R, 1996, J MOL GRAPHICS, V14, P29
   KORADI R, 1996, J MOL GRAPHICS, V14, P51
   LANMAN J, 2003, J MOL BIOL, V325, P759, DOI
   10.1016/S0022-2836(02)01245-7
   LASKOWSKI RA, 1996, J BIOMOL NMR, V8, P477
   LEE W, 1994, FEBS LETT, V350, P87
   LI S, 2000, NATURE, V407, P409
   LUDTKE SJ, 1999, J STRUCT BIOL, V128, P82
   MOMANY C, 1996, NAT STRUCT BIOL, V3, P763
   MORTUZA GB, 2004, NATURE, V431, P481, DOI 10.1038/nature02915
   NERMUT MV, 1998, J STRUCT BIOL, V123, P143
   OTTIGER M, 1998, J MAGN RESON, V131, P373
   PETTERSEN EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PHILLIPS JM, 2008, EMBO J, V27, P1411, DOI 10.1038/emboj.2008.71
   PORNILLOS O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   ROSE S, 1992, PROTEINS, V13, P112
   RUCKERT M, 2000, J AM CHEM SOC, V122, P7793
   SACHSE C, 2007, J MOL BIOL, V371, P812, DOI 10.1016/j.jmb.2007.05.088
   SATTLER M, 1995, J BIOMOL NMR, V5, P97
   SCHWIETERS CD, 2003, J MAGN RESON, V160, P65
   TANG C, 2002, NAT STRUCT BIOL, V9, P537
   TANG JH, 2006, J STRUCT BIOL, V154, P59, DOI 10.1016/j.jsb.2005.10.013
   TERNOIS F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967
   VONSCHWEDLER UK, 2003, J VIROL, V77, P5439, DOI
   10.1128/JVI.77.9.5439-5450.2003
   WONG HC, 2008, BIOCHEMISTRY-US, V47, P2289, DOI 10.1021/bi7022128
   WORTHYLAKE DK, 1999, ACTA CRYSTALLOGR D 1, V55, P85
   WRIGHT ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   YANG RF, 2007, J VIROL, V81, P3749, DOI 10.1128/JVI.02634-06
   YONEKURA K, 2000, ULTRAMICROSCOPY, V84, P15
   YONEKURA K, 2007, ULTRAMICROSCOPY, V107, P1141, DOI
   10.1016/j.ultramic.2007.01.013
   ZWECKSTETTER M, 2000, J AM CHEM SOC, V122, P3791
NR 56
TC 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD NOV 13
PY 2009
VL 139
IS 4
BP 780
EP 790
DI 10.1016/j.cell.2009.10.010
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 519EG
UT ISI:000271747200021
ER

PT J
AU Jin, MJ
   Kawakami, K
   Fukui, Y
   Tsukioka, S
   Oda, M
   Watanabe, G
   Takechi, T
   Oka, T
   Minamoto, T
AF Jin, MingJi
   Kawakami, Kazuyuki
   Fukui, Yousuke
   Tsukioka, Sayaka
   Oda, Makoto
   Watanabe, Go
   Takechi, Teiji
   Oka, Toshinori
   Minamoto, Toshinari
TI Different histological types of non-small cell lung cancer have
   distinct folate and DNA methylation levels
SO CANCER SCIENCE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; COLORECTAL CANCERS; ESOPHAGEAL ADENOCARCINOMA;
   COLON-CANCER; RISK-FACTORS; SMOKING; PHENOTYPE; HYPERMETHYLATION;
   HYDROLASE; PROFILES
AB Aberrant DNA methylation is a commonly observed epigenetic change in
   lung cancer. Folate has been suggested to play a role in the
   homeostasis of DNA methylation and has also been implicated in cancer
   chemotherapy. We investigated a possible role for folate in DNA
   methylation by measuring folate concentrations in tumors and adjacent
   normal tissues from 72 non-small cell lung cancer (NSCLC) patients.
   These were compared to DNA methylation levels and to
   clinicopathological features. Folate concentrations were determined as
   the sum of 5,10-methylenetetrahydrofolate and tetrahydrofolate. The
   MethyLight assay was used to quantitate methylation in promoter regions
   of P16(CDKN2A), APC, CDH13, RARB, RASSF1, RUNX3, and MYOD1. Methylation
   of LINE-1 repeats was used as a surrogate for global methylation.
   Folate levels in tumors correlated positively with LINE-1, CDH13, and
   RUNX3 methylation. Folate concentrations and methylation of LINE-1,
   RASSF1, and RUNX3 were significantly higher in adenocarcinoma compared
   to squamous cell carcinoma (SCC). Two sets of array-based data
   retrieved from the Gene Expression Omnibus consistently showed that
   expression of FOLR1, a folate transport enzyme, and GGH, an enzyme that
   prevents folate retention, were higher and lower, respectively, in
   adenocarcinomas compared to SCC. This was independently validated by
   quantitative RT-PCR in 26 adenocarcinomas and 13 SCC. Our results
   suggest that folate metabolism plays a role in aberrant DNA methylation
   in NSCLC. The histological subtype differences in folate concentration
   and DNA methylation observed here were associated with distinct
   expression patterns for folate metabolizing enzymes. These findings may
   have clinical applications for histology-directed chemotherapy with
   fluoropyrimidine and anti-folates in NSCLC. (Cancer Sci 2009l; 100:
   2325-2330).
C1 [Jin, MingJi; Kawakami, Kazuyuki; Minamoto, Toshinari] Kanazawa Univ, Canc Res Inst, Mol & Cellular Targeting Translat Oncol Ctr, Div Translat & Clin Oncol, Kanazawa, Ishikawa 920, Japan.
   [Fukui, Yousuke; Tsukioka, Sayaka; Oka, Toshinori] Taiho Pharmaceut Co, Tokushima Res Ctr, Tokushima, Japan.
   [Oda, Makoto; Watanabe, Go] Kanazawa Univ, Grad Sch Med Sci, Dept Gen & Cardiothorac Surg, Kanazawa, Ishikawa 920, Japan.
   [Takechi, Teiji] Taiho Pharmaceut Co, Prod Planning & Lifecycle Management Dept, Tokyo, Japan.
RP Kawakami, K, Kanazawa Univ, Canc Res Inst, Mol & Cellular Targeting
   Translat Oncol Ctr, Div Translat & Clin Oncol, Kanazawa, Ishikawa 920,
   Japan.
EM kawakami@med.kanazawa-u.ac.jp
FU Japanese Society for the Promotion of Science 
FX This work was supported in part by Grants-in-Aid for Scientific
   Research from the Japanese Society for the Promotion of Science.
CR AHUJA N, 1998, CANCER RES, V58, P5489
   BROWNSON RC, 1992, EPIDEMIOLOGY, V3, P61
   CHO E, 2006, INT J CANCER, V118, P970, DOI 10.1002/ijc.21441
   EADS CA, 2000, NUCLEIC ACIDS RES, V28, ARTN E32
   EADS CA, 2001, CANCER RES, V61, P3410
   GABRIEL HE, 2006, AM J CLIN NUTR, V83, P835
   HAWKINS N, 2002, GASTROENTEROLOGY, V122, P1376
   IACOPETTA B, 2007, CANCER SCI, V98, P1454
   ISSA JP, 1999, CRIT REV ONCOL HEMAT, V32, P31
   JONES PA, 2002, NAT REV GENET, V3, P415
   KATO H, 2004, NEW ENGL J MED, V350, P1713
   KAWAKAMI K, 2000, J NATL CANCER I, V92, P1805
   KAWAKAMI K, 2003, CLIN CANCER RES 1, V9, P5860
   KEYOMARSI K, 1986, CANCER RES, V46, P5229
   KWABIADDO B, 2007, CLIN CANCER RES, V13, P3796, DOI
   10.1158/1078-0432.CCR-07-0085
   LEE HY, 2009, LUNG CANC
   LIU ZY, 2008, LUNG CANCER, V62, P15, DOI 10.1016/j.lungcan.2008.02.005
   LUBIN JH, 1984, J NATL CANCER I, V73, P383
   MATHERLY LH, 2003, VITAM HORM, V66, P403
   OUGOLKOV AV, 2002, GASTROENTEROLOGY, V122, P60
   PRIEST DG, 1991, J NATL CANCER I, V83, P1806
   RISCH A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605
   SAKAMOTO E, 2008, BIOCHEM BIOPH RES CO, V365, P801, DOI
   10.1016/j.bbrc.2007.11.043
   SAMOWITZ WS, 2005, GASTROENTEROLOGY, V129, P837, DOI
   10.1053/j.gastro.2005.06.020
   SCHNEIDER E, 2006, CLIN CHIM ACTA, V374, P25, DOI
   10.1016/j.cca.2006.05.044
   SHIH C, 1997, CANCER RES, V57, P1116
   SMIT EF, 2009, J CLIN ONCOL, V27, P2038, DOI 10.1200/JCO.2008.19.1650
   SMITH IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889
   SO KJ, 2006, CANCER SCI, V97, P1155, DOI
   10.1111/j.1349-7006.2006.00302.x
   TOYOOKA S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   TOYOOKA S, 2004, INT J CANCER, V110, P462, DOI 10.1002/ijc.20125
   TOYOTA M, 1999, P NATL ACAD SCI USA, V96, P8681
   VAISSIERE T, 2009, CANCER RES, V69, P243, DOI
   10.1158/0008-5472.CAN-08-2489
   VANRIJNSOEVER M, 2002, GUT, V51, P797
   ZOCHBAUERMULLER S, 2001, CANCER RES, V61, P249
NR 35
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD DEC
PY 2009
VL 100
IS 12
BP 2325
EP 2330
DI 10.1111/j.1349-7006.2009.01321.x
PG 6
SC Oncology
GA 518QX
UT ISI:000271709300013
ER

PT J
AU Watanabe, G
   Kato, S
   Nakata, H
   Ishida, T
   Ohuchi, N
   Ishioka, C
AF Watanabe, Gou
   Kato, Shunsuke
   Nakata, Hideyuki
   Ishida, Takanori
   Ohuchi, Noriaki
   Ishioka, Chikashi
TI alpha B-crystallin: A novel p53-target gene required for p53-dependent
   apoptosis
SO CANCER SCIENCE
LA English
DT Article
ID TUMOR-SUPPRESSOR PROTEIN; NON-LENTICULAR TISSUES; TRANSCRIPTIONAL
   ACTIVITY; MUTATION ANALYSIS; TP53 DATABASE; P53; ACTIVATION;
   EXPRESSION; LENS; CASPASE-3
AB The p53 protein is a transcription factor that trans-activates various
   genes in response to DNA-damaging stress. To search for new p53-target
   genes, we applied a cDNA microarray system using two independent
   p53-inducible cell lines, followed by in silico analysis to detect p53
   response elements. Here, we report on crystallin alpha B gene (CRYAB),
   which encodes alpha B-crystallin, and is one of the genes directly
   trans-activated by p53. We confirmed it is directly transcribed by p53
   using promoter analysis, deletion reporter assay, ChIP assay and EMSA.
   alpha B-crystallin is also upregulated in a p53-dependent manner and
   binds to the DNA-binding domain of p53. Overexpression of alpha
   B-crystallin increased p53 protein and, in contrast, repression of
   alpha B-crystallin decreased p53 protein. Interestingly, both
   overexpression and repression of alpha B-crystallin reduced
   p53-dependent apoptosis. In conclusion, we identified that alpha
   B-crystallin was a novel p53-target gene and required for p53-dependent
   apoptosis using two independent p53-inducible cell lines. This is the
   first report associating p53 directly with a heat shock protein through
   trans-activation and physical interaction. (Cancer Sci 2009; 100:
   2368-2375).
C1 [Watanabe, Gou; Kato, Shunsuke; Nakata, Hideyuki; Ishioka, Chikashi] Tohoku Univ, Res Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan.
   [Watanabe, Gou; Ishida, Takanori; Ohuchi, Noriaki] Tohoku Univ, Sch Med, Div Surg Oncol, Sendai, Miyagi 980, Japan.
RP Ishioka, C, Tohoku Univ, Res Inst Dev Aging & Canc, Dept Clin Oncol,
   Sendai, Miyagi 980, Japan.
EM chikashi@idac.tohoku.ac.jp
FU Ministry of Education, Sciences, Sports, and Culture [12217010,
   17015002]; Gonryo Medical Foundation 
FX We thank Shin Takahashi, Satsuki Mashiko, and Atsuko Sato for their
   technical assistance. This study was supported by grants-in-aid from
   the Ministry of Education, Sciences, Sports, and Culture (12217010 and
   17015002), and the Gonryo Medical Foundation to C.I.
CR AOYAMA A, 1993, INT J CANCER, V55, P760
   BAI F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200
   BARAK Y, 1993, EMBO J, V12, P461
   BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319
   CHELOUCHELEV D, 2004, CANCER, V100, P2543, DOI 10.1002/cncr.20304
   DORNAN D, 2004, NATURE, V429, P86
   DUBIN RA, 1989, MOL CELL BIOL, V9, P1083
   DUBIN RA, 1990, GENOMICS, V7, P594
   ELDEIRY WS, 1992, NAT GENET, V1, P45
   ELDEIRY WS, 1993, CELL, V75, P817
   HAMROUN D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269
   HERMEKING H, 1997, MOL CELL, V1, P3
   HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449
   IWAKI T, 1989, CELL, V57, P71
   IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31
   IWAKI T, 1992, AM J PATHOL, V140, P345
   JEN KY, 2005, CANCER RES, V65, P7666, DOI 10.1158/0008-5472.CAN-05-1039
   KAKUDO Y, 2005, CANCER RES, V65, P2108
   KAMRADT MC, 2001, J BIOL CHEM, V276, P16059
   KAMRADT MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200
   KAMRADT MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200
   KASTAN MB, 2003, CELL, V112, P1
   KATO S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI
   10.1073/pnas.1431692100
   KAWAGUCHI T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839
   KHO PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200
   LI DWC, 2001, EXP CELL RES, V266, P279
   LI DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   LIU G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700
   LIU GDS, 2005, EXCLI J, V4, P7
   LIU S, 2007, BIOCHEM BIOPH RES CO, V354, P109, DOI
   10.1016/j.bbrc.2006.12.152
   LOWE J, 1992, J PATHOL, V166, P61
   MAO YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   MARUYAMA R, 2006, CANCER RES, V66, P4574, DOI
   10.1158/0008-5472.CAN-05-2562
   MIYASHITA T, 1995, CELL, V80, P293
   MOYANO JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888
   NAKAMURA Y, 2004, CANCER SCI, V95, P7
   NAKANO K, 2001, MOL CELL, V7, P683
   OLIVIER M, 2002, HUM MUTAT, V19, P607
   SHIMADA A, 1999, CANCER RES, V59, P2781
   SORLIE T, 2001, P NATL ACAD SCI USA, V98, P10869
   STARITA LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200
   WEI CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043
   ZYLICZ M, 2001, EMBO J, V20, P4634
NR 44
TC 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD DEC
PY 2009
VL 100
IS 12
BP 2368
EP 2375
DI 10.1111/j.1349-7006.2009.01316.x
PG 8
SC Oncology
GA 518QX
UT ISI:000271709300020
ER

PT S
AU Mann, DL
   Celluzzi, CM
   Hankey, KG
   Harris, KM
   Watanabe, R
   Hasumi, K
AF Mann, Dean L.
   Celluzzi, Christina M.
   Hankey, Kim G.
   Harris, Kristina M.
   Watanabe, Ryuko
   Hasumi, Kenichiro
ED Steinman, R; Banchereau, J; Finn, OJ
TI Combining Conventional Therapies with Intratumoral Injection of
   Autologous Dendritic Cells and Activated T Cells to Treat Patients with
   Advanced Cancers
SO CANCER VACCINES
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Proceedings Paper
CT 6th International Cancer Vaccine Symposium
CY OCT 28-30, 2008
CL New York, NY
SP New York Acad Sci
DE dendritic cells; activated T cells; combination immunotherapy;
   intratumoral injection; cancer vaccine
ID PERIPHERAL-BLOOD LYMPHOCYTES; ADOPTIVE TRANSFER; TUMOR-CELLS; IN-VIVO;
   ESTABLISHED TUMORS; IMMUNOTHERAPY; CYCLOPHOSPHAMIDE; IMMUNITY;
   RADIATION; APOPTOSIS
AB Dendritic cells (DCs) are potent antigen-presenting cells that have
   been used in cancer immunotherapy. To take advantage of the ability of
   DCs to acquire antigenic materials from their environment and generate
   primary as well as recall immune responses, 37 patients with advanced
   cancers were enrolled in a series of protocols based on direct
   intratumoral injection of immature DCs. To augment antigen uptake and
   antitumor immune response, DC injection was combined with radiotherapy
   or chemotherapy and/or injection of activated T cells. Treatments were
   well tolerated with no adverse reactions. Clinical responses were based
   on Response Evaluation Criteria in Solid Tumors, with the majority of
   patients showing stable disease. One of two patients who also received
   local radiation achieved a sustained complete response at injected and
   metastatic sites. The clinical responses observed in cancer patients
   with advanced disease suggest potential effectiveness of combination
   strategies and establish the basis for the current treatment protocol
   that is underway.
C1 [Mann, Dean L.; Celluzzi, Christina M.; Hankey, Kim G.; Harris, Kristina M.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
RP Mann, DL, Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
EM dmann001@umaryland.edu
CR AWWAD M, 1989, CANCER RES, V49, P1649
   BANCHEREAU J, 1998, NATURE, V392, P245
   BANCHEREAU J, 2003, ANN NY ACAD SCI, V987, P180
   BERD D, 1984, CANCER RES, V44, P5439
   BERGER C, 2003, BLOOD, V101, P476
   BODEY B, 2000, ANTICANCER RES, V20, P2665
   CHI KW, 2005, J IMMUNOTHER, V28, P129
   DENBROK MHMGM, 2005, EXPERT REV VACCINES, V4, P699, DOI
   10.1586/14760584.4.5.699
   DIEUNOSJEAN MC, 1999, J LEUKOCYTE BIOL, V66, P252
   DYNLACHT JR, 1999, RADIAT RES, V152, P590
   GHIRINGHELLI F, 2004, EUR J IMMUNOL, V34, P336
   GOLDRATH AW, 1999, NATURE, V402, P255
   GREENBERG PD, 1981, J EXP MED, V154, P952
   GRIMM EA, 1982, J EXP MED, V155, P1823
   HARRIS KM, 2008, CLIN IMMUNOL, V129, P58
   HATFIELD P, 2005, CLIN ONCOL-UK, V17, P1, DOI 10.1016/j.clon.2004.06.014
   HENRY F, 1999, CANCER RES, V59, P3329
   HODI FS, 2006, ADV IMMUNOL, V90, P341, DOI 10.1016/S0065-2776(06)90009-1
   HOFFMANN TK, 2000, CANCER RES, V60, P3542
   HSU FJ, 1996, NAT MED, V2, P52
   JENNE L, 2000, CANCER RES, V60, P4446
   KUDOSAITO C, 2005, CLIN CANCER RES, V11, P4533
   LAPORT GG, 2003, BLOOD, V102, P2004, DOI 10.1182/blood-2003-01-0095
   LEVINE BJ, 1997, CRIME LAW SOCIAL CH, V28, P1
   LEVINE BL, 2002, NAT MED, V8, P47
   MAUS MV, 2002, NAT BIOTECHNOL, V20, P143
   MORSE MA, 2003, CANCER INVEST, V21, P341, DOI 10.1081/CNV-120018224
   PACZESNY S, 2003, SEMIN CANCER BIOL, V13, P439, DOI
   10.1016/j/semcancer.2003.09.008
   PECHER G, 2002, CANCER IMMUNOL IMMUN, V51, P669, DOI
   10.1007/s00262-002-0317-z
   RAPOPORT AP, 2004, BONE MARROW TRANSPL, V33, P53, DOI
   10.1038/sj.bmt.1704317
   RESTIFO NP, 2000, CURR OPIN IMMUNOL, V12, P597
   SATO T, 2004, CANCER IMMUNOL IMMUN, V53, P53, DOI
   10.1007/s00262-003-0419-2
   SCHNURR M, 2002, CANCER RES, V62, P2347
   SHINOMIYA N, 2000, INT J RADIAT ONCOL, V47, P767
   SMALL EJ, 2000, J CLIN ONCOL, V18, P3894
   SRIVASTAVA PK, 2003, CANC IMMUN, V3, P4
   STAHNKE K, 2001, BLOOD, V98, P3066
   STEINMAN RM, 1999, HUM IMMUNOL, V60, P562
   TANAKA F, 2002, INT J CANCER, V101, P265, DOI 10.1002/ijc.10597
   THOMPSON JA, 2003, CLIN CANCER RES 1, V9, P3562
   TONG YZ, 2001, CANCER RES, V61, P7530
   TRIOZZI PL, 2000, CANCER, V89, P2646
   YAMAZAKI T, 1992, NEUROL MED CHIR TOKY, V32, P255
   YEE C, 2005, J TRANSL MED, V3, P17
NR 44
TC 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND
SN 0077-8923
BN 978-1-57331-759-7
J9 ANN N Y ACAD SCI
JI Ann.NY Acad.Sci.
PY 2009
VL 1174
BP 41
EP 50
DI 10.1111/j.1749-6632.2009.04934.x
PG 10
SC Multidisciplinary Sciences
GA BMC20
UT ISI:000271828500006
ER

PT J
AU Yang, SS
   Huang, HC
AF Yang, Sharon S.
   Huang, Hong-Chih
TI The Impact of Longevity Risk on the Optimal Contribution Rate and Asset
   Allocation for Defined Contribution Pension Plans
SO GENEVA PAPERS ON RISK AND INSURANCE-ISSUES AND PRACTICE
LA English
DT Article
DE longevity risk; asset allocation; income replacement ratio
ID GUARANTEED ANNUITY OPTIONS; MORTALITY; ACCUMULATION; MANAGEMENT;
   VALUATION; SCHEMES; DESIGN; PHASE
AB This research studies the interaction between longevity risk and asset
   allocation for a defined contribution pension plan. We investigate the
   investment strategy during the accumulation phase to deal with
   longevity risk during the decumulation phase. The longevity risk is
   demonstrated using the U. K. mortality experience for pensioners. We
   experiment with three patterns of mortality: base, projection and
   stochastic mortality rates. The optimal asset allocation and
   contribution rate are determined by minimizing the variance of the
   error between the value of pension fund and required pension fund plus
   the square of the expected value of the error. The required pension
   fund is decided by the pension fund target, measured using the income
   replacement ratio. We consider four assets in the asset allocation and
   observe four types of changes to the rebalancing investment strategies.
   The results show a life cycle investment strategy and indicate that
   longevity risk can be hedged by either raising the contribution rate or
   setting a more aggressive asset allocation. The Geneva Papers (2009)
   34, 660-681. doi: 10.1057/gpp.2009.18
C1 [Yang, Sharon S.] Natl Cent Univ, Dept Finance, Tao Yuan, Taiwan.
   [Huang, Hong-Chih] Natl Chengchi Univ, Dept Risk Management & Insurance, Taipei, Taiwan.
RP Yang, SS, Natl Cent Univ, Dept Finance, 300 Rd, Tao Yuan, Taiwan.
EM syang@ncu.edu.tw
   jerry2@nccu.edu.tw
CR *CMIB, 1978, CONT MORT INV REP, P1
   *CMIB, 1988, CONT MORT INV REP, P1
   *CMIB, 1990, CONT MORT INV REP, P1
   *CMIB, 1998, CONT MORT INV REP, P113
   *CMIB, 1999, CONT MORT INV REP, P1
   *CMIB, 2007, 25 CMIB
   BALLOTTA L, 2003, INSUR MATH ECON, V33, P87, DOI
   10.1016/S0167-6687(03)00146-X
   BALLOTTA L, 2006, INSUR MATH ECON, V38, P195, DOI
   10.1016/j.insmatheco.2005.10.002
   BATTOCCHIO P, 2004, INSUR MATH ECON, V34, P79, DOI
   10.1015/j.insmatheco.2003.11.001
   BATTOCCHIO P, 2007, ANN OPER RES, V152, P141, DOI
   10.1007/s10479-006-0144-2
   BLAKE D, 2001, INSUR MATH ECON, V29, P187
   BLAKE D, 2003, INSUR MATH ECON, V33, P29, DOI
   10.1016/S0167-6687(03)00141-0
   BOYLE PP, 2003, ASTIN BULL, V33, P125
   CAIRNS AJG, 2004, PRICING DEATH FRAMEW
   CAIRNS AJG, 2004, STOCHASTIC LIFESTYLI
   CAIRNS AJG, 2009, N AM ACTUARIAL J, V13, P1
   CHARUPAT N, 2002, INSUR MATH ECON, V30, P199
   GERRARD R, 2006, N AM ACTUARIAL J, V10, P84
   HABERMAN S, 2002, INSUR MATH ECON, V31, P35
   HAINAUT D, 2007, INSUR MATH ECON, V41, P134, DOI
   10.1016/j.insmatheco.2006.10.014
   HORNEFF WJ, 2008, INSUR MATH ECON, V42, P396, DOI
   10.1016/j.insmatheco.2007.04.004
   HUANG HC, 2006, INSUR MATH ECON, V38, P113, DOI
   10.1016/j.insmatheco.2005.08.005
   LEE PJ, 2000, WILK HER WATT U ED
   MILEVSKY MA, 2001, INSUR MATH ECON, V29, P299
   ORTH BJ, 2006, N AM ACTUARIAL J, V10, P32
   PELSSER A, 2003, INSUR MATH ECON, V33, P283, DOI
   10.1016/S0167-6687(03)00154-9
   PITACCO E, 2004, INSUR MATH ECON, V35, P279, DOI
   10.1016/j.insmatheco.2004.04.001
   RAIMOND H, 2007, OPTIMAL LIFE CYCLE S
   RENSHAW AE, 2000, 127 CIT U
   RENSHAW AE, 2003, INSUR MATH ECON, V32, P379, DOI
   10.1016/S0167-6687(03)00118-5
   SHERRIS M, 1992, J I ACTUARIES, V119, P87
   VIGNA E, 2001, INSUR MATH ECON, V28, P233
   WILKIE AD, 1986, T FACULTY ACTUARIES, V39, P341
   WILKIE AD, 1995, BRIT ACTUARIAL J, V1, P777
   WILKIE AD, 2003, BRIT ACTUARIAL J, V9, P263
   WILLETS RC, 2004, BRIT ACTUARIAL J, V10, P1027
   WISE AJ, 1984, J I ACTUARIES, V111, P445
   YANG SS, 2001, THESIS HERIOT WATT U
NR 38
TC 2
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 1018-5895
J9 GENEVA PAP RISK INSUR-ISS PR
JI Geneva Pap. Risk Insur.-Issues Pract.
PD OCT
PY 2009
VL 34
IS 4
BP 660
EP 681
DI 10.1057/gpp.2009.18
PG 22
SC Business, Finance
GA 515ME
UT ISI:000271474800013
ER

PT J
AU Zhao, ZM
   Sun, YX
   Hou, N
   Teng, Y
   Wang, YL
   Yang, X
AF Zhao, Zengming
   Sun, Yanxun
   Hou, Ning
   Teng, Yan
   Wang, Youliang
   Yang, Xiao
TI Capn8 Promoter Directs the Expression of Cre Recombinase in Gastric Pit
   Cells of Transgenic Mice
SO GENESIS
LA English
DT Article
DE gastric pit cell; gastric epithelium; Cre recombinase; transgenic
   mouse; calpain-8
ID MOUSE STOMACH; EPITHELIAL-CELLS; PROGENITOR; SECRETION; DYNAMICS;
   CORPUS; LIVER; MODEL; CIS
AB Gastric Pit cells are high-turnover epithelial cells of the gastric
   mucosa. They secrete mucus to protect the gastric epithelium from acid
   and pepsin. To investigate the genetic mechanisms underlying the
   physiological functions of gastric pit cells, we generated a transgenic
   mouse line, namely, Capn8-Cre, in which the expression of Cre
   recombinase was controlled by the promoter of the intracellular
   Ca2+-regulated cysteine protease calpain-8. To test the tissue
   distribution and excision activity of Cre recombinase, the Capn8-Cre
   transgenic mice were bred with the ROSA26 reporter strain and a mouse
   strain that carries Smad4 conditional alleles (Smad4(Co/Co)).
   Multiple-tissue PCR and LacZ staining demonstrated that Capn8-Cre
   transgenic mouse expressed Cre recombinase in the gastric pit cells.
   Cre recombinase activity was also detected in the liver and skin
   tissues. These data suggest that the Capn8-Cre mouse line described
   here could be used to dissect gene function in gastric pit cells.
   genesis 47:674-679, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Zhao, Zengming; Sun, Yanxun; Hou, Ning; Teng, Yan; Wang, Youliang; Yang, Xiao] Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, Beijing 100071, Peoples R China.
   [Yang, Xiao] Shanghai Jiao Tong Univ, Model Organism Div, E Inst, Shanghai Univ, Shanghai 200030, Peoples R China.
RP Yang, X, Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, 20
   Dongdajie, Beijing 100071, Peoples R China.
EM yangx@nic.bmi.ac.cn
FU Chinese National Key Program on Basic Research [2005CB522506,
   2006CB943501, 2006BA123B01-3]; Key Project for Drug Discoven and
   Development in China [20019ZX09501]; Key Project for Infections
   Diseases in China [2008ZX10002-016]; National Natural Science
   Foundation of China [30671077, 30430350]; Beijing Municipal Project
   [Z0006303041231]; E-Institutes of Shanghai Municipal Education
   Commission [F03003]
FX Contract grant sponsor: Chinese National Key Program on Basic Research,
   Contract grant numbers: 2005CB522506, 2006CB943501, 2oo6BA123B01-3;
   Contract grant sponsor: Key Project for Drug Discoven and Development
   in China; Contract grant number: 20019ZX09501-027; Contract grant
   sponsor: Key Project for Infections Diseases in China, Contract grant
   number: 2008ZX10002-016; Contract giant sponsor: National Natural
   Science Foundation of China, Contract grant numbers: 30671077,
   30430350; Contract grant sponsor: Beijing Municipal Project, Contract
   grant number: Z0006303041231; Contract grant sponsor: E-Institutes of
   Shanghai Municipal Education Commission, Contract grant nurnher: F03003
CR ASSI K, 2008, GUT, V57, P931, DOI 10.1136/gut.2007.142778
   BREMBECK FH, 2001, GASTROENTEROLOGY, V120, P1720
   FLEMSTROM G, 2001, NEWS PHYSIOL SCI, V16, P23
   FUKAYA M, 2006, GASTROENTEROLOGY, V131, P14, DOI
   10.1053/j.gastro.2006.05.008
   GALMICHE A, 2000, EMBO J, V19, P6361
   GUY LG, 1997, NUCLEIC ACIDS RES, V25, P4400
   HATA S, 2006, J BIOL CHEM, V281, P11214, DOI 10.1074/jbc.M509244200
   KABASHIMA A, 2002, HUM PATHOL, V33, P80
   KARAM SM, 1992, ANAT REC, V232, P231
   KARAM SM, 1993, ANAT REC, V236, P280
   KARAM SM, 2005, STEM CELLS, V23, P433, DOI 10.1634/stemcells.2004-0178
   MEANS AL, 2008, GENESIS, V46, P318, DOI 10.1002/dvg.20397
   MENG FW, 2007, MATRIX BIOL, V26, P54, DOI 10.1016/j.matbio.2006.09.003
   MILLS JC, 2003, J BIOL CHEM, V278, P46138, DOI 10.1074/jbc.M308385200
   PALMITER RD, 1986, ANNU REV GENET, V20, P465
   PEEK RM, 2000, GASTROENTEROLOGY, V118, P48
   POSTIC C, 1999, J BIOL CHEM, V274, P305
   QIAO XT, 2007, GASTROENTEROLOGY, V133, P1989, DOI
   10.1053/j.gastro.2007.09.031
   ROSSANT J, 1999, GENE DEV, V13, P142
   SIMON TC, 1993, J BIOL CHEM, V268, P18345
   SORIANO P, 1999, NAT GENET, V21, P70
   SYDER AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI
   10.1073/pnas.0230380100
   SYDER AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI
   10.1073/pnas.0307983101
   TSUTSUMI S, 2002, EXP BIOL MED, V227, P402
   VERZI MP, 2008, GASTROENTEROLOGY, V135, P591, DOI
   10.1053/j.gastro.2008.04.019
   YANG G, 2005, GENESIS, V42, P33, DOI 10.1002/gene.20120
   YANG X, 2002, GENESIS, V32, P80
NR 27
TC 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD OCT
PY 2009
VL 47
IS 10
BP 674
EP 679
DI 10.1002/dvg.20552
PG 6
SC Developmental Biology; Genetics & Heredity
GA 516SM
UT ISI:000271562900004
ER

PT J
AU Huh, YH
   Ryu, JH
   Shin, S
   Lee, DU
   Yang, S
   Oh, KS
   Chun, CH
   Choi, JK
   Song, WK
   Chun, JS
AF Huh, Yun Hyun
   Ryu, Je-Hwang
   Shin, Sun
   Lee, Dong-Uk
   Yang, Siyoung
   Oh, Kyung-Shin
   Chun, Churl-Hong
   Choi, Jeong-Keun
   Song, Woo Keun
   Chun, Jang-Soo
TI Esophageal cancer related gene 4 (ECRG4) is a marker of articular
   chondrocyte differentiation and cartilage destruction
SO GENE
LA English
DT Article
DE Articular cartilage; Chondrocytes; Collagen II; ECRG4; Osteoarthritis
ID II COLLAGEN EXPRESSION; GROWTH-FACTOR-I; MESENCHYMAL CELLS;
   CHONDROGENESIS; LIMB; OSTEOARTHRITIS; VITRO
AB With the aim of identifying novel genes regulating cartilage
   development and degeneration, we screened a cartilage-specific
   expressed sequence tag database. Esophageal cancer related gene 4
   (ECRG4) was selected, based on the criteria of chondrocyte-specific'
   and 'unknown function.' ECRG4 expression was particularly abundant in
   chondrocytes and cartilage, compared to various other mouse tissues.
   ECRG4 is a secreted protein that undergoes cleavage after secretion.
   The protein is specifically expressed in chondrocytes in a manner
   dependent on differentiation status. The expression is very low in
   mesenchymal cells, and dramatically increased during chondrogenic
   differentiation. The ECRG4 level in differentiated chondrocytes is
   decreased during hypertrophic maturation, both in vitro and in vivo,
   and additionally in dedifferentiating chondrocytes induced by
   interleukin-1 beta or serial subculture, chondrocytes of human
   osteoarthritic cartilage and experimental mouse osteoarthritic
   cartilage. However, ectopic expression or exogenous ECRG4 treatment in
   a primary culture cell system does not affect chondrogenesis of
   mesenchymal cells, hypertrophic maturation of chondrocytes or
   dedifferentiation of differentiated chondrocytes. Additionally,
   cartilage development and organization of extracellular matrix are not
   affected in transgenic mice overexpressing ECRG4 in cartilage tissue.
   However, ectopic expression of ECRG4 reduced proliferation of primary
   culture chondrocytes. While the underlying mechanisms of ECRG4
   expression and specific roles remain to be elucidated in more detail,
   our results support its function as a marker of differentiated
   articular chondrocytes and cartilage destruction. (C) 2009 Elsevier
   B.V. All rights reserved.
C1 [Huh, Yun Hyun; Ryu, Je-Hwang; Shin, Sun; Lee, Dong-Uk; Yang, Siyoung; Oh, Kyung-Shin; Choi, Jeong-Keun; Song, Woo Keun; Chun, Jang-Soo] Gwangju Inst Sci & Technol, Cell Dynam Res Ctr, Kwangju 500712, South Korea.
   [Huh, Yun Hyun; Ryu, Je-Hwang; Shin, Sun; Lee, Dong-Uk; Yang, Siyoung; Oh, Kyung-Shin; Choi, Jeong-Keun; Song, Woo Keun; Chun, Jang-Soo] Gwangju Inst Sci & Technol, BioImaging Res Ctr, Dept Life Sci, Kwangju 500712, South Korea.
   [Chun, Churl-Hong] Wonkwang Univ, Sch Med, Dept Orthopaed Surg, Iksan 570711, South Korea.
RP Chun, JS, Gwangju Inst Sci & Technol, Cell Dynam Res Ctr, Kwangju
   500712, South Korea.
EM jschun@gist.ac.kr
FU Cell Dynamics Research Center, Korea Science and Engineering Foundation
   (KOSEF) [R11-2007-007-01001-0]; Korea Research Foundation
   [KRF-2006-312-C00611]
FX This work was supported by grants from Cell Dynamics Research Center,
   Korea Science and Engineering Foundation (KOSEF R11-2007-007-01001-0)
   and Korea Research Foundation (KRF-2006-312-C00611).
CR ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039
   BLOM AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337
   DELISE AM, 2000, OSTEOARTHR CARTILAGE, V8, P309
   FUKUMOTO T, 2003, OSTEOARTHR CARTILAGE, V11, P55, DOI
   10.1053/joca.2002.0869
   GOLDRING MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   GOUTTENOIRE J, 2004, BIORHEOLOGY, V41, P535
   HONG S, 2005, J BIOL CHEM, V280, P7685, DOI 10.1074/jbc.M412444200
   HUH YH, 2007, J BIOL CHEM, V282, P17123, DOI 10.1074/jbc.M700599200
   KIM JS, 2007, J BIOL CHEM, V282, P29359, DOI 10.1074/jbc.M700965200
   LI LW, 2009, INT J CANCER, V125, P1505, DOI 10.1002/ijc.24513
   LIU X, 2000, GENOMICS, V65, P283
   MALEMUD CJ, 1999, FRONT BIOSCI, V4, D659
   MANKIN HJ, 1971, J BONE JOINT SURG AM, V53, P523
   MARIANI FV, 2003, NATURE, V423, P319, DOI 10.1038/nature01655
   MELLO MA, 1999, IN VITRO CELL DEV-AN, V35, P262
   OH CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200
   PEALE FV, 2001, J PATHOL, V195, P7
   RYU JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601801200
   STECK E, 2002, BIOCHEM BIOPH RES CO, V299, P109
   SU T, 1998, ZHONGHUA ZHONG LIU Z, V20, P254
   TICKLE C, 2002, AM J MED GENET, V112, P250, DOI 10.1002/ajmg.10774
   UETA C, 2001, J CELL BIOL, V153, P87
   VANAJA DK, 2009, CANCER INVEST, V27, P549, DOI 10.1080/07357900802620794
   YOON YM, 2002, J BIOL CHEM, V277, P8412
NR 24
TC 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD DEC 1
PY 2009
VL 448
IS 1
BP 7
EP 15
DI 10.1016/j.gene.2009.08.015
PG 9
SC Genetics & Heredity
GA 516SG
UT ISI:000271562300002
ER

PT J
AU Lai, RH
   Wang, MJ
   Yang, SH
   Chen, JY
AF Lai, Rai-Hua
   Wang, Mei-Jung
   Yang, Shung-Haur
   Chen, Jeou-Yuan
TI Genomic organization and functional characterization of the promoter
   for the human suppressor of cytokine signaling 6 gene
SO GENE
LA English
DT Article
DE SOCS6; Genomic structure; Promoter analysis; Promoter hypermethylation
ID SQUAMOUS-CELL CARCINOMA; CYTOKINE SIGNALING-1; NEGATIVE REGULATOR;
   ABERRANT METHYLATION; COLORECTAL-CANCER; JAK/STAT PATHWAY;
   INSULIN-RECEPTOR; CHROMOSOME 18Q; GASTRIC-CANCER; OVARIAN-CANCER
AB In this study, we report the expression and genomic structure of the
   gene encoding human suppressor of cytokine signaling 6 (SOCS5), and the
   characterization of the functional promoter region. The human SOCS6
   gene, spanning 40 kb on chromosome 18q22.2, is composed of two exons
   separated by an intron of 35 kb. Two transcripts are ubiquitously
   expressed, and both encode the full-length open reading frame of SOCS6.
   A primer extension assay revealed that the major transcription
   initiation site is located 469 bp upstream the ATG codon. Luciferase
   promoter analysis demonstrated that the 5'-flanking region is able to
   drive transcription, and the CpG-rich sequences near the transcription
   initiation site are important for the TATA-less SOCS6 promoter
   activity. Analogous to SOCS1 and SOCS3, which are down-regulated in
   several human cancers, SOCS6 is expressed at lower levels in carcinomas
   of stomach and colon. We demonstrated that hypermethylation of the
   SOCS6 promoter is one of the mechanisms for the epigenetic regulation
   of SOCS6 expression. Firstly, in vitro methylation of the reporter
   promoter plasmid significantly suppressed the promoter activity.
   Secondly, SOCS6 expression in vivo was enhanced by treating cells with
   a methyltransferase inhibitor. The SOCS6 gene from various species
   shares significant homology in amino acid sequences, transcription
   factor binding motifs in promoter regions and the two-exon genomic
   structure, suggesting that the SOCS6 gene is highly conserved. (C) 2009
   Elsevier B.V. All rights reserved.
C1 [Lai, Rai-Hua] Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.
   [Wang, Mei-Jung; Chen, Jeou-Yuan] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Yang, Shung-Haur] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan.
   [Chen, Jeou-Yuan] Natl Yang Ming Univ, Inst Genome Sci, Taipei 112, Taiwan.
RP Chen, JY, 128 Sect,2 Acad Rd, Taipei 11529, Taiwan.
EM bmchen@ibms.sinica.edu.tw
FU National Science Council, Taiwan [95-2320-B-001-043-MY3]
FX We thank Dr. C.-W. Wu (Department of Surgery, Taipei Veterans General
   Hospital, Taiwan) for providing primary gastric tumorous and
   non-tumorous tissues. This work was supported by a research grant
   (95-2320-B-001-043-MY3) to J.Y.C. from the National Science Council,
   Taiwan. We thank Dr. Y.-J. Chen (Institute of Genome Sciences, National
   Yang-Ming University) for providing the RP11-1461316 BAC clone.
CR ARNOLD N, 1996, GENE CHROMOSOME CANC, V16, P46
   BARRATT PL, 2002, LANCET, V360, P1381
   BAYLE J, 2004, J BIOL CHEM, V279, P12249, DOI 10.1074/jbc.M313381200
   BENGEL D, 1997, MOL BRAIN RES, V44, P286
   BLONS H, 2002, ONCOGENE, V21, P5016
   BOYD DB, 2003, INTEGR CANC THER, V2, P315
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294
   DYNAN WS, 1985, NATURE, V316, P774
   FUJITAKE S, 2004, J GASTROENTEROL, V39, P120, DOI
   10.1007/s00535-003-1262-0
   FUKUSHIMA N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039
   GALM O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735
   HASSAN HT, 2009, LEUKEMIA RES, V33, P5, DOI
   10.1016/j.leukres.2008.06.011
   HE B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI
   10.1073/pnas.2232790100
   HEILS A, 1995, J NEURAL TRANSM-GEN, V102, P247
   HERMSEN MAJA, 1996, GENE CHROMOSOME CANC, V15, P1
   HILGERS W, 1999, GENE CHROMOSOME CANC, V25, P370
   HILTON DJ, 1998, P NATL ACAD SCI USA, V95, P114
   HOOGHE B, 2008, NUCLEIC ACIDS RES S, V36, W128, DOI 10.1093/nar/gkn195
   HSU LS, 2001, J BIOL CHEM, V276, P31113
   HUIPING C, 1998, ANTICANCER RES, V18, P1031
   INOUE T, 1998, CLIN CANCER RES, V4, P973
   IZUMI R, 1992, GENE, V112, P189
   JIN HJ, 2007, IMMUNOGENETICS, V59, P673, DOI 10.1007/s00251-007-0232-8
   JIN HJ, 2007, MOL IMMUNOL, V44, P1042, DOI 10.1016/j.molimm.2006.03.003
   JIN HJ, 2008, MOL IMMUNOL, V45, P1258, DOI 10.1016/j.molimm.2007.09.015
   JONES JW, 1997, ARCH OTOLARYNGOL, V123, P610
   KAMURA T, 2001, J BIOL CHEM, V276, P29748
   KARIO E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200
   KREBS DL, 2001, STEM CELLS, V19, P378
   KREBS DL, 2002, MOL CELL BIOL, V22, P4567
   KYTOLA S, 2001, AM J PATHOL, V158, P1803
   LARSEN L, 2002, APMIS, V110, P833
   LASSUS H, 2001, AM J PATHOL, V159, P35
   LI L, 2004, J BIOL CHEM, V279, P34107, DOI 10.1074/jbc.M312672200
   MANDAHL N, 2002, GENE CHROMOSOME CANC, V33, P188
   MASUHARA M, 1997, BIOCHEM BIOPH RES CO, V239, P439
   MOONEY RA, 2001, J BIOL CHEM, V276, P25889
   NAGY A, 2004, HISTOPATHOLOGY, V44, P542
   NAKAO K, 1998, SURG TODAY, V28, P567
   NICHOLSON SE, 1999, EMBO J, V18, P375
   NICHOLSON SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI
   10.1073/pnas.0409675102
   OSHIMO Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521
   RAM PA, 1999, J BIOL CHEM, V274, P35553
   RICKERT CH, 2000, J NEUROPATH EXP NEUR, V59, P815
   TAKEBAYASHI S, 2000, CANCER RES, V60, P3397
   TO KF, 2004, BRIT J CANCER, V91, P1335, DOI 10.1038/sj.bjc.6602133
   WATANABE T, 2001, GYNECOL ONCOL, V81, P172
   WEBER A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818
   WU CW, 2002, GENE CHROMOSOME CANC, V35, P219, DOI 10.1002/gcc.10106
   YOSHIKAWA H, 2001, NAT GENET, V28, P29
   YU JC, 2004, WORLD J GASTROENTERO, V10, P1964
   ZHANG JG, 2001, P NATL ACAD SCI USA, V98, P13261
NR 52
TC 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD DEC 1
PY 2009
VL 448
IS 1
BP 64
EP 73
DI 10.1016/j.gene.2009.07.022
PG 10
SC Genetics & Heredity
GA 516SG
UT ISI:000271562300008
ER

PT J
AU Mizuno, S
   Kobayashi, M
   Tomita, S
   Miki, I
   Masuda, A
   Onoyama, M
   Habu, Y
   Inokuchi, H
   Watanabe, Y
AF Mizuno, Shigeto
   Kobayashi, Masao
   Tomita, Shohken
   Miki, Ikuya
   Masuda, Atsuhiro
   Onoyama, Mitsuko
   Habu, Yasuki
   Inokuchi, Hideto
   Watanabe, Yoshiyuki
TI Validation of the pepsinogen test method for gastric cancer screening
   using a follow-up study
SO GASTRIC CANCER
LA English
DT Article
DE Pepsinogen; Gastric cancer; Screening; Follow-up study
ID SERUM PEPSINOGEN; STOMACH-CANCER; CELLULAR LOCALIZATION; ATROPHIC
   GASTRITIS; JAPAN; RISK; IMMUNOFLUORESCENCE; POPULATION; PROGRAM
AB Serum pepsinogen (PG) measurement has been used for gastric cancer
   screening since the 1990s. However, there are no reports comparing the
   screening validity of the PG test method with that of conventional
   X-ray examination directly in the same population, using a follow-up
   study.
   From April 2000 to March 2001, 12 120 residents of Osaka Prefecture,
   who underwent opportunistic screening at a medical checkup organization
   in Osaka city (hereafter, "the organization"), were enrolled. They
   received both a barium meal examination and PG test simultaneously. All
   the participants were followed up for a 1-year period after the
   screening. For the participants advised to undergo endoscopic
   examination, the results of those who were examined at the organization
   were tallied. The other participants were checked using the Osaka
   Cancer Registry (hereafter, "the registry").
   Of the 12 120 participants, 493 (4.1%) were positive with the PG method
   and 728 (6.0%) were positive with the X-ray method. Fifty-four (0.4%)
   were positive for both methods. Thirteen gastric cancer cases were
   diagnosed by successive esophagogastroduodenoscopies at the
   organization. Six additional gastric cancer cases were identified by
   record linkage with the registry. The sensitivity, specificity, and
   positive predictive values of the PG method with a PGI cutoff level of
   a parts per thousand currency sign30 ng/ml and PGI/PGII ratio of a
   parts per thousand currency sign2.0 were 36.8%, 96.0%, and 1.4%,
   respectively. These values for the direct X-ray examination were 68.4%,
   94.1%, and 1.8%, respectively.
   The PG test method alone with a PGI cutoff level of a parts per
   thousand currency sign30 ng/ml and PGI/PGII a parts per thousand
   currency sign 2.0 is not appropriate for gastric cancer screening.
C1 [Watanabe, Yoshiyuki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Epidemiol Community Hlth & Med, Kamigyo Ku, Kyoto 6028566, Japan.
   [Mizuno, Shigeto; Miki, Ikuya; Masuda, Atsuhiro; Onoyama, Mitsuko] Kobe Pharmaceut Univ, Dept Med Pharmaceut, Kobe, Hyogo 658, Japan.
   [Kobayashi, Masao] Kyoto Second Red Cross Hosp, Dept Hlth Care, Kyoto, Japan.
   [Tomita, Shohken] Kansai Occupat Hlth Assoc, Osaka, Japan.
   [Habu, Yasuki] Saiseikai Noe Hosp, Dept Gastroenterol, Osaka, Japan.
   [Inokuchi, Hideto] Hyogo Canc Ctr, Dept Gastroenterol, Akashi, Hyogo, Japan.
RP Watanabe, Y, Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept
   Epidemiol Community Hlth & Med, Kamigyo Ku, 465 Kajii Cho, Kyoto
   6028566, Japan.
FU Ministry of Health, Labour and Welfare, Japan [H16-025]
FX This work was supported in part by a Grant-in-Aid for Research from the
   Ministry of Health, Labour and Welfare, Japan (H16-025).
CR *ED BOARD CANC STA, 2008, CANC STAT JAP 2008
   *MIN HLTH LAB WELF, 2004, NAT REP CANC SCREEN
   ABE S, 2000, J GASTROENTEROL MASS, V38, P475
   CORREA P, 1992, CANCER RES, V52, P6735
   FUKAO A, 1992, J GASTROENTEROL MASS, V97, P59
   FUKAO A, 1995, INT J CANCER, V60, P45
   HAMASHIMA C, 2008, JPN J CLIN ONCOL, V38, P259, DOI 10.1093/jjco/hyn017
   HATTORI M, 1998, J GASTROENTEROL MASS, V36, P468
   HATTORI Y, 1995, JPN J CANCER RES, V86, P1210
   ISHIDA T, 1994, J GASTROENTEROL MASS, V32, P9
   KIMURA K, 1972, GASTROENTEROLOGY, V63, P584
   KITAHARA F, 1999, GUT, V44, P693
   KODOI A, 1995, J GASTROENTEROL, V30, P452
   MIKI K, 1987, GASTROENTEROL JPN, V22, P133
   MIKI K, 1989, JPN J CANCER RES, V80, P111
   MIKI K, 1993, JPN J CANCER RES, V84, P1086
   MIKI K, 2003, AM J GASTROENTEROL, V98, P735, DOI
   10.1016/S0002-9270(03)00128-X
   MILES A, 2004, CANCER S, V101, P1201, DOI 10.1002/cncr.20505
   MURAKAMI R, 1990, CANCER, V65, P1255
   NOMURA AMY, 1980, ANN INTERN MED, V93, P537
   OHATA H, 2005, CANCER SCI, V96, P713, DOI
   10.1111/j.1349-7006.2005.00098.x
   OSHIMA A, 1986, INT J CANCER, V38, P829
   SAMLOFF IM, 1971, GASTROENTEROLOGY, V61, P185
   SAMLOFF IM, 1973, GASTROENTEROLOGY, V65, P36
   SAMLOFF IM, 1982, GASTROENTEROLOGY, V83, P204
   SIPPONEN P, 1985, INT J CANCER, V35, P173
   STEMMERMANN GN, 1987, CLIN CHIM ACTA, V163, P191
   SUGAWARA N, 1992, J GASTROENTEROL MASS, V95, P184
   TATSUTA M, 1993, INT J CANCER, V53, P70
   YOSHIHARA M, 1997, HIROSHIMA J MED SCI, V46, P81
NR 30
TC 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-3291
J9 GASTRIC CANCER
JI Gastric Cancer
PD OCT
PY 2009
VL 12
IS 3
BP 158
EP 163
DI 10.1007/s10120-009-0522-y
PG 6
SC Oncology; Gastroenterology & Hepatology
GA 515VX
UT ISI:000271502100007
ER

PT J
AU Krueger, B
   Haerteis, S
   Yang, LM
   Hartner, A
   Rauh, R
   Korbmacher, C
   Diakov, A
AF Krueger, Bettina
   Haerteis, Silke
   Yang, Limin
   Hartner, Andrea
   Rauh, Robert
   Korbmacher, Christoph
   Diakov, Alexei
TI Cholesterol Depletion of the Plasma Membrane Prevents Activation of the
   Epithelial Sodium Channel (ENaC) by SGK1
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Epithelial sodium channel (ENaC); Serum- and glucocorticoid-induced
   kinase isoform 1; Lipid raft; Methyl-beta-cyclodextrin; Cholesterol;
   Xenopus laevis oocytes
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL-SURFACE EXPRESSION; LIPID
   RAFTS; CYSTIC-FIBROSIS; ION CHANNELS; NEDD4-2-DEPENDENT MECHANISM; OPEN
   PROBABILITY; APICAL MEMBRANE; XENOPUS-OOCYTES; SLIT DIAPHRAGM
AB The lipid environment of the epithelial sodium channel (ENaC) and its
   possible association with so-called lipid rafts may be relevant to its
   function. The aim of our study was to confirm the association of ENaC
   with lipid rafts and to analyze the effect of cholesterol depletion of
   the plasma membrane by methyl-beta-cyclodextrin (M beta CD) on channel
   function and regulation. Using sucrose density gradient centrifugation
   we demonstrated that a significant portion of ENaC protein distributes
   to low density fractions thought to be typical lipid raft fractions.
   Importantly, cholesterol depletion of cell lysate by M beta CD shifted
   ENaC to non-raft fractions of higher density. Live cell imaging
   demonstrated that treatment with M beta CD largely reduced filipin
   staining over time, confirming cholesterol depletion of the plasma
   membrane. For electrophysiological studies intact oocytes were exposed
   to 20 mM M beta CD for three hours. M beta CD treatment had no
   consistent effect on baseline whole-cell ENaC currents. In addition to
   the typical single channel conductance of about 5 pS, subconductance
   states of ENaC were occasionally observed in patches from M beta CD
   treated but not from control oocytes. Importantly, in outside-out patch
   clamp recordings the stimulatory effect of recombinant SGK1 in the
   pipette solution was essentially abolished in oocytes pretreated with M
   beta CD. These results indicate that ENaC activation by cytosolic SGK1
   is compromised by removing cholesterol from the plasma membrane. Thus,
   ENaC activation by SGK1 may require the presence of an intact lipid
   environment and/or of lipid rafts as signalling platform. Copyright (C)
   2009 S. Karger AG, Basel
C1 [Krueger, Bettina; Haerteis, Silke; Yang, Limin; Rauh, Robert; Korbmacher, Christoph; Diakov, Alexei] Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, D-91054 Erlangen, Germany.
   [Hartner, Andrea] Univ Erlangen Nurnberg, Kinder & Jugendklin Univ Klinikums Erlangen, D-91054 Erlangen, Germany.
RP Korbmacher, C, Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol,
   Waldstr 6, D-91054 Erlangen, Germany.
EM christoph.korbmacher@physiologie2.med.uni-erlangen.de
FU Deutsche Forschungsgemeinschaft [SFB423]; Johannes and Frieda Marohn
   Stiftung ; Elitenetwork Bavaria ; BioMedTec International Graduate
   School (BIGSS) ; Fritz Thyssen Foundation 
FX The expert technical assistance of Ralf Rinke, Jessica Ott and Celine
   Harlay is gratefully acknowledged. We thank Johannes Loffing for his
   help with the characterization of the antibodies. This study was
   supported by grants of the Deutsche Forschungsgemeinschaft (SFB423:
   Kidney injury: Pathogenesis and Regenerative Mechanisms; project A12;
   C. K.), the Johannes and Frieda Marohn Stiftung (C. K.), an
   Elitenetwork Bavaria (ENB) fellowship (S. H.), and the BioMedTec
   International Graduate School (BIGSS) 'Lead Structures of Cell
   Function' of the ENB (S. H.), and by a travel grant to B. K. from the
   Fritz Thyssen Foundation.
CR ALVAREZ DLR, 2000, ANNU REV PHYSIOL, V62, P573
   AWAYDA MS, 2004, J GEN PHYSIOL, V123, P709, DOI 10.1085/jgp.200308983
   BALUT C, 2006, AM J PHYSIOL-CELL PH, V290, C87, DOI
   10.1152/ajpcell.00184.2005
   BECCHETTI A, 2002, AM J PHYSIOL-RENAL, V283, F1030, DOI
   10.1152/ajprenal.000011.2002
   BROWN DA, 1992, CELL, V68, P533
   CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, C1682
   CHIGAEV A, 2001, AM J PHYSIOL-RENAL, V280, F1030
   CHRISTIAN AE, 1997, J LIPID RES, V38, P2264
   CURCIO CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DIAKOV A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200
   DIAKOV A, 2008, J PHYSIOL-LONDON, V586, P4587, DOI
   10.1113/jphysiol.2008.154435
   FIRSOV D, 1996, P NATL ACAD SCI USA, V93, P15370
   GARTY H, 1997, PHYSIOL REV, V77, P359
   HANWELL D, 2002, J BIOL CHEM, V277, P9772
   HARRIS M, 2008, J BIOL CHEM, V283, P7455, DOI 10.1074/jbc.M707399200
   HILL WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200
   HILL WG, 2007, J BIOL CHEM, V282, P37402, DOI 10.1074/jbc.M704084200
   HOEKSTRA D, 2003, J LIPID RES, V44, P869, DOI 10.1194/jlr.R300003-JLR200
   HUBER TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI
   10.1073/pnas.0607465103
   HUBER TB, 2007, NEPHRON EXP NEPHROL, V106, E27, DOI 10.1159/000101789
   IKONEN E, 1998, SEMIN CELL DEV BIOL, V9, P503
   IKONEN E, 2001, CURR OPIN CELL BIOL, V13, P470
   ISHIKAWA Y, 2005, AM J PHYSIOL-CELL PH, V289, C1303, DOI
   10.1152/ajpcell.00211.2005
   KELLENBERGER S, 2002, PHYSIOL REV, V82, P735
   KLEYMAN TR, 2009, J BIOL CHEM, V284, P20447, DOI 10.1074/jbc.R800083200
   KONSTAS AA, 2002, J BIOL CHEM, V277, P25377
   KOWALSKI MP, 2004, J IMMUNOL, V172, P418
   KRAUS C, 2007, CELL PHYSIOL BIOCHEM, V19, P239, DOI 10.1159/000100643
   LAI EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087
   LANG F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005
   LEE IH, 2009, J BIOL CHEM, V284, P12663, DOI 10.1074/jbc.M809737200
   LI XH, 2001, J PHYSIOL-LONDON, V537, P537
   LOFFING J, 2009, PFLUG ARCH EUR J PHY, V458, P111, DOI
   10.1007/s00424-009-0656-0
   MARTENS JR, 2004, TRENDS PHARMACOL SCI, V25, P16, DOI
   10.1016/j.tips.2003.11.007
   MARTIN TFJ, 2001, CURR OPIN CELL BIOL, V13, P493
   MASILAMANI S, 1999, J CLIN INVEST, V104, R19
   MICHLIG S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200
   MORROW IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x
   MUNRO S, 2003, CELL, V115, P377
   PIKE LJ, 2004, BIOCHEM J 2, V378, P281, DOI 10.1042/BJ20031672
   PIKE LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   PLANT PJ, 2000, J CELL BIOL, V149, P1473
   POCHYNYUK O, 2008, CURR OPIN NEPHROL HY, V17, P533
   PRINCE LS, 1998, BIOCHEM J 3, V336, P705
   PRINCE LS, 1999, AM J PHYSIOL-CELL PH, V276, C1346
   RAUH R, 2006, PFLUG ARCH EUR J PHY, V452, P290, DOI
   10.1007/s00424-005-0026-5
   RIZZO MA, 2001, J BIOL CHEM, V276, P34928
   ROSSIER BC, 2009, ANNU REV PHYSIOL, V71, P361, DOI
   10.1146/annurev.physiol.010908.163108
   ROTIN D, 2001, AM J PHYSIOL-RENAL, V281, F391
   SCHERMER B, 2009, J AM SOC NEPHROL, V20, P473, DOI
   10.1681/ASN.2008070694
   SCHUCK S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI
   10.1073/pnas.0631579100
   SHI HK, 2002, J BIOL CHEM, V277, P13539
   SHIBATA EF, 2006, J CARDIOVASC ELEC S1, V17, S34
   SHIMKETS RA, 1998, P NATL ACAD SCI USA, V95, P3301
   SIMONS K, 1997, NATURE, V387, P569
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104
   SOUNDARARAJAN R, 2009, P NATL ACAD SCI USA, V106, P7804, DOI
   10.1073/pnas.0809892106
   SVENNINGSEN P, 2009, J AM SOC NEPHROL, V20, P299, DOI
   10.1681/ASN.2008040364
   TOSELLI M, 2005, BIOPHYS J, V89, P2443, DOI 10.1529/biophysj.105.065623
   VERGHESE GM, 2006, AM J PHYSIOL-CELL PH, V291, C1258, DOI
   10.1152/ajpcell.00637.2005
   WANG J, 2009, AM J PHYSIOL-RENAL, V296, F284, DOI
   10.1152/ajprenal.90647.2008
   WEI SP, 2007, J MEMBRANE BIOL, V220, P21, DOI 10.1007/s00232-007-9071-7
   WELKER P, 2008, AM J PHYSIOL-RENAL, V295, F789, DOI
   10.1152/ajprenal.90227.2008
   WEST TA, 2005, CELL PHYSIOL BIOCHEM, V16, P263
   WIELPUTZ MO, 2007, J BIOL CHEM, V282, P28264, DOI 10.1074/jbc.M702168200
   YARBROUGH TL, 2002, CIRC RES, V90, P443
NR 66
TC 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2009
VL 24
IS 5-6
BP 605
EP 618
DI 10.1159/000257516
PG 14
SC Cell Biology; Physiology
GA 516IP
UT ISI:000271535900029
ER

PT J
AU Nishiyama, A
   Xin, L
   Sharov, AA
   Thomas, M
   Mowrer, G
   Meyers, E
   Piao, YL
   Mehta, S
   Yee, S
   Nakatake, Y
   Stagg, C
   Sharova, L
   Correa-Cerro, LS
   Bassey, U
   Hoang, H
   Kim, E
   Tapnio, R
   Qian, Y
   Dudekula, D
   Zalzman, M
   Li, MX
   Falco, G
   Yang, HT
   Lee, SL
   Monti, M
   Stanghellini, I
   Islam, MN
   Nagaraja, R
   Goldberg, I
   Wang, WD
   Longo, DL
   Schlessinger, D
   Ko, MSH
AF Nishiyama, Akira
   Xin, Li
   Sharov, Alexei A.
   Thomas, Marshall
   Mowrer, Gregory
   Meyers, Emily
   Piao, Yulan
   Mehta, Samir
   Yee, Sarah
   Nakatake, Yuhki
   Stagg, Carole
   Sharova, Lioudmila
   Correa-Cerro, Lina S.
   Bassey, Uwem
   Hoang, Hien
   Kim, Eugene
   Tapnio, Richard
   Qian, Yong
   Dudekula, Dawood
   Zalzman, Michal
   Li, Manxiang
   Falco, Geppino
   Yang, Hsih-Te
   Lee, Sung-Lim
   Monti, Manuela
   Stanghellini, Ilaria
   Islam, Md. Nurul
   Nagaraja, Ramaiah
   Goldberg, Ilya
   Wang, Weidong
   Longo, Dan L.
   Schlessinger, David
   Ko, Minoru S. H.
TI Uncovering Early Response of Gene Regulatory Networks in ESCs by
   Systematic Induction of Transcription Factors
SO CELL STEM CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; GENOME-WIDE; DEVELOPMENTAL REGULATORS; SIGNALING
   PATHWAYS; MOUSE EMBRYOS; SELF-RENEWAL; PLURIPOTENCY; EXPRESSION;
   DIFFERENTIATION; CHROMATIN
AB To examine transcription factor (TF) network(s), we created mouse ESC
   lines, in each of which 1 of 50 TFs tagged with a FLAG moiety is
   inserted into a ubiquitously controllable tetracycline-repressible
   locus. Of the 50 TFs, Cdx2 provoked the most extensive transcriptome
   perturbation in ESCs, followed by Esx1, Sox9, Tcf3, KIN, and Gata3.
   ChIP-Seq revealed that CDX2 binds to promoters of upregulated target
   genes. By contrast, genes downregulated by CDX2 did not show CDX2
   binding but were enriched with binding sites for POU5F1, SOX2, and
   NANOG. Genes with binding sites for these core TFs were also
   downregulated by the induction of at least 15 other TFs, suggesting a
   common initial step for ESC differentiation mediated by interference
   with the binding of core TFs to their target genes. These ESC lines
   provide a fundamental resource to study biological networks in ESCs and
   mice.
C1 [Nishiyama, Akira; Xin, Li; Sharov, Alexei A.; Thomas, Marshall; Mowrer, Gregory; Meyers, Emily; Piao, Yulan; Mehta, Samir; Yee, Sarah; Nakatake, Yuhki; Stagg, Carole; Sharova, Lioudmila; Correa-Cerro, Lina S.; Bassey, Uwem; Hoang, Hien; Kim, Eugene; Tapnio, Richard; Qian, Yong; Dudekula, Dawood; Zalzman, Michal; Li, Manxiang; Falco, Geppino; Yang, Hsih-Te; Lee, Sung-Lim; Monti, Manuela; Stanghellini, Ilaria; Islam, Md. Nurul; Nagaraja, Ramaiah; Goldberg, Ilya; Wang, Weidong; Longo, Dan L.; Schlessinger, David; Ko, Minoru S. H.] NIA, NIH, Baltimore, MD 21224 USA.
RP Ko, MSH, NIA, NIH, Baltimore, MD 21224 USA.
EM kom@mail.nih.gov
FU Intramural Research Program of the NIH, National Institute on Aging 
FX We thank Dr. Hitoshi Niwa for providing the Tet-inducible vector system
   and some cDNA clones and for discussion. This research was supported
   entirely by the Intramural Research Program of the NIH, National
   Institute on Aging.
CR AIBA L, 2009, DNA RES, V16, P73, DOI 10.1093/dnares/dsn035
   AZUARA V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   BERGER MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024
   BERNSTEIN BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   BOYER LA, 2005, CELL, V122, P947
   BOYER LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   CARTER MG, 2005, GENOME BIOL, V6, ARTN R61
   CHAMBERS I, 2003, CELL, V113, P643
   CHEN X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   CLOONAN N, 2008, NAT METHODS, V5, P613, DOI 10.1038/nmeth.1223
   COLLINS FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018
   DAVIDSON EH, 2006, REGULATORY GENOME GE
   DELCORRAL RD, 2001, NAT REV NEUROSCI, V2, P835
   DENSLOW SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   EVANS MJ, 1981, NATURE, V292, P154
   IVANOVA N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915
   JAENISCH R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015
   KAJI K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372
   KANAMORI M, 2004, BIOCHEM BIOPH RES CO, V322, P787, DOI
   10.1016/j.bbrc.2004.07.179
   KIM JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039
   KLAFFKY E, 2001, DEV BIOL, V239, P161
   LANGE A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200
   LEE TI, 2006, CELL, V125, P301
   LIANG J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   LIM CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004
   LOH YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   MARTIN GR, 1981, P NATL ACAD SCI USA, V78, P7634
   MASUI S, 2005, NUCLEIC ACIDS RES, V33, ARTN e43
   MATOBA R, 2006, PLOS ONE, V1, ARTN e26
   MESHORER E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   MESSINA DN, 2004, GENOME RES, V14, P2041
   MIKKELSEN TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   MITSUI K, 2003, CELL, V113, P631
   MURRY CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   NAKATAKE Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06
   NATALE DR, 2002, MECH DEVELOP S1, V119, S21
   NAYA FJ, 1999, CURR OPIN CELL BIOL, V11, P683
   NICHOLS J, 1998, CELL, V95, P379
   NIWA H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040
   NIWA H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   PRITSKER M, 2006, P NATL ACAD SCI USA, V103, P6946, DOI
   10.1073/pnas.0509861103
   ROH TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI
   10.1073/pnas.0607617103
   SCHOLER HR, 1991, CELL, V66, P291
   SHAROV AA, 2005, BIOINFORMATICS, V21, P2548, DOI
   10.1093/bioinformatics/bti343
   SHAROV AA, 2008, BMC GENOMICS, V9, ARTN 269
   SHAROV AA, 2009, DNA RES IN PRESS
   SILVA J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006
   SIMMONS DG, 2005, DEV BIOL, V284, P12, DOI 10.1016/j.ydbio.2005.05.010
   SKARNES WC, 2004, NAT GENET, V36, P543
   SOLTER D, 2006, NAT REV GENET, V7, P319, DOI 10.1038/nrg1827
   SORIANO P, 1999, NAT GENET, V21, P70
   STRUMPF D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801
   SU AI, 2002, P NATL ACAD SCI USA, V99, P4465
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   WALKER E, 2007, CELL STEM CELL, V1, P71, DOI 10.1016/j.stem.2007.04.002
   WANG JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284
   YANG JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI
   10.1073/pnas.0809321105
   YUAN HB, 1995, GENE DEV, V9, P2635
   ZHOU Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI
   10.1073/pnas.0701014104
NR 59
TC 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 2
PY 2009
VL 5
IS 4
BP 420
EP 433
DI 10.1016/j.stem.2009.07.012
PG 14
SC Cell & Tissue Engineering; Cell Biology
GA 514NP
UT ISI:000271401900013
ER

PT J
AU Oze, I
   Matsuo, K
   Suzuki, T
   Kawase, T
   Watanabe, M
   Hiraki, A
   Ito, H
   Hosono, S
   Ozawa, T
   Hatooka, S
   Yatabe, Y
   Hasegawa, Y
   Shinoda, M
   Kiura, K
   Tajima, K
   Tanimoto, M
   Tanaka, H
AF Oze, Isao
   Matsuo, Keitaro
   Suzuki, Takeshi
   Kawase, Takakazu
   Watanabe, Miki
   Hiraki, Akio
   Ito, Hidemi
   Hosono, Satoyo
   Ozawa, Taijiro
   Hatooka, Shunzo
   Yatabe, Yasuhi
   Hasegawa, Yasuhisa
   Shinoda, Masayuki
   Kiura, Katsuyuki
   Tajima, Kazuo
   Tanimoto, Mitsune
   Tanaka, Hideo
TI Impact of Multiple Alcohol Dehydrogenase Gene Polymorphisms on Risk of
   Upper Aerodigestive Tract Cancers in a Japanese Population
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ALDEHYDE DEHYDROGENASES;
   ENVIRONMENTAL-FACTORS; ESOPHAGEAL CANCER; POOLED ANALYSIS; HEAVY
   DRINKERS; NECK-CANCER; ADH GENES; DRINKING; SMOKING
AB Alcohol intake is positively associated with the risk of upper
   aerodigestive tract (UAT) cancer. The genes that encode
   alcohol-metabolizing enzymes, primarily alcohol dehydrogenases (ADH)
   and aldehyde dehydrogenases (ALDH), are polymorphic. In Caucasians,
   significant associations between polymorphisms in ADH1B (rs1229984) and
   ADH1C (rs698 and rs1693482), and UAT cancer have been observed, despite
   strong linkage disequilibrium among them. Moreover, UAT cancer was
   significantly associated with rs1573496 in ADH7, and not with rs1984362
   in ADH4. However, little evidence is available concerning ADH4 or ADH7
   polymorphisms in Asian populations. We conducted a matched case-control
   study to clarify the role of ADH polymorphisms in a Japanese
   population. Cases and controls were 585 patients with UAT cancer and
   1,170 noncancer outpatients. Geno-typing for ADHs and ALDH2 was done
   using TaqMan assays. Associations between polymorphisms and UAT cancer
   were assessed by odds ratios and 95% confidence intervals using
   conditional logistic regression models that adjusted for age, sex,
   smoking, drinking, and ALDH2. Adjusted odds ratios were significant for
   rs4148887 and rs3805322 in ADH4, rs1229984 in ADH1B, rs698 and
   rs1693482 in ADH1C, and rs284787, rs1154460, and rs3737482 in ADH7. We
   also observed that ADH7 rs3737482 and ADH4 rs4148887 had independently
   and statistically significant effects on UAT cancer. The magnitude of
   effect of these ADH polymorphisms was greater in subjects who were
   heavy drinkers, heavy smokers, and had esophageal cancer. These
   findings show that multiple ADH gene polymorphisms were associated with
   UAT cancer in this Japanese population. Further studies in various
   ethnicities are required. (Cancer Epidemiol Biomarkers Prev
   2009;18(11):3097-102)
C1 [Matsuo, Keitaro] Aichi Canc Ctr, Div Epidemiol & Prevent, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Ozawa, Taijiro; Hasegawa, Yasuhisa] Cent Hosp, Aichi Canc Ctr, Dept Head Neck Surg, Nagoya, Aichi, Japan.
   [Hatooka, Shunzo; Shinoda, Masayuki] Cent Hosp, Aichi Canc Ctr, Dept Thorac Surg, Nagoya, Aichi, Japan.
   [Yatabe, Yasuhi] Cent Hosp, Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan.
   [Suzuki, Takeshi] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan.
   [Hiraki, Akio] Okayama Univ, Ctr Hlth, Okayama, Japan.
   [Oze, Isao; Kiura, Katsuyuki; Tanimoto, Mitsune] Okayama Univ, Dept Hematol Oncol & Resp Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Matsuo, Keitaro; Tanaka, Hideo] Nagoya Univ, Dept Epidemiol, Grad Sch Med, Nagoya, Aichi 4648601, Japan.
RP Matsuo, K, Aichi Canc Ctr, Div Epidemiol & Prevent, Res Inst, Chikusa
   Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
EM kmatsuo@aichi-cc.jp
FU Ministry of Education, Science, Sports, Culture and Technology of Japan
   ; Ministry of Health, Labour and Welfare of Japan ; Foundation for
   Promotion of Cancer Research in Japan ; Uehara Memorial Foundation 
FX Grant support: Grants-in-Aid for Scientific Research from the Ministry
   of Education, Science, Sports, Culture and Technology of Japan, for
   Cancer Research from the Ministry of Health, Labour and Welfare of
   Japan, and for the Third Term Comprehensive 10-year Strategy for Cancer
   Control from the Ministry of Health, Labour and Welfare of Japan, This
   study was also Supported in part by the Foundation for Promotion of
   Cancer Research in Japan and by a research grant from the Uehara
   Memorial Foundation. These grantors were not Involved in the study
   design, subject enrollment, study analysis or interpretation, or
   submission of the manuscript for this study
CR *AM I CANC RES WOR, 2007, FOOD NUTR PHYS ACT P
   ALTSHULER D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   ASAKAGE T, 2007, CARCINOGENESIS, V28, P865, DOI 10.1093/carcin/bgl206
   BRENNAN P, 2004, AM J EPIDEMIOL, V159, P1
   HAMAJIMA N, 2001, ASIAN PACIFIC J CANC, V2, P99
   HAMAJIMA N, 2002, ASIAN PACIFIC J CANC, V3, P197
   HASHIBE M, 2006, CANCER EPIDEM BIOMAR, V15, P696, DOI
   10.1158/1055-9965.EPl-05-0/10
   HASHIBE M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179
   HASHIBE M, 2008, NAT GENET, V40, P707, DOI 10.1038/ng.151
   HOMANN N, 2000, CARCINOGENESIS, V21, P663
   HOMANN N, 2006, INT J CANCER, V118, P1998, DOI 10.1002/ijc.21583
   INOUE M, 1997, J CLIN EPIDEMIOL, V50, P69
   LI YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564
   LIN DY, 2006, J AM STAT ASSOC, V101, P89, DOI 10.1198/016214505000000808
   MARCHENKO YV, 2008, STATA J, V8, P305
   MATSUO K, 2001, CARCINOGENESIS, V22, P913
   MATSUO K, 2007, HUM MUTAT, V28, P506, DOI 10.1002/humu.20477
   OSIER MV, 2002, AM J HUM GENET, V71, P84
   PETERS ES, 2005, CANCER EPIDEM BIOMAR, V14, P476
   SEITZ HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191
   SOLOMON PR, 2008, ORAL DIS, V14, P633, DOI
   10.1111/j.1601-0825.2007.01437.x
   SPINKA C, 2005, GENET EPIDEMIOL, V29, P108, DOI 10.1002/gepi.20085
   TAJIMA K, 2000, ASIAN PACIFIC J CANC, V1, P35
   YANG CX, 2005, ASIAN PAC J CANCER P, V6, P256
   YOKOYAMA A, 1996, CANCER EPIDEM BIOMAR, V5, P99
   YOKOYAMA A, 2002, CARCINOGENESIS, V23, P1851
NR 26
TC 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMARKER PREV
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2009
VL 18
IS 11
BP 3097
EP 3102
DI 10.1158/1055-9965.EPI-09-0499
PG 6
SC Oncology; Public, Environmental & Occupational Health
GA 516SJ
UT ISI:000271562600043
ER

PT J
AU Lorenzo, VF
   Yang, YZ
   Simonson, TS
   Nussenzveig, R
   Jorde, LB
   Prchal, JT
   Ge, RL
AF Lorenzo, Felipe, V
   Yang, Yingzhong
   Simonson, Tatum S.
   Nussenzveig, Roberto
   Jorde, Lynn B.
   Prchal, Josef T.
   Ge, Ri-Li
TI Genetic adaptation to extreme hypoxia: Study of high-altitude pulmonary
   edema in a three-generation Han Chinese family
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE Hypoxia; Erythropoietin; High-altitude pulmonary edema (HAPE);
   Endothelial nitric oxide (eNOS); Hypoxia inducible factor (HIF)
ID OXIDE SYNTHASE GENE; CHRONIC MOUNTAIN-SICKNESS; ASSOCIATION;
   EXPRESSION; RESPONSES; POLYMORPHISMS; TIBETAN; HIF-1
AB Organismal response to hypoxia is essential for critical regulation of
   erythropoiesis, other physiological functions, and survival. There is
   evidence of individual variation in response to hypoxia as some but not
   all of the affected individuals develop polycythemia, and or pulmonary
   and cerebral edema. A significant population difference in response to
   hypoxia exist as many highland Tibetan, Ethiopian, and Andean natives
   developed adaptive mechanisms to extreme hypoxia. A proportion of
   non-adapted individuals exposed to high attitude develop pulmonary
   edema (HAPE), pulmonary hypertension, cerebral edema, and extreme
   polycythemia. The isolation of causative gene(s) responsible for HAPE
   and other extreme hypoxia complications would provide a rational basis
   for specific targeted therapy of HAPE, allow its targeted prevention
   for at-risk populations, and clarify the pathophysiology of other
   hypoxic maladaptations. The only suggested genetic linkage among
   unrelated individuals with HAPE has been with endothelial nitric oxide
   synthase (eNOS) gene. Here we describe a family with multiple members
   affected with HAPE in three generations. Families with multiple
   affected members with HAPE have not been described. We first ruled out
   linkage of HAPE with the eNOS gene. We then performed an analysis of
   the whole genome using high-density SNP arrays (Affymetrix v5.0) and,
   assuming a single gene causation of HAPE, ruled out linkage with 34
   other candidate genes. Only the HIF2A haplotype was shared by
   individuals who exhibit the HAPE phenotype, and work on its possible
   causative role in HAPE is in progress. The small size of our family
   does not provide sufficient power for a conclusive analysis of linkage.
   We hope that collaboration with other investigators with access to more
   HAPE patients will lead to the identification of gene(s) responsible
   for HAPE and possibly other maladaptive hypoxic complications. (C) 2009
   Elsevier Inc. All rights reserved.
C1 [Lorenzo, Felipe, V; Yang, Yingzhong; Prchal, Josef T.] Univ Utah, Sch Med, Div Hematol, Salt Lake City, UT 84132 USA.
   [Yang, Yingzhong; Ge, Ri-Li] Qinghai Univ, Res Ctr High Attitude Med, Xining 810001, Qinghai, Peoples R China.
   [Simonson, Tatum S.; Jorde, Lynn B.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA.
   [Nussenzveig, Roberto; Prchal, Josef T.] ARUP Labs, Salt Lake City, UT 84108 USA.
RP Prchal, JT, Univ Utah, Sch Med, Div Hematol, SOM 5C210,30 N 1900 E,
   Salt Lake City, UT 84132 USA.
EM josef.prchal@hsc.utah.edu
   geriligao@hotmail.com
FU NIH [R01 HL50077-11, GM-59290]
FX The presented study was supported by R01 HL50077-11, VAH Merit review
   grant (JTP) NIH grant GM-59290 (LJ).
CR *AFF, 2006, BRLMM IMPR GEN CALL
   ABECASIS GR, 2002, NAT GENET, V30, P97
   AHSAN A, 2006, CHEST, V130, P1511, DOI 10.1378/chest.130.5.1511
   ANGELO G, 2003, J BIOL CHEM, V278, P38183
   BEALL CM, 2006, INTEGR COMP BIOL, V46, P18, DOI 10.1093/icb/icj004
   BEALL CM, 2007, P NATL ACAD SCI U S1, V104, P8655, DOI
   10.1073/pnas.0701985104
   CATTARUZZA M, 2004, CIRC RES, V95, P841, DOI
   10.1161/01.RES.0000145359.47708.2f
   DROMA Y, 2002, CIRCULATION, V106, P826, DOI
   10.1161/01.CIR.0000024409.30143.70
   FUKUDA R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   GE RL, 2001, APPL PHYSL, V92, P2361
   GLUECKER T, 1999, RADIOGRAPHICS, V19, P1507
   HIROTA K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI
   10.1016/j.citrevonc.2005.12.003
   JEDLICKOVA K, 2003, BLOOD CELL MOL DIS, V31, P175, DOI
   10.1016/S1079-9796(03)00153-0
   JEFFERSON JA, 2002, LANCET, V359, P407
   KAWASHIMA A, 1989, J APPL PHYSIOL, V67, P1982
   KLINE DD, 2002, P NATL ACAD SCI USA, V99, P821
   KONG A, 1997, AM J HUM GENET, V61, P1179
   LIU SP, 2007, J INFRARED MILLIM W, V26, P217
   MAGGIORINI M, 2006, CARDIOVASC RES, V72, P41, DOI
   10.1016/j.cardiores.2006.07.004
   MANALO DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   MATSUZAWA Y, 1989, J APPL PHYSIOL, V66, P1152
   MEJIA OM, 2005, HAEMATOLOGICA, V90, P13
   MIYAMOTO Y, 2000, HUM MOL GENET, V9, P2629
   QUTUB AA, 2007, BBA-MOL CELL RES, V1773, P1511, DOI
   10.1016/j.bbamcr.2007.07.004
   RANKIN EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117
   TESAURO M, 2000, P NATL ACAD SCI USA, V97, P2832
   TSUKADA T, 1998, BIOCHEM BIOPH RES CO, V245, P190
   WANG XL, 2000, FEBS LETT, V471, P45
NR 28
TC 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD NOV-DEC
PY 2009
VL 43
IS 3
BP 221
EP 225
DI 10.1016/j.bcmd.2009.04.006
PG 5
SC Hematology
GA 515PO
UT ISI:000271484600001
ER

PT J
AU Zhang, T
   Liu, SX
   Yang, PY
   Han, CF
   Wang, JL
   Liu, J
   Han, YM
   Yu, YZ
   Cao, XT
AF Zhang, Ting
   Liu, Shuxun
   Yang, Pengyuan
   Han, Chaofeng
   Wang, Jianli
   Liu, Juan
   Han, Yanmei
   Yu, Yizhi
   Cao, Xuetao
TI Fibronectin maintains survival of mouse natural killer (NK) cells via
   CD11b/Src/beta-catenin pathway
SO BLOOD
LA English
DT Article
ID REGULATORY DENDRITIC CELLS; BETA-CATENIN; EXTRACELLULAR-MATRIX; STROMAL
   CELLS; I INTERFERON; INTEGRINS; GENE; PHOSPHORYLATION; DIFFERENTIATION;
   MACROPHAGES
AB Tissue microenvironment and stroma-derived extracellular matrix (ECM)
   molecules play important roles in the survival and differentiation of
   cells. Mouse natural killer (NK) cells usually die within 24 hours once
   isolated ex vivo. Exogenous cytokines such as interleukin-12 (IL-12)
   and IL-15 are required to maintain the survival and activity of mouse
   NK cells cultured in vitro. Whether and how ECM molecules such as
   fibronectin can support the survival of NK cells remain unknown. We
   demonstrate that fibronectin, just like IL-15, can maintain survival of
   mouse NK cells in vitro. Furthermore, we show that fibronectin binds to
   the CD11b on NK cells, and then CD11b recruits and activates Src. Src
   can directly interact with beta-catenin and trigger nuclear
   translocation of beta-catenin. The activation of beta-catenin promotes
   extracellular signal-related kinase (ERK) phosphorylation, resulting in
   the increased expression of antiapoptotic protein B-cell leukemia 2
   (Bcl-2), which may con-tribute to the maintenance of NK-cell survival.
   Consistently, fibronectin cannot maintain the survival of CD11b(-) NK
   cells and beta-catenin-deficient NK cells in vitro, and the number of
   NK cells is dramatically decreased in the beta-catenin-deficient mice.
   Therefore, fibronectin can maintain survival of mouse NK cells by
   activating ERK and up-regulating Bcl-2 expression via
   CD11b/Src/beta-catenin pathway. (Blood. 2009; 114: 4081-4088)
C1 [Zhang, Ting; Wang, Jianli; Cao, Xuetao] Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058, Zhejiang, Peoples R China.
   [Zhang, Ting; Liu, Shuxun; Yang, Pengyuan; Han, Chaofeng; Liu, Juan; Han, Yanmei; Yu, Yizhi; Cao, Xuetao] Mil Med Coll 2, Natl Key Lab Med Immunol, Shanghai, Peoples R China.
   [Zhang, Ting; Liu, Shuxun; Yang, Pengyuan; Han, Chaofeng; Liu, Juan; Han, Yanmei; Yu, Yizhi; Cao, Xuetao] Mil Med Coll 2, Inst Immunol, Shanghai, Peoples R China.
RP Cao, XT, Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058,
   Zhejiang, Peoples R China.
EM caoxt@public3.sta.net.cn
FU National Natural Science Foundation of China [30672386, 30572121,
   30721091]; National Key Basic Research Program of China [2007CB512403,
   2009CB522402]
FX This work was supported by grants from the National Natural Science
   Foundation of China ( 30672386, 30572121, 30721091) and National Key
   Basic Research Program of China ( 2007CB512403, 2009CB522402).
CR ABRAM CL, 2009, ANNU REV IMMUNOL, V27, P339, DOI
   10.1146/annurev.immunol.021908.132554
   AN HZ, 2008, NAT IMMUNOL, V9, P542, DOI 10.1038/ni.1604
   ANDONIOU CE, 2008, EUR J IMMUNOL, V38, P2938
   BECKNELL B, 2008, J IMMUNOTHER, V31, P685
   BRAULT V, 2001, DEVELOPMENT, V128, P1253
   BURROWS TD, 1995, CELL IMMUNOL, V166, P53
   CHIOSSONE L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179
   CLEVERS H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   DALEY WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064
   DING Y, 2008, NAT MED, V14, P162, DOI 10.1038/nm1707
   DSOUZA WN, 2008, J IMMUNOL, V181, P7617
   EIDENSCHENK C, 2006, J IMMUNOL, V177, P8835
   EVANS R, 2009, J CELL SCI, V122, P215, DOI 10.1242/jcs.019117
   HEINO J, 2009, CURR PHARM DESIGN, V15, P1309
   HUNTINGTON ND, 2007, NAT IMMUNOL, V8, P856, DOI 10.1038/ni1487
   HUNTINGTON ND, 2009, J EXP MED, V206, P5
   IOANNIDIS V, 2003, J IMMUNOL, V171, P769
   LEISS M, 2008, CURR OPIN CELL BIOL, V20, P502, DOI
   10.1016/j.ceb.2008.06.001
   LI HQ, 2009, J IMMUNOL, V182, P240
   LI Q, 2008, EUR J IMMUNOL, V38, P2751, DOI 10.1002/eji.200838542
   LI YQ, 1997, J IMMUNOTHER, V20, P123
   LIU XG, 2008, BLOOD, V112, P4961, DOI 10.1182/blood-2008-03-144022
   MOSIMANN C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654
   NELSON WJ, 2004, SCIENCE, V303, P1483
   PARSONS SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160
   PLUSKOTA E, 2008, J IMMUNOL, V181, P3609
   ROURA S, 1999, J BIOL CHEM, V274, P36734
   SUN JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665
   TANG H, 2006, BLOOD, V108, P1189, DOI 10.1182/blood-2006-01-007187
   TAURIN S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   TSUKADA Y, 2009, BIOCHEM BIOPH RES CO, V381, P733, DOI
   10.1016/j.bbrc.2009.02.158
   VICENTEMANZANARES M, 2009, J CELL SCI, V122, P199, DOI
   10.1242/jcs.018564
   VIVIER E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582
   WANG YZ, 2007, BLOOD, V110, P962, DOI 10.1182/blood-2007-01-066027
   WHITE ES, 2008, J PATHOL, V216, P1, DOI 10.1002/path.2388
   XIA S, 2008, BLOOD, V112, P3175, DOI 10.1182/blood-2008-05-159921
   XIA S, 2008, MOL IMMUNOL, V45, P2831, DOI 10.1016/j.molimm.2008.01.035
   XIE HM, 2005, J IMMUNOL, V175, P7981
   XU YY, 2003, NAT IMMUNOL, V4, P1177, DOI 10.1038/ni1008
   ZHANG B, 2008, INT IMMUNOPHARMACOL, V8, P989, DOI
   10.1016/j.intimp.2008.03.001
   ZHANG MH, 2004, NAT IMMUNOL, V5, P1124, DOI 10.1038/ni1130
   ZHENG XD, 2008, MOL IMMUNOL, V45, P2559, DOI
   10.1016/j.molimm.2008.01.001
NR 42
TC 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 5
PY 2009
VL 114
IS 19
BP 4081
EP 4088
DI 10.1182/blood-2009-05-219881
PG 8
SC Hematology
GA 515TJ
UT ISI:000271495500020
ER

PT J
AU Huang, SC
   Cho, A
   Norton, S
   Liu, ES
   Park, J
   Zhou, AY
   Munagala, ID
   Ou, AC
   Yang, G
   Wickrema, A
   Tang, TK
   Benz, EJ
AF Huang, Shu-Ching
   Cho, Aeri
   Norton, Stephanie
   Liu, Eva S.
   Park, Jennie
   Zhou, Anyu
   Munagala, Indira D.
   Ou, Alexander C.
   Yang, Guang
   Wickrema, Amittha
   Tang, Tang K.
   Benz, Edward J., Jr.
TI Coupled transcription-splicing regulation of mutually exclusive
   splicing events at the 5 ' exons of protein 4.1R gene
SO BLOOD
LA English
DT Article
ID PRE-MESSENGER-RNA; ALTERNATIVE 1ST EXONS; ERYTHROID-DIFFERENTIATION;
   POLYMERASE-II; MAMMALIAN-CELLS; PROMOTER USAGE; SR PROTEINS; SITE AG;
   IN-VIVO; EXPRESSION
AB The tightly regulated production of distinct erythrocyte protein 4.1R
   isoforms involves differential splicing of 3 mutually exclusive first
   exons (1A, 1B, 1C) to the alternative 3' splice sites (ss) of exon
   2'/2. Here, we demonstrate that exon 1 and 2'/2 splicing diversity is
   regulated by a transcription-coupled splicing mechanism. We also
   implicate distinctive regulatory elements that promote the splicing of
   exon 1A to the distal 3' ss and exon 1B to the proximal 3' ss in murine
   erythroleukemia cells. A hybrid minigene driven by cytomegalovirus
   promoter mimicked 1B-promoter-driven splicing patterns but differed
   from 1A-promoter-driven splicing patterns, suggesting that promoter
   identity affects exon 2'/2 splicing. Furthermore, splicing factor
   SF2/ASF ultraviolet (UV) cross- linked to the exon 2'/2 junction
   CAGAGAA, a sequence that overlaps the distal U2AF35-binding 3'ss.
   Consequently, depletion of SF2/ASF allowed exon 1B to splice to the
   distal 3' ss but had no effect on exon 1A splicing. These findings
   identify for the first time that an SF2/ASF binding site also can serve
   as a 3' ss in a transcript-dependent manner. Taken together, our
   results suggest that 4.1R gene expression involves transcriptional
   regulation coupled with a complex splicing regulatory network. (Blood.
   2009; 114:4233-4242)
C1 [Huang, Shu-Ching; Cho, Aeri; Norton, Stephanie; Liu, Eva S.; Park, Jennie; Zhou, Anyu; Munagala, Indira D.; Ou, Alexander C.; Yang, Guang; Benz, Edward J., Jr.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Huang, Shu-Ching; Zhou, Anyu; Yang, Guang; Benz, Edward J., Jr.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Wickrema, Amittha] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Tang, Tang K.] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Benz, Edward J., Jr.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
   [Benz, Edward J., Jr.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Benz, Edward J., Jr.] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.
RP Huang, SC, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM shu-ching_huang@dfci.harvard.edu
FU National Institutes of Health [HL24385]
FX We thank Shailja Pathania and David Livingston for assistance with the
   ChIP and ChRIP experiments, Karla Neugebauer for using modified Figures
   2A and 2C illustrating the ChIP and ChRIP procedures, and Woan- Yuh
   Tarn for helpful discussion.
   This study was supported by the National Institutes of Health grant
   HL24385 (to E.J.B.) and Claudia BarrAward (to S.C.H.).
CR BAKLOUTI F, 1996, BLOOD, V87, P3934
   BENTLEY D, 1999, CURR OPIN CELL BIOL, V11, P347
   BIRD G, 2004, MOL CELL BIOL, V24, P8963, DOI
   10.1128/MCB.24.20.8963-8969.2004
   BLOBEL GA, 1998, P NATL ACAD SCI USA, V95, P2061
   BURATOWSKI S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679
   CACERES JF, 2002, TRENDS GENET, V18, P186
   CHASIS JA, 1993, J CLIN INVEST, V91, P329
   CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062
   CRAMER P, 1999, MOL CELL, V4, P251
   DAS R, 2007, MOL CELL, V26, P867, DOI 10.1016/j.molcel.2007.05.036
   DEGUILLIEN M, 2001, BLOOD, V98, P3809
   DELAMATA M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475
   GIARRATANA MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047
   GRAVELEY BR, 1998, MOL CELL, V1, P765
   HIROSE Y, 2000, GENE DEV, V14, P1415
   HOU VC, 2002, EMBO J, V21, P6195
   KOGERMAN P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865
   KORNBLIHTT AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI
   10.1016/j.ceb.2005.04.014
   KRAUSS SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI
   10.1073/pnas.1934680100
   LANDRY JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014
   LISTERMAN I, 2006, NAT STRUCT MOL BIOL, V13, P815, DOI 10.1038/nsmb1135
   MAHMUD DL, 2002, ONCOGENE, V21, P1556
   MANIATIS T, 2002, NATURE, V416, P499
   MERENDINO L, 1999, NATURE, V402, P838
   MESHORER E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200
   MISTELI T, 1997, NATURE, V387, P523
   NOGUES G, 2003, IUBMB LIFE, V55, P235, DOI 10.1080/1521654031000119830
   NOGUES G, 2003, J BIOL CHEM, V278, P52166, DOI 10.1074/jbc.M309156200
   NOZELL S, 2002, ONCOGENE, V21, P1285
   PADDISON PJ, 2004, NAT METHODS, V1, P163
   PARRA MK, 2003, BLOOD, V101, P4164, DOI 10.1182/blood-200-06-1796
   PARRA MK, 2008, EMBO J, V27, P122, DOI 10.1038/sj.emboj.7601957
   PATEL VP, 1987, J CELL BIOL, V105, P3105
   PECCI A, 2001, J BIOL CHEM, V276, P21062
   PEREZFERREIRO CM, 2004, J CELL SCI, V117, P6197, DOI 10.1242/jcs.01544
   PFEIFER I, 2004, NUCLEIC ACIDS RES, V32, P4550, DOI 10.1093/nar/gkh792
   PHATNANI HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006
   PONTHIER JL, 2006, J BIOL CHEM, V281, P12468, DOI 10.1074/jbc.M511556200
   PROUDFOOT N, 2000, TRENDS BIOCHEM SCI, V25, P290
   SANTOSROSA H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   SMITH CL, 1997, J BIOL CHEM, V272, P27493
   TAN JS, 2006, BLOOD, V107, P2557, DOI 10.1182/blood-2005-07-2957
   TANG TK, 1990, J CELL BIOL, V110, P617
   TOKI T, 2000, EXP HEMATOL, V28, P1113
   VALCARCEL J, 1996, SCIENCE, V273, P1706
   WU SP, 1999, NATURE, V402, P832
   YANG G, 2005, BLOOD, V105, P2146, DOI 10.1182/blood-2004-05-1757
   YANG G, 2008, BLOOD, V111, P392, DOI 10.1182/blood-2007-01-068940
NR 49
TC 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 5
PY 2009
VL 114
IS 19
BP 4233
EP 4242
DI 10.1182/blood-2009-02-206219
PG 10
SC Hematology
GA 515TJ
UT ISI:000271495500036
ER

PT J
AU Namkung, J
   Elston, RC
   Yang, JM
   Park, T
AF Namkung, Junghyun
   Elston, Robert C.
   Yang, Jun-Mo
   Park, Taesung
TI Identification of Gene-Gene Interactions in the Presence of Missing
   Data Using the Multifactor Dimensionality Reduction Method
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE gene-gene interaction; multifactor dimensionality reduction; missing
   genotypes; association study
ID COMPLEX TRAITS; EM ALGORITHM; SUSCEPTIBILITY; ASSOCIATION; EPISTASIS;
   POLYMORPHISMS; STRATEGIES; CANCER
AB Gene-gene interaction is believed to play an important role in
   understanding complex traits. Multifactor dimensionality reduction
   (MDR) was proposed by Ritchie et al. [2001. Am J Hum Genet 69:138-147]
   to identify multiple loci that simultaneously affect disease
   susceptibility. Although the MDR method has been widely used to detect
   gene-gene interactions, few studies have been reported on MDR analysis
   when there are missing data. Currently, there are four approaches
   available in MDR analysis to handle missing data. The first approach
   uses only complete observations that have no missing data, which can
   cause a severe loss of data. The second approach is to treat missing
   values as an additional genotype category, but interpretation of the
   results may then be not clear and the conclusions may be misleading.
   Furthermore, it performs poorly when the missing rates are unbalanced
   between the case and control groups. The third approach is a simple
   imputation method that imputes missing genotypes as the most frequent
   genotype, which may also produce biased results. The fourth approach,
   Available, uses all data available for the given loci to increase
   power. In any real data analysis, it is not clear which MDR approach
   one should use when there are missing data. In this article, we
   consider a new EM Impute approach to handle missing data more
   appropriately. Through simulation studies, we compared the performance
   of the proposed EM Impute approach with the current approaches. Our
   results showed that Available and EM Impute approaches perform better
   than the three other current approaches in terms of power and
   precision. Genet. Epidemiol. 33:646-656, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Park, Taesung] Seoul Natl Univ, Dept Stat, Seoul 151747, South Korea.
   [Namkung, Junghyun; Park, Taesung] Seoul Natl Univ, Bioinformat Program, Seoul 151747, South Korea.
   [Namkung, Junghyun; Yang, Jun-Mo] Sungkyunkwan Univ, Sch Med, Dept Dermatol, Seoul, South Korea.
   [Elston, Robert C.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
RP Park, T, Seoul Natl Univ, Dept Stat, Seoul 151747, South Korea.
EM tspark@stats.snu.ac.kr
CR ANDREW AS, 2006, CARCINOGENESIS, V27, P1030, DOI 10.1093/carcin/bgi284
   BUSH WS, 2006, BIOINFORMATICS, V22, P2173, DOI
   10.1093/bioinformatics/btl347
   CHUNG YJ, 2007, BIOINFORMATICS, V23, P71, DOI
   10.1093/bioinformatics/btl557
   DEMPSTER AP, 1977, J ROY STAT SOC B, V39, P1
   HAHN LW, 2003, BIOINFORMATICS, V19, P376, DOI
   10.1093/bioinformatics/btf869
   KIM HT, 2007, J DERMATOL SCI, V46, P143, DOI
   10.1016/j.jdermsci.2006.12.001
   LITTLE RJA, 2002, STAT ANAL MISSING DA
   MOORE JH, 2002, ANN MED, V34, P88
   MOORE JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735
   MOORE JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036
   MOTSINGER AA, 2006, HUM GENOMICS, V2, P318
   QIN ZHS, 2002, AM J HUM GENET, V71, P1242
   RISCH N, 1990, AM J HUM GENET, V46, P222
   RITCHIE MD, 2001, AM J HUM GENET, V69, P138
   RITCHIE MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218
   SCHEET P, 2006, AM J HUM GENET, V78, P629
   SCHULTZLARSEN F, 1993, J AM ACAD DERMATOL, V28, P719
   SHERRIFF A, 2001, ADV GENET, V42, P287
   TAHRIDAIZADEH N, 2003, GENOME RES, V13, P1952, DOI 10.1101/gr.1254203
   VELEZ DR, 2007, GENET EPIDEMIOL, V31, P306, DOI 10.1002/gepi.20211
   WOLF JB, 2000, EPISTATSIS EVOLUTION
   WU CFJ, 1983, ANN STAT, V11, P95
   ZHANG HP, 2000, GENET EPIDEMIOL, V19, P323
NR 23
TC 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD NOV
PY 2009
VL 33
IS 7
BP 646
EP 656
DI 10.1002/gepi.20416
PG 11
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 514PB
UT ISI:000271406100009
ER

PT J
AU Yang, H
   Youm, YH
   Vandanmagsar, B
   Rood, J
   Kumar, KG
   Butler, AA
   Dixit, VD
AF Yang, Hyunwon
   Youm, Yun-Hee
   Vandanmagsar, Bolormaa
   Rood, Jennifer
   Kumar, K. Ganesh
   Butler, Andrew A.
   Dixit, Vishwa Deep
TI Obesity accelerates thymic aging
SO BLOOD
LA English
DT Article
ID PROINFLAMMATORY CYTOKINE EXPRESSION; CALORIC RESTRICTION;
   IMMUNE-SYSTEM; MELANOCORTIN-4 RECEPTOR; LIPID-METABOLISM;
   INFLUENZA-VIRUS; T-CELLS; MICE; LEPTIN; AGE
AB As the expanding obese population grows older, their successful
   immunologic aging will be critical to enhancing the health span.
   Obesity increases risk of infections and cancer, suggesting adverse
   effects on immune surveillance. Here, we report that obesity
   compromises the mechanisms regulating T-cell generation by inducing
   premature thymic involution. Diet-induced obesity reduced thymocyte
   counts and significantly increased apoptosis of developing T-cell
   populations. Obesity accelerated the age-related reduction of T-cell
   receptor (TCR) excision circle bearing peripheral lymphocytes, an index
   of recently generated T cells from thymus. Consistent with reduced
   thymopoiesis, dietary obesity led to reduction in peripheral naive T
   cells with increased frequency of effector-memory cells. Defects in
   thymopoiesis in obese mice were related with decrease in the
   lymphoid-primed multipotent progenitor (Lin(-)Sca1(+)Kit(+) Flt3(+)) as
   well as common lymphoid progenitor (Lin(-)Sca1(+)CD117(lo)CD127(+))
   pools. The TCR spectratyping analysis showed that obesity compromised
   V-beta TCR repertoire diversity. Furthermore, the obesity induced by
   melanocortin 4 receptor deficiency also constricted the T-cell
   repertoire diversity, recapitulating the thymic defects observed with
   diet-induced obesity. In middle-aged humans, progressive adiposity with
   or without type 2 diabetes also compromised thymic output.
   Collectively, these findings establish that obesity constricts T-cell
   diversity by accelerating age-related thymic involution. (Blood. 2009;
   114: 3803-3812)
C1 [Yang, Hyunwon; Youm, Yun-Hee; Vandanmagsar, Bolormaa; Dixit, Vishwa Deep] Louisiana State Univ Syst, Lab Neuroendocrine Immunol, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
   [Rood, Jennifer] Louisiana State Univ Syst, Clin Chem Core, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
   [Kumar, K. Ganesh; Butler, Andrew A.] Louisiana State Univ Syst, Neuropeptide Lab, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
RP Dixit, VD, Louisiana State Univ Syst, Lab Neuroendocrine Immunol,
   Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
EM Vishwa.Dixit@pbrc.edu
FU Coypu and Pennington Foundation ; National Institutes of Health (NIH)
   [1 P20 RR02/1945]; Pennington Center of Biomedical Research Excellence
   and Clinical Nutrition Research Unit [P30 DK072476]
FX This work was supported in part by Coypu and Pennington Foundation
   grants (V. D. D.). The present work used the facilities of the Genomics
   and Cell Biology & Cell Imaging Core facilities supported by National
   Institutes of Health (NIH) grant 1 P20 RR02/1945 and Cell Biology and
   Bioimaging Core Facility of the Pennington Center of Biomedical
   Research Excellence and Clinical Nutrition Research Unit (NIH P30
   DK072476).
CR AKASHI K, 2000, NATURE, V404, P193
   ALBARADO DC, 2004, ENDOCRINOLOGY, V145, P243, DOI 10.1210/en.2003-0452
   AMAR S, 2007, P NATL ACAD SCI USA, V104, P20466
   ANDERSON G, 2001, NAT REV IMMUNOL, V1, P31
   ANDERSON G, 2007, NAT REV IMMUNOL, V7, P954, DOI 10.1038/nri2187
   ANDERSON MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   BARGER JL, 2003, EXP GERONTOL, V38, P1343, DOI
   10.1016/j.exger.2003.10.017
   BHANDOOLA A, 2007, IMMUNITY, V26, P678, DOI 10.1016/j.immuni.2007.05.009
   BRESNAHAN MR, 1968, BR J EXP PATHOL, V49, P223
   BUTLER AA, 2001, NAT NEUROSCI, V4, P605
   DAMJANOVIC AK, 2007, J IMMUNOL, V179, P4249
   DEROSA V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011
   DIXIT VD, 2003, ENDOCRINOLOGY, V144, P5595, DOI 10.1210/en.2003-0600
   DIXIT VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JC1200421134
   DIXIT VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248
   DIXIT VD, 2008, J LEUKOCYTE BIOL, V84, P882, DOI 10.1189/jlb.0108028
   DIXIT VD, 2009, BLOOD, V113, P5202, DOI 10.1182/blood-2008-09-181255
   DORSHKIND K, 2009, NAT REV IMMUNOL, V9, P57, DOI 10.1038/nri2471
   DUTTON RW, 1998, ANNU REV IMMUNOL, V16, P201
   ELIAKIM A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326
   FALAGAS ME, 2006, LANCET INFECT DIS, V6, P438
   FAROOQI IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693
   FAROOQI S, 2006, ENDOCR REV, V27, P710
   FLEGAL KM, 2007, JAMA-J AM MED ASSOC, V298, P2028
   FLORES KG, 1999, J CLIN INVEST, V104, P1031
   FONTAINE KR, 2001, OBES REV, V2, P173
   FONTAINE KR, 2003, JAMA-J AM MED ASSOC, V289, P187
   FRIEDMAN JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563
   GOROCHOV G, 1998, NAT MED, V4, P215
   GORONZY JJ, 2005, CURR OPIN IMMUNOL, V17, P468, DOI
   10.1016/j.coi.2005.07.020
   GRAY DHD, 2005, CURR OPIN IMMUNOL, V17, P137, DOI
   10.1016/j.coi.2005.02.001
   GUI JG, 2007, INT IMMUNOL, V19, P1201, DOI 10.1093/intimm/dxm095
   HAYNES L, 2006, IMMUNITY, V24, P663, DOI 10.1016/j.immuni.2006.06.003
   HOTAMISLIGIL GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   HOWARD JK, 1999, J CLIN INVEST, V104, P1051
   KYEWSKI B, 2006, ANNU REV IMMUNOL, V24, P571, DOI
   10.1146/annurev.immunol.23.021704.115601
   LINTON PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033
   MILLER RA, 1996, SCIENCE, V273, P70
   MIN H, 2004, J IMMUNOL, V173, P245
   NIKOLICHZUGICH J, 2005, EXP GERONTOL, V40, P884, DOI
   10.1016/j.exger.2005.06.007
   NIKOLICHZUGICH J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318
   NOGUEIRAS R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JC131743
   PALMER G, 2006, J IMMUNOL, V177, P2899
   PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319
   PETRIE HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI
   10.1146/annurev.immunol.23.021704.115715
   SEMPOSSKI GD, 2002, MOL IMMUNOL, V38, P841
   SMITH AG, 2007, J NUTR, V137, P1236
   SMITH AG, 2009, IMMUNOLOGY, V126, P268, DOI
   10.1111/j.1365-2567.2008.02895.x
   STEINMANN GG, 1986, CURR TOP PATHOL, V75, P43
   SUTTON GM, 2006, ENDOCRINOLOGY, V147, P2183, DOI 10.1210/en.2005-1209
   TANAKA S, 2001, CLIN ENDOCRINOL, V54, P347
   WANG YC, 2007, OBESITY, V15, P2855
   WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187
   YANG H, 2009, J LEUKOCYTE BIOL, V85, P928, DOI 10.1189/jlb.1008621
   YANG HW, 2009, J IMMUNOL, V183, P3040, DOI 10.4049/jimmunol.0900562
   YOUM YH, 2009, J BIOL CHEM, V284, P7068, DOI 10.1074/jbc.M808302200
   ZEDIAK VP, 2007, BLOOD, V110, P1161, DOI 10.1182/blood-2007-01-071605
NR 57
TC 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 29
PY 2009
VL 114
IS 18
BP 3803
EP 3812
DI 10.1182/blood-2009-03-213595
PG 10
SC Hematology
GA 512RO
UT ISI:000271268100015
ER

PT J
AU Qian, JF
   Hong, S
   Wang, SQ
   Zhang, L
   Sun, LH
   Wang, M
   Yang, J
   Kwak, LW
   Hou, J
   Yi, Q
AF Qian, Jianfei
   Hong, Sungyoul
   Wang, Siqing
   Zhang, Liang
   Sun, Luhong
   Wang, Michael
   Yang, Jing
   Kwak, Larry W.
   Hou, Jian
   Yi, Qing
TI Myeloma cell line-derived, pooled heat shock proteins as a universal
   vaccine for immunotherapy of multiple myeloma
SO BLOOD
LA English
DT Article
ID METASTATIC MELANOMA PATIENTS; CYTOTOXIC T-LYMPHOCYTES; TUMOR-SPECIFIC
   IMMUNITY; PEPTIDE COMPLEXES; REGULATORY CELLS; IN-VIVO; CPG
   OLIGODEOXYNUCLEOTIDES; CANCER-IMMUNOTHERAPY; CD8-T-CELL MEMORY;
   ADJUVANT ACTIVITY
AB Tumor cell-derived heat shock proteins are used as vaccines for
   immunotherapy of cancer patients. However, current approaches require
   the generation of custom-made products and are clinically ineffective.
   To improve the applicability of heat shock protein-based immunotherapy
   in cancers and to enhance clinical efficacy, we explored combinational
   treatments in a myeloma setting using pooled heterogeneous or
   allogeneic myeloma cell line-derived glycoprotein 96 (gp96) as
   universal vaccines, and clearly demonstrated that pooled but not single
   gp96 from heterogeneous or allogeneic myeloma cell lines was as
   effective as autologous gp96 in protecting mice from tumor challenge
   and re-challenge and in treating established myeloma. We showed that
   interferon gamma and CD4(+) and CD8(+) T cells were required for
   gp96-induced antimyeloma responses and that pooled gp96 induced broader
   immune responses that protected mice from developing different myeloma.
   Furthermore, pooled gp96 plus CpG in combination with anti-B7H1 or
   anti-interleukin-10 monoclonal anti-bodies were effective in treating
   mice with large tumor burdens. Thus, this study strongly suggests that
   pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines
   from autologous tumors for immunotherapy and induce immune responses
   against broader tumor antigens that may protect against tumor
   recurrence and development of unrelated tumors in vaccinated myeloma
   patients. (Blood. 2009; 114: 3880-3889)
C1 [Qian, Jianfei; Hong, Sungyoul; Wang, Siqing; Zhang, Liang; Sun, Luhong; Wang, Michael; Yang, Jing; Kwak, Larry W.; Yi, Qing] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.
   [Qian, Jianfei; Hong, Sungyoul; Wang, Siqing; Zhang, Liang; Sun, Luhong; Wang, Michael; Yang, Jing; Kwak, Larry W.; Yi, Qing] MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA.
   [Hou, Jian] Shanghai Chang Zheng Hosp, Dept Hematol, Shanghai, Peoples R China.
RP Yi, Q, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe
   Blvd,Unit 0903, Houston, TX 77030 USA.
EM houjian@medmail.com.cn
   qyi@mdanderson.org
FU University of Texas M. D. Anderson Cancer Center ; National Cancer
   Institute [R01 CA96569, R01 CA103978, R01 CA138402]; Leukemia &
   Lymphoma Society ; Multiple Myeloma Research Foundation ; Commonwealth
   Foundation for Cancer Research ; National Natural Science Foundation of
   China [30828017]
FX This work was supported by institutional start-up funds from the
   University of Texas M. D. Anderson Cancer Center, grants from the
   National Cancer Institute (R01 CA96569, R01 CA103978, and R01
   CA138402), the Leukemia & Lymphoma Society, Multiple Myeloma Research
   Foundation, Commonwealth Foundation for Cancer Research, and the
   National Natural Science Foundation of China (no. 30828017).
CR ATANACKOVIC D, 2008, HAEMATOL-HEMATOL J, V93, P423, DOI
   10.3324/haematol.11897
   BELIAKOFF J, 2004, ANTI-CANCER DRUG, V15, P651, DOI
   10.1097/01.cad.0000136876.11928.be
   BELLI F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134
   BERNARD MP, 2007, CLIN IMMUNOL, V125, P138, DOI
   10.1016/j.clim.2007.07.006
   CASARES N, 2003, J IMMUNOL, V171, P5931
   CIOCCA DR, 1993, J NATL CANCER I, V85, P1558
   COUPER KN, 2009, J IMMUNOL, V182, P3985, DOI 10.4049/jimmunol.0803053
   DEBOER RJ, 2003, J IMMUNOL, V171, P3928
   DOODY ADH, 2004, J IMMUNOL, V172, P6087
   FOULDS KE, 2002, J IMMUNOL, V168, P1528
   FULCHER DA, 1999, IMMUNOL CELL BIOL, V77, P559
   GARRETT IR, 1997, BONE, V20, P515
   IEZZI G, 1998, IMMUNITY, V8, P89
   IEZZI G, 1999, EUR J IMMUNOL, V29, P4092
   ITO A, 2005, J BIOSCI BIOENG, V100, P36, DOI 10.1263/jbb.100.36
   JANETZKI S, 1998, J IMMUNOTHER, V21, P269
   JANETZKI S, 2000, INT J CANCER, V88, P232
   JELLEYGIBBS DM, 2000, J IMMUNOL, V165, P5017
   KANAI T, 2003, J IMMUNOL, V171, P4156
   KLINMAN DM, 2006, INT REV IMMUNOL, V25, P135, DOI
   10.1080/08830180600743057
   KRONING H, 1997, ACTA HAEMATOL-BASEL, V98, P116
   KWAK LW, 1996, P NATL ACAD SCI USA, V93, P10972
   LI Z, 1997, SEMIN IMMUNOL, V9, P315
   LOLLINI PL, 2006, NAT REV CANCER, V6, P204, DOI 10.1038/nrc1815
   LONG SA, 2009, EUR J IMMUNOL, V39, P612, DOI 10.1002/eji.200838819
   LUTZ MB, 1999, J IMMUNOL METHODS, V223, P77
   MAZZAFERRO V, 2003, CLIN CANCER RES, V9, P3235
   MUNDY G, 2001, SEMIN ONCOL S11, V28, P2
   OKI Y, 2004, EXPERT REV VACCINES, V3, P403
   OKI Y, 2007, CANCER, V109, P77, DOI 10.1002/cncr.22389
   PILLA L, 2006, CANCER IMMUNOL IMMUN, V55, P958, DOI
   10.1007/s00262-005-0084-8
   PRABHALA RH, 2006, BLOOD, V107, P301, DOI 10.1182/blood-2005-08-3101
   PRZEPIORKA D, 1998, MOL MED TODAY, V4, P478
   QIAN JF, 2005, CLIN CANCER RES 1, V11, P8808, DOI
   10.1158/1078-0432.CCR-05-1553
   QIAN JF, 2007, BLOOD, V110, P1587, DOI 10.1182/blood-2007-03-082529
   RADL J, 1979, J IMMUNOL, V122, P609
   RIVOLTINI L, 2003, J IMMUNOL, V171, P3467
   ROSENBERG SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   SENGUPTA D, 2004, J IMMUNOL, V173, P1987
   SHEDLOCK DJ, 2003, SCIENCE, V300, P337
   SILLA S, 1999, EUR CYTOKINE NETW, V10, P181
   SRIVASTAVA P, 2002, ANNU REV IMMUNOL, V20, P395
   SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728
   SRIVASTAVA PK, 1997, METHODS, V12, P165
   SRIVASTAVA PK, 2001, METHOD MOL BIOL, V156, P175
   STEVENSON FK, 2000, IMMUNOL TODAY, V21, P170
   SUN JC, 2003, SCIENCE, V300, P339
   TAMURA Y, 1997, SCIENCE, V278, P117
   TESTORI A, 2008, J CLIN ONCOL, V26, P955
   UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077
   URBANSKARYS H, 2000, EUR CYTOKINE NETW, V11, P443
   VANSTIPDONK MJB, 2001, NAT IMMUNOL, V2, P423
   WANG SQ, 2007, FRONT BIOSCI, V12, P3566, DOI 10.2741/2334
   WEN YJ, 2001, BLOOD, V97, P1750
   WUTHRICH M, 2005, J IMMUNOL, V175, P5288
   YANG J, 2006, CANCER CELL, V10, P295, DOI 10.1016/j.ccr.2006.08.025
   YU M, 2006, CANCER IMMUNOL IMMUN, V55, P119, DOI
   10.1007/s00262-005-0008-7
   ZHANG ML, 2003, P NATL ACAD SCI USA, V100, P1891, DOI
   10.1073/pnas.0437788100
NR 58
TC 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 29
PY 2009
VL 114
IS 18
BP 3880
EP 3889
DI 10.1182/blood-2009-06-227355
PG 10
SC Hematology
GA 512RO
UT ISI:000271268100023
ER

PT J
AU Yang, Y
   Liu, JH
   Mao, HH
   Hu, YA
   Yan, Y
   Zhao, CJ
AF Yang, Yang
   Liu, Junhua
   Mao, Huihua
   Hu, Yu-An
   Yan, Yan
   Zhao, Chunjie
TI The expression pattern of Follistatin-like 1 in mouse central nervous
   system development
SO GENE EXPRESSION PATTERNS
LA English
DT Article
DE Follistatin-like 1; Follistatin; Telencephalon; Cortex; Hippocampus;
   Cortical hem; Diencephalon; Midbrain; Cerebellum; Spinal cord;
   Expression pattern; Mouse
ID OCC1 MESSENGER-RNA; VISUAL-CORTEX; MACAQUES; PROTEIN; CLONING; GENE;
   LINE
AB Follistatin-like 1 (Fstl1), also named TSC-36 (TGF-beta-stimulated
   clone 36), was first cloned from the mouse osteoblastic MC3T3-E1 cell
   line and can be up-regulated by TGF-beta. To better study the function
   of Fstl1 during the development of the mouse central nervous system
   (CNS), we examined Fstl1 expression in the developing mouse CNS, in
   detail, by in situ hybridization Our results show that Fstl1 is
   strongly expressed in the telencephalon, diencephalon, brainstem,
   limbic system and spinal cord. In the telencephalon, Fstl1 positive
   cells are mainly located in the ventricular zone (VZ) and the
   subventricular zone (SVZ); a relatively weak signal was observed in
   layers II and III of the neocortex at postnatal stages. Fstl1
   expression is robust in the developing hippocampus and persists to P20.
   In the developing diencephalon and hindbrain. abundant Fstl1 signals
   were also detected in nuclei including the medial habenular nucleus,
   the medial dorsal nucleus, the cochlear nuclei and so on In addition, a
   strong expression of Fstl1 was detected in the thalamencephalic signal
   center, as well as in the olfactory cortex from E14.5 to P0. Meanwhile,
   Fstl1 was expressed in the septal area and the cingulate gyrus of the
   limbic system after birth. A high level of expression was also observed
   in the ventral horn of the spinal cord. These results indicate that
   Fstl1 may play an important role during CNS development in the mouse.
   (C) 2009 Elsevier B.V. All rights reserved.
C1 [Yang, Yang; Liu, Junhua; Mao, Huihua; Hu, Yu-An; Yan, Yan; Zhao, Chunjie] Southeast Univ, Key Lab Dev Genes & Human Dis, MOE, Sch Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Yang, Yang; Liu, Junhua; Mao, Huihua; Hu, Yu-An; Yan, Yan; Zhao, Chunjie] Southeast Univ, Inst Brain Sci, Sch Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Hu, Yu-An] Jinling Hosp, Inst Lab Med, Nanjing 210002, Peoples R China.
RP Zhao, CJ, Southeast Univ, Key Lab Dev Genes & Human Dis, MOE, Sch Med,
   87 Dingjiaoqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
FU National Nature Science Foundation of China [30525017, 30770696];
   Ministry of Science and Technology of China [2007CB512303]
FX We thank Yiquan Wei, Li Liu and Xiaoxuan Lu for technical assistance,
   as well as Yiping Li and other members in the laboratory for valuable
   discussions. This work was supported by funds 30525017, 30770696 from
   The National Nature Science Foundation of China and The National Basic
   Research Program of China 2007CB512303 from The Ministry of Science and
   Technology of China to C.Z.
CR ADAMS D, 2007, GENE EXPR PATTERNS, V7, P491, DOI
   10.1016/j.modgep.2006.10.009
   HU YA, 2008, GENE EXPR PATTERNS, V8, P515, DOI 10.1016/j.gep.2008.06.001
   OKABAYASHI K, 1999, BIOCHEM BIOPH RES CO, V254, P42
   SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13
   TAKAHATA T, 2008, J CHEM NEUROANAT, V35, P146, DOI
   10.1016/j.jchemneu.2007.09.001
   TOCHITANI S, 2001, EUR J NEUROSCI, V13, P297
   TOCHITANI S, 2003, NEUROSCI LETT, V337, P114, DOI
   10.1016/S0304-3940(02)01311-3
   TOCHITANI S, 2003, NEUROSCI LETT, V346, P105, DOI
   10.1016/S0304-3940(03)00595-0
   TOWERS P, 1999, DEV BIOL, V214, P298
   ZHAO CJ, 2006, BRAIN RES, V1077, P48, DOI 10.1016/j.brainres.2006.01.042
NR 10
TC 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-133X
J9 GENE EXPR PATTERNS
JI Gene Expr. Patterns
PD OCT
PY 2009
VL 9
IS 7
BP 532
EP 540
DI 10.1016/j.gep.2009.07.001
PG 9
SC Developmental Biology; Genetics & Heredity
GA 510NF
UT ISI:000271094600010
ER

PT J
AU Yang, XJ
   Feng, M
   Jiang, X
   Wu, ZL
   Li, ZM
   Aau, MY
   Yu, Q
AF Yang, Xiaojing
   Feng, Min
   Jiang, Xia
   Wu, Zhenlong
   Li, Zhimei
   Aau, Meiyee
   Yu, Qiang
TI miR-449a and miR-449b are direct transcriptional targets of E2F1 and
   negatively regulate pRb-E2F1 activity through a feedback loop by
   targeting CDK6 and CDC25A
SO GENES & DEVELOPMENT
LA English
DT Article
DE CDC25A; CDK6; DZNep; E2F1; miR-449
ID EMBRYONIC STEM-CELLS; MICRORNA TARGETS; CANCER; EXPRESSION; APOPTOSIS;
   GENOME; METHYLATION; SIGNATURE; GENES; PLURIPOTENT
AB The Rb-E2F pathway drives cell cycle progression and cell
   proliferation, and the molecular strategies safeguarding its activity
   are not fully understood. Here we report that E2F1 directly
   transactivates miR-449a/b. miR-449a/b targets and inhibits oncogenic
   CDK6 and CDC25A, resulting in pRb dephosphorylation and cell cycle
   arrest at G1 phase, revealing a negative feedback regulation of the
   pRb-E2F1 pathway. Moreover, miR-449a/b expression in cancer cells is
   epigenetically repressed through histone H3 Lys27 trimethylation, and
   epigenetic drug treatment targeting histone methylation results in
   strong induction of miR-449a/b. Our study reveals a tumor suppressor
   function of miR-449a/b through regulating Rb/E2F1 activity, and
   suggests that escape from this regulation through an aberrant
   epigenetic event contributes to E2F1 deregulation and unrestricted
   proliferation in human cancer.
C1 [Yang, Xiaojing; Feng, Min; Jiang, Xia; Wu, Zhenlong; Li, Zhimei; Aau, Meiyee; Yu, Qiang] ASTAR, Genome Inst Singapore, Singapore 138672, Singapore.
   [Yu, Qiang] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
RP Yu, Q, ASTAR, Genome Inst Singapore, Singapore 138672, Singapore.
EM yuq@gis.a-star.edu.sg
FU Agency for Science, Technology, and Research (A<SUP>star</SUP>Star) of
   Singapore 
FX We thank Dr. Kristian Helin for the ER-E2F1 plasmids. This work was
   supported by Agency for Science, Technology, and Research
   (A<SUP>star</SUP>Star) of Singapore.
CR AMBROS V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   AZUARA V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   BERNSTEIN BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   CHANG TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   ESQUELAKERSCHER A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   HE L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   ILIOPOULOS D, 2009, CANCER RES, V69, P3278, DOI
   10.1158/0008-5472.CAN-09-0155
   JIANG X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   KANG T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002
   LEWIS BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   LIANG Y, 2008, BMC MED GENOMICS, V1, ARTN 61
   LU C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112
   MARSON A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   MIKKELSEN TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   NOONAN EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   ODONNELL KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   OOI SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   OZSOLAK F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   PAN GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   PETROCCA F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   PICKERING MT, 2009, ONCOGENE, V28, P140, DOI 10.1038/onc.2008.372
   RAVERSHAPIRA N, 2007, MOL CELL, V26, P731, DOI
   10.1016/j.molcel.2007.05.017
   RAY D, 2007, CANCER RES, V67, P984, DOI 10.1158/0008-5772.CAN-06-3927
   SHERR CJ, 2002, CANCER CELL, V2, P103
   SYLVESTRE Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200
   TRIMARCHI JM, 2002, NAT REV MOL CELL BIO, V3, P11
   VENTURA A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   VIGO E, 1999, MOL CELL BIOL, V19, P6379
   VOLINIA S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI
   10.1073/pnas.0510565103
   WEBER M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   WOODS K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   XU XD, 2003, CLIN CANCER RES, V9, P1764
   YANG L, 2007, BIOMED MATER, V2, P21, DOI 10.1088/1748-6041/2/1/004
   YANG XJ, 2009, PLOS ONE, V4, ARTN e5011
   ZHAO XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   ZHAO Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI
   10.1073/pnas.0505585102
NR 36
TC 19
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD OCT 15
PY 2009
VL 23
IS 20
BP 2388
EP 2393
DI 10.1101/gad.1819009
PG 6
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 507JP
UT ISI:000270849700006
ER

PT J
AU Tysome, JR
   Briat, A
   Alusi, G
   Cao, F
   Gao, D
   Yu, J
   Wang, P
   Yang, S
   Dong, Z
   Wang, S
   Deng, L
   Francis, J
   Timiryasova, T
   Fodor, I
   Lemoine, NR
   Wang, Y
AF Tysome, J. R.
   Briat, A.
   Alusi, G.
   Cao, F.
   Gao, D.
   Yu, J.
   Wang, P.
   Yang, S.
   Dong, Z.
   Wang, S.
   Deng, L.
   Francis, J.
   Timiryasova, T.
   Fodor, I.
   Lemoine, N. R.
   Wang, Y.
TI Lister strain of vaccinia virus armed with endostatin-angiostatin
   fusion gene as a novel therapeutic agent for human pancreatic cancer
SO GENE THERAPY
LA English
DT Article
DE human pancreatic cancer; adenovirus; vaccinia virus; angiogenesis;
   endostatin; angiostatin
ID PHASE-II TRIAL; SMALLPOX VACCINATION; THYMIDINE KINASE; BLADDER-CANCER;
   GM-CSF; MICE; TUMORS; ANGIOGENESIS; GEMCITABINE; ADENOVIRUS
AB Survival after pancreatic cancer remains poor despite incremental
   advances in surgical and adjuvant therapy, and new strategies for
   treatment are needed. Oncolytic virotherapy is an attractive approach
   for cancer treatment. In this study, we have evaluated the
   effectiveness of the Lister vaccine strain of vaccinia virus armed with
   the endostatin-angiostatin fusion gene (VVhEA) as a novel therapeutic
   approach for pancreatic cancer. The Lister vaccine strain of vaccinia
   virus was effective against all human pancreatic carcinoma cells tested
   in vitro, especially those insensitive to oncolytic adenovirus. The
   virus displayed inherently high selectivity for cancer cells, sparing
   normal cells both in vitro and in vivo, with effective infection of
   tumors after both intravenous (i.v.) and intratumoral (i.t.)
   administrations. The expression of the endostatin-angiostatin fusion
   protein was confirmed in a pancreatic cancer model both in vitro and in
   vivo, with evidence of inhibition of angiogenesis. This novel vaccinia
   virus showed significant antitumor potency in vivo against the Suit-2
   model by i.t. administration. This study suggests that the novel Lister
   strain of vaccinia virus armed with the endostatin-angiostatin fusion
   gene is a potential therapeutic agent for pancreatic cancer. Gene
   Therapy (2009) 16, 1223-1233; doi: 10.1038/gt.2009.74; published online
   9 July 2009
C1 [Tysome, J. R.; Briat, A.; Alusi, G.; Francis, J.; Lemoine, N. R.; Wang, Y.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Mol Oncol & Imaging, London EC1 6BQ, England.
   [Cao, F.; Gao, D.; Yu, J.; Wang, P.; Yang, S.; Dong, Z.; Lemoine, N. R.; Wang, Y.] Zhengzhou Univ, Dept Pathol, Sino British Res Ctr Mol Oncol, Zhengzhou, Peoples R China.
   [Wang, S.; Deng, L.] Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Natl Lab Biomacromol, Beijing 100080, Peoples R China.
   [Timiryasova, T.; Fodor, I.] Loma Linda Univ, Ctr Hlth Dispar & Mol Med, Loma Linda, CA 92350 USA.
RP Lemoine, NR, Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr
   Mol Oncol & Imaging, Charterhouse Sq, London EC1 6BQ, England.
EM director@qmcr.qmul.ac.uk
   yaohe.wang@qmul.ac.uk
FU Cancer Research UK [C633A6253/A6251]; Nature Sciences Foundation of
   China [30530800]; Royal College of Surgeons of England ; Barts and The
   London Research Advisory Board ; US Army/National Medical Technology
   Testbed Inc 
FX This project is supported by Cancer Research UK (C633A6253/A6251),
   Nature Sciences Foundation of China (30530800) and The Royal College of
   Surgeons of England (JT) and Barts and The London Research Advisory
   Board. IF was sponsored by the US Army/National Medical Technology
   Testbed Inc. We appreciate the critical and insightful comments from Dr
   Gunnel Hallden. We are grateful to Mr John Overton for his pilot
   experiments in vitro. We also appreciate Vipul Bhakta, Keyur Trivedi
   and Mohamed Ikram for IHC staining.
CR ALEMANY R, 2008, LANCET ONCOL, V9, P507
   BHATTACHARRYA M, 2006, BEST PRACT RES CL GA, V20, P285, DOI
   10.1016/j.bpg.2005.10.004
   DENES B, 2006, J GENE MED, V8, P814, DOI 10.1002/jgm.907
   DIRKX AEM, 2006, FASEB J, V20, P621, DOI 10.1093/fj.05-4493com
   FERRARI V, 2006, CANCER CHEMOTH PHARM, V57, P185, DOI
   10.1007/s00280-005-0028-1
   FODOR I, 2005, J UROLOGY, V173, P604, DOI
   10.1097/01.ju.0000143196.37008.2c
   FRIESS H, 2006, BMC CANCER, V6, ARTN 285
   GARBER K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111
   GARCEA G, 2006, ANZ J SURG, V76, P830, DOI
   10.1111/j.1445-2197.2006.03872.x
   GARCEL A, 2007, J GEN VIROL 7, V88, P1906, DOI 10.1099/vir.0.82708-0
   GNANT MFX, 1999, CANCER RES, V59, P3396
   GOMELLA LG, 2001, J UROLOGY, V166, P1291
   GUO ZS, 2004, EXPERT OPIN BIOL TH, V4, P901
   GURVICH EB, 1986, J HYG EPID MICROB IM, V30, P177
   HEBERT C, 2005, INT J CANCER, V114, P195, DOI 10.1002/ijc.20692
   HECHT JR, 2003, CLIN CANCER RES, V9, P555
   HERMISTON TW, 2002, CANCER GENE THER, V9, P1022, DOI
   10.1038/sj.cgt.7700542
   HEZEL AF, 2006, GENE DEV, V20, P1218
   HUNG CF, 2007, GENE THER, V14, P20, DOI 10.1038/sj.gt.3302840
   HUTT L, 1975, J HYG, V74, P301
   IKEDA N, 1999, BRIT J CANCER, V79, P1553
   KAUFMAN HL, 2005, J CLIN INVEST, V115, P1903, DOI 10.1172/JCI24624
   KELLY KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036
   KIM JH, 2006, MOL THER, V14, P361, DOI 10.1016/j.ymthe.2006.05.008
   KIRN DH, 2007, PLOS MED, V4, P2001, ARTN e353
   KLEEFF J, 2006, PANCREAS, V33, P111
   LEMOINE NR, 1992, J PATHOL, V166, P7
   LI X, 2008, CLIN CANCER RES, V14, P291, DOI
   10.1158/1078-0432.CCR-07-0867
   LUKER KE, 2005, VIROLOGY, V341, P284, DOI 10.1016/j.virol.2005.06.049
   MASTRANGELO MJ, 1999, CANCER GENE THER, V6, P409
   MCCART JA, 2001, CANCER RES, V61, P8751
   NIE SL, 2002, HEPATOB PANCREAT DIS, V1, P452
   OBER BT, 2002, J VIROL, V76, P7713
   POLAND GA, 2005, VACCINE, V23, P2078
   PUHLMANN M, 2000, CANCER GENE THER, V7, P66
   RAIKWAR SP, 2005, MOL THER, V12, P1091, DOI 10.1016/j.ymthe.2005.07.690
   REIN DT, 2006, FUTURE ONCOL, V2, P137
   ROCHLITZ C, 2003, J GENE MED, V5, P690, DOI 10.1002/jgm.397
   SCAPPATICCI FA, 2001, ANGIOGENESIS, V4, P263
   SCHMITZ V, 2004, GUT, V53, P561, DOI 10.1136/gut.2003.019307
   SLOBOD KS, 2004, EUR J CLIN MICROBIOL, V23, P106, DOI
   10.1007/s10096-003-1075-3
   STEIN RA, 2000, J MOL EVOL, V50, P397
   THORNE SH, 2005, CURR GENE THER, V5, P429
   THORNE SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JC132727
   TIMIRYASOVA TM, 2001, BIOTECHNIQUES, V31, P534
   TIMIRYASOVA TM, 2001, BIOTECHNIQUES, V31, P538
   TIMIRYASOVA TM, 2001, BIOTECHNIQUES, V31, P540
   TZAHAR E, 1998, EMBO J, V17, P5948
   WANG YH, 2003, NAT BIOTECHNOL, V21, P1328, DOI 10.1038/nbt887
   WANG YH, 2005, CANCER RES, V65, P1523
   WEISS JM, 2004, CANCER GENE THER, V11, P346, DOI 10.1038/sj.cgt.7700686
   XUE Y, 2008, P NATL ACAD SCI USA, V105, P18513, DOI
   10.1073/pnas.0807967105
   YANG CT, 2005, ANTICANCER RES, V25, P2049
   YU YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   ZHANG Q, 2007, CANCER RES, V67, P10038, DOI
   10.1158/0008-5472.CAN-07-0146
   ZHANG XF, 2007, CLIN CANCER RES, V13, P3968, DOI
   10.1158/1078-0432.CCR-07-0245
NR 56
TC 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD OCT
PY 2009
VL 16
IS 10
BP 1223
EP 1233
DI 10.1038/gt.2009.74
PG 11
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 508LW
UT ISI:000270933900007
ER

PT J
AU Zhou, Y
   Zhang, JY
   Zheng, RQ
   Yu, BG
   Yang, G
AF Zhou, Yan
   Zhang, Jia-Yong
   Zheng, Rong-Quan
   Yu, Bao-Gen
   Yang, Guang
TI Complete nucleotide sequence and gene organization of the mitochondrial
   genome of Paa spinosa (Anura: Ranoidae)
SO GENE
LA English
DT Article
DE Paa spinosa; Mitochondrial genome; Tandem duplication of tRNA-Met gene;
   Phylogenetic tree
ID TRANSFER-RNA GENES; PHYLOGENETIC-RELATIONSHIPS; EVOLUTIONARY
   IMPLICATIONS; LIVING AMPHIBIANS; RANID FROGS; FAMILY RHACOPHORIDAE;
   LARVAL CHARACTERS; SOUTHERN AFRICA; DNA-SEQUENCES; TREE FROG
AB The mt genome of Paa spinosa (Anura: Ranoidae) is a circular molecule
   of 18,012 by in length, containing 38 genes (including an extra copy of
   tRNA-Met gene). This mt genome is characterized by three distinctive
   features: a cluster of rearranged tRNA genes (LTPF tRNA gene cluster),
   a tandem duplication of tRNA-Met gene (Met1 and Met2), and distinct
   repeat regions at both 5' and 3'-sides in the control region. Comparing
   the locations and the sequences of all tRNA-Met genes among Ranoidae,
   and constructing NJ tree of the nucleotide of those tRNA-Met genes, we
   suggested a tandem duplication of tRNA-Met gene can be regarded as a
   synapomorphy of Dicroglossinae. To further investigate the phylogenetic
   relationships of anurans. phylogenetic analyses (BI, ML and MP) based
   on the nucleotide dataset and the corresponding amino acid dataset of
   11 protein-coding genes (except ND5 and ATP8) arrived at the similar
   topology. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhou, Yan; Zhang, Jia-Yong; Zheng, Rong-Quan; Yu, Bao-Gen] Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Zhejiang, Peoples R China.
   [Yang, Guang] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Biodivers & Biotechnol, Nanjing 210046, Peoples R China.
RP Zheng, RQ, Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Zhejiang,
   Peoples R China.
EM zhengrq@zjnu.cn
FU Science Technology Commission of Zhejiang Province of China [2006022031]
FX We thank Xu Shixia and Zhou Yan for their assistance in the laboratory
   work. This research was supported by the Science Technology Commission
   of Zhejiang Province of China (No. 2006022031) to Zheng.
CR ABASCAL F, 2005, BIOINFORMATICS, V21, P2104, DOI
   10.1093/bioinformatics/bti263
   AVIS JC, 1994, MOL MARKERS NATURAL
   BOORE JL, 1994, NAUTILUS S, V2, P61
   BOORE JL, 1998, CURR OPIN GENET DEV, V8, P668
   BOORE JL, 1999, NUCLEIC ACIDS RES, V27, P1767
   BOORE JL, 2000, COMP GENOMICS, P133
   BOORE JL, 2001, MOL BIOL EVOL, V18, P1413
   BROWN WM, 1983, EVOLUTION GENES PROT, P62
   BURLAND TG, 2000, METH MOL B, V132, P71
   CAO SY, 2006, MITOCHONDRION, V6, P186, DOI 10.1016/j.mito.2006.07.003
   CASTRESANA J, 2000, MOL BIOL EVOL, V17, P540
   CHANNING A, 1999, T ROY SOC S AFR 1, V54, P121
   CHE J, 2007, MOL PHYLOGENET EVOL, V43, P1, DOI
   10.1016/j.ympev.2006.11.032
   CHEN LQ, 2005, HERPETOL J, V15, P231
   DUBOIS A, 1992, B MENS SOC LINN LYON, V61, P305
   DUBOIS A, 2001, ALYTES, V19, P53
   DUBOIS A, 2005, ALYTES, V23, P1
   DUELLMAN WE, 1975, U KANS OCCAS PAP MUS, V42, P1
   DUELLMAN WE, 1986, BIOL AMPHIBIANS
   FORD LS, 1993, HERPETOL MONOGR, V7, P94
   FRANKY B, 2000, EVOLUTION, V97, P6585
   FROST DR, 2006, B AM MUS NAT HIST, P8
   FROST DR, 2009, AMPHIBIAN SPECIES WO
   GARCIAPARIS M, 2003, MOL PHYLOGENET EVOL, V28, P12, DOI
   10.1016/S1055-7903(03)00036-8
   GISSI C, 2006, GENE, V366, P228, DOI 10.1016/j.gene.2005.07.034
   GUINDON S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   HAAS A, 2003, CLADISTICS, V19, P23, DOI 10.1016/S0748-3007(03)00006-9
   HAY JM, 1995, MOL BIOL EVOL, V12, P928
   HIXSON JE, 1986, J BIOL CHEM, V261, P2384
   HUELSENBECK JP, 2001, BIOINFORMATICS, V17, P754
   IGAWA T, 2008, GENE, V407, P116, DOI 10.1016/j.gene.2007.10.001
   JIANG JP, 2005, HERPETOL J, V15, P1
   KUMAR S, 2008, BRIEF BIOINFORM, V9, P299, DOI 10.1093/bib/bbn017
   KUMAZAWA Y, 1993, J MOL EVOL, V37, P380
   KURABAYASHI A, 2005, ZOOL SCI, V22, P525
   KURABAYASHI A, 2006, MOL PHYLOGENET EVOL, V39, P223, DOI
   10.1016/j.ympev.2005.11.021
   KURABAYASHI A, 2008, MOL BIOL EVOL, V25, P874, DOI 10.1093/molbev/msn031
   LIU ZQ, 2005, GENE, V346, P145, DOI 10.1016/j.gene.2004.10.013
   LOWE TM, 1997, NUCLEIC ACIDS RES, V25, P955
   MACEY JR, 1998, MOL BIOL EVOL, V15, P71
   MACEY JR, 2000, SYST BIOL, V49, P257
   MASAYUKI S, 2001, GENES GENET SYST, V76, P311
   MORITZ C, 1987, ANNU REV ECOL SYST, V18, P269
   OJALA D, 1981, NATURE, V290, P470
   POSADA D, 1998, BIOINFORMATICS, V14, P817
   PUGENER LA, 2003, ZOOL J LINN SOC-LOND, V139, P129
   REN ZM, 2009, GENE, V441, P148, DOI 10.1016/j.gene.2008.09.010
   ROE BA, 1985, J BIOL CHEM, V260, P9759
   ROELANTS K, 2004, MOL PHYLOGENET EVOL, V31, P730, DOI
   10.1016/j.ympev.2003.09.011
   ROELANTS K, 2005, SYST BIOL, V54, P111, DOI 10.1080/10635150590905894
   SACCONE C, 1999, GENE, V238, P195
   SAMBROOK J, 2001, MOL CLONING LAB MANU
   SANMAURO D, 2004, GENE, V343, P357, DOI 10.1016/j.gene.2004.10.001
   SANMAURO D, 2004, MOL PHYLOGENET EVOL, V33, P413, DOI
   10.1016/j.ympev.2004.05.014
   SANMAURO D, 2005, AM NAT, V165, P590
   SANO N, 2004, GENES GENET SYST, V79, P151
   SANO N, 2005, GENES GENET SYST, V80, P213
   SBISA E, 1997, GENE, V205, P125
   SHI YF, 2003, ACTA ZOOL SINICA, V49, P629
   SIMON C, 1994, ANN ENTOMOL SOC AM, V87, P651
   SU X, 2007, GENE, V394, P25
   SUMIDA M, 2001, GENES GENET SYST, V76, P311
   SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN
   SZYMURA JM, 2000, MOL ECOL, V9, P891
   TAMURA K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673
   VANDERMEIJDEN A, 2004, P ROY SOC LOND B  S5, V271, S378, DOI
   10.1098/rsvi.2004.0196
   VANDERMEIJDEN A, 2005, MOL PHYLOGENET EVOL, V37, P674, DOI
   10.1016/j.ympev.2005.05.001
   VENCES M, 2001, SPIXIANA, V24, P85
   WOLSTENHOLME DR, 1992, MITOCHONDRIAL GENOME, P173
   WU XB, 2003, CHINESE SCI BULL, V48, P2050, DOI 10.1360/03wc0076
   XIA X, 2001, J HERED, V92, P371
   XIA XH, 2003, MOL PHYLOGENET EVOL, V26, P1
   YOSHINORI K, 1999, MOL BIOL EVOL, V16, P784
   ZARDOYA R, 2000, GENETICS, V155, P765
   ZHANG JY, 2008, GENE, V424, P18, DOI 10.1016/j.gene.2008.07.037
   ZHANG P, 2003, MOL PHYLOGENET EVOL, V28, P620, DOI
   10.1016/S1055-7903(03)00059-9
   ZHANG P, 2005, GENE, V346, P133, DOI 10.1016/j.gene.2004.10.012
   ZHANG P, 2005, SYST BIOL, V54, P391, DOI 10.1080/10635150590945278
NR 79
TC 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD NOV 15
PY 2009
VL 447
IS 2
BP 86
EP 96
DI 10.1016/j.gene.2009.07.009
PG 11
SC Genetics & Heredity
GA 506LF
UT ISI:000270775600003
ER

PT J
AU Junge, HJ
   Yang, S
   Burton, JB
   Paes, K
   Shu, X
   French, DM
   Costa, M
   Rice, DS
   Ye, WL
AF Junge, Harald J.
   Yang, Stacey
   Burton, Jeremy B.
   Paes, Kim
   Shu, Xiao
   French, Dorothy M.
   Costa, Mike
   Rice, Dennis S.
   Ye, Weilan
TI TSPAN12 Regulates Retinal Vascular Development by Promoting Norrin- but
   Not Wnt-Induced FZD4/beta-Catenin Signaling
SO CELL
LA English
DT Article
ID FAMILIAL EXUDATIVE VITREORETINOPATHY; CATENIN PATHWAY; DISEASE GENE;
   ANGIOGENESIS; MUTATIONS; EXPRESSION; RECEPTORS; EVOLUTION; OLIGOMERS;
   ACTIVATE
AB Mutations in the genes encoding the Wnt receptor Frizzled-4 (FZD4),
   coreceptor LRP5, or the ligand Norrin disrupt retinal vascular
   development and cause ophthalmic diseases. Although Norrin is
   structurally unrelated to Wnts, it binds FZD4 and activates the
   canonical Wnt pathway. Here we show that the tetraspanin Tspan12 is
   expressed in the retinal vasculature, and loss of Tspan12 phenocopies
   defects seen in Fzd4, Lrp5, and Norrin mutant mice. In addition,
   Tspan12 genetically interacts with Norrin or Lrp5. Overexpressed
   TSPAN12 associates with the Norrin-receptor complex and significantly
   increases Norrin/beta-catenin but not Wnt/beta-catenin signaling,
   whereas Tspan12 siRNA abolishes transcriptional responses to Norrin but
   not Wnt3A in retinal endothelial cells. Signaling defects caused by
   Norrin or FZD4 mutations that are predicted to impair receptor
   multimerization are rescued by overexpression of TSPAN12. Our data
   indicate that Norrin multimers and TSPAN12 cooperatively promote
   multimerization of FZD4 and its associated proteins to elicit
   physiological levels of signaling.
C1 [Junge, Harald J.; Yang, Stacey; Burton, Jeremy B.; Shu, Xiao; Ye, Weilan] Genentech Inc, Tumor Biol & Angiogenesis Dept, San Francisco, CA 94080 USA.
   [French, Dorothy M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Costa, Mike] Genentech Inc, Dept Canc Targets, San Francisco, CA 94080 USA.
   [Paes, Kim; Rice, Dennis S.] Lexicon Pharmaceut Inc, Dept Ophthalmol, The Woodlands, TX 77381 USA.
RP Ye, WL, Genentech Inc, Tumor Biol & Angiogenesis Dept, 1 DNA Way, San
   Francisco, CA 94080 USA.
EM loni@gene.com
CR BERGER W, 2001, METABOLIC MOL BASES, P5977
   BILIC J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   BOUCHEIX C, 2001, CELL MOL LIFE SCI, V58, P1189
   CARRON C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451
   CONG F, 2004, DEVELOPMENT, V131, P5103
   DANEMAN R, 2009, P NATL ACAD SCI USA, V106, P641, DOI
   10.1073/pnas.0805165106
   DANN CE, 2001, NATURE, V412, P86
   FIGUEROA DJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1357
   FRUTTIGER M, 2007, ANGIOGENESIS, V10, P77, DOI 10.1007/s10456-007-9065-1
   GARCIAESPANA A, 2008, GENOMICS, V91, P326, DOI
   10.1016/j.ygeno.2007.12.005
   GORDON MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   HARTZER MK, 1999, BRAIN RES BULL, V49, P355
   HEMLER ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   ISASHIKI Y, 1995, BRIT J OPHTHALMOL, V79, P703
   KAYKAS A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081
   LIEBNER S, 2008, J CELL BIOL, V183, P409
   LOBOV IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   LUHMANN UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI
   10.1167/iovs.05-0174
   PEREZVILAR J, 1997, J BIOL CHEM, V272, P33410
   PHNG LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009
   REHM HL, 2002, J NEUROSCI, V22, P4286
   SERRU V, 2000, BBA-PROTEIN STRUCT M, V1478, P159
   SMALLWOOD PM, 2007, J BIOL CHEM, V282, P4057, DOI 10.1074/jbc.M609618200
   STENMAN JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   TOOMES C, 2004, INVEST OPHTH VIS SCI, V45, P2083, DOI
   10.1167/iovs.03-1044
   TOOMES C, 2005, BRIT J OPHTHALMOL, V89, P194, DOI
   10.1136/bjo.2004.042507
   VANAMERONGEN R, 2006, TRENDS GENET, V22, P678, DOI
   10.1016/j.tig.2006.10.001
   VANAMERONGEN R, 2008, SCI SIGNAL, V1, ARTN re9
   VITT UA, 2001, MOL ENDOCRINOL, V15, P681
   WANG YS, 2001, J NEUROSCI, V21, P4761
   WARDEN SM, 2007, SEMIN OPHTHALMOL, V22, P211
   XIA CH, 2008, HUM MOL GENET, V17, P1605, DOI 10.1093/hmg/ddn047
   XU Q, 2004, CELL, V116, P883
NR 33
TC 24
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD OCT 16
PY 2009
VL 139
IS 2
BP 299
EP 311
DI 10.1016/j.cell.2009.07.048
PG 13
SC Biochemistry & Molecular Biology; Cell Biology
GA 507MI
UT ISI:000270857500014
ER

PT J
AU Zheng, YH
   Cai, Z
   Wang, SQ
   Zhang, X
   Qian, JF
   Hong, S
   Li, HY
   Wang, M
   Yang, J
   Yi, Q
AF Zheng, Yuhuan
   Cai, Zhen
   Wang, Siqing
   Zhang, Xiang
   Qian, Jianfei
   Hong, Sungyoul
   Li, Haiyan
   Wang, Michael
   Yang, Jing
   Yi, Qing
TI Macrophages are an abundant component of myeloma microenvironment and
   protect myeloma cells from chemotherapy drug-induced apoptosis
SO BLOOD
LA English
DT Article
ID MULTIPLE-MYELOMA; DENDRITIC CELLS
AB Multiple myeloma remains an incurable disease. One of the major
   problems is that myeloma cells develop drug resistance on interaction
   with bone marrow stromal cells. In this study, we examined the effects
   of macrophages (M phi s), a type of stromal cells, on myeloma cell
   survival and response to chemotherapy. We showed that M phi, in
   particular tumor-associated M phi, is a protector of myeloma cells. The
   protective effect was dependent on direct contact between M phi s and
   myeloma cells. M phi s protected both myeloma cell lines and primary
   myeloma cells from spontaneous and chemotherapy drug-induced apoptosis
   by attenuating the activation and cleavage of caspase-dependent
   apoptotic signaling. These findings are clinically relevant because we
   found that CD68(+) M phi s heavily infiltrate the bone marrow of
   patients with myeloma but not the bone marrow of control patients.
   Thus, our results indicate that M phi s may contribute to myeloma cell
   survival and resistance to chemotherapeutic treatment in vivo. (Blood.
   2009;114:3625-3628)
C1 [Zheng, Yuhuan; Cai, Zhen; Wang, Siqing; Zhang, Xiang; Qian, Jianfei; Hong, Sungyoul; Li, Haiyan; Wang, Michael; Yang, Jing; Yi, Qing] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Ctr Canc Immunol Res, Houston, TX 77030 USA.
   [Cai, Zhen] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
RP Zheng, YH, Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma,
   Div Canc Med, Ctr Canc Immunol Res, 1515 Holcombe Blvd,Unit 0903,
   Houston, TX 77030 USA.
EM qyi@mdanderson.org
FU National Cancer Institute [R01 CA96569, R01 CA103978, CA138402];
   Leukemia & Lymphoma Society Translational Research ; Multiple Myeloma
   Research Foundation ; Commonwealth Foundation for Cancer Research 
FX This work was supported by the National Cancer Institute (grants R01
   CA96569, R01 CA103978, and CA138402), the Leukemia & Lymphoma Society
   Translational Research Grant, Multiple Myeloma Research Foundation, and
   Commonwealth Foundation for Cancer Research.
CR DALTON WS, 2002, SEMIN ONCOL S17, V29, P21, DOI 10.1053/sonc.2002.34073
   EPSTEIN J, 2003, HEMATOL J, V4, P310
   KIKUCHI T, 2001, J CLIN INVEST, V108, P917
   KLEIN B, 1990, EUR CYTOKINE NETW, V1, P193
   KYLE RA, 2004, NEW ENGL J MED, V351, P1860
   MANTOVANI A, 2002, TRENDS IMMUNOL, V23, P549
   WANG SQ, 2006, BLOOD, V108, P4071, DOI 10.1182/blood-2006-04-016980
   YACCOBY S, 2004, CANCER RES, V64, P2016
   YANG J, 2006, CANCER CELL, V10, P295, DOI 10.1016/j.ccr.2006.08.025
   YANG J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008
NR 10
TC 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 22
PY 2009
VL 114
IS 17
BP 3625
EP 3628
DI 10.1182/blood-2009-05-220285
PG 4
SC Hematology
GA 509NK
UT ISI:000271024500016
ER

PT J
AU Zhang, XY
   Meng, ZJ
   Qiu, S
   Xu, Y
   Yang, DL
   Schlaak, JF
   Roggendorf, M
   Lu, MJ
AF Zhang, Xiaoyong
   Meng, Zhongji
   Qiu, Song
   Xu, Yang
   Yang, Dongliang
   Schlaak, Joerg F.
   Roggendorf, Michael
   Lu, Mengji
TI Lipopolysaccharide-induced innate immune responses in primary
   hepatocytes downregulates woodchuck hepatitis virus replication via
   interferon-independent pathways
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID PERIPHERAL-BLOOD LYMPHOCYTES; TOLL-LIKE RECEPTORS; KAPPA-B ACTIVATION;
   GENE-EXPRESSION; IN-VIVO; SIGNALING PATHWAYS; MONONUCLEAR-CELLS; VIRAL
   CLEARANCE; INFECTION; LIVER
AB P>Our previous studies have shown that Toll-like receptor (TLR)
   ligands, Poly I:C and lipopolysaccharide (LPS), are able to activate
   non-parenchymal liver cells and trigger the production of interferon
   (IFN) to inhibit hepatitis B virus replication in vivo and in vitro.
   However, little is known about TLR-mediated cellular responses in
   primary hepatocytes. By the model of woodchuck hepatitis virus (WHV)
   infected primary woodchuck hepatocytes (PWHs), Poly I:C and LPS
   stimulation resulted in upregulation of cellular antiviral genes and
   relevant TLRs mRNA expression respectively. LPS stimulation led to a
   pronounced reduction of WHV replicative intermediates without a
   significant IFN induction. Poly I:C transfection resulted in the
   production of IFN and a highly increased expression of antiviral genes
   in PWHs and slight inhibitory effect on WHV replication. LPS could
   activate nuclear factor kappa B, MAPK and PI-3k/Akt pathways in PWHs.
   Further, inhibitors of MAPK-ERK and PI-3k/Akt pathways, but not that of
   IFN signalling pathway, were able to block the antiviral effect of LPS.
   These results indicate that IFN- independent pathways which activated
   by LPS are able to downregulate hepadnaviral replication in hepatocytes.
C1 [Zhang, Xiaoyong; Meng, Zhongji; Roggendorf, Michael; Lu, Mengji] Univ Hosp Essen, Inst Virol, Essen, Germany.
   [Qiu, Song; Schlaak, Joerg F.] Univ Hosp Essen, Dept Gastroenterol & Hepatol, Essen, Germany.
   [Zhang, Xiaoyong; Qiu, Song; Xu, Yang; Lu, Mengji] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Microbiol, Wuhan 430074, Peoples R China.
   [Yang, Dongliang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Div Clin Immunol, Wuhan 430074, Peoples R China.
   [Meng, Zhongji] Taihe Hosp, Yunyang Med Coll, Dept Infect Dis, Shiyan, Peoples R China.
RP Lu, MJ, Univ Hosp Essen, Inst Virol, Essen, Germany.
EM mengji.lu@uni-due.de
FU Thekla Kemper and Barbara Bleekmann ; Deutsche Forschungsgemeinschaft
   [Lu 669/2-1, GRK1045/1, Lu 669/5-1]; Federal Ministry of Education and
   Research [GU0207]
FX We are grateful for excellent technical assistance of Thekla Kemper and
   Barbara Bleekmann. This work is partly supported by grants of Deutsche
   Forschungsgemeinschaft (Lu 669/2-1, GRK1045/1, and Lu 669/5-1) and
   Federal Ministry of Education and Research (GU0207).
CR ADEREM A, 2000, NATURE, V406, P782
   AKIRA S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   BACCARANI U, 2003, LIVER TRANSPLANT, V9, P506, DOI
   10.1053/jlts.2003.50087
   CHEN Z, 2008, CLIN IMMUNOL, V128, P400, DOI 10.1016/j.clim.2008.04.006
   CHIN R, 2007, J HEPATOL, V47, P325, DOI 10.1016/j.jhep.2007.03.025
   CHUA BY, 2008, VACCINE, V26, P4866, DOI 10.1016/j.vaccine.2008.03.032
   COOPER CL, 2008, CLIN INFECT DIS, V46, P1310, DOI 10.1086/533467
   FIEDLER M, 2004, J VIROL, V78, P10111, DOI
   10.1128/JVI.78.18.10111-10121.2004
   GUIDOTTI LG, 1999, SCIENCE, V284, P825
   GUIDOTTI LG, 2006, ANNU REV PATHOL-MECH, V1, P23, DOI
   10.1146/annurev.pathol.1.110304.100230
   GUO H, 2009, J VIROL, V83, P847, DOI 10.1128/JVI.02008-08
   GUO HT, 2007, J VIROL, V81, P10072, DOI 10.1128/JVI.00541-07
   HARTMAN ZC, 2007, J VIROL, V81, P1796, DOI 10.1128/JVI.01936-06
   HORNUNG V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505
   HUANG CC, 2006, PHYSIOL GENOMICS, V26, P125, DOI
   10.1152/physiolgenomics.00002.2006
   ISOGAWA M, 2005, J VIROL, V79, P7269, DOI
   10.1128/JVI.79.11.7269-7272.2005
   KAWAI T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   KORBA BE, 1988, SCIENCE, V241, P1213
   KORBA BE, 1989, J INFECT DIS, V160, P572
   KULKARNI K, 2007, CLIN LIVER DIS, V11, P707
   LI K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200
   LIN YC, 2009, CELL MICROBIOL, V11, P645, DOI
   10.1111/j.1462-5822.2008.01280.x
   LIU SB, 2002, INFECT IMMUN, V70, P3433
   LU MJ, 2002, J VIROL, V76, P58
   LU MJ, 2007, EXPERT OPIN INV DRUG, V16, P787, DOI
   10.1517/13543784.16.6.787
   LU MJ, 2008, J VIROL, V82, P2598, DOI 10.1128/JVI.01613-07
   LU YP, 2008, CYTOKINE, V41, P127, DOI 10.1016/j.cyto.2007.11.002
   MAILLIARD ME, 2006, ANNU REV MED, V57, P155, DOI
   10.1146/annurev.med.57.121304.131422
   MATSUMOTO M, 2003, J IMMUNOL, V171, P3154
   MCCLARY H, 2000, J VIROL, V74, P2255
   MENG ZJ, 2009, VIROLOGY, V384, P88, DOI 10.1016/j.virol.2008.11.012
   MURUVE DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   NOCIARI M, 2007, J VIROL, V81, P4145, DOI 10.1128/JVI.02685-06
   PARK SG, 2005, GASTROENTEROLOGY, V128, P2042, DOI
   10.1053/j.gastro.2005.03.002
   PARVEZ MK, 2006, WORLD J GASTROENTERO, V12, P3006
   PELTEKIAN C, 2005, J HEPATOL, V43, P965, DOI 10.1016/j.jhep.2005.06.019
   PREISS S, 2008, J VIRAL HEPATITIS, V15, P888
   PURO R, 2007, J VIROL, V81, P7351, DOI 10.1128/JVI.00554-07
   REHERMANN B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   SCHILDGEN O, 2006, IMMUNOL LETT, V102, P31, DOI
   10.1016/j.imlet.2005.06.007
   SCHWABE RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI
   10.1053/j.gastro.2006.01.038
   SEKI E, 2008, HEPATOLOGY, V48, P322
   SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533
   SZABO G, 2007, SEMIN LIVER DIS, V27, P339, DOI 10.1055/s-2007-991511
   THIMME R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003
   VISVANATHAN K, 2007, HEPATOLOGY, V45, P102, DOI 10.1002/hep.21482
   WU J, 2007, HEPATOLOGY, V46, P1769, DOI 10.1002/hep.21897
   ZHU JG, 2007, J VIROL, V81, P3170, DOI 10.1128/JVI.02192-06
   ZUCCHINI N, 2008, J IMMUNOL, V180, P5799
NR 49
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-5814
J9 CELL MICROBIOL
JI Cell Microbiol.
PD NOV
PY 2009
VL 11
IS 11
BP 1624
EP 1637
DI 10.1111/j.1462-5822.2009.01353.x
PG 14
SC Cell Biology; Microbiology
GA 504UE
UT ISI:000270642400008
ER

PT J
AU Du, W
   Jiang, P
   Li, N
   Mei, Y
   Wang, X
   Wen, L
   Yang, X
   Wu, M
AF Du, W.
   Jiang, P.
   Li, N.
   Mei, Y.
   Wang, X.
   Wen, L.
   Yang, X.
   Wu, M.
TI Suppression of p53 activity by Siva1
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE Siva1; p53; Hdm2; ubiquitination
ID EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MDM2; APOPTOSIS; TARGET;
   BINDS; DEGRADATION; PROTEIN; PATHWAY; RESCUE
AB The tumor suppressor p53 induces potent anti-proliferative responses in
   stressed cells; in unstressed cells this ability of p53 is restrained
   by Hdm2. Expression of Hdm2 is also induced by p53, thereby
   establishing feedback inhibition. Regulation of the p53-Hdm2
   interaction and the feedback inhibition of p53 are not well understood.
   Here, we show that the p53-Hdm2 interaction in unstressed cells is
   promoted by Siva1, which, like Hdm2, is the product of a p53 target
   gene. Siva1 binds to both p53 and Hdm2 through distinct regions and
   enhances Hdm2-mediated p53 ubiquitination and degradation. Siva1
   strongly inhibits p53-mediated gene expression and apoptosis. In
   xenograft mouse models, downregulation of Siva1 markedly inhibits tumor
   formation because of the activation of p53. On DNA damage, the
   interactions of Siva1 with both p53 and Hdm2 are diminished. The
   function of Siva1 seems to be related to its ability to form a
   homo-oligomer as the oligomerization defective splicing variant Siva2
   fails to destabilize p53. These results identify Siva1 as an important
   adaptor promoting p53 degradation through Hdm2. Siva1 may be part of
   the negative feedback loop that inhibits p53 activity at the end of a
   non-lethal stress response. Cell Death and Differentiation (2009) 16,
   1493-1504; doi:10.1038/cdd.2009.89; published online 10 July 2009
C1 [Wu, M.] Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230027, Anhui, Peoples R China.
   [Du, W.; Jiang, P.; Li, N.; Wang, X.; Wen, L.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.
   [Mei, Y.; Yang, X.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Mei, Y.; Yang, X.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA.
RP Wu, M, Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol,
   Huangshan Rd, Hefei 230027, Anhui, Peoples R China.
EM xyang@mail.med.upenn.edu
   wumian@ustc.edu.cn
FU National Natural Science Foundation of China [30530200, 30871290,
   30728003]; Ministry of Science and Technology of China [2006CB933300,
   2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]; NIH
   [CA088868]
FX We thank Dr. Serge Benichou (Departement de Maladies Infectieuses,
   Institut Cochin, France) for kindly providing GFP-Siva1. Plasmid
   pcDNA3-Hdm2 was a gift of Dr. Geoffrey M Wahl (The Salk Institute, La
   Jolla, USA). This research was supported by grants from the National
   Natural Science Foundation of China (30530200, 30871290, and 30728003),
   the Ministry of Science and Technology of China (2006CB933300 and
   2006CB910300), the Chinese Academy of Sciences (KSCX1-YW-R-57), and the
   NIH (CA088868).
CR BARAK Y, 1993, EMBO J, V12, P461
   CHENE P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991
   FORTIN A, 2004, J BIOL CHEM, V279, P28706, DOI 10.1074/jbc.M400376200
   HAUPT Y, 1997, NATURE, V387, P296
   HIGASHITSUJI H, 2005, CANCER CELL, V8, P75, DOI
   10.1016/j.ccr.2005.06.006
   HORN HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263
   JACOBS SBR, 2007, CELL DEATH DIFFER, V14, P1374, DOI
   10.1038/sj.cdd.4402128
   JONES SN, 1995, NATURE, V378, P206
   KUBBUTAT MHG, 1997, NATURE, V387, P299
   LUNA RMD, 1995, NATURE, V378, P203
   MICHAEL D, 2003, SEMIN CANCER BIOL, V13, P49
   POYUROVSKY MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465
   PRASAD KVS, 1997, P NATL ACAD SCI USA, V94, P6346
   PY B, 2004, J IMMUNOL, V172, P4008
   SHILOH Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   SUI GC, 2004, CELL, V117, P859
   TANG J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442
   ULDRIJAN S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469
   VASSILEV LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   VOGELSTEIN B, 2000, NATURE, V408, P307
   VOUSDEN KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   XUE L, 2002, P NATL ACAD SCI USA, V99, P6925
NR 22
TC 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD NOV
PY 2009
VL 16
IS 11
BP 1493
EP 1504
DI 10.1038/cdd.2009.89
PG 12
SC Biochemistry & Molecular Biology; Cell Biology
GA 505GE
UT ISI:000270679000008
ER

PT J
AU Oehler, VG
   Guthrie, KA
   Cummings, CL
   Sabo, K
   Wood, BL
   Gooley, T
   Yang, TM
   Epping, MT
   Shou, YP
   Pogosova-Agadjanyan, E
   Ladne, P
   Stirewalt, DL
   Abkowitz, JL
   Radich, JP
AF Oehler, Vivian G.
   Guthrie, Katherine A.
   Cummings, Carrie L.
   Sabo, Kathleen
   Wood, Brent L.
   Gooley, Ted
   Yang, Taimei
   Epping, Mirjam T.
   Shou, Yaping
   Pogosova-Agadjanyan, Era
   Ladne, Paula
   Stirewalt, Derek L.
   Abkowitz, Janis L.
   Radich, Jerald P.
TI The preferentially expressed antigen in melanoma (PRAME) inhibits
   myeloid differentiation in normal hematopoietic and leukemic progenitor
   cells
SO BLOOD
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RETINOIC
   ACID RECEPTORS; IN-VITRO; GENE-EXPRESSION; STEM-CELLS; PROGNOSIS;
   CANCER; MARKER; VIVO
AB The preferentially expressed antigen in melanoma (PRAME) is expressed
   in several hematologic malignancies, but either is not expressed or is
   expressed at only low levels in normal hematopoietic cells, making it a
   target for cancer therapy. PRAME is a tumor-associated antigen and has
   been described as a corepressor of retinoic acid signaling in solid
   tumor cells, but its function in hematopoietic cells is unknown. PRAME
   mRNA expression increased with chronic myeloid leukemia (CML) disease
   progression and its detection in late chronic-phase CML patients before
   tyrosine kinase inhibitor therapy was associated with poorer
   therapeutic responses and ABL tyrosine kinase domain point mutations.
   In leukemia cell lines, PRAME protein expression inhibited granulocytic
   differentiation only in cell lines that differentiate along this
   lineage after all-trans retinoic acid (ATRA) exposure. Forced PRAME
   expression in normal hematopoietic progenitors, however, inhibited
   myeloid differentiation both in the presence and absence of ATRA, and
   this phenotype was reversed when PRAME was silenced in primary CML
   progenitors. These observations suggest that PRAME inhibits myeloid
   differentiation in certain myeloid leukemias, and that its function in
   these cells is lineage and phenotype dependent. Lastly, these
   observations suggest that PRAME is a target for both prognostic and
   therapeutic applications. (Blood. 2009; 114: 3299-3308)
C1 [Oehler, Vivian G.; Guthrie, Katherine A.; Cummings, Carrie L.; Gooley, Ted; Yang, Taimei; Pogosova-Agadjanyan, Era; Ladne, Paula; Stirewalt, Derek L.; Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
   [Sabo, Kathleen; Abkowitz, Janis L.] Univ Washington, Div Hematol, Seattle, WA 98195 USA.
   [Wood, Brent L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Epping, Mirjam T.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.
   [Shou, Yaping] Novartis Pharmaceut, Novartis Inst BioMed Res, Cambridge, MA USA.
RP Oehler, VG, 1100 Fairview Ave N,D4-100,Box 19024, Seattle, WA 98109 USA.
EM voehler@u.washington.edu
FU National Cancer Institute (NCI) [CA18029, CA106796]; Leukemia &
   Lymphoma Society Translational Research Program ; V Foundation for
   Cancer Research V Scholar 
FX We are grateful to the following people: Drs Pierre Coulie and Rene
   Bernards for providing the original PRAME antibody and retroviral shRNA
   vectors used in these experiments; Dr C. A. Blau for providing the
   lentiviral expression vectors; Dr Stephen Collins for the kind loan of
   the K562 RARA and control cell lines; and Dr Hans P. Kiem and his
   laboratory for lentiviral shRNA vectors and assistance with the
   preparation of viral supernatants (Core Grant no. DK56465). We also
   thank Karen McDougall and August J. Salvado of Novartis Pharmaceuticals
   Corporation for providing outcomes data for the RIGHT study patients
   and Hongyue Dai of Rosetta Inpharmatics, Merck and Co for assistance
   with microarray analysis of the CML progression data.
   This work was supported by National Cancer Institute (NCI) grants
   CA18029 (J. P. R.) and CA106796, a Leukemia & Lymphoma Society
   Translational Research Program grant, and a V Foundation for Cancer
   Research V Scholar grant (V. G. O.).
CR *GEN ONT, OP BIOM ONT
   *NAT CTR BIOT INF, GEN EXPR OMN GEO
   *NAT I ALL INF DIS, DAT ANN VIS INT DISC
   BRANFORD S, 2002, BLOOD, V99, P3472
   CHARLES RJ, 1996, BLOOD, V87, P4831
   COLLINS SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718
   DENNIS G, 2003, GENOME BIOL, V4, P3
   EPPING MT, 2005, CELL, V122, P835
   EPPING MT, 2006, CANCER RES, V66, P10639, DOI
   10.1158/0008-5472.CAN-06-2522
   EPPING MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI
   10.1073/pnas.0702518104
   EPPING MT, 2008, BRIT J CANCER, V99, P398, DOI 10.1038/sj.bjc.6604494
   ERKELAND SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207
   EVANS T, 2005, EXP HEMATOL, V33, P1055, DOI 10.1016/j.exphem.2005.06.007
   FISKUS W, 2006, MOL CANCER THER, V5, P3096, DOI
   10.1158/1535-7163.MCT-06-0418
   HUGHES TR, 2001, NAT BIOTECHNOL, V19, P342
   IKEDA H, 1997, IMMUNITY, V6, P199
   JAMIESON CHM, 2004, NEW ENGL J MED, V351, P657
   KESSLER JH, 2001, J EXP MED, V193, P73
   LAWSON ND, 1999, EXP HEMATOL, V27, P1355
   LEWIS ID, 2000, EXP HEMATOL, V28, P1087
   MCELWAINE S, 2004, BRIT J HAEMATOL, V125, P729, DOI
   10.1111/j.1365-2141.2004.04982.x
   NAGASAWA Y, 2006, STEM CELLS, V24, P908, DOI 10.1634/stemcells.2005-0484
   OBERTHUER A, 2004, CLIN CANCER RES, V10, P4307
   ORTMANN CA, 2008, ANN HEMATOL, V87, P809, DOI 10.1007/s00277-008-0514-8
   PASSERON T, 2009, J CLIN INVEST, V119, P954, DOI 10.1172/JCI34015
   PAYDAS S, 2007, LEUKEMIA RES, V31, P365, DOI
   10.1016/j.leukres.2006.06.022
   PETZER AL, 1996, P NATL ACAD SCI USA, V93, P1470
   QUINTARELLI C, 2008, BLOOD, V112, P1876, DOI
   10.1182/blood-2008-04-150045
   RADICH JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI
   10.1073/pnas.0510423103
   RADOMSKA HS, 1998, MOL CELL BIOL, V18, P4301
   REZVANI K, 2009, BLOOD, V113, P2245, DOI 10.1182/blood-2008-03-144071
   ROBERTSON KA, 1991, BLOOD, V77, P340
   ROMANGOMEZ J, 2007, LEUKEMIA RES, V31, P1521
   SANTAMARIA C, 2008, HAEMATOL-HEMATOL J, V93, P1797, DOI
   10.3324/haematol.13214
   SANTAMARIA CM, 2009, BLOOD, V114, P148, DOI 10.1182/blood-2008-11-187724
   STEINBACH D, 2002, CANCER GENET CYTOGEN, V133, P118
   STIREWALT DL, 2004, GENOMICS, V83, P321, DOI 10.1016/j.ygeno.2003.08.008
   STIREWALT DL, 2009, LEUKEMIA, V23, P391, DOI 10.1038/leu.2008.176
   TAJEDDINE N, 2005, CANCER RES, V65, P7348, DOI
   10.1158/0008-5472.CAN-04-4011
   TAJEDDINE N, 2008, LEUKEMIA LYMPHOMA, V49, P1123, DOI
   10.1080/10428190802035933
   VANBAREN N, 1998, BRIT J HAEMATOL, V102, P1376
   YONG ASM, 2008, LEUKEMIA, V22, P1721, DOI 10.1038/leu.2008.161
   YOSHIDA H, 2007, MOL CELL BIOL, V27, P5819, DOI 10.1128/MCB.02422-06
   ZAULI G, 1995, BRIT J HAEMATOL, V90, P274
NR 44
TC 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 8
PY 2009
VL 114
IS 15
BP 3299
EP 3308
DI 10.1182/blood-2008-07-170282
PG 10
SC Hematology
GA 504DW
UT ISI:000270595700023
ER

PT J
AU Zhao, BQ
   Chauhan, AK
   Canault, M
   Patten, IS
   Yang, JJ
   Dockal, M
   Scheiflinger, F
   Wagner, DD
AF Zhao, Bing-Qiao
   Chauhan, Anil K.
   Canault, Matthias
   Patten, Ian S.
   Yang, Janie J.
   Dockal, Michael
   Scheiflinger, Friedrich
   Wagner, Denisa D.
TI vonWillebrand factor-cleaving protease ADAMTS13 reduces ischemic brain
   injury in experimental stroke
SO BLOOD
LA English
DT Article
ID VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; MOUSE
   MODEL; P-SELECTIN; INFLAMMATION; DISEASE; MICE; HEMOSTASIS; HEMORRHAGE;
   FIBRINOGEN
AB Stroke is a leading cause of death and disability. The only therapy
   available is recombinant tissue plasminogen activator, but side effects
   limit its use. Platelets play a crucial role during stroke, and the
   inflammatory reaction promotes neurodegeneration. von Willebrand factor
   (VWF), an adhesion molecule for platelets, is elevated in patients with
   acute stroke. The activity of VWF is modulated by ADAMTS13 (a
   disintegrin-like and metalloprotease with thrombospondin type I
   repeats-13) that cleaves VWF to smaller less-active forms. We recently
   documented that ADAMTS13 negatively regulates both thrombosis and
   inflammation. We report that deficiency or reduction of VWF reduces
   infarct volume up to 2-fold after focal cerebral ischemia in mice, thus
   showing the importance of VWF in stroke injury. In contrast, ADAMTS13
   deficiency results in larger infarctions, but only in mice that have
   VWF. Importantly, infusion of a high dose of recombinant human ADAMTS13
   into a wild-type mouse immediately before reperfusion reduces infarct
   volume and improves functional outcome without producing cerebral
   hemorrhage. Furthermore, recombinant ADAMTS13 did not enhance bleeding
   in a hemorrhagic stroke model. Our findings show the importance of VWF
   in regulating infarction and suggest that recombinant ADAMTS13 could be
   considered as a new therapeutic agent for prevention and/or treatment
   of stroke. (Blood. 2009; 114: 3329-3334)
C1 [Zhao, Bing-Qiao; Chauhan, Anil K.; Canault, Matthias; Patten, Ian S.; Yang, Janie J.; Wagner, Denisa D.] Immune Dis Inst, Boston, MA 02115 USA.
   [Zhao, Bing-Qiao; Chauhan, Anil K.; Canault, Matthias; Patten, Ian S.; Yang, Janie J.; Wagner, Denisa D.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Zhao, Bing-Qiao; Chauhan, Anil K.; Canault, Matthias; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Dockal, Michael; Scheiflinger, Friedrich] Baxter Biosci, Vienna, Austria.
RP Wagner, DD, Immune Dis Inst, 3 Blackfan Cir, Boston, MA 02115 USA.
EM wagner@idi.harvard.edu
CR *AM HEART ASS, 2009, HEART DIS STROK STAT
   BATH PMW, 1998, PLATELETS, V9, P155
   BONGERS TN, 2006, STROKE, V37, P2672, DOI
   10.1161/01.STR.0000244767.39962.f7
   BOUET V, 2007, EXP NEUROL, V203, P555, DOI
   10.1016/j.expneurol.2006.09.006
   CHAUHAN AK, 2006, J EXP MED, V203, P767, DOI 10.1084/jem.20051732
   CHAUHAN AK, 2008, BLOOD, V111, P3452, DOI 10.1182/blood-2007-08-108571
   CHAUHAN AK, 2008, J EXP MED, V205, P2065, DOI 10.1084/jem.20080130
   CHENG T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498
   CHOUDHRI TF, 1998, J CLIN INVEST, V102, P1301
   DELZOPPO GJ, 1999, THROMB HAEMOSTASIS, V82, P938
   DENIS C, 1998, P NATL ACAD SCI USA, V95, P9524
   DENIS CV, 2007, ARTERIOSCL THROM VAS, V27, P728, DOI
   10.1161/01.ATV.0000259359.52265.62
   FURLAN M, 1998, NEW ENGL J MED, V339, P1578
   GOERGE T, 2008, BLOOD, V111, P4958, DOI 10.1182/blood-2007-11-123620
   HACKE W, 1999, NEUROLOGY S4, V53, S3
   HRACHOVINOVA I, 2003, NAT MED, V9, P1020, DOI 10.1038/nm899
   KEIGHTLEY AM, 1999, BLOOD, V93, P4277
   KLEINSCHNITZ C, 2007, CIRCULATION, V115, P2323, DOI
   10.1161/CIRCULATIONAHA.107.691279
   KLEINSCHNITZ C, 2009, BLOOD, V113, P3600
   KOKAME K, 2005, BRIT J HAEMATOL, V129, P93, DOI
   10.1111/j.1365-2141.2005.05420.x
   MANEA M, 2007, EUR J PEDIATR, V166, P249, DOI 10.1007/s00431-006-0354-2
   MOTTO DG, 2005, J CLIN INVEST, V115, P2752, DOI 10.1172/JCI26007
   NI HY, 2000, J CLIN INVEST, V106, P385
   OFFNER H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI
   10.1038/sj.jcbfm.9600217
   PENDU R, 2006, BLOOD, V108, P3746
   PINSKY DJ, 1996, J CLIN INVEST, V97, P493
   RUGGERI ZM, 2003, J THROMB HAEMOST, V1, P1335
   SADLER JE, 2005, ANNU REV MED, V56, P173, DOI
   10.1146/annurev.med.56.082103.104713
   SADLER JE, 2008, BLOOD, V112, P11, DOI 10.1182/blood-2008-02-078170
   SOEJIMA K, 2006, J BIOCHEM, V139, P147, DOI 10.1093/jb/mvj013
   TSAI HM, 1998, NEW ENGL J MED, V339, P1585
   VISCHER UM, 2006, J THROMB HAEMOST, V4, P1186
   WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217
   ZHAO BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387
NR 34
TC 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 8
PY 2009
VL 114
IS 15
BP 3329
EP 3334
DI 10.1182/blood-2009-03-213264
PG 6
SC Hematology
GA 504DW
UT ISI:000270595700027
ER

PT J
AU Liu, LY
   Xie, R
   Yang, CF
   McKeehan, WL
AF Liu, Leyuan
   Xie, Rui
   Yang, Chaofeng
   McKeehan, Wallace L.
TI Dual function microtubule- and mitochondria-associated proteins mediate
   mitotic cell death
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Aneuploidy; C19ORF5; genetic instability; LRPPRC; microtubule dynamics;
   mitochondrial dynamics; RASSF1A; paclitaxel; tumor suppression;
   mitochondria aggregation
ID TUMOR-SUPPRESSOR RASSF1; SPINDLE POLES; CANCER; DYNAMICS; AGGREGATION;
   ANEUPLOIDY; MACHINERY; COMPLEX; C19ORF5; FAMILY
AB Background: Survival and evolution of aneuploid cells after an
   asymmetric segregation of chromosomes at mitosis may be the common
   initiating event and underlying cause of the genetic diversity and
   adaptability of cancers. We hypothesize that mechanisms exist to detect
   impending aneuploidy and prevent it before completion of an aberrant
   mitosis.
   Methods: The distribution of isoforms of C19ORF5, an interactive
   partner with mitochondria-associated LRPPRC and tumor suppressor
   RASSF1A, state of spindle microtubules and mitochondrial aggregation
   was analyzed in synchronized mitotic cells and cells stalled in mitosis
   after treatment with paclitaxel.
   Results: C19ORF5 distributed broadly across the mitotic spindle and
   reversibly accumulated during reversible mitotic arrest. Prolonged
   stabilization of microtubules caused an accumulation of a C19ORF5
   product with dual MAP and MtAP properties that caused irreversible
   aggregation of mitochondria and death of mitotic cells.
   Conclusion: Dual function microtubule-associated (MAP) and
   mitochondria-associated (MtAP) proteins generated by prolonged mitotic
   arrest trigger mitochondrial-induced mitotic cell death. This is a
   potential mechanism to prevent minimal survivable aneuploidy resulting
   from an aberrant cell division and cancers in general at their earliest
   common origin.
C1 [Liu, Leyuan; Xie, Rui; Yang, Chaofeng; McKeehan, Wallace L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA.
RP McKeehan, WL, Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc &
   Stem Cell Biol, Houston, TX 77030 USA.
EM wmckeehan@ibt.tamhsc.edu
FU Public Health Service [CA59971, DK35310]; DOD New Investigator Award
   [W81XWH-08-1-0475]; John S. Dunn Research Foundation 
FX We thank Dr. Le Sun and Joe Corvera (A&G Pharmaceuticals, Inc.,
   Columbia, MD) for anti-C19ORF5 mouse monoclonal antibody 4G1. This work
   was supported by Public Health Service Grants CA59971 and DK35310
   (WLM), DOD New Investigator Award W81XWH-08-1-0475 (LL), and aid from
   the John S. Dunn Research Foundation (WLM).
CR AGATHANGGELOU A, 2005, CANCER RES, V65, P3497
   BOVERI T, 1914, FRAGE ENTSTEHUNG MAL
   COOPER MP, 2006, GENE DEV, V20, P2996, DOI 10.1101/gad.1483906
   DALLOL A, 2004, CANCER RES, V64, P4112
   DUESBERG P, 2000, CELL MOTIL CYTOSKEL, V47, P81
   DUESBERG P, 2007, SCI AM, V296, P52
   FANG CH, 1998, INT J MOL MED, V1, P163
   FRAZIER AE, 2006, BIOL CHEM, V387, P1551, DOI 10.1515/BC.2006.193
   KLINESMITH SL, 2004, MOL CELL, V15, P317
   LIU LY, 2002, IN VITRO CELL DEV-AN, V38, P582
   LIU LY, 2005, CANCER RES, V65, P1830
   LIU LY, 2005, CANCER RES, V65, P4191
   LIU, 2009, CELL CYCLE IN PRESS, V8
   MOSS TN, 2007, IN VITRO CELL DEV-AN, V43, P139, DOI
   10.1007/s11626-007-9016-6
   MULLER M, 2005, EXP CELL RES, V303, P114, DOI
   10.1016/j.yexcr.2004.09.025
   ORBANNEMETH Z, 2005, J BIOL CHEM, V280, P2257, DOI
   10.1074/jbc.M408984200
   PETERS JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988
   PIHAN GA, 1999, SEMIN CANCER BIOL, V9, P289
   SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712
   SKULACHEV VP, 2001, TRENDS BIOCHEM SCI, V26, P23
   SONG MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200
   SORGER PK, 1997, CURR OPIN CELL BIOL, V9, P807
   VALE RD, 1987, ANNU REV CELL BIOL, V3, P347
   WEAVER BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI
   10.1016/j.ceb.2006.10.002
   YAFFE MP, 1999, SCIENCE, V283, P1493
   YAFFE MP, 2003, P NATL ACAD SCI USA, V100, P11424, DOI
   10.1073/pnas.1534703100
   ZHAO HW, 2005, MOL BIOL CELL, V16, P5857, DOI 10.1091/mbc.E05-08-0705
   ZHAO J, 2000, J CELL SCI, V113, P4363
NR 28
TC 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1570-5870
J9 CELL ONCOL
JI Cell. Oncol.
PY 2009
VL 31
IS 5
BP 393
EP 405
DI 10.3233/CLO-2009-0484
PG 13
SC Oncology; Cell Biology; Pathology
GA 502MD
UT ISI:000270463400007
ER

PT J
AU Yoo, KH
   Jang, IK
   Lee, MW
   Kim, HE
   Yang, MS
   Eom, Y
   Lee, JE
   Kim, YJ
   Yang, SK
   Jung, HL
   Sung, KW
   Kim, CW
   Koo, HH
AF Yoo, Keon Hee
   Jang, In Keun
   Lee, Myoung Woo
   Kim, Hyo Eun
   Yang, Mal Sook
   Eom, Youngwoo
   Lee, Jong Eun
   Kim, Young Jin
   Yang, Seong Kyu
   Jung, Hye Lim
   Sung, Ki Woong
   Kim, Cheol Woo
   Koo, Hong Hoe
TI Comparison of immunomodulatory properties of mesenchymal stem cells
   derived from adult human tissues
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Mesenchymal stem cells; Immunomodulation; IFN-gamma; TNF-alpha;
   Indoleamine 2,3-dioxygenase
ID MARROW STROMAL CELLS; BONE-MARROW; LYMPHOCYTE-PROLIFERATION;
   INTERFERON-GAMMA; PROGENITOR CELLS; ADIPOSE-TISSUE; TRANSPLANTATION;
   INHIBIT; RESPONSES; REPAIR
AB Mesenchymal stem cells (MSCs), which evoke only minimal immune
   reactivity, may have anti-inflammatory and immunomodulatory effects. In
   this study, we conducted a comparative analysis of the immunomodulatory
   properties of MSCs derived from adult human tissues including bone
   marrow (BM), adipose tissues (AT), umbilical cord blood (CB), and cord
   Wharton's jelly (WJ). Using a multiple cytokine detection assay, we
   showed that there were no significant differences in levels of secreted
   factors from non-stimulated MSCs. We compared the immunosuppressive
   effect of BM-MSCs, AT-MSCs, CB-MSCs, and WJ-MSCs on
   phytohemagglutinin-induced T-cell proliferation. AT-MSCs, CB-MSCs, and
   WJ-MSCs effectively suppressed mitogen-induced T-cell proliferation as
   effectively as did BM-MSCs. Levels of interferon (IFN)-gamma and tumor
   necrosis factor (TNF)-alpha secreted from activated T-cells increased
   over time, but these levels were significantly reduced when cocultured
   with each type of MSCs. In addition, the expression of hepatocyte
   growth factor, IL-10, transforming growth factor-beta(1),
   cyclooxygenase (COX)-1, and COX-2 were unchanged in MSCs treated with
   IFN-gamma and/or TNF-alpha, while indoleamine 2,3-dioxygenase (IDO)
   expression increased. IFN-gamma and/or TNF-alpha produced by activated
   T-cells were correlated with induction of IDO expression by MSCs,
   which, in turn, suppressed T-cell proliferation. These findings suggest
   that MSCs derived from AT, CB, or WJ could be substituted for BM-MSCs
   for treatment of allogeneic conflicts. (C) 2009 Elsevier Inc. All
   rights reserved.
C1 [Yoo, Keon Hee; Lee, Myoung Woo; Yang, Seong Kyu; Jung, Hye Lim; Sung, Ki Woong; Koo, Hong Hoe] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pediat, Seoul 135710, South Korea.
   [Jang, In Keun; Kim, Hyo Eun; Yang, Mal Sook; Eom, Youngwoo; Lee, Jong Eun; Kim, Young Jin] LifeCord Inc, Biomed Res Inst, Suwon, South Korea.
   [Yoo, Keon Hee; Kim, Cheol Woo] Seoul Natl Univ, Dept Pathol, Sch Med, Seoul, South Korea.
RP Koo, HH, Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pediat, 50
   Irwon Dong, Seoul 135710, South Korea.
EM hhkoo@skku.edu
FU National R&D Program for Cancer Control ; Ministry for Health, Welfare
   and Family affairs ; Republic of Korea [0720230]
FX This study was supported by a grant from the National R&D Program for
   Cancer Control, Ministry for Health, Welfare and Family affairs,
   Republic of Korea (Project No: 0720230).
CR AGGARWAL S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   ANGELOPOULOU M, 2003, EXP HEMATOL, V31, P413, DOI
   10.1016/S0301-472X(03)00042-0
   ANGOULVANT D, 2004, BIORHEOLOGY, V41, P469
   AUGELLO A, 2005, EUR J IMMUNOL, V35, P1482, DOI 10.1002/eji.200425405
   BARTHOLOMEW A, 2002, EXP HEMATOL, V30, P42
   BEYTH S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641
   CHAN JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood-2006-01-0057
   DENNIS JE, 1996, J CELL PHYSIOL, V167, P523
   DEXTER TM, 1976, METHOD CELL BIOL, V14, P387
   DIEZRUIZ A, 1995, EUR J HAEMATOL, V54, P1
   DINICOLA M, 2002, BLOOD, V99, P3838
   DJOUAD F, 2003, BLOOD, V102, P3837
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263
   FRIEDRICH C, 1996, BLOOD, V87, P4596
   GOTHERSTROM C, 2003, BONE MARROW TRANSPL, V32, P265, DOI
   10.1038/sj.bmt.1704111
   INTANKER PS, 2003, EXP HEMATOL, V31, P881
   JANG IK, 2006, ARTIF ORGANS, V30, P424
   JIANG YH, 2002, NATURE, V418, P41
   JURGENS WJFM, 2008, CELL TISSUE RES, V332, P415, DOI
   10.1007/s00441-007-0555-7
   KRAMPERA M, 2003, BLOOD, V101, P3722
   KRAMPERA M, 2006, STEM CELLS, V24, P386
   LEBLANC K, 2003, SCAND J IMMUNOL, V57, P11
   LEE MW, 2004, BIOCHEM BIOPH RES CO, V320, P273, DOI
   10.1016/j.bbrc.2004.04.206
   MEISEL R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909
   MUNN DH, 1998, SCIENCE, V281, P1191
   ORTIZ LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI
   10.1073/pnas.1432929100
   OWEN M, 1988, J CELL SCI S10, P63
   PITTENGER MF, 1999, SCIENCE, V284, P147
   POLCHERT D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129
   PROCKOP DJ, 2003, P NATL ACAD SCI U S1, V100, P11917, DOI
   10.1073/pnas.1834138100
   RINGDEN O, 2002, J CLIN ONCOL, V20, P4655, DOI 10.1200/JCO.2002.12.049
   RUBINSTEIN P, 1993, BLOOD, V81, P1679
   SATO K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246
   SPEES JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI
   10.1073/pnas.0437997100
   TERADA N, 2002, NATURE, V416, P542
   TSE WT, 2003, TRANSPLANTATION, V75, P389, DOI
   10.1097/01.TP.0000045055.63901.A9
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417
   YOUNG RG, 1998, J ORTHOPAED RES, V16, P406
   ZAPPIA E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496
   ZUK PA, 2001, TISSUE ENG, V7, P211
NR 42
TC 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 259
IS 2
BP 150
EP 156
DI 10.1016/j.cellimm.2009.06.010
PG 7
SC Cell Biology; Immunology
GA 501IG
UT ISI:000270374300006
ER

PT J
AU Wang, HZ
   Xiao, W
   Zhou, QB
   Chen, Y
   Yang, S
   Sheng, JS
   Yin, YQ
   Fan, J
   Zhou, JW
AF Wang, Hanzhi
   Xiao, Wei
   Zhou, Qinbo
   Chen, Yun
   Yang, Shuo
   Sheng, Jiansong
   Yin, Yanqing
   Fan, Jia
   Zhou, Jiawei
TI Bystin-like protein is upregulated in hepatocellular carcinoma and
   required for nucleologenesis in cancer cell proliferation
SO CELL RESEARCH
LA English
DT Article
DE Bystin-like; nucleologenesis; nucleolar proteins; cell growth;
   hepatocellular carcinoma
ID PRE-RIBOSOMAL-RNA; ENDOMETRIAL EPITHELIAL-CELLS; C-MYC AMPLIFICATION;
   PRENUCLEOLAR BODIES; LIVING CELLS; U3 SNRNA; EXPRESSION; NUCLEOLUS;
   TROPHININ; MITOSIS
AB The bystin-like (BYSL) gene was previously characterized to encode an
   accessory protein for cell adhesion that participates in early embryo
   implantation. It is also involved in 40S ribosomal subunit biogenesis
   and is found to be expressed in rapidly growing embryo and cancer cell
   lines. In order to explore the role of BYSL in cancer cell
   proliferation and growth, we used hepatocellular carcinoma (HCC) as a
   model. Here, we report that BYSL is crucial for HCC cell growth both in
   vitro and in vivo. Expression levels of BYSL mRNA and protein in human
   HCC specimens were markedly increased compared with those seen in
   adjacent non-cancerous tissue. In vitro, inhibition of BYSL by short
   hairpin RNA decreased HCC cell proliferation, induced apoptosis and
   partially arrested the cell cycle in the G2/M phase. In vivo, HCC cells
   treated with BYSL siRNA failed to form tumors in nude mice after
   subcutaneous implantation. To determine the cellular basis for BYSL
   RNAi-induced cell growth arrest, BYSL subcellular localization in
   mitotic and interphase HepG2 cells was examined. BYSL was present at
   multiple stages during nucleologenesis, including in nucleolus-derived
   foci (NDF), perichromosomal regions and the prenucleolar body (PNB)
   during mitosis. BYSL depletion remarkably suppressed NDF and PNB
   formation, and disrupted nucleoli assembly after mitosis, resulting in
   increased apoptosis and reduced tolerance of HCC cells to serum
   starvation. Taken together, our studies indicate that upregulated BYSL
   expression plays a role in hepatocarcinogenesis.
C1 [Wang, Hanzhi; Zhou, Qinbo; Yang, Shuo; Sheng, Jiansong; Zhou, Jiawei] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.
   [Wang, Hanzhi; Zhou, Qinbo; Yin, Yanqing; Zhou, Jiawei] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, State Key Lab Neurosci, Shanghai 200031, Peoples R China.
   [Xiao, Wei] First Peoples Hosp, Dept Pathol, Taizhou 225300, Jiangsu, Peoples R China.
   [Chen, Yun] 411 Hosp, Dept Pathol, Shanghai 200081, Peoples R China.
   [Fan, Jia] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp,Liver Canc Inst, Key Lab Carcinogenesis & Canc Invas, Shanghai 200032, Peoples R China.
RP Zhou, JW, Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell
   Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.
EM jwzhou@ion.ac.cn
FU Chinese Academy of Sciences ; National Natural Science Foundation of
   China [30525041, 30623003]; State Key Program for Basic Research of
   China [2006CB500704]
FX We thank Dr ZJ Chen of Institute of Biochemistry and Cell Biology,
   Shanghai Institutes for Biological Sciences, Chinese Academy of
   Sciences for kindly providing HCC samples and Dr YZ Wang of Institute
   of Neuroscience, Shanghai Institutes for Biological Science, Chinese
   Academy of Sciences for the nucleolin antibody. We also thank Dr G Chen
   of Shanghai Chest Hospital for help in examining human pathological
   specimens. This work was supported by grants from the Chinese Academy
   of Sciences, National Natural Science Foundation of China ( Nos.
   30525041 and 30623003) and State Key Program for Basic Research of
   China ( No. 2006CB500704).
CR ABOUELELLA A, 1996, MODERN PATHOL, V9, P95
   ADACHI K, 2007, MOL CELL BIOL, V27, P2202, DOI 10.1128/MCB.01908-06
   ALLEY MC, 1988, CANCER RES, V48, P589
   ALON U, 1999, P NATL ACAD SCI USA, V96, P6745
   ANGELIER N, 2005, MOL BIOL CELL, V16, P2862, DOI 10.1091/E05-01-0041
   AOKI R, 2006, FEBS LETT, V580, P6062, DOI 10.1016/j.febslet.2006.09.072
   AZUMGELADE MC, 1994, J CELL SCI 2, V107, P463
   BASSO K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532
   BASSOE CF, 1998, LEUKEMIA RES, V22, P329
   CALVISI DF, 2005, J HEPATOL, V42, P842, DOI 10.1016/j.jhep.2005.01.029
   CHEN WD, 2003, NUCLEIC ACIDS RES, V31, P690, DOI 10.1093/nar/gkg145
   DEMIGLIO MR, 1999, MOL CARCINOGEN, V25, P21
   DERENZINI M, 1995, LAB INVEST, V73, P497
   DUNDR M, 1998, MOL BIOL CELL, V9, P2407
   DUNDR M, 2000, J CELL BIOL, V150, P433
   FACCHINI LM, 1998, FASEB J, V12, P633
   FERRARI S, 1990, CANCER RES, V50, P5825
   FOMPROIX N, 1998, J CELL SCI 3, V111, P359
   FUKUDA MN, 1999, SEMIN REPROD ENDOCR, V17, P229
   GAUTIER T, 1994, BIOL CELL, V82, P81
   GUO SY, 2007, BRAZ J MED BIOL RES, V40, P621
   HATAKEYAMA S, 2004, CANCER RES, V64, P4257
   HENRIKSSON M, 1996, ADV CANCER RES, V68, P109
   HERNANDEZVERDUN D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI
   10.1007/s00418-005-0046-4
   JIMENEZGARCIA LF, 1994, MOL BIOL CELL, V5, P955
   KASUGAI Y, 2005, CLIN CANCER RES, V11, P8265, DOI
   10.1158/1078-0432.CCR-05-1028
   KODOUSEK R, 1991, ACTA U PALACKI OLOMU, V131, P9
   KONDOH N, 2001, ANTICANCER RES, V21, P2429
   LEONG TYM, 2005, HPB, V7, P5
   MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809
   MIYOSHI M, 2007, BIOCHEM J 3, V404, P373, DOI 10.1042/BJ20061597
   PAN QW, 2007, ACTA PHARMACOL SIN, V28, P1996, DOI
   10.1111/j.1745-7254.2007.00672.x
   PARIA BC, 1992, P NATL ACAD SCI USA, V89, P10051
   PASCALE RM, 1996, INT J CANCER, V68, P136
   RUGGERO D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   RUGGERO D, 2003, SCIENCE, V299, P259
   RUSSELL J, 2006, BIOCH SOC S, V73, P203
   SAVINO TM, 1999, J CELL SCI, V112, P1889
   SAVINO TM, 2001, J CELL BIOL, V153, P1097
   SCHAFER T, 2003, EMBO J, V22, P1370
   SIRRI V, 2000, MICRON, V31, P121
   SIRRI V, 2002, J CELL BIOL, V156, P969
   STORCK S, 2007, SUBCELL BIOCH, V41, P125
   SUGIHARA K, 2007, P NATL ACAD SCI USA, V104, P3799, DOI
   10.1073/pnas.0611516104
   SUZUKI N, 1998, P NATL ACAD SCI USA, V95, P5027
   SUZUKI N, 1999, BIOL REPROD, V60, P621
   TOLLERVEY D, 1997, CURR OPIN CELL BIOL, V9, P337
   WANG Y, 2002, CANCER, V95, P2346, DOI 10.1002/cncr.10963
   WILLIG TN, 1999, BLOOD, V94, P4294
   YANG S, 2008, FASEB J, V22, P1960, DOI 10.1096/fj.07-081463
   YASWEN P, 1985, MOL CELL BIOL, V5, P780
   YUN JP, 2007, BRIT J CANCER, V96, P477, DOI 10.1038/sj.bjc.660574
   ZHANG XK, 1990, ONCOGENE, V5, P909
   ZHU DH, 1979, ZHONGLIU FANGZHI YAN, V5, P7
NR 54
TC 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1150
EP 1164
DI 10.1038/cr.2009.99
PG 15
SC Cell Biology
GA 503IP
UT ISI:000270527600004
ER

PT J
AU Ren, B
   Liang, Y
   Deng, Y
   Chen, QG
   Zhang, J
   Yang, XH
   Zuo, JR
AF Ren, Bo
   Liang, Yan
   Deng, Yan
   Chen, Qingguo
   Zhang, Jian
   Yang, Xiaohui
   Zuo, Jianru
TI Genome-wide comparative analysis of type-A Arabidopsis response
   regulator genes by overexpression studies reveals their diverse roles
   and regulatory mechanisms in cytokinin signaling
SO CELL RESEARCH
LA English
DT Article
DE Arabidopsis; cytokinin; MG132; protein stability; type-A ARR
ID TO-ASP PHOSPHORELAY; HISTIDINE KINASE; NEGATIVE REGULATOR;
   CIRCADIAN-CLOCK; PHYTOCHROME-B; HIS-KINASE; TRANSDUCTION; THALIANA;
   RECEPTOR; GROWTH
AB Cytokinin is a critical growth regulator for various aspects of plant
   growth and development. In Arabidopsis, cytokinin signaling is mediated
   by a two-component system-based phosphorelay that transmits a signal
   from the receptors, through histidine phosphotransfer proteins, to the
   downstream response regulators (ARRs). Of these ARRs, type-A ARR genes,
   whose transcription can be rapidly induced by cytokinin, act as
   negative regulators of cytokinin signaling. However, because of
   functional redundancy, the function of type-A ARR genes in plant growth
   and development is not well understood by analyzing loss-of-function
   mutants. In this study, we performed a comparative functional study on
   all ten type-A ARR genes by analyzing transgenic plants overexpressing
   these ARR genes fused to a MYC epitope tag. Overexpression of ARR genes
   results in a variety of cytokinin-associated phenotypes. Notably,
   overexpression of different ARR transgenes causes diverse phenotypes,
   even between phylogenetically closely-related gene pairs, such as
   within the ARR3-ARR4 and ARR5-ARR6 pairs. We found that the
   accumulation of a subset of ARR proteins (ARR3, ARR5, ARR7, ARR16 and
   ARR17; possibly ARR8 and ARR15) is increased by MG132, a specific
   proteasomal inhibitor, indicating that stability of these proteins is
   regulated by proteasomal degradation. Moreover, similar to that of
   previously characterized ARR5, ARR6 and ARR7, stability of ARR16 and
   ARR17, possibly including ARR8 and ARR15, is regulated by cytokinin.
   These results suggest that type-A ARR proteins are regulated by a
   combinatorial mechanism involving both the cytokinin and proteasome
   pathways, thereby executing distinctive functions in plant growth and
   development.
C1 [Ren, Bo; Liang, Yan; Deng, Yan; Chen, Qingguo; Zhang, Jian; Yang, Xiaohui; Zuo, Jianru] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Plant Genom, Beijing 100101, Peoples R China.
   [Ren, Bo; Liang, Yan; Deng, Yan; Chen, Qingguo; Zhang, Jian; Yang, Xiaohui; Zuo, Jianru] Chinese Acad Sci, Inst Genet & Dev Biol, Natl Plant Gene Res Ctr Beijing, Beijing 100101, Peoples R China.
   [Ren, Bo; Deng, Yan; Chen, Qingguo] Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China.
RP Zuo, JR, Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Plant
   Genom, Beijing 100101, Peoples R China.
EM jrzuo@genetics.ac.cn
FU National Natural Science Foundation of China [90817107]; Ministry of
   Science and Technology of China [2007CB948203]; Chinese Academy of
   Sciences [KSCX2-YW-N-015]
FX We thank Dr Joe Kieber ( University of North Carolina, USA) and the
   Arabidopsis Biological Resource Center ( Ohio State University) for
   providing seeds. We thank Dr Shuhua Yang ( China Agricultural
   University) for critically reading the manuscript. This work was
   supported by grants from the National Natural Science Foundation of
   China ( 90817107), the Ministry of Science and Technology of China
   (2007CB948203) and Chinese Academy of Sciences (KSCX2-YW-N-015).
CR ARGYROS RD, 2008, PLANT CELL, V20, P2102, DOI 10.1105/tpc.108.059584
   BRANDSTATTER I, 1998, PLANT CELL, V10, P1009
   CLOUGH SJ, 1998, PLANT J, V16, P735
   DAGOSTINO IB, 1999, TRENDS BIOCHEM SCI, V24, P452
   DAGOSTINO IB, 2000, PLANT PHYSIOL, V124, P1706
   DAVIES J, 2004, PLANT HORMONES BIOSY
   FENG HZ, 2007, PLANT PHYSIOL, V144, P1531, DOI 10.1104/pp.107.098079
   FERREIRA FJ, 2005, CURR OPIN PLANT BIOL, V8, P518, DOI
   10.1016/j.pbi.2005.07.013
   HABERER G, 2002, PLANT PHYSIOL, V128, P354
   HEYL A, 2003, CURR OPIN PLANT BIOL, V6, P480, DOI
   10.1016/S1369-5266(03)00087-6
   HEYL A, 2008, PLANT PHYSIOL, V147, P1380, DOI 10.1104/pp.107.115436
   HIGUCHI M, 2004, P NATL ACAD SCI USA, V101, P8821
   HUTCHISON CE, 2002, PLANT CELL, V14, S247
   HUTCHISON CE, 2006, PLANT CELL, V18, P3073, DOI 10.1105/tpc.106.045674
   HWANG I, 2001, NATURE, V413, P383
   HWANG I, 2002, PLANT PHYSIOL, V129, P500
   IMAMURA A, 1998, P NATL ACAD SCI USA, V95, P2691
   IMAMURA A, 2003, PLANT CELL PHYSIOL, V44, P122
   INOUE T, 2001, NATURE, V409, P1060
   ISHIDA K, 2008, BIOSCI BIOTECH BIOCH, V72, P3025, DOI 10.1271/bbb.80402
   ISHIDA K, 2008, PLANT CELL PHYSIOL, V49, P47, DOI 10.1093/pcp/pcm165
   KAKIMOTO T, 1996, SCIENCE, V274, P982
   KAKIMOTO T, 2003, ANNU REV PLANT BIOL, V54, P605, DOI
   10.1146/annurev.arplant.54.031902.134802
   KIBA T, 2003, PLANT CELL PHYSIOL, V44, P868
   KIBA T, 2004, PLANT CELL PHYSIOL, V45, P1063
   KIM HJ, 2006, P NATL ACAD SCI USA, V103, P814, DOI
   10.1073/pnas.0505150103
   LEE DJ, 2007, MOL GENET GENOMICS, V277, P115, DOI
   10.1007/s00438-006-0177-x
   LEE DJ, 2008, PLANTA, V227, P577, DOI 10.1007/s00425-007-0640-x
   LEIBFRIED A, 2005, NATURE, V438, P1172, DOI 10.1038/nature04270
   MAHONEN AP, 2000, GENE DEV, V14, P2938
   MAHONEN AP, 2006, CURR BIOL, V16, P1116, DOI 10.1016/j.cub.2006.04.030
   MAHONEN AP, 2006, SCIENCE, V311, P94, DOI 10.1126/science.1118875
   MASON MG, 2004, PLANT PHYSIOL, V135, P927, DOI 10.1104/pp.103.038109
   MASON MG, 2005, PLANT CELL, V17, P3007, DOI 10.1105/tpc.105.035451
   MOK DWS, 2001, ANNU REV PLANT PHYS, V52, P89
   MULLER B, 2007, SCIENCE, V318, P68, DOI 10.1126/science.1145461
   MULLER B, 2008, NATURE, V453, P1094, DOI 10.1038/nature06943
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473
   NAKAMURA A, 1999, BIOSCI BIOTECH BIOCH, V63, P1627
   NISHIMURA C, 2004, PLANT CELL, V16, P1365, DOI 10.1105/tpc.021477
   OSAKABE Y, 2002, BIOCHEM BIOPH RES CO, V293, P806
   REED JW, 2001, TRENDS PLANT SCI, V6, P420
   RIEFLER M, 2006, PLANT CELL, V18, P40, DOI 10.1105/tpc.105.037796
   SAKAI H, 2000, PLANT J, V24, P703
   SAKAI H, 2001, SCIENCE, V294, P1519
   SALOME PA, 2006, PLANT CELL, V18, P55, DOI 10.1105/tpc.105.037994
   SMALLE J, 2002, PLANT CELL, V14, P17
   SUN JQ, 2003, PLANT PHYSIOL, V131, P167, DOI 10.1104/pp.011494
   SUZUKI T, 1998, PLANT CELL PHYSIOL, V39, P1258
   SUZUKI T, 2000, BIOSCI BIOTECH BIOCH, V64, P2486
   SUZUKI T, 2001, PLANT CELL PHYSIOL, V42, P107
   SWEERE U, 2001, SCIENCE, V294, P1108
   TAJIMA Y, 2004, PLANT CELL PHYSIOL, V45, P28
   TO JPC, 2004, PLANT CELL, V16, P658, DOI 10.1105/tpc.018978
   TO JPC, 2007, PLANT CELL, V19, P3901, DOI 10.1105/tpc.107.052662
   TO JPC, 2008, TRENDS PLANT SCI, V13, P85, DOI
   10.1016/j.tplants.2007.11.005
   VOGEL JP, 1998, GENETICS, V149, P417
   YAMADA H, 2001, PLANT CELL PHYSIOL, V42, P1017
   YOKOYAMA A, 2007, PLANT CELL PHYSIOL, V48, P84, DOI 10.1093/pcp/pcl040
   ZHENG BL, 2006, PHYSIOL PLANTARUM, V127, P277, DOI
   10.1111/j.1399-3054.2006.00660.x
NR 60
TC 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1178
EP 1190
DI 10.1038/cr.2009.88
PG 13
SC Cell Biology
GA 503IP
UT ISI:000270527600006
ER

PT J
AU Huang, XZ
   Zhang, XY
   Yang, SH
AF Huang, Xiaozhen
   Zhang, Xiaoyan
   Yang, Shuhua
TI A novel chloroplast-localized protein EMB1303 is required for
   chloroplast development in Arabidopsis
SO CELL RESEARCH
LA English
DT Article
DE EMB1303; albino; chloroplast development; embryogenesis; Arabidopsis
ID NUCLEAR GENE-EXPRESSION; EMBRYO DEVELOPMENT; PLASTID DIFFERENTIATION;
   4-PHOSPHATE PATHWAY; PLANT DEVELOPMENT; PHOTOSYSTEM-II; THALIANA;
   BIOSYNTHESIS; CELL; PHOTOSYNTHESIS
AB To understand the molecular mechanisms underlying chloroplast
   development, we isolated and characterized the albino mutant emb1303-1
   in Arabidopsis. The mutant displayed a severe dwarf phenotype with
   small albino rosette leaves and short roots on a synthetic medium
   containing sucrose. It is pigment-deficient and seedling lethal when
   grown in soil. Embryo development was delayed in the mutant, although
   seed germination was not significantly impaired. The plastids of
   emb1303-1 were arrested in early developmental stages without the
   classical stack of thylakoid membrane. Genetic and molecular analyses
   uncovered that the EMB1303 gene encodes a novel chloroplast-localized
   protein. Microarray and RT-PCR analyses revealed that a number of
   nuclear- and plastid-encoded genes involved in photosynthesis and
   chloroplast biogenesis were substantially downregulated in the mutant.
   Moreover, the accumulation of several major chloroplast proteins was
   severely compromised in emb1303-1. These results suggest that EMB1303
   is essential for chloroplast development.
C1 [Huang, Xiaozhen; Zhang, Xiaoyan; Yang, Shuhua] China Agr Univ, Coll Biol Sci, State Key Lab Plant Physiol & Biochem, Beijing 100193, Peoples R China.
   [Yang, Shuhua] Natl Plant Gene Res Ctr, Beijing 100193, Peoples R China.
RP Yang, SH, China Agr Univ, Coll Biol Sci, State Key Lab Plant Physiol &
   Biochem, Beijing 100193, Peoples R China.
EM yangshuhua@cau.edu.cn
FU National Natural Science Foundation of China [30670181, 30770202];
   Ministry of Science and Technology of China [2009CB119103]; Program for
   New Century Excellent Talents in University [NCET-05-0124]; Key Project
   of Chinese Ministry of Education [106037]
FX We thank Dr Lixin Zhang ( Institute of Botany, Chinese Academy of
   Sciences) for providing antibodies of D1, D2, LHCII, and AtpB; and
   Arabidopsis Biological Research Center for T-DNA mutant seeds. We are
   grateful to Drs Jian Hua ( Cornell University) and Hao Yu ( National
   University of Singapore) for critically reviewing the manuscript. This
   work was supported by grants from National Natural Science Foundation
   of China ( Nos. 30670181 and 30770202), the Ministry of Science and
   Technology of China ( No. 2009CB119103), Program for New Century
   Excellent Talents in University ( No. NCET-05-0124), and the Key
   Project of Chinese Ministry of Education ( No. 106037).
CR APUYA NR, 2001, PLANT PHYSIOL, V126, P717
   APUYA NR, 2002, PLANT PHYSIOL, V129, P691
   BANG WY, 2008, PLANT CELL PHYSIOL, V49, P1350, DOI 10.1093/pcp/pcn111
   BARNECHE F, 2006, EMBO J, V25, P5907, DOI 10.1038/sj.emboj.7601472
   BELLAOUI M, 2003, PLANT MOL BIOL, V53, P531
   BORISJUK L, 2005, NEW PHYTOL, V167, P761, DOI
   10.1111/j.1469-8137.2005.01474.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248
   CLOUGH SJ, 1998, PLANT J, V16, P735
   DONG HL, 2007, CELL RES, V17, P458, DOI 10.1038/CR.2007.37
   EMANUELSSON O, 1999, PROTEIN SCI, V8, P978
   GARCION C, 2006, PLANT J, V48, P895, DOI
   10.1111/j.1365-313X.2006.02922.x
   GUEVARAGARCIA A, 2005, PLANT CELL, V17, P628, DOI 10.1105/tpc.104.028860
   GUTIERREZNAVA MDL, 2004, PLANT PHYSIOL, V135, P471, DOI
   10.1104/pp.103.036996
   HAJDUKIEWICZ PTJ, 1997, EMBO J, V16, P4041
   HSIEH MH, 2008, PLANT MOL BIOL, V66, P663, DOI 10.1007/s11103-008-9297-5
   IFUKU K, 2005, PLANT PHYSIOL, V139, P1175, DOI 10.1104/pp.105.068643
   KLOSTERMANN E, 2002, BIOCHEM J 3, V368, P777, DOI 10.1042/BJ20021291
   KOBAYASHI K, 2007, PLANT CELL PHYSIOL, V48, P322, DOI 10.1093/pcp/pcm005
   KOCH KE, 1996, ANNU REV PLANT PHYS, V47, P509
   KONCZ C, 1986, MOL GEN GENET, V204, P383
   KOUSSEVITZKY S, 2007, SCIENCE, V316, P715, DOI 10.1126/science.1140516
   LICHTENTHALER HK, 1983, BIOCHEM SOC T, V11, P591
   LOPEZJUEZ E, 2005, INT J DEV BIOL, V49, P557, DOI 10.1387/ijdb.051997el
   MCELVER J, 2001, GENETICS, V159, P1751
   MEURER J, 1996, PLANTA, V198, P385
   MOTOHASHI R, 2001, P NATL ACAD SCI USA, V98, P10499
   NOTT A, 2006, ANNU REV PLANT BIOL, V57, P739
   OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229
   PATEL R, 2008, PLANT PHYSIOL, V148, P235, DOI 10.1104/pp.108.122754
   PLUCKEN H, 2002, FEBS LETT, V532, P85
   QIN GJ, 2007, CELL RES, V17, P471, DOI 10.1038/cr.2007.40
   STAEHELIN LA, 2000, BIOCH MOL BIOL PLANT, P2
   SUNDBERG E, 1997, PLANT CELL, V9, P717
   TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211
   UWER U, 1998, PLANT CELL, V10, P1277
   WALTER M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x
   WANG YQ, 1996, J PLANT PHYSIOL, V147, P521
   YANG SH, 2006, PLANT J, V45, P166, DOI 10.1111/j.1365-313X.2005.02585.x
   YOO SD, 2007, NAT PROTOC, V2, P1565
   YU B, 2004, PLANT CELL PHYSL, V45, P503
NR 40
TC 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1205
EP 1216
DI 10.1038/cr.2009.84
PG 12
SC Cell Biology
GA 503IP
UT ISI:000270527600008
ER

PT J
AU Jia, GS
   Wang, WX
   Li, H
   Mao, Z
   Cai, GH
   Sun, J
   Wu, H
   Xu, M
   Yang, P
   Yuan, W
   Chen, S
   Zhu, B
AF Jia, Guangshuai
   Wang, Weixiang
   Li, Hong
   Mao, Zhuo
   Cai, Gaihong
   Sun, Jian
   Wu, Hui
   Xu, Mo
   Yang, Peng
   Yuan, Wen
   Chen, She
   Zhu, Bing
TI A systematic evaluation of the compatibility of histones containing
   methyl-lysine analogues with biochemical reactions
SO CELL RESEARCH
LA English
DT Letter
ID TRIMETHYLATION
C1 [Jia, Guangshuai; Wang, Weixiang; Li, Hong; Mao, Zhuo; Cai, Gaihong; Sun, Jian; Wu, Hui; Xu, Mo; Yang, Peng; Yuan, Wen; Chen, She; Zhu, Bing] Natl Inst Biol Sci, Beijing 102206, Peoples R China.
   [Jia, Guangshuai] Chinese Acad Sci, Kunming Inst Zool, Immunobiol Lab & Overseas Team, Key Lab Anim Model & Human Dis Mech, Kunming 650223, Peoples R China.
   [Jia, Guangshuai] Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China.
   [Mao, Zhuo; Wu, Hui; Xu, Mo] Peking Union Med Coll, Grad Program, Beijing 100730, Peoples R China.
   [Mao, Zhuo; Wu, Hui; Xu, Mo] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
   [Yang, Peng] Peking Univ, Coll Life Sci, Beijing 1000871, Peoples R China.
   [Yuan, Wen] China Agr Univ, State Key Lab Plant Physiol & Biochem, Beijing 100094, Peoples R China.
RP Zhu, B, Natl Inst Biol Sci, Beijing 102206, Peoples R China.
EM zhubing@nibs.ac.cn
CR ALLIS CD, 2006, EPIGENETICS, P23
   BOTUYAN MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   COLLINS RE, 2008, NAT STRUCT MOL BIOL, V15, P245, DOI 10.1038/nsmb.1384
   DESANTA F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   EDMUNDS JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967
   SCHNEIDER J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024
   SCHOTTA G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   SIMON MD, 2007, CELL, V128, P1003, DOI 10.1016/j.cell.2006.12.041
   TSUKADA Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   YUAN W, 2009, J BIOL CHEM, V284, P15701, DOI 10.1074/jbc.M808431200
NR 10
TC 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1217
EP 1220
DI 10.1038/cr.2009.110
PG 4
SC Cell Biology
GA 503IP
UT ISI:000270527600009
ER

PT J
AU Yu, KQ
   Luo, C
   Qin, GR
   Xu, ZJ
   Li, N
   Liu, H
   Shen, X
   Ma, JP
   Wang, QH
   Yang, CG
   Zhu, WL
   Jiang, HL
AF Yu, Kunqian
   Luo, Cheng
   Qin, Guangrong
   Xu, Zhijian
   Li, Ning
   Liu, Hong
   Shen, Xu
   Ma, Jianpeng
   Wang, Qinghua
   Yang, Caiguang
   Zhu, Weiliang
   Jiang, Hualiang
TI Why are oseltamivir and zanamivir effective against the newly emerged
   influenza A virus (A/H1N1)?
SO CELL RESEARCH
LA English
DT Letter
ID AVIAN INFLUENZA; NEURAMINIDASE NA; DRUG DESIGN; H5N1; INHIBITORS
C1 [Yu, Kunqian; Luo, Cheng; Qin, Guangrong; Xu, Zhijian; Li, Ning; Liu, Hong; Shen, Xu; Yang, Caiguang; Zhu, Weiliang; Jiang, Hualiang] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China.
   [Ma, Jianpeng; Wang, Qinghua] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Jiang, Hualiang] E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China.
RP Jiang, HL, Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug
   Res, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China.
EM wlzhu@mail.shcnc.ac.cn
   hljiang@mail.shcnc.ac.cn
CR ALEXANDER DJ, 2007, VACCINE, V25, P5637, DOI
   10.1016/j.vaccine.2006.10.051
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403
   CHEN LL, 2005, J VIROL, V79, P7095
   COLLINS PJ, 2008, NATURE, V453, P1258, DOI 10.1038/nature06956
   MIHAJLOVIC ML, 2008, BIOPHYS CHEM, V136, P152, DOI
   10.1016/j.bpc.2008.06.003
   MISHIN VP, 2005, ANTIMICROB AGENTS CH, V49, P4515, DOI
   10.1128/AAC.49.11.4515-4520.2005
   MITRASINOVIC PM, 2009, BIOPHYS CHEM, V140, P35, DOI
   10.1016/j.bpc.2008.11.004
   MORRIS GM, 1998, J COMPUT CHEM, V19, P1639
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1
   RAMEIXWELTI MA, 2008, PLOS PATHOG, V4, ARTN e1000103
   RUSSELL RJ, 2006, NATURE, V443, P45, DOI 10.1038/nature05114
   SKEIK N, 2008, INT J INFECT DIS, V12, P233, DOI
   10.1016/j.ijid.2007.07.002
   TAUBENBERGER JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230
   TUMPEY TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212
   WADE RC, 1997, STRUCTURE, V5, P1139
NR 15
TC 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1221
EP 1224
DI 10.1038/cr.2009.111
PG 4
SC Cell Biology
GA 503IP
UT ISI:000270527600010
ER

PT J
AU Huang, XZ
   Zhang, XY
   Yang, SH
AF Huang, Xiaozhen
   Zhang, Xiaoyan
   Yang, Shuhua
TI A novel chloroplast-localized protein EMB1303 is required for
   chloroplast development in Arabidopsis (vol 19, pg 1205, 2009)
SO CELL RESEARCH
LA English
DT Correction
ID GENES
CR HUANG XZ, 2009, CELL RES, V19, P1205, DOI 10.1038/cr.2009.84
   MEINKE D, 2008, TRENDS PLANT SCI, V13, P483, DOI
   10.1016/j.tplants.2008.06.003
   TZAFRIR I, 2004, PLANT PHYSIOL, V135, P1206
NR 3
TC 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD OCT
PY 2009
VL 19
IS 10
BP 1225
EP 1225
DI 10.1038/cr.2009.116
PG 1
SC Cell Biology
GA 503IP
UT ISI:000270527600011
ER

PT J
AU Xie, XY
   Chen, Y
   Xue, P
   Fan, Y
   Deng, YQ
   Peng, G
   Yang, FQ
   Xu, T
AF Xie, Xiangyang
   Chen, Yu
   Xue, Peng
   Fan, Yong
   Deng, Yongqiang
   Peng, Gong
   Yang, Fuquan
   Xu, Tao
TI RUVBL2, a novel AS160-binding protein, regulates insulin-stimulated
   GLUT4 translocation
SO CELL RESEARCH
LA English
DT Article
DE GLUT4; AS160; RUVBL2; tandem affinity purification (TAP); adipocytes;
   insulin
ID GTPASE-ACTIVATING-PROTEIN; SKELETAL-MUSCLE; RABGAP AS160; DNA HELICASE;
   TRAFFICKING; DOMAIN; GLUCOSE-TRANSPORTER-4; INHIBITION; MEMBRANE; TBC1D1
AB In fat and muscle cells, insulin-stimulated glucose uptake is mainly
   mediated by glucose transporter 4 (GLUT4), which translocates from
   intracellular compartments to the cell surface in response to insulin
   stimulation. AS160 is one of the substrates of Akt and plays important
   roles in insulin-regulated GLUT4 translocation. In this study,
   RuvB-like protein 2 (RUVBL2) is identified as a new AS160-binding
   protein using mammalian tandem affinity purification (TAP) combined
   with mass spectrometry. In 3T3-L1 adipocytes, RUVBL2 is highly
   expressed and is mainly distributed in the cytosol. Depletion of RUVBL2
   in adipocytes inhibits insulin-stimulated GLUT4 translocation and
   glucose uptake through reducing insulin-stimulated AS160
   phosphorylation. However, introduction of human RUVBL2 can reverse this
   inhibitory effect. These data suggest that RUVBL2 plays an important
   role in insulin-stimulated GLUT4 translocation through its interaction
   with AS160.
C1 [Xie, Xiangyang; Chen, Yu; Xue, Peng; Fan, Yong; Deng, Yongqiang; Peng, Gong; Yang, Fuquan; Xu, Tao] Chinese Acad Sci, Inst Biophys, Natl Key Lab Biomacromol, Beijing 100101, Peoples R China.
   [Xie, Xiangyang; Chen, Yu; Fan, Yong; Deng, Yongqiang; Peng, Gong] Chinese Acad Sci, Grad Sch, Beijing 100101, Peoples R China.
RP Xu, T, Chinese Acad Sci, Inst Biophys, Natl Key Lab Biomacromol,
   Beijing 100101, Peoples R China.
EM fqyang@ibp.ac.cn
   xutao@ibp.ac.cn
FU National Natural Science Foundation of China [30630020]; National Basic
   Research Program of China [2004CB720000]; CAS Project [KSCX1-YW-02-1]
FX We would like to thank our colleagues, Prof Hong Tang for providing
   pCTAP-A expression vector and Dr Li Zheng for valuable discussion. This
   work is supported by the National Natural Science Foundation of China
   (NO. 30630020), the National Basic Research Program of China
   (2004CB720000), and the CAS Project (KSCX1-YW-02-1).
CR BAI L, 2007, CELL METAB, V5, P47, DOI 10.1016/j.cmet.2006.11.013
   BRYANT NJ, 2002, NAT REV MOL CELL BIO, V3, P267
   CHAVEZ JA, 2008, J BIOL CHEM, V283, P9187, DOI 10.1074/jbc.M708934200
   CHEN Y, 2008, FEBS J, V275, P705, DOI 10.1111/j.1742-4658.2007.06232.x
   EGUEZ L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005
   GALLANT P, 2007, TRENDS CELL BIOL, V17, P187, DOI
   10.1016/j.tcb.2007.02.005
   JIANG L, 2008, J BIOL CHEM, V283, P8508, DOI 10.1074/jbc.M708688200
   KANE S, 2002, J BIOL CHEM, V277, P22115
   KANEMAKI M, 1999, J BIOL CHEM, V274, P22437
   KRAMER HF, 2007, DIABETES, V56, P2854, DOI 10.2337/db07-0681
   LARANCE M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200
   LI CH, 2004, CELL RES, V14, P480
   MIINEA CP, 2005, BIOCHEM J 1, V391, P87, DOI 10.1042/BJ20050887
   MIZUNO K, 2006, MOL REPROD DEV, V73, P437, DOI 10.1002/mrd.20395
   RAMM G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200
   ROUSSEAU B, 2007, HEPATOLOGY, V46, P1108, DOI 10.1002/hep.21770
   SANO H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200
   SANO H, 2007, CELL METAB, V5, P293, DOI 10.1016/j.cmet.2007.03.001
   SANO H, 2008, BIOCHEM J 1, V411, P89, DOI 10.1042/BJ20071318
   TAYLOR EB, 2008, J BIOL CHEM, V283, P9787, DOI 10.1074/jbc.M708839200
   WATSON RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011
   ZEIGERER A, 2004, MOL BIOL CELL, V15, P4406
NR 22
TC 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD SEP
PY 2009
VL 19
IS 9
BP 1090
EP 1097
DI 10.1038/cr.2009.68
PG 8
SC Cell Biology
GA 503IN
UT ISI:000270527400007
ER

PT J
AU Yuk, JM
   Shin, DM
   Lee, HM
   Yang, CS
   Jin, HS
   Kim, KK
   Lee, ZW
   Lee, SH
   Kim, JM
   Jo, EK
AF Yuk, Jae-Min
   Shin, Dong-Min
   Lee, Hye-Mi
   Yang, Chul-Su
   Jin, Hyo Sun
   Kim, Kwang-Kyu
   Lee, Zee-Won
   Lee, Sang-Hee
   Kim, Jin-Man
   Jo, Eun-Kyeong
TI Vitamin D3 Induces Autophagy in Human Monocytes/Macrophages via
   Cathelicidin
SO CELL HOST & MICROBE
LA English
DT Article
ID INNATE IMMUNE-RESPONSES; TOLL-LIKE RECEPTORS;
   MYCOBACTERIUM-TUBERCULOSIS; PHOSPHATIDYLINOSITOL 3-KINASE;
   PROTEIN-KINASE; HOST-DEFENSE; C/EBP-BETA; MACROPHAGES; CELLS; INHIBITION
AB Autophagy and vitamin D3-mediated innate immunity have been shown to
   confer protection against infection with intracellular Mycobacterium
   tuberculosis. Here, we show that these two antimycobacterial defenses
   are physiologically linked via a regulatory function of human
   cathelicidin (hCAP-18/LL-37), a member of the cathelicidin family of
   antimicrobial proteins. We show that 1,25-dihydroxyvitamin D (1,25D3),
   the active form of vitamin D, induced autophagy in human monocytes via
   cathelicidin, which activated transcription of the autophagy-related
   genes Beclin-1 and Atg5. 1,25D3 also induced the colocalization of
   mycobacterial phagosomes with autophagosomes in human macrophages in a
   cathelicidin-dependent manner. Furthermore, the antimycobacterial
   activity in human macrophages mediated by physiological levels of
   1,25D3 required autophagy and cathelicidin. These results indicate that
   human cathelicidin, a protein that has direct antimicrobial activity,
   also serves as a mediator of vitamin D3-induced autophagy.
C1 [Yuk, Jae-Min; Shin, Dong-Min; Lee, Hye-Mi; Yang, Chul-Su; Jin, Hyo Sun; Kim, Kwang-Kyu; Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Dept Microbiol, Taejon 301747, South Korea.
   [Yuk, Jae-Min; Shin, Dong-Min; Lee, Hye-Mi; Yang, Chul-Su; Jin, Hyo Sun; Kim, Kwang-Kyu; Kim, Jin-Man; Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Infect Signaling Network Res Ctr, Taejon 301747, South Korea.
   [Kim, Jin-Man] Chungnam Natl Univ, Coll Med, Dept Pathol, Taejon 301747, South Korea.
   [Lee, Zee-Won] Korea Basic Sci Inst, Glyc Team, Taejon 305333, South Korea.
   [Lee, Sang-Hee] Korea Adv Inst Sci & Technol, Dept Biol Sci, Mol Genom Lab, Taejon 305701, South Korea.
RP Jo, EK, Chungnam Natl Univ, Coll Med, Dept Microbiol, Taejon 301747,
   South Korea.
EM hayoungj@cnu.ac.kr
FU Korea Science & Engineering Foundation through Infection Signaling
   Network Research Center [R13-2007-020-01000-0]
FX We thank K.S. Song, G.M. Hur, K.K. Kim, and J.W. Shon for discussion
   and reagents; T. Yoshimori for plasmids; and J.S. Kim for critical
   reading of the manuscript. This work was supported by the Korea Science
   & Engineering Foundation through the Infection Signaling Network
   Research Center (R13-2007-020-01000-0) at Chungnam National University.
   The authors have no financial conflict of interest.
CR BAEHRECKE EH, 2005, NAT REV MOL CELL BIO, V6, P505
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P13
   CHAN ED, 2008, CURR OPIN INFECT DIS, V21, P587, DOI
   10.1097/QCO.0b013e328319bce6
   COLOMBO MI, 2006, AUTOPHAGY, V2, P162
   COWLAND JB, 1995, FEBS LETT, V368, P173
   CROWLE AJ, 1987, INFECT IMMUN, V55, P2945
   DELGADO MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   DEMASTERS G, 2006, MOL CANCER THER, V5, P2786, DOI
   10.1158/1535-7163.MCT-06-0316
   DERETIC V, 2005, TRENDS IMMUNOL, V26, P523, DOI 10.1016/j.it.2005.08.003
   DYE C, 1999, JAMA-J AM MED ASSOC, V282, P677
   GUTIERREZ MG, 2004, CELL, V119, P753
   HOYERHANSEN M, 2005, CELL DEATH DIFFER, V12, P1297, DOI
   10.1038/sj.cdd.4401651
   HOYERHANSEN M, 2007, AUTOPHAGY, V3, P381
   JI Y, 2004, CANCER RES, V64, P370
   KABEYA Y, 2000, EMBO J, V19, P5720
   KAILARSEN Y, 2008, FRONT BIOSCI, V13, P3760, DOI 10.2741/2964
   KEANE J, 2000, J IMMUNOL, V164, P2016
   KIM J, 2007, P NATL ACAD SCI USA, V104, P1800, DOI
   10.1073/pnas.0611137104
   KLIONSKY DJ, 2000, SCIENCE, V290, P1717
   LEE HM, 2009, CELL MICROBIOL, V11, P678, DOI
   10.1111/j.1462-5822.2009.01285.x
   LEVINE B, 2008, CELL, V132, P27
   LI X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI
   10.1073/pnas.0703771104
   LIANG XH, 1999, NATURE, V402, P672
   LIU L, 1995, BLOOD, V85, P1095
   LIU PT, 2006, SCIENCE, V311, P1770
   LIU PT, 2007, J IMMUNOL, V179, P2060
   LIU PT, 2008, CURR OPIN IMMUNOL, V20, P371, DOI
   10.1016/j.coi.2008.05.014
   LOEUILLET C, 2006, J IMMUNOL, V177, P6245
   MIZUSHIMA N, 2001, J CELL BIOL, V152, P657
   MIZUSHIMA N, 2007, AUTOPHAGY, V3, P542
   NIJNIK A, 2009, CURR OPIN HEMATOL, V16, P41, DOI
   10.1097/MOH.0b013e32831ac517
   OHSUMI Y, 2001, NAT REV MOL CELL BIO, V2, P211
   ORVEDAHL A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159
   SANJUAN MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   SCARLATTI F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   SCHERZSHOUVAL R, 2007, TRENDS CELL BIOL, V17, P422, DOI
   10.1016/j.tcb.2007.07.009
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889
   SINGH SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   SLY LM, 2001, J BIOL CHEM, V276, P35482
   SORENSEN O, 1997, BLOOD, V90, P2796
   SUN QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI
   10.1073/pnas.0810452105
   WANG JR, 2008, J BIOL CHEM, V283, P25596, DOI 10.1074/jbc.M801716200
   XU Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   YANG CS, 2009, J IMMUNOL, V182, P3696, DOI 10.4049/jimmunol.0802217
NR 45
TC 35
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 17
PY 2009
VL 6
IS 3
BP 231
EP 243
DI 10.1016/j.chom.2009.08.004
PG 13
SC Microbiology
GA 500HW
UT ISI:000270290700007
ER

PT J
AU Yang
AF Yang
TI SALL4 is a key regulator of survival and apoptosis in human leukemic
   cells (vol 112, pg 805, 2008)
SO BLOOD
LA English
DT Correction
CR YANG JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326
NR 1
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 1
PY 2009
VL 114
IS 14
BP 3131
EP 3131
DI 10.1182/blood-2009-06-230185
PG 1
SC Hematology
GA 501MX
UT ISI:000270387100040
ER

PT J
AU Blachon, S
   Cai, XY
   Roberts, KA
   Yang, K
   Polyanovsky, A
   Church, A
   Avidor-Reiss, T
AF Blachon, Stephanie
   Cai, Xuyu
   Roberts, Kela A.
   Yang, Kevin
   Polyanovsky, Andrey
   Church, Allen
   Avidor-Reiss, Tomer
TI A Proximal Centriole-Like Structure Is Present in Drosophila Spermatids
   and Can Serve as a Model to Study Centriole Duplication
SO GENETICS
LA English
DT Article
ID 9-FOLD SYMMETRY; BASAL BODIES; PROTEIN; CENTROSOME; MELANOGASTER;
   TUBULIN; GENES; SPERMATOGENESIS; SPERMIOGENESIS; GAMETOGENESIS
AB Most animals have two centrioles in spermatids (the distal and proximal
   centrioles), but insect spermatids seem to contain only one centriole
   (FULLER 1993), which functionally resembles the distal centriole. Using
   fluorescent centriolar markers, we identified a structure near the fly
   distal centriole that. is reminiscent of a proximal centriole (i.e.,
   proximal centriole-like, or PCL). We show that the PCL exhibits several
   features of daughter centrioles. First, a single PCL forms near the
   proximal segment of the older centriole. Second, the centriolar
   proteins SAS-6, Anal, and Bld10p/Cep135 are in the PCL. Third, PCL
   formation depends oil SAK/PLK4 and SAS-6. Using a genetic screen for
   PCL defect, we identified a mutation in the gene encoding the conserved
   centriolar protein POC1 which is part of the daughter centriole
   initiation site (KILBURN et al. 2007) in Tetrahymena. We conclude that
   the PCL resembles an early intermediate structure of a forming
   centriole, which may explain why no typical centriolar structure is
   observed tinder electron microscopy. We propose that, during the
   evolution of insects, the proximal centriole was simplified by
   eliminating the later steps in centriole assembly. The PCL may provide
   a unique model to study early steps of centriole formation.
C1 [Blachon, Stephanie; Cai, Xuyu; Roberts, Kela A.; Yang, Kevin; Church, Allen; Avidor-Reiss, Tomer] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
   [Polyanovsky, Andrey] Russian Acad Sci, Sechenov Inst, St Petersburg 194223, Russia.
RP Avidor-Reiss, T, Harvard Univ, Sch Med, Dept Cell Biol, 250 Longwood
   Ave, Boston, MA 02115 USA.
EM tomer_avidor-reiss@hms.harvard.edu
FU Fondation pour la Recherche Medicale ; Russian Foundation for Basic
   Research [07-04-01127]
FX We thank the Havard Medical School EM facility for their help with
   electron microscopy, J. W. Raff for the GFP-PACT flies, and T C.
   Kaufman for Cnn antibodies. This work was supported partially by a
   grant from the Hellman Family Fund Program. Stephanie Blachon was
   Supported partially by a Fondation pour la Recherche Medicale grant.
   Andrey Polyanovsky way supported by the Russian Foundation for Basic
   Research grant no. 07-04-01127.
CR ALLEN RD, 1969, J CELL BIOL, V40, P716
   ANDERSEN JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166
   ANDERSON WA, 1967, MOL GEN GENET, V99, P257
   AVIDORREISS T, 2004, CELL, V117, P527
   AZIMZADEH J, 2007, J CELL SCI, V120, P2139, DOI 10.1242/jcs.005231
   BAKER JD, 2004, DEVELOPMENT, V131, P3411, DOI 10.1242/dev.01229
   BASTO R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025
   BETTENCOURTDIAS M, 2005, CURR BIOL, V15, P2199, DOI
   10.1016/j.cub.2005.11.042
   BLACHON S, 2008, GENETICS, V180, P2081, DOI 10.1534/genetics.108.095141
   BUTCHER RDJ, 2004, J CELL SCI, V117, P1191, DOI 10.1242/jcs.00979
   CALLAINI G, 1999, BIOL CELL, V91, P355
   CATALANO RD, 1997, MOL HUM REPROD, V3, P215
   CENCI G, 1994, J CELL SCI 12, V107, P3521
   DAMMERMANN A, 2008, J CELL BIOL, V180, P771, DOI 10.1083/jcb.200709102
   DELATTRE M, 2006, CURR BIOL, V16, P1844, DOI 10.1016/j.cub.2006.07.059
   DIPPELL RV, 1968, P NATL ACAD SCI USA, V61, P461
   EBERL DF, 2000, J NEUROSCI, V20, P5981
   FRIEDLANDER M, 1971, J MORPHOL, V134, P383
   FULLER MT, 1993, SPERMATOGENESIS
   GOSHIMA G, 2007, SCIENCE, V316, P417, DOI 10.1126/science.1141314
   HIRAKI M, 2007, CURR BIOL, V17, P1778, DOI 10.1016/j.cub.2007.09.021
   HSU WB, 2008, EXP CELL RES, V314, P2591, DOI 10.1016/j.yexcr.2008.05,012
   HUNG LY, 2000, MOL CELL BIOL, V20, P7813
   KELLER LC, 2005, CURR BIOL, V15, P1090
   KELLER LC, 2008, MOL BIOL CELL, V20, P1150
   KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673
   KILBURN CL, 2007, J CELL BIOL, V178, P905, DOI 10.1083/jcb.200703109
   KIRKHAM M, 2003, CELL, V112, P575
   KLEYLEINSOHN J, 2007, DEV CELL, V13, P190, DOI
   10.1016/j.devcel.2007.07.002
   KOUNDAKJIAN EJ, 2004, GENETICS, V167, P203
   KRIOUTCHKOVA MM, 1999, INT REV CYTOL, V185, P107
   LI KJ, 1996, CELL, V85, P585
   LUCAS EP, 2007, J CELL BIOL, V178, P725, DOI 10.1083/jcb.200704081
   MARTINEZCAMPOS M, 2004, J CELL BIOL, V165, P673, DOI
   10.1083/jcb.200402130
   MEGRAW TL, 1999, DEVELOPMENT, V126, P2829
   MEGRAW TL, 2000, CURR TOP DEV BIOL, V49, P385
   NAKAZAWA Y, 2007, CURR BIOL, V17, P2169, DOI 10.1016/j.cub.2007.11.046
   NEER EJ, 1996, CELL, V84, P175
   PEEI N, 2007, CURR BIOL, V17, P834
   PELLETIER L, 2006, NATURE, V444, P619, DOI 10.1038/nature05318
   PHILLIPS DM, 1970, J CELL BIOL, V44, P243
   RODRIGUESMARTINS A, 2007, CURR BIOL, V17, P1465, DOI
   10.1016/j.cub.2007.07.034
   ROTHWELL WF, 2000, DROSOPHILA PROTOCOLS, P141
   SATHANANTHAN AH, 2001, ITAL J ANAT EMBRYOL, V106, P61
   SCHATTEN G, 1994, DEV BIOL, V165, P299
   SOROKIN SP, 1968, J CELL SCI, V3, P207
   STRNAD P, 2007, DEV CELL, V13, P203, DOI 10.1016/j.devcel.2007.07.004
   STRNAD P, 2008, TRENDS CELL BIOL, V18, P389
   TATES AD, 1971, CYTODIFFERENTIATION
   TEXADA MJ, 2008, J CELL SCI, V121, P1926, DOI 10.1242/jcs.026559
   THIBAULT ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314
   TOKUYASU KT, 1975, J ULTRA MOL STRUCT R, V53, P93
   TOKUYASU KT, 1975, J ULTRASTRUCT RES, V50, P117
   VARMARK H, 2007, CURR BIOL, V17, P1735, DOI 10.1016/i.cub.2007.09.031
   WILSON PG, 1997, DEV BIOL, V184, P207
NR 55
TC 13
PU GENETICS
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD MAY
PY 2009
VL 182
IS 1
BP 133
EP 144
DI 10.1534/genetics.109.101709
PG 12
SC Genetics & Heredity
GA 499IX
UT ISI:000270213800013
ER

PT J
AU Hines, KA
   Cryderman, DE
   Flannery, KM
   Yang, HB
   Vitalini, MW
   Hazelrigg, T
   Mizzen, CA
   Wallrath, LL
AF Hines, Karrie A.
   Cryderman, Diane E.
   Flannery, Kaitlin M.
   Yang, Hongbo
   Vitalini, Michael W.
   Hazelrigg, Tulle
   Mizzen, Craig A.
   Wallrath, Lori L.
TI Domains of Heterochromatin Protein 1 Required for Drosophila
   melanogaster Heterochromatin Spreading
SO GENETICS
LA English
DT Article
ID POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; ORIGIN
   RECOGNITION COMPLEX; HISTONE H3; PERICENTRIC HETEROCHROMATIN;
   CHROMATIN-STRUCTURE; HP1 LOCALIZATION; GENE-EXPRESSION;
   METHYLTRANSFERASE; METHYLATION
AB Centric regions of eukaryotic genomes are packaged into
   heterochromatin, which possesses I-lie ability to spread along the
   chromosome and silence gene expression. The process of spreading has
   been challenging to study at the molecular level due to repetitious
   sequences within centric regions. A heterochromatin protein 1 (HP1)
   tethering system was developed that generates "ectopic heterochromatin
   at sites within euchromatic regions of the Drosophila melanogaster
   genome. Using this system, we show that HP1 dimerization and die PxVxL
   interaction platform formed by dimerization of the HP1 chromo shadow
   domain are necessary, to spreading to a downstream reporter gene
   located 3.7 kb away. Surprisingly, either the HP1 chromo domain or the
   chromo shadow domain alone is sufficient. for spreading and silencing
   at a downstream reporter gene located 1.9 kb away. Spreading is
   dependent on at least two H3K9 methyltransferases, with SU(VAR)3-9
   playing a greater role at the 7-kb reporter and dSETDB1 predominately
   acting at the 1.9 kb reporter. These data Support a model whereby HP1
   takes part in multiple mechanisms of silencing and spreading.
C1 [Hines, Karrie A.; Cryderman, Diane E.; Flannery, Kaitlin M.; Vitalini, Michael W.; Wallrath, Lori L.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.
   [Yang, Hongbo; Mizzen, Craig A.] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA.
   [Hazelrigg, Tulle] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.
RP Wallrath, LL, Univ Iowa, Dept Biochem, 3136 MERF, Iowa City, IA 52242
   USA.
EM lori-wallrath@uiowa.edu
FU National Institutes of Health (NIH) [GM61511]; American Heart
   Association [0415328Z]; National Research Service [GM08574]; National
   Science Foundation (NSF) [MCB-0821893]
FX We thank members of the Wallrath lab for comments on the manuscript. We
   are grateful for research support from the National Institutes of
   Health (NIH) (GM61511) to L.L.W., a predoctoral fellowship to K.A.H.
   from the American Heart Association (0415328Z), art NIH Ruth L.
   Kirschtein National Research Service Award postdoctoral fellowship
   (GM08574) to M.W.V, a National Science Foundation (NSF) grant
   (MCB-0821893) to C.A.M., and an NSF grant to T.H.
CR ALVAREZVENEGAS R, 2002, GENE, V285, P25
   AYYANATHAN K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   BADUGU R, 2005, CHROMOSOMA, V113, P370, DOI 10.1007/s00412-004-0324-2
   BANNISTER AJ, 2001, NATURE, V410, P120
   BELYAEVA ES, 1991, CHROMOSOMA, V100, P453
   BRASHER SV, 2000, EMBO J, V19, P1587
   BRINK MC, 2006, HISTOCHEM CELL BIOL, V125, P53, DOI
   10.1007/s00418-005-0088-7
   BROWERTOLAND B, 2007, GENE DEV, V21, P2300, DOI 10.1101/gad.1564307
   BROWERTOLAND B, 2009, GENETICS, V181, P1303, DOI
   10.1534/genetics.108.100271
   CLOUGH E, 2007, DEVELOPMENT, V134, P157, DOI 10.1242/dev.02698
   COWIESON NP, 2000, CURR BIOL, V10, P517
   CRYDERMAN DE, 2005, DEV DYNAM, V232, P767, DOI 10.1002/dvdy.20310
   DANZER JR, 2004, DEVELOPMENT, V131, P3571, DOI 10.1242/dev.01223
   DENG H, 2008, DEVELOPMENT, V135, P699, DOI 10.1242/dev.015362
   EBERT A, 2004, GENE DEV, V18, P2973, DOI 10.1101/gad.323004
   EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923
   ELGIN SCR, 2003, CURR BIOL, V13, R895
   FANTI L, 1998, MOL CELL, V2, P527
   FANTI L, 2003, GENETICA, V117, P135
   HALE TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016
   HAYNES KA, 2006, CURR BIOL, V16, P2222, DOI 10.1016/j.cub.2006.09.035
   HUANG DW, 1998, J CELL BIOL, V142, P307
   IRVINE DV, 2006, SCIENCE, V313, P1134, DOI 10.1126/science.1128813
   JACOBS SA, 2001, EMBO J, V20, P5232
   JAMES TC, 1986, MOL CELL BIOL, V6, P3862
   JAMES TC, 1989, EUR J CELL BIOL, V50, P170
   KOTELNIKOV RN, 2009, NUCLEIC ACIDS RES, V37, P3254, DOI
   10.1093/nar/gkp167
   KRISTJUHAN A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI
   10.1073/pnas.1332299100
   LECHNER MS, 2000, MOL CELL BIOL, V20, P6449
   LECHNER MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI
   10.1016/j.bbrc.2005.04.016
   LI YH, 2002, P NATL ACAD SCI U S4, V99, P16462, DOI
   10.1073/pnas.162371699
   LI YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405
   LOCKE J, 1988, GENETICS, V120, P181
   MAISON C, 2002, NAT GENET, V30, P329
   MALONE CD, 2009, CELL, V137, P522, DOI 10.1016/j.cell.2009.03.040
   MUCHARDT C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194
   NIELSEN AL, 2001, MOL CELL, V7, P729
   PAK DTS, 1997, CELL, V91, P311
   PALBHADRA M, 2004, SCIENCE, V303, P669
   PERROD S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI
   10.1007/s00018-003-3245-x
   ROBINETT CC, 1996, J CELL BIOL 2, V135, P1685
   ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041
   RUBIN GM, 1982, SCIENCE, V218, P348
   SAKAGUCHI A, 2008, GENETICS, V179, P317, DOI 10.1534/genetics.108.087650
   SCHOTTA G, 2002, EMBO J, V21, P1121
   SCHOTTA G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   SCHULTZ DC, 2002, GENE DEV, V16, P919
   SCHWENDEMANN A, 2008, P NATL ACAD SCI USA, V105, P204, DOI
   10.1073/pnas.0705595105
   SEUM C, 2007, PLOS GENET, V3, P709, ARTN e76
   STRUKOV YG, 2009, BIOPHYS J, V96, P1617, DOI 10.1016/j.bpj.2008.10.051
   SUKA N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017
   SUN FL, 2001, MOL CELL BIOL, V21, P2867
   SUN FL, 2004, MOL CELL BIOL, V24, P8210, DOI
   10.1128/MCB.24.18.8210.8220.2004
   TALBERT PB, 2000, GENETICS, V154, P259
   TARTOF KD, 1989, DEV GENET, V10, P162
   THIRU A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088
   TZENG TY, 2007, P NATL ACAD SCI USA, V104, P12691, DOI
   10.1073/pnas.0705534104
   VAZQUEZ J, 2002, CURR BIOL, V12, P1473
   VERDEL A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686
   VERSCHURE PJ, 2005, MOL CELL BIOL, V25, P4552, DOI
   10.1128/MCB.25.11.4552-4564.2005
   WALLRATH LL, 1995, GENE DEV, V9, P1263
   WEILER KS, 1995, ANNU REV GENET, V29, P577
   WILLIAMS L, 2000, TRENDS PLANT SCI, V5, P239
   YAMAMOTO K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI
   10.1016/S0006-291X(02)03021-8
   YANG HB, 2008, J BIOL CHEM, V283, P12085, DOI 10.1074/jbc.M707974200
   YOON J, 2008, PLOS ONE, V3, ARTN e2234
   ZHANG CL, 2002, MOL CELL BIOL, V22, P7302, DOI
   10.1128/MCB.22.20.7302-7312.2002
NR 67
TC 2
PU GENETICS
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD AUG
PY 2009
VL 182
IS 4
BP 967
EP 977
DI 10.1534/genetics.109.105338
PG 11
SC Genetics & Heredity
GA 499IZ
UT ISI:000270214000005
ER

PT J
AU Uebele, VN
   Nuss, CE
   Fox, SV
   Garson, SL
   Cristescu, R
   Doran, SM
   Kraus, RL
   Santarelli, VP
   Li, YX
   Barrow, JC
   Yang, ZQ
   Schlegel, KAS
   Rittle, KE
   Reger, TS
   Bednar, RA
   Lemaire, W
   Mullen, FA
   Ballard, JE
   Tang, CY
   Dai, G
   McManus, OB
   Koblan, KS
   Renger, JJ
AF Uebele, Victor N.
   Nuss, Cindy E.
   Fox, Steven V.
   Garson, Susan L.
   Cristescu, Razvan
   Doran, Scott M.
   Kraus, Richard L.
   Santarelli, Vincent P.
   Li, Yuxing
   Barrow, James C.
   Yang, Zhi-Qiang
   Schlegel, Kelly-Ann S.
   Rittle, Kenneth E.
   Reger, Thomas S.
   Bednar, Rodney A.
   Lemaire, Wei
   Mullen, Faith A.
   Ballard, Jeanine E.
   Tang, Cuyue
   Dai, Ge
   McManus, Owen B.
   Koblan, Kenneth S.
   Renger, John J.
TI Positive Allosteric Interaction of Structurally Diverse T-Type Calcium
   Channel Antagonists
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE T-type calcium channel; CaV3; CACNA1I; Synergy; Radioligand; Absence
   epilepsy; Seizure
ID CA2+ CHANNELS; ABSENCE EPILEPSY; BLOCKERS; MECHANISMS; PHARMACOLOGY;
   DISCOVERY; CANCER; PROLIFERATION; INHIBITORS; THALAMUS
AB Low-voltage-activated (T-type) calcium channels play a role in diverse
   physiological responses including neuronal burst firing, hormone
   secretion, and cell growth. To better understand the biological role
   and therapeutic potential of the target, a number of structurally
   diverse antagonists have been identified. Multiple drug interaction
   sites have been identified for L-type calcium channels, suggesting a
   similar possibility exists for the structurally related T-type
   channels. Here, we radiolabel a novel amide T-type calcium channel
   antagonist (TTA-A1) and show that several known antagonists, including
   mibefradil, flunarizine, and pimozide, displace binding in a
   concentration-dependent manner. Further, we identify a novel
   quinazolinone T-type antagonist (TTA-Q4) that enhanced amide
   radioligand binding, increased affinity in a saturable manner and
   slowed dissociation. Functional evaluation showed these compounds to be
   state-dependent antagonists which show a positive allosteric
   interaction. Consistent with slowing dissociation, the duration of
   efficacy was prolonged when compounds were co-administered to WAG/Rij
   rats, a genetic model of absence epilepsy. The development of a T-type
   calcium channel radioligand has been used to demonstrate structurally
   distinct TTAs interact at allosteric sites and to confirm the potential
   for synergistic inhibition of T-type calcium channels with structurally
   diverse antagonists.
C1 [Uebele, Victor N.; Nuss, Cindy E.; Fox, Steven V.; Garson, Susan L.; Cristescu, Razvan; Doran, Scott M.; Kraus, Richard L.; Santarelli, Vincent P.; Li, Yuxing; Renger, John J.] Merck Res Labs, Dept Depress & Circadian Disorders, West Point, PA 19486 USA.
   [Barrow, James C.; Yang, Zhi-Qiang; Schlegel, Kelly-Ann S.; Rittle, Kenneth E.; Reger, Thomas S.; Bednar, Rodney A.; Lemaire, Wei; Mullen, Faith A.] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA.
   [Dai, Ge; McManus, Owen B.; Koblan, Kenneth S.] Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA.
RP Uebele, VN, Merck Res Labs, Dept Depress & Circadian Disorders, 770
   Sumneytown Pike,WP26-270, West Point, PA 19486 USA.
EM victor_uebele@merck.com
CR AVANZINI G, 2000, CLIN NEUROPHYSIOL S2, V111, S19
   BARRETT TD, 2005, MOL INTERV, V5, P84, DOI 10.1124/mi.5.2.6
   BARROW JC, 2006, 2006098969, WO
   BARROW JC, 2007, 2007120729, WO
   BARTON ME, 2005, EUR J PHARMACOL, V521, P79, DOI
   10.1016/j.ejphar.2005.08.017
   BOURINET E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515
   BROICHER T, 2008, MOL CELL NEUROSCI, V39, P384, DOI
   10.1016/j.mcn.2008.07.012
   CHEN XL, 1999, AM J PHYSIOL-RENAL, V276, F674
   CONTRERAS D, 2006, CNS NEUROL DISORD-DR, V5, P571
   DAI G, 2008, ASSAY DRUG DEV TECHN, V6, P195, DOI 10.1089/adt.2008.136
   DODDAREDDY MR, 2004, BIOORGAN MED CHEM, V12, P1605, DOI
   10.1016/j.bmc.2004.01.034
   DODDAREDDY MR, 2007, BIOORGAN MED CHEM, V15, P1091, DOI
   10.1016/j.bmc.2006.10.013
   ERNST WL, 2009, J NEUROSCI, V29, P1615, DOI
   10.1523/JNEUROSCI.2081-08.2009
   ERTEL EA, 2000, NEURON, V25, P533
   GLOSSMANN H, 1984, J CARDIOVASC PHAR S4, V6, S608
   GRAY LS, 2006, CELL CALCIUM, V40, P115, DOI 10.1016/j.ceca.2006.04.014
   HOCKERMAN GH, 1997, ANNU REV PHARMACOL, V37, P361
   HORN R, 1988, J GEN PHYSIOL, V92, P145
   IJJAALI I, 2007, CHANNELS, V1, P300
   KIM D, 2001, NEURON, V31, P35
   LACINOVA L, 2004, CURR DRUG TARGETS CN, V3, P105
   LLINAS RR, 1999, P NATL ACAD SCI USA, V96, P15222
   LORY P, 2007, EXPERT OPIN THER TAR, V11, P717, DOI
   10.1517/14728222.11.5.717
   LOTSHAW DP, 2001, MOL CELL ENDOCRINOL, V175, P157
   MAY LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI
   10.1146/annurev.pharmtox.47.120505.105159
   MCCORMICK DA, 1997, ANNU REV NEUROSCI, V20, P185
   MCCORMICK DA, 2001, ANNU REV PHYSIOL, V63, P815
   MCCORMICK DA, 2002, INT REV NEUROBIOL, V49, P99
   MCGIVERN JG, 2006, CNS NEUROL DISORD-DR, V5, P587
   MITTERDORFER J, 1998, J BIOENERG BIOMEMBR, V30, P319
   PANNER A, 2006, CELL CALCIUM, V40, P253, DOI 10.1016/j.ceca.2006.04.029
   SHIPE WD, 2008, J MED CHEM, V51, P3692, DOI 10.1021/jm800419w
   TAYLOR JT, 2008, CANCER LETT, V267, P116, DOI
   10.1016/j.canlet.2008.03.032
   TAYLOR JT, 2008, WORLD J GASTROENTERO, V14, P4984, DOI
   10.3748/wjg.14.4984
   TODOROVIC SM, 2006, CNS NEUROL DISORD-DR, V5, P639
   TRIGGLE DJ, 1991, AM J HYPERTENS, V4, S422
   TRIGGLE DJ, 1992, CLEV CLIN J MED, V59, P617
   TRIGGLE DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI
   10.1016/j.bcp.2007.01.016
   UEBELE VN, 2009, J CLIN INVEST, V119, P1659, DOI 10.1172/JCI36954
   UEBELE VN, 2009, NEUROREPORT, V20, P257, DOI
   10.1097/WNR.0b013e3283200111
   XIA MH, 2004, ANAL BIOCHEM, V327, P74, DOI 10.1016/j.ab.2004.01.003
   XIE XM, 2007, ASSAY DRUG DEV TECHN, V5, P191, DOI 10.1089/adt.2006.054
   YANG ZQ, 2008, J MED CHEM, V51, P6471, DOI 10.1021/jm800830n
   ZAMPONI GW, 2008, BRAIN RES REV, V60, P84
NR 44
TC 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD NOV
PY 2009
VL 55
IS 2
BP 81
EP 93
DI 10.1007/s12013-009-9057-4
PG 13
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 495WO
UT ISI:000269926100002
ER

PT J
AU Fandy, TE
   Herman, JG
   Kerns, P
   Jiemjit, A
   Sugar, EA
   Choi, SH
   Yang, AS
   Aucott, T
   Dauses, T
   Odchimar-Reissig, R
   Licht, J
   McConnell, MJ
   Nasrallah, C
   Kim, MKH
   Zhang, WJ
   Sun, YZ
   Murgo, A
   Espinoza-Delgado, I
   Oteiza, K
   Owoeye, I
   Silverman, LR
   Gore, SD
   Carraway, HE
AF Fandy, Tamer E.
   Herman, James G.
   Kerns, Patrick
   Jiemjit, Anchalee
   Sugar, Elizabeth A.
   Choi, Si-Ho
   Yang, Allen S.
   Aucott, Timothy
   Dauses, Tianna
   Odchimar-Reissig, Rosalie
   Licht, Jonathan
   McConnell, Melanie J.
   Nasrallah, Chris
   Kim, Marianne K. H.
   Zhang, Weijia
   Sun, Yezou
   Murgo, Anthony
   Espinoza-Delgado, Igor
   Oteiza, Katharine
   Owoeye, Ibitayo
   Silverman, Lewis R.
   Gore, Steven D.
   Carraway, Hetty E.
TI Early epigenetic changes and DNA damage do not predict clinical
   response in an overlapping schedule of 5-azacytidine and entinostat in
   patients with myeloid malignancies
SO BLOOD
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; 5-AZA-2'-DEOXYCYTIDINE DECITABINE
   TREATMENT; MYELODYSPLASTIC SYNDROME; VALPROIC ACID; METHYLTRANSFERASE
   INHIBITORS; HEMATOPOIETIC MALIGNANCIES; HEMATOLOGIC MALIGNANCIES;
   METHYLATION STATUS; HUMAN CANCER; LEUKEMIA
AB Sequential administration of DNA methyltransferase (DNMT) inhibitors
   and histone deacetylase (HDAC) inhibitors has demonstrated clinical
   efficacy in patients with hematologic malignancies. However, the
   mechanism behind their clinical efficacy remains controversial. In this
   study, the methylation dynamics of 4 TSGs (p15(INK4B), CDH-1, DAPK-1,
   and SOCS-1) were studied in sequential bone marrow samples from 30
   patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia
   (AML) who completed a minimum of 4 cycles of therapy with 5-azacytidine
   and entinostat. Reversal of promoter methylation after therapy was
   observed in both clinical responders and nonresponders across all
   genes. There was no association between clinical response and either
   baseline methylation or methylation reversal in the bone marrow or
   purified CD34(+) population, nor was there an association with change
   in gene expression. Transient global hypomethylation was observed in
   samples after treatment but was not associated with clinical response.
   Induction of histone H3/H4 acetylation and the DNA damage-associated
   variant histone gamma-H2AX was observed in peripheral blood samples
   across all dose cohorts. In conclusion, methylation reversal of
   candidate TSGs during cycle 1 of therapy was not predictive of clinical
   response to combination "epigenetic" therapy. This trial is registered
   with http://www.clinicaltrials.gov under NCT00101179. (Blood.
   2009;114:2764-2773)
C1 [Fandy, Tamer E.; Herman, James G.; Kerns, Patrick; Jiemjit, Anchalee; Aucott, Timothy; Dauses, Tianna; Oteiza, Katharine; Owoeye, Ibitayo; Gore, Steven D.; Carraway, Hetty E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Sugar, Elizabeth A.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Sugar, Elizabeth A.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Choi, Si-Ho; Yang, Allen S.] Univ So Calif, Norris Canc Ctr, Div Hematol, Los Angeles, CA USA.
   [Odchimar-Reissig, Rosalie; Silverman, Lewis R.] Mt Sinai Med Ctr, Div Med Oncol, New York, NY 10029 USA.
   [Licht, Jonathan; Kim, Marianne K. H.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA.
   [McConnell, Melanie J.] Malaghan Inst Med Res, Wellington, New Zealand.
   [Nasrallah, Chris] Univ Calif Berkeley, Ctr Theoret Evolutionary Genet, Berkeley, CA 94720 USA.
   [Zhang, Weijia] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA.
   [Sun, Yezou] Mt Sinai Sch Med, Personalized Med Res Program, New York, NY USA.
   [Murgo, Anthony; Espinoza-Delgado, Igor] NCI, Canc Therapy Evaluat Program, Rockville, MD USA.
RP Gore, SD, 1650 Orleans St,Canc Res Bldg 1,Rm 288, Baltimore, MD 21231
   USA.
EM gorest@jhmi.edu
CR *NAT CTR BIOT INF, GEN EXPR OMN GEO
   BAKKENIST CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   BAYLIN SB, 2005, NAT CLIN PRACT ON S1, V2, S1
   BAYLIN SB, 2005, NAT CLIN PRACT ON S1, V2, S4
   BHALLA KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   BLUM W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169
   BRUECKNER B, 2007, CANCER J, V13, P17
   CAMERON EE, 1999, BLOOD, V94, P2445
   CAMERON EE, 1999, NAT GENET, V21, P103
   CHESON BD, 2000, BLOOD, V96, P3671
   CHOI SH, 2007, BRIT J HAEMATOL, V138, P616, DOI
   10.1111/j.1365-2141.2007.06707.x
   DASKALAKIS M, 2002, BLOOD, V100, P2957
   DESMET C, 1996, P NATL ACAD SCI USA, V93, P7149
   ESTELLER M, 2001, CANCER RES, V61, P3225
   FANDY T, 2007, AACR M ABSTR, P2483
   FANDY TE, 2007, CANCER J, V13, P40
   GALM O, 2005, ANN HEMATOL S1, V84, P39, DOI 10.1007/s00277-005-0005-0
   GARCIAMANERO G, 2006, BLOOD, V108, P3271, DOI
   10.1182/blood-2006-03-009142
   GOJO I, 2007, BLOOD, V109, P2781, DOI 10.1182/blood-2006-05-021873
   GORE SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   GORE SD, 2008, CANC CONTROL S, V15, P40
   HERMAN JG, 1996, P NATL ACAD SCI USA, V93, P9821
   ISSA JPJ, 2004, BLOOD, V103, P1635
   JIEMJIT A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   JONES PA, 1980, CELL, V20, P85
   KANTARJIAN H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162
   KARPF AR, 2002, ONCOGENE, V21, P5496
   LEONE G, 2003, CLIN IMMUNOL, V109, P89, DOI
   10.1016/S1521-6616(03)00207-9
   LYKO F, 2005, J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   MURGO AJ, 2005, SEMIN ONCOL, V32, P458, DOI
   10.1053/j.seminoncol.2005.07.004
   OKI Y, 2008, BLOOD, V111, P2382, DOI 10.1182/blood-2007-07-103960
   PALII SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   RAJ K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796
   ROSATO RR, 2005, EXPERT OPIN THER TAR, V9, P809, DOI
   10.1517/14728222.9.4.809
   SAITO A, 1999, P NATL ACAD SCI USA, V96, P4592
   SCHAEFER HE, 2005, ANN HEMATOL S1, V84, P67, DOI
   10.1007/s00277-005-0034-8
   SIGALOTTI L, 2003, BLOOD, V101, P4644
   SILVERMAN LR, 2005, NAT CLIN PRACT ON S1, V2, S12
   SILVERMAN LR, 2006, J CLIN ONCOL, V24, P3895, DOI
   10.1200/JCO.2005.05.4346
   SORIANO AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576
   STRESEMANN C, 2008, MOL CANCER THER, V7, P2998, DOI
   10.1158/1535-7163.MCT-08-0411
   SUZUKI H, 2002, NAT GENET, V31, P141
   YANG AS, 2004, NUCLEIC ACIDS RES, V32, ARTN e38
   YANG AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385
NR 44
TC 40
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 24
PY 2009
VL 114
IS 13
BP 2764
EP 2773
DI 10.1182/blood-2009-02-203547
PG 10
SC Hematology
GA 498KK
UT ISI:000270138600029
ER

PT J
AU Lin, CC
   Kuo, CT
   Cheng, CY
   Wu, CY
   Lee, CW
   Hsieh, HL
   Lee, IT
   Yang, CM
AF Lin, Chih-Chung
   Kuo, Chang-Ting
   Cheng, Ching-Yi
   Wu, Cheng-Ying
   Lee, Chiang-Wen
   Hsieh, Hsi-Lung
   Lee, I-Ta
   Yang, Chuen-Mao
TI IL-1 beta promotes A549 cell migration via MAPKs/AP-1-and NF-kappa
   B-dependent matrix metalloproteinase-9 expression
SO CELLULAR SIGNALLING
LA English
DT Article
DE Cytokines; Matrix metalloproteinases; Mitogen-activated protein
   kinases; Transcription factors; Pulmonary epithelial cells
ID SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA;
   P42/P44 MAPK; TNF-ALPHA; P38 MAPK; MATRIX METALLOPROTEINASES;
   EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; DIVERGENT REGULATION
AB Matrix metalloproteinases (MMPs), in particular MMP-9, is induced by
   cytokines including IL-1 beta and contributes to airway injury and
   remodeling. However, the mechanisms underlying IL-1 beta-induced MMP-9
   expression and cell migration in human A549 cells remain unclear. Here,
   we report that the IL-1 beta-induced MMP-9 gene expression was mediated
   through the activation of p42/p44 MAPK, p38 MAPK, and JNK1/2 in A549
   cells, determined by zymographic RT-PCR. and Westem blotting. The
   involvement of MAPKs in the IL-1 beta-induced responses was further
   ensured by transfection with siRNA of MEK1, p42, p38, or JNK2.
   Moreover, the IL-1 beta-induced MMP-9 gene expression was also mediated
   through the translocation of NF-kappa B (p65) into the nucleus and the
   degradation of I kappa B alpha In addition, the IL-1 beta-induced c-Jun
   phosphorylation was reduced by pretreatment with U0126 or SP600125.
   ILAP stimulated the transcriptional activity of wild-type MMP-9
   promoter in A549 cells, which was inhibited by U0126, SB203580,
   SP600125, and helenalin. In contrast, IL-1 beta had no effect on the
   cells transfected with a NF-kappa B-mutated MMP-9 promoter construct,
   suggesting that NF-kappa B is required for this response. Finally, the
   IL-1 beta-inducecl MMP-9 expression led to cell migration which was
   attenuated by pretreatment with U0126, SB203580, SP600125, helenalin,
   or MMP-2/9 inhibitor. These results suggested that in A549 cells, the
   activation of p42/p44 MAPK p38 MAPK JNK1/2, NF-kappa B, and AP-1 are
   essential for the IL-1 beta-induced MMP-9 gene expression and cell
   migration. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Cheng, Ching-Yi; Wu, Cheng-Ying; Lee, I-Ta; Yang, Chuen-Mao] Chang Gung Univ, Dept Pharmacol, Tao Yuan, Taiwan.
   [Lin, Chih-Chung] Chang Gung Mem Hosp, Tao Yuan, Taiwan.
   [Kuo, Chang-Ting] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Dept Pharm, Taipei, Taiwan.
   [Lin, Chih-Chung] Chang Gung Univ, Dept Anesthet, Tao Yuan, Taiwan.
   [Lee, Chiang-Wen] Chang Gung Inst Technol, Div Basic Med Sci, Dept Nursing, Chiayi, Taiwan.
   [Hsieh, Hsi-Lung] Chang Gung Inst Technol, Dept Nursing, Tao Yuan, Taiwan.
RP Yang, CM, Chang Gung Univ, Dept Pharmacol, 259 Wen Hwa 1st Rd, Tao
   Yuan, Taiwan.
EM chuenmao@mail.cgu.edu.tw
CR ADCOCK IM, 2008, LANCET, V372, P1073
   ARAI K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255
   ATKINSON JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI
   10.1165/rcmb.2002-0166TR
   BARNES PJ, 1997, NEW ENGL J MED, V336, P1066
   BENBOW U, 1997, MATRIX BIOL, V15, P519
   BENNETT BL, 2001, P NATL ACAD SCI USA, V98, P13681
   BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958
   CUENDA A, 1995, FEBS LETT, V364, P229
   DANIELS SE, 1996, NATURE, V383, P247
   EBERHARDT W, 2000, J IMMUNOL, V165, P5788
   EDER J, 1997, TRENDS PHARMACOL SCI, V18, P319
   ELKINGTON PT, 2007, AM J RESP CELL MOL, V37, P431, DOI
   10.1165/rcmb.2007-0011OC
   FABUNMI RP, 1996, BIOCHEM J 1, V315, P335
   FAVATA MF, 1998, J BIOL CHEM, V273, P18623
   GHOSH S, 1998, ANNU REV IMMUNOL, V16, P225
   HAN J, 1994, SCIENCE, V265, P808
   HAN ZN, 2001, J CLIN INVEST, V108, P73
   HOLGATE ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262
   HOZUMI A, 2001, AM J PHYSIOL-LUNG C, V281, P1444
   HSIEH HL, 2004, CELL SIGNAL, V16, P1163, DOI
   10.1016/j.cellsig.2004.03.021
   HSIEH HL, 2008, GLIA, V56, P619, DOI 10.1002/glia.20637
   KELLY EAB, 2000, AM J RESP CRIT CARE, V162, P1157
   KYRIAKIS JM, 1994, NATURE, V369, P156
   LAITINEN LA, 1995, INT ARCH ALLERGY IMM, V107, P215
   LEE CW, 2007, AM J PHYSIOL-LUNG C, V292, L799, DOI
   10.1152/ajplung.00311.2006
   LIANG KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992
   LIN CC, 2004, CELL SIGNAL, V16, P597, DOI 10.1016/j.cellsig.2003.10.002
   LIN FS, 2005, J CELL PHYSIOL, V202, P464, DOI 10.1002/jcp.20142
   LYSS G, 1998, J BIOL CHEM, V273, P33508
   MAUTINO G, 1997, AM J RESP CELL MOL, V17, P583
   MOSSMAN BT, 2006, AM J RESP CELL MOL, V34, P666, DOI
   10.1165/rcmb.2006-0047SF
   NIE M, 2003, MOL CELL BIOL, V23, P9233, DOI
   10.1128/MCB.23.24.9233-9244.2003
   OKADA Y, 1992, J BIOL CHEM, V267, P21712
   RIES C, 1995, BIOL CHEM H-S, V376, P345
   SCHWINGSHACKL A, 1999, J ALLERGY CLIN IMMUN, V104, P983
   SHAULIAN E, 2001, ONCOGENE, V20, P2390
   STAMENKOVIC I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   SUBBARAMAIAH K, 2000, J BIOL CHEM, V275, P14838
   VECIL GG, 2000, J NEUROSCI RES, V61, P212
   VU TH, 2000, GENE DEV, V14, P2123
   WANG CC, 2005, AM J PHYSIOL-LUNG C, V288, L227, DOI
   10.1152/ajplung.00224.2004
   WANG XY, 2002, J NEUROTRAUM, V19, P615
   WU CY, 2004, J NEUROCHEM, V90, P1477, DOI
   10.1111/j.1471-4159.2004.02682.x
   YANG CM, 2000, BRIT J PHARMACOL, V130, P891
   YAO PM, 1997, AM J PHYSIOL-LUNG C, V273, L866
   YOKOO T, 1996, AM J PHYSIOL-RENAL, V270, F123
   ZEIGLER ME, 1999, J CELL PHYSIOL, V180, P271
NR 47
TC 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD NOV
PY 2009
VL 21
IS 11
BP 1652
EP 1662
DI 10.1016/j.cellsig.2009.07.002
PG 11
SC Cell Biology
GA 496VJ
UT ISI:000270007300013
ER

PT J
AU Hoshida, Y
   Nijman, SMB
   Kobayashi, M
   Chan, JA
   Brunet, JP
   Chiang, DY
   Villanueva, A
   Newell, P
   Ikeda, K
   Hashimoto, M
   Watanabe, G
   Gabriel, S
   Friedman, SL
   Kumada, H
   Llovet, JM
   Golub, TR
AF Hoshida, Yujin
   Nijman, Sebastian M. B.
   Kobayashi, Masahiro
   Chan, Jennifer A.
   Brunet, Jean-Philippe
   Chiang, Derek Y.
   Villanueva, Augusto
   Newell, Philippa
   Ikeda, Kenji
   Hashimoto, Masaji
   Watanabe, Goro
   Gabriel, Stacey
   Friedman, Scott L.
   Kumada, Hiromitsu
   Llovet, Josep M.
   Golub, Todd R.
TI Integrative Transcriptome Analysis Reveals Common Molecular Subclasses
   of Human Hepatocellular Carcinoma
SO CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; BETA-CATENIN; INTRAHEPATIC RECURRENCE; FUNCTIONAL
   GENOMICS; HUMAN CANCER; TGF-BETA; CLASSIFICATION; DEFINES; PROGRESSION;
   INTERFERON
AB Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and
   prior attempts to develop genomic-based classification for HCC have
   yielded highly divergent results, indicating difficulty in identifying
   unified molecular anatomy. We performed a meta-analysis of gene
   expression profiles in data sets from eight independent patient cohorts
   across the world. In addition, aiming to establish the real world
   applicability of a classification system, we profiled 118
   formalin-fixed, paraffin-embedded tissues from an additional patient
   cohort. A total of 603 patients were analyzed, representing the major
   etiologies of HCC (hepatitis B and C) collected from Western and
   Eastern countries. We observed three robust HCC subclasses (termed S1,
   S2, and S3), each correlated with clinical parameters such as tumor
   size, extent of cellular differentiation, and serum alpha-fetoprotein
   levels. An analysis of the components of the signatures indicated that
   S1 reflected aberrant activation of the WNT signaling pathway, S2 was
   characterized by proliferation as well as MYC and AKT activation, and
   S3 was associated with hepatocyte differentiation. Functional studies
   indicated that the WNT pathway activation signature characteristic of
   St tumors was not simply the result of beta-catenin mutation but rather
   was the result of transforming growth factor-beta activation, thus
   representing a new mechanism of WNT pathway activation in HCC. These
   experiments establish the first consensus classification framework for
   HCC based on gene expression profiles and highlight the power of
   integrating multiple data sets to define a robust molecular taxonomy of
   the disease. [Cancer Res 2009;69(18):7385-92]
C1 [Hoshida, Yujin; Nijman, Sebastian M. B.; Chan, Jennifer A.; Brunet, Jean-Philippe; Chiang, Derek Y.; Gabriel, Stacey; Golub, Todd R.] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA.
   [Hoshida, Yujin; Nijman, Sebastian M. B.; Chan, Jennifer A.; Brunet, Jean-Philippe; Chiang, Derek Y.; Gabriel, Stacey; Golub, Todd R.] Harvard Univ, Cambridge, MA 02138 USA.
   [Hoshida, Yujin; Golub, Todd R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Golub, Todd R.] Harvard Univ, Childrens Hosp Boston, Sch Med, Boston, MA 02115 USA.
   [Golub, Todd R.] Howard Hughes Med Inst, Boston, MA 02115 USA.
   [Nijman, Sebastian M. B.] Austrian Acad Sci, Ctr Mol Med, A-1010 Vienna, Austria.
   [Kobayashi, Masahiro; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Kumada, Hiromitsu] Toranomon Gen Hosp, Tokyo, Japan.
   [Chan, Jennifer A.] Univ Calgary, Calgary, AB, Canada.
   [Villanueva, Augusto; Llovet, Josep M.] IDIBAPS, Hosp Clin, CIBERehd, Barcelona Clin Liver Canc Grp,Liver Unit, Barcelona, Spain.
   [Llovet, Josep M.] Inst Catalana Recerca Estudis Avancats, Barcelona, Spain.
   [Newell, Philippa; Friedman, Scott L.; Llovet, Josep M.] Mt Sinai Sch Med, Liver Canc Program, New York, NY USA.
RP Golub, TR, Harvard Univ, Broad Inst, 7 Cambridge Ctr, Cambridge, MA
   02142 USA.
EM golub@broad.mit.edu
FU NIH/National Cancer Institute [5U54 CA112962-03]; NIH/National
   Institutes of Diabetes, Digestive and Kidney Diseases [1R01DK076986];
   NIH (Spain) [SAF-2007-61898]; Samuel Waxman Cancer Research Foundation
   ; Charles A. King Trust fellowship ; Netherlands Organisation for
   Scientific Research (Rubicon) ; Dutch Cancer Society fellowships 
FX Grant support: NIH/National Cancer Institute grant 5U54 CA112962-03
   (T.R. Golub), NIH/National Institutes of Diabetes, Digestive and Kidney
   Diseases grant 1R01DK076986 (J.M. Llovet), NIH (Spain) grant I+D
   Program SAF-2007-61898 (J.M. Llovet), and Samuel Waxman Cancer Research
   Foundation. Y. Hoshida is supported by Charles A. King Trust
   fellowship. S.M.B. Nijman was supported by the Netherlands Organisation
   for Scientific Research (Rubicon) and Dutch Cancer Society fellowships.
   The costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be hereby marked
   advertisement in accordance with 18 U.S.C. Section 1734 solely to
   indicate this fact.
   We thank Menno Creyghton for reagents and helpful suggestion; So Young
   Kim, Ron Firestein, William Hahn. and David Root for the shRNA
   constructs; Megan Hanna for technical help; Weijia Zhang for critical
   reading of the manuscript; and Jadwiga. Grabarek and Mariko Kobayashi
   for general support.
CR BOYAULT S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467
   BREUHAHN K, 2004, CANCER RES, V64, P6058
   BRUIX J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933
   BRUNET JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI
   10.1073/pnas.0308531101
   CHEN X, 2002, MOL BIOL CELL, V13, P1929
   CHIANG DY, 2008, CANCER RES, V68, P6779, DOI
   10.1158/0008-5472.CAN-08-0742
   COULOUARN C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283
   EISERAG HB, 2007, GASTROENTEROLOGY, V132, P2557
   FAN JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504
   FARAZI PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   FISCHER ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121
   GIANNELLI G, 2005, GASTROENTEROLOGY, V129, P1375, DOI
   10.1053/j.gastro.2005.09.055
   HOSHIDA Y, 2007, PLOS ONE, V2, ARTN e1195
   HOSHIDA Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525
   HOSHIDA Y, 2009, EXPERT REV GASTROENT, V3, P101
   IIZUKA N, 2003, LANCET, V361, P923
   IMAMURA H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4
   JIAN HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   KAPOSINOVAK P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236
   LEE JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375
   LEE JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481
   LEE JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377
   LLOVET JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506
   MAZZAFERRO V, 2006, HEPATOLOGY, V44, P1543, DOI 10.1002/hep.21415
   MIDORIKAWA Y, 2004, CANCER RES, V64, P7263
   MILLER JR, 1996, GENE DEV, V10, P2527
   MUTO Y, 1996, NEW ENGL J MED, V334, P1561
   SAHIN F, 2004, CLIN CANCER RES, V10, P8421
   SUBRAMANIAN A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI
   10.1073/pnas.0506580102
   THORGEIRSSON SS, 2006, HEPATOLOGY S1, V43, S145, DOI 10.1002/hep.21063
   VILLANUEVA A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171
   VILLANUEVA A, 2008, GASTROENTEROLOGY, V135, P1972, DOI
   10.1053/j.gastro.2008.08.008
   VOUSDEN KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   XU L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344
   YAMASHITA T, 2008, CANCER RES, V68, P1451, DOI
   10.1158/0008-5472.CAN-07-6013
   YE QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
   ZAVADIL J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   ZUCMANROSSI J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824
NR 38
TC 39
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD SEP 15
PY 2009
VL 69
IS 18
BP 7385
EP 7392
DI 10.1158/0008-5472.CAN-09-1089
PG 8
SC Oncology
GA 496FC
UT ISI:000269954000033
ER

PT J
AU Zhang, X
   Zhang, CS
   Liu, YC
   Yang, XQ
   Xiong, SH
   Wen, Y
   Jiang, EP
   Li, R
   Zhang, ZY
   Liu, F
   Ye, Y
AF Zhang, Xi
   Zhang, Chuan-Sen
   Liu, Yan-Chun
   Yang, Xiang-Qun
   Xiong, Shao-Hu
   Wen, Yu
   Jiang, Er-Peng
   Li, Rui
   Zhang, Zhi-Ying
   Liu, Fang
   Ye, Yong
TI Isolation, Culture and Characterization of Cardiac Progenitor Cells
   Derived from Human Embryonic Heart Tubes
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Cardiac pacemaking cells; Cardiac progenitor cells; Cardiomyocytes;
   Smooth muscle cells
ID GATA-4 TRANSCRIPTION FACTOR; STEM-CELLS; MYOCARDIAL REGENERATION;
   INFARCTED MYOCARDIUM; CONDUCTION SYSTEM; PRECURSOR CELLS;
   SMOOTH-MUSCLE; ADULT; DIFFERENTIATION; MULTIPOTENT
AB A variety of studies have reported on the isolation and expansion of
   cardiac stem cells from adult hearts. However, there is little
   information concerning cardiac stem/progenitor cells derived from
   embryonic hearts/heart tubes. To provide more evidence for embryonic
   heart-derived stem/progenitor cells, Nkx2.5+ human cardiac progenitor
   cells (hCPCs) were isolated and cloned from human heart tubes. The
   cells stained positive for Nkx2.5 and Oct-4, and negative for
   alpha-smooth muscle actin (alpha-SMA), cytokeratin, factor-VIII,
   alpha-sarcomeric actin and c-Kit. GATA-4 expression of Nkx2.5+ hCPCs
   was higher than that of embryonic limb bud mesenchymal cells of the
   control group (p < 0.05). These cells were passaged continuously for >3
   months (23 passages) and proliferated actively in vitro. After being
   treated with 5-azacytidine, Nkx2.5+ hCPCs underwent cardiomyogenic
   differentiation. Ultrastructural observation confirmed that the
   longitudinal section of these cardiomyogenic differentiation cells
   clearly revealed typical sarcomeres and intercalated discs. alpha-MHC,
   alpha-sarcomeric actin and GATA-4 levels were increased in Nkx2.5+
   hCPCs treated with 5-azacytidine compared to untreated cells. Nkx2.5+
   hCPCs exhibited positive staining and had a higher expression for
   alpha-SMA when cocultured with canine vascular endothelial cells. After
   Nkx2.5+ hCPCs were treated with endothelin-1, all cells displayed
   spontaneous electrical activity and spontaneous beating. Connexin-40
   and -45 were stained positive in the treated cells. In conclusion,
   Nkx2.5+ hCPCs derived from heart tubes have been isolated and cloned in
   vitro. These cells are capable of long-term self-renewal and possess a
   potential to differentiate into cardiac muscle-like cells, cardiac
   pacemaking cells and smooth muscle-like cells. They could have a
   significant impact on cardiac regeneration medicine and developmental
   biology. Copyright (C) 2009 S. Karger AG, Basel
C1 [Zhang, Chuan-Sen] Mil Med Coll 2, Inst Biomed Engn, Dept Anat, Shanghai 200433, Peoples R China.
RP Zhang, CS, Mil Med Coll 2, Inst Biomed Engn, Dept Anat, 800 Xiangyin
   Rd, Shanghai 200433, Peoples R China.
EM chuansen@yahoo.com
FU National Natural Science Foundation of China [30772158]; Shanghai
   Natural Science Foundation of China [07ZR14140, 05JC14045, 06DJ1402]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30772158), the Shanghai Natural Science Foundation of China
   (No. 07ZR14140, No. 05JC14045) and in part by the Shanghai Natural
   Science Foundation of China (No. 06DJ1402). The authors would like to
   thank H. U. Kaimeng for his help during the performance of PCR, and are
   grateful to all professors who helped us improve the quality of the
   manuscript.
CR ALCOLEA S, 2004, CIRC RES, V94, P100, DOI
   10.1161/01.RES.0000108261.67979.2A
   ANVERSA P, 2006, CIRCULATION, V113, P1451, DOI
   10.1161/CIRCULATIONAHA.105.595181
   BEARZI C, 2007, P NATL ACAD SCI USA, V104, P14068, DOI
   10.1073/pnas.0706760104
   BELTRAMI AP, 2003, CELL, V114, P763
   CHOI SC, 2004, EXP MOL MED, V36, P515
   COPPEN SR, 1999, DEV GENET, V24, P82
   DANIEL JG, 2006, CELL, V127, P1101
   DELORME B, 1995, DEV DYNAM, V204, P358
   GREPIN C, 1997, DEVELOPMENT, V124, P2387
   HIDAKA K, 2003, FASEB J, V17, P740
   IP HS, 1994, MOL CELL BIOL, V14, P7517
   LAUGWITZ KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215
   LINKE A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI
   10.1073/pnas.0502678102
   LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27
   MAKINO S, 1999, J CLIN INVEST, V103, P697
   MARTIN CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028
   MATSUURA K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200
   MESSINA E, 2004, CIRC RES, V95, P911, DOI
   10.1161/01.RES.0000147315.71699.51
   MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947
   MORETTI A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029
   OH H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI
   10.1073/pnas.2132126100
   OH H, 2004, ANN NY ACAD SCI, V1015, P182, DOI 10.1196/annals.1302.015
   SUGI Y, 1996, DEV BIOL, V175, P66
   URBANEK K, 2005, CIRC RES, V97, P663, DOI
   10.1161/01.RES.0000183733.53101.11
   URBANEK K, 2005, P NATL ACAD SCI USA, V102, P8692
   VERKERK AO, 2007, C P IEEE ENG MED BIO, P904
   WEI Y, 2000, DEV DYNAM, V219, P505
   WU SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028
   XU CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
NR 29
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1422-6405
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 190
IS 4
BP 194
EP 208
DI 10.1159/000204750
PG 15
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 494DD
UT ISI:000269788800002
ER

PT J
AU Gan, L
   Liu, P
   Lu, H
   Chen, S
   Yang, J
   McCarthy, JB
   Knudsen, KE
   Huang, H
AF Gan, L.
   Liu, P.
   Lu, H.
   Chen, S.
   Yang, J.
   McCarthy, J. B.
   Knudsen, K. E.
   Huang, H.
TI Cyclin D1 promotes anchorage-independent cell survival by inhibiting
   FOXO-mediated anoikis
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE FOXO1; FOXO3a; cyclin D1; cyclin-dependent kinase; anoikis; prostate
   cancer
ID TRANSCRIPTION FACTORS; PROSTATE-CANCER; GENE-EXPRESSION;
   DOWN-REGULATION; NUCLEAR EXPORT; PHOSPHORYLATION; APOPTOSIS; BIM;
   INTEGRINS; PROLIFERATION
AB O-class forkhead box (FOXO) transcription factors are critical
   regulators of diverse cellular processes, including apoptosis,
   cell-cycle arrest, DNA damage repair and oxidative stress resistance.
   Here, we show that FOXO1 and FOXO3a have an essential function in
   promoting cell detachment-induced anoikis, resistance to which is
   implicated in cancer development and metastasis. In contrast, the
   oncoprotein cyclin D1 inhibits anoikis. We further show that cyclin D1
   interacts with FOXO proteins and impedes their transcriptional
   regulatory and anoikis-promoting functions. This effect of cyclin D1
   requires its transcription repression domain but is independent of
   cyclin-dependent kinases CDK4 and CDK6. Moreover, we show that
   cancer-derived mutants of cyclin D1 are much more stable than wild-type
   cyclin D1 under anchorage-independent conditions and possess a greater
   antagonistic effect on FOXO-regulated anoikis and anchorage-independent
   growth of cancer cells. These data suggest that cyclin D1 may have a
   critical function in tumorigenesis and cancer metastasis by inhibiting
   the anoikis-promoting function of FOXO proteins.
C1 [Gan, L.; Liu, P.; Lu, H.; Chen, S.; Huang, H.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA.
   [Gan, L.; Liu, P.; Lu, H.; Chen, S.; Yang, J.; McCarthy, J. B.; Huang, H.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [Knudsen, K. E.] Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA USA.
RP Huang, H, Univ Minnesota, Mason Canc Ctr, MMC 806,420 Delaware St SE,
   Minneapolis, MN 55455 USA.
EM huang253@umn.edu
FU Department of Defense [W81XWH-07-1-0137, PC080591]; Brainstorm Award
   from the University of Minnesota Masonic Cancer Center ; National
   Institutes of Health [CA82295, CA099996]; National Natural Science
   Foundation of China [30500109]
FX We thank DJ Tindall, KL Guan, M Pagano, CY Young, and SW Hayward for
   plasmids and cell lines, Y Shimizu, V Bardwell, KL Schwertfeger, SM
   Dehm and members of Huang laboratory, especially LR Bohrer for critical
   reading of the manuscript. This work was supported in part by funds
   from the Department of Defense (W81XWH-07-1-0137 and PC080591) and the
   Brainstorm Award from the University of Minnesota Masonic Cancer Center
   (to HH), the National Institutes of Health (CA82295 to JBM and CA099996
   to KEK), and the National Natural Science Foundation of China (30500109
   to LG). All authors claim no conflict of interest with this study.
CR AGGARWAL P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007
   BENZENO S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644
   BRUNET A, 1999, CELL, V96, P857
   CREIGHTON CJ, 2008, PLOS ONE, V3, ARTN e1816
   DIEHL JA, 1997, GENE DEV, V11, P957
   DROBNJAK M, 2000, CLIN CANCER RES, V6, P1891
   EWEN ME, 2004, TRENDS MOL MED, V10, P158, DOI
   10.1016/j.molmed.2004.02.005
   FRISCH SM, 1994, J CELL BIOL, V124, P619
   FRISCH SM, 1997, CURR OPIN CELL BIOL, V9, P701
   GIANCOTTI FG, 1999, SCIENCE, V285, P1028
   GILLEY J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026
   GLADDEN AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147
   GREER EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   HUANG HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512
   HUANG HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   KIM HRC, 1999, CANCER RES, V59, P4148
   KLIER M, 2008, LEUKEMIA, V22, P2097, DOI 10.1038/leu.2008.213
   KNUDSEN KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371
   LAMB J, 2003, CELL, V114, P323
   LI ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI
   10.1073/pnas.0710905105
   LIN DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738
   LIOTTA LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a
   LIU P, 2008, CANCER RES, V68, P10290, DOI 10.1158/0008-5472.CAN-08-2038
   LIU P, 2008, ONCOGENE, V27, P4733, DOI 10.1038/onc.2008.104
   MAILLEUX AA, 2007, DEV CELL, V12, P221
   MASSOUMI R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.06.041
   MODUR V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200
   PETREDRAVIAM CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200
   RADU A, 2003, MOL CELL BIOL, V23, P6139, DOI
   10.1128/MCB.23.17.6139-6149.2003
   REGINATO MJ, 2003, NAT CELL BIOL, V5, P733
   SAUTER D, 2009, J HEPATOL, V50, P861, DOI 10.1016/j.jhep.2008.11.024
   SCHWARTZ MA, 1997, J CELL BIOL, V139, P575
   SHERR CJ, 1996, SCIENCE, V274, P1672
   SHERR CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504
   WANG TC, 1994, NATURE, V369, P669
   WEINSTEIN IB, 2002, SCIENCE, V297, P63
   WENG ZG, 2002, J BIOL CHEM, V277, P18677
   WOODS NT, 2007, CANCER RES, V67, P10744, DOI
   10.1158/0008-5472.CAN-07-3148
   YU QY, 2001, NATURE, V411, P1017
NR 39
TC 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD OCT
PY 2009
VL 16
IS 10
BP 1408
EP 1417
DI 10.1038/cdd.2009.86
PG 10
SC Biochemistry & Molecular Biology; Cell Biology
GA 494BU
UT ISI:000269785100011
ER

PT J
AU Choong, ML
   Yang, H
   Lee, MA
   Lane, DP
AF Choong, Meng Ling
   Yang, Henry
   Lee, May Ann
   Lane, David P.
TI Specific activation of the p53 pathway by low dose actinomycin D A new
   route to p53 based cyclotherapy
SO CELL CYCLE
LA English
DT Article
DE microarray; apoptosis; cell cycle; tumor; drug combinations
ID MICROTUBULE-ACTIVE DRUGS; P53-DEPENDENT APOPTOSIS;
   CHECKPOINT-DEFICIENT; MDM2 ANTAGONISTS; TARGET GENES; CANCER-CELLS;
   HUMAN GENOME; PHOSPHORYLATION; THERAPY; TRANSLOCATION
AB The activation of p53 has been proposed as a novel anti-cancer
   treatment in two distinct contexts. In the first activation of p53 in
   tumor cells can promote apoptosis and senescence and enhance the
   anti-tumor activity of cytotoxic chemotherapeutic drugs. In the second
   application activation of p53 in normal tissues can cause a reversible
   cell cycle arrest that can be used to protect normal cells from the
   action of anti-mitotics. In this cyclotherapy role p53 mutant tumor
   cells are not arrested and remain sensitive to anti- mitotics. The
   advent of specific p53 activating molecules such as nutlin-3 has
   encouraged both approaches. We have sought for a clinically approved
   drug that can mimic nutlin-3. We show here that low doses of
   actinomycin D mimic nutlin-3 in the highly specific activation of p53
   dependant transcription, in the induction of a reversible protective
   growth arrest in normal cells and in the enhancement of the activity of
   chemotherapeutic drug induced killing of p53 positive human tumor
   cells. While high doses of actinomycin D reveal its more non-specific
   activities, low doses of the drug will allow exploration of the value
   of p53 activation in preclinical and clinical models before nutlin-3
   like drugs are approved.
C1 [Lane, David P.] Agcy Sci Technol & Res, Lab P53, Singapore 138668, Singapore.
   [Choong, Meng Ling; Lee, May Ann] Ctr Expt Therapeut, Singapore, Singapore.
   [Yang, Henry] Singapore Immunol Network, Singapore, Singapore.
RP Lane, DP, Agcy Sci Technol & Res, Lab P53, 20 Biopolis Way,08-01 Ctr,
   Singapore 138668, Singapore.
EM dplane@p53Lab.a-star.edu.sg
CR ARIMA Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200
   BANIN S, 1998, SCIENCE, V281, P1674
   BERKSON RG, 2005, INT J CANCER, V115, P701, DOI 10.1002/ijc.20968
   BERNS K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371
   BLAGOSKLONNY MV, 2000, J CLIN INVEST, V105, P533
   BLAGOSKLONNY MV, 2001, CANCER RES, V61, P4301
   BLAGOSKLONNY MV, 2002, CELL CYCLE, V1, P375
   BLAGOSKLONNY MV, 2002, INT J CANCER, V98, P161
   BLAGOSKLONNY MV, 2002, ONCOGENE, V21, P6249, DOI 10.1038/sj.onc.1205793
   BLAGOSKLONNY MV, 2008, CELL CYCLE, V7, P1307
   BROGHAMMER M, 2005, CANC LETT, V214, P225
   CARVAJAL D, 2005, CANCER RES, V65, P1918
   CHEOK CF, 2007, MOL CANCER RES, V5, P1133, DOI
   10.1158/1541-7786.MCR-07-0161
   CHUA SW, 2006, NUCLEIC ACIDS RES, V34, E38
   DEMIDENKO ZN, 2005, CANCER RES, V65, P4401
   FENG LJ, 2006, CELL CYCLE, V5, P2812
   HIETANEN S, 2000, P NATL ACAD SCI USA, V97, P8501
   HUPP TR, 1992, CELL, V71, P875
   JIANG M, 2007, J BIOL CHEM, V282, P2636, DOI 10.1074/jbc.M606928200
   KANNAN K, 2001, ONCOGENE, V20, P2225
   KEYOMARSI K, 2003, PROG CELL CYCLE RES, V5, P527
   KHO PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200
   LAIN S, 1999, EXP CELL RES, V248, P457
   LAIN S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004
   LJUNGMAN M, 1999, ONCOGENE, V18, P583
   MARCHENKO ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560
   MATSUZAKI H, 2001, CLIN CANCER RES, V7, P407
   PERRY RP, 1970, J CELL PHYSIOL, V76, P127
   PLUNKETT TA, 2002, J CLIN ONCOL, V20, P4273
   REN B, 2002, GENE DEV, V16, P245
   SECCHIERO P, 2006, BLOOD, V107, P4122, DOI 10.1182/blood-2005-11-4465
   SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328
   THOMPSON T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200
   TOVAR C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI
   10.1073/pnas.0507493103
   VASSILEV LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   VOGELSTEIN B, 2000, NATURE, V408, P307
   WANG LQ, 2001, J BIOL CHEM, V276, P43604
   WEI CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043
   ZHAO RB, 2000, GENE DEV, V14, P981
NR 39
TC 17
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD SEP 1
PY 2009
VL 8
IS 17
BP 2810
EP 2818
PG 9
SC Cell Biology
GA 494FK
UT ISI:000269795800029
ER

PT J
AU Tobinai, K
   Ishizawa, K
   Ogura, M
   Itoh, K
   Morishima, Y
   Ando, K
   Taniwaki, M
   Watanabe, T
   Yamamoto, J
   Uchida, T
   Nakata, M
   Terauchi, T
   Nawano, S
   Matsusako, M
   Hayashi, M
   Hotta, T
AF Tobinai, Kensei
   Ishizawa, Ken-ichi
   Ogura, Michinori
   Itoh, Kuniaki
   Morishima, Yasuo
   Ando, Kiyoshi
   Taniwaki, Masafumi
   Watanabe, Takashi
   Yamamoto, Joji
   Uchida, Toshiki
   Nakata, Masanobu
   Terauchi, Takashi
   Nawano, Shigeru
   Matsusako, Masaki
   Hayashi, Masaki
   Hotta, Tomomitsu
TI Phase II study of oral fludarabine in combination with rituximab for
   relapsed indolent B-cell non-Hodgkin lymphoma
SO CANCER SCIENCE
LA English
DT Article
ID LOW-GRADE LYMPHOMA; COOPERATIVE-ONCOLOGY-GROUP; BENDAMUSTINE PLUS
   RITUXIMAB; FOLLICULAR LYMPHOMA; MANTLE CELL; CHOP CHEMOTHERAPY;
   RESPONSE CRITERIA; FOLLOW-UP; CYCLOPHOSPHAMIDE; PHOSPHATE
AB Oral fludarabine is more convenient than intravenous fludarabine in an
   outpatient setting. To assess the efficacy and toxicity of oral
   fludarabine in combination with rituximab in patients with relapsed
   indolent B-cell non-Hodgkin lymphoma (B-NHL), we conducted a
   multicenter phase II study. Patients with relapsed indolent B-NHL with
   two or fewer prior regimens and up to 16 doses of rituximab were
   eligible. Patients received 375 mg/m<SU2</SU rituximab on day 1, and 40
   mg/m<SU2</SU oral fludarabine once daily on days 1 through 5 every 28
   days for up to six cycles. The primary endpoint was the overall
   response rate. Forty-one patients were enrolled, including 38 (93%)
   with follicular lymphoma. Thirty-four patients (83%) had received
   rituximab as prior therapy. Twenty-seven patients (66%) completed the
   planned six cycles. Dose reduction of oral fludarabine was required in
   17 patients (41%). The overall response rate was 76% (31 of 41
   patients; 95% confidence interval, 60-88%) with a complete response
   rate of 68% (28 of 41 patients; 95% confidence interval, 52-82%).
   Median progression-free survival for the 41 patients was 19.7 months
   (95% confidence interval, 12.3-26.5 months). Hematological toxicities,
   including grade 4 neutropenia (68%), were the most frequent toxicities.
   Non-hematological toxicities were mild, except for one patient who died
   of Pneumocystis jiroveci pneumonia 4 months after the protocol
   treatment. In conclusion, oral fludarabine in combination with
   rituximab is a highly effective and convenient therapy for patients
   with relapsed indolent B-NHL who have mostly been pretreated with
   rituximab. (ClinicalTrials.gov number, NCT00311129.) (Cancer Sci 2009;
   100: 1951-1956).
C1 [Tobinai, Kensei; Watanabe, Takashi] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Tokyo, Japan.
   [Ishizawa, Ken-ichi; Yamamoto, Joji] Tohoku Univ Hosp, Sendai, Miyagi, Japan.
   [Ogura, Michinori; Uchida, Toshiki] Nagoya Daini Red Cross Hosp, Dept Hematol & Oncol, Nagoya, Aichi, Japan.
   [Itoh, Kuniaki; Nakata, Masanobu] Natl Canc Ctr Hosp E, Div Hematol & Oncol, Chiba, Japan.
   [Nawano, Shigeru] Natl Canc Ctr Hosp E, Div Diagnost Radiol, Chiba, Japan.
   [Morishima, Yasuo] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi 464, Japan.
   [Ando, Kiyoshi] Tokai Univ, Sch Med, Dept Hematol & Oncol, Kanagawa 2591100, Japan.
   [Taniwaki, Masafumi] Kyoto Prefectural Univ Med, Dept Hematol & Oncol, Kyoto, Japan.
   [Terauchi, Takashi] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Screening Technol & Dev Div, Tokyo 104, Japan.
   [Matsusako, Masaki] St Lukes Int Hosp, Dept Radiol, Tokyo, Japan.
   [Hayashi, Masaki] Bayer HealthCare, Dept Clin Dev, Osaka, Japan.
   [Hotta, Tomomitsu] Nagoya Med Ctr, Nagoya, Aichi, Japan.
   [Nakata, Masanobu] Sapporo Hokuyu Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan.
   [Nawano, Shigeru] Int Univ Hlth & Welf, Mita Hosp, Dept Radiol, Tokyo, Japan.
   [Hayashi, Masaki] Nakagami Hosp, Dept Internal Med, Okinawa, Japan.
RP Tobinai, K, Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, 1-1
   Tsukiji 5 chome, Tokyo, Japan.
EM ktobinai@ncc.go.jp
CR ALAS S, 2000, ANTICANCER RES, V20, P2961
   ALAS S, 2001, CLIN CANCER RES, V7, P709
   CHESON BD, 1999, J CLIN ONCOL, V17, P1244
   CZUCZMAN MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020
   CZUCZMAN MS, 2005, J CLIN ONCOL, V23, P694, DOI 10.1200/JCO.2005.02.172
   DEMIDEM A, 1997, CANCER BIOTHER RADIO, V12, P177
   DIGAETANO N, 2001, BRIT J HAEMATOL, V114, P800
   FLINN IW, 2000, BLOOD, V96, P71
   HARRIS NL, 1999, J CLIN ONCOL, V17, P3835
   HIDDEMANN W, 2005, BLOOD, V106, P3725
   HOCHSTER H, 2002, P AN M AM SOC CLIN, V21, A282
   HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28
   HOCHSTER HS, 2000, J CLIN ONCOL, V18, P987
   HORNING SJ, 1993, SEMIN ONCOL, V20, P75
   IGARASHI T, 2002, ANN ONCOL, V13, P928
   ITOH K, 2008, J CLIN ONCOL S, V26, S482
   KLASA RJ, 2002, J CLIN ONCOL, V20, P4649, DOI 10.1200/JCO.2002.11.068
   MARCUS R, 2008, J CLIN ONCOL, V26, P4579, DOI 10.1200/JCO.2007.13.5376
   MCLAUGHLIN P, 1996, J CLIN ONCOL, V14, P1262
   MCLAUGHLIN P, 1998, J CLIN ONCOL, V16, P2825
   NITTA E, 2007, ANN ONCOL, V18, P364, DOI 10.1093/annonc/mdl393
   OGAWA Y, 2006, ANN ONCOL, V17, P330, DOI 10.1093/annonc/mdj069
   OGURA M, 2004, INT J HEMATOL, V80, P267, DOI 10.1532/IJH97.04077
   OGURA M, 2006, CANCER SCI, V97, P305, DOI
   10.1111/j.1349-7006.2006.00173.x
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649
   REDMAN JR, 1992, J CLIN ONCOL, V10, P790
   ROBINSON KS, 2008, J CLIN ONCOL, V26, P4473, DOI
   10.1200/JCO.2008.17.0001
   RUMMEL MJ, 2005, J CLIN ONCOL, V23, P3383, DOI 10.1200/JCO.2005.08.100
   SCHULZ H, 2007, J NATL CANCER I, V99, P706, DOI 10.1093/jnci/djk152
   SOLALCELIGNY P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434
   TOBINAI K, 2006, J CLIN ONCOL, V24, P174, DOI 10.1200/JCO.2005.03.9313
   TSIMBERIDOU AM, 2002, BLOOD, V100, P4351, DOI 10.1182/blood-2001-12-0269
   TSIMBERIDOU AM, 2005, CANCER, V104, P345, DOI 10.1002/cncr.21151
   WITZIG TE, 2002, J CLIN ONCOL, V20, P2453
NR 34
TC 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD OCT
PY 2009
VL 100
IS 10
BP 1951
EP 1956
DI 10.1111/j.1349-7006.2009.01247.x
PG 6
SC Oncology
GA 494HH
UT ISI:000269802000025
ER

PT J
AU Konishi, K
   Shen, L
   Jelinek, J
   Watanabe, Y
   Ahmed, S
   Kaneko, K
   Kogo, M
   Takano, T
   Imawari, M
   Hamilton, SR
   Issa, JPJ
AF Konishi, Kazuo
   Shen, Lanlan
   Jelinek, Jaroslav
   Watanabe, Yoshiyuki
   Ahmed, Saira
   Kaneko, Kazuhiro
   Kogo, Mari
   Takano, Toshihumi
   Imawari, Michio
   Hamilton, Stanley R.
   Issa, Jean-Pierre J.
TI Concordant DNA Methylation in Synchronous Colorectal Carcinomas
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID CPG ISLAND METHYLATION; ULCERATIVE-COLITIS; COLON-CANCER;
   MICROSATELLITE INSTABILITY; THERAPEUTIC IMPLICATIONS; RECTUM;
   PHENOTYPE; P53; MUTATIONS; POLYPS
AB Epigenetic changes have been proposed as mediators of the field defect
   in colorectal carcinogenesis, which has implications for risk
   assessment and cancer prevention. As a test of this hypothesis, we
   evaluated the methylation status of eight genes (MINT1, 2, 31, MLH1,
   p16, p14, MGMT, and ESR1), as well as BRAF and KRAS mutations, in 57
   multiple colorectal neoplasias (M-CRN) and compared these to 69
   solitary colorectal cancers (S-CRC). There were no significant
   differences in methylation between M-CRNs and S-CRCs except for p14 and
   MGMT that was significantly higher in M-CRNs than S-CRCs (16.1% versus
   9.3%; 26.5% versus 17.3%, respectively; P < 0.05). We found significant
   (P < 0.05) correlations for MINT1 (r = 0.8), p16 (r = 0.8), MLH1 (r =
   0.9), and MGMT (r = 0.6) methylation between tumors pairs of the same
   site (proximal/proximal and distal/distal). KRAS showed no concordance
   in mutations. BRAF mutation showed concordance in proximal site pairs
   but was discordant in different site pairs. Histologically, eight of 10
   paired cancers with similar locations were concordant for a cribriform
   glandular configuration. We conclude that synchronous colorectal tumors
   of the same site are highly concordant for methylation of multiple
   genes, BRAF mutations, and a cribriform glandular configuration, all
   consistent with a patient-specific predisposition to particular
   subtypes of colorectal cancers. Screening for and secondary prevention
   of colon cancer should take this fact into account.
C1 [Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit428, Houston, TX 77030 USA.
   [Hamilton, Stanley R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Konishi, Kazuo; Kaneko, Kazuhiro; Imawari, Michio] Showa Univ, Sch Med, Dept Gastroenterol, Tokyo 142, Japan.
   [Kogo, Mari] Showa Univ, Sch Pharm, Promot Ctr Pharmaceut Educ, Tokyo 142, Japan.
   [Watanabe, Yoshiyuki] St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan.
   [Takano, Toshihumi] St Marianna Univ, Sch Med, Dept Diagnost Pathol, Kanagawa, Japan.
RP Issa, JPJ, Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit428,
   1515 Holcombe Blvd, Houston, TX 77030 USA.
EM jpissa@mdanderson.org
FU NIH [CA098006, CA105346]; F. M. Kirby Foundation 
FX Grant support: NIH grants CA098006 and CA105346. J.P. Issa is an
   American Cancer Society Clinical Research Professor supported by a
   generous gift from the F. M. Kirby Foundation.
CR ADLOFF M, 1989, AM J SURG, V157, P299
   AHUJA N, 1998, CANCER RES, V58, P5489
   ALEXANDER J, 2001, AM J PATHOL, V158, P527
   CHIRIEAC LR, 2005, AM J SURG PATHOL, V29, P429
   CHU DZJ, 1986, CANCER, V57, P445
   COLELLA S, 2003, BIOTECHNIQUES, V35, P146
   COPELAND EM, 1969, ARCH SURG-CHICAGO, V98, P141
   CUNLIFFE WJ, 1984, BRIT J SURG, V71, P941
   DELATTRE O, 1989, LANCET, V2, P353
   EGUCHI K, 2000, MODERN PATHOL, V13, P131
   EVERS BM, 1988, DIS COLON RECTUM, V31, P518
   FINAN PJ, 1987, BRIT J SURG, V74, P945
   GIOVANNUCCI E, 2005, J NATL CANCER I, V97, P1317, DOI
   10.1093/jnci/dji305
   HEALD RJ, 1975, DIS COLON RECTUM, V18, P6
   HONG WK, 1990, NEW ENGL J MED, V323, P795
   HUSSAIN SP, 2000, CANCER RES, V60, P3333
   ISSA JP, 2000, ANN NY ACAD SCI, V910, P140
   ISSA JP, 2000, ANN NY ACAD SCI, V910, P153
   ISSA JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   ISSA JPJ, 2001, CANCER RES, V61, P3573
   JASS JR, 1998, GUT, V42, P673
   JERNVALL P, 1997, INT J CANCER, V74, P97
   JONES PA, 1999, NAT GENET, V21, P163
   KAIBARA N, 1984, CANCER, V54, P1870
   KAMBARA T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   KINZLER KW, 1996, CELL, V87, P159
   KONISHI K, 1999, GUT, V45, P818
   KONISHI K, 2003, GASTROINTEST ENDOSC, V57, P48, DOI 10.1067/mge.2003.31
   KONISHI K, 2007, GASTROENTEROLOGY, V132, P1254, DOI
   10.1053/j.gastro.2007.01.035
   KUDO SE, 1996, GASTROINTEST ENDOSC, V44, P8
   LAIRD PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LANGEVIN JM, 1984, AM J SURG, V147, P330
   LASSER A, 1978, DIS COLON RECTUM, V21, P20
   LEEDHAM SJ, 2009, GASTROENTEROLOGY, V136, P542, DOI
   10.1053/j.gastro.2008.10.086
   MOERTEL CG, 1958, GASTROENTEROLOGY, V34, P85
   MORSON BC, 1985, BRIT J SURG, V72, S23
   NORRIE MWA, 2002, DIS COLON RECTUM, V45, P674
   OGINO S, 2006, MODERN PATHOL, V19, P1083, DOI 10.1038/modpathol.3800618
   REILLY JC, 1982, DIS COLON RECTUM, V25, P532
   SAMOWITZ WS, 2005, GASTROENTEROLOGY, V129, P837, DOI
   10.1053/j.gastro.2005.06.020
   SHEN L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102
   SHEN LL, 2005, J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   SHEN LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI
   10.1073/pnas.0704652104
   SLATER G, 1990, SURG GYNECOL OBSTET, V171, P283
   TOYOTA M, 1999, P NATL ACAD SCI USA, V96, P8681
   TOYOTA M, 2000, P NATL ACAD SCI USA, V97, P710
   VANRIJNSOEVER M, 2002, GUT, V51, P797
   YOO CB, 2008, CANCER PREV RES, V1, P233, DOI
   10.1158/1940-6207.CAPR-07-0008
NR 48
TC 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD SEP
PY 2009
VL 2
IS 9
BP 814
EP 822
DI 10.1158/1940-6207.CAPR-09-0054
PG 9
SC Oncology
GA 492YY
UT ISI:000269700400008
ER

PT J
AU Zhou, YQ
   Yang, ZL
   Xu, L
   Li, P
   Hu, YZ
AF Zhou, Yong-Qiang
   Yang, Zhong-Lin
   Xu, Lei
   Li, Ping
   Hu, Yu-Zhu
TI Akebia saponin D, a saponin component from Dipsacus asper Wall,
   protects PC 12 cells against amyloid-beta induced cytotoxicity
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Dipsacus asper Wall; Akebia Saponin D; Amyloid beta; Alzheimer's disease
ID SALVIANOLIC-ACID-B; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; IN-VITRO;
   TAU-PHOSPHORYLATION; MODEL; NANOPARTICLES; ANTIOXIDANT; MECHANISMS;
   ESTROGEN
AB According to Traditional Chinese Medicine, Alzheimer's disease (AD) is
   regarded as senile dementia, and the etiopathogenesis lies in kidney
   deficiency during aging. Dipsacus asper Wall (DAW), a well-known
   traditional Chinese medicine for enhancing kidney activity, may possess
   the therapeutic effects against AD. Our objectives were to investigate
   the protective effects of DAW against the amyloid-beta peptide (A
   beta)-induced cytotoxicity and explore its major active components.
   Injury of PC 12 cells mediated by A beta(25-35) was adopted to assess
   the cytoprotective effects of DAW aqueous extract and various
   fractions. Salvianolic acid B, a polyphenol compound isolated from
   Salvia miltiorrhiza, was employed as a positive control agent due to
   its markedly protective effect against neurotoxicity of amyloid beta.
   Five chemical fractions (i.e. alkaloids, essential oil, saponins,
   iridoid glucoside and polysaccharides) were prepared for activity test
   and analyzed by HPLC for active components identification. In addition,
   Akebia saponin D (the most important compound in DAW saponins) and
   hederagenin (the mother nucleus of akebia saponin D) were prepared for
   testing of their activity. DAW water extract, saponins fraction and
   akebia saponin D had the neuroprotective capacity to antagonize A
   beta(25-35)-induced cytotoxicity in PC 12 cells. In contrast, other
   fractions and hederagenin had no cytoprotective action. This research
   suggests that DAW may represent a potential treatment strategy for AD
   and akebia saponin D is one of its active components. (C) 2009
   International Federation for Cell Biology. Published by Elsevier Ltd.
   All rights reserved.
C1 [Zhou, Yong-Qiang; Yang, Zhong-Lin; Xu, Lei; Li, Ping] China Pharmaceut Univ, Key Lab Modern Chinese Med, Minist Educ, Nanjing 210009, Peoples R China.
   [Hu, Yu-Zhu] Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Peoples R China.
RP Yang, ZL, China Pharmaceut Univ, Key Lab Modern Chinese Med, Minist
   Educ, 24 Tongjia Lane, Nanjing 210009, Peoples R China.
EM yzl1950cpu@163.com
FU National Natural Science Foundation of China [30730113]
FX This work was supported by the National Natural Science Foundation of
   China (Grant no. 30730113).
CR ANDREASEN N, 2002, PEPTIDES, V23, P1205
   BERTS A, 2000, EUR J PHARMACOL, V389, P35
   DURAIRAJAN SSK, 2008, NEUROCHEM INT, V52, P741, DOI
   10.1016/j.neuint.2007.09.006
   GAO XL, 2006, BIOMATERIALS, V27, P3482, DOI
   10.1016/j.biomaterials.2006.01.038
   HERSKOVITS AZ, 2006, NEUROBIOL DIS, V23, P398, DOI
   10.1016/j.nbd.2006.04.004
   HUNG TM, 2006, J ETHNOPHARMACOL, V108, P188, DOI
   10.1016/j.jep.2006.04.029
   JAMSA A, 2004, BIOCHEM BIOPH RES CO, V319, P993, DOI
   10.1016/j.bbrc.2004.05.075
   KAJTA M, 2005, DEV BRAIN RES, V160, P40, DOI
   10.1016/j.devbrainres.2005.08.002
   KAUNO I, 1990, PHYTOCHEMISTRY, V29, P338
   LEVINE AJ, 2004, ARCH CLIN NEUROPSYCH, V19, P769, DOI
   10.1016/j.acn.2003.09.004
   LIN YH, 2006, BIOCHEM BIOPH RES CO, V348, P593, DOI
   10.1016/j.bbrc.2006.07.110
   LIU CS, 2007, PHYTOMEDICINE, V14, P492, DOI 10.1016/j.phymed.2006.11.002
   MAILLIOT C, 1998, NEUROSCI LETT, V255, P13
   MISITI F, 2005, NEUROCHEM INT, V46, P575, DOI
   10.1016/j.neuint.2005.01.001
   MORINAGA A, 2007, BIOCHEM BIOPH RES CO, V359, P697, DOI
   10.1016/j.bbrc.2007.05.158
   NIIKURA T, 2000, BIOCHEM BIOPH RES CO, V274, P445
   RONEY C, 2005, J CONTROL RELEASE, V108, P193, DOI
   10.1016/j.jconrel.2005.07.024
   SUH HW, 2000, J ETHNOPHARMACOL, V71, P211
   SULTANA R, 2006, J CHROMATOGR B, V833, P3, DOI
   10.1016/j.jchromb.2005.09.024
   TOMITA H, 1996, PHYTOCHEMISTRY, V42, P239
   VISSER CC, 2005, EUR J PHARM SCI, V25, P299, DOI
   10.1016/j.ejps.2005.03.008
   WU FZ, 2008, PHARM CLIN RES, V16, P249
   WU ZX, 1994, J CHINA PHARM U, V25, P202
   YANG SJ, 1993, J CHINA PHARM U, V24, P281
   ZHANG YW, 1991, ACTA PHARMACOL SINIC, V26, P676
   ZHANG ZJ, 2003, LIFE SCI, V73, P2443, DOI 10.1016/S0024-3205(03)00649-0
NR 26
TC 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD OCT
PY 2009
VL 33
IS 10
BP 1102
EP 1110
DI 10.1016/j.cellbi.2009.06.028
PG 9
SC Cell Biology
GA 491JA
UT ISI:000269573500009
ER

PT J
AU Wilcox, RA
   Feldman, AL
   Wada, DA
   Yang, ZZ
   Comfere, NI
   Dong, HD
   Kwon, ED
   Novak, AJ
   Markovic, SN
   Pittelkow, MR
   Witzig, TE
   Ansell, SM
AF Wilcox, Ryan A.
   Feldman, Andrew L.
   Wada, David A.
   Yang, Zhi-Zhang
   Comfere, Nneka I.
   Dong, Haidong
   Kwon, Eugene D.
   Novak, Anne J.
   Markovic, Svetomir N.
   Pittelkow, Mark R.
   Witzig, Thomas E.
   Ansell, Stephen M.
TI B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell
   lymphoproliferative disorders
SO BLOOD
LA English
DT Article
ID ABSOLUTE LYMPHOCYTE COUNT; LEUKOCYTE ANTIGEN-DR; NON-HODGKIN-LYMPHOMA;
   FOLLICULAR LYMPHOMAS; PROGNOSTIC MARKER; TYROSINE KINASE;
   TUMOR-IMMUNITY; EXPRESSION; SURVIVAL; IDENTIFICATION
AB Stromal elements present within the tumor microenvironment may suppress
   host immunity and promote the growth of malignant lymphocytes in B
   cell-derived non-Hodgkin lymphoma (NHL). In contrast, little is known
   about the microenvironment's role in T cell-derived NHL. B7-H1 (PD-L1,
   CD274), a member of the B7 family of costimulatory/coinhibitory ligands
   expressed by both malignant cells and stromal cells within the tumor
   microenvironment, has emerged as an important immune modulator capable
   of suppressing host immunity. Therefore, B7-H1 expression and function
   were analyzed in cutaneous and peripheral T-cell NHL. B7-H1 was
   expressed by tumor cells, monocytes, and monocyte-derived cells within
   the tumor microenvironment in T-cell NHL and was found to inhibit
   T-cell proliferation and promote the induction of FoxP3(+) regulatory T
   cells. Collectively, the data presented provide the first evidence
   implicating B7-H1 in the suppression of host immunity in T-cell
   lymphoproliferative disorders and suggest that the targeting of B7-H1
   may represent a novel therapeutic approach. (Blood. 2009; 114:
   2149-2158)
C1 [Wilcox, Ryan A.; Yang, Zhi-Zhang; Novak, Anne J.; Markovic, Svetomir N.; Witzig, Thomas E.; Ansell, Stephen M.] Mayo Clin, Div Hematol, Rochester, MN 55905 USA.
   [Feldman, Andrew L.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Wada, David A.; Comfere, Nneka I.; Pittelkow, Mark R.] Mayo Clin, Dept Dermatol, Rochester, MN 55905 USA.
   [Dong, Haidong] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.
   [Kwon, Eugene D.] Mayo Clin, Dept Urol, Rochester, MN 55905 USA.
RP Ansell, SM, Mayo Clin, Div Hematol & Internal Med, 200 1st St SW,
   Rochester, MN 55905 USA.
EM ansell.stephen@mayo.edu
FU National Institutes of Health [CA92104, CA97274]
FX This work was supported in part by the National Institutes of Health
   (grants CA92104 and CA97274).
CR ANDERSON KC, 2005, SEMIN HEMATOL S4, V42, S3, DOI
   10.1053/j.seminhematol.2005.10.001
   ANSELL SM, 2001, J CLIN ONCOL, V19, P720
   AZUMA T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141
   BEHL D, 2007, BRIT J HAEMATOL, V137, P409, DOI
   10.1111/j.1365-2141.2007.06596.x
   BERGER CL, 2005, BLOOD, V105, P1640, DOI 10.1082/blood-2004-06-2181
   BETTS MR, 2003, J IMMUNOL METHODS, V281, P65, DOI
   10.1016/S0022-1759(03)00265-5
   BROWN JA, 2003, J IMMUNOL, V170, P1257
   CHEN WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   CRANE CA, 2009, ONCOGENE, V28, P306, DOI 10.1038/onc.2008.384
   CURIEL TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863
   DAVE SS, 2004, NEW ENGL J MED, V351, P2159
   DONG HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   DONG HD, 2003, J MOL MED-JMM, V81, P281, DOI 10.1007/s00109-003-0430-2
   FELDMAN AL, 2008, LEUKEMIA, V22, P1139
   FILIPAZZI P, 2007, J CLIN ONCOL, V25, P2546, DOI
   10.1200/JCO.2006.08.5829
   FLIES DB, 2007, J IMMUNOTHER, V30, P251
   FREEMAN G, 2000, J EXP MED, V192, P1
   FUMEAUX T, 2002, AM J RESP CRIT CARE, V166, P1475, DOI
   10.1164/rrcm.200203-217OC
   GABRILOVICH DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GALON J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   GJERDRUM LM, 2007, LEUKEMIA, V21, P2512, DOI 10.1038/sj.leu.2404913
   HORNING SJ, 1984, NEW ENGL J MED, V311, P1471
   JEONG HY, 2008, J LEUKOCYTE BIOL, V83, P755
   KEIR ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI
   10.1146/annurev.immunol.26.021607.090331
   LENZ G, 2008, NEW ENGL J MED, V359, P2313
   LOERCHER AE, 1999, J IMMUNOL, V163, P6251
   MARZEC M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346
   MARZEC M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI
   10.1073/pnas.0810958105
   NEWCOM SR, 1988, AM J PATHOL, V131, P569
   OKI Y, 2008, EUR J HAEMATOL, V81, P448, DOI
   10.1111/j.1600-0609.2008.01129.x
   PARDOLL D, 2003, ANNU REV IMMUNOL, V21, P807, DOI
   10.1146/annurev.immunol.21.120601.141135
   PARSA AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517
   RABINOVICH GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI
   10.1146/annurev.immunol.25.022106.141609
   ROSENBERG SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   SATOH A, 2002, PANCREAS, V25, P245
   SHIH T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015
   SIDDIQUI M, 2006, BRIT J HAEMATOL, V134, P596, DOI
   10.1111/j.1365-2141.2006.06232.x
   STABER PB, 2007, BLOOD, V110, P3374, DOI 10.1182/blood-2007-02-071258
   SU IJ, 1989, AM J PATHOL, V135, P439
   TAYLOR AL, 2005, CRIT REV ONCOL HEMAT, V56, P155, DOI
   10.1016/j.critrevonc.2005.03.015
   THOMPSON RH, 2006, CANCER RES, V66, P3381, DOI
   10.1158/0008-5472.CAN-05-4303
   TSUSHIMA F, 2007, BLOOD, V110, P180, DOI 10.1182/blood-2006-11-060087
   VANDENBERK JMM, 1997, TRANSPLANTATION, V63, P1846
   VONDERHEID EC, 2001, J INVEST DERMATOL, V117, P654
   WANG L, 2008, P NATL ACAD SCI USA, V105, P9331, DOI
   10.1073/pnas.0710441105
   WILCOX RA, 2008, BLOOD, V112
   YANG ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376
   YANG ZZ, 2007, BLOOD, V110, P2537, DOI 10.1182/blood-2007-03-082578
   YAO S, 2006, TRENDS MOL MED, V12, P244, DOI 10.1016/j.molmed.2006.04.007
   YAWALKAR N, 2003, BLOOD, V102, P4059, DOI 10.1182/blood-2003-04-1044
NR 50
TC 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 3
PY 2009
VL 114
IS 10
BP 2149
EP 2158
DI 10.1182/blood-2009-04-216671
PG 10
SC Hematology
GA 490RZ
UT ISI:000269523300021
ER

PT J
AU Cao, DY
   Yang, JY
   Yue, SQ
   Tao, KS
   Song, ZS
   Wang, DS
   Yang, YL
   Dou, KF
AF Cao, Da-Yong
   Yang, Jing-Yue
   Yue, Shu-Qiang
   Tao, Kai-Shan
   Song, Zhen-Shun
   Wang, De-Sheng
   Yang, Yan-Ling
   Dou, Ke-Feng
TI Comparative analysis of DC fused with allogeneic hepatocellular
   carcinoma cell line HepG2 and autologous tumor cells as potential
   cancer vaccines against hepatocellular carcinoma
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Dendritic cells; Cytotoxic T lymphocytes; Immunotherapy; Allogeneic;
   HepG2
ID DENDRITIC CELLS; ANTITUMOR IMMUNITY; T-CELLS; VACCINATION; RESPONSES;
   IMMUNOTHERAPY; GENERATION; LYSATE; EPIDEMIOLOGY; MELANOMA
AB Fusions of patient-derived dendritic cells (DCs) and autologous tumor
   cells induce T-cell responses against autologous tumors in animal
   models and human clinical trials. These fusion cells require
   patient-derived tumor cells, which are not, however, always available.
   Here we fused autologous DCs from patients with hepatocellular
   carcinoma (HCC) to an allogeneic HCC cell line (HepG2). These fusion
   cells co-expressed tumor-associated antigens (TAAs) and DC-derived
   costimulatory and MHC molecules. Both CD4(+) and CD8(+) T cells were
   activated by the fusion cells. Cytotoxic T lymphocytes (C7Ls) induced
   by the fusion cells were able to kill autologous HCC by HLA-A2- and/or
   HLA-A24-restricted mechanisms. CTL activity against shared TAAs
   indicates that the presence of alloantigens does not prevent the
   development of CTLs with activity against autologous HCC cells. These
   fusion cells may have applications in anti-tumor immunotherapy through
   cross-priming against shared tumor antigens and may provide a platform
   for adoptive immunotherapy. Crown Copyright (C) 2009 Published by
   Elsevier Inc. All rights reserved.
C1 [Cao, Da-Yong; Yue, Shu-Qiang; Tao, Kai-Shan; Song, Zhen-Shun; Wang, De-Sheng; Yang, Yan-Ling; Dou, Ke-Feng] Fourth Mil Med Univ, Dept Hepatobiliary Surg, State Key Discipline Cell Biol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
   [Yang, Jing-Yue] Fourth Mil Med Univ, Dept Clin Oncol, State Key Discipline Cell Biol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
RP Dou, KF, Fourth Mil Med Univ, Dept Hepatobiliary Surg, State Key
   Discipline Cell Biol, Xijing Hosp, 17 Chonglexi Rd, Xian 710032,
   Shaanxi, Peoples R China.
EM DouKF@sohu.com
CR BALKOW S, 2009, EXP DERMATOL, V18, P78, DOI
   10.1111/j.1600-0625.2008.00800.x
   BERCOVICI N, 2008, J IMMUNOTHER, V31, P101
   CAO DY, 2007, HUM IMMUNOL, V68, P334, DOI 10.1016/j.humimm.2007.01.008
   COHEN S, 2009, J IMMUNOL, V182, P1667
   DEGRUIJL TD, 2008, CANCER IMMUNOL IMMUN, V57, P1569, DOI
   10.1007/s00262-008-0536-z
   HOLTL L, 2005, CANCER IMMUNOL IMMUN, V54, P663, DOI
   10.1007/s00262-004-0629-2
   HOMMA S, 2005, EUR J CLIN INVEST, V35, P279
   HOMMA S, 2006, CLIN EXP IMMUNOL, V144, P41, DOI
   10.1111/j.1365-2249.2006.03029.x
   IBRAHIM SM, 2008, WORLD J GASTROENTERO, V14, P1664, DOI
   10.3748/wjg.14.1664
   ISHIDA A, 2007, SCAND J IMMUNOL, V66, P546
   KOIDO S, 2005, CLIN CANCER RES, V11, P7891, DOI
   10.1158/1078-0432.CCR-05-1330
   KOIDO S, 2007, VACCINE, V25, P2610, DOI 10.1016/j.vaccine.2006.12.035
   KUMAGI T, 2005, ONCOL REP, V14, P969
   LEHMAN EM, 2009, INT J CANCER, V124, P690, DOI 10.1002/ijc.23937
   LU J, 2008, ASIAN J ANDROL, V10, P883, DOI
   10.1111/j.1745-7262.2008.00431.x
   OVALI E, 2007, J EXP CLIN CANC RES, V26, P209
   SHEN XY, 2008, IMMUNOL INVEST, V37, P798, DOI 10.1080/08820130802403358
   SHERMAN M, 2005, SEMIN LIVER DIS, V25, P143
   SHI MQ, 2005, TUMORI, V91, P531
   TREVOR KT, 2004, CANCER IMMUNOL IMMUN, V53, P705, DOI
   10.1007/s00262-004-0512-1
   VUCKOVIC S, 2008, EXP HEMATOL, V36, P1496, DOI
   10.1016/j.exphem.2008.06.011
   YANG JY, 2006, CELL IMMUNOL, V240, P14, DOI
   10.1016/j.cellimm.2006.06.005
   YASUDA T, 2006, ONCOL REP, V16, P1317
   YU JY, 2009, INT J BIOL SCI, V5, P135
   YUFENG D, 2008, MED ONCOL, V20
   ZIMMERMAN MA, 2008, ARCH SURG-CHICAGO, V143, P182
NR 26
TC 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 259
IS 1
BP 13
EP 20
DI 10.1016/j.cellimm.2009.05.007
PG 8
SC Cell Biology; Immunology
GA 488NJ
UT ISI:000269356200003
ER

PT J
AU Lin, WT
   Huang, CC
   Lin, TJ
   Chen, JR
   Shieh, MJ
   Peng, HC
   Yang, SC
   Huang, CY
AF Lin, Wan-Teng
   Huang, Chi-Chang
   Lin, Tien-Jen
   Chen, Jiun-Rong
   Shieh, Ming-Jer
   Peng, Hsiang-Chi
   Yang, Suh-Ching
   Huang, Chih-Yang
TI Effects of beta-carotene on antioxidant status in rats with chronic
   alcohol consumption
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE alcoholic liver disease; antioxidant capacity; beta-carotene; lipid
   peroxidation; oxidative stress
ID ALPHA-TOCOPHEROL; LIVER-DISEASE; LIPID-PEROXIDATION; OXIDATIVE STRESS;
   ASCORBIC-ACID; IN-VIVO; ETHANOL; ENZYMES; DIET
AB This study examined the effects of beta-carotene on antioxidant status
   in rats with chronic alcohol consumption. At the beginning of
   experiment (week 0), according to both the plasma aspartate
   aminotransferase (AST) and alanine aminotransferase (ALT) activities,
   rats (n = 24) were divided into 3 groups and fed with a standard diet
   (group C), a diet containing ethanol (group E), or a diet containing
   ethanol and beta-carotene (group E+B). After 10 weeks, plasma AST and
   ALT, fat accumulation in the liver, antioxidant enzyme activities in
   erythrocytes and the liver, malondialdehyde (MDA), and alpha-tocopherol
   and retinol in plasma and hepatic samples were analyzed. The chronic
   alcohol diet significantly increased AST and ALT levels in plasma, and
   these changes were prevented by supplementing the diet with
   beta-carotene. Glutathione (GSH) in erythrocytes and in the liver was
   significantly elevated in rats fed with a diet containing
   beta-carotene. The results indicate that beta-carotene supplementation
   can prevent ethanol-induced liver damage and increase GSH
   concentrations in erythrocytes and the liver. Copyright (C) 2009 John
   Wiley & Sons, Ltd.
C1 [Chen, Jiun-Rong; Shieh, Ming-Jer; Peng, Hsiang-Chi; Yang, Suh-Ching] Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei 11031, Taiwan.
   [Lin, Wan-Teng] Tunghai Univ, Coll Agr, Dept Hospitality Management, Taichung 40704, Taiwan.
   [Huang, Chi-Chang] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
   [Lin, Tien-Jen] Municipal Wan Fang Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan.
   [Lin, Tien-Jen] Taipei Med Univ, Grad Inst Injury Prevent, Taipei 11031, Taiwan.
   [Huang, Chih-Yang] Grad Inst Chinese Med Sci, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Huang, Chih-Yang] China Med Univ, Taichung, Taiwan.
   [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
RP Yang, SC, Taipei Med Univ, Sch Nutr & Hlth Sci, 250 Wu Xin St, Taipei
   11031, Taiwan.
EM sokei@tmu.edu.tw
   cyhuang@mail.cmu.edu.tw
FU National Science Council of Taiwan [NSC89-2320-B-038-034]
FX This study is supported by the National Science Council of Taiwan
   (NSC89-2320-B-038-034).
CR AHMED S, 1994, AM J CLIN NUTR, V60, P430
   ALBANES D, 1996, J NATL CANCER I, V88, P1560
   BAILEY SM, 2001, ALCOHOL CLIN EXP RES, V25, P726
   BARUA AB, 2000, J NUTR, V130, P1996
   BEERS RF, 1952, J BIOL CHEM, V195, P133
   CHANG CY, 2009, PHYTOTHER RES, V23, P251, DOI 10.1002/ptr.2602
   DIPLOCK AT, 1991, AM J CLIN NUTR, V53, P189
   HUANG CC, 2005, WORLD J GASTROENTERO, V11, P2603
   KAWASE T, 1989, HEPATOLOGY, V10, P815
   KIM Y, 2006, CARCINOGENESIS, V27, P1410, DOI 10.1093/carcin/bgi340
   LEDERMAN JD, 1998, J NUTR, V128, P271
   LEO MA, 1993, HEPATOLOGY, V17, P977
   LIEBER CS, 1991, ALCOHOL CLIN EXP RES, V15, P573
   LIEBER CS, 1994, METHOD ENZYMOL, V233, P585
   LIEBER CS, 1997, ADV PHARMACOL, V38, P601
   LOGUERCIO C, 1997, ITAL J GASTROENTEROL, V29, P168
   MOCHIZUKI S, 1989, J NUTR SCI VITAMINOL, V35, P431
   NAVDER KP, 1997, J NUTR, V127, P1800
   PALOZZA P, 1991, FREE RADICAL BIO MED, V11, P407
   PALOZZA P, 2005, BBA-MOL BASIS DIS, V1740, P215, DOI
   10.1016/j.bbadis.2004.12.008
   PAN MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   PIROLA RC, 1975, J NUTR, V105, P1544
   POLAVARAPU R, 1998, HEPATOLOGY, V27, P1317
   ROSELL M, 1999, J INTERN MED, V246, P219
   SHYUR LF, 2008, PHYTOCHEMISTRY, V69, P1348, DOI
   10.1016/j.phytochem.2008.01.017
   YANG SC, 2004, BRIT J NUTR, V92, P209, DOI 10.1079/BJN20041190
   YANG SC, 2007, J AM COLL NUTR, V26, P416
NR 27
TC 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0263-6484
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD AUG
PY 2009
VL 27
IS 6
BP 344
EP 350
DI 10.1002/cbf.1579
PG 7
SC Biochemistry & Molecular Biology; Cell Biology
GA 488XX
UT ISI:000269384800003
ER

PT J
AU Zhang, HQ
   Yang, RW
   Zhang, L
   Ding, CB
   Zeng, J
   Zhou, YH
AF Zhang, Hai-Qin
   Yang, Rui-Wu
   Zhang, Li
   Ding, Chun-Bang
   Zeng, Jian
   Zhou, Yong-Hong
TI Genetic diversity and phylogeny in Hystrix (Poaceae, Triticeae) and
   related genera inferred from Giemsa C-banded karyotypes
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE C-banding; Elymus; genome; Hystrix; Leymus; Triticeae
ID MEIOTIC PAIRING BEHAVIOR; PSATHYROSTACHYS-JUNCEA; SYNTHETIC HYBRIDS;
   LEYMUS POACEAE; ELYMUS; SEQUENCES; PATULA
AB The phylogenetic relationships of 15 taxa from Hystrix and the related
   genera Leymus (NsXm), Elymus (StH), Pseudoroegneria (St), Hordeum (H),
   Psathyrostachys (Ns), and Thinopyrum (E) were examined by using the
   Giemsa C-banded karyotype. The Hy. patula C-banding pattern was similar
   to those of Elymus species, whereas C-banding patterns of the other
   Hystrix species were similar to those of Leymus species. The results
   suggest high genetic diversity within Hystrix, and support treating Hy.
   patula as E. hystrix L., and transferring Hy. coreana, Hy. duthiei ssp.
   duthiei and Hy. duthiei ssp. longearistata to the genus Leymus. On
   comparing C-banding patterns of Elymus species with their diploid
   ancestors (Pseudoroegneria and Hordeum), there are indications that
   certain chromosomal re-arrangements had previously occurred in the St
   and H genomes. Furthermore, a comparison of the C-banding patterns of
   the Hystrix and Leymus species with the potential diploid progenitors
   (Psathyrostachys and Thinopyrum) suggests that Hy. coreana and some
   Leymus species are closely related to the Ns genome of Psathyrostachys,
   whereas Hy. duthiei ssp. duthiei, Hy. duthiei ssp. longearistata and
   some of the Leymus species have a close relationship with the E genome.
   The results suggest a multiple origin of the polyploid genera Hystrix
   and Leymus.
C1 [Zhang, Hai-Qin; Zeng, Jian; Zhou, Yong-Hong] Sichuan Agr Univ, Triticeae Res Inst, Wenjiang 611130, Sichuan, Peoples R China.
   [Zhang, Hai-Qin; Zhou, Yong-Hong] Sichuan Agr Univ, Minist Educ, Key Lab Crop Genet Resources & Improvement, Wenjiang 611130, Sichuan, Peoples R China.
   [Yang, Rui-Wu; Zhang, Li; Ding, Chun-Bang] Sichuan Agr Univ, Coll Biol & Sci, Wenjiang 611130, Sichuan, Peoples R China.
RP Zhou, YH, Sichuan Agr Univ, Triticeae Res Inst, Wenjiang 611130,
   Sichuan, Peoples R China.
EM zhouyh@sicau.edu.cn
FU Program for Changjiang Scholars ; Innovative Research Team in
   University (PCSIRT) China [IRT 0453]; National Natural Science
   Foundation of China [30670150]; Science and Technology Bureau ;
   Education Bureau of Sichuan Province, China 
FX We wish to thank Mr. Huan-Lin Shu (Triticeae Research Institute,
   Sichuan Agricultural University, China) for his valuable suggestions on
   C-banding analysis. We are grateful to Dr. S. Sakamoto (Kyoto
   University, Japan) and the American National Plant Germplasm System
   (Pullman, Washington, USA) for providing a part of the seed-material
   used in this study. This study was support by grants from the Program
   for Changjiang Scholars and the Innovative Research Team in University
   (PCSIRT) China (No. IRT 0453), the National Natural Science Foundation
   of China (No. 30670150) and the Science and Technology Bureau and the
   Education Bureau of Sichuan Province, China.
CR ANAMTHAWATJONSS.K, 2005, P 5 INT TRIT S PRAG, P13
   ANAMTHAWATJONSSON K, 2001, AM J BOT, V88, P553
   BADEN C, 1997, NORD J BOT, V17, P449
   BOR NL, 1960, GRASSES BURMA CEYLON
   CHURCH GL, 1967, RHODORA, V69, P121
   CHURCH GL, 1967, RHODORA, V69, P330
   DEWEY DR, 1967, B TORREY BOT CLUB, V94, P388
   DEWEY DR, 1971, AM J BOT, V58, P902
   DEWEY DR, 1982, GRASSES GRASSLANDS, P51
   ELLENSKOGSTAAM P, 2007, PLANT SYST EVOL, V265, P241
   FAN X, 2007, PLANT SCI, V172, P701, DOI 10.1016/j.plantsci.2006.11.012
   GE RC, 2004, GRASSLAND CHINA, V26, P72
   GILL BS, 1991, GENOME, V34, P830
   HITCHCOCK AS, 1951, USDA MISC PUBL, V200, P230
   JENSEN KB, 1997, INT J PLANT SCI, V158, P872
   KUO PC, 1987, POOIDEAE FLORA REIPU, V9, P34
   LINDELAURSEN I, 1986, PLANT SYST EVOL, V151, P203
   LINDELAURSEN I, 1994, HEREDITAS, V120, P11
   LOVE A, 1984, FEDDES REPERT, V95, P425
   MASONGAMER RJ, 2002, GENOME, V45, P991, DOI 10.1139/G02-065
   MOENCH C, 1794, METHODUS PLANTAS HOR
   MORRIS KLD, 1987, GENOME, V29, P247
   OSADA T, 1993, ILLUSTRATED GRASSES
   SUN GL, 1995, PLANT SYST EVOL, V197, P225
   TZVELEV NN, 1976, POACEAE
   WANG RRC, 1994, P 2 INT TRIT S LOG U, P29
   WANG SL, 1999, ACTA BOT SIN, V41, P258
   WEI JZ, 1995, GENOME, V38, P1262
   YANG K, 2006, SOLID STATE COMMUN, V139, P144, DOI
   10.1016/j.ssc.2006.05.040
   ZHANG HB, 1991, AM J BOT, V78, P871
   ZHANG HQ, 2006, CHROMOSOME RES, V14, P595, DOI 10.1007/s10577-006-1057-2
   ZHANG HQ, 2006, PLANT SYST EVOL, V258, P129, DOI
   10.1007/s00606-005-0394-5
   ZHANG HQ, 2008, PLANT BIOLOGY, V10, P635, DOI
   10.1111/j.1438-8677.2008.00065.x
   ZHOU YH, 1999, ACTA PHYTOTAXON SIN, V37, P386
NR 34
TC 0
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2009
VL 32
IS 3
BP 521
EP 527
PG 7
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 485MT
UT ISI:000269128100015
ER

PT J
AU Wang, Y
   Zhang, H
   Chen, YP
   Sun, YM
   Yang, F
   Yu, WH
   Liang, J
   Sun, LY
   Yang, XH
   Shi, L
   Li, RF
   Li, YY
   Zhang, Y
   Li, Q
   Yi, X
   Shang, YF
AF Wang, Yan
   Zhang, Hua
   Chen, Yupeng
   Sun, Yimin
   Yang, Fen
   Yu, Wenhua
   Liang, Jing
   Sun, Luyang
   Yang, Xiaohan
   Shi, Lei
   Li, Ruifang
   Li, Yanyan
   Zhang, Yu
   Li, Qian
   Yi, Xia
   Shang, Yongfeng
TI LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis
   Programs in Breast Cancer
SO CELL
LA English
DT Article
ID RECEPTOR-REGULATED TRANSCRIPTION; HISTONE LYSINE DEMETHYLASES;
   TGF-BETA; ENDOMETRIAL CARCINOGENESIS; MESENCHYMAL TRANSITIONS;
   MOLECULAR-MECHANISMS; MI-2/NURD COMPLEX; GENE-REGULATION; EMERGING
   ROLES; ESTROGEN
AB Lysine-specific demethylase 1 (LSD1) exerts pathway-specific activity
   in animal development and has been linked to several high-risk cancers.
   Here, we report that LSD1 is an integral component of the
   Mi-2/nucleosome remodeling and deacetylase (NuRD) complex.
   Transcriptional target analysis revealed that the LSD1/NuRD complexes
   regulate several cellular signaling pathways including TGF beta 1
   signaling pathway that are critically involved in cell proliferation,
   survival, and epithelial-to-mesenchymal transition. We demonstrated
   that LSD1 inhibits the invasion of breast cancer cells in vitro and
   suppresses breast cancer metastatic potential in vivo. We found that
   LSD1 is downregulated in breast carcinomas and that its level of
   expression is negatively correlated with that of TGFb1. Our data
   provide a molecular basis for the interplay of histone demethylation
   and deacetylation in chromatin remodeling. By enlisting LSD1, the NuRD
   complex expands its chromatin remodeling capacity to include ATPase,
   histone deacetylase, and histone demethylase.
C1 [Wang, Yan; Zhang, Hua; Chen, Yupeng; Sun, Yimin; Yang, Fen; Yu, Wenhua; Liang, Jing; Sun, Luyang; Yang, Xiaohan; Shi, Lei; Li, Ruifang; Li, Yanyan; Zhang, Yu; Li, Qian; Yi, Xia; Shang, Yongfeng] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China.
RP Shang, YF, Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab
   Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R
   China.
EM yshang@hsc.pku.edu.cn
FU National Natural Science Foundation of China [30830032, 30621002,
   30470912]; Ministry of Science and Technology of China [2006AA02Z466,
   2005CB522404, 2007CB914503]
FX We thank Joanne Balmer Green (Penn State University) for editorial
   assistance. This work was supported by grants (30830032, 30621002 and
   30470912, to Y.S.) from the National Natural Science Foundation of
   China and grants (863 Program: 2006AA02Z466 and 973 Program:
   2005CB522404 and 2007CB914503, to Y.S.) from the Ministry of Science
   and Technology of China.
CR BOWEN NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI
   10.1016/j.bbaexp.2003.10.010
   CHENG XD, 2007, MUTAT RES-FUND MOL M, V618, P102, DOI
   10.1016/j.mrfmmm.2006.05.041
   DENSLOW SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   DISTEFANO L, 2007, CURR BIOL, V17, P808, DOI 10.1016/j.cub.2007.03.068
   DUMONT N, 2003, CANCER CELL, V3, P531
   FORNERIS F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI
   10.1016/j.tibs.2008.01.003
   FUJITA N, 2003, CELL, V113, P207
   HUANG J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   KAHL P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   KUMAR R, 2003, SEMIN ONCOL S16, V30, P30, DOI
   10.1053/S0093-7754(03)00438-X
   KWON YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI
   10.1073/pnas.0700715104
   LAN F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI
   10.1016/j.ceb.2008.03.004
   LAPING NJ, 2002, MOL PHARMACOL, V62, P58
   LEE MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   LEE MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   MANAVATHI B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200
   MASSAGUE J, 2000, CELL, V103, P295
   MASSAGUE J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   MUKHERJEE S, 2005, J BIOINFORM COMPUT B, V3, P491
   PADUA D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   SASAI N, 2008, CELL, V133, P878, DOI 10.1016/j.cell.2008.03.035
   SHANG YF, 2000, CELL, V103, P843
   SHANG YF, 2002, SCIENCE, V295, P2465
   SHANG YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   SHI B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   SHI Y, 2007, NAT REV GENET, V8, P829
   SHI YJ, 2004, CELL, V119, P941
   SHI YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   SIEGEL PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   THIERY JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   WANG GG, 2007, TRENDS MOL MED, V13, P363, DOI
   10.1016/j.molmed.2007.07.003
   WANG JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678
   WU HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   YAMAZAKI K, 2006, BIOCHEM BIOPH RES CO, V346, P802, DOI
   10.1016/j.bbrc.2006.05.178
   YANG J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   YANG L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   YE ZH, 2008, METH MOL B, V430, P243
   YIN N, 2004, CANCER RES, V64, P5870
   YOU A, 2001, P NATL ACAD SCI USA, V98, P1454
   ZAVADIL J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   ZHANG H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704
   ZHANG H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306
   ZHANG Y, 2007, EMBO J, V26, P2645, DOI 10.1038/sj.emboj.7601710
NR 44
TC 39
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD AUG 21
PY 2009
VL 138
IS 4
BP 660
EP 672
DI 10.1016/j.cell.2009.05.050
PG 13
SC Biochemistry & Molecular Biology; Cell Biology
GA 485WS
UT ISI:000269156100009
ER

PT J
AU Yamada, Y
   Itoh, Y
   Aoki, S
   Nakamura, K
   Taki, T
   Naruse, K
   Tobiume, M
   Zennami, K
   Katsuda, R
   Kato, Y
   Watanabe, M
   Nishikawa, G
   Minami, M
   Nakahira, M
   Ukai, S
   Sawada, M
   Kitamura, A
   Honda, N
AF Yamada, Yoshiaki
   Itoh, Youko
   Aoki, Shigeyuki
   Nakamura, Kogenta
   Taki, Tomohiro
   Naruse, Katsuya
   Tobiume, Motoi
   Zennami, Kenji
   Katsuda, Remi
   Kato, Yoshiharu
   Watanabe, Masahito
   Nishikawa, Genya
   Minami, Miwako
   Nakahira, Mariko
   Ukai, Sayaka
   Sawada, Masaki
   Kitamura, Akiko
   Honda, Nobuaki
TI Preliminary results of M-VAC chemotherapy combined with mild
   hyperthermia, a new therapeutic strategy for advanced or metastatic
   transitional cell carcinoma of the urothelium
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Mild hyperthermia; M-VAC chemotherapy; Heat-shock protein (HSP);
   Transitional cell carcinoma; Urothelial cancer
ID GEMCITABINE PLUS CISPLATIN; MOLECULAR TARGETED THERAPY; IN-SITU
   HYBRIDIZATION; BLADDER-CANCER; RADICAL CYSTECTOMY; PHASE-III;
   METHOTREXATE; VINBLASTINE; DOXORUBICIN; COMBINATION
AB We evaluated the efficacy and safety of M-VAC chemotherapy combined
   with mild hyperthermia, a new therapeutic strategy for advanced
   metastatic transitional cell carcinoma of the urothelium.
   The subjects were 12 patients diagnosed with advanced metastatic
   transitional cell carcinoma of the urothelium. For mild hyperthermia,
   the patients' oral temperature was elevated to about 38A degrees C by
   heating for 20 min and retaining the heat for 20 min with a
   far-infrared heater. The antitumor effect was evaluated according to
   the RECIST, while adverse drug reactions were assessed based on the
   NCI-CTC.
   The antitumor effect was rated as partial remission (PR) in 10 of the
   12 patients and stable disease in 2 patients, with an efficacy rate of
   83% (10/12). All 10 patients who had achieved PR received three courses
   of treatment. Of the 12 patients, 5 died during the observation period,
   with survival for 9-23 months (mean: 15.6 months). Adverse drug
   reactions included myelosuppression in all patients (Grade 3 in 4
   patients, Grade 4 in 8), and gastrointestinal toxicity, such as nausea
   or vomiting, which was mild (Grade 0 in 2 patients, Grade 1 in 8, Grade
   2 in 1, Grade 3 in 1).
   The results of the present study suggest that M-VAC chemotherapy
   combined with mild hyperthermia, which potentiates the anticancer
   effect and reduces adverse drug reactions such as gastrointestinal
   symptoms, is a useful and safe method for the treatment of advanced
   transitional cell carcinoma of the urothelium.
C1 [Yamada, Yoshiaki; Aoki, Shigeyuki; Nakamura, Kogenta; Taki, Tomohiro; Naruse, Katsuya; Tobiume, Motoi; Zennami, Kenji; Katsuda, Remi; Kato, Yoshiharu; Watanabe, Masahito; Nishikawa, Genya; Honda, Nobuaki] Aichi Med Univ, Dept Urol, Sch Med, Aichi 4801195, Japan.
   [Itoh, Youko] Aichi Med Univ, Radioisotope Res Ctr, Sch Med, Aichi, Japan.
   [Minami, Miwako; Nakahira, Mariko; Ukai, Sayaka; Sawada, Masaki; Kitamura, Akiko] Aichi Med Univ Hosp, Div Nursing, Aichi, Japan.
RP Yamada, Y, Aichi Med Univ, Dept Urol, Sch Med, Aichi 4801195, Japan.
EM yy1124@aichi-med-u.ac.jp
CR *NAT CANC I, 2006, NAT CANC I COMM TOX
   AHMED K, 2008, THERMAL MED, V24, P1
   BASSI P, 1999, J UROLOGY, V161, P1494
   CIARDIELLO F, 2000, CLIN CANCER RES, V6, P2053
   DOGLIOTTI L, 2007, EUR UROL, V52, P134, DOI 10.1016/j.eururo.2006.12.029
   GHONEIM MA, 1997, J UROLOGY, V158, P393
   ITOH Y, 2005, JPN J HYPERTHERMIC O, V21, P209
   ITOH Y, 2008, JPN J CLIN PHYSL, V38, P13
   ITOH YH, 2000, INT J HYPERTHER, V16, P183
   JAFFE CC, 2006, J CLIN ONCOL, V24, P1773
   LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066
   MATSUBARA H, 2008, ONCOL REP, V19, P57
   MIYATA K, 2005, JPN J HYPERTHERMIC O, V21, P33
   ONO H, 2006, JPN J HYPERTHERMIC O, V22, P23
   SAXMAN SB, 1997, J CLIN ONCOL, V15, P2564
   SCHUSTER TG, 2001, SEMIN UROL ONCOL, V19, P45
   STERNBERG CN, 1985, J UROLOGY, V133, P403
   STERNBERG CN, 1989, CANCER, V64, P2448
   TERUNUMA H, 2007, THERMAL MED, V23, P41
   VONDERMAASE H, 2000, J CLIN ONCOL, V18, P3068
   VONDERMAASE H, 2005, J CLIN ONCOL, V23, P4602, DOI
   10.1200/JCO.2005.07.757
   WAEHRE H, 1993, CANCER, V72, P3044
   YAMADA Y, 2007, ONCOL REP, V18, P1183
   YATSUZUKA M, 2005, JPN J HYPERTHERMIC O, V21, P231
NR 24
TC 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTHER PHARMACOL
JI Cancer Chemother. Pharmacol.
PD NOV
PY 2009
VL 64
IS 6
BP 1079
EP 1083
DI 10.1007/s00280-009-0964-2
PG 5
SC Oncology; Pharmacology & Pharmacy
GA 485HU
UT ISI:000269112600003
ER

PT J
AU Yang, B
   Zwaans, BMM
   Eckersdorff, M
   Lombard, DB
AF Yang, Bo
   Zwaans, Bernadette M. M.
   Eckersdorff, Mark
   Lombard, David B.
TI The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic
   stability
SO CELL CYCLE
LA English
DT Letter
DE sirtuin; SIRT6; H3 K56Ac; DNA damage; Sir2; chromatin
ID HISTONE H3; ACETYLATION
C1 [Yang, Bo; Zwaans, Bernadette M. M.; Eckersdorff, Mark; Lombard, David B.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Lombard, David B.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA.
RP Lombard, DB, Univ Michigan, Dept Pathol, 3015 BSRB,109 Zina Pitcher Pl,
   Ann Arbor, MI 48109 USA.
EM davidlom@umich.edu
CR DAS C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861
   LISZT G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200
   LOMBARD DB, 2009, AGING-US, V1, P12
   MCCORD RA, 2009, AGING-US, V1, P109
   MICHISHITA E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   MOSTOSLAVSKY R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044
   OZDEMIR A, 2006, CELL CYCLE, V5, P2602
   SCHWER B, 2008, CELL METAB, V7, P104, DOI 10.1016/j.cmet.2007.11.006
   TJEERTES JV, 2009, EMBO J
   YUAN J, 2009, CELL CYCLE, V8, P1747
NR 10
TC 19
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD AUG 15
PY 2009
VL 8
IS 16
BP 2662
EP 2663
PG 2
SC Cell Biology
GA 483QY
UT ISI:000268983900035
ER

PT J
AU Watanabe, J
   Nishimura, Y
   Tsunoda, S
   Kawaguchi, M
   Okayasu, I
   Kuramoto, H
AF Watanabe, Jun
   Nishimura, Yukari
   Tsunoda, Shinpei
   Kawaguchi, Miwa
   Okayasu, Isao
   Kuramoto, Hiroyuki
TI Liquid-Based Preparation for Endometrial Cytology-Usefulness for
   Predicting the Prognosis of Endometrial Carcinoma Preoperatively
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE endometrial carcinoma; endometrial cytology; liquid-based cytology;
   immunocytochemistry; immunohistochemistry; clinicopathologic parameter;
   prognosis
ID PROGESTERONE RECEPTOR-A; ESTROGEN-RECEPTOR; STEROID-RECEPTORS;
   ER-ALPHA; CYCLIN-A; PAP TEST; ADENOCARCINOMA; EXPRESSION; P53;
   PERFORMANCE
AB The authors evaluated the applicability and usefulness of
   immunocytochemical staining for cyclin A, p53, estrogen receptor alpha
   (ER-alpha), and progesterone receptor B (PR-B) as a preoperative
   prognostic indicators for endometrial carcinoma using endometrial
   cytology with the liquid-based cytology (LBC) method. METHODS:
   Cytologic specimens from 44 patients who had endometrial carcinoma were
   prepared with the LBC method. The results of immunocytochemical and
   immunohistochemical staining for cyclin A, p53, ER-alpha, and PR-B were
   compared with clinicopathologic parameters and prognosis. RESULTS:
   Patients who had positive results for cyclin A and p53 and negative
   results for ER-alpha and PR-B appeared to have unfavorable
   clinicopathologic characteristics, such as high-grade histology,
   advanced clinical stage, lymphovascular space involvement (LVSI), and
   deeper myometrial invasion (MI), and had a poor prognosis. In contrast,
   patients who had positive results for ER-alpha and PR-B, and negative
   results for cyclin A and p53 had favorable characteristics, such well
   differentiated tumor, early clinical stage, negative LVSI, and less MI,
   and had a good prognosis. Immunostaining results from cytologic
   specimens obtained in the clinic and at surgery and from histologic
   specimens obtained at surgery were correlated positively. CONCLUSIONS:
   Consistent specimens that were prepared using the LBC method
   facilitated multiple immunocytochemical analyses. Endometrial cytology
   with the LBC method was useful for predicting the prognosis of patients
   with endometrial carcinoma before therapy. Cancer (Cancer Cytopathol)
   2009;117:254-63. (c) 2009 American Cancer Society.
C1 [Watanabe, Jun; Okayasu, Isao] Kitasato Univ, Sch Med, Dept Pathol, Kanagawa 2288555, Japan.
   [Watanabe, Jun; Nishimura, Yukari; Kuramoto, Hiroyuki] Kitasato Univ, Grad Sch Med Sci, Dept Clin Cytol, Kanagawa 2288555, Japan.
   [Tsunoda, Shinpei; Kawaguchi, Miwa; Kuramoto, Hiroyuki] Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Kanagawa 2288555, Japan.
   [Kuramoto, Hiroyuki] Kanagawa Hlth Serv Assoc, Kanagawa, Japan.
RP Watanabe, J, Kitasato Univ, Sch Med, Dept Pathol, 1-15-1 Kitasato,
   Kanagawa 2288555, Japan.
EM watajun@med.kitasato-u.ac.jp
FU Graduate School of Medical Sciences, Kitasato University, Japan
   [1998-A03, 2002-A07]
FX Supported by grants-in-aid for the Integrated Research Program
   (1998-A03 and 2002-A07) of the Graduate School of Medical Sciences,
   Kitasato University, Japan.
CR ALKUSHI A, 2004, INT J GYNECOL PATHOL, V23, P129, DOI
   10.1097/01.pgp.0000116612.98868.fb
   ARNETTMANSFIELD RL, 2001, CANCER RES, V61, P4576
   BEDARD YC, 2003, ACTA CYTOL, V47, P979
   BEERENS E, 2005, CYTOPATHOLOGY, V16, P199
   BIRCAN S, 2005, PATHOL ONCOL RES, V11, P32
   BUCCOLIERO AM, 2007, DIAGN CYTOPATHOL, V35, P398, DOI 10.1002/dc.20655
   DAVISDEVINE S, 2005, AM J CLIN PATHOL, V124, P24, DOI
   10.1309/BFWU29HCC5RCKY5
   ENGELSEN IB, 2006, AM J OBSTET GYNECOL, V195, P979, DOI
   10.1016/j.ajog.2006.02.045
   GARCIA F, 2003, J REPROD MED, V48, P882
   GUO M, 2004, AM J CLIN PATHOL, V122, P894, DOI 10.1309/0DGGQAMJCJBXB
   HU K, 2005, INT J GYNECOL CANCER, V15, P537
   IMAI M, 2001, EUR J GYNAECOL ONCOL, V22, P217
   JOBO T, 2000, EUR J GYNAECOL ONCOL, V21, P119
   JONES JB, 1997, J N AMER BENTHOL SOC, V16, P3
   KAMATA Y, 2004, EUR J GYNAECOL ONCOL, V25, P55
   KYUSHIMA N, 2002, J CANCER RES CLIN, V128, P307
   LEUNG SW, 1999, AM J CLIN PATHOL, V112, P50
   MAKSEM JA, 1996, DIAGN CYTOPATHOL, V14, P367
   MAKSEM JA, 2000, DIAGN CYTOPATHOL, V22, P186
   MIYAMOTO T, 2004, J STEROID BIOCHEM, V92, P111, DOI
   10.1016/j.jsbmb.2004.07.007
   MYLONAS I, 2005, ANTICANCER RES, V25, P1679
   NAKAGAWAOKAMURA C, 2002, ACTA CYTOL, V46, P277
   NEGRI G, 2003, AM J SURG PATHOL, V27, P187
   NISHIMURA Y, 2005, CANCER CYTOPATHOL, V105, P8, DOI 10.1002/cncr.20787
   ONO E, 1988, J JPN SOC CYTOL, V27, P449
   ORESKOVIC S, 2004, GYNECOL ONCOL, V93, P34, DOI
   10.1016/j.ygyno.2003.12.038
   PAPAEFTHIMIOU M, 2005, CANCER CYTOPATHOL, V105, P56, DOI
   10.1002/cncr.21025
   PAPAEFTHIMIOU M, 2005, CYTOPATHOLOGY, V16, P32
   SAQI A, 2002, DIAGN CYTOPATHOL, V27, P365, DOI 10.1002/dc.10205
   SASS MA, 2004, ACTA CYTOL, V48, P17
   SHIH HC, 2003, HUM PATHOL, V34, P471, DOI 10.1016/S0046-8177(03)00124-2
   STUDEMAN KD, 2003, ACTA CYTOL, V47, P605
   TISSERAND P, 2003, CANCER CYTOPATHOL, V99, P223, DOI 10.1002/cncr.11258
   WATANABE J, 2003, CELL MOL BIOL ENDOME, P225
NR 34
TC 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1934-662X
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD AUG 25
PY 2009
VL 117
IS 4
BP 254
EP 263
DI 10.1002/cncy.20035
PG 10
SC Oncology; Pathology
GA 484CX
UT ISI:000269022000003
ER

PT J
AU Tsukuda, M
   Ishitoya, J
   Mikami, Y
   Matsuda, H
   Horiuchi, C
   Taguchi, T
   Satake, K
   Kawano, T
   Takahashi, M
   Nishimura, G
   Kawakami, M
   Sakuma, Y
   Watanabe, M
   Shiono, O
   Komatsu, M
   Yamashita, Y
AF Tsukuda, Mamoru
   Ishitoya, Junichi
   Mikami, Yasukazu
   Matsuda, Hideki
   Horiuchi, Choichi
   Taguchi, Takahide
   Satake, Kenichi
   Kawano, Toshiro
   Takahashi, Masahiro
   Nishimura, Goshi
   Kawakami, Mariko
   Sakuma, Yasunori
   Watanabe, Makiko
   Shiono, Osamu
   Komatsu, Masanori
   Yamashita, Yukiko
TI Analysis of feasibility and toxicity of concurrent chemoradiotherapy
   with S-1 for locally advanced squamous cell carcinoma of the head and
   neck in elderly cases and/or cases with comorbidity
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE S-1; Chemoradiotherapy; Elderly cases; Cases with comorbidity
ID POOR PERFORMANCE STATUS; RADIATION-THERAPY; ORAL FLUOROPYRIMIDINE;
   ORGAN PRESERVATION; PHASE-I; CANCER; 5-FLUOROURACIL; CISPLATIN;
   CHEMOTHERAPY; RADIOTHERAPY
AB The aim of this study was to evaluate the feasibility and toxicity of
   concurrent chemoradiotherapy (CCRT) with S-1 in patients with locally
   advanced squamous cell carcinoma of the head and neck (SCCHN) in
   elderly cases and/or cases with comorbidity.
   Fifty eligible patients with stage III (15 cases) or stage IV (35
   cases) SCCHN were treated with CCRT. Thirteen cases had an advanced age
   of over 75 years and 37 cases had comorbidity. Definitive radiotherapy
   was delivered up to a total dose of 66-70.2 Gy. The patients received
   two courses of oral S-1 (40 or 50 mg twice a day [80 or 100 mg/day])
   for 2 weeks followed by 1 week of rest while receiving CCRT.
   All the patients received the planned radiotherapy and at least one
   course of S-1. Grade 3 mucositis occurred in 20% of the patients
   (10/50). Grade 3 neutropenia occurred in 12% (6/50) and leukocytopenia
   occurred in 6% (3/50) of the cases. Pathologically, the complete
   response rates were 93% in stage III and 54% in stage IV.
   Concurrent chemoradiotherapy with S-1 is a safe, well-tolerated and
   effective regimen for locally advanced SCCHN in elderly cases and/or
   cases with comorbidity.
C1 [Tsukuda, Mamoru; Mikami, Yasukazu; Matsuda, Hideki; Horiuchi, Choichi; Taguchi, Takahide; Satake, Kenichi; Takahashi, Masahiro; Nishimura, Goshi; Kawakami, Mariko; Watanabe, Makiko] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan.
   [Ishitoya, Junichi; Kawano, Toshiro; Sakuma, Yasunori; Shiono, Osamu; Komatsu, Masanori; Yamashita, Yukiko] Yokohama City Univ, Med Ctr, Dept Otorhinolaryngol, Minami Ku, Yokohama, Kanagawa 2320024, Japan.
RP Tsukuda, M, Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head &
   Neck Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM mtsukuda@med.yokohama-cu.ac.jp
CR ADELSTEIN DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008
   BENSADOUN RJ, 2006, INT J RADIAT ONCOL, V64, P983, DOI
   10.1016/j.ijrobp.2005.09.041
   BYFIELD JE, 1982, INT J RADIAT ONCOL, V8, P1923
   COHEN EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147
   DOUPLE EB, 1985, CANCER TREAT REV, V12, P111
   FORASTIERE AA, 2003, NEW ENGL J MED, V349, P2091
   FUJII M, 2004, INT J CLIN ONCOL, V9, P107
   HARADA K, 2005, CANCER LETT, V226, P161, DOI
   10.1016/j.canlet.2004.12.048
   HARADA K, 2007, ONCOL REP, V18, P1077
   HIRATA K, 1999, CLIN CANCER RES, V5, P2000
   INUYAMA Y, 2001, GAN TO KAGAKU RYOHO, V28, P1381
   JEREMIC B, 1997, RADIOTHER ONCOL, V43, P29
   KATORI H, 2004, BRIT J CANCER, V90, P348, DOI 10.1038/sj.bjc.660147
   KATORI H, 2007, ACTA OTO-LARYNGOL, V127, P1099, DOI
   10.1080/00016480701200251
   KATORI H, 2007, CANCER CHEMOTH PHARM, V59, P789, DOI
   10.1007/s00280-006-0335-1
   KOSMAS C, 2008, J CANCER RES CLIN, V134, P75, DOI
   10.1007/s00432-007-0250-9
   KOUSSIS H, 2008, ANTICANCER RES, V28, P1383
   LO TCM, 1976, AM J ROENTGENOL, V126, P229
   NAKATA E, 2006, ONCOL REP, V16, P465
   NISHIMURA G, 2007, INT J CLIN ONCOL, V12, P120
   POSNER MR, 2007, NEW ENGL J MED, V357, P1705
   SCHOFFSKI P, 2004, ANTI-CANCER DRUG, V15, P85, DOI
   10.1097/01.cad.0000114631.91268.39
   SEIWERT TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510
   SHIRASAKA T, 1996, ANTI-CANCER DRUG, V7, P548
   SHIRASAKA T, 1996, CANCER RES, V56, P2602
   SMALLEY SR, 1991, INT J RADIAT ONCOL, V20, P207
   TAGUCHI T, 2006, ACTA OTO-LARYNGOL, V126, P408, DOI
   10.1080/00016480500401019
   TSUJI H, 2006, ONCOLOGY-BASEL, V71, P369, DOI 10.1159/000108385
   TSUKUDA M, 2005, BRIT J CANCER, V93, P884, DOI 10.1038/sj.bjc.6602804
   URBA SG, 2005, J CLIN ONCOL, V23, P88, DOI 10.1200/JCO.2005.04.017
   YAMADA Y, 2003, BRIT J CANCER, V89, P816, DOI 10.1038/sj.bjc.6601224
NR 31
TC 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTHER PHARMACOL
JI Cancer Chemother. Pharmacol.
PD OCT
PY 2009
VL 64
IS 5
BP 945
EP 952
DI 10.1007/s00280-009-0946-4
PG 8
SC Oncology; Pharmacology & Pharmacy
GA 484VN
UT ISI:000269076700011
ER

PT J
AU Peng, PD
   Cohen, CJ
   Yang, S
   Hsu, C
   Jones, S
   Zhao, Y
   Zheng, Z
   Rosenberg, SA
   Morgan, RA
AF Peng, P. D.
   Cohen, C. J.
   Yang, S.
   Hsu, C.
   Jones, S.
   Zhao, Y.
   Zheng, Z.
   Rosenberg, S. A.
   Morgan, R. A.
TI Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer
   to peripheral blood lymphocytes confers antigen-specific antitumor
   reactivity
SO GENE THERAPY
LA English
DT Article
DE Sleeping Beauty transposon; TCR gene therapy; adoptive immunotherapy;
   nonviral vector; T-cell gene transfer
ID ADOPTIVE CELL TRANSFER; PRIMARY T-CELLS; HUMAN TUMOR; MUTATIONAL
   ANALYSIS; RETROVIRAL VECTOR; TRANSFER THERAPY; EXPRESSION; CANCER;
   INTEGRATION; SYSTEM
AB Genetically engineered lymphocytes hold promise for the treatment of
   genetic disease, viral infections and cancer. However, current methods
   for genetic transduction of peripheral blood lymphocytes rely on viral
   vectors, which are hindered by production and safety-related problems.
   In this study, we demonstrated an efficient novel nonviral platform for
   gene transfer to lymphocytes. The Sleeping Beauty transposon-mediated
   approach allowed for long-term stable expression of transgenes at
   similar to 50% efficiency. Utilizing transposon constructs expressing
   tumor antigen-specific T-cell receptor genes targeting p53 and MART-1,
   we demonstrated sustained expression and functional reactivity of
   transposon-engineered lymphocytes on encountering target antigen
   presented on tumor cells. We found that transposon- and
   retroviral-modified lymphocytes had comparable transgene expression and
   phenotypic function. These results demonstrate the promise of nonviral
   ex vivo genetic modification of autologous lymphocytes for the
   treatment of cancer and immunologic disease. Gene Therapy (2009) 16,
   1042-1049; doi: 10.1038/gt.2009.54; published online 4 June 2009
C1 [Peng, P. D.; Cohen, C. J.; Yang, S.; Hsu, C.; Jones, S.; Zhao, Y.; Zheng, Z.; Rosenberg, S. A.; Morgan, R. A.] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Morgan, RA, NCI, Surg Branch, Ctr Canc Res, NIH, 10 Ctr Dr,Bldg 10,CRC
   3W-3864, Bethesda, MD 20892 USA.
EM rmorgan@mail.nih.gov
FU National Institute of Health, National Cancer Institute, Center for
   Cancer Research 
FX We thank Dr Steven R Yant and Dr Mark A Kay of the Departments of
   Pediatrics and Genetics, Stanford University School of Medicine,
   Stanford, CA, for their generous gift of the Sleeping Beauty transposon
   plasmids and hyperactive transposase, as well as for their helpful
   suggestions on this project. We thank FACS lab and TIL lab in Surgery
   Branch for providing technical support and maintenance of tumor cells
   from patients. This work is supported by the Intramural Research
   Program of the National Institute of Health, National Cancer Institute,
   Center for Cancer Research.
CR CAVALIERI S, 2003, BLOOD, V102, P497, DOI 10.1182/blood-2003-01-0297
   COHEN CJ, 2005, J IMMUNOL, V175, P5799
   COHEN CJ, 2006, CANCER RES, V66, P8878, DOI
   10.1158/0008-5472.CAN-06-1450
   DUDLEY ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240
   DUDLEY ME, 2007, SEMIN ONCOL, V34, P524, DOI
   10.1053/j.seminoncol.2007.09.002
   GATTINONI L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480
   GEURTS AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6
   HACEINBEYABINA S, 2003, NEW ENGL J MED, V348, P255
   HACKETT PB, 2005, ADV GENET, V54, P189
   HUANG X, 2006, BLOOD, V107, P483, DOI 10.1182/blood-2005-05-2133
   HUANG X, 2008, MOL THER, V16, P580, DOI 10.1038/sj.mt.6300404
   HUGHES MS, 2005, HUM GENE THER, V16, P457
   IVICS Z, 2006, CURR GENE THER, V6, P593
   IVICS Z, 2007, MOL THER, V15, P1137, DOI 10.1038/sj.mt.6300169
   JOHNSON LA, 2006, J IMMUNOL, V177, P6548
   KERSHAW MH, 2005, NAT REV IMMUNOL, V5, P928, DOI 10.1038/nri1729
   KERSHAW MH, 2006, CLIN CANCER RES 1, V12, P6106, DOI
   10.1158/1078-0432.CCR-06-1183
   KUBALL J, 2005, IMMUNITY, V22, P117, DOI 10.1016/j.immuni.2004.12.005
   LAMERS CH, 2006, J CLIN ONCOL, V24, E20
   LIU GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086
   LIU L, 2006, MOL THER, V13, P1006, DOI 10.1016/j.ymthe.2005.11.021
   LIZEE G, 2004, HUM GENE THER, V15, P393
   MORGAN RA, 2003, J IMMUNOL, V171, P3287
   MORGAN RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003
   ORTIZURDA S, 2003, GENE THER, V10, P1099, DOI 10.1038/sj.gt.3301978
   PANNELL D, 2001, REV MED VIROL, V11, P205
   PARK JR, 2007, MOL THER, V15, P825, DOI 10.1038/mt.sj.6300104
   RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189
   ROSENBERG SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355
   SINGH H, 2008, CANCER RES, V68, P2961, DOI 10.1158/0008-5472.CAN-07-5600
   SU Z, 2003, CANCER RES, V63, P2127
   SWINDLE CS, 2002, J HEMATOTH STEM CELL, V11, P449
   SZYMCZAK AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957
   TILL BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843
   WILBER A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014
   WU XL, 2003, SCIENCE, V300, P1749
   YANT SR, 2000, NAT GENET, V25, P35
   YANT SR, 2004, MOL CELL BIOL, V24, P9239, DOI
   10.1128/MCB.24.20.92309-9247.2004
   YANT SR, 2005, MOL CELL BIOL, V25, P2085, DOI
   10.1128/MCB.25.6.2085-2094.2005
   YANT SR, 2007, NUCLEIC ACIDS RES, V35, ARTN e50
   ZAYED H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024
   ZHAO YB, 2005, J IMMUNOL, V174, P4415
   ZHAO YB, 2006, MOL THER, V13, P151, DOI 10.1016/j.ymthe.2005.07.688
   ZHOU XZ, 2003, HUM GENE THER, V14, P1089
NR 44
TC 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD AUG
PY 2009
VL 16
IS 8
BP 1042
EP 1049
DI 10.1038/gt.2009.54
PG 8
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 482VH
UT ISI:000268916800012
ER

PT J
AU Yuan, GH
   Wang, YH
   Gluhak-Heinrich, J
   Yang, GB
   Chen, L
   Li, T
   Wu, LA
   Chen, Z
   MacDougall, M
   Chen, S
AF Yuan, Guohua
   Wang, Yinghua
   Gluhak-Heinrich, Jelica
   Yang, Guobin
   Chen, Lei
   Li, Tong
   Wu, Li-An
   Chen, Zhi
   MacDougall, Mary
   Chen, Shuo
TI Tissue-specific expression of dentin sialophosphoprotein (DSPP) and its
   polymorphisms in mouse tissues
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Dentin sialophosphoprotein (DSPP); Dentin sialoprotein (DSP); Dentin
   phosphoprotein (DPP); Polymorphism; Dentinogenesis
ID CASEIN KINASE-I; SUBSTRATE DETERMINANTS; SPATIAL EXPRESSION; MATRIX
   PROTEIN-1; SIALOPROTEIN DSP; GENE; PHOSPHOPROTEIN; BIOMINERALIZATION;
   PHOSPHOPHORYN; MUTATIONS
AB Dentin sialophosphoprotein (DSPP) consists of dentin sialoprotein (DSP)
   and dentin phosphoprotein (DPP). DSPP is highly expressed in
   mineralized tissues. However, recent studies have shown that DSPP is
   also expressed in several active metabolic ductal epithelial tissues
   and exists in a variety of sequences. We have investigated DSPP
   expression in various mouse tissues using RT-PCR, in situ hybridization
   and immunohistochemical analyses. To identify DSPP gene polymorphisms,
   we screened a mouse tooth cDNA library as well as isolated and
   characterized DSPP variations. Our results show that DSPP is
   predominantly expressed in teeth and moderately in bone tissues. We
   also have characterized a full-length DSPP cDNA clone with an
   open-reading frame of 940 codons and this polyadenylation signal.
   Compared to previously reported mouse DSPP cDNAs, 13 sequence
   variations were identified, including 8 non-synonymous single
   nucleotide polymorphisms and an in-frame indel (8 amino acids) at DPP
   domain of the mouse DSPP. These 8 amino acids are rich in aspartic acid
   and serine residues. Northern blot assay showed a prominent band at 4.4
   kb. RT-PCR demonstrated that this mouse DSPP gene was dominantly
   expressed in teeth. The predicted secondary structure of DPP domain of
   this DSPP showed differences from the previously published mouse DPPs,
   implying that they play different roles during tooth development and
   formation. (C) 2009 International Federation for Cell Biology.
   Published by Elsevier Ltd. All rights reserved.
C1 [MacDougall, Mary] Univ Alabama, Sch Dent, Dept Oral Maxillofacial Surg, Birmingham, AL 35294 USA.
   [Yuan, Guohua; Wang, Yinghua; Yang, Guobin; Chen, Lei; Li, Tong; Wu, Li-An; Chen, Shuo] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat Dent, San Antonio, TX 78229 USA.
   [Gluhak-Heinrich, Jelica] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthoped, Sch Dent, San Antonio, TX 78229 USA.
   [Yuan, Guohua] Wuhan Univ, Key Lab Oral Biomed Engn, Minist Educ, Sch & Hosp Stomatol, Wuhan 430072, Peoples R China.
   [Chen, Zhi] Wuhan Univ, Dept Cariol & Endodont, Sch & Hosp Stomatol, Wuhan 430072, Peoples R China.
RP MacDougall, M, Univ Alabama, Sch Dent, Dept Oral Maxillofacial Surg,
   1919 7th Ave S,SDB 702, Birmingham, AL 35294 USA.
EM macdougall@uab.edu
   chens0@uthscsa.edu
FU NIDCR, National Institutes of Health [DE113221, DE019802]; China
   Scholarship Council Award [CSC20073020]
FX We thank Dr Russel Reiter for critical reading of the manuscript. This
   work was supported by NIDCR, National Institutes of Health, Grant
   DE113221 (M. M.), DE019802 (S. C.) and China Scholarship Council Award
   CSC20073020 (G. Y.).
CR ALVARES K, 2006, DEV DYNAM, V235, P2980, DOI 10.1002/dvdy.20935
   BABA O, 2004, EUR J ORAL SCI, V112, P163
   BENJAMIN JB, 2006, CELL, V126, P37
   CHEN S, 2002, CONNECT TISSUE RES, V43, P338
   CHEN S, 2005, J BIOL CHEM, V280, P29717, DOI 10.1074/jbc.M502929200
   DAHLIN S, 1998, EUR J ORAL SCI S1, V106, P239
   DSOUZA RN, 1997, J BONE MINER RES, V12, P2040
   EVERETT CM, 2004, BRAIN 11, V127, P2385, DOI 10.1093/brain/awh278
   FENG JQ, 1998, J BIOL CHEM, V273, P9457
   FLOTOW H, 1990, J BIOL CHEM, V265, P14264
   FLOTOW H, 1991, J BIOL CHEM, V266, P3724
   GEORGE A, 1993, J BIOL CHEM, V268, P12624
   GREENAMYRE JT, 2007, NEW ENGL J MED, V356, P518
   GU K, 2000, EUR J ORAL SCI, V108, P35
   HAO JJ, 2009, J HISTOCHEM CYTOCHEM, V57, P227, DOI
   10.1369/jhc.2008.952119
   HE G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200
   JOHNSON JM, 2003, SCIENCE, V302, P2141
   KIM JW, 2007, J DENT RES, V86, P392
   LAIZE V, 2006, J BIOL CHEM, V281, P15037, DOI 10.1074/jbc.M600373200
   LINDE A, 1993, CRIT REV ORAL BIOL M, V4, P679
   MACDOUGALL M, 1997, J BIOL CHEM, V272, P835
   MACDOUGALL M, 1998, J BONE MINER RES, V13, P422
   MCKNIGHT DA, 2008, HUM MUTAT, V29, P1392, DOI 10.1002/humu.20783
   MOOERS BHM, 2005, P NATL ACAD SCI USA, V102, P16626, DOI
   10.1073/pnas.0505873102
   NAPIERALA M, 2005, J BIOL CHEM, V280, P37366, DOI 10.1074/jbc.M508065200
   OGBUREKE KUE, 2005, KIDNEY INT, V68, P155
   PAINE ML, 2005, J BIOL CHEM, V280, P31991, DOI 10.1074/jbc.M502991200
   QIN C, 2002, J DENT RES, V81, P392
   RAJPAR MH, 2002, HUM MOL GENET, V11, P2559
   RITCHIE HH, 1997, EUR J ORAL SCI 1, V105, P405
   RITCHIE HH, 2000, BBA-GENE STRUCT EXPR, V1493, P27
   RITCHIE HH, 2001, BBA-GENE STRUCT EXPR, V1520, P212
   SAMBROK J, 2001, MOL CLONING LAB MANU
   SFEIR C, 1998, P 6 INT C VITT FRANC, P181
   SONG YL, 2008, J MED GENET, V45, P457, DOI 10.1136/jmg.2007.056911
   SREENATH T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200
   STOLC V, 2004, SCIENCE, V306, P655
   TRAUB W, 1992, MATRIX, V12, P251
   VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409
   VERDELIS K, 2008, BONE, V43, P983, DOI 10.1016/j.bone.2008.08.110
   WHITE SN, 2007, J BIOL CHEM, V282, P5340, DOI 10.1074/jbc.M604814200
   XIAO SX, 2001, NAT GENET, V27, P201
   YAMAKOSHI Y, 2003, EUR J ORAL SCI, V111, P60
   YAMAKOSHI Y, 2005, J BIOL CHEM, V280, P17472, DOI 10.1074/jbc.M413220200
   YAMAKOSHI Y, 2008, J BIOL CHEM, V283, P14835, DOI 10.1074/jbc.M800633200
NR 45
TC 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD AUG
PY 2009
VL 33
IS 8
BP 816
EP 829
DI 10.1016/j.cellbi.2009.05.001
PG 14
SC Cell Biology
GA 481HT
UT ISI:000268799100002
ER

PT J
AU Yang, K
   Jiang, ZL
   Wang, D
   Lian, XH
   Yang, T
AF Yang, Ke
   Jiang, Zilin
   Wang, Dong
   Lian, Xiaohua
   Yang, Tian
TI Corneal epithelial-like transdifferentiation of hair follicle stem
   cells is mediated by pax6 and beta-catenin/Lef-1
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Hair follicle stem cells; Cornea; Pax6; beta-Catenin; Lef-1;
   Transdifferentiation; k12
ID OCULAR SURFACE; BETA-CATENIN; BULGE; SKIN; DIFFERENTIATION;
   RECONSTRUCTION; ENRICHMENT; EPIDERMIS; ANIRIDIA
AB Several types of adult stem cells are capable of transdifferentiaton
   into other types of tissues. The hair follicle bulge area is an
   abundant and easily accessible source of pluripotent adult stem cells.
   We demonstrate that the bulge KSCs have the potential for
   transdifferentiation into corneal epithelial-like cells. Bulge KSCs
   isolated by collagen type IV adhesiveness possessed the highest colony
   formation efficiency (CFE), and expressed specific markers (CD34 and
   alpha 6-integrin). The isolated cells transdifferentiate into corneal
   epithelial-like cells in conditioned medium containing corneal limbus
   soluble factors, including their specific marker, keratin12. The
   transdifferentiation depends on upregulation of pax6 and downregulation
   of beta-catenin and Lef-1. Furthermore, overexpression of pax6 in bulge
   KSCs induced their expression of k12. The expressions of beta-catenin
   and Lef-1 were not suppressed in the pax6-transfected bulge KSCs, but
   which were downregulated pax6-transfected cells cultured in the
   conditioned medium. Bulge KSCs may have potential therapeutic
   application as cell source for the construction of bioengineered
   corneas. (C) 2009 International Federation for Cell Biology. Published
   by Elsevier Ltd. All rights reserved.
C1 [Yang, Ke; Lian, Xiaohua; Yang, Tian] Third Mil Med Univ, Dept Cell Biol, Chongqing 400038, Peoples R China.
   [Jiang, Zilin] Chongqing Univ, Bioengn Coll, Chongqing 400038, Peoples R China.
   [Wang, Dong] Third Mil Med Univ, Dept Ultrasound, XinQiao Hosp, Chongqing 400038, Peoples R China.
RP Lian, XH, Third Mil Med Univ, Dept Cell Biol, Chongqing 400038, Peoples
   R China.
EM tiany@163.net
FU Chongqing Science and Technology Commission [CSTC 2004AC5074]
FX We thank Dr. Masaharu Sakai, Hokkaido University Graduate School of
   Medicine, Japan for providing the plasmid pAct/Pax6. This work was
   supported by Chongqing Science and Technology Commission (No. CSTC
   2004AC5074).
CR AHMAD S, 2007, STEM CELLS, V25, P1145, DOI 10.1634/stemcells.2006-0516
   AMOH Y, 2004, P NATL ACAD SCI USA, V101, P13291, DOI
   10.1073/pnas.0405250101
   AMOH Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI
   10.1073/pnas.0501263102
   COLLINSON JM, 2003, DEV BIOL, V255, P303, DOI
   10.1016/S0012-1606(02)00095-7
   COTSARELIS G, 1989, CELL, V57, P201
   GOTTARDI CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153
   HAYASHIDA Y, 2005, INVEST OPHTH VIS SCI, V46, P1632, DOI
   10.1167/iovs.04-0813
   HUELSKEN J, 2001, CELL, V105, P533
   JONES PH, 1993, CELL, V73, P713
   KIM DS, 2004, CELL MOL LIFE SCI, V61, P2774, DOI
   10.1007/s00018-004-4288-4
   LIU JJ, 1999, EXP EYE RES, V68, P295
   MUKHOPADHYAY M, 2006, DEVELOPMENT, V133, P2149, DOI 10.1242/dev.02381
   OHYAMA M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
   PEARTON DJ, 2005, P NATL ACAD SCI USA, V102, P3714, DOI
   10.1073/pnas.0500344102
   RAMAESH T, 2003, INVEST OPHTH VIS SCI, V44, P1871, DOI
   10.1167/iovs.02-0576
   RAMAESH T, 2005, EXP EYE RES, V81, P224, DOI 10.1016/j.exer.2005.02.002
   RIVERA FJ, 2006, NEUROSCI LETT, V406, P49, DOI
   10.1016/j.neulet.2006.07.049
   SIEBERBLUM M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129
   TAYLOR G, 2000, CELL, V102, P451
   TREMPUS CS, 2003, J INVEST DERMATOL, V120, P501
   UENO H, 2007, CORNEA, V26, P1220
   ZHOU JX, 2004, HUM REPROD, V19, P968, DOI 10.1093/humrep/deh166
NR 22
TC 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD AUG
PY 2009
VL 33
IS 8
BP 861
EP 866
DI 10.1016/j.cellbi.2009.04.009
PG 6
SC Cell Biology
GA 481HT
UT ISI:000268799100007
ER

PT J
AU Yamaguchi, N
   Ito, T
   Azuma, S
   Ito, E
   Honma, R
   Yanagisawa, Y
   Nishikawa, A
   Kawamura, M
   Imai, J
   Watanabe, S
   Semba, K
   Inoue, J
AF Yamaguchi, Noritaka
   Ito, Taku
   Azuma, Sakura
   Ito, Emi
   Honma, Reiko
   Yanagisawa, Yuka
   Nishikawa, Akira
   Kawamura, Mika
   Imai, Jun-ichi
   Watanabe, Shinya
   Semba, Kentaro
   Inoue, Jun-ichiro
TI Constitutive activation of nuclear factor-kappa B is preferentially
   involved in the proliferation of basal-like subtype breast cancer cell
   lines
SO CANCER SCIENCE
LA English
DT Article
ID MAMMARY-GLAND DEVELOPMENT; REED-STERNBERG CELLS; GENE-EXPRESSION;
   MULTIPLE-MYELOMA; KINASE; PROGRESSION; TUMORS; DIFFERENTIATION;
   TUMORIGENESIS; RECEPTOR
AB Constitutive nuclear factor (NF)-kappa B activation is thought to be
   involved in survival, invasion, and metastasis in various types of
   cancers. However, neither the subtypes of breast cancer cells with
   constitutive NF-kappa B activation nor the molecular mechanisms leading
   to its constitutive activation have been clearly defined. Here, we
   quantitatively analyzed basal NF-kappa B activity in 35 human breast
   cancer cell lines and found that most of the cell lines with high
   constitutive NF-kappa B activation were categorized in the estrogen
   receptor negative, progesterone receptor negative, ERBB2 negative
   basal-like subtype, which is the most malignant form of breast cancer.
   Inhibition of constitutive NF-kappa B activation by expression of I
   kappa B alpha super-repressor reduced proliferation of the basal-like
   subtype cell lines. Expression levels of mRNA encoding NF-kappa
   B-inducing kinase (NIK) were elevated in several breast cancer cell
   lines, and RNA interference-mediated knockdown of NIK reduced NF-kappa
   B activation in a subset of the basal-like subtype cell lines with
   upregulated NIK expression. Taken together, these results suggest that
   constitutive NF-kappa B activation, partially dependent on NIK, is
   preferentially involved in proliferation of basal-like subtype breast
   cancer cells and may be a useful therapeutic target for this subtype of
   cancer. (Cancer Sci 2009; 100: 1668-1674).
C1 [Yamaguchi, Noritaka; Ito, Taku; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Tokyo, Japan.
   [Azuma, Sakura; Semba, Kentaro] Waseda Univ, Dept Life Sci & Med Biosci, Tokyo, Japan.
   [Yamaguchi, Noritaka; Semba, Kentaro] Consolidated Res Inst Adv Sci Med Care, Tokyo, Japan.
   [Ito, Emi; Honma, Reiko; Yanagisawa, Yuka; Nishikawa, Akira; Kawamura, Mika; Imai, Jun-ichi; Watanabe, Shinya] Fukushima Med Univ, Tokyo Branch, Dept Clin Genom, Translat Res Ctr, Tokyo, Japan.
   [Nishikawa, Akira] Nippon Gene Co, Toyama, Japan.
   [Kawamura, Mika] Medicrome, Kanagawa, Japan.
RP Inoue, J, Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, 4-6-1
   Shirokanedai, Tokyo, Japan.
EM jun-i@ims.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan 
FX We thank Dr Y. Kanegae and Dr I. Saito (University of Tokyo, Japan) for
   preparation of the adenoviral vectors. We also thank Ms K. Shimizu, M.
   Hashimoto, J. Kuritani, and K. Semba for secretarial assistance. This
   study was supported by a Grant-in-Aid for Scientific Research on
   Priority Areas and 'Establishment of Consolidated Research Institute
   for Advanced Science and Medical Care' Project, Ministry of Education,
   Culture, Sports, Science, and Technology, Japan; 'Encouraging
   Development Strategic Research Centers Program', New Energy and
   Industrial Technology Development Organization.
CR ANNUNZIATA CM, 2007, CANCER CELL, V12, P115, DOI
   10.1016/j.ccr.2007.07.004
   BENPORATH I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   BERTRAND MJM, 2008, MOL CELL, V30, P689, DOI
   10.1016/j.molcel.2008.05.014
   BISWAS DK, 2004, P NATL ACAD SCI USA, V101, P10137
   BOEHM JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   CAO YX, 2001, CELL, V107, P763
   CAO YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI
   10.1073/pnas.0706728104
   CHARAFEJAUFFRET E, 2006, ONCOGENE, V25, P2273, DOI
   10.1038/sj.onc.1209254
   DHAWAN P, 2008, J BIOL CHEM, V283, P15399, DOI 10.1074/jbc.M708272200
   FATA JE, 2000, CELL, V103, P41
   FURUTA S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI
   10.1073/pnas.0503793102
   HAYDEN MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   HONETH G, 2008, BREAST CANCER RES, V10, ARTN R53
   HORIE R, 2002, ONCOGENE, V21, P2493
   INOUE J, 2007, CANCER SCI, V98, P268, DOI
   10.1111/j.1349-7006.2007.00389.x
   ITO E, 2007, FEBS LETT, V581, P3909, DOI 10.1016/j.febslet.2007.07.016
   KARIN M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   KEATS JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   KISHORE N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200
   LEE H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   LIAO GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   LIU MR, 2009, AM J PATHOL, V174, P1910, DOI 10.2353/ajpath.2009.080706
   LIU S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI
   10.1073/pnas.0711613105
   MAHONEY DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI
   10.1073/pnas.0711122105
   NAKSHATRI H, 1997, MOL CELL BIOL, V17, P3629
   NEVE RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   NISHIMURA T, 2000, AM J REPROD IMMUNOL, V43, P351
   PETERS RT, 2000, MOL CELL, V5, P513
   RAKHA EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   SAITOH Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635
   SMALLEY M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212
   STINGL J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2112
   VARFOLOMEEV E, 2008, J BIOL CHEM, V283, P24295, DOI
   10.1074/jbc.C800128200
   VARGOGOGOLA T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   YAMAGUCHI N, 2008, CANCER RES, V68, P1881, DOI
   10.1158/0008-5472.CAN-07-1597
NR 35
TC 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD SEP
PY 2009
VL 100
IS 9
BP 1668
EP 1674
DI 10.1111/j.1349-7006.2009.01228.x
PG 7
SC Oncology
GA 482XL
UT ISI:000268923800016
ER

PT J
AU Fu, HY
   Xue, DY
   Zhang, XD
   Yang, PY
AF Fu, Hao-Yue
   Xue, Ding-Yu
   Zhang, Xiang-de
   Yang, Pei-Ying
TI Assessing potential miRNA targets based on a Markov model
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Markov chain model; Machine-learning method; MicroRNA target
   prediction; Maximum likelihood estimation; Potential target assessment
ID MICRORNA TARGETS; COMPUTATIONAL IDENTIFICATION; BINDING-SITES;
   PREDICTION; DROSOPHILA; MICROINSPECTOR; SEQUENCE; GENES
AB At present, studies on microRNA mainly focus on the identification of
   microRNA genes and their mRNA targets. Although researchers have
   identified many microRNA genes, relatively few microRNA targets have
   been identified by experimental methods. Computational programs
   designed for predicting potential microRNA targets provide numerous
   targets for experimental validation. We used a Markov model to examine
   base-pairing binding patterns of known microRNA targets. Using this
   model, potential microRNA targets in human species predicted by four
   well-known computational programs were assessed. Each potential target
   was assigned a score reflecting consistency with known target binding
   patterns. Targets with scores higher than the cutoff value would be
   identified by our model. The predicted targets identified by our model
   have base-pairing binding patterns consistent with known targets. This
   model was efficient for evaluating the extent to which a potential
   target was accurately predicted.
C1 [Fu, Hao-Yue; Zhang, Xiang-de] Northeastern Univ, Coll Sci, Shenyang, Peoples R China.
   [Fu, Hao-Yue; Xue, Ding-Yu; Yang, Pei-Ying] Northeastern Univ, Coll Informat Sci & Engn, Shenyang, Peoples R China.
RP Fu, HY, Northeastern Univ, Coll Sci, Shenyang, Peoples R China.
EM fuhaoyue@tom.com
CR BRENNECKE J, 2003, CELL, V113, P25
   BROWN JR, 2005, DRUG DISCOV TODAY, V10, P595
   BURGLER C, 2005, BMC GENOMICS, V6, ARTN 88
   DAVIS N, 2008, COMPUT BIOL CHEM, V32, P222, DOI
   10.1016/j.compbiolchem.2008.02.004
   ENRIGHT AJ, 2004, GENOME BIOL, V5, ARTN R1
   GRUN D, 2005, PLOS COMPUT BIOL, V1, P51, ARTN e13
   JOHN B, 2004, PLOS BIOL, V2, P1862, ARTN e363
   KAWASAKI H, 2005, PURE APPL CHEM, V77, P313, DOI 10.1351/pac200577010313
   KIM SK, 2006, BMC BIOINFORMATICS, V7, ARTN 411
   KIRIAKIDOU M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704
   KREK A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   LEWIS BP, 2003, CELL, V115, P787
   LEWIS BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   PEKARSKY Y, 2006, CANCER RES, V66, P11590, DOI
   10.1158/0008-5472.CAN-06-3613
   POY MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   RAJEWSKY N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003
   REHMSMEIER M, 2004, RNA, V10, P1507, DOI 10.1021/rna.5248604
   ROBINS H, 2005, P NATL ACAD SCI USA, V102, P4006, DOI
   10.1073/pnas.0500775102
   RUSINOV V, 2005, NUCLEIC ACIDS RES S2, V33, W696, DOI 10.1093/nar/gki364
   SAETROM O, 2005, RNA, V11, P995, DOI 10.1261/rna.7290705
   SETHUPATHY P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606
   STARK A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060
   XU PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1
   ZHANG BH, 2006, COMPUT BIOL CHEM, V30, P395, DOI
   10.1016/j.compbiolchem.2006.08.006
NR 24
TC 0
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA HUDSON 655, JARDIM CANADA, RIBEIRAO PRETO, SP, BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2009
VL 8
IS 3
BP 848
EP 860
DI 10.4238/vol8-3gmr604
PG 13
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 479BP
UT ISI:000268634100011
ER

PT J
AU Hu, SQ
   Song, E
   Tian, R
   Ma, SC
   Yang, T
   Mu, Y
   Li, Y
   Shao, C
   Gao, SJ
   Gao, YH
AF Hu, Siqi
   Song, Eli
   Tian, Rui
   Ma, Sucan
   Yang, Tao
   Mu, Yi
   Li, Yuan
   Shao, Chen
   Gao, Shijuan
   Gao, Youhe
TI Systematic Analysis of a Simple Adaptor Protein PDZK1: Ligand
   Identification, Interaction and Functional Prediction of Complex
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Adaptor protein; Literature mining; PDZ; PDZK1; Protein interaction
ID DOMAIN-CONTAINING PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;
   CYSTIC-FIBROSIS; MOLECULAR-MECHANISM; INTERACTION NETWORK; KINASE-C;
   BINDING; CELLS; CFTR; EXPRESSION
AB PDZK1 is a simple adaptor protein with four protein interaction PDZ
   domains, but without any other known functional domains. Here, we used
   yeast two-hybrid screening of a random peptide library and
   high-throughput validation screening of a specialized PDZ ligand
   candidate library to systematically and comprehensively identify PDZK1
   ligands. The potential functional associations of the ligands were
   predicted by functional annotations from a MILANO literature search and
   subcellular localizations. The ligands were considered more likely to
   be functionally associated if they had similar patterns of functions or
   closely related functions. For some functionally associated ligand
   pairs, interaction with one ligand was found to be influenced by
   another ligand in a yeast three-hybrid system. Many G-protein signaling
   pathway-related proteins were found to interact with PDZK1, and they
   were likely to be functionally associated with transporters based on
   their closely related functions. This strategy can be extended to the
   study of other adaptor proteins that contain peptide-binding domains.
   Copyright (C) 2009 S. Karger AG, Basel
C1 [Hu, Siqi; Song, Eli; Tian, Rui; Ma, Sucan; Yang, Tao; Mu, Yi; Li, Yuan; Shao, Chen; Gao, Shijuan; Gao, Youhe] Chinese Acad Sci, Peking Union Med Coll, Inst Basic Med Sci,Sch Basic Med, Natl Key Lab Med Mol Biol,Dept Physiol & Pathophy, Beijing 100005, Peoples R China.
RP Gao, YH, Chinese Acad Sci, Peking Union Med Coll, Inst Basic Med
   Sci,Sch Basic Med, Natl Key Lab Med Mol Biol,Dept Physiol & Pathophy, 5
   Dong Dan San Tiao, Beijing 100005, Peoples R China.
EM gaoyouhe@pumc.edu.cn
FU National Science Fund for Distinguished Young Scholar [30725009]; The
   National High Technology Research and Development Program of China (863
   Program) [2006AA02Z308]; Ministry of Public Health [20082007]; Beijing
   Natural Science Foundation [5072037]; Specialized Research Fund for the
   Doctoral Program of Higher Education [20070023021]
FX This work was supported by grants from National Science Fund for
   Distinguished Young Scholar 30725009, The National High Technology
   Research and Development Program of China (863 Program) 2006AA02Z308,
   The Research Grant for Public Interest from Ministry of Public Health
   20082007, Beijing Natural Science Foundation 5072037 and Specialized
   Research Fund for the Doctoral Program of Higher Education 20070023021.
CR AHN W, 2001, J BIOL CHEM, V276, P17236
   ANZAI N, 2004, J BIOL CHEM, V279, P45942, DOI 10.1074/jbc.M406724200
   BEZPROZVANNY I, 2001, FEBS LETT, V509, P457
   BOSSARD F, 2007, AM J PHYSIOL-LUNG C, V292, L1085, DOI
   10.1152/ajplung.00445.2005
   CHANG JM, 2006, CLIN NEPHROL, V66, P25
   CHUNG HJ, 2006, J CELL PHYSIOL, V209, P131, DOI 10.1002/jcp.20714
   CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525
   CUSTER M, 1997, AM J PHYSIOL-RENAL, V273, F801
   DONG L, 2005, PROG BIOCHEM BIOPHYS, V32, P1026
   ERCLIK MS, 2002, AM J PHYSIOL-ENDOC M, V282, E534
   FANNING AS, 1999, J CLIN INVEST, V103, P767
   FAVIA M, 2006, BIOCHEM BIOPH RES CO, V347, P452, DOI
   10.1016/j.bbrc.2006.06.112
   GENTZSCH M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200
   GISLER SM, 2001, J BIOL CHEM, V276, P9206
   GISLER SM, 2003, KIDNEY INT, V64, P1733
   HALL RA, 1998, NATURE, V392, P626
   HARRIS MA, 2004, NUCLEIC ACIDS RES, V32, D258, DOI 10.1093/nar/gkh036
   HUANG HM, 2004, CHIN MED SCI J, V19, P97
   HUANG HM, 2005, MOL BIOTECHNOL, V30, P135
   IKEMOTO M, 2000, P NATL ACAD SCI USA, V97, P6538
   IM YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200
   JELEN F, 2003, ACTA BIOCHIM POL, V50, P985
   KATO Y, 2004, PHARM RES, V21, P1886
   KATO Y, 2005, MOL PHARMACOL, V67, P734, DOI 10.1124/mol.104.002212
   KATO Y, 2006, EUR J PHARM SCI, V27, P487, DOI 10.1016/j.ejps.2005.11.006
   KIM EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517
   KO SBH, 2002, EMBO J, V21, P5662
   KOCHER O, 1999, LAB INVEST, V79, P1161
   MALMBERG EK, 2004, J CELL SCI, V117, P5535, DOI 10.1242/jcs.01472
   MAXWELL PJ, 2003, CANCER RES, V63, P4602
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247
   MINTY A, 2000, J BIOL CHEM, V275, P36316
   MIYAZAKI H, 2005, J AM SOC NEPHROL, V16, P3498, DOI
   10.1681/ASN.2005030306
   MONTELL C, 1998, CURR OPIN NEUROBIOL, V8, P389
   NAKAYAMA M, 2002, GENOME RES, V12, P1773, DOI 10.1101/gr.406902
   NOURRY C, 2003, SCI STKE, RE7
   PENKERT RR, 2004, NAT STRUCT MOL BIOL, V11, P1122, DOI 10.1038/nsmb839
   PONTING CP, 1997, BIOESSAYS, V19, P469
   RESNICK CE, 1998, ENDOCRINOLOGY, V139, P1249
   ROSSMANN H, 2005, BIOCHEMISTRY-US, V44, P4477, DOI 10.1021/bi048828b
   RUAL JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209
   RUBINSTEIN R, 2005, BMC BIOINFORMATICS, V6, ARTN 12
   SCHLIEKER C, 2004, CELL, V117, P417
   SONG E, 2006, MOL CELL PROTEOMICS, V5, P1368, DOI
   10.1074/mcp.M600072-MCP200
   SONGYANG Z, 1997, SCIENCE, V275, P73
   STELZL U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029
   SUZUKI E, 1999, CIRC RES, V84, P611
   SYKES SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026
   TANG X, 2007, ONCOGENE, V26, P7302, DOI 10.1038/sj.onc.1210542
   WANG SS, 2000, CELL, V103, P169
   WENTE W, 2005, J BIOL CHEM, V280, P32419, DOI 10.1074/jbc.M507198200
   WONG HC, 2003, MOL CELL, V12, P1251
   XU XZS, 1998, J CELL BIOL, V142, P545
   YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152
   YUN CHC, 1998, J BIOL CHEM, V273, P25856
NR 55
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2009
VL 24
IS 3-4
BP 231
EP 242
DI 10.1159/000233258
PG 12
SC Cell Biology; Physiology
GA 479RZ
UT ISI:000268679900012
ER

PT J
AU Liao, WB
   Zhong, J
   Yu, JX
   Xie, J
   Liu, YJ
   Du, L
   Yang, SG
   Liu, PX
   Xu, J
   Wang, JM
   Han, ZB
   Han, ZC
AF Liao, Wenbin
   Zhong, Jian
   Yu, Jingxia
   Xie, Jiang
   Liu, Yongjun
   Du, Lei
   Yang, Shaoguang
   Liu, Pengxia
   Xu, Jie
   Wang, Jiming
   Han, Zhibo
   Han, Zhong Chao
TI Therapeutic Benefit of Human Umbilical Cord Derived Mesenchymal Stromal
   Cells in Intracerebral Hemorrhage Rat: Implications of
   Anti-inflammation and Angiogenesis
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Human umbilical cord; Mesenchymal stromal cells; Intracerebral
   hemorrhage; Anti-inflammation; Angiogenesis
ID STEM-CELLS; BONE-MARROW; IN-VITRO; IMMUNOLOGICAL-PROPERTIES;
   MYOCARDIAL-INFARCTION; PARKINSONS-DISEASE; CEREBRAL-ISCHEMIA; MOUSE
   MODEL; TRANSPLANTATION; PROLIFERATION
AB Cell-based therapy represents a promising strategy in the treatment of
   neurological disorders. Human umbilical cord tissue has recently been
   recognized as an ideal source of mesenchymal stromal cells due to
   accessibility, vast abundance and safety. Here, an intracerebral
   hemorrhage (ICH) rat model was established by injection of bacterial
   collagenase VII and CM-Dil labeled human umbilical cord tissue derived
   mesenchymal stromal cells (UC-MSC) were intracerebrally transplanted
   into rat brain 24h after ICH. The results demonstrated that UC-MSC
   treatment significantly improved neurological function deficits and
   decreased injury volume of ICH rats. Leukocytes infiltration,
   microglial activation, ROS level and matrix metalloproteinases (MMPs)
   production were substantially reduced in peri-ICH area in cell-treated
   group as compared with PBS control at day 3 post-transplantation. In
   addition, UC-MSC treatment significantly increased vascular density in
   peri-ICH area and transplanted UC-MSC were found to be able to
   incorporate into cerebral vasculature in ipsilateral hemisphere at 14
   days after transplantation. In summary, intracerebral administration of
   UC-MSC could accelerate neurological function recovery of ICH rat, the
   underlying mechanism may ascribe to their ability to inhibit
   inflammation and promote angiogenesis. Thus UC-MSC may provide a
   potential cell candidate for cell-based therapy in neurological
   disorders. Copyright (C) 2009 S. Karger AG, Basel
C1 [Liao, Wenbin; Yu, Jingxia; Xie, Jiang; Liu, Yongjun; Yang, Shaoguang; Liu, Pengxia; Xu, Jie; Han, Zhibo; Han, Zhong Chao] CAMS & PUMC, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Zhong, Jian; Liu, Yongjun; Wang, Jiming; Han, Zhong Chao] AmCellGene Co Ltd, Natl Engn Res Ctr Cell Prod, Tianjin, Peoples R China.
   [Zhong, Jian] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Du, Lei] Hebei Med Univ, Shijiazhuang, Peoples R China.
RP Han, ZC, CAMS & PUMC, Inst Hematol, State Key Lab Expt Hematol, 288
   Nanjing Rd, Tianjin 300020, Peoples R China.
EM tihzchan@public.tpt.tj.cn
FU Ministry Science & Technology of China [2006AA02A110]; National Natural
   Science Foundation of China [30570905, 30600238]; Tianjin Municipal
   Science and Technology Commission [07JCYBJC11200, 08ZCKFSF03200]
FX This study was supported by 863 projects from Ministry Science &
   Technology of China (2006AA02A110), National Natural Science Foundation
   of China (30570905 and 30600238) and Tianjin Municipal Science and
   Technology Commission (07JCYBJC11200 and 08ZCKFSF03200).
CR ARONOWSKI J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225
   BAKSH D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709
   BARONE FC, 1999, J CEREBR BLOOD F MET, V19, P819
   CHEN JL, 2001, STROKE, V32, P1005
   CHEN JL, 2003, CIRC RES, V92, P692, DOI
   10.1161/01.RES.0000063425.51108.8D
   CRISAN M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   FACCHINETTI F, 1998, CELL MOL NEUROBIOL, V18, P667
   FATAR M, 2008, NEUROSCI LETT, V443, P174, DOI
   10.1016/j.neulet.2008.07.077
   FRIEDMAN R, 2007, BIOL BLOOD MARROW TR, V13, P1477, DOI
   10.1016/j.bbmt.2007.08.048
   GEISLER S, 2002, HISTOCHEM CELL BIOL, V117, P69
   GERDONI E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076
   GHOSH A, 2007, P NATL ACAD SCI USA, V104, P18754, DOI
   10.1073/pnas.0704908104
   GONG C, 2000, BRAIN RES, V871, P57
   GUO J, 2007, INFLAMMATION, V30, P97, DOI 10.1007/s10753-007-9025-3
   HANISCH UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   HORWITZ EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   JOMURA S, 2007, STEM CELLS, V25, P98, DOI 10.1634/stemcells.2006-0055
   KIM GW, 2002, STROKE, V33, P809
   KINNAIRD T, 2004, CIRCULATION, V109, P1543, DOI
   10.1161/01.CIR.0000124062.31102.57
   KRAMPERA M, 2003, BLOOD, V101, P3722
   LAPCHAK PA, 2002, CURR NEUROL NEUROSCI, V2, P38
   LEBLANC K, 2003, EXP HEMATOL, V31, P890
   LEBLANC K, 2004, LANCET, V363, P1439
   LIAO WB, 2009, TRANSPLANTATION, V87, P350, DOI
   10.1097/TP.0b013e318195742e
   LU LL, 2006, HAEMATOL-HEMATOL J, V91, P1017
   MARTI HJH, 2000, AM J PATHOL, V156, P965
   MASADA T, 2003, ACT NEUR S, V86, P463
   MAYNE M, 2001, STROKE, V32, P240
   MAZZINI L, 2008, J NEUROL SCI, V265, P78, DOI 10.1016/j.jns.2007.05.016
   MEIRELLES LD, 2008, STEM CELLS, V26, P2287, DOI
   10.1634/stemcells.2007-1122
   MEIRELLES LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   MORRIS R, 1984, J NEUROSCI METH, V11, P47
   NAUTA AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
   ORTIZ LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI
   10.1073/pnas.0704421104
   OSWALD J, 2004, STEM CELLS, V22, P377
   PARK HJ, 2008, J NEUROCHEM, V107, P141, DOI
   10.1111/j.1471-4159.2008.05589.x
   QURESHI AI, 2001, NEW ENGL J MED, V344, P1450
   REN GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   RIBO M, 2006, CURR NEUROL NEUROSCI, V6, P17
   SANCHEZRAMOS J, 2000, EXP NEUROL, V164, P247
   SCHMUED LC, 2000, BRAIN RES, V874, P123
   SECCO M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381
   SPAGGIARI GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997
   SUZDALTSEVA YG, 2008, B EXP BIOL MED+, V145, P228
   TANG JM, 2006, EUR J CARDIO-THORAC, V30, P353, DOI
   10.1016/j.ejcts.2006.02.070
   TANG T, 2007, BRAIN RES, V1175, P134, DOI 10.1016/j.brainres.2007.08.028
   TSE WT, 2003, TRANSPLANTATION, V75, P389, DOI
   10.1097/01.TP.0000045055.63901.A9
   UCCELLI A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   VOYTA JC, 1984, J CELL BIOL, V99, P2034
   WANG J, 2005, BRAIN 7, V128, P1622, DOI 10.1093/brain/awh489
   WANG J, 2005, NEUROCRIT CARE, V3, P77, DOI
   10.1385/Neurocrit.Care2005;3:77-85
   WEISS ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007-1028
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
   WU KH, 2007, ANN THORAC SURG, V83, P1491, DOI
   10.1016/j.athoracsur.2006.10.066
   WU KH, 2007, TRANSPL P, V39, P1620, DOI
   10.1016/j.transproceed.2006.12.041
   ZADEH G, 2003, NEUROSURGERY, V53, P1362, DOI
   10.1227/01.NEU.0000093425.98136.31
   ZADEH G, 2003, NEUROSURGERY, V53, P1374
   ZAZULIA AR, 1999, STROKE, V30, P1167
NR 58
TC 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2009
VL 24
IS 3-4
BP 307
EP 316
DI 10.1159/000233255
PG 10
SC Cell Biology; Physiology
GA 479RZ
UT ISI:000268679900019
ER

PT J
AU Yang, T
   Tsang, KS
   Poon, WS
   Ng, HK
AF Yang, Tao
   Tsang, Kam Sze
   Poon, Wai Sang
   Ng, Ho Keung
TI Neurotrophism of Bone Marrow Stromal Cells to Embryonic Stem Cells:
   Noncontact Induction and Transplantation to a Mouse Ischemic Stroke
   Model
SO CELL TRANSPLANTATION
LA English
DT Article
DE Embryonic stem cell; Stromal cell; Coculture; Differentiation;
   Transplantation; Ischemic stroke
ID NEURAL PROGENITOR CELLS; DOPAMINERGIC-NEURONS; ES CELLS; BRAIN-INJURY;
   DIFFERENTIATION; GENERATION; REORGANIZATION; PROLIFERATION;
   SPECIFICATION; MIGRATION
AB Embryonic stein (ES) cell-derived cell products may serve as it Source
   of cells for regenerative medicine. Currently available technologies
   for the induction of ES cells into neural lineage cells require
   extended culturing in vitro and complex procedural manipulations, with
   variable yields of heterogeneous Cells, which have hindered the
   prospective use of cell derivatives for treatment of ischemic stroke.
   We established a simple and efficient method to derive mouse ES cells
   into neural lineage cells using an 8-day coculture with the bone marrow
   stromal cells MS5, followed by a 6-day propagation culture and a 4-day
   selection Culture. The protocol generated a relatively high yield of
   neural lineage cells without any mesodermal and endodermal lineage
   commitment. In in vivo study, these derived cells could improve the
   cognitive function of ischemic stroke mice. Three weeks after
   transplantation, migration of implanted cells to lesioned areas was
   noted. It was also evident of a normalization of pyramidal neuron
   density and morphology in hippocampal CA1 region. One (1/17) episode of
   teratoma development was noted. Data suggested that MS5 cells may exert
   a neurotrophic effect to enhance neural differentiation of ES cells and
   MS5-induced ES cell-derived cells appeared to be applicable to cell
   therapy for ischemic stroke.
C1 [Yang, Tao; Tsang, Kam Sze; Poon, Wai Sang; Ng, Ho Keung] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   [Yang, Tao; Tsang, Kam Sze; Ng, Ho Keung] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Poon, Wai Sang] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
RP Tsang, KS, Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince
   Wales Hosp, Shatin, Hong Kong, Peoples R China.
EM tsangks@cuhk.edu.hk
FU Li Ka Shing Institute of Health Sciences ; The Chinese University of
   Hong Kong ; Strategic Research Program [SRP 2102]
FX This study was supported in part by stem cell research funding from the
   Li Ka Shing Institute of Health Sciences, The Chinese University of
   Hong Kong, and by the Strategic Research Program SRP 2102, The Chinese
   University of Hong Kong.
CR ABE K, 2000, J CEREBR BLOOD F MET, V20, P1393
   BAIN G, 1995, DEV BIOL, V168, P342
   BARBERI T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   BECERRA GD, 2007, BEHAV BRAIN RES, V179, P118
   BINGHAM B, 2005, BRAIN RES, V1058, P167, DOI
   10.1016/j.brainres.2005.07.075
   DIPORZIO U, 1992, NEUROCHEM INT S, V20, S309
   FONG SP, 2007, J NEUROSCI RES, V85, P1851, DOI 10.1002/jnr.21319
   HAYASHI J, 2006, J CEREBR BLOOD F MET, V26, P906, DOI
   10.1038/sj.jcbfm.9600247
   ISSAAD C, 1993, BLOOD, V81, P2916
   ITOH K, 1989, EXP HEMATOL, V17, P145
   KAWASAKI H, 2000, NEURON, V28, P31
   KAWASAKI H, 2002, P NATL ACAD SCI USA, V99, P1580
   KIM JH, 2002, NATURE, V418, P50
   KIPRIANOVA I, 1999, EXP NEUROL, V159, P511
   KITAGAWA K, 1990, BRAIN RES, V528, P21
   KRAKAUER JW, 2007, EXP NEUROL, V204, P491, DOI
   10.1016/j.expneurol.2006.12.026
   LEE H, 2007, STEM CELLS, V25, P1931, DOI 10.1634/stemcells.2007-0097
   LEE SH, 2000, NAT BIOTECHNOL, V18, P675
   LIEPERT J, 2000, STROKE, V31, P1210
   MATTHEWS DB, 2004, NEUROBIOL LEARN MEM, V82, P299, DOI
   10.1016/j.nlm.2004.06.007
   MORIZANE A, 2002, J NEUROSCI RES, V69, P934, DOI 10.1002/jnr.10363
   MORIZANE A, 2006, J NEUROSCI RES, V83, P1015, DOI 10.1002/jnr.20799
   NAKATOMI H, 2002, CELL, V110, P429
   PACHERNIK J, 2005, PHYSIOL RES, V54, P115
   PERRY R, 2004, J HUMAN BEHAV SOCIAL, V10, P1
   RAPPA G, 2004, NEUROSCIENCE, V124, P823
   SEMMLER A, 2007, EXP NEUROL, V204, P733, DOI
   10.1016/j.expneurol.2007.01.003
   TABAR V, 2005, NAT BIOTECHNOL, V23, P601, DOI 10.1038/nbt1088
   TAKAGI Y, 2005, J NEUROSURG, V103, P304
   THOMSON JA, 1998, SCIENCE, V282, P1147
   TROPEPE V, 2001, NEURON, V30, P65
   WILES MV, 1999, EXP CELL RES, V247, P241
   YAMAZOE H, 2006, CELL TRANSPLANT, V15, P135
   ZHAO LR, 2007, STROKE, V38, P2804, DOI 10.1161/STROKEAHA.107.486217
NR 34
TC 4
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2009
VL 18
IS 4
BP 391
EP 404
PG 14
SC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
GA 478XW
UT ISI:000268623100002
ER

PT J
AU Song, L
   Shi, QM
   Yang, XH
   Xu, ZH
   Xue, HW
AF Song, Li
   Shi, Qiu-Ming
   Yang, Xiao-Hua
   Xu, Zhi-Hong
   Xue, Hong-Wei
TI Membrane steroid-binding protein 1 (MSBP1) negatively regulates
   brassinosteroid signaling by enhancing the endocytosis of BAK1
SO CELL RESEARCH
LA English
DT Article
DE MSBP1; BR signaling; BAK1; endocytosiss
ID RECEPTOR KINASE BRI1; ARABIDOPSIS-THALIANA; CELL ELONGATION;
   EXTRACELLULAR DOMAIN; PLASMA-MEMBRANE; GENE-EXPRESSION; GROWTH; AUXIN;
   TRANSDUCTION; PATHWAY
AB Brassinosteroids (BRs) are perceived by transmembrane receptors and
   play vital roles in plant growth and development, as well as cell in
   responses to environmental stimuli. The transmembrane receptor BRI1 can
   directly bind to brassinolide (BL), and BAK1 interacts with BRI1 to
   enhance the BRI1-mediated BR signaling. Our previous studies indicated
   that a membrane steroid-binding protein 1 (MSBP1) could bind to BL in
   vitro and is negatively involved in BR signaling. To further elucidate
   the underlying mechanism, we here show that MSBP1 specifically
   interacts with the extracellular domain of BAK1 in vivo in a
   BL-independent manner. Suppressed cell expansion and BR responses by
   increased expression of MSBP1 can be recovered by overexpressing BAK1
   or its intracellular kinase domain, suggesting that MSBP1 may suppress
   BR signaling through interacting with BAK1. Subcellular localization
   studies revealed that both MSBP1 and BAK1 are localized to plasma
   membrane and endocytic vesicles and MSBP1 accelerates BAK1 endocytosis,
   which results in suppressed BR signaling by shifting the equilibrium of
   BAK1 toward endosomes. Indeed, enhanced MSBP1 expression reduces the
   interaction between BRI1 and BAK1 in vivo, demonstrating that MSBP1
   acts as a negative factor at an early step of the BR signaling pathway.
C1 [Song, Li; Shi, Qiu-Ming; Yang, Xiao-Hua; Xu, Zhi-Hong; Xue, Hong-Wei] Chinese Acad Sci, Shanghai Inst Biol Sci, Natl Key Lab Plant Mol Genet, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China.
RP Xue, HW, Chinese Acad Sci, Shanghai Inst Biol Sci, Natl Key Lab Plant
   Mol Genet, Inst Plant Physiol & Ecol, 300 Fenglin Rd, Shanghai 200032,
   Peoples R China.
EM hwxue@sibs.ac.cn
FU Chinese Academy of Sciences and National Natural Science Foundation of
   China [30425029, 30421001, 90717001]
FX This study was supported by the Chinese Academy of Sciences and
   National Natural Science Foundation of China (Grants 30425029,
   30421001, 90717001). We greatly thank Prof Hong Ma (Penn. State
   University, USA) for critical reading and writing improvement and Prof
   Nam-Hai Chua (The Rockefeller University, USA) for helpful comments. We
   thank the Salk Institute Genomic Analysis Laboratory for providing the
   sequence-indexed Arabidopsis T-DNA insertion mutants, and Prof Sheng
   Luan (University of California, Berkeley, USA) for providing the
   construct pATC940. We thank Prof Hong-Quan Yang (SIPPE, CAS) for
   providing LexA yeast two-hybrid system and Prof Zhi-Yong Wang (The
   Stanford University, USA) for providing the BRI1 antibody. We thank Mr
   Xiao-Shu Gao for the help on Confocal Laser Scanning Microscopy.
CR BEATO M, 1995, CELL, V83, P851
   BISHOP GJ, 2003, J PLANT GROWTH REGUL, V22, P325, DOI
   10.1007/s00344-003-0064-1
   BRADFORD MA, 1976, ANAL BIOCHEM, V72, P254
   CHINCHILLA D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999
   CLOUGH SJ, 1998, PLANT J, V16, P735
   CLOUSE SD, 1996, PLANT PHYSIOL, V111, P671
   CLOUSE SD, 1998, ANNU REV PLANT PHYS, V49, P427
   DEGRAUWE L, 2005, PLANT CELL PHYSIOL, V46, P827, DOI 10.1093/pcp/pci111
   DHONUKSHE P, 2007, CURR BIOL, V17, P520, DOI 10.1016/j.cub.2007.01.052
   EDWARDS PA, 1999, ANNU REV BIOCHEM, V68, P157
   EPHRITIKHINE G, 1999, PLANT J, V18, P315
   EVANS RM, 1988, SCIENCE, V240, P889
   FRIML J, 2002, NATURE, V415, P806
   GELDNER N, 2001, NATURE, V413, P425
   GELDNER N, 2007, GENE DEV, V21, P1598, DOI 10.1101/gad.1561307
   GLASS CK, 1994, ENDOCR REV, V15, P391
   GOMEZGOMEZ L, 2000, MOL CELL, V5, P1003
   GOODIN MM, 2002, PLANT J, V31, P375
   HE JX, 2002, P NATL ACAD SCI USA, V99, P10185
   HE JX, 2005, SCIENCE, V307, P1634, DOI 10.1126/science.1107580
   HE ZH, 2000, SCIENCE, V288, P2360
   HEESE A, 2007, P NATL ACAD SCI USA, V104, P12217, DOI
   10.1073/pnas.0705306104
   INGHAM PW, 2001, SCIENCE, V294, P1879
   JONES DA, 1997, ADV BOT RES, V24, P89
   KARLOVA R, 2006, PLANT CELL, V18, P626, DOI 10.1105/tpc.105.039412
   KINOSHITA T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227
   KOBE B, 1995, NATURE, V374, P183
   KROGH A, 2001, J MOL BIOL, V305, P567
   KWAAITAAL MACJ, 2005, PROTOPLASMA, V226, P55, DOI
   10.1007/s00709-005-0111-9
   LI J, 2002, CELL, V110, P213
   LI JM, 1996, SCIENCE, V272, P398
   LI JM, 1997, CELL, V90, P929
   LI JM, 2001, PLANT PHYSIOL, V127, P14
   LI JM, 2002, SCIENCE, V295, P1299
   MANGELSDORF DJ, 1995, CELL, V83, P835
   MICHAUX G, 2000, CURR BIOL, V10, P1098
   NAM KH, 2002, CELL, V110, P203
   OSAKABE Y, 2005, PLANT CELL, V17, P1105, DOI 10.1105/tpc.104.027474
   ROBATZEK S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506
   RUSSINOVA E, 2004, PLANT CELL, V16, P3216
   SHAH K, 2002, GENE DEV, V16, P1707
   SHEEN J, 2001, PLANT PHYSIOL, V127, P1466
   SONG WY, 1995, SCIENCE, V270, P1804
   SONNHAMMER ELL, 1998, P 6 INT C INT SYST M, P175
   SZEKERES M, 1996, CELL, V85, P171
   TAKAHASHI T, 1995, GENE DEV, V9, P97
   TANG WQ, 2008, SCIENCE, V321, P557, DOI 10.1126/science.1156973
   VERT G, 2006, NATURE, V441, P96, DOI 10.1038/nature04681
   WANG XF, 2005, PLANT CELL, V17, P1685, DOI 10.1105/tpc.105.031393
   WANG XF, 2008, DEV CELL, V15, P220, DOI 10.1016/j.devcel.2008.06.011
   WANG XL, 2005, DEV CELL, V8, P855, DOI 10.1016/j.devcel.2005.05.001
   WANG XL, 2006, SCIENCE, V313, P1118, DOI 10.1126/science.1127593
   WANG ZY, 2001, NATURE, V410, P380
   WANG ZY, 2002, DEV CELL, V2, P505
   WHIPPO CW, 2005, PLANT PHYSIOL, V139, P448
   XU J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449
   YANG HQ, 2001, PLANT CELL, V13, P2573
   YANG X, 2008, MOL PLANT, V1, P1077, DOI 10.1093/mp/ssn071
   YANG XH, 2005, PLANT CELL, V17, P116, DOI 10.1105/tpc.104.028381
   YIN YH, 2002, CELL, V109, P181
   YIN YH, 2005, CELL, V120, P249, DOI 10.1016/j.cell.2004.11.044
   ZHAO J, 2002, PLANT PHYSIOL, V130, P1221, DOI 10.1104/pp.102.010918
NR 62
TC 2
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD JUL
PY 2009
VL 19
IS 7
BP 864
EP 876
DI 10.1038/cr.2009.66
PG 13
SC Cell Biology
GA 480GR
UT ISI:000268722200008
ER

PT J
AU Yang, HY
   Yu, Y
   Li, WG
   Xu, TL
   Jiang, HL
AF Yang, Huaiyu
   Yu, Ye
   Li, Wei-Guang
   Xu, Tian-Le
   Jiang, Hualiang
TI Conformational sampling on acid-sensing ion channel 1 (ASIC1):
   implication for a symmetric conformation
SO CELL RESEARCH
LA English
DT Letter
C1 [Yang, Huaiyu; Jiang, Hualiang] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Yu, Ye; Li, Wei-Guang; Xu, Tian-Le] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China.
   [Yu, Ye; Li, Wei-Guang; Xu, Tian-Le] Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Neurosci, Shanghai 200031, Peoples R China.
   [Jiang, Hualiang] E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China.
RP Jiang, HL, Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery &
   Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
EM tlxu@ion.ac.cn
   hljiang@mail.shcnc.ac.cn
CR BROOKS BR, 1995, J COMPUT CHEM, V16, P1522
   BROOKS CL, 1988, ADV CHEM PHYS, V71, P1
   CASE DA, 2006, AMBER 9
   JASTI J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163
   LIU XL, 2008, PLOS COMPUT BIOL, V4, ARTN e19
   MA JP, 2005, STRUCTURE, V13, P373, DOI 10.1016/j.str.2005.02.002
   SHAIKH SA, 2008, BIOPHYS J, V95, P5153, DOI 10.1529/biophysj.108.141606
   SHEN YF, 2002, P NATL ACAD SCI USA, V99, P1949
   SUHRE K, 2004, NUCLEIC ACIDS RES S2, V32, W610, DOI 10.1093/nar/gkh368
   WEMMIE JA, 2006, TRENDS NEUROSCI, V29, P578, DOI
   10.1016/j.tins.2006.06.014
   YANG HY, 2009, PLOS BIOL, V7, ARTN e1000151
NR 11
TC 1
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD AUG
PY 2009
VL 19
IS 8
BP 1035
EP 1037
DI 10.1038/cr.2009.90
PG 3
SC Cell Biology
GA 480GS
UT ISI:000268722300014
ER

PT J
AU Sun, T
   Yang, M
   Kantoff, P
   Lee, GSM
AF Sun, Tong
   Yang, Ming
   Kantoff, Philip
   Lee, Gwo-Shu Mary
TI Role of microRNA-221/-222 in cancer development and progression
SO CELL CYCLE
LA English
DT Editorial Material
DE microRNA-221/-222; prostate cancer; CRPC; microRNA; cancer
ID PROSTATE-CANCER; MICRORNA; EXPRESSION; P27(KIP1); RESISTANCE; MIR-222;
   CELLS
C1 [Sun, Tong; Yang, Ming; Kantoff, Philip; Lee, Gwo-Shu Mary] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Lee, GSM, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM gwo-shu_lee@dfci.harvard.edu
CR AMBS S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144
   ESQUELAKERSCHER A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   FELICETTI F, 2008, CANCER RES, V68, P2745
   GAROFALO M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6
   GILLIES JK, 2007, CELL CYCLE, V6, P2005
   LEE EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   LESAGE C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   MILLER TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   SHI XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI
   10.1073/pnas.0706641104
   SPIZZO R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040
   SUN T, 2009, CANCER RES, V69, P3356
   TERASAWA K, 2009, FEBS J, V276, P3269, DOI
   10.1111/j.1742-4658.2009.07041.x
   TONG AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
   VISONE R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129
   ZAO J, 2008, J BIOL CHEM, V283, P31086
NR 15
TC 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD AUG 1
PY 2009
VL 8
IS 15
BP 2315
EP 2316
PG 2
SC Cell Biology
GA 477RH
UT ISI:000268535700003
ER

PT J
AU Yang, J
   Moses, MA
AF Yang, Jiang
   Moses, Marsha A.
TI Lipocalin 2 A multifaceted modulator of human cancer
SO CELL CYCLE
LA English
DT Article
DE lipocalin 2; NGAL; breast cancer; epithelial to mesenchymal transition;
   biomarker; estrogen receptor; Slug
ID GELATINASE-ASSOCIATED LIPOCALIN; ISCHEMIA-REPERFUSION INJURY; HUMAN
   NEUTROPHIL GELATINASE; GENE-EXPRESSION PROFILES; CHRONIC
   MYELOID-LEUKEMIA; BREAST-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER;
   CDNA MICROARRAY; PROTEIN FAMILY
AB Lipocalin 2 (Lcn2), a member of the lipocalin family that transports
   small lipophilic ligands, has gained recent attention as both a
   potential biomarker and a modulator of human cancers. Here we describe
   recent findings of the functions of Lcn2 in breast cancer and the
   potential mechanisms that underlie its actions. Lcn2 has been shown to
   induce the epithelial to mesenchymal transition (EMT) in breast cancer
   cells and to promote breast tumor invasion. Estrogen receptor alpha may
   participate in the pathway that leads to Lcn2-induced EMT. Preliminary
   evidence also suggests that Lcn2 may be useful as a potential
   non-invasive urinary biomarker of breast cancer. Elevated levels of
   Lcn2 have also been reported in other human cancers. The potential
   roles of Lcn2 in epithelial tumors as well as leukemia are also
   reviewed and discussed here.
C1 [Moses, Marsha A.] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.
   Childrens Hosp, Dept Surg, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
RP Moses, MA, Childrens Hosp, Vasc Biol Program, 12-214,300 Longwood Ave,
   Boston, MA 02115 USA.
EM marsha.moses@childrens.harvard.edu
FU NIH [R01 CA118764]; JoAnn Webb Fund for Angiogenesis Research ; Dr. T.
   Quinto and J. Larsen, the Riehl Family Foundation ; S. Elizabeth
   O'Brien Trust ; Advanced Medical Foundation 
FX This work was supported by NIH R01 CA118764, the JoAnn Webb Fund for
   Angiogenesis Research, Dr. T. Quinto and J. Larsen, the Riehl Family
   Foundation, the S. Elizabeth O'Brien Trust and the Advanced Medical
   Foundation. We thank K. Johnson for graphics assistance.
CR BAUER M, 2008, BREAST CANCER RES TR, V108, P389, DOI
   10.1007/s10549-007-9619-3
   BERGER T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI
   10.1073/pnas.0510847103
   BIRKENKAMPDEMTRODER K, 2002, CANCER RES, V62, P4352
   CHAN YR, 2009, J IMMUNOL, V182, P4947, DOI 10.4049/jimmunol.0803282
   CHO H, 2009, J HISTOCHEM CYTOCHEM
   CONROTTO P, 2008, INT J CANCER, V123, P2856, DOI 10.1002/ijc.23861
   COWLAND JB, 1997, GENOMICS, V45, P17
   DEVIREDDY LR, 2001, SCIENCE, V293, P829
   DEVIREDDY LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027
   FERNANDEZ CA, 2005, CLIN CANCER RES, V11, P5390
   FLO TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   FLOWER DR, 1996, BIOCHEM J 1, V318, P1
   FLOWER DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9
   FRIEDL A, 1999, HISTOCHEM J, V31, P433
   FUJITA N, 2003, CELL, V113, P207
   FURUTANI M, 1998, CANCER LETT, V122, P209
   GOETZ DH, 2002, MOL CELL, V10, P1033
   GRONBORG M, 2004, J PROTEOME RES, V3, P1042, DOI 10.1021/pr0499085
   GRUVBERGER S, 2001, CANCER RES, V61, P5979
   HAN HY, 2002, CANCER RES, V62, P2890
   HANAI J, 2005, J BIOL CHEM, V280, P13641, DOI 10.1074/jbc.M413047200
   HEGDE P, 2001, CANCER RES, V61, P7792
   HU LM, 2009, LAB INVEST, V89, P531, DOI 10.1038/labinvest.2009.17
   HULLTHOMPSON J, 2009, PLOS GENET, V5, UNSP 1000460
   HVIDBERG V, 2005, FEBS LETT, V579, P773, DOI
   10.1016/j.febslet.2004.12.031
   IACOBUZIODONAHUE CA, 2003, CANCER RES, V63, P8614
   IANNETTI A, 2008, P NATL ACAD SCI USA, V105, P14058
   KANETA Y, 2003, INT J ONCOL, V23, P681
   KJELDSEN L, 1993, J BIOL CHEM, V268, P10425
   LEE HJ, 2006, INT J CANCER, V118, P2490, DOI 10.1002/ijc.21657
   LENG X, 2008, ONCOGENE, V27, P6110, DOI 10.1038/onc.2008.209
   LIM R, 2007, INT J CANCER, V120, P2426, DOI 10.1002/ijc.22352
   LIN H, 2005, ONCOGENE, V24, P3246, DOI 10.1038/sj.onc.1208500
   MADOZGURPIDE J, 2006, MOL CELL PROTEOMICS, V5, P1471, DOI
   10.1074/mcp.M600048-MCP200
   MISSIAGLIA E, 2004, INT J CANCER, V112, P100, DOI 10.1002/ijc.20376
   MONIAUX N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329
   MORI K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056
   NELSON AM, 2008, J CLIN INVEST, V118, P1468, DOI 10.1172/JCI33869
   NIELSEN BS, 1996, GUT, V38, P414
   PITTERI SJ, 2008, J PROTEOME RES, V7, P1481, DOI 10.1021/pr7007994
   SABO E, 2008, CLIN CANCER RES, V14, P6440, DOI
   10.1158/1078-0432.CCR-08-0302
   SANTIN AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408
   SHAHEEN N, 2002, JAMA-J AM MED ASSOC, V287, P1972
   SHENG Z, 2009, EMBO J, V28, P866, DOI 10.1038/emboj.2009.35
   SHI H, 2008, J EXP CLIN CANC RES, V27, ARTN 83
   SONG MQ, 2001, P NATL ACAD SCI USA, V98, P9265
   STOESZ SP, 1998, INT J CANCER, V79, P565
   THIERY JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   TONG ZM, 2005, BIOCHEM J 2, V391, P441, DOI 10.1042/BJ20051020
   TONG ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540
   TRIEBEL S, 1992, FEBS LETT, V314, P386
   VILLALVA C, 2008, LEUKEMIA LYMPHOMA, V49, P984, DOI
   10.1080/10428190801942360
   WESTERLUND U, 1996, J DENT RES, V75, P1553
   XU SY, 2000, BBA-PROTEIN STRUCT M, V1482, P298
   YAN L, 2001, J BIOL CHEM, V276, P37258
   YANG J, 2002, MOL CELL, V10, P1045
   YANG J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI
   10.1073/pnas.0810617106
   ZHANG HH, 2007, J CLIN PATHOL, V60, P555, DOI 10.1136/jcp.2006.039297
NR 58
TC 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD AUG 1
PY 2009
VL 8
IS 15
BP 2347
EP 2352
PG 6
SC Cell Biology
GA 477RH
UT ISI:000268535700016
ER

PT J
AU Leinninger, GM
   Jo, YH
   Leshan, RL
   Louis, GW
   Yang, HY
   Barrera, JG
   Wilson, H
   Opland, DM
   Faouzi, MA
   Gong, YS
   Jones, JC
   Rhodes, CJ
   Chua, S
   Diano, S
   Horvath, TL
   Seeley, RJ
   Becker, JB
   Munzberg, H
   Myers, MG
AF Leinninger, Gina M.
   Jo, Young-Hwan
   Leshan, Rebecca L.
   Louis, Gwendolyn W.
   Yang, Hongyan
   Barrera, Jason G.
   Wilson, Hilary
   Opland, Darren M.
   Faouzi, Miro A.
   Gong, Yusong
   Jones, Justin C.
   Rhodes, Christopher J.
   Chua, Streamson, Jr.
   Diano, Sabrina
   Horvath, Tamas L.
   Seeley, Randy J.
   Becker, Jill B.
   Muenzberg, Heike
   Myers, Martin G., Jr.
TI Leptin Acts via Leptin Receptor-Expressing Lateral Hypothalamic Neurons
   to Modulate the Mesolimbic Dopamine System and Suppress Feeding
SO CELL METABOLISM
LA English
DT Article
ID MELANIN-CONCENTRATING HORMONE; MESSENGER-RNA EXPRESSION; BODY-WEIGHT;
   FOOD-INTAKE; ARCUATE NUCLEUS; OREXIN NEURONS; ENERGY-BALANCE; REWARD;
   BRAIN; MICE
AB The lateral hypothalamic area (LHA) acts in concert with the ventral
   tegmental area (VTA) and other components of the mesolimbic dopamine
   (DA) system to control motivation, including the incentive to feed. The
   anorexigenic hormone leptin modulates the mesolimbic DA system,
   although the mechanisms underlying this control have remained
   incompletely understood. We show that leptin directly regulates a
   population of leptin receptor (LepRb)-expressing inhibitory neurons in
   the LHA and that leptin action via these LHA LepRb neurons decreases
   feeding and body weight. Furthermore, these LHA LepRb neurons innervate
   the VTA, and leptin action on these neurons restores VTA expression of
   the rate-limiting enzyme in DA production along with mesolimbic DA
   content in leptin-deficient animals. Thus, these findings reveal that
   LHA LepRb neurons link anorexic leptin action to the mesolimbic DA
   system.
C1 [Leinninger, Gina M.; Leshan, Rebecca L.; Louis, Gwendolyn W.; Opland, Darren M.; Faouzi, Miro A.; Gong, Yusong; Jones, Justin C.; Muenzberg, Heike; Myers, Martin G., Jr.] Univ Michigan, Dept Internal Med, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA.
   [Leshan, Rebecca L.; Louis, Gwendolyn W.; Myers, Martin G., Jr.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Yang, Hongyan; Seeley, Randy J.; Becker, Jill B.] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.
   [Jo, Young-Hwan; Chua, Streamson, Jr.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   [Barrera, Jason G.; Wilson, Hilary] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45237 USA.
   [Barrera, Jason G.; Wilson, Hilary] Univ Cincinnati, Genome Res Inst, Cincinnati, OH 45237 USA.
   [Rhodes, Christopher J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Diano, Sabrina; Horvath, Tamas L.] Yale Univ, New Haven, CT 06511 USA.
RP Myers, MG, Univ Michigan, Dept Internal Med, Div Endocrinol Diabet &
   Metab, Ann Arbor, MI 48109 USA.
EM mgmyers@umich.edu
FU Michigan Diabetes Research and Training Center ; Michigan Comprehensive
   Diabetes Center ; American Diabetes Association and American Heart
   Association ; NIH ; Obesity Society 
FX We thank Amylin Pharmaceuticals for the generous gift of leptin and
   thank Gary Schwartz, Bob Kennedy, Maura Perry, and members of the Myers
   lab for helpful discussions. This work was supported by the Michigan
   Diabetes Research and Training Center; Michigan Comprehensive Diabetes
   Center; and grants from the American Diabetes Association and American
   Heart Association (M.G.M.), the NIH (M.G.M., C.J.R., and J.B.B.), and
   the Obesity Society (G. M. L.).
CR ABE H, 2005, J ANDROL, V26, P568, DOI 10.2164/jandrol.04157
   BALTHASAR N, 2004, NEURON, V42, P983
   BERTHOUD HR, 2007, PHYSIOL BEHAV, V91, P486, DOI
   10.1016/j.physbeh.2006.12.016
   COHEN P, 2001, J CLIN INVEST, V108, P1113
   DELUCA C, 2005, J CLIN INVEST, V115, P3484, DOI 10.1172/jc124059
   DHILLON H, 2006, NEURON, V49, P191, DOI 10.1016/j.neuron.2005.12.021
   DILEONE RJ, 2003, LIFE SCI, V73, P759, DOI 10.1016/S0024-3205(03)00408-9
   ELMQUIST JK, 1998, J COMP NEUROL, V395, P535
   ELMQUIST JK, 2005, J COMP NEUROL, V493, P63, DOI 10.1002/cne.20786
   FIGLEWICZ DP, 2007, PHYSIOL BEHAV, V91, P473, DOI
   10.1016/j.physbeh.2006.10.008
   FRANKLIN KBJ, 1997, MOUSE BRAIN STEREOTA
   FRIEDMAN JM, 2002, NUTR REV 2, V60, S1
   FULTON S, 2000, SCIENCE, V287, P125
   FULTON S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006
   GAO Q, 2007, ANNU REV NEUROSCI, V30, P367, DOI
   10.1146/annurev.neuro.30.051606.094324
   GEORGESCU D, 2005, J NEUROSCI, V25, P2933
   HARRIS GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071
   HE TC, 1998, P NATL ACAD SCI USA, V95, P2509
   HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173
   HOMMEL JD, 2006, NEURON, V51, P801, DOI 10.1016/j.neuron.2006.08.023
   HU M, 2003, J NEUROSCI, V23, P693
   JO YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021
   KELLEY AE, 2005, J COMP NEUROL, V493, P72, DOI 10.1002/cne.20769
   LESHAN RL, 2006, OBESITY S5, V14, S208
   LESHAN RL, 2009, J NEUROSCI, V29, P3138, DOI
   10.1523/JNEUROSCI.0155-09.2009
   MAO XH, 1999, P NATL ACAD SCI USA, V96, P5037
   MIEDA M, 2002, CURR OPIN NEUROBIOL, V12, P339
   MORTON GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115
   MORTON GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026
   MUNZBERG H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037
   MUNZBERG H, 2007, J NEUROSCI, V27, P69, DOI
   10.1523/JNEUROSCI.3168-06.2007
   MYERS MG, 2004, RECENT PROG HORM RES, V59, P287
   MYERS MG, 2009, CELL METAB, V9, P117, DOI 10.1016/j.cmet.2008.12.001
   NESTLER EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   PALMITER RD, 2007, TRENDS NEUROSCI, V30, P375, DOI
   10.1016/j.tins.2007.06.004
   QU DQ, 1996, NATURE, V380, P243
   ROSEBERRY AG, 2007, J NEUROSCI, V27, P7021, DOI
   10.1523/JNEUROSCI.1235-07.2007
   ROSIN DL, 2003, J COMP NEUROL, V465, P593, DOI 10.1002/ene.10860
   SCHWARTZ MW, 1997, DIABETES, V46, P2119
   SEELEY RJ, 1996, HORM METAB RES, V28, P664
   SEGALLIEBERMAN G, 2003, P NATL ACAD SCI USA, V100, P10085, DOI
   10.1073/pnas.1633636100
   SWANSON LW, 2005, NEUROSCI LETT, V387, P80, DOI
   10.1016/j.neulet.2005.06.066
   VANDEWALL E, 2008, ENDOCRINOLOGY, V149, P1773
   YAMANAKA A, 2003, NEURON, V38, P701
   ZYLKA MJ, 2005, NEURON, V45, P17
NR 45
TC 44
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD AUG 6
PY 2009
VL 10
IS 2
BP 89
EP 98
DI 10.1016/j.cmet.2009.06.011
PG 10
SC Cell Biology; Endocrinology & Metabolism
GA 480DB
UT ISI:000268711200006
ER

PT J
AU Wan, Y
   Pan, F
   Liu, Y
   Liang, Y
   Yang, Z
   Zhao, HD
   Xua, YY
AF Wan, Yi
   Pan, Feng
   Liu, Ya
   Liang, Ying
   Yang, Zhe
   Zhao, Huadong
   Xua, Yongyong
TI Validation of the Andon KD-391 semiautomated blood pressure monitor in
   adults according to the International Protocol
SO BLOOD PRESSURE MONITORING
LA English
DT Article
DE blood pressure measurement; European Society of Hypertension;
   oscillometry; validation
ID EUROPEAN-SOCIETY; HYPERTENSION; ACCURATE; DEVICES
AB Objective Accurate blood pressure measurement is important for both the
   patients and the health service in appropriate treatment and estimation
   of clinical risk. Few automated devices have been shown to be accurate
   when compared with mercury sphygmomanometer. This study presents the
   validation results of the Andon KD-391 semiautomated blood pressure
   monitor according to the International Protocol of the European Society
   of Hypertension (ESH) in an adult population.
   Methods Sequential measurements of systolic and diastolic blood
   pressures were obtained in 33 participants who fulfilled the
   requirements of the International Protocol using the mercury
   sphygmomanometer (two observers) and the test device (one supervisor).
   According to the ESH validation protocol, 99 couples of test device and
   reference blood pressure measurements were obtained during the two
   phases of the study (three pairs for each of the 33 participants).
   Results In phase 1, the Andon KD-391 device produced 29, 38 and 44
   measurements for systolic blood pressure and 28, 39 and 43 for
   diastolic blood pressure failing within the zones 5, 10 and 15 mmHg,
   respectively. The test device also passed phase 2 of the validation
   study with a mean (+/- SD) device-observer difference of -0.17 +/- 7.07
   mmHg for systolic and -1.01 +/- 5.95 mmHg for diastolic blood pressure.
   Conclusion According to the results of the validation study on the
   basis of the ESH International Protocol, the Andon KD-391 can be
   recommended for clinical use in an adult population. Blood Press Monit
   14:181-184 (C) 2009 Wolters Kluwer Health | Lippincott Williams &
   Wilkins.
C1 [Wan, Yi; Pan, Feng; Liang, Ying; Yang, Zhe; Xua, Yongyong] Fourth Mil Med Univ, Inst Hlth Informat, Xian 710032, Peoples R China.
   [Liu, Ya] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Peoples R China.
   [Zhao, Huadong] Fourth Mil Med Univ, Tangdu Hosp, Xian 710032, Peoples R China.
RP Xua, YY, Fourth Mil Med Univ, Inst Hlth Informat, 169 W Changle Rd,
   Xian 710032, Peoples R China.
EM yongyong_xu@yahoo.com
FU National Natural Science Foundation of China [90612012]
FX This study was supported by a National Natural Science Foundation of
   China (90612012). The authors declare that they have no conflicts of
   interest.
CR MION D, 1998, J HUM HYPERTENS, V12, P245
   OBRIEN E, 1999, BLOOD PRESS MONIT, V4, P53
   OBRIEN E, 2001, BLOOD PRESS MONIT, V6, P275
   OBRIEN E, 2001, BLOOD PRESS MONIT, V6, P281
   OBRIEN E, 2002, BLOOD PRESS MONIT, V7, P3
   OBRIEN E, 2003, J HYPERTENS, V21, P821, DOI
   10.1097/01.hjh.0000059016.82022.ca
   PATER C, 2005, CURR CONTR TRIALS C, V6, ARTN 6
   TURNER MJ, 2007, AUST FAM PHYSICIAN, V36, P834
NR 8
TC 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1359-5237
J9 BLOOD PRESS MONIT
JI Blood Press. Monit.
PD AUG
PY 2009
VL 14
IS 4
BP 181
EP 184
DI 10.1097/MBP.0b013e32832db4c2
PG 4
SC Peripheral Vascular Disease
GA 479VU
UT ISI:000268690600008
ER

PT J
AU Yu, Y
   Iclozan, C
   Yamazaki, T
   Yang, XX
   Anasetti, C
   Dong, C
   Yu, XZ
AF Yu, Yu
   Iclozan, Cristina
   Yamazaki, Tomohide
   Yang, Xuexian
   Anasetti, Claudio
   Dong, Chen
   Yu, Xue-Zhong
TI Abundant c-Fas-associated death domain-like interleukin-1-converting
   enzyme inhibitory protein expression determines resistance of T helper
   17 cells to activation-induced cell death
SO BLOOD
LA English
DT Article
ID SIGNALING COMPLEX; APOPTOSIS; DIFFERENTIATION; INFLAMMATION; DISTINCT;
   LINEAGE; FLIP; TH17; TH2
AB Activation-induced cell death (AICD) plays an important role in
   peripheral T-cell tolerance. AICD in CD4 T helper (Th) cells, including
   Th1 and Th2 effectors, has been extensively studied. Recently,
   interleukin-17-producing CD4(+) T cells (Th17 cells) have been
   identified as a unique Th subset, but their susceptibility to AICD and
   the underlying molecular mechanisms have not been defined. In this
   study, we found that Th17 cells were significantly less susceptible to
   AICD than Th1 cells, and Th17 cell resistance to AICD is due to the
   high levels of c-Fas-associated death domain-like
   interleukin-1-converting enzyme inhibitory protein preventing
   Fas-mediated apoptosis. The resistance of Th17 cells to AICD reveals a
   novel mechanism to explain the high pathogenicity of Th17 cells in
   autoimmune diseases, and may also provide a rationale to generate
   tumor-specific Th17 cells for adoptive immunotherapy. (Blood. 2009;
   114: 1026-1028)
C1 [Yu, Yu; Iclozan, Cristina; Anasetti, Claudio; Yu, Xue-Zhong] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA.
   [Yu, Yu; Iclozan, Cristina; Anasetti, Claudio; Yu, Xue-Zhong] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA.
   [Yamazaki, Tomohide; Yang, Xuexian; Dong, Chen] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.
   [Anasetti, Claudio; Yu, Xue-Zhong] Univ S Florida, Dept Oncol Sci, Tampa, FL USA.
RP Yu, XZ, Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst,
   Dept Immunol, SRB 2,12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Xue.Yu@moffitt.org
FU National Institutes of Health [AI63553, CA118116, AI51693]; American
   Society for Blood and Marrow Transplantation 
FX We thank Drs Amer Beg, Esteban Celis, and Lia Perez for their critical
   discussion on this project. We are grateful for the technical
   assistance provided by Flow Cytometry and Mouse Core Facility at the
   Moffitt Cancer Center.
   This work was supported in part by National Institutes of Health grants
   AI63553, CA118116 ( to X.-Z.Y.), and AI51693 ( to C. A.). X.-Z.Y. is a
   recipient of a New Investigator Award supported by the American Society
   for Blood and Marrow Transplantation.
CR BETTELLI E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   BOISE LH, 1993, CELL, V74, P597
   CLEM RJ, 1998, P NATL ACAD SCI USA, V95, P554
   DEVADAS S, 2006, IMMUNITY, V25, P237, DOI 10.1016/j.immuni.2006.06.011
   HARRINGTON LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   IRMLER M, 1997, NATURE, V388, P190
   KABELITZ D, 1993, IMMUNOL TODAY, V14, P338
   KIRCHHOFF S, 2000, J IMMUNOL, V165, P6293
   KOVALOVICH K, 2001, J BIOL CHEM, V276, P26605
   KRAMMER PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115
   KRUEGER A, 2001, J BIOL CHEM, V276, P20633
   LENARDO M, 1999, ANNU REV IMMUNOL, V17, P221
   MCGEACHY MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001
   MURANSKI P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998
   OUYANG WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004
   PANDIYAN P, 2004, J EXP MED, V199, P831, DOI 10.1084/jem.20031058
   PARK H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   ROBERTS AI, 2003, IMMUNOL RES, V28, P285
   STEINMAN L, 2008, J EXP MED, V205, P1517, DOI 10.1084/jem.20072066
   YANG XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007
   ZHANG XH, 1997, J EXP MED, V185, P1837
NR 21
TC 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUL 30
PY 2009
VL 114
IS 5
BP 1026
EP 1028
DI 10.1182/blood-2009-03-210153
PG 3
SC Hematology
GA 477BH
UT ISI:000268491100016
ER

PT J
AU Wang, Q
   Lin, K
   Yang, SZ
AF Wang, Qian
   Lin, Kai
   Yang, Shu-Zheng
TI Fermions tunnelling from the rotating 5-D Myers-Perry black hole
SO GENERAL RELATIVITY AND GRAVITATION
LA English
DT Article
DE Fermions; Hawking radiation; Tunnelling; Myers-Perry black hole
ID DE-SITTER SPACES; HAWKING RADIATION; DIRAC PARTICLES; ANOMALIES; ENTROPY
AB Recent researches on the Hawking radiation of black holes show that the
   Hawking temperature can be obtained by fermion tunnelling method. In
   this paper, we extend this method to a 5-D space-time and view the
   Hawking radiation of the Myers-Perry black hole with two independent
   angular momenta. As a result, the Hawking temperature is obtained,
   which is the same as that obtained by other methods.
C1 [Wang, Qian; Lin, Kai; Yang, Shu-Zheng] China W Normal Univ, Inst Theoret Phys, Nanchong 637002, Sichuan, Peoples R China.
RP Wang, Q, China W Normal Univ, Inst Theoret Phys, Nanchong 637002,
   Sichuan, Peoples R China.
EM wqlhl@126.com
   lk314159@126.com
   szyang@cwnu.edu.cn
CR AHMED M, 1991, PHYS LETT B, V258, P318
   ANGHEBEN M, 2005, J HIGH ENERGY PHYS, ARTN 014
   BEKENSTEIN JD, 1973, PHYS REV D, V7, P2333
   CHEN DY, 2008, EUR PHYS J C, V56, P119, DOI
   10.1140/epjc/s10052-008-0638-y
   DAMOUR T, 1976, PHYS REV D, V14, P332
   HAWKING SW, 1974, NATURE, V248, P30
   ISO S, 2006, PHYS REV LETT, V96, ARTN 151302
   JIANG QQ, 2006, PHYS REV D, V73, ARTN 064003
   JIANG QQ, 2007, CLASSICAL QUANT GRAV, V24, P4391, DOI
   10.1088/0264-9381/24/17/008
   JIANG QQ, 2007, PHYS LETT B, V647, P200
   JIANG QQ, 2007, PHYS LETT B, V651, P58, DOI
   10.1016/j.physletb.2007.05.058
   JIANG QQ, 2007, PHYS LETT B, V651, P65, DOI
   10.1016/j.physietb.2007.06.003
   JIANG QQ, 2008, PHYS REV D, V78, ARTN 044009
   KERNER R, 2007, PHYS REV D, V75, ARTN 084022
   KERNER R, 2008, CLASSICAL QUANT GRAV, V25, ARTN 095014
   KERNER R, 2008, PHYS LETT B, V665, P277, DOI
   10.1016/j.physletb.2008.06.012
   LI R, 2008, PHYS LETT B, V661, P370, DOI 10.1016/j.physletb.2008.01.077
   LIN K, 2008, CHINESE PHYS LETT, V25, P390
   LIU L, 1980, ACTA PHYS SINICA, V29, P1624
   MEDVED AJM, 2002, PHYS REV D, V66, ARTN 124009
   MEDVED AJM, 2005, MOD PHYS LETT A, V20, P1723
   MYERS RC, 1986, ANN PHYS-NEW YORK, V172, P304
   PARIKH MK, 2000, PHYS REV LETT, V85, P5042
   ROBERTO DC, 2008, EPL-EUROPHYS LETT, V82, P60001
   ROBINSON SP, 2005, PHYS REV LETT, V95, ARTN 011303
   SRINIVASAN K, 1999, PHYS REV D, V60, ARTN 024007
   STROMINGER A, 1996, PHYS LETT B, V379, P99
   WANG SL, 2001, CHINESE PHYS, V10, P234
   WU SQ, 2000, NUOVO CIMENTO B, V115, P143
   YANG SZ, 2005, CHINESE PHYS LETT, V22, P2492
   YANG SZ, 2005, CHINESE PHYS, V14, DOI 10.1088/1009-1963/14/11/016
   ZHANG JY, 2005, J HIGH ENERGY PHYS, ARTN 055
   ZHANG JY, 2005, NUCL PHYS B, V725, P173, DOI
   10.1016/j.nuclphysb.2005.07.024
NR 33
TC 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-7701
J9 GEN RELATIV GRAVIT
JI Gen. Relativ. Gravit.
PD AUG
PY 2009
VL 41
IS 8
BP 1887
EP 1893
DI 10.1007/s10714-009-0765-2
PG 7
SC Astronomy & Astrophysics; Physics, Multidisciplinary; Physics,
   Particles & Fields
GA 475AG
UT ISI:000268326200013
ER

PT J
AU Sun, WJ
   Li, HX
   Yu, Y
   Fan, YH
   Grabiner, BC
   Mao, RF
   Ge, NL
   Zhang, H
   Fu, SB
   Lin, X
   Yang, JH
AF Sun, Wenjing
   Li, Hongxiu
   Yu, Yang
   Fan, Yihui
   Grabiner, Brian C.
   Mao, Renfang
   Ge, Ningling
   Zhang, Hong
   Fu, Songbin
   Lin, Xin
   Yang, Jianhua
TI MEKK3 is required for lysophosphatidic acid-induced NF-kappa B
   activation
SO CELLULAR SIGNALLING
LA English
DT Article
DE NF-kappa B; LPA; GPCR; MEKK3; TAK1
ID KINASE COMPLEX; IKK; BETA; TAK1; LIPOPOLYSACCHARIDE; PHOSPHORYLATION;
   PROTEINS; RECEPTOR; PLAYS; ALPHA
AB Lysophosphatidic acid (LPA) is a potent agonist that exerts various
   cellular functions on many cell types through binding to its cognate G
   protein-coupled receptors (GPCRs). Although LPA induces NF-kappa B
   activation by acting on its GPCR receptor, the molecular mechanism of
   LPA receptor-mediated NF-kappa B activation remains to be well defined.
   In the present study, by using MEKK3-, TAK1-, and IKK beta-deficient
   murine embryonic fibroblasts (MEFs), we found that MEKK3 but not TAK1
   deficiency impairs LPA and protein kinase C (PKC)-induced I kappa B
   kinase (IKK)-NF-kappa B activation, and IKK beta is required for
   PKC-induced NF-kappa B activation. In addition, we demonstrate that LPA
   and PKC-induced IL-6 and MIP-2 production are abolished in the absence
   of MEKK3 but not TAK1. Together, our results provide the genetic
   evidence that MEKK3 but not TAK1 is required for LPA receptor-mediated
   IKK-NF-kappa B activation. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sun, Wenjing; Yu, Yang; Fan, Yihui; Ge, Ningling; Yang, Jianhua] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Sun, Wenjing; Fu, Songbin] Harbin Med Coll, Med Genet Lab, Harbin 150081, Peoples R China.
   [Li, Hongxiu; Grabiner, Brian C.; Lin, Xin] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX USA.
   [Mao, Renfang; Zhang, Hong] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
RP Yang, JH, Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Dan L
   Duncan Canc Ctr, Houston, TX 77030 USA.
EM jianhuay@bcm.tmc.edu
FU National Institutes of Health [1R21CA106513-01A2, 5R01GM079451];
   American Cancer Society [RSG-06-070-01-TBE]; Fleming and Davenport
   Award 
FX We are grateful to Susan Burlingame for the excellent technical
   assistance. We thank Drs. Paul Chiao, Bing Su and Sankar Ghosh for
   providing IKK beta-, MEKK3- and TAK1-deficient MEFs. This research was
   supported in part by the National Institutes of Health Grant
   1R21CA106513-01A2 (to J.Y.), 5R01GM079451 (to X.L.), the American
   Cancer Society grant RSG-06-070-01-TBE (to J.Y.),and the Fleming and
   Davenport Award (to H.Z.).
CR BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P649
   BEG AA, 1993, GENE DEV, V7, P2064
   BEG AA, 1993, MOL CELL BIOL, V13, P3301
   CHAU TL, 2008, TRENDS BIOCHEM SCI, V33, P171, DOI
   10.1016/j.tibs.2008.01.002
   DEACON K, 1999, J BIOL CHEM, V274, P16604
   DIXIT V, 2002, CELL, V111, P615
   GHOSH S, 2002, CELL S, V109, S81
   GRABINER BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507
   HACKER H, 2006, SCI STKE, RE13, DOI 10.1126/STKE.3572006RE13
   HAWIGER J, 1999, BLOOD, V94, P1711
   HAYDEN MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   HUANG QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014
   KARIN M, 2000, ANNU REV IMMUNOL, V18, P621
   KLEMM S, 2007, P NATL ACAD SCI USA, V104, P134, DOI
   10.1073/pnas.0608388103
   LI QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   LI ZW, 1999, J EXP MED, V189, P1839
   LISTERLUCAS LM, 2007, P NATL ACAD SCI USA, V104, P139
   MAY MJ, 1998, IMMUNOL TODAY, V19, P80
   MILLS GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143
   NHO CW, 2004, J BIOL CHEM, V279, P26019, DOI 10.1074/jbc.M309022200
   QIN JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200
   SATO S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   SCHMIDT C, 2003, MOL CELL, V12, P1287
   SHIM JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605
   SHIMADA T, 1999, INT IMMUNOL, V11, P1357
   SUN JY, 2008, P NATL ACAD SCI USA, V105, P17085, DOI
   10.1073/pnas.0802701105
   TANAKA M, 1999, IMMUNITY, V10, P421
   VERMA IM, 1995, GENE DEV, V9, P2723
   WANG C, 2001, NATURE, V412, P346
   WANG DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI
   10.1073/pnas.0601894104
   YANG JH, 2001, NAT IMMUNOL, V2, P620
   YE RD, 2001, J LEUKOCYTE BIOL, V70, P839
   ZANDI E, 1999, MOL CELL BIOL, V19, P4547
   ZHAO Q, 1999, J BIOL CHEM, V274, P8355
NR 34
TC 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2009
VL 21
IS 10
BP 1488
EP 1494
DI 10.1016/j.cellsig.2009.05.007
PG 7
SC Cell Biology
GA 475RN
UT ISI:000268378300004
ER

PT J
AU Zhou, YB
   Frey, TK
   Yang, JJ
AF Zhou, Yubin
   Frey, Teryl K.
   Yang, Jenny J.
TI Viral calciomics: Interplays between Ca2+ and virus
SO CELL CALCIUM
LA English
DT Review
DE Virus; Calcium; Signaling; EF-hand; Structure; Interaction; Apoptosis;
   Infection
ID NONSTRUCTURAL GLYCOPROTEIN NSP4; CALCIUM-BINDING SITE; ACTIVATED
   T-CELLS; TYPE-1 ENVELOPE GLYCOPROTEIN; INDUCED STRUCTURAL-CHANGES;
   TOBACCO MOSAIC-VIRUS; EPSTEIN-BARR VIRUS; HIV-1 PROTEIN TAT; EF-HAND
   FAMILY; NF-KAPPA-B
AB Ca2+ is one of the most universal and versatile signaling molecules and
   is involved in almost every aspect of cellular processes. Viruses are
   adept at utilizing the universal Ca2+ signal to create a tailored
   cellular environment that meets their own demands. This review
   summarizes most of the known mechanisms by which viruses perturb Ca2+
   homeostasis and utilize Ca2+ and cellular Ca2+-binding proteins to
   their benefit in their replication cycles. Ca2+ plays important roles
   in virion structure formation, virus entry, viral gene expression,
   posttranslational processing of viral proteins and virion maturation
   and release. As part of the review, we introduce an algorithm to
   identify linear "EF-hand" Ca2+-binding motifs which resulted in the
   prediction of a total of 93 previously unrecognized Ca2+-binding motifs
   in virus proteins. Many of these proteins are nonstructural proteins, a
   class of proteins among which Ca2+ interactions had not been formerly
   appreciated. The presence of linear Ca2+-binding motifs in viral
   proteins enlarges the spectrum of Ca2+-virus interplay and expands the
   total scenario of viral calciomics. (C) 2009 Elsevier Ltd. All rights
   reserved.
C1 [Frey, Teryl K.] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.
   [Zhou, Yubin; Yang, Jenny J.] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
RP Frey, TK, Georgia State Univ, Dept Biol, 50 Decatur St, Atlanta, GA
   30303 USA.
EM tfrey@gsu.edu
   chejjy@langate.gsu.edu
FU NIAID [R01 AI21389]; NIH [R01 GM 62999]
FX We thank Dan Adams for his help in preparation of this manuscript. This
   work is supported in part by a grant (R01 AI21389) from NIAID to TKF
   and JJY and in part by the R01 GM 62999 (NIH) grant for JJY. YZ is a
   fellow of the Molecular Basis of Disease Area of Focus at GSU.
CR AGIRRE A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200
   ALBRECHT B, 2002, J VIROL, V76, P3493
   ALDABE R, 1997, J VIROL, V71, P6214
   ALEFANTIS T, 2007, BIOMED PHARMACOTHER, V61, P194, DOI
   10.1016/j.biopha.2007.02.005
   ARNOULT D, 2004, P NATL ACAD SCI USA, V101, P7988, DOI
   10.1073/pnas.0401897101
   ATREYA CD, 1995, J VIROL, V69, P3848
   BALL JM, 1996, SCIENCE, V272, P101
   BEATON AR, 2002, P NATL ACAD SCI USA, V99, P13154, DOI
   10.1073/pnas.192432299
   BENALIFURET NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673
   BERGQVIST A, 2001, J VIROL, V75, P772
   BERGQVIST A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200
   BERKOVA Z, 2003, CELL CALCIUM, V34, P55, DOI
   10.1016/S0143-4160(03)00022-8
   BERKOVA Z, 2006, J VIROL, V80, P6061, DOI 10.1128/JVI.02167-05
   BERRIDGE MJ, 1998, NATURE, V395, P645
   BERRIDGE MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   BOATMAN MD, 1999, CURR BIOL, V9, R876
   BOUCHARD MJ, 2001, SCIENCE, V294, P2376
   BOWMAN GD, 2000, J MOL BIOL, V304, P861
   BUGARCIC A, 2006, J VIROL, V80, P12343, DOI 10.1128/JVI.01378-06
   BURMEISTER WP, 1992, EMBO J, V11, P49
   BURMEISTER WP, 1994, J GEN VIROL 2, V75, P381
   CAMPANELLA M, 2004, J BIOL CHEM, V279, P18440, DOI
   10.1074/jbc.M309494200
   CARRETERO M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526
   CHAMI M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200
   CHAMI M, 2006, BBA-MOL CELL RES, V1763, P1344, DOI
   10.1016/j.bbamcr.2006.09.025
   CHEN JJ, 1995, SCIENCE, V269, P529
   CHEN JJ, 1998, J BIOL CHEM, V273, P13537
   CHEN MH, 2005, PLANT PHYSIOL, V138, P1866, DOI 10.1104/pp.105.064386
   CHESHENKO N, 2003, J CELL BIOL, V163, P283, DOI 10.1083/jcb.200301084
   CHOI J, 2003, BIOCHEM BIOPH RES CO, V305, P1049, DOI
   10.1016/S0006-291X(03)00881-7
   CHOI YW, 2005, VIROLOGY, V332, P454, DOI 10.1016/j.virol.2004.11.019
   CHRISTENSEN KA, 2002, J CELL SCI, V115, P599
   CIMINALE V, 1999, ONCOGENE, V18, P4505
   COLOMBO M, 2003, ANTIVIR RES, V60, P145, DOI
   10.1016/j.antiviral.2003.08.010
   CONTRERAS X, 2005, VIROLOGY, V332, P316, DOI 10.1016/j.virol.2004.11.032
   CREUTZ CE, 1992, SCIENCE, V258, P924
   DAGOSTINO DM, 2002, J BIOL CHEM, V277, P34424, DOI
   10.1074/jbc.M203023200
   DAGOSTINO DM, 2005, ADV CANCER RES, V94, P87, DOI
   10.1016/S0065-230X(04)94003-1
   DAGOSTINO DM, 2005, CELL DEATH DIFFER S1, V12, P905, DOI
   10.1038/sj.cdd.4401576
   DAYANITHI G, 1995, CELL CALCIUM, V18, P9
   DEJONG AS, 2006, J BIOL CHEM, V281, P14144, DOI 10.1074/jbc.M511766200
   DEMEYER S, 1999, J HEPATOL, V31, P783
   DEPLA E, 2000, CURR OPIN INVEST DR, V1, P415
   DIMITROV DS, 1993, J VIROL, V67, P1647
   DING W, 2001, J VIROL, V75, P7672
   DING W, 2002, J VIROL, V76, P10374, DOI
   10.1128/JVI.76.20.10374-10382.2002
   DOEDENS JR, 1995, EMBO J, V14, P894
   DONG YJ, 1997, P NATL ACAD SCI USA, V94, P3960
   DORMITZER PR, 1992, VIROLOGY, V189, P828
   DU MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962
   DUGAS B, 1988, J IMMUNOL, V141, P4344
   DUGAS B, 1989, EUR J IMMUNOL, V19, P1867
   DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974
   EBENBICHLER CF, 1996, J VIROL, V70, P1723
   ELLGAARD L, 2003, CELL BIOCHEM BIOPHYS, V39, P223
   EMSLIE KR, 1996, J BIOTECHNOL, V50, P149
   FERRI KF, 2001, NAT CELL BIOL, V3, E255
   FESKE S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702
   FOTI M, 1999, J BIOL CHEM, V274, P34765
   FREY TK, 1994, ADV VIRUS RES, V44, P69
   GAJARDO R, 1997, J VIROL, V71, P2211
   GALLAGHER WH, 1983, J MOL BIOL, V170, P905
   GELEBART P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI
   10.1016/j.biocel.2004.02.030
   GERASIMENKO JV, 1998, CURR BIOL, V8, P1335
   GIRANDA VL, 1992, P NATL ACAD SCI USA, V89, P10213
   GONG GZ, 2001, P NATL ACAD SCI USA, V98, P9599
   GRIFFIN SDC, 2003, FEBS LETT, V535, P34, DOI
   10.1016/S0014-5793(02)03851-6
   GWACK Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007
   HAMILTON SL, 2005, CELL CALCIUM, V38, P253, DOI
   10.1016/j.ceca.2005.06.037
   HAUGHEY NJ, 1999, J NEUROCHEM, V73, P1363
   HAYASHI N, 2002, PROTEIN SCI, V11, P529
   HAYNES JI, 1993, J VIROL, V67, P2486
   HOEFLICH KP, 2002, CELL, V108, P739
   HOLASKA JM, 2002, MOL CELL BIOL, V22, P6286, DOI
   10.1128/MCB.22.17.6286-6297.2002
   HOLDEN CP, 1999, NEUROSCIENCE, V91, P1369
   IKURA M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI
   10.1073/pnas.0508640103
   ILAG LL, 1994, J MOL BIOL, V244, P291
   IRURZUN A, 1995, J VIROL, V69, P5142
   JACOTOT E, 2000, J EXP MED, V191, P33
   JACOTOT E, 2001, J EXP MED, V193, P509
   JOHNSON JM, 2000, AIDS RES HUM RETROV, V16, P1777
   KASAMATSU H, 2006, PROTEIN SCI, V15, P2207, DOI 10.1110/ps.062195606
   KIM S, 1989, J MOL BIOL, V210, P91
   KINO T, 1999, J EXP MED, V189, P51
   KINO T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002
   KINOSHITA S, 1997, IMMUNITY, V6, P235
   KRUMAN II, 1998, EXP NEUROL, V154, P276
   LAAKSO MM, 1993, VIROLOGY, V197, P774
   LANNUZEL A, 1995, EUR J NEUROSCI, V7, P2285
   LARAPEZZI E, 1998, EMBO J, V17, P7066
   LAWRENCE MC, 2004, J MOL BIOL, V335, P1343, DOI
   10.1016/j.jmb.2003.11.032
   LEE BS, 2005, J VIROL, V79, P12173, DOI
   10.1128/JVI.79.19.12173-12184.2005
   LI PP, 2003, J VIROL, V77, P7527, DOI 10.1128/JVI.77.13.7527-7538.2003
   LI PP, 2007, J VIROL, V81, P6099, DOI 10.1128/JVI.02195-06
   LI YC, 2007, FASEB J, V21, P2474, DOI 10.1096/fj.06-7345com
   LIN B, 1999, VIROLOGY, V259, P34
   LORROT M, 2007, VIROL J, V4, ARTN 31
   MA G, 2004, J EXP MED, V200, P1337, DOI 10.1084/jem.20041115
   MANNINEN A, 2002, J EXP MED, V195, P1023
   MANTOVANI F, 2001, ONCOGENE, V20, P7874
   MASON WS, 1993, J HEPATOL, V17, S137
   MATSUBARA M, 2005, PROTEIN SCI, V14, P494, DOI 10.1110/ps.04969605
   MAYRAN N, 2003, EMBO J, V22, P3242
   MCKENNA R, 1992, NATURE, V355, P137
   MICHELANGELI F, 1991, VIROLOGY, V181, P520
   MICHELANGELI F, 1995, J VIROL, V69, P3838
   MIKOSHIBA K, 2000, SCI STKE 2000, PE1
   MIYAWAKI A, 1997, NATURE, V388, P882
   MUCKELBAUER JK, 1995, STRUCTURE, V3, P653
   NAIR AM, 2006, VIROLOGY, V353, P247, DOI 10.1016/j.virol.2006.06.005
   NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473
   NAKHASI HL, 2001, ARCH VIROL, V146, P1
   NATH A, 1995, BRAIN RES, V678, P200
   NIEVA JL, 2003, FEBS LETT, V552, P68, DOI 10.1016/S0014-5793(03)00852-4
   NOKTA M, 1987, VIROLOGY, V157, P259
   OH JC, 2003, EXP MOL MED, V35, P301
   OLDRIDGE J, 1998, TRENDS CELL BIOL, V8, P302
   OTTEKEN A, 1996, J BIOL CHEM, V271, P97
   PALMER AE, 2006, NAT PROTOC, V1, P1057
   PAN ZG, 1996, AM J PATHOL, V149, P903
   PAREKH AB, 1997, PHYSIOL REV, V77, P901
   PATTANAYEK R, 1992, PROTEINS, V12, P128
   PEREZ JF, 1999, J VIROL, V73, P2481
   PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462
   PIETROPAOLO RL, 1997, J VIROL, V71, P9803
   PINTON P, 2000, J CELL BIOL, V148, P857
   PINTON P, 2001, EMBO J, V20, P2690
   POGGI A, 1998, J BIOL CHEM, V273, P7205
   PONCET D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200
   PRAKRIYA M, 2006, NATURE, V443, P230
   PUTNEY JW, 1998, SCIENCE, V279, P191
   PUTNEY JW, 2000, CELL MOL LIFE SCI, V57, P1272
   QU CX, 2000, STRUCTURE, V8, P1095
   RADDING W, 1996, BIOCHEM BIOPH RES CO, V218, P192
   RADDING W, 2000, AIDS RES HUM RETROV, V16, P1519
   RAYNOR CM, 1999, BIOCHEMISTRY-US, V38, P5089
   RIGDEN DJ, 2003, TRENDS MICROBIOL, V11, P295, DOI
   10.1016/S0966-842X(03)00153-7
   RIZZUTO R, 2000, J PHYSIOL-LONDON, V529, P37
   RIZZUTO R, 2004, SCI STKE, RE1
   RONG Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI
   10.1146/annurev.physiol.70.021507.105852
   ROOS J, 2005, J CELL BIOL, V169, P435, DOI 10.1093/jcb.200502019
   RUIZ MC, 2000, CELL CALCIUM, V28, P137
   SATHESHKUMAR PS, 2004, J MOL BIOL, V342, P1001, DOI
   10.1016/j.jmb.2004.07.022
   SELF RL, 2004, BRAIN RES, V995, P39, DOI 10.1016/j.brainres.2003.09.052
   SHARONFRILING R, 2006, P NATL ACAD SCI USA, V103, P19117, DOI
   10.1073/pnas.0609353103
   SHENG WS, 2000, CLIN IMMUNOL, V96, P243
   SIMPSON AA, 2000, J MOL BIOL, V300, P597
   SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770
   SRINIVAS SK, 1993, J BIOL CHEM, V268, P22895
   TARS K, 2003, VIROLOGY, V310, P287, DOI 10.1016/S0042-6822(03)00148-X
   THOMAS AP, 1996, FASEB J, V10, P1505
   TIAN P, 1995, J VIROL, V69, P5763
   TIAN P, 1996, J VIROL, V70, P6973
   TOMITA Y, 1999, J BIOCHEM-TOKYO, V126, P1090
   TULIP WR, 1991, J MOL BIOL, V221, P487
   VANKUPPEVELD FJM, 1997, EMBO J, V16, P3519
   VANKUPPEVELD FJM, 2005, TRENDS MICROBIOL, V13, P41, DOI
   10.1016/j.tim.2004.12.005
   VARGHESE JN, 1983, NATURE, V303, P35
   VENKATACHALAM K, 2002, NAT CELL BIOL, V4, E263
   VERKHRATSKY A, 2007, SUB CELL BIOCHEM, V45, P465
   VIG M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883
   YANG JJ, 2003, PROTEIN PEPTIDE LETT, V10, P331
   YANG W, 2002, PROTEINS, V47, P344
   YUAN T, 1995, BIOCHEMISTRY-US, V34, P10690
   YUAN T, 2001, BIOPOLYMERS, V58, P50
   ZENG WZ, 2003, CURR BIOL, V13, P872, DOI 10.1016/S0960-9822(03)00330-0
   ZHANG SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147
   ZHAO R, 1996, STRUCTURE, V4, P1205
   ZHOU Y, 2006, PROTEINS, V65, P643, DOI 10.1002/prot.21139
   ZHOU YB, 2007, J VIROL, V81, P7517, DOI 10.1128/JVI.00605-07
   ZOCCHI MR, 1998, J IMMUNOL, V161, P2938
NR 171
TC 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
J9 CELL CALCIUM
JI Cell Calcium
PD JUL
PY 2009
VL 46
IS 1
BP 1
EP 17
DI 10.1016/j.ceca.2009.05.005
PG 17
SC Cell Biology
GA 474MT
UT ISI:000268288900001
ER

PT J
AU Chang, YK
   Yang, W
   Zhao, M
   Mok, CC
   Chan, TM
   Wong, RWS
   Lee, KW
   Mok, MY
   Wong, SN
   Ng, IOL
   Lee, TL
   Ho, MHK
   Lee, PPW
   Wong, WHS
   Lau, CS
   Sham, PC
   Lau, YL
AF Chang, Y. K.
   Yang, W.
   Zhao, M.
   Mok, C. C.
   Chan, T. M.
   Wong, R. W. S.
   Lee, K. W.
   Mok, M. Y.
   Wong, S. N.
   Ng, I. O. L.
   Lee, T. L.
   Ho, M. H. K.
   Lee, P. P. W.
   Wong, W. H. S.
   Lau, C. S.
   Sham, P. C.
   Lau, Y. L.
TI Association of BANK1 and TNFSF4 with systemic lupus erythematosus in
   Hong Kong Chinese
SO GENES AND IMMUNITY
LA English
DT Article
DE SLE; BANK1; TNFSF4; Chinese; genetic association
ID GENOME-WIDE ASSOCIATION; OX40 LIGAND
AB Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease
   with complex genetic inheritance. Recently, single nucleotide
   polymorphisms (SNPs) in BANK1 and TNFSF4 have been shown to be
   associated with SLE in Caucasian populations, but it is not known
   whether they are also involved in the disease in other ethnic groups.
   Recent data from our genome-wide association study (GWAS) for 314 SLE
   cases and 920 controls collected in Hong Kong identified SNPs in and
   around BANK1 and TNFSF4 to be associated with SLE risk. On the basis of
   the results of the reported studies and our GWAS, SNPs were selected
   for further genotyping in 949 SLE patients ( overlapping with the 314
   cases in our GWAS) and non-overlapping 1042 healthy controls. We
   confirmed the associations of BANK1 and TNFSF4 with SLE in Chinese
   (BANK1, rs3733197, odds ratio (OR) = 0.84, P = 0.021; BANK1,
   rs17266594, OR = 0.61, P = 4.67 x 10(-9); TNFSF4, rs844648, OR = 1.22,
   P = 2.47 x 10(-3); TNFSF4, rs2205960, OR = 1.30, P = 2.41 x 10(-4)).
   Another SNP located in intron 1 of BANK1, rs4522865, was separately
   replicated by Sequenom in 360 cases and 360 controls and was also
   confirmed to be associated with SLE (OR = 0.725, P = 2.93 x 10(-3)).
   Logistic regression analysis showed that rs3733197 (A383T in ankyrin
   domain) and rs17266594 (a branch point-site SNP) from BANK1 had
   independent contributions towards the disease association (P = 0.037
   and 6.63 x 10(-8), respectively). In TNFSF4, rs2205960 was associated
   with SLE independently from the effect of rs844648 (P = 6.26 x 10(-3)),
   but not vice versa (P = 0.55). These findings suggest that multiple
   independent genetic variants may be present within the gene locus,
   which exert their effects on SLE pathogenesis through different
   mechanisms. Genes and Immunity (2009) 10, 414-420; doi:
   10.1038/gene.2009.16; published online 9 April 2009
C1 [Chang, Y. K.; Yang, W.; Zhao, M.; Lee, T. L.; Ho, M. H. K.; Lee, P. P. W.; Wong, W. H. S.; Lau, Y. L.] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Mok, C. C.] Tuen Mun Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, T. M.; Wong, R. W. S.; Mok, M. Y.; Lau, C. S.] Univ Hong Kong, Dept Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Lee, K. W.] Pamela Youde Nethersole Eastern Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Wong, S. N.] Tuen Mun Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Ng, I. O. L.] Univ Hong Kong, LKS Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Sham, P. C.] Univ Hong Kong, LKS Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China.
RP Lau, YL, Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Hong Kong,
   Peoples R China.
EM lauylung@hkucc.hku.hk
FU Shun Tak District Min Yuen Tong of Hong Kong ; Mr and Mrs SH Wong
   Foundation Scholarship ; BLWong Scholarship ; Yu Chun Keung Memorial
   Scholarship for Master of Research in Medicine ; Edward Sai Kim Hotung
   Paediatric Education and Research Fund ; University Postgraduate
   Studentship ; UGC, UHK [200711159155]
FX This study is partially supported by the Shun Tak District Min Yuen
   Tong of Hong Kong. YKC thanks support from Mr and Mrs SH Wong
   Foundation Scholarship, BLWong Scholarship and Award of Yu Chun Keung
   Memorial Scholarship for Master of Research in Medicine. MZ was
   supported by Edward Sai Kim Hotung Paediatric Education and Research
   Fund, and University Postgraduate Studentship. WY thanks support from
   UGC, UHK (200711159155).
CR BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI
   10.1093/bioinformatics/bth457
   BAUM PR, 1994, EMBO J, V13, P3992
   CORDELL HJ, 2005, LANCET, V366, P1121
   GABRIEL S, 2009, CURR PROTOC HUM GENE, CH2
   GRAHAM DSC, 2008, NAT GENET, V40, P83, DOI 10.1038/ng.2007.47
   ITO T, 2006, P NATL ACAD SCI USA, V103, P13138, DOI
   10.1073/pnas.0603107103
   KOZYREV SV, 2008, NAT GENET, V40, P211, DOI 10.1038/ng.79
   LAU CS, 2006, LUPUS, V15, P715, DOI 10.1177/0961203306072311
   LETTRE G, 2008, HUM MOL GENET, V17, R116, DOI 10.1093/hmg/ddn246
   LI J, 2008, CELL IMMUNOL, V253, P31, DOI 10.1016/j.cellimm.2008.04.010
   MOHLER P, 2003, NATURE, V421, P587
   MOHLER PJ, 2003, NATURE, V421, P589
   MOK CC, 2003, LUPUS, V12, P717, DOI 10.1191/0961203303lu451xx
   PAOHSII F, 2007, ANN NY ACAD SCI, V1108, P114
   PRICE AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   PURCELL S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271
   YANG W, 2009, GENES IMMUN, V10, P219, DOI 10.1038/gene.2009.1
   YOKOYAMA K, 2002, EMBO J, V21, P83
NR 19
TC 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 414
EP 420
DI 10.1038/gene.2009.16
PG 7
SC Genetics & Heredity; Immunology
GA 472YH
UT ISI:000268168800006
ER

PT J
AU Li, QZ
   Zhou, J
   Yang, R
   Yan, M
   Ye, Q
   Liu, K
   Liu, S
   Shao, X
   Li, L
   Zhou, XJ
   Wakeland, EK
   Mohan, C
AF Li, Q-Z
   Zhou, J.
   Yang, R.
   Yan, M.
   Ye, Q.
   Liu, K.
   Liu, S.
   Shao, X.
   Li, L.
   Zhou, X-J
   Wakeland, E. K.
   Mohan, C.
TI The lupus-susceptibility gene kallikrein downmodulates
   antibody-mediated glomerulonephritis
SO GENES AND IMMUNITY
LA English
DT Article
DE Kallikrein; anti-GBM; glomerulonephritis; adenovirus; lupus
ID CONVERTING ENZYME-INHIBITION; STRAIN DISTRIBUTION PATTERN; BRADYKININ
   B2 RECEPTOR; CONGENIC MOUSE STRAINS; INDUCED RENAL INJURY; TISSUE
   KALLIKREIN; ERYTHEMATOSUS PATHOGENESIS; DIABETIC-NEPHROPATHY; SLE
   PATHOGENESIS; KININ SYSTEM
AB Sle3 is a NZM2410/NZW-derived lupus-susceptibility interval on murine
   chromosome 7, which is associated with spontaneous lupus nephritis
   (SLN), and also anti-GBM-induced glomerulonephritis (GN). The tissue
   kallikrein gene cluster is located within the Sle3 interval and
   constitutes potential candidate genes for this locus. We have recently
   reported that renal kallikrein expression was upregulated by anti-GBM
   antibody challenge in a strain-specific manner and that it was
   significantly underexpressed in the anti-GBM-sensitive strains,
   including B6.Sle3. Further sequencing and functional studies reported
   earlier provided evidence that kallikreins could constitute disease
   genes in lupus. In this report, we have used an adenoviral vector to
   deliver the klk1 gene to B6.Sle3 congenics to directly test if
   kallikreins might have a protective effect against anti-GBM-induced
   nephritis. Our data show that klk1 gene delivery ameliorated
   anti-GBM-induced nephritis in B6. Sle3 congenics. Taken together with
   earlier studies, these findings indicate that kallikreins play an
   important protective role in autoantibody-initiated GN and could
   constitute potential candidate genes for anti-GBM-induced GN and SLN.
   Genes and Immunity (2009) 10, 503-508; doi: 10.1038/gene.2009.7;
   published online 5 March 2009
C1 [Li, Q-Z; Zhou, J.; Yang, R.; Ye, Q.; Liu, K.; Liu, S.; Shao, X.; Li, L.; Wakeland, E. K.; Mohan, C.] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA.
   [Li, Q-Z; Yan, M.; Mohan, C.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
   [Zhou, X-J] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
RP Li, QZ, Univ Texas SW Med Ctr Dallas, Dept Immunol, 5323 Harry Hines
   Blvd, Dallas, TX 75390 USA.
EM quan.li@utsouthwestern.edu
   Chandra.mohan@utsouthwestern.edu
CR BASNAKIAN AG, 2002, ANTIOXID REDOX SIGN, V4, P915
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   BLEDSOE G, 2006, HUM GENE THER, V17, P545
   BLEDSOE G, 2006, NEPHROL DIAL TRANSPL, V21, P624, DOI 10.1093/ndt/gfi225
   BLEDSOE G, 2008, TOXICOL SCI, V102, P433, DOI 10.1093/toxsci/kfn008
   BULEON M, 2008, AM J PHYSIOL-RENAL, V294, F1249, DOI
   10.1152/ajprenal.00501.2007
   CARRETERO OA, 1980, AM J PHYSIOL, V238, F247
   CHAO J, 1998, HUM GENE THER, V9, P1
   CHAO J, 2005, EXP PHYSIOL, V90, P291, DOI 10.1113/expphysiol.2004.028464
   CHAO J, 2006, BIOL CHEM, V387, P665, DOI 10.1515/BC.2006.085
   CHAO J, 2007, HYPERTENSION, V49, P490, DOI
   10.1161/01.HYP.0000255925.01707.eb
   CHAO JL, 1998, KIDNEY INT, V54, P1250
   DATTA PK, 2006, EXP BIOL MED, V231, P576
   EDDY AA, 1990, CLIN IMMUNOL IMMUNOP, V57, P441
   ERDOS EG, 1999, TRENDS ENDOCRIN MET, V10, P223
   FOSTER MH, 1999, SEMIN NEPHROL, V19, P173
   FU H, 2007, EUR J PHARMACOL, V563, P197, DOI
   10.1016/j.ejphar.2007.02.015
   FU YY, 2007, CLIN IMMUNOL, V124, P109, DOI 10.1016/j.clim.2007.05.007
   HAHN BH, 1998, NEW ENGL J MED, V338, P1359
   IKEZUMI Y, 2004, J AM SOC NEPHROL, V15, P1775, DOI
   10.1097/01.ASN.0000131272.06958.DE
   KAKOKI M, 2004, P NATL ACAD SCI USA, V101, P13302, DOI
   10.1073/pnat.0405449101
   KONO DH, 2000, INT REV IMMUNOL, V19, P367
   KOTZIN BL, 1996, CELL, V85, P303
   LEFKOWITH JB, 1996, ARTHRITIS RHEUM, V39, P894
   LINZ W, 1995, PHARMACOL REV, V47, P25
   LIU K, J CLIN INVE IN PRESS
   LIU K, 2007, GENES IMMUN, V8, P634, DOI 10.1038/sj.gene.6364426
   MASON AJ, 1983, NATURE, V303, P300
   MOHAN C, 1997, J IMMUNOL, V159, P454
   MOHAN C, 1998, ARTHRITIS RHEUM, V41, P1652
   MOHAN C, 1998, J CLIN INVEST, V101, P1362
   MOHAN C, 1999, J CLIN INVEST, V103, P1685
   MOHAN C, 1999, J IMMUNOL, V162, P6492
   MOHAN C, 2001, CURR OPIN RHEUMATOL, V13, P352
   MOODLEY D, 1996, IMMUNOPHARMACOLOGY, V33, P380
   MOREL L, 1996, MAMM GENOME, V7, P335
   MOREL L, 1997, J IMMUNOL, V158, P6019
   MOREL L, 1999, IMMUNITY, V11, P131
   MOREL L, 2000, P NATL ACAD SCI USA, V97, P6670
   MOREL L, 2001, P NATL ACAD SCI USA, V98, P1787
   NOSE M, 2000, REV IMMUNOGENET, V2, P154
   PISETSKY DS, 2000, CURR OPIN RHEUMATOL, V12, P364
   RANA A, 2001, APOPTOSIS, V6, P83
   REGOLI D, 1990, J CARDIOVASC PHARM, V15, S30
   SCHANSTRA JP, 2002, J CLIN INVEST, V110, P371, DOI 10.1172/JCI200215493
   SCHMAIER AH, 2003, AM J PHYSIOL-REG I, V285, R1, DOI
   10.1152/ajpregu.00535.2002
   SHA SH, 1999, FREE RADICAL BIO MED, V26, P341
   SOBEL ES, 2002, J IMMUNOL, V169, P4025
   STAMBE C, 2003, KIDNEY INT, V64, P2121
   TSCHOPE C, 2003, INT IMMUNOPHARMACOL, V3, P335, DOI
   10.1016/S1567-5769(02)00273-4
   VYSE TJ, 1998, ANNU REV IMMUNOL, V16, P261
   WAKELAND EK, 1999, CURR OPIN IMMUNOL, V11, P701
   WOLF WC, 2000, KIDNEY INT, V58, P730
   XIE C, 2003, ARTHRITIS RHEUM, V48, P1080, DOI 10.1002/art.10887
   XIE C, 2004, J IMMUNOL, V172, P5047
   XIE C, 2008, INT IMMUNOL, V20, P719, DOI 10.1093/intimm/dxn030
   ZHANG JJ, 2004, KIDNEY INT, V66, P733
   ZHOU XJ, 2000, LAB INVEST, V80, P1905
NR 58
TC 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 503
EP 508
DI 10.1038/gene.2009.7
PG 6
SC Genetics & Heredity; Immunology
GA 472YH
UT ISI:000268168800016
ER

PT J
AU Gao, D
   Wang, RP
   Li, BF
   Yang, YL
   Zhai, ZH
   Chen, DY
AF Gao, Dong
   Wang, Ruipeng
   Li, Bingfeng
   Yang, Yongkang
   Zhai, Zhonghe
   Chen, Dan-Ying
TI WDR34 is a novel TAK1-associated suppressor of the
   IL-1R/TLR3/TLR4-induced NF-kappa B activation pathway
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE TAK1; WDR34; IL-1R; TLR4; TLR3; NF-kappa B
ID BETA SIGNAL-TRANSDUCTION; INNATE IMMUNE-RESPONSES; KINASE KINASE
   KINASE; TAK1 MAPKKK; TAK1-BINDING PROTEIN-1; CRITICAL ROLES; TAB1;
   IL-1; DROSOPHILA; BINDING
AB Toll-like receptors (TLRs) act as sensors of microbial components and
   elicit innate immune responses. All TLR signaling pathways activate the
   nuclear factor-kappaB (NF-kappa B), which controls the expression of
   inflammatory cytokine genes. Transforming growth factor-beta-activated
   kinase 1 (TAK1) is a serine/threonine protein kinase that is critically
   involved in the activation of NF-kappa B by tumor necrosis factor (TNF
   alpha), interleukin-1 beta (IL-1 beta) and TLR ligands. In this study,
   we identified a novel protein, WD40 domain repeat protein 34 (WDR34) as
   a TAK1-interacting protein in yeast two-hybrid screens. WDR34
   interacted with TAK1, TAK1-binding protein 2 (TAB2), TAK1-binding
   protein 3 (TAB3) and tumor necrosis factor receptor-associated factor 6
   (TRAF6) in overexpression and under physiological conditions.
   Overexpression of WDR34 inhibited IL-1 beta-, polyI:C- and
   lipopolysaccharide (LPS)-induced but not TNF alpha-induced NF-kappa B
   activation, whereas knockdown of WDR34 by a RNA-interference construct
   potentiated NF-kappa B activation by these ligands. Our findings
   suggest that WDR34 is a TAK1-associated inhibitor of the
   IL-1R/TLR3/TLR4-induced NF-kappa B activation pathway.
C1 [Gao, Dong; Wang, Ruipeng; Li, Bingfeng; Yang, Yongkang; Zhai, Zhonghe; Chen, Dan-Ying] Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Differentiat, Beijing 100871, Peoples R China.
RP Chen, DY, Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell
   Proliferat & Differentiat, Beijing 100871, Peoples R China.
EM dychen@pku.edu.cn
FU National Natural Science Foundation of China [30421004, 30871288];
   Foundation for Authors of National Excellent Doctoral Dissertations of
   PR China [200533]; China 973 Program [2006CB504301]
FX This work was supported by the National Natural Science Foundation of
   China (30421004 and 30871288), the Foundation for Authors of National
   Excellent Doctoral Dissertations of PR China (200533) and the China 973
   Program (2006CB504301). We thank Dr. Hong-Bing Shu and Dr. Zheng-Fan
   Jiang for stimulating discussions and members of our laboratory for
   technical help.
CR BOUTROS M, 2002, DEV CELL, V3, P711
   CHEN DY, 2002, J BIOL CHEM, V277, P15985
   CHEN ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758
   CHEUNG PCF, 2004, BIOCHEM J 1, V378, P27, DOI 10.1042/BJ20031794
   CONNER SH, 2006, BIOCHEM J 3, V399, P427, DOI 10.1042/BJ20061077
   DENG L, 2000, CELL, V103, P351
   INAGAKI M, 2008, J BIOL CHEM, V283, P33080, DOI 10.1074/jbc.M807574200
   ISHITANI T, 2003, EMBO J, V22, P6277
   JIANG ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI
   10.1073/pnas.0308496101
   JIN G, 2004, P NATL ACAD SCI USA, V101, P2028
   KANAYAMA A, 2004, MOL CELL, V15, P535
   KISHIMOTO K, 2000, J BIOL CHEM, V275, P7359
   KOBAYASHI T, 2004, MICROBES INFECT, V6, P1333, DOI
   10.1016/j.micinf.2004.09.001
   KOVALENKO A, 2006, MOL CELL, V22, P433, DOI 10.1016/j.molcel.2006.05.002
   KRAPPMANN D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380
   NINOMIYATSUJI J, 1999, NATURE, V398, P252
   ONO K, 2001, J BIOL CHEM, V276, P24396
   SAKURAI H, 2000, FEBS LETT, V474, P141
   SANJO H, 2003, MOL CELL BIOL, V23, P1231, DOI
   10.1128/MCB.23.4.1231-1238.2003
   SATO S, 2003, J IMMUNOL, V171, P4304
   SATO S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   SHIBUYA H, 1996, SCIENCE, V272, P1179
   SHIBUYA H, 1998, EMBO J, V17, P1019
   SHIM JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605
   SILVERMAN N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200
   SINGHIRUNNUSORN P, 2005, J BIOL CHEM, V280, P7359, DOI
   10.1074/jbc.M407537200
   TADA K, 2001, J BIOL CHEM, V276, P36530
   TAKAESU G, 2000, MOL CELL, V5, P649
   TAKAESU G, 2001, MOL CELL BIOL, V21, P2475
   TAKAESU G, 2003, J MOL BIOL, V326, P105, DOI
   10.1016/S0022-2836(02)01404-3
   VIDAL S, 2001, GENE DEV, V15, P1900
   WANG C, 2001, NATURE, V412, P346
   YAMAGUCHI K, 1995, SCIENCE, V270, P2008
NR 33
TC 0
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD AUG
PY 2009
VL 66
IS 15
BP 2573
EP 2584
DI 10.1007/s00018-009-0059-6
PG 12
SC Biochemistry & Molecular Biology; Cell Biology
GA 472AR
UT ISI:000268102000011
ER

PT J
AU Yang, H
   Lang, S
   Zhai, Z
   Li, L
   Kahr, WHA
   Chen, PG
   Brkic, J
   Spring, CM
   Flick, MJ
   Degen, JL
   Freedman, J
   Ni, HY
AF Yang, Hong
   Lang, Sean
   Zhai, Zhimin
   Li, Ling
   Kahr, Walter H. A.
   Chen, Pingguo
   Brkic, Jelena
   Spring, Christopher M.
   Flick, Matthew J.
   Degen, Jay L.
   Freedman, John
   Ni, Heyu
TI Fibrinogen is required for maintenance of platelet intracellular and
   cell-surface P-selectin expression
SO BLOOD
LA English
DT Article
ID VON-WILLEBRAND-FACTOR; ACTIVATED HUMAN PLATELETS; DEFICIENT MICE;
   IN-VIVO; FIBRONECTIN INTERNALIZATION; INTEGRIN ALPHA(IIB)BETA(3);
   MEDIATED MODULATION; ENDOTHELIAL-CELLS; ADAPTIVE IMMUNITY;
   ALPHA-GRANULES
AB Platelet P-selectin plays important roles in inflammation and
   contributes to thrombosis and hemostasis. Although it has been reported
   that von Willebrand factor (VWF) affects P-selectin expression on
   endothelial cells, little information is available regarding regulation
   of platelet P-selectin expression. Here, we first observed that
   P-selectin expression was significantly decreased on platelets of
   fibrinogen and VWF double-deficient mice. Subsequently, we identified
   this was due to fibrinogen deficiency. Impaired P-selectin expression
   on fibrinogen-deficient platelets was further confirmed in human
   hypofibrinogenemic patients. We demonstrated that this impairment is
   unlikely due to excessive P-selectin shedding, deficient
   fibrinogen-mediated cell surface P-selectin binding, or impaired
   platelet granule release, but rather is due to decreased platelet
   P-selectin content. Fibrinogen transfusion completely recovered this
   impairment in fibrinogen-deficient (Fg(-/-)) mice, and engagement of
   the C-terminus of the fibrinogen gamma chain with beta 3 integrin was
   required for this process. Furthermore, Fg(-/-) platelets significantly
   increased P-selectin expression following transfusion into beta 3
   integrin-deficient mice and when cultured with fibrinogen. These data
   suggest fibrinogen may play important roles in inflammation,
   thrombosis, and hemostasis via enhancement of platelet P-selectin
   expression. Since human fibrinogen levels vary significantly in normal
   and diseased populations, P-selectin as an activation marker on
   platelets should be used with caution. (Blood. 2009; 114: 425-436)
C1 [Ni, Heyu] Univ Toronto, Canadian Blood Serv, St Michaels Hosp,Li Ka Shing Knowledge Inst, Toronto Platelet Immunobiol Grp,Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
   [Yang, Hong; Lang, Sean; Freedman, John; Ni, Heyu] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada.
   [Yang, Hong; Lang, Sean; Chen, Pingguo; Ni, Heyu] Canadian Blood Serv, Toronto, ON, Canada.
   [Yang, Hong; Lang, Sean; Chen, Pingguo; Brkic, Jelena; Spring, Christopher M.; Freedman, John; Ni, Heyu] St Michaels Hosp, Dept Lab Med, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
   [Lang, Sean] Univ Toronto Scarborough, Dept Biol Sci, Toronto, ON, Canada.
   [Zhai, Zhimin] Anhui Med Univ, Affiliated Hosp 2, Ctr Lab, Anhui Prov Hosp, Hefei, Anhui, Peoples R China.
   [Li, Ling; Kahr, Walter H. A.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5B 1W8, Canada.
   [Kahr, Walter H. A.] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Haematol Oncol, Toronto, ON M5B 1W8, Canada.
   [Flick, Matthew J.; Degen, Jay L.] Univ Cincinnati, Cincinnati, OH 45221 USA.
   [Freedman, John; Ni, Heyu] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada.
   [Ni, Heyu] Univ Toronto, Dept Physiol, Toronto, ON M5B 1W8, Canada.
RP Ni, HY, Univ Toronto, Canadian Blood Serv, St Michaels Hosp,Li Ka Shing
   Knowledge Inst, Toronto Platelet Immunobiol Grp,Keenan Res Ctr, 30 Bond
   St,Rm 2-006, Toronto, ON M5B 1W8, Canada.
EM nih@smh.toronto.on.ca
FU Heart and Stroke Foundation of Canada (Ottawa, ON) ; Canadian
   Institutes of Health Research (CIHR) ; Canadian Blood Services ; St
   Michael's Hospital ; Canada Foundation for Innovation ; International
   Cooperation Research Fund of Anhui Provincial Scientific and
   Technologic Committee (China) ; Heart and Stroke Foundation of Ontario 
FX This work was supported in part by the Heart and Stroke Foundation of
   Canada (Ottawa, ON); Canadian Institutes of Health Research (CIHR) and
   Canadian Blood Services; Equipment Funds from St Michael's Hospital,
   Canadian Blood Services, and Canada Foundation for Innovation; and
   International Cooperation Research Fund of Anhui Provincial Scientific
   and Technologic Committee (China). W. H. A. K. was supported by an
   operating grant from CIHR and a Phase II Clinician Scientist Salary
   Award from the Heart and Stroke Foundation of Ontario. H.Y. is a
   recipient of the Heart and Stroke/Richard Lewar Excellence award and a
   Canadian Blood Services postdoctoral fellowship award. S. L. is a
   recipient of the Canadian Blood Services summer internship program and
   the Master's Studentship Award of the Heart and Stroke Foundation of
   Ontario.
CR AJAYI O, 2007, TURK J HEMATOL, V24, P18
   ASHKAR S, 2000, SCIENCE, V287, P860
   AUSTRUP F, 1997, NATURE, V385, P81
   BELLUCCI S, 2002, BLOOD REV, V16, P193, DOI
   10.1016/S0268-960X(02)00030-9
   BERNDT MC, 2007, J THROMB HAEMOST S1, V5, P212
   BONFANTI R, 1989, BLOOD, V73, P1109
   BURGER PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209
   CAMBIEN B, 2004, TRENDS MOL MED, V10, P179, DOI
   10.1016/j.molmed.2004.02.007
   CRONIN C, 1988, ACTA HAEMATOL, V79, P53
   CRUZTOPETE D, 2006, J PATHOL, V210, P325, DOI 10.1002/path.2060
   DENIS CV, 2001, P NATL ACAD SCI USA, V98, P4072
   DENIS MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   DIACOVO TG, 1996, SCIENCE, V273, P252
   DOLE VS, 2005, BLOOD, V106, P2334, DOI 10.1182/blood-2005-04-1530
   DOLE VS, 2007, THROMB HAEMOSTASIS, V98, P806, DOI 10.1160/TH07-03-0207
   DUNLOP LC, 1992, J EXP MED, V175, P1147
   ELZEY BD, 2003, IMMUNITY, V19, P9
   HEIJNEN HFG, 1998, BLOOD, V91, P2313
   HIROSE S, 1988, J BIOL CHEM, V263, P7426
   HOLMBACK K, 1996, EMBO J, V15, P5760
   ITALIANO JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837
   KIRSCHENBAUM LA, 2004, CRIT CARE MED, V32, P1904, DOI
   10.1097/01.CCM.0000139918.80602.57
   KUIJPER PHM, 1997, BLOOD, V89, P166
   LI GH, 2005, AM J PATHOL, V167, P1511
   LINDEMANN S, 2001, J CELL BIOL, V154, P485
   LO B, 2005, BLOOD, V106, P4159, DOI 10.1182/blood-2005-04-1356
   MAURIELLO A, 2000, CIRCULATION, V101, P744
   MCRITCHIE DI, 1991, J LAB CLIN MED, V118, P48
   MERTEN M, 2000, CIRCULATION, V102, P1931
   MICHELSON AD, 1996, P NATL ACAD SCI USA, V93, P11877
   NI HY, 2000, J CLIN INVEST, V106, P385
   NI HY, 2003, BLOOD, V102, P3609, DOI 10.1182/blood-2003-03-0850
   NURDEN AT, 2006, ORPHANET J RARE DIS, V1, ARTN 10
   PABLA R, 1999, J CELL BIOL, V144, P175
   PUJOLMOIX N, 2000, HAEMATOLOGICA, V85, P619
   REHEMAN A, 2009, BLOOD, V113, P1809, DOI 10.1182/blood-2008-04-148361
   ROMO GM, 1999, J EXP MED, V190, P803
   SMILEY ST, 2001, J IMMUNOL, V167, P2887
   SMYTH SS, 2000, THROMB HAEMOSTASIS, V84, P1103
   SPRAGUE DL, 2008, BLOOD, V111, P5028, DOI 10.1182/blood-2007-06-097410
   STENBERG PE, 1985, J CELL BIOL, V101, P880
   THON JN, 2007, TRANSFUSION, V47, P2260, DOI
   10.1111/j.1537-2995.2007.01455.x
   WEYRICH AS, 1998, P NATL ACAD SCI USA, V95, P5556
   WHITE GC, 2007, J THROMB HAEMOST, V5, P2006
   XU XC, 2006, THROMB HAEMOSTASIS, V95, P931, DOI 10.1160/TH06-01-0020
   YANG H, 2006, J THROMB HAEMOST, V4, P2230
   ZHAI Z, 2007, J THROMB HAEMOST, V5, P1740
   ZIMMERMAN GA, 2008, ARTERIOSCL THROM VAS, V28, S17, DOI
   10.1161/ATVBAHA.107.160218
NR 48
TC 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUL 9
PY 2009
VL 114
IS 2
BP 425
EP 436
DI 10.1182/blood-2008-03-145821
PG 12
SC Hematology
GA 471MK
UT ISI:000268061700028
ER

PT J
AU Johnson, LA
   Morgan, RA
   Dudley, ME
   Cassard, L
   Yang, JC
   Hughes, MS
   Kammula, US
   Royal, RE
   Sherry, RM
   Wunderlich, JR
   Lee, CCR
   Restifo, NP
   Schwarz, SL
   Cogdill, AP
   Bishop, RJ
   Kim, H
   Brewer, CC
   Rudy, SF
   VanWaes, C
   Davis, JL
   Mathur, A
   Ripley, RT
   Nathan, DA
   Laurencot, CM
   Rosenberg, SA
AF Johnson, Laura A.
   Morgan, Richard A.
   Dudley, Mark E.
   Cassard, Lydie
   Yang, James C.
   Hughes, Marybeth S.
   Kammula, Udai S.
   Royal, Richard E.
   Sherry, Richard M.
   Wunderlich, John R.
   Lee, Chyi-Chia R.
   Restifo, Nicholas P.
   Schwarz, Susan L.
   Cogdill, Alexandria P.
   Bishop, Rachel J.
   Kim, Hung
   Brewer, Carmen C.
   Rudy, Susan F.
   VanWaes, Carter
   Davis, Jeremy L.
   Mathur, Aarti
   Ripley, Robert T.
   Nathan, Debbie A.
   Laurencot, Carolyn M.
   Rosenberg, Steven A.
TI Gene therapy with human and mouse T-cell receptors mediates cancer
   regression and targets normal tissues expressing cognate antigen
SO BLOOD
LA English
DT Article
ID TUMOR-INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; METASTATIC
   MELANOMA; TCR; AUTOIMMUNITY; RECOGNITION; PERSISTENCE
AB Gene therapy of human cancer using genetically engineered lymphocytes
   is dependent on the identification of highly reactive T-cell receptors
   (TCRs) with antitumor activity. We immunized transgenic mice and also
   conducted high-throughput screening of human lymphocytes to generate
   TCRs highly reactive to melanoma/melanocyte antigens. Genes encoding
   these TCRs were engineered into retroviral vectors and used to
   transduce autologous peripheral lymphocytes administered to 36 patients
   with metastatic melanoma. Transduced patient lymphocytes were CD45RA(-)
   and CD45RO(+) after ex vivo expansion. After infusion, the persisting
   cells displayed a CD45RA(+) and CD45RO(-) phenotype. Gene-engineered
   cells persisted at high levels in the blood of all patients 1 month
   after treatment, responding patients with higher ex vivo antitumor
   reactivity than nonresponders. Objective cancer regressions were seen
   in 30% and 19% of patients who received the human or mouse TCR,
   respectively. However, patients exhibited destruction of normal
   melanocytes in the skin, eye, and ear, and sometimes required local
   steroid administration to treat uveitis and hearing loss. Thus, T cells
   expressing highly reactive TCRs mediate cancer regression in humans and
   target rare cognate -antigen-containing cells throughout the body, a
   finding with important implications for the gene therapy of cancer.
   This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174
   and NCI-07-C-0175. (Blood. 2009; 114: 535-546)
C1 [Johnson, Laura A.; Morgan, Richard A.; Dudley, Mark E.; Cassard, Lydie; Yang, James C.; Hughes, Marybeth S.; Kammula, Udai S.; Royal, Richard E.; Sherry, Richard M.; Wunderlich, John R.; Restifo, Nicholas P.; Schwarz, Susan L.; Cogdill, Alexandria P.; Davis, Jeremy L.; Mathur, Aarti; Ripley, Robert T.; Nathan, Debbie A.; Laurencot, Carolyn M.; Rosenberg, Steven A.] NCI, Surg Branch, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA.
   [Lee, Chyi-Chia R.] NCI, Pathol Lab, Bethesda, MD 20892 USA.
   [Bishop, Rachel J.] NEI, Off Clin Director, Bethesda, MD 20892 USA.
   [Kim, Hung; Brewer, Carmen C.; Rudy, Susan F.; VanWaes, Carter] Natl Inst Deafness & Other Commun Disorders, Otolaryngol Branch, Bethesda, MD USA.
RP Rosenberg, SA, NCI, Surg Branch, Hatfield Clin Res Ctr, Bldg 10CRC,
   Bethesda, MD 20892 USA.
EM SAR@nih.gov
CR BRENTJENS RJ, 2007, CLIN CANCER RES 1, V13, P5426
   COHEN CJ, 2005, J IMMUNOL, V175, P5799
   DUDLEY ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
   DUDLEY ME, 2003, J IMMUNOTHER, V26, P332
   DUDLEY ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240
   DUDLEY ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449
   ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720
   FANG W, 2008, CURR EYE RES, V33, P517, DOI 10.1080/02713680802233968
   GALLEGOS AM, 2006, IMMUNOL REV, V209, P290
   GATTINONI L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842
   HUGHES MS, 2005, HUM GENE THER, V16, P457
   JOHNSON LA, 2006, J IMMUNOL, V177, P6548
   KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515
   KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458
   LEEN AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI
   10.1146/annurev.immunol.25.022106.141527
   MARKTEL S, 2003, BLOOD, V101, P1290
   MORGAN RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003
   MURANSKI P, 2006, NAT CLIN PRACT ONCOL, V3, P668, DOI 10.1038/ncponc0666
   PALMER DC, 2008, P NATL ACAD SCI USA, V105, P8061, DOI
   10.1073/pnas.0710929105
   PARKHURST MR, 2009, CLIN CANCER RES, V15, P169, DOI
   10.1158/1078-0432.CCR-08-1638
   PINTHUS JH, 2004, J CLIN INVEST, V114, P1774, DOI 10.1172/JCI200422284
   PULE MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882
   ROBBINS PF, 2004, J IMMUNOL, V173, P7125
   ROSENBERG SA, 2001, NATURE, V411, P380
   ROSENBERG SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355
   SADELAIN M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971
   SAVOLDO B, 2007, BLOOD, V110, P2620, DOI 10.1182/blood-2006-11-059139
   SIMPSON AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   THEOBALD M, 1995, P NATL ACAD SCI USA, V92, P11993
   THERASSE P, 2000, J NATL CANCER I, V92, P205
   YANG S, 2008, GENE THER, V15, P1411, DOI 10.1038/gt.2008.90
   ZHAO YB, 2005, J IMMUNOL, V174, P4415
NR 32
TC 107
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUL 16
PY 2009
VL 114
IS 3
BP 535
EP 546
DI 10.1182/blood-2009-03-211714
PG 12
SC Hematology
GA 471ML
UT ISI:000268061800012
ER

PT J
AU Frankel, WN
   Yang, Y
   Mahaffey, CL
   Beyer, BJ
   O'Brien, TP
AF Frankel, W. N.
   Yang, Y.
   Mahaffey, C. L.
   Beyer, B. J.
   O'Brien, T. P.
TI Szt2, a novel gene for seizure threshold in mice
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE Epilepsy; feedback; mice; mutagenesis; mutation; seizure threshold
ID EPILEPSY; KCNQ2; MOUSE
AB In a chemical mutagenesis screen we identified Szt2 (seizure threshold
   2) as a gene that confers low seizure threshold to mice and may also
   enhance epileptogenesis. The semidominant phenotype was mapped to
   Chromosome 4 and narrowed further to a critical interval of
   approximately 650 kb. A novel large (> 10 kb) transcript in the
   critical interval was found to have fourfold increased steady-state
   expression at the RNA level in Szt2 homozygous mutant brain. The
   corresponding 72 exon gene encodes a 378-kD protein with no significant
   or suggestive sequence similarities to any other protein. The mutant
   allele of Szt2 contains a splice donor mutation after exon 32,
   predicting transcriptional read-through, translational frameshift and
   premature stop. A second Szt2 allele, containing a gene-trap mutation
   in exon 21, also conferred a low seizure threshold and increased RNA
   expression, but unlike the original allele, some gene-trap homozygotes
   died embryonically. Szt2 is transcribed in many tissues, with the
   highest expression in brain, and it is also expressed during embryonic
   development. Szt2 is highly conserved in evolution, with a clear,
   single orthologue found in all land vertebrates and in many
   invertebrates. Interestingly, in mammals the Szt2 gene resides in a
   highly conserved head-to-head configuration with Med8 (which encodes a
   Mediator complex subunit), separated by only 91 nt. While the
   biological function of Szt2 remains unknown, its high conservation,
   unique structure and effect on seizure threshold suggest that it serves
   an important role in the central nervous system.
C1 [Frankel, W. N.; Yang, Y.; Mahaffey, C. L.; Beyer, B. J.] Jackson Lab, Bar Harbor, ME 04609 USA.
   [O'Brien, T. P.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA.
RP Frankel, WN, Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
EM wayne.frankel@jax.org
FU NIH [NS31348, HD41066, CA34196]
FX We thank Greg Cox and Verity Letts for their feedback on this
   manuscript, Doug Hinerfeld and Rob Wilpan for their assistance with
   mass spectrometry, Ron Conaway for helpful discussions, Rod Bronson for
   reviewing our histological analysis and Steve White for sharing with us
   his pilot studies on corneal kindling in mutants. This work was
   supported by NIH grant NS31348 ( to WNF), NIH grant HD41066 ( to TPO)
   and CA34196 ( JAX Scientific Services).
CR BROWER CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI
   10.1073/pnas.162424199
   FRANKEL WN, 2001, GENOMICS, V74, P306
   KEARNEY JA, 2006, HUM MOL GENET, V15, P1043, DOI 10.1093/hmg/ddl019
   KITAMI T, 2004, MAMM GENOME, V15, P698
   MATAGNE A, 1998, EPILEPSY RES, V31, P59
   POTSCHKA H, 1999, EPILEPSY RES, V37, P109
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281
   SINGH NA, 1998, NAT GENET, V18, P25
   WATERHOUSE AM, 2009, BIOINFORMATICS, V25, P1189, DOI
   10.1093/bioinformatics/btp033
   YANG Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118
   YANG Y, 2007, PLOS GENET, V3, P1275, ARTN e124
NR 11
TC 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601-1848
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD JUL
PY 2009
VL 8
IS 5
BP 568
EP 576
DI 10.1111/j.1601-183X.2009.00509.x
PG 9
SC Behavioral Sciences; Neurosciences
GA 470IG
UT ISI:000267967800010
ER

PT J
AU Liu, WL
   Coleman, RA
   Ma, E
   Grob, P
   Yang, JL
   Zhang, YX
   Dailey, G
   Nogales, E
   Tjian, R
AF Liu, Wei-Li
   Coleman, Robert A.
   Ma, Elizabeth
   Grob, Patricia
   Yang, Joyce L.
   Zhang, Yixi
   Dailey, Gina
   Nogales, Eva
   Tjian, Robert
TI Structures of three distinct activator-TFIID complexes
SO GENES & DEVELOPMENT
LA English
DT Article
DE TAF; TFIID; transcription; activator; structure
ID LEUCINE-ZIPPER DOMAIN; C-JUN; TRANSCRIPTIONAL ACTIVATION; PROTEIN; P53;
   COACTIVATOR; RECRUITMENT; PROMOTER; GENES; FOS
AB Sequence-specific DNA-binding activators, key regulators of gene
   expression, stimulate transcription in part by targeting the core
   promoter recognition TFIID complex and aiding in its recruitment to
   promoter DNA. Although it has been established that activators can
   interact with multiple components of TFIID, it is unknown whether
   common or distinct surfaces within TFIID are targeted by activators and
   what changes if any in the structure of TFIID may occur upon binding
   activators. As a first step toward structurally dissecting
   activator/TFIID interactions, we determined the three-dimensional
   structures of TFIID bound to three distinct activators (i.e., the tumor
   suppressor p53 protein, glutamine-rich Sp1 and the oncoprotein c-Jun)
   and compared their structures as determined by electron microscopy and
   single-particle reconstruction. By a combination of EM and biochemical
   mapping analysis, our results uncover distinct contact regions within
   TFIID bound by each activator. Unlike the coactivator CRSP/Mediator
   complex that undergoes drastic and global structural changes upon
   activator binding, instead, a rather confined set of local conserved
   structural changes were observed when each activator binds holo-TFIID.
   These results suggest that activator contact may induce unique
   structural features of TFIID, thus providing nanoscale information on
   activator-dependent TFIID assembly and transcription initiation.
C1 [Liu, Wei-Li; Coleman, Robert A.; Ma, Elizabeth; Grob, Patricia; Yang, Joyce L.; Zhang, Yixi; Dailey, Gina; Nogales, Eva; Tjian, Robert] Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   [Grob, Patricia; Nogales, Eva] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.
RP Tjian, R, Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell
   Biol, Berkeley, CA 94720 USA.
EM jmlim@berkeley.edu
FU NIH National Cancer Institute [PO1 CA112181]; NIH General Medical
   Sciences [RO1 GM63072]; Howard Hughes Medical Institute Investigators 
FX We thank S. Zheng for providing TAF4 mAb supernatant, D. King for
   peptides, the Tjian laboratory tissue culture facility technicians, M.
   Haggart for assistance, U. Schulze- Gahmen for insect cells, and the
   Tjian laboratory members. We also thank S. Lipscomb, V. Ramey, and H.
   Wang for helpful advice and technical support. We are grateful to J.
   Yao, Z. Zhang, and U. Schulze- Gahmen for critical comments of the
   manuscript. This work was supported by NIH National Cancer Institute
   PO1 CA112181 (R. T. and E. N.), and NIH General Medical Sciences RO1
   GM63072 (E. N.). R. T. and E. N. are Howard Hughes Medical Institute
   Investigators. R. T. is the President of the Howard Hughes Medical
   Institute.
CR AINBINDER E, 2002, MOL CELL BIOL, V22, P6354, DOI
   10.1128/MCB.22.18.6354-6362.2002
   ANDEL F, 1999, SCIENCE, V286, P2153
   BERECZKI O, 2008, BMC MOL BIOL, V9, ARTN 57
   BROWN CE, 2001, SCIENCE, V292, P2333
   CHEN L, 1998, NATURE, V392, P42
   CHI TH, 1996, GENE DEV, V10, P2540
   CHINENOV Y, 2001, ONCOGENE, V20, P2438
   FRANK J, 1996, J STRUCT BIOL, V116, P190
   FRANKLIN CC, 1995, BIOCHEM J 3, V305, P967
   GLOVER JNM, 1995, NATURE, V373, P257
   GROB P, 2006, STRUCTURE, V14, P511, DOI 10.1016/j.str.2005.11.020
   HESS J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   HILTON TL, 2005, MOL CELL BIOL, V25, P4321, DOI
   10.1128/MCB.25.10.4321-4332.2005
   JUNIUS FK, 1996, J BIOL CHEM, V271, P13663
   LEURENT C, 2002, EMBO J, V21, P3424
   LEURENT C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111
   LI HH, 2004, MOL CELL, V13, P867
   LIEBERMAN PM, 1997, MOL CELL BIOL, V17, P6624
   LIU WL, 2008, MOL CELL, V29, P81, DOI 10.1016/j.molcel.2007.11.003
   LIVELY TN, 2004, J BIOL CHEM, V279, P26257, DOI 10.1074/jbc.M400892200
   LU H, 1995, P NATL ACAD SCI USA, V92, P5154
   LUDTKE SJ, 1999, J STRUCT BIOL, V128, P82
   MARTIN DW, 1993, J BIOL CHEM, V268, P13062
   MUNZ C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200
   NAAR AM, 2001, ANNU REV BIOCHEM, V70, P475
   NAAR AM, 2002, GENE DEV, V16, P1339
   NEELY KE, 2002, MOL CELL BIOL, V22, P1615
   PETTERSEN EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   RILEY T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   ROBERTS SGE, 1994, NATURE, V371, P717
   ROJONIERSBACH E, 1999, J BIOL CHEM, V274, P33778
   STARGELL LA, 1996, TRENDS GENET, V12, P311
   TAATJES DJ, 2002, SCIENCE, V295, P1058
   TAATJES DJ, 2004, NAT STRUCT MOL BIOL, V11, P664, DOI 10.1038/nsmb789
   THOMAS MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI
   10.1080/10409230600648736
   THUT CJ, 1995, SCIENCE, V267, P100
   WANG XP, 2007, P NATL ACAD SCI USA, V104, P7839, DOI
   10.1073/pnas.0608570104
   WIERSTRA I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI
   10.1016/j.bbrc.2008.03.074
   WU SY, 2001, J BIOL CHEM, V276, P34235
NR 39
TC 13
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD JUL 1
PY 2009
VL 23
IS 13
BP 1510
EP 1521
DI 10.1101/gad.1790709
PG 12
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 470DN
UT ISI:000267954800006
ER

PT J
AU He, KY
   Yang, SZ
   Shen, DH
   Zhang, LM
   Lu, SD
   Sun, FY
AF He, K-Y
   Yang, S-Z
   Shen, D-H
   Zhang, L-M
   Lu, S-D
   Sun, F-Y
TI Excision repair cross-complementing 1 expression protects against
   ischemic injury following middle cerebral artery occlusion in the rat
   brain
SO GENE THERAPY
LA English
DT Article
DE ERCC1; cerebral ischemia; DNA repair; NER; neuroprotection; brain damage
ID TRANSIENT FOCAL ISCHEMIA; OXIDATIVE DNA-DAMAGE; NEURONAL INJURY; STRAND
   BREAKS; GENE ERCC1; APOPTOSIS; RECOMBINATION; ENDONUCLEASE; CELLS;
   REPERFUSION
AB To study the effects of excision repair cross-complementing 1 (ERCC1)
   on the pathophysiological process of brain ischemia, we examined the
   changes in ERCC1 expression, as well as the functional significance of
   ERCC1 in the rat brain following middle cerebral artery occlusion
   (MCAO). The results were as follows: (1) ERCC1 immunopositive cells
   were widely distributed in various brain regions. ERCC1 expression was
   localized to the nuclei of neurons and astrocytes. (2) ERCC1
   expression, as determined by western blot, increased at 3 days,
   remaining until 14 days, in the ipsilateral cortex and striatum
   following MCAO. Immunohistochemical analysis demonstrated that ischemia
   induced increased ERCC1 expression within the periinfarct core, with
   increasingly less expression toward the core. (3) Knockdown of ERCC1
   expression by intraventricular injection of antisense plasmids
   increased DNA damage and infarct volume in the ischemic brain. (4)
   ERCC1 overproduction, by injection of expression plasmids,
   significantly reduced infarct volume and the accumulation of
   DNA-damaged neurons. Taken together, these results indicate that both
   endogenous ERCC1 and exogenous ERCC1 have an important neuroprotective
   function in the brain. In addition, administration of ERCC1 to the
   brain could prove to be a successful strategy for neuronal protection
   against ischemic injury. Gene Therapy (2009) 16, 840-848;
   doi:10.1038/gt.2009.48; published online 14 May 2009
C1 [He, K-Y; Yang, S-Z; Shen, D-H; Zhang, L-M; Lu, S-D; Sun, F-Y] Fudan Univ, Shanghai Med Coll, Dept Neurobiol, Inst Biomed Sci,State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
RP Sun, FY, Fudan Univ, Shanghai Med Coll, Dept Neurobiol, Inst Biomed
   Sci,State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
EM fysun@shmu.edu.cn
FU National Basic Research Program of China [2006CB504100, 2006CB943702];
   National Natural Science Foundation of China [30770660]; Shanghai
   Metropolitan Fund for Research and Development [04DZ14005, 07DZ14005]
FX This work was supported in part by grants from the National Basic
   Research Program of China (nos. 2006CB504100 and 2006CB943702),
   National Natural Science Foundation of China (no. 30770660) and
   Shanghai Metropolitan Fund for Research and Development (nos. 04DZ14005
   and 07DZ14005).
CR ADAIR GR, 2000, EMBO J, V19, P5552
   CHEN DX, 2003, J CEREBR BLOOD F MET, V23, P88, DOI
   10.1097/01.WCB.0000039286.37737.19
   CHEN J, 1997, J NEUROCHEM, V69, P232
   DELAAT WL, 1999, GENE DEV, V13, P768
   FERRY KV, 2000, BIOCHEM PHARMACOL, V60, P1305
   IMAI H, 2002, EUR J NEUROSCI, V15, P1929
   KAWASE M, 1999, STROKE, V30, P441
   KURAOKA I, 2000, J BIOL CHEM, V275, P26632
   LAN J, 2003, J CEREBR BLOOD F MET, V23, P1324, DOI
   10.1097/01.WCB.0000091540.60196.F2
   LI N, 2007, DNA REPAIR AMST
   LI WJ, 2006, J CEREBR BLOOD F MET, V26, P181, DOI
   10.1038/sj.jcbfm.9600180
   LING X, 1999, ZHONGGUO YAO LI XUE, V20, P15
   LIU PK, 1996, J NEUROSCI, V16, P6795
   LONGA EZ, 1989, STROKE, V20, P84
   MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862
   MOTYCKA TA, 2004, J BIOL CHEM, V279, P13634, DOI 10.1074/jbc.M313779200
   MURAI M, 2001, P NATL ACAD SCI USA, V98, P13379
   NAGAYAMA T, 2000, J NEUROCHEM, V75, P1716
   NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030
   NIEDERNHOFER LJ, 2004, MOL CELL BIOL, V24, P5776, DOI
   10.1128/MCB.24.13.5776-5787.2004
   PAXINOS G, 1986, RAT BRAIN STEREOTAXI
   PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43
   SARGENT RG, 2000, NUCLEIC ACIDS RES, V28, P3771
   SCHMUED LC, 2000, BRAIN RES, V874, P123
   SCHRADER CE, 2004, J EXP MED, V200, P321, DOI 10.1084/jem.20040052
   SELFRIDGE J, 2001, NUCLEIC ACIDS RES, V29, P4541
   SELVAKUMARAN M, 2003, CANCER RES, V63, P1311
   SUGAWARA T, 2001, STROKE, V32, P2388
   SUN FY, 2002, J PINEAL RES, V33, P48
   SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290
   TOMASEVIC G, 1998, MOL BRAIN RES, V60, P168
   WANG YQ, 2007, J NEUROSCI RES, V85, P73
   WOOD RD, 2001, SCIENCE, V291, P1284
   YANG ZJ, 2002, J NEUROSCI RES, V70, P140, DOI 10.1002/jnr.10380
   ZHANG R, 2006, NEUROBIOL DIS, V24, P345, DOI 10.1016/j.nbd.2006.07.012
   ZOU LL, 1999, GENE THER, V6, P994
NR 36
TC 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD JUL
PY 2009
VL 16
IS 7
BP 840
EP 848
DI 10.1038/gt.2009.48
PG 9
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 468HB
UT ISI:000267806600003
ER

PT J
AU Wang, XF
   Wang, XY
   Liu, J
   Feng, JJ
   Mu, WL
   Shi, XJ
   Yang, QQ
   Duan, XC
   Xie, Y
   Lu, ZJ
AF Wang, Xiu-Fang
   Wang, Xiaoyan
   Liu, Jing
   Feng, Jingjing
   Mu, Wenli
   Shi, Xiaojuan
   Yang, QnQing
   Duan, Xiaocui
   Xie, Ying
   Lu, Zhanjun
TI Alu Tandem Sequences Inhibit GFP Gene Expression by Triggering
   Chromatin Wrapping
SO GENES & GENOMICS
LA English
DT Article
DE Alu; GFP; chromatin wrapping; premature transcriptional termination
ID TRANSCRIPTIONAL REPRESSION; ELEMENTS; REPEATS; REGION; LOCUS; EXONS; DNA
AB Alu elements belonging to the short interspersed nuclear elements
   (SINE) of repetitive elements are present in more than one million
   copies which altogether represent 10% of the whole human genome. In
   this study, the roles of Alu tandem sequences in the process of GFP
   gene (GFP) expression and packing into chromatin of its DNA were
   studied. To detect the effect of Alu repeats on gene expression,
   different copies of Alus were inserted GFP downstream respectively in
   pEGFT-C1 vector. We found that Alu sequences decreased the amount of
   GFP transcription, the percentage of GFP positive cells and the
   accessibility to DNase I in length-dependent manner. Inserting Alu
   caused the production of higher-molecular-mass RNA, indicating Ala
   sequence did not induce premature transcriptional termination. Tight
   packing chromatins keep silent and resist to DNase I digestion, which
   is a general phenomenon. We suggested that head and tail tandem Ala
   sequences suppressed GFP expression in length dependent manner by
   triggering chromatin packing.
C1 [Wang, Xiu-Fang; Wang, Xiaoyan; Liu, Jing; Feng, Jingjing; Mu, Wenli; Shi, Xiaojuan; Yang, QnQing; Duan, Xiaocui; Xie, Ying; Lu, Zhanjun] Hebei Med Univ, Dept Genet, Hebei Key Lab Anim, Shijiazhuang, Hebei Province, Peoples R China.
RP Lu, ZJ, Hebei Med Univ, Dept Genet, Hebei Key Lab Anim, Shijiazhuang,
   Hebei Province, Peoples R China.
EM lslab@hebmu.edu.cn
FU Hebei Plovillce Natural Science Foundation of China [C2008001065]
FX This work was supported by Hebei Plovillce Natural Science Foundation
   of China (C2008001065 to Z.J.Lu).
CR ALEMAN C, 2000, NUCLEIC ACIDS RES, V28, P4755
   AMBOR JE, 1993, MOL CELL BIOL, V13, P7056
   ANKE JH, 1995, J MOL BIO, V246, P63
   BANCROFT JD, 1990, GENE, V95, P253
   BATZER MA, 2002, NAT REV GENET, V3, P370
   BROSIUS J, 1999, GENE, V238, P115
   CHEN HL, 1997, NUCLEIC ACIDS RES, V25, P2917
   CHU WM, 1998, MOL CELL BIOL, V18, P58
   DEWANNIEUX M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   EBIHARA M, 2002, GENE, V298, P101
   ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565
   ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091
   GANAPATHI M, 2005, BMC BIOINFORMATICS, V6, ARTN 126
   GANAPATHI M, 2005, BMC BIOINFORMATICS, V6, ARTN 126
   GONZALEZ CI, 2001, GENE, V274, P15
   HAMDI H, 1999, J MOL BIOL, V289, P861
   HAN JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536
   HASLER J, 2006, NUCLEIC ACIDS RES, V34, P2374, DOI 10.1093/nar/gkl246
   HASLER J, 2006, NUCLEIC ACIDS RES, V34, P5491, DOI 10.1093/nar/gkl706
   HIGGS DR, 1990, GENE DEV, V4, P1588
   HONG KW, 2007, KOREAN J GENETIC, V29, P379
   LEVMAOR G, 2003, SCIENCE, V300, P1288
   OKANO K, 2008, APPL ENVIRON MICROB, V74, P1117, DOI 10.1128/AEM.02012-07
   ORGEL LE, 1980, NATURE, V288, P645
   POLAK P, 2006, BMC GENOMICS, V7, ARTN 133
   QUMSIYEH MB, 1999, CELL MOL LIFE SCI, V55, P1129
   SOREK R, 2002, GENOME RES, V12, P1060
   STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106
   SZMULEWICZ MN, 1998, ELECTROPHORESIS, V19, P1260
   TOMILIN NV, 1999, INT REV CYTOL, V186, P1
NR 30
TC 1
PU KOREAN SOC GENETICS
PI SEOUL
PA KOREAN SCIENCE & TECHNOLOGY CENTER, RM 1002, 635-4 YEOKSAM-DONG,
   KANGNAM, SEOUL, 135-703, SOUTH KOREA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD JUN
PY 2009
VL 31
IS 3
BP 209
EP 215
PG 7
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 469DS
UT ISI:000267876500001
ER

PT J
AU Luo, YD
   Yang, CF
   Jin, CL
   Xie, R
   Wang, F
   McKeehan, WL
AF Luo, Yongde
   Yang, Chaofeng
   Jin, Chengliu
   Xie, Rui
   Wang, Fen
   McKeehan, Wallace L.
TI Novel phosphotyrosine targets of FGFR2IIIb signaling
SO CELLULAR SIGNALLING
LA English
DT Article
DE Receptor tyrosine kinases; Fibroblast growth factor (FGF);
   Stromal-epithelial homeostasis; Tumor suppression; Tyrosine phosphatases
ID FIBROBLAST-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; EPITHELIAL-CELL
   ANDROMEDIN; FGF RECEPTOR; INTRAEPITHELIAL NEOPLASIA; CONDITIONAL
   ACTIVATION; CRYSTAL-STRUCTURE; ADAPTER PROTEINS; HEPARAN-SULFATE;
   PROSTATE
AB In partnership exclusively with the epithelial FGFR2IIIb isotype and a
   structurally-specific heparan sulfate motif, stromal-derived FGF7
   delivers both growth-promoting and growth-limiting differentiation
   signals to epithelial cells that promote cellular homeostasis between
   stromal and epithelial compartments. Intercompartmental homeostasis
   supported by FGF7/FGFR2IIIb is subverted in many solid epithelial
   tumors. The normally mesenchymal-derived homologue FGFR1 drives
   proliferation and a progressive tumor-associated phenotype when it
   appears ectopically in epithelial cells. In order to understand the
   mechanism underlying the unique biological effects of FGFR2IIIb, we
   developed an inducible FGFR2IIIb expression system that is specifically
   dependent on FGF7 for activation in an initially unresponsive cell line
   to avoid selection for only the growth-promoting aspects of FGFR2IIIb
   signaling. We then determined FGF7/FGFR2IIIb signaling-specific
   tyrosine phosphorylated proteins within 5 min after FGF7 stimulation by
   phosphopeptide immunoaffinity purification and nano-LC-MS/MS. The
   FGF7/FGFR2 pair caused tyrosine phosphorylation of multiple proteins
   that have been implicated in the growth stimulating activities of FGFR1
   that included multi-substrate organizers FRS2 alpha and IRS4, ERK2 and
   phosphatases SHP2 and SHIP2. It uniquely phosphorylated CDK2 and
   phosphatase PTPN18 on sites involved in the attenuation of cell
   proliferation, and several factors that maintain nuclear-cytosolic
   relationships (emerin and LAP2), protein structure and other cellular
   fine structures as well as some proteins of unknown functions. Several
   of the FGF7/FGFR2IIIb-specific targets have been associated with
   maintenance of function and tumor suppression and disruption in tumors.
   In contrast, a number of pTyr substrates associated with FGF2/FGFR1
   that are generally associated with intracellular Ca2+-phospholipid
   signaling, membrane and cytoskeletal plasticity, cell adhesion,
   migration and the tumorigenic phenotype were not observed with
   FGF7/FGFR2IIIb. Our findings provide specific downstream targets for
   dissection of causal relationships underlying the distinct role of
   FGF7/FGFR2IIIb signaling in epithelial cell homeostasis. (C) 2009
   Elsevier Inc. All rights reserved.
C1 [Luo, Yongde; Yang, Chaofeng; Jin, Chengliu; Xie, Rui; Wang, Fen; McKeehan, Wallace L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA.
   [Luo, Yongde; McKeehan, Wallace L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, IBT Prote & Nanotechnol Lab, Houston, TX 77030 USA.
   [Luo, Yongde; McKeehan, Wallace L.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.
RP McKeehan, WL, Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc &
   Stem Cell Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.
EM wmckeehan@ibt.tamhsc.edu
FU NIH [CA059971, DK47039]; J.S. Dunn Research Foundation ; Alliance for
   NanoHealth (Houston, TX) 
FX This work was supported partially by NIH grant CA059971 and DK47039 (to
   W.L.M.), and by the J.S. Dunn Research Foundation and the Alliance for
   NanoHealth (Houston, TX) (to WIN and Y.L.).
CR ACEVEDO VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004
   AGAZIE YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798
   AOKI N, 2004, J BIOL CHEM, V279, P10765, DOI 10.1074/jbc.M310401200
   BARTOVA I, 2008, J MOL MODEL, V14, P761, DOI 10.1007/s00894-008-0312-1
   CLEMENT S, 2001, NATURE, V409, P92
   DORNER D, 2006, J CELL BIOL, V173, P83, DOI 10.1083/jcb.200511149
   ESWARAKUMAR VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI
   10.1016/j.cytogfr.2005.01.001
   FENG SJ, 1997, CANCER RES, V57, P5369
   FINCH PW, 1989, SCIENCE, V245, P752
   FREEMAN KW, 2003, CANCER RES, V63, P6237
   FURDUI CM, 2006, MOL CELL, V21, P711, DOI 10.1016/j.molcel.2006.01.022
   GARCIAMATA R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07
   GENSLER M, 2004, J BIOL CHEM, V279, P12110, DOI 10.1074/jbc.M309527200
   GOTOH N, 2008, CANCER SCI, V99, P1319, DOI
   10.1111/j.1349-7006.2008.00840.x
   GROSE R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI
   10.1016/j.cytogfr.2005.01.003
   HADARI YR, 2001, P NATL ACAD SCI USA, V98, P8578
   HAN X, 2008, CURR OPIN CHEM BIOL
   HANAFUSA H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200
   HARMER NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031
   HINSBY AM, 2004, J BIOL CHEM, V279, P46438, DOI 10.1074/jbc.M404537200
   HOFMEISTER CC, 2005, CURR HEMATOL REP, V4, P446
   HOU JZ, 1993, PROTEIN SCI, V2, P86
   HOWE LR, 1992, CELL, V71, P335
   HUNDLEY HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247
   ITOH N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007
   JIN CL, 2003, CANCER RES, V63, P8784
   KAN M, 1996, J BIOL CHEM, V271, P26143
   KAN MK, 1993, SCIENCE, V259, P1918
   KONTARIDIS MI, 2002, MOL CELL BIOL, V22, P3875
   KUROSU H, 2007, J BIOL CHEM, V282, P26687, DOI 10.1074/jbc.M704165200
   LAZAR DF, 2006, NAT REV DRUG DISCOV, V5, P333
   LU WQ, 1999, J BIOL CHEM, V274, P12827
   LUO YD, 1998, BIOCHEMISTRY-US, V37, P16506
   LUO YD, 2006, J BIOL CHEM, V281, P21052, DOI 10.1074/jbc.M601559200
   LUO YD, 2006, J CELL BIOCHEM, V97, P1241, DOI 10.1002/jcb.20724
   MANN M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067
   MATSUBARA A, 1998, CANCER RES, V58, P1509
   MATSUMOTO T, 2001, SCI STKE, RE21
   MCKEEHAN WL, 1998, PROG NUCLEIC ACID RE, V59, P135
   MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068
   MOHAMMADI M, 1996, CELL, V86, P577
   MOHAMMADI M, 1996, MOL CELL BIOL, V16, P977
   MOHI MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI
   10.1016/j.gde.2006.12.011
   MURAKAMI M, 2008, CARDIOVASC RES, V78, P223, DOI 10.1093/cvr/cvm086
   NAETAR N, 2008, NAT CELL BIOL, V10, P1341, DOI 10.1038/ncb1793
   ORNITZ DM, 2000, BIOESSAYS, V22, P108
   OSTMAN A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   PELLEGRINI L, 2000, NATURE, V407, P1029
   PESESSE X, 2001, J BIOL CHEM, V276, P28348
   RICOL D, 1999, ONCOGENE, V18, P7234
   SCHLESSINGER J, 2000, MOL CELL, V6, P743
   SCHLESSINGER J, 2004, SCIENCE, V306, P1506
   SHIMADA T, 2001, P NATL ACAD SCI USA, V98, P6500
   TEFFERI A, 2007, CELL CYCLE, V6, P550
   UEMATSU F, 2000, BIOCHEM BIOPH RES CO, V272, P830
   URAKAWA I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   WANG F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311
   WHITE MF, 2002, AM J PHYSIOL-ENDOC M, V283, E413, DOI
   10.1152/ajpendo.00514.2001
   WINTER SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288
   XU H, 1998, J BIOL CHEM, V273, P17987
   YAN GC, 1992, MOL ENDOCRINOL, V6, P2123
   YAN GC, 1993, MOL CELL BIOL, V13, P4513
   ZHANG YY, 2008, MOL ENDOCRINOL, V22, P167, DOI 10.1210/me.2007-0140
NR 63
TC 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2009
VL 21
IS 9
BP 1370
EP 1378
DI 10.1016/j.cellsig.2009.04.004
PG 9
SC Cell Biology
GA 468BC
UT ISI:000267787300004
ER

PT J
AU Lin, WN
   Luo, SF
   Lin, CC
   Hsiao, LD
   Yang, CM
AF Lin, Wei-Ning
   Luo, Shue-Fen
   Lin, Chih-Chung
   Hsiao, Li-Der
   Yang, Chuen-Mao
TI Differential involvement of PKC-dependent MAPKs activation in
   lipopolysaccharide-induced AP-1 expression in human tracheal smooth
   muscle cells
SO CELLULAR SIGNALLING
LA English
DT Article
DE Lipopolysaccharide; Vascular cell adhesion molecule-1; Protein kinase
   C; Mitogen-activated protein kinase; Activator protein-1
ID NF-KAPPA-B; PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; VCAM-1 EXPRESSION;
   P38 MAPK; ADHESION MOLECULE-1; JUN EXPRESSION; FOS EXPRESSION;
   TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION
AB Lipopolysaccharide (LPS) has been shown to up-regulate the expression
   of vascular cell adhesion molecule (VCAM)-1 which contributes to the
   occurrence of airway inflammatory diseases. Genetic analysis reveals
   the existence of activator protein-1 (AP-1) binding site on VCAM-1
   promoter region. However, the role of AP-1 in LPS-induced VCAM-1
   expression in human tracheal smooth muscle cells (HTSMCs) is not known.
   Here, we show that LPS increased VCAM-1 expression and adhesiveness of
   HTSMCs through AP-1, since pretreatment with an AP-1 inhibitor
   tanshinone attenuated LPS-induced VCAM-1 expression and leukocytes
   adhesion. The implication of AP-1 in LPS-induced VCAM-1 expression was
   confirmed by animal studies showing that pretreatment of mice with
   tanshinone attenuated LPS-induced VCAM-1 mRNA expression in airway
   tissues and accumulation of leukocytes in bronchoalveolar lavage. By
   using the pharmacological inhibitors and transfection with siRNA of
   PKC, p42, p38, or JNK2, LPS-induced expression of c-Fos was mediated
   through protein kinase C (PKC), p42/p44 MAPK and p38 MAPK. While, c-Jun
   expression was mediated through PKC and mitogen-activated protein
   kinases (MAPKs, p42/p44 MAPK, p38 MAPK and JNK) in HTSMCs. Pretreatment
   with the inhibitors of PKCs or MAPKs attenuated LPS-stimulated nuclear
   translocation and VCAM-1 promoter binding abilities of AP-1, which
   attenuated promoter activity and gene expression of VCAM-1 and the
   adhesiveness between HTSMCs and leukocytes. These results indicated
   that differential regulation of AP-1 through PKCs-dependent MAPKs
   activation plays central roles in LPS-induced VCAM-1 expression. The
   altered modulation of this axis with inhibitors or siRNAs may
   contribute to the improvement of airway inflammatory diseases. (C) 2009
   Elsevier Inc. All rights reserved.
C1 [Lin, Wei-Ning; Yang, Chuen-Mao] Chang Gung Univ, Dept Physiol & Pharmacol, Tao Yuan, Taiwan.
   [Lin, Wei-Ning; Luo, Shue-Fen; Lin, Chih-Chung; Hsiao, Li-Der; Yang, Chuen-Mao] Chang Gung Mem Hosp, Tao Yuan, Taiwan.
   [Luo, Shue-Fen; Hsiao, Li-Der] Chang Gung Univ, Dept Internal Med, Tao Yuan, Taiwan.
   [Lin, Chih-Chung] Chang Gung Univ, Dept Anesthet, Tao Yuan, Taiwan.
RP Yang, CM, Chang Gung Univ, Dept Pharmacol, 259 Wen Hwa 1st Rd, Tao
   Yuan, Taiwan.
EM chuenmao@mail.cgu.edu.tw
FU Chang Gung Medical Research Foundation [CMRPD170331, CMRPD140252];
   National Science Council, Taiwan [NSC95-2320-B-182047-MY3]
FX This work was supported by grants CMRPD170331 and CMRPD140252 from
   Chang Gung Medical Research Foundation and NSC95-2320-B-182047-MY3 from
   National Science Council, Taiwan.
CR AHMAD M, 1998, J BIOL CHEM, V273, P4616
   BAYAT H, 2008, ARTERIOSCL THROM VAS, V28, P127, DOI
   10.1161/ATVBAHA.107.150250
   BEAUDRY H, 2006, ENDOCRINOLOGY, V147, P4263, DOI 10.1210/en.2006-0411
   CESENA TI, 2007, MOL GENET METAB, V90, P126, DOI
   10.1016/j.ymgme.2006.10.006
   CHAPLIN DD, 2002, IMMUNOL RES, V26, P55
   CHEN D, 2007, CANCER RES, V67, P8914, DOI 10.1158/0008-5472.CAN-06-4751
   CONWAY AM, 2000, CELL SIGNAL, V12, P737
   CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859
   DEMPSEY EC, 2007, PHARMACOL RES, V55, P545, DOI
   10.1016/j.phrs.2007.04.010
   EFERL R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   FAN HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997
   FIELDS AP, 2007, PHARMACOL RES, V55, P487, DOI
   10.1016/j.phrs.2007.04.015
   FUNG H, 1997, CANCER RES, V57, P3101
   GRUBER JR, 1995, EXP CELL RES, V221, P377
   GUPTA P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200
   HAN EKH, 1995, CARCINOGENESIS, V16, P2423
   HSIEH HL, 2006, J CELL PHYSIOL, V206, P246, DOI 10.1002/jcp.20457
   HSIEH HL, 2007, CELL SIGNAL, V19, P330, DOI
   10.1016/j.cellsig.2006.07.006
   HUANG CS, 2000, MOL CARCINOGEN, V27, P65
   JANG BC, 2005, BIOCHEM BIOPH RES CO, V328, P70, DOI
   10.1016/j.bbrc.2004.12.144
   KIM J, 2006, MOL IMMUNOL, V43, P1232, DOI 10.1016/j.molimm.2005.07.006
   LEE CW, 2006, J CELL PHYSIOL, V207, P174, DOI 10.1002/jcp.20549
   LI JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102
   LIN WN, 2007, CELL SIGNAL, V19, P1258, DOI 10.1016/j.cellsig.2007.01.009
   LIN WN, 2008, TOXICOL APPL PHARM, V228, P256, DOI
   10.1016/j.taap.2007.11.026
   MACKAY HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168
   MARINISSEN MJ, 2003, J BIOL CHEM, V278, P46814, DOI
   10.1074/jbc.M305709200
   MARTINYBARON G, 2007, PHARMACOL RES, V55, P477, DOI
   10.1016/j.phrs.2007.04.001
   MATSUBARA M, 2005, BIOCHEM PHARMACOL, V69, P433, DOI
   10.1016/j.bcp.2004.10.006
   MICHEL O, 2003, J ENDOTOXIN RES, V9, P293, DOI
   10.1179/096805103225002539
   NIE M, 2003, MOL CELL BIOL, V23, P9233, DOI
   10.1128/MCB.23.24.9233-9244.2003
   PARDO VG, 2006, INT J BIOCHEM CELL B, V38, P1181, DOI
   10.1016/j.biocel.2005.12.018
   PARK SH, 2003, INT J BIOCHEM CELL B, V35, P168
   REDDY SPM, 2002, AM J PHYSIOL-LUNG C, V283, L1161, DOI
   10.1152/ajplung.00140.2002
   SHIMAMOTO A, 2006, ANN THORAC SURG, V82, P2017, DOI
   10.1016/j.athoracsur.2006.06.079
   SIEGFRIED JM, 2007, MOL PHARM, V35, P168
   SILVERS AL, 2003, NEOPLASIA, V5, P319
   SMITH ER, 2001, J BIOL CHEM, V276, P32094
   TOGBE D, 2007, INT J EXP PATHOL, V88, P387, DOI
   10.1111/j.1365-2613.2007.00566.x
   UENO H, 2006, CARDIOVASC TOXICOL, V6, P39
   UHAL BD, 2007, BASIC CLIN PHARMACOL, V100, P59
   VERNA L, 2006, ARTERIOSCL THROM VAS, V26, P1344, DOI
   10.1161/01.ATV.0000222152.83069.3f
   WANG CC, 2005, AM J PHYSIOL-LUNG C, V288, L227, DOI
   10.1152/ajplung.00224.2004
   YU XF, 2006, BIOCHEM BIOPH RES CO, V342, P286, DOI
   10.1016/j.bbrc.2006.01.147
NR 44
TC 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2009
VL 21
IS 9
BP 1385
EP 1395
DI 10.1016/j.cellsig.2009.04.006
PG 11
SC Cell Biology
GA 468BC
UT ISI:000267787300006
ER

PT J
AU Chang, CJ
   Yin, PH
   Yang, DM
   Wang, CH
   Hung, WY
   Chi, CW
   Wei, YH
   Lee, HC
AF Chang, C. -J.
   Yin, P. -H.
   Yang, D. -M.
   Wang, C. -H.
   Hung, W. -Y.
   Chi, C. -W.
   Wei, Y. -H.
   Lee, H. -C.
TI Mitochondrial dysfunction-induced amphiregulin upregulation mediates
   chemo-resistance and cell migration in HepG2 cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE ROS; Ca2+; ADAM17; EGFR; oligomycin; mtDNA depletion
ID HUMAN HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR; DNA MUTATIONS;
   BREAST-CANCER; COPY NUMBER; D-LOOP; TUMOR PROGRESSION; RECEPTOR
   PATHWAY; PHASE-II; STRESS
AB The aim of this study was to investigate the contribution of
   mitochondrial dysfunction to chemoresistance and migration of hepatoma
   cells. We found that inhibition of mitochondrial respiration and
   mitochondrial DNA (mtDNA) depletion resulted in induction of
   amphiregulin (AR) expression in HepG2 cells. Upon oligomycin treatment
   of HepG2 cells, the cytosolic Ca2+ was significantly raised after 30
   min, and the intracellular level of reactive oxygen species (ROS) was
   elevated 2.2-fold after 4 h. Moreover, the condition medium of
   oligomycin-treated HepG2 cells was found to stimulate the migration of
   SK-Hep-1 cells. On the other hand, oligomycin-induced
   cisplatin-resistance and cell migration of HepG2 cells were attenuated
   by AR-specific RNA interference (#L-017435, Dharmacon) and a
   neutralizing antibody (MAB262, R&D Systems), respectively. Together,
   these findings suggest that mitochondrial dysfunction induced Ca2+
   mobilization, and ROS overproduction, which modulated the
   chemo-resistance and migration of hepatoma cells through the induction
   and activation of AR.
C1 [Chang, C. -J.; Wang, C. -H.; Hung, W. -Y.; Chi, C. -W.; Lee, H. -C.] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan.
   [Chang, C. -J.; Wei, Y. -H.] Natl Yang Ming Univ, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   [Yin, P. -H.; Yang, D. -M.; Chi, C. -W.] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.
   [Yang, D. -M.] Natl Yang Ming Univ, Inst Biophoton, Taipei 112, Taiwan.
   [Chang, C. -J.] Chinese Culture Univ, Sch Agr, Dept Food, Hlth & Nutr Sci, Taipei, Taiwan.
RP Wei, YH, Natl Yang Ming Univ, Dept Biochem & Mol Biol, Taipei 112,
   Taiwan.
EM zjr6@faculty.pccu.edu.tw
   joeman@ym.edu.tw
   hclee2@ym.edu.tw
CR AMUTHAN G, 2001, EMBO J, V20, P1910
   AMUTHAN G, 2002, ONCOGENE, V21, P7839
   ASSEFA Z, 2000, J BIOL CHEM, V275, P21416
   BERASAIN C, 2005, J BIOL CHEM, V280, P19012, DOI 10.1074/jbc.M413344200
   BERASAIN C, 2007, CANCER LETT, V254, P30, DOI
   10.1016/j.canlet.2007.01.015
   BISWAS G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028
   BRANDON M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   CASTILLO J, 2006, CANCER RES, V66, P6129, DOI
   10.1158/0008-5472.CAN-06-0404
   CHANG CJ, 2006, EUR J CLIN INVEST, V36, P588
   CHANG CJ, 2006, MENOPAUSE, V13, P967, DOI
   10.1097/01.gme.0000227025.96686.8b
   CHANG MY, 2008, INT J BIOL MACROMOL, V43, P48, DOI
   10.1016/j.ijbiomac.2007.10.004
   CHANG YF, 2008, TOXICOL APPL PHARM, V227, P430, DOI
   10.1016/j.taap.2007.11.025
   CHATTERJEE A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   CHAU GY, 2006, ANN SURG ONCOL, V13, P1329, DOI 10.1245/s10434-006-9004-1
   CHEN CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509
   CUEZVA JM, 2002, CANCER RES, V62, P6674
   DESBOISMOUTHON C, 2006, INT J CANCER, V119, P2557, DOI 10.1002/ijc.22221
   ECKSTEIN N, 2008, J BIOL CHEM, V283, P739, DOI 10.1074/jbc.M706287200
   FONTANINI G, 1998, CLIN CANCER RES, V4, P241
   GUHA M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M61193200
   IKEDA M, 2005, CANCER, V103, P756, DOI 10.1002/cncr.20841
   INDO HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   ISHIKAWA N, 2005, CANCER RES, V65, P9176, DOI
   10.1158/0008-5472.CAN-05-1556
   JOHANSSON CC, 2004, ENDOCRINOLOGY, V145, P5177, DOI 10.1210/en.2004-0232
   LEE HC, 2000, BIOCHEM J 2, V348, P425
   LEE HC, 2004, MUTAT RES-FUND MOL M, V547, P71, DOI
   10.1016/j.mrfmmm.2003.12.011
   LEE HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011
   LEE HC, 2007, MITOCHONDRION, V7, P157, DOI 10.1016/j.mito.2006.11.016
   LEE J, 2004, CANCER CHEMOTH PHARM, V54, P385, DOI
   10.1007/s00280-004-0837-7
   LEE SB, 1999, CELL, V98, P663
   LI CH, 2005, J BIOL CHEM, V280, P26193, DOI 10.1074/jbc.M501371200
   MERCY L, 2005, FEBS J, V272, P5031, DOI 10.1111/j.1742-4658.2005.04913.x
   MI HY, 2007, NUCLEIC ACIDS RES, V35, D247, DOI 10.1093/nar/gkl869
   MODICANAPOLITANO JS, 2007, CURR MOL MED, V7, P121
   OKOCHI O, 2002, CLIN CANCER RES, V8, P2875
   OREILLY SM, 2006, AM J PHYSIOL-CELL PH, V290, C592, DOI
   10.1152/ajpcell.00278.2005
   OWUSUANSAH E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50
   PARK SH, 2006, BMC CANC, V6
   PETROS JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI
   10.1073/pnas.0408894102
   PRIGIONE A, 2007, AUTOPHAGY, V3, P377
   SHIDARA Y, 2005, CANCER RES, V65, P1655
   STERNLICHT MD, 2008, J MAMMARY GLAND BIOL, V13, P181, DOI
   10.1007/s10911-008-9084-6
   TAMORI A, 2004, J GASTROENTEROL, V39, P1063, DOI
   10.1007/s00535-004-1445-3
   TSENG LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   WALLACE DC, 2005, ANNU REV GENET, V39, P359
   WARBURG O, 1930, METABOLISM TUMORS, P254
   WARBURG O, 1956, SCIENCE, V124, P269
   WU CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213
   YAMADA S, 2006, EJSO, V32, P303, DOI 10.1016/j.ejso.2006.01.002
   YIN PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838
NR 50
TC 2
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2009
VL 66
IS 10
BP 1755
EP 1765
DI 10.1007/s00018-009-8767-5
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 470TO
UT ISI:000268003600010
ER

PT J
AU Zeng, SC
   Yang, Q
AF Zeng, Sicong
   Yang, Qin
TI The MUS81 endonuclease is essential for telomerase negative cell
   proliferation
SO CELL CYCLE
LA English
DT Article
DE ALT; APBs; MUS81; telomere recombination
ID PROMYELOCYTIC LEUKEMIA BODIES; HOLLIDAY JUNCTIONS; DNA-DAMAGE;
   MAMMALIAN TELOMERES; RNA INTERFERENCE; IN-VITRO; RECOMBINATION; LOOP;
   IDENTIFICATION; MAINTENANCE
AB A substantial number of human tumors (similar to 10%) are telomerase
   negative, and cells in such tumors have been proposed to maintain
   telomere length by the alternative lengthening of telomeres (ALT)
   pathway. Although details of the molecular mechanism of ALT are largely
   unknown, previous studies have shown that telomere homologous
   recombination (HR) is implicated in the ALT pathway. MUS81 is a DNA
   structure-specific recombination endonuclease and functions on aberrant
   DNA replication and recombination. Recently, we demonstrate that MUS81
   plays a key role in the maintenance of telomeres in ALT cells (Zeng, et
   al. Nature Cell Biology, 2009). The MUS81 endonuclease specifically
   localizes to ALT-associated promyelocytic leukemia nuclear bodies
   (APBs) and interacts with telomeres in ALT cells. Depletion of MUS81
   leads to reduced telomere recombination resulting in the growth arrest
   of ALT cells. The endonuclease activity of MUS81, regulated by its
   binding partner TRF2, is found to be essential for telomere
   post-replicative recombination. This study provides the first direct
   evidence that MUS81 specifically functions on ALT recombination-based
   cell survival. The specific function of MUS81 on the ALT pathway
   provides a potential powerful diagnostic marker and a therapeutic
   target for ALT tumors.
C1 [Yang, Qin] Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, St Louis, MO 63108 USA.
RP Yang, Q, Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc
   Biol, 4511 Forest Pk, St Louis, MO 63108 USA.
EM qyang@wustl.edu
FU Concern Foundation 
FX We thank Roger R. Reddel for providing the ALT cells, and Clare H.
   McGowan for providing the wild- type and mutant MUS81 constructs, MUS81
   antibody and Mus81+/+ and Mus81-/MEFs. This work is supported in part
   by grants from Concern Foundation (Q.Y.).
CR BAILEY SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691
   BLAIS V, 2004, MOL BIOL CELL, V15, P552, DOI 10.1091/mbc.E03-08-0580
   BODDY MN, 2001, CELL, V107, P537
   BRYAN TM, 1995, EMBO J, V14, P4240
   BRYAN TM, 1997, NAT MED, V3, P1271
   CESARE AJ, 2008, MECH AGEING DEV, V129, P99, DOI
   10.1016/j.mad.2007.11.006
   CHEN XB, 2001, MOL CELL, V8, P1117
   DELANGE T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   DENDOUGA N, 2005, MOL CELL BIOL, V25, P7569, DOI
   10.1128/MCB.25.17.7569-7579.2005
   DUNHAM MA, 2000, NAT GENET, V26, P447
   EHMSEN KT, 2008, NUCLEIC ACIDS RES, V36, P2182, DOI 10.1093/nar/gkm1152
   FASCHING CL, 2007, CANCER RES, V67, P7072, DOI
   10.1158/0008-5472.CAN-07-1556
   GAILLARD PHL, 2003, MOL CELL, V12, P747
   GAO H, 2003, MOL BIOL CELL, V14, P4826, DOI 10.1091/mbc.E03-05-0276
   GREIDER CW, 1985, CELL, V43, P405
   GRIFFITH JD, 1999, CELL, V97, P503
   GROBELNY JV, 2000, J CELL SCI, V113, P4577
   HEYER WD, 2004, CURR BIOL, V14, P56
   HOLLINGSWORTH NM, 2004, GENE DEV, V18, P117, DOI 10.1101/gad.1165904
   JIANG WQ, 2007, ONCOGENE, V26, P4635, DOI 10.1038/sj.onc.1210260
   LONDONOVALLEJO JA, 2004, CANCER RES, V64, P2324
   MCPHERSON JP, 2004, SCIENCE, V304, P1822
   MOLENAAR C, 2003, EMBO J, V22, P6631
   MUNTONI A, 2005, HUM MOL GENET, V14, P191
   OSMAN F, 2003, MOL CELL, V12, P761
   OSMAN F, 2007, DNA REPAIR, V6, P1004, DOI 10.1016/j.dnarep.2007.02.019
   PALM W, 2008, ANNU REV GENET, V42, P301, DOI
   10.1146/annurev.genet.41.110306.130350
   STANSEL RM, 2001, EMBO J, V20, P5532
   WANG RC, 2004, CELL, V119, P355
   WHITBY MC, 2004, NAT STRUCT MOL BIOL, V11, P693, DOI
   10.1038/nsmb0804-693
   WU GK, 2000, J BIOL CHEM, V275, P30618
   YANG Q, 2008, CYTOGENET GENOME RES, V122, P211, DOI 10.1159/000167806
   YEAGER TR, 1999, CANCER RES, V59, P4175
   ZENG SC, 2009, NAT CELL BIOL, V11, P616, DOI 10.1038/ncb1867
NR 34
TC 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUL 15
PY 2009
VL 8
IS 14
BP 2157
EP 2160
PG 4
SC Cell Biology
GA 470IQ
UT ISI:000267968800016
ER

PT J
AU Gupta, A
   Yang, Q
   Pandita, RK
   Hunt, CR
   Xiang, T
   Misri, S
   Zeng, SC
   Pagan, J
   Jeffery, J
   Puc, J
   Kumar, R
   Feng, ZH
   Powell, SN
   Bhat, A
   Yaguchi, T
   Wadhwa, R
   Kaul, SC
   Parsons, R
   Khanna, KK
   Pandita, TK
AF Gupta, Arun
   Yang, Qin
   Pandita, Raj K.
   Hunt, Clayton R.
   Xiang, Tao
   Misri, Sandeep
   Zeng, Sicong
   Pagan, Julia
   Jeffery, Jessie
   Puc, Janusz
   Kumar, Rakesh
   Feng, Zhihui
   Powell, Simon N.
   Bhat, Audesh
   Yaguchi, Tomoko
   Wadhwa, Renu
   Kaul, Sunil C.
   Parsons, Ramon
   Khanna, Kum Kum
   Pandita, Tej K.
TI Cell cycle checkpoint defects contribute to genomic instability in PTEN
   deficient cells independent of DNA DSB repair
SO CELL CYCLE
LA English
DT Article
DE genomic instability; checkpoint defects; DNA damage response; ATM;
   PTEN; Rad51
ID DOUBLE-STRAND BREAKS; IONIZING-RADIATION; TUMOR-SUPPRESSOR;
   ATAXIA-TELANGIECTASIA; HISTONE H2AX; MAMMALIAN-CELLS; GAMMA-H2AX FOCI;
   PROSTATE-CANCER; X-IRRADIATION; NUCLEAR PTEN
AB Chromosomes in PTEN deficient cells display both numerical as well as
   structural alterations including regional amplification. We found that
   PTEN deficient cells displayed a normal DNA damage response (DDR) as
   evidenced by the ionizing radiation (IR)-induced phosphorylation of
   Ataxia Telangiectasia Mutated (ATM) as well as its effectors. PTEN
   deficient cells also had no defect in Rad51 expression or DNA damage
   repair kinetics post irradiation. In contrast, caffeine treatment
   specifically increased IR-induced chromosome aberrations and mitotic
   index only in cells with PTEN, and not in cells deficient for PTEN,
   suggesting that their checkpoints were defective. Furthermore,
   PTEN-deficient cells were unable to maintain active spindle checkpoint
   after taxol treatment. Genomic instability in PTEN deficient cells
   could not be attributed to lack of PTEN at centromeres, since no
   interaction was detected between centromeric DNA and PTEN in wild type
   cells. These results indicate that PTEN deficiency alters multiple cell
   cycle checkpoints possibly leaving less time for DNA damage repair
   and/or chromosome segregation as evidenced by the increased structural
   as well as numerical alterations seen in PTEN deficient cells.
C1 [Pandita, Tej K.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63108 USA.
   [Pagan, Julia; Jeffery, Jessie; Khanna, Kum Kum] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
   [Puc, Janusz; Parsons, Ramon] Columbia Univ, Inst Genet, New York, NY USA.
   [Yaguchi, Tomoko; Wadhwa, Renu; Kaul, Sunil C.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan.
RP Pandita, TK, Washington Univ, Sch Med, Dept Radiat Oncol, 4511 Forest
   Pk Ave, St Louis, MO 63108 USA.
EM pandita@wustl.edu
FU National Institute of Health [CA129537, CA123232]
FX This work was supported by National Institute of Health grants CA129537
   and CA123232 (T. K. P.). We thank Shyam K. Sharan, Yuxin Yin, Titia
   DeLange, Susana Gonzalo, Todd Waldman, T. Halazonetis and C. Eng for
   providing the reagents, sharing data and advice. We thank the members
   of Pandita laboratory for their help and thoughtful discussion.
CR AGARWAL M, 2008, CANCER RES, V68, P3370, DOI
   10.1158/0008-5472.CAN-07-5831
   BAKKENIST CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   BASSING CH, 2002, CELL S, V109, P45
   BASSING CH, 2002, P NATL ACAD SCI USA, V99, P8173
   BREWER BJ, 1987, CELL, V51, P463
   CANTLEY LC, 1999, P NATL ACAD SCI USA, V96, P4240
   CHEN HT, 2000, SCIENCE, V290, P1962
   COHEN S, 1996, MOL CELL BIOL, V16, P2002
   DHAR S, 2000, MOL CELL BIOL, V20, P7764
   FERNANDEZCAPETI.O, 2003, CELL CYCLE, V2, P426
   GONZALO S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386
   GUPTA A, 2005, MOL CELL BIOL, V25, P5292, DOI
   10.1128/MCB.25.5292-5305.2005
   HUNT CR, 2004, MOL CELL BIOL, V24, P899, DOI
   10.1128/MCB.24.2.899-911.2004
   HUNT CR, 2007, CANCER RES, V67, P3010, DOI 10.1158/0008-5472.CAN-06-4328
   JEGGO PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011
   KAO GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200
   LACHYANKAR MB, 2000, J NEUROSCI, V20, P1404
   LAVIN MF, 1999, INT J RADIAT BIOL, V75, P1201
   LEE JO, 1999, CELL, V99, P323
   LI DM, 1997, CANCER RES, V57, P2124
   LUKAS J, 2004, DNA REPAIR, V3, P997, DOI 10.1111/j.dnarep.2004.03.006
   MAHADEVAIAH SK, 2001, NAT GENET, V27, P271
   MOCHAN TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017
   PANDITA RK, 2006, MOL CELL BIOL, V26, P1850, DOI
   10.1128/MCB.26.5.1850-1864.2006
   PANDITA TK, 1983, HUM GENET, V63, P189
   PANDITA TK, 1992, RADIAT RES, V130, P94
   PANDITA TK, 1992, RADIAT RES, V131, P214
   PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95
   PANDITA TK, 1996, RADIAT RES, V145, P730
   PANDITA TK, 1999, MOL CELL BIOL, V19, P5096
   PANDITA TK, 2000, ONCOGENE, V19, P1386
   PAPPAS G, 2007, CANCER GENE THER, V14, P543, DOI 10.1038/sj.cgt.7701050
   PETERSEN S, 2001, NATURE, V414, P660
   PILCH DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/003-042
   PUC J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009
   RADFORD IR, 1985, INT J RADIAT BIOL, V48, P45
   RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611
   RIBALLO E, 2004, MOL CELL, V16, P715
   ROGAKOU EP, 1998, J BIOL CHEM, V273, P5858
   ROSSER CJ, 2004, CANCER GENE THER, V11, P273, DOI 10.1038/sj.cgt.7700673
   SALMENA L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   SANO T, 1999, CANCER RES, V59, P1820
   SCHERTHAN H, 2000, MOL CELL BIOL, V20, P7773
   SCOTT SP, 2006, J CELL BIOCH
   SHARMA GG, 2003, MOL CELL BIOL, V23, P8363, DOI
   10.1128/MCB.23.22.8363-8376.2003
   SHARMA GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063
   SHEN WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   SHILOH Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   STAMBOLIC V, 1998, CELL, V95, P29
   SUN H, 1999, P NATL ACAD SCI USA, V96, P6199
   VANGENT DC, 2001, NAT REV GENET, V2, P196
   WAHL GM, 2001, NATURE CELL BIOL, V3, P277
   WARD IM, 2001, J BIOL CHEM, V276, P47759
   WEAVER BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI
   10.1016/j.ceb.2006.10.002
   WHANG YE, 1998, P NATL ACAD SCI USA, V95, P5246
   WICK W, 1999, ONCOGENE, V18, P3936
   YILMAZ OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   ZHOU BBS, 2000, NATURE, V408, P433
   ZIV Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446
NR 59
TC 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUL 15
PY 2009
VL 8
IS 14
BP 2198
EP 2210
PG 13
SC Cell Biology
GA 470IQ
UT ISI:000267968800023
ER

PT J
AU Yang, ZC
   Wang, KS
   Wu, Y
   Zou, XQ
   Xiang, YY
   Chen, XP
   Li, YJ
AF Yang, Zhi-Chun
   Wang, Kuan-Song
   Wu, Yan
   Zou, Xiao-Qing
   Xiang, Yue-Yun
   Chen, Xiao-Ping
   Li, Yuan-Jian
TI Asymmetric Dimethylarginine Impairs Glucose Utilization via ROS/TLR4
   Pathway in Adipocytes: an Effect Prevented by Vitamin E
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Asymmetric dimethylarginine; Glucose; Adipocytes; Oxidative stress;
   Toll-like receptor 4
ID HUMAN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; TOLL-LIKE RECEPTOR;
   NF-KAPPA-B; INSULIN-RESISTANCE; GLUT4 TRANSLOCATION; DIABETES-MELLITUS;
   3T3-L1 ADIPOCYTES; OXIDATIVE STRESS; 3T3L1 ADIPOCYTES
AB Background: Asymmetric dimethylarginine (ADMA), the inhibitor of nitric
   oxide synthase (NOS), has been reported to be associated with glucose
   metabolism, but its mechanisms remain unknown. Methods: In 3T3-L1
   adipocytes, we measured the effects of ADMA on glucose transport
   process under basal or insulin-induced condition, and examined the
   production of nitric oxide (NO), reactive oxygen species ( ROS) and
   tumor necrosis factor alpha (TNF-alpha), and the expression of
   toll-like receptor 4 (TLR4). Results: ADMA significantly impaired basal
   or insulin-stimulated 2-deoxy- [H-3] glucose uptake, and decreased the
   expression of insulin receptor substrate-1 (IRS-1) and glucose
   transporter-4 (GLUT4). Phosphorylated protein of IRS-1 and
   translocation of GLUT4 with insulin-stimulation were also inhibited by
   ADMA. NO decreased, while production of ROS and TNF-alpha, and
   expression of TLR4 increased after ADMA treatment. Vitamin E reduced
   the effects of ADMA on glucose transport system, and on NO, ROS and
   TLR4. Moreover, vitamin E decreased ADMA contents by up-regulating
   dimethylarginine dimethylaminohydrolase (DDAH) activity in adipocytes.
   Though L-arginine also increased NO level, but failed to reduce the
   effects of ADMA. Conclusion: ADMA significantly impairs both basal and
   insulin-stimulated glucose transport in adipocytes, which may relate to
   activation of the ROS/TLR4 pathway. Copyright (C) 2009 S. Karger AG,
   Basel
C1 [Yang, Zhi-Chun; Wu, Yan; Zou, Xiao-Qing; Chen, Xiao-Ping; Li, Yuan-Jian] Cent S Univ, Dept Pharmacol, Sch Pharmaceut Sci, Changsha 410078, Hunan, Peoples R China.
   [Wang, Kuan-Song] Cent S Univ, Dept Pathol, Sch Basic Med, Changsha 410078, Hunan, Peoples R China.
   [Xiang, Yue-Yun] Cent S Univ, Dept Docimasiol, Xiang Ya Sch Med, Changsha 410078, Hunan, Peoples R China.
RP Li, YJ, Cent S Univ, Dept Pharmacol, Sch Pharmaceut Sci, Xiang Ya Rd
   110, Changsha 410078, Hunan, Peoples R China.
EM yuan_jianli@yahoo.com
CR ASEHNOUNE K, 2004, J IMMUNOL, V172, P2522
   BELTOWSKI J, 2006, PHARMACOL REP, V58, P159
   BEVERS LM, 2006, HYPERTENSION, V47, P87, DOI
   10.1161/01.HYP.0000196735.85398.0e
   BLOCHDAMTI A, 2006, DIABETOLOGIA, V49, P2463, DOI
   10.1007/s00125-006-0349-6
   BOGER RH, 2006, ANN MED, V38, P126, DOI 10.1080/07853890500472151
   BUREN J, 2003, EUR J ENDOCRINOL, V148, P157
   ENGELI S, 2004, J LIPID RES, V45, P1640, DOI 10.1194/jlr.M300322-JLR200
   FU YC, 2007, J BIOL CHEM, V282, P31525, DOI 10.1074/jbc.M701132200
   HEUTLING D, 2008, J CLIN ENDOCR METAB, V93, P82, DOI
   10.1210/jc.2007-0842
   JACOBI J, 2008, AM J PHYSIOL-HEART C, V294, H1058, DOI
   10.1152/ajpheart.01103.2007
   JIA SJ, 2006, VASC PHARMACOL, V44, P143, DOI 10.1016/j.vph.2005.09.005
   KABAYAMA K, 2005, GLYCOBIOLOGY, V15, P21, DOI 10.1093/glycob/cwh135
   KADDAI V, 2008, AM J PHYSIOL-ENDOC M, V295, E162, DOI
   10.1152/ajpendo.00622.2007
   KIELSTEIN JT, 2006, EUR J CLIN PHARM S13, V62, P39, DOI
   10.1007/s00228-005-0010-1
   KIM F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851
   KIM JK, 2006, CELL METAB, V4, P417, DOI 10.1016/j.cmet.2006.11.008
   KONUKOGLU D, 2008, METABOLISM, V57, P110, DOI
   10.1016/j.metabol.2007.08.013
   LIN KY, 2002, CIRCULATION, V106, P987, DOI
   10.1161/01.CIR.0000027109.14149.67
   MITTERMAYER F, 2007, J INTERN MED, V261, P392, DOI
   10.1111/j.1365-2796.2007.01772.x
   MUNZEL T, 2005, ARTERIOSCL THROM VAS, V25, P1551, DOI
   10.1161/01.ATV.0000168896.64927.bb
   PESSLER D, 2001, DIABETOLOGIA, V44, P2156
   POGGI M, 2007, DIABETOLOGIA, V50, P1267, DOI 10.1007/s00125-007-0654-8
   ROBERTS CK, 1997, AM J PHYSIOL-ENDOC M, V273, E220
   SHIMOYAMA T, 2006, METABOLISM, V55, P722, DOI
   10.1016/j.metabol.2006.01.019
   SONG MJ, 2006, BIOCHEM BIOPH RES CO, V346, P739, DOI
   10.1016/j.bbrc.2006.05.170
   SYDOW K, 2008, ARTERIOSCL THROM VAS, V28, P692, DOI
   10.1161/ATVBAHA.108.162073
   TAIN YL, 2007, FASEB J, V21, A453
   TAKAGURI A, 2008, J PHARMACOL SCI, V107, P80, DOI 10.1254/jphs.FP0072403
   TSUKUMO DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595
   VITSEVA OI, 2008, OBESITY, V16, P932, DOI 10.1038/oby.2008.25
   WELLS SM, 2007, AM J RESP CELL MOL, V36, P520, DOI
   10.1165/rcmb.2006-0302SM
   WORTHLEY MI, 2007, J AM COLL CARDIOL, V49, P304, DOI
   10.1016/j.jacc.2006.08.053
   WUWONG JSR, 1999, J BIOL CHEM, V274, P8103
   YAKARYILMAZ F, 2007, INTERN MED J, V37, P229, DOI
   10.1111/j.1445-5994.2006.01295.x
   YANG ZC, 2007, MICROVASC RES, V73, P131, DOI 10.1016/j.mvr.2006.04.008
NR 35
TC 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2009
VL 24
IS 1-2
BP 115
EP 124
DI 10.1159/000227819
PG 10
SC Cell Biology; Physiology
GA 466GY
UT ISI:000267650600013
ER

PT J
AU Wang, CT
   Zhang, P
   Wang, YS
   Ruan, XZ
   Li, ZY
   Peng, F
   Yang, HS
   Wei, YQ
AF Wang, Chun-Ting
   Zhang, Peng
   Wang, Yong-Sheng
   Ruan, Xu-Zhi
   Li, Zhi-Yong
   Peng, Feng
   Yang, Han-Shuo
   Wei, Yu-Quan
TI RNA interference against Biot2, a novel mouse testis - specific gene,
   inhibits the growth of tumor cells
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE RNA interference; Biot2; Testis-specific; Proliferation
ID DIFFERENTIATION ANTIGEN; BREAST-CANCER; CANCER/TESTIS ANTIGENS;
   MULTIPLE-MYELOMA; MAMMARY-GLAND; EXPRESSION; IMMUNOTHERAPY; NY-BR-1;
   RESPONSES; PROTEIN
AB Biot2 is a novel murine testis-specific gene that was first identified
   using the SEREX technique, and named by our laboratory. Using
   conventional RT-PCR and real time RT-PCR, we tested the expression
   profile of Biot2 in normal tissues and various murine tumor cell lines.
   Using RNA interference, we studied the biological function of Biot2 in
   tumorigenesis. We applied various types of growth assay, such as the in
   vitro MTT, colony-forming and BrdU incorporation assays, along with in
   vivo tumorigenicity assays, to reveal its inhibition of tumor cell
   proliferation. The results revealed that the Biot2 transcript was
   detected only and strongly in the testis tissues and abundantly in five
   types of murine cancer cell line. Treating B16 murine melanoma, LL/2
   murine Lewis lung carcinoma and CT26 murine colorectal adenocarcinoma
   with special shRNA targeting Biot2 can significantly reduce the
   proliferation rate of these three tumor cell lines in vitro, as
   measured by the MTT, colony-forming and BrdU incorporation assays. The
   tumorigenicity of the CT26 cells transfected with special shRNA
   targeting Biot2 was also decreased distinctly in vivo compared with the
   control. It was therefore concluded that Biot2 plays a key role in
   tumorigenesis and could be a potential target for biotherapy.
C1 [Wang, Chun-Ting; Wang, Yong-Sheng; Ruan, Xu-Zhi; Li, Zhi-Yong; Peng, Feng; Yang, Han-Shuo; Wei, Yu-Quan] Sichuan Univ, State Key Lab Biotherapy, W China Hosp, W China Med Sch, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Peng] Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Sichuan, Peoples R China.
   [Peng, Feng] Sichuan Univ, Dept Thorac Oncol, Ctr Canc, W China Hosp,W China Med Sch, Chengdu 610041, Sichuan, Peoples R China.
RP Peng, F, Sichuan Univ, State Key Lab Biotherapy, W China Hosp, W China
   Med Sch, Keyuan Rd 4, Chengdu 610041, Sichuan, Peoples R China.
EM evenforeven@yahoo.com.cn
   yhansh@scu.edu.cn
FU National Natural Science Foundation of China [30700969, 30801048];
   National 863 Projects 
FX This work was supported by National Natural Science Foundation of China
   (30700969 and 30801048) and National 863 Projects.
CR BARROW C, 2006, CLIN CANCER RES 1, V12, P764, DOI
   10.1158/1078-0432.CCR-05-1544
   BELLATI F, 2007, EUR J CANCER, V43, P2621, DOI
   10.1016/j.ejca.2007.08.031
   BLACKBURN JS, 2007, CANCER RES, V67, P10849, DOI
   10.1158/0008-5472.CAN-07-1791
   CHEN Y, 2003, BIOCHEM BIOPH RES CO, V311, P398, DOI
   10.1016/j.bbrc.2003.10.009
   CHEN YT, 1997, P NATL ACAD SCI USA, V94, P1914
   CONDOMINES M, 2007, J IMMUNOL, V178, P3307
   GURE AO, 2005, CLIN CANCER RES, V11, P8055, DOI
   10.1158/1078-0432.CCR-05-1203
   HOUET L, 2006, EUR J CANCER, V42, P1653, DOI 10.1016/j.ejca.2006.03.008
   JAGER D, 1999, CANCER RES, V59, P6197
   JAGER D, 2001, CANCER RES, V61, P2055
   JAGER D, 2005, CANC IMMUN, V5, P11
   JAGER D, 2007, APPL IMMUNOHISTO M M, V15, P77
   JAGER E, 2006, P NATL ACAD SCI USA, V103, P14453, DOI
   10.1073/pnas.0606512103
   OKADA T, 2006, CLIN CANCER RES, V12, P191, DOI
   10.1158/1078-0432.CCR-05-1206
   PARMIGIANI RB, 2006, P NATL ACAD SCI USA, V103, P18066, DOI
   10.1073/pnas.0608853103
   PENG F, 2004, J SICHUAN U MED SCI, V35, P30
   SCANLAN MJ, 2002, IMMUNOL REV, V188, P22
   SEGAL NH, 2005, CANC IMMUN, V5, P4
   SEIL I, 2007, INT J CANCER, V120, P2635, DOI 10.1002/ijc.22620
   SHEN YM, 2007, ACTA OBSTET GYN SCAN, V86, P1503, DOI
   10.1080/00016340701736946
   SIMPSON AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   THEURILLAT JP, 2007, CANCER IMMUNOL IMMUN, V56, P1723, DOI
   10.1007/s00262-007-0316-1
   VALMORI D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI
   10.1073/pnas.0703395104
   VELAZQUEZ EF, 2007, CANC IMMUN, V7, P11
NR 24
TC 2
PU VERSITA
PI WARSAW 41
PA 9 DRUGA POPRZECNA ST, 04-604 WARSAW 41, POLAND
SN 1425-8153
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD SEP
PY 2009
VL 14
IS 3
BP 363
EP 376
DI 10.2478/s11658-009-0004-6
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 464DF
UT ISI:000267484600001
ER

PT J
AU Yang, KM
   Pyo, JO
   Kim, GY
   Yu, R
   Han, IS
   Ju, SA
   Kim, WH
   Kim, BS
AF Yang, Kyung Min
   Pyo, Jong Ok
   Kim, Gyu-Yeol
   Yu, Rina
   Han, In Seob
   Ju, Seong A.
   Kim, Won Ho
   Kim, Byung-Sam
TI Capsaicin induces apoptosis by generating reactive oxygen species and
   disrupting mitochondrial transmembrane potential in human colon cancer
   cell lines
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE Capsaicin; Colon cancer cell line; Apoptosis; Mitochondrial
   transmembrane potential; Reactive oxygen species; Caspase 3
ID VANILLOID CAPSAICIN; INDUCTION; MECHANISMS; DEATH; INHIBITION;
   COMPONENT; GROWTH; P53
AB Although genetic factors are a well-known cause of colorectal cancer,
   environmental factors contribute more to its development. Despite
   advances in the fields of surgery, radiotherapy and chemotherapy, the
   cure rates for colon cancer have not substantially improved over the
   past few decades. Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide),
   the principal pungent ingredient of hot chili pepper, has exhibited an
   anti-tumor effect in many cell types. However, the mechanisms
   responsible for the anti-tumor effect of capsaicin are not yet
   completely understood. In this study, we investigated whether capsaicin
   induces apoptosis in colon cancer cell lines. Capsaicin decreased cell
   viability in a dose-dependent manner in Colo320DM and LoVo cells. In
   addition, capsaicin produced cell morphology changes and DNA
   fragmentation, decreased the DNA contents, and induced
   phosphatidylserine translocation, which is a hallmark of apoptotic cell
   death. We showed that capsaicin-induced apoptosis is associated with an
   increase in ROS generation and a disruption of the mitochondrial
   transmenbrane potential. A possible mechanism of capsaicin-induced
   apoptosis is the activation of caspase 3, a major apoptosis-executing
   enzyme. Treatment with capsaicin induced a dramatic increase in caspase
   3 activity, as assessed by the cleavage of Ac-DEVD-AMC, a fluorogenic
   substrate. In conclusion, our results clearly showed that capsaicin
   induced apoptosis in colon cancer cells. Although the actual mechanisms
   of capsaicin-induced apoptosis remain uncertain, it may be a beneficial
   agent for colon cancer treatment and chemoprevention.
C1 [Han, In Seob; Kim, Byung-Sam] Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea.
   [Yang, Kyung Min; Kim, Won Ho] Yonsei Univ, Coll Med, Dept Internal Med, Inst Gastroenterol, Seoul, South Korea.
   [Pyo, Jong Ok] Seoul Natl Univ, Sch Biol Sci, Bio MAX Inst, Seoul, South Korea.
   [Kim, Gyu-Yeol] Univ Ulsan, Dept Surg, Ulsan Univ Hosp, Coll Med, Ulsan 680749, South Korea.
   [Yu, Rina] Univ Ulsan, Dept Food Sci & Nutr, Ulsan 680749, South Korea.
   [Ju, Seong A.] Univ Ulsan, Biomed Res Ctr, Ulsan Univ Hosp, Coll Med, Ulsan 680749, South Korea.
RP Kim, BS, Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea.
EM bskim@ulsan.ac.kr
FU Korean Ministry of Education and Human Resources Development
   [KRF-2007-412-J00302]; Korea Health 21 RD project 
FX This study was supported by the Korean Ministry of Education and Human
   Resources Development (KRF-2007-412-J00302) and the Korea Health 21 R&D
   project.
CR BEDI A, 1995, CANCER RES, V55, P1811
   CASTILLOOLIVARE.A, 1998, ARCH BIOCHEM BIOPHYS, V358, P125
   COHEN GM, 1997, BIOCHEM J 1, V326, P1
   CORDELL GA, 1993, ANN PHARMACOTHER, V27, P330
   DESAGHER S, 2000, TRENDS CELL BIOL, V10, P369
   DRAY A, 1992, BIOCHEM PHARMACOL, V44, P611
   GOVINDARAJAN VS, 1991, CRIT REV FOOD SCI, V29, P435
   GREEN DR, 1998, SCIENCE, V281, P1309
   HALL PA, 1994, J CELL SCI 12, V107, P3569
   HOLZER P, 1991, PHARMACOL REV, V43, P144
   ITO K, 2004, CANCER RES, V64, P1071
   JANICKE RU, 1998, J BIOL CHEM, V273, P9357
   KIM CS, 2004, J MED FOOD, V7, P267
   KIM JD, 1997, CANCER LETT, V120, P235
   KIM S, 2004, ARCH PHARM RES, V27, P845
   LEE YS, 2004, FREE RADICAL RES, V38, P405, DOI
   10.1080/10715760410001665262
   LOEFFLER M, 2000, EXP CELL RES, V256, P19
   MACHO A, 1999, CELL DEATH DIFFER, V6, P155
   MORI A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087
   SANCHEZ AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z
   SZALLASI A, 1990, BRAIN RES, V524, P106
   SZALLASI A, 1999, PHARMACOL REV, V51, P159
   VAUX DL, 1999, CELL, V96, P245
   VERMEULEN K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x
   WOO M, 1998, GENE DEV, V12, P806
NR 25
TC 4
PU VERSITA
PI WARSAW 41
PA 9 DRUGA POPRZECNA ST, 04-604 WARSAW 41, POLAND
SN 1425-8153
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD SEP
PY 2009
VL 14
IS 3
BP 497
EP 510
DI 10.2478/s11658-009-0016-2
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 464DF
UT ISI:000267484600010
ER

PT J
AU Cheng, MT
   Yang, HW
   Chen, TH
   Lee, OKS
AF Cheng, M-T.
   Yang, H-W.
   Chen, T-H.
   Lee, O. K-S.
TI Isolation and characterization of multipotent stem cells from human
   cruciate ligaments
SO CELL PROLIFERATION
LA English
DT Article
ID MARROW STROMAL CELLS; TERM-FOLLOW-UP; ANTERIOR CRUCIATE; BONE-MARROW;
   IN-VITRO; ADIPOSE-TISSUE; REPAIR; GROWTH; KNEES; TEARS
AB Objectives:
   Mesenchymal stem cells have great potential for tissue regeneration,
   and these cells can be harvested from a variety of tissues; however, up
   to now it has not been clear whether stem cells could be isolated from
   cruciate ligaments of the knee joint. The aim of our study was to
   isolate and characterize stem cells from both anterior and posterior
   cruciate ligaments (ACL and PCL) of humans.
   Materials and methods:
   Cruciate igaments were obtained from patients receiving total knee
   arthroplasty for advanced osteoarthritis and plastic-adherent cells
   were serially passaged. In vitro chondrogenic, osteogenic and
   adipogenic abilities of the cells were evaluated by reverse
   transcriptase-polymerase chain reaction and histological study.
   Karyotyping and surface immunophenotyping of the cells were performed.
   Results:
   It was found that a population of ligament-derived cells could be
   expanded and subcultured extensively. These cells were able to
   differentiate into osteoblasts, chondrocytes and adipocytes under
   appropriate inductions. Their phenotypic characteristics were similar
   to those of bone marrow mesenchymal stem cells. Karyotyping was normal
   after serial passage.
   Conclusions:
   In summary, our study demonstrates that human multipotent stem cells
   can be isolated and expanded from human ACL and PCL, which are easily
   obtained from patients following total knee or cruciate ligament
   reconstructive surgery. Self-renewal and mesodermal differentiation
   potential of these cells make them a viable alternative source for use
   in regenerative medicine.
C1 [Lee, O. K-S.] Natl Yang Ming Univ, Inst Clin Med, Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei 11217, Taiwan.
   [Cheng, M-T.; Lee, O. K-S.] Natl Yang Ming Univ, Inst Clin Med, Taipei 11217, Taiwan.
   [Cheng, M-T.] Tao Yuan Gen Hosp, Tao Yuan, Taiwan.
RP Lee, OKS, Natl Yang Ming Univ, Inst Clin Med, Taipei Vet Gen Hosp, Dept
   Orthopaed & Traumatol, 201 Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.
EM kslee@vghtpe.gov.tw
FU Ministry of Education, Aim for the Top University Plan, Taiwan 
FX Grant from Ministry of Education, Aim for the Top University Plan,
   Taiwan.
CR AGUNG M, 2006, KNEE SURG SPORT TR A, V14, P1307, DOI
   10.1007/s00167-006-0124-8
   AMIEL D, 1990, J APPL PHYSIOL, V69, P902
   BARRACK RL, 1990, CLIN ORTHOP RELAT R, P192
   BEYNNON BD, 2002, J ORTHOPAED RES, V20, P332
   BI YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   BRANDSSON S, 2002, AM J SPORT MED, V30, P361
   BRAY RC, 2002, J ORTHOPAED RES, V20, P984
   BRAY RC, 2003, J ORTHOPAED RES, V21, P1118, DOI
   10.1016/S0736-0266(03)00078-0
   CABORN DNM, 1993, CLIN SPORT MED, V12, P625
   CAMERON ML, 1994, KNEE SURG SPORT TR A, V2, P38
   CAO BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008
   DEBARI C, 2001, ARTHRITIS RHEUM, V44, P1928
   DEMOS M, 2007, BMC MUSCULOSKEL DIS, V8, ARTN 16
   DOMINICI M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   DONG ZG, 1994, CARCINOGENESIS, V15, P1001
   FEAGIN JA, 1976, AM J SPORTS MED, V4, P95
   FRANK CB, 1997, J BONE JOINT SURG  A, V79, P1556
   FRUENSGAARD S, 1989, J BONE JOINT SURG BR, V71, P526
   FUKUMOTO T, 2003, OSTEOARTHR CARTILAGE, V11, P55, DOI
   10.1053/joca.2002.0869
   GE ZG, 2005, CELL TRANSPLANT, V14, P573
   HORWITZ EM, 1999, NAT MED, V5, P262
   JIANG YH, 2002, NATURE, V418, P41
   KAPLAN N, 1990, AM J SPORT MED, V18, P354
   KLEINER JB, 1986, T ORTHOP RES SOC, V11, P131
   LEE KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   LEE OK, 2004, BLOOD, V103, P1669
   LEE SY, 2007, J CELL PHYSIOL, V210, P561, DOI 10.1002/jcp.20890
   LIN TM, 2005, STEM CELLS DEV, V14, P92
   MARESCHI K, 2006, J CELL BIOCHEM, V97, P744, DOI 10.1002/jcb.20681
   MIN JY, 2002, ANN THORAC SURG, V74, P1568
   MONONEN T, 1997, ARCH ORTHOP TRAUM SU, V116, P283
   MURPHY JM, 2003, ARTHRITIS RHEUM, V48, P3464, DOI 10.1002/art.11365
   NAGINENI CN, 1992, J ORTHOP RES, V10, P465
   NOYES FR, 1989, J BONE JOINT SURG BR, V71, P825
   ORLIC D, 2001, NATURE, V410, P701
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857
   PHINNEY DG, 2007, STEM CELLS, V25, P2896, DOI
   10.1634/stemcells.2007-0637
   PITTENGER MF, 1999, SCIENCE, V284, P143
   PITTENGER MF, 2004, CIRC RES, V95, P9, DOI
   10.1161/01.RES.0000135902.99383.6f
   QUARTO R, 2001, NEW ENGL J MED, V344, P385
   SAKAGUCHI Y, 2005, ARTHRITIS RHEUM, V52, P2521, DOI 10.1002/art.21212
   SEKIYA I, 2002, STEM CELLS, V20, P530
   SHEFELBINE SJ, 2006, J ORTHOP RES, V24, P1208, DOI 10.1002/jor.20139
   SHIH YRV, 2006, STEM CELLS, V24, P2391, DOI 10.1634/stemcells.2006-0253
   SMITH JR, 2004, STEM CELLS, V22, P823
   STRAND T, 2005, ARCH ORTHOP TRAUM SU, V125, P217, DOI
   10.1007/s00402-004-0766-2
   TOMA C, 2002, CIRCULATION, V105, P93
   TRAGER D, 1995, ARCH ORTHOP TRAUM SU, V114, P278
   VACANTI CA, 2001, NEW ENGL J MED, V344, P1511
   VANEIJK F, 2004, TISSUE ENG, V10, P893
   WAKITANI S, 2002, OSTEOARTHR CARTILAGE, V10, P199
   WARNKE PH, 2004, LANCET, V364, P766
   ZUK PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 53
TC 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD AUG
PY 2009
VL 42
IS 4
BP 448
EP 460
DI 10.1111/j.1365-2184.2009.00611.x
PG 13
SC Cell Biology
GA 464VZ
UT ISI:000267538300004
ER

PT J
AU Shih, YRV
   Kuo, TK
   Yang, AH
   Lee, OK
   Lee, CH
AF Shih, Y-R. V.
   Kuo, T. K.
   Yang, A-H.
   Lee, O. K.
   Lee, C-H.
TI Isolation and characterization of stem cells from the human parathyroid
   gland
SO CELL PROLIFERATION
LA English
DT Article
ID UMBILICAL-CORD BLOOD; IN-VITRO; TRANSCRIPTIONAL REGULATION;
   ENDOTHELIAL-CELLS; DIFFERENTIATION; EXPRESSION; PERICYTES;
   MICROVASCULATURE; THERAPY; MARKERS
AB Objectives:
   Somatic stem cells can be obtained from a variety of adult human
   tissues. However, it was not clear whether human parathyroid glands,
   which secrete parathyroid hormones and are essential in maintaining
   homeostasis levels of calcium ions in the circulation, contained stem
   cells. We aimed to investigate the possibility of isolating such
   parathyroid-derived stem cells (PDSC).
   Materials and methods:
   Surgically removed parathyroid glands were obtained with informed
   consent. Cell cytogenetics was used to observe chromosomal
   abnormalities. Surface phenotypes were characterized by flow cytometry.
   Telomerase repeat amplification protocol (TRAP) assay was performed to
   observe the telomerase activity. RT-PCR and real-time PCR was was used
   to detect gene expressions. Real-time calcium uptake imaging was
   performed for extent of calcium uptake and transmission electron
   microscopy and immunofluorecent staining for smooth muscle actin.
   Results:
   After enzymatic digestion and primary culture, plastic-adherent,
   fibroblast-like cells appeared in culture and a morphologically
   homogeneous population was derived from subsequent limiting dilution
   and clonal expansion. Karyotyping was normal and doubling time of
   clonal cell growth was estimated to be 70.7 +/- 14.5 h (mean +/-
   standard deviation). The surface phenotype of the cells was positive
   for CD73, CD166, CD29, CD49a, CD49b, CD49d, CD44, CD105, and MHC class
   I, and negative for CD34, CD133, CD117, CD114, CD31, CD62P, EGF-R,
   ICAM-3, CD26, CXCR4, CD106, CD90 and MHC class II, similar to
   mesenchymal stem cells (MSC). Detectable levels of telomerase activity
   along with pluripotency Sall4 gene expression were observed from the
   isolated PDSCs. Expression of calcium-sensing receptor gene along with
   alpha-smooth muscle actin was induced and cellular uptake of
   extracellular calcium ions was observed. Furthermore, PDSCs possessed
   osteogenic, chondrogenic and adipogenic differentiation potentials.
   Conclusions:
   Our results reveal that PDSCs were similar phenotypically to MSCs and
   further studies are needed to formulate induction conditions to
   differentiate PDSCs into parathyroid hormone-secreting chief cells.
C1 [Shih, Y-R. V.; Lee, O. K.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Kuo, T. K.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
   [Yang, A-H.] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan.
   [Lee, O. K.] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
   [Lee, O. K.] Natl Taiwan Univ, Stem Cell Res Inst, Taipei 10764, Taiwan.
   [Lee, C-H.] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan.
   [Lee, C-H.] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
RP Lee, OK, 201 Shi Pai Rd,Sec 2, Taipei 11221, Taiwan.
EM kslee@vghtpe.gov.tw
   chlee@vghtpe.gov.tw
FU Taipei Veterans General Hospital, Taiwan [V95E1-009, V96E1-005]
FX This work was supported by intramural research grants from Taipei
   Veterans General Hospital, Taiwan (V95E1-009 and V96E1-005).
CR BHATIA M, 1997, P NATL ACAD SCI USA, V94, P5320
   BIANCO P, 2001, STEM CELLS, V19, P180
   BONNERWEIR S, 2000, P NATL ACAD SCI USA, V97, P7999
   BROWN EM, 1991, PHYSIOL REV, V71, P371
   DANIELS JT, 2001, WOUND REPAIR REGEN, V9, P483
   DEASY BM, 2001, BLOOD CELL MOL DIS, V27, P924
   FARRINGTONROCK C, 2004, CIRCULATION, V110, P2226, DOI
   10.1161/01.CIR.0000144457.55518.E5
   GRONTHOS S, 2000, P NATL ACAD SCI USA, V97, P13625
   HIERLIHY AM, 2002, FEBS LETT, V530, P239
   HIRSCHI KK, 1996, CARDIOVASC RES, V32, P687
   KIM NW, 1994, SCIENCE, V266, P2011
   KIM SW, 2006, STEM CELLS, V24, P1620, DOI 10.1634/stemcells.2005-0365
   KRUMLAUF R, 1994, CELL, V78, P191
   LEE KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   LEE OK, 2004, BLOOD, V103, P1669
   MCKAY R, 1997, SCIENCE, V276, P66
   MEIRELLES LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   MOCHIZUKI T, 2006, ARTHRITIS RHEUM, V54, P843, DOI 10.1002/art.21651
   PAGANO SF, 2000, STEM CELLS, V18, P295
   PETERS H, 1998, GENE DEV, V12, P2735
   PITTENGER MF, 1999, SCIENCE, V284, P143
   POTTS JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   RAFII S, 1994, BLOOD, V84, P10
   REHMAN J, 2004, CIRCULATION, V109, P1292, DOI
   10.1161/01.CIR.0000121425.42966.F1
   RODDA DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200
   ROH C, 2004, PHYSIOL GENOMICS, V19, P207, DOI
   10.1152/physiolgenomics.00134.2004
   RONNE M, 1990, IN VIVO, V4, P337
   ROUSSANNE MC, 1998, J BONE MINER RES, V13, P354
   SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335
   SONG L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005-0604
   SPRINGER ML, 2002, CELL MOTIL CYTOSKEL, V51, P177
   THOMAS T, 2006, THYROID, V16, P537
   URBANEK K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI
   10.1073/pnas.1832855100
   XU PX, 2002, DEVELOPMENT, V129, P3033
   YANG JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI
   10.1073/pnas.0704001104
   YEN ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006-0295
   ZANNETTINO ACW, 2003, J CELL BIOCHEM, V89, P56, DOI 10.1002/jcb.10481
   ZHANG JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481
NR 38
TC 8
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD AUG
PY 2009
VL 42
IS 4
BP 461
EP 470
DI 10.1111/j.1365-2184.2009.00614.x
PG 10
SC Cell Biology
GA 464VZ
UT ISI:000267538300005
ER

PT J
AU Cheng, MT
   Yang, HW
   Chen, TH
   Lee, OKS
AF Cheng, M-T.
   Yang, H-W.
   Chen, T-H.
   Lee, O. K-S.
TI Isolation and characterization of multipotent stem cells from human
   cruciate ligaments (vol 42, pg 448, 2009)
SO CELL PROLIFERATION
LA English
DT Correction
CR CHENG MT, 2009, CELL PROLIFERAT, V42, P448, DOI
   10.1111/j.1365-2184.2009.00611.x
   CHENG MT, 2009, CELL PROLIFERAT, V42, P448, DOI
   10.1111/j.1365-2184.2009.00611.x
   SHIH YRV, 2009, CELL PROLIFERAT, V42, P461, DOI
   10.1111/j.1365-2184.2009.00614.x
NR 3
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD AUG
PY 2009
VL 42
IS 4
BP 569
EP 569
PG 1
SC Cell Biology
GA 464VZ
UT ISI:000267538300016
ER

PT J
AU Shih, YRV
   Kuo, TK
   Yang, AH
   Lee, OK
   Lee, CH
AF Shih, Y-R. V.
   Kuo, T. K.
   Yang, A-H.
   Lee, O. K.
   Lee, C-H.
TI Virtual glioblastoma: growth, migration and treatment in a
   three-dimensional mathematical model (vol 42, pg 511, 2009)
SO CELL PROLIFERATION
LA English
DT Correction
CR CHENG MT, 2009, CELL PROLIFERAT, V42, P448, DOI
   10.1111/j.1365-2184.2009.00611.x
   EIKENBERRY SE, 2009, CELL PROLIFERAT, V42, P511, DOI
   10.1111/j.1365-2184.2009.00613.x
   SHIH YRV, 2009, CELL PROLIFERAT, V42, P461, DOI
   10.1111/j.1365-2184.2009.00614.x
NR 3
TC 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD AUG
PY 2009
VL 42
IS 4
BP 570
EP 570
DI 10.1111/j.1365-2184.2009.00644.x
PG 1
SC Cell Biology
GA 464VZ
UT ISI:000267538300017
ER

PT J
AU Thao, LB
   Vu, HA
   Yasuda, K
   Taniguchi, S
   Yagasaki, F
   Taguchi, T
   Watanabe, T
   Sato, Y
AF Thao, Le Ba
   Vu, Hoang Anh
   Yasuda, Kazuki
   Taniguchi, Shigeki
   Yagasaki, Fumiharu
   Taguchi, Takahiro
   Watanabe, Toshiki
   Sato, Yuko
TI Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal
   tumor cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE GISTs; Cas-L; SRC; KIT; imatinib
ID METASTASIS; MECHANISMS; INHIBITOR; RECEPTORS; INTEGRINS; APOPTOSIS;
   MESYLATE; MUTATION; INSIGHT; KINASE
AB Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
   tumors in the gastrointestinal tract. Most GISTs patients respond to
   imatinib, yet will eventually exhibit resistance, and the mechanisms of
   imatinib resistance have not yet been fully elucidated.
   To clarify the mechanisms of secondary imatinib-resistant
   gastrointestinal stromal tumors, we generated resistant cells from the
   imatinib-sensitive GIST-T1 cells by exposing them to increasing
   concentrations of imatinib for 6 m. GIST-T1 IR (imatinib-resistant)
   cells showing an IC50 of imatinib 5-7 mu M were generated. In GIST-T1
   IR cells, KIT and its downstream signaling molecules remained
   phosphorylated with the presence of 1 mu M imatinib, and no new
   mutations were found in KIT, PDGFRA, PKC theta and JAK2. DNA
   micro-array analysis showed the overexpression of Cas-L in the
   resistant cells with 513 fold higher than that in the parental cells.
   Cas-L overexpression and SRC hyper-activation were also observed in the
   resistant cells at protein level and they were markedly decreased in
   KIT siRNA transfected GIST-T1 IR cells. Interestingly, GIST-T1 IR cells
   transfected with Cas-L siRNA turned out to become again sensitive to
   imatinib. Imatinib or PP1, a SRC inhibitor, alone was not enough to
   suppress the activation of KIT and its downstream signaling molecules,
   but the combination of them showed strong inhibitory effects on those
   in the resistant cells.
   We report for the first time that the mechanism of imatinib-resistant
   GISTs, at least in one cell line, involves KIT/Cas-L/SRC signaling.
   Cas-L depletion sensitized the resistant GIST-T1 IR cells to imatinib.
C1 [Thao, Le Ba; Vu, Hoang Anh; Sato, Yuko] Res Inst Int Med Ctr Japan, Div Ultra Fine Struct, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan.
   [Thao, Le Ba; Watanabe, Toshiki] Univ Tokyo, Inst Med Sci, Dept Med Genome Sci, Tokyo, Japan.
   [Yasuda, Kazuki; Taniguchi, Shigeki] Res Inst Int Med Ctr Japan, Dept Metab Disorder, Tokyo 1628655, Japan.
   [Yagasaki, Fumiharu] Saitama Med Sch, Dept Internal Med 1, Saitama, Japan.
   [Taguchi, Takahiro] Kochi Univ, Grad Sch Kuroshio Sci, Div Human Hlth & Med Sci, Nanko Ku, Kochi 780, Japan.
RP Sato, Y, Res Inst Int Med Ctr Japan, Div Ultra Fine Struct, Dept
   Pathol, Shinjuku Ku, Toyama 1-21-1, Tokyo 1628655, Japan.
EM ysato@ri.imcj.go.jp
FU Japan Foundation for Promotion of International Medical Research
   Co-operation (JF-PIMRC) 
FX This work was supported by The Japan Foundation for Promotion of
   International Medical Research Co-operation (JF-PIMRC). We are grateful
   to Ms. Kazuko Hamada for analyzing gene expression profile.
CR ANTONESCU CR, 2005, CLIN CANCER RES, V11, P4182
   BAUER S, 2007, ONCOGENE
   CORLESS CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140
   DAMATO G, 2005, CANC CONTROL, V12, P44
   DEBIECRYCHTER M, 2004, EUR J CANCER, V40, P689, DOI
   10.1016/j.ejca.2003.11.025
   DEBIECRYCHTER M, 2005, GASTROENTEROLOGY, V128, P270, DOI
   10.1053/j.gastro.2004.11.020
   DEMATTEO RP, 2000, ANN SURG, V231, P51
   DEMETRI GD, 2002, NEW ENGL J MED, V347, P472
   GIANCOTTI FG, 1999, SCIENCE, V285, P1028
   HEINRICH MC, 2006, J CLIN ONCOL, V24, P4764, DOI
   10.1200/JCO.2006.06.2265
   HYNES RO, 1987, CELL, V48, P549
   KIM M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008
   MINN AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   NATARAJAN M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199
   ONEILL GM, 2007, CANCER RES, V67, P8975, DOI
   10.1158/0008-5472.CAN-07-1328
   ROSKOSKI R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI
   10.1016/j.bbrc.2005.08.055
   RUOSLAHTI E, 1994, CELL, V77, P477
   SEO S, 2005, J IMMUNOL, V175, P3492
   SEO S, 2006, CRIT REV IMMUNOL, V26, P391
   SHINOMURA Y, 2005, J GASTROENTEROL, V40, P775, DOI
   10.1007/s00535-005-1674-0
   SINGH MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI
   10.1007/s12013-007-0036-3
   SLEIJFER S, 2007, ONCOLOGIST, V12, P719, DOI
   10.1634/theoncologist.12-6-719
   SLEIJFER S, 2008, NAT CLIN PRACT ONCOL, V5, P102, DOI 10.1038/ncponc1037
   SPRINGER TA, 1990, NATURE, V346, P425
   TA HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426
   TAGUCHI T, 2002, LAB INVEST, V82, P663
   TATTON L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200
   TORNILLO L, 2006, J CLIN PATHOL, V59, P557, DOI 10.1136/jcp.2005.031112
   WARDELMANN E, 2007, VIRCHOWS ARCH, V451, P743, DOI
   10.1007/s00428-007-0473-9
NR 29
TC 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD APR 15
PY 2009
VL 8
IS 8
BP 683
EP 688
PG 6
SC Oncology
GA 463CJ
UT ISI:000267405800015
ER

PT J
AU Azhar, M
   Yin, M
   Bommireddy, R
   Duffy, JJ
   Yang, JQ
   Pawlowski, SA
   Boivin, GP
   Engle, SJ
   Sanford, LP
   Grisham, C
   Singh, RR
   Babcock, GF
   Doetschman, T
AF Azhar, Mohamad
   Yin, Moying
   Bommireddy, Ramireddy
   Duffy, John J.
   Yang, Junqi
   Pawlowski, Sharon A.
   Boivin, Gregory P.
   Engle, Sandra J.
   Sanford, L. P.
   Grisham, Christina
   Singh, Ram R.
   Babcock, George F.
   Doetschman, Thomas
TI Generation of Mice With a Conditional Allele for Transforming Growth
   Factor beta 1 Gene
SO GENESIS
LA English
DT Article
DE transforming growth factor beta; conditional knockout mice
ID TGF-BETA; EXPRESSION PATTERNS; II RECEPTOR; IN-VIVO; TGF-BETA-1;
   GROWTH-FACTOR-BETA-1; CELLS; ACTIVATION; DIFFERENTIATION; LYMPHOCYTES
AB Transforming growth factor beta 1 (TGF beta 1) is a multifunctional
   growth factor involved in wound healing, tissue fibrosis, and in the
   pathogenesis of many syndromic diseases (e.g., Marfan syndrome,
   Camurati-Engelmann disease) and muscular, neurological, ophthalmic,
   cardiovascular and immunological disorders, and cancer. Since the
   generation of Tgfb1 knockout mice, there has been extraordinary
   progress in understanding its physiological and pathophysiological
   function. Here, we report the generation of a conditional knockout
   allele for Tgfb1 in which its exon 6 is flanked with LoxP sites. As
   proof of principle, we crossed these mice to LckCre transgenic mice and
   specifically disrupted Tgfb1 in T cells. The results indicate that
   T-cell-produced TGF beta 1 is required for normal in vivo regulation of
   peripheral T-cell activation, maintenance of T-cell homeostasis, and
   suppression of autoimmunity. genesis 47:423-431, 2009. (C) 2009
   Wiley-Liss, Inc.
C1 [Azhar, Mohamad; Bommireddy, Ramireddy; Sanford, L. P.; Doetschman, Thomas] Univ Arizona, Inst BIO5, Tucson, AZ USA.
   [Azhar, Mohamad; Doetschman, Thomas] Univ Arizona, Dept Cell Biol, Tucson, AZ USA.
   [Yin, Moying; Duffy, John J.; Pawlowski, Sharon A.; Grisham, Christina] Univ Cincinnati, Dept Mol Genet, Cincinnati, OH USA.
   [Bommireddy, Ramireddy] Univ Arizona, Dept Immunobiol, Tucson, AZ USA.
   [Yang, Junqi] Univ Cincinnati, Dept Canc & Cell Biol, Cincinnati, OH USA.
   [Boivin, Gregory P.] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA.
   [Engle, Sandra J.] Pfizer Inc, Groton, CT 06340 USA.
   [Singh, Ram R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Babcock, George F.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA.
   [Babcock, George F.] Shriners Hosp Children, Cincinnati, OH USA.
RP Azhar, M, 1656 E Mabel St,POB 245217, Tucson, AZ 85724 USA.
EM azharm@email.arizona.edu
   tdoetsch@u.arizona.edu
FU National Institutes of Health [CA084291, AI067903]; Arizona Biomedical
   Research Commission [0901]; Steven M. Gootter Foundation ; BIO5
   Institute of the University of Arizona 
FX Contract grant sponsor: National Institutes of Health Grant, Contract
   grant numbers: CA084291, AI067903; Contract grant sponsor: Arizona
   Biomedical Research Commission, Contract grant number ABRC #0901;
   Contract grant sponsors: Steven M. Gootter Foundation; BIO5 Institute
   of the University of Arizona
CR AZHAR M, 2003, CYTOKINE GROWTH F R, V14, P391, DOI
   10.1016/S1359-6101(03)00044-3
   AZHAR M, 2008, DEV DYNAM, V238, P351
   BOMMIREDDY R, 2003, J IMMUNOL, V170, P3645
   BOMMIREDDY R, 2003, J IMMUNOL, V170, P4612
   BOMMIREDDY R, 2007, TRENDS MOL MED, V13, P492, DOI
   10.1016/j.molmed.2007.08.005
   DERYNCK R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   DICKSON MC, 1995, DEVELOPMENT, V121, P1845
   ENGLE SJ, 1999, CANCER RES, V59, P3379
   KAARTINEN V, 1995, NAT GENET, V11, P415
   KEHRL JH, 1986, J EXP MED, V163, P1037
   KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770
   LEVEEN P, 2005, BLOOD, V106, P4234, DOI 10.1182/blood-2005-05-1871
   LI MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014
   LI MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025
   LONGENECKER G, 2002, CYTOKINE, V18, P43
   LUCAS PJ, 2000, J EXP MED, V191, P1187
   MARIE JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276
   MASSAGUE J, 2006, FEBS LETT, V580, P2811, DOI
   10.1016/j.febslet.2006.04.033
   MCLENNAN IS, 2002, INT J DEV BIOL, V46, P559
   MILLAN FA, 1991, DEVELOPMENT, V111, P131
   ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861
   PELTON RW, 1991, J CELL BIOL, V115, P1091
   PROETZEL G, 1995, NAT GENET, V11, P409
   RAJAN S, 2006, PHYSIOL GENOMICS, V27, P309, DOI
   10.1152/physiolgenomics.00072.2006
   ROBINSON RT, 2007, J IMMUNOL, V179, P71
   SANFORD LP, 1997, DEVELOPMENT, V124, P2659
   SAXENA V, 2008, J IMMUNOL, V180, P1903
   SHULL MM, 1992, NATURE, V359, P693
   SPORN MB, 2006, CYTOKINE GROWTH F R, V17, P3, DOI
   10.1016/j.cytogfr.2005.09.012
   THOMPSON NL, 1989, J CELL BIOL, V108, P661
   YANG ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044
NR 31
TC 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD JUN
PY 2009
VL 47
IS 6
BP 423
EP 431
DI 10.1002/dvg.20516
PG 9
SC Developmental Biology; Genetics & Heredity
GA 462KW
UT ISI:000267352400009
ER

PT J
AU Ren, FR
   Tanaka, H
   Yang, ZH
AF Ren, Fengrong
   Tanaka, Hiroshi
   Yang, Ziheng
TI A likelihood look at the supermatrix-supertree controversy
SO GENE
LA English
DT Article
DE Bayesian; Combined analysis; Likelihood; Likelihood supertree;
   Supermatrix; Supertree
ID MAXIMUM-LIKELIHOOD; PHYLOGENETIC ANALYSIS; EVOLUTIONARY RATES; DATA
   SETS; SUBSTITUTION MODELS; MOLECULAR EVOLUTION; DNA-SEQUENCES; TREES;
   PHYLOGENOMICS; SITES
AB Supermatrix and supertree methods are two strategies advocated for
   phylogenetic analysis of sequence data from multiple gene loci,
   especially when some species are missing at some loci. The supermatrix
   method concatenates sequences from multiple genes into a data
   supermatrix for phylogenetic analysis, and ignores differences in
   evolutionary dynamics among the genes. The supertree method analyzes
   each gene separately and assembles the subtrees estimated from
   individual genes into a supertree for all species. Most algorithms
   suggested for supertree construction lack statistical justifications
   and ignore uncertainties in the subtrees. instead of supermatrix or
   supertree, we advocate the use of likelihood function to combine data
   from multiple genes while accommodating their differences in the
   evolutionary process. This combines the strengths of the supermatrix
   and supertree methods while avoiding their drawbacks. We conduct
   computer simulation to evaluate the performance of the supermatrix,
   supertree, and maximum likelihood methods applied to two phylogenetic
   problems: molecular-clock dating of species divergences and
   reconstruction of species phylogenies. The results confirm the
   theoretical superiority of the likelihood method. Supertree or separate
   analyses of data of multiple genes may be useful in revealing the
   characteristics of the evolutionary process of multiple gene loci, and
   the information may be used to formulate realistic models for combined
   analysis of all genes by likelihood. (C) 2008 Elsevier B.V. All rights
   reserved.
C1 [Yang, Ziheng] UCL, Dept Biol, London WC1E 6BT, England.
   [Ren, Fengrong; Tanaka, Hiroshi] Tokyo Med & Dent Univ, Ctr Informat Med, Tokyo, Japan.
   [Yang, Ziheng] Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo, Japan.
RP Yang, ZH, UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT,
   England.
EM z.yang@ucl.ac.uk
FU Ministry of Education, Culture, Sports, and Technology of Japan ;
   Natural Environment Research Council 
FX We thank David A. Morrison, Andrew Roger, and Ed Susko for comments.
   This study is supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, and Technology of Japan to
   F.R. and H.T. and by a Natural Environment Research Council grant to
   Z.Y.
CR ADACHI J, 1996, COMPUT SCI MONOGR, V28, P1
   BAUM BR, 2002, TAXON, V41, P3
   BERRY V, 2006, SYSTEMATIC BIOL, V55, P270, DOI 10.1080/10635150500541649
   BININDAEMONDS ORP, 2002, ANNU REV ECOL SYST, V33, P265, DOI
   10.1146/annurex.ecolysis.33.010802.150511
   BININDAEMONDS ORP, 2004, PHYLOGENETIC SUPERTR
   BININDAEMONDS ORP, 2004, TRENDS ECOL EVOL, V19, P315, DOI
   10.1016/j.tree.2004.03.015
   BININDAEMONDS ORP, 2005, METHOD ENZYMOL, V395, P745
   BOFKIN L, 2007, MOL BIOL EVOL, V24, P513, DOI 10.1093/molbev/msl178
   BUCKLEY TR, 2001, SYST BIOL, V50, P67
   BURLEIGH JG, 2006, SYSTEMATIC BIOL, V55, P426, DOI
   10.1080/10635150500541722
   CREEVEY CJ, 2005, BIOINFORMATICS, V21, P390, DOI
   10.1093/bioinformatics/bti020
   CRISCUOLO A, 2006, SYSTEMATIC BIOL, V55, P740, DOI
   10.1080/10635150600969872
   DEQUEIROZ A, 2007, TRENDS ECOL EVOL, V22, P34, DOI
   10.1016/j.tree.2006.10.002
   DRUMMOND AJ, 2006, PLOS BIOL, V4, P699, ARTN e88
   EDWARDS AWF, 1992, LIKELIHOOD
   EULENSTEIN O, 2004, SYST BIOL, V53, P299, DOI 10.1080/10635150490423719
   FELSENSTEIN J, 1981, J MOL EVOL, V17, P368
   FELSENSTEIN J, 2001, J MOL EVOL, V53, P447
   FELSENSTEIN J, 2004, INFERRING PHYLOGENIE
   GATESY J, 2002, SYST BIOL, V51, P652, DOI 10.1080/10635150290102311
   GATESY J, 2004, SYST BIOL, V53, P342, DOI 10.1080/10635150490423971
   GOLOBOFF PA, 2002, CLADISTICS, V18, P514
   GOLOBOFF PA, 2005, CLADISTICS, V21, P282
   HILLIS DM, 1998, SYST BIOL, V47, P3
   HUELSENBECK JP, 1995, MOL BIOL EVOL, V12, P843
   HUELSENBECK JP, 1996, TRENDS ECOL EVOL, V11, P152
   HUSON DH, 1999, J COMPUT BIOL, V6, P369
   KIMURA M, 1980, J MOL EVOL, V16, P111
   KUHNER MK, 1994, MOL BIOL EVOL, V11, P459
   LEIGH JW, 2008, SYSTEMATIC BIOL, V57, P104, DOI
   10.1080/10635150801910436
   MOORE BR, 2006, SYSTEMATIC BIOL, V55, P662
   NISHIHARA H, 2007, GENOME BIOL, V8, ARTN R199
   NYLANDER JAA, 2004, SYST BIOL, V53, P47, DOI 10.1080/10635150490264699
   PHILIPPE H, 2005, MOL BIOL EVOL, V22, P1246
   PISANI D, 2002, SYSTEMATIC BIOL, V51, P151
   POE S, 1999, NATURE, V398, P300
   POLLOCK DD, 2002, SYST BIOL, V51, P664, DOI 10.1080/10635150290102357
   PUPKO T, 2002, MOL BIOL EVOL, V19, P2294
   RAGAN MA, 1992, MOL PHYLOGENET EVOL, V1, P53
   RANNALA B, 1998, SYST BIOL, V47, P702
   RANNALA B, 2008, ANN REV GENOM HUM GE
   REN FR, 2005, SYSTEMATIC BIOL, V54, P808, DOI 10.1080/10635150500354688
   RONQUIST F, 2004, PHYLOGENETIC SUPERTR, P193
   ROSENBERG MS, 2003, SYST BIOL, V52, P119, DOI 10.1080/10635150390132894
   SANDERSON MJ, 1998, TRENDS ECOL EVOL, V13, P105
   SANDERSON MJ, 2003, MOL BIOL EVOL, V20, P1036, DOI 10.1093/molbev/msg115
   SEMPLE C, 2000, DISCRETE APPL MATH, V105, P147
   SHAPIRO B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   SIMON C, 2006, ANNU REV ECOL EVOL S, V37, P545, DOI
   10.1146/annurev.ecolsys.37.091305.110018
   SPRINGER MS, 2001, SCIENCE, V291, P1709
   SUCHARD MA, 2003, SYST BIOL, V52, P649, DOI 10.1080/10635150390238879
   TATENO Y, 1994, MOL BIOL EVOL, V11, P261
   THORNE JL, 1998, MOL BIOL EVOL, V15, P1647
   WIENS JJ, 2005, SYSTEMATIC BIOL, V54, P731, DOI
   10.1080/10635150500234583
   WILKINSON M, 2005, SYST BIOL, V54, P419
   YANG Z, 2004, ACTA ZOOL SINICA, V50, P645
   YANG Z, 2006, COMPUTATIONAL MOL EV
   YANG ZH, 1994, J MOL EVOL, V39, P306
   YANG ZH, 1995, J MOL EVOL, V40, P689
   YANG ZH, 1996, J MOL EVOL, V42, P587
   YANG ZH, 1997, COMPUT APPL BIOSCI, V13, P555
   YANG ZH, 2006, MOL BIOL EVOL, V23, P212, DOI 10.1093/molbev/msj024
   ZWICKL DJ, 2002, SYST BIOL, V51, P588, DOI 10.1080/10635150290102339
NR 63
TC 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JUL 15
PY 2009
VL 441
IS 1-2
SI Sp. Iss. SI
BP 119
EP 125
DI 10.1016/j.gene.2008.04.002
PG 7
SC Genetics & Heredity
GA 460YP
UT ISI:000267229600015
ER

PT J
AU Watanabe, G
   Behrns, KE
   Kim, JS
   Kim, RD
AF Watanabe, Go
   Behrns, Kevin E.
   Kim, Jae-Sung
   Kim, Robin D.
TI Heat shock protein 90 inhibition abrogates hepatocellular cancer growth
   through cdc2-mediated G(2)/M cell cycle arrest and apoptosis
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Hepatocellular cancer; Hsp90; 17-AAG; Xenograft; cdc2
ID SIGNAL-TRANSDUCTION; DOWN-REGULATION; MOLECULAR CHAPERONE; MITOTIC
   CATASTROPHE; GENE-EXPRESSION; HSP90 FUNCTION; BREAST-CANCER;
   LIVER-CANCER; CDC2; GELDANAMYCIN
AB 17-(demethoxy), 17-allylamino geldanamycin (17-AAG) suppresses growth
   in some cancers by inhibiting Heat shock protein 90 (Hsp90). We
   examined the effects of 17-AAG-mediated Hsp90 inhibition on human
   hepatocellular carcinoma (HCC) growth in vitro and in vivo.
   Human HCC cell lines, Hep3B and HuH7, were exposed to 17-AAG and cell
   viabilities and apoptosis were determined. Cell cycle profiles were
   analyzed and the G(2)/M cell cycle checkpoint proteins cdc2 and cyclin
   B1 were examined. Studies were performed to determine whether
   17-AAG-mediated cdc2 decrease was due to altered gene expression,
   transcription, or protein degradation. The effects of 17-AAG on Hep3B
   and HuH7 xenograft growth in athymic nude mice were also examined.
   Hep3B and HuH7 treated with 17-AAG versus untreated controls showed
   decreased cell viability and increased apoptosis. Cells treated with
   17-AAG also showed an increased fraction in G(2)/M phase and an
   associated decrease in cdc2 through protein degradation rather than
   through other mechanisms. Hsp90 inhibition by 17-AAG also decreased HCC
   xenograft growth in association with decreased cdc2 expression.
   17-AAG-mediated inhibition of Hsp90 abrogates human HCC cell growth in
   vitro and in vivo through cdc2 decrease, which in turn induces G(2)/M
   cell cycle arrest and apoptosis. Hsp90 is a mediator of HCC growth and
   survival and its inhibition may serve as a potential treatment.
C1 [Watanabe, Go; Behrns, Kevin E.; Kim, Jae-Sung; Kim, Robin D.] Univ Florida, Dept Surg, Coll Med, Gainesville, FL 32610 USA.
RP Kim, RD, Univ Florida, Dept Surg, Coll Med, 1600 SW Archer Rd,Room
   6142, Gainesville, FL 32610 USA.
EM robin.kim@surgery.ufl.edu
CR BAGATELL R, 2001, CLIN CANCER RES, V7, P2076
   BAGATELL R, 2004, MOL CANCER THER, V3, P1021
   BANERJEE S, 2005, ADV MATER, V17, P17, DOI 10.1002/adma.200401340
   BANERJI U, 2005, CLIN CANCER RES 1, V11, P7023, DOI
   10.1158/1078-0432.CCR-05-0518
   BELIAKOFF J, 2004, ANTI-CANCER DRUG, V15, P651, DOI
   10.1097/01.cad.0000136876.11928.be
   BOSCH FX, 2004, GASTROENTEROLOGY S1, V127, S5, DOI
   10.1053/j.gastro.2004.09.011
   BOSSI G, 2007, HEAD NECK-J SCI SPEC, V29, P272, DOI 10.1002/hed.20529
   BURGER AM, 2004, ANTI-CANCER DRUG, V15, P377, DOI
   10.1097/01.cad.0000124496.74538.e4
   CALVISI DF, 2007, REV RECENT CLIN TRIA, V2, P217
   CASTEDO M, 2002, CELL DEATH DIFFER, V9, P1287, DOI
   10.1038/sj.cdd.4401130
   CHIOSIS G, 2003, MOL CANCER THER, V2, P123
   CLARKE PA, 2000, ONCOGENE, V19, P4125
   DECARCER G, 2004, CANCER RES, V64, P5106
   FUJII T, 2006, HEPATOLOGY, V43, P1267, DOI 10.1002/hep.21181
   GANNON JV, 1998, GENES CELLS, V3, P17
   GARCIAMORALES P, 2007, ONCOGENE, V26, P7185, DOI 10.1038/sj.onc.1210534
   GEORGAKIS GV, 2006, CLIN CANCER RES, V12, P584, DOI
   10.1158/1078-0432.CCR-05-1194
   GIOVANNETTI E, 2007, BRIT J CANCER, V96, P769, DOI
   10.1038/sj.bjc.6603639
   GOMEZFLORES R, 1995, J CLIN MICROBIOL, V33, P1842
   GREM JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085
   HOSTEIN I, 2001, CANCER RES, V61, P4003
   JURCHOTT K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200
   KELLAND LR, 1999, J NATL CANCER I, V91, P1940
   KLIONSKY DJ, 2000, SCIENCE, V290, P1717
   LEGAC G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200
   LIM SO, 2005, WORLD J GASTROENTERO, V11, P2072
   LUK JM, 2006, PROTEOMICS, V6, P1049, DOI 10.1002/pmic.200500306
   MEIJER L, 1997, EUR J BIOCHEM, V243, P527
   MORLA AO, 1989, CELL, V58, P193
   NOMURA M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090
   NOMURA N, 2007, BIOCHEM PHARMACOL, V73, P1528, DOI
   10.1016/j.bcp.2007.01.022
   OKAMOTO J, 2008, J THORAC ONCOL, V3, P1089
   PASCALE RM, 2005, HEPATOLOGY, V42, P1310, DOI 10.1002/hep.20962
   PRATT WB, 1998, P SOC EXP BIOL MED, V217, P420
   RONNEN EA, 2006, INVEST NEW DRUG, V24, P543, DOI
   10.1007/s10637-006-9208-z
   RUBINSZTEIN DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   SCHEUFLER C, 2000, CELL, V101, P199
   SCHULTE TW, 1998, CANCER CHEMOTH PHARM, V42, P273
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889
   SENJU M, 2006, J CANCER RES CLIN, V132, P150, DOI
   10.1007/s00432-005-0047-7
   TAKAYAMA S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114
   WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093
   WELCH WJ, 1982, J BIOL CHEM, V257, P4949
   WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324
   WHITESELL L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   WOLF F, 2007, CELL CYCLE, V6, P1408
   WORKMAN P, 2004, TRENDS MOL MED, V10, P47, DOI
   10.1016/j.molmed.2003.12.005
   YANG J, 2001, CANCER RES, V61, P4010
   YIN XY, 2005, CLIN CANCER RES, V11, P3889
   YOUNG JC, 2001, J CELL BIOL, V154, P267
NR 50
TC 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTHER PHARMACOL
JI Cancer Chemother. Pharmacol.
PD JUL
PY 2009
VL 64
IS 3
BP 433
EP 443
DI 10.1007/s00280-008-0888-2
PG 11
SC Oncology; Pharmacology & Pharmacy
GA 458QP
UT ISI:000267038900001
ER

PT J
AU Oku, H
   Li, CC
   Shimatani, M
   Iwasaki, H
   Toda, T
   Okabe, T
   Watanabe, H
AF Oku, Hirosuke
   Li, Changchun
   Shimatani, Masayuki
   Iwasaki, Hironori
   Toda, Takayoshi
   Okabe, Takafumi
   Watanabe, Hisami
TI Tumor specific cytotoxicity of beta-glucosylceramide:
   structure-cytotoxicity relationship and anti-tumor activity in vivo
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Glucosylceramide; Tumor selective; Cytotoxicity; Structure-activity
   relationship; Antitumor immunity
ID KILLER T-CELLS; ALPHA-GALACTOSYLCERAMIDE; NKT CELLS; SPHINGOSINE
   KINASE; LIVER-INJURY; APOPTOSIS; MICE; SPHINGOLIPIDS; CERAMIDE;
   LYMPHOCYTES
AB This study describes the structure-cytotoxicity relationship of
   beta-glucosylceramide (beta-GluCer) and its antitumor activity in vivo.
   Unglycosylated ceramide had no selective cytotoxicity which
   demonstrated that the sugar moiety plays a critical role for the
   expression of selective cytotoxicity by beta-GluCer.
   beta-Galactosylceramide also showed tumor specific cytotoxicity
   suggesting that the chemical structure of sugar group is not a factor
   for the selective toxicity. Similarly, unglycosylated ceramides of
   short acyl chain also selectively inhibited the growth of cancer cells.
   These findings in concert point to the importance of the hydrophilicity
   of the ceramide molecule rather than the chemical structure for the
   cyto-selectivity. Treatment of the cells with beta-GluCer increased the
   concentration of reactive oxygen species leading to cell cycle arrest
   and necrosis. Intraperitoneal administration of beta-GluCer
   significantly suppressed the growth of tumor implanted to the back of
   mice. beta-GluCer also induced antitumor immunity via the activation of
   NKT cells in vivo, and decreased the tumor metastasis of lymphoma
   cells. The present study thus demonstrated the antitumor activity of
   beta-GluCer in vivo, and discussed the mechanisms responsible for the
   growth inhibition.
C1 [Oku, Hirosuke; Li, Changchun; Iwasaki, Hironori; Okabe, Takafumi; Watanabe, Hisami] Univ Ryukyus, Ctr Mol Biosci, Okinawa 9030213, Japan.
   [Shimatani, Masayuki] Univ Ryukyus, Grad Sch Agr, Okinawa 9030213, Japan.
   [Toda, Takayoshi] Univ Ryukyus Hosp, Sch Med, Dept Clin Lab Med, Okinawa 9030125, Japan.
RP Oku, H, Univ Ryukyus, Ctr Mol Biosci, Okinawa 9030213, Japan.
EM okuhiros@comb.u-ryukyu.ac.jp
CR BENDELAC A, 1997, ANNU REV IMMUNOL, V15, P535
   BIBURGER M, 2005, J IMMUNOL, V175, P1540
   BROSSAY L, 1998, J EXP MED, V188, P1521
   BURDIN N, 1998, J IMMUNOL, V161, P3271
   CRISPE IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981
   DIMARCO R, 1999, AUTOIMMUNITY, V31, P75
   EBERL G, 1998, IMMUNITY, V9, P345
   EMOTO M, 2003, TRENDS IMMUNOL, V24, P364, DOI
   10.1016/S1471-4906(03)00162-5
   EMOTO M, 2004, MED ELECT MICROSC, V37, P29
   FUJII H, 2005, VIRCHOWS ARCH, V446, P663, DOI 10.1007/s00428-005-1265-8
   FUTERMAN AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208
   GOLSTEIN P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI
   10.1016/j.tibs.2006.11.001
   GUO RR, 2008, BIOL PHARM BULL, V31, P696
   HETZ CA, 2005, BIOCHEM CELL BIOL, V83, P579, DOI 10.1139/005-065
   HLA T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI
   10.1016/j.semcdb.2004.05.002
   ISHIHARA S, 1999, EUR J IMMUNOL, V29, P2406
   ISHIHARA S, 2000, J IMMUNOL, V165, P1659
   KAWANO T, 1997, SCIENCE, V278, P1626
   KOBAYASHI E, 1995, ONCOL RES, V7, P529
   KOBAYASHI E, 1996, BIOORGAN MED CHEM, V4, P615
   LI C, 2005, CELL IMMUNOL, V231, P96
   MACEYKA M, 2002, BBA-MOL CELL BIOL L, V1585, P193
   MENGUBAS K, 1999, EXP CELL RES, V249, P116
   NAKAGAWA R, 2001, J IMMUNOL, V166, P6578
   OGRETMEN B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   OGRETMEN B, 2006, FEBS LETT, V580, P5467, DOI
   10.1016/j.febslet.2006.08.052
   OKU H, 2007, CANCER CHEMOTH PHARM, V60, P767, DOI
   10.1007/s00280-007-0422-y
   PANDEY S, 2007, EXP MOL PATHOL, V82, P298, DOI
   10.1016/j.yexmp.2006.07.009
   PHILLIPS DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15
   PRETET JL, 2003, APOPTOSIS, V8, P655
   RAMOS B, 2003, MOL PHARMACOL, V64, P502
   SAUBERMANN LJ, 2000, GASTROENTEROLOGY, V119, P119
   SCHMELZ EM, 1998, NUTRITION, V14, P717
   SNEDECOR GW, 1967, STAT METHODS, P258
   SULLARDS MC, 2000, J MASS SPECTROM, V35, P347
   TAHA TA, 2006, J BIOCHEM MOL BIOL, V39, P113
   TEJERA AM, 2001, BREAST CANCER RES TR, V65, P93
   VILLENA J, 2008, FREE RADICAL BIO MED, V44, P1146, DOI
   10.1016/j.freeradbiomed.2007.12.017
   ZHOU DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science/1103440
   ZIGMOND E, 2007, GUT, V56, P82, DOI 10.1136/gut.2006.095497
NR 40
TC 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTHER PHARMACOL
JI Cancer Chemother. Pharmacol.
PD JUL
PY 2009
VL 64
IS 3
BP 485
EP 496
DI 10.1007/s00280-008-0896-2
PG 12
SC Oncology; Pharmacology & Pharmacy
GA 458QP
UT ISI:000267038900006
ER

PT J
AU Yang, H
   Cheng, XP
   Li, JW
   Yao, Q
   Ju, G
AF Yang, Hao
   Cheng, Xi-Ping
   Li, Jing-Wen
   Yao, Qin
   Ju, Gong
TI De-differentiation Response of Cultured Astrocytes to Injury Induced by
   Scratch or Conditioned Culture Medium of Scratch-Insulted Astrocytes
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Astrocyte; De-differentiation; Rat; Nestin; GFAP
ID NEURAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY;
   RAT SPINAL-CORD; RADIAL-GLIA; NERVOUS-SYSTEM; SUBVENTRICULAR ZONE;
   REACTIVE ASTROCYTES; PROGENITOR CELLS; MULLER CELLS
AB Our previous reports indicated that astrocytes (ASTs) in injured adult
   rat spinal cord underwent a process of de-differentiation, and may
   acquire the potential of neural stem cells (NSCs). However, the AST
   de-differentiation and transitional rejuvenation process following
   injury is still largely unclear. The aim of the present study was to
   determine whether injured in vitro ASTs can re-enter the
   multipotential-like stem cell pool and regain NSC characteristics, and
   to further understand the mechanism of AST de-differentiation. We used
   an in vitro scratch-wound model to evoke astrocytic response to
   mechanical injury. GFAP and nestin double-labeled indirect
   immunofluorescence were carried out to characterize these scratched
   cells at various periods. Western-blot analysis was used to determine
   the changes of GFAP and nestin expression following injury.
   Furthermore, the rate of proliferation was determined by
   immunocytochemical detection of BrdU incorporating cells. These
   scratch-wound ASTs were cultured with stem cells medium to explore
   their ability to generate neurospheres and examine the self-renewal and
   multi-potency of such neurospheres. Moreover, scratched AST culture
   supernatant as conditioned cultured medium (ACM) was used to
   investigate if some diffusible factors derived from injured ASTs could
   induce de-differentiation of AST. The results showed: (1) the nestin
   positivity first appeared in GFAP-positive cells at the edge of the
   scratch, subsequently, disseminated into un-insulted zone. The
   expression of nestin in AST was increased with longer culture, while
   that of GFAP was decreased. Furthermore, these nestin-immunoreactive
   ASTs could generate neurospheres, which showed self-renewal and could
   be differentiated into neurons, ASTs and oligodendrocytes. (2)
   Scratched ASTs culture supernatant can induce astrocytic proliferation
   and de-differentiation. These results reveal that the in vitro injured
   ASTs can de-differentiate into nestin-positive stem/precursor cells,
   the process of de-differentiation may arise from direct injury or some
   diffusible factors released from injured ASTs.
C1 [Yang, Hao; Cheng, Xi-Ping; Li, Jing-Wen; Yao, Qin; Ju, Gong] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi, Peoples R China.
RP Ju, G, Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi,
   Peoples R China.
EM jugong@fmmu.edu.cn
FU National Basic Research Program of China [2003CB515301]; Chinese PLA
   national scientific technological project [06G089]
FX We thank Dr. Gautam Hebbar and Dr. Zhe Liang from Emory University for
   critical reading of the manuscript. This work was supported by the
   National Basic Research Program of China (2003CB515301) and Chinese PLA
   national scientific technological project (06G089).
CR AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625
   BARKER RA, 2004, NEURORX, V1, P472
   BONFANTI L, 2007, PROG NEUROBIOL, V83, P24, DOI
   10.1016/j.pneurobio.2006.11.002
   BOTTAI D, 2003, J HEMATOTH STEM CELL, V12, P655
   BRAWLEY C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676
   CHALMERSREDMAN RME, 1997, NEUROSCIENCE, V76, P1121
   CHANG ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x
   CHEN J, 2005, EUR J NEUROSCI, V22, P1895, DOI
   10.1111/j.1460-9568.2005.04348.x
   DELCORRAL RD, 2003, NEURON, V40, P65
   DOETSCH F, 1999, CELL, V97, P703
   DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279
   DUGGAL N, 1997, BRAIN RES, V768, P1
   FADEN AI, 2002, CURR OPIN NEUROL, V15, P707, DOI
   10.1097/01.wco.0000044767.39452.bf
   FISCHER AJ, 2002, J NEUROSCI, V22, P9387
   GIULIAN D, 1985, SCIENCE, V228, P497
   GREEN PJ, 1996, BIOESSAYS, V18, P639
   HUNG CH, 2006, BIOMATERIALS, V27, P5901, DOI
   10.1016/j.biomaterials.2006.08.009
   HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061
   ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70
   ITOH T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8
   KAYA SS, 1999, BRAIN RES, V840, P153
   KOHNO H, 2006, GRAEF ARCH CLIN EXP, V244, P90, DOI
   10.1007/s00417-005-0030-7
   LANG B, 2004, NEUROSCIENCE, V128, P775, DOI
   10.1016/j.neuroscience.2004.06.033
   LAYWELL ED, 2000, P NATL ACAD SCI USA, V97, P13883
   LEAVITT BR, 1999, EXP NEUROL, V157, P43
   LEE J, 2003, DEV BIOL, V253, P84, DOI 10.1006/dbio.2002.0868
   LEPORE AC, 2006, NEUROSCIENCE, V142, P287
   LIU Y, 2004, BIOL CELL, V96, P279, DOI 10.1016/j.biolcel.2004.02.001
   MALHOTRA SK, 1990, CYTOBIOS, V61, P133
   MARTINEZSERRANO A, 1997, TRENDS NEUROSCI, V20, P530
   MERRILL JE, 1996, TRENDS NEUROSCI, V19, P331
   MONNIN J, 2007, NEUROSCI LETT, V421, P22, DOI
   10.1016/j.neulet.2007.04.073
   MORGANTIKOSSMAN.MC, 1992, TRENDS PHARMACOL SCI, V13, P286
   MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163
   MORI T, 2005, CURR TOP DEV BIOL, V69, P67, DOI
   10.1016/S0070-2153(05)69004-7
   NOVITCH BG, 2003, NEURON, V40, P81
   OOTO S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI
   10.1073/pnas.0402129101
   PHIFER CB, 1986, PHYSIOL BEHAV, V38, P887
   PILLAI R, 2006, EXP CELL RES, V312, P2336, DOI
   10.1016/j.yexcr.2006.03.031
   RAO MS, 1999, ANAT REC, V257, P137
   RAYMOND PA, 2006, BMC DEV BIOL, V6, ARTN 36
   ROWITCH DH, 2002, TRENDS NEUROSCI, V25, P417
   RUTISHAUSER U, 1996, TRENDS NEUROSCI, V19, P422
   SCHMID RS, 2003, P NATL ACAD SCI USA, V100, P4251, DOI
   10.1073/pnas.0630496100
   SERGENTTANGUY S, 2003, J NEUROSCI METH, V129, P73, DOI
   10.1016/S0165-0270(03)00210-3
   SERGENTTANGUY S, 2006, J NEUROSCI RES, V83, P1515, DOI 10.1002/jnr.20846
   SERI B, 2001, J NEUROSCI, V21, P7153
   STEINDLER DA, 2003, GLIA, V43, P62, DOI 10.1002/glia.10242
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   TIMIRAS PS, 2005, MECH AGEING DEV, V126, P3, DOI
   10.1016/j.mad.2004.09.020
   YANG H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4
   YU T, 2006, J CELL BIOCHEM, V99, P1096, DOI 10.1002/jcb.20979
   ZHOU RX, 2001, BRAIN RES BULL, V56, P37
NR 53
TC 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JUN
PY 2009
VL 29
IS 4
BP 455
EP 473
DI 10.1007/s10571-008-9337-3
PG 19
SC Cell Biology; Neurosciences
GA 457IH
UT ISI:000266921200005
ER

PT J
AU Yang, XF
   Yang, Y
   Luo, YG
   Li, G
   Wang, JZ
   Yang, ES
AF Yang, Xifei
   Yang, Ying
   Luo, Yougen
   Li, Geng
   Wang, Jianzhi
   Yang, Edward S.
TI Hyperphosphorylation and Accumulation of Neurofilament Proteins in
   Transgenic Mice with Alzheimer Presenilin 1 Mutation
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Neurofilaments; Hyperphosphorylation; JNK; Presenilin-1; Alzheimer's
   disease
ID PAIRED HELICAL FILAMENTS; AMYOTROPHIC-LATERAL-SCLEROSIS;
   AXONAL-TRANSPORT; IN-VIVO; PHOSPHORYLATION; DISEASE; TAU; APOPTOSIS;
   NEURONS; GENE
AB Neurofilaments (NFs) are hyperphosphorylated and accumulate in
   Alzheimer's disease (AD) brains. In this study, employing the
   transgenic mouse model, we explored the effect of presenilin 1 (PS-1)
   mutation on the phosphorylation and distribution of NFs. Western blot
   analysis showed that there was a significant increase in the
   phosphorylation of NF-H and NF-M subunits with a concomitant increase
   in phosphorylated c-Jun N-terminal protein kinase 1/2 (JNK1/2)
   mitogen-activated protein kinase (MAPK) in hippocampus of PS-1
   transgenic mice compared to that of wild-type littermates.
   Immunohistochemical analysis revealed that phosphorylated NFs
   accumulated throughout the hippocampal neurons of the transgenic mice.
   These findings suggest that PS-1 mutation may induce
   hyperphosphorylation and accumulation of NFs via a JNK1/2-involved
   mechanism.
C1 [Li, Geng; Yang, Edward S.] Hong Kong Appl Sci & Technol Res Inst Co Ltd, Hong Kong, Hong Kong, Peoples R China.
   [Yang, Xifei; Yang, Ying; Luo, Yougen; Wang, Jianzhi] Huazhong Univ Sci & Technol, Dept Pathophysiol, Inst Neurosci, Tongji Med Coll, Wuhan 430074, Peoples R China.
RP Li, G, Hong Kong Appl Sci & Technol Res Inst Co Ltd, Hong Kong, Hong
   Kong, Peoples R China.
EM ligenggeng@gmail.com
FU National Natural Science Foundation of China [30700277]
FX This study was supported by a grant from National Natural Science
   Foundation of China (30700277).
CR ARBEZ N, 2007, EXP GERONTOL, V42, P951, DOI 10.1016/j.exger.2007.05.007
   BORCHELT DR, 1996, NEURON, V17, P1005
   COLLARD JF, 1995, NATURE, V375, P61
   FERNYHOUGH P, 1999, DIABETES, V48, P881
   GIBB BJM, 1998, J NEUROCHEM, V70, P492
   GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913
   HARPER SJ, 2003, EXPERT OPIN THER TAR, V7, P187
   HUANG XG, 2003, EXP NEUROL, V183, P673, DOI
   10.1016/S0014-4886(03)00242-5
   JUNG CW, 1999, CELL MOTIL CYTOSKEL, V42, P230
   LEE MK, 1996, ANNU REV NEUROSCI, V19, P187
   LEE VMY, 1991, SCIENCE, V251, P675
   MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642
   MASAKI R, 2000, J NEUROSCI RES, V62, P75
   NIXON RA, 1994, J CELL BIOL, V126, P1031
   NIXON RA, 1998, CURR OPIN CELL BIOL, V10, P87
   PERRY G, 1985, P NATL ACAD SCI USA, V82, P3916
   PIGINO G, 2001, J NEUROSCI, V21, P834
   POLLANEN MS, 1994, ACTA NEUROPATHOL, V88, P1
   SHOJI M, 2000, BRAIN RES MOL BRAIN, V85, P221
   STARR R, 1996, J NEUROSCI RES, V44, P328
   STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274
   TANEMURA K, 2006, J BIOL CHEM, V281, P5037, DOI 10.1074/jbc.MS09145200
   TANZI RE, 1996, NEUROBIOL DIS, V3, P159
   YAO MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005
   ZHU XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000057426
NR 25
TC 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JUN
PY 2009
VL 29
IS 4
BP 497
EP 501
DI 10.1007/s10571-008-9341-7
PG 5
SC Cell Biology; Neurosciences
GA 457IH
UT ISI:000266921200008
ER

PT J
AU Yu, KM
   Hou, L
   Zhu, JQ
   Ying, XP
   Yang, WX
AF Yu, Keming
   Hou, Lin
   Zhu, Jun-Quan
   Ying, Xue-Ping
   Yang, Wan-Xi
TI KIFC1 participates in acrosomal biogenesis, with discussion of its
   importance for the perforatorium in the Chinese mitten crab Eriocheir
   sinensis
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Spermatogenesis; Acrosome; KIFC1; Chinese mitten crab; Eriocheir
   sinensis (Crustacea)
ID KINESIN SUPERFAMILY PROTEINS; EPIDIDYMAL MATURATION; MAMMALIAN
   SPERMATOGENESIS; INTRACELLULAR-TRANSPORT; CANDIDATE MOTORS; GERM-CELLS;
   SPERM; SPERMIOGENESIS; DYNAMICS; SPERMATOZOA
AB Spermatogenesis is a complicated process during which spermatogonia
   undergo proliferation and divisions leading, after a series of dramatic
   changes, to the production of mature spermatozoa. Many molecular motors
   are involved in this process. KIFC1, a C-terminal kinesin motor,
   participates in acrosome biogenesis and nuclear shaping. We report here
   the expression profile of KIFC1 during spermatogenesis in the Chinese
   mitten crab, Eriocheir sinensis. KIFC1 mainly localizes around the
   nucleus but is also present within the nucleus of the spermatogonium
   and spermatocyte. At the early spermatid stage, KIFC1 begins to be
   distributed on the nuclear membrane at the region where the
   proacrosomal vesicle is located. By the late spermatid stage, KIFC1 is
   found on the acrosome. Immunocytochemical and ultrastructural analyses
   have shown that KIFC1 localizes on the perforatorium, which is composed
   of an apical cap and an acrosomal tubule. We demonstrate that, during
   spermatogenesis in E. sinensis, KIFC1 probably plays important roles in
   the biogenesis of the acrosome and in its maintenance. KIFC1 may also
   be essential for the eversion of the acrosome during fertilization.
C1 [Yu, Keming; Yang, Wan-Xi] Zhejiang Univ, Coll Life Sci, Inst Cell Biol & Genet, Sperm Lab, Hangzhou 310058, Zhejiang, Peoples R China.
   [Yu, Keming; Hou, Lin] Liaoning Normal Univ, Coll Life Sci, Dalian 116029, Peoples R China.
   [Zhu, Jun-Quan] Ningbo Univ, Fac Life Sci & Biotechnol, Ningbo 315211, Zhejiang, Peoples R China.
   [Ying, Xue-Ping] Wenzhou Univ, Sch Biol & Environm Sci, Wenzhou 325027, Peoples R China.
RP Yang, WX, Zhejiang Univ, Coll Life Sci, Inst Cell Biol & Genet, Sperm
   Lab, Hangzhou 310058, Zhejiang, Peoples R China.
EM wxyang@spermlab.org
CR ABOUHAILA A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173
   AJDUK A, 2006, BIOL REPROD, V75, P442, DOI 10.1095/biolreprod.106.053223
   ALI MY, 2008, P NATL ACAD SCI USA, V105, P4691, DOI
   10.1073/pnas.0711531105
   BENETTI AS, 2008, MICRON, V39, P337, DOI 10.1016/j.micron.2007.04.004
   BRAY JD, 2004, MOL REPROD DEV, V69, P387, DOI 10.1002/mrd.20171
   BREED WG, 2004, J MORPHOL, V261, P52, DOI 10.1002/jmor.10228
   BURKIN HR, 2004, MOL REPROD DEV, V68, P500, DOI 10.1002/mrd.20108
   CAI YF, 2001, J BIOL CHEM, V276, P41594
   CHRISTOVA Y, 2004, MOL CELL ENDOCRINOL, V216, P41
   DIEFENBACH RJ, 1998, BIOCHEMISTRY-US, V37, P16663
   DU NS, 1987, OCEANOLOGICA LIMNOLO, V18, P119
   DU NS, 1988, OCEANOL LIMNOL SIN, V19, P71
   HEHNLY H, 2007, FEBS LETT, V581, P2112, DOI
   10.1016/j.febslet.2007.01.094
   HINSCH GW, 1980, TISSUE CELL, V12, P255
   HIROKAWA N, 2004, EXP CELL RES, V301, P50, DOI
   10.1016/j.yexcr.2004.08.010
   HIROKAWA N, 2008, PHYSIOL REV, V88, P1089, DOI
   10.1152/physrev.00023.2007
   HYENNE V, 2007, REPRODUCTION, V133, P563, DOI 10.1530/RFP-06-0271
   ILANGO K, 2005, J BIOSCIENCES, V30, P733
   KALLIO M, 1995, ENVIRON MOL MUTAGEN, V25, P106
   KOTAJA N, 2004, NAT METHODS, V1, P249
   KOTAJA N, 2004, P NATL ACAD SCI USA, V101, P10620
   KREMLING H, 1991, GENOMICS, V11, P828
   LAWRENCE CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113
   MEDINA PMB, 2008, PLOS ONE, V3, ARTN e3054
   MORENO RD, 2000, BIOL REPROD, V63, P89
   NATH S, 2007, MOL BIOL CELL, V18, P1839
   NAVOLANIC PM, 2000, BIOL REPROD, V62, P1360
   RAMALHOSANTOS J, 2001, EXP CELL RES, V267, P45
   RAMALHOSANTOS J, 2002, BIOL REPROD, V67, P1043, DOI
   10.1095/biolreprod.102.005967
   RORANDELLI R, 2008, J MORPHOL, V269, P259, DOI 10.1002/jmor.10566
   ROSS JL, 2008, CURR OPIN CELL BIOL, V20, P41, DOI
   10.1016/j.ceb.2007.11.006
   ROUX A, 2008, ANN NY ACAD SCI, V1123, P119, DOI 10.1196/annals.1420.014
   SMITA M, 2004, J MORPHOL, V262, P484, DOI 10.1002/jmor.10258
   SPERRY AO, 1996, MOL BIOL CELL, V7, P289
   TOSHIMORI K, 1998, CELL TISSUE RES, V293, P177
   VAID KS, 2007, BIOL REPROD, V77, P1037, DOI
   10.1095/biolreprod.107.063735
   VANHORCK FPG, 2008, SCI SIGNAL, V1, ARTN pe11
   WANG R, 2008, BMC CELL BIOL, V9, ARTN 9
   YANG WX, 2003, BIOL REPROD, V69, P1719, DOI
   10.1095/biolreprod.102.014878
   YANG WX, 2006, BIOL REPROD, V74, P684, DOI 10.1095/biolreprod.105.049312
   YOSHINAGA K, 2001, CELL TISSUE RES, V303, P253
   YOSHINAGA K, 2003, MICROSC RES TECHNIQ, V61, P39, DOI 10.1002/jemt.10315
   ZAMA U, 2004, TISSUE CELL, V36, P29, DOI 10.1016/j.tice.2003.08.003
   ZHANG Y, 2004, DEV BIOL, V275, P23, DOI 10.1016/j.ydbio.2004.07.014
   ZHANG YG, 2004, CELL MOTIL CYTOSKEL, V58, P213, DOI 10.1002/cm.20008
   ZOU Y, 2002, BIOL REPROD, V66, P843
NR 46
TC 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD JUL
PY 2009
VL 337
IS 1
BP 113
EP 123
DI 10.1007/s00441-009-0800-3
PG 11
SC Cell Biology
GA 457EC
UT ISI:000266910300010
ER

PT J
AU Kim, D
   Kim, CH
   Moon, JI
   Chung, YG
   Chang, MY
   Han, BS
   Ko, S
   Yang, E
   Cha, KY
   Lanza, R
   Kim, KS
AF Kim, Dohoon
   Kim, Chun-Hyung
   Moon, Jung-Il
   Chung, Young-Gie
   Chang, Mi-Yoon
   Han, Baek-Soo
   Ko, Sanghyeok
   Yang, Eungi
   Cha, Kwang Yul
   Lanza, Robert
   Kim, Kwang-Soo
TI Generation of Human Induced Pluripotent Stem Cells by Direct Delivery
   of Reprogramming Proteins
SO CELL STEM CELL
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; HUMAN SOMATIC-CELLS; PARKINSONS-DISEASE;
   HUMAN FIBROBLASTS; DEFINED FACTORS; CELLULAR UPTAKE; TAT PROTEIN; IPS
   CELLS; INDUCTION; MACROMOLECULES
C1 [Chung, Young-Gie; Lanza, Robert] Stern Cell & Regenerat Med Int, Worcester, MA 01605 USA.
   [Kim, Dohoon; Kim, Chun-Hyung; Moon, Jung-Il; Chang, Mi-Yoon; Han, Baek-Soo; Ko, Sanghyeok; Yang, Eungi; Kim, Kwang-Soo] Harvard Univ, Sch Med, Mol Neurobiol Lab, Dept Psychiat, Belmont, MA 02478 USA.
   [Kim, Dohoon; Kim, Chun-Hyung; Moon, Jung-Il; Chang, Mi-Yoon; Han, Baek-Soo; Ko, Sanghyeok; Yang, Eungi; Kim, Kwang-Soo] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA.
   [Kim, Kwang-Soo] Harvard Stem Cell Inst, Belmont, MA 02478 USA.
RP Lanza, R, Stern Cell & Regenerat Med Int, 381 Plantat St, Worcester, MA
   01605 USA.
EM rlanza@advancedcell.com
   kskim@mclean.harvard.edu
FU National Institutes of Health (NIH) [MH48866, DC 006501]; CHA
   University ; Korean Stem Cell Research Center ; Dongyang Corporation
   Co. in Korea 
FX This work was supported by National Institutes of Health (NIH) grants
   MH48866 and DC 006501 and by International Grants from the CHA
   University, Korean Stem Cell Research Center, and Dongyang Corporation
   Co. in Korea. The authors thank Dr. V. Morgan (Harvard Partners Center
   for Genetics and Genomics), Dr. J. Kim (Harvard Medical School), and
   Dr. J. Lee (Shippensburg University) for microarray analysis and Ms. J.
   Johnson (Cell Line Genetics) for karyotyping analysis. R.L. is an
   employee and shareholder of Advanced Cell Technology and a scientific
   advisor for Stem Cell and Regenerative Medicine International. K.Y.C.
   is a shareholder of CHA Bio and Diostech Co., Ltd., and Stem Cell and
   Regenerative Medicine International.
CR BELTING M, 2005, ADV DRUG DELIVER REV, V57, P505, DOI
   10.1016/j.addr.2004.10.004
   CHUNG Y, 2009, CLONING STEM CELLS, DOI 10.1089/CL0.2009.0004
   ELSAYED A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   FRANKEL AD, 1988, CELL, V55, P1189
   FRANKEL AD, 1988, SCIENCE, V240, P70
   FRENCH AJ, 2008, STEM CELLS, V26, P485, DOI 10.1634/stemcells.2007-0252
   HANNA J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   HUANGFU DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   KAJI K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   LI WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014
   MAHERALI N, 2007, CELL STEM CELL, V1, P55
   OKITA K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   OKITA K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   PARK IH, 2008, NATURE, V451, P141, DOI 10.1038/nature06534
   SHI Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   SOLDNER F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013
   STADTFELD M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   TAKAHASHI K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAKAHASHI K, 2007, CELL, V131, P861
   WENDER PA, 2000, P NATL ACAD SCI USA, V97, P13003
   WERNIG M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   WERNIG M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI
   10.1073/pnas.0801677105
   WILMUT I, 1997, NATURE, V385, P813
   WOLTJEN K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   YAMANAKA S, 2007, CELL STEM CELL, V1, P39
   YAMANAKA S, 2009, CELL, V137, P13, DOI 10.1016/j.cell.2009.03.034
   YU JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   YU JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   ZHOU HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   ZIEGLER A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 30
TC 221
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUN 5
PY 2009
VL 4
IS 6
BP 472
EP 476
DI 10.1016/j.stem.2009.05.005
PG 5
SC Cell & Tissue Engineering; Cell Biology
GA 455UY
UT ISI:000266793600005
ER

PT J
AU Tobinai, K
   Watanabe, T
   Tanimoto, K
   Maruyama, D
   Nakata, M
   Itoh, K
   Morishima, Y
   Ogura, M
   Usui, N
   Kasai, M
   Terauchi, T
   Nawano, S
   Matsusako, M
   Matsuno, Y
   Nakamura, S
   Mori, S
   Ohashi, Y
AF Tobinai, Kensei
   Watanabe, Takashi
   Tanimoto, Kazuki
   Maruyama, Dai
   Nakata, Masanobu
   Itoh, Kuniaki
   Morishima, Yasuo
   Ogura, Michinori
   Usui, Noriko
   Kasai, Masaharu
   Terauchi, Takashi
   Nawano, Shigeru
   Matsusako, Masaki
   Matsuno, Yoshihiro
   Nakamura, Shigeo
   Mori, Shigeo
   Ohashi, Yasuo
TI Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in
   Japanese patients with relapsed indolent B-cell lymphoma mostly
   pretreated with rituximab
SO CANCER SCIENCE
LA English
DT Article
ID NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY TREATED
   PATIENTS; ADVANCED LOW-GRADE; 2-CHLORODEOXYADENOSINE CLADRIBINE;
   FOLLICULAR LYMPHOMA; INTRAVENOUS-INFUSION; RESPONSE CRITERIA;
   COMBINATION; CYCLOPHOSPHAMIDE
AB We conducted a phase I/II study to investigate the toxicity,
   pharmacokinetics, and efficacy profiles of cladribine with 2-h
   intravenous infusion for five consecutive days every four weeks in
   Japanese patients with relapsed indolent B-cell lymphoma. This was a
   dose-escalation study to confirm the safety of the doses which have
   been recommended for Caucasian patients (phase I), and to further
   evaluate the efficacy and safety (phase II). In the phase I portion for
   nine patients, no dose-limiting toxicities were observed at levels 1
   (0.09 mg/kg/day, n = 3) and 2 (0.12 mg/kg/day, n = 6). No appreciable
   accumulation of plasma cladribine concentration was suggested. We
   enrolled a total of 20 patients, and an additional 14 patients in the
   phase II portion at level 2 (0.12 mg/kg/day). Eighteen patients,
   including 13 with follicular lymphoma, were eligible for efficacy
   evaluation, and 15 (83%) were pretreated with rituximab. The overall
   response rate was 50% (9/18; 80% confidence interval, 35-65%), with 11%
   (2/18) complete response. With a median follow-up of 296 days, the
   estimated median time to progression for 18 eligible patients was 382
   days. The most frequent adverse events were hematologic toxicities,
   including grade 4 neutropenia. Non-hematologic toxicities were mild. In
   conclusion, cladribine with 2-h intravenous infusion for five
   consecutive days every four weeks is effective with acceptable
   toxicities for Japanese patients with relapsed indolent B-cell
   lymphoma, including those pretreated with rituximab. (Cancer Sci 2009;
   100: 1344-1350)
C1 [Tobinai, Kensei; Watanabe, Takashi; Tanimoto, Kazuki; Maruyama, Dai] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Chuo Ku, Tokyo 1040045, Japan.
   [Matsuno, Yoshihiro] Natl Canc Ctr, Clin Lab Div, Chuo Ku, Tokyo 1040045, Japan.
   [Nakata, Masanobu; Itoh, Kuniaki] Natl Canc Ctr Hosp E, Div Hematol & Oncol, Kashiwa, Chiba 2778577, Japan.
   [Nawano, Shigeru] Natl Canc Ctr Hosp E, Diagnost Radiol Div, Kashiwa, Chiba 2778577, Japan.
   [Morishima, Yasuo; Ogura, Michinori] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Usui, Noriko] Jikei Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol, Tokyo 1058471, Japan.
   [Kasai, Masaharu] Sapporo Hokuyu Hosp, Dept Internal Med, Shiroishi Ku, Sapporo, Hokkaido 0030006, Japan.
   [Terauchi, Takashi] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Screening Technol & Dev Div, Chuo Ku, Tokyo 1040045, Japan.
   [Matsusako, Masaki] St Lukes Int Hosp, Dept Radiol, Chuo Ku, Tokyo 1048560, Japan.
   [Nakamura, Shigeo] Nagoya Univ Hosp, Pathol & Clin Labs, Showa Ku, Nagoya, Aichi 4668560, Japan.
   [Mori, Shigeo] Teikyo Univ, Sch Med, Dept Pathol, Itabashi Ku, Tokyo 1738606, Japan.
   [Ohashi, Yasuo] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Bunkyo Ku, Tokyo 1138655, Japan.
RP Tobinai, K, Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Chuo
   Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM ktobinai@ncc.go.jp
CR ARMITAGE JO, 2004, INT J HEMATOL, V79, P311
   BEUTLER E, 1992, LANCET, V340, P952
   CARSON DA, 1983, BLOOD, V62, P737
   CHESON BD, 1999, J CLIN ONCOL, V17, P1244
   FISHER RI, 2005, J CLIN ONCOL, V23, P8447, DOI 10.1200/JCO.2005.03.1674
   FRIDRIK MA, 1998, EUR J CANCER, V34, P1560
   HARRIS NL, 1999, J CLIN ONCOL, V17, P3835
   HIDDEMANN W, 2005, BLOOD, V106, P3725
   HOFFMAN M, 1994, J CLIN ONCOL, V12, P788
   ITOH K, 2008, J CLIN ONCOL, V26, P482
   JULIUSSON G, 1993, J CLIN ONCOL, V11, P679
   KALINKAWARZOCHA E, 2008, CANCER, V113, P367, DOI 10.1002/cncr.23558
   KAY AC, 1992, J CLIN ONCOL, V10, P371
   LILIEMARK J, 1995, CLIN CANCER RES, V1, P385
   LILIEMARK J, 1997, LEUKEMIA LYMPHOMA, V25, P313
   MACHII T, 2005, INT J HEMATOL, V82, P230, DOI 10.1532/IJH97.04128
   MARCUS R, 2008, J CLIN ONCOL, V26, P4579, DOI 10.1200/JCO.2007.13.5376
   MORSCHHAUSER F, 2008, J CLIN ONCOL, V26, P5156, DOI
   10.1200/JCO.2008.17.2015
   OGURA M, 2004, INT J HEMATOL, V80, P267, DOI 10.1532/IJH97.04077
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649
   PIRO LD, 1990, NEW ENGL J MED, V322, P1117
   ROBAK T, 1997, LEUKEMIA LYMPHOMA, V26, P99
   ROBAK T, 1999, LEUKEMIA LYMPHOMA, V32, P359
   ROBAK T, 2004, LEUKEMIA LYMPHOMA, V45, P937, DOI
   10.1080/1042819032000159825
   ROBAK T, 2005, CHEMOTHERAPY, V51, P247, DOI 10.1159/000087251
   ROBAK T, 2006, BLOOD, V108, P473, DOI 10.1182/blood-2005-12-4828
   RUMMEL MJ, 1999, LEUKEMIA LYMPHOMA, V35, P129
   SAVEN A, 1996, J CLIN ONCOL, V14, P978
   SAVEN A, 1998, BLOOD, V92, P1918
   SIGAL DS, 2008, EXPERT REV ANTICANC, V8, P535, DOI
   10.1586/14737140.8.4.535
   TALLMAN MS, 1995, J CLIN ONCOL, V13, P983
   TOBINAI K, 1997, JPN J CLIN ONCOL, V27, P146
   TOBINAI K, 2002, EXPERT OPIN EMERG DR, V7, P289
   TOBINAI K, 2003, INT J HEMATOL, V77, P512
   TOBINAI K, 2006, J CLIN ONCOL, V24, P174, DOI 10.1200/JCO.2005.03.9313
   TONDINI C, 2000, ANN ONCOL, V11, P231
   TULPULE A, 1998, CANCER, V83, P2370
NR 37
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD JUL
PY 2009
VL 100
IS 7
BP 1344
EP 1350
DI 10.1111/j.1349-7006.2009.01162.x
PG 7
SC Oncology
GA 458AL
UT ISI:000266982000028
ER

PT J
AU Yamada, H
   Takano, T
   Ito, Y
   Matsuzuka, F
   Miya, A
   Kobayashi, K
   Yoshida, H
   Watanabe, M
   Iwatani, Y
   Miyauchi, A
AF Yamada, Hiroya
   Takano, Toru
   Ito, Yasuhiro
   Matsuzuka, Fumio
   Miya, Akihiro
   Kobayashi, Kaoru
   Yoshida, Hiroshi
   Watanabe, Mikio
   Iwatani, Yoshinori
   Miyauchi, Akira
TI Expression of nestin mRNA is a differentiation marker in thyroid tumors
SO CANCER LETTERS
LA English
DT Article
DE Nestin; Cancer stem cell; Anaplastic thyroid carcinoma; Thyroid
   transcription factor-1; Gene expression
ID INTERMEDIATE-FILAMENT NESTIN; FETAL CELL CARCINOGENESIS; QUANTITATIVE
   MEASUREMENT; ANAPLASTIC CARCINOMA; STEM-CELLS; TRANSCRIPTION; CANCER;
   THYROGLOBULIN; HYPOTHESIS; PAPILLARY
AB Nestin is a maker that identifies stem cells in some adult tissues, and
   its expression is believed to relate to malignancy in cancer cells. In
   this study, we measured the expression levels of nestin mRNA in various
   kinds of thyroid tumor by the real-time quantitative reverse
   transcription-polymerase chain reaction. Unexpectedly, nestin mRNA was
   detected in almost all differentiated thyroid tumors and normal thyroid
   tissues, whereas extremely decreased expression was observed in
   anaplastic carcinomas, which are the most malignant of the thyroid
   follicular cell-derived tumors. These results suggest that nestin mRNA
   is a differentiation marker, and its expression does not relate to
   malignant characteristics in thyroid tumors. (C) 2009 Elsevier Ireland
   Ltd. All rights reserved.
C1 [Yamada, Hiroya; Takano, Toru] Osaka Univ, Sch Med, Dept Lab Med, Osaka 5650871, Japan.
   [Yamada, Hiroya; Watanabe, Mikio; Iwatani, Yoshinori] Osaka Univ, Grad Sch Med, Div Hlth Sci, Osaka 5650871, Japan.
   [Ito, Yasuhiro; Matsuzuka, Fumio; Miya, Akihiro; Kobayashi, Kaoru; Yoshida, Hiroshi; Miyauchi, Akira] Kuma Hosp, Chuo Ku, Kobe, Hyogo 6500011, Japan.
RP Takano, T, Osaka Univ, Sch Med, Dept Lab Med, 2-2 D2, Osaka 5650871,
   Japan.
EM ttakano@labo.med.osaka-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [20590570]; Princess Takamatsu Cancer Research Fund [04-23606]
FX This research was supported by the Ministry of Education, Culture,
   Sports, Science and Technology of Japan, a Grant-in-Aid for Scientific
   Research C, 2008-2010, No.20590570, and a Research Grant of the
   Princess Takamatsu Cancer Research Fund 04-23606 of Japan.
CR AIN KB, 1998, THYROID, V8, P715
   ALMQVIST PM, 2002, J HISTOCHEM CYTOCHEM, V50, P147
   BERMAN DM, 2002, SCIENCE, V297, P1559
   DAHLSTRAND J, 1992, CANCER RES, V52, P5334
   KLEEBERGER W, 2007, CANCER RES, V67, P9199, DOI
   10.1158/0008-5472.CAN-07-0806
   KOBAYASHI M, 1998, PEDIATR RES, V43, P386
   LAZZARO D, 1991, DEVELOPMENT, V113, P1093
   LENDAHL U, 1990, CELL, V60, P585
   LOBO MVT, 2004, CELL TISSUE RES, V316, P369, DOI
   10.1007/s00441-003-0848-4
   LONIGRO R, 2001, J BIOL CHEM, V276, P47807
   PELIZZOI R, 2008, INT J DEV BIOL, V52, P55, DOI 10.1387/ijdb.062196rp
   REYA T, 2001, NATURE, V414, P105
   TAKANO T, 1998, BRIT J CANCER, V78, P221
   TAKANO T, 1999, CANCER RES, V59, P4542
   TAKANO T, 2001, BRIT J CANCER, V85, P102
   TAKANO T, 2005, THYROID, V15, P432
   TAKANO T, 2007, JPN J CLIN ONCOL, V37, P647, DOI 10.1093/jjco/hym084
   TAKANO T, 2007, ONCOL REP, V18, P715
   TAKANO T, 2007, SEMIN CANCER BIOL, V17, P233
   TSUJIMURA T, 2001, AM J PATHOL, V158, P817
   VESELSKA R, 2006, BMC CANCER, V6, ARTN 32
   WIESE C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI
   10.1007/s00018-004-4144-6
   YANG XH, 2008, J CLIN PATHOL, V61, P467, DOI 10.1136/jcp.2007.047605
   ZHANG P, 2006, PATHOL INT, V56, P485, DOI
   10.1111/j.1440-1827.2006.01995.x
NR 24
TC 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JUL 18
PY 2009
VL 280
IS 1
BP 61
EP 64
DI 10.1016/j.canlet.2009.02.006
PG 4
SC Oncology
GA 458GM
UT ISI:000267003500007
ER

PT J
AU Yang, WS
   Tsai, TJ
   Shih, CL
   Huang, JW
   Chuang, HF
   Chen, MH
   Fang, CC
AF Yang, Wei-Shun
   Tsai, Tun-Jun
   Shih, Chung-Liang
   Huang, Jenq-Wen
   Chuang, Hsueh-Fang
   Chen, Meng-Han
   Fang, Cheng-Chung
TI Intraperitoneal Vascular Endothelial Growth Factor C Level Is Related
   to Peritoneal Dialysis Ultrafiltration
SO BLOOD PURIFICATION
LA English
DT Article
DE Interleukin-6; Peritoneal dialysis; Ultrafiltration; Vascular
   endothelial growth factor-C
ID RESIDUAL RENAL-FUNCTION; ARTERIAL STIFFNESS; MESOTHELIAL CELLS;
   TRANSPORT RATE; EXPRESSION; VEGF; INFLAMMATION; ANGIOGENESIS;
   ASSOCIATION; PREDICTOR
AB Background: Local inflammation and neovascularization have a negative
   influence on peritoneal dialysis (PD). Patients with higher peritoneal
   transport have higher interleukin-6 (IL-6) and vascular endothelial
   growth factor-A (VEGF-A) levels in their dialysate. However, the
   relationship of other members of the VEGF family, such as VEGF-C, to
   peritoneal transport or ultrafiltration (UF) is yet to be studied.
   Methods: Peritoneal cytokine and growth factor levels were determined
   during the peritoneal equilibration test (PET). Ultrafiltration,
   peritoneal clearance and residual renal function were also considered.
   Results: Forty-two PD patients were enrolled. They had been on PD for
   at least 1 month and free of peritonitis for at least 1 month prior to
   the study. Patients with high or high average PET had higher dialysate
   IL-6 and VEGF-C. Dialysate IL-6 and VEGF-C correlated negatively with
   PET and UF. Conclusions: Dialysate VEGF-C is related to higher
   transport rate and poorer UF. The role of VEGF-C in PD deserves further
   study. Copyright (C) 2009 S. Karger AG, Basel
C1 [Shih, Chung-Liang; Fang, Cheng-Chung] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei 100, Taiwan.
   [Chuang, Hsueh-Fang; Chen, Meng-Han] Natl Taiwan Univ Hosp, Dept Nursing, Taipei 100, Taiwan.
   [Tsai, Tun-Jun; Huang, Jenq-Wen] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Yang, Wei-Shun] Tao Yuan Gen Hosp, Dept Internal Med, Tao Yuan, Taiwan.
RP Fang, CC, Natl Taiwan Univ Hosp, Dept Emergency Med, 7 Chung Shan S Rd,
   Taipei 100, Taiwan.
EM conrad@ntu.edu.tw
FU Tao-Yuan General Hospital Study Found ; Ta-Tung Kidney Foundation ;
   Mrs. Hsiu-Chin Lee Kidney Research Fund. ; Department of Medical
   Research of the National Taiwan University Hospital 
FX This study was supported by the Tao-Yuan General Hospital Study Found,
   Ta-Tung Kidney Foundation and the Mrs. Hsiu-Chin Lee Kidney Research
   Fund. This work was also supported in part by the Department of Medical
   Research of the National Taiwan University Hospital. The authors wish
   to thank Prof. Wan-Yu Chen, Ms. Shu-Li Hung and Ms. Yuan-Ting Chuang,
   Department of Internal Medicine, National Taiwan University Hospital,
   for their kind assistance.
CR BURKART JM, 2004, PRINCIPLES PRACTICE, P181
   CHEN W, 2007, BLOOD PURIFICAT, V25, P260, DOI 10.1159/000101699
   CHUNG SH, 2001, NEPHROL DIAL TRANSPL, V16, P2240
   DECAL M, 2008, BLOOD PURIFICAT, V26, P249, DOI 10.1159/000122110
   DEVRIESE AS, 2001, J AM SOC NEPHROL, V12, P1734
   DIAZBUXO JA, 2008, BLOOD PURIFICAT, V26, P12, DOI 10.1159/000110557
   FLESSNER MF, 2006, AM J PHYSIOL-RENAL, V290, F232, DOI
   10.1152/ajprenal.00211.2005
   GU Y, 2008, BLOOD PURIFICAT, V26, P340, DOI 10.1159/000132465
   HUANG WH, 2008, BLOOD PURIFICAT, V26, P133, DOI 10.1159/000113013
   IO H, 2004, KIDNEY INT, V65, P1927
   KORBET SM, 2004, PRINCIPLES PRACTICE, P206
   LEUNG JCK, 2005, NEPHROL DIAL TRANSPL, V20, P1336, DOI
   10.1093/ndt/gfh814
   MANDLWEBER S, 2002, KIDNEY INT, V61, P570
   NARKO K, 1999, INT J EXP PATHOL, V80, P109
   PECOITSFILHO R, 2002, NEPHROL DIAL TRANSPL, V17, P1480
   ROY H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   SCAVELLI C, 2004, J ANAT, V204, P433
   STOMPOR T, 2002, PERITON DIALYSIS INT, V22, P670
   SZETO CC, 2004, KIDNEY INT, V65, P1947
   TAKAHASHI H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TWARDOWSKI ZJ, 1989, BLOOD PURIFICAT, V7, P95
   VANWESTRHENEN R, 2007, BLOOD PURIFICAT, V25, P466, DOI 10.1159/000112475
   YANG JH, 2008, BLOOD PURIFICAT, V26, P399, DOI 10.1159/000141956
   YU ZZ, 2008, BLOOD PURIFICAT, V26, P386, DOI 10.1159/000141930
   ZWEERS MM, 2001, J LAB CLIN MED, V137, P125
NR 25
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
J9 BLOOD PURIFICAT
JI Blood Purif.
PY 2009
VL 28
IS 1
BP 69
EP 74
DI 10.1159/000218008
PG 6
SC Hematology; Urology & Nephrology
GA 456WP
UT ISI:000266883100012
ER

PT J
AU Yee, LJ
   Im, K
   Borg, B
   Yang, H
   Liang, TJ
AF Yee, L. J.
   Im, K.
   Borg, B.
   Yang, H.
   Liang, T. J.
CA Virahep C Study
TI Interleukin-6 haplotypes and the response to therapy of chronic
   hepatitis C virus infection
SO GENES AND IMMUNITY
LA English
DT Article
DE hepatitis C; race; therapy; response; African American
ID PEGINTERFERON ALPHA-2B; AMERICAN PATIENTS; RIBAVIRIN; ASSOCIATION;
   POLYMORPHISMS; GENOTYPE-1; GENE
AB Chronic hepatitis C virus (HCV) infection affects nearly 170 million
   individuals worldwide. Treatment of HCV with pegylated
   interferon-alpha-2a is successful in eradicating virus from only 30 to
   80% of those treated. Interleukin-6 (IL-6) is an important cytokine
   involved in the immune response to infectious agents and in vitro
   studies suggest that host genetic variation, particularly haplotypes,
   may affect IL-6 expression. We examined the contribution of haplotypes
   in the IL-6 gene on sustained viral response (SVR) to the therapy for
   chronic HCV infection. We observed the IL-6 T-T-G-G-G-G-C-A-G-A
   haplotype to be associated with a lower risk of achieving SVR among
   Caucasian Americans (CAs) ((relative risk) RR = 0.80; 95% CI:
   0.66-0.98; P = 0.0261). Using a sliding window approach, the
   rs1800797-(G)-rs1800796-(G)-rs1800795-( G) haplotype was associated
   with a reduced chance of SVR (RR = 0.79; 95% CI: 0.66-0.94; P =
   0.0081), as was the rs1800796-(G)-rs1800795-(G)-rs2069830-(C) haplotype
   (RR = 0.78; 95% CI: 0.66-0.94; P = 0.0065) among CAs. Overall, the
   rs1800797-(G)-rs1800796(G)-rs1800795-(G) haplotype was independently
   associated with a reduced chance of SVR (RR 0.78; 95% CI: 0.62-1.0; P =
   0.0489) after adjustment for potential confounding factors. Our
   findings further illustrate the complexity of IL-6 genetic regulation
   and the potential importance of haplotypes on IL-6 expression. Our
   findings provide additional support for the potential importance of
   genetic variation in the IL-6 gene and the response to HCV therapy.
   Genes and Immunity (2009) 10, 365-372; doi:10.1038/gene.2009.26;
   published online 23 April 2009
C1 [Yee, L. J.; Im, K.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Im, K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Borg, B.; Liang, T. J.] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA.
   [Yang, H.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
RP Yee, LJ, Univ Pittsburgh, Dept Epidemiol, A511 Crabtree Hall,
   Pittsburgh, PA 15261 USA.
EM YeeL@edc.pitt.edu
   JakeL@bdg10.niddk.nih.gov
FU National Center on Minority Health and Health Disparities (NCMHD) [U01
   DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01
   DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01
   DK60346, U01 DK60349, U01 DK60341]; NIDDKNational Center for Research
   Resources (NCRR) ; NIH ; Center for Cancer Research ; New York
   Presbyterian [M01 RR00645]; University of California, San Francisco
   [M02 RR000079]; University of Maryland [M01 RR16500]; University of
   Michigan [M01 RR000042]; University of North Carolina [M01 RR00046];
   National Institutes of Health Clinical Research Career Development
   [1KL2 RR024154-02]
FX This clinical study was a co-operative agreement funded by the NIDDK
   and co-funded by the National Center on Minority Health and Health
   Disparities (NCMHD), with a Co-operative Research and Development
   Agreement (CRADA) with Roche Laboratories Inc., Grant numbers: U01
   DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01
   DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01
   DK60346, U01 DK60349 and U01 DK60341. Other support: National Center
   for Research Resources (NCRR), Intramural Research Program of the NIH,
   NIDDK, Center for Cancer Research, General Clinical Research Centers
   Program Grants: M01 RR00645 (New York Presbyterian), M02 RR000079
   (University of California, San Francisco), M01 RR16500 (University of
   Maryland), M01 RR000042 (University of Michigan) and M01 RR00046
   (University of North Carolina). In addition support for Dr Leland J Yee
   was provided by a National Institutes of Health Clinical Research
   Career Development Award Grant (1KL2 RR024154-02).
CR ARMSTRONG GL, 2006, ANN INTERN MED, V144, P705
   BROWN RS, 2005, NATURE, V436, P973, DOI 10.1038/nature04083
   CONJEEVARAM HS, 2006, GASTROENTEROLOGY, V131, P470, DOI
   10.1053/j.gastro.2006.06.008
   FISHMAN D, 1998, J CLIN INVEST, V102, P1369
   FRIED MW, 2002, HEPATOLOGY S1, V36, S237, DOI 10.1053/jhep.2002.36810
   HUANG Y, 2007, GASTROENTEROLOGY, V132, P733, DOI
   10.1053/j.gastro.2006.11.045
   ISHAK K, 1995, J HEPATOL, V22, P696
   JEFFERS LJ, 2004, HEPATOLOGY, V39, P1702, DOI 10.1002/hep.20212
   MANNS MP, 2001, LANCET, V358, P958
   MATHIAS RA, 2006, BMC GENET, V7, ARTN 38
   MUIR AJ, 2004, NEW ENGL J MED, V350, P2265
   NATTERMANN J, 2007, HEPATOLOGY, V46, P1016, DOI 10.1002/hep.21778
   PRITCHARD JK, 2000, AM J HUM GENET, V67, P170
   PRITCHARD JK, 2000, GENETICS, V155, P945
   RAMADORI G, 1999, SEMIN LIVER DIS, V19, P141
   TERRY CF, 2000, J BIOL CHEM, V275, P18138
   YEE LJ, 2007, HEPATOLOGY, V46, P74, DOI 10.1002/hep.21636
   ZOU GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 18
TC 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2009
VL 10
IS 4
BP 365
EP 372
DI 10.1038/gene.2009.26
PG 8
SC Genetics & Heredity; Immunology
GA 452UO
UT ISI:000266566900009
ER

PT J
AU Xu, HM
   Wang, WC
   Li, CL
   Yu, HY
   Yang, AC
   Wang, BB
   Jin, Y
AF Xu, Huiming
   Wang, Weicheng
   Li, Chunliang
   Yu, Hongyao
   Yang, Acong
   Wang, Beibei
   Jin, Ying
TI WWP2 promotes degradation of transcription factor OCT4 in human
   embryonic stem cells
SO CELL RESEARCH
LA English
DT Article
DE transcription factor OCT4; WWP2; protein degradation; embryonic stem
   cells
ID DOMAIN-CONTAINING PROTEINS; UBIQUITIN LIGASE; HUMAN BLASTOCYSTS; RNA
   INTERFERENCE; MAMMALIAN EMBRYO; GENE-EXPRESSION; DIFFERENTIATION;
   IDENTIFICATION; UBIQUITYLATION; PLURIPOTENCY
AB POU transcription factor OCT4 not only plays an essential role in
   maintaining the pluripotent and self-renewing state of embryonic stem
   (ES) cells but also acts as a cell fate determinant through a gene
   dosage effect. However, the molecular mechanisms that control the
   intracellular OCT4 protein level remain elusive. Here, we report that
   human WWP2, an E3 ubiquitin (Ub)-protein ligase, interacts with OCT4
   specifically through its WW domain and enhances Ub modification of OCT4
   both in vitro and in vivo. We first demonstrated that endogenous OCT4
   in human ES cells can be post-translationally modified by Ub.
   Furthermore, we found that WWP2 promoted degradation of OCT4 through
   the 26S proteasome in a dosage-dependent manner, and the active site
   cysteine residue of WWP2 was required for both its enzymatic activity
   and proteolytic effect on OCT4. Remarkably, our data show that the
   endogenous OCT4 protein level was significantly elevated when WWP2
   expression was downregulated by specific RNA interference (RNAi),
   suggesting that WWP2 is an important regulator for maintaining a proper
   OCT4 protein level in human ES cells. Moreover, northern blot analysis
   showed that the WWP2 transcript was widely present in diverse human
   tissues/organs and highly expressed in undifferentiated human ES cells.
   However, its expression level was quickly decreased after human ES
   cells differentiated, indicating that WWP2 expression might be
   developmentally regulated. Our findings demonstrate that WWP2 is an
   important regulator of the OCT4 protein level in human ES cells.
C1 [Xu, Huiming; Wang, Weicheng; Yang, Acong; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Shanghai Stem Cell Inst, Shanghai 200025, Peoples R China.
   [Xu, Huiming; Wang, Weicheng; Li, Chunliang; Yu, Hongyao; Yang, Acong; Wang, Beibei; Jin, Ying] Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med,Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, Shanghai 200031, Peoples R China.
   [Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Shanghai 200025, Peoples R China.
RP Jin, Y, Shanghai Jiao Tong Univ, Sch Med, Shanghai Stem Cell Inst, 225
   S Chongqing Rd, Shanghai 200025, Peoples R China.
EM yjin@sibs.ac.cn
FU National High Technology Research and Development Program of China
   [2006CB943900]; National Natural Science Foundation of China
   [30500088]; Shanghai Jiao Tong University School of Medicine ; Shanghai
   Institutes for Biological Sciences, Chinese Academy of Sciences ;
   Shanghai Leading Academic Deciline [S30201]
FX We are grateful to Dr DA Melton (Harvard University) for sharing his
   human ES cells with us. The study was supported by grants from the
   National High Technology Research and Development Program of China
   (2006CB943900), the National Natural Science Foundation of China
   (General Program, 30500088), the Shanghai Jiao Tong University School
   of Medicine, and the Shanghai Institutes for Biological Sciences,
   Chinese Academy of Sciences. The study was also supported by the
   Shanghai Leading Academic Deciline Project (S30201).
CR ATLASI Y, 2007, INT J CANCER, V120, P1598, DOI 10.1002/ijc.22508
   BOIANI M, 2002, GENE DEV, V16, P1209
   CIECHANOVER A, 1998, EMBO J, V17, P7151
   CONAWAY RC, 2002, SCIENCE, V296, P1254
   COWAN CA, 2004, NEW ENGL J MED, V350, P1353
   DONOVAN PJ, 2001, NAT GENET, V29, P246
   FLORES SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI
   10.1007/s00424-003-1027-x
   GIDEKEL S, 2003, CANCER CELL, V4, P361
   GINIS I, 2004, DEV BIOL, V269, P360, DOI 10.1016/j.ydbio.2003.12.034
   GROPP M, 2003, MOL THER, V7, P281, DOI 10.1016/S1525-0016(02)00047-3
   HANSIS C, 2000, MOL HUM REPROD, V6, P999
   HARVEY KF, 1999, TRENDS CELL BIOL, V9, P166
   HAY DC, 2004, STEM CELLS, V22, P225
   HORROCKS GA, 2003, BIOCHEM BIOPH RES CO, V304, P411, DOI
   10.1016/S0006-291X(03)00611-9
   HUANG L, 1999, SCIENCE, V286, P1321
   HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563
   HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249
   JOAZEIRO CAP, 2000, CELL, V102, P549
   JOSEPHSON R, 2007, STEM CELLS, V25, P437, DOI
   10.1634/stemcells.2006-0236
   KATO Y, 2004, J BIOL CHEM, V279, P31833, DOI 10.1074/jbc.M404719200
   MAYER RJ, 2000, NAT REV MOL CELL BIO, V1, P145
   MCDONALD FJ, 2002, AM J PHYSIOL-RENAL, V283, F431, DOI
   10.1152/ajprenal.00080.2002
   MURILLAS R, 2002, J BIOL CHEM, V277, P2897
   NAUJOKAT C, 2002, LAB INVEST, V82, P965, DOI
   10.1097/01.LAB.0000022226.23741.37
   NICHOLS J, 1998, CELL, V95, P379
   NIWA H, 2000, NAT GENET, V24, P372
   NIWA H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   OKAMOTO K, 1990, CELL, V60, P461
   PIROZZI G, 1997, J BIOL CHEM, V272, P14611
   PRZYBORSKI SA, 2004, STEM CELLS DEV, V13, P400
   ROCHE S, 2007, J CELL BIOCHEM, V101, P271, DOI 10.1002/jcb.21185
   ROSNER MH, 1990, NATURE, V345, P686
   RUBINSON DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   SCHOLER HR, 1990, EMBO J, V9, P2185
   SINAWAT S, 2007, J MED ASSOC THAILAND, V90, P1253
   SUN BW, 2006, HUM MOL GENET, V15, P65, DOI 10.1093/hmg/ddi427
   SUO GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI
   10.1016/j.bbrc.2005.09.157
   THOMSON JA, 1998, SCIENCE, V282, P1147
   TROSKO JE, 2006, ANN NY ACAD SCI, V1089, P36, DOI
   10.1196/annals.1386.018
   VANDEWETERING M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865
   WEISSMAN AM, 2001, NAT REV MOL CELL BIO, V2, P169
   WOOD JD, 1998, MOL CELL NEUROSCI, V11, P149
   XU HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200
   ZAEHRES H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252
   ZANGROSSI S, 2007, STEM CELLS, V25, P1675, DOI
   10.1634/stemcells.2006-0611
NR 45
TC 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD MAY
PY 2009
VL 19
IS 5
BP 561
EP 573
DI 10.1038/cr.2009.31
PG 13
SC Cell Biology
GA 452GG
UT ISI:000266527600006
ER

PT J
AU Wang, LP
   Yin, HF
   Qian, Q
   Yang, J
   Huang, CF
   Hu, XH
   Luo, D
AF Wang, Liping
   Yin, Hengfu
   Qian, Qian
   Yang, Jun
   Huang, Chaofeng
   Hu, Xiaohe
   Luo, Da
TI NECK LEAF 1, a GATA type transcription factor, modulates organogenesis
   by regulating the expression of multiple regulatory genes during
   reproductive development in rice
SO CELL RESEARCH
LA English
DT Article
DE elongation of upper internodes; organogenesis; panicle development;
   phase transition; NECK LEAF 1; GATA-like transcription factor
ID PHASE-CHANGE; CYTOCHROME-P450 MONOOXYGENASE; INTERNODE ELONGATION;
   PLANT ARCHITECTURE; FLOWER DEVELOPMENT; LEAF INITIATION; ARABIDOPSIS;
   MUTANT; PLASTOCHRON1; HOMOLOG
AB In the monocot rice species Oryza sativa L., one of the most striking
   morphological processes during reproductive development is the
   concurrence of panicle development with the sequential elongation of
   upper internodes (UPIs). To elucidate the underlying molecular
   mechanisms, we cloned the rice gene NECK LEAF 1 (NL1), which when
   mutated results in delays in flowering time, smaller panicles with
   overgrown bracts and abnormal UPI elongation patterns. The NL1 gene
   encodes a GATA-type transcription factor with a single zinc finger
   domain, and its transcripts are detected predominantly in the bract
   primordia, which normally degenerate in the wild-type plants.
   Overexpression of NL1 in transgenic plants often gives rise to severe
   growth retardation, less vegetative phytomers and smaller leaves,
   suggesting that NL1 plays an important role in organ differentiation. A
   novel mutant allele of PLASTOCHRON1 (PLA1), a gene known to play a key
   role in regulating leaf initiation, was identified in this study.
   Genetic analysis demonstrated an interaction between nl1 and pla1, with
   NL1 acting upstream of PLA1. The expression level and spatial pattern
   of PLA1 were found to be altered in the nl1 mutant. Furthermore, the
   expression of two regulators of flowering, Hd3a and OsMADS1, was also
   affected in the nl1 mutant. On the basis of these findings, we propose
   that NL1 is an intrinsic factor that modulates and coordinates
   organogenesis through regulating the expression of PLA1 and other
   regulatory genes during reproductive development in rice.
C1 [Wang, Liping; Yin, Hengfu; Yang, Jun; Huang, Chaofeng; Hu, Xiaohe; Luo, Da] Chinese Acad Sci, Grad Sch, Natl Key Lab Plant Mol Genet, Inst Plant Physiol & Ecol,Shanghai Inst Biol Sci, Shanghai 200032, Peoples R China.
   [Qian, Qian] Chinese Acad Agr Sci, China Natl Rice Res Inst, Hangzhou 310006, Zhejiang, Peoples R China.
RP Luo, D, Chinese Acad Sci, Grad Sch, Natl Key Lab Plant Mol Genet, Inst
   Plant Physiol & Ecol,Shanghai Inst Biol Sci, Shanghai 200032, Peoples R
   China.
EM dluo@sibs.ac.cn
FU Ministry of Science and Technology of China [2006AA10A102]
FX We thank Dr Hongxuan Lin at the Institute of Plant Physiology and
   Ecology for the kind support on NL1 mapping. We are grateful to Shuping
   Xu (Institute of Plant Physiology and Ecology, Chinese Academy of
   Sciences) and Meixian Yan (China National Rice Research Institute) for
   the help of transgenic work, and we acknowledge financial support of
   National High-Tech Projects from the Ministry of Science and Technology
   of China (grant number: 2006AA10A102).
CR AGRAWAL G, 2005, PLANT MOL BIOL, V59, P125, DOI
   10.1007/s11103-005-2161-y
   AHN O, 2002, THEOR APPL GENET, V105, P654
   ASAI K, 2002, DEVELOPMENT, V129, P265
   CHUNG YY, 1994, PLANT MOL BIOL, V26, P657
   COEN ES, 1990, CELL, V63, P1311
   DOI K, 2004, GENE DEV, V18, P926, DOI 10.1101/gad.1189604
   HAYAMA R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549
   HERR JM, 1982, STAIN TECHNOL, V57, P161
   HONG Z, 2003, PLANT CELL, V15, P2900, DOI 10.1105/tpc.014712
   HONG Z, 2005, PLANT CELL, V17, P2243, DOI 10.1105/tpc.105.030973
   HOSHIKAWA K, 1989, GROWING RICE PLANT A
   ITOH J, 2005, PLANT CELL PHYSIOL, V46, P23, DOI 10.1093/pcp/pci501
   ITOH JI, 1998, PLANT CELL, V10, P1511
   JEONG MJ, 2003, BIOCHEM BIOPH RES CO, V300, P555, DOI
   10.1016/S0006-291X(02)02892-9
   KAWAKATSU T, 2006, PLANT CELL, V18, P612, DOI 10.1105/tpc.105.037622
   KIKUCHI K, 2003, NATURE, V421, P167, DOI 10.1038/nature01218
   LEE SY, 2004, PLANT J, V38, P754, DOI 10.1111/j.1365-313X.2004.02082.x
   LUO AD, 2006, PLANT CELL PHYSIOL, V47, P181, DOI 10.1093/pcp/pci233
   MIYOSHI K, 2004, P NATL ACAD SCI USA, V101, P875, DOI
   10.1073/pnas.2636936100
   NAGAO S, 1963, J FAC AGR HOKKAIDO U, V53, P72
   POETHIG RS, 1990, SCIENCE, V250, P923
   POETHIG RS, 2003, SCIENCE, V301, P334
   REYES JC, 2004, PLANT PHYSIOL, V134, P1718, DOI 10.1104/pp.103.037788
   SAKAMOTO T, 2004, PLANT PHYSIOL, V134, P1642, DOI 10.1104/pp.103.033696
   SASAKI A, 2002, NATURE, V416, P701
   SATO Y, 1999, EMBO J, V18, P992
   SUSSEX IM, 2001, CURR OPIN PLANT BIOL, V4, P33
   TAKEDA K, 1977, GAMMA FIELD S, V16, P1
   TANABE S, 2005, PLANT CELL, V17, P776, DOI 10.1105/tpc.104.024950
   TEAKLE GR, 1998, TRENDS BIOCHEM SCI, V23, P100
   TEAKLE GR, 2002, PLANT MOL BIOL, V50, P43
   WANG YH, 2005, PLANT MOL BIOL, V59, P75, DOI 10.1007/s11103-004-4038-x
   YAMAMURO C, 2000, PLANT CELL, V12, P1591
   YANO M, 2000, PLANT CELL, V12, P2473
   ZENG DL, 2003, ACTA BOT SIN, V45, P1116
   ZHAO YX, 2004, PLANT CELL, V16, P2586, DOI 10.1105/tpc.104.024869
   ZHU YY, 2006, PLANT CELL, V18, P442, DOI 10.1105/tpc.105.038455
NR 37
TC 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD MAY
PY 2009
VL 19
IS 5
BP 598
EP 611
DI 10.1038/cr.2009.36
PG 14
SC Cell Biology
GA 452GG
UT ISI:000266527600009
ER

PT J
AU Li, XQ
   Yang, XM
   Xu, YL
   Jiang, XJ
   Li, X
   Nan, FJ
   Tang, H
AF Li, Xiaoqi
   Yang, Xuanming
   Xu, Youli
   Jiang, Xuejun
   Li, Xin
   Nan, Fajun
   Tang, Hong
TI Troglitazone inhibits cell proliferation by attenuation of epidermal
   growth factor receptor signaling independent of peroxisome
   proliferator-activated receptor gamma
SO CELL RESEARCH
LA English
DT Article
DE EGFR; PPAR gamma; troglitazone; endocytosis; growth arrest
ID BREAST-CANCER CELLS; PPAR-GAMMA; ENDOTHELIAL-CELLS; PROTEIN-KINASE;
   IN-VITRO; PROSTATE-CANCER; LUNG-CANCER; APOPTOSIS; ENDOCYTOSIS; LIGAND
AB Peroxisome proliferator-activated receptors (PPAR) belong to the
   nuclear hormone receptor superfamily of ligand-dependent transcription
   factors. Recent results have shown that agonists of PPAR gamma, such as
   troglitazone (TGZ), can inhibit cell proliferation and promote cell
   differentiation independent of PPAR gamma. In the present study, we
   provide evidence that TGZ may bind directly to EGFR and trigger its
   signaling and internalization independent of PPAR gamma. Detailed
   studies revealed that prolonged incubation with TGZ effectively
   attenuated EGFR signaling by targeting the receptor to the
   endo-lysosomal degradation machinery. Although the extracellular
   signal-regulated kinase-signaling pathway was transiently activated by
   TGZ in EGFR overexpressing cancer cells, inhibition of EGF-induced Akt
   phosphorylation most likely accounted for the growth arrest of tumor
   cells caused by TGZ at pharmacologically achievable concentrations.
   Therefore, we have provided a new line of evidence indicating that TGZ
   inhibits cell proliferation by promoting EGFR degradation and
   attenuating Akt phosphorylation.
C1 [Li, Xiaoqi; Yang, Xuanming; Xu, Youli; Tang, Hong] Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Beijing 100101, Peoples R China.
   [Li, Xiaoqi; Yang, Xuanming; Xu, Youli; Tang, Hong] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Li, Xin; Nan, Fajun] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Jiang, Xuejun] Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China.
RP Tang, H, Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Beijing
   100101, Peoples R China.
EM tanghong@moon.ibp.ac.cn
FU Ministry of Science and Technology, China [2007DFC30190]; Chinese
   Academy of Sciences [kscx-1-YW-10]
FX We thank Dr Yongfeng Shang (Beijing University, Health Science Center)
   for the PPAR gamma. reporter plasmid and Dr Youyong Lu (Beijing
   University, School of Oncology) for Du145 cells. We especially thank Mr
   Chunchun Liu of Institute of Biophysics, Chinese Academy of Sciences
   for expert technical assistance. This work was supported in part by
   grants to Hong Tang from the National Basic Research Program of the
   Ministry of Science and Technology, China (2007DFC30190) and Chinese
   Academy of Sciences (kscx-1-YW-10).
CR AKASAKI Y, 2006, J BIOL CHEM, V281, P6165, DOI 10.1074/jbc.M505266200
   BAEK SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200
   BERGER J, 2002, ANNU REV MED, V53, P409
   CALNEK DS, 2003, ARTERIOSCL THROM VAS, V23, P52, DOI
   10.1161/01.ATV.0000044461.01844.C9
   CHAFFER CL, 2006, BMC CANCER, V6, ARTN 53
   CHEN JJ, 2007, ARTERIOSCL THROM VAS, V27, P2005, DOI
   10.1161/ATVBAHA.107.145961
   CHEN YL, 2006, BIOCHEM BIOPH RES CO, V345, P106, DOI
   10.1016/j.bbrc.2006.04.034
   DANKORT D, 2001, MOL CELL BIOL, V21, P1540
   DEMETRI GD, 1999, P NATL ACAD SCI USA, V96, P3951
   DREYER C, 1992, CELL, V68, P879
   ELSTNER E, 1998, P NATL ACAD SCI USA, V95, P8806
   EVANS RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   FEINSTEIN DL, 2005, BIOCHEM PHARMACOL, V70, P177, DOI
   10.1016/j.bcp.2005.03.033
   FISCHER OM, 2003, BIOCHEM SOC T 6, V31, P1203
   GARDNER OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200
   GARDNER OS, 2005, J BIOL CHEM, V280, P10109, DOI 10.1074/jbc.M410445200
   GOETZE S, 2002, BIOCHEM BIOPH RES CO, V293, P1431
   HEDVAT M, 2004, CANCER CELL, V5, P565
   HU ED, 1996, SCIENCE, V274, P2100
   HYNES NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   ICHIKI T, 2004, BIOCHEM BIOPH RES CO, V323, P402, DOI
   10.1016/j.bbrc.2004.08.101
   ISSEMANN I, 1990, NATURE, V347, P645
   JIANG XJ, 2002, MOL BIOL CELL, V13, P1522
   KAMER AR, 2004, INT J MOL MED, V13, P143
   KESHAMOUNI VG, 2004, ONCOGENE, V23, P100, DOI 10.1038/sj.onc.1206885
   KHAN EM, 2006, J BIOL CHEM, V281, P14486
   KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355
   KOEFFLER HP, 2003, CLIN CANCER RES, V9, P1
   KUBOTA T, 1998, CANCER RES, V58, P3344
   LENNON AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200
   LEROY C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571
   LI MY, 2006, J CELL PHYSIOL, V209, P428, DOI 10.1002/jcp.20738
   MANGELSDORF DJ, 1995, CELL, V83, P835
   MOSCATELLO DK, 1995, CANCER RES, V55, P5536
   MOUNHO BJ, 1999, TOXICOL APPL PHARM, V159, P125
   PALAKURTHI SS, 2001, CANCER RES, V61, P6213
   ROKOS CL, 1997, J BIOL CHEM, V272, P13452
   SARRAF P, 1998, NAT MED, V4, P1046
   SHIAU CW, 2005, CANCER RES, V65, P1561
   SIGISMUND S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI
   10.1073/pnas.0409817102
   SORKIN A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883
   SORKINA T, 2002, J BIOL CHEM, V277, P27433
   TARI AM, 1999, ONCOGENE, V18, P1325
   TATIN F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787
   TONTONOZ P, 1994, CELL, V79, P1147
   TONTONOZ P, 1997, P NATL ACAD SCI USA, V94, P237
   WATERMAN H, 2001, FEBS LETT, V490, P142
   WILLSON TM, 2000, J MED CHEM, V43, P527
   YARDEN Y, 2001, NAT REV MOL CELL BIO, V2, P137
   YIN F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.oric.1207598
   ZHAO XR, 2006, CELL BIOL INT, V30, P653, DOI
   10.1016/j.cellbi.2006.04.004
NR 51
TC 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD JUN
PY 2009
VL 19
IS 6
BP 720
EP 732
DI 10.1038/cr.2009.53
PG 13
SC Cell Biology
GA 452GJ
UT ISI:000266528000006
ER

PT J
AU Zhang, J
   Zheng, XD
   Yang, X
   Liao, K
AF Zhang, Jing
   Zheng, Xiudan
   Yang, Xiao
   Liao, Kan
TI CIN85 associates with endosomal membrane and binds phosphatidic acid
SO CELL RESEARCH
LA English
DT Article
DE CIN85; the coiled-coil domain; phosphatidic acid; EGFR endocytosis;
   ESCRT assembly
ID RECEPTOR DOWN-REGULATION; GROWTH-FACTOR RECEPTORS; PHOSPHOLIPASE-D;
   TYROSINE KINASES; MAMMALIAN-CELLS; EGF RECEPTORS; C-CBL; PROTEIN;
   COMPLEX; TRAFFICKING
AB CIN85 (Cbl-interacting protein of 85 kDa) is an important molecule
   involved in receptor tyrosine kinase endocytosis. Here we report that
   through its positively charged C-terminus, CIN85 associates with a
   fusogenic lipid - phosphatidic acid. Its coiled-coil domain plays an
   important role in mediating this protein-lipid interaction. Deletion of
   the coiled-coil domain results in loss of membrane association, and
   reduced interaction with c-cbl, finally causing the blockage of
   epidermal growth factor receptor downregulation. In addition, a
   significant portion of CIN85 is located on the endosomal compartment
   and is related to endocytic cargo sorting, characterized by CIN85's
   localization on the "E class" compartment and EGF degradation blockage
   in CIN85 knockdown cells. Taken together, our results suggest that
   CIN85 may function as a scaffold molecule in both the internalization
   and endocytic cargo sorting processes through its association with the
   endosomal membrane.
C1 [Zhang, Jing; Zheng, Xiudan; Yang, Xiao; Liao, Kan] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.
RP Liao, K, Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol
   Sci, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.
EM kliao@sibs.ac.cn
FU National Nature Sciences Foundation of China [90208007, 30521005,
   30623002]; Ministry of Sciences and Technology of China [2002CB513000,
   2006CB910700]
FX We thank Dr Margo Myers (UCSF, USA) for providing the plasmid of c-Cbl,
   Dr Remy Sadoul (Universite Joseph Fourier, France) for providing the
   plasmids of Alix and truncated forms of Alix, and Dr Uta von Schwedler
   (University of Utah, USA) for providing the plasmids of Vps4 and Vps4
   M, and CHMP4B. This work was supported by grants 90208007, 30521005 and
   30623002 from the National Nature Sciences Foundation of China, and
   grants 2002CB513000 and 2006CB910700 from the Ministry of Sciences and
   Technology of China.
CR BURKHARD P, 2001, TRENDS CELL BIOL, V11, P82
   CORMONT M, 2003, TRAFFIC, V4, P97
   DIFIORE PP, 2001, CELL, V106, P1
   DIKIC I, 2002, FEBS LETT, V529, P110
   DOYOTTE A, 2008, P NATL ACAD SCI USA, V105, P6308
   FUJITA H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213
   GAIDOS G, 2007, J CELL SCI, V120, P2366, DOI 10.1242/jcs.004333
   HAGLUND K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI
   10.1073/pnas.19462299
   HUGHES WE, 2001, BIOCHEM J 3, V356, P727
   HUO HR, 2003, J BIOL CHEM, V278, P11561, DOI 10.1074/jbc.M211785200
   HUTTNER WB, 2000, CURR OPIN NEUROBIOL, V10, P543
   JENKINS GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI
   10.1007/s00018-005-5195-z
   JOZIC D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000
   KATZMANN DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973
   KIRSCH KH, 1999, P NATL ACAD SCI USA, V96, P6211
   KOWANETZ K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200
   KOWANETZ K, 2004, MOL BIOL CELL, V15, P3155
   LIN Y, 2005, J BIOL CHEM, V280, P12799, DOI 10.1074/jbc.M413968200
   LISCOVITCH M, 1996, J LIPID MEDIAT CELL, V14, P215
   MATSUO H, 2004, SCIENCE, V303, P531
   MCDERMOTT M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/003-079
   MOBIUS W, 2003, TRAFFIC, V4, P222
   MORINO C, 2004, EXP CELL RES, V297, P380, DOI
   10.1016/j.yexcr.2004.03.038
   PETRELLI A, 2002, NATURE, V416, P187
   RAIBORG C, 2001, EMBO J, V20, P5008
   RAIBORG C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI
   10.1016/S0955-0674(03)00080-2
   SCHMIDT MHH, 2004, MOL CELL BIOL, V24, P8981, DOI
   10.1128/MCB.24.20.8981-8993.2004
   SHEN YJ, 2001, MOL CELL BIOL, V21, P595
   SIMPSON F, 1999, NAT CELL BIOL, V1, P119
   SOUBEYRAN P, 2002, NATURE, V416, P183
   STACE CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI
   10.1016/j.bbalip.2006.03.006
   SZYMKIEWICZ I, 2002, J BIOL CHEM, V277, P39666, DOI
   10.1074/jbc.M205535200
   SZYMKIEWICZ I, 2004, BIOCHEM J 1, V383, P1, DOI 10.1042/BJ20040913
   TAKE H, 2000, BIOCHEM BIOPH RES CO, V268, P321
   THIEN CBF, 2001, NAT REV MOL CELL BIO, V2, P294
   WELSCH T, 2005, AM J PHYSIOL-RENAL, V289, F1134, DOI
   10.1152/ajprenal.00178.2005
   WHITLEY P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200
   WILLIAMS RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162
   YOSHIMORI T, 2000, MOL BIOL CELL, V11, P747
   ZHAO C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594
NR 40
TC 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD JUN
PY 2009
VL 19
IS 6
BP 733
EP 746
DI 10.1038/cr.2009.51
PG 14
SC Cell Biology
GA 452GJ
UT ISI:000266528000007
ER

PT J
AU Xu, HM
   Wang, WC
   Li, CL
   Yu, HY
   Yang, AC
   Wang, BB
   Jin, Y
AF Xu, Huiming
   Wang, Weicheng
   Li, Chunliang
   Yu, Hongyao
   Yang, Acong
   Wang, Beibei
   Jin, Ying
TI WWP2 promotes degradation of transcription factor OCT4 in human
   embryonic stem cells (vol 19, pg 561, 2009)
SO CELL RESEARCH
LA English
DT Correction
C1 [Xu, Huiming; Wang, Weicheng; Yu, Hongyao; Yang, Acong; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China.
   [Xu, Huiming; Wang, Weicheng; Yu, Hongyao; Yang, Acong; Jin, Ying] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China.
   [Xu, Huiming; Wang, Weicheng; Li, Chunliang; Yang, Acong; Wang, Beibei; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Shanghai Stem Cell Inst, Shanghai 200025, Peoples R China.
   [Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ, Shanghai 200025, Peoples R China.
RP Xu, HM, Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem
   Cell Biol, 225 S Chongqing Rd, Shanghai 200025, Peoples R China.
CR XU HM, 2009, CELL RES, V19, P561, DOI 10.1038/cr.2009.31
NR 1
TC 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD JUN
PY 2009
VL 19
IS 6
BP 796
EP 796
DI 10.1038/cr.2009.63
PG 1
SC Cell Biology
GA 452GJ
UT ISI:000266528000013
ER

PT J
AU Sha, HB
   He, Y
   Chen, H
   Wang, C
   Zenno, A
   Shi, H
   Yang, XY
   Zhang, XM
   Qi, L
AF Sha, Haibo
   He, Yin
   Chen, Hui
   Wang, Cindy
   Zenno, Anna
   Shi, Hang
   Yang, Xiaoyong
   Zhang, Xinmin
   Qi, Ling
TI The IRE1 alpha-XBP1 Pathway of the Unfolded Protein Response Is
   Required for Adipogenesis
SO CELL METABOLISM
LA English
DT Article
ID PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR XBP-1;
   ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; KINASE-ACTIVITY;
   PPAR-GAMMA; BINDING; IRE1; REVEALS; BIOLOGY
AB Signaling cascades during adipogenesis culminate in the expression of
   two essential adipogenic factors, PPAR gamma and C/EBP alpha. Here we
   demonstrate that the IRE1 alpha-XBP1 pathway, the most conserved branch
   of the unfolded protein response (UPR), is indispensable for
   adipogenesis. Indeed, XBP1-deficient mouse embryonic fibroblasts and
   3T3-L1 cells with XBP1 or IRE1 alpha knockdown exhibit profound defects
   in adipogenesis. Intriguingly, C/EBP beta, a key early adipogenic
   factor, induces Xbp1 expression by directly binding to its proximal
   promoter region. Subsequently, XBP1 binds to the promoter of Cebpa and
   activates its gene expression. The posttranscriptional splicing of Xbp1
   mRNA by IRE1 alpha is required as only the spliced form of XBP1 (XBP1s)
   rescues the adipogenic defect exhibited by XBP1-deficient cells. Taken
   together, our data show that the IRE1 alpha-XBP1 pathway plays a key
   role in adipocyte differentiation by acting as a critical regulator of
   the morphological and functional transformations during adipogenesis.
C1 [Sha, Haibo; Chen, Hui; Wang, Cindy; Zenno, Anna; Qi, Ling] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
   [Qi, Ling] Cornell Univ, Grad Program Genet & Dev, Ithaca, NY 14853 USA.
   [Shi, Hang] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27157 USA.
   [Yang, Xiaoyong] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06519 USA.
   [Zhang, Xinmin] Roche Nimblegen Inc, Madison, WI 53719 USA.
RP Qi, L, Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
EM lq35@cornell.edu
FU Cornell start-up package ; American Federation for Aging Research
   [RAG08061]; American Diabetes Association (ADA) [7-08-JF-47]; National
   Institutes of Health [R01DK082582]; 2008 Rosalinde and Arthur
   Foundation/American Federation for Aging Research New Investigator
   Award in Alzheimer's Diseases ; ADA Junior Faculty Award ; ADA grant
   [7-08-JF-47]
FX We thank Drs. L. Glimcher, L. Kraus, and J. Pleiss for reagents; Drs.
   K. L. Guan, S. Lee, M. Montminy, and three anonymous reviewers for
   insightful comments and suggestions. The Qi laboratory is supported by
   the Cornell start-up package and grants from American Federation for
   Aging Research (RAG08061), American Diabetes Association (ADA)
   (7-08-JF-47), and National Institutes of Health (R01DK082582). L.Q. is
   the recipient of the 2008 Rosalinde and Arthur Foundation/American
   Federation for Aging Research New Investigator Award in Alzheimer's
   Diseases and the ADA Junior Faculty Award. The study was funded by the
   Cornell start-up package and an ADA grant (7-08-JF-47).
CR ACOSTAALVEAR D, 2007, MOL CELL, V27, P53, DOI
   10.1016/j.molcel.2007.06.011
   BLAIS A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105
   CAO ZD, 1991, GENE DEV, V5, P1538
   CLAUSS IM, 1993, DEV DYNAM, V197, P146
   CLAUSS IM, 1996, NUCLEIC ACIDS RES, V24, P1855
   COX JS, 1993, CELL, V73, P1197
   FARMER SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   GREGOR MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200
   HARDING HP, 2001, MOL CELL, V7, P1153
   IWAKOSHI NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   IWAWAKI T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970
   KAJIMURA S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108
   KINOSHITA E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI
   10.1074/mcp.T500024-MCP200
   KLEIN U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357
   KORENNYKH AV, 2009, NATURE, V457, P687, DOI 10.1038/nature07661
   LEE AH, 2003, MOL CELL BIOL, V23, P7448, DOI
   10.1128/MCB.23.21.7448-7459.2003
   LEE AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903
   LEE AH, 2008, SCIENCE, V320, P1492, DOI 10.1126/science.1158042
   LEE KPK, 2008, CELL, V132, P89, DOI 10.1016/j.cell.2007.10.057
   LEFTEROVA MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008
   MASAKI T, 1999, BIOCHEM BIOPH RES CO, V261, P350
   MORI K, 1993, CELL, V74, P743
   NOVIKOFF AB, 1980, J CELL BIOL, V87, P180
   OSADA S, 1996, J BIOL CHEM, V271, P3891
   PAPA FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031
   QI L, 2009, CELL METAB, V9, P277, DOI 10.1016/j.cmet.2009.01.006
   REIMOLD AM, 2000, GENE DEV, V14, P152
   REIMOLD AM, 2001, NATURE, V412, P300
   RON D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   SHAFFER AL, 2004, IMMUNITY, V21, P81
   TIRASOPHON W, 2000, GENE DEV, V14, P2725
   TONTONOZ P, 2008, ANNU REV BIOCHEM, V77, P289, DOI
   10.1146/annurev.biochem.77.061307.091829
   ZHANG KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848
   ZHOU JH, 2006, P NATL ACAD SCI USA, V103, P14343, DOI
   10.1073/pnas.0606480103
NR 34
TC 24
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD JUN 3
PY 2009
VL 9
IS 6
BP 556
EP 564
DI 10.1016/j.cmet.2009.04.009
PG 9
SC Cell Biology; Endocrinology & Metabolism
GA 453ZU
UT ISI:000266652200010
ER

PT J
AU Dixit, VD
   Yang, HW
   Cooper-Jenkins, A
   Giri, BB
   Patel, K
   Taub, DD
AF Dixit, Vishwa D.
   Yang, Hyunwon
   Cooper-Jenkins, Anthony
   Giri, Banabihari B.
   Patel, Kalpesh
   Taub, Dennis D.
TI Reduction of T cell-derived ghrelin enhances proinflammatory cytokine
   expression: implications for age-associated increases in inflammation
SO BLOOD
LA English
DT Article
ID SECRETAGOGUE RECEPTOR; LEPTIN; PROLIFERATION; ACTIVATION; SECRETION
AB Ghrelin (Grln) is a peptide hormone that is predominantly produced in
   the stomach and stimulates appetite and induces growth hormone (GH)
   release. We have previously reported that ghrelin is also expressed in
   T cells and exerts prothymic and anti-inflammatory effects. However,
   the biologic relevance of T cell-derived ghrelin remains to be
   determined. Here, we report that acylated-bioactive ghrelin is
   expressed in human T cells and preferentially segregates within the
   lipid raft domains upon TCR ligation. The RNA interference
   (RNAi)-mediated down-regulation of ghrelin in primary human T cells
   activates IkB, and increases Th1 cytokines and IL-17 secretion. Ghrelin
   expression declines with increasing age in spleen and T cells and
   exogenous ghrelin administration in old mice reduces proinflammatory
   cytokines. These findings demonstrate that ghrelin functions in an
   autocrine and paracrine capacity to regulate proinflammatory cytokine
   expression in human and murine T cells and may contribute in regulating
   "inflamm-aging." (Blood. 2009; 113: 5202-5205)
C1 [Taub, Dennis D.] NIA, Clin Immunol Sect, Immunol Lab, Intramural Res Program,NIH, Baltimore, MD 21224 USA.
RP Taub, DD, NIA, Clin Immunol Sect, Immunol Lab, Intramural Res
   Program,NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.
EM taubd@grc.nia.nih.gov
FU NIA, National Institutes of Health 
FX This research was entirely supported by the Intramural Research Program
   of the NIA, National Institutes of Health.
CR BESEDOVSKY HO, 1996, ENDOCR REV, V17, P64
   DEROSA V, 2006, J CLIN INVEST, V116, P447, DOI 10.1172/JCI26523
   DEROSA V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011
   DIXIT VD, 2003, ENDOCRINOLOGY, V144, P5595, DOI 10.1210/en.2003-0600
   DIXIT VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JC1200421134
   DIXIT VD, 2006, J BIOL CHEM, V281, P16681
   DIXIT VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248
   FRIEDMAN JM, 1998, NATURE, V395, P763
   GIRI B, 2007, EUR J IMMUNOL, V37, P2104, DOI 10.1002/eji200636680
   GNANAPAVAN S, 2002, J CLIN ENDOCR METAB, V87, P2988
   GONZALEZREY E, 2006, GASTROENTEROLOGY, V130, P1707, DOI
   10.1053/j.gastro.2006.01.041
   GRANADO M, 2005, AM J PHYSIOL-ENDOC M, V288, P486
   HATTORI N, 2001, J CLIN ENDOCR METAB, V86, P4284
   HOFFMANN A, 2006, IMMUNOL REV, V210, P171
   HOSODA H, 2003, J BIOL CHEM, V278, P64, DOI 10.1074/jbc.M205366200
   KOJIMA M, 1999, NATURE, V402, P656
   LI WG, 2004, CIRCULATION, V109, P2221, DOI
   10.1161/01.CIR.0000127956.43874.F2
   MCCABE JB, 2001, MOL BIOL CELL, V12, P3601
   NAKAZATO M, 2001, NATURE, V409, P194
   XIA Q, 2004, REGUL PEPTIDES, V122, P173, DOI
   10.1016/j.regpep.2004.06.016
   YANG H, 2007, PEPTIDES, V28, P1931, DOI 10.1016/j.peptides.2007.07.030
NR 21
TC 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 21
PY 2009
VL 113
IS 21
BP 5202
EP 5205
DI 10.1182/blood-2008-09-181255
PG 4
SC Hematology
GA 450ML
UT ISI:000266404500026
ER

PT J
AU Banno, F
   Chauhan, AK
   Kokame, K
   Yang, J
   Miyata, S
   Wagner, DD
   Miyata, T
AF Banno, Fumiaki
   Chauhan, Anil K.
   Kokame, Koichi
   Yang, Jin
   Miyata, Shigeki
   Wagner, Denisa D.
   Miyata, Toshiyuki
TI The distal carboxyl-terminal domains of ADAMTS13 are required for
   regulation of in vivo thrombus formation
SO BLOOD
LA English
DT Article
ID VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IB-ALPHA; THROMBOCYTOPENIC PURPURA;
   ADAMTS13-DEFICIENT MICE; PLATELET-AGGREGATION; FLOW CONDITIONS; MOUSE
   MODEL; CLEAVAGE; DEFICIENCY; SUBSTRATE
AB ADAMTS13 is a multidomain protease that limits platelet thrombogenesis
   through the cleavage of von Willebrand factor (VWF). We previously
   identified 2 types of mouse Adamts13 gene: the 129/Sv-strain Adamts13
   gene encodes the long-form ADAMTS13 having the same domains as human
   ADAMTS13, whereas the C57BL/6-strain Adamts13 gene encodes the
   short-form ADAMTS13 lacking the distal C-terminal domains. To assess
   the physiologic significance of the distal C-terminal domains of
   ADAMTS13, we generated and analyzed 129/Sv-genetic background congenic
   mice (Adamts13(S/S)) that carry the short-form ADAMTS13. Similar to
   wild-type 129/Sv mice (Adamts13(L/L)), Adamts13S/S did not have
   ultralarge VWF multimers in plasma, in contrast to 129/Sv-genetic
   background ADAMTS13-deficient mice (Adamts13(-/-)). However, in vitro
   thrombogenesis under flow at a shear rate of 5000 s(-1) was accelerated
   in Adamts13(S/S) compared with Adamts13(L/L). Both in vivo thrombus
   formation in ferric chloride-injured arterioles and thrombocytopenia
   induced by collagen plus epinephrine challenge were more dramatic in
   Adamts13(S/S) than in Adamts13(L/L) but less than in Adamts13(-/-).
   These results suggested that the C-terminally truncated ADAMTS13
   exhibited decreased activity in the cleavage of VWF under high shear
   rate. Role of the C-terminal domains may become increasingly important
   under prothrombotic conditions. (Blood. 2009; 113: 5323-5329)
C1 [Banno, Fumiaki; Kokame, Koichi; Yang, Jin; Miyata, Toshiyuki] Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan.
   [Chauhan, Anil K.; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Chauhan, Anil K.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
   [Miyata, Shigeki] Natl Cardiovasc Ctr, Div Transfus Med, Suita, Osaka 565, Japan.
RP Miyata, T, Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka
   5658565, Japan.
EM miyata@ri.ncvc.go.jp
FU Ministry of Health, Labor, and Welfare of Japan, Tokyo, Japan ;
   Ministry of Education, Culture, Sports, Science, and Technology of
   Japan, Tokyo, Japan ; Japan Society for the Promotion of Science,
   Tokyo, Japan ; Program for Promotion of Fundamental Studies in Health
   Sciences of the National Institute of Biochemical Innovation of Japan,
   Ibaraki, Japan ; Baxter Bioscience, Vienna, Austria ; National Heart,
   Lung, and Blood Institute of the National Institutes of Health
   [P01-HL066105]
FX This work was supported in part by grants-in-aid from the Ministry of
   Health, Labor, and Welfare of Japan, Tokyo, Japan (T. M.); the Ministry
   of Education, Culture, Sports, Science, and Technology of Japan, Tokyo,
   Japan (F. B., K. K., and T. M.); the Japan Society for the Promotion of
   Science, Tokyo, Japan (K. K. and T. M.); and from the Program for
   Promotion of Fundamental Studies in Health Sciences of the National
   Institute of Biochemical Innovation of Japan, Ibaraki, Japan (T. M.); a
   Sponsored Research Agreement from Baxter Bioscience, Vienna, Austria
   (A. K. C. and D. D. W.) and a National Heart, Lung, and Blood Institute
   of the National Institutes of Health grant P01-HL066105 (D. D. W.).
CR AI JH, 2005, J BIOL CHEM, V280, P29428, DOI 10.1074/jbc.M505513200
   BANNO F, 2004, J BIOL CHEM, V279, P30896, DOI 10.1074/jbc.M314184200
   BANNO F, 2006, BLOOD, V107, P3161, DOI 10.1182/blood-2005-07-2765
   BANNO F, 2008, REC ADV THROMB HEM, P162
   BERGMEIER W, 2008, THROMB HAEMOSTASIS, V99, P264, DOI
   10.1160/TH07-10-0638
   CHAUHAN AK, 2006, J EXP MED, V203, P767, DOI 10.1084/jem.20051732
   CHAUHAN AK, 2008, BLOOD, V111, P3452, DOI 10.1182/blood-2007-08-108571
   CUI JS, 2000, BLOOD, V96, P4222
   DESCH KC, 2007, ARTERIOSCL THROM VAS, V27, P1901, DOI
   10.1161/ATVBAHA.107.145797
   DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57
   DONADELLI R, 2006, BLOOD, V107, P1943
   DONG JF, 2007, CURR OPIN HEMATOL, V14, P270
   FRENETTE PS, 1998, BLOOD, V91, P1318
   GAO WQ, 2006, P NATL ACAD SCI USA, V103, P19099, DOI
   10.1073/pnas.0607264104
   JACKSON SP, 2007, BLOOD, V109, P5087, DOI 10.1182/blood-2007-02-027696
   KOKAME K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861
   KOKAME K, 2005, BRIT J HAEMATOL, V129, P93, DOI
   10.1111/j.1365-2141.2005.05420.x
   KONSTANTINIDES S, 2006, J THROMB HAEMOST, V4, P2014
   MAJERUS EM, 2005, J BIOL CHEM, V280, P21773
   MIYATA T, 2007, CURR OPIN HEMATOL, V14, P277
   MOTTO DG, 2005, J CLIN INVEST, V115, P2752, DOI 10.1172/JCI26007
   NI HY, 2000, J CLIN INVEST, V106, P385
   NISHIO K, 2004, P NATL ACAD SCI USA, V101, P10578
   SHIDA Y, 2008, BLOOD, V111, P1295, DOI 10.1182/blood-2007-09-110700
   SHIM K, 2008, BLOOD, V111, P651, DOI 10.1182/blood-2007-05-093021
   SMYTH SS, 2001, BLOOD, V98, P1055
   SOEJIMA K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908
   SUH TT, 1995, GENE DEV, V9, P2020
   TAO ZY, 2005, BLOOD, V106, P141, DOI 10.1182/blood-2004-11-4188
   TAO ZY, 2005, BLOOD, V106, P4139, DOI 10.1182/blood-2005-05-2029
   TOOMEY JR, 1997, P NATL ACAD SCI USA, V94, P6922
   TSAI HM, 2007, HEMATOL ONCOL CLIN N, V21, P609, DOI
   10.1016/j.c.2007.06.003
   TSUJI S, 1999, BLOOD, V94, P968
   WEILER H, 2001, ARTERIOSCL THROM VAS, V21, P1531
   ZHANG P, 2007, BLOOD, V110, P1887, DOI 10.1182/blood-2007-04-083329
   ZHENG XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200
   ZHENG XL, 2008, ANNU REV PATHOL-MECH, V3, P249, DOI
   10.1146/annurev.pathol.3.121806.154311
   ZHOU WH, 2007, BLOOD, V110, P886, DOI 10.1182/blood-2007-01-070953
NR 38
TC 15
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 21
PY 2009
VL 113
IS 21
BP 5323
EP 5329
DI 10.1182/blood-2008-07-169359
PG 7
SC Hematology
GA 450ML
UT ISI:000266404500040
ER

PT J
AU Horkheimer, I
   Quigley, M
   Zhu, JG
   Huang, XP
   Chao, NJ
   Yang, YP
AF Horkheimer, Ian
   Quigley, Michael
   Zhu, Jiangao
   Huang, Xiaopei
   Chao, Nelson J.
   Yang, Yiping
TI Induction of type I IFN is required for overcoming tumor-specific
   T-cell tolerance after stem cell transplantation
SO BLOOD
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; DENDRITIC CELLS; TRANSGENIC MICE;
   PERIPHERAL TOLERANCE; METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE;
   IMMUNE-RESPONSES; REGULATORY CELLS; CANCER VACCINES; TGF-BETA
AB Tumor-specific T-cell tolerance represents one major mechanism of
   tumor-induced immune evasion. Myeloablative chemotherapy with stem cell
   transplantation may offer the best chance of achieving a state of
   minimal residual disease and, thus, minimize tumor-induced immune
   evasion. However, studies have shown that tumor-specific T-cell
   tolerance persists after transplantation. Here, we showed that
   CD4(+)CD25(+) regulatory T (T-Reg) cells play a critical role in
   tumor-specific CD8(+) T-cell tolerance after trans-plantation. Removal
   of T-Reg cells from the donor lymphocyte graft did not overcome this
   tolerance because of rapid conversion of donor CD4(+)CD25(-) T cells
   into CD4(+)CD25(+)Foxp3(+) T-Reg cells in recipients after
   transplantation, and depletion of T-Reg cells in recipients was
   necessary for the reversal of tumor-specific tolerance. These results
   suggest that strategies capable of overcoming T-cell tolerance in
   recipients are required to promote antitumor immunity after
   transplantation. Toward this goal, we showed that dendritic cell (DC)
   vaccines coadministered with the TLR9 ligand, CpG could effectively
   overcome tumor-specific tolerance, leading to significant prolongation
   of tumor-free survival after transplantation. We further showed that
   CpG-induced type I interferon was critical for the reversal of
   tumor-specific tolerance in vivo. Collectively, these results may
   suggest effective immunotherapeutic strategies for treating cancer
   after stem cell transplantation. (Blood. 2009; 113: 5330-5339)
C1 [Horkheimer, Ian; Zhu, Jiangao; Huang, Xiaopei; Chao, Nelson J.; Yang, Yiping] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Quigley, Michael; Chao, Nelson J.; Yang, Yiping] Duke Univ, Med Ctr, Div Immunol, Durham, NC 27710 USA.
RP Yang, YP, Duke Univ, Med Ctr, Dept Med, Box 103005, Durham, NC 27710
   USA.
EM yang0029@mc.duke.edu
FU National Institutes of Health (Bethesda, MD) [CA111807, CA047741,
   CA136934]; Alliance for Cancer Gene Therapy (Stamford, CT) 
FX This work was supported by grants CA111807 (Y. Y.), CA047741 (N. J.
   C.), and CA136934 (Y. Y.) from the National Institutes of Health
   (Bethesda, MD) and by a grant from the Alliance for Cancer Gene Therapy
   (Stamford, CT; Y. Y.).
CR BACH JF, 2003, NAT REV IMMUNOL, V3, P189, DOI 10.1038/nri1026
   BOGEN B, 1996, EUR J IMMUNOL, V26, P2671
   BORRELLO I, 2000, BLOOD, V95, P3011
   BURKLY LC, 1989, NATURE, V342, P564
   CHEN WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   COLONNA M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141
   CUI Y, 2003, NAT MED, V9, P952, DOI 10.1038/nm882
   CURIEL TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   DELAFAILLE MAC, 2004, J IMMUNOL, V173, P7259
   FINN OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150
   GOLGHER D, 2002, EUR J IMMUNOL, V32, P3267
   GUILLAUME T, 1998, BLOOD, V92, P1471
   HEMMI H, 2000, NATURE, V408, P740
   HUANG XP, 2004, EUR J IMMUNOL, V34, P1351, DOI 10.1002/eji.200324734
   HUANG XP, 2005, J IMMUNOL, V175, P4283
   HUANG XP, 2006, IMMUNOLOGY, V118, P361, DOI
   10.1111/j.1365-2567.2006.02381.x
   HUI K, 1984, NATURE, V311, P750
   IWASAKI A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   JONULEIT H, 2003, J IMMUNOL, V171, P6323
   KORNGOLD R, 1994, TRANSPLANTATION, V58, P278
   LEE PP, 1999, NAT MED, V5, P677
   LIANG S, 2005, J EXP MED, V201, P127, DOI 10.1084/jem.20041201
   MACKALL CL, 1996, J IMMUNOL, V156, P4609
   MIRMONSEF P, 2008, BLOOD, V111, P2112, DOI 10.1182/blood-2007-06-096586
   MORAHAN G, 1991, P NATL ACAD SCI USA, V88, P11421
   MORGAN DJ, 1996, J IMMUNOL, V157, P978
   MORSE MA, 2004, CURR PROB SURG, V41, P15
   MOSER M, 2003, IMMUNITY, V19, P5
   NOVY P, 2007, J IMMUNOL, V179, P8243
   OCHSENBEIN AF, 2001, NATURE, V411, P1058
   OGARRA A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801
   ONIZUKA S, 1999, CANCER RES, V59, P3128
   PARDOLL DM, 1998, NAT MED S, V4, P525
   PARDOLL DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774
   PASARE C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   PHAN GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI
   10.1073/pnas.1533209100
   PULENDRAN B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   QUIGLEY M, 2007, J IMMUNOL, V179, P5768
   RESTIFO NP, 1993, J EXP MED, V177, P265
   RUBINSTEIN S, 1981, J VIROL, V37, P755
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   SAKAGUCHI S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   SHEVACH EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821
   SHIMIZU J, 1999, J IMMUNOL, V163, P5211
   SOMASUNDARAM R, 2002, CANCER RES, V62, P5267
   STAVELEYOCARROLL K, 1998, P NATL ACAD SCI USA, V95, P1178
   SUTMULLER RPM, 2001, J EXP MED, V194, P823
   THEOFILOPOULOS AN, 2005, ANNU REV IMMUNOL, V23, P307
   TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486
   VIGUIER M, 2004, J IMMUNOL, V173, P1444
   VONBOEHMER H, 2003, J EXP MED, V198, P845, DOI 10.1084/jem.20031358
   YANG YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059
   YE XH, 1994, P NATL ACAD SCI USA, V91, P3916
   ZELENAY S, 2005, P NATL ACAD SCI USA, V102, P4091, DOI
   10.1073/pnas.0408679102
   ZHOU G, 2007, J IMMUNOL, V178, P2155
   ZHU JG, 2007, J VIROL, V81, P3170, DOI 10.1128/JVI.02192-06
   ZOU WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806
NR 57
TC 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 21
PY 2009
VL 113
IS 21
BP 5330
EP 5339
DI 10.1182/blood-2008-05-155150
PG 10
SC Hematology
GA 450ML
UT ISI:000266404500041
ER

PT J
AU Kataru, RP
   Jung, K
   Jang, C
   Yang, H
   Schwendener, RA
   Baik, JE
   Han, SH
   Alitalo, K
   Koh, GY
AF Kataru, Raghu P.
   Jung, Keehoon
   Jang, Cholsoon
   Yang, Hanseul
   Schwendener, Reto A.
   Baik, Jung Eun
   Han, Seung Hyun
   Alitalo, Kari
   Koh, Gou Young
TI Critical role of CD11b(+) macrophages and VEGF in inflammatory
   lymphangiogenesis, antigen clearance, and inflammation resolution
SO BLOOD
LA English
DT Article
ID HIGH ENDOTHELIAL VENULES; DRAINING LYMPH-NODES; MONOCYTE RECRUITMENT/;
   LIPOTEICHOIC ACID; TRANSGENIC MICE; IN-VIVO; CELLS; GROWTH; VESSELS;
   EXPRESSION
AB Using a bacterial pathogen-induced acute inflammation model in the
   skin, we defined the roles of local lymphatic vessels and draining
   lymph nodes (DLNs) in antigen clearance and inflammation resolution. At
   the peak day of inflammation, robust expansion of lymphatic vessels and
   profound infiltration of CD11b(+)/Gr-1(+) macrophages into the inflamed
   skin and DLN were observed. Moreover, lymph flow and inflammatory cell
   migration from the inflamed skin to DLNs were enhanced. Concomitantly,
   the expression of lymphangiogenic growth factors such as vascular
   endothelial growth factor C (VEGF-C), VEGF-D, and VEGF-A were
   significantly up-regulated in the inflamed skin, DLNs, and particularly
   in enriched CD11b(+) macrophages from the DLNs. Depletion of
   macrophages, or blockade of VEGF-C/D or VEGF-A, largely attenuated
   these phenomena, and produced notably delayed antigen clearance and
   inflammation resolution. Conversely, keratin 14 (K14)-VEGF-C transgenic
   mice, which have dense and enlarged lymphatic vessels in the skin
   dermis, exhibited accelerated migration of inflammatory cells from the
   inflamed skin to the DLNs and faster antigen clearance and inflammation
   resolution. Taken together, these results indicate that VEGF-C,-D,
   and-A derived from the CD11b(+)/Gr-1(+) macrophages and local inflamed
   tissues play a critical role in promoting antigen clearance and
   inflammation resolution. (Blood. 2009; 113: 5650-5659)
C1 [Kataru, Raghu P.; Jung, Keehoon; Jang, Cholsoon; Yang, Hanseul; Koh, Gou Young] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Kataru, Raghu P.; Jung, Keehoon; Jang, Cholsoon; Yang, Hanseul; Koh, Gou Young] Korea Adv Inst Sci & Technol, Natl Res Lab Vasc Biol, Taejon 305701, South Korea.
   [Schwendener, Reto A.] Univ Zurich, Lab Liposome Res, Inst Mol Canc Res, Zurich, Switzerland.
   [Baik, Jung Eun; Han, Seung Hyun] Seoul Natl Univ, Dept Oral Microbiol & Immunol, Dent Res Inst, Sch & Program Dent BK21, Seoul, South Korea.
   [Han, Seung Hyun] Int Vaccine Inst, Seoul, South Korea.
   [Alitalo, Kari] Univ Helsinki, Biomedicum Helsinki, Lab Mol Canc Biol, Helsinki, Finland.
RP Koh, GY, Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong
   Dong, Taejon 305701, South Korea.
EM gykoh@kaist.ac.kr
FU Korea Science and Engineering Foundation (KOSEF) [2004-02376]; Ministry
   of Science and Technology [20080401034061]
FX This work was supported by the Korea Science and Engineering Foundation
   (KOSEF) through the National Research Laboratory Program (2004-02376,
   G.Y.K.) funded by the Ministry of Science and Technology and BioGreen
   21 Program, Rural Development Administration (20080401034061, S. H.
   H.), Republic of Korea.
CR ALITALO K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   ANGELI V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003
   ANGELI V, 2006, LYMPHAT RES BIOL, V4, P217, DOI 10.1089/lrb.2006.4406
   BALUK P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037
   BALUK P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596
   BELLINGAN GJ, 1996, J IMMUNOL, V157, P2577
   CUENI LN, 2006, J INVEST DERMATOL, V126, P2167, DOI
   10.1038/sj.jid.5700464
   CURSIEFEN C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   DRAYTON DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330
   GOLPON HA, 2004, FASEB J, V18, P1716
   HALIN C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811
   HAMRAH P, 2004, EXP EYE RES, V79, P553, DOI 10.1016/j.exer.2004.06.028
   HAN SH, 2003, INFECT IMMUN, V71, P5541, DOI
   10.1128/IAI.71.10.5541-5548.2003
   HARRELL MI, 2007, AM J PATHOL, V170, P774, DOI
   10.2353/ajpath.2007.060761
   HIRAKAWA S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758
   HOLASH J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI
   10.1073/pnas.172398299
   JANATPOUR MJ, 2001, J EXP MED, V194, P1375
   JELTSCH M, 1997, SCIENCE, V276, P1423
   JEON BH, 2008, CANCER RES, V68, P1100, DOI 10.1158/0008-5472.CAN-07-2572
   JI RC, 2006, LYMPHAT RES BIOL, V4, P83
   JOHNSON LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759
   KERJASCHKI D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI6354
   KERJASCHKI D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340
   KIM HJ, 2007, J LEUKOCYTE BIOL, V81, P983, DOI 10.1189/jlb.0906588
   KOH YJ, 2007, J CLIN INVEST, V117, P3684, DOI 10.1172/JCI32504
   LAWRENCE T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915
   LAWRENCE T, 2007, INT J EXP PATHOL, V88, P85, DOI
   10.1111/j.1365-2613.2006.00507.x
   LIAO S, 2006, J IMMUNOL, V177, P3369
   MAKINEN T, 2001, NAT MED, V7, P199
   MARUYAMA K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874
   MARUYAMA K, 2007, AM J PATHOL, V170, P1178, DOI
   10.2353/ajpath.2007.060018
   MULLER WA, 2001, J EXP MED, V194, F47
   NAGY JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   NOLAN A, 2004, INFLAMMATION, V28, P271, DOI 10.1007/s10753-004-6050-3
   OKABE M, 1997, FEBS LETT, V407, P313
   OLIVER G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI
   10.1146/annurev.cellbio.21.012704.132338
   PALFRAMAN RT, 2001, J EXP MED, V194, P1361
   PULLINGER BD, 1937, J PATHOL BACTERIOL, V45, P157
   RANDOLPH GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670
   SAARISTO A, 2004, FASEB J, V18, P1707
   SCHLEDZEWSKI K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942
   SERHAN CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   SERHAN CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev
   TAMMELA T, 2005, TRENDS CELL BIOL, V15, P434, DOI
   10.1016/j.tcb.2005.06.004
   TOBLER NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653
   VONANDRIAN UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222
   XIA YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793
   ZEISBERGER SM, 2006, BRIT J CANCER, V95, P272, DOI
   10.1038/sj.bjc.6603240
   ZHANG X, 2008, J PATHOL, V214, P161, DOI 10.1002/path.2284
NR 49
TC 28
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 28
PY 2009
VL 113
IS 22
BP 5650
EP 5659
DI 10.1182/blood-2008-09-176776
PG 10
SC Hematology
GA 453TD
UT ISI:000266634700038
ER

PT J
AU Punj, V
   Matta, H
   Schamus, S
   Yang, TB
   Chang, Y
   Chaudhary, PM
AF Punj, Vasu
   Matta, Hittu
   Schamus, Sandra
   Yang, Tianbing
   Chang, Yuan
   Chaudhary, Preet M.
TI Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus:
   role of viral FLICE inhibitory protein K13-induced NF-kappa B activation
SO BLOOD
LA English
DT Article
ID MICROVASCULAR ENDOTHELIAL-CELLS; PRIMARY EFFUSION LYMPHOMA;
   GENE-EXPRESSION; HUMAN-HERPESVIRUS-8 INFECTION; INDUCED APOPTOSIS;
   CHEMOKINE LARC; KINASE COMPLEX; SPINDLE CELLS; K13; TRANSFORMATION
AB Kaposi sarcoma-associated herpesvirus (KSHV), also known as human
   herpesvirus 8, is the etiologic agent of Kaposi sarcoma (KS), an
   angioproliferative lesion characterized by dramatic angiogenesis and
   inflammatory infiltration. In this study, we report that expression of
   chemokine CCL20, a potent chemoattractant of dendritic cells and
   lymphocytes, is strongly induced in cultured cells either by KSHV
   infection or on ectopic expression of viral FLICE inhibitory protein
   K13. This induction is caused by transcriptional activation of CCL20
   gene, which is mediated by binding of the p65, p50, and c-Rel subunits
   of the transcription factor nuclear factor-kappa B (NF-kappa B) to an
   atypical NF-kappa B-binding site present in the CCL20 gene promoter.
   The CCL20 gene induction is defective in K13 mutants that lack NF-kappa
   B activity, and can be blocked by specific genetic and pharmacologic
   inhibitors of the NF-kappa B pathway. CCR6, the specific receptor for
   CCL20, is also induced in cultured cells either by KSHV infection or on
   K13 expression. Finally, expression of CCL20 and CCR6 is increased in
   clinical samples of KS. These results suggest that KSHV and
   K13-mediated induction of CCL20 and CCR6 may contribute to the
   recruitment of dendritic cells and lymphocytes into the KS lesions, and
   to tumor growth and metastases. (Blood. 2009; 113: 5660-5668)
C1 [Chaudhary, Preet M.] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Dept Med,Div Hematol Oncol, Pittsburgh, PA 15213 USA.
   [Yang, Tianbing] Univ Pittsburgh, Spang Translat Res Core Facil, Inst Canc, Pittsburgh, PA 15213 USA.
   [Chang, Yuan] Univ Pittsburgh, Dept Pathol, Inst Canc, Pittsburgh, PA 15213 USA.
RP Chaudhary, PM, Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Dept
   Med,Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213
   USA.
EM chaudharypm@upmc.edu
FU National Institutes of Health (Bethesda, MD) [CA85177, CA124621,
   HL085189]; Leukemia & Lymphoma Society (White Plains, NY) ; Mario
   Lemieux Foundation (Pittsburgh, PA) 
FX The authors thank Dr Hiroyasu Nakano and Dr Gutian Xiao for providing
   MEFs lacking the NF-kappa B p65 and p50 subunits, respectively; Dr
   Tomoko Kohno for pGL2-CCL20/MIP-alpha (CCL20 WT-Luc) and
   pGL2-CCL20/MIP-3 alpha/kappa BM (CCL20 Delta NF-kappa B-Luc) for
   luciferase reporter constructs; the National Cancer Research
   Institute-sponsored AIDS and Cancer Specimen Resources at University of
   California, San Francisco, CA, and George Washington University,
   Washington, DC, for providing patient samples; Marie Acquafondata
   (Tissue and Research Pathology Services) for help with
   immunohistochemistry; and Dr Siddhartha Kar and Aletheia Tamewitz for
   critical reading of the manuscript.
   This work was supported by the National Institutes of Health (Bethesda,
   MD; grants CA85177, CA124621, and HL085189), the Leukemia & Lymphoma
   Society (White Plains, NY), and the Mario Lemieux Foundation
   (Pittsburgh, PA).
CR AHN GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7
   BABA M, 1997, J BIOL CHEM, V272, P14893
   BAXTER A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI
   10.1016/j.bmcl.2004.03.058
   BECKSTEAD JH, 1985, AM J PATHOL, V119, P294
   BRINKMANN MM, 2007, J VIROL, V81, P42, DOI 10.1128/JVI.00648-06
   CARROLL PA, 2004, VIROLOGY, V328, P7, DOI 10.1016/j.virol.2004.07.008
   CASELLI E, 2007, BLOOD, V109, P2718, DOI 10.1182/blood-2006-03-012500
   CHAUDHARY PM, 1999, ONCOGENE, V18, P5738
   CHUGH P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI
   10.1073/pnas.0408577102
   CIUFO DM, 2001, J VIROL, V75, P5614
   CORBEIL J, 1991, J IMMUNOL, V146, P2972
   CUZZOLA M, 2003, CLIN INFECT DIS, V37, E102
   DORFMAN RF, 1984, LYMPHOLOGY, V17, P76
   DOUGLAS JL, 2007, PANMINERVA MED, V49, P119
   ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8
   ENSOLI B, 1998, CYTOKINE GROWTH F R, V9, P63
   ENSOLI B, 2000, SEMIN CANCER BIOL, V10, P367
   ENSOLI B, 2001, EUR J CANCER, V37, P1251
   FIORELLI V, 1998, BLOOD, V91, P956
   FLORE O, 1998, NATURE, V394, P588
   GILL PS, 2007, J NATL CANCER I, V99, P1063, DOI 10.1093/jnci/djm063
   GROSSMANN C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05
   GUASPARRI I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467
   HARANT H, 2001, FEBS LETT, V509, P439
   HIDESHIMA T, 2002, J BIOL CHEM, V277, P16639
   HIESHIMA K, 1997, J BIOL CHEM, V272, P5846
   HONG YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383
   HROMAS R, 1997, BLOOD, V89, P3315
   IMAIZUMI Y, 2002, INT IMMUNOL, V14, P147
   JENNER RG, 2001, J VIROL, V75, P891
   KELLER SA, 2000, BLOOD, V96, P2537
   KENNEDY MM, 1998, MOL PATHOL, V51, P14
   KLEEFF J, 1999, INT J CANCER, V81, P650
   LANE BR, 2002, J VIROL, V76, P11570, DOI
   10.1128/JVI.76.22.11570-11583.2002
   LIU L, 2002, J BIOL CHEM, V277, P13745
   LIVAK KJ, 2001, METHOD METHODS, V4, P402
   LUPPI M, 2000, NEW ENGL J MED, V343, P1378
   MARAL T, 2000, ANN PLAS SURG, V44, P646
   MASOOD R, 1993, CURR OPIN ONCOL, V5, P831
   MATTA H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200
   MATTA H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI
   10.1073/pnas.0308016101
   MATTA H, 2007, J BIOL CHEM, V282, P24858
   MATTA H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931
   MATTA H, 2008, ONCOGENE, V27, P5243, DOI 10.1038/onc.2008.150
   MOSES AV, 1999, J VIROL, V73, P6892
   MOSES AV, 2002, J VIROL, V76, P8383
   MURATA T, 2004, BIOORG MED CHEM LETT, V14, P4019, DOI
   10.1016/j.bmcl.2004.05.041
   NARANATT PP, 2004, CANCER RES, V64, P72
   NICHOLAS J, 2005, J INTERF CYTOK RES, V25, P373
   PAULOSEMURPHY M, 2001, J VIROL, V75, P4843
   PELLET C, 2006, J INVEST DERMATOL, V126, P621, DOI
   10.1038/sj.jid.5700083
   POOLE LJ, 2002, J VIROL, V76, P3395
   ROSSI DL, 1997, J IMMUNOL, V158, P1033
   SADAGOPAN S, 2007, J VIROL, V81, P3949, DOI 10.1128/JVI.02333-06
   SCHUTYSER E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI
   10.1016/S1359-6101(03)00049-2
   STURZL M, 1999, J NATL CANCER I, V91, P1725
   SUGITA S, 2002, J IMMUNOL, V168, P5621
   SUN Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072
   SUN Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298
   SUN QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200
   THOME M, 1997, NATURE, V386, P517
   WANG HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384
   XU YY, 2007, J GEN VIROL 1, V88, P46, DOI 10.1099/vir.0.82375-0
   ZHAO JS, 2007, PLOS ONE, V2, ARTN e1067
NR 64
TC 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 28
PY 2009
VL 113
IS 22
BP 5660
EP 5668
DI 10.1182/blood-2008-10-186403
PG 9
SC Hematology
GA 453TD
UT ISI:000266634700039
ER

PT J
AU Mosnier, LO
   Zampolli, A
   Kerschen, EJ
   Schuepbach, RA
   Banerjee, Y
   Fernandez, JA
   Yang, XV
   Riewald, M
   Weiler, H
   Ruggeri, ZM
   Griffin, JH
AF Mosnier, Laurent O.
   Zampolli, Antonella
   Kerschen, Edward J.
   Schuepbach, Reto A.
   Banerjee, Yajnavalka
   Fernandez, Jose A.
   Yang, Xia V.
   Riewald, Matthias
   Weiler, Hartmut
   Ruggeri, Zaverio M.
   Griffin, John H.
TI Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C
   mutant
SO BLOOD
LA English
DT Article
ID COAGULATION-FACTOR VA; RANDOMIZED CONTROLLED-TRIAL; SEVERE SEPSIS;
   ACTIVATED RECEPTOR-1; ANTICOAGULANT ACTIVITY; CRYSTAL-STRUCTURE;
   BLOOD-COAGULATION; ENDOTHELIAL-CELLS; ANTITHROMBIN-III; CLOTTING FACTORS
AB Activated protein C (APC) reduces mortality in severe sepsis patients.
   APC exerts anticoagulant activities via inactivation of factors Va and
   VIIIa and cytoprotective activities via endothelial protein C receptor
   and protease activated receptor-1. APC mutants with selectively altered
   and opposite activity profiles, that is, greatly reduced anticoagulant
   activity or greatly reduced cytoprotective activities, are compared
   here. Glu149Ala-APC exhibited enhanced in vitro anticoagulant and in
   vivo antithrombotic activity, but greatly diminished in vitro
   cytoprotective effects and in vivo reduction of endotoxin-induced
   murine mortality. Thus, residue Glu149 and the C-terminal region of
   APC's light chain are identified as functionally important for
   expression of multiple APC activities. In contrast to Glu149Ala-APC,
   5A-APC (Lys191-193Ala + Arg229/230Ala) with protease domain mutations
   lacked in vivo antithrombotic activity, although it was potent in
   reducing endotoxin-induced mortality, as previously shown. These data
   imply that APC molecular species with potent antithrombotic activity,
   but without robust cyto-protective activity, are not sufficient to
   reduce mortality in endotoxemia, emphasizing the need for APC's
   cytoprotective actions, but not anticoagulant actions, to reduce
   endotoxin-induced mortality. Protein engineering can provide APC
   mutants that permit definitive mechanism of action studies for APC's
   multiple activities, and may also provide safer and more effective
   second generation APC mutants with reduced bleeding risk. (Blood. 2009;
   113: 5970-5978)
C1 [Mosnier, Laurent O.; Zampolli, Antonella; Banerjee, Yajnavalka; Fernandez, Jose A.; Yang, Xia V.; Ruggeri, Zaverio M.; Griffin, John H.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
   [Kerschen, Edward J.; Weiler, Hartmut] Blood Res Inst, Milwaukee, WI USA.
   [Schuepbach, Reto A.; Riewald, Matthias] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
RP Griffin, JH, Scripps Res Inst, Dept Mol & Expt Med MEM 180, 10550 N
   Torrey Pines Rd, La Jolla, CA 92037 USA.
EM jgriffin@scripps.edu
FU National Heart, Lung, and Blood Institute [HL087618, HL073318,
   HL060655, HL093388, HL031950, HL31950, HL52246]
FX This work was supported in part by National Heart, Lung, and Blood
   Institute grants HL087618 (to L. O. M.), HL073318 (to M. R.), HL060655
   and HL093388 (to H. W.), HL031950 (to Z. M. R.), and HL31950 and
   HL52246 (to J. H. G.).
CR ABRAHAM E, 2003, JAMA-J AM MED ASSOC, V290, P238
   BAE JS, 2007, J BIOL CHEM, V282, P9251, DOI 10.1074/jbc.M610547200
   BERNARD GR, 2001, NEW ENGL J MED, V344, P699
   BERNARD GR, 2003, CRIT CARE, V7, P155, DOI 10.1186/cc2167
   BERNARD GR, 2004, CHEST, V125, P2206
   BODE W, 1992, PROTEIN SCI, V1, P426
   CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508
   CHENG T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826
   CLARK IA, 2007, IMMUNOL CELL BIOL, V85, P271, DOI 10.1038/sj.icb.7100062
   COLLEN D, 2005, THROMB HAEMOSTASIS, V93, P627, DOI 10.1160/TH04-11-0724
   DAHLBACK B, 2005, ARTERIOSCL THROM VAS, V25, P1311, DOI
   10.1161/01.ATV.0000168421.13467.82
   DICERA E, 2007, J THROMB HAEMOST S1, V5, P196
   ESMON CT, 2003, CHEST, V124, P26
   FEISTRITZER C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   FERNANDEZ JA, 2003, BLOOD CELL MOL DIS, V30, P271, DOI
   10.1016/S1079-9796(03)00034-2
   FINIGAN JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   FOURRIER F, 1992, CHEST, V101, P816
   FUMAGALLI R, 2007, CRIT CARE S5, V11, ARTN S6
   GALE AJ, 2000, BLOOD, V96, P585
   GALE AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200
   GALE AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002
   GUO H, 2004, NEURON, V41, P563
   HAN MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559
   HARMON S, 2008, J BIOL CHEM, V283, P30531, DOI 10.1074/jbc.M802338200
   HEMKER HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   JOYCE DE, 2001, J BIOL CHEM, V276, P11199
   KERSCHEN EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404
   KONSTANTINIDES S, 2006, J THROMB HAEMOST, V4, P2014
   LEVI M, 2005, TRENDS CARDIOVAS MED, V15, P254
   LEVI M, 2008, CURR OPIN HEMATOL, V15, P481
   MATHER T, 1996, EMBO J, V15, P6822
   MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656
   MOSNIER LO, 2003, BIOCHEM J 1, V373, P65, DOI 10.1042/BJ20030341
   MOSNIER LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110
   MOSNIER LO, 2006, FRONT BIOSCI, V11, P2381
   MOSNIER LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004
   MOSNIER LO, 2007, J BIOL CHEM, V282, P33022, DOI 10.1074/jbc.M705824200
   OGANESYAN V, 2002, J BIOL CHEM, V277, P24851
   PAPACONSTANTINOU ME, 2008, CELL MOL LIFE SCI, V65, P1943, DOI
   10.1007/s00018-008-8179-y
   PIERCE GF, 2007, J THROMB HAEMOST, V5, P901
   PIPE SW, 2005, J THROMB HAEMOST, V3, P1692
   REGAN LM, 1997, J BIOL CHEM, V272, P26279
   REMICK DG, 2007, AM J PATHOL, V170, P1435, DOI
   10.2353/ajpath.2007.060872
   RIEWALD M, 2002, SCIENCE, V296, P1880
   SCHUEPBACH RA, 2008, BLOOD, V111, P2667, DOI
   10.1182/blood-2007-09-113076
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918
   WARREN BL, 2001, JAMA-J AM MED ASSOC, V286, P1869
   YAN SCB, 1990, BIO-TECHNOL, V8, P655
   YANG LK, 2007, J BIOL CHEM, V282, P25493, DOI 10.1074/jbc.M702131200
   YE XF, 1999, BIOCHEM BIOPH RES CO, V259, P671
   YEGNESWARAN S, 1997, J BIOL CHEM, V272, P25013
   ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828
NR 52
TC 20
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 4
PY 2009
VL 113
IS 23
BP 5970
EP 5978
DI 10.1182/blood-2008-10-183327
PG 9
SC Hematology
GA 454BH
UT ISI:000266656100040
ER

PT J
AU Yang, LJ
   Shen, L
   Shao, YH
   Zhao, Q
   Zhang, W
AF Yang, Lijun
   Shen, Lian
   Shao, Yuehu
   Zhao, Qing
   Zhang, Wei
TI Cytoplasmic domain of human Fcalpha/mu receptor is required for ligand
   internalization
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Fcalpha/mu receptor; Igm; IgA; Internalization
ID FC-ALPHA/MU-R; NATURAL-KILLER-CELLS; MU-RECEPTOR; EPSILON-RI; T-CELLS;
   IGM; BINDING; EXPRESSION; SPECIFICITY; TISSUES
AB The Fcalpha/mu receptor (Fc alpha/mu R), a type I tramsmembrane
   protein, is an immunoglobulin Fc receptor for both IgA and IgM. Its
   functions in immune defense are not clear at present. In this work,
   human Fc alpha/mu R was expressed in CHO, 293T, and COS-7 cells to
   study its biochemical functions. Fc alpha/mu R expressed by CHO and
   293T was only in monomer form in cytoplasma and the monomeric receptor
   could not bind IgA or IgM. In comparison, Fc alpha/mu R expressed by
   COS-7 cells had both monomer and dimer forms. The binding assay showed
   that Fc alpha/mu R expressed by COS-7 cells could bind IgM strongly and
   IgA weakly, implying that dimeric receptor could be expressed on cell
   membrane and functioned. The bound IgM could be internalized and the
   internalization was abolished when the cytoplasmic domain of Fc
   alpha/mu R was truncated. Therefore, the cytoplasmic portion of human
   Fc alpha/mu R is required in the internalization. (C) 2009 Elsevier
   Inc. All rights reserved
C1 [Yang, Lijun; Shen, Lian; Shao, Yuehu; Zhao, Qing; Zhang, Wei] Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China.
RP Zhang, W, Inst Basic Med Sci, Dept Immunol, 5 Dong Dan San Tiao,
   Beijing 100005, Peoples R China.
EM wzhang@pumc.edu.cn
FU National Natural Science Foundation of China [30571693]; Glasgow
   University, UK 
FX This work is supported by a grant (No. 30571693) from the National
   Natural Science Foundation of China. The authors thank Dr. Alan Jardine
   (Glasgow University, UK) for donating human Fcot/ pR cDNA.
CR ANDERSON CC, 1998, CRIT REV IMMUNOL, V18, P525
   CHO Y, 2006, BIOCHEM BIOPH RES CO, V345, P474, DOI
   10.1016/j.bbrc.2006.04.084
   DAERON M, 1997, ANNU REV IMMUNOL, V15, P203
   GHUMRA A, 2009, EUR J IMMUNOL
   GRIFFIN M, 2002, BIOCHEM J 2, V368, P377
   KIKUNO K, 2007, EUR J IMMUNOL, V37, P3540, DOI 10.1002/eji.2007376551
   KINET JP, 1999, ANNU REV IMMUNOL, V17, P931
   KURITA N, 2009, MOL IMMUNOL, V46, P749, DOI 10.1016/j.molimm.2008.10.002
   LANIER LL, 1989, SCIENCE, V246, P1611
   MATHUR A, 1988, J IMMUNOL, V140, P143
   MATHUR A, 1988, J IMMUNOL, V141, P1855
   MCDONALD KJ, 2002, BIOCHEM BIOPH RES CO, V290, P438
   NAKAMURA T, 1993, J IMMUNOL, V151, P6933
   NIMMERJAHN F, 2006, IMMUNITY, V24, P19
   OHNO T, 1990, J EXP MED, V172, P1165
   PHALIPON A, 2002, IMMUNITY, V17, P107
   PHALIPON A, 2003, TRENDS IMMUNOL, V24, P55
   PRICOP L, 1993, J IMMUNOL, V151, P3018
   RABINOWICH H, 1996, J IMMUNOL, V157, P1485
   RAVETCH JV, 1997, CURR OPIN IMMUNOL, V9, P121
   RAVETCH JV, 2001, ANNU REV IMMUNOL, V19, P275
   SAKAMOTO N, 2001, EUR J IMMUNOL, V31, P1310
   SAUTES C, 1992, IMMUNOBIOLOGY, V185, P207
   SHIBUYA A, 2000, NAT IMMUNOL, V1, P441
   SHIBUYA A, 2006, SPRINGER SEMIN IMMUN, V28, P377, DOI
   10.1007/s00281-006-0050-3
   STRONG RK, 2004, STRUCTURE, V12, P1919, DOI 10.1016/j.str.2004.10.001
   TAKAI T, 1994, CELL, V76, P519
   TURNER H, 1999, NATURE S, V402, B24
   WANG R, 2009, BIOCHEM BIOPH RES CO, V381, P148, DOI
   10.1016/j.bbrc.2009.01.176
   ZHANG M, 2007, IMMUNOL RES, V37, P1
   ZHANG W, 1995, CLIN EXP IMMUNOL, V101, P507
NR 31
TC 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 258
IS 1
BP 78
EP 82
DI 10.1016/j.cellimm.2009.03.015
PG 5
SC Cell Biology; Immunology
GA 451CU
UT ISI:000266449100010
ER

PT J
AU Cai, G
   Yang, JH
   Wang, HZ
   Cai, Q
   Zhao, DB
   Shen, Q
AF Cai Gang
   Yang Jiahui
   Wang Huaizhou
   Cai Qing
   Zhao Dongbao
   Shen Qian
TI Defects of mitogen-activated protein kinase in ICOS signaling pathway
   lead to CD4(+) and CD8(+) T-cell dysfunction in patients with active SLE
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Systemic lupus erythematosus; MAP kinase; IL-2; Inducible costimulator
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INDUCIBLE COSTIMULATOR; B-CELL;
   EXPRESSION; MOLECULE; CD28; PROLIFERATION; INVOLVEMENT; AILIM/ICOS;
   CRITERIA
AB in this study, hypoproliferation and defects of effectors and cytokines
   in CD4(+) and CD8(+) T-cells via ICOS costimulation were found in
   active SLE patients, relative to normal individuals and RA patient
   controls. Exogenous IL-2 can partially reverse those defects. In
   addition, low level of ERK phosphorylation in ICOS-mediated signaling
   pathway was discovered in lupus CD4(+) and CD8(+) T-cells. When blocked
   with ERK-specific chemical inhibitor PD98059, cell proliferation and
   IL-2 production via ICOS costimulation from both CD4(+) and CD8(+)
   T-cells will be severely inhibited. These findings confirmed the
   dysfunction of both CD4(+) and CD8(+) T-cells after ICOS costimulation
   in lupus patients and most importantly pointed out that impairment of
   ERK activation might be one of the critical factors involved in
   ICOS-mediated IL-2 and T-cell hypoproliferation in active SLE. (C) 2009
   Elsevier Inc. All rights reserved.
C1 [Cai Gang; Yang Jiahui; Wang Huaizhou; Shen Qian] Shanghai Changhai Hosp, Dept Expt Diag, Shanghai 200433, Peoples R China.
   [Cai Qing; Zhao Dongbao] Shanghai Changhai Hosp, Dept Rheumatol, Shanghai, Peoples R China.
RP Shen, Q, Shanghai Changhai Hosp, Dept Expt Diag, 168 Changhai Rd,
   Shanghai 200433, Peoples R China.
EM laoshenqch@yahoo.cn
FU Cancer Research Institution, The Second Military Medical University
   [CD3 (12-176]; Hi-tech Research and Development Program of China
   [2002AA214091]; Shanghai Natural Science foundation [3ZR14026]
FX We are grateful to Prof. Yajun Guo (Cancer Research Institution, The
   Second Military Medical University) for providing the mAb specific for
   human CD3 (12-176).
   This work was supported by a grant from the Hi-tech Research and
   Development Program of China 2002AA214091 and Shanghai Natural Science
   foundation Grant 3ZR14026.
CR ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
   AZUMA M, 1993, NATURE, V366, P76
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630
   BROMLEY SK, 2001, NAT IMMUNOL, V2, P1159
   COHEN PL, 1993, J INVEST DERMATOL, V100, S69
   DONG C, 2000, NATURE, V405, P91
   HUTLOFF A, 1999, NATURE, V397, P263
   HUTLOFF A, 2004, ARTHRITIS RHEUM, V50, P3211, DOI 10.1002/art.20519
   KAWAMOTO M, 2006, ARTHRITIS RES THER, V8, ARTN R62
   KEVIL CG, 1999, AM J MED, V106, P677
   LACAVA A, 2009, LUPUS, V18, P196, DOI 10.1177/0961203308098191
   MCADAM AJ, 2000, J IMMUNOL, V165, P5035
   MILLS JA, 1994, NEW ENGL J MED, V330, P1871
   NAMBIAR MP, 2003, ARTHRITIS RHEUM, V48, P1948, DOI 10.1002/art.11072
   NURIEVA RI, 2005, CLIN IMMUNOL, V115, P19, DOI
   10.1016/j.clim.2005.02.010
   OKAMOTO N, 2003, BIOCHEM BIOPH RES CO, V310, P691, DOI
   10.1016/j.bbrc.2003.09.065
   PINALS RS, 1982, B RHEUM DIS, V32, P7
   RATHMELL JC, 1998, J EXP MED, V188, P651
   SHILLING RA, 2006, CLIN IMMUNOL, V121, P13, DOI
   10.1016/j.clim.2006.04.574
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271
   TEZUKA K, 2000, BIOCHEM BIOPH RES CO, V276, P335
   TSUZAKA K, 2003, J IMMUNOL, V171, P2496
   UHM WS, 2003, RHEUMATOLOGY, V42, P935, DOI 10.1093/rheumatology/keg255
   YANG JH, 2005, RHEUMATOLOGY, V44, P1245, DOI 10.1093/rheumatology/keh724
   YOSHINAGA SK, 1999, NATURE, V402, P827
NR 25
TC 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 258
IS 1
BP 83
EP 89
DI 10.1016/j.cellimm.2009.03.016
PG 7
SC Cell Biology; Immunology
GA 451CU
UT ISI:000266449100011
ER

PT J
AU Gu, WY
   Cochrane, M
   Leggatt, GR
   Payne, E
   Choyce, A
   Zhou, F
   Tindle, R
   McMillan, NAJ
AF Gu, Wenyi
   Cochrane, Melanie
   Leggatt, Graham R.
   Payne, Elizabeth
   Choyce, Allison
   Zhou, Fang
   Tindle, Robert
   McMillan, Nigel A. J.
TI Both treated and untreated tumors are eliminated by short hairpin
   RNA-based induction of target-specific immune responses
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE antigen presentation; cancer; CTL epitope; RNAi
ID SMALL INTERFERING RNA; DOUBLE-STRANDED-RNA; DEFECTIVE RIBOSOMAL
   PRODUCTS; HUMAN-PAPILLOMAVIRUS TYPE-16; DENDRITIC CELLS;
   CROSS-PRESENTATION; MAMMALIAN-CELLS; T-CELLS; IN-VIVO; ANTIGEN
AB RNA interference (RNAi) for cancer treatment relies on the ability to
   directly kill cancer cells via down-regulation of target genes, but
   issues of delivery and efficacy have limited clinical adoption.
   Furthermore, current studies using immune-deficient animal models
   disregard potential interactions with the adaptive immune system. It
   has previously been observed that certain viral antigens appear to be
   more rapidly presented to the immune system than normal proteins due to
   the production of defective ribosomal products by the virus. Given that
   RNAi could potentially result in the generation of truncated mRNAs, we
   wondered whether a similar mechanism of immune presentation of a target
   gene was possible. Here we show that RNAi-cleaved mRNAs can be
   translated into incomplete protein, and if cleavage was downstream of
   cytotoxic T cell epitopes, resulted in increased presentation of target
   protein and the generation of a tumor-protective immune response. We
   show that mice inoculated with tumor cells treated with such short
   hairpin RNAs (shRNAs) were protected from subsequent challenge with
   untreated tumors. However, protection was only found if shRNAs were
   targeted downstream of the dominant cytotoxic T cell (CTL) epitope. Our
   work suggests that RNAi can alter immunity to targets and shows that
   not all tumor cells require direct RNAi exposure for treatment to be
   effective in vivo, pointing the way to a new class of RNAi-based
   therapy.
C1 [Gu, Wenyi; Leggatt, Graham R.; Payne, Elizabeth; Choyce, Allison; Zhou, Fang; McMillan, Nigel A. J.] Univ Queensland Diamantina, Inst Canc Immunol & Metab Med, Brisbane, Qld 4072, Australia.
   [Cochrane, Melanie; Tindle, Robert] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Brisbane, Qld 4072, Australia.
   [Cochrane, Melanie; Tindle, Robert] Univ Queensland, Clin Med Virol Ctr, Brisbane, Qld 4072, Australia.
RP McMillan, NAJ, Univ Queensland Diamantina, Inst Canc Immunol & Metab
   Med, Brisbane, Qld 4072, Australia.
EM n.mcmillan@uq.edu.au
FU National Health and Medical Research Council of Australia ; The Cancer
   Council of Queensland 
FX This work was funded by grants from the National Health and Medical
   Research Council of Australia and The Cancer Council of Queensland.
CR BEILHARZ TH, 2007, RNA, V13, P982, DOI 10.1261/rna.569407
   CHEN W, 2004, J IMMUNOL, V173, P5021
   DOAN T, 1998, VIROLOGY, V244, P352
   ELBASHIR SM, 2001, GENE DEV, V15, P188
   ESQUIVEL F, 1992, J EXP MED, V175, P163
   FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242
   GANTIER MP, 2007, CYTOKINE GROWTH F R, V18, P363, DOI
   10.1016/j.cytogfr.2007.06.016
   GU W, 2006, CANCER GENE THER, V13, P1023, DOI 10.1038/sj.cgt.7700971
   HILL JA, 2003, J IMMUNOL, V171, P691
   HORNUNG V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   JUDGE AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   KHAMMANIVONG V, 2003, IMMUNOL CELL BIOL, V81, P1
   LE TTT, 2001, VACCINE, V19, P4669
   LELOUARD H, 2004, J CELL BIOL, V164, P667, DOI 10.1083/jcb.200312073
   LIN KY, 1996, CANCER RES, V56, P21
   MARQUES JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205
   MARTINEZ J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904
   MATSUMOTO K, 2004, J NATL CANCER I, V96, P1611, DOI 10.1093/jnci/dhj301
   MOORE MW, 1988, CELL, V54, P777
   NGUYEN T, 2008, CURR OPIN MOL THER, V10, P158
   NOWAK AK, 2003, J IMMUNOL, V170, P4905
   NYKANEN A, 2001, CELL, V107, P309
   ORBAN TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505
   POECK H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887
   QIAN SB, 2006, J IMMUNOL, V177, P227
   RIPBERGER E, 2003, J CLIN IMMUNOL, V23, P415
   SCHWARZ DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008
   SCHWITALLE Y, 2004, CANC IMMUN, V4, P14
   SLEDZ CA, 2004, BIOCHEM SOC T 6, V32, P952
   STALLWOOD Y, 2006, J IMMUNOL, V177, P885
   TINDLE RW, 1995, CLIN EXP IMMUNOL, V101, P265
   XUE W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   YEWDELL JW, 1996, J IMMUNOL, V157, P1823
   YEWDELL JW, 2006, TRENDS IMMUNOL, V27, P368, DOI
   10.1016/j.it.2006.06.008
   ZAMORE PD, 2000, CELL, V101, P25
NR 35
TC 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 PROC NAT ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 19
PY 2009
VL 106
IS 20
BP 8314
EP 8319
DI 10.1073/pnas.0812085106
PG 6
SC Multidisciplinary Sciences
GA 447RH
UT ISI:000266209000042
ER

PT J
AU Li, XY
   Liu, HZ
   Yang, SL
   Tang, ZL
   Ma, YH
   Chu, MX
   Li, K
AF Li, Xinyun
   Liu, Huazhen
   Yang, Shulin
   Tang, Zhonglin
   Ma, Yuehui
   Chu, Mingxing
   Li, Kui
TI Characterization analysis and polymorphism detection of the porcine
   Myd88 gene
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE Myd88; TLR; polymorphism; pig; chromosome mapping
ID ENDOTOXIN-TOLERANT CELLS; TOLL-LIKE RECEPTORS; INNATE IMMUNITY; IL-1;
   RECOGNITION; CLONING; FAMILY; PIGS
AB The myeloid differentiation primary response protein 88 (Myd88) is an
   essential adaptor protein, which mediates in all Toll-like receptor
   (TLR) members signal transduction, except for TLR3. In this study, the
   4464 bp genomic sequence of porcine Myd88 was first isolated, whereupon
   tissue distribution, chromosome mapping and single nucleotide
   polymorphism (SNP) were analyzed. Our results revealed that porcine
   Myd88 gene, which was located at chromosome 13 linked with marker S0288
   (distance = 40 cR; LOD = 8.66), was widely expressed in all the
   examined tissues. There were 16 potential SNPs in the isolated genome
   fragment. SNP 797T/C in the first intron was studied, with no
   significant association being found between the genotype and immune
   traits in pigs (p > 0.05). The porcine Myd88 protein contained both the
   death domain (DD) and the Toll/IL-1 receptor domain (TIR). Leu
   residues, essential for its structure, were the most abundant
   encountered in the DD. The TIR contained two conserved motifs which may
   play important roles in the Myd88 function.
C1 [Li, Xinyun; Yang, Shulin; Tang, Zhonglin; Ma, Yuehui; Chu, Mingxing; Li, Kui] Chinese Acad Agr Sci, Inst Anim Sci, Key Lab Farm Anim Genet Resources & Utlizat, Minist Agr China, Beijing 100094, Peoples R China.
   [Li, Xinyun; Liu, Huazhen] Huazhong Agr Univ, Key Lab Anim Genet Breeding & Reprod, Minist Educ China, Wuhan, Peoples R China.
RP Li, K, Chinese Acad Agr Sci, Inst Anim Sci, Key Lab Farm Anim Genet
   Resources & Utlizat, Minist Agr China, Beijing 100094, Peoples R China.
EM kuili@iascaas.net.cn
FU State Platform of Technology Infrastructure [2005DKA21101]; Key Project
   of National Basic Research and Developmental Plan of China
   [G2006CB102105]; National High Science and Technology Foundation of
   China [20060110Z1039]; National Natural Science Foundation of China
   [30571300]; National Scientific and Technology Mainstay Project
   [2006BDA13B08]; Project of Science and Technology Innovation Team 
FX We are grateful to Dr. Yerle for supplying the RH panel. This research
   was supported by the State Platform of Technology Infrastructure
   (2005DKA21101), the Key Project of National Basic Research and
   Developmental Plan of China (G2006CB102105), the National High Science
   and Technology Foundation of China (20060110Z1039), the National
   Natural Science Foundation of China (30571300), the National Scientific
   and Technology Mainstay Project (2006BDA13B08) and the Project of
   Science and Technology Innovation Team for "Research and Improvement of
   Domestic Animal Germplasm" of IAS, CAAS.
CR 3DJIGSAW PROGRAM
   CLUSTAL W PROGRAM
   IMPRH MAPPING TOOL
   NETPHOS PROGRAM
   ADACHI O, 1998, IMMUNITY, V9, P143
   BONNERT TP, 1997, FEBS LETT, V402, P81
   HARDIMAN G, 1996, ONCOGENE, V13, P2467
   LEMAITRE B, 1996, CELL, V86, P973
   LI CS, 2005, J BIOL CHEM, V280, P26152, DOI 10.1074/jbc.M503262200
   LI LW, 2000, J BIOL CHEM, V275, P23340
   MEDVEDEV AE, 2002, J IMMUNOL, V169, P5209
   MEDZHITOV R, 1997, CELL, V91, P295
   MILAN D, 2000, BIOINFORMATICS, V16, P558
   NISHIYA T, 2007, FEBS LETT, V581, P3223, DOI
   10.1016/j.febslet.2007.06.008
   PALLADINO MA, 2007, BIOL REPROD, V76, P958, DOI
   10.1095/biolreprod.106.059410
   POLTORAK A, 1998, SCIENCE, V282, P2085
   SCANGA CA, 2002, J IMMUNOL, V168, P5997
   SUN HFS, 1999, CYTOGENET CELL GENET, V85, P273
   TAKEDA K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   TOHNO M, 2007, CELL MOL IMMUNOL, V4, P369
   UEMATSU S, 2006, J MOL MED-JMM, V84, P712, DOI 10.1007/s00109-006-0084-y
   VANHEUGTEN E, 1994, J ANIM SCI, V72, P658
   XU YW, 2000, NATURE, V408, P111
   YAMAMOTO M, 2004, NIPPON RINSHO, V62, P2197
   YERLE M, 1998, CYTOGENET CELL GENET, V82, P182
   ZAREMBER KA, 2002, J IMMUNOL, V168, P554
NR 26
TC 0
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2009
VL 32
IS 2
BP 295
EP 300
PG 6
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 448SC
UT ISI:000266281300015
ER

PT J
AU Chen, YF
   Kao, CH
   Chen, YT
   Wang, CH
   Wu, CY
   Tsai, CY
   Liu, FC
   Yang, CW
   Wei, YH
   Hsu, MT
   Tsai, SF
   Tsai, TF
AF Chen, Yi-Fan
   Kao, Cheng-Heng
   Chen, Ya-Ting
   Wang, Chih-Hao
   Wu, Chia-Yu
   Tsai, Ching-Yen
   Liu, Fu-Chin
   Yang, Chu-Wen
   Wei, Yau-Huei
   Hsu, Ming-Ta
   Tsai, Shih-Feng
   Tsai, Ting-Fen
TI Cisd2 deficiency drives premature aging and causes
   mitochondria-mediated defects in mice
SO GENES & DEVELOPMENT
LA English
DT Article
DE Cisd2; Wolfram syndrome 2; autophagy; knockout mice; mitochondria;
   premature aging
ID WOLFRAM DIDMOAD SYNDROME; PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM
   STRESS; OPTIC ATROPHY; PROGEROID SYNDROME; DIABETES-MELLITUS;
   TRANSMEMBRANE PROTEIN; INSULIN-SECRETION; DEAFNESS DIDMOAD; MOUSE MODELS
AB CISD2, the causative gene for Wolfram syndrome 2 (WFS2), is a
   previously uncharacterized novel gene. Significantly, the CISD2 gene is
   located on human chromosome 4q, where a genetic component for longevity
   maps. Here we show for the first time that CISD2 is involved in
   mammalian life-span control. Cisd2 deficiency in mice causes
   mitochondrial breakdown and dysfunction accompanied by autophagic cell
   death, and these events precede the two earliest manifestations of
   nerve and muscle degeneration; together, they lead to a panel of
   phenotypic features suggestive of premature aging. Our study also
   reveals that Cisd2 is primarily localized in the mitochondria and that
   mitochondrial degeneration appears to have a direct phenotypic
   consequence that triggers the accelerated aging process in Cisd2
   knockout mice; furthermore, mitochondrial degeneration exacerbates with
   age, and the autophagy increases in parallel to the development of the
   premature aging phenotype. Additionally, our Cisd2 knockout mouse work
   provides strong evidence supporting an earlier clinical hypothesis that
   WFS is in part a mitochondria-mediated disorder; specifically, we
   propose that mutation of CISD2 causes the mitochondria-mediated
   disorder WFS2 in humans. Thus, this mutant mouse provides an animal
   model for mechanistic investigation of Cisd2 protein function and help
   with a pathophysiological understanding of WFS2.
C1 [Chen, Yi-Fan; Chen, Ya-Ting; Wu, Chia-Yu; Tsai, Ching-Yen; Tsai, Shih-Feng; Tsai, Ting-Fen] Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.
   [Kao, Cheng-Heng] Chang Gung Univ, Ctr Gen Educ, Tao Yuan 333, Taiwan.
   [Chen, Ya-Ting; Tsai, Shih-Feng; Tsai, Ting-Fen] Natl Hlth Res Inst, Div Mol & Genom Med, Zhunan 350, Miaoli County, Taiwan.
   [Wang, Chih-Hao; Wei, Yau-Huei; Hsu, Ming-Ta] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Liu, Fu-Chin] Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan.
   [Yang, Chu-Wen] Soochow Univ, Dept Microbiol, Taipei 111, Taiwan.
RP Tsai, TF, Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.
EM tftsai@ym.edu.tw
FU National Research Program for Genomic Medicine (NRPGM) ; National
   Science Council ; National Science Council [NRPGM 95HC007,
   NSC96-2752-B-010004-PAE, NSC97-2320-B-010-015-MY3]; Ministry of
   Education 
FX We thank Dr. Lian-Fu Deng (Affiliated Ruijin Hospital of Shanghai
   Second Medical University, Shanghai Institute of Traumatology and
   Orthopeadics); Dr. An-Guor Wang (Taipei Veterans General Hospital); Dr.
   Ming-Ling Kuo (Chang Gung University); Dr. Chih-Cheng Chen (Academia
   Sinica); and Dr. Alan M. Lin, Dr. Hen-Li Chen, Dr. Chun-Ming Chen, Dr.
   ChiChang Juan, Yi-Shin Lai, Ching-Wen Cheng, and Hui-Wen Zhuang
   (National Yang-Ming University) for their insight and technical
   assistance. We thank the Microarray and Gene Expression Analysis Core
   Facility of the National Yang-Ming University Genome Research Center.
   The Core Facility is supported by the National Research Program for
   Genomic Medicine (NRPGM), National Science Council. We acknowledge
   support from the National Science Council (NRPGM 95HC007,
   NSC96-2752-B-010004-PAE, and NSC97-2320-B-010-015-MY3) and a grant from
   the Ministry of Education, Aim for the Top University Plan.
CR AMR S, 2007, AM J HUM GENET, V81, P673, DOI 10.1086/520961
   BARRETT TG, 1997, EYE 6, V11, P882
   BARRETT TG, 1997, J MED GENET, V34, P838
   BARRETT TG, 2000, J MED GENET, V37, P463
   BARRIENTOS A, 1996, AM J HUM GENET, V58, P963
   BOUCQUEY M, 2006, J NEUROCHEM, V99, P657
   BU XD, 1993, LANCET, V342, P598
   BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315
   CHEN CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509
   COLCA JR, 2004, AM J PHYSIOL-ENDOC M, V286, E252, DOI
   10.1152/ajpendo.00424.2003
   COLEMAN DL, 1992, METABOLISM, V41, P1134
   DOMENECH E, 2006, PEDIAT ENDOCRINOL RE, V3, P249
   ESKELINEN EL, 2008, METH MOL B, V445, P11
   FADER CM, 2009, CELL DEATH DIFFER, V16, P70, DOI 10.1038/cdd.2008.168
   FONSECA SG, 2005, J BIOL CHEM, V280, P39609, DOI 10.1074/jbc.M507426200
   HASTY P, 2003, SCIENCE, V299, P1355
   HOFMANN S, 1997, GENOMICS, V39, P8
   INOUE H, 1998, NAT GENET, V20, P143
   ISHIHARA H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125
   JUAN CC, 2004, AM J PHYSIOL-ENDOC M, V287, E948, DOI
   10.1152/ajpendo.00536.2003
   KABEYA Y, 2000, EMBO J, V19, P5720
   KAO CH, 1995, ATHEROSCLEROSIS, V116, P27
   KIM I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI
   10.1016/j.abb.2007.03.034
   KIPLING D, 2004, SCIENCE, V305, P1426
   KUJOTH GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   KUROO M, 1997, NATURE, V390, P45
   KUROSU H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   MAO HZ, 2006, BBA-MOL BASIS DIS, V1762, P440, DOI
   10.1016/j.bbidis.2006.01.002
   MIZUSHIMA N, 2004, MOL BIOL CELL, V15, P1101, DOI
   10.1091/mbc.E03-09-0704
   MIZUSHIMA N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   MOUNKES LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631
   MTANDA AT, 1986, OPHTHALMIC PAED GEN, V7, P159
   NIEDERNHOFER LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456
   PAGLIARINI DJ, 2005, MOL CELL, V19, P197, DOI
   10.1016/j.molcel.2005.06.008
   PINTON P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380
   PUCA AA, 2001, P NATL ACAD SCI USA, V98, P10505
   RIGGS AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4
   ROTIG A, 1993, J INHERIT METAB DIS, V16, P527
   ROUAULT TA, 2008, TRENDS GENET, V24, P398, DOI 10.1016/j.tig.2008.05.008
   SAMALI A, 1999, EMBO J, V18, P2040
   SCHRINER SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SCOTT RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   SHIMIZU S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   STROM TM, 1998, HUM MOL GENET, V7, P2021
   TAKEDA K, 2001, HUM MOL GENET, V10, P477
   TERAUCHI Y, 2003, J BIOL CHEM, V278, P14284, DOI 10.1074/jbc.M211045200
   TORRACO A, 2009, BBA-MOL CELL RES, V1793, P171, DOI
   10.1016/j.bbamcr.2008.06.003
   TRAN TT, 2008, CELL METAB, V7, P410, DOI 10.1016/j.cmet.2008.04.004
   TRIFUNOVIC A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   VERMULST M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   VORA AJ, 1993, LANCET, V342, P1059
   WALLACE DC, 2001, AM J MED GENET, V106, P71
   WEI YH, 1998, ANN NY ACAD SCI, V854, P155
   WILEY SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI
   10.1073/pnas.0701078104
   YAMADA T, 2006, HUM MOL GENET, V15, P1600, DOI 10.1093/hmg/ddl081
   YOUNG B, 2003, WHEATERS FUNCTIONAL
   ZATYKA M, 2008, HUM MOL GENET, V17, P190, DOI 10.1093/hmg/ddm296
NR 57
TC 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD MAY 15
PY 2009
VL 23
IS 10
BP 1183
EP 1194
DI 10.1101/gad.1779509
PG 12
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 447QD
UT ISI:000266205300006
ER

PT J
AU Yang, J
   Ahmed, A
   Ashcroft, M
AF Yang, Jun
   Ahmed, Afshan
   Ashcroft, Margaret
TI Activation of a unique p53-dependent DNA damage response
SO CELL CYCLE
LA English
DT Letter
DE small molecule activator; DNA damage response; hypoxia
ID CANCER-THERAPY; P53; ANTAGONISTS; PATHWAY; MDM2
C1 [Ahmed, Afshan; Ashcroft, Margaret] UCL, Ctr Cell Signalling & Mol Genet, Div Med, Hypoxia Signalling & Angiogenesis Lab, London WC1E 6JJ, England.
   [Yang, Jun; Ashcroft, Margaret] Canc Res UK Ctr Canc Therapeut, Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Sutton, Surrey, England.
RP Ashcroft, M, UCL, Ctr Cell Signalling & Mol Genet, Div Med, Hypoxia
   Signalling & Angiogenesis Lab, Rayne Bldg,5 Univ St, London WC1E 6JJ,
   England.
EM m.ashcroft@ucl.ac.uk
CR BYKOV VJN, 2003, ANN MED, V35, P458, DOI 10.1080/07853890310017152
   CARROLL VA, 2005, EXPERT REV MOL MED, V7, P1, DOI
   10.1017/S1462399405009117
   FOSTER BA, 1999, SCIENCE, V286, P2507
   ISSAEVA N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146
   RAVI R, 2000, GENE DEV, V14, P34
   SEMENZA GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   TOVAR C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI
   10.1073/pnas.0507493103
   VASSILEV LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   YANG J, 2009, MOL CELL BI IN PRESS
NR 9
TC 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 15
PY 2009
VL 8
IS 10
BP 1630
EP 1632
PG 3
SC Cell Biology
GA 446IP
UT ISI:000266115600031
ER

PT J
AU Yang, Q
   Mao, ZX
AF Yang, Qian
   Mao, Zixu
TI Regulation of MEF2s by chaperone-mediated autophagy
SO CELL CYCLE
LA English
DT Editorial Material
ID SURVIVAL
C1 [Mao, Zixu] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
RP Mao, ZX, Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.
EM zmao@pharm.emory.edu
CR ARNOLD MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   BOLAND B, 2006, MOL ASPECTS MED, V27, P503, DOI
   10.1016/j.mam.2006.08.009
   BUTTS BD, 2005, MOL CELL NEUROSCI, V30, P279, DOI
   10.1016/j.mcn.2005.07.011
   MASSEY AC, 2006, CURR TOP DEV BIOL, V73, P205, DOI
   10.1016/S0070-2153(05)73007-6
   MORA S, 2001, ENDOCRINOLOGY, V142, P1999
   PANDEY UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   WANG XM, 2004, GASTROENTEROLOGY, V127, P1174, DOI
   10.1053/j.gastro.2004.07.007
   YANG Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
NR 8
TC 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2009
VL 8
IS 9
BP 1304
EP 1304
PG 1
SC Cell Biology
GA 446IF
UT ISI:000266114600004
ER

PT J
AU Yuan, K
   Li, N
   Huo, Y
   Yan, F
   Yang, Y
   Ward, T
   Jin, CJ
   Yao, XB
AF Yuan, Kai
   Li, Na
   Huo, Yuda
   Yan, Feng
   Yang, Yong
   Ward, Tarsha
   Jin, Changjiang
   Yao, Xuebiao
TI Recruitment of separase to mitotic chromosomes is regulated by Aurora B
SO CELL CYCLE
LA English
DT Article
DE chromosome segregation; chromosome arm; separase; cohesin; aurora B
ID SISTER-CHROMATID SEPARATION; SPINDLE-ASSEMBLY CHECKPOINT; HUMAN-CELLS;
   CENTROSOME DUPLICATION; ANAPHASE; COHESIN; CLEAVAGE; KINETOCHORE;
   INHIBITION; METAPHASE
AB Accurate segregation of chromosome, initiated by abrupt and
   irreversible dissolution of sister-chromatid cohesion at anaphase, is
   crucial for the faithful inheritance of parental genomes during
   eukaryotic cell division. The dissolution of sister-chromatid cohesion
   is catalyzed by separase after the destruction of securin by the
   anaphase-promoting complex/cyclosome (APC/C). However, separase was
   localized to the mitotic centrosome, raising the question as how
   separase hydrolyzes sister-chromatid cohesion of centromere at the
   anaphase onset. Here we show that separase is associated with mitotic
   chromosomes and this association is regulated by Aurora B kinase. Using
   a panel of separase antibodies, we found that separase protein was
   accumulated in mitosis and degraded at the end of telophase. To study
   the spatiotemporal distribution of separase in mitosis, we carried out
   immunofluorescence microscopic analyses. Surprisingly, separase was
   found to be associated with mitotic chromosomes from prophase to
   metaphase and dissociated from the chromosomes in anaphase right after
   sister chromatids separation. Staining of isolated mitotic chromosomes
   from Nocodazole-arrested cells revealed that separase is concentrated
   at the centromeric cohesion. To examine if any mitotic kinases are
   responsible for chromosomal localization of separase in mitosis, we
   carried out RNAi-mediated knockdown and found that association of
   separase with mitotic chromosomes was a function of Aurora B.
   Consistent with the phenotype seen in the Aurora B-repressed cells,
   inhibition of Aurora B kinase by hersperadin prevents the association
   of separase with chromosomes. Our results suggest that Aurora B kinase
   activity helps coordinate the association of separase with chromosome
   and the initiation of sister-chromatid separation.
C1 [Yuan, Kai; Li, Na; Huo, Yuda; Yan, Feng; Yang, Yong; Jin, Changjiang; Yao, Xuebiao] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   [Yuan, Kai; Li, Na; Huo, Yuda; Yan, Feng; Yang, Yong; Jin, Changjiang; Yao, Xuebiao] Univ Sci & Technol China, Anhui Lab Cellular Dynam & Chem Biol, Hefei 230027, Anhui, Peoples R China.
   [Yuan, Kai; Yan, Feng; Yang, Yong; Ward, Tarsha] Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA.
RP Jin, CJ, Univ Sci & Technol China, Lab Cellular Dynam, 96 Jinzhai Rd,
   Hefei 230027, Anhui, Peoples R China.
EM jincj@ustc.edu.cn
   yaoxb@ustc.edu.cn
FU Chinese Academy of Science [KSCX1-YW-R65, KSCX2YW- H10]; Chinese 973
   project [2002CB713700, 2007CB914503, 2006CB943600]; Chinese Natural
   Science Foundation [30270654, 30070349, 90508002, 30121001]; American
   Cancer Society [RPG-99-173-01]; Georgia Cancer Coalition Breast Cancer
   Research ; University of Science and Technology of China USTC 
FX We thank Dr. Zou Hui for generously providing the separase antibody. We
   thank the anonymous reviewers for comments on the manuscript. This work
   is supported by grants from the Chinese Academy of Science
   KSCX1-YW-R65, KSCX2YW- H10), Chinese 973 project 2002CB713700,
   2007CB914503 and 2006CB943600), Chinese Natural Science Foundation
   30270654, 30070349, 90508002 and 30121001), American Cancer Society
   RPG-99-173-01) and a Georgia Cancer Coalition Breast Cancer Research
   grant to X. Y.). K. Y. is supported by the innovation foundation from
   University of Science and Technology of China USTC).
CR CHESTUKHIN A, 2003, P NATL ACAD SCI USA, V100, P4574, DOI
   10.1073/pnas.0730733100
   CIOSK R, 1998, CELL, V93, P1067
   DIAZMARTINEZ LA, 2007, PLOS ONE, V2, P318
   DIAZMARTINEZ LA, 2008, J CELL SCI, V121, P2107, DOI 10.1242/jcs.029132
   DOU Z, 2004, FEBS LETT, V572, P51, DOI 10.1016/j.febslet.2004.06.092
   GASSMANN R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001
   GASSMANN R, 2007, METHODS, V41, P177, DOI 10.1016/j.ymeth.2006.07.027
   GIMENEZABIAN JF, 2004, CURR BIOL, V14, P1187, DOI
   10.1016/j.cub.2004.06.052
   GIMENEZABIAN JF, 2005, CELL CYCLE, V4, P1576
   GORR IH, 2005, MOL CELL, V19, P135, DOI 10.1016/j.molcel.2005.05.022
   HAUF S, 2001, SCIENCE, V293, P1320
   HAUF S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092
   HAUF S, 2005, PLOS BIOL, V3, P69
   HORNIG NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303
   JALLEPALLI PV, 2001, NAT REV CANCER, V1, P109
   KUENG S, 2006, CELL, V127, P955, DOI 10.1016/j.cell.2006.09.040
   LOSADA A, 2000, J CELL BIOL, V150, P405
   MEI JJ, 2001, CURR BIOL, V11, P1197
   MUSACCHIO A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163
   NAKAJIMA M, 2007, J CELL SCI
   NASMYTH K, 2005, PHILOS T R SOC B, V360, P483
   NIGG EA, 2007, TRENDS CELL BIOL, V17, P215, DOI
   10.1016/j.tcb.2007.03.003
   PAULSON JR, 1982, CHROMOSOMA, V85, P571
   PFLEGHAAR K, 2005, PLOS BIOL, V3, P416
   SESSA F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031
   STEMMANN O, 2001, CELL, V107, P715
   STRAIGHT AF, 2003, SCIENCE, V299, P1743
   SUN Y, 2008, MOL BIOL CELL, V19, P1210
   TSOU MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985
   UHLMANN F, 1999, NATURE, V400, P37
   UHLMANN F, 2000, CELL, V103, P375
   WAIZENEGGER IC, 2000, CELL, V103, P399
   WAIZENEGGER IC, 2002, CURR BIOL, V12, P1368
   YANG Y, 2008, J BIOL CHEM, V283, P26726, DOI 10.1074/jbc.M804207200
   YAO XB, 1997, J CELL BIOL, V139, P435
   YUAN K, 2007, J BIOL CHEM, V282, P27414, DOI 10.1074/jbc.M703555200
   ZOU H, 1999, SCIENCE, V285, P418
   ZOU H, 2002, FEBS LETT, V528, P246, PII S0014-5793(02)03238-6
NR 38
TC 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2009
VL 8
IS 9
BP 1433
EP 1443
PG 11
SC Cell Biology
GA 446IF
UT ISI:000266114600031
ER

PT J
AU Yang, W
   Ng, P
   Zhao, M
   Hirankarn, N
   Lau, CS
   Mok, CC
   Chan, TM
   Wong, RWS
   Lee, KW
   Mok, MY
   Wong, SN
   Avihingsanon, Y
   Lee, TL
   Ho, MHK
   Lee, PPW
   Wong, WHS
   Lau, YL
AF Yang, W.
   Ng, P.
   Zhao, M.
   Hirankarn, N.
   Lau, C. S.
   Mok, C. C.
   Chan, T. M.
   Wong, R. W. S.
   Lee, K. W.
   Mok, M. Y.
   Wong, S. N.
   Avihingsanon, Y.
   Lee, T. L.
   Ho, M. H. K.
   Lee, P. P. W.
   Wong, W. H. S.
   Lau, Y. L.
TI Population differences in SLE susceptibility genes: STAT4 and BLK, but
   not PXK, are associated with systemic lupus erythematosus in Hong Kong
   Chinese
SO GENES AND IMMUNITY
LA English
DT Article
DE systemic lupus erythematosus; STAT4; PXK; BLK; population difference
ID GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; JAPANESE POPULATION;
   DISEASE; ITGAM; RISK; HAPLOTYPE; VARIANTS
AB In this study, we compared the association of several newly discovered
   susceptibility genes for systemic lupus erythematosus (SLE) between
   populations of European origin and two Asian populations. Using 910 SLE
   patients and 1440 healthy controls from Chinese living in Hong Kong,
   and 278 SLE patients and 383 controls in Thailand, we studied
   association of STAT4, BLK and PXK with the disease. Our data confirmed
   association of STAT4 (rs7574865, odds ratio (OR) 1.71, P = 3.55 x
   10(-23)) and BLK (rs13277113, OR = 0.77, P = 1.34 x 10(-5)) with SLE.
   It was showed that rs7574865 of STAT4 is also linked to hematologic
   disorders and potentially some other subphenotypes of the disease. More
   than one genetic variant in STAT4 were found to be associated with the
   disease independently in our populations (rs7601754, OR = 0.59, P =
   1.39 x 10(-9), and P = 0.00034 when controlling the effect of
   rs7574865). With the same set of samples, however, our study did not
   detect any significant disease association for PXK, a risk factor for
   populations of European origin (rs6445975, joint P = 0.36, OR = 1.06,
   95% confidence interval: 0.93-1.21). Our study indicates that some of
   the susceptibility genes for this disease may be population specific.
   Genes and Immunity (2009) 10, 219-226; doi:10.1038/gene.2009.1;
   published online 19 February 2009
C1 [Yang, W.; Ng, P.; Zhao, M.; Lee, T. L.; Ho, M. H. K.; Lee, P. P. W.; Wong, W. H. S.; Lau, Y. L.] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Hirankarn, N.] Chulalongkorn Univ, Fac Med, Dept Microbiol, Lupus Res Unit, Bangkok 10330, Thailand.
   [Lau, C. S.; Chan, T. M.; Wong, R. W. S.; Mok, M. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Mok, C. C.] Tuen Mun Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Lee, K. W.] Pamela Youde Nethersole Eastern Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Wong, S. N.] Tuen Mun Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Avihingsanon, Y.] Chulalongkorn Univ, Fac Med, Dept Med, Lupus Res Unit, Bangkok 10330, Thailand.
RP Lau, YL, Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent
   Med, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
EM lauylung@hkucc.hku.hk
FU Shun Tak District Min Yuen Tong of Hong Kong ; Edward Sai Kim Hotung
   Paediatric Education and Research Fund ; University Postgraduate
   Studentship ; UGC ; UHK [200711159155]
FX This study was partially supported by the Shun Tak District Min Yuen
   Tong of Hong Kong. PN and MZ were supported by Edward Sai Kim Hotung
   Paediatric Education and Research Fund, and University Postgraduate
   Studentship. WY acknowledges support from UGC, UHK (200711159155).
CR BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI
   10.1093/bioinformatics/bth457
   CLATWORTHY MR, 2007, P NATL ACAD SCI USA, V104, P7169, DOI
   10.1073/pnas.0608889104
   DANCHENKO N, 2006, LUPUS, V15, P308, DOI 10.1191/0961203306lu2305xx
   HARLEY JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81
   HIRANKARN N, 2007, INT J IMMUNOGENET, V34, P425, DOI
   10.1111/j.1744-313X.2007.00715.x
   HOM G, 2008, NEW ENGL J MED, V358, P900
   KAWASAKI A, 2008, ARTHRITIS RES THER, V10, ARTN R113
   KOBAYASHI S, 2008, ARTHRITIS RHEUM, V58, P1940, DOI 10.1002/art.23494
   KORMAN BD, 2008, GENES IMMUN, V9, P267, DOI 10.1038/gene.2008.1
   LOVATO P, 2003, J BIOL CHEM, V278, P16777, DOI 10.1074/jbc.M207999200
   MARTINEZ A, 2008, ARTHRITIS RHEUM, V58, P2598, DOI 10.1002/art.23792
   MOK CC, 2003, LUPUS, V12, P717, DOI 10.1191/0961203303lu451xx
   MOK CC, 2004, AM J MED, V117, P791, DOI 10.1016/j.amjmed.2004.04.029
   NATH SK, 2008, NAT GENET, V40, P152, DOI 10.1038/ng.71
   PALOMINOMORALES RJ, 2008, GENES IMMUN, V9, P379, DOI
   10.1038/gene.2008.30
   PURCELL S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   REMMERS EF, 2007, NEW ENGL J MED, V357, P977
   SELIGMAN VA, 2002, AM J MED, V112, P726
   SIGURDSSON S, 2008, HUM MOL GENET, V17, P2868, DOI 10.1093/hmg/ddn184
   SKOL AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   TAYLOR KE, 2008, PLOS GENET, V4, ARTN e1000084
   WILLCOCKS LC, 2008, J EXP MED, V205, P1573, DOI 10.1084/jem.20072413
NR 22
TC 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD APR
PY 2009
VL 10
IS 3
BP 219
EP 226
DI 10.1038/gene.2009.1
PG 8
SC Genetics & Heredity; Immunology
GA 444DS
UT ISI:000265961300003
ER

PT J
AU Chu, X
   Dong, C
   Lei, R
   Sun, L
   Wang, Z
   Dong, Y
   Shen, M
   Wang, Y
   Wang, B
   Zhang, K
   Yang, L
   Li, Y
   Yuan, W
   Wang, Y
   Song, H
   Jin, L
   Xiong, M
   Huang, W
AF Chu, X.
   Dong, C.
   Lei, R.
   Sun, L.
   Wang, Z.
   Dong, Y.
   Shen, M.
   Wang, Y.
   Wang, B.
   Zhang, K.
   Yang, L.
   Li, Y.
   Yuan, W.
   Wang, Y.
   Song, H.
   Jin, L.
   Xiong, M.
   Huang, W.
TI Polymorphisms in the interleukin 3 gene show strong association with
   susceptibility to Graves' disease in Chinese population
SO GENES AND IMMUNITY
LA English
DT Article
DE Graves' disease; IL3; single-nucleotide polymorphism
ID AUTOIMMUNE THYROID-DISEASE; RHEUMATOID-ARTHRITIS; CATION TRANSPORTER;
   JAPANESE PATIENTS; HUMAN IL-3; LINKAGE; GENOME; LOCI; VARIANTS; PROMOTER
AB Graves' disease (GD) is a common organ-specific autoimmune disorder,
   which is multifactorial and develops in genetically susceptible
   individuals. We had earlier mapped a susceptibility locus for GD to
   chromosome 5q31-33 in a linkage study. Here we used tag
   single-nucleotide polymorphisms (SNPs) to search for genetic variants
   associated with GD, and examined 19 functional candidate genes in this
   chromosomal region. We identified 192 polymorphisms by re-sequencing
   the candidate genes, and selected 51 tagSNPs to genotype in a
   case-control collection of 1118 south Han Chinese subjects (428 cases
   and 690 controls). Initial analysis suggested that a non-synonymous SNP
   rs40401 (P27S) of interleukin 3 (IL3) was associated with GD, and
   further fine-mapping showed that rs40401, or its perfect proxy SNP
   rs31480 in the 50 flanking region of IL3, fully accounted for the
   association signal at this locus. We replicated significant association
   of rs40401 with GD in an independent sample collection of 839 north Han
   Chinese subjects. A combined analysis revealed strong validation of
   this association (odds ratio (ORcommon) 1.63, combined P (P-comb) = 4 x
   10(-6) in the Recessive disease model). This study provides convincing
   evidence that the IL3 gene is a susceptibility locus for GD in the
   Chinese population. Genes and Immunity (2009) 10, 260-266;
   doi:10.1038/gene.2009.3; published online 5 March 2009
C1 [Chu, X.; Lei, R.; Song, H.; Huang, W.] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200025, Peoples R China.
   [Chu, X.; Dong, C.; Sun, L.; Wang, Z.; Shen, M.; Wang, Y.; Wang, B.; Zhang, K.; Yang, L.; Li, Y.; Yuan, W.; Wang, Y.; Jin, L.; Huang, W.] Chinese Natl Human Genome Ctr, Dept Genet, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China.
   [Dong, Y.] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Endocrinol, Shanghai 200025, Peoples R China.
   [Jin, L.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Xiong, M.] Univ Texas Houston Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
RP Huang, W, Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, 197 Rui Jin II
   Rd, Shanghai 200025, Peoples R China.
EM huangwei@chgc.sh.cn
FU Chinese High-Tech Program [2006AA020706, 2006AA02A406]; National Key
   Project for Basic Research [2004CB518605]; Chinese National Natural
   Science Fund for Distinguished Young Scholars [30625019]; Shanghai
   Science and Technology Committee [06XD14015]; Chinese National Natural
   Science Fund [30771029]
FX We gratefully acknowledge Prof Zhu Chen for insightful instruction.
   This work was supported by the grants from Chinese High-Tech Program
   (2006AA020706, 2006AA02A406), National Key Project for Basic Research
   (2004CB518605), Chinese National Natural Science Fund for Distinguished
   Young Scholars (30625019), Shanghai Science and Technology Committee
   (06XD14015) and Chinese National Natural Science Fund (30771029).
CR AKAMIZU T, 2003, J HUM GENET, V48, P236, DOI 10.1007/s10038-003-0017-3
   BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI
   10.1093/bioinformatics/bth457
   BEDNARCZUK T, 2003, CLIN ENDOCRINOL, V59, P519
   CHEN RH, 2007, ENDOCRINE, V32, P170, DOI 10.1007/s12020-007-9027-9
   CHONG KKL, 2008, INVEST OPHTH VIS SCI, V49, P2409, DOI
   10.1167/iovs.07-1433
   DEBAKKER PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   DERIJK RH, 2002, J STEROID BIOCHEM, V81, P103
   DOGAN RNE, 2003, J IMMUNOL, V170, P2195
   EBNER S, 2002, J IMMUNOL, V168, P6199
   ELENKOV IJ, 2000, PHARMACOL REV, V52, P595
   GABRIEL SB, 2002, SCIENCE, V296, P2225
   HAWWARI A, 2002, J IMMUNOL, V169, P1876
   HIGGINS JPT, 2003, BRIT MED J, V327, P560
   HIROMATSU Y, 2005, J CLIN ENDOCR METAB, V90, P296, DOI
   10.1210/jc.2004-0931
   HOLLOWELL JG, 2002, J CLIN ENDOCR METAB, V87, P489
   HUNT PJ, 2000, J CLIN ENDOCR METAB, V85, P1984
   JIN Y, 2003, J CLIN ENDOCR METAB, V88, P1798, DOI 10.1210/jc.2001-011980
   LOHOFF M, 1997, IMMUNITY, V6, P681
   NAKKUNTOD J, 2004, J MED ASS THAI S2, V87, S123
   PARK BL, 2004, J HUM GENET, V49, P517, DOI 10.1007/s10038-004-0184-x
   PELTEKOVA VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339
   PLENGE RM, 2005, AM J HUM GENET, V77, P1044
   PURCELL S, 2003, BIOINFORMATICS, V19, P149
   SAKAI K, 2001, HUM MOL GENET, V10, P1379
   SCHWEIGER A, 2001, J ALLERGY CLIN IMMUN, V107, P505
   SHIAU MY, 2007, CLIN BIOCHEM, V40, P213, DOI
   10.1016/j.clinbiochem.2006.11.009
   SILVERBERG MS, 2007, EUR J HUM GENET, V15, P328, DOI
   10.1038/sj.ejhg.5201756
   SIMMONDS MJ, 2005, CLIN ENDOCRINOL, V63, P695, DOI
   10.1111/j.1365-2265.2005.02385.x
   TAYLOR JC, 2006, J CLIN ENDOCR METAB, V91, P646, DOI
   10.1210/jc.2005-0686
   TELLORUIZ MK, 2006, EUR J HUM GENET, V14, P780, DOI
   10.1068/sj.ejhg.5201612
   TOKUHIRO S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267
   TOMER Y, 2003, AM J HUM GENET, V73, P736
   WANDSTRAT A, 2001, NAT IMMUNOL, V2, P802
   YAMADA R, 2001, AM J HUM GENET, V68, P674
   YANG Y, 2005, J HUM GENET, V50, P574
   ZHANG K, 2002, CHIN J ENDOCRINOL ME, V18, P342
NR 36
TC 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD APR
PY 2009
VL 10
IS 3
BP 260
EP 266
DI 10.1038/gene.2009.3
PG 7
SC Genetics & Heredity; Immunology
GA 444DS
UT ISI:000265961300008
ER

PT J
AU Zeng, YW
   Yang, SM
   Cui, H
   Yang, XJ
   Xu, LM
   Du, J
   Pu, XY
   Li, ZC
   Cheng, ZQ
   Huang, XQ
AF Zeng, Yawen
   Yang, Shuming
   Cui, Hong
   Yang, Xiaojuan
   Xu, Liming
   Du, Juan
   Pu, Xiaoying
   Li, Zichao
   Cheng, Zaiquan
   Huang, Xingqi
TI QTLs of Cold Tolerance-Related Traits at the Booting Stage for NIL-RILs
   in Rice Revealed by SSR
SO GENES & GENOMICS
LA English
DT Article
DE cold tolerance-related traits; near-isogenic line at booting stage;
   quantitative trait loci (QTL); rice (Oryza sativa L.)
ID ORYZA-SATIVA L.; NEAR-ISOGENIC LINES; JAPONICA RICE; LOCUS;
   IDENTIFICATION; POPULATION; YUNNAN; CHINA; YIELD; CROSS
AB QTLs for cold tolerance-related traits at the booting stage using
   balanced population for 1525 recombinant inbred lines of near-isogenic
   lines (viz-NIL-RILs for BC5F3 and BC5F4 and BC5F5) over 3 years and two
   locations by backcrossing the strongly cold-tolerant landrace
   (Kunmingxiaobaigu) and a cold-sensitive cultivar (Towada) was analyzed.
   In this study, 676 microsatellite markers were employed to identify
   QTLs conferring cold tolerance at booting stage. Single marker analysis
   revealed that 12 markers associated with cold tolerance on chromosome
   1, 4 and 5. Using a LOD significance threshold of 3.0,compositive
   interval mapping based on a mixed linear model revealed eight QTLs for
   10 cold tolerance-related traits on chromosomes 1, 4, and 5. They were
   tentatively designated qCTB-1-1, qCTB-4-1, qCTB-4-2, qCTB-4-3,
   qCTB-4-4, qCTB4-5, qCTB-4-6, and qCTB-5-1. The marker intervals of them
   were narrowed to 0.3-6.8 cM. Genetic distances between the peaks of the
   QTL and nearest markers varied from 0 to 0.04 cM. We were noticed in
   some traits associated cold tolerance, such as qCTB-1-1 for 5 traits
   (plant height, panicle exsertion, spike length, blighted grains per
   spike and spikelet fertility), qCTB-4-1 for 8 traits (plant height,
   node length under spike, leaf length, leaf width, spike length, full
   grains per spike, total grains per spike and spikelet fertility),
   qCTB-4-2 for 3 traits (spike length, full grains per spike and spikelet
   fertility), qCTB5-1 for 5 traits (plant height, particle exsertion,
   blighted grains per spike, full grains per spike and spikelet
   fertility). The variance explained by a single QTL ranged from 0.80 to
   16.80%. Three QTLs (qCTB-1-1, qCTB-4-1, qCTB-4-2 were detected in two
   or more trials. Our study sets a foundation for cloning cold-tolerance
   genes and provides opportunities to understand the mechanism of cold
   tolerance at the booting stage.
C1 [Zeng, Yawen; Yang, Shuming; Du, Juan; Pu, Xiaoying; Cheng, Zaiquan; Huang, Xingqi] Yunnan Acad Agr Sci, Biotechnol & Genet Resources Inst, Kunming 650205, Peoples R China.
   [Cui, Hong] Yunnan Univ, Sch Life Sci, Kunming 650001, Peoples R China.
   [Zeng, Yawen; Yang, Xiaojuan] Yunnan Agr Univ, Sch Agron & Biotechnol, Kunming 650201, Peoples R China.
   [Xu, Liming; Li, Zichao] China Agr Univ, Beijing 100094, Peoples R China.
RP Zeng, YW, Yunnan Acad Agr Sci, Biotechnol & Genet Resources Inst,
   Kunming 650205, Peoples R China.
EM zengyw1967@126.com
FU National Natural Science Foundation of China [30571140, 39760042,
   30660092]; Yunnan Province Natural Science Foundation [2004CO01OZ];
   Cooperation Program between Province and Zhejiang Umiversty [2006YX
   12]; Yunnan Introduction and Foster Talent [2005PY01-14]
FX This work was funded by the National Natural Science Foundation of
   China (Nos. 30571140, 39760042 and 30660092), and Yunnan Province
   Natural Science Foundation (No. 2004CO01OZ), Cooperation Program
   between Province and Zhejiang Umiversty from Yunnan provincial
   Scientific and Technology Department (2006YX 12) and Yunnan
   Introduction and Foster Talent (No. 2005PY01-14).
CR ANDAYA VC, 2003, THEOR APPL GENET, V106, P1084, DOI
   10.1007/s00122-002-1126-7
   ANDAYA VC, 2007, MOL BREEDING, V20, P349, DOI 10.1007/s11032-007-9096-8
   FRARY A, 2000, SCIENCE, V289, P85
   GUI M, 2006, YICHUAN, V28, P972
   HITTALMANI S, 2002, EUPHYTICA, V125, P207
   KUROKI M, 2007, THEOR APPL GENET, V115, P593, DOI
   10.1007/s00122-007-0589-y
   LINCOLN S, 1992, GENOMICS, V1, P174
   LOU QJ, 2007, EUPHYTICA, V158, P87, DOI 10.1007/s10681-007-9431-5
   MANICKAVELU A, 2006, PLANT GROWTH REGUL, V50, P121, DOI
   10.1007/s10725-006-9109-3
   MATSUMOTO T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895
   MCCOUCH SR, 1997, RICE GENET NEWSLETT, V14, P11
   MCCOUCH SR, 2002, DNA RES, V9, P199
   NISHIMURA M, 1995, BREEDING SCI, V45, P479
   PRABUDDHA HR, 2008, EUPHYTICA, V160, P357, DOI 10.1007/s10681-007-9546-8
   ROGERS SO, 1988, PLANT MOL BIOL MAN A, V6, P1
   SAITO K, 2004, THEOR APPL GENET, V109, P515, DOI
   10.1007/s00122-004-1667-z
   SHEN SQ, 2005, CHINESE J RICE SCI, V19, P217
   SONG BK, 2007, KOREAN J GENETIC, V29, P447
   TAKEUCHI Y, 2001, BREEDING SCI, V51, P191
   XIAO J, 1996, THEOR APPL GENET, V92, P230
   XU K, 2000, MOL GEN GENET, V263, P681
   XUE WY, 2008, NAT GENET, V40, P761, DOI 10.1038/ng.143
   YANO M, 2000, PLANT CELL, V12, P2473
   ZENG Y, 1999, PLANT GENET RESOURC, V117, P43
   ZENG YW, 2005, PLANT GENET RESOUR N, V143, P51
   ZENG YW, 2006, CHINESE J RICE SCI, V20, P265
   ZENG YW, 2006, INDIAN J GENET PL BR, V66, P100
   ZENG YW, 2007, BREEDING SCI, V57, P91
   ZHANG HL, 2006, GENOME, V50, P72
   ZHU J, 1998, HEREDITAS BEIJING S, V20, P137
NR 30
TC 2
PU KOREAN SOC GENETICS
PI SEOUL
PA KOREAN SCIENCE & TECHNOLOGY CENTER, RM 1002, 635-4 YEOKSAM-DONG,
   KANGNAM, SEOUL, 135-703, SOUTH KOREA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD APR
PY 2009
VL 31
IS 2
BP 143
EP 154
PG 12
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 445DH
UT ISI:000266029400004
ER

PT J
AU Du, P
   Ling, YH
   Sang, XC
   Zhao, FM
   Xie, R
   Yang, ZL
   He, GH
AF Du, Peng
   Ling, Ying-Hua
   Sang, Xian-Chun
   Zhao, Fang-Ming
   Xie, Rong
   Yang, Zheng-Lin
   He, Guang-Hua
TI Gene Mapping Related to Yellow Green Leaf in a Mutant Line in Rice
   (Oryza sadva L.)
SO GENES & GENOMICS
LA English
DT Article
DE rice (Oryza sadva L.); yellow green leaf mutant; chlorophyll;
   fluorescence kinetic parameters; gene mapping
ID CHLOROPHYLL SYNTHESIS; MG-CHELATASE; BIOSYNTHESIS; REGULATOR; MARKER;
   SYSTEM; SERIES; MAIZE; GUN4; DNA
AB A mutant, which derived from the restorer line Jinhui10 treated with
   EMS, showed completely yellow green leaves, and it had low chlorophyll
   content and poor agronomic characteristics during the growing stage.
   The F, plants from the cross between normal x the mutant showed normal
   green leaves, and the segregation ratio of normal to yellow green
   leaves was 3: 1 in F-2 population. It indicated that the trait was
   controlled by a single recessive nuclear gene, temporarily designated
   as ygl3. The gene ygl3 was mapped between RM468 and RM3684 with genetic
   distances 8.4 cM and 1.8 cM on chromosome 3. This result would be used
   as genetic information for fine mapping and map-based cloning of ygl3
   gene.
C1 [Du, Peng; Ling, Ying-Hua; Sang, Xian-Chun; Zhao, Fang-Ming; Yang, Zheng-Lin; He, Guang-Hua] Southwest Univ, Rice Res Inst, Key Lab Biotechnol & Crop Qual Improvement, Minist Agr, Chongqing 400715, Peoples R China.
   [Xie, Rong] Sichuan Acad Agr Sci, Rice & Sorghum Inst, Luzhou 646000, Sichuan, Peoples R China.
RP He, GH, Southwest Univ, Rice Res Inst, Key Lab Biotechnol & Crop Qual
   Improvement, Minist Agr, Chongqing 400715, Peoples R China.
EM hegh1968@yahoo.com.cn
FU National Natural Sciences Foundation [30800598]; Excellent Youth
   Foundation Project of Chongqing [2008BA1033]; Natural Sciences
   Foundation Project of Chongqing [2008BB1258]; Fine Animals and Plants
   Breeding Project of Chongqing [2007AA1019]
FX This research was supported by the National Natural Sciences Foundation
   (30800598), the Excellent Youth Foundation Project of Chongqing (CSTC,
   2008BA1033), the Natural Sciences Foundation Project of Chongqing
   (CSTC, 2008BB1258) and the Fine Animals and Plants Breeding Project of
   Chongqing (CSTC, 2007AA1019).
CR AYUMI T, 2006, CURR OPIN PLANT BIOL, V9, P248
   BEALE SI, 2005, TRENDS PLANT SCI, V10, P309, DOI
   10.1016/j.tplants.2005.05.005
   BRAUN DM, 2006, PLANT PHYSIOL, V142, P1511, DOI 10.1104/pp.106.090381
   DAVISON PA, 2005, BIOCHEMISTRY-US, V44, P7603, DOI 10.1021/bi050240x
   DONG FG, 1995, CHINESE J RICE SCI, V9, P65
   FALBEL TG, 1996, PLANT PHYSIOL, V112, P821
   HIROCHIKA H, 2004, PLANT MOL BIOL, V54, P325
   HUANG XQ, 2007, CHINESE J RICE SCI, V21, P355
   IWATA N, 1977, JPN J BREED S1, V27, P250
   JUN W, 2006, CHINESE J RICE SCI, V20, P455
   JUNG KH, 2003, PLANT CELL PHYSIOL, V44, P463
   KRAUSE GH, 1991, ANNU REV PLANT PHYS, V313, P349
   KURATA N, 2005, PLANT CELL PHYSIOL, V46, P48, DOI 10.1093/pcp/pci506
   LANDER ES, 1987, GENOMICS, V1, P174
   LARKIN RM, 2003, SCIENCE, V299, P902
   LEE S, 2005, PLANT MOL BIOL, V57, P805, DOI 10.1007/s11103-005-2066-9
   LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350
   LUO ZK, 2007, GENOME, V50, P811, DOI 10.1139/G07-064
   MEINKE D, 1997, PLANT J, V12, P247
   MIURA E, 2007, PLANT CELL, V19, P1313, DOI 10.1105/tpc.106.049270
   MOCHIZUKI N, 2001, P NATL ACAD SCI USA, V98, P2053
   MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321
   NAGATA N, 2005, PLANT CELL, V17, P233, DOI 10.1105/tpc.104.027276
   NOTHNAGEL T, 2003, PLANT BREEDING, V122, P339
   PANAUD O, 1996, MOL GEN GENET, V252, P597
   SANG XC, 2006, EUPHYTICA, V152, P177, DOI 10.1007/s10681-006-9196-2
   SATO Y, 2007, P NATL ACAD SCI USA, V104, P14169, DOI
   10.1073/pnas.0705521104
   STERN DB, 2004, TRENDS PLANT SCI, V9, P293
   WU DX, 2002, EUPHYTICA, V123, P195
   WU ZM, 2007, PLANT PHYSIOL, V145, P29, DOI 10.1104/pp.107.100321
   ZHANG HT, 2006, PLANT MOL BIOL, V62, P325, DOI 10.1007/s11103-006-9024-z
   ZHAO Y, 2000, PLANT BREEDING, V119, P131
NR 32
TC 1
PU KOREAN SOC GENETICS
PI SEOUL
PA KOREAN SCIENCE & TECHNOLOGY CENTER, RM 1002, 635-4 YEOKSAM-DONG,
   KANGNAM, SEOUL, 135-703, SOUTH KOREA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD APR
PY 2009
VL 31
IS 2
BP 165
EP 171
PG 7
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 445DH
UT ISI:000266029400006
ER

PT J
AU French, D
   Yang, WJ
   Cheng, C
   Raimondi, SC
   Mullighan, CG
   Downing, JR
   Evans, WE
   Pui, CH
   Relling, MV
AF French, Deborah
   Yang, Wenjian
   Cheng, Cheng
   Raimondi, Susana C.
   Mullighan, Charles G.
   Downing, James R.
   Evans, William E.
   Pui, Ching-Hon
   Relling, Mary V.
TI Acquired variation outweighs inherited variation in whole genome
   analysis of methotrexate polyglutamate accumulation in leukemia
SO BLOOD
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; ACUTE
   LYMPHOCYTIC-LEUKEMIA; FOLATE CARRIER EXPRESSION; HIGH-DOSE
   METHOTREXATE; CANCER-GROUP CCG; GENE-EXPRESSION; IN-VIVO;
   FOLYLPOLYGLUTAMATE SYNTHETASE; DIHYDROFOLATE-REDUCTASE
AB Methotrexate polyglutamates (MTXPGs) determine in vivo efficacy in
   acute lymphoblastic leukemia (ALL). MTXPG accumulation differs by
   leukemic subtypes, but genomic determinants of MTXPG variation in ALL
   remain unclear. We analyzed 3 types of whole genome variation: leukemia
   cell gene expression and somatic copy number variation, and inherited
   single nucleotide polymorphism (SNP) genotypes and determined their
   association with MTXPGs in leukemia cells. Seven genes (FHOD3, IMPA2,
   ME2, RASSF4, SLC39A6, SMAD2, and SMAD4) displayed all 3 types of
   genomic variation associated with MTXPGs (P < .05 for gene expression,
   P < .01 for copy number variation and SNPs): 6 on chromosome 18 and 1
   on chromosome 10. Increased chromosome 18 (P = .002) or 10 (P = .036)
   copy number was associated with MTXPGs even after adjusting for ALL
   subtype. The expression of the top 7 genes in leukemia cells accounted
   for more variation in MTXPGs (46%) than did the expression of the top 7
   genes in normal HapMap cell lines (20%). The top 7 inherited SNPs in
   patients accounted for approximately the same degree of variation (17%)
   in MTXPGs as did the top 7 SNP genotypes in HapMap cell lines (20%). We
   conclude that acquired genetic variation in leukemia cells has a
   stronger influence on MTXPG accumulation than inherited genetic
   variation. (Blood. 2009;113:4512-4520)
C1 [French, Deborah; Yang, Wenjian; Evans, William E.; Relling, Mary V.] St Jude Childrens Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
   [Cheng, Cheng] St Jude Childrens Hosp, Dept Biostat, Memphis, TN 38105 USA.
   [Cheng, Cheng; Raimondi, Susana C.; Mullighan, Charles G.; Downing, James R.; Evans, William E.; Pui, Ching-Hon; Relling, Mary V.] St Jude Childrens Hosp, Hematol Malignancies Program, Memphis, TN 38105 USA.
   [Raimondi, Susana C.; Mullighan, Charles G.; Downing, James R.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA.
   [Raimondi, Susana C.; Evans, William E.; Pui, Ching-Hon; Relling, Mary V.] Univ Tennessee, Memphis, TN USA.
   [Pui, Ching-Hon] St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA.
RP Relling, MV, St Jude Childrens Hosp, Dept Pharmaceut Sci, 262 Danny
   Thomas Pl, Memphis, TN 38105 USA.
EM mary.relling@stjude.org
FU National Cancer Institute [CA51001, CA78224, CA21765]; National
   Institutes of Health/National Institute of General Medical Sciences
   Pharmacogenetics Research Network and Database [U01GM61393, UO1GM61374,
   PS207998, PS207999]; Phelan Foundation ; State of Tennessee ; American
   Lebanese Syrian Associated Charities 
FX We thank the patients and their families, and our research faculty and
   staff for participating; Dr J. Carl Panetta for the pharmacokinetic
   analysis; Nancy Kornegay, Diana Chan, and MarkWilkinson for database
   and computer expertise; and Yaqin Chu, May Chung, Natalya Lenchik,
   Margaret Needham, Emily Melton, and Siamac Salehy for outstanding
   technical assistance.
   This work was supported by National Cancer Institute (CA51001, CA78224,
   CA21765), the National Institutes of Health/National Institute of
   General Medical Sciences Pharmacogenetics Research Network and Database
   (U01GM61393, UO1GM61374; www. pharmgkb. org PS207998 and PS207999), the
   Phelan Foundation, a Center of Excellence grant from the State of
   Tennessee, and the American Lebanese Syrian Associated Charities.
CR ARMSTRONG SA, 2002, NAT GENET, V30, P41
   BARREDO JC, 1994, BLOOD, V84, P564
   BELKOV VM, 1999, BLOOD, V93, P1643
   CAVALIERI D, 2007, ONCOL RES, V16, P535
   CHANG TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200
   CHENG Q, 2005, CELL CYCLE, V4, P1506
   CHENG Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612
   CHEOK MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151
   DARGENIO DZ, 1990, ADAPT 2 USERS GUIDE
   DERVIEUX T, 2003, CLIN CHEM, V49, P1632
   DERVIEUX T, 2003, CLIN PHARMACOL THER, V73, P506, DOI
   10.1016/S0009-9236(03)00063-8
   EVANS WE, 1984, LANCET, V1, P359
   EVANS WE, 1986, NEW ENGL J MED, V314, P471
   FABRE G, 1983, CANCER RES, V43, P4648
   FERNANDES DJ, 1988, CANCER RES, V48, P5638
   FINE BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518
   FRENCH D, 2008, PLOS ONE, V3, ARTN e2144
   GALIVAN J, 1980, MOL PHARMACOL, V17, P105
   GALPIN AJ, 1997, MOL PHARMACOL, V52, P155
   GAYNON PS, 2000, LEUKEMIA, V14, P2223
   GEE NS, 1988, BIOCHEM J, V249, P883
   GORLICK R, 1997, BLOOD, V89, P1013
   GREAVES MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164
   HARMS DO, 2000, LEUKEMIA, V14, P2234
   HARRIS MB, 1992, BLOOD, V79, P3316
   HEEREMA NA, 2007, GENE CHROMOSOME CANC, V46, P684, DOI 10.1002/gcc.20451
   HUANG RS, 2007, P NATL ACAD SCI USA, V104, P9758, DOI
   10.1073/pnas.0703736104
   KAGER L, 2005, J CLIN INVEST, V115, P110, DOI 10.1172/JCI200522477
   KAMEN BA, 1986, METHOD ENZYMOL, V122, P339
   KAWAMATA N, 2008, BLOOD, V111, P776, DOI 10.1182/blood-2007-05-088310
   LIN M, 2004, BIOINFORMATICS, V20, P1233, DOI
   10.1093/bioinformatics/bth069
   MASSON E, 1996, J CLIN INVEST, V97, P73
   MATHERLY LH, 1997, BLOOD, V90, P578
   MOGHRABI A, 2007, BLOOD, V109, P896, DOI 10.1182/blood-2006-06-027714
   MOORMAN AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128
   MORICKE A, 2008, BLOOD, V111, P4477, DOI 10.1182/blood-2007-09-112920
   MULLIGHAN CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   MULLIGHAN CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866
   PANETTA JC, 2002, CANCER CHEMOTH PHARM, V50, P419, DOI
   10.1007/s00280-002-0511-x
   PIETERS R, 2008, PEDIATR CLIN N AM, V55, P1, DOI
   10.1016/j.pcl.2007.11.002
   PUI CH, 2004, ANN HEMATOL S1, V83, S124
   PUI CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616
   PUI CH, 2006, NEW ENGL J MED, V354, P166
   RAIMONDI SC, 1996, LEUKEMIA, V10, P213
   RAIMONDI SC, 1998, METHOD MOL BIOL, P209
   RELLING MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405
   ROSS ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338
   SCHLIEBEN S, 1996, LEUKEMIA, V10, P957
   SCHRAPPE M, 2000, BLOOD, V95, P3310
   SCHULTZ KR, 2007, BLOOD, V109, P926, DOI 10.1182/blood-2006-01-024729
   SILVERMAN LB, 2001, BLOOD, V97, P1211
   SORICH MJ, 2008, PLOS MED, V5, P646, ARTN e83
   SUTCLIFFE MJ, 2005, LEUKEMIA, V19, P734, DOI 10.1038/sj.leu.2403673
   SYNOLD TW, 1994, J CLIN INVEST, V94, P1996
   VANTRIEST B, 1999, CLIN CANCER RES, V5, P643
   WHITEHEAD VM, 1998, LEUKEMIA LYMPHOMA, V31, P507
   WHITEHEAD VM, 2001, LEUKEMIA, V15, P1081
   WONSEY DR, 2002, P NATL ACAD SCI USA, V99, P6649
   YEOH EJ, 2002, CANCER CELL, V1, P133
NR 59
TC 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 7
PY 2009
VL 113
IS 19
BP 4512
EP 4520
DI 10.1182/blood-2008-07-172106
PG 9
SC Hematology
GA 443LC
UT ISI:000265910300012
ER

PT J
AU Liu, CY
   Yang, Q
   Cupples, LA
   Melgs, JB
   Dupuis, J
AF Liu, Chunyu
   Yang, Qiong
   Cupples, L. Adrienne
   Melgs, James B.
   Dupuis, Josee
TI Selection of the Most Informative Individuals From Families With
   Multiple Siblings for Association Studies
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE linkage analysis; association study; linkage disequilibrium;
   identity-by-descent (IBD)
ID QUANTITATIVE-TRAIT LOCI; LINKAGE DISEQUILIBRIUM; POWER; PAIRS
AB Association analyses may follow an initial linkage analysis for mapping
   and identifying genes underlying complex quantitative traits and may be
   conducted on unrelated subsets of individuals where only one member of
   a family is included. We evaluate two methods to select one sibling per
   sibship when multiple siblings are available: (1) one sibling with the
   most extreme trait value; and (2) one sibling using a combination score
   statistic based on extreme trait values and identity-by-descent sharing
   information. We compare the type 1 error and power. Furthermore, we
   compare these selection strategies with a strategy that randomly
   selects one sibling per sibship and with an approach that includes all
   siblings, using both simulation Study and an application to fasting
   blood glucose in the Framingham Heart Study. When genetic effect is
   homogeneous, we find that using the combination score call increase
   power by 30-40% compared to a random selection strategy, and loses only
   8-13% of power compared to the full sibship analysis, across all
   additive models considered, but offers at least 50% genotyping cost
   saving. In the presence of genetic heterogeneity, the score of fers a
   50% increase in power over a random selection strategy, but there is
   substantial loss compared to the full sibship analysis. In application
   to fasting blood sample, two SNPs are found in common for the selection
   strategies and the full sample among the 10 highest ranked single
   nucleotide polymorphisms. The EV strategy tends to agree with the
   IBD-EV strategy and the analysis of the full sample. Genet. Epidemiol.
   33:299-307, 2009. (C) 2008 Wiley-Liss, Inc.
C1 [Liu, Chunyu] Biogen Idec, Dept Drug Discovery, Genet & Genom, Cambridge, MA USA.
   [Yang, Qiong; Cupples, L. Adrienne; Dupuis, Josee] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
   [Melgs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
   [Melgs, James B.] Harvard Univ, Sch Med, Boston, MA USA.
RP Liu, CY, Biogen Idec, Dept Drug Discovery, Genet & Genom, 12 Cambridge
   Ctr, Cambridge, MA USA.
EM chunyu.liu@biogenidec.com
FU NIH NCRR [1S10RR163736-01A1]; National Heart, Lung and Blood
   Institute's Framingham Heart Study [N01-HC-25195]; American Diabetes
   Association 
FX Contract grant sponsor: NIH NCRR; Contract grant number:
   1S10RR163736-01A1; Contract grant sponsor: National Heart, Lung and
   Blood Institute's Framingham Heart Study; Contract grant number:
   N01-HC-25195; Contract grant sponsor: American Diabetes Association.
CR ABECASIS GR, 2002, NAT GENET, V30, P97
   ALLISON DB, 1999, AM J HUM GENET, V65, P531
   AMOS CI, 1994, AM J HUM GENET, V54, P535
   CAREY G, 1991, AM J HUM GENET, V49, P786
   CHEN ZH, 2005, AM J HUM GENET, V77, P661
   CUPPLES LA, 2007, BMC MED GENET S1, V8, ARTN S1
   EAVES L, 1994, BEHAV GENET, V24, P443
   ELSTON RC, 2000, GENET EPIDEMIOL, V19, P1
   FINGERLIN TE, 2004, AM J HUM GENET, V74, P432
   FISHER RA, 1935, DESIGN EXPT
   GOOD PI, 2005, PERMUTATION PARAMETR
   HALDANE JBS, 1919, J GENET-CAMB, V8, P299
   HASEMAN JK, 1972, BEHAV GENET, V2, P3
   PALMER LJ, 2005, LANCET, V366, P1223
   RISCH N, 1995, SCIENCE, V268, P1584
   SLATKIN M, 1999, AM J HUM GENET, V64, P1764
   WANG T, 2006, BMC GENET       1116
   WANG T, 2006, BMC GENET, V7, ARTN 5
NR 18
TC 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD MAY
PY 2009
VL 33
IS 4
BP 299
EP 307
DI 10.1002/gepi.20380
PG 9
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA 440UJ
UT ISI:000265724900003
ER

PT J
AU Wang, L
   Sun, LH
   Zhang, YL
   Wu, HW
   Li, C
   Pan, ZW
   Lu, YJ
   Yang, BF
AF Wang, Ling
   Sun, Lihua
   Zhang, Yanli
   Wu, Huiwei
   Li, Chao
   Pan, Zhenwei
   Lu, Yanjie
   Yang, Baofeng
TI Ionic Mechanisms Underlying Action Potential Prolongation by Focal
   Cerebral Ischemia in Rat Ventricular Myocytes
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Cerebral ischemia; Arrhythmia; QT prolongation; Ion currents
ID OUTWARD POTASSIUM CURRENT; CARDIAC AUTONOMIC DERANGEMENT; CURRENT I-TO;
   MOLECULAR-BASIS; MESSENGER-RNA; QT INTERVAL; K+ CURRENT; STROKE;
   CHANNEL; REPOLARIZATION
AB Despite prolongation of the QTc interval in humans during cerebral
   ischemia, little is known about the mechanisms that underlie these
   actions. Cerebral ischemic model was established by middle cerebral
   artery occlusion (MCAO) for 24 h. In rat ventricular myocytes, the
   effect of cerebral ischemia on action potential duration (APD) and
   underlying electrophysiologic mechanisms were investigated by
   whole-cell patch clamp. We demonstrated that heart rate-corrected QT
   interval and APD were prolonged with frequent occurrence of ventricular
   tachyarrhythmias in a rat model of MCAO. The I-Na density was overall
   smaller in cerebral ischemic myocytes relative to sham myocytes (P <
   0.01). The Nav1.5 protein and mRNA levels (pore-forming subunit for
   I-Na) were decreased by about 20% (P < 0.01) in cerebral ischemic rat
   hearts than those in sham-operated rat hearts. Peak transient outward
   K+ current (I-to) at +60 mV was found decreased by similar to 32.3% (P
   < 0.01) in cerebral ischemic rats. The peak amplitude of L-type Ca2+
   current (I-Ca,I-L) was increased and the inactivation kinetics were
   slowed (P < 0.01). Protein level of the pore-forming subunit for I-to
   was decreased, but that for I-Ca,I-L was increased. The inward
   rectifier K+ current (I-K1) at -120 mV and its protein level were
   unaffected. Our study represents the first documentation of I-Na, I-to
   and I-Ca,I-L channelopathy as the major ionic mechanism for cerebral
   ischemic QT prolongation. Copyright (C) 2009 S. Karger AG, Basel
C1 [Wang, Ling] Harbin Med Coll, Dept Physiol, Harbin 150081, Heilongjiang, Peoples R China.
   [Lu, Yanjie; Yang, Baofeng] Harbin Med Coll, Inst Cardiovasc Res, Harbin 150081, Heilongjiang, Peoples R China.
   [Wang, Ling; Sun, Lihua; Zhang, Yanli; Wu, Huiwei; Li, Chao; Pan, Zhenwei; Lu, Yanjie; Yang, Baofeng] Harbin Med Coll, Dept Pharmacol, State Prov Key Lab China, Harbin 150081, Heilongjiang, Peoples R China.
RP Wang, L, Harbin Med Coll, Dept Pharmacol, State Prov Key Lab China,
   Harbin 150081, Heilongjiang, Peoples R China.
EM wangling66@yahoo.com.cn
FU National Basic Research Program of China Foundation (973 Program)
   [2007CB512000, 2007CB512006]; Department of Education of Heilongjiang
   province of China Foundation [11521081]; Specialized Research Fund for
   the Doctoral Program of Higher Education [20060226019]
FX This work was supported by the National Basic Research Program of China
   Foundation (973 Program) (NO 2007CB512000, 2007CB512006), the
   Department of Education of Heilongjiang province of China Foundation
   (NO 11521081), and the Specialized Research Fund for the Doctoral
   Program of Higher Education (20060226019).
CR AKAR FG, 2004, AM J PHYSIOL-HEART C, V286, H602, DOI
   10.1152/ajpheart.00673.2003
   ARAB D, 2003, J INTENSIVE CARE MED, V18, P119
   ASPEY BS, 1998, NEUROPATH APPL NEURO, V24, P487
   BAILLARD C, 2000, HYPERTENSION, V36, P350
   BASSANI RA, 2006, BRAZ J MED BIOL RES, V39, P393
   BERS DM, 2002, NATURE, V415, P198
   BOYETT MR, 1980, PROG BIOPHYS MOL BIO, V36, P1
   CARMELIET E, 1993, EUR HEART J, V14, P3
   CHAE JE, 2007, ANESTHESIOLOGY, V107, P67
   CHIU EH, 2006, ACTA NEUROL TAIWAN, V15, P232
   COLIVICCHI F, 2004, STROKE, V35, P2094, DOI
   10.1161/01.STR.0000138452.81003.4c
   COLIVICCHI F, 2005, STROKE, V36, P1710, DOI
   10.1161/01.STR.0000173400.19346.bd
   DIXON JE, 1994, CIRC RES, V75, P252
   ECKARDT M, 1999, EUR NEUROL, V42, P190
   FINK JN, 2005, ARCH NEUROL-CHICAGO, V62, P1081
   HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399
   KAPRIELIAN R, 1999, J PHYSIOL-LONDON, V517, P229
   LI GR, 2004, HEART RHYTHM, V1, P460, DOI 10.1016/j.hrthm.2004.06.003
   LINZ KW, 2000, PFLUG ARCH EUR J PHY, V439, P588
   NAKAMURA TY, 1998, AM J PHYSIOL-HEART C, V274, H892
   NICHOLS CG, 1996, CIRC RES, V78, P1
   OPPENHEIMER S, 2006, CLIN AUTON RES, V16, P6, DOI
   10.1007/s1028-006-0276-0
   OUDIT GY, 2001, J MOL CELL CARDIOL, V33, P851
   REDFERN WS, 2003, CARDIOVASC RES, V58, P32, DOI
   10.1016/S0008-6363(02)00846-5
   SAH R, 2001, J PHYSIOL-LONDON, V533, P201
   SAH R, 2003, J PHYSIOL-LONDON, V546, P5, DOI
   10.1113/jphysiol.2002.026468
   SCHUILING WJ, 2006, ACTA NEUROCHIR, V148, P853, DOI
   10.1007/s00701-006-0808-3
   SCHULTZ JH, 2005, J MOL CELL CARDIOL, V39, P269, DOI
   10.1016/j.yjmcc.2005.02.025
   STRONG K, 2007, LANCET NEUROL, V6, P182
   SUN LH, 2008, CELL PHYSIOL BIOCHEM, V22, P147, DOI 10.1159/000149792
   SUN XY, 2005, J PHYSIOL-LONDON, V564, P411, DOI
   10.1113/jphysiol.2004.077263
   TOMASELLI GF, 1994, CIRCULATION, V90, P2534
   WANG ZG, 1999, CIRC RES, V84, P551
   WETTWER E, 1993, CARDIOVASC RES, V27, P1662
   WONG KYK, 2003, HEART, V89, P377
   YANG BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569
   YEOLA SW, 1997, CARDIOVASC RES, V33, P540
NR 37
TC 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2009
VL 23
IS 4-6
BP 305
EP 316
DI 10.1159/000218177
PG 12
SC Cell Biology; Physiology
GA 442TY
UT ISI:000265864700009
ER

PT J
AU Decker, WK
   Xing, D
   Li, S
   Robinson, SN
   Yang, H
   Steiner, D
   Komanduri, KV
   Shpall, EJ
AF Decker, William K.
   Xing, Dongxia
   Li, Sufang
   Robinson, Simon N.
   Yang, Hong
   Steiner, David
   Komanduri, Krishna V.
   Shpall, Elizabeth J.
TI Th-1 polarization is regulated by dendritic-cell comparison of MHC
   class I and class II antigens
SO BLOOD
LA English
DT Article
ID TRANSFER-RNA-SYNTHETASE; HELPER T-CELLS; LINKED RECOGNITION;
   IMMUNE-RESPONSES; CUTTING EDGE; CD83; AUTOANTIBODIES; MYOSITIS;
   INDUCTION; EXPRESSION
AB In the control of T-helper type I (Th-1) polarization, dendritic cells
   (DCs) must interpret a complex array of stimuli, many of which are
   poorly understood. Here we demonstrate that Th-1 polarization is
   heavily influenced by DC-autonomous phenomena triggered by the loading
   of DCs with antigenically matched major histocompatibility complex
   (MHC) class I and class II determinants, that is, class I and II
   peptide epitopes exhibiting significant amino acid sequence overlap (
   such as would be physiologically present during infectious processes
   requiring Th-1 immunity for clearance). Data were derived from 13
   independent antigenic models including whole-cell systems,
   single-protein systems, and 3 different pairs of overlapping class I
   and II binding epitopes. Once loaded with matched class I and II
   antigens, these "Th-1 DCs" exhibited differential cytokine secretion
   and surface marker expression, a distinct transcriptional signature,
   and acquired the ability to enhance generation of CD8(+) T lymphocytes.
   Mechanistically, tRNA-synthetases were implicated as components of a
   putative sensor complex involved in the comparison of class I and II
   epitopes. These data provide rigorous conceptual explanations for the
   process of Th-1 polarization and the antigenic specificity of cognate
   T-cell help, enhance the understanding of Th-1 responses, and should
   contribute to the formulation of more effective vaccination strategies.
   ( Blood. 2009; 113: 4213-4223)
C1 [Decker, William K.; Xing, Dongxia; Li, Sufang; Robinson, Simon N.; Yang, Hong; Steiner, David; Komanduri, Krishna V.; Shpall, Elizabeth J.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
RP Decker, WK, Univ Texas MD Anderson Canc Ctr, Dept Stem Cell
   Transplantat & Cellular Therapy, Unit 065,1515 Holcombe Blvd, Houston,
   TX 77030 USA.
EM wkdecker@mdanderson.org
FU National Institutes of Health [5-R01 CA061508-13]
FX This work was supported in part by National Institutes of Health (NIH,
   Bethesda, MD) grant no. 5-R01 CA061508-13 ( to E.J.S.).
CR AERTSTOEGAERT C, 2007, EUR J IMMUNOL, V37, P686, DOI
   10.1002/eji.200636535
   AGRIS PF, 1976, P NATL ACAD SCI USA, V73, P3857
   ARNETT FC, 1996, ARTHRITIS RHEUM, V39, P1507
   ARNEZ JG, 1999, J MOL BIOL, V286, P1449
   BEAULANDE M, 1998, NUCLEIC ACIDS RES, V26, P521
   BECKER HF, 1999, RNA, V5, P865
   BECKER Y, 2003, VIRUS GENES, V26, P119
   BEHRENS G, 2004, IMMUNOL CELL BIOL, V82, P84
   BENNETT SRM, 1997, J EXP MED, V186, P65
   BENNETT SRM, 1998, NATURE, V393, P478
   BRETSCHER PA, 1986, J IMMUNOL, V137, P3726
   BUNN CC, 1986, J EXP MED, V163, P1281
   DANG CV, 1988, FASEB J, V2, P2376
   DECKER WK, 2006, BIOL BLOOD MARROW TR, V12, P113, DOI
   10.1016/j.bbmt.2005.09.003
   DECKER WK, 2006, VACCINE, V24, P3203, DOI 10.1016/j.vaccine.2006.01.029
   DECKER WK, 2008, HUM VACCIN, V4, P1
   DECKER WK, 2008, J IMMUNOTHER, V31, P157
   GARCIAMARTINEZ LF, 2004, J IMMUNOL, V173, P2995
   HEATH WR, 2004, IMMUNOL REV, V199, P9
   HORNUNG VJ, 2004, J IMMUNOL, V172, P5935
   IOANNOU Y, 1999, CURR OPIN RHEUMATOL, V11, P468
   JANEWAY CA, 1997, IMMUNOBIOLOGY IMMUNE
   JANSSEN EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   KOBELT D, 2003, CURR TOP MICROBIOL, V276, P145
   KUIPER HM, 1995, J IMMUNOL, V155, P1776
   LECHMANN M, 2001, J EXP MED, V194, P1813
   LECHMANN M, 2002, TRENDS IMMUNOL, V23, P273
   LEKKERKERKER AN, 2006, CURR HIV RES, V4, P169
   LOPEZ CB, 2001, J INTERF CYTOK RES, V21, P763
   LOPEZ CB, 2004, J IMMUNOL, V173, P6882
   LOTZE MT, 2001, DENDRITIC CELLS
   MATHEWS MB, 1983, NATURE, V304, P177
   OAKS MK, 2000, J IMMUNOL, V164, P5015
   OHOSONE Y, 1998, ARTHRITIS RHEUM, V41, P1625
   PILARSKI LM, 1977, J EXP MED, V145, P709
   SAFDAR A, 2009, VACCINE         0205
   SANSOM DM, 2006, IMMUNOL REV, V212, P131
   SCHOENBERGER SP, 1998, NATURE, V393, P480
   SCHOLLER N, 2001, J IMMUNOL, V166, P3865
   SCHOLLER N, 2002, J IMMUNOL, V168, P2599
   SHEDLOCK DJ, 2003, SCIENCE, V300, P337
   SHIRAI M, 1994, J IMMUNOL, V152, P549
   TARGOFF IN, 1993, J CLIN INVEST, V91, P2556
   TUCKER MJ, 1982, J EXP MED, V155, P1037
   VARTANYAN OA, 1991, MOL BIOL, V25, P1033
   YEWDELL J, 1999, IMMUNOL REV, V172, P97
   YORK IA, 1999, IMMUNOL REV, V172, P49
   ZHANG B, 2005, NUCLEIC ACIDS RES S2, V33, W741, DOI 10.1093/nar/gki475
   ZINSER E, 2004, J EXP MED, V200, P345
NR 49
TC 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 30
PY 2009
VL 113
IS 18
BP 4213
EP 4223
DI 10.1182/blood-2008-10-185470
PG 11
SC Hematology
GA 442MW
UT ISI:000265846300017
ER

PT J
AU Beriou, G
   Costantino, CM
   Ashley, CW
   Yang, L
   Kuchroo, VK
   Baecher-Allan, C
   Hafler, DA
AF Beriou, Gaelle
   Costantino, Cristina M.
   Ashley, Charles W.
   Yang, Li
   Kuchroo, Vijay K.
   Baecher-Allan, Clare
   Hafler, David A.
TI IL-17-producing human peripheral regulatory T cells retain suppressive
   function
SO BLOOD
LA English
DT Article
ID GROWTH-FACTOR-BETA; ROR-GAMMA-T; TH17 CELLS; TGF-BETA; IN-VITRO;
   AUTOIMMUNE INFLAMMATION; RHEUMATOID-ARTHRITIS; HELPER-CELLS;
   DIFFERENTIATION; FOXP3
AB Although implicated in antagonistic functions, both regulatory T cells
   (Tregs) and Th17 effector cells play an important role in controlling
   autoimmune pathogenesis. Paradoxically, recent studies indicate that
   Tregs have the capacity to produce interleukin-17 (IL-17), although the
   ability of these cells to retain their suppressive function remains
   unknown. Here we report that human Tregs within the CD4(+) CD45RA(-)
   CD25(high)CCR6(+) HLA-DR(-)FoxP3(+) population produce IL-17 when
   activated in the presence of the proinflammatory cytokines IL-1 beta
   and IL-6, whereas IL-17 secretion was inhibited by TGF beta. To assess
   the ability of a single Treg to secrete IL-17 and to suppress in vitro
   immune function, we isolated clones from this population. We found that
   IL-17(+)/FoxP3(+) Treg clones retain suppressive function and exhibit
   the plasticity to secrete IL-17 or suppress depending on the nature of
   the stimulus provided. IL-17 production by these Treg clones was
   accompanied by sustained FoxP3 expression and concomitant, but
   reversible, loss of suppressive activity. Our data demonstrate that at
   the single cell level a subset of in vitro suppressive FoxP3(+) cells
   can be driven to secrete IL-17 under inflammatory conditions. These
   findings suggest a new mechanism by which inflammation can drive Tregs
   to secrete IL-17, thereby dampening suppression and promoting an
   inflammatory milieu. ( Blood. 2009;113:4240-4249)
C1 [Beriou, Gaelle; Costantino, Cristina M.; Ashley, Charles W.; Yang, Li; Kuchroo, Vijay K.; Baecher-Allan, Clare; Hafler, David A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Mol Immunol,Ctr Neurol Dis, Boston, MA USA.
RP Baecher-Allan, C, NRB 641,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM callan@rics.bwh.harvard.edu
FU National Multiple Sclerosis Society [FG1744A1, RG3825A1]; National
   Institutes of Health [U19AI070352, R01NS024247, P01AI03971,
   P01NS038037]; National Institute of Neurological Disorders and Stroke 
FX This work was supported by the National Multiple Sclerosis Society
   grants FG1744A1 ( G. B.) and RG3825A1 ( C. B. A.) and by the National
   Institutes of Health grants U19AI070352, R01NS024247, P01AI03971, and
   P01NS038037 ( D. A. H.). D. A. H. is a Jacob Javits Scholar of the
   National Institute of Neurological Disorders and Stroke.
CR ACOSTARODRIGUEZ EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467
   ACOSTARODRIGUEZ EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496
   ANNUNZIATO F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   BAECHERALLAN C, 2001, J IMMUNOL, V167, P1245
   BAECHERALLAN C, 2002, J IMMUNOL, V169, P6210
   BAECHERALLAN C, 2006, J IMMUNOL, V176, P4622
   BENNETT CL, 2001, NAT GENET, V27, P20
   BETTELLI E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   COSMI L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397
   CUA DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   DIECKMANN D, 2001, J EXP MED, V193, P1303
   EHRENSTEIN MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165
   EVANS HG, 2007, P NATL ACAD SCI USA, V104, P17034, DOI
   10.1073/pnas.0708426104
   HIROTA K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   IVANOV II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   JONULEIT H, 2001, J EXP MED, V193, P1285
   KOENEN HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967
   LEVINGS MK, 2001, J EXP MED, V193, P1295
   LIU WH, 2006, J EXP MED, V203, P1701
   MANEL N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   MURPHY CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   PASARE C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   PENE J, 2008, J IMMUNOL, V180, P7423
   RADHAKRISHNAN S, 2008, J IMMUNOL, V181, P3137
   SCHUBERT LA, 2001, J BIOL CHEM, V276, P37672
   SEDDIKI N, 2006, J EXP MED, V203, P1693
   SUGIYAMA H, 2005, J IMMUNOL, V174, P164
   THORNTON AM, 1998, J EXP MED, V188, P287
   TRAN DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   VIGLIETTA V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579
   VOLPE E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613
   WAN YY, 2007, IMMUNOL REV, V220, P199
   XU LL, 2007, J IMMUNOL, V178, P6725
   YANG L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
   ZHOU L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
NR 35
TC 72
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 30
PY 2009
VL 113
IS 18
BP 4240
EP 4249
DI 10.1182/blood-2008-10-183251
PG 10
SC Hematology
GA 442MW
UT ISI:000265846300020
ER

PT J
AU Chan, G
   Kalaitzidis, D
   Usenko, T
   Kutok, JL
   Yang, WT
   Mohi, MG
   Neel, BG
AF Chan, Gordon
   Kalaitzidis, Demetrios
   Usenko, Tatiana
   Kutok, Jeffery L.
   Yang, Wentian
   Mohi, M. Golam
   Neel, Benjamin G.
TI Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via
   cell-autonomous effects on multiple stages of hematopoiesis
SO BLOOD
LA English
DT Article
ID TYROSINE-PHOSPHATASE SHP-2; COLONY-STIMULATING FACTOR; ONCOGENIC K-RAS;
   ERYTHROID-DIFFERENTIATION; NOONAN-SYNDROME; MOUSE MODEL; STEM-CELLS;
   IN-VIVO; STEM/PROGENITOR CELLS; FUNCTIONAL-ANALYSIS
AB PTPN11, which encodes the tyrosine phosphatase SHP2, is mutated in
   approximately 35% of patients with juvenile myelomonocytic leukemia
   (JMML) and at a lower incidence in other neoplasms. To model JMML
   pathogenesis, we generated knockin mice that conditionally express the
   leukemia-associated mutant Ptpn11(D61Y). Expression of Ptpn11(D61Y) in
   all hematopoietic cells evokes a fatal myeloproliferative disorder
   (MPD), featuring leukocytosis, anemia, hepatosplenomegaly, and
   factor-independent colony formation by bone marrow (BM) and spleen
   cells. The Lin(-)Sca1(+)cKit(+) (LSK) compartment is expanded and
   "right-shifted," accompanied by increased stem cell factor (SCF)-evoked
   colony formation and Erk and Akt activation. However, repopulating
   activity is decreased in diseased mice, and mice that do engraft with
   Ptpn11(D61Y) stem cells fail to develop MPD. Ptpn11(D61Y) common
   myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs)
   produce cytokine-independent colonies in a cell-autonomous manner and
   demonstrate elevated Erk and Stat5 activation in response to
   granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulation.
   Ptpn11(D61Y) megakaryocyte-erythrocyte progenitors (MEPs) yield
   increased numbers of erythrocyte burst-forming units (BFU-Es), but MEPs
   and erythrocyte-committed progenitors (EPs) produce fewer erythrocyte
   colony-forming units (CFU-Es), indicating defective erythroid
   differentiation. Our studies provide a mouse model for Ptpn11-evoked
   MPD and show that this disease results from cell-autonomous and
   distinct lineage-specific effects of mutant Ptpn11 on multiple stages
   of hematopoiesis. (Blood. 2009; 113: 4414-4424)
C1 [Chan, Gordon; Usenko, Tatiana; Neel, Benjamin G.] Ontario Canc Inst, Dept Stem Cell & Dev Biol, Toronto, ON M5G 1L7, Canada.
   [Chan, Gordon; Kalaitzidis, Demetrios; Yang, Wentian; Mohi, M. Golam; Neel, Benjamin G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Kutok, Jeffery L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Chan, G, Ontario Canc Inst, Dept Stem Cell & Dev Biol, 101 Coll St,TMDT
   Rm 8-301, Toronto, ON M5G 1L7, Canada.
EM gordon.chan@uhnresearch.ca
FU National Institutes of Health (NIH; Bethesda, MD) [5T32-HL07623-20, RO1
   CA114945]; Deutsche Jose Carreras Leukamie-Stiftung e. V. (Munchen,
   Germany) ; American Society of Hematology (Washington, DC) 
FX We thank Dr Norman Iscove (Ontario Cancer Institute [OCI]) for critical
   reading of this paper; John Daley (Dana-Farber Cancer Institute
   [DFCI]), Susan Lazo-Kallanian (DFCI), Michelle Tseng (Hospital for Sick
   Children, [HSC], Toronto, ON) Leanne Jamieson (HSC), and Pier-Andre
   Pentilla (HSC) for expert assistance with flow cytometry; and Jason
   Gilliland (Beth Israel Deaconess Medical Center, [BIDMC]) Sonja
   Boet-Whitaker (BIDMC), Tarun Sharma (OCI), and Ashley Sanders (OCI) for
   technical assistance.
   D. K. was supported by a National Institutes of Health (NIH; Bethesda,
   MD) postdoctoral institutional training grant in hematology
   (5T32-HL07623-20). M. G. M. was supported by a fellowship from the
   Deutsche Jose Carreras Leukamie-Stiftung e. V. (Munchen, Germany; and a
   scholar award from the American Society of Hematology (Washington, DC).
   This work was supported by NIH RO1 CA114945 awarded to B. G. N.
CR ALTMAN AJ, 1974, BLOOD, V43, P341
   ARAKI T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084
   BARFORD D, 1998, STRUCTURE, V6, P249
   BIRNBAUM RA, 2000, MOL CELL, V5, P189
   BRAUN BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI
   10.1073/pnas.0307203101
   BRAUN BS, 2006, BLOOD, V108, P2041, DOI 10.1182/blood-2006-01-013490
   CHAN G, 2008, CANCER METAST REV, V27, P179, DOI
   10.1007/s10555-008-9126-y
   CHAN IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476
   CHAN RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002
   CHAN RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829
   EMANUEL PD, 1991, BLOOD, V77, P925
   EMANUEL PD, 2008, LEUKEMIA, V22, P1335, DOI 10.1038/leu.2008.162
   GERON I, 2008, CANCER CELL, V13, P321, DOI 10.1016/j.ccr.2008.02.017
   HAYASHI S, 2002, DEV BIOL, V244, P305
   HEINRICH AC, 2004, BLOOD, V104, P659, DOI 10.1182/blood-2003-05-1442
   HOF P, 1998, CELL, V92, P441
   KALAITZIDIS D, 2008, PLOS ONE, V3, ARTN e3776
   KEILHACK H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200
   KIEL MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   KIM A, 2007, BLOOD, V109, P1687
   KONIECZNA I, 2008, J CLIN INVEST, V118, P853, DOI 10.1172/JCI33742
   KOTECHA N, 2008, CANCER CELL, V14, P335, DOI 10.1016/j.ccr.2008.08.014
   KUHN R, 1995, SCIENCE, V269, P1427
   LACORAZZA HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017
   LAKSO M, 1996, P NATL ACAD SCI USA, V93, P5860
   LE DT, 2004, BLOOD, V103, P4243, DOI 10.1182/blood-2003-08-2650
   MIN IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015
   MOHI MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010
   MOHI MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI
   10.1016/j.gde.2006.12.011
   PURTON LE, 2007, CELL STEM CELL, V1, P263, DOI
   10.1016/j.stem.2007.08.016
   SCHUBBERT S, 2005, BLOOD, V106, P311, DOI 10.1182/blood-2004-11-4207
   SCHUBBERT S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   TARTAGLIA M, 2001, NAT GENET, V29, P465
   TARTAGLIA M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI
   10.1146/annurev.genom.6.080604.162305
   TERSZOWSKI G, 2005, BLOOD, V105, P1937, DOI 10.1182/blood-2004-09-3459
   VANMETER MEM, 2007, BLOOD, V109, P3945, DOI 10.1182/blood-2006-09-047530
   WALKLEY CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055
   WALKLEY CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   WERNING G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009
   ZHANG J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479
   ZHANG J, 2007, BLOOD, V109, P5238, DOI 10.1182/blood-2006-09-047050
   ZHANG YY, 2001, J CLIN INVEST, V108, P709
NR 42
TC 13
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 30
PY 2009
VL 113
IS 18
BP 4414
EP 4424
DI 10.1182/blood-2008-10-182626
PG 11
SC Hematology
GA 442MW
UT ISI:000265846300037
ER

PT J
AU Huang, CW
   Cheng, YS
   Rouvier, R
   Yang, KT
   Wu, CP
   Huang, HL
   Huang, MC
AF Huang, Chang-Wen
   Cheng, Yu-Shin
   Rouvier, Roger
   Yang, Kuo-Tai
   Wu, Chean-Ping
   Huang, Hsiu-Lin
   Huang, Mu-Chiou
TI Duck (Anas platyrhynchos) linkage mapping by AFLP fingerprinting
SO GENETICS SELECTION EVOLUTION
LA English
DT Article
ID QUAIL COTURNIX-JAPONICA; GENETIC-LINKAGE; SELECTION RESPONSES;
   DNA-SEQUENCES; MARKERS; GENOME; MAP; MICROSATELLITES; POULTRY; CATTLE
AB Amplified fragment length polymorphism (AFLP) with multicolored
   fluorescent molecular markers was used to analyze duck (Anas
   platyrhynchos) genomic DNA and to construct the first AFLP genetic
   linkage map. These markers were developed and genotyped in 766 F2
   individuals from six families from a cross between two different
   selected duck lines, brown Tsaiya and Pekin. Two hundred and ninety-six
   polymorphic bands (64% of all bands) were detected using 18 pairs of
   fluorescent TaqI/EcoRI primer combinations. Each primer set produced a
   range of 7 to 29 fragments in the reactions, and generated on average
   16.4 polymorphic bands. The AFLP linkage map included 260 co-dominant
   markers distributed in 32 linkage groups. Twenty-one co-dominant
   markers were not linked with any other marker. Each linkage group
   contained three to 63 molecular markers and their size ranged between
   19.0 cM and 171.9 cM. This AFLP linkage map provides important
   information for establishing a duck chromosome map, for mapping
   quantitative trait loci (QTL mapping) and for breeding applications.
C1 [Huang, Chang-Wen; Yang, Kuo-Tai; Wu, Chean-Ping; Huang, Hsiu-Lin; Huang, Mu-Chiou] Natl Chung Hsing Univ, Dept Anim Sci, Taichung 402, Taiwan.
   [Huang, Chang-Wen] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Cheng, Yu-Shin] Council Agr, Livestock Res Inst, Tainan 712, Taiwan.
   [Rouvier, Roger] INRA, Stn Ameliorat Genet Anim, Ctr Rech Toulouse, F-31326 Castanet Tolosan, France.
   [Yang, Kuo-Tai] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Wu, Chean-Ping] Natl Chiayi Univ, Dept Anim Sci, Chiayi 600, Taiwan.
RP Huang, MC, Natl Chung Hsing Univ, Dept Anim Sci, 250 Kuo Kung Rd,
   Taichung 402, Taiwan.
EM amino0116@yahoo.com.tw
   yushin@mail.tlri.gov.tw
   rouvier@germinal.toulouse.inra.fr
   ktyang@ibms.sinica.edu.tw
   wucheanp@yahoo.com.tw
   hlhuang2001@yahoo.com
   mchuang@mail.nchu.edu.tw
FU National Science Council, Executive Yuan, Taiwan [NSC92-2313-B005-106]
FX This study was funded by a grant awarded by the National Science
   Council, Executive Yuan, Taiwan (Grant No. NSC92-2313-B005-106).
CR AERTS J, 2003, CYTOGENET GENOME RES, V102, P297, DOI 10.1159/000075766
   AJMONEMARSAN P, 1997, ANIM GENET, V28, P418
   BENSCH S, 2005, MOL ECOL, V14, P2899, DOI
   10.1111/j.1365-294X.2005.02655.x
   BONNE ACM, 2003, BIOCHEM GENET, V41, P77
   CHENG YS, 2002, GENET SEL EVOL, V34, P597, DOI 10.1051/gse:2002025
   CHENG YS, 2003, WORLD POULTRY SCI J, V59, P509
   CHENG YS, 2005, BRIT POULTRY SCI, V46, P565, DOI
   10.1080/00071660500273193
   DENJEAN B, 1997, REV MED VET-TOULOUSE, V148, P695
   DINTINGER J, 2005, THEOR APPL GENET, V111, P347, DOI
   10.1007/s00122-005-2027-3
   EMARA MG, 2003, POULTRY SCI, V82, P952
   GROENEN MAM, 2000, GENOME RES, V10, P137
   GURYEV V, 2006, GENOME RES, V16, P491
   HERBERGS J, 1999, ANIM GENET, V30, P274
   HORNG YM, 2003, THERIOGENOLOGY, V59, P841
   HORNG YM, 2004, THERIOGENOLOGY, V62, P1536, DOI
   10.1016/j.theriogenology.2004.02.015
   HUANG CW, 2007, BRIT POULTRY SCI, V48, P323, DOI
   10.1080/00071660701370459
   HUANG MC, 2003, BRIT POULTRY SCI, V44, P359, DOI
   10.1080/0007166031000085562
   HUANG YH, 2006, GENETICS, V173, P287, DOI 10.1534/genetics.105.053256
   IHARA N, 2004, GENOME RES, V14, P1987, DOI 10.1101/gr.2741704
   KIKUCHI S, 2005, ANIM GENET, V36, P227, DOI
   10.1111/j.1365-2052.2005.01295.x
   KLEIN PE, 2000, GENOME RES, V10, P789
   KNORR C, 1999, ANIM GENET, V30, P28
   MASIGA DK, 2004, METH MOL B, V270, P173
   MCRAE AF, 2006, MAMM GENOME, V17, P346, DOI 10.1007/s00335-005-0087-y
   MUELLER UG, 1999, TRENDS ECOL EVOL, V14, P389
   PETERS JL, 2004, THEOR APPL GENET, V108, P321, DOI
   10.1007/s00122-003-1427-5
   PRIMMER CR, 1997, GENOME RES, V7, P471
   REED KM, 2003, CYTOGENET GENOME RES, V102, P331, DOI 10.1159/000075771
   ROSTOKS N, 2005, MOL GENET GENOMICS, V274, P515, DOI
   10.1007/s00438-005-0046-z
   ROUSSOT O, 2003, GENET SEL EVOL, V35, P559, DOI 10.1051/gse:2003039
   SONG QJ, 2005, THEOR APPL GENET, V110, P550, DOI
   10.1007/s00122-004-1871-x
   SREEKUMAR GP, 2001, POULTRY SCI, V80, P1
   VAIMAN D, 1996, GENETICS, V144, P279
   VANHAERINGEN WA, 2002, GENOME, V45, P914, DOI 10.1139/G02-060
   VOORRIPS RE, 2001, MAPCHART VERSION 2 2
   VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407
   WATANABE T, 2005, ZOOL SCI, V22, P883
   YEN NT, 2001, ASIAN AUSTRAL J ANIM, V14, P447
   ZHANG QJ, 2006, ACTA GENET SINICA, V33, P152
NR 39
TC 3
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 0999-193X
J9 GENET SEL EVOL
JI Genet. Sel. Evol.
PD MAR 17
PY 2009
VL 41
AR 28
DI 10.1186/1297-9686-41-28
PG 8
SC Agriculture, Dairy & Animal Science; Genetics & Heredity
GA 438LC
UT ISI:000265555900001
ER

PT J
AU Yang, JS
   Jing, XG
   Li, WJ
   Hu, XK
   Wei, W
   Wang, ZZ
AF Yang, Jian-She
   Jing, Xigang
   Li, Wen-Jian
   Hu, Xiang-Kai
   Wei, Wei
   Wang, Zhuan-Zi
TI A new potential radiosensitizer- multi-walled carbon nanotubes modified
   by ammonium persulfate
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE ammonium persulfate; multi-walled carbon nanotubes
ID ENDOCYTOSIS; PEPTIDES; GROWTH
AB Here we prepare carbon nanotubes modified with ammonium persulfate,
   very short carbon nanotubes with 50-100 nanometer length was obtained,
   and the higher Z potential of 52 mV was detected, these supporting the
   successful modification. HeLa cells were irradiated with gamma rays via
   adding or absent above functionalized carbon nanotubes (f-WCNTs) into
   cell culture medium with different concentration and radiation dosage.
   Confocal microscopy images and fluorescence-labeled DNA detection
   verified the successfully pure multi-wailed carbon nanotubes (p-WCNTs)
   and f-WCNTs penetrated into cells. Compared with pure radiation, by MTT
   test, f-WCNTs induced cell death markedly with about 8.7 times higher
   than former one under little dose of radiation; meanwhile, no obvious
   toxicity was observed both in p-WCNTs and f-WCNTs without of radiation
   exposure. We hypothesized that large amount of hydroxyl and carbonyl
   organs on the surface of very short f-WCNTs changed into free radicals
   result from radiations led cell damage. These implied that f-WCNTs
   could be regarded as a new radiosensitizer.
C1 [Yang, Jian-She] NW Normal Univ, Sch Life Sci, Lanzhou 730070, Peoples R China.
   [Yang, Jian-She; Jing, Xigang; Li, Wen-Jian; Hu, Xiang-Kai; Wei, Wei; Wang, Zhuan-Zi] Chinese Acad Sci, Inst Modern Phys, Lanzhou 730000, Peoples R China.
RP Yang, JS, NW Normal Univ, Sch Life Sci, Lanzhou 730070, Peoples R China.
EM yangjs@impcas.ac.cn
FU MOST [2006CB705600]; National Natural Science Foundation [10475109]; K.
   C. Wong Education Foundation, Hong Kong [20060037]; China Postdoctoral
   Science Foundation [20060400686]
FX Financial support from the 973 program of MOST (Grant No.
   2006CB705600). National Natural Science Foundation (Grant No.
   10475109), K. C. Wong Education Foundation, Hong Kong (Grant No.
   20060037) and China Postdoctoral Science Foundation (Grant No.
   20060400686) are greatly acknowledged.
CR ALBANO E, 2006, P NUTR SOC, V65, P278, DOI 10.1079/PNS2006496
   BUMP EA, 1982, SCIENCE, V217, P544
   CHEN J, 1998, SCIENCE, V282, P95
   CUNEO KC, 2007, CANCER RES, V67, P4886, DOI
   10.1158/0008-5472.CAN-06-3684
   KALIBEROV SA, 2007, GENE THER, V14, P1111, DOI 10.1038/sj.gt.3302965
   KINSELLA TJ, 2007, INT J RADIAT ONCOL, V69, P1254, DOI
   10.1016/j.ijrobp.2007.08.004
   KUELTZO LA, 2003, J PHARM SCI, V92, P1754, DOI 10.1002/jps.10448
   LALLY BE, 2007, CANCER RES, V67, P8791
   LIU J, 1998, SCIENCE, V280, P1253
   MARIA GA, 2008, WORLD RABBIT SCI, V16, P81
   MATTSON MP, 2000, J MOL NEUROSCI, V14, P175
   PANTAROTTO D, 2003, CHEM BIOL, V10, P961, DOI
   10.1016/j.chembiol.2003.09.011
   PANTAROTTO D, 2004, CHEM COMMUN     0107, P16, DOI 10.1039/b311254c
   SANO M, 2001, SCIENCE, V293, P1299
   SAVIC R, 2003, SCIENCE, V300, P615
   SHIKAM NW, 2004, J AM CHEM SOC, V126, P6850
   SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669
   SPECENIER PM, 2007, ANN ONCOL, V18, P1856, DOI 10.1093/annonc/mdm346
   VIDA TA, 1995, J CELL BIOL, V128, P779
   YANG JS, 2005, WORLD J GASTROENTERO, V11, P4098
   ZHANG AL, 2007, PROSTATE, V67, P1630, DOI 10.1002/pros.20638
NR 21
TC 1
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2008
VL 12B
BP 247
EP 252
PG 6
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
GA 439JM
UT ISI:000265623400010
ER

PT J
AU Xu, Y
   Zheng, FQ
   Fang, J
   Zhang, QW
   Qin, YD
   Liu, Y
   Yang, RJ
   Wu, B
AF Xu, Yin
   Zheng, Fei-qun
   Fang, Jia
   Zhang, Qun-wei
   Qin, Yi-de
   Liu, Yang
   Yang, Ren-jie
   Wu, Bin
TI Attenuation of experimental liver fibrosis by hepatocyte growth factor
   gene delivery mediated by adenovirus
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Liver fibrosis; Hepatocyte growth factor; Transforming growth factor;
   Gene therapy; Adenovirus
ID ENDOTHELIAL-CELL MOTILITY; SCATTER FACTOR-RECEPTOR;
   CARBON-TETRACHLORIDE; MICE; RATS; REGENERATION; IDENTIFICATION;
   ACTIVATION; CIRRHOSIS; THERAPY
AB The hepatocyte growth factor (HGF), originally identified and cloned as
   a potent mitogen for hepatocytes, has an essential part in the
   development and regeneration of the liver. In this study, HGF
   expression in vitro and in vivo was determined using ELISA. Rats were
   injected subcutaneously with CCl4 for eight weeks to induce liver
   fibrosis, and then divided randomly into groups for administration of
   various doses of adenovirus HGF (Ad-HGF) or vehicle. All rats were
   sacrificed 8 weeks after obtaining samples of serum and hepatic tissue.
   The results showed that glutamic oxaloacetic transaminase (GOT),
   glutamate pyruvate transaminase (GPT), total protein (TP), albumin
   (ALB), and total bilirubin (TBil) in serum were significantly recovered
   after gene therapy (P<0.05). Ad-HGF also attenuated the expression of
   TGF-beta 1 and the deposition of collagen. We conclude that intravenous
   administration of Ad-HGF may be useful for the treatment of fibrotic
   liver by promoting liver function recovery and collagenolytic
   capacities.
C1 [Xu, Yin; Zheng, Fei-qun; Fang, Jia; Zhang, Qun-wei; Liu, Yang; Wu, Bin] Beijing Inst Radiat Med, Dept Expt Hematol, Beijing 100850, Peoples R China.
   [Xu, Yin; Fang, Jia; Qin, Yi-de] Anhui Med Univ, Basic Med Sci Sch, Hefei 230032, Anhui, Peoples R China.
   [Zheng, Fei-qun; Yang, Ren-jie] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Intervent Therapy, Beijing Canc Hosp & Inst,Sch Oncol,Dept Intervent, Beijing 100036, Peoples R China.
RP Wu, B, Beijing Inst Radiat Med, Dept Expt Hematol, 27 Taiping Rd,
   Beijing 100850, Peoples R China.
EM renjieyang2007@163.com
   wubin63@yahoo.com.cn
FU Chinese National High-Tech RD Program [2003AA216081]
FX This project was supported by Chinese National High-Tech R&D Program,
   No. 2003AA216081.
CR BORKHAMKAMPHORST E, 2007, J HEPATOL, V46, P1064, DOI
   10.1016/j.jhep.2007.01.029
   BOTTARO DP, 1991, SCIENCE, V251, P802
   BRINKMANN V, 1995, J CELL BIOL 1, V131, P1573
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629
   CHAPARRO M, 2007, ANN HEPATOL, V6, P208
   CHEN MH, 2005, J ETHNOPHARMACOL, V97, P7, DOI 10.1016/j.jep.20043.09.040
   CLOUTHIER DE, 1997, J CLIN INVEST, V100, P2697
   CUI CP, 2008, HEPATOLOGY, V47, P986, DOI 10.1002/hep.22126
   DOH KO, 2008, INT J MOL MED, V21, P33
   DUAN HF, 2003, MOL THER, V8, P467, DOI 10.1016/S1525-0016(03)00186-2
   DUAN HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049
   FRISCH SM, 1994, J CELL BIOL, V124, P619
   GIORDANO S, 1989, NATURE, V339, P155
   GORELIK L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704
   GRAZIANI A, 1993, J BIOL CHEM, V268, P9165
   HAYASHI S, 2008, EUR J PHARMACOL, V580, P380, DOI
   10.1016/j.ejphar.2007.11.015
   HUH CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI
   10.1073/pnas.0306068101
   JIANG D, 2008, EUR J APPL PHYSL, P489
   KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357
   LEE CH, 2007, BIOL PHARM BULL, V30, P1898
   MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643
   MEDICO E, 1996, MOL BIOL CELL, V7, P495
   MONTESANO R, 1991, CELL, V67, P901
   NAGANO K, 2007, J OCCUP HEALTH, V49, P249
   NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489
   NALDINI L, 1995, J BIOL CHEM, V270, P603
   OGURA Y, 2001, HEPATO-GASTROENTEROL, V48, P545
   PINZANI M, 2004, DIGEST LIVER DIS, V36, P231, DOI
   10.1016/j.dld.2004.01.003
   PLANAGUMA A, 2005, FASEB J, V19, P1120
   PONZETTO C, 1993, MOL CELL BIOL, V13, P4600
   PONZETTO C, 1994, CELL, V77, P261
   PURDIE KJ, 2002, CARDIOVASC RES, V54, P659
   REN YX, 2007, ACTA PHARMACOL SIN, V28, P518, DOI
   10.1111/j.1745-7254.2007.00524.x
   SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808
   STOKER M, 1987, NATURE, V327, P239
   TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1
   UEKI T, 1999, NAT MED, V5, P226
   VANBELLE E, 1998, CIRCULATION, V97, P381
   XIA JL, 2006, AM J PATHOL, V168, P1500, DOI 10.2353/ajpath.2006.050747
   XUE F, 2003, GUT, V52, P694
   YAO X, 2007, BIOCHEM BIOPH RES CO, V362, P419, DOI
   10.1016/j.bbrc.2007.08.001
NR 41
TC 0
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2008
VL 12B
BP 387
EP 394
PG 8
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
GA 439JM
UT ISI:000265623400021
ER

PT J
AU Ding, KK
   Yang, CJ
   Shen, JJ
   Xu, LL
   Li, YL
   Zhou, PK
   Zeng, YJ
AF Ding, Kuke
   Yang, Chunjie
   Shen, Jingjing
   Xu, Lili
   Li, Yanling
   Zhou, Pinkun
   Zeng, Yanjun
TI Gamma-ray Up-regulated Holocarboxylase Synthetase Gene
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Radiation effect; Gene expression; Holocarboxylase synthetase
ID MULTIPLE CARBOXYLASE DEFICIENCY; DROSOPHILA-MELANOGASTER; HISTONE
   BIOTINYLATION; BIOTIN DEFICIENCY; EXPRESSION; MICE; PATTERNS
AB Purpose: To investigate the effects of holocarboxylase synthetase (HCS)
   gene to irradiation in a time- and dose-dependent manner. Materials and
   methods: AHH-1 cells, Hela cells, and the nude mice inoculated with
   tumor cells were exposed to gamma-ray of cobalt 60. The mRNA level of
   HCS was detected using real-time PCR. The profiles of mRNA of HCS after
   radiation were analyzed and described. Results: The expression of HCS
   gene was higher in AHH-1 cells than that in Hela cells. Furthermore,
   both AHH-1 and Hela displayed similar time-dependent transcriptional
   levels of HCS gene to radiations at the dose of 2 and 10 Gy. We set the
   parameters of D, V, R, F, N to quantitatively analyze HCS gene
   regulation in response to irradiation. We also observed that
   irradiation resulted in higher levels of HCS in human hepatocyte
   xenografts, compared with three other types of human tumor xenografts.
   2 and 4 Gy radiation had little influence on the HCS gene of human lung
   cancer and brain cancer, mammary gland cancer was more sensitive to the
   4 Gy gamma-ray dose compared with the 2 Gy gamma-ray dose. Conclusion:
   HCS is a good radiation-responsive gene. It may be used as a candidate
   for developing novel biomarkers of radiation damage and it has a great
   potential to be used in radiation-therapy of liver tumors.
C1 [Zeng, Yanjun] Beijing Univ Technol, Biomed Engn Sch, Beijing 100124, Peoples R China.
   [Ding, Kuke; Shen, Jingjing; Xu, Lili; Li, Yanling] Capital Med Univ, Biomed Engn Sch, Beijing 100069, Peoples R China.
   [Ding, Kuke; Zhou, Pinkun] Beijing Inst Radiat Med, Dept Radiat Toxicol & Oncol, Beijing 100850, Peoples R China.
   [Yang, Chunjie] Hebei Med Univ, Hosp 2, Shijiazhuang 050000, Hebei Province, Peoples R China.
RP Zeng, YJ, Beijing Univ Technol, Biomed Engn Sch, 100 Pingleyuan Rd,
   Beijing 100124, Peoples R China.
EM yjzeng@bjut.edu.cn
FU National Natural Science Foundation of China [30770533]; Chinese
   National High Technology "863'' Programs [2004AA221160]; foundation of
   Beijing municipal education commission [Km200710025007]
FX This study was supported by the grants from National Natural Science
   Foundation of China (No. 30770533) and Chinese National High Technology
   "863'' Programs (No. 2004AA221160), and the foundation of Beijing
   municipal education commission (No. Km200710025007).
CR CAMPOREALE G, 2006, J NUTR, V136, P2735
   CAMPOREALE G, 2007, J NUTR, V137, P885
   DIANA PA, 2002, ARCH MED RES, V33, P439
   DUPUIS L, 1996, HUM MOL GENET, V5, P1011
   FU HQ, 2007, PROT RAD, V21, P89
   LONG XH, 2006, PROT RAD, V26, P78
   MOCK DM, 2005, J NUTR BIOCHEM, V16, P435, DOI
   10.1016/j.jnutbio.2005.03.022
   MORRONE A, 2002, AM J MED GENET, V111, P10
   NARANG MA, 2004, HUM MOL GENET, V13, P15, DOI 10.1093/hmg/ddh006
   OKADA A, 2005, BIRTH DEFECTS RES A, V73, P229, DOI 10.1002/bdra.20131
   PETERS DM, 2002, AM J PHYSIOL-CELL PH, V283, C878, DOI
   10.1152/ajpcell.00107.2002
   SEALEY WM, 2005, J NUTR, V135, P973
   SHENG FJ, 2005, RAD RES J RAD CRAFT, V23, P316
   TACHIIRI S, 2006, INT J RADIAT ONCOL, V64, P272, DOI
   10.1016/j.ijrobp.2005.08.030
   WANG QH, 2006, IEEE NETWORK, V20, P26
   WANG XM, 2004, CHIN RAD HYG, V13, P10
   ZHONG M, 2005, CHIN PUBLIC HYG, V21, P545
NR 17
TC 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD MAY
PY 2009
VL 29
IS 3
BP 383
EP 389
DI 10.1007/s10571-008-9330-x
PG 7
SC Cell Biology; Neurosciences
GA 438SI
UT ISI:000265575300010
ER

PT J
AU Wang, DD
   Weng, QJ
   Zhang, L
   He, QJ
   Yang, B
AF Wang, Duoduo
   Weng, Qinjie
   Zhang, Lei
   He, Qiaojun
   Yang, Bo
TI VEGF and Bcl-2 Interact Via MAPKs Signaling Pathway in the Response to
   Hypoxia in Neuroblastoma
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Hypoxia; VEGF; Bcl-2; MAPKs
ID ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR VEGF; P38 MAPK; C-JUN;
   GENE-TRANSCRIPTION; PROSTATE CARCINOMA; INDUCED APOPTOSIS; OXIDATIVE
   STRESS; CANCER-CELLS; IN-VIVO
AB Tumor hypoxia has been reported to be a negative prognostic factor in a
   number of tumor sites, which suggests a positive correlation between
   tumor hypoxia and increased metastatic efficiency. Evidence shows that
   vascular endothelial growth factor (VEGF) stimulates angiogenesis in
   tumor growth and mediates neuroprotection to prevent an apoptotic cell
   death. Human neuroblastoma cells (CHP126) were exposed to moderate
   hypoxia for different time spans to explore the molecular stress
   responses. Apoptotic features as an increase of Bax/Bcl-2 ratio and
   activation of caspase 3 were observed at early period of exposure time,
   but these effects were reversed with the extension of hypoxic
   treatment. Hypoxia also activated MAPKs signaling pathways in a
   time-relative manner, which were involved in the regulation of
   hypoxia-related resistance of CHP126 cells. Meanwhile, VEGF and its
   receptor KDR were found to interact with MAPKs signaling pathways
   except the effect of hypoxia. Furthermore, rhVEGF(165) was utilized to
   discern that VEGF increased Bcl-2 and procaspase 3 expressions,
   contributing to a synergistic relationship of an angiogenic response
   with Bcl-2 in hypoxia via a cross talk, while the activation of ERK
   MAPK is important for both productions. These altered signals may be
   critical to predict a poor outcome; therefore, our knowledge provides
   new insight into apoptosis and angiogenesis control of tumor cells and
   suggests a strategy based on the blockade of hypoxia-induced VEGF
   signaling under hypoxia in neuroblastoma.
C1 [Wang, Duoduo; Weng, Qinjie; Zhang, Lei; He, Qiaojun; Yang, Bo] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Hangzhou 310058, Zhejiang, Peoples R China.
RP He, QJ, Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol,
   388 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM qiaojunhe@zju.edu.cn
   yang924@zju.edu.cn
FU National Natural Science Foundation [30672484]; Natural Science
   Foundation of Zhejiang Province [R20512]; Zhejiang Provincial Program 
FX The authors thank the grant sponsors. Grant information: This study
   received financial support from the National Natural Science Foundation
   (30672484), the Natural Science Foundation of Zhejiang Province
   (R20512), and Zhejiang Provincial Program for the cultivation of
   High-level Innovative Health talents.
CR ADAMS JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   ALFRANCA A, 2002, MOL CELL BIOL, V22, P12
   ANAI S, 2007, MOL CANCER THER, V6, P101, DOI
   10.1158/1535-7163.MCT-06-0367
   BALLIF BA, 2001, CELL GROWTH DIFFER, V12, P397
   BARONE FC, 2001, MED RES REV, V21, P129
   BENASCIUTTI E, 2004, BLOOD, V104, P256, DOI 10.1182/blood.2004-08-2661
   BERRA E, 2000, BIOCHEM PHARMACOL, V60, P1171
   BICKLER PE, 2000, J NEUROSCI, V20, P3522
   BOLDT S, 2002, CARCINOGENESIS, V23, P1831
   BRUNET A, 1999, EMBO J, V18, P664
   BYZOVA TV, 2000, MOL CELL, V6, P851
   CHOI WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200
   CONRAD PW, 1999, J BIOL CHEM, V274, P23570
   DEWIL M, 2007, NEUROBIOL DIS, V26, P332, DOI 10.1016/j.nbd.2006.12.023
   DIAS S, 2002, BLOOD, V99, P2532
   FENG H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041
   FERNANDEZ A, 2001, J NATL CANCER I, V93, P208
   FERRARA N, 2003, NAT MED, V9, P669
   FOLKMAN J, 1990, J NATL CANCER I, V82, P4
   HELMLINGER G, 1997, NAT MED, V3, P177
   HOU ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200
   JIN KL, 2002, J NEUROCHEM, V80, P119
   JUNN E, 2001, J NEUROCHEM, V78, P374
   KILIC E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje
   KIM DS, 2003, ARCH PHARM RES, V26, P739
   KRAEMER M, 1999, CELL GROWTH DIFFER, V10, P193
   LENICULESCU H, 1999, MOL CELL BIOL, V19, P751
   MACKAY K, 1999, J BIOL CHEM, V274, P6272
   MAKIN G, 2001, BREAST CANCER RES, V3, P150
   MARTIN JL, 2001, CIRC RES, V89, P750
   MAULIK D, 2008, NEUROSCI LETT, V439, P94, DOI
   10.1016/j.neulet.2008.02.037
   MEISTER B, 1999, EUR J CANCER, V35, P445
   NEUFELD G, 1999, FASEB J, V13, P9
   POULAKI V, 2002, J CLIN INVEST, V109, P805
   QIAN D, 2004, BIOL REPROD, V70, P1822, DOI 10.1095/biolreprod.103.025031
   ROSSER CJ, 2003, INT J RADIAT ONCOL, V56, P1, DOI
   10.1016/S0630-3016(02)04468-1
   SCHLESINGER HR, 1976, CANCER RES, V36, P3094
   SEMENZA GL, 2001, CURR OPIN CELL BIOL, V13, P167
   SHAKIBAEI M, 2001, J BIOL CHEM, V276, P13289
   TAKAHASHI H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TOKUDA H, 2003, J ENDOCRINOL, V177, P101
   TRISCIUOGLIO D, 2004, J BIOL CHEM, V279, P6737, DOI
   10.1074/jbc.M308938200
   TRISCIUOGLIO D, 2005, MOL BIOL CELL, V16, P4153
   YOKOI K, 2004, CLIN CANCER RES, V10, P2299
   ZACHARY I, 2003, BIOCHEM SOC T 6, V31, P1171
   ZEITLIN BD, 2006, CANCER RES, V66, P8698, DOI
   10.1158/0008-5472.CAN-05-3691
   ZHANG Y, 2008, GROWTH FACTORS, V26, P125, DOI 10.1080/08977190802105909
   ZHU XW, 2005, NEUROCHEM RES, V30, P791, DOI 10.1007/s11064-005-6872-x
NR 48
TC 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD MAY
PY 2009
VL 29
IS 3
BP 391
EP 401
DI 10.1007/s10571-008-9331-9
PG 11
SC Cell Biology; Neurosciences
GA 438SI
UT ISI:000265575300011
ER

PT J
AU Huang, Y
   Liu, YH
   Chen, Y
   Yu, XW
   Yang, JL
   Lu, MD
   Lu, QY
   Ke, Q
   Shen, AG
   Yan, MJ
AF Huang, Ye
   Liu, Yonghua
   Chen, Ying
   Yu, Xiaowei
   Yang, Junling
   Lu, Mudan
   Lu, Qiuyan
   Ke, Qing
   Shen, Aiguo
   Yan, Meijuan
TI Peripheral Nerve Lesion Induces an Up-regulation of Spy1 in Rat Spinal
   Cord
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Glial cells; Proliferation; Sciatic nerve injury; Spinal cord; Spy1
ID CELL-CYCLE REGULATOR; CDK INHIBITORS; DNA-DAMAGE; PROGRESSION;
   ACTIVATION; PHOSPHORYLATION; REGENERATION; EXPRESSION; P27(KIP1);
   PROTEINS
AB Spy1, as a member of the Speedy/RINGO family and a novel activator of
   cyclin-dependent kinases, was shown to promote cell cycle progression
   and cell survival in response to DNA damage. While its expression and
   roles in nervous system lesion and repair were still unknown. Here, we
   performed an acute sciatic nerve injury model in adult rats and studied
   the dynamic changes of Spy1 expression in lumbar spinal cord.
   Temporally, Spy1 expression was increased shortly after sciatic nerve
   crush and peaked at day 2. Spatially, Spy1 was widely expressed in the
   lumbar spinal cord including neurons and glial cells. While after
   injury, Spy1 expression was increased predominantly in astrocytes and
   microglia, which were largely proliferated. Moreover, there was a
   concomitant up-regulation of CDK2 activity and down-regulation of p27.
   Collectively, we hypothesized peripheral nerve injury induced an
   up-regulation of Spy1 in lumbar spinal cord, which was associated with
   glial proliferation.
C1 [Huang, Ye; Liu, Yonghua; Yu, Xiaowei; Shen, Aiguo; Yan, Meijuan] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Peoples R China.
   [Huang, Ye; Liu, Yonghua; Yu, Xiaowei; Shen, Aiguo; Yan, Meijuan] Nanjing Med Univ, Orthopaed Affiliated Hosp 2, Nantong 226001, Peoples R China.
   [Liu, Yonghua; Yang, Junling; Lu, Mudan; Lu, Qiuyan; Ke, Qing] Nantong Univ, Coll Med, Dept Microbiol & Immunol, Nantong 226001, Peoples R China.
   [Chen, Ying] Nantong Univ, Coll Med, Dept Histol & Embryol, Nantong 226001, Peoples R China.
RP Shen, AG, Nantong Univ, Jiangsu Key Lab Neuroregenerat, 19 Qi Xiu Rd,
   Nantong 226001, Peoples R China.
EM lyh656338268_2006@126.com
   ymz_888@yahoo.com.cn
FU National Natural Scientific Foundation of China [30300099, 30770488];
   Natural Scientific Foundation of Jiangsu Province [BK2003035,
   BK2006547]; College and University Natural Scientific Research
   Programme of Jiangsu Province [03KJB180109, 04KJB320114]; Technology
   Guidance Plan for Social Development of Jiangsu Province [BS2004526];
   Health Project of Jiangsu Province [H200632]; Jiangsu Province [CX08S_
   026Z]
FX This study was supported by the National Natural Scientific Foundation
   of China Grant (No. 30300099 and No. 30770488), Natural Scientific
   Foundation of Jiangsu Province Grant (No. BK2003035 and No. BK2006547),
   College and University Natural Scientific Research Programme of Jiangsu
   Province (No. 03KJB180109 and No. 04KJB320114), Technology Guidance
   Plan for Social Development of Jiangsu Province Grant (BS2004526),
   Health Project of Jiangsu Province (H200632), and Liu- Da- Ren- Cai-
   Gao- Feng'' Financial Assistance of Jiangsu Province Grant (No. 2),
   Postgraduate Scientific Innovation Program of Jiangsu Province (No.
   CX08S_ 026Z).
CR BARNES EA, 2003, CANCER RES, V63, P3701
   BHATTACHARJEE RN, 2001, MOL CELL BIOL, V21, P5417
   CHENG A, 2005, CELL CYCLE, V4, P155
   DINARINA A, 2005, BIOCHEM J 2, V386, P349, DOI 10.1042/BJ20041779
   FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43
   FERBY I, 1999, GENE DEV, V13, P2177
   FU SY, 1997, MOL NEUROBIOL, V14, P67
   GASTWIRT RF, 2006, J BIOL CHEM, V281, P35425, DOI 10.1074/jbc.M604720200
   HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22
   HUNTER T, 1994, CELL, V79, P573
   KARAISKOU A, 2001, J BIOL CHEM, V276, P36028
   LENORMAND JL, 1999, EMBO J, V18, P1869
   MCANDREW CW, 2007, CELL CYCLE, V6, P1937
   MORGAN DO, 1995, NATURE, V374, P131
   MORRIS GF, 1989, J BIOL CHEM, V264, P13856
   NEBREDA AR, 2006, CURR OPIN CELL BIOL, V18, P192, DOI
   10.1016/j.ceb.2006.01.001
   PORTER LA, 2002, J CELL BIOL, V157, P357
   PORTER LA, 2003, MOL BIOL CELL, V14, P3664, DOI 10.1091/mbc.E02-12-0820
   SHERR CJ, 1999, GENE DEV, V13, P1501
   SHI SX, 2007, J MOL NEUROSCI, V32, P64, DOI 10.1007/s12031-007-0015-6
NR 20
TC 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD MAY
PY 2009
VL 29
IS 3
BP 403
EP 411
DI 10.1007/s10571-008-9332-8
PG 9
SC Cell Biology; Neurosciences
GA 438SI
UT ISI:000265575300012
ER

PT J
AU Zhang, BH
   Li, M
   Chen, L
   Yang, K
   Shan, YF
   Zhu, LH
   Sun, SG
   Li, L
   Wang, C
AF Zhang, Bianhong
   Li, Meng
   Chen, Liang
   Yang, Kai
   Shan, Yufei
   Zhu, Lianhui
   Sun, Shaogang
   Li, Lin
   Wang, Chen
TI The TAK1-JNK cascade is required for IRF3 function in the innate immune
   response
SO CELL RESEARCH
LA English
DT Article
DE JNK; TAK1; IRF3; innate immunity
ID INTERFERON REGULATORY FACTOR-3; NF-KAPPA-B; DOUBLE-STRANDED-RNA;
   TOLL-LIKE RECEPTORS; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; ANTIVIRAL
   RESPONSE; TERMINAL KINASE; ADAPTER MOLECULE; CUTTING EDGE
AB Interferon regulatory factor (IRF)3 is critical for the transcriptional
   induction of chemokines and cytokines during viral or bacterial
   invasion. The kinases Tank binding kinase (TBK)1 and Ikappa B kinase
   (IKK)epsilon can phosphorylate the C-terminal part of IRF3 and play
   important roles in IRF3 activation. In this study, we show that another
   kinase, c-Jun-NH2-terminal kinase (JNK), phosphorylates IRF3 on its
   N-terminal serine 173 residue, and TAK1 can stimulate IRF3
   phosphorylation via JNK. JNK specific inhibitor SP600125 inhibits the
   N-terminal phosphorylation without affecting the C-terminal
   phosphorylation. In addition, IRF3-mediated gene expressions on
   lipopolysaccharide (LPS) or polyinosinic-cytidylic acid (polyI:C)
   treatment are severely impaired by SP600125, as well as for reporter
   gene assay of IRF3 activation. Knockdown of TAK1 further confirmed
   these observations. Interestingly, constitutive active IRF3(5D) can be
   inhibited by SP600125; JNK1 can synergize the action of IRF3(5D), but
   not the S173A-IRF3( 5D) mutant. More importantly, polyI: C failed to
   induce the phosphorylation of mutant S173A and SP600125 dramatically
   abrogated IRF3 phosphorylation and dimerization that was stimulated by
   polyI: C. Thus, this study demonstrates that the TAK1-JNK cascade is
   required for IRF3 function, in addition to TBK1/IKK epsilon, uncovering
   a new mechanism for mitogen-activated protein (MAP) kinase to regulate
   the innate immunity.
C1 [Zhang, Bianhong; Li, Meng; Chen, Liang; Yang, Kai; Shan, Yufei; Zhu, Lianhui; Sun, Shaogang; Li, Lin; Wang, Chen] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.
RP Wang, C, Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell
   Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R
   China.
EM lli@sibs.ac.cn
   cwang01@sibs.ac.cn
FU Chinese Academy Renovation Program [KSCX1-YW-R-06]; Ministry of Science
   and Technology of China [2002CB513000, 2006AA02Z121, 2007CB914504)];
   National Natural Science Foundation of China [30225013, 30623003,
   30521005]
FX We thank Prof. John Hiscott (McGill University, Canada), Melanie Cobb
   (University of Texas Southwest Medical Center, USA), Stephan Ludwig
   (Heinrich-Heine-University, Duesseldorf, Germany) and Hong-Bing Shu
   (College of Life Sciences, Wuhan University, Wuhan, China) for
   providing plasmids for this study. We thank Prof. Zhengfan Jiang
   (Beijing University, China) for providing the 293-TLR3 cell line. This
   study is partly supported by grants from the Chinese Academy Renovation
   Program (KSCX1-YW-R-06), the Ministry of Science and Technology of
   China (2002CB513000, 2006AA02Z121 and 2007CB914504) and the National
   Natural Science Foundation of China (30225013, 30623003 and 30521005).
CR AKASHI S, 2000, J IMMUNOL, V164, P3471
   AKIRA S, 2001, NAT IMMUNOL, V2, P675
   ALEXOPOULOU L, 2001, NATURE, V413, P732
   AU WC, 1995, P NATL ACAD SCI USA, V92, P11657
   BENNETT BL, 2001, P NATL ACAD SCI USA, V98, P13681
   BIBEAUPOIRIER A, 2006, J IMMUNOL, V177, P5059
   CAO ZD, 1996, NATURE, V383, P443
   CHIANG E, 2006, J IMMUNOL, V176, P5720
   CLEMENT JF, 2008, J VIROL, V82, P3984, DOI 10.1128/JVI.02526-07
   COLLINS SE, 2004, J VIROL, V78, P1706, DOI
   10.1128/JVI.78.4.1706-1717.2004
   DAUBER B, 2006, J VIROL, V80, P11667, DOI 10.1128/JVI.01142-06
   DIAO LR, 2005, EXP CELL RES, V308, P196, DOI 10.1016/j.yexcr.2005.04.016
   EHRHARDT C, 2004, FEBS LETT, V567, P230, DOI
   10.1016/j.febslet.2004.04.069
   FITZGERALD KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   GRAFF JW, 2007, J GEN VIROL 2, V88, P613, DOI 10.1099/vir.0.82255-0
   HAN KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200
   HEMMI H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520
   HEYLBROECK C, 2000, J VIROL, V74, P3781
   JIANG ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI
   10.1073/pnas.0308496101
   JOHNSON J, 2007, J BIOL CHEM, V282, P15022, DOI 10.1074/jbc.M700421200
   KIM T, 1999, J BIOL CHEM, V274, P30686
   KIM T, 2000, J BIOL CHEM, V275, P16910
   KOEDEL U, 2000, J INFECT DIS, V182, P1437
   LEWIS TS, 1998, ADV CANCER RES, V74, P139
   LIN RT, 1999, MOL CELL BIOL, V19, P959
   LIN RT, 2004, J VIROL, V78, P1675, DOI 10.1128/JVI.78.4.1675-1684.2004
   LIU MK, 1994, J IMMUNOL, V153, P2642
   LU G, 2006, CELL MOL BIOL, V52, P29, DOI 10.1170/T695
   MCWHIRTER SM, 2004, P NATL ACAD SCI USA, V101, P233
   MEURS EF, 2007, WORLD J GASTROENTERO, V13, P2446
   MEYLAN E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946
   ONEILL LAJ, 2002, TRENDS IMMUNOL, V23, P296
   ONO K, 2001, J BIOL CHEM, V276, P24396
   OSHIUMI H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200
   OSHIUMI H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886
   PRINARAKIS E, 2008, EMBO J, V27, P865, DOI 10.1038/emboj.2008.28
   RAWADI G, 1998, J IMMUNOL, V160, P1330
   SAITOH T, 2006, NAT IMMUNOL, V7, P598, DOI 10.1038/ni1347
   SARKAR SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847
   SATO S, 2003, J IMMUNOL, V171, P4304
   SERVANT MJ, 2001, J BIOL CHEM, V276, P355
   SETH RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019
   SHARMA S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315
   SHIBUYA H, 1996, SCIENCE, V272, P1179
   SHIRAKABE K, 1997, J BIOL CHEM, V272, P8141
   SPIEGEL M, 2005, J VIROL, V79, P2079, DOI
   10.1128/JVI.79.4.2079-2086.2005
   SUHARA W, 2000, J BIOCHEM-TOKYO, V128, P301
   TAKEDA K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   TAKEUCHI O, 2001, INT IMMUNOPHARMACOL, V1, P625
   VANBOXELDEZAIRE AHH, 2006, IMMUNITY, V25, P361, DOI
   10.1016/j.immuni.2006.08.014
   VIATOUR P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI
   10.1016/j.tiba.2004.11.009
   YAMAMOTO M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986
   YAMAMOTO M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   YANG K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853
   YONEYAMA M, 1998, EMBO J, V17, P1087
   YONEYAMA M, 2002, J INTERF CYTOK RES, V22, P73
NR 56
TC 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2009
VL 19
IS 4
BP 412
EP 428
DI 10.1038/cr.2009.8
PG 17
SC Cell Biology
GA 440KV
UT ISI:000265700100004
ER

PT J
AU Zuo, Y
   Xiang, BG
   Yang, J
   Sun, XX
   Wang, YM
   Cang, H
   Yi, J
AF Zuo, Yong
   Xiang, Binggang
   Yang, Jie
   Sun, Xuxu
   Wang, Yumei
   Cang, Hui
   Yi, Jing
TI Oxidative modification of caspase-9 facilitates its activation via
   disulfide-mediated interaction with Apaf-1
SO CELL RESEARCH
LA English
DT Article
DE oxidative modification; ROS; caspase-9; apoptosis; disulfide
ID CYTOCHROME-C; INHIBITS APOPTOSIS; MAMMALIAN-CELLS; IN-VIVO;
   MITOCHONDRIA; PROTEINS; STRESS; DEATH; CYTOTOXICITY; THIOREDOXIN
AB Intracellular reactive oxygen species (ROS) are known to regulate
   apoptosis. Activation of caspase-9, the initial caspase in the
   mitochondrial apoptotic cascade, is closely associated with ROS, but it
   is unclear whether ROS regulate caspase-9 via direct oxidative
   modification. The present study aims to elucidate the molecular
   mechanisms by which ROS mediate caspase-9 activation. Our results show
   that the cellular oxidative state facilitates caspase-9 activation.
   Hydrogen peroxide treatment causes the activation of caspase-9 and
   apoptosis, and promotes an interaction between caspase-9 and apoptotic
   protease-activating factor 1 (Apaf-1) via disulfide formation. In
   addition, in an in vitro mitochondria-free system, the thiol-oxidant
   diamide promotes auto-cleavage of caspase-9 and the caspase-9/Apaf-1
   interaction by facilitating the formation of disulfide-linked
   complexes. Finally, a point mutation at C403 of caspase-9 impairs both
   H2O2-promoted caspase-9 activation and interaction with Apaf-1 through
   the abolition of disulfide formation. The association between
   cytochrome c and the C403S mutant is significantly weaker than that
   between cytochrome c and wild-type caspase-9, indicating that oxidative
   modification of caspase-9 contributes to apoptosome formation under
   oxidative stress. Taken together, oxidative modification of caspase-9
   by ROS can mediate its interaction with Apaf-1, and can thus promote
   its auto-cleavage and activation. This mechanism may facilitate
   apoptosome formation and caspase-9 activation under oxidative stress.
C1 [Zuo, Yong; Xiang, Binggang; Yang, Jie; Sun, Xuxu; Wang, Yumei; Cang, Hui; Yi, Jing] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci,Dept Cell Biol, Educ Minist Cell Differentiat & Apoptosis,Key Lab, Shanghai 200025, Peoples R China.
RP Yi, J, Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci,Dept Cell Biol,
   Educ Minist Cell Differentiat & Apoptosis,Key Lab, Shanghai 200025,
   Peoples R China.
EM yangjieyj@126.com
   yijing@shsmu.edu.cn
FU National Natural Science Foundation of China [30570965, 30600105];
   Ministry of Sciences and Technologies of China [2006CB910104]; Shanghai
   Education Committee [05BZ17]
FX We thank Drs T Ozaki and T Yamamoto(Kochi University Medical School,
   Japan) for their gifts of the wild-type and antisense Mn-SOD OSC cell
   lines. We also thank Drs GS Salvesen and SJ Riedl (Burnham Institute
   for Medical Research, USA) for their gift of the caspase-9 construct.
   Dr Hua Jing (Scripps Research Institute, USA) is especially thanked for
   her aid with the cysteine-positioning predictions. This work was
   supported by grants from the National Natural Science Foundation of
   China (30570965, J Yi; 30600105, J Yang), the Ministry of Sciences and
   Technologies of China (2006CB910104, J Yi) and the Shanghai Education
   Committee (05BZ17, J Yang).
CR ALNEMRI ES, 1996, CELL, V87, P171
   ANDOH T, 2002, J BIOL CHEM, V277, P9655
   BAKER A, 2000, BIOCHEM BIOPH RES CO, V268, P78
   BARFORD D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI
   10.1016/j.sbi.2004.09.012
   BISWAS S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI
   10.1016/j.bcp.2005.10.044
   BURGOYNE JR, 2007, SCIENCE, V317, P1393, DOI 10.1126/science.1144318
   ENGLAND K, 2005, REDOX REP, V10, P237, DOI 10.1179/135100005X70224
   GEORGIOU G, 2002, CELL, V111, P607
   HAO ZY, 2005, CELL, V121, P579
   HOGG PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI
   10.1016/S0968-0004(03)00057-4
   JING YW, 2006, FREE RADICAL BIO MED, V40, P2183, DOI
   10.1016/j.freeradbiomed.2006.02.016
   KAGAN VE, 2006, CHEM-BIOL INTERACT, V163, P15, DOI
   10.1016/j.cbi.2006.04.019
   KAMATA H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   KATOH I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200
   LEE Y, 1999, J BIOL CHEM, V274, P19792
   LI P, 1997, CELL, V91, P479
   LIN DB, 2005, J BIOL CHEM, V280, P13682, DOI 10.1074/jbc.M407762200
   MACPHERSON LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544
   MADESH M, 2001, J CELL BIOL, V155, P1003
   MANNICK JB, 1999, SCIENCE, V284, P651
   MOUNGJAROEN J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI
   10.1124/jpet.106.110965
   NICHOLSON DW, 1999, CELL DEATH DIFFER, V6, P1028
   RIEDL SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   ROSSIG L, 1999, J BIOL CHEM, V274, P6823
   SATO T, 2004, J IMMUNOL, V173, P285
   SHI YG, 2004, CELL, V117, P855
   SLEE EA, 1999, J CELL BIOL, V144, P281
   SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946
   TOROK NJ, 2002, CANCER RES, V62, P1648
   UETA E, 1999, JPN J CANCER RES, V90, P555
   YANG J, 2004, FREE RADICAL BIO MED, V37, P2027, DOI
   10.1016/j.freeradbiomed.2004.09.016
   YANG Y, 2007, P NATL ACAD SCI USA, V104, P10813
   YI J, 2004, CANCER RES, V64, P108
   YU XC, 2006, J MOL BIOL, V355, P577, DOI 10.1016/j.jmb.2005.10.040
   ZHENG M, 1998, SCIENCE, V279, P1718
NR 35
TC 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2009
VL 19
IS 4
BP 449
EP 457
DI 10.1038/cr.2009.19
PG 9
SC Cell Biology
GA 440KV
UT ISI:000265700100007
ER

PT J
AU Jiang, H
   Wu, JC
   He, C
   Yang, WD
   Li, HL
AF Jiang, Hai
   Wu, Jianchun
   He, Chen
   Yang, Wending
   Li, Honglin
TI Tumor suppressor protein C53 antagonizes checkpoint kinases to promote
   cyclin-dependent kinase 1 activation
SO CELL RESEARCH
LA English
DT Article
DE C53; Cdk1; checkpoint kinases
ID DNA-DAMAGE CHECKPOINT; BINDING-PROTEIN; WIP1 PHOSPHATASE; AURORA-A;
   CHK1; CELL; PHOSPHORYLATION; ATR; CENTROSOMES; REPLICATION
AB Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 complex is the driving force
   for mitotic entry, and its activation is tightly regulated by the G2/M
   checkpoint. We originally reported that a novel protein C53 (also known
   as Cdk5rap3 and LZAP) potentiates DNA damage-induced cell death by
   modulating the G2/M checkpoint. More recently, Wang et al. (2007) found
   that C53/LZAP may function as a tumor suppressor by way of inhibiting
   NF-kappa B signaling. We report here the identification of C53 protein
   as a novel regulator of Cdk1 activation. We found that knockdown of C53
   protein causes delayed Cdk1 activation and mitotic entry. During DNA
   damage response, activation of checkpoint kinase 1 and 2 (Chk1 and
   Chk2) is partially inhibited by C53 overexpression. Intriguingly, we
   found that C53 interacts with Chk1 and antagonizes its function.
   Moreover, a portion of C53 protein is localized at the centrosome, and
   centrosome-targeting C53 potently promotes local Cdk1 activation. Taken
   together, our results strongly suggest that C53 is a novel negative
   regulator of checkpoint response. By counteracting Chk1, C53 promotes
   Cdk1 activation and mitotic entry in both unperturbed cell-cycle
   progression and DNA damage response.
C1 [Jiang, Hai; Wu, Jianchun; He, Chen; Yang, Wending; Li, Honglin] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Chicago, IL 60614 USA.
RP Li, HL, Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr,
   Chicago, IL 60614 USA.
EM h-li2@northwestern.edu
FU NIH [R21 AG027840, R01 GM081776]; Children's Memorial Research Center ;
   Clarke family 
FX We thank Dr J Bartek (Danish Cancer Society) for Chk1-GFP-PACT
   construct. We are grateful for the insightful advice from Drs Junying
   Yuan (Harvard Medical School), Qingshen Gao, Jacek Topczewski, Kathy
   Randell, Bernard Mirkin (Northwestern University) and Marcus Peter
   (University of Chicago), and the help from Drs Francis Szele and Ed
   Kang (Children's Memorial Research Center and Northwestern University)
   on time-lapse video-microscopy and William Goossens (Children's
   Memorial Research Center) on confocal microscopy. The project was
   supported by NIH grant R21 AG027840 and R01 GM081776 (to H Li),
   Children's Memorial Research Center and the Clarke family.
CR BARTEK J, 2003, CANCER CELL, V3, P421
   BROWN EJ, 2000, GENE DEV, V14, P397
   CHING YP, 2000, GENE, V242, P285
   CIMPRICH KA, 1996, P NATL ACAD SCI USA, V93, P2850
   DOXSEY S, 2005, ANNU REV CELL DEV BI, V21, P411
   DOXSEY S, 2005, TRENDS CELL BIOL, V15, P303, DOI
   10.1016/j.tcb.2005.04.008
   DOZIER C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010
   DUTERTRE S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108
   FUJIMOTO H, 2006, CELL DEATH DIFFER, V13, P1170, DOI
   10.1038/sj.cdd.4401801
   FURNARI B, 1997, SCIENCE, V277, P1495
   GUO ZJ, 2000, GENE DEV, V14, P2745
   HIROTA T, 2003, CELL, V114, P585
   JACKMAN M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918
   JIANG H, 2005, J BIOL CHEM, V280, P20651, DOI 10.1074/jbc.M413431200
   KRAMER A, 2004, CELL CYCLE, V3, P1390
   KRAMER A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165
   LI HL, 1997, J BIOL CHEM, V272, P21010
   LIU QH, 2000, GENE DEV, V14, P1448
   LU XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305
   MATSUOKA S, 1998, SCIENCE, V282, P1893
   NG CP, 2004, J BIOL CHEM, V279, P8808, DOI 10.1074/jbc.M312215200
   NIIDA H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200
   NOJIMA H, 2004, METH MOL B, V280, P3
   OLIVATRASTOY M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927
   SANCAR A, 2004, ANNU REV BIOCHEM, V73, P39
   SHIEH SY, 2000, GENE DEV, V14, P289
   SHILOH Y, 1997, ANNU REV GENET, V31, P635
   SHIROMIZU T, 2006, GENES CELLS, V11, P477, DOI
   10.1111/j.1365-2443.2006.00955.x
   SYLJUASEN RG, 2005, MOL CELL BIOL, V25, P3553
   TAKAI H, 2000, GENE DEV, V14, P1439
   TSVETKOV L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200
   WANG JL, 2006, BIOCHEM J 2, V393, P489, DOI 10.1042/BJ20050960
   WANG JL, 2007, CANCER CELL, V12, P239, DOI 10.1016/j.ccr.2007.07.002
   WARD IM, 2001, J BIOL CHEM, V276, P47759
   YIN XL, 2005, INT J MOL MED, V16, P251
   ZHOU BBS, 2000, NATURE, V408, P433
   ZHOU BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296
NR 37
TC 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2009
VL 19
IS 4
BP 458
EP 468
DI 10.1038/cr.2009.14
PG 11
SC Cell Biology
GA 440KV
UT ISI:000265700100008
ER

PT J
AU Yang, XR
   Chan, C
AF Yang, Xuerui
   Chan, Christina
TI Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells
   through regulation of Bcl-2
SO CELL RESEARCH
LA English
DT Article
DE palmitate; apoptosis; HepG2; PKR; phosphorylation of Bcl-2; NF-kappa B;
   JNK
ID DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; FREE
   FATTY-ACIDS; ENDOPLASMIC-RETICULUM STRESS; TUMOR-SUPPRESSOR P53;
   HEPATOMA-CELLS; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAYS;
   IMMUNOHISTOCHEMICAL DETECTION
AB The present study shows that double-stranded RNA-dependent protein
   kinase (PKR) regulates the protein expression level and phosphorylation
   of Bcl-2 and plays an anti-apoptotic role in human hepatocellular
   carcinoma cells (HepG2). In various types of cells, saturated free
   fatty acids (FFAs), such as palmitate, have been shown to induce
   cellular apoptosis by several mechanisms. Palmitate down-regulates the
   activity of PKR and thereby decreases the level of Bcl-2 protein,
   mediated in part by reduced activation of the NF-kappa B transcription
   factor. In addition to the level of Bcl-2 protein, the phosphorylation
   of Bcl-2 at different amino acid residues, such as Ser70 and Ser87, is
   also important in regulating cellular apoptosis. The decrease in the
   phosphorylation of Bcl-2 at Ser70 upon exposure to palmitate is
   mediated by inhibition of PKR and possibly by c-Jun N-terminal kinase
   (JNK), whereas the phosphorylation of Bcl-2 at Ser87 is unaffected by
   palmitate or PKR. In summary, PKR mediates the regulation of the
   protein level and the phosphorylation status of Bcl-2, providing a
   novel mechanism of palmitate-induced apoptosis in HepG2 cells.
C1 [Yang, Xuerui; Chan, Christina] Michigan State Univ, Dept Chem Engn & Mat Sci, E Lansing, MI 48824 USA.
   [Yang, Xuerui; Chan, Christina] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
RP Chan, C, Michigan State Univ, Dept Chem Engn & Mat Sci, E Lansing, MI
   48824 USA.
EM krischan@egr.msu.edu
FU National Science Foundation [BES 0425821]; Environmental Protection
   Agency [RD83184701]; Whitaker Foundation ; National Institute of Health
   [R01GM079688-01, R21CA126136-01, R21RR024439]; MSU Foundation ; Center
   for Systems Biology 
FX We thank Michael J Opperman for his help with some of the experiments.
   The work was supported in part by the National Science Foundation (BES
   0425821), the Environmental Protection Agency (RD83184701), the
   Whitaker Foundation, the National Institute of Health (R01GM079688-01,
   R21CA126136-01, and R21RR024439), and the MSU Foundation and the Center
   for Systems Biology.
CR AKTAS H, 1998, P NATL ACAD SCI USA, V95, P8280
   ANDRE ND, 2007, CANCER LETT, V258, P118, DOI
   10.1016/j.canlet.2007.08.021
   ASSIMACOPOULOSJEANNET F, 2004, INT J OBESITY S4, V28, S53, DOI
   10.1038/sj.ijo.0802857
   BARBER GN, 2005, CELL DEATH DIFFER, V12, P563, DOI
   10.1038/sj.cdd.4401643
   BARREYRO FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200
   BASU A, 2000, INT J ONCOL, V16, P497
   BLAGOSKLONNY MV, 2001, LEUKEMIA, V15, P869
   BRECKENRIDGE DG, 2004, CURR OPIN CELL BIOL, V16, P647
   CHANG LF, 2001, NATURE, V410, P37
   CHARLOTTE F, 1994, AM J PATHOL, V144, P460
   CHEN CL, 2000, MOL CELL BIOL, V20, P2687
   CHEN YN, 2003, BRIT J PHARMACOL, V140, P461, DOI 10.1038/sj.bjp.0705461
   CUDDIHY AR, 1999, MOL CELL BIOL, V19, P2475
   DALESSIO M, 2004, FASEB J, V18, P1609
   DAVIS RJ, 2000, CELL, V103, P239
   DECHIARA G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200
   DENG XM, 2000, P NATL ACAD SCI USA, V97, P1578
   DENG XM, 2001, J BIOL CHEM, V276, P23681
   DEY M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041
   DONZE O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078
   ELEY HL, 2007, J BIOL CHEM, V282, P7087, DOI 10.1074/jbc.M610378200
   FELDSTEIN AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283
   FELDSTEIN AE, 2006, AM J PHYSIOL-GASTR L, V290, P1339
   FENG LF, 2006, J DRUG TARGET, V14, P21, DOI 10.1080/10611860500527947
   GIL J, 2000, ONCOGENE, V19, P1369
   GILFOY FD, 2007, J VIROL, V81, P11148, DOI 10.1128/JVI.00446-07
   GIORDANO A, 2005, CELL DEATH DIFFER, V12, P603, DOI
   10.1038/sj.cdd.4401636
   GOH KC, 2000, EMBO J, V19, P4292
   HANDAYANI T, 2007, ANTICANCER RES, V27, P965
   HE B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   HIASA Y, 2003, AM J GASTROENTEROL, V98, P2528, DOI
   10.1016/S0002-9270(03)01696-4
   HICKSONBICK DLM, 2002, AM J PHYSIOL-HEART C, V282, H656
   HUANG DS, 2005, WORLD J GASTROENTERO, V11, P204
   ICHIJO H, 1997, SCIENCE, V275, P90
   ITO T, 1997, J BIOL CHEM, V272, P11671
   JAMMI NV, 2003, BIOCHEM BIOPH RES CO, V308, P50, DOI
   10.1016/S0006-291X(03)01318-4
   KIM SH, 2000, ONCOGENE, V19, P3086
   KIM SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987
   KOROMILAS AE, 1992, SCIENCE, V257, P1685
   KUCHARCZAK J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230
   KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288
   KUMAR A, 1997, EMBO J, V16, P406
   LANDAU Z, 2006, APOPTOSIS, V11, P717, DOI 10.1007/s10495-006-5425-3
   LEMAIRE PA, 2005, J MOL BIOL, V345, P81, DOI 10.1016/j.jmb.2004.10.031
   LI M, 2001, J BIOL CHEM, V276, P1185
   LI Z, 2007, BMC BIOINFORMATICS, V8, ARTN 202
   LIEDTKE C, 2002, HEPATOLOGY, V36, P315
   LISTENBERGER LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI
   10.1073/pnas.0630588100
   LIU J, 2005, CELL RES, V15, P36
   LU ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI
   10.1016/S0006-291X(03)00449-2
   MAI HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200
   MALHI H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200
   MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232
   MEUSEL TR, 2002, J IMMUNOL, V168, P6429
   NISHIKAWA T, 2006, J HEPATOL, V44, P1074, DOI 10.1016/j.jhep.2005.11.045
   ONUKI R, 2004, EMBO J, V23, P959
   PATAER A, 2005, MOL THER, V11, P717, DOI 10.1016/j.ymthe.2005.01.018
   PETERS T, 1996, ALL ALBUMIN BIOCH GE
   PIANKO S, 2000, J GASTROEN HEPATOL, V15, P798
   REMIZOV O, 2003, MOL CELL ENDOCRINOL, V212, P1, DOI
   10.1016/j.mce.2003.09.026
   RUVOLO PP, 1999, J BIOL CHEM, V274, P20296
   SALOMONI P, 1997, P NATL ACAD SCI USA, V94, P3296
   SIMIZU S, 2004, CANCER SCI, V95, P266
   SRIVASTAVA RK, 1999, P NATL ACAD SCI USA, V96, P3775
   SRIVASTAVA S, 2007, BMC GENOMICS, V8, ARTN 364
   SRIVASTAVA S, 2007, FREE RADICAL RES, V41, P38, DOI
   10.1080/10715760600943900
   STARK GR, 1998, ANNU REV BIOCHEM, V67, P227
   TAKIZAWA T, 2002, EUR J BIOCHEM, V269, P6126, DOI
   10.1046/j.1432-1033.2002.03325.x
   TAMATANI M, 1999, J BIOL CHEM, V274, P8531
   TAYLOR D, 1996, GENE DEV, V10, P2732
   TAYLOR SS, 2005, CELL, V122, P823
   TERADA T, 1996, PATHOL INT, V46, P764
   WANG CY, 1998, SCIENCE, V281, P1680
   WATANABE MAE, 2003, EUR J PHARMACOL, V465, P205, DOI
   10.1016/S0014-2999(03)01480-8
   WEBERNORDT RM, 1996, BLOOD, V88, P809
   WEI YR, 2006, AM J PHYSIOL-ENDOC M, V291, E275, DOI
   10.1152/ajpendo.00644.2005
   WHITMARSH AJ, 1998, SCIENCE, V281, P1671
   WILLIAMS BR, 2001, SCI STKE, RE2
   WILLIS SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI
   10.1016/j.ceb.2005.10.001
   WU HY, 1994, J BIOL CHEM, V269, P20067
   XU Z, 2000, MOL CELL BIOL, V20, P5285
   YAMAGISHI S, 2002, MOL MED, V8, P179
   YEUNG MC, 1998, J BIOL CHEM, V273, P25198
   ZEPPA P, 1996, ACTA CYTOL, V40, P861
   ZHANG F, 2001, J BIOL CHEM, V276, P24946
   ZHANG H, 2004, CANCER SCI, V95, P878
   ZHAO M, 1994, HISTOPATHOLOGY, V25, P237
   ZHOU HR, 2003, TOXICOL SCI, V74, P335, DOI 10.1093/toxsci/kfg148
NR 88
TC 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2009
VL 19
IS 4
BP 469
EP 486
DI 10.1038/cr.2009.25
PG 18
SC Cell Biology
GA 440KV
UT ISI:000265700100009
ER

PT J
AU Du, J
   Yang, S
   An, D
   Hu, F
   Yuan, W
   Zhai, CL
   Zhu, TH
AF Du, Jun
   Yang, Shuang
   An, Di
   Hu, Fen
   Yuan, Wei
   Zhai, Chunli
   Zhu, Tianhui
TI BMP-6 inhibits microRNA-21 expression in breast cancer through
   repressing delta EF1 and AP-1
SO CELL RESEARCH
LA English
DT Article
DE BMP-6; microRNA-21; AP-1; delta EF1; breast cancer invasion
ID BONE MORPHOGENETIC PROTEIN-6; TUMOR-SUPPRESSOR GENE; TGF-BETA; CADHERIN
   EXPRESSION; CELLS; METASTASIS; TARGETS; MIR-21; PROGRESSION; PATHWAYS
AB MicroRNAs (miRNAs), which are small noncoding RNA molecules, play
   important roles in the post-transcriptional regulation process. The
   microRNA-21 gene (miR-21) has been reported to be highly expressed in
   various solid tumors, including breast cancer. Bone morphogenetic
   protein-6 (BMP-6) has been identified as an inhibitor of breast cancer
   epithelial-mesenchymal transition (EMT) through rescuing E-cadherin
   expression. We initiated experiments to identify the relationships
   between miR-21 and BMP-6 in breast cancer progression. Real-time PCR
   analysis showed that miR-21 expression was very high in MDA-MB-231
   cells that expressed little BMP-6. A reverse correlation between BMP-6
   and miR-21 was also determined in breast cancer tissue samples.
   Moreover, BMP-6 inhibited miR-21 transcription in MDA-MB-231 cells. In
   order to investigate how BMP-6 inhibited the miR-21 promoter
   (miPPR-21), we constructed a series of miPPR-21 reporters. Luciferase
   assay results indicated that BMP-6 inhibited miPPR-21 activity through
   the E2-box and AP-1-binding sites. We also demonstrated that both delta
   EF1 and TPA induced miR-21 expression. Using site-directed mutation and
   CHIP assay, we found that delta EF1 induced miPPR-21 activity by
   binding to the E2-box on miPPR-21. Moreover, TPA triggered miPPR-21
   activity through the AP-1 binding sites. BMP-6 treatment significantly
   reduced the binding of these factors to miPPR-21 by decreasing the
   expression of delta EF1 and c-Fos/c-Jun. We also demonstrated that
   BMP-6-induced downregulation of miR-21 modified the activity of PDCD4
   3'UTR and inhibited MDA-MB-231 cell invasion. delta EF1 overexpression
   and TPA induction blocked this inhibitory effect of BMP-6. In
   conclusion, BMP-6-induced inhibition of miR-21 suggests that BMP-6 may
   function as an anti-metastasis factor by a mechanism involving
   transcriptional repression of miR-21 in breast cancer.
C1 [Du, Jun; Yang, Shuang; An, Di; Hu, Fen; Yuan, Wei; Zhai, Chunli; Zhu, Tianhui] Nankai Univ, Coll Med, Lab Med Mol Biol, Tianjin 300071, Peoples R China.
RP Zhu, TH, Nankai Univ, Coll Med, Lab Med Mol Biol, 94 Weijin Rd, Tianjin
   300071, Peoples R China.
EM zhuth@nankai.edu.cn
CR ASANGANI IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11
   BUIJS JT, 2007, CLIN EXP METASTAS, V24, P609, DOI
   10.1007/s10585-007-9118-2
   CROCE CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   DERYNCK R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   DILLNER NB, 2004, DNA CELL BIOL, V23, P25
   DU J, 2007, BRAIN RES, V1163, P10, DOI 10.1016/j.brainres.2007.06.002
   DU J, 2008, J CELL BIOCHEM, V103, P1584, DOI 10.1002/jcb.21547
   FRANKEL LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   FUJITA S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015
   IORIO MV, 2005, CANCER RES, V65, P7065, DOI
   10.1158/0008-5472.CAN-05-1783
   LEWIS BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   LU Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   MA L, 2008, CELL CYCLE, V7, P570
   MENG FY, 2007, GASTROENTEROLOGY, V133, P647, DOI
   10.1053/j.gastro.2007.05.022
   OXMANN D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025
   PARKIN DM, 2002, CA CANC J CLIN, V55, P74
   RUGO HS, 2008, BREAST S1, V17, S3
   SASSEN S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2
   TANG SJ, 1998, DEVELOPMENT, V125, P1877
   VARGA AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688
   YANG S, 2007, BMC CANCER, V7, ARTN 211
   ZHANG M, 2007, J STEROID BIOCHEM, V105, P91, DOI
   10.1016/j.jsbmb.2007.01.002
   ZHU SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
   ZHU SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 25
TC 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD APR
PY 2009
VL 19
IS 4
BP 487
EP 496
DI 10.1038/cr.2009.34
PG 10
SC Cell Biology
GA 440KV
UT ISI:000265700100010
ER

PT J
AU Pan, K
   Yan, S
   Ge, S
   Li, S
   Zhao, Y
   Yang, P
AF Pan, K.
   Yan, S.
   Ge, S.
   Li, S.
   Zhao, Y.
   Yang, P.
TI Effects of core binding factor alpha 1 or bone morphogenic protein-2
   overexpression on osteoblast/cementoblast-related gene expressions in
   NIH3T3 mouse cells and dental follicle cells
SO CELL PROLIFERATION
LA English
DT Article
ID HUMAN OSTEOGENIC PROTEIN-1; GROWTH-FACTOR BETA-1; OSTEOBLAST
   DIFFERENTIATION; PERIODONTAL REGENERATION; CLEIDOCRANIAL DYSPLASIA;
   PRECURSOR CELLS; PAPIO-URSINUS; IN-VITRO; REPAIR; CBFA1
AB Bone morphogenic protein-2 (BMP-2) has long been used to promote bone
   and periodontal regeneration, while core binding factor alpha 1 (CBFA1)
   plays important roles in both osteogenic differentiation and tooth
   morphogenesis. The aim of this study was to evaluate the effects of
   CBFA1 or BMP-2 overexpression on osteoblast/cementoblast-related gene
   expressions in NIH3T3 cells and dental follicle cells (DFCs).
   CBFA1 or BMP-2 overexpression in NIH3T3 and DFCs was achieved by
   infection with retroviral vectors containing CBFA1 or BMP-2 cDNA. Cells
   stably integrated with CBFA1 or BMP-2 cDNA were selected with G418 for
   14 days. Western blotting, real-time reverse transcriptase-polymerase
   chain reaction, and in vitro mineralization assay were performed to
   evaluate effects of CBFA1 or BMP-2 overexpression in cells undergoing
   osteoblast/cementoblast differentiation.
   Our results demonstrated that osteoblast/cementoblast-related gene
   expression levels in CBFA1-overexpressing NIH3T3 cells were higher than
   those in BMP-2-overexpressing cells. More mineral nodules were observed
   in CBFA1-overexpressing NIH3T3 cells than in BMP-2-overexpressing
   cells. CBFA1 overexpression in DFCs also increased
   osteoblast/cementoblast-related gene expression and promoted mineral
   nodule formation. However, no significant changes in gene expression
   levels nor mineral nodule formation were found in BMP-2-overexpressing
   DFCs when compared with empty vector transduced DFCs.
   CBFA1 overexpression up-regulated expression levels of
   osteoblast/cementoblast-related genes and enhanced in vitro osteogenic
   differentiation more efficiently than BMP-2 in both NIH3T3 cells and
   DFCs.
C1 [Pan, K.; Yan, S.; Ge, S.; Li, S.; Yang, P.] Shandong Univ, Sch Dent, Dept Periodontol, Jinan 250012, Peoples R China.
   [Pan, K.; Yan, S.; Ge, S.; Li, S.; Yang, P.] Shandong Univ, Sch Dent, Inst Oral Biomed, Jinan 250012, Peoples R China.
   [Zhao, Y.] Tianjin Med Univ, Stomatol Hosp, Dept Orthodont, Tianjin, Peoples R China.
RP Yang, P, Shandong Univ, Sch Dent, Dept Periodontol, 44-1 Wenhuaxi Rd,
   Jinan 250012, Peoples R China.
EM yangps@sdu.edu.cn
FU Doctoral Foundation of China [20050422044]
FX This work was supported by Doctoral Foundation of China (20050422044).
CR BANERJEE C, 1997, J CELL BIOCHEM, V66, P1
   BAUM BJ, 2002, J AM DENT ASSOC, V133, P35
   BESSA PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   BOSSHARDT DD, 2005, CELL TISSUE RES, V320, P399, DOI
   10.1007/s00441-005-1106-8
   CANALIS E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843
   CHEN D, 1998, J CELL BIOL, V142, P295
   CHEN D, 2004, GROWTH FACTORS, V22, P233, DOI
   10.1080/08977190412331279890
   CHOI SH, 2002, J PERIODONTOL, V73, P63
   DSOUZA RN, 1999, DEVELOPMENT, V126, P2911
   DUCY P, 1997, CELL, V89, P747
   DUCY P, 1999, GENE DEV, V13, P1025
   FRIEDLAENDER GE, 2001, J BONE JOINT SURG AM, V83, S118
   GIANNOBILE WV, 1996, BONE, V19, P23
   GORI F, 1999, J BONE MINER RES, V14, P1522
   GOVENDER S, 2002, J BONE JOINT SURG  A, V84, P2123
   HARADA H, 1999, J BIOL CHEM, V274, P6972
   HITCHIN AD, 1975, BR DENT J, V139, P313
   JENSEN BL, 1990, J ORAL PATHOL, V19, P89
   KAIGLER D, 2006, EXPERT OPIN DRUG DEL, V3, P647
   KANG Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   KAO RT, 2005, J CALIF DENT ASSOC, V33, P205
   KEMOUN P, 2007, CELL TISSUE RES, V329, P283, DOI
   10.1007/s00441-007-0397-3
   KINOSHITA A, 1997, J PERIODONTOL, V68, P103
   KOBAYASHI T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343
   KWON YJ, 2003, J VIROL, V77, P5712, DOI 10.1128/JVI.77.10.5715-5720.2003
   LEE KS, 2000, MOL CELL BIOL, V20, P8783
   LEE MH, 1999, J CELL BIOCHEM, V73, P114
   LEKIC P, 1996, ANAT RECORD, V244, P50
   LIMON A, 1997, BLOOD, V90, P3316
   MCKAY WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264-007-0418-6
   MELCHER AH, 1976, J PERIODONTOL, V47, P256
   MIYAZONO K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI
   10.1016/j.cytogfr.2005.01.009
   MULLIGAN RC, 1993, SCIENCE, V260, P926
   MUNDLOS S, 1997, CELL, V89, P773
   PRINCE M, 2001, J CELL BIOCHEM, V80, P424
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177
   REDDI AH, 2001, J BONE JOINT SURG AM, V83, P1
   RIPAMONTI U, 1996, ARCH ORAL BIOL, V41, P121
   RIPAMONTI U, 1996, BONE MORPHOGENETIC P, P189
   RIPAMONTI U, 2001, EUR J ORAL SCI, V109, P241
   SIGURDSSON TJ, 1995, J PERIODONTOL, V66, P131
   STEIN GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   THIRUNAVUKKARASU K, 1998, MOL CELL BIOL, V18, P4197
   TU QS, 2007, WOUND REPAIR REGEN, V15, P404, DOI
   10.1111/j.1524-475X.2007.00243.x
   URIST MR, 1965, SCIENCE, V150, P893
   WISE GE, 1992, CELL TISSUE RES, V267, P483
   WOZNEY JM, 1988, SCIENCE, V242, P1528
   ZHAO M, 2002, J BONE MINER RES, V17, P1441
   ZHAO M, 2003, J DENT RES, V82, P23
NR 50
TC 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7722
J9 CELL PROLIFERATION
JI Cell Prolif.
PD JUN
PY 2009
VL 42
IS 3
BP 364
EP 372
DI 10.1111/j.1365-2184.2009.00599.x
PG 9
SC Cell Biology
GA 437IT
UT ISI:000265481300010
ER

PT J
AU Li, LD
   Borodyansky, L
   Yang, YX
AF Li, Linda
   Borodyansky, Laura
   Yang, Youxin
TI Genomic instability en route to and from cancer stem cells
SO CELL CYCLE
LA English
DT Article
DE cancer stem cells; genomic instability; CSC; GIN; hES; mES
ID CHROMOSOMAL INSTABILITY; TRANSFORMATION; ABNORMALITIES; ENGINE
AB Cancer is caused by successive gene mutations that amount to confer
   malignant phenotype. Genomic instability (GIN) is considered a key
   endogenous mechanism for accumulation of mutations, and therefore, has
   been proposed as an engine of tumorigenesis. Recently, cancer stem
   cells, or tumor initiating cells, have been identified in a variety of
   human cancers. These cancer stem cells (CSCs) are believed to be
   responsible for the initiation of malignant growth and metastasis of
   some, and perhaps all cancer types. How are these two engines of
   tumorigenesis related to each other? Is GIN a driving force in the
   genesis of cancer stem cells? Is the genome in CSCs inherently
   unstable? Could GIN in CSCs be the cause of the observed cancer cell
   heterogeneity? In this article, we will discuss some early clues
   indicating that these two driving forces of tumorigenesis appear to be
   intimately connected.
C1 [Li, Linda; Borodyansky, Laura; Yang, Youxin] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, GI Canc Lab,Div Gastroenterol, Boston, MA 02215 USA.
RP Yang, YX, Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, GI Canc
   Lab,Div Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.
EM yyang@BIDMC.harvard.edu
CR AGUILERA A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268
   AILLES LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI
   10.1016/j.copbio.2007.10.007
   AOKI K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141
   BAO SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   BLAGOSKLONNY MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743
   BLAGOSKLONNY MV, 2007, CANCER BIOL THER, V6, P1684
   BODNAR MS, 2004, STEM CELLS DEV, V13, P243
   CLARKE MF, 2006, CANCER RES, V66, P9339
   CONWAY AE, 2009, STEM CELLS, V27, P18, DOI 10.1634/stemcells.2008-0529
   DICK JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941
   DRAPER JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   GERSON SL, 2006, ERNST SCHERING FDN S, V5, P231
   GRICHNIK JM, 2006, J INVEST DERMATOL, V126, P1214, DOI
   10.1038/sj.jid.5700240
   IMREH MP, 2006, J CELL BIOCHEM, V99, P508, DOI 10.1002/jcb.20897
   JALLEPALLI PV, 2001, NAT REV CANCER, V1, P109
   JONES S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   JU ZY, 2006, EUR J CANCER, V42, P1197, DOI 10.1016/j.ejca.2006.01.040
   LAGASSE E, 2008, GENE THER, V15, P136, DOI 10.1038/sj.gt.3303068
   LEFORT N, 2008, NAT BIOTECHNOL, V26, P1364, DOI 10.1038/nbt.1509
   MANTEL C, 2007, BLOOD, V109, P4518, DOI 10.1182/blood-2006-10-054247
   MIURA M, 2006, STEM CELLS, V24, P1095
   SHIRAS A, 2007, STEM CELLS, V25, P1478, DOI 10.1634/stemcells.2006-0585
   SOLE RV, 2008, J THEOR BIOL, V253, P629, DOI 10.1016/j.jtbi.2008.03.034
   SPITS C, 2008, NAT BIOTECHNOL, V26, P1361, DOI 10.1038/nbt.1510
   VENKITARAMAN AR, 2007, CELL CYCLE, V6, P2341
   WANG E, 2006, J INVEST DERMATOL, V126, P1372, DOI 10.1038/sj.jid.5700193
   WICHA MS, 2006, CANCER RES, V66, P1883, DOI
   10.1158/0008-5472.CAN-05-3153
   WONG DJ, 2008, CELL CYCLE, V7, P3622
NR 28
TC 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD APR 1
PY 2009
VL 8
IS 7
BP 1000
EP 1002
PG 3
SC Cell Biology
GA 438YW
UT ISI:000265593900012
ER

PT J
AU Yang, Q
   Mao, ZX
AF Yang, Qian
   Mao, Zixu
TI Regulation of MEF2s by chaperone-mediated autophagy
SO CELL CYCLE
LA English
DT Editorial Material
ID SURVIVAL
C1 [Mao, Zixu] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
RP Mao, ZX, Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.
EM zmao@pharm.emory.edu
CR ARNOLD MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   BOLAND B, 2006, MOL ASPECTS MED, V27, P503, DOI
   10.1016/j.mam.2006.08.009
   BUTTS BD, 2005, MOL CELL NEUROSCI, V30, P279, DOI
   10.1016/j.mcn.2005.07.011
   MASSEY AC, 2006, CURR TOP DEV BIOL, V73, P205, DOI
   10.1016/S0070-2153(05)73007-6
   MORA S, 2001, ENDOCRINOLOGY, V142, P1999
   PANDEY UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   WANG XM, 2004, GASTROENTEROLOGY, V127, P1174, DOI
   10.1053/j.gastro.2004.07.007
   YANG Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
NR 8
TC 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2009
VL 8
IS 8
BP 1105
EP 1105
PG 1
SC Cell Biology
GA 438YZ
UT ISI:000265594200001
ER

PT J
AU Tao, YG
   Leteur, C
   Yang, CY
   Zhang, P
   Castedo, M
   Pierre, A
   Golsteyn, RM
   Bourhis, J
   Kroemer, G
   Deutsch, E
AF Tao, Yungan
   Leteur, Celine
   Yang, Ceyao
   Zhang, Ping
   Castedo, Maria
   Pierre, Alain
   Golsteyn, Roy M.
   Bourhis, Jean
   Kroemer, Guido
   Deutsch, Eric
TI Radiosensitization by Chir-124, a selective CHK1 inhibitor Effects of
   p53 and cell cycle checkpoints
SO CELL CYCLE
LA English
DT Article
DE CHK1; radiation; G(2)-M checkpoint; p53
ID P53-DEFICIENT CANCER-CELLS; DNA-DAMAGE CHECKPOINT; MITOTIC CATASTROPHE;
   SPINDLE CHECKPOINT; RADIATION RESPONSE; KINASE; INDUCTION; ARREST;
   CYTOTOXICITY; CHEMOTHERAPY
AB Checkpoint kinase-1 (CHK1) is a key regulator of the DNA
   damage-elicited G(2)-M checkpoints. The aim of the present study was to
   investigate the effects of a selective CHK1 inhibitor, Chir124, on cell
   survival and cell cycle progression following ionizing radiation (IR).
   Treatment with Chir-124 resulted in reduced clonogenic survival and
   abrogated the IR-induced G(2)-M arrest in a panel of isogenic HCT116
   cell lines after IR. This radiosensitizing effect was relatively
   similar between p53(-/-) and p53-sufficient wild type (WT) HCT116
   cells. However, the number of mitotic cells (as measured by assessing
   the phosphorylation of mitotic proteins) increased dramatically in
   p53(-/-) HCT116 cells after concomitant Chir-124 exposure, compared to
   IR alone, while no such effect was observed in p53-sufficient WT HCT116
   cells. In p53(-/-) cells, Chir-124 treatment induced a marked
   accumulation of polyploid cells that were characterized by
   micronucleation or multinucleation. p21(-/-) HCT116 cells displayed a
   similar pattern of response as p53(-/-) cells. Chir-124 was able to
   radiosensitize HCT116 cells that lack checkpoint kinase-2 (CHK2) or
   that were deficient for the spindle checkpoint protein Mad2. Finally,
   Chir-124 could radiosensitize tetraploid cell lines, which were
   relatively resistant against DNA damaging agents. Altogether these
   results suggest that Chir-124-mediated radiosensitization is profoundly
   influenced by the p53 and cell cycle checkpoint system.
C1 [Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France.
   [Tao, Yungan; Yang, Ceyao; Bourhis, Jean; Deutsch, Eric] Univ Paris 11, Le Kremlin Bicetre, France.
   [Pierre, Alain] Servier Lab, Res Ctr, Croissy Sur Seine, France.
   [Golsteyn, Roy M.] Univ Lethbridge, Lethbridge, AB T1K 3M4, Canada.
RP Kroemer, G, Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille
   Desmoulins, F-94805 Villejuif, France.
EM kroemer@igr.fr
   deutsch@igr.fr
FU Association pour la Recherche sur le Cancer ; Ligue contre le Cancer ;
   Agence Nationale pour la Recherche ; Institut National du Cancer ;
   Canceropole Ile-de-France and European Union 
FX We are grateful to Dr. Bert Vogelstein, Johns Hopkins University, for
   kindly providing the wild-type, p53<SUP>-/-</SUP>, p21<SUP>-/-</SUP>,
   CHK2<SUP>-/-</SUP> and 14-3-3 sigma<SUP>-/-</SUP> HCT116 cell lines. We
   also thank Dr. Robert Benezra, Memorial Sloan-Kettering Cancer Center
   for kindly providing Mad<SUP>+/-</SUP> HCT116 cells. We thank Servier
   for kindly providing Chir-124 for experimental studies. We thank
   Safietou Mansaly for her assistance in the experiments. This study was
   supported by a grant from Association pour la Recherche sur le Cancer
   (to E. D.), as well as by grants from Ligue contre le Cancer (equipe
   labellisee), Agence Nationale pour la Recherche, Institut National du
   Cancer, Canceropole Ile-de-France and European Union (Active p53,
   Apop-Train, Apo-Sys, RIGHT) to G. K.
CR BAO SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   BARTEK J, 2003, CANCER CELL, V3, P421
   BLASINA A, 2008, MOL CANCER THER, V7, P2394, DOI
   10.1158/1535-7163.MCT-07-2391
   BOOHER RN, 1997, J BIOL CHEM, V272, P22300
   BUNZ F, 1998, SCIENCE, V282, P1497
   BUNZ F, 1999, J CLIN INVEST, V104, P263
   CASTEDO M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127
   CHAN TA, 1999, NATURE, V401, P616
   CHEN ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198
   CHENCOLLINS ARM, 2003, BMC INFECT DIS, V3, ARTN 9
   GASCOIGNE KE, 2008, CANCER CELL, V14, P111, DOI
   10.1016/j.ccr.2008.07.002
   HARVEY SL, 2005, CELL, V122, P407, DOI 10.1016/j.cell.2005.05.029
   JALLEPALLI PV, 2003, J BIOL CHEM, V278, P20475, DOI
   10.1074/jbc.M213159200
   KASTAN MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   KIM JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650
   KONIARAS K, 2001, ONCOGENE, V20, P7453
   KRAMER A, 2004, CELL CYCLE, V3, P1390
   KRAMER A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165
   LEE J, 2001, MOL BIOL CELL, V12, P551
   LEVESQUE AA, 2008, MOL CANCER THER, V7, P252, DOI
   10.1158/1535-7163.MCT-07-2066
   LOBRICH M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248
   MICHEL LS, 2001, NATURE, V409, P355
   PAWLIK TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI
   10.1016/j.ijrobp.2004.03.005
   SANCHEZ Y, 1997, SCIENCE, V277, P1497
   SCHMITT E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200
   SENDEROWICZ AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954
   SYLJUASEN RG, 2004, CANCER RES, V64, P9035
   TAO WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003
   TAO Y, 2007, BRIT J CANCER, V97, P1664, DOI 10.1038/sj.bjc.6604083
   TAO Y, 2008, ONCOGENE, V27, P3244, DOI 10.1038/sj.onc.1210990
   TSE AN, 2004, CANCER RES, V64, P6635
   TSE AN, 2007, CLIN CANCER RES 1, V13, P591, DOI
   10.1158/1078-0432.CCR-06-1424
   VITALE I, 2007, PLOS ONE, V2, P1337
   VOGEL C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200
   VOGEL C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548
   WALDMAN T, 1995, CANCER RES, V55, P5187
   ZACHOS G, 2007, CELL CYCLE, V6, P810
   ZACHOS G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003
   ZHOU BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296
NR 39
TC 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2009
VL 8
IS 8
BP 1196
EP 1205
PG 10
SC Cell Biology
GA 438YZ
UT ISI:000265594200022
ER

PT J
AU Dabaghmanesh, N
   Matsubara, A
   Miyake, A
   Nakano, K
   Ishida, T
   Katano, H
   Horie, R
   Umezawa, K
   Watanabe, T
AF Dabaghmanesh, Nazanin
   Matsubara, Aiko
   Miyake, Ariko
   Nakano, Kazumi
   Ishida, Takaomi
   Katano, Harutaka
   Horie, Ryoichi
   Umezawa, Kazuo
   Watanabe, Toshiki
TI Transient inhibition of NF-kappa B by DHMEQ induces cell death of
   primary effusion lymphoma without HHV-8 reactivation
SO CANCER SCIENCE
LA English
DT Article
ID VIVO ANTITUMOR-ACTIVITY; IN-VIVO; INDUCED APOPTOSIS; KAPOSIS-SARCOMA;
   HERPES-VIRUS; BIOLOGICAL-ACTIVITIES; KSHV VFLIP; LEUKEMIA; EXPRESSION;
   INDUCTION
AB Primary effusion lymphoma (PEL) is a refractory malignancy caused by
   human herpes virus 8 (HHV-8) in immunocompromised individuals. The
   tumor cells of PEL are characterized by constitutive NF-kappa B
   activation. Dehydroxymethylepoxyquinomicin (DHMEQ) is a new NF-kappa B
   inhibitor and is effective on various tumor cells with constitutively
   activated NF-kappa B. Thus, in search for a new therapeutic modality of
   PEL, we examined the effect of DHMEQ on PEL cells. We confirmed
   constitutive activation of NF-kappa B with subcomponents of p50 and p65
   in PEL cell lines. DHMEQ quickly and transiently abrogated NF-kappa B
   activation and reduced the cell viability in dose- and time-dependent
   manners, inducing apoptosis through activation of both mitochondrial
   and membrane pathways. Array analysis revealed that DHMEQ
   down-regulated expression levels of NF-kappa B target genes, such as
   interleukin-6 (IL6), Myc, chemokine (C-C motif) receptor 5 (CCR5) and
   NF-kappa B1, whereas it up-regulated expression levels of some genes
   involved in apoptosis, and cell cycle arrest. DHMEQ did not reactivate
   HHV-8 lytic genes, indicating that NF-kB inhibition by DHMEQ did not
   induce virus replication. DHEMQ rescued CB-17 SCID mice xenografted
   with PEL cells, reducing the gross appearance of effusion. Thus, DHMEQ
   transiently abrogated the NF-kappa B activation, irreversibly
   triggering the apoptosis cascade without HHV-8 reactivation. In
   addition, DHMEQ could rescue the PEL-xenograft mice. Therefore, we
   suggest DHMEQ as a promising candidate for molecular target therapy of
   the PEL. (Cancer Sci 2009; 100: 737-746)
C1 [Dabaghmanesh, Nazanin; Matsubara, Aiko; Miyake, Ariko; Nakano, Kazumi; Ishida, Takaomi; Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Minato Ku, Tokyo 1088639, Japan.
   [Matsubara, Aiko] Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Katano, Harutaka] Natl Inst Infect Dis, Dept Pathol, Shinjyuku Ku, Tokyo 1628640, Japan.
   [Horie, Ryoichi] Kitasato Univ, Fac Med, Dept Hematol, Sagamihara, Kanagawa 2288555, Japan.
   [Umezawa, Kazuo] Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan.
RP Watanabe, T, Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci,
   Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
EM tnabe@ims.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology ;
   Ministry of Health, Labour and Welfare, Japan 
FX This work was supported in part by Grants-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology, and by a Research Grant from the Ministry of Health, Labour
   and Welfare, Japan.
CR ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499
   BERGER N, 2007, EXP HEMATOL, V35, P1495, DOI
   10.1016/j.exphem.2007.07.006
   BOULANGER E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084
   BROWN HJ, 2003, J VIROL, V77, P8532, DOI
   10.1128/JVI.77.15.8532-8540.2003
   CAHIRMCFARLAND ED, 2004, J VIROL, V78, P4108, DOI
   10.1128/JVI.78.8.4108-4119.2004
   CHAUDHARY PM, 1999, ONCOGENE, V18, P5738
   CHEN LF, 2003, J MOL MED-JMM, V81, P549, DOI 10.1007/s00109-003-0469-0
   CHEN LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   CORY S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   COWLING V, 2002, CELL DEATH DIFFER, V9, P1046, DOI
   10.1038/sj.cdd.4401065
   DREXLER HG, 1998, LEUKEMIA, V12, P1507
   FIELD N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691
   GHOSH SK, 2003, BLOOD, V101, P2321, DOI 10.1182/blood-2002-08-2525
   GUASPARRI I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467
   HENGGE UR, 2002, LANCET INFECT DIS, V2, P344
   HORIE R, 2006, LEUKEMIA, V20, P800, DOI 10.1038/sj.leu.2404167
   JARVILUOMA A, 2006, BBA-REV CANCER, V1766, P140, DOI
   10.1016/j.bbcan.2006.05.001
   KATANO H, 1999, J MED VIROL, V58, P394
   KELLER SA, 2000, BLOOD, V96, P2537
   KELLER SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730
   KLEPFISH A, 2001, LEUKEMIA LYMPHOMA, V41, P439
   KRISHNAN HH, 2004, J VIROL, V78, P3601, DOI
   10.1128/JVI.78.7.3601-3620.2004
   LENARDO MJ, 1989, CELL, V58, P227
   LIU L, 2002, J BIOL CHEM, V277, P13745
   MATSUMOTO G, 2005, CLIN CANCER RES, V11, P1287
   MATSUMOTO G, 2005, INT J ONCOL, V27, P1247
   MATSUMOTO N, 2000, BIOORG MED CHEM LETT, V10, P865
   MIYAKE A, 2008, MICROBES INFECT, V10, P748, DOI
   10.1016/j.micinf.2008.04.002
   NADOR RG, 1996, BLOOD, V88, P645
   NIEMINEN AI, 2007, CELL CYCLE, V6, P2464
   NISHIMURA D, 2006, INT J ONCOL, V29, P713
   ODONOVAN M, 2001, MOL PATHOL, V54, P80
   OHSUGI T, 2005, CARCINOGENESIS, V26, P1382, DOI 10.1093/carcin/bgi095
   OHSUGI T, 2006, LEUKEMIA RES, V30, P90, DOI
   10.1016/j.leukres.2005.06.001
   PIERCE JW, 1997, J BIOL CHEM, V272, P21096
   SGARBANTI M, 2004, ONCOGENE, V23, P5770, DOI 10.1038/sj.onc.1207707
   SHARMA SV, 2006, CLIN CANCER RES, V12, P4392
   SHARMA SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   SUN Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072
   UMEZAWA K, 2002, MOL CELLS, V14, P163
   WATANABE M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646
   WATANABE M, 2005, INT J CANCER, V114, P32, DOI 10.1002/ijc.20688
   WATANABE M, 2007, LAB INVEST, V87, P372, DOI 10.1038/labinvest.3700528
   WEINSTEIN IB, 2000, CARCINOGENESIS, V21, P857
   YOO SM, 2005, VIROLOGY, V343, P47, DOI 10.1016/j.virol.2005.08.019
NR 45
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2009
VL 100
IS 4
BP 737
EP 746
DI 10.1111/j.1349-7006.2009.01083.x
PG 10
SC Oncology
GA 438TK
UT ISI:000265578100025
ER

PT J
AU Chen, JG
   Fiskus, W
   Eaton, K
   Fernandez, P
   Wang, YC
   Rao, R
   Lee, P
   Joshi, R
   Yang, Y
   Kolhe, R
   Balusu, R
   Chappa, P
   Natarajan, K
   Jillella, A
   Atadja, P
   Bhalla, KN
AF Chen, Jianguang
   Fiskus, Warren
   Eaton, Kelly
   Fernandez, Pravina
   Wang, Yongchao
   Rao, Rekha
   Lee, Pearl
   Joshi, Rajeshree
   Yang, Yonghua
   Kolhe, Ravindra
   Balusu, Ramesh
   Chappa, Prasanthi
   Natarajan, Kavita
   Jillella, Anand
   Atadja, Peter
   Bhalla, Kapil N.
TI Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma
   to lethal action of HDAC7-Nur77-based mechanism
SO BLOOD
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; ORPHAN STEROID-RECEPTOR; ACUTE
   MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; NEGATIVE SELECTION; CANCER
   CELLS; APOPTOSIS; NUR77; VORINOSTAT; EXPRESSION
AB Pan-histone deacetylase inhibitors, for example, vorinostat and
   panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have
   shown clinical efficacy against advanced cutaneous T-cell lymphoma
   (CTCL). However, the molecular basis of this activity remains unclear.
   HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in
   thymocytes, where it represses expression of the proapoptotic nuclear
   orphan receptor Nur77. Here, we demonstrate that treatment with
   panobinostat rapidly inhibits the in vitro and intracellular activity,
   as well as the mRNA and protein levels of HDAC7, and induces expression
   and translocation of Nur77 to the mitochondria. There, Nur77 converts
   death resistance protein Bcl-2 into a killer protein, promoting cell
   death of cultured and patient-derived human CTCL cells. Treatment with
   panobinostat improved survival of athymic nude mice implanted with
   human CTCL cells. Ectopic expression of Nur77 induced apoptosis and
   sensitized HH cells to panobinostat, whereas combined knockdown of
   Nur77 and its family member Nor1 was necessary to inhibit
   panobinostat-induced apoptosis of CTCL cells. Cotreatment with the
   Bcl-2/Bcl-x(L) antagonist ABT-737 decreased resistance and
   synergistically induced apoptosis of human CTCL cells. These findings
   mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL
   cells to panobinostat as well as suggest that cotreatment with an anti
   Bcl-2 agent would augment the anti-CTCL activity of panobinostat.
   (Blood. 2009;113:4038-4048)
C1 [Chen, Jianguang; Fiskus, Warren; Eaton, Kelly; Fernandez, Pravina; Wang, Yongchao; Rao, Rekha; Lee, Pearl; Joshi, Rajeshree; Yang, Yonghua; Kolhe, Ravindra; Balusu, Ramesh; Chappa, Prasanthi; Natarajan, Kavita; Jillella, Anand; Bhalla, Kapil N.] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA.
   [Atadja, Peter] Novartis Inst Biomed Res, Cambridge, MA USA.
RP Bhalla, KN, Med Coll Georgia, Ctr Canc, 1120 15th St,CN 2101, Augusta,
   GA 30912 USA.
EM kbhalla@mcg.edu
CR CALNAN BJ, 1995, IMMUNITY, V3, P273
   CHENG LEC, 1997, EMBO J, V16, P1865
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P7
   DEQUIEDT F, 2003, IMMUNITY, V18, P687
   DEQUIEDT F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034
   DOKMANOVIC M, 2007, MOL CANCER THER, V6, P2525, DOI
   10.1158/1535-7163.MCT-07-0251
   DUVIC M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   EDWARDS A, 2007, MOL CANCER THER, V6, P2515, DOI
   10.1158/1535-7163.MCT-06-0761
   ELLIS L, 2008, CLIN CANCER RES, V14, P4500, DOI
   10.1158/1078-0432.CCR-07-4262
   FANTIN VR, 2008, CANCER RES, V68, P3785, DOI
   10.1158/0008-5472.CAN-07-6091
   FISKUS W, 2006, BLOOD, V108, P645, DOI 10.1182/blood-2005-11-4639
   FISKUS W, 2006, MOL CANCER THER, V5, P3096, DOI
   10.1158/1535-7163.MCT-06-0418
   FISKUS W, 2007, P ASS CAN RES
   GEORGE P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413
   GLASER KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI
   10.1016/j.bcp.2007.04.007
   GUO F, 2004, CANCER RES, V64, P2580
   HAN YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358
   IBRADO AM, 1996, CELL GROWTH DIFFER, V7, P1087
   KASLER HG, 2007, MOL CELL BIOL, V27, P5184, DOI 10.1128/MCB.02091-06
   KHAN N, 2008, BIOCHEM J 2, V409, P581, DOI 10.1042/BJ20070779
   KIM EJ, 2007, J CLIN INVEST, V117, P836, DOI 10.1172/JCI24826C1
   KONOPLEVA M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006
   LI H, 2000, SCIENCE, V289, P1159
   LIN BZ, 2004, CELL, V116, P527
   MANGELSDORF DJ, 1995, CELL, V83, P841
   MANN BS, 2007, CLIN CANCER RES, V13, P2318, DOI
   10.1158/1078-0432.CCR-06-2672
   MINUCCI S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   MOLL UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601
   MULLICAN SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579
   OLSEN EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   OLTERSDORF T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   PARRA M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107
   PIEKARZ RL, 2001, BLOOD, V98, UNSP FR901228)
   QUERFELD C, 2005, CURR OPIN HEMATOL, V12, P273
   RAJPAL A, 2003, EMBO J, V22, P6526
   RAPAK A, 2007, APOPTOSIS, V12, P1873, DOI 10.1007/s10495-007-0107-3
   SCOTT FL, 2008, J BIOL CHEM, V283, P19499
   SHIPP MA, 2002, NAT MED, V8, P68
   THOMPSON J, 2008, J EXP MED, V205, P1029, DOI 10.1084/jem.20080101
   VOGLER M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137
   WEIH F, 1996, P NATL ACAD SCI USA, V93, P5533
   WILLEMZE R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502
   WILSON AJ, 2003, CANCER RES, V63, P5401
   WINOTO A, 2002, CELL S, V109, S57
   WRIGHT CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JC126251
   YANG XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   YANG YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644
   YU H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   ZHANG CL, 2005, J INVEST DERMATOL, V125, P1045, DOI
   10.1111/j.0022-202X.2005.23925.x
   ZHOU Q, 2008, MOL CANCER RES, V6, P873, DOI
   10.1158/1541-7786.MCR-07-0330
   ZHOU T, 1996, J EXP MED, V183, P1879
NR 51
TC 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 23
PY 2009
VL 113
IS 17
BP 4038
EP 4048
DI 10.1182/blood-2008-08-176024
PG 11
SC Hematology
GA 436WO
UT ISI:000265447000023
ER

PT J
AU Yang, O
   Popova, OV
   Suthoff, U
   Luking, I
   Dietz, KJ
   Golldack, D
AF Yang, Oksoon
   Popova, Olga V.
   Suethoff, Ulrike
   Lueking, Ines
   Dietz, Karl-Josef
   Golldack, Dortje
TI The Arabidopsis basic leucine zipper transcription factor AtbZIP24
   regulates complex transcriptional networks involved in abiotic stress
   resistance
SO GENE
LA English
DT Article
DE AtbZIP24; Transcription factor; RNAi; Salt tolerance; Arabidopsis
ID VACUOLAR H+-ATPASE; NA+/H+ ANTIPORTER GENE; ZINC-FINGER PROTEIN;
   ORYZA-SATIVA L.; SALT TOLERANCE; HIGH-SALINITY; ABSCISIC-ACID;
   PLANT-CELLS; FUNCTIONAL-ANALYSIS; FREEZING TOLERANCE
AB Soil salinity severely affects plant growth and agricultural
   productivity. AtbZIP24 encodes a bZIP transcription factor that is
   induced by salt stress in Arabidopsis thaliana but suppressed in the
   salt-tolerant relative Lobularia maritima. Transcriptional repression
   of AtbZIP24 using RNA interference improved salt tolerance in A.
   thaliana. Under non-stress growth conditions, transgenic A. thaliana
   lines with decreased AtbZIP24 expression activated the expression of
   stress-inducible genes involved in cytoplasmic ion homeostasis and
   osmotic adjustment: the Na+ transporter AtHKT1, the Na+/H+ antiporter
   AtSOS1, the aquaporin AtPIP2.1, and a glutamine synthetase. In
   addition, candidate target genes of AtbZIP24 with functions in plant
   growth and development were identified such as an argonaute
   (AGO1)-related protein and cyclophilin AtCYP19. The salt tolerance in
   transgenic plants correlated with reduced Na+ accumulation in leaves.
   In vivo interaction of AtbZIP24 as a homodimer was shown using
   fluorescence energy transfer (FRET) with cyan fluorescent protein (CFP)
   and yellow fluorescent protein (YFP) as fused FRET pairs. Translational
   fusion of AtbZIP24 with GFP showed subcellular localization of the
   protein in nucleus and cytoplasm in plants grown under control
   conditions whereas in response to salt stress AtbZIP24 was
   preferentially targeted to the nucleus. It is concluded that AtbZIP24
   is an important regulator of salt stress response in plants. The
   modification of transcriptional control by regulatory transcription
   factors provides a useful strategy for improving salt tolerance in
   plants. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Yang, Oksoon; Popova, Olga V.; Suethoff, Ulrike; Lueking, Ines; Dietz, Karl-Josef; Golldack, Dortje] Univ Bielefeld, Fac Biol, Dept Biochem & Physiol Plants, D-33615 Bielefeld, Germany.
RP Golldack, D, Univ Bielefeld, Fac Biol, Dept Biochem & Physiol Plants,
   D-33615 Bielefeld, Germany.
EM dortje.golldack@uni-bielefeld.de
FU Deutsche Forschungsgerneinschaft (Germany) 
FX The work was supported by the Deutsche Forschungsgerneinschaft
   (Germany).
CR BENSMIHEN S, 2005, J EXP BOT, V56, P597, DOI 10.1093/jxb/eri050
   BERARDINI TZ, 2001, SCIENCE, V291, P2405
   BERTHOMIEU P, 2003, EMBO J, V22, P2004
   BOHMERT K, 1998, EMBO J, V17, P170
   BROCARDGIFFORD I, 2004, PLANT CELL, V16, P406, DOI 10.1105/tpc.018077
   CHOI HI, 2000, J BIOL CHEM, V275, P1723
   CLOUGH SJ, 1998, PLANT J, V16, P735
   DUBOUZET JG, 2003, PLANT J, V33, P751
   FUKAZAWA J, 2000, PLANT CELL, V12, P901
   FUKUDA A, 2004, PLANT CELL PHYSIOL, V45, P146
   GARG AK, 2002, P NATL ACAD SCI USA, V99, P15898, DOI
   10.1073/pnas.252637799
   GAXIOLA RA, 2001, P NATL ACAD SCI USA, V98, P11444
   GOLLDACK D, 2001, PLANT PHYSIOL, V125, P1643
   GOLLDACK D, 2002, J BIOL CHEM, V277, P5541
   HAMADA A, 2001, PLANT MOL BIOL, V46, P35
   HASEGAWA PM, 2000, ANNU REV PLANT PHYS, V51, P463
   IWATA Y, 2005, P NATL ACAD SCI USA, V102, P5280, DOI
   10.1073/pnas.0408941102
   JAKOBY M, 2002, TRENDS PLANT SCI, V7, P106
   KADER MA, 2006, J EXP BOT, V57, P4257, DOI 10.1093/jxb/erl199
   KANG JY, 2002, PLANT CELL, V14, P343
   KARIMI M, 2005, TRENDS PLANT SCI, V10, P103, DOI
   10.1016/j.tplants.2005.01.008
   KASUGA M, 1999, NAT BIOTECHNOL, V17, P287
   KIDNER CA, 2005, DEV BIOL, V280, P504, DOI 10.1016/j.ydbio.2005.01.031
   KIM JC, 2001, PLANT J, V25, P247
   KLEINEVEHN J, 2006, PLANT CELL, V18, P3171, DOI 10.1105/tpc.106.042770
   KLUGE C, 2004, BMC CELL BIOL, V5, ARTN 29
   KREPS JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532
   KUREK I, 1999, PLANT PHYSIOL, V119, P693
   LAURIE S, 2002, PLANT J, V32, P139
   LIAO Y, 2008, PLANTA, V228, P225, DOI 10.1007/s00425-008-0731-3
   LIU JP, 2000, P NATL ACAD SCI USA, V97, P3730
   MALLORY AC, 2008, CURR OPIN PLANT BIOL, V11, P560, DOI
   10.1016/j.pbi.2008.06.008
   MUKHOPADHYAY A, 2004, P NATL ACAD SCI USA, V101, P6309, DOI
   10.1073/pnas.0401572101
   PAUWELS L, 2008, P NATL ACAD SCI USA, V105, P1380, DOI
   10.1073/pnas.0711203105
   POPOVA OV, 2003, PLANT MOL BIOL, V52, P569
   POPOVA OV, 2007, J PLANT PHYSIOL, V164, P1278, DOI
   10.1016/j.jplph.2006.08.011
   POPOVA OV, 2008, GENE, V423, P142, DOI 10.1016/j.gene.2008.07.017
   QIU QS, 2002, P NATL ACAD SCI USA, V99, P8436
   ROMANO PGN, 2004, PLANT PHYSIOL, V134, P1268, DOI 10.1104/pp.103.022160
   RUS A, 2004, PLANT PHYSIOL, V136, P2500, DOI 10.1104/pp.104.042234
   SAKAMOTO H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599
   SEIDEL T, 2004, J BIOTECHNOL, V112, P165, DOI
   10.1016/j.jbiotec.2004.04.027
   SEKI M, 2002, PLANT J, V31, P279
   SERRANO R, 2001, CURR OPIN CELL BIOL, V13, P399
   SHEVELEVA E, 1997, PLANT PHYSIOL, V115, P1211
   SHI HZ, 2003, NAT BIOTECHNOL, V21, P81, DOI 10.1038/nbt766
   SHI HZ, 2003, PLANT CELL, V15, P19, DOI 10.1105/tpc.007872
   TRAN LSP, 2004, PLANT CELL, V16, P2481, DOI 10.1105/tpc.104.022699
   UNO Y, 2000, P NATL ACAD SCI USA, V97, P11632
   WANG YL, 2008, NATURE, V456, P209, DOI 10.1038/nature07315
   WELTMEIER F, 2006, EMBO J, V25, P3133, DOI 10.1038/sj.emboj.7601206
   XIONG LM, 2002, P NATL ACAD SCI USA, V99, P10899, DOI
   10.1073/pnas.162111599
   ZHANG HX, 2001, NAT BIOTECHNOL, V19, P765
   ZHANG HX, 2001, P NATL ACAD SCI USA, V98, P12832
   ZHU JK, 2001, TRENDS PLANT SCI, V6, P66
   ZOU MJ, 2008, PLANT MOL BIOL, V66, P675, DOI 10.1007/s11103-008-9298-4
NR 56
TC 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAY 1
PY 2009
VL 436
IS 1-2
BP 45
EP 55
DI 10.1016/j.gene.2009.02.010
PG 11
SC Genetics & Heredity
GA 435KO
UT ISI:000265343000007
ER

PT J
AU Kim, S
   Choi, JH
   Lim, HI
   Lee, SK
   Kim, WW
   Cho, SJ
   Kim, JS
   Kim, JH
   Choe, JH
   Nam, SJ
   Lee, JE
   Yang, JH
AF Kim, Sangmin
   Choi, Jae Hyuck
   Lim, Hye In
   Lee, Se-Kyung
   Kim, Wan Wook
   Cho, Sungjin
   Kim, Jee Soo
   Kim, Jung-Han
   Choe, Jun-Ho
   Nam, Seok Jin
   Lee, Jeong Eon
   Yang, Jung-Hyun
TI EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but
   not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line
SO CELLULAR SIGNALLING
LA English
DT Article
DE JAKs; STAT-3; ERK; MMP-9; SKBR3 cells
ID EPIDERMAL-GROWTH-FACTOR; MATRIX METALLOPROTEINASES; CONSTITUTIVE
   ACTIVATION; STAT PATHWAY; RECEPTOR; KINASE; METASTASIS; INVASION;
   MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS
AB The number of epidermal growth factor receptors (FGFRs) and their
   ligands are highly expressed in malignant tumor cells. The EGF
   signaling pathway is also activated in up to one-third of patients with
   breast cancer. In this study, we investigated the novel function of the
   JAK3 inhibitor, WHI-P131, on EGF-induced MMP-9 expression and the
   regulatory mechanism of EGF-induced MMP-9 expression in SKBR3 cells. We
   observed that EGF increased MMP-9 mRNA and protein expression in a
   dose-dependent manner. EGF also induced the phosphorylation of ECFR,
   ERK, and STAT-3, and these effects were inhibited by the EGFR
   inhibitor, AG1478. To investigate the involvement of the STAT-3 pathway
   on EGF-induced MMP-9 expression, we pretreated SKBR3 cells with JAK1,
   JAK2, and JAK3 inhibitors prior to EGF treatment. The results showed
   that the JAK3 inhibitor, WHI-P131, as well as JAK3 siRNA transfection,
   but not the JAK1 and JAK2 inhibitors, significantly decreased
   EGF-induced MMP-9 expression. In addition, EGF-induced STAT-3
   phosphorylation was only inhibited by WHI-P131. We then transfected
   cells with adenoviral STAT-3 (Ad-STAT-3), followed by treatment with
   EGF. Interestingly, EGF-induced MMP-9 expression was decreased by
   Ad-STAT-3 overexpression in a dose-dependent manner, while it was
   significantly increased by STAT-3 siRNA transfection. Our results also
   showed that basal levels of MMP-9 expression were significantly
   increased by constitutive active-MEK (CA-MEK) overexpression.
   EGF-induced ERK phosphorylation was prevented by WHI-P131, but not by
   JAM and JAK2 inhibitors. On the other hand, EGF-induced MMP-9
   expression was decreased by the MEK1/2 inhibitor, UO126. Therefore, for
   the first time, we suggest that the JAK3 inhibitor, WHI-P131, inhibits
   EGF-induced STAT3 phosphorylation as well as ERK phosphorylation. The
   JAK3/ERK pathway may play an important role in EGF-induced MMP-9
   expression in SKBR3 cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kim, Sangmin; Choi, Jae Hyuck; Lim, Hye In; Lee, Se-Kyung; Kim, Wan Wook; Cho, Sungjin; Kim, Jee Soo; Kim, Jung-Han; Choe, Jun-Ho; Nam, Seok Jin; Lee, Jeong Eon; Yang, Jung-Hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
RP Lee, JE, Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Ilwon
   Dong 50, Seoul 135710, South Korea.
EM paojlus@hanmail.net
   drjh.yang@samsung.com
FU In-SUNG Foundation [C-A8-826-1]; Samsung Biomedical Research Institute
   [C-A9-313-1]
FX This work was supported in part by Grant C-A8-826-1 from In-SUNG
   Foundation for Medical Research and by the Samsung Biomedical Research
   Institute grant, #SBRI C-A9-313-1.
CR AASLAND R, 1990, INT J CANCER, V46, P382
   ANDL CD, 2004, AM J PHYSIOL-GASTR L, V287, P1227
   BJORKLUND M, 2005, BBA-REV CANCER, V1755, P37, DOI
   10.1016/j.bbcan.2005.03.001
   BOONSTRA J, 1995, CELL BIOL INT, V19, P413
   BROMBERG J, 2002, J CLIN INVEST, V109, P1139
   CAUWE B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI
   10.1080/10409230701340019
   CHAMBERS AF, 1997, J NATL CANCER I, V89, P1260
   COX G, 2000, CLIN CANCER RES, V6, P2349
   CROWE DL, 1999, NEOPLASIA, V1, P368
   CROWE DL, 2001, NEOPLASIA, V3, P27
   DEARMOND D, 2003, ONCOGENE, V22, P7781, DOI 10.1038/sj.onc.1206966
   EGEBLAD M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   ELLERBROEK SM, 1998, INT J CANCER, V78, P331
   FRANK SJ, 1995, J BIOL CHEM, V270, P14776
   GAO B, 2001, FEBS LETT, V488, P179
   GARCIA R, 2001, ONCOGENE, V20, P2499
   HANAHAN D, 2000, CELL, V100, P57
   HAYAKAWA F, 2006, ANN NY ACAD SCI, V1086, P213, DOI
   10.1196/annals.1377.002
   HEBENSTREIT D, 2005, DRUG NEWS PERSPECT, V18, P243, DOI
   10.1358/dnp.2005.18.4.908658
   HILL CS, 1995, CELL, V80, P199
   HSUAN JJ, 1997, INT J BIOCHEM CELL B, V29, P415
   HYNES NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   IHLE JN, 1995, TRENDS GENET, V11, P69
   KHAZAIE K, 1993, CANCER METAST REV, V12, P255
   KIM S, 2008, PHYTOMEDICINE, V15, P340, DOI 10.1016/j.phymed.2007.09.011
   KONDAPAKA SB, 1997, INT J CANCER, V70, P722
   MENDELSOHN J, 2000, ONCOGENE, V19, P6550
   NAKAJIMA M, 1993, CANCER RES, V53, P5802
   NIU GL, 2002, ONCOGENE, V21, P2000
   OC P, 2000, CANCER RES, V60, P1121
   PARK OK, 1996, P NATL ACAD SCI USA, V93, P13704
   PAWSON T, 1995, NATURE, V373, P573
   SAINSBURY JRC, 1987, LANCET, V1, P1398
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621
   SIMON C, 1998, CANCER RES, V58, P1135
   TSAREVA SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820
   ULLRICH A, 1990, CELL, V61, P203
   WEI DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122
NR 38
TC 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2009
VL 21
IS 6
BP 892
EP 898
DI 10.1016/j.cellsig.2009.01.034
PG 7
SC Cell Biology
GA 437FK
UT ISI:000265471900008
ER

PT J
AU Huang, YL
   Shi, GY
   Lee, H
   Jiang, MJ
   Huang, BM
   Wu, HL
   Yang, HY
AF Huang, Yuan-Li
   Shi, Guey-Yueh
   Lee, Hsinyu
   Jiang, Meei-Jyh
   Huang, Bu-Miin
   Wu, Hua-Lin
   Yang, Hsi-Yuan
TI Thrombin induces nestin expression via the transactivation of EGFR
   signalings in rat vascular smooth muscle cells
SO CELLULAR SIGNALLING
LA English
DT Article
DE Nestin; Proliferation; Thrombin; EGFR transactivation; Vascular smooth
   muscle cells
ID INTERMEDIATE FILAMENT PROTEIN; GROWTH-FACTOR RECEPTOR; ACTIVATED
   RECEPTORS; COUPLED RECEPTORS; ENDOTHELIAL-CELLS; SKELETAL-MUSCLE;
   DNA-SYNTHESIS; PHOSPHORYLATION; THROMBOMODULIN; VIMENTIN
AB Regulation of nestin gene expression is largely unknown despite that it
   is widely used as a progenitor cell marker. In this study, we showed
   that nestin expression is regulated by the thrombin-mediated EGFR
   transactivation in serum-deprived primary cultures of rat vascular
   smooth muscle cells (VSMCs). This resulted from the direct binding of
   thrombin to PAR-1 rather than indirectly affecting through the binding
   to thrombomodulin, as demonstrated by thrombomodulin RNAi. In this
   process, the PAR-1-induced c-Src plays a critical role through two
   routes; one was the direct intracellular phosphorylation of EGFR and
   the other was the extracellular activation of the MMP-2-mediated
   shedding of HB-EGF. The transactivated EGFR then led to the downstream
   Ras-Raf-ERK signaling axis, but not the p38 or JNK pathways. In
   addition, the EMSA experiment showed that the transcriptional factor
   Sp1 is critical for the thrombin-induced nestin expression in rat
   VSMCs. Furthermore, RNAi of nestin attenuated the thrombin-induced cell
   proliferation, indicating that thrombin-induced nestin expression and
   cell proliferation share the same EGFR transactivation mechanism. This
   study also suggested that nestin may play an important role in cell
   proliferation induced by the thrombin-mediated EGFR transactivation.
   Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.
C1 [Yang, Hsi-Yuan] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 106, Taiwan.
   [Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Tainan 701, Taiwan.
   [Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Cardiovasc Res Ctr, Tainan 701, Taiwan.
   [Lee, Hsinyu] Natl Taiwan Univ, Inst Zool, Taipei 106, Taiwan.
   [Jiang, Meei-Jyh] Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan 701, Taiwan.
RP Wu, HL, Natl Taiwan Univ, Inst Mol & Cellular Biol, 1,Sec 4,Roosevelt
   Rd, Taipei 106, Taiwan.
EM hyhy@ntu.edu.tw
FU National Science Council, Executive Yuan, Taiwan
   [NSC96-2752-B-006-003-PAE, NSC96-2752-B-006-004-PAE,
   NSC96-2752-B-006-005-PAE]
FX We would like to thank Georgiana Cho-Chen Wu for editing assistance.
   This work was supported by the National Science Council, Executive
   Yuan, Taiwan through grant NSC96-2752-B-006-003-PAE,
   NSC96-2752-B-006-004-PAE, and NSC96-2752-B-006-005-PAE.
CR BADIMON L, 1994, HAEMOSTASIS, V24, P69
   CAO HQ, 2006, AM J PHYSIOL-CELL PH, V290, C172, DOI
   10.1152/ajpcell.00284.2005
   CHAN AK, 2003, J VASC SURG, V37, P644, DOI 10.1067/mva.2003.92
   CHENG LP, 2004, FEBS LETT, V565, P195, DOI 10.1016/j.febslet.2004.03.097
   CHOU YH, 2003, MOL BIOL CELL, V14, P1468, DOI 10.1091/mbc.E02-08-0545
   COULOMBE PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699
   DANIEL C, 2008, LAB INVEST, V88, P387, DOI 10.1038/labinvest.2008.5
   DAUB H, 1996, NATURE, V379, P557
   DEBUS E, 1983, EMBO J, V2, P2305
   FRISEN J, 1995, J CELL BIOL, V131, P453
   HAN M, 2006, AM J PHYSIOL-CELL PH, V291, C50, DOI
   10.1152/ajpcell.00524.2005
   HSIEH HL, 2008, BBA-MOL CELL RES, V1783, P1563, DOI
   10.1016/j.bbamcr.2008.03.016
   HUANG YL, 2008, BIOCHEM BIOPH RES CO, V377, P361, DOI
   10.1016/j.bbrc.2008.09.143
   JOSEPHSON R, 1998, DEVELOPMENT, V125, P3087
   KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843
   KALMES A, 2000, CIRC RES, V87, P92
   LANE DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710
   LEGER AJ, 2006, CIRCULATION, V114, P1070, DOI
   10.1161/CIRCULATIONAHA.105.574830
   LENDAHL U, 1990, CELL, V60, P585
   LI YH, 2007, THROMB HAEMOSTASIS, V97, P658, DOI 10.1160/TH06-12-0690
   LUCCHESI PA, 2004, CIRCULATION, V110, P3587, DOI
   10.1161/01.CIR.0000148780.36121.47
   MADSEN CS, 1997, J BIOL CHEM, V272, P29842
   MARTORELL L, 2008, THROMB HAEMOSTASIS, V99, P305, DOI
   10.1160/TH07-08-0481
   OHTSU H, 2006, AM J PHYSIOL-CELL PH, V291, C1, DOI
   10.1152/ajpcell.00620.2005
   OLIVOT JM, 2001, CIRC RES, V88, P681
   OSSOVSKAYA VS, 2004, PHYSIOL REV, V84, P579, DOI
   10.1152/physrev.00028.2003
   OWENS GK, 1995, PHYSIOL REV, V75, P487
   PALLARI HM, 2006, SCI STKE, PE53
   PRENZEL N, 1999, NATURE, V402, P884
   RAUCH BH, 2004, CIRC RES, V94, P340, DOI
   10.1161/01.RES.0000111805.09592.D8
   SEJERSEN T, 1993, J CELL SCI 4, V106, P1291
   VAITTINEN S, 2001, J NEUROPATH EXP NEUR, V60, P588
   WERRY TD, 2005, TRENDS ENDOCRIN MET, V16, P26, DOI
   10.1016/j.tem.2004.11.008
   WETZKER R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173
   WILCOX JN, 1994, CIRC RES, V75, P1029
   WU HL, 2008, BIOCHEM BIOPH RES CO, V367, P162, DOI
   10.1016/j.bbrc.2007.12.135
   WU WD, 2002, J BIOL CHEM, V277, P24252
   YANG HY, 1992, CELL MOTIL CYTOSKEL, V22, P185
   YANG HY, 1997, EXP NEUROL, V146, P199
   ZHANG H, 2008, CIRC RES, V102, P1275, DOI 10.1161/CIRCRESAHA.108.171728
NR 40
TC 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2009
VL 21
IS 6
BP 954
EP 968
DI 10.1016/j.cellsig.2009.02.005
PG 15
SC Cell Biology
GA 437FK
UT ISI:000265471900015
ER

PT J
AU Gwak, SJ
   Bhang, SH
   Yang, HS
   Kim, SS
   Lee, DH
   Lee, SH
   Kim, BS
AF Gwak, So-Jung
   Bhang, Suk H.
   Yang, Hee S.
   Kim, Sang-Soo
   Lee, Dae-Hee
   Lee, Soo-Hong
   Kim, Byung-Soo
TI In vitro cardiomyogenic differentiation of adipose-derived stromal
   cells using transforming growth factor-beta 1
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE adult stem cell; adipose-derived stromal cells; cardiomyogenic
   differentiation; transforming growth factor-beta 1; osteogenic
   differentiation
ID MESENCHYMAL STEM-CELLS; HUMAN BONE-MARROW; MYOCARDIAL-INFARCTION;
   TGF-BETA; TISSUE; TRANSPLANTATION; CARDIOMYOCYTES; EXPRESSION;
   IMPLANTATION; GROWTH
AB Transplanting stem cells differentiated towards a cardiac lineage can
   regenerate cardiac muscle tissues to treat myocardial infarction. In
   this study, we tested the hypothesis that transforming growth
   factor-beta 1 (TGF-beta 1) induces cardiomyogenic differentiation of
   adipose-derived stromal cells (ADSCs) in vitro. Rat ADSCs were cultured
   with TGF-beta 1 (10 ng ml(-1)) for 2 weeks in vitro. ADSCs cultured
   without TGF-beta 1 served as a control. The mRNA expression of
   cardiac-specific gene was induced by TGF-beta 1, while the control
   culture did not show cardiac-specific gene expression.
   Immunocytochemical analyses showed that a small fraction of ADSCs
   cultured with TGF-beta 1 for 2 weeks stained positively for cardiac
   myosin heavy chain (MHC) and alpha-sarcomeric actin. Flow cytometric
   analyses showed that the proportion of cells expressing cardiac MHC
   increased with TGF-beta 1. However, no mesenchymal differentiation
   (e.g., osteogenic and adipogenic differentiation) was detected other
   than cardiomyogenic differentiation. These results showed that TGF-beta
   1 induce ADSC cardiomyogenic differentiation in vitro, which could be
   useful for myocardial infarction stem cell therapy. Copyright (c) 2009
   John Wiley & Sons, Ltd.
C1 [Bhang, Suk H.; Yang, Hee S.; Kim, Sang-Soo; Kim, Byung-Soo] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.
   [Gwak, So-Jung] Hanyang Univ, Dept Chem Engn, Seoul 133791, South Korea.
   [Lee, Dae-Hee; Lee, Soo-Hong] Pochon CHA Univ, Cell & Gene Therapy Res Inst, Seoul, South Korea.
RP Kim, BS, Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.
EM bskim@hanyang.ac.kr
FU Korea Health 21 R&D project, Ministry of Health & Welfare, Republic of
   Korea [A050082]
FX This work was supported by the Korea Health 21 R&D project, Ministry of
   Health & Welfare (A050082), Republic of Korea.
CR AFIZAH H, 2007, TISSUE ENG, V13, P659, DOI 10.1089/ten.2006.0118
   AKHURST RJ, 1990, DEVELOPMENT, V108, P645
   BARTUNEK J, 2007, AM J PHYSIOL-HEART C, V292, P1095
   BEHFAR A, 2002, FASEB J, V16, P1558
   CAO Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI
   10.1016/j.bbrc.2005.04.135
   CHO SW, 2006, BIOCHEM BIOPH RES CO, V340, P573, DOI
   10.1016/j.bbrc.2005.12.044
   CHO SW, 2006, BIOCHEM BIOPH RES CO, V345, P588, DOI
   10.1016/j.bbrc.2006.04.089
   CHO SW, 2007, EUR J HEART FAIL, V9, P974, DOI
   10.1016/j.ejheart.2007.06.012
   FUKUHARA S, 2003, J THORAC CARDIOV SUR, V125, P1470, DOI
   10.1016/S0022-5223(02)73610-6
   GRONTHOS S, 2001, J CELL PHYSIOL, V189, P54
   HAHN JY, 2008, J AM COLL CARDIOL, V51, P933, DOI
   10.1016/j.jacc.2007.11.040
   HALVORSEN YDC, 2001, TISSUE ENG, V7, P729
   HAUTMANN MB, 1999, ARTERIOSCL THROM VAS, V19, P2049
   HELDER MN, 2007, TISSUE ENG, V13, P1799, DOI 10.1089/ten.2006.0165
   HONG K, 2005, J MICROBIOL BIOTECHN, V15, P823
   HUANG JI, 2004, PLAST RECONSTR SURG, V113, P585, DOI
   10.1097/01.PRS.0000101063.27008.E1
   KIM HC, 2006, J MICROBIOL BIOTECHN, V16, P360
   KUMAR D, 2005, BIOCHEM BIOPH RES CO, V332, P135, DOI
   10.1016/j.bbrc.2005.04.098
   LEE RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   LEE WCC, 2007, BIOMECH MODEL MECHAN, V6, P265, DOI
   10.1007/s10237-006-0053-y
   LI TS, 2005, CIRCULATION, V111, P2438
   LIU Y, 2003, CARDIOVASC RES, V58, P460, DOI
   10.1016/S0008-6363(03)00265-7
   MAKINO S, 1999, J CLIN INVEST, V103, P697
   MENARD C, 2005, LANCET, V366, P1005
   MIYAHARA Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391
   MOSES HL, 1996, CURR OPIN GENET DEV, V6, P581
   ORLIC D, 2001, ANN NY ACAD SCI, V938, P221
   PLANATBENARD V, 2004, CIRC RES, V94, P223, DOI
   10.1161/01.RES.0000109792.43271.47
   RANGAPPA S, 2003, ANN THORAC SURG, V75, P775
   RYU JH, 2005, BIOMATERIALS, V26, P319, DOI
   10.1016/j.biomaterials.2004.02.058
   SAKAMOTO O, 2001, EUR RESPIR J, V17, P969
   SONG H, 2006, J MICROBIOL BIOTECHN, V16, P37
   STAMM C, 2003, LANCET, V361, P45
   STRAUER BE, 2002, CIRCULATION, V106, P1913, DOI
   10.1161/01.CIR.0000034046.87607.1C
   STRAUER BE, 2005, J AM COLL CARDIOL, V46, P1651, DOI
   10.1016/j.jacc.2005.01.069
   TSE HF, 2003, LANCET, V361, P47
   YAMADA Y, 2007, STEM CELLS, V25, P1326, DOI 10.1634/stemcells.2006-0588
   YOO KJ, 2008, CAN J SURG, V51, P269
   ZUK PA, 2001, TISSUE ENG, V7, P211
   ZUK PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 40
TC 9
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0263-6484
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD APR
PY 2009
VL 27
IS 3
BP 148
EP 154
DI 10.1002/cbf.1547
PG 7
SC Biochemistry & Molecular Biology; Cell Biology
GA 434ZI
UT ISI:000265312500005
ER

PT J
AU Sun, XF
   Xiao, B
   Zhang, GC
   Yang, XE
AF Sun, Xiao-Feng
   Xiao, Bin
   Zhang, Guang Cheng
   Yang, Xiao-E
TI INFRARED AND C-13 MAS NUCLEAR MAGNETIC RESONANCE SPECTROSCOPIC STUDY OF
   PERIPLOCA SEPIUM ACETYLATION
SO CELLULOSE CHEMISTRY AND TECHNOLOGY
LA English
DT Article
DE fiber; acetylation; N-bromosccinamide; infrared spectroscopy; nuclear
   magnetic resonance
ID WOOD; HEMICELLULOSES; CELLULOSE; WHEAT
AB Periploca sepium represents in important part of the local vegetation
   in the sandy land of China. This paper describes a novel method for
   modifying the Periploca sepium fiber under mild conditions. Both raw
   and modified Fibers were chemically studied by non-destructive methods,
   infrared spectroscopy (IR) and cross-polarisation nuclear magnetic
   resonance (CP-MAS C-13 NMR). The results showed that, during the
   reaction with acetic anhydride, the use of N-bromosuccinamide (NBS)
   catalyst resulted in a high mass percent gain (WPG - 20%). IR and
   CP-MAS C-13 NMR analysis elucidated in detail the chemical features of
   the natural and acetylated fiber, providing clear evidence of the
   successful acetylation.
C1 [Sun, Xiao-Feng; Zhang, Guang Cheng] NW Polytech Univ, Coll Sci, Dept Appl Chem, Xian 710072, Peoples R China.
   [Xiao, Bin] NW A&F Univ, Coll Hort, Yangling 712100, Peoples R China.
   [Yang, Xiao-E] Zhejiang Univ, Inst Agrichem, MOE Key Lab Environm Remediat & Ecosyst Hlth, Hangzhou 310029, Zhejiang, Peoples R China.
RP Sun, XF, NW Polytech Univ, Coll Sci, Dept Appl Chem, Xian 710072,
   Peoples R China.
FU National Natural Science Foundation of China [20707016]; Northwestern
   Polytechnical University 
FX The authors are grateful for the financial support provided by the
   National Natural Science Foundation of China (No. 20707016) and by the
   Northwestern Polytechnical University.
CR BARDET M, 2002, ANAL CHEM, V74, P386
   DAWSON BSW, 1999, HOLZFORSCHUNG, V53, P1951
   DREHER WA, 1964, FOREST PROD J, V14, P66
   KACURAKOVA M, 2000, CARBOHYD POLYM, V43, P195
   KARIMI B, 2001, SYNLETT          APR, P519
   KAUPPLNEN JK, 1981, ANAL CHEM, V53, P454
   KOPPERS DL, 1961, RDW400, E106
   KRYLOVA AN, 1970, MODIFICATION WOOD LA, P59
   KUMAR S, 1979, J TIMBER DEV ASS IND, V25, P5
   OHKOSHI M, 1997, MOKUZAI GAKKAISHI, V43, P327
   ROWELL RM, 1983, FOR PROD ABSTR, V6, P363
   ROWELL RM, 1991, WOOD CELLULOSIC CHEM, P709
   ROWELL RM, 1994, WOOD FIBER SCI, V26, P11
   SAIKIA CN, 1995, IND CROP PROD, V4, P233
   SIDORENKO AK, 1973, LESN ZH, V16, P157
   SUN RC, 2002, IND CROP PROD, V16, P225
   SUN XF, 2002, J AGR POOD CHEM, V50, P428
   SUN XF, 2005, J AGR FOOD CHEM, V53, P860, DOI 10.1021/jf040456q
   TARKOW H, 1950, 1593 USDA FOR SERV F
   ZHAN H, 2002, RES DEV PROGRAMS PUL, P56
   ZHANG KB, 1989, J ARID ENVIRON, V16, P3
NR 21
TC 0
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 0576-9787
J9 CELL CHEM TECHNOL
JI Cell Chem. Technol.
PD JAN-MAR
PY 2008
VL 42
IS 1-3
BP 17
EP 22
PG 6
SC Materials Science, Paper & Wood
GA 434IE
UT ISI:000265267600003
ER

PT J
AU Yang, P
   Wang, CS
   Shi, ZB
   Huang, X
   Dang, XQ
   Xu, SL
   Wang, KZ
AF Yang, Pei
   Wang, Chunsheng
   Shi, Zhibin
   Huang, Xin
   Dang, Xiaoqian
   Xu, Shanglong
   Wang, Kunzheng
TI Prefabrication of Vascularized Porous Three-Dimensional Scaffold
   Induced from rhVEGF(165): A Preliminary Study in Rats
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Tissue engineering; Angiogenesis; Scaffolds, prefabrication; Vascular
   endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; CALCIUM-PHOSPHATE CEMENT; SEGMENTAL BONE
   DEFECTS; CHEMOTACTIC MIGRATION; ANGIOGENESIS; VEGF; TISSUE;
   REGENERATION; MATRICES; RELEASE
AB Background/Aims: Several shortcomings have limited the routine use of
   autogenous vascularized bone graft. The present study investigates the
   prefabrication of vascularized scaffold with the desired shape and
   microarchitecture combined with recombinant human vascular endothelial
   growth factor 165 (rhVEGF(165)) to mimic autogenous vascularized bone
   graft. Methods: Eighty-five porous calcium phosphate cement scaffolds
   constructed by rapid prototyping technology were divided into four
   groups: group A [rhVEGF(165)-fibrin sealant (FS) scaffold], group B
   (hVEGF(165) scaffold), group C (FS scaffold), and group D (scaffold
   alone). The release of rhVEGF(165) from the scaffolds was examined in
   vitro. The vessel density, relative functionalized vessels, vessel
   diameter and relative vessel area were also measured. Results: The
   sustained release of hVEGF(165) lasted 14 days in the absence of
   plasmin and 12 days in the presence of plasmin in group A and 10 days
   in group B. There was no statistical difference between groups A and B
   at 2 or 4 weeks in terms of vessel density, relative functionalized
   vessels, vessel diameter, and relative vessel area, as between groups C
   and D. However, the above parameters were greater in groups A and B
   than groups C and D. Conclusion: The scaffolds with the desired shape
   and microarchitecture combined with rhVEGF(165) could shorten the time
   needed for the construction of prefabricated vascularized grafts and
   accelerate the maturation of the vessels. Copyright (C) 2008 S. Karger
   AG, Basel
C1 [Yang, Pei; Wang, Chunsheng; Shi, Zhibin; Dang, Xiaoqian; Wang, Kunzheng] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Xian 710004, Shaanxi, Peoples R China.
   [Huang, Xin] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1,Dept Cardiol,Educ Minist, Ion Channel Dis Lab,Key Lab Environm & Genes Rela, Xian 710004, Shaanxi, Peoples R China.
   [Xu, Shanglong] Xi An Jiao Tong Univ, State Key Lab Mfg Syst Engn, Xian 710004, Shaanxi, Peoples R China.
RP Wang, KZ, Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 2, Dept
   Orthoped, 157 Xiwu Rd, Xian 710004, Shaanxi, Peoples R China.
EM kunzhengwang@126.com
FU National Science Foundation of China [30371443]
FX This study was supported by the National Science Foundation of China
   (30371443). We thank Prof. Zengtie Zhang for his help with histology.
   We also thank Dr. Xudong Li of the Department of Orthopaedic Surgery,
   University of Virginia for the preparation of the manuscript.
CR ALON T, 1995, NAT MED, V1, P1024
   CELIK M, 2000, J ORAL MAXIL SURG, V58, P292
   CHEN ZZ, 2004, RAPID PROTOTYPING J, V10, P327, DOI
   10.1108/13552540410562368
   CLARKE SA, 2007, BONE, V40, P939, DOI 10.1016/j.bone.2006.11.004
   COMUZZI L, 2002, CLIN ORAL IMPLAN RES, V13, P304
   DENBOER FC, 2003, J ORTHOPAED RES, V21, P521, DOI
   10.1016/S0736-0266(02)00205-X
   ENGSIG MT, 2000, J CELL BIOL, V151, P879
   FERRARA N, 1997, ENDOCR REV, V18, P4
   FIEDLER J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI
   10.1016/j.bbrc.2005.06.116
   GEIGER F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   GERBER HP, 1997, J BIOL CHEM, V272, P23659
   GIARDINO R, 2006, BIOMED PHARMACOTHER, V60, P386, DOI
   10.1016/j.biopha.2006.07.004
   GREENWALD AS, 2001, J BONE JOINT  A S2 2, V83, P98
   HARRIS LD, 1998, J BIOMED MATER RES, V42, P396
   HU YY, 2003, J BIOMED MATER RES A, V67, P591, DOI 10.1002/jbm.a.10070
   HULBERT SF, 1972, J BIOMED MATER RES, V6, P347
   KAUSHIVA A, 2007, ACTA BIOMATER, V3, P631, DOI
   10.1016/j.actbio.2007.03.003
   KLEINHEINZ J, 2005, J ORAL MAXIL SURG, V63, P1310, DOI
   10.1016/j.joms.2005.05.303
   LEE WK, 2003, J BIOMED MATER RES A, V67, P1087, DOI 10.1002/jbm.a.10570
   LEVY Y, 2006, J BIOMED MATER RES A, V79, P779, DOI 10.1002/jbm.a.30825
   LO H, 1996, J BIOMED MATER RES, V30, P475
   LODE A, 2007, J BIOMED MATER RES A, V81, P474, DOI 10.1002/jbm.a.31024
   MAYRWOHLFART U, 2002, BONE, V30, P472
   NAKAGAWA M, 2000, FEBS LETT, V473, P161
   NAKAMAE A, 2004, J ORTHOPAED RES, V22, P509, DOI
   10.1016/j.orthres.2003.10.001
   NILLESEN STM, 2007, BIOMATERIALS, V28, P1123, DOI
   10.1016/j.biomaterials.2006.10.029
   OBRIEN FJ, 2005, BIOMATERIALS, V26, P433, DOI
   10.1016/j.biomaterials.2004.02.052
   OOMS EM, 2002, J BIOMED MATER RES, V61, P9
   PIEPER JS, 2002, J BIOMED MATER RES, V62, P185, DOI 10.1002/jbm.10267
   RABIE ABM, 1997, CONNECT TISSUE RES, V36, P337
   RABIE ABM, 2004, ARCH ORAL BIOL, V49, P1025, DOI
   10.1016/j.archoralbio.2004.05.012
   RICKERT D, 2003, CLIN HEMORHEOL MICRO, V28, P175
   RUHE PQ, 2004, BIOMATERIALS, V25, P2123, DOI
   10.1016/j.biomaterials.2003.09.007
   SCHLAGETER KE, 1999, MICROVASC RES, V58, P312
   SPYRIDOPOULOS I, 1997, J MOL CELL CARDIOL, V29, P1321
   TAMAI N, 2002, J BIOMED MATER RES, V59, P110
   XU SL, 2007, BIO-MED MATER ENG, V17, P1
   ZISCH AH, 2001, J CONTROL RELEASE, V72, P101
NR 38
TC 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1422-6405
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 189
IS 5
BP 327
EP 337
DI 10.1159/000142162
PG 11
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 433BM
UT ISI:000265178600003
ER

PT J
AU Ehnfors, J
   Kost-Alimova, M
   Persson, NL
   Bergsmedh, A
   Castro, J
   Levchenko-Tegnebratt, T
   Yang, L
   Panaretakis, T
   Holmgren, L
AF Ehnfors, J.
   Kost-Alimova, M.
   Persson, N. Luna
   Bergsmedh, A.
   Castro, J.
   Levchenko-Tegnebratt, T.
   Yang, L.
   Panaretakis, T.
   Holmgren, L.
TI Horizontal transfer of tumor DNA to endothelial cells in vivo
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE cell fusion; apoptosis; gene transfer; phagocytosis; neovascularization
ID FIBROBLAST-GROWTH-FACTOR; GENETIC ALTERATIONS; APOPTOTIC BODIES;
   MICRODISSECTED STROMA; BREAST-CANCER; FUSION; TUMORIGENESIS;
   ANGIOGENESIS; CARCINOMA
AB Tumor endothelial cells have long been regarded as genomically stable
   and therefore less likely to develop resistance to antiangiogenic
   therapies. However, recent findings have challenged this notion. We
   have shown that DNA can be transferred between cells through
   phagocytosis of apoptotic bodies by adjacent viable cells. Propagation
   of the ingested DNA is prevented by the activation of the p53-p21
   pathway. In this study, we examined whether concomitant transfer of
   tumor DNA with genes that inactivate the p53 pathway could overcome the
   barrier to tumor DNA propagation. Our results demonstrate that
   fibroblasts and endothelial cells are capable of acquiring and
   replicating tumor DNA when the apoptotic tumor cells contain the SV40
   large T antigen. Analysis of the tumor stroma of xenotransplanted
   tumors in severe combined immunodeficient mice revealed that a
   sub-population of the endothelial cells contained tumor DNA. These
   cells maintained the ability to form functional vessels in an in vivo
   assay and concurrently express tumor-encoded and endothelial-specific
   genes.
C1 [Ehnfors, J.; Persson, N. Luna; Bergsmedh, A.; Castro, J.; Levchenko-Tegnebratt, T.; Yang, L.; Panaretakis, T.; Holmgren, L.] CCK, Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.
   [Kost-Alimova, M.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden.
RP Holmgren, L, CCK, Karolinska Inst, Dept Pathol & Oncol, S-17176
   Stockholm, Sweden.
EM lars.holmgren@ki.se
FU Swedish Research Council ; Swedish Cancer Society ; Karolinska
   Institutet, Cancerforeningen, Stockholm, Sweden ; EUCAAD [FP7]
FX We dedicate this paper to the memory of Judah Folkman. This study was
   supported by grants from the Swedish Research Council, Swedish Cancer
   Society, Karolinska Institutet, Cancerforeningen, Stockholm, Sweden,
   and EUCAAD FP7. We thank Dr. Raja Choudhury for proofreading the paper.
CR BERGSMEDH A, 2001, P NATL ACAD SCI USA, V98, P6407
   BERGSMEDH A, 2002, CANCER RES, V62, P575
   BERGSMEDH A, 2006, MOL CANCER RES, V4, P187, DOI
   10.1158/1541-7786.MCR-05-0262
   CHEN W, 2003, HISTOL HISTOPATHOL, V18, P541
   DELATAILLE A, 1999, CANCER RES, V59, P5461
   FOLKMAN J, 1995, NAT MED, V1, P27
   FUKINO K, 2004, CANCER RES, V64, P7231
   HANAHAN D, 1996, CELL, V86, P353
   HIDA K, 2004, CANCER RES, V64, P8249
   HILL R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030
   HOLMGREN L, 1999, BLOOD, V93, P3956
   HOLMGREN L, 2002, VOX SANG S1, V83, P305
   KUROSE K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   MANIOTIS AJ, 1999, AM J PATHOL, V155, P739
   MATSUMOTO N, 2003, CANCER RES, V63, P6158
   MOINFAR F, 2000, CANCER RES, V60, P2562
   OGLE BM, 2005, NAT REV MOL CELL BIO, V6, P567, DOI 10.1038/nrm1678
   PASSANITI A, 1992, LAB INVEST, V67, P519
   PATERSON RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747
   PAWELEK JM, 2000, MELANOMA RES, V10, P507
   RELF M, 1997, CANCER RES, V57, P963
   SPETZ AL, 1999, J IMMUNOL, V163, P736
   STREUBEL B, 2004, NEW ENGL J MED, V351, P250
   TERADA N, 2002, NATURE, V416, P542
   TUHKANEN H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733
   TYSNES BB, 2007, BBA-REV CANCER, V1775, P283, DOI
   10.1016/j.bbcan.2007.01.001
   VASSILOPOULOS G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539
   WANG X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531
   WEINER F, 1971, J CELL SCI, V8, P681
   WERNERT N, 2001, ANTICANCER RES, V21, P2259
NR 30
TC 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD MAY
PY 2009
VL 16
IS 5
BP 749
EP 757
DI 10.1038/cdd.2009.7
PG 9
SC Biochemistry & Molecular Biology; Cell Biology
GA 433ZQ
UT ISI:000265245400010
ER

PT J
AU Osawa, T
   Muramatsu, M
   Watanabe, M
   Shibuya, M
AF Osawa, Tsuyoshi
   Muramatsu, Masashi
   Watanabe, Makoto
   Shibuya, Masabumi
TI Hypoxia and low-nutrition double stress induces aggressiveness in a
   murine model of melanoma
SO CANCER SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER METASTASIS; RENAL-CELL
   CARCINOMA; STEM-CELLS; ANGIOGENESIS; LYMPHANGIOGENESIS;
   THROMBOSPONDIN-1; BEVACIZUMAB; MECHANISMS; RESISTANCE
AB Antiangiogenic therapy is a potent cancer treatment, however, the
   possibility of recurrence and resistance to this approach remains. Here
   we show that hypoxia and low-nutrition double-deprivation stress
   induces reversible tumor aggressiveness. In a stress-cycle-dependent
   manner, murine melanoma cells showed morphological changes,
   up-regulated phospho-Akt, and abnormal regulation of multiple genes
   including fibroblast growth factor-21, a metabolic regulator, resulting
   in increased cell proliferation in vitro, and increased tumorigenesis
   and invasive potential in vivo. In this system, altered cellular
   metabolism participates in the adaptation of tumor to the
   double-deprivation stress. Our results suggest the targeting of a minor
   population of cancer cells resistant to both hypoxia and low nutrition
   to be an effective new antitumor strategy in combination with
   antiangiogenic therapy. (Cancer Sci 2009; 100: 844-851).
C1 [Osawa, Tsuyoshi; Muramatsu, Masashi; Shibuya, Masabumi] Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Tokyo, Japan.
   [Watanabe, Makoto] Univ Tokyo, Inst Med Sci, Div Syst Biomed Technol, Tokyo, Japan.
RP Shibuya, M, Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol,
   Tokyo, Japan.
EM shibuya@ims.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [17014020]; Japan Society for Promotion of Science ; Organization for
   Pharmaceutical Safety and Research 
FX This work was supported by a Grant-in-Aid for Special Project Research
   on Cancer-Bioscience (No. 17014020) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan; a grant from the
   program 'Research for the Future' from the Japan Society for Promotion
   of Science; and a grant from the program 'Promotion of Fundamental
   Research in Health Science' from the Organization for Pharmaceutical
   Safety and Research. We thank Dr Y. Yuasa and Dr T. Koda (Tokyo Dental
   and Medical University, Tokyo, Japan), and Dr M. Murakami, Dr S.
   Yamamoto, and Ms. S Yamaguchi (Institute of Medical Science, University
   of Tokyo, Tokyo, Japan) for helpful discussions.
CR CALABRESE C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   DAS B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575
   ESCUDIER B, 2007, NEW ENGL J MED, V356, P125
   FANG D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   FERRARA N, 1997, ENDOCR REV, V18, P4
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 2004, APMIS, V112, P496
   FUKUMOTO S, 2008, ENDOCR J, V55, P23
   GATENBY RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   GLADE BJ, 2004, DRUG RESIST UPDATE, V7, P289
   GOTOH N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI
   10.1073/pnas.0407577101
   GUERTIN DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   HARRIS AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   HUDES G, 2007, NEW ENGL J MED, V356, P2271
   HURWITZ H, 2004, NEW ENGL J MED, V350, P2335
   IKEDA E, 1995, J BIOL CHEM, V270, P19761
   IRUELAARISPE ML, 1999, CIRCULATION, V100, P1423
   ITOH N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007
   KAWADA K, 2004, CANCER RES, V64, P4010
   KEITH B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   KERBEL RS, 2001, CANCER METAST REV, V20, P79
   KHARITONENKOV A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606
   KOPFSTEIN L, 2007, AM J PATHOL, V170, P1348, DOI
   10.2353/ajpath.2007.060835
   LU J, 2004, CANCER SCI, V95, P547
   MENENDEZ JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   MOORE DD, 2007, SCIENCE, V316, P1436, DOI 10.1126/science.1144837
   MORITA S, 2000, GENE THER, V7, P1063
   MULLER A, 2001, NATURE, V410, P50
   MUSTONEN T, 1995, J CELL BIOL, V129, P895
   POTIER E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   POUYSSEGUR J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   RISAU W, 1997, NATURE, V386, P671
   SANDLER A, 2006, NEW ENGL J MED, V355, P2542
   SHIBUYA M, 2001, CELL STRUCT FUNCT, V26, P25
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107
   SKOBE M, 2001, NAT MED, V7, P192
   TAKASU M, 1999, CLIN EXP METASTAS, V17, P409
   TOKER A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-074
   VIGNOT S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   WARBURG O, 1956, SCIENCE, V123, P309
   YAMAUCHI M, 2007, CANCER SCI, V98, P1491, DOI
   10.1111/j.1349-7006.2007.00534.x
NR 41
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2009
VL 100
IS 5
BP 844
EP 851
DI 10.1111/j.1349-7006.2009.01105.x
PG 8
SC Oncology
GA 434CA
UT ISI:000265251600009
ER

PT J
AU Shibata, H
   Yamakoshi, H
   Sato, A
   Ohori, H
   Kakudo, Y
   Kudo, C
   Takahashi, Y
   Watanabe, M
   Takano, H
   Ishioka, C
   Noda, T
   Iwabuchi, Y
AF Shibata, Hiroyuki
   Yamakoshi, Hiroyuki
   Sato, Atsuko
   Ohori, Hisatsugu
   Kakudo, Yuichi
   Kudo, Chieko
   Takahashi, Yayoi
   Watanabe, Mika
   Takano, Hiroshi
   Ishioka, Chikashi
   Noda, Tetsuo
   Iwabuchi, Yoshiharu
TI Newly synthesized curcumin analog has improved potential to prevent
   colorectal carcinogenesis in vivo
SO CANCER SCIENCE
LA English
DT Article
ID FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; COLON-CANCER; APC;
   TRANSCRIPTION; ACTIVATION; MODEL
AB Curcumin (diferuloylmethane) has chemopreventive and chemotherapeutic
   potentials against various types of cancers. We have developed a series
   of curcumin analogs to improve its low bioavailability by enhancing its
   potentials. The newly synthesized analog GO-Y030 [(1E,
   4E)-1,5-bis-(3,5(-bismethoxymethoxyphenyl) penta-1,4-dien-3-one] showed
   a 30-fold greater growth suppression in vitro via similar molecular
   mechanisms to curcumin. The availability of this analog was examined by
   using a mouse model harboring the germ-line mutation of Apc,
   Apc(580D/+), in vivo. Apc(580D/+) mice had a very limited survival time
   with an intestinal obstruction due to polyposis. The average tumor
   number in mice fed GO-Y030 was reduced to 61.2% of those that were fed
   the basal diet (P < 0.05). Compared with Apc(580D/+) mice fed the basal
   diet (median survival time = 166.5 days), a significantly prolonged
   lifespan (213 days) was observed in Apc(580D/+) mice fed GO-Y030. The
   chemopreventive effect with GO-Y030 was improved, compared with
   curcumin (191 days). The survival benefit corresponded to the
   diminished intestinal tumor incidence in Apc(580D/+) mice fed GO-Y030.
   No adverse reactions were observed, judging from body weight or
   biochemical data concerning liver and renal damage. Degradation of
   accumulated beta-catenin with curcumin is one of the major mechanisms
   of chemoprevention in colorectal carcinogenesis. It was demonstrated
   that the number of beta-catenin-positive adenoma cells in Apc(580D/+)
   mice fed GO-Y030 was reduced. (Cancer Sci 2009; 100: 956-960).
C1 [Shibata, Hiroyuki; Sato, Atsuko; Ohori, Hisatsugu; Kakudo, Yuichi; Kudo, Chieko; Ishioka, Chikashi] Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan.
   [Shibata, Hiroyuki; Ohori, Hisatsugu; Kakudo, Yuichi; Kudo, Chieko; Ishioka, Chikashi] Tohoku Univ, Univ Hosp, Dept Clin Oncol, Sendai, Miyagi 980, Japan.
   [Yamakoshi, Hiroyuki; Iwabuchi, Yoshiharu] Tohoku Univ, Grad Sch Pharmaceut, Dept Organ Chem, Sendai, Miyagi 980, Japan.
   [Takahashi, Yayoi; Watanabe, Mika] Tohoku Univ Hosp, Dept Pathol, Sendai, Miyagi, Japan.
   [Takano, Hiroshi; Noda, Tetsuo] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 170, Japan.
RP Shibata, H, Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol,
   Sendai, Miyagi 980, Japan.
EM hiroyuki@idac.tohoku.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [17015002]
FX Grants-in-aid were received from the HIROMI Medical Reserarch
   Foundation, Sendai, Japan (H. Shibata) and Miyagi Health Service
   Association (C. Ishioka). Grants-in-Aid for Scientific Research on
   Priority Areas (Cancer, No. 17015002) were received from the Ministry
   of Education, Culture, Sports, Science and Technology, Japan (H.
   Shibata and C. Ishioka). The immunohistchemical analysis of
   beta-catenin was conducted at Kotobiken Medical Laboratories, Tokyo,
   Japan.
CR GOEL A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI
   10.1016/j.bcp.2007.08.016
   HAHM ER, 2004, BIOCHEM BIOPH RES CO, V321, P337, DOI
   10.1016/j.bbrc.2004.06.119
   HE TC, 1998, SCIENCE, V281, P1509
   IRESON CR, 2002, CANCER EPIDEM BIOMAR, V11, P105
   MAHMOUD NN, 2000, CARCINOGENESIS, V21, P921
   MENON LG, 1999, CANCER LETT, V141, P159
   MORIN PJ, 1997, SCIENCE, V275, P1787
   MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046
   OHORI H, 2006, MOL CANCER THER, V5, P2563, DOI
   10.1158/1535-7163.MCT-06-0174
   ORFORD K, 1997, J BIOL CHEM, V272, P24735
   OSHIMA H, 1997, CANCER RES, V57, P1644
   PERKINS S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   PETROVA TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020
   SHARMA RA, 2001, CLIN CANCER RES, V7, P1894
   SHIBATA H, 1997, SCIENCE, V278, P120
   SHIBATA H, 2007, P NATL ACAD SCI USA, V104, P18199, DOI
   10.1073/pnas.0705730104
   SINGH S, 1995, J BIOL CHEM, V270, P24995
   TETSU O, 1999, NATURE, V398, P422
NR 18
TC 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2009
VL 100
IS 5
BP 956
EP 960
DI 10.1111/j.1349-7006.2009.01127.x
PG 5
SC Oncology
GA 434CA
UT ISI:000265251600024
ER

PT J
AU Xu, XL
   Yang, YJ
   Zhu, NS
AF Xu, Xiulin
   Yang, Yujing
   Zhu, Naishuo
TI Characteristics and Molecular Mechanism of Adhesion Proteins on Reused
   Hemodialysis Membranes
SO BLOOD PURIFICATION
LA English
DT Article
DE Reusable dialysis; Adhesion protein; Two-dimensional electrophoresis;
   Mass spectrum; Adhesion mechanism
ID DIALYZER REUSE; PERACETIC-ACID; POLYSULFONE; ACTIVATION; ADSORPTION;
   SOLUTE; COMPLEMENT; TRANSPORT; FICOLINS; REMOVAL
AB In order to study the mechanism of protein adhesion on the Fresenius F6
   polysulfone membrane dialyzer, two-dimensional gel electrophoresis,
   LC-ESI-MS/MS and bioinformatics methods were used to analyze the
   protein which adhered to the dialyzer membrane. Six of the adhered
   proteins account for more than 50% of the total 179 proteins, i.e.
   ficolin precursor, complement C3 precursor, 3 variants of MASP1 and
   albumin. The results also showed that easily adhered proteins have a
   greater percentage of acidic amino acids (p < 0.01). The isoelectric
   point of the 20 proteins with the most deposits is 6.2 +/- 1.08, which
   is obviously lower than of those with the least deposits (7.56 +/-
   1.36, p < 0.01). The dipole moment of a polysulfone membrane molecule
   has a tendency to absorb molecules with a negative charge. These
   results are of significance in understanding and improving membrane
   protein interactions. Copyright (C) 2009 S. Karger AG, Basel
C1 [Zhu, Naishuo] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Lab Mol Immunol, Shanghai 200433, Peoples R China.
   [Xu, Xiulin; Yang, Yujing] Shanghai Univ Sci & Technol, Inst Med Device & Food Sci, Shanghai 201800, Peoples R China.
RP Zhu, NS, Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Lab Mol
   Immunol, Shanghai 200433, Peoples R China.
EM nzhu@fudan.edu.cn
FU science foundation of the Shanghai education committee [04EB18]
FX This work was supported by the science foundation of the Shanghai
   education committee (No. 04EB18).
CR RD472002 ANSIAAMI
   BIAN SS, 2006, CHIN J BLOOD PURIF, V5, P205
   BOUMAN CSC, 1998, BLOOD PURIFICAT, V16, P261
   CHEUNG AK, 1990, KIDNEY INT, V37, P1055
   CLARK WR, 2007, CONTRIB NEPHROL, V158, P20
   CORNELIUS RM, 2002, ASAIO J, V48, P300
   FENG L, 1995, COLLOID SURFACE B, V4, P313
   FRANK RD, 2001, KIDNEY INT, V60, P1972
   GAN H, 2004, SECT CLIN BIOCH LAB, V25, P519
   GOLDMAN M, 1989, INT J ARTIF ORGANS, V12, P373
   HIGUCHI A, 2002, BIOMATERIALS, V23, P2659
   HUANG ZW, 2006, CHIN J CLIN REHAB, V10, P78
   KAPLAN AA, 2000, SEMIN DIALYSIS, V13, P271
   KAZUHIKO I, 2002, ARTIF ORGANS, V26, P1014
   LE Y, 1997, J IMMUNOL METHODS, V204, P43
   LI G, 2005, J HANDAN MED COLL, V18, P599
   MATSUSHITA M, 1996, J BIOL CHEM, V271, P2448
   MATSUSHITA M, 2001, INT IMMUNOPHARMACOL, V1, P359
   MATSUSHITA M, 2002, IMMUNOBIOLOGY, V205, P490
   PARK JY, 2006, BIOMATERIALS, V27, P856, DOI
   10.1016/j.biomaterials.2005.07.010
   QIAO B, 2003, CHEM LIFE, V23, P358
   RAYMOND M, 1985, AM J MED, V78, P575
   ROBINSON BM, 2005, SEMIN DIALYSIS, V18, P175
   RONCO C, 2005, CONTRIB NEPHROL, V149, P10
   RONCO C, 2007, CONTRIB NEPHROL, V158, P34
   SCOTT MK, 1999, AM J KIDNEY DIS, V33, P87
   SHAO J, 2007, ARTIF ORGANS, V31, P452, DOI
   10.1111/j.1525-1594.2007.00387.x
   TANAKA N, 2000, ARTIF ORGANS, V24, P921
   TOMO T, 2008, BLOOD PURIFICAT, V26, P347, DOI 10.1159/000133430
   TWARDOWSKI ZJ, 2006, SEMIN DIALYSIS, V19, P41
   VIGANO SM, 2008, CONTRIB NEPHROL, V161, P162
   WARD RA, 2006, BLOOD PURIFICAT, V24, P6, DOI 10.1159/000089429
   WOLFF SH, 2005, ARTIF ORGANS, V29, P166
   YASUHIKO I, 2003, ARTIF ORGANS, V6, P260
   ZHANG YS, 2004, INFORM MED EQUIP, V19, P48
NR 35
TC 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
J9 BLOOD PURIFICAT
JI Blood Purif.
PY 2009
VL 27
IS 4
BP 321
EP 329
DI 10.1159/000207199
PG 9
SC Hematology; Urology & Nephrology
GA 432HE
UT ISI:000265123300002
ER

PT J
AU Qi, XH
   Yang, JH
   Yu, JQ
   Zhang, MF
AF Qi, Xiao-Hua
   Yang, Jing-Hua
   Yu, Jing-Quan
   Zhang, Ming-Fang
TI Genetic and heterosis analysis for important agronomic traits of
   Chinese vegetable mustard (Brassica juncea) in different environments
SO GENETICA
LA English
DT Article
DE Agronomic traits; Brassica juncea; Genetic analysis; Genotype
   environment interaction; Heterosis
ID QUALITY TRAITS; RICE; IDENTIFICATION; CROSSES; MODEL
AB Genetic effects and genotype by environment (GE) interaction effects
   for some important agronomic traits of Chinese vegetable mustard were
   analyzed by using a genetic model including additive, dominance,
   additive x additive effects and their interaction effects with the
   environment. Four variations of Chinese vegetable mustard as parental
   lines and their F-1s, F-2s were evaluated in two locations. It was
   revealed that the agronomic traits of Chinese vegetable mustard were
   mainly controlled by genetic effects except plant weight (PW) and leaf
   weight (LW) were observed to be more affected by GE interaction
   effects. Among the genetic effects, additive effects took the main
   proportion for tiller number (TN), leaf number (LN), leaf breadth (LB)
   and LW; dominance effects were the main components of PW, leaf length
   (LL), root weight (RW) and plant height (PH); additive x additive
   effects were the main components of plant breadth (PB). Among the GE
   interaction effects, additive x environment interaction effects mainly
   affected LB, LW and RW, while PW, LL, PH and PB were mainly controlled
   by dominance x environment interaction effects. Besides, additive x
   additive x environment interaction was the main factor, which
   controlled TN and LN of Chinese vegetable mustard. For heterosis
   analyses, TN, LN, LB and LW of Chinese vegetable mustard showed
   positive H-PM and negative H-PB. The other traits showed positive H-PM
   and H-PB. Heterosis arising from GE interaction was found to varying
   degree for different environments. It was shown that genetic heterosis
   and GE interaction effects were important factors for agronomic traits
   in Chinese vegetable mustard.
C1 [Qi, Xiao-Hua; Yang, Jing-Hua; Yu, Jing-Quan; Zhang, Ming-Fang] Zhejiang Univ, Dept Hort Sci, Lab Genet Resources & Funct Improvement Hort Plan, Hangzhou 310029, Zhejiang, Peoples R China.
   [Qi, Xiao-Hua; Yang, Jing-Hua; Yu, Jing-Quan; Zhang, Ming-Fang] Minist Agr, Lab Hort Plant Growth Dev & Biotechnol, Hangzhou 310029, Zhejiang, Peoples R China.
RP Zhang, MF, Zhejiang Univ, Dept Hort Sci, Lab Genet Resources & Funct
   Improvement Hort Plan, Hangzhou 310029, Zhejiang, Peoples R China.
EM xiaohuasea@126.com
   mfzhang@zju.edu.cn
FU National Natural Science Foundation of China (NSFC) [30571270]
FX Our work was supported by a grant from the National Natural Science
   Foundation of China (NSFC, 30571270). We are grateful Shaoxing Academy
   of Agricultural Science of Zhejiang province for providing us
   experiment locations. We appreciate Dr. Hai-Ming Xu and Dr. Mikio
   Nakazono, for their generous advice and support in the study. The
   authors are very grateful to two anonymous referees for their helpful
   and valuable suggestions.
CR COX TS, 1990, THEOR APPL GENET, V79, P241
   ENGQVIST GM, 1991, EUPHYTICA, V58, P31
   KNIGHT R, 1973, THEOR APPL GENET, V43, P318
   LIONNETON E, 2004, THEOR APPL GENET, V109, P792, DOI
   10.1007/s00122-004-1682-0
   LIU PY, 1996, CHINESE MUSTARD, P46
   MILLER RG, 1974, BIOMETRIKA, V61, P1
   NEGI MS, 2000, THEOR APPL GENET, V101, P146
   ORAM RN, 2005, AUST J AGR RES, V56, P581, DOI 10.1071/AR04295
   SHI CH, 1997, THEOR APPL GENET, V95, P294
   STUBER CW, 1992, GENETICS, V132, P823
   TONG NK, 1992, ACTA HORTIC SIN, V19, P151
   VIANA JMS, 1999, GENET MOL BIOL, V22, P591
   VIRMANI SS, 1982, THEOR APPL GENET, V63, P373
   XU ZC, 1999, HEREDITY 5, V82, P510
   YOUNG J, 1990, EUPHYTICA, V51, P87
   ZENG GP, 1998, J NANJING AGR U, V21, P31
   ZHU J, 1993, J BIOMATH, V8, P32
   ZHU J, 1994, THEOR APPL GENET, V89, P153
   ZHU J, 1996, THEOR APPL GENET, V92, P1
   ZHU J, 1997, ANAL METHODS GENETIC, P88
NR 20
TC 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
J9 GENETICA
JI Genetica
PD MAY
PY 2009
VL 136
IS 1
BP 89
EP 95
DI 10.1007/s10709-008-9316-0
PG 7
SC Genetics & Heredity
GA 428GJ
UT ISI:000264835700010
ER

PT J
AU Yang, F
   Green, JJ
   Dinio, T
   Keung, L
   Cho, SW
   Park, H
   Langer, R
   Anderson, DG
AF Yang, F.
   Green, J. J.
   Dinio, T.
   Keung, L.
   Cho, S-W
   Park, H.
   Langer, R.
   Anderson, D. G.
TI Gene delivery to human adult and embryonic cell-derived stem cells
   using biodegradable nanoparticulate polymeric vectors
SO GENE THERAPY
LA English
DT Article
DE stem cells; gene delivery; biodegradable; polymeric vectors
ID POLY(BETA-AMINO ESTER)S; CATIONIC POLYMERS; PLASMID DNA; THERAPY;
   TRANSFECTION; LIBRARY; TISSUE; EFFICIENT; NEURONS; MODEL
AB Gene delivery to stem cells holds great potential for tissue
   regeneration and delivery of therapeutic proteins. The major barrier is
   the lack of safe and efficient delivery methods. Here, we report
   enhanced gene delivery systems for human stem cells using biodegradable
   polymeric vectors. A library of poly (beta- amino esters) end-modified
   derivatives was developed and optimized for high transfection
   efficiency and low cytotoxicity for three human stem cell lines
   including human mesenchymal stem cells (hMSCs), human adipose-derived
   stem cells (hADSCs) and human embryonic stem cell-derived cells
   (hESCds). In the presence of 10% serum, leading end-modified C32
   polymeric vectors exhibited significantly high transfection efficiency
   in hMSCs (27 +/- 2%), hADSCs (24 +/- 3%) and hESCds (56 +/- 11%), with
   high cell viability (87 - 97%) achieved in all cell types. Our results
   show that poly(beta-amino esters) as a class, and end-modified versions
   of C32 in particular, are efficient polymeric vectors for gene delivery
   to both adult and embryonic-derived stem cells.
C1 [Yang, F.; Green, J. J.; Keung, L.; Cho, S-W; Langer, R.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Dinio, T.] Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA.
   [Park, H.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Langer, R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Langer, R.; Anderson, D. G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
RP Anderson, DG, MIT, Koch Inst Integrat Canc Res, 77 Massachusetts
   Ave,E25-342, Cambridge, MA 02139 USA.
EM dgander@mit.edu
FU NIH [R01-EB000244-27, R01-DE01651603]; National Institutes of Health
   for National Research Service [1F32 AR056567-01]
FX We thank the NIH (R01-EB000244-27 and R01-DE01651603) for funding. FY
   gratefully acknowledge the National Institutes of Health for National
   Research Service Award postdoctoral fellowship (1F32 AR056567-01). We
   also thank the laboratory of Professor Johnny Huard at the University
   of Pittsburgh for kindly providing us the DNA plasmid-encoding human
   vascular endothelial growth factor 165 used in this study.
CR AKINC A, 2003, BIOCONJUGATE CHEM, V14, P979, DOI 10.1021/bc034067y
   ANDERSON DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI
   10.1002/anie.200351244
   ANDERSON DG, 2004, P NATL ACAD SCI USA, V101, P16028, DOI
   10.1073/pnas.0407218101
   ANDERSON DG, 2005, MOL THER, V11, P426, DOI 10.1016/j.ymthe.2004.11.015
   ASLAN H, 2006, TISSUE ENG, V12, P877
   BALDWIN HS, 1994, DEVELOPMENT, V120, P2539
   BETZ VM, 2008, FRONT BIOSCI, V13, P833
   BIGGER BW, 2006, GENE THER, V13, P117, DOI 10.1038/sj.gt.3302638
   CONRAD C, 2007, CURR GENE THER, V7, P249
   DENIS CV, 2002, INT J HEMATOL, V75, P3
   FARRELL LL, 2007, EUR J PHARM BIOPHARM, V65, P388, DOI
   10.1016/j.ejpb.2006.11.026
   GOESSLER UR, 2006, CELLS TISSUES ORGANS, V183, P169, DOI
   10.1159/000096508
   GREEN J, 2007, ADV MATER, V19, P7
   GREEN JJ, 2006, BIOCONJUGATE CHEM, V17, P1162, DOI 10.1021/bc0600968
   HWANG NS, 2006, TISSUE ENG, V12, P2695
   JANKOWSKI RJ, 2002, GENE THER, V9, P642
   KIM TI, 2005, BIOCONJUGATE CHEM, V16, P1140, DOI 10.1021/bc0497012
   KOBAYASHI N, 2005, BIRTH DEFECTS RES C, V75, P10
   KUMAR S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   LAKSHMIPATHY U, 2004, STEM CELLS, V22, P531
   LIM YB, 2002, BIOCONJUGATE CHEM, V13, P952, DOI 10.1021/bc025541n
   LYNN DM, 2000, J AM CHEM SOC, V122, P10761
   LYNN DM, 2001, J AM CHEM SOC, V123, P8155
   OGRIS M, 1998, GENE THER, V5, P1425
   PACK DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   PARK TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI
   10.1016/j.addr.2006.03.007
   PEISTER A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163
   PITTENGER MF, 1999, SCIENCE, V284, P143
   REYNOLDS BA, 1992, SCIENCE, V255, P1707
   SHAMBLOTT MJ, 1998, P NATL ACAD SCI USA, V95, P13726
   SONG HJ, 2002, NAT NEUROSCI, V5, P438
   STRULOVICI Y, 2007, MOL THER, V15, P850, DOI 10.1038/mt.sj.6300125
   SUEBLINVONG V, 2007, CLIN CHEST MED, V28, P361, DOI
   10.1016/j.ccm.2007.02.004
   SURI C, 1996, CELL, V87, P1171
   THOMAS M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI
   10.1007/s00253-003-1321-8
   THOMSON JA, 1998, SCIENCE, V282, P1147
   WICKHAM MQ, 2003, CLIN ORTHOP RELA JUL, P196, DOI
   10.1097/01.blo.0000072467.53786.ca
   ZACHOS T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   ZHONG L, 2006, CURR GENE THER, V6, P683
   ZUGATES GT, 2007, MOL THER, V15, P1306, DOI 10.1038/sj.mt.6300132
   ZUK PA, 2001, TISSUE ENG, V7, P211
NR 41
TC 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THERAPY
JI Gene Ther.
PD APR
PY 2009
VL 16
IS 4
BP 533
EP 546
DI 10.1038/gt.2008.182
PG 14
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
GA 430WL
UT ISI:000265021400011
ER

PT J
AU Huang, HG
   Zhao, WM
   Tang, ZL
   Yang, SL
   Wu, ZF
   Zhao, SH
   Cui, WT
   Mu, YL
   Chu, MX
   Li, K
AF Huang, Honggang
   Zhao, Weimin
   Tang, Zhonglin
   Yang, Shulin
   Wu, Zhengfang
   Zhao, Shuhong
   Cui, Wentao
   Mu, Yulian
   Chu, Mingxing
   Li, Kui
TI Characterization of porcine MMP-2 and its association with immune traits
SO GENE
LA English
DT Article
DE Pig; MMP-2; Genomic structure; Promotor; Mapping; Association analysis;
   Immune traits
ID NF-KAPPA-B; MATRIX-METALLOPROTEINASE; GELATINASE-A; CYTOKINE
   REGULATION; GENE-EXPRESSION; INFLAMMATION; ANGIOGENESIS; INVASION;
   CELLS; MICE
AB Matrix metalloproteinase-2 (MMP-2) plays important roles in
   inflammation and immunity besides its basic role in degrading and
   remodelling extracellular matrix (ECM). The expression of MMP-2 is
   up-regulated in many human as well as animal models of inflammatory and
   immune diseases. In this study, we cloned the 5'-upstream sequence,
   3'-downstream sequence as well as other missed genomic sequences of
   porcine MMP-2, the genomic Structure and the promotor sequence were
   analyzed and found to share high similarity with those of human MMP-2.
   Porcine MMP-2 was assigned to SSC6p14-p15, and closely linked to
   microsatellite SW1108 (53cR, LOD score 7.59) by IMpRH panel. Real-time
   PCR analysis revealed that the expression of porcine MMP-2 was
   remarkably different in diverse tissues, a high level expression was
   observed in the testis and uterus, relatively low expression in other
   tissues. Allele frequencies determination in different pig breeds and
   association study were performed on the selected SNP and indel. The
   results showed that the SNP Acyl in exon 12 was significantly
   associated with white blood cell count (WBC) of neonate piglets at 0
   day (P=0.0079), and classical swine fever virus antibody level
   (CSFV-AB) of pigs at 17 days (P=0.0461), the indel MspI in intron 4 had
   remarkable correlation with mean corpuscular hemoglobin (MCH) of pigs
   at 17 days (P<0.0001). (C) 2009 Elsevier B.V. All rights reserved.
C1 [Huang, Honggang; Zhao, Weimin; Tang, Zhonglin; Yang, Shulin; Cui, Wentao; Mu, Yulian; Chu, Mingxing; Li, Kui] Chinese Acad Agr Sci, Inst Anim Sci, Minist Agr China, Key Lab Farm Anim Genet Resources & Utilizat, Beijing 100193, Peoples R China.
   [Zhao, Weimin; Zhao, Shuhong] Huazhong Agr Univ, Coll Anim Sci & Technol, Minist Educ China, Key Lab Agr Anim Genet Breeding & Repprod, Wuhan 430070, Hubei, Peoples R China.
   [Wu, Zhengfang] Huanan Agr Univ, Coll Anim Sci, Guangzhou 510642, Guangdong, Peoples R China.
RP Li, K, Chinese Acad Agr Sci, Inst Anim Sci, Minist Agr China, Key Lab
   Farm Anim Genet Resources & Utilizat, Beijing 100193, Peoples R China.
EM kuili@iascaas.net.cn
FU National Natural Science Foundation of China ; National High Science
   and Technology Foundation of China ; Key Project of National Basic
   Research and Development Plan of China ; State Platform of Technology
   Infrastructure [2005DK21101]; National Support Plan and Innovation
   Group Foundation of IAS, CAAS 
FX The authors thank Dr Martine Yerle of INRA, France for Providing the RH
   panel. We thank Xiangdong Liu, Prof Qin Zhang and Yong Li for advice
   and help. This work was supported by National Natural Science
   Foundation of China, National High Science and Technology Foundation of
   China, Key Project of National Basic Research and Development Plan of
   China and State Platform of Technology Infrastructure (2005DK21101),
   National Support Plan and Innovation Group Foundation of IAS, CAAS.
CR ARIMURA K, 2004, EUR J HAEMATOL, V73, P17
   BODE W, 1993, FEBS LETT, V331, P134
   CARON C, 2001, J DENT RES, V80, P1660
   CATALDO D, 2000, INT ARCH ALLERGY IMM, V123, P259
   CORRY DB, 2002, NAT IMMUNOL, V3, P347
   EGEBLAD M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   FELX M, 2006, CLIN SCI, V110, P645, DOI 10.1042/CS20050286
   GOUREAU A, 1996, GENOMICS, V36, P252
   HAAS TL, 1999, TRENDS CARDIOVAS MED, V9, P70
   HANKINS JS, 2008, BRIT J HAEMATOL, V140, P80
   HOLLA LI, 2000, ALLERGY, V55, P900
   HUHTALA P, 1990, J BIOL CHEM, V265, P11077
   ITOH T, 1997, J BIOL CHEM, V272, P22389
   JANOWSKAWIECZOR.A, 2000, HEMATOLOGY, V4, P515
   KATO T, 2001, FEBS LETT, V508, P187
   KELLY EAB, 2000, AM J RESP CRIT CARE, V162, P1157
   KHERADMAND F, 2002, J CELL SCI, V115, P839
   KUMAGAI K, 1999, J IMMUNOL, V162, P4212
   LEE SM, 2005, VIROLOGY, V342, P47, DOI 10.1016/j.virol.2005.07.034
   LEVI E, 1996, P NATL ACAD SCI USA, V93, P7069
   LIU Y, 2007, MITOCHONDR DNA, V18, P4257
   MA GJ, 2008, MOL IMMUNOL, V45, P2797, DOI 10.1016/j.molimm.2008.02.007
   MADRI JA, 1996, BIOCHEM CELL BIOL, V74, P749
   MARQUEZCURTIS LA, 2001, BRIT J HAEMATOL, V115, P595
   MATSUI K, 1998, J IMMUNOL, V161, P3469
   MATSUMURA S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304
   MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288
   MCQUIBBAN GA, 2000, SCIENCE, V289, P1202
   MILAN D, 2000, BIOINFORMATICS, V16, P558
   MISRA S, 2008, AM J PHYSIOL-HEART C, V294, P2219
   PAGEMCCAW A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   PARKS WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   QIN HW, 1999, J BIOL CHEM, V274, P29130
   RIBEIRO LA, 2007, VET RES COMMUN S1, V31, P193
   RIES C, 1995, BIOL CHEM H-S, V376, P345
   SAWICKI G, 1997, NATURE, V386, P616
   STAMENKOVIC I, 2000, SEMIN CANCER BIOL, V10, P415
   STERNLICHT MD, 1999, GUIDEBOOK EXTRACELLU, P503
   STOCKER W, 1995, PROTEIN SCI, V4, P823
   WANG H, 2007, BIOCHEM GENET, V45, P51, DOI 10.1007/s10528-006-9065-7
   WESTERMARCK J, 1999, FASEB J, V13, P781
   WISEMAN BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090
   XIE ZL, 2004, J BIOL CHEM, V279, P39513, DOI 10.1074/jbc.M405844200
   YERLE M, 1998, CYTOGENET CELL GENET, V82, P182
   YU AE, 1996, BIOCHEM CELL BIOL, V74, P823
   ZAHRADKA P, 2004, AM J PHYSIOL-HEART C, V287, P2861
   ZENI P, 2007, AM J PHYSIOL-CELL PH, V293, P855
   ZHENG T, 2000, J CLIN INVEST, V106, P1081
NR 48
TC 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD APR 15
PY 2009
VL 435
IS 1-2
BP 63
EP 71
DI 10.1016/j.gene.2009.01.002
PG 9
SC Genetics & Heredity
GA 430UL
UT ISI:000265014600009
ER

PT J
AU Wang, F
   Feng, MH
   Xu, P
   Xiao, H
   Niu, P
   Yang, XB
   Bai, Y
   Peng, Y
   Yao, PF
   Tan, H
   Tanguay, RM
   Wu, TC
AF Wang, Feng
   Feng, Maohui
   Xu, Ping
   Xiao, Han
   Niu, Piye
   Yang, Xiaobo
   Bai, Yun
   Peng, Ying
   Yao, Pinfang
   Tan, Hao
   Tanguay, Robert M.
   Wu, Tangchun
TI The level of Hsp27 in lymphocytes is negatively associated with a
   higher risk of lung cancer
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Biomarker; Hsp27; Hsp70; Hsps; Lung cancer; Lymphocyte; Risk
ID HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; OXIDATIVE STRESS;
   GENE-EXPRESSION; HEAT-SHOCK-PROTEIN-70 LEVELS; ESTROGEN-RECEPTOR;
   TRANSGENIC MICE; ISCHEMIC-INJURY; HUMAN MONOCYTES; TOBACCO-SMOKE
AB Heat shock proteins (Hsps) can protect cells, organs, and whole
   organisms against damage caused by abnormal environmental hazards. Some
   studies have reported that lymphocyte Hsps may serve as biomarkers for
   evaluating disease status and exposure to environmental stresses;
   however, few epidemiologic studies have examined the associations
   between lymphocyte Hsps levels and lung cancer risk. We examined
   lymphocyte levels of Hsp27 and Hsp70 in 263 lung cancer cases and age-
   and gender-matched cancer-free controls by flow cytometry. Multivariate
   logistic regression models were used to estimate the association
   between lymphocyte Hsps levels and lung cancer risk. Our results showed
   that Hsp27 levels were significantly lower in lung cancer cases than in
   controls (16.5 vs 17.8 mean fluorescence intensity, P < 0.001). This
   was not observed for Hsp70 levels. Further stratification analysis
   revealed that lymphocyte Hsp27 levels were negatively associated with
   lung cancer risk especially in males and heavy smokers. There was a
   statistical trend of low odd ratios (95% confidence intervals) and
   upper tertile levels of Hsp27 [1.000, 0.904 (0.566-1.444) and 0.382
   (0.221-0.658, P (trend) = 0.001) in males and 1.000, 0.9207
   (0.465-1.822) and 0.419 (0.195-0.897, P (trend) = 0.036) in heavy
   smokers] after adjustment for confounding factors. These results
   suggest that lower lymphocyte Hsp27 levels might be associated with an
   increased risk of lung cancer. Our findings need to be validated in a
   large prospective study.
C1 [Wang, Feng; Feng, Maohui; Xiao, Han; Niu, Piye; Yang, Xiaobo; Bai, Yun; Tan, Hao; Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Feng; Feng, Maohui; Xiao, Han; Niu, Piye; Yang, Xiaobo; Bai, Yun; Tan, Hao; Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan 430030, Hubei, Peoples R China.
   [Feng, Maohui] Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China.
   [Xu, Ping; Peng, Ying] Wugang Staff Worker Hosp, Dept Oncol, Wuhan 430085, Peoples R China.
   [Yao, Pinfang] Hubei Canc Hosp, Inst Canc, Wuhan 430030, Peoples R China.
   [Tanguay, Robert M.] Univ Laval, Dept Med, Fac Med, Lab Cellular & Dev Genet, Quebec City, PQ G1V 0A6, Canada.
   [Tanguay, Robert M.] Univ Laval, PROTEO, Quebec City, PQ G1V 0A6, Canada.
RP Wu, TC, Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth,
   Dept Occupat & Environm Hlth, 2nd Bldg,13 Hangkong Rd, Wuhan 430030,
   Hubei, Peoples R China.
EM wut@mails.tjmu.edu.cn
FU National Natural Science Foundation of China [30525031, 30600491];
   National Key Basic Research and Development Program [2002CB512905];
   NNSFC-CIHR 
FX We thank all individuals who volunteered to participate in this study
   and the members of health examination center of Wugang Worker-Staff
   Hospital and Qingyi Wei of The University of M. D. Anderson Cancer
   Center for his critical review and scientific editing. This work was
   supported by research funds from the National Natural Science
   Foundation of China (NNSFC 30525031 and 30600491) and the National Key
   Basic Research and Development Program (2002CB512905), and a NNSFC-CIHR
   (Canadian Institutes of Health Research) joint research program to
   Tangchun Wu and Robert M Tanguay.
CR ALBERG AJ, 2003, CHEST S1, V123, P21
   ARRIGO AP, 2005, ANTIOXID REDOX SIGN, V7, P414
   ARRIGO AP, 2005, METHODS, V35, P126, DOI 10.1016/j.ymeth.2004.08.003
   BECK FX, 2000, AM J PHYSIOL-RENAL, V279, F203
   BELLMANN K, 2000, J BIOL CHEM, V275, P18172
   BONASSI S, 2002, MUTAT RES-REV MUTAT, V511, P73
   CIOCCA DR, 2005, CELL STRESS CHAPERON, V10, P86
   CURRIE RW, 1993, CIRCULATION, V87, P963
   DIERICK I, 2007, HUM MUTAT, V28, P830
   DUNN DK, 1993, J STEROID BIOCHEM, V46, P469
   FAVATIER F, 1997, CELL STRESS CHAPERON, V2, P141
   FERRIGNO D, 1994, EUR RESPIR J, V7, P186
   FINKEL T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985
   GARRIDO C, 2006, CELL CYCLE, V5, P2592
   HOLLANDER JM, 2004, CIRCULATION, V110, P3544, DOI
   10.1161/01.CIR.0000148825.99184.50
   JIN XF, 2004, AM J MED, V117, P406, DOI 10.1016/j.amjmed.2004.03.026
   JIN XF, 2004, CELL STRESS CHAPERON, V9, P69
   JINDAL S, 1996, TRENDS BIOTECHNOL, V14, P17
   JOLLY C, 2000, J NATL CANCER I, V92, P1564
   LI SL, 2005, NEUROBIOL DIS, V18, P432, DOI 10.1016/j.nbd.2004.12.014
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631
   MARBER MS, 1995, J CLIN INVEST, V95, P1446
   MEHLEN P, 1997, BIOCHEM BIOPH RES CO, V241, P187
   MERENDINO AM, 2002, CELL STRESS CHAPERON, V7, P269
   MILNE KJ, 2008, MED SCI SPORT EXER, V40, P655, DOI
   10.1249/MSS.0b0136181621311
   MORIMOTO RI, 1994, PROGR PERSPECTIVES B, P1
   MORIMOTO RI, 1998, GENE DEV, V12, P3788
   MOSSER DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529
   NIU PY, 2006, CELL STRESS CHAPERON, V11, P162
   NJEMINI R, 2002, J CLIN IMMUNOL, V22, P195
   NJEMINI R, 2006, EXP GERONTOL, V41, P312, DOI
   10.1016/j.exger.2006.01.006
   NJEMINI R, 2007, BIOGERONTOLOGY, V8, P353, DOI 10.1007/s10522-006-9078-y
   NOLLEN EAA, 1999, MOL CELL BIOL, V19, P2069
   PLUMIER JCL, 1997, CELL STRESS CHAPERON, V2, P162
   RADFORD NB, 1996, P NATL ACAD SCI USA, V93, P2339
   ROGALLA T, 1999, J BIOL CHEM, V274, P18947
   RYDER MI, 2004, ORAL MICROBIOL IMMUN, V19, P39
   SARTO C, 2000, ELECTROPHORESIS, V21, P1218
   SHI YH, 1998, GENE DEV, V12, P654
   TAN H, 2007, CELL STRESS CHAPERON, V12, P230
   TANGUAY RM, 2006, HEAT SHOCK PROTEINS, P407
   VARGAS SO, 1998, CANCER, V82, P1495
   VAYSSIER M, 1998, BIOCHEM BIOPH RES CO, V252, P249
   VAYSSIERTAUSSAT M, 2001, AM J PHYSIOL-HEART C, V280, P1293
   VOSS MR, 2003, AM J PHYSIOL-HEART C, V285, H687, DOI
   10.1152/ajpheart.01000.2002
   WANO C, 2004, EXP CELL RES, V298, P584, DOI 10.1016/j.yexcr.2004.04.048
   WONG HR, 1997, AM J PHYSIOL-LUNG C, V273, L1
   WU TC, 2006, CELL STRESS CHAPERON, V11, P1
   XIAO CF, 2002, CELL STRESS CHAPERON, V7, P396
   XIAO CF, 2003, CELL STRESS CHAPERON, V8, P86
   YANG XB, 2007, ENVIRON HEALTH PERSP, V115, P1573, DOI 10.1289/ehp.10104
   YOUNG JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492
NR 52
TC 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
J9 CELL STRESS CHAPERONES
JI Cell Stress Chaperones
PD MAY
PY 2009
VL 14
IS 3
BP 245
EP 251
DI 10.1007/s12192-008-0078-5
PG 7
SC Cell Biology
GA 428FI
UT ISI:000264833000002
ER

PT J
AU Liu, XH
   Ren, Z
   Zhan, R
   Wang, XX
   Wang, XM
   Zhang, ZQ
   Leng, X
   Yang, ZH
   Qian, LJ
AF Liu, XiaoHua
   Ren, Zhe
   Zhan, Rui
   Wang, XinXing
   Wang, XiaoMing
   Zhang, ZhiQing
   Leng, Xue
   Yang, ZhiHua
   Qian, LingJia
TI Prohibitin protects against oxidative stress-induced cell injury in
   cultured neonatal cardiomyocyte
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Apoptosis; Cardiomyocyte; Mitochondria; Oxidative stress; Prohibitin
ID MITOCHONDRIAL PROTEINS; SACCHAROMYCES-CEREVISIAE; CANCER CELLS;
   APOPTOSIS; RAT; FAMILY; PROLIFERATION; STABILIZATION; INHERITANCE;
   MAINTAINS
AB Oxidative stress is one of the main causes of myocardial injury, which
   is associated with cardiomyocyte death. Mitochondria play a key role in
   triggering the necrosis and apoptosis pathway of cardiomyocytes under
   oxidative stress. Although prohibitin (PHB) has been acknowledged as a
   mitochondrial chaperone, its functions in cardiomyocytes are poorly
   characterized. The present research was designed to investigate the
   cardioprotective role of PHB in mitochondria. Oxidative stress can
   increase the PHB content in mitochondria in a time-dependent manner.
   Overexpression of PHB in cultured cardiomyocytes by transfection of
   recombinant adenovirus vector containing PHB sense cDNA resulted in an
   increase of PHB in mitochondria. Compared with the non-transfection
   cardiomyocytes, PHB overexpression could protect the mitochondria from
   oxidative stress-induced injury. The mitochondria-mediated apoptosis
   pathway was consistently suppressed in PHB-overexpressed cardiomyocytes
   after hydrogen peroxide (H2O2) treatment, including a reduced change in
   mitochondrial membrane permeability transition and an inhibited release
   of cytochrome c from mitochondria to cytoplasma. As a result, the
   oxidative stress-induced cardiomyocyte apoptosis was suppressed. These
   data indicated that PHB protected the cardiomyocytes from oxidative
   stress-induced damage, and that increasing PHB content in mitochondria
   constituted a new therapeutic target for myocardium injury.
C1 [Liu, XiaoHua; Ren, Zhe; Zhan, Rui; Wang, XinXing; Wang, XiaoMing; Zhang, ZhiQing; Leng, Xue; Yang, ZhiHua; Qian, LingJia] Inst Hlth Environm Med, Dept Stress Med, Tianjin 300050, Peoples R China.
RP Qian, LJ, Inst Hlth Environm Med, Dept Stress Med, DaLi Rd 1, Tianjin
   300050, Peoples R China.
EM newjia@vip.sina.com
FU Chinese National Natural Science Foundation [30570753]; Major Research
   Plan of the Chinese National Natural Science Foundation [30430590,
   30393134]
FX This research was supported by the General Program of the Chinese
   National Natural Science Foundation (grant no. 30570753) and the Major
   Research Plan of the Chinese National Natural Science Foundation (grant
   nos. 30430590 and 30393134).
CR ARTALSANZ M, 2003, J BIOL CHEM, V278, P32091
   BERGER KH, 1998, MOL CELL BIOL, V18, P4043
   CHOWDHURY I, 2006, ENDOCRINOLOGY, V148, P206, DOI 10.1210/EN.2006-0187
   COATES PJ, 1997, CURR BIOL, V7, P607
   ESCH T, 2002, MED SCI MONITOR, V8, RA103
   FELLENBERG J, 2003, INT J CANCER, V105, P636, DOI 10.1002/ijc.11135
   FERRER I, 2007, NEUROSCI LETT, V415, P205, DOI
   10.1016/j.neulet.2007.01.026
   FUSARO G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200
   GAMBLE SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444
   GREGORYBASS RC, 2008, INT J CANCER, V122, P1923, DOI 10.1002/ijc.23351
   HE B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400
   IKONEN E, 1995, FEBS LETT, V358, P273
   IRVING RJ, 1998, J PHARM TOXICOL METH, V38, P157
   KASASHIMA K, 2008, EXP CELL RES, V314, P988, DOI
   10.1016/j.yexcr.2008.01.005
   KLUCK RM, 1997, SCIENCE, V275, P1132
   KNARDAHL S, 1990, AM J PHYSIOL, V259, H248
   LIU XH, 2004, PROTEOMICS, V4, P3167, DOI 10.1002/pmic.200300845
   MCDOUGALL SJ, 2000, HYPERTENSION 1, V35, P126
   MERKWIRTH C, 2008, GENE DEV, V22, P476
   MONTANO MM, 1999, P NATL ACAD SCI USA, V96, P6947
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271
   NIJTMANS LGJ, 2000, EMBO J, V19, P2444
   NIJTMANS LGJ, 2002, CELL MOL LIFE SCI, V59, P143
   NUELL MJ, 1991, MOL CELL BIOL, V11, P1372
   OSMAN C, 2007, MOL BIOL CELL, V18, P627, DOI 10.1091/mbc.E06-09-0839
   QIAN LJ, 2004, CELL STRESS CHAPERON, V9, P281
   RAJALINGAM K, 2005, CELL CYCLE, V4, P1503
   SCHLEICHER M, 2008, J CELL BIOL, V180, P101
   SHARMA A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI
   10.1073/pnas.0407536101
   SIMPSON P, 1982, CIRC RES, V50, P101
   TERASHIMA M, 1994, EMBO J, V13, P3782
   THOMPSON WE, 1999, ANAT REC, V256, P40
   THOMPSON WE, 2003, BIOL REPROD, V69, P254, DOI
   10.1095/biolreprod.102.010975
   VANDERHEIDEN MG, 2002, J BIOL CHEM, V277, P44870, DOI
   10.1074/jbc.M2048882000
   VESSAL M, 2006, FEBS J, V273, P568, DOI 10.1111/j.1742-4658.2005.05090.x
   WANG S, 1999, MOL CELL BIOL, V19, P7447
   WANG S, 1999, ONCOGENE, V18, P3501
   WARD MW, 2000, J NEUROSCI, V20, P7208
NR 38
TC 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
J9 CELL STRESS CHAPERONES
JI Cell Stress Chaperones
PD MAY
PY 2009
VL 14
IS 3
BP 311
EP 319
DI 10.1007/s12192-008-0086-5
PG 9
SC Cell Biology
GA 428FI
UT ISI:000264833000009
ER

PT J
AU Shih, TTF
   Hou, HA
   Liu, CY
   Chen, BB
   Tang, JL
   Chen, HY
   Wei, SY
   Yao, M
   Huang, SY
   Chou, WC
   Hsu, SC
   Tsay, W
   Yu, CW
   Hsu, CY
   Tien, HF
   Yang, PC
AF Shih, Tiffany Ting-Fang
   Hou, Hsin-An
   Liu, Chieh-Yu
   Chen, Bang-Bin
   Tang, Jih-Luh
   Chen, Hsuan-Yu
   Wei, Shwu-Yuan
   Yao, Ming
   Huang, Shang-Yi
   Chou, Wen-Chien
   Hsu, Szu-Chun
   Tsay, Woei
   Yu, Chih-Wei
   Hsu, Chao-Yu
   Tien, Hwei-Fang
   Yang, Pan-Chyr
TI Bone marrow angiogenesis magnetic resonance imaging in patients with
   acute myeloid leukemia: peak enhancement ratio is an independent
   predictor for overall survival
SO BLOOD
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MICROVESSEL DENSITY; MULTIPLE-MYELOMA;
   MYELODYSPLASTIC SYNDROMES; VASCULOGENIC MIMICRY; TUMOR ANGIOGENESIS;
   IN-VIVO; CERVICAL-CARCINOMA; LUMBAR SPINE; DYNAMIC MRI
AB Emerging evidence suggests that progression of hematologic malignancies
   is associated with angiogenesis. Dynamic contrast-enhanced magnetic
   resonance imaging (DCE-MRI) can provide global and functional imaging
   of tumor angiogenesis. In this study, we performed bone marrow DCE-MRI
   prospectively at diagnosis and after induction chemotherapy in 78 de
   novo acute myeloid leukemia (AML) patients and correlated it with
   treatment outcome. An algorithm to assess bone marrow angiogenesis by
   measuring the DCE-MRI time-intensity curve pixel by pixel was developed
   using 3 distinct parameters: peak enhancement ratio (Peak) to indicate
   tissue blood perfusion; amplitude (Amp) to reflect vascularity; and
   volume transfer constant (K trans) to indicate vascular permeability.
   The Peak and Amp decreased significantly at remission status after
   induction chemotherapy. Patients with higher Peak or Amp at diagnosis
   had shorter overall survival and disease-free survival than others. Cox
   multivariate analysis identified higher Peak value (hazard ratio,
   9.181; 95% confidence interval, 1.740-48.437; P = .009) as an
   independent predictor for overall survival in addition to unfavorable
   karyotype and old age. Our findings provide evidence that increased
   bone marrow angiogenesis measured by DCE-MRI can predict adverse
   clinical outcome in AML patients. DCE-MRI may help to select high-risk
   phenotype AML patients for tailored antiangiogenic therapy and to
   monitor treatment response. (Blood. 2009; 113:3161-3167)
C1 [Hou, Hsin-An; Tang, Jih-Luh; Yao, Ming; Huang, Shang-Yi; Tsay, Woei; Tien, Hwei-Fang; Yang, Pan-Chyr] Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Shih, Tiffany Ting-Fang; Chen, Bang-Bin; Wei, Shwu-Yuan; Yu, Chih-Wei; Hsu, Chao-Yu] Natl Taiwan Univ Hosp & Coll Med, Dept Med Imaging & Radiol, Taipei, Taiwan.
   [Hou, Hsin-An] Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Taipei, Yun Lin County, Taiwan.
   [Liu, Chieh-Yu] Natl Taipei Coll Nursing, Biostat Consulting Lab, Dept Nursing, Taipei, Taiwan.
   [Chen, Hsuan-Yu] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan.
   [Chou, Wen-Chien; Hsu, Szu-Chun] Natl Taiwan Univ Hosp & Coll Med, Dept Lab Med, Taipei, Taiwan.
RP Tien, HF, Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, 7 Chung
   Shan S Rd, Taipei, Taiwan.
EM hftien@ntu.edu.tw
   pcyang@ntu.edu.tw
FU National Science Council [NSC 94-2314-B-002-182, NSC
   95-2314-B-002-061]; National Taiwan University Hospital [NTUH. 94A19-1]
FX This work was supported by a grant from the National Science Council
   (NSC 94-2314-B-002-182; NSC 95-2314-B-002-061) and the National Taiwan
   University Hospital (NTUH. 94A19-1).
CR AGUAYO A, 2000, BLOOD, V96, P2240, UNSP 10979972
   ATRI M, 2006, J CLIN ONCOL, V24, P3299, DOI 10.1200/JCO.2006.06.6159
   BELL J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624
   BENNETT JM, 1985, ANN INTERN MED, V103, P620
   BERTOLINI F, 2000, EXP HEMATOL, V28, P993
   BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621
   BUCKLEY DL, 1994, MAGNET RESON MED, V32, P646
   CARMELIET P, 2000, NATURE, V407, P249
   CHEN WT, 2001, RADIOLOGY, V220, P213
   DICKSON DJ, 2001, LEUKEMIA LYMPHOMA, V42, P847
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1995, NEW ENGL J MED, V333, P1757
   GRIEBEL J, 1997, J MAGN RESON IMAGING, V7, P111
   HAWIGHORST H, 1997, CANCER RES, V57, P4777
   HAWIGHORST H, 1998, CLIN CANCER RES, V4, P2305
   HAWIGHORST H, 1999, JMRI-J MAGN RESON IM, V10, P286
   HLATKY L, 2002, J NATL CANCER I, V94, P883
   HOFFMANN U, 1995, MAGN RESON MED, V33, P506
   HUSSONG JW, 2000, BLOOD, V95, P309
   HYLTON N, 2006, J CLIN ONCOL, V24, P3293, DOI 10.1200/JCO2006.06.8080
   JAIN RK, 1988, CANCER RES, V48, P2641
   KINI AR, 2001, BLOOD, V97, P3919
   KUZU I, 2004, LEUKEMIA LYMPHOMA, V45, P1185, DOI
   10.1080/1042819032000159915
   LANGHEIER JM, 2004, PHARMACOGENOMICS, V5, P1
   LIU G, 2005, J CLIN ONCOL, V23, P5464, DOI 10.1200/JCO.2005.04.143
   MANIOTIS AJ, 1999, AM J PATHOL, V155, P739
   MAYR NA, 2000, J MAGN RESON IMAGING, V12, P1027
   MCDONALD DM, 2003, NAT MED, V9, P713
   MILLER JC, 2005, J NATL CANCER I, V97, P172
   MOEHLER TM, 2001, INT J CANCER, V93, P862
   MOEHLER TM, 2003, CRIT REV ONCOL HEMAT, V45, P227, DOI
   10.1016/S1040-8428(02)00135-X
   MORGAN MA, 2006, ANN HEMATOL, V85, P139, DOI 10.1007/s00277-005-0051-7
   MUNSHI NC, 2001, SEMIN ONCOL, V28, P565
   OCONNOR JPB, 2007, BRIT J CANCER, V96, P189, DOI 10.1038/sj.bjc.6603515
   PADRO T, 2000, BLOOD, V95, P2637
   RABITSCH W, 2004, LEUKEMIA LYMPHOMA, V45, P1369, DOI
   10.1080/10428190410001663707
   RAJKUMAR SV, 2000, CLIN CANCER RES, V6, P3111
   SCHERER A, 2002, ROFO-FORTSCHR RONTG, V174, P164
   SCHUCH G, 2002, BLOOD, V100, P4622
   SCHUCH G, 2005, LEUKEMIA, V19, P1312
   SHARMA N, 2002, PROSTATE, V50, P189
   SHIH TTF, 2004, RADIOLOGY, V231, P24, DOI 10.1148/radiol2311030382
   SHIH TTF, 2006, LEUKEMIA, V20, P357, DOI 10.1038/sj.leu.2404066
   SHIRAKAWA K, 2002, CANCER RES, V62, P560
   TOFTS PS, 1991, MAGN RESON MED, V17, P357
   TOFTS PS, 1997, J MAGN RESON IMAGING, V7, P91
   TOFTS PS, 1999, J MAGN RESON IMAGING, V10, P223
   TUNCBILEK N, 2005, EUR J RADIOL, V53, P500, DOI
   10.1016/j.ejrad.2004.04.012
   VACCA A, 1999, BLOOD, V93, P3064
   WEBER WA, 2001, Q J NUCL MED, V45, P179
NR 50
TC 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 2
PY 2009
VL 113
IS 14
BP 3161
EP 3167
DI 10.1182/blood-2008-08-173104
PG 7
SC Hematology
GA 428LH
UT ISI:000264848900008
ER

PT J
AU Cerchietti, LC
   Yang, SN
   Shaknovich, R
   Hatzi, K
   Polo, JM
   Chadburn, A
   Dowdy, SF
   Melnick, A
AF Cerchietti, Leandro C.
   Yang, Shao Ning
   Shaknovich, Rita
   Hatzi, Katerina
   Polo, Jose M.
   Chadburn, Amy
   Dowdy, Steven F.
   Melnick, Ari
TI A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in
   vitro and in vivo
SO BLOOD
LA English
DT Article
ID GERMINAL-CENTER FORMATION; B-CELL LYMPHOMAS; BTB DOMAIN; EXPRESSION;
   PEPTIDE; DIFFERENTIATION; GENE; TRANSCRIPTION; INFLAMMATION; COREPRESSOR
AB The BCL6 transcriptional repressor is the most commonly involved
   oncogene in diffuse large B-cell lymphomas (DLBCLs). BCL6 lymphomagenic
   activity is dependent on its ability to recruit corepressor proteins to
   a unique binding site on its N-terminal BTB domain. A recombinant
   peptide fragment of the SMRT (silencing mediator for retinoid and
   thyroid hormone receptor) corepressor that blocks this site can inhibit
   BCL6 biologic functions. Shortening and conversion of this peptide to
   D-amino acid and retro configuration as well as the addition of a
   fusogenic motif yielded a far more potent and stable BCL6 inhibitor
   that still retained the specificity of the original SMRT fragment. Like
   the L-peptide, retroinverso BCL6 peptide inhibitor (RI-BPI) selectively
   killed BCR rather than OxPhos-type DLBCL cells. The RI-BPI could
   recapitulate the failure to form germinal centers seen in BCL6 null
   mice yet was nontoxic and nonimmunogenic even when administered for up
   to 52 weeks. RI-BPI showed superior duration of tissue penetration and
   could accordingly powerfully suppress the growth of human DLBCLs
   xenografts in a dose-dependent manner. Finally, RI-BPI could kill
   primary human DLBCL cells but had no effect on normal lymphoid tissue
   or other tumors. (Blood. 2009; 113: 3397-3405)
C1 [Cerchietti, Leandro C.; Yang, Shao Ning; Hatzi, Katerina; Melnick, Ari] Weill Cornell Coll Med, Dept Med, Div Hematol & Med Oncol, New York, NY USA.
   [Shaknovich, Rita; Chadburn, Amy] Weill Cornell Coll Med, Dept Pathol, New York, NY USA.
   [Polo, Jose M.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.
   [Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
RP Melnick, A, Cornell Univ, Div Hematol & Med Oncol, Dept Med, Weill
   Cornel Med Coll, 525 E 68th St, New York, NY 10065 USA.
EM amm2014@med.cornell.edu
FU National Cancer Institute [R01 CA104348]; Chemotherapy Foundation ; Sam
   Waxman Cancer Research Foundation ; GP Foundation ; Leukemia & Lymphoma
   Society 
FX A. M. was supported by the National Cancer Institute (Bethesda, MD; R01
   CA104348), The Chemotherapy Foundation (New York, NY), The Sam Waxman
   Cancer Research Foundation (New York, NY), and the G&P Foundation (New
   York, NY) and is a Leukemia & Lymphoma Society (White Plains, NY)
   Scholar.
CR AHMAD KF, 2003, MOL CELL, V12, P1551
   BARON BW, 2004, P NATL ACAD SCI USA, V101, P14198, DOI
   10.1073/pnas.0406138101
   CATTORETTI G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037
   DENT AL, 1997, SCIENCE, V276, P589
   MELNICK A, 2002, MOL CELL BIOL, V22, P1804
   MENDEZ LM, 2008, MOL CELL BIOL, V28, P2175, DOI 10.1128/MCB.01400-07
   MONTI S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004.07.2947
   PAREKH S, 2007, BLOOD, V110, P2067, DOI 10.1182/blood-2007-01069575
   PASQUALUCCI L, 2001, NATURE, V412, P341
   PHAN RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147
   PHAN RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245
   POLO JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134
   POLO JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI
   10.1073/pnas.0611399104
   RANUNCOLO SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478
   SHAFFER AL, 2002, IMMUNITY, V17, P51
   SNYDER EL, 2004, PLOS BIOL, V2, P186, ARTN e36
   TONEY LM, 2000, NAT IMMUNOL, V1, P214
   TUNYAPLIN C, 2004, J IMMUNOL, V173, P1158
   WADIA JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WADIA JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI
   10.1016/j.addr.2004.10.005
   YE BH, 1993, SCIENCE, V262, P747
   YE BH, 1997, NAT GENET, V16, P161
NR 22
TC 17
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 9
PY 2009
VL 113
IS 15
BP 3397
EP 3405
DI 10.1182/blood-2008-07-168773
PG 9
SC Hematology
GA 431HN
UT ISI:000265052300004
ER

PT J
AU Wang, H
   Asavaroengchai, W
   Yeap, BY
   Wang, MG
   Wang, SM
   Sykes, M
   Yang, YG
AF Wang, Hui
   Asavaroengchai, Wannee
   Yeap, Beow Yong
   Wang, Min-Guang
   Wang, Shumei
   Sykes, Megan
   Yang, Yong-Guang
TI Paradoxical effects of IFN-gamma in graft-versus-host disease reflect
   promotion of lymphohematopoietic graft-versus-host reactions and
   inhibition of epithelial tissue injury
SO BLOOD
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; CD8 T-CELLS; REFRACTORY HEMATOLOGIC
   MALIGNANCIES; IDIOPATHIC PNEUMONIA SYNDROME; CYTOKINE GENE-EXPRESSION;
   ANTIGEN-PRESENTING CELLS; MURINE RENAL-CANCER; INTERFERON-GAMMA; ALPHA;
   MICE
AB Interferon-gamma (IFN-gamma) inhibits graft-versus-host disease (GVHD)
   in lethally irradiated mice receiving allogeneic hematopoietic cell
   transplantation (allo-HCT) but promotes lethality in unirradiated and
   sublethally irradiated recipients. We investigated the role of
   IFN-gamma in GVHD in sublethally irradiated B6D2F1 recipients of B6
   allo-HCT. B6D2F1 mice receiving wild-type B6 splenocytes alone died
   rapidly, whereas those receiving wild-type B6 splenocytes plus marrow
   survived long-term. Mice in both groups showed rapid elimination of
   host hematopoietic cells but minimal parenchymal tissue injury.
   However, mice receiving allo-HCT from IFN-gamma-deficient donors died
   rapidly regardless of whether donor marrow was given, and they
   exhibited severe parenchymal injury but prolonged survival of host
   hematopoietic cells. IFN-gamma plays a similar role in another model
   involving delayed B6 donor leukocyte infusion (DLI) to established
   mixed allogeneic (B6 -> BALB/c) chimeras. IFN-gamma promotes
   DLI-mediated conversion from mixed to full donor chimerism while
   attenuating GVHD. Importantly, IFN-gamma enhances graft-versus-leukemia
   (GVL) effects in both models. Our data indicate that previously
   reported IFN-gamma-induced early mortality in allo-HCT recipients is
   due to augmentation of lymphohematopoietic graft-versus-host reaction
   (LGVHR) and can be avoided by providing an adequate source of donor
   hematopoietic stem/progenitor cells. Furthermore, the magnitude of GVL
   is correlated with the strength of LGVHR, and IFN-gamma reduces the
   potential of this allo-reactivity to cause epithelial tissue GVHD.
   (Blood. 2009; 113: 3612-3619)
C1 [Wang, Hui; Asavaroengchai, Wannee; Wang, Shumei; Sykes, Megan; Yang, Yong-Guang] Harvard Univ, Transplantat Biol Res Ctr, Massachusetts Gen Hosp, Sch Med,Bone Marrow Transplantat Sect, Boston, MA 02129 USA.
   [Yeap, Beow Yong] Harvard Univ, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02129 USA.
   [Wang, Min-Guang] Lower Columbia Pathologists, Longview, WA USA.
RP Yang, YG, Harvard Univ, Transplantat Biol Res Ctr, Massachusetts Gen
   Hosp, Sch Med,Bone Marrow Transplantat Sect, MGH E,Bldg 149-5102,13th
   St, Boston, MA 02129 USA.
EM yongguang.yang@tbrc.mgh.harvard.edu
FU National Institutes of Health (Bethesda, MD) [5P01CA111519-020002];
   American Cancer Society (Atlanta, GA) [RSG-03-227-01-LIB]
FX The authors thank Drs Christene Huang and Giovanna Andreola for
   critical review of this manuscript, Mr Orlando Moreno for outstanding
   animal husbandry, and Ms Kelly Walsh for expert assistance with the
   manuscript.
   This work was supported by grants from National Institutes of Health
   (Bethesda, MD; 5P01CA111519-020002) and American Cancer Society
   (Atlanta, GA; RSG-03-227-01-LIB).
CR ASAVAROENGCHAI W, 2007, BIOL BLOOD MARROW TR, V13, P46, DOI
   10.1016/j.bbmt.2006.09.014
   BADOVINAC VP, 2000, SCIENCE, V290, P1354
   BAKER J, 2001, BLOOD, V97, P2923
   BOHM W, 1998, J IMMUNOL, V161, P897
   BROK HPM, 1993, J IMMUNOL, V151, P6451
   BRUNDA MJ, 1987, INT J CANCER, V40, P807
   BURMAN AC, 2007, BLOOD, V110, P1064, DOI 10.1182/blood-2006-12-063982
   CARLSON MJ, 2008, BLOOD, V113, P1365
   COHEN JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090
   DAS H, 2001, BONE MARROW TRANSPL, V27, P373
   DOR FJMF, 2006, EXP HEMATOL, V34, P1573, DOI
   10.1016/j.exphem.2006.06.016
   ELLISON CA, 1998, J IMMUNOL, V161, P631
   ERMANN J, 2005, BLOOD, V105, P2220, DOI 10.1182/blood-2004-05-2044
   FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571
   FLAISHON L, 2000, J EXP MED, V192, P1381
   FRUCHT DM, 2001, TRENDS IMMUNOL, V22, P556
   HARRINGTON LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   KAPPEL LW, 2009, BLOOD, V113, P945, DOI 10.1182/blood-2008-08-172155
   LIU Y, 1990, J EXP MED, V172, P1735
   MAPARA MY, 2002, BLOOD, V100, P1903, DOI 10.1182/blood-2002-01-0023
   MAUERMANN N, 2008, AM J RESP CRIT CARE, V178, P379, DOI
   10.1164/rccm.200711-1648OC
   MURPHY WJ, 1998, J CLIN INVEST, V102, P1742
   NASTALA CL, 1994, J IMMUNOL, V153, P1697
   NOVELLI F, 1997, J IMMUNOL, V159, P206
   OYAIZU N, 1994, BLOOD, V84, P2622
   PARK H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   PELOT MR, 1999, BIOL BLOOD MARROW TR, V5, P133
   REDDY P, 2001, J EXP MED, V194, P1433
   ROTTMAN M, 2008, PLOS MED, V5, P152, ARTN e26
   SAWITZKI B, 2005, J EXP MED, V201, P1925, DOI 10.1084/jem.20050419
   SAYERS TJ, 1990, CANCER RES, V50, P5414
   SAYERS TJ, 1998, J IMMUNOL, V161, P3957
   SPITZER TR, 2000, BIOL BLOOD MARROW TR, V6, P309
   SPITZER TR, 2003, TRANSPLANTATION, V75, P1748, DOI
   10.1097/01.TP.0000064211.23536.AD
   SYKES M, 1988, J EXP MED, V168, P2391
   SYKES M, 1999, LANCET, V353, P1755
   TAN J, 1998, J IMMUNOTHER, V21, P48
   TANAKA J, 1995, LEUKEMIA LYMPHOMA, V16, P413
   TESHIMA T, 1999, J CLIN INVEST, V104, P317
   WELNIAK LA, 2000, BIOL BLOOD MARROW TR, V6, P604
   WELNIAK LA, 2007, ANNU REV IMMUNOL, V25, P139, DOI
   10.1146/annurev.immunol.25.022106.141606
   YANG YG, 1997, BLOOD, V90, P4651
   YANG YG, 1998, J CLIN INVEST, V102, P2126
   YANG YG, 1999, BLOOD, V94, S635
   YANG YG, 2002, BLOOD, V99, P4207
   YI TS, 2008, BLOOD, V112, P2101, DOI 10.1182/blood-2007-12-126987
NR 46
TC 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 9
PY 2009
VL 113
IS 15
BP 3612
EP 3619
DI 10.1182/blood-2008-07-168419
PG 8
SC Hematology
GA 431HN
UT ISI:000265052300030
ER

PT J
AU Yan, JZ
   Yang, X
   Mortin, MA
   Shahabuddin, M
AF Yan, Jizhou
   Yang, Xiang
   Mortin, Mark A.
   Shahabuddin, Mohammed
TI Malaria Sporozoite Antigen-Directed Genome-Wide Response in Transgenic
   Drosophila
SO GENESIS
LA English
DT Article
DE Drosophila melanogaster; immunity; malaria; microarray; mosquito;
   Plasmodium falciparum
ID PARASITE PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN;
   IMMUNE-RESPONSE; SURFACE PROTEIN-2; ANOPHELES-GAMBIAE; BLOOD STAGES;
   INVASION; SEQUENCE; GENE; THROMBOSPONDIN
AB Malaria kills a million people annually. Understanding the relationship
   between a causative parasite, Plasmodium falciparum, and the mosquito
   vector might suggest novel prevention approaches. We created and
   transformed into Drosophila two genes encoding, thrombospondin-related
   adhesive protein (TRAP) and circumsporozoite protein (CSP), found on
   the cell surface of Plasmodium sporozoites. To understand a model
   insect's response, we induced these proteins separately and together,
   performing whole genome microarray analysis measuring gene expression
   changes. Gene ontology classification of responding genes reveals that
   TRAP and CSP strongly and differentially influence Drosophila genes
   involved with cell motility and gene regulation, respectively; however,
   the most striking effects are on the immune system. While
   immune-related genes are but modestly elevated compared with responses
   to sepsis, there is a marked repression of the Toll pathway. This
   suggests: (1) how Plasmodium infection of the mosquito might use TRAP
   and CSP to modulate the host insect's physiology to promote sporozoite
   survival and transmission to man and (2) that approaches to elevate
   expression of the mosquito's Toll pathway might lead to novel methods
   of malaria prevention. genesis 47:196203, 2009. (c) 2009 Wiley-Liss,
   Inc.
C1 [Mortin, Mark A.] Eunice Kennedy Shriver NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA.
   [Yan, Jizhou; Shahabuddin, Mohammed] NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA.
   [Yan, Jizhou] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Yang, Xiang; Mortin, Mark A.] NCI, Biochem Lab, Bethesda, MD 20892 USA.
RP Mortin, MA, Eunice Kennedy Shriver NICHHD, Mol Genet Lab, NIH, 6 Ctr
   Dr,Bldg 6B,Room 3B331, Bethesda, MD 20892 USA.
EM jyan2@mail.med.upenn.edu
   mortinm@mail.nih.gov
CR CHAROENVIT Y, 1997, INFECT IMMUN, V65, P3430
   DAME JB, 1984, SCIENCE, V225, P593
   DEGREGORIO E, 2001, P NATL ACAD SCI USA, V98, P12590
   DEGREGORIO E, 2002, EMBO J, V21, P2568
   DIMOPOULOS G, 2002, P NATL ACAD SCI USA, V99, P8814
   GREENWOOD BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996
   HUNG MC, 1981, NUCLEIC ACIDS RES, V9, P6407
   IRVING P, 2001, P NATL ACAD SCI USA, V98, P15119
   KAPPE SHI, 2004, ANNU REV CELL DEV BI, V20, P29, DOI
   10.1146/annurev.cellbio.20.011603.150935
   KHUSH RS, 2000, TRENDS GENET, V16, P442
   KLEIN U, 2001, J EXP MED, V194, P1625
   MENARD R, 1997, NATURE, V385, P336
   RATHORE D, 2000, P NATL ACAD SCI USA, V97, P8530
   ROBSON KJH, 1988, NATURE, V335, P79
   ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176
   ROSINSKICHUPIN I, 2007, CELL MICROBIOL, V9, P708, DOI
   10.1111/j.1462-5822.2006.00822.x
   SCHNEIDER D, 2000, SCIENCE, V288, P2376
   SHARMA P, 1996, INFECT IMMUN, V64, P2172
   SULTAN AA, 1997, CELL, V90, P511
   TAHAR R, 2002, EMBO J, V21, P6673
   TARDIEUX I, 2008, TRAFFIC, V9, P627, DOI
   10.1111/j.1600-0854.2008.00703.x
   VLACHOU D, 2005, CURR BIOL, V15, P1185, DOI 10.1016/j.cub.2005.06.044
   XU XJ, 2005, MOL BIOCHEM PARASIT, V142, P76, DOI
   10.1016/j.molbiopara.2005.02.013
NR 23
TC 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD MAR
PY 2009
VL 47
IS 3
BP 196
EP 203
DI 10.1002/dvg.20483
PG 8
SC Developmental Biology; Genetics & Heredity
GA 425RT
UT ISI:000264655500008
ER

PT J
AU Zuber, J
   Radtke, I
   Pardee, TS
   Zhao, Z
   Rappaport, AR
   Luo, WJ
   McCurrach, ME
   Yang, MM
   Dolan, ME
   Kogan, SC
   Downing, JR
   Lowe, SW
AF Zuber, Johannes
   Radtke, Ina
   Pardee, Timothy S.
   Zhao, Zhen
   Rappaport, Amy R.
   Luo, Weijun
   McCurrach, Mila E.
   Yang, Miao-Miao
   Dolan, M. Eileen
   Kogan, Scott C.
   Downing, James R.
   Lowe, Scott W.
TI Mouse models of human AML accurately predict chemotherapy response
SO GENES & DEVELOPMENT
LA English
DT Article
DE AML; AML1/ETO; MLL; chemotherapy; mouse models
ID ACUTE MYELOID-LEUKEMIA; MLL FUSION PROTEINS; DNA-DAMAGE; STEM-CELLS;
   P53; MUTATIONS; CANCER; RESISTANCE; CHEMORESISTANCE; LEUKEMOGENESIS
AB The genetic heterogeneity of cancer influences the trajectory of tumor
   progression and may underlie clinical variation in therapy response. To
   model such heterogeneity, we produced genetically and pathologically
   accurate mouse models of common forms of human acute myeloid leukemia
   (AML) and developed methods to mimic standard induction chemotherapy
   and efficiently monitor therapy response. We see that murine AMLs
   harboring two common human AML genotypes show remarkably diverse
   responses to conventional therapy that mirror clinical experience.
   Specifically, murine leukemias expressing the AML1/ETO fusion
   oncoprotein, associated with a favorable prognosis in patients, show a
   dramatic response to induction chemotherapy owing to robust activation
   of the p53 tumor suppressor network. Conversely, murine leukemias
   expressing MLL fusion proteins, associated with a dismal prognosis in
   patients, are drug-resistant due to an attenuated p53 response. Our
   studies highlight the importance of genetic information in guiding the
   treatment of human AML, functionally establish the p53 network as a
   central determinant of chemotherapy response in AML, and demonstrate
   that genetically engineered mouse models of human cancer can accurately
   predict therapy response in patients.
C1 [Zuber, Johannes; Pardee, Timothy S.; Zhao, Zhen; Rappaport, Amy R.; Luo, Weijun; McCurrach, Mila E.; Yang, Miao-Miao; Lowe, Scott W.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Radtke, Ina; Downing, James R.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA.
   [Zhao, Zhen] SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA.
   [Rappaport, Amy R.; Lowe, Scott W.] Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA.
   [Dolan, M. Eileen] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.
   [Kogan, Scott C.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Lowe, Scott W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA.
RP Lowe, SW, Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724
   USA.
EM lowe@cshl.edu
FU Specialized Center of Research grant from the Leukemia and Lymphoma
   Society ; Ambassador Felix Schnyder Memorial Grant ; Lauri Strauss
   Leukemia Foundation ; German Research Foundation ( DFG) ; Andrew
   Seligson Memorial Fellow at CSHL ; NIH traineeship and the Barbara
   McClintock fellowship ; Leslie Rutherford Leukemia and Lymphoma Society
   Scholar ; Howard Hughes Medical Institute 
FX We thank Christian Buske and Irving Weissman for providing cDNA
   constructs. We gratefully acknowledge Meredith Taylor, Mei Lin
   Maunakea, Shannon Delaney, Eileen Earl, Lisa Bianco, and her team for
   excellent technical assistance; Zhenyu Xuan and Sohail Khan for
   microarray analysis, and Jeffrey Rubnitz, Raul Ribeiro, Stanley Pounds,
   and Xueyuan Cao for sharing clinical data and providing statistical
   analysis. We also thank Enrique Cepero, Lars Zender, Cornelius
   Miething, Mona Spector, Katherine McJunkin, Christof Fellmann, and
   other members of the Lowe lab as well as Michelle LeBeau, Kevin
   Shannon, and David Largaespada for constructive criticism and advice.
   This work was supported by a Specialized Center of Research grant from
   the Leukemia and Lymphoma Society, generous gifts from the Don Monti
   Memorial Research Foundation, and the Ambassador Felix Schnyder
   Memorial Grant of the Lauri Strauss Leukemia Foundation. J. Z. was
   supported by a research fellowship from the German Research Foundation
   ( DFG) and is the Andrew Seligson Memorial Fellow at CSHL. A. R. R. was
   supported by an NIH traineeship and the Barbara McClintock fellowship.
   S. C. K. is the Leslie Rutherford Leukemia and Lymphoma Society
   Scholar; S. W. L. is a Howard Hughes Medical Institute investigator.
CR ANENSEN N, 2006, CLIN CANCER RES, V12, P3985, DOI
   10.1158/1078-0432.CCR-05-1970
   BYRD JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772
   COZZIO A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403
   DAI MH, 2005, NUCLEIC ACIDS RES, V33, ARTN e175
   DENNIS G, 2003, GENOME BIOL, V4, P3
   DOHNER H, 2007, HEMATOLOGY AM SOC HE, P412
   ESTEY E, 2006, LANCET, V368, P1894
   GALMARINI CM, 2002, LEUKEMIA RES, V26, P621
   GILLILAND DG, 2004, HEMATOLOGY AM SOC HE, P80
   GRIMWADE D, 1998, BLOOD, V92, P2322
   HAFERLACH C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143
   HIDDEMANN W, 1991, ANN HEMATOL, V62, P119
   HOCHREITER S, 2006, BIOINFORMATICS, V22, P943, DOI
   10.1093/bioinformatics/btl033
   KELLY LM, 2002, P NATL ACAD SCI USA, V99, P8283
   KREJCI O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682
   KUO YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014
   LAFIURA KM, 2008, ONCOGENE, V27, P4933, DOI 10.1038/onc.2008.134
   LEY TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485
   LOWE SW, 1993, CELL, V74, P957
   LOWE SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   MEGONIGAL MD, 1998, ONCOGENE, V16, P1351
   MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302
   MULLIGHAN CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   OGATA H, 1999, NUCLEIC ACIDS RES, V27, P29
   ONO R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725
   PARIKH C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498
   PETITJEAN A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
   RITCHIE MD, 2001, AM J HUM GENET, V69, P138
   SCHLENK RF, 2008, NEW ENGL J MED, V358, P1909
   SCHMITT CA, 1999, GENE DEV, V13, P2670
   SCHMITT CA, 2000, NAT MED, V6, P1029
   SCHMITT CA, 2002, CANCER CELL, V1, P289
   SCHOCH C, 2003, BLOOD, V102, P2395
   SHARPLESS NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110
   TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5116
   VANDYKE T, 2002, CELL, V108, P135
   VANMETER MEM, 2007, BLOOD, V109, P3945, DOI 10.1182/blood-2006-09-047530
   VELDERS GA, 2004, BLOOD, V103, P340, DOI 10.1182/blood-2002-07-2270
   VOGELSTEIN B, 2000, NATURE, V408, P307
   WATTEL E, 1994, BLOOD, V84, P3148
   WEI J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020
   WIEDERSCHAIN D, 2005, J BIOL CHEM, V280, P24315, DOI
   10.1074/jbc.M412237200
   YAN M, 2004, P NATL ACAD SCI USA, V101, P17186
   YAN M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443
   YIN B, 2006, EXP HEMATOL, V34, P631, DOI 10.1016/j.exphem.2006.01.015
NR 45
TC 16
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD APR 1
PY 2009
VL 23
IS 7
BP 877
EP 889
DI 10.1101/gad.1771409
PG 13
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 427MP
UT ISI:000264783700011
ER

PT J
AU McCrann, DJ
   Yang, D
   Chen, HJ
   Carroll, S
   Ravid, K
AF McCrann, Donald J.
   Yang, Dan
   Chen, Hongjie
   Carroll, Shannon
   Ravid, Katya
TI Upregulation of Nox4 in the aging vasculature and its association with
   smooth muscle cell polyploidy
SO CELL CYCLE
LA English
DT Article
DE NADPH oxidase 4 (Nox4); vascular smooth muscle; polyploidy; aging;
   hypertrophy
ID ANGIOTENSIN-II; OXIDATIVE STRESS; NAD(P)H OXIDASE; NADPH OXIDASE;
   CANCER-CELLS; GENETIC-HYPERTENSION; RESISTANCE ARTERIES; INDUCED
   APOPTOSIS; DOWN-REGULATION; P38 MAPK
AB Our recent reports indicated that polyploidization of aortic vascular
   smooth muscle cells (VSMC) serves as a biomarker for aging, and that
   the polyploid state is linked to a higher incidence of senescence in
   vivo. Here, we found that NADPH oxidase 4 (Nox4) expression is
   augmented in VSMC from aortas of old rats and that Nox4 levels are
   increased in polyploid VSMC in comparison to diploid cells in vivo.
   Seeking to determine if Nox4 upregulation plays a causal role in the
   accumulation of polyploid cells, we performed ploidy analysis on
   primary VSMC transduced with Nox4 adenovirus. We observed a consistent
   accumulation of polyploid cells and a concomitant decrease in the
   percentage of diploid cells in Nox4 overexpressing cells in comparison
   to controls or to cells overexpressing dominant negative Nox4. Further
   exploration of this phenomenon in VSMC cultures identified a
   Nox4-induced decrease in the chromosome passenger protein, survivin,
   whose absence and mislocalization during polyploidization was
   previously shown to induce VSMC polyploidy. Taken together, our study
   is the first to show increased Nox4 levels in VSMC during aging, and to
   demonstrate its role in induction of polyploidy in this lineage.
C1 [Ravid, Katya] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA.
RP Ravid, K, Boston Univ, Sch Med, Dept Biochem, K225, Boston, MA 02118
   USA.
EM ravid@biochem.bumc.bu.edu
FU NHLBI [HL80442]
FX We thank Hao G. Nguyen and Maria Makitalo for their technical
   assistance. This work was supported by NHLBI grant HL80442 to K. R. K.
   R. is an Established Investigator with the American Heart Association.
   The authors declare no competing financial interests.
CR BELTRAMI E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200
   BLAGOSKLONNY MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750
   BLAGOSKLONNY MV, 2007, CELL CYCLE, V6, P2997
   BLAGOSKLONNY MV, 2008, CELL CYCLE, V7, P3344
   BRANDES RP, 2003, ANTIOXID REDOX SIGN, V5, P803
   CHEN J, 2000, NEOPLASIA, V2, P235
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156
   COLAVITTI R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890
   CSISZAR A, 2007, AGING CELL, V6, P783, DOI
   10.1111/j.1474-9726.2007.00339.x
   DANGIOLELLA V, 2007, CELL CYCLE, V6, P576
   DEMIDENKO ZN, 2008, CELL CYCLE, V7, P3355
   DESHPANDE NN, 2002, ANTIOXID REDOX SIGN, V4, P845
   DEVLIN A, 1998, AM J PHYSIOL, V274, P52
   DEVLIN AM, 1995, J HUM HYPERTENS, V9, P497
   DIKALOVA A, 2005, CIRCULATION, V112, P2668, DOI
   10.1161/CIRCULATIONAHA.105.538934
   DJORDJEVIC T, 2005, ARTERIOSCL THROM VAS, V25, P519, DOI
   10.1161/01.ATV.0000154279.98244.eb
   DOMINICZAK AF, 1996, HYPERTENSION 2, V27, P752
   ESTEVE PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200
   FINKEL T, 2000, NATURE, V408, P239
   FULDA S, 2004, CANCER RES, V64, P337
   GEISZT M, 2000, P NATL ACAD SCI USA, V97, P8010
   GINGRAS AC, 1999, GENE DEV, V13, P1422
   GORLA GR, 2001, J CELL SCI, V114, P2943
   GRIENDLING KK, 1994, CIRC RES, V74, P1141
   HANNA IR, 2002, ANTIOXID REDOX SIGN, V4, P899
   HILENSKI LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI
   10.1161/01.ATV.0000112024.13727.2c
   HIXON ML, 2000, J BIOL CHEM, V275, P40434
   HIXON ML, 2000, J CLIN INVEST, V106, P1011
   HU Y, 2007, BIOL CHEM, V388, P207, DOI 10.1515/BC.2007.023
   JIN HO, 2006, BIOCHEM PHARMACOL, V72, P1228, DOI
   10.1016/j.bcp.2006.07.026
   JONES MR, 2004, J BIOL CHEM, V279, P5306, DOI 10.1074/jbc.M308406200
   KUNIEDA T, 2006, CIRCULATION, V114, P953, DOI
   10.1161/CIRCULATIONAHA.106.626606
   KURATA S, 2000, J BIOL CHEM, V275, P23413
   LASSEGUE B, 2001, CIRC RES, V88, P888
   LI FZ, 1999, NAT CELL BIOL, V1, P461
   MACIP S, 2006, ONCOGENE, V25, P6037, DOI 10.1038/sj.onc.1209629
   MAHADEV K, 2004, MOL CELL BIOL, V24, P1844
   MARTIN KA, 2004, AM J PHYSIOL-CELL PH, V286, P507
   MATTHEWS C, 2006, CIRC RES, V99, P156, DOI
   10.1161/01.RES.000023315.38086.bc
   MENON SG, 2007, ONCOGENE, V26, P1101, DOI 10.1038/sj.onc.1209895
   MOLLNAU H, 2002, CIRC RES, V90, P58
   MOON SK, 2001, AM J PHYSIOL-HEART C, V280, P2779
   NAGATA Y, 2005, EXP CELL RES, V305, P277, DOI
   10.1016/j.yexcr.2004.12.028
   RASLOVA H, 2006, BLOOD, V107, P2303, DOI 10.1182/blood-2005-07-3005
   SEO SK, 2007, APOPTOSIS, V12, P195, DOI 10.1007/s10495-006-0527-5
   SESHIAH PN, 2002, CIRC RES, V91, P406, DOI
   10.1161/01.RES.0000033523.08033.16
   SIMBULA G, 2007, APOPTOSIS, V12, P113, DOI 10.1007/s10495-006-0487-9
   STOCKER R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   STURROCK A, 2007, AM J PHYSIOL-LUNG C, V292, P1543
   TOUYZ RM, 1999, HYPERTENSION S 2, V34, P976
   TOUYZ RM, 2002, CIRC RES, V90, P1205
   TOUYZ RM, 2005, EXP PHYSIOL, V90, P449, DOI
   10.1113/expphysiol.2005.030080
   VALLET P, 2005, NEUROSCIENCE, V132, P233, DOI
   10.1016/j.neuroscience.2004.12.038
   VITALE I, 2007, PLOS ONE, V2, P1337
   VITALE I, 2008, CELL CYCLE, V7, P1956
   WALEN KH, 2008, CELL CYCLE, V7, P1623
   WINGLER K, 2001, FREE RADIC BIOL MED, V31, P1456
   XU D, 2000, FEBS LETT, V470, P20
   YANG D, 2007, AGING CELL, V6, P257, DOI 10.1111/j.1474-9726.2007.00274.x
   ZHANG Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365
   ZHAO ZH, 1997, MICROVASC RES, V54, P243
NR 61
TC 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAR 15
PY 2009
VL 8
IS 6
BP 902
EP 908
PG 7
SC Cell Biology
GA 426KG
UT ISI:000264706600020
ER

PT J
AU Yang, ZJ
   Rao, ZR
   Jiang, XD
   Yuan, H
   Duan, L
   Chen, LW
   Wang, Y
   Xu, RX
   Zeng, YJ
AF Yang, Zhijun
   Rao, Zhiren
   Jiang, Xiaodan
   Yuan, Hua
   Duan, Li
   Chen, Liangwei
   Wang, Ying
   Xu, Ruxiang
   Zeng, Yanjun
TI Reciprocal pathway between medullary visceral zone and hypothalamic
   supraoptic nucleus or paraventricular nucleus involved in hyperosmotic
   regulation
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Neuron; Astrocyte; Osmotic pressure; Medullary visceral zone; Glial
   fibrillary acidic protein; Rat
ID GLIAL-NEURONAL INTERACTIONS; SYNAPTIC-TRANSMISSION;
   NOXIOUS-STIMULATION; MATURE ASTROCYTES; RAT; BRAIN; CELLS;
   REGENERATION; SYNAPSES; EXPRESSION
AB In this study we try to simultaneously investigate the response of
   neurons and astrocytes of rats following hyperosmotic stimulation and
   test the possibility that the reciprocal pathways between medullary
   visceral zone (MVZ) and hypothalamic paraventricular nucleus (PVN) or
   supraoptic nucleus (SON). Hyperosmotic pressure animal model was
   established by administering 3% sodium chloride as drinking water to
   rats. The distribution and expression of the HRP retrogradely labeled
   neurons, Fos, tyrosine hydroxylase (TH) or vasopressin (VP) positive
   neuron and glial fibrillary acidic protein (GFAP) positive astrocytes
   in the MVZ, SON and PVN were observed by quadruplicate-labeling methods
   of WGA-HRP retrograde tracing combined with anti-Fos, TH (or VP) and
   GFAP immunohistochemical technique. Fos positive neurons within the
   MVZ, PVN and SON increased markedly. There were also a large number of
   GFAP positive structures in the brain and their distribution pattern
   was fundamentally similar or analogous to Fos positive neurons in the
   above-mentioned areas. The augmented GFAP reactivities took on
   hypertrophic cell bodies, thicker and longer processes. Quadruplicate
   immunohistochemical staining showed that a neuron could be closely
   surrounded by many astrocytes and they formed neuron-astrocytic complex
   (N-ASC). Fos+/TH+/HRP+/GFAP+ and Fos+/VP+/HRP+/GFAP+ quadruplicate
   labeled N-ASC could be found in the MVZ, PVN and SON, respectively. The
   present results indicated that the neurons and astrocytes might be very
   active following hyperosmotic pressure and N-ASC as a functional unit
   might serve to modulate osmotic pressure. There were reciprocal
   osmoregulation pathways between the MVZ and SON or PVN in the brain.
   (C) 2008 Published by Elsevier Ltd on behalf of International
   Federation for Cell Biology.
C1 [Yang, Zhijun; Jiang, Xiaodan; Xu, Ruxiang] So Med Univ, Zhujiang Hosp, Neuromed Inst, Guangzhou 510282, Guangdong, Peoples R China.
   [Yang, Zhijun; Rao, Zhiren; Yuan, Hua; Duan, Li; Chen, Liangwei; Wang, Ying] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.
   [Zeng, Yanjun] Beijing Univ Technol, Biomech & Med Informat Inst, Beijing 100022, Peoples R China.
RP Xu, RX, So Med Univ, Zhujiang Hosp, Neuromed Inst, 253 Gongye Rd,
   Guangzhou 510282, Guangdong, Peoples R China.
EM zjxuruxiang@163.com
   yjzeng@bjpu.edu.cn
FU Natural Science Found of China [30270491, 30400464]; Funds for Key
   Sci-tech Research Projects of Guangdong Province ; PLA of PR China
   [01Z054]
FX This research was supported by Natural Science Found of China
   (30270491, 30400464) and also by the Funds for Key Sci-tech Research
   Projects of Guangdong Province [YUEKEJIBAN (2000) 25, (2004) 08, (2007)
   05/06:7005206], [YUE CAIQI (2001) 367, (2003) 209, YUE KEJIZI (2004)
   112] and PLA [01Z054] of PR China.
CR ARAQUE A, 1999, TRENDS NEUROSCI, V22, P208
   ARMSTRONG WE, 2005, J COMP NEUROL, V491, P175, DOI 10.1002/cne.20679
   BAERTSCHI AJ, 1995, AM J PHYSIOL-REG I, V268, R236
   CASTONGUAY A, 2001, PROG BRAIN RES, V132, P227
   CIURA S, 2006, J NEUROSCI, V26, P9069, DOI
   10.1523/JNEUROSCI.0877-06.2006
   DONG YX, 1997, NEUROSCI RES, V27, P155
   DUAN L, 2004, WORLD J GASTROENTERO, V10, P117
   FROES MM, 2002, NEUROCHEM INT, V41, P367
   GROSCHE J, 1999, NAT NEUROSCI, V2, P139
   HATTON GI, 2002, ADV PHYSIOL EDUC, V26, P225, DOI
   10.1152/advan.00038.2002
   HAYDON PG, 2001, NAT REV NEUROSCI, V2, P185
   HELMUTH L, 2001, SCIENCE, V291, P569
   HUSSY N, 2000, ADV EXP MED BIOL, V483, P227
   IADECOLA C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003
   JIN GR, 1994, BRAIN RES, V648, P196
   KORZHEVSKII DE, 2005, NEUROSCI BEHAV PHYSL, V35, P789
   KUDO Y, 2007, BRAIN NERVE, V59, P655
   NEWMAN EA, 2003, TRENDS NEUROSCI, V26, P536, DOI
   10.1016/S0166-2236(03)00237-6
   ONEIL RG, 2005, PFLUG ARCH EUR J PHY, V451, P193, DOI
   10.1007/s00424-005-1424-4
   PAXINOS G, 1999, RAT BRAIN STEREOTAXI
   PEKNY M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645
   RAMER MS, 2003, J NEUROSCI, V23, P9770
   RANSOM BR, 1996, TRENDS NEUROSCI, V19, P352
   RAO ZR, 1994, ACTA ANAT SINICA, V25, P219
   RAO ZR, 1998, SOC NEUR ABSTR, V24, P1612
   REICHENBACH A, 1993, J CHEM NEUROANAT, V6, P201
   ROUACH N, 2000, J CELL BIOL, V149, P1513
   SCHOUSBOE A, 1991, J NEUROSCI RES, V30, P661
   SUN YN, 2005, WORLD J GASTROENTERO, V11, P4827
   VACCARINO FM, 2007, NEUROSCIENTIST, V13, P173, DOI
   10.1177/1073858406298336
   VENTURA R, 1999, J NEUROSCI, V19, P6897
   VERWER RWH, 2007, BRAIN 12, V130, P3321, DOI 10.1093/brain/awm264
   VESCE S, 2001, NEWS PHYSIOL SCI, V16, P178
   WEISS ML, 1990, BRAIN RES BULL, V25, P561
   XU KX, 1999, GLIA, V25, P390
NR 35
TC 0
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD APR
PY 2009
VL 33
IS 4
BP 475
EP 482
DI 10.1016/j.cellbi.2008.07.024
PG 8
SC Cell Biology
GA 427XX
UT ISI:000264813500003
ER

PT J
AU Yang, XF
   Figueiredo, LM
   Espinal, A
   Okubo, E
   Li, B
AF Yang, Xiaofeng
   Figueiredo, Luisa M.
   Espinal, Amin
   Okubo, Eiji
   Li, Bibo
TI RAP1 Is Essential for Silencing Telomeric Variant Surface Glycoprotein
   Genes in Trypanosoma brucei
SO CELL
LA English
DT Article
ID DNA-BINDING DOMAIN; CELL-CYCLE ARREST; ANTIGENIC VARIATION; AFRICAN
   TRYPANOSOMES; SACCHAROMYCES-CEREVISIAE; EXPRESSION SITES; FISSION
   YEAST; HISTONE H3; PROTEIN; KU
AB Trypanosoma brucei expresses variant surface glycoprotein (VSG) genes
   in a strictly monoallelic fashion in its mammalian hosts, but it is
   unclear how this important virulence mechanism is enforced. Telomere
   position effect, an epigenetic phenomenon, has been proposed to play a
   critical role in VSG regulation, yet no telomeric protein has been
   identified whose disruption led to VSG derepression. We now identify
   tbRAP1 as an intrinsic component of the T. brucei telomere complex and
   a major regulator for silencing VSG expression sites (ESs). Knockdown
   of tbRAP1 led to derepression of all VSGs in silent ESs, but not VSGs
   located elsewhere, and resulted in stronger derepression of genes
   located within 10 kb from telomeres than genes located further
   upstream. This graduated silencing pattern suggests that telomere
   integrity plays a key role in tbRAP1-dependent silencing and VSG
   regulation.
C1 [Yang, Xiaofeng; Li, Bibo] Cleveland State Univ, Dept Biol Geol & Environm Sci, Ctr Gene Regulat Hlth Dis, Cleveland, OH 44115 USA.
   [Yang, Xiaofeng] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Xian 710061, Shaanxi Prov, Peoples R China.
   [Figueiredo, Luisa M.; Espinal, Amin; Okubo, Eiji; Li, Bibo] Rockefeller Univ, Mol Parasitol Lab, New York, NY 10065 USA.
RP Li, B, Cleveland State Univ, Dept Biol Geol & Environm Sci, Ctr Gene
   Regulat Hlth Dis, Cleveland, OH 44115 USA.
EM b.li37@csuohio.edu
FU National Institute of Health [AI050614, AI21729, AI066095]
FX We are grateful to Piet Borst for the VSG9 antibody and Keith Gull for
   the RNA Pol I and tubulin antibodies. We greatly appreciate Titia de
   Lange and George A.M. Cross for insightful discussions, and we thank
   Margaret J. Irwin, Audrey Lynn, and members of the Li and Cross labs
   for comments on the manuscript, critical discussions, and technical
   support. DeltaVision Microscopy was carried out at the RU Bio-Imaging
   Resource Center with guidance from Alison North and in BGES Department
   at CSU. FACS analysis was done at the Flow Cytometry Resource Center at
   RU and the Flow Cytometry Core at CCF. This work was supported by
   National Institute of Health grants to G.A.M. Cross (AI050614 and
   AI21729) and to B.L. (AI066095).
CR ALSFORD S, 2001, MOL BIOCHEM PARASIT, V113, P79
   ALSFORD S, 2005, MOL BIOCHEM PARASIT, V144, P142, DOI
   10.1016/j.molbiopara.2005.08.009
   ALSFORD S, 2007, MOL MICROBIOL, V63, P724, DOI
   10.1111/j.1365-2958.2006.05553.x
   BARRY JD, 2001, ADV PARASIT, V49, P1
   BASTIN P, 1996, MOL BIOCHEM PARASIT, V77, P235
   BERRIMAN M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642
   BORK P, 1997, FASEB J, V11, P68
   BOULTON SJ, 1998, EMBO J, V17, P1819
   BROCCOLI D, 1997, NAT GENET, V17, P231
   CALLEBAUT I, 1997, FEBS LETT, V400, P25
   CHAVES I, 1999, EMBO J, V18, P4846
   CONWAY C, 2002, J BIOL CHEM, V277, P21269
   DELANGE T, 1982, NATURE, V299, P451
   DELANGE T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   DREESEN O, 2005, NUCLEIC ACIDS RES, V33, P4536, DOI 10.1093/nar/gki769
   DREESEN O, 2007, NAT REV MICROBIOL, V5, P70, DOI 10.1038/nrmicro1577
   DURAISINGH MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036
   EVANS SK, 1998, CHROMOSOMA, V107, P352
   FIGUEIREDO LM, 2008, PLOS BIOL, V6, P1539, ARTN e161
   FREITASJUNIOR LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037
   GAO Q, 2007, STEM CELLS, V25, P3085, DOI 10.1634/stemcells.2007-0478
   GASSER SM, 2001, GENE, V279, P1
   GLOVER L, 2006, EMBO REP, V7, P93, DOI 10.1038/sj.embor.7400575
   GLOVER L, 2007, NUCLEIC ACIDS RES, V35, P872, DOI 10.1093/nar/gkl1100
   GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745
   GOTTSCHLING DE, 1990, CELL, V63, P751
   GRUNSTEIN M, 1997, CURR OPIN CELL BIOL, V9, P383
   GUNZL A, 2003, EUKARYOT CELL, V2, P542, DOI 10.1128/EC.2.3.542-551.2003
   HANAOKA S, 2001, J MOL BIOL, V312, P167
   HERTZFOWLER C, 2008, PLOS ONE, V3, ARTN e3527
   HOEK M, 2002, MOL BIOCHEM PARASIT, V120, P269
   HORN D, 1995, CELL, V83, P555
   HORN D, 1997, EMBO J, V16, P7422
   HORN D, 2005, CHROMOSOME RES, V13, P525, DOI 10.1007/s10577-005-0991-8
   HUGHES K, 2007, EMBO J, V26, P2400, DOI 10.1038/sj.emboj.7601678
   JANZEN CJ, 2004, NUCLEIC ACIDS RES, V32, P6575, DOI 10.1093/nar/gkh991
   KANOH J, 2001, CURR BIOL, V11, P1624
   KONIG P, 1996, CELL, V85, P125
   KONIG P, 1997, TRENDS BIOCHEM SCI, V22, P43
   KYTE J, 1982, J MOL BIOL, V157, P105
   LANDEIRA D, 2007, J CELL BIOL, V176, P133, DOI 10.1083/jcb.200607174
   LI B, 2005, MOL CELL BIOL, V25, P5011, DOI
   10.1128/MCB.25.12.5011-5021.2005
   LI BB, 1996, GENE DEV, V10, P1310
   LI BB, 2000, CELL, V101, P471
   LOWELL JE, 2004, J CELL SCI, V117, P5937, DOI 10.1242/jcs.01515
   MARCELLO L, 2007, GENOME RES, V17, P1344, DOI 10.1101/gr.6421207
   MICHISHITA E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   MISHRA K, 1999, CURR BIOL, V9, P1123
   NAVARRO M, 1996, MOL CELL BIOL, V16, P3615
   NAVARRO M, 2001, NATURE, V414, P759
   OGATA K, 1994, CELL, V79, P639
   PARK MJ, 2002, MOL CELLS, V13, P327
   PAYS E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI
   10.1016/j.mib.2004.05.001
   PEDRAM M, 2006, MOL CELL BIOL, V26, P1865, DOI
   10.1128/MCB.26.5.1865-1878.2006
   PINA B, 2003, MOL GENET GENOMICS, V268, P791, DOI
   10.1007/s00438-002-0801-3
   PRYDE FE, 1999, EMBO J, V18, P2538
   RENAULD H, 1993, GENE DEV, V7, P1133
   SHEADER K, 2005, P NATL ACAD SCI USA, V102, P8716
   SHORE D, 1994, TRENDS GENET, V10, P408
   SIEGEL TN, 2005, MOL CELL BIOL, V25, P9586, DOI
   10.1128/MCB.25.21.9586-9594.2005
   TEIXEIRA MT, 2005, CHROMOSOME RES, V13, P535, DOI
   10.1007/s10577-005-0999-0
   VANDERPLOEG LHT, 1984, CELL, V36, P459
   VANHAMME L, 2000, MOL MICROBIOL, V36, P328
   VANLEEUWEN F, 1996, NUCLEIC ACIDS RES, V24, P2476
   VOJTEK AB, 1993, CELL, V74, P205
   WANG RC, 2004, CELL, V119, P355
   WIRTZ E, 1999, MOL BIOCHEM PARASIT, V99, P89
   ZHANG XD, 1998, EMBO J, V17, P6404
NR 68
TC 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 2
PY 2009
VL 137
IS 1
BP 99
EP 109
DI 10.1016/j.cell.2009.01.037
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 427XV
UT ISI:000264813300017
ER

PT J
AU Piao, LZ
   Li, YW
   Kim, SJ
   Sohn, KC
   Yang, KJ
   Park, YA
   Byun, HS
   Won, MH
   Hong, JH
   Hur, GM
   Seok, JH
   Shong, MH
   Sack, R
   Brazil, DP
   Hemmings, BA
   Park, J
AF Piao, Longzhen
   Li, Yuwen
   Kim, Soung Jung
   Sohn, Kyung-Cheol
   Yang, Keum-Jin
   Park, Yeong Ah
   Byun, Hee Sun
   Won, Minho
   Hong, Janghee
   Hur, Gang Min
   Seok, Jeong Ho
   Shong, Minho
   Sack, Ragna
   Brazil, Derek P.
   Hemmings, Brian A.
   Park, Jongsun
TI Regulation of OPA1-mediated mitochondrial fusion by leucine
   zipper/EF-hand-containing transmembrane protein-1 plays a role in
   apoptosis
SO CELLULAR SIGNALLING
LA English
DT Article
DE CTMP; Mitochondria; Apoptosis; Wolf-Hirschhorn syndrome; LETM11
ID WOLF-HIRSCHHORN-SYNDROME; DOMINANT OPTIC ATROPHY; CYTOCHROME-C RELEASE;
   MAMMALIAN-CELLS; LIVING CELLS; OPA1; GENE; MORPHOLOGY; MEMBRANE; FISSION
AB Carboxyl-terminal modulator protein (CTMP) is a tumor suppressor-like
   binding partner of Protein kinase B (PKB/Akt) that negative regulates
   this kinase. In the course of our recent work, we identified that CTMP
   is consistently associated with leucine zipper/EF-hand-containing
   transmembrane-1 (LETM1). Here, we report that adenovirus-LETM1
   increased the sensitivity of HeLa cells to apoptosis, induced by either
   staurosporine or actinomycin D. As shown previously, LETM1 localized to
   the inner mitochondrial membrane. Electron-microscopy analysis of
   adenovirus-LETM1 transduced cells revealed that mitochondrial cristae
   were swollen in these cells, a phenotype similar to that observed in
   optic atrophy type-1 (OPA1)-ablated cells. OPA1 cleavage was increased
   in LETM1-overexpressing cells, and this phenotype was reversed by
   overexpression of OPA1 variant-7, a cleavage resistant form of OPA1.
   Taken together, these data suggest that LETM1 is a novel binding
   partner for CTMP that may play an important role in mitochondrial
   fragmentation via OPA1-cleavage. (C) 2009 Elsevier Inc. All rights
   reserved
C1 [Piao, Longzhen; Li, Yuwen; Yang, Keum-Jin; Park, Yeong Ah; Byun, Hee Sun; Won, Minho; Hong, Janghee; Hur, Gang Min; Seok, Jeong Ho; Park, Jongsun] Chungnam Natl Univ, Coll Med, Dept Pharmacol,Daejeon Reg Canc Ctr, Canc Res Inst,Res Inst Med Sci, Taejon 301131, South Korea.
   [Kim, Soung Jung; Shong, Minho] Chungnam Natl Univ, Dept Internal Med, Coll Med, Taejon 301131, South Korea.
   [Sohn, Kyung-Cheol] Chungnam Natl Univ, Coll Med, Dept Dermatol, Taejon 301131, South Korea.
   [Sack, Ragna; Hemmings, Brian A.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland.
   [Brazil, Derek P.] Univ Coll Dublin, UCD Conway Inst, UCD Diabet Res Ctr, Dublin 4, Ireland.
RP Park, J, Chungnam Natl Univ, Coll Med, Dept Pharmacol,Daejeon Reg Canc
   Ctr, Canc Res Inst,Res Inst Med Sci, 6 Munhwa Dong, Taejon 301131,
   South Korea.
EM insulin@cnu.ac.kr
FU Korea Science & Engineering Foundation (KOSEF) grant funded by the
   Korea government (MOST) [R11-2002-100-02006-0]; Cancer Control Ministry
   of Health & Welfare, Republic of Korea [0720560]; KOSEF/MOST
   [M10753020001-07N5302-00110]; Science Foundation Ireland ; Irish Health
   Research Board ; Novartis Research Foundation. 
FX We would like to thank Dr. JW Lee (Korea Basic Science Institute,
   Korea) for TEM analysis. We also thank Drs. SY Jung and KS Yoon (Aju
   University, Korea) for critical comments on the manuscript. This work
   was supported by the Science Research Center (SRC)/Engineering Research
   Center (ERC) Program (R11-2002-100-02006-0) of the Korea Science &
   Engineering Foundation (KOSEF) grant funded by the Korea government
   (MOST) and by a grant from the National R&D Program for Cancer Control
   Ministry of Health & Welfare, Republic of Korea. (No: 0720560). SJ. Kim
   and M. Shong were supported by KOSEF/MOST (M10753020001-07N5302-00110).
   Work in the laboratory of D. Brazil is supported by Science Foundation
   Ireland and the Irish Health Research Board. The Friedrich Miescher
   Institute is part of the Novartis Research Foundation.
CR ALEXANDER C, 2000, NAT GENET, V26, P211
   BARICAULT L, 2007, EXP CELL RES, V313, P3800, DOI
   10.1016/j.yexcr.2007.08.008
   BATTAGLIA A, 2001, ADV PEDIATR, V48, P75
   BEREITERHAHN J, 1990, INT REV CYTOL, V122, P1
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198
   BERGEMANN AD, 2005, TRENDS GENET, V21, P188, DOI
   10.1016/j.tig.2005.01.008
   CHAE KS, 2005, J NEUROPHYSIOL, V93, P1174, DOI 10.1152/jn.00796.2004
   CHEN HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   CHEN HC, 2005, HUM MOL GENET, V14, R283, DOI 10.1093/hmg/ddi270
   CIPOLAT S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021
   COOPER H, 1961, MAMMALIAN CHROM NWSL, V4, P14
   DELETTRE C, 2000, NAT GENET, V26, P207
   DESAGHER S, 2000, TRENDS CELL BIOL, V10, P369
   DIMMER KS, 2008, HUM MOL GENET, V17, P201
   ENDELE S, 1999, GENOMICS, V60, P218
   FRANK S, 2001, DEV CELL, V1, P515
   FRAZIER AE, 2006, J CELL BIOL, V172, P553
   FROSCHAUER E, 2005, BBA-BIOMEMBRANES, V1711, P41, DOI
   10.1016/j.bbamem.2005.02.018
   GRIPARIC L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   HASEGAWA A, 2007, HUM MOL GENET, V16, P2061, DOI 10.1093/hmg/ddm154
   HWANG SK, 2007, GENE THER, V14, P1721, DOI 10.1038/sj.gt.3303042
   ISHIHARA N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI
   10.1016/S0006-291X(03)00050-0
   ISHIHARA N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184
   KARBOWSKI M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082
   KNOBBE CB, 2004, J NATL CANCER I, V96, P483, DOI 10.1093/jnci/djh064
   LEE YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   LIEBER A, 1996, J VIROL, V70, P8944
   LIGUORI M, 2008, J NEUROL, V255, P127, DOI 10.1007/s00415-008-0571-x
   LURIE IW, 1980, CLIN GENET, V17, P375
   MAIRA SM, 2001, SCIENCE, V294, P374
   MANFREDI G, 2002, METHODS, V26, P317
   NOWIKOVSKY K, 2004, J BIOL CHEM, V279, P30307, DOI
   10.1074/jbc.M403607200
   OLICHON A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   OLICHON A, 2007, CELL DEATH DIFFER, V14, P682, DOI
   10.1038/sj.cdd.4402048
   RIZZUTO R, 1995, CURR BIOL, V5, P635
   RYAN MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI
   10.1146/annurev.biochem.76.052305.091720
   SANTEL A, 2001, J CELL SCI, V114, P867
   SCHLICKUM S, 2004, GENOMICS, V83, P254, DOI 10.1016/j.ygeno.2003.08.013
   ZANNA C, 2008, BRAIN 2, V131, P352, DOI 10.1093/brain/awm335
   ZHANG Y, 2007, FEBS LETT, V581, P2168, DOI 10.1016/j.febslet.2007.01.095
NR 40
TC 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD MAY
PY 2009
VL 21
IS 5
BP 767
EP 777
DI 10.1016/j.cellsig.2009.01.020
PG 11
SC Cell Biology
GA 423UN
UT ISI:000264521300015
ER

PT J
AU Biesinger, MC
   Payne, BP
   Lau, LWM
   Gerson, A
   Smart, RSC
AF Biesinger, Mark C.
   Payne, Brad P.
   Lau, Leo W. M.
   Gerson, Andrea
   Smart, Roger St. C.
TI X-ray photoelectron spectroscopic chemical state quantification of
   mixed nickel metal, oxide and hydroxide systems
SO SURFACE AND INTERFACE ANALYSIS
LA English
DT Article
DE X-ray photoelectron spectroscopy (XPS); nickel; oxides; film thickness;
   chemical state quantification
ID XPS SPECTRA; SURFACES; OXYGEN; NIO; MECHANISM; CHROMIUM; NI(110);
   ALLOY; IRON
AB Quantitative chemical state X-ray photoelectron spectroscopic analysis
   of mixed nickel metal, oxide, hydroxide and oxyhydroxide systems is
   challenging due to the complexity of the Ni 2p peak shapes resulting
   from multiplet splitting, shake-up and plasmon loss structures.
   Quantification of mixed nickel chemical states and the qualitative
   determination of low concentrations of Ni(III) species are demonstrated
   via an approach based on standard spectra from quality reference
   samples (Ni, NiO, Ni(OH)(2), NiOOH), subtraction of these spectra, and
   data analysis that integrates information from the Ni 2p spectrum and
   the 0 1s spectra. Quantification of a commercial nickel powder and a
   thin nickel oxide film grown at 1 -Torr O-2 and 300 degrees C for 20
   min is demonstrated. The effect of uncertain relative sensitivity
   factors (e.g. Ni 2.67 +/- 0.54) is discussed, as is the depth of
   measurement for thin film analysis based on calculated inelastic mean
   free paths. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Biesinger, Mark C.; Lau, Leo W. M.] Univ Western Ontario, Western Sci Ctr, London, ON N6A 5B7, Canada.
   [Biesinger, Mark C.; Gerson, Andrea; Smart, Roger St. C.] ACeSSS, Mawson Lakes, SA 5095, Australia.
   [Payne, Brad P.; Lau, Leo W. M.] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada.
RP Biesinger, MC, Univ Western Ontario, Western Sci Ctr, Room G1, London,
   ON N6A 5B7, Canada.
EM biesingr@uwo.co
CR *US SECR COMM, 2000, NIST EL IN MEAN FREE
   BANERJEE D, 1999, GEOCHIM COSMOCHIM AC, V63, P3025
   BENNDORF C, 1982, SURF SCI, V121, P249
   BIESINGER MC, 2004, SURF INTERFACE ANAL, V36, P1550, DOI
   10.1002/sia.1983
   BOSCHLOO G, 2001, J PHYS CHEM B, V105, P3039
   CARLEY AF, 1983, SURF SCI, V135, P35
   CARLEY AF, 1985, P ROY SOC LOND A MAT, V399, P167
   CARLEY AF, 1999, SURF SCI, V440, L868
   CARLSON TA, 1972, J ELECTRON SPECTROSC, V1, P161
   FUJIMOTO S, 2002, 201 M EL SOC PHIL PE, P278
   GROSVENOR AP, 2004, SURF INTERFACE ANAL, V36, P1564, DOI
   10.1002/sia.1984
   GROSVENOR AP, 2006, SURF SCI, V600, P1771, DOI
   10.1016/j.susc.2006.01.041
   GUPTA RP, 1974, PHYS REV           B, V10, P71
   GUPTA RP, 1975, PHYS REV B, V12, P12
   HAGELINWEAVER HAE, 2004, J ELECTRON SPECTROSC, V134, P139, DOI
   10.1016/j.elspec.2003.10.002
   HAGELINWEAVER HAE, 2005, J ALLOY COMPD, V389, P34, DOI
   10.1016/j.jallcom.2004.07.039
   JANG HJ, 2005, ELECTROCHIM ACTA, V50, P3503, DOI
   10.1016/j.electacta.2004.12.027
   MATIENZO LJ, 1973, INORG CHEM, V12, P2762
   MCINTYRE NS, 1978, APPL SURF SCI, V2, P55
   MILLER DJ, 2002, SURF INTERFACE ANAL, V33, P299
   MORONEY LM, 1983, J CHEM SOC FARAD T 1, V79, P1769
   MOULDER JF, 1992, HDB XRAY PHOTOELECTR
   NESBITT HW, 1998, AM MINERAL, V83, P305
   NORTON PR, 1977, SURF SCI, V65, P13
   PAYNE BP, 2007, SURF INTERFACE ANAL, V9, P582
   PAYNE BP, 2009, J ELECT SPECTR UNPUB
   ROBERTS MW, 1984, J CHEM SOC FARAD T 1, V80, P2957
   SMITH GC, 1998, HDB SURFACE INTERFAC, P184
   STROHMEIER BR, 1990, SURF INTERFACE ANAL, V15, P51
   TANUMA S, 1991, SURF INTERFACE ANAL, V17, P927
   TIELSCH BJ, 1996, SURF INTERFACE ANAL, V24, P459
   TOUGAARD S, 2000, QUASES SOFTWARE QUAN
   WAGNER CD, 2003, NIST STANDARD REFERE
   WANG YP, 2006, SPECTROSC SPECT ANAL, V26, P690
NR 34
TC 14
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0142-2421
J9 SURF INTERFACE ANAL
JI Surf. Interface Anal.
PD APR
PY 2009
VL 41
IS 4
BP 324
EP 332
DI 10.1002/sia.3026
PG 9
SC Chemistry, Physical
GA 422MB
UT ISI:000264431100007
ER

PT J
AU Yang, ZH
   MacQuarrie, KL
   Analau, E
   Tyler, AE
   Dilworth, FJ
   Cao, Y
   Diede, SJ
   Tapscott, SJ
AF Yang, Zhihong
   MacQuarrie, Kyle L.
   Analau, Erwin
   Tyler, Ashlee E.
   Dilworth, F. Jeffery
   Cao, Yi
   Diede, Scott J.
   Tapscott, Stephen J.
TI MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an
   arrested myoblast phase to a differentiated state
SO GENES & DEVELOPMENT
LA English
DT Article
DE E2A; Musculin; MyoD; myogenesis; rhabdomyosarcoma
ID LOOP-HELIX PROTEINS; E-BOX ELEMENTS; TRANSCRIPTION FACTOR; TERMINAL
   DIFFERENTIATION; HOMEODOMAIN PROTEIN; MUSCLE DEVELOPMENT;
   GENE-EXPRESSION; MYOGENESIS; E2A; ACTIVATION
AB Rhabdomyosarcomas are characterized by expression of myogenic
   specification genes, such as MyoD and/or Myf5, and some muscle
   structural genes in a population of cells that continues to replicate.
   Because MyoD is sufficient to induce terminal differentiation in a
   variety of cell types, we have sought to determine the molecular
   mechanisms that prevent MyoD activity in human embryonal
   rhabdomyosarcoma cells. In this study, we show that a combination of
   inhibitory Musculin: E-protein complexes and a novel splice form of E2A
   compete with MyoD for the generation of active full-length E-protein:
   MyoD heterodimers. A forced heterodimer between MyoD and the
   full-length E12 robustly restores differentiation in rhabdomyosarcoma
   cells and broadly suppresses multiple inhibitory pathways. Our studies
   indicate that rhabdomyosarcomas represent an arrested progress through
   a normal transitional state that is regulated by the relative abundance
   of heterodimers between MyoD and the full-length E2A proteins. The
   demonstration that multiple inhibitory mechanisms can be suppressed and
   myogenic differentiation can be induced in the RD rhabdomyosarcomas by
   increasing the abundance of MyoD: E-protein heterodimers suggests a
   central integrating function that can be targeted to force
   differentiation in muscle cancer cells.
C1 [Yang, Zhihong; MacQuarrie, Kyle L.; Analau, Erwin; Tyler, Ashlee E.; Cao, Yi; Diede, Scott J.; Tapscott, Stephen J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.
   [MacQuarrie, Kyle L.] Univ Washington, Med Scientist Training Program, Seattle, WA 98105 USA.
   [Dilworth, F. Jeffery] Ottawa Hlth Res Inst, Sprott Ctr Stem Cell Res, Ottawa, ON K1Y 4E9, Canada.
   [Tapscott, Stephen J.] Univ Washington, Dept Neurol, Seattle, WA 98105 USA.
RP Tapscott, SJ, Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA
   98109 USA.
EM stapscot@fhcrc.org
FU NIH [AR045113]
FX This work was supported by NIH-AR045113 ( to S. J. T.) and F32CA117622
   ( to Z. Y.), and FHCRC/ Amgen Interdisciplinary Training Grant ( to Z.
   Y.). We thank Z. Yao, A. E. Tyler, L. D. Snider, S. Collins, I.
   Bernstein, L. Rott, and P. Gafken for experimental support and review
   of the text.
CR AZMI S, 2004, J BIOL CHEM, V279, P52643, DOI 10.1074/jbc.M409188200
   BENEZRA R, 1990, CELL, V61, P49
   BERGSTROM DA, 2002, MOL CELL, V9, P587
   BERKES CA, 2004, MOL CELL, V14, P465
   BERKES CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI
   10.1016/j.semcdb.2005.07.006
   BHALLA S, 2008, J IMMUNOL, V180, P1694
   BUAS MF, 2009, J CELL PHYSIOL, V218, P84, DOI 10.1002/jcp.21571
   CHEN AC, 1996, CELL, V86, P731
   COBB LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028
   CONWAY K, 2004, DIFFERENTIATION, V72, P327
   DILWORTH FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI
   10.1073/pnas.0404192101
   FIDDLER TA, 1996, MOL CELL BIOL, V16, P5048
   FINCKENSTEIN FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835
   FLORA A, 2007, P NATL ACAD SCI USA, V104, P15382, DOI
   10.1073/pnas.0707456104
   FUJIMOTO K, 2007, INT J MOL MED, V19, P925
   GENTLEMAN RC, 2004, GENOME BIOL, V5, ARTN R80
   GINGRAS AC, 2005, J PHYSIOL-LONDON, V563, P11, DOI
   10.1113/jphysiol.2004.080440
   HAHN H, 2000, J BIOL CHEM, V275, P28341
   INABA T, 1992, SCIENCE, V257, P531
   KING AM, 2007, J IMMUNOL, V178, P3521
   KOPHENGNAVONG T, 2000, MOL CELL BIOL, V20, P261
   KURODA K, 1999, J BIOL CHEM, V274, P7238
   LANGENAU DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007
   LU JR, 1999, P NATL ACAD SCI USA, V96, P552
   LU JR, 2002, SCIENCE, V298, P2378
   LU Q, 1994, MOL CELL BIOL, V14, P3938
   MARAMPON F, 2006, MOL CANCER, V5, ARTN 31
   MARKUS M, 2002, J BIOL CHEM, V277, P6469
   MARTIN D, 2007, EUR J MIGR LAW, V9, P141, DOI 10.1163/138836407X179346
   MASSARI ME, 1999, MOL CELL, V4, P63
   MASSARI ME, 2000, MOL CELL BIOL, V20, P429
   MATHAS S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285
   MCALLISTER RM, 1969, CANCER, V24, P520
   MERLINO G, 1999, ONCOGENE, V18, P5340
   MIZRAK D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283
   NEUHOLD LA, 1993, CELL, V74, P1033
   NOFZIGER D, 1999, DEVELOPMENT, V126, P1689
   NUTT SL, 2007, IMMUNITY, V26, P715, DOI 10.1016/j.immuni.2007.05.010
   OTTEN AD, 1997, CELL GROWTH DIFFER, V8, P1151
   PEINADO H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   PURI PL, 2000, GENE DEV, V14, P574
   RIGAUT G, 1999, NAT BIOTECHNOL, V17, P1030
   ROTHSCHILD G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05
   SALIH DAM, 2004, P NATL ACAD SCI USA, V101, P4314, DOI
   10.1073/pnas.0400230101
   SAWADO T, 2001, P NATL ACAD SCI USA, V98, P10226
   SCHWARTZ R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI
   10.1073/pnas.0603728103
   SHARP R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787
   SNIDER L, 2001, MOL CELL BIOL, V21, P1866
   STPIERRE B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200
   STRAUSBERG RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI
   10.1073/pnas.242603899
   SUN JX, 2001, J BIOL CHEM, V276, P18591
   TAPSCOTT SJ, 1988, SCIENCE, V242, P405
   TAPSCOTT SJ, 1993, SCIENCE, V259, P1450
   VONSCHEVEN G, 2006, GENE EXPR PATTERNS, V6, P383, DOI
   10.1016/j.modgep.2005.09.008
   WANG K, 2008, EUR J COMBIN, V29, P369, DOI 10.1016/j.ejc.2007.02.009
   WEINTRAUB H, 1991, SCIENCE, V251, P761
   ZHANG JS, 2004, SCIENCE, V305, P1286
   ZHAO P, 2006, BIOCHEM BIOPH RES CO, V342, P835, DOI
   10.1016/j.bbrc.2006.01.188
   ZHUANG Y, 1996, MOL CELL BIOL, V16, P2898
NR 59
TC 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD MAR 15
PY 2009
VL 23
IS 6
BP 694
EP 707
DI 10.1101/gad.1765109
PG 14
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 421LM
UT ISI:000264360400005
ER

PT J
AU Huynh, KM
   Kim, G
   Kim, DJ
   Yang, SJ
   Park, SM
   Yeom, YI
   Fisher, PB
   Kang, D
AF Huynh, Kim Mai
   Kim, Gyoungmi
   Kim, Dong-Joon
   Yang, Suk-Jin
   Park, Seong-Min
   Yeom, Young-Il
   Fisher, Paul B.
   Kang, Dongchul
TI Gene expression analysis of terminal differentiation of human melanoma
   cells highlights global reductions in cell cycle-associated genes
SO GENE
LA English
DT Article
DE Microarray; Mezerein; Interferon-beta; PKC; Mitosis; Calpain 3
ID PROTEIN-KINASE-C; LEUKEMIA-CELLS; GROWTH ARREST; I INTERFERONS;
   MEZEREIN; INDUCTION; CANCER; FOXM1; RETRODIFFERENTIATION; MICROARRAYS
AB Defects in differentiation are frequently observed in cancer cells. By
   appropriate treatment specific tumor cell types can be induced to
   terminally differentiate. Metastatic HO-1 human melanoma cells treated
   with IFN-beta plus mezerein (MEZ) undergo irreversible growth arrest
   and terminal differentiation followed by apoptosis. In order to define
   the molecular changes associated with this process, changes in gene
   expression were analyzed by cDNA microarray hybridization and by
   semi-quantitative and quantitative RT-PCRs of representative 44 genes.
   The expression of 210 genes was changed more than two-fold at either 8
   or 24 h post-treatment (166 up and 44 down). Major biological processes
   associated with the up-regulated genes were response to
   endogenous/exogenous stimuli (38%), cell proliferation (13%), cell
   death (16%) and development (30%). Approximately 34% of the
   down-regulated genes were associated with cell cycle, 9% in DNA
   replication and 11% in chromosome organization, respectively.
   Suppression of cell cycle associated genes appeared to directly
   correlate with growth arrest observed in the terminal differentiation
   process. Expression of Calpain 3 (CAPN3) variant 6 was suppressed by
   the combined treatment and maintained high in various melanoma cell
   lines. However, over-expression of the CAPN3 did not significantly
   affect growth kinetics and cell viability, suggesting that
   up-regulation of CAPN3 alone may not be a causative, but an associated
   change with melanoma development. This analysis provides further
   insights into the spectrum of up-regulated and the first detailed
   investigation of down-regulated gene changes associated with and
   potentially causative of induction of loss of proliferative capacity
   and terminal differentiation in human melanoma cells. (C) 2008 Elsevier
   B.V. All rights reserved.
C1 [Huynh, Kim Mai; Kim, Gyoungmi; Kang, Dongchul] Hallym Univ, Ilsong Inst Life Sci, Anyang 431060, Kyonggi Do, South Korea.
   [Kim, Dong-Joon; Yang, Suk-Jin; Park, Seong-Min; Yeom, Young-Il] KRIBB, Med Genom Res Ctr, Taejon 305806, South Korea.
   [Fisher, Paul B.] Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Massey Canc Ctr,Dept Human & Mol Genet, Richmond, VA 23298 USA.
RP Kang, D, Hallym Univ, Ilsong Inst Life Sci, 1605-4 Gwanyang Dong,
   Anyang 431060, Kyonggi Do, South Korea.
EM dckang@hallym.ac.kr
FU Korea Research Foundation [C00421]
FX The present studies were supported by Korea Research Foundation Grant
   C00421 to DK. PBF holds the Thelma Newmeyer Corman Chair in Cancer
   Research in the Massey Cancer Center of VCU, School of Medicine and is
   a Samuel Waxman Cancer Research Foundation (SWCRF) Investigator.
CR COSTA RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108
   DELMAS C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200
   DEVEER MJ, 2001, J LEUKOCYTE BIOL, V69, P912
   FISHER PB, 1985, J INTERFERON RES, V5, P11
   FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143
   FISHER PB, 2005, CANCER RES, V65, P10128, DOI
   10.1158/0008-5472.CAN-05-3127
   HASS R, 1992, EUR J CELL BIOL, V58, P1
   HASS R, 1994, CRIT REV ONCOGENESIS, V5, P359
   HUANG F, 1999, GENE, V236, P125
   HUANG F, 1999, ONCOGENE, V18, P3546
   JIANG H, 1993, MOL CELL DIFFER, V1, P285
   JIANG HP, 1995, ONCOGENE, V10, P1855
   JIANG HP, 2000, P NATL ACAD SCI USA, V97, P12684
   JUAN HF, 2002, ELECTROPHORESIS, V23, P2490
   KANG DC, 2002, P NATL ACAD SCI USA, V99, P637
   KANG DC, 2004, ONCOGENE, V23, P1789, DOI 10.1038/sj.onc.1207300
   KIM G, 2006, KOR J GERONTOL, V16, P201
   KLEINSZANTO AJP, 1980, CARCINOGENESIS, V1, P399
   LAOUKILI J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   LEE HS, 2007, LIFE SCI, V80, P690, DOI 10.1016/j.lfs.2006.10.024
   LESZCZYNIECKA M, 2001, PHARMACOL THERAPEUT, V90, P105
   LESZCZYNIECKA M, 2003, GENE, V316, P143, DOI
   10.1016/S0378-1119(03)00752-2
   MIYAKE R, 1984, BIOCHEM BIOPH RES CO, V121, P649
   MOLVEN A, 1996, GENOMICS, V38, P72
   MORIN MJ, 1987, J BIOL CHEM, V262, P11758
   MUFSON RA, 1979, CANCER RES, V39, P4791
   ROVERA G, 1979, SCIENCE, V204, P868
   SHARMA SC, 2000, J BIOL CHEM, V275, P33718
   SPIRA AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI
   10.1016/S1471-4892(03)00081-X
   STAUDT MR, 2009, J CELL PHYSIOL, V218, P304, DOI 10.1002/jcp.21602
   STETSON DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007
   TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5116
   VANNUCCHI S, 2007, CURR MED CHEM, V14, P667
   VERTEGAAL ACO, 2000, CELL SIGNAL, V12, P759
   WANG IC, 2005, MOL CELL BIOL, V25, P10875, DOI
   10.1128/MCB.25.24.10875-10894.2005
   WEERARATNA AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337
   WIERSTRA I, 2007, BIOL CHEM, V388, P1257
   ZHENG X, 2002, NUCLEIC ACIDS RES, V30, P4489
NR 38
TC 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAR 15
PY 2009
VL 433
IS 1-2
BP 32
EP 39
DI 10.1016/j.gene.2008.11.013
PG 8
SC Genetics & Heredity
GA 421AX
UT ISI:000264331400005
ER

PT J
AU Li, HY
   Wang, YC
   Jiang, J
   Liu, GF
   Gao, CQ
   Yang, CP
AF Li, Huiyu
   Wang, Yucheng
   Jiang, Jing
   Liu, Guifeng
   Gao, Caiqiu
   Yang, Chuanping
TI Identification of genes responsive to salt stress on Tamarix hispida
   roots
SO GENE
LA English
DT Article
DE Roots; Salinity stress; Expressed sequence tags; Gene expression
   profiling; Real-time RT-PCR
ID EXPRESSED SEQUENCE TAGS; TRANSLATION INITIATION-FACTOR; TOLERANCE;
   LEAVES; PLANTS; TRANSCRIPTOME; RICE; ESTS; NACL; PCR
AB Plant roots are the primary site of perception and injury for salinity
   stress. In order to characterize the complexity of adaptation to salty
   environments in roots of Tamarix hispida, a woody halophyte, expressed
   sequence tag (EST) analysis was performed. Three cDNA libraries were
   generated from root tissues of T hispida that were exposed to 0.4 M
   NaCl for 0 (control), 24 and 48 h. A total of 7726 ESTs were generated
   from the three libraries, and were assembled into 1142 contigs and 3026
   singletons. EST analysis was performed to compare gene expression in
   the three cDNA libraries. Ninety redundant unique transcripts
   responsive to NaCl treatment were identified. Of them, 21 genes were
   novel or of unknown function while others were involved in the
   functional activities, such as ROS scavenging, lipid metabolism,
   osmolyte biosynthesis, signal transduction, transport, lignin synthesis
   and homeostasis. The genes, including those for metallothionein-like
   protein, polyubiquitin, hypothetical protein, and glycine-rich cell
   wall structural protein, were abundant in the libraries and showed
   obvious up-regulation after NaCl treatments, suggesting important roles
   in NaCl tolerance. The results of this study may contribute to our
   understanding of the molecular mechanism of salt tolerance in the roots
   of plants. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Li, Huiyu; Wang, Yucheng; Jiang, Jing; Liu, Guifeng; Gao, Caiqiu; Yang, Chuanping] NE Forestry Univ, Minist Educ, Key Lab Forest Tree Genet Improvement & Biotechno, Harbin 150040, Peoples R China.
RP Yang, CP, NE Forestry Univ, Minist Educ, Key Lab Forest Tree Genet
   Improvement & Biotechno, Hexing Rd 26, Harbin 150040, Peoples R China.
EM yangchuanpingnefu@yahoo.com
FU National Natural Science Foundation of China [30571509]; Chinese
   Ministry of Education [107037]; Key Research Projects of Heilongjiang
   Province [GB06B303-1]
FX This work has been supported by the National Natural Science Foundation
   of China (No. 30571509), Key Project of Science-Technology Research
   granted by the Chinese Ministry of Education (No. 107037) and the Key
   Research Projects of Heilongjiang Province (GB06B303-1).
CR ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402
   BOHNERT HJ, 2001, PLANT PHYSIOL BIOCH, V39, P295
   CHOU WC, 2004, PHYSIOL PLANTARUM, V121, P50
   CREELMAN RA, 1997, ANNU REV PLANT PHYS, V48, P355
   GUEGUEN Y, 2003, GENE, V303, P139, DOI 10.1016/S0378-1119(02)01149-6
   HOUDE M, 2006, BMC GENOMICS, V13, P149
   HOUDE M, 2006, BMC GENOMICS, V13, P7
   HUANG XQ, 1999, GENOME RES, V9, P868
   ITURRIAGA G, 2006, PLANT SCI, V170, P1173, DOI
   10.1016/j.plantsci.2006.02.004
   JANICKARUSSAK M, 2007, J PLANT PHYSIOL, V164, P295, DOI
   10.1016/j.jplph.2006.01.014
   JIANG Y, 2006, BMC PLANT BIOL, V12, P6
   JIN H, 2006, PLANT SCI, V170, P1081, DOI 10.1016/j.plantsci.2006.01.002
   KOREEDA S, 2004, GENE, V341, P83, DOI 10.1016/j.gene.2004.06.037
   KRAMELL R, 2000, PLANT PHYSIOL, V123, P177
   LIVAK KJ, 2001, METHODS, V25, P402
   MEHTA PA, 2005, THEOR APPL GENET, V110, P416, DOI
   10.1007/s00122-004-1801-y
   MISHRA RN, 2007, PLANT MOL BIOL, V64, P713, DOI
   10.1007/s11103-007-9193-4
   NANJO T, 2004, PLANT CELL PHYSIOL, V45, P1738, DOI 10.1093/pcp/pci009
   OLIVER MJ, 2004, BMC GENOMICS, V5, ARTN 89
   RAUSELL A, 2003, PLANT J, V34, P257
   RENSINK W, 2005, GENOME, V48, P598, DOI 10.1139/G05-034
   SAMBROOK J, 1998, MOL CLONING LAB MANU, P27
   SANCHEZAGUAYO I, 2004, PLANTA, V220, P278, DOI 10.1007/s00425-004-1350-2
   SHIOZAKI N, 2005, THEOR APPL GENET, V110, P1177, DOI
   10.1007/s00122-005-1931-x
   SIBOLE JV, 2005, PLANTA, V221, P557, DOI 10.1007/s00425-004-1456-6
   SREENIVASULU N, 2007, GENE, V388, P1, DOI 10.1016/j.gene.2006.10.009
   TABUCHI T, 2005, PLANT CELL PHYSIOL, V46, P505, DOI 10.1093/pcp/pci050
   WANG ZI, 2004, PLANT SCI, V166, P609, DOI 10.1016/j.plantsci.2003.10.030
   WONG CE, 2005, PLANT MOL BIOL, V58, P561, DOI 10.1007/s11103-005-6163-6
NR 29
TC 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAR 15
PY 2009
VL 433
IS 1-2
BP 65
EP 71
DI 10.1016/j.gene.2008.12.007
PG 7
SC Genetics & Heredity
GA 421AX
UT ISI:000264331400009
ER

PT J
AU Hooper, AT
   Butler, JM
   Nolan, DJ
   Kranz, A
   Iida, K
   Kobayashi, M
   Kopp, HG
   Shido, K
   Petit, I
   Yanger, K
   James, D
   Witte, L
   Zhu, ZP
   Wu, Y
   Pytowski, B
   Rosenwaks, Z
   Mittal, V
   Sato, TN
   Rafii, S
AF Hooper, Andrea T.
   Butler, Jason M.
   Nolan, Daniel J.
   Kranz, Andrea
   Iida, Kaoruko
   Kobayashi, Mariko
   Kopp, Hans-Georg
   Shido, Koji
   Petit, Isabelle
   Yanger, Kilangsungla
   James, Daylon
   Witte, Larry
   Zhu, Zhenping
   Wu, Yan
   Pytowski, Bronislaw
   Rosenwaks, Zev
   Mittal, Vivek
   Sato, Thomas N.
   Rafii, Shahin
TI Engraftment and Reconstitution of Hematopoiesis Is Dependent on
   VEGFR2-Mediated Regeneration of Sinusoidal Endothelial Cells
SO CELL STEM CELL
LA English
DT Article
ID MARROW VASCULAR NICHE; STEM-CELLS; PROGENITOR CELLS; GROWTH-FACTOR;
   DIFFERENTIATION; IDENTIFICATION; ANGIOGENESIS; MOBILIZATION;
   QUIESCENCE; SURVIVAL
AB Myelosuppression damages the bone marrow (BM) vascular niche, but it is
   unclear how regeneration of bone marrow vessels contributes to
   engraftment of transplanted hematopoietic stem and progenitor cells
   (HSPCs) and restoration of hematopoiesis. We found that chemotherapy
   and sublethal irradiation induced minor regression of BM sinusoidal
   endothelial cells (SECs), while lethal irradiation induced severe
   regression of SECs and required BM transplantation (BMT) for
   regeneration. Within the BM, VEGFR2 expression specifically demarcated
   a continuous network of arterioles and SECs, with arterioles uniquely
   expressing Sca1 and SECs uniquely expressing VEGFR3. Conditional
   deletion of VEGFR2 in adult mice blocked regeneration of SECs in
   sublethally irradiated animals and prevented hematopoietic
   reconstitution. Similarly, inhibition of VEGFR2 signaling in lethally
   irradiated wild-type mice rescued with BMT severely impaired SEC
   reconstruction and prevented engraftment and reconstitution of HSPCs.
   Therefore, regeneration of SECs via VEGFR2 signaling is essential for
   engraftment of HSPCs and restoration of hematopoiesis.
C1 [Hooper, Andrea T.; Butler, Jason M.; Nolan, Daniel J.; Kobayashi, Mariko; Kopp, Hans-Georg; Shido, Koji; Petit, Isabelle; Yanger, Kilangsungla; James, Daylon; Rosenwaks, Zev; Rafii, Shahin] Weill Cornell Med Coll, Howard Hughes Med Inst, New York, NY 10065 USA.
   [Hooper, Andrea T.; Butler, Jason M.; Nolan, Daniel J.; Kobayashi, Mariko; Kopp, Hans-Georg; Shido, Koji; Petit, Isabelle; Yanger, Kilangsungla; James, Daylon; Rosenwaks, Zev; Rafii, Shahin] Weill Cornell Med Coll, Ansary Stem Cell Inst, New York, NY 10065 USA.
   [Hooper, Andrea T.; Butler, Jason M.; Nolan, Daniel J.; Kobayashi, Mariko; Kopp, Hans-Georg; Shido, Koji; Petit, Isabelle; Yanger, Kilangsungla; James, Daylon; Rosenwaks, Zev; Rafii, Shahin] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA.
   [Kranz, Andrea; Iida, Kaoruko; Sato, Thomas N.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY 10065 USA.
   [Witte, Larry; Zhu, Zhenping; Wu, Yan; Pytowski, Bronislaw] ImClone Syst Inc, New York, NY 10014 USA.
   [Mittal, Vivek] Weill Cornell Med Coll, Dept Surg, New York, NY 10065 USA.
   [Rosenwaks, Zev] Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY 10065 USA.
RP Rafii, S, Weill Cornell Med Coll, Howard Hughes Med Inst, New York, NY
   10065 USA.
EM srafii@med.cornell.edu
FU Howard Hughes Medical Institute ; Ansary Stem Cell Institute ; Deutsche
   Forschungsgerneinschaft [2154/2-1]
FX S.R. and T.N.S. are funded by NIH. S,R. is supported by Howard Hughes
   Medical Institute and Ansary Stem Cell Institute. A.K. was supported in
   part by Deutsche Forschungsgerneinschaft (KR 2154/2-1). We thank Mollie
   Goetz, Keith Kobylarz, and Allison Spencer for their excellent
   technical assistance.
CR ARAI F, 2004, CELL, V118, P149
   AVECILLA ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973
   CALVI LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   DACIC S, 2001, J BONE MINER RES, V16, P1228
   EMA M, 2006, BLOOD, V107, P111
   FONG GH, 1999, DEVELOPMENT, V126, P3015
   GERBER HP, 2002, NATURE, V417, P954
   HARUTA H, 2001, FEBS LETT, V507, P45
   HATTORI K, 2002, NAT MED, V8, P841
   HEISSIG B, 2002, CELL, V109, P625
   KATAOKA M, 1985, BLOOD, V65, P1163
   KIEL MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   KIEL MJ, 2006, IMMUNITY, V25, P862, DOI 10.1016/j.immuni.2006.11.003
   KOLLET O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   KOPP HG, 2005, BLOOD, V106, P505, DOI 10.1182/blood-2004-11-4269
   KOPP HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   KOPP HG, 2006, J CLIN INVEST, V116, P3277, DOI 10.1172/JCI29314
   LEE S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   LI XM, 2008, EXP HEMATOL, V36, P1143, DOI 10.1016/j.exphem.2008.06.009
   MOHLE R, 1997, P NATL ACAD SCI USA, V94, P663
   NAIYER AJ, 1999, BLOOD, V94, P4011
   PREWETT M, 1999, CANCER RES, V59, P5209
   PYTOWSKI B, 2005, J NATL CANCER I, V97, P14, DOI 10.1093/jnci/dji003
   RAFII S, 1994, BLOOD, V84, P10
   RAFII S, 1995, BLOOD, V86, P3353
   SAPOZNIKOV A, 2008, NAT IMMUNOL, V9, P388, DOI 10.1038/ni1571
   SHALABY F, 1995, NATURE, V376, P62
   SIPKINS DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   SLAYTON WB, 2007, STEM CELLS, V25, P2945, DOI
   10.1634/stemcells.2007-0158
   SUGIYAMA T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   TAKAKURA N, 2000, CELL, V102, P199
   TAMMELA T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   YOSHIHARA H, 2007, CELL STEM CELL, V1, P685, DOI
   10.1016/j.stem.2007.10.020
   ZHANG JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 34
TC 36
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAR 6
PY 2009
VL 4
IS 3
BP 263
EP 274
DI 10.1016/j.stem.2009.01.006
PG 12
SC Cell & Tissue Engineering; Cell Biology
GA 421OX
UT ISI:000264369300016
ER

PT J
AU Yang, YM
   Liu, M
   Gu, Y
   Lin, SY
   Ding, F
   Gu, XS
AF Yang, Yumin
   Liu, Mei
   Gu, Yun
   Lin, Sheyu
   Ding, Fei
   Gu, Xiaosong
TI Effect of chitooligosaccharide on neuronal differentiation of PC-12
   cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Chitosan; Chitooligosaccharide; Nerve cell affinity; Neuronal
   differentiation; PC-12 cells
ID NERVE REGENERATION; IN-VITRO; NEUROFILAMENTS; EXPRESSION; VIVO
AB Chitosan is now being widely used biomaterial in the tissue engineering
   field, and has great potential as a candidate material for preparing
   nerve guidance conduits due to its various favorable properties,
   especially that of good nerve cell affinity. Chitosan can be degraded
   in vivo into chitooligosaccharide. We have investigated the in vitro
   effects of chitooligosaccharide on neuronal differentiation of PC-12
   cells to see what effects chitooligosaccharide have on certain
   functions in the regenerating neurons. The morphologic observation and
   assessment using the specific reagent of tetrazolium salt WST-8
   indicated that neurite outgrowths from PC-12 cells and the viability of
   PC-12 cells were enhanced by treatment of chitooligosaccharide. The
   real-time quantitative RT-PCR and Western blot analysis revealed showed
   that chitooligosaccharide could upregulate the expression of
   neurofilament-H mRNA or protein and N-cadherin protein in PC-12 cells.
   The maximum effect of 0.1 mg/ml chitooligosaccharide was obtained after
   2 week culture. All the data suggest that chitooligosaccharide
   possesses good nerve cell affinity by supporting nerve cell adhesion
   and promoting neuronal differentiation and neurite outgrowth. (C) 2009
   International Federation for Cell Biology. Published by Elsevier Ltd.
   All rights reserved.
C1 [Yang, Yumin; Liu, Mei; Gu, Yun; Lin, Sheyu; Ding, Fei; Gu, Xiaosong] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China.
RP Gu, XS, Nantong Univ, Jiangsu Key Lab Neuroregenerat, 19 Qixiu Rd,
   Nantong 226001, Jiangsu, Peoples R China.
EM neurongu@public.nt.js.cn
FU Hi-Tech Research and Development Program of China [2006AA02A128];
   Nature Science Foundation of china [30770585]; Basic Research Program
   of Jiangsu Education Department [07KJA31025]; Program for New Century
   Excellent Talents in University 
FX The financial supports of the Hi-Tech Research and Development Program
   of China ( 863 Program, Grant no. 2006AA02A128), the Nature Science
   Foundation of china ( Grant no. 30770585), Basic Research Program of
   Jiangsu Education Department ( Grant no. 07KJA31025) and Program for
   New Century Excellent Talents in University are gratefully acknowledged.
CR BINI TB, 2005, J MATER SCI-MATER M, V16, P367, DOI
   10.1007/s10856-005-0637-6
   BIXBY JL, 1990, J CELL BIOL, V110, P1253
   CHRISTINA A, 2006, J CELLULAR MOL MED, V10, P770
   FREIER T, 2005, BIOMATERIALS, V26, P5872, DOI
   10.1016/j.biomaterials.2005.02.033
   GIANLUCA C, 2006, MACROMOLECULAR BIOSC, V6, P13
   GONG HP, 2000, J BIOMED MATER RES, V52, P285
   GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424
   HUANG R, 2006, LIFE SCI, V78, P2399, DOI 10.1016/j.lfs.2005.09.039
   ISAMU Y, 2003, BIOMATERIALS, V24, P3285
   JACOMY H, 1999, J NEUROCHEM, V73, P972
   JIA ZS, 2002, CARBOHYD POLYM, V49, P393
   JULIEN JP, 1998, PROG NUCLEIC ACID RE, V61, P1
   JUNG WK, 2006, LIFE SCI, V78, P970, DOI 10.1016/j.lfs.2005.06.006
   LEE MK, 1993, J CELL BIOL, V122, P1337
   LIU M, 2006, J MOL NEUROSCI, V29, P123, DOI 10.1385/JMN/29:02:123
   MENDIS E, 2007, LIFE SCI, V80, P2118, DOI 10.1016/j.lfs.2007.03.016
   OHARA N, 2004, BIOMATERIALS, V25, P1749, DOI
   10.1016/j.biomaterials.2003.08.022
   SHAO J, 2003, POLYM DEGRADATION ST, V82, P393
   SUZUKI S, 1992, ADV CHITIN CHITOSAN, P277
   WANG XD, 2005, BRAIN 8, V128, P1897, DOI 10.1093/brain/awh517
   YANG YM, 2004, BIOTECHNOL LETT, V26, P1793
   YANG YM, 2006, EUR FOOD RES TECHNOL, V222, P36, DOI
   10.1007/s00217-005-0028-8
   YANNAS IV, 2004, BIOMATERIALS, V25, P1593, DOI
   10.1016/S0142-9612(03)00505-2
   YUAN Y, 2004, BIOMATERIALS, V25, P4273, DOI
   10.1016/j.biomaterials.2003.11.029
   ZHENG F, 2007, LIFE SCI, V80, P388, DOI 10.1016/j.lfs.2006.09.040
NR 25
TC 6
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD MAR
PY 2009
VL 33
IS 3
BP 352
EP 356
DI 10.1016/j.cellbi.2009.01.005
PG 5
SC Cell Biology
GA 414UH
UT ISI:000263890200012
ER

PT J
AU Mancino, M
   Esposito, C
   Watanabe, K
   Nagaoka, T
   Gonzales, M
   Bianco, C
   Normanno, N
   Salomon, DS
   Strizzi, L
AF Mancino, Mario
   Esposito, Claudia
   Watanabe, Kazuhide
   Nagaoka, Tadahiro
   Gonzales, Monica
   Bianco, Caterina
   Normanno, Nicola
   Salomon, David S.
   Strizzi, Luigi
TI Neuronal Guidance Protein Netrin-1 Induces Differentiation in Human
   Embryonal Carcinoma Cells
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY-GLAND; SELF-RENEWAL; STEM-CELLS; TERATOCARCINOMA; EXPRESSION;
   CRIPTO-1; FAMILY; MORPHOGENESIS; GROWTH; TUMORS
AB Pluripotent cells within embryonal carcinoma (EC) can differentiate in
   vivo or in vitro on treatment with specific agents. Differentiating EC
   cells express lower levels of stem cell-related genes, such as
   Cripto-1. We show that migration of human EC cells (NTERA/2 and NCCIT)
   can be reduced following treatment with the guidance molecule Netrin-1.
   Moreover, Netrin-1 treatment increased the levels of beta-III tubulin,
   glial filament acidic protein, Nestin, and gamma-ammobutyric acid and
   reduced the expressions of Cripto-1, Nanog, and Oct4 in EC cells. These
   Netrin-l-induced effects in the EC cells were mediated via binding of
   Netrin-l to the Neogemn receptor and activation of SHP-2, resulting in
   increased levels of inactive phosphorylated c-sre((Y527)). These
   results suggest that Netrin-1 can induce neuroectodermal-like
   differentiation of human EC cells by affecting c-src signaling via
   SHP-2 activation and regulation of Nanog, Oct4, and Cripto-1
   expressions. [Cancer Res 2009;69(5):1717-21]
C1 [Mancino, Mario; Watanabe, Kazuhide; Nagaoka, Tadahiro; Gonzales, Monica; Bianco, Caterina; Salomon, David S.; Strizzi, Luigi] NCI, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA.
   [Esposito, Claudia; Normanno, Nicola] CROM Ist Nazl Tumori Pascale Napoli, Mercogliano, AV, Italy.
   [Normanno, Nicola] Ist Nazl Tumori Fdn Pascale, Cell Biol & Proclin Models Unit, Naples, Italy.
RP Mancino, M, NCI, Mammary Biol & Tumorigenesis Lab, 37 Convent Dr,Room
   1112, Bethesda, MD 20892 USA.
EM mario.mancino@cro-m.eu
CR ANDREWS PW, 1986, DIFFERENTIATION, V31, P119
   ANNEREN C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200
   ASSOU S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352
   BALDASSARRE G, 1997, ONCOGENE, V15, P927
   BARALLOBRE MJ, 2005, BRAIN RES REV, V49, P22, DOI
   10.1016/j.brainresrev.2004.11.003
   CLARK AT, 2004, STEM CELLS, V22, P169
   COLE SJ, 2007, INT J BIOCHEM CELL B, V39, P1569, DOI
   10.1016/j.biocel.2006.11.009
   FENG GS, 2007, CELL RES, V17, P37, DOI 10.1038/sj.cr.7310140
   ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549
   LOH YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   LOOIJENGA LHJ, 2003, CANCER RES, V63, P2244
   MANCINO M, 2008, J CELL PHYSIOL, V215, P192, DOI 10.1002/jcp.21301
   NEEL BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI
   10.1016/S0968-0004(03)00091-4
   NIKOLOPOULOS SN, 2005, CELL CYCLE, V4, E131
   ROUND J, 2007, CURR OPIN NEUROBIOL, V17, P15, DOI
   10.1016/j.conb.2007.01.003
   SRINIVASAN K, 2003, DEV CELL, V4, P371
   STRIZZI L, 2005, J CELL SCI, V118, P4633, DOI 10.1242/jcs.02574
   STRIZZI L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918
   STRIZZI L, 2008, J CELL PHYSIOL, V216, P824, DOI 10.1002/jcp.21462
   TONG JF, 2001, J BIOL CHEM, V276, P40917
NR 20
TC 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2009
VL 69
IS 5
BP 1717
EP 1721
DI 10.1158/0008-5472.CAN-08-2985
PG 5
SC Oncology
GA 415ML
UT ISI:000263937800005
ER

PT J
AU Hung, CY
   Chen, YL
   Chen, CS
   Yang, CS
   Peng, SJ
AF Hung, Chung-Ying
   Chen, Yung-Liang
   Chen, Chiou-Shya
   Yang, Chwei-Shiun
   Peng, Sheng-Jeng
TI Association of Leptin with Hemodialysis-Related Muscle Cramps: A
   Cross-Sectional Study
SO BLOOD PURIFICATION
LA English
DT Article
DE Cramps; Hemodialysis; Leptin; Neuronal activity
ID CENTRAL-NERVOUS-SYSTEM; STAGE RENAL-DISEASE; PLASMA LEPTIN; SERUM
   LEPTIN; FOOD-INTAKE; OB RNA; EXPRESSION; OBESE; GENE; HEMODIAFILTRATION
AB Background/Aims: The mechanism of muscle cramp in hemodialysis patients
   is not well understood. Leptin, a middle molecule uremic toxin, is able
   to affect neuronal activity. This study aimed to determine the
   association between leptin and hemodialysis-related muscle cramps.
   Methods: A total of 79 hemodialysis patients were enrolled. The
   episodes of hemodialysis-related muscle cramps were recorded over a
   28-day period. Serum levels of leptin were measured on the 15th day, a
   mid-week dialysis session. Results: Frequent hemodialysis-related
   cramps were associated with old age and elevated serum leptin levels.
   The risk of frequent hemodialysis-related cramps increased with
   increasing tertiles of leptin concentration. This relationship remained
   significant after adjustment for age, mean ultrafiltration ratio,
   gender, body mass index, insulin, resistin, c-reactive protein,
   albumin, peripheral arterial disease, electrolytes, and
   beta(2)-microglobulin. Conclusion: Leptin levels are associated with
   frequent hemodialysis-related cramps. Further studies are necessary to
   elucidate the underlying mechanisms. Copyright (C) 2009 S. Karger AG,
   Basel
C1 [Yang, Chwei-Shiun; Peng, Sheng-Jeng] Cathay Gen Hosp, Dept Internal Med, Div Nephrol, Taipei 106, Taiwan.
   [Hung, Chung-Ying] Cathay Gen Hosp, Hsinchu Branch, Div Nephrol, Hsinchu, Taiwan.
   [Chen, Chiou-Shya] Cathay Gen Hosp, Hsinchu Branch, Dept Lab Med, Hsinchu, Taiwan.
   [Chen, Chiou-Shya] Yuanpei Univ Sci & Technol, Dept Med Technol, Hsinchu, Taiwan.
   [Hung, Chung-Ying] Fu Jen Catholic Univ, Coll Med, Sch Med, Taipei, Taiwan.
RP Peng, SJ, Cathay Gen Hosp, Dept Internal Med, Div Nephrol, 280,Sect
   4,Ren Ai Rd, Taipei 106, Taiwan.
EM kennethpeng@cgh.org.tw
FU Cathay General Hospital [CMRI9506]
FX This study was supported by Cathay General Hospital grant CMRI9506. We
   would like to acknowledge the assistance of Hisahide Hiura of Japan
   Clinical Laboratories, Inc., who kindly supplied the anti-leptin
   antibodies 14C9 and 3D10. We also thank Chyi-Huey Bai, PhD, of the
   Central Laboratory, Shin Kong WHS Memorial Hospital, Taipei, Taiwan,
   for statistical advice. Furthermore, we express our appreciation to Dr.
   Simon J. T. Mao of National Chiao Tung University, Hsinchu, Taiwan, for
   important suggestions in preparing the manuscript.
CR ABDULLA AJJ, 1999, INT J CLIN PRACT, V53, P494
   ALQUIST M, 1999, INT J ARTIF ORGANS, V22, P811
   ALTIERI P, 2001, NEPHROL DIAL TRANSPL, V16, P1207
   BJORBAEK C, 2004, RECENT PROG HORM RES, V59, P305
   CANZANELLO VJ, 1991, ASAIO T, V37, P649
   CHEUNG W, 2005, J CLIN INVEST, V115, P1659, DOI 10.1172/JCI22521
   CONSIDINE RV, 1996, NEW ENGL J MED, V334, P292
   DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
   DUNBAR JC, 1999, BRAIN RES BULL, V50, P215
   HICKEY MS, 1996, BIOCHEM MOL MED, V59, P1
   HORN R, 1996, EXP CLIN ENDOCR DIAB, V104, P454
   JENKINS PG, 1975, T AM SOC ART INT ORG, V21, P479
   JOCHEM J, 2004, J PHYSIOL PHARMACO 1, V55, P57
   KERR PB, 1992, KIDNEY INT, V41, P1035
   KIMURA E, 2000, CLIN CHIM ACTA, V296, P45
   LEROY P, 1996, J BIOL CHEM, V271, P2365
   MAFFEI M, 1995, NAT MED, V1, P1155
   MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957
   MERABET E, 1997, J CLIN ENDOCR METAB, V82, P847
   MILLER TM, 2005, MUSCLE NERVE, V32, P431, DOI 10.1002/mus.20341
   MILUTINOVICH J, 1979, ANN INTERN MED, V90, P926
   NAYLOR JR, 1994, AGE AGEING, V23, P418
   NORDFORS L, 1998, KIDNEY INT, V54, P1267
   ROUX M, 1976, EXPERIENTIA, V32, P657
   SCHWARTZ MW, 1996, J CLIN INVEST, V98, P1101
   SCHWARTZ MW, 2000, NATURE, V404, P661
   SHA L, 1999, NEUROSCI LETT, V263, P93
   SHANLEY LJ, 2001, J NEUROSCI, V21, ARTN RC186
   SHARMA K, 1998, KIDNEY INT, V53, P1483
   STEWART WK, 1972, LANCET, V1, P1049
   TAKENAKA T, 2001, BLOOD PURIFICAT, V19, P10
   TARTAGLIA LA, 1995, CELL, V83, P1263
   WANG Q, 1997, DIABETES, V46, P335
   WAYNER MJ, 2004, PEPTIDES, V25, P991, DOI 10.1016/j.peptides.2004.03.018
   WIDJAJA A, 2000, NEPHROL DIAL TRANSPL, V15, P846
   ZHANG YY, 1994, NATURE, V372, P425
NR 36
TC 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
J9 BLOOD PURIFICAT
JI Blood Purif.
PY 2009
VL 27
IS 2
BP 159
EP 164
DI 10.1159/000190781
PG 6
SC Hematology; Urology & Nephrology
GA 415DM
UT ISI:000263914500001
ER

PT J
AU Quigley, M
   Martinez, J
   Huang, XP
   Yang, YP
AF Quigley, Michael
   Martinez, Jennifer
   Huang, Xiaopei
   Yang, Yiping
TI A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal
   expansion and memory formation following vaccinia viral infection
SO BLOOD
LA English
DT Article
ID FORKHEAD TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTORS; KAPPA-B ACTIVATION;
   PROTEIN-KINASE AKT; CUTTING EDGE; INNATE IMMUNITY; IFN-GAMMA; IN-VIVO;
   SURVIVAL; EXPRESSION
AB Recent advances have suggested a crucial role of the innate immunity in
   shaping adaptive immune responses. How activation of innate immunity
   promotes adaptive T-cell responses to pathogens in vivo is not fully
   understood. It has been thought that Toll-like receptor (TLR)-mediated
   control of adaptive T-cell responses is mainly achieved by the
   engagement of TLRs on antigen-presenting cells to promote their
   maturation and function. In this study, we showed that direct
   TLR2-myeloid differentiating factor 88 (MyD88) signaling in CD8 T cells
   was also required for their efficient clonal expansion by promoting the
   survival of activated T cells on vaccinia viral infection in vivo.
   Effector CD8 T cells that lacked direct TLR2-MyD88 signaling did not
   survive the contraction phase to differentiate into long-lived memory
   cells. Furthermore, we observed that direct TLR2 ligation on CD8 T
   cells promoted CD8 T-cell proliferation and survival in vitro in a
   manner dependent on the phosphatidylinositol 3-kinase (PI3K)-Akt
   pathway activation and that activation of Akt controlled memory cell
   formation in vivo. These results identify a critical role for intrinsic
   TLR2-MyD88 signaling and PI3K-Akt pathway activation in CD8 T-cell
   clonal expansion and memory formation in vivo and could lead to the
   development of new vaccine approaches. (Blood. 2009; 113: 2256-2264)
C1 [Quigley, Michael; Martinez, Jennifer; Huang, Xiaopei; Yang, Yiping] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Quigley, Michael; Martinez, Jennifer; Huang, Xiaopei; Yang, Yiping] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.
RP Yang, YP, Duke Univ, Med Ctr, Dept Med, Box 103005, Durham, NC 27710
   USA.
EM yang0029@mc.duke.edu
FU National Institutes of Health [CA111807, CA047741]; Alliance for Cancer
   Gene Therapy 
FX We thank S. Akira for providing MyD88<SUP>-/-</SUP> and
   TLR2<SUP>-/-</SUP> mice and Z. Songyang for providing the pMSCV and
   pMSCV-dnAkt constructs.
   This work was supported by the National Institutes of Health (grants
   CA111807 and CA047741) and a grant from the Alliance for Cancer Gene
   Therapy (Y.Y.).
CR ADACHI O, 1998, IMMUNITY, V9, P143
   AKIRA S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   AKIRA S, 2006, CELL, V124, P783
   BADOVINAC VP, 2002, NAT IMMUNOL, V3, P619
   BADOVINAC VP, 2007, IMMUNITY, V26, P827
   BENDIGS S, 1999, EUR J IMMUNOL, V29, P1209
   BEVAN MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   BLANDER JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596
   BRUNET A, 1999, CELL, V96, P857
   BUSCH DH, 1998, IMMUNITY, V8, P353
   CARON G, 2005, J IMMUNOL, V175, P1551
   CHANDELE A, 2005, J IMMUNOL, V175, P5619
   COTTALORDA A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181
   COUDRONNIERE N, 2000, P NATL ACAD SCI USA, V97, P3394
   DELPESO L, 1997, SCIENCE, V278, P687
   DUDEK H, 1997, SCIENCE, V275, P661
   GELMAN AE, 2004, J IMMUNOL, V172, P6065
   GELMAN AE, 2006, IMMUNITY, V25, P783, DOI 10.1016/j.immuni.2006.08.023
   IWASAKI A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   JONES RG, 2000, J EXP MED, V191, P1721
   KAECH SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   KAECH SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   KANE LP, 2001, NAT IMMUNOL, V2, P37
   KANE LP, 2003, IMMUNOL REV, V192, P7
   KLONOWSKI KD, 2006, J IMMUNOL, V177, P4247
   KOLUMAM GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   KOONPAEW S, 2006, J EXP MED, V203, P119
   LACOMBE MH, 2005, J IMMUNOL, V175, P4400
   MADAKAMUTIL LT, 2004, SCIENCE, V304, P590
   MARZO AL, 2005, NAT IMMUNOL, V6, P793, DOI 10.1038/ni1227
   MEDVEDEV AE, 2002, J IMMUNOL, V169, P5209
   MORGAN DJ, 1996, J IMMUNOL, V157, P978
   NOMURA F, 2000, J IMMUNOL, V164, P3476
   NOVY P, 2007, J IMMUNOL, V179, P8243
   PAP M, 1998, J BIOL CHEM, V273, P19929
   PASARE C, 2004, IMMUNITY, V21, P733
   QUIGLEY M, 2007, J IMMUNOL, V179, P5768
   QUIGLEY M, 2008, J IMMUNOL, V180, P2158
   SCHNARE M, 2001, NAT IMMUNOL, V2, P947
   SONG JX, 2004, NAT IMMUNOL, V5, P150, DOI 10.1038/ni1030
   SONGYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345
   SPORRI R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162
   STAHL M, 2002, J IMMUNOL, V168, P5024
   TSCHARKE DC, 2006, J VIROL, V80, P6318, DOI 10.1128/JVI.00427-06
   TUTTLE RL, 2001, NAT MED, V7, P1133
   VANPARIJS L, 1999, IMMUNITY, V11, P281
   YANG YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059
   YAROVINSKY F, 2006, IMMUNITY, V25, P655, DOI
   10.1016/j.immuni.2006.07.015
   YUSUF I, 2004, BLOOD, V104, P784
   ZAREMBER KA, 2002, J IMMUNOL, V168, P554
   ZHU JG, 2007, BLOOD, V109, P619, DOI 10.1182/blood-2006-06-027136
NR 51
TC 19
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 5
PY 2009
VL 113
IS 10
BP 2256
EP 2264
DI 10.1182/blood-2008-03-148809
PG 9
SC Hematology
GA 415EZ
UT ISI:000263918400018
ER

PT J
AU O'Shea, D
   O'Riain, C
   Gupta, M
   Waters, R
   Yang, Y
   Wrench, D
   Gribben, J
   Rosenwald, A
   Ott, G
   Rimsza, LM
   Holte, H
   Cazier, JB
   Johnson, NA
   Campo, E
   Chan, WC
   Gascoyne, RD
   Young, BD
   Staudt, LM
   Lister, TA
   Fitzgibbon, J
AF O'Shea, Derville
   O'Riain, Ciaran
   Gupta, Manu
   Waters, Rachel
   Yang, Youwen
   Wrench, David
   Gribben, John
   Rosenwald, Andreas
   Ott, German
   Rimsza, Lisa M.
   Holte, Harald
   Cazier, Jean-Baptiste
   Johnson, Nathalie A.
   Campo, Elias
   Chan, Wing C.
   Gascoyne, Randy D.
   Young, Bryan D.
   Staudt, Louis M.
   Lister, T. Andrew
   Fitzgibbon, Jude
TI Regions of acquired uniparental disomy at diagnosis of follicular
   lymphoma are associated with both overall survival and risk of
   transformation
SO BLOOD
LA English
DT Article
ID GENE-EXPRESSION; COPY NUMBER; REVEALS; EVOLUTION; CELLS; ARRAY
AB Acquired homozygosity in the form of segmental acquired uniparental
   disomy (aUPD) has been described in follicular lymphoma (FL) and is
   usually due to mitotic recombination. SNP array analysis was performed
   with the use of the Affymetrix 10K 2.0 Gene-chip array on DNA from 185
   diagnostic FL patients to assess the prognostic relevance of aUPD.
   Genetic abnormalities were detected in 118 (65%) of 182 patients.
   Number of abnormalities was predictive of outcome; more than 3
   abnormalities was associated with inferior overall survival (OS; P <
   .03). Sites of recurrent aUPD were detected on 6p (n = 25), 16p (n =
   22), 12q (n = 17), 1p36 (n = 14), 10q (n = 8), and 6q (n = 8). On
   multivariate analysis aUPD on 1p36 correlated with shorter OS (P =
   .05). aUPD on 16p was predictive of transformation (P = .03) and
   correlated with poorer progression-free survival (P = .02). aUPD is
   frequent at diagnosis of FL and affects probability of disease
   transformation and clinical outcome. (Blood. 2009; 113: 2298-2301)
C1 [O'Shea, Derville; O'Riain, Ciaran; Gupta, Manu; Yang, Youwen; Wrench, David; Gribben, John; Cazier, Jean-Baptiste; Gascoyne, Randy D.; Young, Bryan D.; Lister, T. Andrew; Fitzgibbon, Jude] Barts & London Queen Marys Sch Med & Dent, Ctr Med Oncol, London EC1M 6BQ, England.
   [Waters, Rachel] Univ Oxford, Ctr Stat Med, Oxford, England.
   [Rosenwald, Andreas; Ott, German] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany.
   [Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany.
   [Rimsza, Lisa M.] Univ Arizona, Dept Pathol, Tucson, AZ USA.
   [Rimsza, Lisa M.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
   [Holte, Harald] Univ Oslo, Rikshosp, Norwegian Radium Hosp, Canc Clin,Dept Oncol, N-0027 Oslo, Norway.
   [Cazier, Jean-Baptiste] Canc Res UK, Bioinformat & Biostat, London, England.
   [Johnson, Nathalie A.] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, Canada.
   [Johnson, Nathalie A.] British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada.
   [Campo, Elias] Univ Barcelona, IDIBAPS, Dept Pathol, Barcelona, Spain.
   [Campo, Elias] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain.
   [Chan, Wing C.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
   [Staudt, Louis M.] NCI, NIH, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
RP O'Shea, D, Barts & London Queen Marys Sch Med & Dent, Ctr Med Oncol,
   London EC1M 6BQ, England.
EM derville.oshea@cancer.org.uk
FU Cancer Research UK ; Medical Research Council ; National Institutes of
   Health [5UO1CA114778]
FX This work was supported by grants from Cancer Research UK, the Medical
   Research Council, and the National Institutes of Health (SPEC grant
   5UO1CA114778). D.O. is supported by a Medical Research Council Clinical
   Research Fellow grant. C.O. is a Cancer Research UK Barts-Cambridge
   Molecular Pathology Clinical Research Fellow.
CR BASTION Y, 1997, J CLIN ONCOL, V15, P1587
   CHEUNG KJJ, 2009, BLOOD, V113, P137, DOI 10.1182/blood-2008-02-140616
   DAVE SS, 2004, NEW ENGL J MED, V351, P2159
   FISHER RI, 2005, J CLIN ONCOL, V23, P8447, DOI 10.1200/JCO.2005.03.1674
   FITZGIBBON J, 2007, LEUKEMIA, V21, P1514, DOI 10.1038/sj.leu.2404696
   GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470
   GONDEK LP, 2008, BLOOD, V111, P1534, DOI 10.1182/blood-2007-05-092304
   GUPTA M, 2008, GENES CHROMOSOMES CA
   HOGLUND M, 2004, GENE CHROMOSOME CANC, V39, P195, DOI 10.1002/gcc.10314
   HORSMAN DE, 2001, GENE CHROMOSOME CANC, V30, P375
   KEMP Z, 2006, HUM MOL GENET, V15, P2903, DOI 10.1093/hmg/ddl231
   LIU Q, 2006, J CLIN ONCOL, V24, P1582, DOI 10.1200/JCO.2005.03.3696
   MATSUZAKI H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904
   MILANI L, 2007, NUCLEIC ACIDS RES, V35, ARTN E34
   MONTOTO S, 2007, J CLIN ONCOL, V25, P2426, DOI 10.1200/JCO.2006.09.3260
   NERI A, 1996, LEUKEMIA LYMPHOMA, V23, P43
   OKEEFE CL, 2006, BLOOD, V108
   RAGHAVAN M, 2005, CANCER RES, V65, P375
   ROSS CW, 2007, CLIN CANCER RES, V13, P4777, DOI
   10.1158/1078-0432.CCR-07-0456
   SCHWAENEN C, 2009, GENE CHROMOSOME CANC, V48, P39, DOI 10.1002/gcc.20617
   TILLY H, 1994, BLOOD, V84, P1043
   VIARDOT A, 2002, J CLIN ONCOL, V20, P4523, DOI 10.1200/JCO.2002.12.006
   VIARDOT A, 2003, SEMIN CANCER BIOL, V13, P183, DOI
   10.1016/S1044-579X(03)00014-2
   WALKER BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood-2006-02-005496
NR 24
TC 20
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 5
PY 2009
VL 113
IS 10
BP 2298
EP 2301
DI 10.1182/blood-2008-08-174953
PG 4
SC Hematology
GA 415EZ
UT ISI:000263918400023
ER

PT J
AU Li, Y
   Chen, S
   Yuan, J
   Yang, YZ
   Li, JL
   Ma, J
   Wu, XH
   Freund, M
   Pollok, K
   Hanenberg, H
   Goebel, WS
   Yang, FC
AF Li, Yan
   Chen, Shi
   Yuan, Jin
   Yang, Yanzhu
   Li, Jingling
   Ma, Jin
   Wu, Xiaohua
   Freund, Marcel
   Pollok, Karen
   Hanenberg, Helmut
   Goebel, W. Scott
   Yang, Feng-Chun
TI Mesenchymal stem/progenitor cells promote the reconstitution of
   exogenous hematopoietic stem cells in Fancg(-/-) mice in vivo
SO BLOOD
LA English
DT Article
ID INDUCED APOPTOTIC RESPONSES; ACUTE MYELOID-LEUKEMIA; WILD-TYPE CELLS;
   FANCONI-ANEMIA; BONE-MARROW; PROGENITOR CELLS; STROMAL CELLS;
   OSTEOGENESIS IMPERFECTA; REPOPULATING ABILITY; ENHANCES ENGRAFTMENT
AB Fanconi anemia (FA) is a heterogeneous genetic disorder characterized
   by bone marrow failure and complex congenital anomalies. Although
   mutations in FA genes result in a characteristic phenotype in the
   hematopoietic stem/progenitor cells (HSPCs), little is known about the
   consequences of a nonfunctional FA pathway in other stem/progenitor
   cell compartments. Given the intense functional interactions between
   HSPCs and the mesenchymal microenvironment, we investigated the FA
   pathway on the cellular functions of murine mesenchymal stem/progenitor
   cells (MSPCs) and their interactions with HSPCs in vitro and in vivo.
   Here, we show that loss of the murine homologue of FANCG (Fancg)
   results in a defect in MSPC proliferation and in their ability to
   support the adhesion and engraftment of murine syngeneic HSPCs in vitro
   or in vivo. Transplantation of wild-type (WT) but not Fancg(-/-) MSPCs
   into the tibiae of Fancg(-/-) recipient mice enhances the HSPC
   engraftment kinetics, the BM cellularity, and the number of progenitors
   per tibia of WT HSPCs injected into lethally irradiated Fancg(-/-)
   recipients. Collectively, these data show that FA proteins are required
   in the BM microenvironment to maintain normal hematopoiesis and provide
   genetic and quantitative evidence that adoptive transfer of WT MSPCs
   enhances hematopoietic stem cell engraftment. (Blood. 2009; 113:
   2342-2351)
C1 [Yang, Feng-Chun] Indiana Univ, Sch Med, Canc Res Inst, Dept Pediat, Indianapolis, IN 46202 USA.
   [Li, Yan; Chen, Shi; Yuan, Jin; Yang, Yanzhu; Li, Jingling; Wu, Xiaohua; Pollok, Karen; Hanenberg, Helmut; Goebel, W. Scott; Yang, Feng-Chun] Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Ma, Jin; Freund, Marcel; Hanenberg, Helmut] Univ Dusseldorf, Childrens Hosp, Dept Pediat Oncol Hematol & Clin Immunol, D-4000 Dusseldorf, Germany.
   [Yang, Feng-Chun] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
RP Yang, FC, Indiana Univ, Sch Med, Canc Res Inst, Dept Pediat, 1044 W
   Walnut St,R4-427, Indianapolis, IN 46202 USA.
EM fyang@iupui.edu
FU Simmons Clinical Studies Fund (Indiana University, Indianapolis, IN) ;
   Department of Defense [NF073112]; March of Dimes [6-FY08-246]; National
   Institutes of Health, (Bethesda, MD) ; Showalter Trust Award (Indiana
   University, Indianapolis, IN) ; Deutsche Forschungsgemeinschaft (Bonn,
   Germany) [K08 HL075253, DFG SPP1230 HA2322/2-1, PPG-P01-HL533586]
FX This work was supported by the Simmons Clinical Studies Fund (Indiana
   University, Indianapolis, IN; F.-C.Y.), the Department of Defense
   (NF073112; F.-C.Y.), the March of Dimes (6-FY08-246; F.-C.Y.), National
   Institutes of Health, (Bethesda, MD), the Showalter Trust Award
   (Indiana University, Indianapolis, IN; W. S. G.), and Deutsche
   Forschungsgemeinschaft (Bonn, Germany; K08 HL075253; W. S. G.; DFG
   SPP1230 HA2322/2-1; H. H.; and PPG-P01-HL533586; H. H. and K. P.).
CR ARAI F, 2005, INT J HEMATOL, V82, P371, DOI 10.1532//IJH97.05100
   AUERBACH AD, 1982, AM J HEMATOL, V12, P289
   AUERBACH AD, 2002, GENETIC BASIS HUMAN, P289
   BADILLO AT, 2006, STEM CELL REV, V2, P241
   BAGBY GC, 1993, EXP HEMATOL, V21, P1419
   BAGBY GC, 2006, SEMIN HEMATOL, V43, P147, DOI
   10.1053/j.seminhematol.2006.04.005
   BENSIDHOUM M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121
   CALVI LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   DAZZI F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   DICK JE, 1985, CELL, V42, P71
   DILLOO D, 1995, PEDIATR RES, V38, P716
   DING W, 2001, J CELL SCI, V114, P1011
   GREENBERG BR, 1981, BRIT J HAEMATOL, V48, P85
   GUPTA V, 1987, EXP HEMATOL, V15, P1153
   HANELINE LS, 1998, BLOOD, V91, P4092
   HANELINE LS, 1999, BLOOD, V94, P1
   HANELINE LS, 2003, BLOOD, V101, P1299
   HANENBERG H, 2002, EXP HEMATOL, V30, P410
   HO AD, 2007, CURR OPIN HEMATOL, V14, P330
   HONCZARENKO M, 2006, STEM CELLS, V24, P1030, DOI
   10.1634/stemcells.2005-0319
   HORWITZ EM, 2002, P NATL ACAD SCI USA, V99, P8932
   ISSAAD C, 1993, BLOOD, V81, P2916
   KASSEM M, 2004, BASIC CLIN PHARMACOL, V95, P209
   KASSEM M, 2004, CLONING STEM CELLS, V6, P369
   KELLY PF, 2007, MOL THER, V15, P211, DOI 10.1038/sj.mt.6300033
   KIEL MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   KOC ON, 2000, J CLIN ONCOL, V18, P307
   KOOK H, 2005, HEMATOLOGY S1, V10, P108, DOI 10.1080/10245330512331390096
   KRAUSE DS, 2002, GENE THER, V9, P754
   KUNG SKP, 2000, J VIROL, V74, P3668
   KUTLER DI, 2003, BLOOD, V101, P1249
   LEE HS, 2003, STEM CELLS, V21, P190
   LEMISCHKA IR, 1986, CELL, V45, P917
   LEURS C, 2003, HUM GENE THER, V14, P509
   LI XX, 2003, BLOOD, V102, P2081
   LI XX, 2004, BLOOD, V104, P1204, DOI 10.1182/blood-2004-03-1094
   LI ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI
   10.1016/j.tibs.2006.08.001
   LIU JM, 1999, HUM GENE THER, V10, P2337
   MATHEW CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878
   MEIRELLES LD, 2003, BRIT J HAEMATOL, V123, P702
   MICHALOGLOU C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   MUGURUMA Y, 2006, BLOOD, V107, P1878, DOI 10.1182/blood-2005-06-2211
   NARDI NB, 2006, HDB EXP PHARM, V174, P249
   NOORT WA, 2002, EXP HEMATOL, V30, P870
   PAPAYANNOPOULOU T, 2001, BLOOD, V98, P2403
   PLOEMACHER RE, 1989, BLOOD, V74, P2755
   PROCKOP DJ, 2004, NEW ENGL J MED, V350, P2302
   RAAIJMAKERS MHGP, 2008, CURR OPIN HEMATOL, V15, P301
   RATHBUN RK, 1997, BLOOD, V90, P974
   RATHBUN RK, 2000, BLOOD, V96, P4204
   SACCHETTI B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   SCADDEN DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   SCOTT LM, 2003, MOL CELL BIOL, V23, P9349, DOI
   10.1128/MCB.23.24.9349-9360.2003
   SI Y, 2005, THESIS INDIANA U IND
   SI Y, 2006, BLOOD, V108, P4283, DOI 10.1182/blood-2006-03-007997
   SMOGORZEWSKA A, 2007, CELL, V129, P289
   STARK R, 1993, BRIT J HAEMATOL, V83, P560
   TANKER PS, 2003, EXP HEMATOL, V31, P881, DOI
   10.1016/S0301-472X(03)00202-9
   TERPSTRA W, 1997, BLOOD, V90, P3735
   TULI R, 2003, STEM CELLS, V21, P681
   WAGNER W, 2008, CELLS TISSUES ORGANS, V188, P160, DOI 10.1159/000112821
   WAGNER WG, 2007, STEM CELLS, V25, P2638, DOI 10.1634/stemcells.2007-0280
   WANG JQ, 2006, BIOORG MED CHEM LETT, V16, P331, DOI
   10.1016/j.bmcl.2005.09.082
   WIERENGA ATJ, 2006, BLOOD, V107, P4326
   WILLIAMS DA, 2005, CURR OPIN MOL THER, V7, P461
   WU XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   XU MJ, 1998, BLOOD, V92, P2032
   YANG FC, 1998, BLOOD, V92, P4632
   YANG FC, 2000, IMMUNITY, V12, P557
   YANG FC, 2001, P NATL ACAD SCI USA, V98, P5614
   YANG Y, 2001, BLOOD, V98, P3435
   YIN T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   ZHANG JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 73
TC 13
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 5
PY 2009
VL 113
IS 10
BP 2342
EP 2351
DI 10.1182/blood-2008-07-168138
PG 10
SC Hematology
GA 415EZ
UT ISI:000263918400028
ER

PT J
AU Chi, XF
   Lou, XY
   Yang, M
   Shu, QY
AF Chi, Xiao-Fei
   Lou, Xiang-Yang
   Yang, Mark C. K.
   Shu, Qing-Yao
TI An optimal DNA pooling strategy for progressive fine mapping
SO GENETICA
LA English
DT Article
DE Fine mapping; DNA pooling; Experimental cost; Genotyping efficiency;
   Experimental populations
ID QUANTITATIVE TRAIT LOCUS; RECOMBINATION HOT-SPOTS; LARGE-SCALE
   ASSOCIATION; ORYZA-SATIVA L.; COMPLEX TRAITS; MEIOTIC RECOMBINATION;
   GENETIC DISSECTION; POSITIONAL CLONING; LINKAGE DISEQUILIBRIUM;
   ARABIDOPSIS-THALIANA
AB We present a cost-effective DNA pooling strategy for fine mapping of a
   single Mendelian gene in controlled crosses. The theoretical argument
   suggests that it is potentially possible for a single-stage pooling
   approach to reduce the overall experimental expense considerably by
   balancing costs for genotyping and sample collection. Further, the
   genotyping burden can be reduced through multi-stage pooling. Numerical
   results are provided for practical guidelines. For example, the
   genotyping effort can be reduced to only a small fraction of that
   needed for individual genotyping at a small loss of estimation accuracy
   or at a cost of increasing sample sizes slightly when recombination
   rates are 0.5% or less. An optimal two-stage pooling scheme can reduce
   the amount of genotyping to 19.5%, 14.5% and 6.4% of individual
   genotyping efforts for identifying a gene within 1, 0.5, and 0.1 cM,
   respectively. Finally, we use a genetic data set for mapping the rice
   xl(t) gene to demonstrate the feasibility and efficiency of the DNA
   pooling strategy. Taken together, the results demonstrate that this DNA
   pooling strategy can greatly reduce the genotyping burden and the
   overall cost in fine mapping experiments.
C1 [Lou, Xiang-Yang] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22911 USA.
   [Chi, Xiao-Fei; Shu, Qing-Yao] Zhejiang Univ, Zhejiang Univ Collaborating Ctr, IAEA, Hangzhou 310029, Zhejiang, Peoples R China.
   [Chi, Xiao-Fei; Shu, Qing-Yao] Zhejiang Univ, Inst Nucl Agr Sci, Natl Key Lab Rice Biol, Hangzhou 310029, Zhejiang, Peoples R China.
   [Yang, Mark C. K.] Univ Florida, Dept Stat, Gainesville, FL 32611 USA.
   [Shu, Qing-Yao] IAEA, Joint FAO IAEA Div Nucl Techn Food & Agr, A-1400 Vienna, Austria.
RP Lou, XY, Univ Virginia, Dept Psychiat & Neurobehav Sci, 1670 Discovery
   Dr,Suite 110, Charlottesville, VA 22911 USA.
EM XL5N@virginia.edu
   qyshu@zju.edu.cn
FU National Science Foundation of China [30571131, 30000097]
FX We greatly thank Dr. J. S. Wu for his assistance in checking the
   mathematical equations in this article for correctness. This project
   was funded in part by the National Science Foundation of China 30571131
   to QYS and 30000097 to XYL.
CR ANDERSSON L, 2004, NAT REV GENET, V5, P202, DOI 10.1038/nrg1294
   ARNHEIM N, 1985, P NATL ACAD SCI USA, V82, P6970
   BARRATT BJ, 2002, ANN HUM GENET 5-6, V66, P393, DOI
   10.1017/S0003480002001252
   CHEN SH, 2006, PLANT SCI, V171, P505, DOI 10.1016/j.plantsci.2006.05.013
   CHURCHILL GA, 1993, P NATL ACAD SCI USA, V90, P16
   COLLINS FS, 1992, NAT GENET, V1, P3
   COLLINS FS, 1995, NAT GENET, V9, P347
   DARVASI A, 1994, GENETICS, V138, P1365
   DARVASI A, 1998, NAT GENET, V18, P19
   DEMPSTER AP, 1977, J ROY STAT SOC B, V39, P1
   DENG YW, 2006, THEOR APPL GENET, V113, P705, DOI
   10.1007/s00122-006-0338-7
   DROUAUD J, 2006, GENOME RES, V16, P106, DOI 10.1101/gr.4319006
   FLURY BD, 1992, AM STAT, V46, P31
   FRARY A, 2000, SCIENCE, V289, P85
   GLAAB WE, 1999, MUTAT RES-FUND MOL M, V430, P1
   GLAZIER AM, 2002, SCIENCE, V298, P2345
   GUO SW, 2000, THEOR POPUL BIOL, V57, P1
   HALDANE JBS, 1931, GENETICS, V16, P357
   HILLEL J, 1997, POULTRY SCI, V76, P1115
   HWANG FK, 1976, BIOMETRICS, V32, P939
   JANDER G, 2002, PLANT PHYSIOL, V129, P440
   JAWAID A, 2002, EUR J HUM GENET, V10, P125
   KENNEDY BG, 2006, MOL BREEDING, V18, P185, DOI 10.1007/s11032-006-9020-7
   KLIEBENSTEIN DJ, 2007, PLANT J, V51, P1062, DOI
   10.1111/j.1365-313X.2007.03205.x
   KORSTANJE R, 2002, NAT GENET, V31, P235
   LANDER E, 1995, NAT GENET, V11, P241
   LANDER ES, 1994, SCIENCE, V265, P2037
   LEE WC, 2005, CANCER EPIDEM BIOMAR, V14, P958
   LI CB, 2006, SCIENCE, V311, P1936, DOI 10.1126/science.1123604
   LI XY, 2003, NATURE, V422, P618, DOI 10.1038/nature01518
   LI YH, 2003, PLANT CELL, V15, P2020, DOI 10.1105/tpc.011775
   LIU QL, 2007, THEOR APPL GENET, V114, P803, DOI
   10.1007/s00122-006-0478-9
   LUKOWITZ W, 2000, PLANT PHYSIOL, V123, P795
   MEZARD C, 2006, BIOCHEM SOC T 4, V34, P531
   MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828
   MYERS S, 2006, BIOCHEM SOC T 4, V34, P526
   NADEAU JH, 2000, NAT GENET, V25, P381
   NORTON N, 2004, ANN MED, V36, P146, DOI 10.1080/07853890310021724
   PANAUD O, 1996, MOL GEN GENET, V252, P597
   PETES TD, 2001, NAT REV GENET, V2, P360
   PRESS WH, 1992, NUMERICAL RECIPES C
   RISCH N, 1998, GENOME RES, V8, P1273
   ROBERT CP, 1997, J ROY STAT SOC B, V59, P758
   RONIN Y, 2003, GENETICS, V164, P1657
   SALVI S, 2005, TRENDS PLANT SCI, V10, P297
   SHAM P, 2002, NAT REV GENET, V3, P862, DOI 10.1038/nrg930
   SHEFFIELD VC, 1995, CURR OPIN GENE DEV, V5, P335
   SKALSKI GT, 2006, GENETICS, V173, P863, DOI 10.1534/genetics.105.053702
   SOBEL M, 1966, TECHNOMETRICS, V8, P631
   SONG WY, 1995, SCIENCE, V270, P1804
   TANKSLEY SD, 1995, TRENDS GENET, V11, P63
   TEMNYKH S, 2000, THEOR APPL GENET, V100, P697
   THOMPSON KH, 1962, BIOMETRICS, V18, P568
   VARSHNEY RK, 2006, TRENDS BIOTECHNOL, V24, P490, DOI
   10.1016/j.tibtech.2006.08.006
   WU JZ, 2003, PLANT J, V36, P720, DOI 10.1046/j.1365-313X.2003.01903.x
   YANO M, 2001, CURR OPIN PLANT BIOL, V4, P130
   YAO YC, 1990, J STAT PLANNING INFE, V24, P167
   ZHOU XS, 2006, FIELD CROP RES, V96, P71, DOI 10.1016/j.fcr.2005.05.008
NR 58
TC 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
J9 GENETICA
JI Genetica
PD APR
PY 2009
VL 135
IS 3
BP 267
EP 281
DI 10.1007/s10709-008-9275-5
PG 15
SC Genetics & Heredity
GA 413ZO
UT ISI:000263833900002
ER

PT J
AU Fang, M
   Jiang, D
   Gao, HJ
   Sun, DX
   Yang, RQ
   Zhang, Q
AF Fang, Ming
   Jiang, Dan
   Gao, Huijiang
   Sun, Dongxiao
   Yang, Runqing
   Zhang, Qin
TI A new Bayesian automatic model selection approach for mapping
   quantitative trait loci under variance component model
SO GENETICA
LA English
DT Article
DE Bayesian; Mapping QTL; MCMC; Model selection
ID CHAIN MONTE-CARLO; LINKAGE; PEDIGREES; IDENTITY; DESCENT; MARKERS;
   GENOME
AB Bayesian variable selection implemented via reversible jump Markov
   chain Monte Carlo (RJMCMC) is an effective method for mapping multiple
   QTL. Recently, it has been used for QTL mapping both in inbred line
   crosses and in outbred populations. However, by RJMCMC, since the
   model-dimension is variable, the parameters are usually subject to poor
   mixing and difficult to converge. In inbred lines, the fixed effect
   model is used for mapping QTL, various approaches which keep the
   model-dimension unchanged have been proposed, and it is proved that the
   mixing properties of Markov chains is substantially improved compared
   with RJMCMC. In outbred populations, the random effect model is used
   and the implementation via RJMCMC for variable selection still is the
   mainstream to map multiple QTL. Due to the poor performance RJMCMC has,
   it is meaningful to develop a model-dimension fixed approach for
   mapping QTL under random effect model. In this article, we proposed a
   new model-dimension fixed approach called Bayesian automatic model
   selection method for mapping multiple QTL under random effect model. By
   the new approach, all variances of QTL are subject to estimate, in
   which the variance of zero-effect QTL will exactly converge to zero,
   and those of non-zero effect QTL will be estimated precisely.
   Therefore, no special model selection is required. A series of
   simulation experiments have been conducted to investigate the
   performance of the method, the result showed that the new approach is
   very efficient for mapping multiple QTL. A computer program written in
   FORTRAN is available to interested users on request.
C1 [Fang, Ming] Heilongjiang August First Land Reclamat Univ, Life Sci Coll, Daqing 163319, Peoples R China.
   [Fang, Ming; Gao, Huijiang; Sun, Dongxiao; Zhang, Qin] China Agr Univ, Coll Anim Sci & Technol, Beijing 100094, Peoples R China.
   [Jiang, Dan] China Agr Univ, Coll Agron & Biotechnol, Beijing 100094, Peoples R China.
   [Gao, Huijiang] NE Agr Univ, Coll Anim Sci & Technol, Harbin 150030, Peoples R China.
   [Yang, Runqing] Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai 201101, Peoples R China.
RP Fang, M, Heilongjiang August First Land Reclamat Univ, Life Sci Coll,
   Daqing 163319, Peoples R China.
EM fangming618@126.com
FU Heilongjiang August First Land Reclamation University ; 863 Project
   [2007AA10Z157]
FX The research was supported by Heilongjiang August First Land
   Reclamation University and the "863" Project Grant 2007AA10Z157 to DS.
CR ALMASY L, 1998, AM J HUM GENET, V62, P1198
   AMOS CI, 1994, AM J HUM GENET, V54, P535
   FANG M, 2008, GENETICA, DOI 10.1007/S10709-008-9244-Z
   FULKER DW, 1994, AM J HUM GENET, V54, P1092
   GESSLER DDG, 1996, AM J HUM GENET, V59, P1382
   GOLDGAR DE, 1990, AM J HUM GENET, V47, P957
   HALEY CS, 1992, HEREDITY, V69, P315
   HASEMAN JK, 1972, BEHAV GENET, V2, P3
   HASTINGS WK, 1970, BIOMETRIKA, V57, P97
   KAO CH, 1999, GENETICS, V152, P1203
   LANDER ES, 1989, GENETICS, V121, P185
   LIU JF, 2007, AM J HUM GENET, V81, P304, DOI 10.1086/519495
   METROPOLIS N, 1953, J CHEM PHYS, V21, P1087
   SATAGOPAN JM, 1996, GENETICS, V144, P805
   SILLANPAA MJ, 1998, GENETICS, V148, P1373
   STEPHENS DA, 1998, BIOMETRICS, V54, P1334
   WANG H, 2005, GENETICS, V170, P465, DOI 10.1534/genetics.104.039354
   XU SH, 1995, GENETICS, V141, P1189
   XU SZ, 1998, GENET RES, V71, P73
   XU SZ, 2003, GENETICS, V163, P789
   YANG RQ, 2007, GENETICS, V176, P1169, DOI 10.1534/genetics.106.064279
   YI NJ, 2000, GENETICS, V155, P1391
   YI NJ, 2000, GENETICS, V156, P411
   YI NJ, 2003, GENETICS, V164, P1129
   YI NJ, 2003, GENETICS, V165, P867
   YI NJ, 2004, GENETICS, V167, P967
   YI NJ, 2005, GENETICS, V170, P1333, DOI 10.1534/genetics.104.040386
   YI NJ, 2007, GENETICS, V176, P1855, DOI 10.1534/genetics.107.071142
   YI NJ, 2007, GENETICS, V176, P1865, DOI 10.1534/genetics.107.071365
   ZENG ZB, 1994, GENETICS, V136, P1457
   ZHANG YM, 2005, RECENT RES DEV GENET, V2, P1
NR 31
TC 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
J9 GENETICA
JI Genetica
PD APR
PY 2009
VL 135
IS 3
BP 429
EP 437
DI 10.1007/s10709-008-9291-5
PG 9
SC Genetics & Heredity
GA 413ZO
UT ISI:000263833900018
ER

PT J
AU Ma, FX
   Zhang, DM
   Yang, HS
   Sun, HQ
   Wu, W
   Gan, Y
   Balducci, J
   Wei, YQ
   Zhao, X
   Huang, Y
AF Ma, Fanxin
   Zhang, Dongmei
   Yang, Hansuo
   Sun, Huaqin
   Wu, Wen
   Gan, Yan
   Balducci, James
   Wei, Yu-quan
   Zhao, Xia
   Huang, Yao
TI Endothelial cell-specific molecule 2 (ECSM2) modulates actin remodeling
   and epidermal growth factor receptor signaling
SO GENES TO CELLS
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; FOCAL ADHESION PROTEIN; BREAST-CANCER CELLS;
   EGF RECEPTOR; CYTOSKELETAL DYNAMICS; VASCULAR DEVELOPMENT; INCREASED
   MOTILITY; TYROSINE KINASES; STRESS FIBERS; F-ACTIN
AB Endothelial cell-specific molecules (ECSMs) play a pivotal role in the
   pathogenesis of many angiogenesis-related diseases. Since its initial
   discovery, the exact function of human ECSM2 has not been defined. In
   this study, by database mining, we identified a number of hypothetical
   proteins across species exhibiting substantial sequence homology to the
   human ECSM2. We showed that ECSM2 is preferentially expressed in
   endothelial cells and blood vessels. Their characteristic structures
   and unique expression patterns suggest that ECSM2 is an evolutionarily
   conserved gene and may have important functions. We further explored
   the potential roles of human ECSM2 at the molecular and cellular level.
   Using a reconstitution mammalian cell system, we demonstrated that
   ECSM2 mainly resides at the cell membrane, is critically involved in
   cell-shape changes and actin cytoskeletal rearrangement, and suppresses
   tyrosine phosphorylation signaling. More importantly, we uncovered that
   ECSM2 can cross-talk with epidermal growth factor receptor (EGFR) to
   attenuate the EGF-induced cell migration, possibly via inhibiting the
   Shc-Ras-ERK (MAP kinase) pathway. Given the importance of growth factor
   and receptor tyrosine kinase-mediated signaling and cell migration in
   angiogenesis-related diseases, our findings regarding the inhibitory
   effects of ECSM2 on EGF-mediated signaling and cell motility may have
   important therapeutic implications.
C1 [Ma, Fanxin; Zhang, Dongmei; Yang, Hansuo; Sun, Huaqin; Wei, Yu-quan; Zhao, Xia] Sichuan Univ, Coll Life Sci, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
   [Ma, Fanxin; Wu, Wen; Gan, Yan; Balducci, James; Huang, Yao] St Josephs Hosp, Dept Obstet & Gynecol, Lab Signal Transduct, Phoenix, AZ USA.
RP Zhao, X, Sichuan Univ, Coll Life Sci, W China Hosp, State Key Lab
   Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
EM xiao-zhao@126.com
   yhuang@chw.edu
FU St. Joseph's Foundation Startup Fund ; National Basic Research Program
   of China [2004CB518800, 2005CB522506]; National Natural Science
   foundation of China [30300408]; China Scholarship Council (CSC) 
FX This work was supported by a St. Joseph's Foundation Startup Fund (to
   Y.H.) and grants from the National Basic Research Program of China
   (2004CB518800 and 2005CB522506) and the National Natural Science
   foundation of China (30300408) (to Y.Q.W.). F. Ma is the recipient of a
   China Scholarship Council (CSC) scholarship. The authors appreciate
   helpful discussion with Drs. Y. Chang, X. Mo, and G. Samuelson, and
   generous provision of reagents by those named in the text.
CR AFFOLTER M, 2005, DEV CELL, V9, P19, DOI 10.1016/j.devcel.2005.06.003
   ARAO T, 2004, CANCER RES, V64, P9101
   BENNETT CM, 2001, BLOOD, V98, P643
   BRYAN BA, 2007, CELL MOL LIFE SCI, V64, P2053, DOI
   10.1007/s00018-007-7008-z
   CACERES M, 2005, EXP CELL RES, V309, P229, DOI
   10.1016/j.yexcr.2005.05.020
   CSERZO M, 1997, PROTEIN ENG, V10, P673
   DENHARTIGH JC, 1992, J CELL BIOL, V119, P349
   FAISAL A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200
   FAIX J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI
   10.1016/j.ceb.2005.11.002
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211
   FOLKMAN J, 1996, CELL, V87, P1153
   GRANT S, 2002, FRONT BIOSCI, V7, D376
   GU JG, 1999, J CELL BIOL, V146, P389
   HALL A, 1998, SCIENCE, V279, P509
   HO M, 2003, PHYSIOL GENOMICS, V13, P249, DOI
   10.1152/physiolgenomics.00186.2002
   HUANG C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   HUANG Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200
   HUANG Y, 2006, ONCOGENE, V25, P7565, DOI 10.1038/sj.onc.1209740
   HUMINIECKI L, 2000, GENOME RES, V10, P1796
   KATZ M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI
   10.1016/j.bbamcr.2007.01.002
   KATZ M, 2007, NAT CELL BIOL, V9, P961
   KIMMEL CB, 1995, DEV DYNAM, V203, P253
   KLEINER S, 2007, FEBS J, V274, P227, DOI
   10.1111/j.1742-4658.2006.05578.x
   KLEMKE RL, 1997, J CELL BIOL, V137, P481
   KLOTH MT, 2002, J BIOL CHEM, V277, P8693
   KRUEGER JS, 2001, ONCOGENE, V20, P4209
   LAMALICE L, 2007, CIRC RES, V100, P782, DOI
   10.1161/01.RES.0000259593.07661.1e
   LARSON JD, 2004, DEV DYNAM, V231, P204, DOI 10.1002/dvdy.20102
   MARCOUX N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712
   MARCOUX N, 2005, CELL SIGNAL, V17, P1449, DOI
   10.1016/j.cellsig.2005.03.001
   NATALICCHIO A, 2004, J BIOL CHEM, V279, P43900, DOI
   10.1074/jbc.M403936200
   NEWMAN PJ, 1990, SCIENCE, V247, P1219
   NEWMAN PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI
   10.1161/01.ATV.0000071347.69358.D9
   NOBES CD, 1995, CELL, V81, P53
   PARSONS JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373
   PULLIKUTH AK, 2007, CELL SIGNAL, V19, P1621, DOI
   10.1016/j.cellsig.2007.04.012
   RAVICHANDRAN KS, 2001, ONCOGENE, V20, P6322
   RIDLEY AJ, 2003, SCIENCE, V302, P1704
   RISAU W, 1997, NATURE, V386, P671
   SAHAI E, 2001, EMBO J, V20, P755
   SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417
   SHIBAYAMA S, 1997, 0682113A2, EP
   SMALL JV, 2005, CURR OPIN CELL BIOL, V17, P517, DOI
   10.1016/j.ceb.2005.08.004
   STEFONEK TJ, 2007, WOUND REPAIR REGEN, V15, P847, DOI
   10.1111/j.1524-475X.2007.00288.x
   TANG J, 2003, BIOCHEM BIOPH RES CO, V312, P930, DOI
   10.1016/j.bbrc.2003.11.016
   THISSE B, 2004, METHOD CELL BIOL, V77, P505
   THOMAS D, 1995, J BIOL CHEM, V270, P28924
   TORAL C, 2003, J CELL PHYSIOL, V195, P80, DOI 10.1002/jcp.10231
   TU YZ, 2001, J CELL BIOL, V153, P585
   VIAL E, 2003, CANCER CELL, V4, P67
   VIAL E, 2004, ANN NY ACAD SCI, V1030, P208, DOI 10.1196/annals.1329.027
   VIGNJEVIC D, 2008, SEMIN CANCER BIOL, V18, P12, DOI
   10.1016/j.semcancer.2007.08.001
   WEBB DJ, 2002, NAT CELL BIOL, V4, P97
   WEINSTEIN BM, 2002, SEMIN CELL DEV BIOL, V13, P515, DOI
   10.1016/S1084-9521(02)00105-2
   WELLS A, 1999, CELL MOTIL CYTOSKEL, V44, P227
   WOODFIN A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI
   10.1161/ATVBAHA.107.151456
   WU J, 2007, J NEUROPHYSIOL, V98, P5, DOI 10.1152/jn.00165.2007
   XIE H, 1998, J CELL SCI 5, V111, P615
   ZEIGLER ME, 1999, J CELL PHYSIOL, V180, P271
   ZHANG YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200
NR 60
TC 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1356-9597
J9 GENES CELLS
JI Genes Cells
PD MAR
PY 2009
VL 14
IS 3
BP 281
EP 293
DI 10.1111/j.1365-2443.2008.01267.x
PG 13
SC Cell Biology; Genetics & Heredity
GA 411YY
UT ISI:000263691600001
ER

PT J
AU Yan, Y
   Li, YP
   Hu, CY
   Gu, XC
   Liu, JH
   Hu, YA
   Yang, Y
   Wei, YQ
   Zhao, CJ
AF Yan, Yan
   Li, Yiping
   Hu, Chuanyin
   Gu, Xiaochun
   Liu, Junhua
   Hu, Yu-An
   Yang, Yang
   Wei, Yiquan
   Zhao, Chunjie
TI Expression of Frizzled10 in mouse central nervous system
SO GENE EXPRESSION PATTERNS
LA English
DT Article
DE Wnt; Frizzled10; Telencephalon; Cortex; Hippocampus; Cortical hem;
   Diencephalon; Midbrain; Cerebellum; Spinal cord; Expression pattern;
   Mouse
ID WNT; GENES; RECEPTORS; HEM
AB Frizzled transmembrane proteins (Fzd) are receptors of Wnts, and they
   play key roles during central nervous system (CNS) development in
   vertebrates. Here we report the expression pattern of Frizzled 10 in
   mouse CNS from embryonic stages to adulthood. Frizzled10 is expressed
   strongly at embryonic days E8.5 and E9.5 in the neural tube and tail
   bud. At E10.5, Frizzled10 is expressed in the forebrain vesicle, the
   fourth ventricle and the dorsal spinal cord. From E12.5 to E16.5,
   Frizzled10 expression is mainly observed in the cortical hem/fimbria,
   the neuroepithelium of the third ventricular zone, midbrain, developing
   cerebellum, and dorsal spinal cord. At P0, with the exception of
   expression in the fimbria, Frizzled10 mRNA expression is limited to
   specific nuclei including the ventral posterior thalamic nucleus (VP)
   and the dorsal lateral geniculate nucleus (DLG) in the developing
   thalamus as well as in the proliferative ventricular zone of the
   developing cerebellum. From P20 to adult, Frizzled10 mRNA is detected
   only in the internal capsule (ic). Our data show that expression of
   Frizzled10 is very strong during embryonic development of the CNS and
   suggest that Frizzled10 may play an essential role in spatial and
   temporal regulation during neural development. (C) 2008 Elsevier B.V.
   All rights reserved.
C1 [Yan, Yan; Li, Yiping; Hu, Chuanyin; Gu, Xiaochun; Liu, Junhua; Hu, Yu-An; Yang, Yang; Wei, Yiquan; Zhao, Chunjie] Southeast Univ, Sch Med, MOE, Key Lab Dev Genes & Human Dis, Nanjing 210009, Jiangsu, Peoples R China.
   [Yan, Yan; Li, Yiping; Hu, Chuanyin; Gu, Xiaochun; Liu, Junhua; Hu, Yu-An; Yang, Yang; Wei, Yiquan; Zhao, Chunjie] Southeast Univ, Sch Med, Inst Brain Sci, Nanjing 210009, Jiangsu, Peoples R China.
   [Hu, Yu-An] Jinling Hosp, Inst Lab Med, Nanjing 210002, Peoples R China.
RP Zhao, CJ, Southeast Univ, Sch Med, MOE, Key Lab Dev Genes & Human Dis,
   87 Dingjiaoqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM zhaocj@seu.edu.cn
FU National Nature Science Foundation of China [30770696, 30525017];
   Ministry of Education of China and National Basic Research Program of
   China (973 program) [106083]; Ministry of Science and Technology of
   China [2007CB512303]
FX We thank Samuel J. Pleasure (UCSF) for Frizzled10 EST clone, Li Liu and
   Xiaoxuan Lu for technical assistance and other members of the
   laboratory for valuable discussions. This work was supported by funds
   30770696, 30525017 from National Nature Science Foundation of China,
   106083 from The Ministry of Education of China and National Basic
   Research Program of China (973 program) 2007CB512303 from The Ministry
   of Science and Technology of China to C.Z.
CR CIANI L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665
   CORREIA KM, 2001, METHODS, V23, P335
   FISCHER T, 2007, NEUROSCIENCE, V147, P693, DOI
   10.1016/j.neuroscience.2007.04.060
   GROVE EA, 1998, DEVELOPMENT, V125, P2315
   JACOBOWITZ DM, 1998, CHEMOARCHITECTONIC A
   KAUFMAN MH, 1992, ATLAS MOUSE DEV
   KAWAKAMI Y, 2000, MECH DEVELOP, V91, P375
   KEMP CR, 2007, DEV DYNAM, V236, P2011, DOI 10.1002/dvdy.21198
   KIKUCHI A, 2007, CELL SIGNAL, V19, P659, DOI
   10.1016/j.cellsig.2006.11.001
   KIM AS, 2001, MECH DEVELOP, V103, P167
   KOIKE J, 1999, BIOCHEM BIOPH RES CO, V262, P39
   LUO JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   NASEVICIUS A, 2000, MECH DEVELOP, V92, P311
   NUSSE R, 2005, CELL RES, V15, P28
   STARK MR, 2000, MECH DEVELOP, V93, P195
   ZHAO CJ, 2006, BRAIN RES, V1077, P48, DOI 10.1016/j.brainres.2006.01.042
NR 16
TC 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-133X
J9 GENE EXPR PATTERNS
JI Gene Expr. Patterns
PD MAR
PY 2009
VL 9
IS 3
BP 173
EP 177
DI 10.1016/j.gep.2008.11.001
PG 5
SC Developmental Biology; Genetics & Heredity
GA 412GW
UT ISI:000263714100007
ER

PT J
AU Chan, KW
   Yang, CH
   Lin, JW
   Wang, HC
   Lin, FY
   Kuo, ST
   Wong, ML
   Hsu, WL
AF Chan, Kun-Wei
   Yang, Cheng-Hsiung
   Lin, Jen-Wei
   Wang, Hsien-Chi
   Lin, Fong-Yuan
   Kuo, Shu-Ting
   Wong, Min-Liang
   Hsu, Wei-Li
TI Phylogenetic analysis of parapoxviruses and the C-terminal
   heterogeneity of viral ATPase proteins
SO GENE
LA English
DT Article
DE Parapoxviruses; Orf virus; A32L gene; B2L gene; E3L gene
ID ORF-VIRUS; VACCINIA VIRUS; INTERFERON RESISTANCE; SEQUENCE ALIGNMENT;
   GENE; OUTBREAK; GOATS; IDENTIFICATION; INTEGRINS; HOMOLOG
AB Two outbreaks of orf virus (a parapoxvirus) infection in goats found in
   Nantou and Taiping of central Taiwan were investigated. The nucleotide
   and the amino acid sequences of viral B2L, E3L and A32L genes in these
   two outbreaks were analyzed, and each of their phylogenetic trees were
   also constructed. In the A32L gene, an unexpected deletion of 24
   nucleotides was found in the Taiping strain. The A32L gene can encode
   an ATPase and is supposed to be involved in virion DNA packaging. The
   24 nucleotides correspond to 8 amino acids residues of the viral
   ATPase, which are located near the C-terminal region of the enzyme.
   Moreover, two copies of the RGD sequence at C-terminal region of ATPase
   were found in the Nantou strain. The 24 nucleotide difference in the
   A32L gene indicated that the Nantou strain and the Taiping strain were
   two separate strains, and it can be used in differential molecular
   diagnosis. Moreover, the C-terminal heterogeneity was found to be a
   general feature of the viral ATPase. Lastly, similar functional motifs
   of the ATPase and the Ras proto-oncoprotein (a GTPase) are discussed.
   (c) 2008 Elsevier B.V. All rights reserved.
C1 [Chan, Kun-Wei; Lin, Jen-Wei; Wang, Hsien-Chi; Lin, Fong-Yuan; Wong, Min-Liang] Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung 402, Taiwan.
   [Yang, Cheng-Hsiung] Livestock Dis Control Ctr Taichung Cty, Taichung, Taiwan.
   [Hsu, Wei-Li] Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Vet, Taichung 402, Taiwan.
   [Kuo, Shu-Ting] Council Agr, Anim Hlth Res Inst, Tamsui 251, Taiwan.
RP Wong, ML, Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung
   402, Taiwan.
EM mlwong@dragon.nchu.edu.tw
   wlhsu@dragon.nchu.edu.tw
FU Bureau of Animal and Plant Health Inspection and Quarantine (BAPHIQ) ;
   Council of Agriculture, Taiwan 
FX The authors thank Dr. Sarah M. Richart, Department of Biology and
   Chemistry, Azusa Pacific University, CA, USA for her critical reading
   and suggestion. This work was supported in part by a grant from The
   Bureau of Animal and Plant Health Inspection and Quarantine (BAPHIQ),
   Council of Agriculture, Taiwan.
CR BAEK SH, 1997, J BIOL CHEM, V272, P32042
   CASSETTI MC, 1998, J VIROL, V72, P5769
   CHAN KW, 2007, VIRUS GENES, V35, P705, DOI 10.1007/s11262-007-0144-6
   CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825
   DELHON G, 2004, J VIROL, V78, P168, DOI 10.1128/JVI.78.1.168-177.2004
   FENNER F, 2001, FIELDS VIROLOGY, P2885
   GUMBRELL RC, 1997, VET REC, V141, P150
   HAIG DM, 1998, IMMUNOLOGY, V93, P335
   HAIG DM, 1998, VET RES, V29, P311
   IYER LM, 2001, J VIROL, V75, P11720
   KNOPF CW, 1998, VIRUS GENES, V16, P47
   KOONIN EV, 1993, VIRUS GENES, V7, P89
   KOONIN EV, 1997, SCIENCE, V275, P1489
   KUMAR S, 2004, BRIEF BIOINFORM, V5, P150
   LEDERMAN ER, 2007, PEDIATR INFECT DIS J, V26, P740, DOI
   10.1097/INF.0b013e31806211bf
   LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851
   MAZUR C, 1989, VET REC, V125, P419
   MCINNES CJ, 1998, VIRUS GENES, V17, P107
   MERCER AA, 2006, VIRUS RES, V116, P146, DOI
   10.1016/j.virusres.2005.09.011
   MONDAL B, 2006, VET RES COMMUN, V30, P531, DOI 10.1007/s11259-006-3270-z
   MOSS B, 2007, FIELDS VIROLOGY, P2905
   OGURA T, 2001, GENES CELLS, V6, P575
   REID HW, 1991, DIS SHEEP, P265
   RUOSLAHTI E, 1996, ANNU REV CELL DEV BI, V12, P697
   SMITH GL, 1991, J GEN VIROL 6, V72, P1349
   STEWART PL, 2007, TRENDS MICROBIOL, V15, P500, DOI
   10.1016/j.tim.2007.10.001
   SULLIVAN JT, 1994, VIROLOGY, V202, P968
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673
   VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637
   WALKER JE, 1982, EMBO J, V1, P945
   YU D, 1998, VIROLOGY, V243, P32
NR 31
TC 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD MAR 1
PY 2009
VL 432
IS 1-2
BP 44
EP 53
DI 10.1016/j.gene.2008.10.029
PG 10
SC Genetics & Heredity
GA 412GJ
UT ISI:000263712400006
ER

PT J
AU Cui, J
   Yang, H
   Lee, US
AF Cui, J.
   Yang, H.
   Lee, U. S.
TI Molecular mechanisms of BK channel activation
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Channel gating; MaxiK; calcium activation; voltage activation; metal
   binding; allosteric
ID CA2+-ACTIVATED K+ CHANNELS; ADRENAL CHROMAFFIN CELLS; BLADDER
   SMOOTH-MUSCLE; DEPENDENT POTASSIUM CHANNELS; HIPPOCAMPAL PYRAMIDAL
   CELLS; PRESYNAPTIC ACTIVE ZONES; PLANAR LIPID BILAYERS; SACCULAR
   HAIR-CELLS; RAT SKELETAL-MUSCLE; LARGE-CONDUCTANCE
AB Large conductance, Ca2+-activated potassium (BK) channels are widely
   expressed throughout the animal kingdom and play important roles in
   many physiological processes, such as muscle contraction, neural
   transmission and hearing. These physiological roles derive from the
   ability of BK channels to be synergistically activated by membrane
   voltage, intracellular Ca2+ and other ligands. Similar to voltage-gated
   K+ channels, BK channels possess a pore-gate domain (S5-S6
   transmembrane segments) and a voltage-sensor domain (S1-S4). In
   addition, BK channels contain a large cytoplasmic C-terminal domain
   that serves as the primary ligand sensor. The voltage sensor and the
   ligand sensor allosterically control K+ flux through the pore-gate
   domain in response to various stimuli, thereby linking cellular
   metabolism and membrane excitability. This review summarizes the
   current understanding of these structural domains and their mutual
   interactions in voltage-, Ca2+ - and Mg2+ -dependent activation of the
   channel.
C1 [Cui, J.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA.
   Washington Univ, Cardiac Bioelect & Arrhythmia Ctr, St Louis, MO 63130 USA.
RP Cui, J, Washington Univ, Dept Biomed Engn, 1 Brookings Dr, St Louis, MO
   63130 USA.
EM jcui@biomed.wustl.edu
FU National Institutes of Health [R01-HL70393]
FX We thank Chris Lingle (Washington University, St. Louis, MO) for
   critical discussions. This work was supported by National Institutes of
   Health grant R01-HL70393 (to J.C.) J.C. is an associate professor of
   biomedical engineering on the Spencer T. Olin Endowment.
CR ADAMS PR, 1982, NATURE, V296, P746
   ADELMAN JP, 1992, NEURON, V9, P209
   ALBRIGHT RA, 2006, CELL, V126, P1147, DOI 10.1016/j.cell.2006.08.028
   AMBERG GC, 2003, CIRC RES, V93, P965, DOI
   10.1161/01.RES.0000100068.43006.36
   AMBERG GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684
   ART JJ, 1987, J PHYSIOL-LONDON, V385, P207
   ART JJ, 1995, J GEN PHYSIOL, V105, P49
   ATKINSON NS, 1991, SCIENCE, V253, P551
   AVDONIN V, 2003, BIOPHYS J, V84, P2969
   BAO L, 2002, J GEN PHYSIOL, V120, P173, DOI 10.1085/jgp.20028627
   BAO L, 2004, J GEN PHYSIOL, V123, P475, DOI 10.1085/jgp.200409052
   BAO L, 2005, J GEN PHYSIOL, V126, P393, DOI 10.1085/jgp.200509346
   BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211
   BERKEFELD H, 2006, SCIENCE, V314, P615, DOI 10.1126/science.1132915
   BEZANILLA F, 2000, PHYSIOL REV, V80, P555
   BIAN S, 2001, P NATL ACAD SCI USA, V98, P4776
   BRAUN AP, 2001, J PHYSIOL-LONDON, V533, P681
   BRAVOZEHNDER M, 2000, P NATL ACAD SCI USA, V97, P13114
   BRAYDEN JE, 1992, SCIENCE, V256, P532
   BRELIDZE TI, 2003, P NATL ACAD SCI USA, V100, P9017, DOI
   10.1073/pnas.1532257100
   BRELIDZE TI, 2005, J GEN PHYSIOL, V126, P105, DOI 10.1085/jgp.200509286
   BRENNER R, 2000, J BIOL CHEM, V275, P6453
   BRENNER R, 2000, NATURE, V407, P870
   BRENNER R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573
   BRUENINGWRIGHT A, 2007, J GEN PHYSIOL, V130, P601, DOI
   10.1085/jgp.200709828
   BUTLER A, 1993, SCIENCE, V261, P221
   CALDERONE V, 2002, CURR MED CHEM, V9, P1385
   CHANG TJ, 2006, AM J HYPERTENS, V19, P678, DOI
   10.1016/j.amjhyper.2006.01.014
   CHAVIS P, 1998, EUR J NEUROSCI, V10, P2322
   CIBULSKY SA, 2005, J NEUROPHYSIOL, V93, P1393, DOI 10.1152/jn.00789.2004
   CLAPHAM DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   COX DH, 1997, J GEN PHYSIOL, V110, P257
   COX DH, 2000, J GEN PHYSIOL, V116, P411
   COX DH, 2005, J GEN PHYSIOL, V125, P253, DOI 10.1085/jgp.200509270
   COX DH, 2007, BIOL MED PHYS BIOMED, P171
   CUI J, 1997, J GEN PHYSIOL, V109, P647
   CUI JM, 2000, BIOCHEMISTRY-US, V39, P15612
   DIAZ L, 1998, J BIOL CHEM, V273, P32430
   DICHIARA TJ, 1995, J PHYSIOL-LONDON, V489, P403
   DING SH, 2005, J GEN PHYSIOL, V126, P213, DOI 10.1085/jgp.200509287
   DU W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585
   DUDEV T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n
   FABER ESL, 2003, J PHYSIOL-LONDON, V552, P483, DOI
   10.1113/jphysiol.2003.050120
   FABER ESL, 2003, NEUROSCIENTIST, V9, P181, DOI 10.1177/107385840325673
   FERNANDEZFERNANDEZ JM, 2004, J CLIN INVEST, V113, P1032, DOI
   10.1172/JCI200420347
   FINDLAY I, 1985, J MEMBRANE BIOL, V83, P169
   FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259
   FLYNN GE, 2001, NEURON, V30, P689
   FODOR AA, 2006, J GEN PHYSIOL, V127, P755, DOI 10.1085/jgp.200509419
   FODOR AA, 2009, ANN REV PHYSL, V71
   FUCHS PA, 1988, J NEUROSCI, V8, P2460
   FUCHS PA, 1990, J PHYSIOL-LONDON, V429, P529
   FURY M, 2002, SCI STKE, PE12
   GANDHI CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678
   GHATTA S, 2006, PHARMACOL THERAPEUT, V110, P103, DOI
   10.1016/j.pharmthera.2005.10.007
   GOLA M, 1993, NEURON, V10, P689
   GOLOWASCH J, 1986, J EXP BIOL, V124, P5
   GOUAUX E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666
   GU N, 2007, J PHYSIOL-LONDON, V580, P859, DOI
   10.1113/jphysiol.2006.126367
   GUO ZH, 2008, BIOPHYS J, V94, P3714
   HARDING MM, 2004, ACTA CRYSTALLOGR D 5, V60, P849, DOI
   10.1107/S0907444904004081
   HAUG T, 2004, J GEN PHYSIOL, V124, P173, DOI 10.1085/jgp.200308949
   HAUG T, 2004, J GEN PHYSIOL, V124, P185, DOI 10.1085/jgp.200308950
   HERRERA GM, 2000, AM J PHYSIOL-REG I, V279, R60
   HERRERA GM, 2005, AM J PHYSIOL-REG I, V289, R402, DOI
   10.1152/ajpregu.00488.2004
   HILLE B, 1999, NAT MED, V5, P1105
   HILLE B, 2001, ION CHANNELS EXCITAB
   HORRIGAN FT, 1999, J GEN PHYSIOL, V114, P277
   HORRIGAN FT, 1999, J GEN PHYSIOL, V114, P305
   HORRIGAN FT, 2002, J GEN PHYSIOL, V120, P267, DOI 10.1085/jgp.20028605
   HORRIGAN FT, 2005, J GEN PHYSIOL, V126, P7, DOI 10.1085/jgp.200509262
   HORRIGAN FT, 2008, J GEN PHYSIOL, V131, P13, DOI 10.1085/jgp.200709877
   HOU SW, 2008, NAT STRUCT MOL BIOL, V15, P403, DOI 10.1038/nsmb.1398
   HOU SW, 2008, P NATL ACAD SCI USA, V105, P4039, DOI
   10.1073/pnas.0800304105
   HU H, 2001, J NEUROSCI, V21, P9585
   HU L, 2003, P NATL ACAD SCI USA, V100, P10488, DOI
   10.1073/pnas.1834300100
   HU L, 2006, J GEN PHYSIOL, V127, P35, DOI 10.1085/jgp.200509317
   HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P237
   HUDSPETH AJ, 1988, J PHYSL, V400, P275
   INOUE R, 1985, PFLUG ARCH EUR J PHY, V405, P173
   ISAACSON JS, 2001, NEURON, V31, P1027
   ISSA NP, 1994, P NATL ACAD SCI USA, V91, P7578
   JIANG YX, 2001, NEURON, V29, P593
   JIANG YX, 2002, NATURE, V417, P515
   JIANG YX, 2002, NATURE, V417, P523
   JONES TR, 1990, J PHARMACOL EXP THER, V255, P697
   KIM HJ, 2006, J BIOL CHEM, V281, P38573, DOI 10.1074/jbc.M604769200
   KIM HJ, 2008, BIOPHYS J, V94, P446, DOI 10.1529/biophysj.107.108738
   KNAUS HG, 1996, J NEUROSCI, V16, P955
   KNOT HJ, 1998, J PHYSIOL-LONDON, V508, P211
   KOTLIKOFF MI, 1993, PHARMACOL THERAPEUT, V58, P1
   KOVAL OM, 2007, J GEN PHYSIOL, V129, P209, DOI 10.1085/jgp.200609662
   KRAUSS JK, 1996, PARK REL DISORD, V2, P35
   KRISHNAMOORTHY G, 2005, J GEN PHYSIOL, V126, P227, DOI
   10.1085/jgp.200509321
   KUME H, 1989, NATURE, V341, P152
   KUME H, 1992, P NATL ACAD SCI USA, V89, P11051
   LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187
   LATORRE R, 1982, P NATL ACAD SCI USA, V79, P805
   LATORRE R, 1983, J MEMBRANE BIOL, V71, P11
   LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385
   LATORRE R, 2006, BIOL RES, V39, P385
   LEDOUX J, 2006, PHYSIOLOGY, V21, P69, DOI 10.1152/physiol.00040.2005
   LEDWELL JL, 1999, J GEN PHYSIOL, V113, P389
   LI WY, 2004, J GEN PHYSIOL, V124, P43, DOI 10.1085/jgp.200409067
   LI WY, 2006, J GEN PHYSIOL, V128, P423, DOI 10.1085/jgp.200609521
   LING SZ, 2003, J PHYSIOL-LONDON, V553, P65, DOI
   10.1113/jphysiol.2003.051631
   LINGLE CJ, 1996, ION CHANNEL, V4, P261
   LINGLE CJ, 2001, J GEN PHYSIOL, V117, P583
   LINGLE CJ, 2002, J GEN PHYSIOL, V120, P261, DOI 10.1085/jgp.20028689
   LINGLE CJ, 2007, J GEN PHYSIOL, V129, P101, DOI 10.1085/jgp.200709739
   LINGLE CJ, 2008, J GEN PHYSIOL, V131, P5, DOI 10.1085/jgp.200709937
   LIPPIAT JD, 2000, J PHYSIOL-LONDON, V529, P131
   LIU G, 2008, J GEN PHYSIOL, V131, P537, DOI 10.1085/jgp.200809968
   LIU GX, 2008, P NATL ACAD SCI USA, V105, P10727, DOI
   10.1073/pnas.0805212105
   LONG SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269
   LU R, 2006, J PHYSIOL-LONDON, V570, P65
   LU Z, 2001, NATURE, V413, P809
   LU Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696
   LUNIN VV, 2006, NATURE, V440, P833, DOI 10.1038/nature04642
   MA ZM, 2006, J GEN PHYSIOL, V127, P309, DOI 10.1085/jgp.200509421
   MAGIDOVICH E, 2004, BIOCHEMISTRY-US, V43, P13242, DOI 10.1021/bi048377v
   MAGLEBY KL, 2001, J GEN PHYSIOL, V118, P583
   MAGLEBY KL, 2003, J GEN PHYSIOL, V121, P81
   MAMMANO F, 2007, PHYSIOLOGY, V22, P131, DOI 10.1152/physiol.00040.2006
   MARKWARDT F, 1992, J GEN PHYSIOL, V99, P841
   MARRION NV, 1998, NATURE, V395, P900
   MARTY A, 1983, TRENDS NEUROSCI, V6, P262
   MARTY A, 1985, J PHYSIOL-LONDON, V367, P117
   MAUE RA, 1987, J GEN PHYSIOL, V90, P95
   MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, H767
   MCCORMACK K, 1994, NEURON, V12, P301
   MCMANUS OB, 1991, J PHYSIOL-LONDON, V443, P739
   MCMANUS OB, 1995, NEURON, V14, P645
   MEERA P, 1996, FEBS LETT, V382, P84
   MEERA P, 1997, P NATL ACAD SCI USA, V94, P14066
   MEREDITH AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200
   METHFESSEL C, 1982, BIOPHYS STRUCT MECH, V9, P35
   MOCZYDLOWSKI E, 1983, J GEN PHYSIOL, V82, P511
   MONOD J, 1965, J MOL BIOL, V12, P88
   MORROW JP, 2006, P NATL ACAD SCI USA, V103, P5096, DOI
   10.1073/pnas.0600907103
   MOSS GWJ, 1996, BIOCHEMISTRY-US, V35, P16024
   MOSS GWJ, 1996, J GEN PHYSIOL, V108, P473
   NEELY A, 1992, J PHYSIOL-LONDON, V453, P133
   NEELY A, 1992, J PHYSIOL-LONDON, V453, P97
   NELSON MT, 1995, SCIENCE, V270, P633
   NIMIGEAN CM, 1999, J GEN PHYSIOL, V113, P425
   NIMIGEAN CM, 2000, J GEN PHYSIOL, V115, P719
   NIMIGEAN CM, 2003, BIOCHEMISTRY-US, V42, P9263, DOI 10.1021/bi0348720
   NIU XW, 2002, P NATL ACAD SCI USA, V99, P11441, DOI
   10.1073/pnas.172254699
   NIU XW, 2004, NEURON, V42, P745
   OBERHAUSER A, 1988, J GENERAL PHYSL, V92, P67
   OHMORI H, 1984, J PHYSIOL-LONDON, V350, P561
   ORIO P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002
   ORIO P, 2005, J GEN PHYSIOL, V125, P395, DOI 10.1085/jgp.200409236
   ORIO P, 2006, J GEN PHYSIOL, V127, P191, DOI 10.1085/jgp.200509370
   PALLANCK L, 1994, HUM MOL GENET, V3, P1239
   PALLOTTA BS, 1981, NATURE, V293, P471
   PALLOTTA BS, 1985, J GEN PHYSIOL, V86, P601
   PATTERSON AJ, 2002, TRENDS CARDIOVAS MED, V12, P78
   PETKOV GV, 2001, J PHYSIOL-LONDON, V537, P443
   PICO AR, 2003, RCK DOMAIN MODEL CAL
   PISKOROWSKI R, 2002, NATURE, V420, P499, DOI 10.1038/nature01199
   PISKOROWSKI RA, 2006, J GEN PHYSIOL, V127, P557, DOI
   10.1085/jgp.200509482
   PLUGER S, 2000, CIRC RES, V87, E53
   PYOTT SJ, 2007, J BIOL CHEM, V282, P3312, DOI 10.1074/jbc.M608726200
   QIAN X, 2003, P NATL ACAD SCI USA, V100, P10061, DOI
   10.1073/pnas.1731650100
   QIAN X, 2006, J GEN PHYSIOL, V128, P389, DOI 10.1085/jgp.200609486
   QUIRK JC, 2001, NEURON, V32, P13
   ROBERTS WM, 1990, J NEUROSCI, V10, P3664
   ROBITAILLE R, 1992, J NEUROSCI, V12, P297
   ROBITAILLE R, 1993, NEURON, V11, P645
   ROOSILD TP, 2004, TRENDS BIOCHEM SCI, V29, P39, DOI
   10.1016/j.tibs.2003.11.008
   ROTHBERG BS, 2000, J GEN PHYSIOL, V116, P75
   ROTHBERG BS, 2004, SCI STKE, PE16
   SALKOFF L, 2006, NAT REV NEUROSCI, V7, P921, DOI 10.1038/nrn1992
   SANTARELLI LC, 2004, J GEN PHYSIOL, V124, P357, DOI
   10.1085/jgp.200409144
   SANTARELLI LC, 2006, J PHYSIOL-LONDON, V571, P329, DOI
   10.1113/jphysiol.2005.101089
   SAUSBIER M, 2004, P NATL ACAD SCI USA, V101, P9474
   SAVALLI N, 2006, P NATL ACAD SCI USA, V103, P12619, DOI
   10.1073/pnas.0601176103
   SAVARIA D, 1992, AM J PHYSIOL 1, V262, L327
   SCHMALHOFER WA, 2005, BIOCHEMISTRY-US, V44, P10135, DOI
   10.1021/bi050527u
   SCHOPPA NE, 1998, J GEN PHYSIOL, V111, P271
   SCHREIBER M, 1997, BIOPHYS J, V73, P1355
   SCHREIBER M, 1999, NAT NEUROSCI, V2, P416
   SCHUBERT R, 2001, TRENDS PHARMACOL SCI, V22, P505
   SEIBOLD MA, 2008, HUM MOL GENET, V17, P2681, DOI 10.1093/hmg/ddn168
   SEMENOV I, 2006, AM J PHYSIOL-LUNG C, V291, L802, DOI
   10.1152/ajplung.00104.2006
   SENTI M, 2005, CIRC RES, V97, P1360, DOI
   10.1161/01.RES.0000196557.93717.95
   SHAO LR, 1999, J PHYSIOL-LONDON, V521, P135
   SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440
   SHI JY, 2001, J GEN PHYSIOL, V118, P589
   SHI JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941
   SILVERMAN WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI
   10.1073/pnas.0636603100
   SOLARO CR, 1995, J NEUROSCI, V15, P6110
   SOLERLLAVINA GJ, 2006, NEURON, V52, P623, DOI
   10.1016/j.neuron.2006.10.005
   STEFANI E, 1997, P NATL ACAD SCI USA, V94, P5427
   STORM JF, 1987, J PHYSIOL-LONDON, V385, P733
   TALUKDER G, 2000, BIOPHYS J, V78, P761
   TANG XD, 2001, J GEN PHYSIOL, V117, P253
   TANG XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003
   TANG XD, 2004, NAT STRUCT MOL BIOL, V11, P171, DOI 10.1038/nsmb725
   THORNELOE KS, 2005, AM J PHYSIOL-RENAL, V289, F604, DOI
   10.1152/ajprenal.00060.2005
   TIWARIWOODRUFF SK, 1997, BIOPHYS J, V72, P1489
   TORO L, 1991, AM J PHYSIOL, V260, H1779
   TORO L, 1998, NEWS PHYSIOL SCI, V13, P112
   TORRES YP, 2007, J BIOL CHEM, V282, P24485, DOI 10.1074/jbc.R700022200
   VAITHIANATHAN T, 2008, J GEN PHYSIOL, V132, P13, DOI
   10.1085/jgp.200709913
   VERGARA C, 1998, CURR OPIN NEUROBIOL, V8, P321
   WALLNER M, 1996, P NATL ACAD SCI USA, V93, P14922
   WALLNER M, 1999, P NATL ACAD SCI USA, V96, P4137
   WANG B, 2006, J GEN PHYSIOL, V128, P731, DOI 10.1085/jgp.200609596
   WEBSTER SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468
   WEI A, 1994, NEURON, V13, P671
   WEIGER TM, 2002, J COMP PHYSIOL A, V188, P79
   WERNER ME, 2007, AM J PHYSIOL-REG I, V292, R616, DOI
   10.1152/ajpregu.00036.2006
   WILKENS CM, 2006, J GEN PHYSIOL, V128, P347, DOI 10.1085/jgp.200609579
   WOMACK MD, 2004, J NEUROSCI, V24, P8818, DOI
   10.1523/JNEUROSCI.2915-04.2004
   WONG BS, 1982, BIOPHYS J, V39, P313
   WU SN, 2003, CURR MED CHEM, V10, P649
   WU YC, 1995, PROG BIOPHYS MOL BIO, V63, P131
   XIA XM, 1999, J NEUROSCI, V19, P5255
   XIA XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956
   XIA XM, 2003, J GEN PHYSIOL, V121, P125
   XIA XM, 2004, J NEUROSCI, V24, P5585, DOI 10.1523/JNEUROSCI.1296-04.2004
   YANG H, 2007, P NATL ACAD SCI USA, V104, P18270, DOI
   10.1073/pnas.0705873104
   YANG H, 2008, THESIS WASHINGTON U
   YANG HH, 2006, BIOPHYS J, V91, P2892, DOI 10.1529/biophysj.106.090159
   YANG HH, 2008, BIOPHYS J, V94, P4678, DOI 10.1529/biophysj.107.121596
   YANG HH, 2008, NAT STRUCT MOL BIOL, V15, P1152, DOI 10.1038/nsmb.1507
   YE S, 2006, CELL, V126, P1161, DOI 10.1016/j.cell.2006.08.029
   YUSIFOV T, 2008, P NATL ACAD SCI USA, V105, P376, DOI
   10.1073/pnas.0705261105
   ZENG XH, 2005, J GEN PHYSIOL, V125, P273, DOI 10.1085/jgp.200409239
   ZHANG X, 2001, J GEN PHYSIOL, V118, P607
   ZHANG Z, 2006, J NEUROSCI, V26, P11833, DOI
   10.1523/JNEUROSCI.3812-06.2006
NR 234
TC 37
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2009
VL 66
IS 5
BP 852
EP 875
DI 10.1007/s00018-008-8609-x
PG 24
SC Biochemistry & Molecular Biology; Cell Biology
GA 413XP
UT ISI:000263826400009
ER

PT J
AU Chang, B
   Liu, GZ
   Yang, G
   Mercado-Uribe, I
   Huang, M
   Liu, JS
AF Chang, Bin
   Liu, Guangzhi
   Yang, Gong
   Mercado-Uribe, Imelda
   Huang, Miao
   Liu, Jinsong
TI REDD1 is required for RAS-mediated transformation of human ovarian
   epithelial cells
SO CELL CYCLE
LA English
DT Article
DE REDD1; RAS; ovarian cancer; transformation; anti-apoptosis
ID GENE-EXPRESSION; HYPOXIA; TUMORS; IDENTIFICATION; MUTATIONS; RTP801;
   PROTOONCOGENE; SUPPRESSION; STRESS; CANCER
AB REDD1 is a gene induced by hypoxia and stimuli from multiple DNA
   damage. Here we show that REDD1 expression was elevated in
   RAS-transformed ovarian epithelial cells lines and that this
   overexpression increased these cells' growth rate and
   anchorage-independent growth on soft agar. Injection of immortalized
   ovarian epithelial cells overexpressing REDD1 into nude mice resulted
   in tumor growth that developed into papillary serous carcinoma in the
   peritoneal cavity. Knockdown of REDD1 expression blocked the
   RAS-mediated transformation of these cell lines. REDD1 overexpression
   decreased apoptosis and associated with increased expression of Bcl-xL
   or Bcl-2 and decreased expression of FADD, caspase1, caspase8, caspase
   9, caspase 10, BAX, Bad and Bcl-XS. Our data demonstrated that REDD1 is
   a key mediator in RAS-mediated transformation through an effect on
   anti-apoptosis.
C1 [Liu, Jinsong] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA.
   [Chang, Bin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China.
   [Chang, Bin] Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China.
RP Liu, JS, Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515
   Holcombe Blvd, Houston, TX 77030 USA.
EM jliu@mdanderson.org
FU American Cancer Society [RSG-04-0281-CCE]; National Institutes of
   Health/National Cancer Institute (NIH/NCI) [R01 CA131183-01]
FX J.L. is supported by a Research Scholar Grant (RSG-04-0281-CCE) from
   the American Cancer Society R01 CA131183-01 from the National
   Institutes of Health/National Cancer Institute (NIH/NCI) and an
   institutional research grant.
CR ADELMAN DM, 1999, GENE DEV, V13, P2478
   AN SJ, 2005, BIOMED ENVIRON SCI, V18, P302
   BRAFMAN A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI
   10.1167/iovs.04-0052
   BRUGAROLAS J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   CAO L, 2007, CARCINOGENESIS, V28, P1401, DOI 10.1093/carcin/bgm060
   CUATRECASAS M, 1997, CANCER, V79, P1581
   CUATRECASAS M, 1998, CANCER-AM CANCER SOC, V82, P1088
   DEYOUNG MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608
   ELLISEN LW, 2002, MOL CELL, V10, P995
   FUJITA M, 1994, JPN J CANCER RES, V85, P1247
   ICHIKAWA Y, 1994, CANCER RES, V54, P33
   KIM JR, 2003, EXP MOL MED, V35, P403
   LANG CH, 2008, ALCOHOL CLIN EXP RES, V32, P796, DOI
   10.1111/j.1530-0277.2008.00637.x
   LIN L, 2005, BIOCHEM J 1, V392, P93, DOI 10.1042/BJ20050553
   LIU JS, 2004, CANCER RES, V64, P1655
   MOK SCH, 1993, CANCER RES, V53, P1489
   SCHEID A, 2000, PEDIATR SURG INT, V16, P232
   SCHWARZER R, 2005, ONCOGENE, V24, P1138
   SEMENZA GL, 2000, ADV EXP MED BIOL, V475, P123
   SHOSHANI T, 2002, MOL CELL BIOL, V22, P2283
   TANG Y, 2006, NEUROBIOL DIS, V21, P18, DOI 10.1016/j.nbd.2005.06.002
   THULLBERG M, 2008, CELL CYCLE, V7, P984
   VARRAS MN, 1999, ONCOLOGY-BASEL, V56, P89
   YANG G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858
NR 24
TC 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAR 1
PY 2009
VL 8
IS 5
BP 780
EP 786
PG 7
SC Cell Biology
GA 412KJ
UT ISI:000263723400022
ER

PT J
AU Fujita, N
   Miyachi, H
   Tanaka, H
   Takeo, M
   Nakagawa, N
   Kobayashi, Y
   Iwasa, M
   Watanabe, S
   Takei, Y
AF Fujita, Naoki
   Miyachi, Hirohide
   Tanaka, Hideaki
   Takeo, Masaki
   Nakagawa, Naoki
   Kobayashi, Yoshinao
   Iwasa, Motoh
   Watanabe, Shozo
   Takei, Yoshiyuki
TI Iron Overload Is Associated with Hepatic Oxidative Damage to DNA in
   Nonalcoholic Steatohepatitis
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID FATTY LIVER-DISEASE; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA;
   GENETIC HEMOCHROMATOSIS; TRANSFERRIN RECEPTORS; STRESS;
   HYPERFERRITINEMIA; REDISTRIBUTION; PHLEBOTOMY; DEPLETION
AB Several lines of evidence have suggested that oxidative stress plays an
   important role for the pathogenesis of nonalcoholic steatohepatitis
   (NASH). Therefore, by using immunohistochemical staining of liver
   biopsy samples, we measured hepatic 7,8-dihydro-8-oxo-2' deoxyguanosine
   (8-oxodG), a DNA base-modified product generated by hydroxyl radicals,
   of 38 NASH patients and compared with 24 simple steatosis and 10
   healthy subjects. Relation of hepatic 8-oxodG with clinical,
   biochemical, and histologic variables and changes after iron reduction
   therapy (phlebotomy plus iron-restricted diet) were also examined.
   Hepatic 8-oxodG levels were significantly higher in NASH compared with
   simple steatosis (17.5 versus 2.0 8-oxodG -positive cells/10(5) mu
   m(2); P < 0.0001). 8-oxodG was significantly related to iron overload
   condition, glucose-insulin metabolic abnormality, and severities of
   hepatic steatosis in NASH patients. Logistic regression analysis also
   showed that hepatic iron deposit and insulin resistance were
   independent variables associated with elevated hepatic 8-oxodG. After
   the iron reduction therapy, hepatic 8-oxodG levels were significantly
   decreased (from 20.7 to 13.8 positive cells/10(5) mu m(2); P < 0.01)
   with concomitant reductions of serum transaminase levels in NASH
   patients. In conclusion, iron overload may play an important role in
   the pathogenesis of NASH by generating oxidative DNA damage and iron
   reduction therapy may reduce hepatocellular carcinoma incidence in
   patients with NASH. (Cancer Epidemiol Biomarkers Prev 2009;18(2):424-32)
C1 [Fujita, Naoki; Miyachi, Hirohide; Tanaka, Hideaki; Takeo, Masaki; Nakagawa, Naoki; Kobayashi, Yoshinao; Iwasa, Motoh; Takei, Yoshiyuki] Mie Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Div Clin Med & Biomed Sci,Inst Med Sci, Tsu, Mie 5148507, Japan.
   [Watanabe, Shozo] Mie Univ, Ctr Phys & Mental Hlth, Tsu, Mie 5148507, Japan.
RP Fujita, N, Mie Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Div
   Clin Med & Biomed Sci,Inst Med Sci, 2-174 Edobashi, Tsu, Mie 5148507,
   Japan.
EM nfujita@clin.medic.mie-u.ac.jp
CR *JAP SOC STUD OB, 2000, J JPN SOC STUDY OBES, V6, P18
   BERTELSEN M, 2001, DIABETOLOGIA, V44, P605
   BLENDIS L, 2000, GASTROENTEROLOGY, V118, P981
   BROWN KE, 2003, LIVER INT, V23, P232
   BRUNT EM, 1999, AM J GASTROENTEROL, V94, P2467
   BUGIANESI E, 2002, GASTROENTEROLOGY, V123, P134
   BUGIANESI E, 2004, HEPATOLOGY, V39, P179
   CHITTURI S, 2003, CURR GASTROENTEROL R, V5, P18
   CORNEJO P, 2005, NITRIC OXIDE-BIOL CH, V13, P54, DOI
   10.1016/j.niox.2005.04.009
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   DAY CP, 1998, GASTROENTEROLOGY, V114, P842
   DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050
   DEUGNIER YM, 1993, HEPATOLOGY, V17, P30
   FACCHINI FS, 1998, DIABETES CARE, V21, P2190
   FACCHINI FS, 2002, GASTROENTEROLOGY, V122, P931
   FARGION S, 2001, AM J GASTROENTEROL, V96, P2448
   FERNANDEZREAL JM, 2002, DIABETES, V51, P1000
   FORD ES, 1999, DIABETES CARE, V22, P1978
   FUJIMOTO S, 1995, BIOL PHARM BULL, V18, P396
   FUJITA N, 2007, FREE RADICAL BIO MED, V42, P353, DOI
   10.1016/j.freeradbiomed.2006.11.001
   GAVIN JR, 1997, DIABETES CARE, V20, P1183
   GEORGE DK, 1998, GASTROENTEROLOGY, V114, P311
   KADIISKA MB, 1995, J CLIN INVEST, V96, P1653
   KASAI H, 1997, MUTAT RES-REV MUTAT, V387, P147
   KOWDLEY KV, 2004, GASTROENTEROLOGY S1, V127, S79, DOI
   10.1016/j.gastro.2004.09.019
   MATTEONI CA, 1999, GASTROENTEROLOGY, V116, P1413
   MENDLER MH, 1999, GASTROENTEROLOGY, V117, P1155
   PIPERNO A, 1998, HEPATOLOGY, V28, P1105
   ROSEN P, 2001, DIABETES METAB RES, V17, P189
   SALONEN JT, 1998, BRIT MED J, V317, P727
   SEKI S, 2002, J HEPATOL, V37, P56
   SHIBUTANI S, 1991, NATURE, V349, P431
   SILVA VSS, 2005, J GASTROEN HEPATOL, V20, P243, DOI
   10.1111/j.1400-1746.2004.03549.x
   SUMIDA Y, 2003, J HEPATOL, V38, P32
   TANNER LI, 1987, J BIOL CHEM, V262, P8975
   TESILOVA Z, 2005, AM J GASTROENTEROL, V100, P850
   VALENTI L, 2007, AM J GASTROENTEROL, V102, P1251, DOI
   10.1111/j.1572-0241.2007.01192.x
   VIDELA LA, 2003, BIOMETALS, V16, P103
   YAMAMOTO M, 2007, J GASTROEN HEPATOL, V22, P498, DOI
   10.1111/j.1440-1746.2006.04548.x
NR 39
TC 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMARKER PREV
JI Cancer Epidemiol. Biomarkers Prev.
PD FEB
PY 2009
VL 18
IS 2
BP 424
EP 432
DI 10.1158/1055-9965.EPI-08-0725
PG 9
SC Oncology; Public, Environmental & Occupational Health
GA 410AS
UT ISI:000263547800009
ER

PT J
AU Yokoyama, A
   Kumagai, Y
   Yokoyama, T
   Omori, T
   Kato, H
   Igaki, H
   Tsujinaka, T
   Muto, M
   Yokoyama, M
   Watanabe, H
AF Yokoyama, Akira
   Kumagai, Yoshiya
   Yokoyama, Tetsuji
   Omori, Tai
   Kato, Hoichi
   Igaki, Hiroyasu
   Tsujinaka, Toshimasa
   Muto, Manabu
   Yokoyama, Masako
   Watanabe, Hiroshi
TI Health Risk Appraisal Models for Mass Screening for Esophageal and
   Pharyngeal Cancer: An Endoscopic Follow-up Study of Cancer-Free
   Japanese Men
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; UPPER AERODIGESTIVE TRACT; ALDEHYDE
   DEHYDROGENASES; GENETIC POLYMORPHISMS; ALCOHOL; CONSUMPTION; GENOTYPES;
   DRINKING; SMOKING; DIET
AB Purpose: To assess the performance of our health risk appraisal (HRA)
   models for screening individuals at high risk of esophageal/pharyngeal
   squamous cell carcinoma (EPSCC).
   Methods: Based on the results of our previous case-control study, we
   invented HRA models that enable screening for EPSCC cases in Japanese
   men with high sensitivity and specificity based on either their
   aldehyde dehydrogenase-2 genotype (HRA-G model) or alcohol flushing
   (HRA-F model) and drinking, smoking, and dietary habits. Follow-up
   endoscopy combined with esophageal iodine staining (median follow-up
   period: 5.0 years) was done on 404 Japanese men (50-78 years) who were
   registered as cancer-free controls in the previous study.
   Results: The follow-up endoscopy resulted in a diagnosis of 6
   esophageal SCC (T-is in 5 and T-1 in 1), 1 hypopharyngeal SCC (TO, and
   1 oropharyngeal SCC (T-2). Seven and 6 of the 8 EPSCC cases were in the
   top 10% risk group at baseline according to the HRA-G and HRA-F models,
   respectively. The EPSCC detection rates per 100 person-years in the top
   10% risk groups by the HRA-G and HRA-F models were 4.38 (95% confidence
   interval, 1.76-9.01) and 3.48 (95% confidence interval, 1.28-7.58),
   respectively. Their age-adjusted relative risk was 95.1- and 26.3-fold,
   respectively (P < 0.0001), higher than in the bottom 90% risk groups.
   Conclusions: The high detection rates for EPSCC in the top 10% risk
   group of this preliminary follow-up study were in good agreement with
   those predicted by the HRA models and thus encouraged the screening
   based on our HRA models in larger populations of Japanese men. (Cancer
   Epidemiol Biomarkers Prev 2009;18(2):651-5)
C1 [Yokoyama, Akira] Kurihama Alcoholism Ctr, Natl Hosp Org, Kanagawa 2390841, Japan.
   [Kumagai, Yoshiya] Kumagai Satellite Clin, Tokyo, Japan.
   [Yokoyama, Masako] Mitsukoshi Hlth & Welf Fdn, Tokyo, Japan.
   [Watanabe, Hiroshi] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 160, Japan.
   [Yokoyama, Tetsuji] Natl Inst Publ Hlth, Dept Human Resources Dev, Wako, Saitama 3510197, Japan.
   [Omori, Tai] Kawasaki Municipal Hosp, Dept Gastroenterol, Kawasaki, Kanagawa, Japan.
   [Omori, Tai] Kawasaki Municipal Hosp, Dept Surg, Kawasaki, Kanagawa, Japan.
   [Kato, Hoichi] Natl Canc Ctr, Ctr Canc Control & Informat Serv, Tokyo 104, Japan.
   [Kato, Hoichi; Igaki, Hiroyasu] Natl Canc Ctr, Div Surg, Chuo Ku, Tokyo, Japan.
   [Tsujinaka, Toshimasa] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan.
   [Muto, Manabu] Kyoto Univ, Sch Med, Dept Gastroenterol & Hepatol, Kyoto 606, Japan.
RP Yokoyama, A, Kurihama Alcoholism Ctr, Natl Hosp Org, 5-3-1 Nobi,
   Kanagawa 2390841, Japan.
EM a_yokoyama@kurihama1.hosp.go.jp
FU Ministry of Health, Labour and Welfare of Japan [12-12, 16-11]
FX Grant support: Ministry of Health, Labour and Welfare of Japan
   Grants-in-Aid for Cancer Research 12-12 and 16-11.
CR *IARC, 1985, IARC MON EV CARC RIS, V36, P101
   ARIMA M, 2007, ESOPHAGUS, V4, P145
   ASAKAGE T, 2007, CARCINOGENESIS, V28, P865, DOI 10.1093/carcin/bgl206
   BAAN R, 2007, LANCET ONCOL, V8, P292
   CHEN YJ, 2006, INT J CANCER, V119, P2827, DOI 10.1002/ijc.22199
   HAMASHIMA C, 2006, JPN J CLIN ONCOL, V36, P301, DOI 10.1093/jjco/hyl022
   HARADA S, 1981, LANCET, V2, P982
   HIGUCHI S, 1995, AM J PSYCHIAT, V152, P1219
   LEE CH, 2008, INT J CANCER, V122, P1347, DOI 10.1002/ijc.23264
   MAKUUCHI H, 2001, GASTROINTEST ENDOSC, V11, P445
   MOMMA K, 2007, ESOPHAGUS, V4, P93
   MUTO M, 2004, CANCER, V101, P1375, DOI 10.1002/cncr.20482
   SATO Y, 2006, SHOKAKI NAISHIKYO, V18, P1407
   YANG CX, 2005, ASIAN PAC J CANCER P, V6, P256
   YOKOYAMA A, 1995, CANCER, V76, P928
   YOKOYAMA A, 2002, CARCINOGENESIS, V23, P1851
   YOKOYAMA A, 2003, JPN J CLIN ONCOL, V33, P111
   YOKOYAMA A, 2005, J GASTROENTEROL, V40, P676, DOI
   10.1007/s00535-005-1610-3
   YOKOYAMA A, 2006, ALCOHOL CLIN EXP RES, V30, P491, DOI
   10.1111/j.1530-0277.2006.00053.x
   YOKOYAMA A, 2006, CANCER EPIDEM BIOMAR, V15, P2209, DOI
   10.1158/1055-9965.EPI-06-0435
   YOKOYAMA A, 2008, CANCER SCI, V99, P1164, DOI
   10.1111/j.1349-7006.2008.00807.x
   YOKOYAMA T, 2003, CANCER EPIDEM BIOMAR, V12, P1227
   YOKOYAMA T, 2008, CANCER EPIDEM BIOMAR, V17, P2846, DOI
   10.1158/1055-9965.EPI-08-0397
NR 23
TC 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMARKER PREV
JI Cancer Epidemiol. Biomarkers Prev.
PD FEB
PY 2009
VL 18
IS 2
BP 651
EP 655
DI 10.1158/1055-9965.EPI-08-0758
PG 5
SC Oncology; Public, Environmental & Occupational Health
GA 410AS
UT ISI:000263547800038
ER

PT J
AU Yang, H
   Kadia, T
   Xiao, LC
   Bueso-Ramos, CE
   Hoshino, K
   Thomas, DA
   O'Brien, S
   Jabbour, E
   Pierce, S
   Rosner, GL
   Kantarjian, HM
   Garcia-Manero, G
AF Yang, Hui
   Kadia, Tapan
   Xiao, Lianchun
   Bueso-Ramos, Carlos E.
   Hoshino, Koyu
   Thomas, Deborah Ann
   O'Brien, Susan
   Jabbour, Elias
   Pierce, Sherry
   Rosner, Gary L.
   Kantarjian, Hagop M.
   Garcia-Manero, Guillermo
TI Residual DNA methylation at remission is prognostic in adult
   Philadelphia chromosome-negative acute lymphocytic leukemia
SO BLOOD
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CYCLE REGULATORY PATHWAY; HYPER-CVAD;
   GENES; THERAPY; P57KIP2; REGIMEN; RELAPSE; DISEASE; CANCER
AB Pretreatment aberrant DNA methylation patterns are stable at time of
   relapse in acute lymphocytic leukemia (ALL). We hypothesized that the
   detection of residual methylation alterations at the time of
   morphologic remission may predict for worse prognosis. We developed a
   real-time bisulfite polymerase chain reaction assay and analyzed the
   methylation levels of p73, p15, and p57(KIP2) at the time of initial
   remission in 199 patients with Philadelphia chromosome-negative and
   MLL- ALL. Residual p73 methylation was detected in 18 (9.5%) patients,
   p15 in 33 (17.4%), and p57KIP2 in 7 (3.7%); 140 (74%) patients had
   methylation of 0 genes and 48 (25%) of more than or equal to 1 gene. In
   123 (65%) patients, matched pretreatment samples were also studied and
   compared with remission ones: in 82 of those with initial aberrant
   methylation of at least one gene, 59 (72%) had no detectable
   methylation at remission and 23 (28%) had detectable residual
   methylation. By multivariate analysis, the presence of residual p73
   methylation was associated with a significant shorter duration of first
   complete remission (hazard ratio = 2.68, P = .003) and overall survival
   (hazard ratio = 2.69, P = .002). In conclusion, detection of epigenetic
   alterations allows the identification of patients with ALL with
   standard risk but with poor prognosis. (Blood. 2009; 113: 1892-1898)
C1 [Yang, Hui; Kadia, Tapan; Hoshino, Koyu; Thomas, Deborah Ann; O'Brien, Susan; Jabbour, Elias; Pierce, Sherry; Kantarjian, Hagop M.; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Xiao, Lianchun; Rosner, Gary L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   [Bueso-Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
RP Garcia-Manero, G, Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Box
   428,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ggarciam@mdanderson.org
FU National Cancer Institute [CA100067, CA105771]; Commonwealth Foundation 
FX This work was supported by the National Cancer Institute (grants
   CA100067 and CA105771) and by the University of Texas
   Physician-Scientist Program funded by the Commonwealth Foundation for
   Cancer Research at the University of Texas M. D. Anderson Cancer Center
   and the Leukemia & Lymphoma Society of America (G.G.-M.).
CR AGRAWAL S, 2007, CANCER RES, V67, P1370, DOI
   10.1158/0008-5472.CAN-06-1681
   BENSON DA, 2008, NUCLEIC ACIDS RES, V36, D25, DOI 10.1093/nar/gkm929
   BUESORAMOS C, 2005, J CLIN ONCOL, V23, P3932, DOI
   10.1200/JCO.2005.02.998
   CANALLI AA, 2005, LEUKEMIA RES, V29, P881, DOI
   10.1016/j.leukres.2004.11.023
   GARCIAMANERO G, 2000, HEMATOL ONCOL CLIN N, V14, P1381
   GARCIAMANERO G, 2001, HEMATOL ONCOL CLIN N, V15, P163
   GARCIAMANERO G, 2002, CLIN CANCER RES, V8, P1897
   GARCIAMANERO G, 2002, CLIN CANCER RES, V8, P2217
   GARCIAMANERO G, 2006, BLOOD, V108, P3271, DOI
   10.1182/blood-2006-03-009142
   GILES FJ, 2001, BLOOD 1, V98, A629
   GUTIERREZ MI, 2003, LEUKEMIA, V17, P1845, DOI 10.1038/sj.leu.2403060
   HOELZER DF, 1993, HEMATOL ONCOL CLIN N, V7, P139
   JONES PA, 2002, NAT REV GENET, V3, P415
   KANTARJIAN HM, 2000, J CLIN ONCOL, V18, P547
   PUI C, 2004, NEW ENGL J MED, V350, P1535
   ROBERTSON KD, 2000, NAT REV GENET, V1, P11
   ROMANGOMEZ J, 2004, BLOOD, V104, P2492
   SHEN LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466
   THOMAS DA, 2004, BLOOD, V103, P4396, DOI 10.1182/blood-2003-08-2958
   XIONG ZG, 1997, NUCLEIC ACIDS RES, V25, P2532
   YANG H, 2007, J CLIN ONCOL, V25, P7072
NR 21
TC 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 26
PY 2009
VL 113
IS 9
BP 1892
EP 1898
DI 10.1182/blood-2008-02-141002
PG 7
SC Hematology
GA 412KM
UT ISI:000263723700005
ER

PT J
AU Li, ZX
   Beutel, G
   Rhein, M
   Meyer, J
   Koenecke, C
   Neumann, T
   Yang, M
   Krauter, J
   von Neuhoff, N
   Heuser, M
   Diedrich, H
   Gohring, G
   Wilkens, L
   Schlegelberger, B
   Ganser, A
   Baum, C
AF Li, Zhixiong
   Beutel, Gernot
   Rhein, Mathias
   Meyer, Johann
   Koenecke, Christian
   Neumann, Thomas
   Yang, Min
   Krauter, Juergen
   von Neuhoff, Nils
   Heuser, Michael
   Diedrich, Helmut
   Goehring, Gudrun
   Wilkens, Ludwig
   Schlegelberger, Brigitte
   Ganser, Arnold
   Baum, Christopher
TI High-affinity neurotrophin receptors and ligands promote leukemogenesis
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; NERVE GROWTH-FACTOR; ACUTE
   LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TYROSINE KINASES;
   TRANSCRIPTION FACTORS; CELL SURVIVAL; EXPRESSION; TRK; FLT3
AB Neurotrophins (NTs) and their receptors play a key role in neurogenesis
   and survival. The TRK (tropomyosin-related kinase) receptor protein
   tyrosine kinases (TRKA, TRKB, TRKC) are high-affinity NT receptors that
   are expressed in a variety of human tissues. Their role in normal and
   malignant hematopoiesis is poorly understood. In a prospective study
   involving 94 adult patients we demonstrate for the first time
   cell-surface expression of the 3 TRKs and constitutive activation in
   blasts from patients with de novo or secondary acute leukemia. At least
   one TRK was expressed in 55% of the analyzed cases. We establish a
   clear correlation between the TRK expression pattern and FAB
   classification. Although only few point mutations were found in TRK
   sequences by reverse-transcriptase polymerase chain reaction (RT-PCR),
   we observed coexpression of BDNF (ligand for TRKB) in more than 50% of
   TRKB+ cases (16/30). Activation of TRKA or TRKB by NGF and BDNF,
   respectively, efficiently rescued murine myeloid cells from
   irradiation-induced apoptosis. Coexpression of TRKB/BDNF or TRKA/NGF in
   murine hematopoietic cells induced leukemia. Moreover, activation of
   TRKs was important for survival of both human and murine leukemic
   cells. Our findings suggest that TRKs play an important role in
   leukemogenesis and may serve as a new drug target. (Blood. 2009; 113:
   2028-2037)
C1 [Li, Zhixiong; Rhein, Mathias; Meyer, Johann; Neumann, Thomas; Yang, Min; Baum, Christopher] Hannover Med Sch, Dept Expt Hematol, D-30625 Hannover, Germany.
   [Beutel, Gernot; Koenecke, Christian; Krauter, Juergen; Heuser, Michael; Diedrich, Helmut; Ganser, Arnold] Hannover Med Sch, Dept Hematol, D-30625 Hannover, Germany.
   [Beutel, Gernot; Koenecke, Christian; Krauter, Juergen; Heuser, Michael; Diedrich, Helmut; Ganser, Arnold] Hannover Med Sch, Dept Hemostasis, D-30625 Hannover, Germany.
   [Beutel, Gernot; Koenecke, Christian; Krauter, Juergen; Heuser, Michael; Diedrich, Helmut; Ganser, Arnold] Hannover Med Sch, Dept Oncol, D-30625 Hannover, Germany.
   [Beutel, Gernot; Koenecke, Christian; Krauter, Juergen; Heuser, Michael; Diedrich, Helmut; Ganser, Arnold] Hannover Med Sch, Dept Stem Cell Transplantat, D-30625 Hannover, Germany.
   [von Neuhoff, Nils; Goehring, Gudrun; Wilkens, Ludwig; Schlegelberger, Brigitte] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany.
   [Baum, Christopher] Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA.
RP Li, ZX, Hannover Med Sch, Dept Expt Hematol, OE6960,Carl Neuberg Str 1,
   D-30625 Hannover, Germany.
EM li.zhixiong@mh-hannover.de
   baum.christopher@mh-hannover.de
FU Deutsche Krebshilfe (Bonn, Germany) [10-2090-Li I]; Deutsche
   Forschungsgemeinschaft (DFG, Bonn, Germany) [KO 3582/1-1]; National
   Cancer Institute [R01-CA107492-01A2]; Deutsche Jose Carreras
   Leukamie-Stiftung (Munchen, Germany) [DJCLS F05/10]
FX We are very grateful to Stefan Bartels and Ludwig Hoy for help with
   statistical analysis; Axel Schambach for providing vector backbones;
   Michael Morgan for providing reagents and critical reading of this
   paper; Peter Horn and Martin Sauer for providing cells; Vanessa Prox,
   Christine Garen, Rene Kirstein, Ellen Neumann, Elke Sturmer, Elvira
   Lux, and Cindy Elfers for technical assistance; and Rolf Baumann, Hans
   Grundtke, Jorg Fruhauf, Anne Koop, and Bernd Polivka (all MHH) for
   irradiation of animals and cells. We also thank Dr D. Martin-Zanca for
   providing cDNA of TPM3/TRK.
   This study was supported by the Deutsche Krebshilfe (Bonn, Germany;
   grant: 10-2090-Li I) and by the Deutsche Forschungsgemeinschaft (DFG,
   Bonn, Germany; excellence cluster REBIRTH). C. B. was also supported by
   the National Cancer Institute (R01-CA107492-01A2). M. R. is a student
   of the MD/PhD program at Hannover Medical School (MHH), and received
   support from the Deutsche Jose Carreras Leukamie-Stiftung (Munchen,
   Germany; grant: DJCLS F05/10). C. K. was supported by DFG (KO 3582/1-1).
CR AVELLINO R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929
   BARTKOWSKA K, 2007, DEVELOPMENT, V134, P4369, DOI 10.1242/dev.008227
   BAXTER EJ, 2005, LANCET, V365, P1054
   BENE MC, 1995, LEUKEMIA, V9, P1783
   BEUTEL G, 2005, BRIT J HAEMATOL, V131, P67, DOI
   10.1111/j.1365-2141.2005.05717.x
   BLUMEJENSEN P, 2001, NATURE, V411, P355
   BOISSEL N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188
   CHEVALIER S, 1994, BLOOD, V83, P1479
   COULIER F, 1990, MOL CELL BIOL, V10, P4202
   DAI C, 2001, GENE DEV, V15, P1913
   DEGUCHI K, 2002, LEUKEMIA, V16, P740
   DESCAMPS S, 2001, CANCER RES, V61, P4337
   DIAS S, 2001, P NATL ACAD SCI USA, V98, P10857
   DOUMA S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   DRUKER BJ, 2006, NEW ENGL J MED, V355, P2408
   EGGERT A, 2001, J CLIN ONCOL, V19, P689
   EGUCHI M, 1999, BLOOD, V93, P1355
   GARACI E, 1999, P NATL ACAD SCI USA, V96, P14013
   GEIGER TR, 2007, CANCER RES, V67, P6221, DOI
   10.1158/0008-5472.CAN-07-0121
   GLASS DJ, 1991, CELL, V66, P405
   HEUSER M, 2006, BLOOD, V108, P3898, DOI 10.1182/blood-2006-04-014845
   HO R, 2002, CANCER RES, V62, P6462
   HU J, 2007, ADV CANCER RES, V98, P191, DOI 10.1016/S0065-230X(06)98006-3
   JECHLINGER M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JC124652
   JIN W, 2007, ONCOGENE, V26, P7684, DOI 10.1038/sj.onc.1210571
   KAEBISCH A, 1996, BRIT J HAEMATOL, V95, P102
   KERMANI P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655
   KRAUSE DS, 2005, NEW ENGL J MED, V353, P172
   LABOUYRIE E, 1999, AM J PATHOL, V154, P405
   LASALA A, 2000, J LEUKOCYTE BIOL, V68, P104
   LEE FS, 2001, CURR OPIN NEUROBIOL, V11, P281
   LEE FS, 2001, P NATL ACAD SCI USA, V98, P3555
   LI ZX, 2002, SCIENCE, V296, P497
   LIU Q, 2000, EMBO J, V19, P1827
   LOEB DM, 1991, CELL, V66, P961
   LORIAUX MM, 2008, BLOOD, V111, P4788, DOI 10.1182/blood-2007-07-101394
   LOWENBERG B, 1999, NEW ENGL J MED, V341, P1051
   MARODER M, 1996, J IMMUNOL, V157, P2864
   MARTINZANCA D, 1986, NATURE, V319, P743
   MCGREGOR LM, 1999, P NATL ACAD SCI USA, V96, P4540
   MEYER J, 2007, LEUKEMIA, V21, P2171, DOI 10.1038/sj.leu.2404882
   MULLOY JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI
   10.1073/pnas.0404701102
   NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847
   NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759
   PEARSE RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096
   PINCELLI C, 2000, J DERMATOL SCI, V22, P71
   PYLE AD, 2006, NAT BIOTECHNOL, V24, P344, DOI 10.1038/nbt1189
   RAJAGOPAL R, 2004, J NEUROSCI, V24, P6650, DOI
   10.1523/JNEUROSCI.0010-04.2004
   REUTHER GW, 2000, MOL CELL BIOL, V20, P8655
   SCHEIJEN B, 2002, ONCOGENE, V21, P3314
   SCHOLL C, 2007, J CLIN INVEST, V117, P1037, DOI 10.1172/JCI30182
   STOMMEL JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946
   TICKENBROCK L, 2006, EXPERT OPIN EMERG DR, V11, P153, DOI
   10.1517/14728214.11.1.153
   TOMASSON MH, 2008, BLOOD, V111, P4797
   TORCIA M, 1996, CELL, V85, P345
   TROEGER A, 2007, BRIT J HAEMATOL, V139, P450, DOI
   10.1111/j.1365-2141.2007.06818.x
   VEGA JA, 2003, J ANAT, V203, P1
   WHITMAN SP, 2008, BLOOD, V111, P1552, DOI 10.1182/blood-2007-08-107946
   ZHANG WG, 2008, J NATL CANCER I, V100, P184, DOI 10.1093/jnci/djm328
   ZHENG R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969
NR 60
TC 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 26
PY 2009
VL 113
IS 9
BP 2028
EP 2037
DI 10.1182/blood-2008-05-155200
PG 10
SC Hematology
GA 412KM
UT ISI:000263723700021
ER

PT J
AU Kessler, JD
   Hasegawa, H
   Brun, SN
   Emmenegger, BA
   Yang, ZJ
   Dutton, JW
   Wang, F
   Wechsler-Reya, RJ
AF Kessler, Jessica D.
   Hasegawa, Hiroshi
   Brun, Sonja N.
   Emmenegger, Brian A.
   Yang, Zeng-Jie
   Dutton, John W.
   Wang, Fan
   Wechsler-Reya, Robert J.
TI N-myc alters the fate of preneoplastic cells in a mouse model of
   medulloblastoma (vol 23, pg 157, 2009)
SO GENES & DEVELOPMENT
LA English
DT Correction
C1 [Kessler, Jessica D.; Brun, Sonja N.; Emmenegger, Brian A.; Yang, Zeng-Jie; Dutton, John W.; Wechsler-Reya, Robert J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   [Hasegawa, Hiroshi; Wang, Fan] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
RP Kessler, JD, Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC
   27710 USA.
CR KESSLER JD, 2009, GENE DEV, V23, P157, DOI 10.1101/gad.1759909
NR 1
TC 0
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD FEB 15
PY 2009
VL 23
IS 4
BP 535
EP 535
PG 1
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 410TH
UT ISI:000263600700013
ER

PT J
AU Lau, KK
   Yang, Y
   Cook, GA
   Wyatt, RJ
   Nishimura, H
AF Lau, Keith K.
   Yang, Yimu
   Cook, George A.
   Wyatt, Robert J.
   Nishimura, Hiroko
TI Control of aquaporin 2 expression in collecting ducts of quail kidneys
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article
DE Avian aquaporin; AQP2; Water channel; Urine concentration; Medullary
   collecting duct; Coturnix quail; ADH
ID IN-SITU HYBRIDIZATION; WATER-CHANNEL; ARGININE VASOTOCIN;
   FUNCTIONAL-CHARACTERIZATION; GENE-EXPRESSION; JAPANESE-QUAIL; AVIAN
   KIDNEY; RAT-KIDNEY; VASOPRESSIN; RECEPTOR
AB Birds and mammals are the only vertebrates that can concentrate urine.
   Avian kidneys contain structurally primitive loopless nephrons and also
   more advanced looped nephrons, in the cortical and medullary regions,
   respectively. We have identified the gene sequence of an aquaporin 2
   (AQP2)-homologue water channel in collecting ducts of kidneys from
   adult quail, Coturnix japonica. Although immunoreactive quail AQP2
   (qAQP2) was found in both types of nephrons, the expression is enhanced
   more clearly in the medullary regions after water deprivation. We
   therefore hypothesized that regulation of qAQP2 expression in quail
   kidneys via antidiuretic hormone (ADH) may require more advanced
   nephron structure. In this study, we determined the expression of qAQP2
   mRNA in tissues isolated from the cortical and medullary regions before
   and after water deprivation, by conventional reverse
   transcriptase-polymerase chain reaction (RT-PCR) and quantitative
   real-time PCR. In both normally hydrated and water-deprived groups,
   qAQP2 mRNA levels in the medullary regions were significantly higher (P
   < 0.01) than in the cortical regions. In medullary areas, qAQP2 mRNA
   levels (real-time PCR normalized with 18S) were significantly higher (P
   < 0.01, ANOVA) after water deprivation (1.09 +/- 0.10) than in normally
   hydrated controls (0.46 +/- 0.08). In cortical areas, qAQP2 mRNA levels
   were also higher after water deprivation (0.37 +/- 0.05) than in
   controls (0.11 +/- 0.02). qAQP2 mRNA signals determined by in situ
   hybridization of digoxigenin-labeled riboprobe were also enhanced after
   water deprivation in both cortical and medullary collecting ducts. The
   results suggest that, contrary to our hypothesis, the endogenous
   production of ADH by water deprivation stimulates qAQP2 mRNA in both
   loopless and looped nephrons. (C) 2008 Elsevier Inc. All rights
   reserved.
C1 [Lau, Keith K.; Yang, Yimu; Nishimura, Hiroko] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Physiol, Memphis, TN 38163 USA.
   [Cook, George A.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38163 USA.
   [Lau, Keith K.; Wyatt, Robert J.] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA.
RP Nishimura, H, Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Physiol, 894
   Union Ave, Memphis, TN 38163 USA.
EM nishimur@physio1.utmem.edu
FU NSF [IBN-9986633]; NIH [HL52881]; NKF [MG61943]; Le Bonheur Small Grant
   ; Accredo Health Care Foundation 
FX The authors are grateful for support by NSF Grant IBN-9986633 (PI:
   Hiroko Nishimura), NIH Grant HL52881 (PI: Hiroko Nishimura), NKF Grant
   MG61943 (PI: Keith Lau), Le Bonheur Small Grant (PI: Keith Lau), and a
   generous grant from the Accredo Health Care Foundation (PI: Keith Lau).
   We also thank Ms. Guibin Su for her excellent technical assistance
   throughout the experiments. Rabbit anti-rat AQP2 was a generous gift
   from Dr. Sei Sasaki, Tokyo Medical and Dental University, Tokyo, Japan.
CR AGRE P, 2000, J AM SOC NEPHROL, V11, P764
   BRAUN EJ, 1972, AM J PHYSIOL, V222, P617
   BRAUN EJ, 1988, AM J PHYSIOL, V255, F500
   BRAUN EJ, 1997, HDB PHYSL COMP PHYSL, V1, P481
   CHATURVEDI CM, 1997, PEPTIDES, V18, P1383
   CHATURVEDI CM, 2000, GEN COMP ENDOCR, V117, P129
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159
   DANTZLER WH, 1980, AM J PHYSIOL, V239, R197
   DANTZLER WH, 1989, ZOOPHYSIOLOGY, V22, P1
   FUSHIMI K, 1993, NATURE, V361, P549
   FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, F573
   GOLDSTEIN DL, 1989, AM J PHYSIOL, V256, R501
   GOLDSTEIN DL, 2006, GEN COMP ENDOCR, V147, P78, DOI
   10.1016/j.ygcen.2005.09.018
   HASEGAWA T, 2003, ENDOCRINOLOGY, V144, P4087, DOI 10.1210/en.2003-0418
   HAYASHI M, 1994, J CLIN INVEST, V94, P1778
   KLEMPT M, 1992, J ENDOCRINOL, V133, P264
   KNEPPER MA, 1997, CURR OPIN CELL BIOL, V9, P560
   KNEPPER MA, 1998, AM J PHYSIOL-RENAL, V275, F332
   KRANE CM, 2007, MAMM GENOME, V18, P452, DOI 10.1007/s00335-007-9041-5
   LAYCOCK JF, 1998, J ENDOCRINOL, V159, P361
   NISHIMURA H, 1989, AM J PHYSIOL 2, V257, F994
   NISHIMURA H, 1993, NEW INSIGHTS VERTEBR, P189
   NISHIMURA H, 1996, AM J PHYSIOL-REG I, V271, R1535
   NISHIMURA H, 2003, AM J PHYSIOL-REG I, V285, R231, DOI
   10.1152/ajpregu.00481.2002
   NISHIMURA H, 2007, AM J PHYSIOL-REG I, V293, R2147, DOI
   10.1152/ajpregu.00163.2007
   NISHIMURA H, 2008, PFLUG ARCH EUR J PHY, V456, P755, DOI
   10.1007/s00424-008-0469-6
   NITTA H, 2003, APPL IMMUNOHISTO M M, V11, P183
   NOUWEN EJ, 1984, J ENDOCRINOL, V102, P345
   OGUSHI Y, 2007, ENDOCRINOLOGY, V148, P5891, DOI 10.1210/en.2007-0613
   PROCINO G, 2008, J CELL SCI, V121, P2097, DOI 10.1242/jcs.022210
   SCHMIDTNIELSEN B, 1979, YALE J BIOL MED, V52, P545
   STALLONE JN, 1986, AM J PHYSIOL, V250, R644
   VANOS CH, 1998, NEPHROL DIAL TRANSPL, V13, P1645
   VERKMAN AS, 2000, AM J PHYSIOL-RENAL, V278, F13
   YAMAMOTO T, 1998, KIDNEY INT, V54, P1041
   YANG Y, 2004, AM J PHYSIOL-REG I, V287, R915, DOI
   10.1152/ajpregu.00589.2003
   YANG YM, 2007, COMP BIOCHEM PHYS A, V147, P84, DOI
   10.1016/j.cbpa.2006.11.019
NR 37
TC 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
J9 GEN COMP ENDOCRINOL
JI Gen. Comp. Endocrinol.
PD FEB
PY 2009
VL 160
IS 3
BP 288
EP 294
DI 10.1016/j.ygcen.2008.12.007
PG 7
SC Endocrinology & Metabolism
GA 410JO
UT ISI:000263573500009
ER

PT J
AU Nagayama, S
   Yamada, E
   Kohno, Y
   Aoyama, T
   Fukukawa, C
   Kubo, H
   Watanabe, G
   Katagiri, T
   Nakamura, Y
   Sakai, Y
   Toguchida, J
AF Nagayama, Satoshi
   Yamada, Eiji
   Kohno, Yoshiki
   Aoyama, Tomoki
   Fukukawa, Chikako
   Kubo, Hajime
   Watanabe, Go
   Katagiri, Toyomasa
   Nakamura, Yusuke
   Sakai, Yoshiharu
   Toguchida, Junya
TI Inverse correlation of the up-regulation of FZD10 expression and the
   activation of beta-catenin in synchronous colorectal tumors
SO CANCER SCIENCE
LA English
DT Article
ID SIGNALING PATHWAY; SYNOVIAL SARCOMAS; RETINOIC ACID; COLON-CANCER; NT2
   CELLS; WNT; FRIZZLED-10; INHIBITION
AB We investigated the immunohistochemical expression patterns of Frizzled
   homolog 10 (FZD10), a cell-surface receptor for molecules in the Wnt
   pathway, in tissue samples derived from 104 patients with colorectal
   cancers (CRCs). There was no immunoreactivity for FZD10 in normal
   colonic mucosa, and only tumor cells in polyps and CRC tissues showed
   spotted immunostaining patterns in apical sides of the cytoplasm. In
   metastatic liver lesions, tumor cells showed cytoplasmic immunostaining
   similar to primary lesions, whereas normal liver parenchyma showed
   almost no immunostaining. Frequencies of FZD10-immunopositive cells in
   tumor tissues were significantly higher in CRCs than those in polyps
   (3.3 +/- 10.3% vs 20.5 +/- 31.7%, P = 0.0016), and almost equivalent
   with those in metastatic liver lesions (33.2 +/- 39.7% vs 26.4 +/-
   33.4%, P = 0.133). Analyses of paired samples (polyps and CRCs, or CRCs
   and metastatic liver lesions from the same patient) suggested that a
   subset of CRCs possessed intrinsic genetic mechanisms causing the
   evolution of FZD10-positive clones during tumor progression, making
   FZD10 a promising candidate for molecular imaging and a target for
   therapy. To our surprise, cancer cells immunopositive for FZD10 showed
   significantly less nuclear accumulation of beta-catenin, compared to
   FZD10-immunonegative cancer cells, and there was a strong inverse
   correlation between nuclear immunostaining scores for beta-catenin
   expression and expression patterns of FZD10 (P = 0.0002), suggesting
   that FZD10 has a distinct role from other FZDs in canonical Wnt signal
   transduction. (Cancer Sci 2009; 100: 405-412).
C1 [Nagayama, Satoshi; Yamada, Eiji; Kubo, Hajime; Watanabe, Go; Sakai, Yoshiharu] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan.
   [Yamada, Eiji; Kohno, Yoshiki; Aoyama, Tomoki; Toguchida, Junya] Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Kyoto 6068507, Japan.
   [Kohno, Yoshiki] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan.
   [Fukukawa, Chikako; Katagiri, Toyomasa; Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1088639, Japan.
   [Toguchida, Junya] Kyoto Univ, Ctr iPS Res & Applicat, ICeMS, Kyoto 6068507, Japan.
RP Nagayama, S, Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan.
EM nagayama@kuhp.kyoto-u.ac.jp
CR BRYJA V, 2007, ACTA PHYSIOL, V190, P55, DOI
   10.1111/j.1748-1716.2007.01688.x
   FUKUKAWA C, 2008, CANCER SCI, V99, P432, DOI
   10.1111/j.1349-7006.2007.00701.x
   GILES RH, 2003, BBA-REV CANCER, V1653, P1, DOI
   10.1016/S0304-419X(03)00005-2
   GOLAN T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200
   HAMA Y, 2007, CANCER RES, V67, P2791, DOI 10.1158/0008-5472.CAN-06-3315
   HOLCOMBE RF, 2002, MOL PATHOL, V55, P220
   KATOH M, 2002, INT J MOL MED, V10, P683
   KRAJEWSKA M, 1996, AM J PATHOL, V148, P1567
   LI JN, 2005, GASTROENTEROLOGY, V128, P1907, DOI
   10.1053/j.gastro.2005.02.067
   NAGAYAMA S, 2002, CANCER RES, V62, P5859
   NAGAYAMA S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780
   REYA T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   ROMANROMAN S, 2004, J BIOL CHEM, V279, P5725, DOI 10.1074/jbc.M309233200
   SAITOH T, 2002, INT J ONCOL, V20, P117
   SCHNEIKERT J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310
   SEGDITSAS S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   SPARKS AB, 1998, CANCER RES, V58, P1130
   TERASAKI H, 2002, INT J MOL MED, V9, P107
   UENO MHK, 2008, NEOPLASIA, V10, P697
   VINCAN E, 2004, FRONT BIOSCI, V9, P1023
   ZIMMERMANN KC, 1999, CANCER RES, V59, P198
NR 21
TC 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAR
PY 2009
VL 100
IS 3
BP 405
EP 412
DI 10.1111/j.1349-7006.2008.01052.x
PG 8
SC Oncology
GA 408QR
UT ISI:000263450200007
ER

PT J
AU Shimizu, Y
   Takamori, A
   Utsunomiya, A
   Kurimura, M
   Yamano, Y
   Hishizawa, M
   Hasegawa, A
   Kondo, F
   Kurihara, K
   Harashima, N
   Watanabe, T
   Okamura, J
   Masuda, T
   Kannagi, M
AF Shimizu, Yukiko
   Takamori, Ayako
   Utsunomiya, Atae
   Kurimura, Mayumi
   Yamano, Yoshihisa
   Hishizawa, Masakatsu
   Hasegawa, Atsuhiko
   Kondo, Fumiaki
   Kurihara, Kiyoshi
   Harashima, Nanae
   Watanabe, Toshiki
   Okamura, Jun
   Masuda, Takao
   Kannagi, Mari
TI Impaired Tax-specific T-cell responses with insufficient control of
   HTLV-1 in a subgroup of individuals at asymptomatic and smoldering
   stages
SO CANCER SCIENCE
LA English
DT Article
ID VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; PERIPHERAL-BLOOD
   LYMPHOCYTES; LEUKEMIA-LYMPHOMA; PROVIRAL DNA; IMMUNE-RESPONSE;
   CARRIERS; LEUKEMIA/LYMPHOMA; EXPRESSION; LOAD
AB Human T-cell leukemia virus type-1 (HTLV-1)-specific T-cell immunity, a
   potential antitumor surveillance system in vivo, is impaired in adult
   T-cell leukemia (ATL). In this study, we aimed to clarify whether the
   T-cell insufficiency in ATL is present before the disease onset or
   occurs as a consequence of the disease. We investigated T-cell
   responses against Tax protein in peripheral blood mononuclear cells
   (PBMCs) from individuals at earlier stages of HTLV-1-infection,
   including 21 asymptomatic HTLV-1 carriers (ACs) and four patients with
   smoldering-type ATL (sATL), whose peripheral lymphocyte count was in
   normal range. About 30% of samples tested showed clear Tax-specific
   interferon (IFN)-gamma producing responses. Proviral loads in this
   group were significantly lower than those in the other less-specific
   response group. The latter group was further divided to two subgroups
   with or without emergence of Tax-specific responses following depletion
   of CC chemokine receptor 4 (CCR4)(+) cells that contained
   HTLV-1-infected cells. In the PBMCs with Tax-specific responses, CD8(+)
   cells efficiently suppressed HTLV-1 p19 production in culture. The
   remaining group without the emergence of Tax-specific response after
   CCR4(+) cell-depletion included at least two sATL and one AC samples,
   which spontaneously produced HTLV-1 p19 in culture, where
   tetramer-binding, Tax-specific cytotoxic T-lymphocytes were either
   undetectable or unresponsive. Our results indicated that
   HTLV-1-specific T-cell responsiveness widely differed among HTLV-1
   carriers, and that impairment of HTLV-1-specific T-cell responses was
   observed not only in advanced ATL patients but also in a subpopulation
   at earlier stages, which was associated with insufficient control of
   HTLV-1. (Cancer Sci 2009; 100: 481-489).
C1 [Shimizu, Yukiko; Takamori, Ayako; Hasegawa, Atsuhiko; Kondo, Fumiaki; Kurihara, Kiyoshi; Harashima, Nanae; Masuda, Takao; Kannagi, Mari] Tokyo Med & Dent Univ, Dept Immunotherapeut, Grad Sch, Bunkyo Ku, Tokyo 1138519, Japan.
   [Utsunomiya, Atae] Imamura Bunin Hosp, Dept Hematol, Kagoshima 8900064, Japan.
   [Kurimura, Mayumi] Kamigotoh Hosp, Shin Kamigoto, Nagasaki, Japan.
   [Yamano, Yoshihisa] St Marianna Univ, Sch Med, Inst Med Sci, Dept Genome Sci,Miyamae Ku, Kawasaki, Kanagawa 2168512, Japan.
   [Hishizawa, Masakatsu] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 5058507, Japan.
   [Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan.
   [Okamura, Jun] Kyushu Natl Canc Ctr, Div Clin Res, Minami Ku, Fukuoka 8111395, Japan.
RP Kannagi, M, Tokyo Med & Dent Univ, Dept Immunotherapeut, Grad Sch,
   Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM kann.impt@tmd.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology of
   Japan [17013028]; Ministry of Health, Welfare, and Labor of Japan ;
   Public Trust Haraguchi Memorial Cancer Research Fund 
FX We thank Ms. Minako Nakashima and Ms. Yasuko Tsuji (Imamura Bun-in
   Hospital, Kagoshima, Japan) for coordination of clinical samples. This
   study was supported by Grant 17013028 from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan; a grant for an
   anticancer project from the Ministry of Health, Welfare, and Labor of
   Japan; and the Public Trust Haraguchi Memorial Cancer Research Fund.
   The authors have no financial conflict of interest.
CR ARISAWA K, 2000, INT J CANCER, V85, P319
   ARNULF B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176
   ASQUITH B, 2005, J GEN VIROL 5, V86, P1515, DOI 10.1099/vir.0.08766-0
   BANGHAM CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970
   CHEN SM, 2006, INT IMMUNOL, V18, P269, DOI 10.1093/intimm/dxh366
   GESSAIN A, 1985, LANCET, V2, P407
   HANABUCHI S, 2001, J NATL CANCER I, V93, P1775
   HARASHIMA N, 2004, CANCER RES, V64, P391
   HARASHIMA N, 2005, J VIROL, V79, P10088, DOI
   10.1128/JVI.79.15.10088-10092.2005
   HASEGAWA A, 2003, J VIROL, V77, P2956, DOI
   10.1128/JVI.77.5.2956-2963.2003
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476
   HISADA M, 1998, INT J CANCER, V77, P188
   HISADA M, 2001, INT J CANCER, V91, P497
   IELLEM A, 2001, J EXP MED, V194, P847
   ISHIDA T, 2003, CLIN CANCER RES 1, V9, P3625
   ITOYAMA Y, 1988, NEUROLOGY, V38, P1302
   IWATSUKI K, 1995, BRIT J DERMATOL, V133, P861
   JACOBSON S, 1988, ANN NEUROL S, V23, S196
   JACOBSON S, 1990, NATURE, V348, P245
   KANNAGI M, 1983, J IMMUNOL, V130, P2942
   KANNAGI M, 1984, J IMMUNOL, V133, P1037
   KARUBE K, 2004, BRIT J HAEMATOL, V126, P81, DOI
   10.1111/j.1365-2141.2004.04999.x
   KATSUKI T, 1987, JPN J CANCER RES, V78, P639
   KOHNO T, 2005, CANCER SCI, V96, P527, DOI
   10.1111/j.1349-7006.2005.00080.x
   KOMORI K, 2006, J VIROL, V80, P7375, DOI 10.1128/JVI.00230-06
   KRAMER A, 1989, LANCET, V2, P923
   KURIHARA K, 2006, J IMMUNOL METHODS, V313, P61, DOI
   10.1016/j.jim.2006.03.013
   MATSUBARA Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038/sj.leu.2403628
   NAGAI M, 1998, J NEUROVIROL, V4, P586
   NAKADA K, 1987, INT J CANCER, V40, P145
   OHASHI T, 2000, J VIROL, V74, P9610
   OKAYAMA A, 2004, INT J CANCER, V110, P621, DOI 10.1002/ijc.20144
   OSAME M, 1986, LANCET, V1, P1031
   PARKER CE, 1992, VIROLOGY, V188, P628
   POIESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415
   SAKAGUCHI S, 2001, IMMUNOL REV, V182, P18
   SAKAI JA, 2001, BLOOD, V98, P1506
   SEBASTIANI S, 2001, J IMMUNOL, V166, P996
   SHEVACH EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821
   SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428
   SONODA J, 2004, CANCER SCI, V95, P596
   TAJIMA K, 1990, INT J CANCER, V45, P237
   TANAKA G, 2005, J INFECT DIS, V191, P1140
   UCHIYAMA T, 1977, BLOOD, V50, P481
   YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169
   YOSHIE O, 2002, BLOOD, V99, P1505
NR 46
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD MAR
PY 2009
VL 100
IS 3
BP 481
EP 489
DI 10.1111/j.1349-7006.2008.01054.x
PG 9
SC Oncology
GA 408QR
UT ISI:000263450200017
ER

PT J
AU Yang, JJ
   Yang, WJ
   Cheng, C
   Devidas, M
   Cao, XY
   Campana, D
   Borowitz, MJ
   Willman, CL
   Bowman, WP
   Reaman, G
   Carroll, WL
   Hunger, SP
   Evans, WE
   Pui, CH
   Relling, MV
AF Yang, Jun J.
   Yang, Wenjian
   Cheng, Cheng
   Devidas, Meenakshi
   Cao, Xueyuan
   Campana, Dario
   Borowitz, Michael. J.
   Willman, Cheryl L.
   Bowman, William Paul
   Reaman, Gregory
   Carroll, William L.
   Hunger, Stephen P.
   Evans, William E.
   Pui, Ching-Hon
   Relling, Mary V.
TI Genetically Defined Racial Differences Underlie Risk of Relapse in
   Childhood Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Jun J.; Yang, Wenjian; Cheng, Cheng; Cao, Xueyuan; Campana, Dario; Evans, William E.; Pui, Ching-Hon; Relling, Mary V.] St Jude Childrens Hosp, Memphis, TN 38105 USA.
   [Devidas, Meenakshi] Univ Florida, Coll Med, Dept Epidemiol & Hlth Policy Res, Gainesville, FL USA.
   [Borowitz, Michael. J.] Johns Hopkins Univ, Baltimore, MD USA.
   [Willman, Cheryl L.] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA.
   [Bowman, William Paul] Cook Childrens Med Ctr, Ft Worth, TX USA.
   [Reaman, Gregory] Childrens Natl Med Ctr, Washington, DC 20010 USA.
   [Carroll, William L.] NYU, Inst Canc, New York, NY USA.
   [Hunger, Stephen P.] Childrens Hosp, Aurora, CO USA.
   [Hunger, Stephen P.] Univ Colorado, Denver Sch Med, Aurora, CO USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 11
EP 12
PG 2
SC Hematology
GA 389OP
UT ISI:000262104700015
ER

PT J
AU Amn, A
   Lin, J
   Yang, GP
   Stemkowski, S
AF Amn, Alpesh
   Lin, Jay
   Yang, Guiping
   Stemkowski, Steve
TI Clinical and Economic Outcomes Following Full or Partial ACCP
   Recommended Prophylaxis in Cancer Patients at Risk of Venous
   Thromboembolism
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Amn, Alpesh] Univ Calif Irvine, Div Gen Internal Med, Dept Med, Orange, CA 92668 USA.
   [Lin, Jay] Sanofi Aventis Us Inc, Bridgewater, NJ USA.
   [Yang, Guiping; Stemkowski, Steve] Premier Inc, Charlotte, NC USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 69
EP 70
PG 2
SC Hematology
GA 389OP
UT ISI:000262104700170
ER

PT J
AU Chen, SH
   Yang, WJ
   Fang, YP
   Stocco, G
   Crews, KR
   Pui, CH
   Evans, WE
   Relling, MV
AF Chen, Shih-Hsiang
   Yang, Wenjian
   Fang, Yiping
   Stocco, Gabriele
   Crews, Kristine R.
   Pui, Ching-Hon
   Evans, William E.
   Relling, Mary V.
TI A Genome-Wide Approach Identifies Variations in the Aspartate
   Metabolism Pathway That Are Associated with Asparaginase Sensitivity
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chen, Shih-Hsiang] Chang Gung Mem Hosp, Dept Pediat, Div Hematol Oncol, Tao Yuan, Taiwan.
   [Yang, Wenjian; Stocco, Gabriele; Crews, Kristine R.; Evans, William E.; Relling, Mary V.] St Jude Childrens Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
   [Fang, Yiping] St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA.
   [Pui, Ching-Hon] St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 86
EP 86
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700214
ER

PT J
AU Trevino, LR
   Shimasaki, N
   Yang, WJ
   Panetta, JC
   Cheng, C
   Pei, DQ
   Chan, D
   Sparreboom, A
   Giacomini, KM
   Pui, CH
   Evans, WE
   Relling, MV
AF Trevino, Lisa R.
   Shimasaki, Noriko
   Yang, Wenjian
   Panetta, John C.
   Cheng, Cheng
   Pei, Deqing
   Chan, Diana
   Sparreboom, Alex
   Giacomini, Kathleen M.
   Pui, Ching-Hon
   Evans, William E.
   Relling, Mary V.
TI A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of
   Methotrexate Pharmacokinetics and Adverse Effects
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Trevino, Lisa R.; Shimasaki, Noriko; Yang, Wenjian; Panetta, John C.; Cheng, Cheng; Pei, Deqing; Chan, Diana; Sparreboom, Alex; Pui, Ching-Hon; Evans, William E.; Relling, Mary V.] St Jude Childrens Hosp, Memphis, TN 38105 USA.
   [Giacomini, Kathleen M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 86
EP 86
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700215
ER

PT J
AU Yang, Y
   Ritchie, JP
   Swain, T
   Naggi, A
   Torri, G
   Casu, B
   Pisano, C
   Carminati, P
   Vlodavsky, I
   Sanderson, RD
AF Yang, Yang
   Ritchie, Joseph P.
   Swain, Telisha
   Naggi, Annamaria
   Torri, Giangiacomo
   Casu, Benito
   Pisano, Claudio
   Carminati, Paolo
   Vlodavsky, Israel
   Sanderson, Ralph D.
TI The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma
   Growth In Vivo
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Yang; Ritchie, Joseph P.; Swain, Telisha; Sanderson, Ralph D.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Yang, Yang; Ritchie, Joseph P.; Swain, Telisha; Sanderson, Ralph D.] Univ Alabama, Dept Pathol, Ctr Metab Bone Dis, Birmingham, AL 35294 USA.
   [Naggi, Annamaria; Torri, Giangiacomo; Casu, Benito] GRonzoni Inst Chem & Biochem Res, Milan, Italy.
   [Pisano, Claudio] Sigma Tau Ind Farmaceut Riunite SpA, Pomezia, Italy.
   [Carminati, Paolo] Sigma Tau Res Switzerland SA, Milan, Italy.
   [Vlodavsky, Israel] Technion Israel Inst Technol, Canc & Vasc Biol Res Ctr, Bruce Rappaport Fac Med, IL-32000 Haifa, Israel.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 97
EP 98
PG 2
SC Hematology
GA 389OP
UT ISI:000262104700247
ER

PT J
AU Huang, G
   Elf, S
   Yan, XM
   Wang, L
   Liu, Y
   Sashida, G
   Gural, A
   Menendez, S
   Lee, J
   Yang, YY
   Zhao, XY
   Nimer, SD
AF Huang, Gang
   Elf, Shannon
   Yan, Xiaomei
   Wang, Lan
   Liu, Yan
   Sashida, Goro
   Gural, Alex
   Menendez, Silvia
   Lee, Jennifer
   Yang, Youyang
   Zhao, Xinyang
   Nimer, Stephen D.
TI Previously Unknown Interactions Between AML1 and MLL Provide Epigenetic
   Regulation of Gene Expression in Normal Hematopoiesis and in Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Huang, Gang; Elf, Shannon; Yan, Xiaomei; Wang, Lan; Liu, Yan; Sashida, Goro; Gural, Alex; Menendez, Silvia; Lee, Jennifer; Yang, Youyang; Zhao, Xinyang; Nimer, Stephen D.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
NR 0
TC 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 110
EP 110
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700283
ER

PT J
AU Alipio, Z
   Xu, D
   Yang, JC
   Fink, LM
   Xu, W
   Ward, DC
   Ma, YP
AF Alipio, Zaida
   Xu, Dan
   Yang, Jianchang
   Fink, Louis M.
   Xu, Wilson
   Ward, David C.
   Ma, Yupo
TI Reprogrammed Murine Fibroblasts Differentiated into Hematopoietic
   Progenitors Are Able to Successfully Engraft and Repopulate the Bone
   Marrow
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Alipio, Zaida; Xu, Dan; Yang, Jianchang; Fink, Louis M.; Xu, Wilson; Ward, David C.; Ma, Yupo] Nevada Canc Inst, Las Vegas, NV USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 150
EP 150
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700390
ER

PT J
AU Mullighan, CG
   Su, XP
   Zhang, JH
   Radtke, I
   Phillips, LA
   Miller, CB
   Ma, J
   Liu, W
   Cheng, C
   Harvey, RC
   Chen, IM
   Clifford, R
   Carroll, WL
   Reaman, G
   Devidas, M
   Gerhard, DS
   Yang, WJ
   Bowman, WP
   Shurtleff, SA
   Relling, MV
   Smith, M
   Hunger, SP
   Willman, CL
   Downing, JR
AF Mullighan, Charles G.
   Su, Xiaoping
   Zhang, Jinghui
   Radtke, Ina
   Phillips, Letha A.
   Miller, Christopher B.
   Ma, Jing
   Liu, Wei
   Cheng, Cheng
   Harvey, Richard C.
   Chen, I-Ming
   Clifford, Robert
   Carroll, William L.
   Reaman, Gregory
   Devidas, Meenakshi
   Gerhard, Daniela S.
   Yang, Wenjian
   Bowman, W. Paul
   Shurtleff, Sheila A.
   Relling, Mary V.
   Smith, Malcolm
   Hunger, Stephen P.
   Willman, Cheryl L.
   Downing, James R.
TI Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired
   Maturation in B-Progenitor Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ma, Jing] St Jude Childrens Hosp, Hartwell Ctr, Memphis, TN 38105 USA.
   [Zhang, Jinghui] NCI, Ctr Biomed Informat & Informat Technol, NIH, Rockville, MD USA.
   [Harvey, Richard C.; Chen, I-Ming; Willman, Cheryl L.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
   [Clifford, Robert] NCI, Lab Populat Genet, NIH, Rockville, MD USA.
   [Carroll, William L.] NYU, Inst Canc, New York, NY USA.
   [Reaman, Gregory] Childrens Natl Med Ctr, Washington, DC 20010 USA.
   [Devidas, Meenakshi] Childrens Oncol Grp, Gainesville, FL USA.
   [Devidas, Meenakshi] Univ Florida, Gainesville, FL USA.
   [Smith, Malcolm] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
   [Bowman, W. Paul] Cook Childrens Med Ctr, Ft Worth, TX USA.
   [Hunger, Stephen P.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
   [Hunger, Stephen P.] Childrens Hosp, Aurora, CO USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 163
EP 163
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700428
ER

PT J
AU Xu, D
   Alipio, Z
   Yang, JC
   Fink, LM
   Xu, W
   Ward, DC
   Ma, YP
AF Xu, Dan
   Alipio, Zaida
   Yang, Jianchang
   Fink, Louis M.
   Xu, Wilson
   Ward, David C.
   Ma, Yupo
TI Phenotypic Correction of Hemophilia a Using An Ips-Based Cellular
   Therapy
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Xu, Dan; Alipio, Zaida; Yang, Jianchang; Fink, Louis M.; Xu, Wilson; Ward, David C.; Ma, Yupo] Nevada Canc Inst, Las Vegas, NV USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 194
EP 194
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700515
ER

PT J
AU Lopes, EC
   Cerchietti, L
   Yang, SN
   Melnick, A
   Chiosis, G
AF Lopes, Eloisi Caldas
   Cerchietti, Leandro
   Yang, Shao Ning
   Melnick, Ari
   Chiosis, Gabriela
TI Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in
   Diffuse Large-B Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lopes, Eloisi Caldas; Chiosis, Gabriela] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Cerchietti, Leandro; Yang, Shao Ning; Melnick, Ari] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 225
EP 225
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700603
ER

PT J
AU Yang, J
   Cao, YB
   Hong, SY
   Li, HY
   Kwak, LW
   Yi, Q
AF Yang, Jing
   Cao, Yabing
   Hong, Sungyongl
   Li, Haiyan
   Kwak, Larry W.
   Yi, Qing
TI Human-Like Mouse Models for Testing the Efficacy and Safety of
   Anti-beta(2)-Microglobulin Monoclonal Antibodies to Treat Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Jing; Cao, Yabing; Hong, Sungyongl; Li, Haiyan; Kwak, Larry W.; Yi, Qing] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 239
EP 239
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700642
ER

PT J
AU Yang, XV
   Banerjee, Y
   Femandez, JA
   Deguchi, H
   Xu, X
   Mosnier, LO
   Urbanus, R
   Degroot, PG
   White, TC
   McCarty, OJT
   Griffin, JH
AF Yang, Xia V.
   Banerjee, Yajnavalka
   Femandez, Jose A.
   Deguchi, Hiroshi
   Xu, Xiao
   Mosnier, Laurent O.
   Urbanus, Roift
   Degroot, Phillip G.
   White, Tara C.
   McCarty, Owen J. T.
   Griffin, John H.
TI Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a
   Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2)
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Xia V.; Banerjee, Yajnavalka; Femandez, Jose A.; Deguchi, Hiroshi; Xu, Xiao; Mosnier, Laurent O.; Griffin, John H.] Scripps Res Inst, La Jolla, CA 92037 USA.
   [Degroot, Phillip G.] Univ Med Ctr Utrecht, Lab Clin Chem & Haemataol, Utrecht, Netherlands.
   [White, Tara C.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Sch Med, Div Biomed Engn, Portland, OR 97201 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 259
EP 259
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700696
ER

PT J
AU Zhuang, JL
   Yang, L
   Lwin, ST
   Edwards, CM
   Edwards, JR
   Mundy, GR
AF Zhuang, Junling
   Yang, Li
   Lwin, Seint T.
   Edwards, Claire M.
   Edwards, James R.
   Mundy, Gregory R.
TI Osteoclasts in Myeloma Are Derived from Gr-1(+)CD11b(+) Myeloid Immune
   Suppressor Cells of the Bone Marrow Niche in Vivo
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Li] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 273
EP 273
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700737
ER

PT J
AU Yang, L
   Orlowski, RZ
AF Yang, Lin
   Orlowski, Robert Z.
TI ZKSCAN3, a Novel Zinc Finger Transcription Factor, Regulates Cyclin D2
   Expression in Multiple Myeloma (MM) Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Lin] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 278
EP 278
PG 1
SC Hematology
GA 389OP
UT ISI:000262104700750
ER

PT J
AU Wang, JB
   Wu, T
   Yang, JF
   Zhang, JP
   Cao, XY
   Yin, YM
   Sun, Y
   Luo, RM
   Lu, DP
   Tong, CR
AF Wang, Jing-Bo
   Wu, Tong
   Yang, Jun-Fang
   Zhang, Jian-Ping
   Cao, Xing-Yu
   Yin, Yu-Ming
   Sun, Yuan
   Luo, Rong-Mu
   Lu, Dao-Pei
   Tong, Chun-Rong
TI Management of Early Leukemia Relapse after Allogeneic Hematopoietic
   Stem Cell Transplantation by Donor's Dendritic Cell-Primed
   Cytokine-Induced Killer Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Jing-Bo; Wu, Tong; Yang, Jun-Fang; Zhang, Jian-Ping; Cao, Xing-Yu; Yin, Yu-Ming; Sun, Yuan; Luo, Rong-Mu; Lu, Dao-Pei; Tong, Chun-Rong] Beijing Daopei Hosp, Beijing, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 307
EP 308
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701053
ER

PT J
AU Yang, Y
   Ritchie, JP
   Suva, LJ
   Sanderson, RD
AF Yang, Yang
   Ritchie, Joseph P.
   Suva, Larry J.
   Sanderson, Ralph D.
TI Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Yang; Ritchie, Joseph P.; Sanderson, Ralph D.] Univ Alabama, Dept Pathol, Ctr Metab Bone Dis, Birmingham, AL 35294 USA.
   [Yang, Yang; Ritchie, Joseph P.; Sanderson, Ralph D.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Suva, Larry J.] Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Little Rock, AR 72205 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 311
EP 312
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701065
ER

PT J
AU Rao, R
   Fiskus, W
   Yang, YH
   Joshi, R
   Fernandez, P
   Lee, P
   Jillella, A
   Tao, JG
   Atadja, P
   Sotomayor, E
   Bhalla, KN
AF Rao, Rekha
   Fiskus, Warren
   Yang, Yonghua
   Joshi, Rajeshree
   Fernandez, Pravina
   Lee, Pearl
   Jillella, Anand
   Tao, Jianguo
   Atadja, Peter
   Sotomayor, Eduardo
   Bhalla, Kapil N.
TI Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded
   Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human
   Mantle Cell Lymphoma Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Rao, Rekha; Fiskus, Warren; Yang, Yonghua; Joshi, Rajeshree; Fernandez, Pravina; Lee, Pearl; Jillella, Anand; Bhalla, Kapil N.] Med Coll Georgia, MCG Canc Ctr, Augusta, GA 30912 USA.
   [Tao, Jianguo; Sotomayor, Eduardo] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   [Atadja, Peter] Novartis Inst Biomed Res, Cambridge, MA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 327
EP 328
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701111
ER

PT J
AU Lange, B
   Yang, RK
   Gan, J
   Hank, JA
   Sievers, E
   Gerbing, R
   Alonzo, T
   Sondel, PM
AF Lange, Beverly
   Yang, Richard K.
   Gan, Jacek
   Hank, Jaqueline A.
   Sievers, Eric
   Gerbing, Robert
   Alonzo, Todd
   Sondel, Paul M.
TI Clinical and Serologic Interleukin 2 Receptor alpha Response to
   Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric
   Acute Myeloid Leukemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lange, Beverly] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Yang, Richard K.; Gan, Jacek; Hank, Jaqueline A.; Sondel, Paul M.] Univ Wisconsin, Sch Med, Madison, WI 53706 USA.
   [Sievers, Eric] Seattle Genet Inc, Bothell, WA USA.
   [Gerbing, Robert] Childrens Oncol Grp, Arcadia, CA USA.
   [Alonzo, Todd] Univ So Calif, Keck Sch Med, Arcadia, CA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 353
EP 353
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701183
ER

PT J
AU Yang, LK
   Sun, MF
   Manithody, C
   Gailani, D
   Rezaie, AR
AF Yang, Likui
   Sun, Mao-fu
   Manithody, Chandrashekhara
   Gailani, David
   Rezaie, Alireza R.
TI Characterization of Heparin Binding Site Residues on the Catalytic
   Domain of Factor XIa.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Likui; Manithody, Chandrashekhara; Rezaie, Alireza R.] St Louis Univ, Sch Med, St Louis, MO USA.
   [Sun, Mao-fu; Gailani, David] Vanderbilt Univ, Nashville, TN USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 374
EP 375
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701242
ER

PT J
AU Chen, HR
   Si, YJ
   He, XP
   Yang, K
   Hu, B
   Du, ZL
   Zhang, XM
   Zhang, CC
AF Chen, Huiren
   Si, Yingjian
   He, Xuepeng
   Yang, Kai
   Hu, Bo
   Du, Zhenlan
   Zhang, Xiaomei
   Zhang, Chuancang
TI HLA-Mismatched Hematopoietic Stem Cell Transplantation for Treatment of
   Chronic Myelogenous Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chen, Huiren; Si, Yingjian; He, Xuepeng; Yang, Kai; Hu, Bo; Du, Zhenlan; Zhang, Xiaomei; Zhang, Chuancang] Gen Hosp Beijing Millitary Reg, Beijing, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 406
EP 407
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701337
ER

PT J
AU Ye, JY
   Chan, GC
   Chan, S
   Luo, JC
   Yang, M
AF Ye, Jie Yu
   Chan, Godfrey ChiFung
   Chan, Shing
   Luo, Jue Cong
   Yang, Mo
TI Recombinant PDGF-BB Enhances Platelet Recovery in Mice with Radiation
   Induced Thromobocytopenia.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ye, Jie Yu; Chan, Shing; Luo, Jue Cong; Yang, Mo] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Godfrey ChiFung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 448
EP 448
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701454
ER

PT J
AU Yang, M
   Chan, GC
   Ye, JY
   Liu, C
AF Yang, Mo
   Chan, Godfrey ChiFung
   Ye, Jie Yu
   Liu, Chang
TI Angelica Polysaccharides Promotes Thrombopoiesis through the
   Phosphatidylinositol 3-Kinase/Akt Pathway.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Mo; Ye, Jie Yu] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Godfrey ChiFung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Chang] Univ Hong Kong, Mol Chinese Med Lab, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 450
EP 451
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701462
ER

PT J
AU Yang, M
   Zhou, M
   Ye, JY
   Cheung, YF
   Chan, S
   Ha, SY
   Chan, GC
AF Yang, Mo
   Zhou, Min
   Ye, Jie Yu
   Cheung, Yiu Fai
   Chan, Shing
   Ha, Shau Yin
   Chan, Godfrey ChiFung
TI The Effect and Underlying Mechanism of Melatonin on Platelet Formation
   and Survival in a Thrombocytopenic Model.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Mo; Ye, Jie Yu; Cheung, Yiu Fai; Chan, Shing; Ha, Shau Yin] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Zhou, Min] Chengdu Childres Hosp, Dept Hematol, Chengdu, Peoples R China.
   [Chan, Godfrey ChiFung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 451
EP 451
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701463
ER

PT J
AU Yang, SJ
   Hong, SH
   Lee, GY
   Jung, JY
   Oh, IH
AF Yang, Seung-Jip
   Hong, Seong-Hyun
   Lee, Ga-Young
   Jung, Ju-Young
   Oh, Il-Hoan
TI HoxB4 Effects on Hematopoietic Stem Cells Are Dependent on STAT3
   Activity; A Potential Convergence of Self-Renewing Signals.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Seung-Jip; Hong, Seong-Hyun; Lee, Ga-Young; Jung, Ju-Young] Catholic Univ Korea, Catholic Cell Therapy Ctr, Seoul, South Korea.
   [Oh, Il-Hoan] Catholic Univ Korea, Cell Therapy Ctr, Seoul, South Korea.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 494
EP 495
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701600
ER

PT J
AU Mani, M
   Venkatasubrahmanyam, S
   Sanyal, M
   Yang, YJ
   Huang, J
   Levy, S
   Butte, A
   Weinberg, KI
   Jahn, T
AF Mani, Maheswaran
   Venkatasubrahmanyam, Shivkumar
   Sanyal, Mrinmoy
   Yang, Yujun
   Huang, Jing
   Levy, Shoshana
   Butte, Atul
   Weinberg, Kenneth I.
   Jahn, Thomas
TI Wiskott-Aldrich Syndrome Protein (WASP) Is An Effector of Kit Signaling.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Mani, Maheswaran; Yang, Yujun; Huang, Jing; Weinberg, Kenneth I.; Jahn, Thomas] Stanford Univ, Sch Med, Pediat Stem Cell Transplantat, Stanford, CA 94305 USA.
   [Venkatasubrahmanyam, Shivkumar; Butte, Atul] Stanford Univ, Sch Med, Ctr Biomed Informat Res, Stanford, CA 94305 USA.
   [Sanyal, Mrinmoy; Levy, Shoshana] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 503
EP 503
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701632
ER

PT J
AU Kalra, VK
   Patel, N
   Gonsalves, C
   Yang, MY
   Malik, P
AF Kalra, Vijay K.
   Patel, Nitin
   Gonsalves, Caryn
   Yang, Minyang
   Malik, Punam
TI Placenta Growth Factor Induces 5-Lipoxygenase-Activating Protein Via
   Hypoxia-Inducible Factor-1 alpha and Contributes to Increased
   Leukotrienes in Sickle Cell Disease
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kalra, Vijay K.; Patel, Nitin; Gonsalves, Caryn] USC Keck Sch Med, Los Angeles, CA USA.
   [Yang, Minyang; Malik, Punam] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Expt Hematol & Canc Biol, Cincinnati, OH USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 516
EP 516
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701669
ER

PT J
AU Yang, DT
   Wuerzberger-Davis, S
   Chen, YH
   Yu, M
   Zeng, H
   Bates, P
   Wen, RR
   Wang, D
   Miyamoto, S
AF Yang, David T.
   Wuerzberger-Davis, Shelly
   Chen, Yuhong
   Yu, Mei
   Zeng, Hu
   Bates, Paul
   Wen, Renren
   Wang, Demin
   Miyamoto, Shigeki
TI The Critical Role of I kappa b alpha Dependent Nuclear Export of
   NF-kappa b in B-Cell Development
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, David T.; Wuerzberger-Davis, Shelly; Bates, Paul; Miyamoto, Shigeki] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
   [Chen, Yuhong; Yu, Mei; Zeng, Hu; Wen, Renren; Wang, Demin] Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 545
EP 545
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701754
ER

PT J
AU Yang, ZZ
   Novak, A
   Witzig, TE
   Ansell, SM
AF Yang, Zhi-Zhang
   Novak, Anne
   Witzig, Thomas E.
   Ansell, Stephen M.
TI Malignant B Cell-Derived TGF-beta Controls the Generation of T(H)1,
   T(H)17 and T-reg Cells in the Tumor Microenvironment of B-Cell
   Non-Hodgkin Lymohoma (NHL)
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Zhi-Zhang; Witzig, Thomas E.; Ansell, Stephen M.] Mayo Clin, Rochester, MN USA.
   [Novak, Anne] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 550
EP 551
PG 2
SC Hematology
GA 389OP
UT ISI:000262104701772
ER

PT J
AU Buhmann, R
   Yang, T
   Schifferer, M
   Obermeier, M
   Jaeger, G
   Kolb, HJ
AF Buhmann, Raymund
   Yang, Ting
   Schifferer, Monica
   Obermeier, Martin
   Jaeger, Gundula
   Kolb, Hans-Jochem
TI Therapeutic Nucleic Acids: A Potential Source of Resistance to Cancer,
   Antiviral and Immunosuppressive Therapy
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Buhmann, Raymund; Kolb, Hans-Jochem] Univ Munich, Klinikum Grosshadern, Med Clin 3, KGMC, D-8000 Munich, Germany.
   [Yang, Ting] Fujian Med Univ, Union Hosp, Dept Hematol, Fuzhou, Fujian, Peoples R China.
   [Schifferer, Monica] Helmholtz Zentrum Munchen, Munich, Germany.
   [Obermeier, Martin; Jaeger, Gundula] Max Von Pettenkofer Inst, D-8000 Munich, Germany.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 571
EP 571
PG 1
SC Hematology
GA 389OP
UT ISI:000262104701835
ER

PT J
AU Brown, RD
   Kabani, K
   Yang, S
   Esther, A
   Ho, PJ
   Gibson, J
   Joshua, DE
AF Brown, Ross D.
   Kabani, Karieshma
   Yang, Shihong
   Esther, Aklilu
   Ho, Phoebe Joy
   Gibson, John
   Joshua, Douglas E.
TI Trogocytosis in Multiple Myeloma
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Brown, Ross D.; Kabani, Karieshma; Yang, Shihong; Esther, Aklilu; Ho, Phoebe Joy; Gibson, John; Joshua, Douglas E.] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 594
EP 594
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702015
ER

PT J
AU Zhang, W
   Yang, M
   Chan, S
   Chan, GC
AF Zhang, Wei
   Yang, Mo
   Chan, Shing
   Chan, Godfrey ChiFung
TI TPO Exerts a Protective Effect on Iron-Induced Apoptosis Via Erk1/2
   Signaling in Human Mesenchymal Stem Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhang, Wei] Tianjin Univ, Coll Med, Sch Lab Med, Tianjin 300072, Peoples R China.
   [Yang, Mo; Chan, Shing] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Godfrey ChiFung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 656
EP 656
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702204
ER

PT J
AU Yang, M
   Chan, S
   Cheung, YF
   Hai, SY
   Chan, GC
AF Yang, Mo
   Chan, Shing
   Cheung, Yiu Fai
   Hai, Shau Yin
   Chan, Godfrey ChiFung
TI Iron-Overload Induces Apoptosis in Cardiomyocytes and Hepatocytes Via
   Mitochondrial/Caspase-3 Pathways
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Mo; Chan, Shing; Cheung, Yiu Fai; Hai, Shau Yin] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Godfrey ChiFung] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 656
EP 656
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702205
ER

PT J
AU Wang, CH
   Lin, CY
   Yang, CC
   Chuang, YJ
AF Wang, Chieh-Hue
   Lin, Chia-Yi
   Yang, Chung-Chi
   Chuang, Yung-Jen
TI Placenta Endothelial Protein 1 Is a Novel Neural Guidance Molecule on
   Angiogenesis.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Chieh-Hue; Lin, Chia-Yi; Chuang, Yung-Jen] Inst Bioinformat & Struct Biol, Dept Life Sci, Hsinchu, Taiwan.
   [Yang, Chung-Chi] Tao Yuan Armed Forces Gen Hosp, Dept Med, Div Cardiol, Tao Yuan, Taiwan.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 663
EP 664
PG 2
SC Hematology
GA 389OP
UT ISI:000262104702231
ER

PT J
AU Douer, D
   Watkins, K
   Mark, L
   Ann, M
   Yang, AS
   Avramis, VI
AF Douer, Dan
   Watkins, Kristy
   Mark, Lisa
   Ann, Mohrbacher
   Yang, Allen S.
   Avramis, Vassilios I.
TI Sustained and Prolonged Asparagine Depletion by Multiple Doses of
   Intravenous Pegylated Asparaginase in the Treatment of Adults with
   Newly Diagnosed Acute Lymphoblastic Leukemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Douer, Dan; Watkins, Kristy; Mark, Lisa; Ann, Mohrbacher; Yang, Allen S.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Avramis, Vassilios I.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 673
EP 673
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702261
ER

PT J
AU Wang, JM
   Lue, SQ
   Yang, JM
   Song, XM
   Chen, L
   Hou, J
   Zhang, WP
   Huan, CM
   Ni, X
   Qiu, HY
AF Wang, Jianmin
   Lue, Shuqing
   Yang, Jianmin
   Song, Xianmin
   Chen, Li
   Hou, Jun
   Zhang, Weiping
   Huan, Chongmei
   Ni, Xiong
   Qiu, Huiying
TI A Homoharringtonine-Based Protocol Is Superior to Daunorubicin and
   Idarubicin-Based Protocols in Elderly Patients with Newly-Diagnosed
   Acute Myeloid Leukemia with Comparable Effects and Low Toxicities:
   Experience in a Chinese Center.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Wang, Jianmin; Lue, Shuqing; Yang, Jianmin; Song, Xianmin; Chen, Li; Hou, Jun; Zhang, Weiping; Huan, Chongmei; Ni, Xiong; Qiu, Huiying] Mil Med Coll 2, Changhai Hosp, Dept Hematol, Shanghai, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 679
EP 679
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702279
ER

PT J
AU Yang, DH
   Ahn, JS
   Kim, YK
   Lee, JJ
   Choi, YJ
   Shin, HJ
   Chung, JS
   Moon, JH
   Chae, YS
   Kim, JG
   Sohn, SK
   Kim, HJ
AF Yang, Deok-Hwan
   Ahn, Jae Sook
   Kim, Yeo-Kyeoung
   Lee, Je-Jung
   Choi, Young Jin
   Shin, Ho Jin
   Chung, Joo-Seop
   Moon, Joon Ho
   Chae, Yee Soo
   Kim, Jong Gwang
   Sohn, Sang Kyun
   Kim, Hyeoung-Joon
TI Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large
   B-Cell Lymphoma: Which Has a More Differential Potential for Predicting
   the Outcomes after R-CHOP Chemotherapy
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Deok-Hwan; Ahn, Jae Sook] Chonnam Natl Univ, Hwasun Hosp, Jeollanam Do, South Korea.
   [Ahn, Jae Sook; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon] Chonnam Natl Univ, Sch Med, Jeollanam Do, South Korea.
   [Choi, Young Jin; Shin, Ho Jin; Chung, Joo-Seop] Pusan Natl Univ, Sch Med, Pusan, South Korea.
   [Moon, Joon Ho; Chae, Yee Soo; Kim, Jong Gwang] Kyungpook Natl Univ Hosp, Taegu, South Korea.
   [Sohn, Sang Kyun] Korean Soc Hematol, Seoul, South Korea.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 698
EP 699
PG 2
SC Hematology
GA 389OP
UT ISI:000262104702336
ER

PT J
AU Lin, CN
   Kao, CY
   Hong, CL
   Ye, PQ
   Miao, CH
   Hamaguchi, N
   Wu, HL
   Shi, GY
   Yang, YL
   Yu, IS
   Tao, MH
   Fang, CC
   Liu, YL
   High, KA
   Lin, SW
AF Lin, Chia-Ni
   Kao, Chung-Yang
   Hong, Chia-Lun
   Ye, Peiqing
   Miao, Carol H.
   Hamaguchi, Nobuko
   Wu, Hua-Lin
   Shi, Guey-Yueh
   Yang, Yung-Li
   Yu, I-Shing
   Tao, Mi-Hua
   Fang, Cheng-Chieh
   Liu, Yi-Lin
   High, Katherine A.
   Lin, Shu-Wha
TI Engineered Factor IX with Augmented Clotting Activities in a Hemophilia
   B Mouse Model.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lin, Chia-Ni; Kao, Chung-Yang; Hong, Chia-Lun; Yu, I-Shing; Lin, Shu-Wha] Natl Taiwan Univ, Coll Med, Dept Clin Sci & Med Biotechnol, Taipei 10764, Taiwan.
   [Ye, Peiqing; Miao, Carol H.] Seattle Childrens Hosp Res Inst, Seattle, WA USA.
   [Miao, Carol H.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Hamaguchi, Nobuko] Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA.
   [Wu, Hua-Lin; Shi, Guey-Yueh] Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan.
   [Yang, Yung-Li] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   [Tao, Mi-Hua; Fang, Cheng-Chieh] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Liu, Yi-Lin] Childrens Hosp Philadelphia, Dept Hematol, Philadelphia, PA 19104 USA.
   [High, Katherine A.] Childrens Hosp Philadelphia, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 706
EP 706
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702358
ER

PT J
AU Yang, YW
   Wrench, DJ
   Lister, TA
   Fitzgibbon, J
AF Yang, Youwen
   Wrench, David J.
   Lister, T. Andrew
   Fitzgibbon, Jude
TI Recurrent Chromosomal Intermingling Interactions at the BCL2 Locus in
   T(14;18) +Ve and -Ve Cell Lines
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Youwen; Wrench, David J.; Lister, T. Andrew; Fitzgibbon, Jude] Barts & London Queen Marys Sch Med & Dent, London, England.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 713
EP 713
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702381
ER

PT J
AU Ang, AL
   Wang, ZP
   Yang, LY
   Natesan, V
   Poon, M
   Koh, LP
   Goh, YT
   Chowbay, B
   Chuah, C
AF Ang, Ai Leen
   Wang, Zhen Ping
   Yang, Li Yi
   Natesan, Vallalan
   Poon, Michelle
   Koh, Liang Piu
   Goh, Yeow Tee
   Chowbay, Balram
   Chuah, Charles
TI The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with
   Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with
   Imatinib Plasma Levels.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ang, Ai Leen; Yang, Li Yi; Natesan, Vallalan; Goh, Yeow Tee] Singapore Gen Hosp, Singapore 0316, Singapore.
   [Wang, Zhen Ping; Chowbay, Balram] Natl Canc Ctr, Singapore, Singapore.
   [Poon, Michelle; Koh, Liang Piu] Natl Univ Singapore Hosp, Singapore 0511, Singapore.
   [Chuah, Charles] Singapore Gen Hosp Duke NUS, Grad Sch Med, Singapore, Singapore.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 739
EP 739
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702455
ER

PT J
AU Cataland, S
   Yang, SB
   Horne, A
   Lin, SL
   George, J
   Wu, HF
AF Cataland, Spero
   Yang, Shangbin
   Horne, April
   Lin, Shili
   George, James
   Wu, Haifeng
TI Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor
   in Early Remission Are Associated with a Higher Probability of TTP
   Exacerbation.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cataland, Spero; Yang, Shangbin; Horne, April; Lin, Shili; Wu, Haifeng] Ohio State Univ, Columbus, OH 43210 USA.
   [George, James] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 802
EP 802
PG 1
SC Hematology
GA 389OP
UT ISI:000262104702632
ER

PT J
AU Dierov, JK
   Kim, TK
   Yang, XW
   Perl, A
   Burke, BA
   Wang, Z
   Gu, TL
   Gewirtz, AM
   Corey, SJ
   Polakiewicz, R
   Carroll, M
AF Dierov, Jamil K.
   Kim, Tae Kon
   Yang, Xiaowei
   Perl, Alexander
   Burke, Beth A.
   Wang, Zhu
   Gu, Ting-Lei
   Gewirtz, Alan M.
   Corey, Seth J.
   Polakiewicz, Roberto
   Carroll, Martin
TI Phosphoproteomic Analysis of Primary Acute Myeloid Leukemia Cells
   Reveals Redundant Roles for Src Family Kinases in AML Survival
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Dierov, Jamil K.; Yang, Xiaowei; Wang, Zhu] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Kim, Tae Kon] Univ Miami, Dept Med, Stem Cell Transplant Program, Miami, FL USA.
   [Perl, Alexander] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Gu, Ting-Lei; Polakiewicz, Roberto] Cell Signaling Technol Inc, Danvers, MA USA.
   [Gewirtz, Alan M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Corey, Seth J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol & Transplanat Pediat, Chicago, IL 60611 USA.
   [Carroll, Martin] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 917
EP 917
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703090
ER

PT J
AU Yang, ML
   Yang, GQ
   Jia, JH
   Ostrov, D
   May, WS
AF Yang, Mingli
   Yang, George Q.
   Jia, Jinghua
   Ostrov, David
   May, W. Stratford
TI JAZ "Targeting" Compounds Induce G1 Cell Cycle Arrest Followed by Cell
   Death in Human Leukemia Cells
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Mingli; Yang, George Q.; Jia, Jinghua; May, W. Stratford] Univ Florida, Dept Med, Gainesville, FL USA.
   [Yang, Mingli; Yang, George Q.; Jia, Jinghua; May, W. Stratford] Univ Florida, UF Shands Canc Ctr, Gainesville, FL USA.
   [Ostrov, David] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 919
EP 919
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703098
ER

PT J
AU Kirk, CJ
   Jiang, J
   Muchamuel, T
   Dajee, M
   Swinarski, D
   Aujay, M
   Bennett, MK
   Yang, JF
   Lewis, E
   Laidig, G
   Molineaux, CJ
AF Kirk, Christopher J.
   Jiang, Jing
   Muchamuel, Tony
   Dajee, Maya
   Swinarski, Deborah
   Aujay, Monette
   Bennett, Mark K.
   Yang, Jinfu
   Lewis, Evan
   Laidig, Guy
   Molineaux, Christopher J.
TI The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in
   Experimental Animals with Dose Intensive Administration.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kirk, Christopher J.; Jiang, Jing; Muchamuel, Tony; Dajee, Maya; Swinarski, Deborah; Aujay, Monette; Bennett, Mark K.; Yang, Jinfu; Lewis, Evan; Laidig, Guy] Proteolix Inc, Res, San Francisco, CA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 954
EP 954
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703204
ER

PT J
AU Rhein, M
   Yang, M
   Kaever, V
   Meyer, J
   Baum, C
   Li, ZX
AF Rhein, Mathias
   Yang, Min
   Kaever, Volkhard
   Meyer, Johann
   Baum, Christopher
   Li, Zhixiong
TI Leukemia Induced by Altered TRK-Signaling Is Sensitive to Rapamycin
   Treatment in a Preclinical Model.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kaever, Volkhard] Hannover Med Sch, Inst Pharmacol, D-3000 Hannover, Germany.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 984
EP 984
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703290
ER

PT J
AU Yang, H
   Lang, S
   Zhai, ZM
   Spring, CM
   Reheman, A
   Chen, PG
   Flick, MJ
   Degen, JL
   Li, L
   Kahr, WHA
   Freedman, J
   Ni, HY
AF Yang, Hong
   Lang, Sean
   Zhai, Zhimin
   Spring, Christopher M.
   Reheman, Adili
   Chen, Pingguo
   Flick, Matthew J.
   Degen, Jay L.
   Li, Ling
   Kahr, Walter H. A.
   Freedman, John
   Ni, Heyu
TI Engagement of Fibrinogen and beta 3 Integrin Is Required for
   Maintenance of Platelet Intracellular and Cell Surface P-Selectin
   Expression.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Hong; Lang, Sean; Reheman, Adili; Ni, Heyu] Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada.
   [Yang, Hong; Lang, Sean; Spring, Christopher M.; Chen, Pingguo; Ni, Heyu] Canadian Blood Serv, Toronto, ON, Canada.
   [Zhai, Zhimin] Anhui Med Univ, Affiliated Hosp 2, Anhui Prov Hosp, Canc Lab, Hefei, Peoples R China.
   [Spring, Christopher M.; Chen, Pingguo] St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada.
   [Flick, Matthew J.; Degen, Jay L.] Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA.
   [Flick, Matthew J.; Degen, Jay L.] Univ Cincinnati, Cincinnati, OH USA.
   [Li, Ling] Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada.
   [Kahr, Walter H. A.] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada.
   [Ni, Heyu] Univ Toronto, St Michaels Hosp, Dept Med & Physiol, Toronto, ON M5B 1W8, Canada.
   [Freedman, John] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada.
   [Freedman, John] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 989
EP 989
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703307
ER

PT J
AU Xing, DX
   Ramsay, AG
   Gribben, JG
   Decker, WK
   Burt, JK
   Li, SF
   Simon, SN
   Yang, H
   Cooper, L
   McMannis, JD
   Champlin, RE
   Shpall, EJ
   Zweidler-McKay, P
   Bollard, CM
AF Xing, Dongxia
   Ramsay, Alan G.
   Gribben, John G.
   Decker, William K.
   Burt, Jared K.
   Li, Sufang
   Simon, Simon N.
   Yang, Hong
   Cooper, Laurence
   McMannis, John D.
   Champlin, Richard E.
   Shpall, Elizabeth J.
   Zweidler-McKay, Patrick
   Bollard, Catherine M.
TI Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired
   Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Xing, Dongxia; Decker, William K.; Burt, Jared K.; Li, Sufang; Simon, Simon N.; Yang, Hong; Cooper, Laurence; McMannis, John D.; Champlin, Richard E.; Shpall, Elizabeth J.; Zweidler-McKay, Patrick] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Ramsay, Alan G.; Gribben, John G.] Barts & London Queen Marys Sch Med & Dent, Ctr Med Oncol, London, England.
   [Bollard, Catherine M.] Baylor Coll Med, Houston, TX 77030 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 999
EP 999
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703342
ER

PT J
AU Jiang, EZ
   Yu, M
   Hsieh, YT
   DeLaTorre, B
   Kadavallore, A
   Scharman, C
   Park, E
   Yang, AS
   Muschen, M
   Groffen, J
   Heisterkamp, N
   Kim, YM
AF Jiang, Enzi
   Yu, Min
   Hsieh, Yao-Te
   DeLaTorre, Brian
   Kadavallore, Asha
   Scharman, Carlton
   Park, Eugene
   Yang, Allen S.
   Muschen, Markus
   Groffen, John
   Heisterkamp, Nora
   Kim, Yong-Mi
TI Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug
   Resistant Philadelphia Chromosome Positive and Negative ALL
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Jiang, Enzi; Yu, Min; Hsieh, Yao-Te; DeLaTorre, Brian; Kadavallore, Asha; Scharman, Carlton; Park, Eugene; Muschen, Markus; Groffen, John; Heisterkamp, Nora; Kim, Yong-Mi] CHLA USC, Los Angeles, CA USA.
   [Yang, Allen S.] Univ So Calif, Jane Anne Nohl Div Hematol, Los Angeles, CA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1005
EP 1005
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703359
ER

PT J
AU Yang, BY
   Sheehan, JP
AF Yang, Buyue
   Sheehan, John P.
TI Depolymerized Holothurian Glycosaminoglycan Inhibits Plasma Thrombin
   Generation Via Interaction with the Factor IXa Heparin-Binding Exosite
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Sheehan, John P.] Univ Wisconsin, Dept Med Hematol Oncol, Madison, WI USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1058
EP 1058
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703518
ER

PT J
AU Koh, Y
   Kim, DY
   Kwon, HC
   Kim, MK
   Kim, BS
   Kim, YK
   Kim, I
   Kim, JS
   Kim, JS
   Kim, CS
   Kim, HJ
   Kwak, JY
   Lee, NR
   Min, YH
   Park, CW
   Sohn, SK
   Shin, HJ
   Oh, SJ
   Yoon, SS
   Lee, JH
   Zang, DY
   Chung, J
   Cheong, JW
   Jung, CW
   Jo, DY
   Chung, YJ
   Jung, SH
   Xu, HD
   Byun, HM
   Yang, AS
   Park, S
AF Koh, Youngil
   Kim, Dae-Young
   Kwon, Hyuk-Chan
   Kim, Min Kyoung
   Kim, Byung-Soo
   Kim, Yu-Kyung
   Kim, Inho
   Kim, Jae Seog
   Kim, Jin Seog
   Kim, Chul Soo
   Kim, Hyeoung-Joon
   Kwak, Jae-Yong
   Lee, Na-Ri
   Min, Yoo-Hong
   Park, Chong Won
   Sohn, Sang Kyun
   Shin, Ho-Jin
   Oh, Suk Joong
   Yoon, Sung-Soo
   Lee, Jung-Hee
   Zang, Dae Young
   Chung, Jooseop
   Cheong, Jun-Won
   Jung, Chul W.
   Jo, Deog-Yeon
   Chung, Yeun-Jun
   Jung, Seung-Hyun
   Xu, Hai-Dong
   Byun, Hyang-Min
   Yang, Allen S.
   Park, Seonyang
TI Molecular Predictive Markers in Dose Escalation Treatment for
   Suboptimal Responders to Standard Dose Imatinib in CML
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Koh, Youngil; Kwon, Hyuk-Chan; Kim, Min Kyoung; Kim, Yu-Kyung; Kim, Inho; Kim, Jae Seog; Kim, Jin Seog; Kim, Hyeoung-Joon; Kwak, Jae-Yong; Min, Yoo-Hong; Park, Chong Won; Sohn, Sang Kyun; Shin, Ho-Jin; Oh, Suk Joong; Zang, Dae Young; Chung, Jooseop; Cheong, Jun-Won; Jung, Chul W.; Jo, Deog-Yeon] Korean Soc Hematol, CML Working Party, Seoul, South Korea.
   [Kim, Dae-Young] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea.
   [Kim, Byung-Soo] Korea Univ, Med Ctr, Seoul, South Korea.
   [Kim, Chul Soo] Inha Univ, Seoul, South Korea.
   [Lee, Na-Ri] Cheonbuk Natl Univ, Sch Med, Cheonju, South Korea.
   [Park, Seonyang] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
   [Chung, Yeun-Jun; Jung, Seung-Hyun; Xu, Hai-Dong] Catholic Univ, Coll Med, Integrated Res Ctr Genome Polymorphism, Dept Microbiol, Seoul, South Korea.
   [Byun, Hyang-Min] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA.
   [Yang, Allen S.] Univ So Calif, Jane Anne Nohl Div Hematol, Los Angeles, CA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1105
EP 1106
PG 2
SC Hematology
GA 389OP
UT ISI:000262104703658
ER

PT J
AU Cortes, J
   O'Brien, S
   Ault, P
   Borthakur, G
   Jabbour, E
   Bradley-Garelik, B
   Debreczeni, K
   Yang, D
   Liu, D
   Kantarjian, H
AF Cortes, Jorge
   O'Brien, Susan
   Ault, Patricia
   Borthakur, Gautam
   Jabbour, Elias
   Bradley-Garelik, Brigid
   Debreczeni, Krisztina
   Yang, Daniel
   Liu, David
   Kantarjian, Hagop
TI Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated
   with Dasatinib
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Cortes, Jorge; O'Brien, Susan; Ault, Patricia; Borthakur, Gautam; Jabbour, Elias; Kantarjian, Hagop] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Bradley-Garelik, Brigid; Yang, Daniel; Liu, David] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
   [Debreczeni, Krisztina] Bristol Myers Squibb Co, Pennington, NJ USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1109
EP 1109
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703667
ER

PT J
AU Lipton, JH
   le Coutre, PD
   Wang, J
   Yang, M
   Szczudlo, T
   Giles, F
AF Lipton, Jeffrey H.
   le Coutre, Philipp D.
   Wang, Jim
   Yang, Mindy
   Szczudlo, Tomasz
   Giles, Francis
TI Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase
   (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety
   Analysis
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Lipton, Jeffrey H.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   [le Coutre, Philipp D.] Humboldt Univ, Charite, Dept Hematol & Oncol, Berlin, Germany.
   [Wang, Jim] Novartis Pharmaceut, E Hanover, NJ USA.
   [Yang, Mindy; Szczudlo, Tomasz] Novartis Pharmaceut, E Hanover, NJ USA.
   [Giles, Francis] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1110
EP 1110
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703670
ER

PT J
AU Maddipoti, SC
   Bueso-Ramos, C
   Yang, H
   Fernandez, M
   Kuang, SQ
   Fang, ZH
   Stevenson, W
   Wei, Y
   Pierce, S
   Garcia-Manero, G
AF Maddipoti, Sirisha C.
   Bueso-Ramos, Carlos
   Yang, Hui
   Fernandez, Michael
   Kuang, Shaoquing
   Fang, Zihong
   Stevenson, William
   Wei, Yue
   Pierce, Sherry
   Garcia-Manero, Guillermo
TI Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in
   Patients with Acute Myeloid Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Maddipoti, Sirisha C.; Yang, Hui; Kuang, Shaoquing; Fang, Zihong; Stevenson, William; Wei, Yue; Pierce, Sherry; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Bueso-Ramos, Carlos; Fernandez, Michael] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1148
EP 1148
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703777
ER

PT J
AU Bhojwani, D
   Wang, J
   Yang, JJ
   Morrison, D
   Devidas, M
   Raetz, E
   Hunger, SP
   Relling, MV
   Carroll, WL
AF Bhojwani, Deepa
   Wang, Jinhua
   Yang, Jun J.
   Morrison, Debra
   Devidas, Meenakshi
   Raetz, Elizabeth
   Hunger, Stephen P.
   Relling, Mary V.
   Carroll, William L.
TI Evolution of Gene Expression Signatures in Relapsed Childhood Acute
   Lymphoblastic Leukemia Differs Based on Timing of Relapse
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Bhojwani, Deepa; Yang, Jun J.; Relling, Mary V.] St Jude Childrens Hosp, Memphis, TN 38105 USA.
   [Wang, Jinhua; Morrison, Debra; Raetz, Elizabeth] NYU, Med Ctr, New York, NY 10016 USA.
   [Devidas, Meenakshi] Univ Florida, Coll Med, Dept Epidemiol & Hlth Policy Res, Gainesville, FL USA.
   [Hunger, Stephen P.] Childrens Hosp, Aurora, CO USA.
   [Hunger, Stephen P.] Univ Colorado, Sch Dent Med, Aurora, CO USA.
   [Carroll, William L.] NYU, Inst Canc, New York, NY USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1149
EP 1149
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703781
ER

PT J
AU Kuang, SQ
   Zweidler-McKay, P
   Yang, H
   Fang, ZH
   Tong, WG
   Garcia-Mancro, G
AF Kuang, Shaoqing
   Zweidler-McKay, Patrick
   Yang, Hui
   Fang, Zhi Hong
   Tong, Weigang
   Garcia-Mancro, Guillermo
TI Epigenetic Inactivation of Notch Signaling Target Genes RES in B Cell
   Acute Lymphoblastic Leukemia
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kuang, Shaoqing; Yang, Hui; Fang, Zhi Hong; Tong, Weigang; Garcia-Mancro, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Zweidler-McKay, Patrick] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1157
EP 1157
PG 1
SC Hematology
GA 389OP
UT ISI:000262104703808
ER

PT J
AU Zhou, RF
   Ou-Yang, J
   Chang, DY
   Xu, JY
   Chen, B
   Yang, YG
   Zhang, QG
   Shao, XY
AF Zhou, Rong-Fu
   Ou-yang, Jian
   Chang, Da-Yu
   Xu, Jing-Yan
   Chen, Bing
   Yang, Yong-Gong
   Zhang, Qi-Guo
   Shao, Xiao-Yan
TI Profiles of Th1, Th2, Th17 and Treg Cells in Patients with Chronic
   Idiopathic Thrombocytopenic Purpura
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhou, Rong-Fu; Ou-yang, Jian; Chang, Da-Yu; Xu, Jing-Yan; Chen, Bing; Yang, Yong-Gong; Zhang, Qi-Guo; Shao, Xiao-Yan] Nanjing Univ, Nanjing Drum Tower Hosp, Nanjing, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1168
EP 1168
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704022
ER

PT J
AU Zhang, XL
   Chen, SH
   Yang, LJ
   Zhu, K
   Li, YQ
AF Zhang, Xueli
   Chen, Shaohua
   Yang, Lijian
   Zhu, Kanger
   Li, Yangqiu
TI The Feature of TCR V gamma And TCR V delta Repertoire Distribution and
   Clonality in Patients with Immune Thrombocytopeine Purpura
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Zhang, Xueli; Zhu, Kanger] Jinan Univ, Dept Hematol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Chen, Shaohua; Yang, Lijian] Jinan Univ, Inst Hematol, Coll Med, Guangzhou, Guangdong, Peoples R China.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1169
EP 1169
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704027
ER

PT J
AU Kundu, M
   Yang, CY
   McCastlain, K
   Wu, JM
   Zhang, J
   Lindsten, T
   Ney, P
   Thompson, CB
AF Kundu, Mondira
   Yang, Chia-Ying
   McCastlain, Kelly
   Wu, Junmin
   Zhang, Ji
   Lindsten, Tullia
   Ney, Paul
   Thompson, Craig B.
TI Hsp90 regulates Ulk1-mediated autophagic clearance of mitochondria
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kundu, Mondira; McCastlain, Kelly; Zhang, Ji] Dept Pathol, Memphis, TN USA.
   [Wu, Junmin; Lindsten, Tullia] Abramson Family Canc IRes Inst, Philadelphia, PA USA.
   [Ney, Paul] St Jude Childrens Rsch Hosp, Memphis, TN USA.
   [Thompson, Craig B.] Univ Penn, Sch Med, Myeloma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1186
EP 1186
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704076
ER

PT J
AU Chang, MH
   Kim, SJ
   Kim, WS
   Choi, CW
   Suh, C
   Kim, SH
   Yang, DH
   Won, JH
   Il Lee, S
AF Chang, Myung Hee
   Kim, Seck Jin
   Kim, Won Seog
   Choi, Chul Won
   Suh, Cheolwon
   Kim, Sung Hyun
   Yang, Deok-Hwan
   Won, Jong-Ho
   Il Lee, Soon
TI Treatment Outcome and Prognostic Factors in Patients with Precursor B
   and T Lymphoblastic Lymphoma.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chang, Myung Hee; Kim, Seck Jin; Kim, Won Seog] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   [Choi, Chul Won] Korea Univ, Guro Hosp, Seoul, South Korea.
   [Suh, Cheolwon] Asan Med Ctr, Seoul, South Korea.
   [Kim, Sung Hyun] Dong A Univ Hosp, Dept Hem Onc, Pusan, South Korea.
   [Yang, Deok-Hwan] Chonnam Natl Univ, Hwasun Hosp, Jeollanam Do, South Korea.
   [Won, Jong-Ho] Soon Chun Hyang Univ Hosp, Seoul, South Korea.
   [Il Lee, Soon] Dankook Univ, Coll Med, Cheonan, South Korea.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1232
EP 1232
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704219
ER

PT J
AU Muchamuel, T
   Aujay, M
   Bennett, MK
   Dajee, M
   Demo, S
   Kirk, CJ
   Fang, Y
   Jiang, J
   Lewis, E
   Lu, Y
   Laidig, G
   Parlati, F
   Shields, J
   Sun, CM
   Yang, JF
   Zhou, HJ
AF Muchamuel, Tony
   Aujay, Monette
   Bennett, Mark K.
   Dajee, Maya
   Demo, Susan
   Kirk, Christopher J.
   Fang, Ying
   Jiang, Jing
   Lewis, Evan
   Lu, Yan
   Laidig, Guy
   Parlati, Francesco
   Shields, Jamie
   Sun, Congcong m
   Yang, Jinfiu
   Zhou, Han-Jie
TI Preclinical Pharmacology and in Vitro Characterization of PR-047, An
   Oral Inhibitor of the 20S Proteasome
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Muchamuel, Tony; Aujay, Monette; Bennett, Mark K.; Dajee, Maya; Demo, Susan; Kirk, Christopher J.; Fang, Ying; Jiang, Jing; Lewis, Evan; Lu, Yan; Laidig, Guy; Parlati, Francesco; Shields, Jamie; Sun, Congcong m; Yang, Jinfiu; Zhou, Han-Jie] Proteolix Inc, Res, San Francisco, CA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1257
EP 1257
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704289
ER

PT J
AU Kim, YK
   Lee, JJ
   Sohn, SK
   Shin, HJ
   Chung, JS
   Choi, YJ
   Moon, JH
   Chae, YS
   Kim, JG
   Ahn, JS
   Yang, DH
   Kim, HJ
AF Kim, Yeo-Kyeoung
   Lee, Je-Jung
   Sohn, Sang-Kyun
   Shin, Ho-Jin
   Chung, Joo-Seop
   Choi, Young-Jin
   Moon, Joon-Ho
   Chae, Yee-Soo
   Kim, Jong-Gwang
   Ahn, Jae-Sook
   Yang, Deok-Hwan
   Kim, Hyeoung-Joon
CA KMMWP
TI Results of a Phase II Multicenter Study of Immunochemotherapy with
   Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic
   Waldenstrom's Macroglobulinemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kim, Yeo-Kyeoung; Lee, Je-Jung; Ahn, Jae-Sook; Yang, Deok-Hwan; Kim, Hyeoung-Joon] Chonnam Natl Univ, Sch Med, Kwangju, South Korea.
   [Sohn, Sang-Kyun; Moon, Joon-Ho; Chae, Yee-Soo; Kim, Jong-Gwang] Kyungpook Natl Univ, Sch Med, Taegu, South Korea.
   [Shin, Ho-Jin; Chung, Joo-Seop; Choi, Young-Jin] Pusan Natl Univ, Sch Med, Pusan, South Korea.
   [KMMWP] KMMWP, Seoul, South Korea.
NR 0
TC 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1265
EP 1265
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704311
ER

PT J
AU Yang, Z
   Kondo, T
   Voorhorst, CS
   Nabinger, SC
   Ndong, L
   Yin, FQ
   Chan, EM
   Wurstlin, O
   Kratz, C
   Niemeyer, CM
   Flotho, C
   Hashino, E
   Chan, R
AF Yang, Zhenyun
   Kondo, Takako
   Voorhorst, Cara S.
   Nabinger, Sarah C.
   Ndong, Leila
   Yin, Fuqin
   Chan, Edward M.
   Wurstlin, Oliver
   Kratz, Christian
   Niemeyer, Charlotte Marie
   Flotho, Christian
   Hashino, Eri
   Chan, Rebecca
TI Increased C-Jun and Reduced GATA2 Expression Promotes Aberrant
   Monocytic Differentiation and Expansion Induced by Activating PTPN11
   Mutants
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Zhenyun; Kondo, Takako; Voorhorst, Cara S.; Nabinger, Sarah C.; Ndong, Leila; Yin, Fuqin; Hashino, Eri; Chan, Rebecca] Indiana Univ, Sch Med, Indianapolis, IN USA.
   [Chan, Edward M.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Wurstlin, Oliver; Kratz, Christian; Niemeyer, Charlotte Marie; Flotho, Christian] Univ Freiburg, Freiburg, Germany.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1275
EP 1276
PG 2
SC Hematology
GA 389OP
UT ISI:000262104704338
ER

PT J
AU Chan, G
   Kalaitzidis, D
   Usenko, T
   Kutok, J
   Yang, WT
   Mohi, G
   Neel, B
AF Chan, Goedon
   Kalaitzidis, Demetrios
   Usenko, Tatiana
   Kutok, Jeffery
   Yang, Wentian
   Mohi, Golam
   Neel, Benjamin
TI Expression of Leukemogenic Ptpn11 Causes a Fatal Myeloproliferative
   Disorder by Affecting Multiple Stages of Hematopoiesis.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chan, Goedon; Usenko, Tatiana] Ontario Canc Inst, Dept Stem Cell & Dev Biol, Toronto, ON M4X 1K9, Canada.
   [Neel, Benjamin] Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02215 USA.
   [Kutok, Jeffery] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Yang, Wentian] Brown Univ, Alpert Med Sch, Dept Orthoped, Providence, RI 02912 USA.
   [Mohi, Golam] Upstate Med Univ, Dept Pharmacol, Syracuse, NY USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1280
EP 1280
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704351
ER

PT J
AU Ansell, SM
   Novak, A
   Yang, ZZ
   Fredericksen, ZS
   Wang, AH
   Kay, N
   Liebow, M
   Dogan, A
   Call, TG
   Witzig, T
   Habermann, TM
   Slager, SL
   Cerhan, JR
AF Ansell, Stephen M.
   Novak, Anne
   Yang, Zhi-Zhang
   Fredericksen, Zachary S.
   Wang, Alice H.
   Kay, Neil
   Liebow, Mark
   Dogan, Ahmet
   Call, Timothy G.
   Witzig, Thomas
   Habermann, Thomas M.
   Slager, Susan L.
   Cerhan, James R.
TI Genetic Variation in Genes That Regulate T-Cell Differentiation and
   Function Is Associated with An Increased Risk of Developing B-Cell
   Non-Hodgkin Lymphoma.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ansell, Stephen M.; Novak, Anne; Yang, Zhi-Zhang; Fredericksen, Zachary S.; Wang, Alice H.; Kay, Neil; Liebow, Mark; Dogan, Ahmet; Call, Timothy G.; Witzig, Thomas; Habermann, Thomas M.; Slager, Susan L.; Cerhan, James R.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1288
EP 1289
PG 2
SC Hematology
GA 389OP
UT ISI:000262104704380
ER

PT J
AU Yang, J
   Liu, X
   Nyland, S
   Zhang, R
   Thomas, K
   Jarbadan, RN
   Loughran, TP
AF Yang, Jun
   Liu, Xin
   Nyland, Susan
   Zhang, Ranran
   Thomas, Kendall
   Jarbadan, Ruth Nancy
   Loughran, Thomas P., Jr.
TI Platelet-Derived Growth Factor (PDGF)-BB Mediates Survival of Leukemic
   Large Granular Lymphocyte Via An Autocrine Regulatory Pathway
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Yang, Jun; Liu, Xin; Zhang, Ranran; Thomas, Kendall; Jarbadan, Ruth Nancy; Loughran, Thomas P., Jr.] Penn State Hershey Canc Inst, Hershey, PA USA.
   [Nyland, Susan] NIH, Rare Dis Clin Res Network, Bone Marrow Failure Dis Consortium, Bethesda, MD USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1301
EP 1301
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704421
ER

PT J
AU Chen, XL
   Huang, YH
   Yan, L
   Brault, M
   Wang, ZZ
   Arildsen, MT
   Yang, E
AF Chen, Xiaolan
   Huang, Yuhui
   Yan, Ling
   Brault, Marie
   Wang, Zhizhang
   Arildsen, Maryann T.
   Yang, Elizabeth
TI p19Arf Cooperates with Shp2 in Lymphoid Leukemogenesis
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Chen, Xiaolan; Huang, Yuhui; Yan, Ling; Brault, Marie; Wang, Zhizhang; Arildsen, Maryann T.; Yang, Elizabeth] Vanderbilt Univ, Nashville, TN USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1302
EP 1302
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704426
ER

PT J
AU Kim, KT
   Borgstein, NG
   Yang, YJ
   Haltom, E
   Mook, L
   Ababa, MD
   Reddy, SK
   Sherman, ML
AF Kim, Kenneth T.
   Borgstein, Niels G.
   Yang, Yijun
   Haltom, Eric
   Mook, Louisa
   Ababa, Michelle D.
   Reddy, Sandeep K.
   Sherman, Matthew Leigh
TI ACE-011, a Soluble Activin Receptor Type IIa IgG-Fc Fusion Protein,
   Increases Hemoglobin and Hematocrit Levels in Postmenopausal Healthy
   Women
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American- Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Kim, Kenneth T.; Ababa, Michelle D.] W Coast Clin Trials, Cypress, CA USA.
   [Borgstein, Niels G.; Yang, Yijun; Haltom, Eric; Mook, Louisa; Sherman, Matthew Leigh] Acceleron Pharma, Cambridge, MA USA.
NR 0
TC 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 1316
EP 1316
PG 1
SC Hematology
GA 389OP
UT ISI:000262104704473
ER

PT J
AU Maillard, I
   Chen, YX
   Friedman, A
   Yang, YQ
   Tubbs, AT
   Shestova, O
   Pear, WS
   Hua, XX
AF Maillard, Ivan
   Chen, Ya-Xiong
   Friedman, Ann
   Yang, Yuqing
   Tubbs, Anthony T.
   Shestova, Olga
   Pear, Warren S.
   Hua, Xianxin
TI Menin regulates the function of hematopoietic stem cells and lymphoid
   progenitors
SO BLOOD
LA English
DT Article
ID HISTONE METHYLTRANSFERASE COMPLEX; HOX GENE-EXPRESSION; MLL-MUTANT
   MICE; TRANSFORMATION; LEUKEMIA; DEFECTS; PROLIFERATION; TARGETS; BMI-1;
   LOCUS
AB Men1 is a tumor suppressor gene mutated in endocrine neoplasms. Besides
   its endocrine role, the Men1 gene product menin interacts with the
   mixed lineage leukemia (MLL) protein, a histone H3 lysine 4
   methyltransferase. Although menin and MLL fusion proteins cooperate to
   activate Homeobox (Hox) gene expression during transformation, little
   is known about the normal hematopoietic functions of menin. Here, we
   studied hematopoiesis after Men1 ablation. Menin loss modestly impaired
   blood neutrophil, lymphocyte, and platelet counts. Without
   hematopoietic stress, multilineage and myelo-erythroid bone marrow
   progenitor numbers were preserved, while B lymphoid progenitors were
   decreased. In contrast, competitive transplantation revealed a marked
   functional defect of long-term hematopoietic stem cells (HSC) in the
   absence of menin, despite normal initial homing of progenitors to the
   bone marrow. HoxA9 gene expression was only modestly decreased in
   menin-deficient HSCs. These observations reveal a novel and essential
   role for menin in HSC homeostasis that was most apparent during
   situations of hematopoietic recovery, suggesting that menin regulates
   molecular pathways that are essential during the adaptive HSC response
   to stress. (Blood. 2009; 113: 1661-1669)
C1 [Maillard, Ivan; Friedman, Ann] Univ Michigan, Inst Life Sci, Ctr Stem Cell Biol, Ann Arbor, MI 48109 USA.
   [Maillard, Ivan] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
   [Maillard, Ivan] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.
   [Maillard, Ivan] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA.
   [Maillard, Ivan; Chen, Ya-Xiong; Yang, Yuqing; Tubbs, Anthony T.; Shestova, Olga; Pear, Warren S.; Hua, Xianxin] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Chen, Ya-Xiong; Yang, Yuqing; Tubbs, Anthony T.; Pear, Warren S.; Hua, Xianxin] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA.
   [Shestova, Olga] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Pear, Warren S.] Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA.
RP Maillard, I, Univ Michigan, Inst Life Sci, Ctr Stem Cell Biol, Ann
   Arbor, MI 48109 USA.
EM imaillar@umich.edu
   huax@mail.med.upenn.edu
FU National Institutes of Health (Bethesda, MD) ; Leukemia & Lymphoma
   Society (White Plains, NY) ; Specialized Center of Research (SCOR) [R01
   CA113962, R01CA100912]; Damon Runyon Cancer Research Foundation (New
   York, NY) [DRG-102-05]; University of Michigan's Biological Sciences
   Scholar Program (Ann Arbor, MI) 
FX We thank Dr Sean Morrison and Dr Jay Hess for advice and critical
   reading of the manuscript.
   This work was supported by grants from the National Institutes of
   Health (Bethesda, MD) and a Leukemia & Lymphoma Society (White Plains,
   NY) Specialized Center of Research (SCOR) grant (R01 CA113962 and
   R01CA100912, X. H. and W. S. P.). I. M. was supported by a grant from
   the Damon Runyon Cancer Research Foundation (New York, NY; DRG-102-05)
   and by the University of Michigan's Biological Sciences Scholar Program
   (Ann Arbor, MI).
CR AGARWAL SK, 2004, ANN NY ACAD SCI, V1014, P189, DOI
   10.1196/annals.1294.020
   AGARWAL SK, 2007, NEOPLASIA, V9, P101, DOI 10.1593/neo.06706
   AKASHI K, 2000, NATURE, V404, P193
   AYTON PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603
   BERTOLINO P, 2003, MECH DEVELOP, V120, P549, DOI
   10.1016/S0925-4773(03)00039-X
   CASLINI C, 2007, CANCER RES, V67, P7275, DOI
   10.1158/0008-5472.CAN-06-2369
   CHEN YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI
   10.1073/pnas.0510347103
   CRABTREE JS, 2003, MOL CELL BIOL, V23, P6075, DOI
   10.1128/MCB.23.17.6075-6085.2003
   DEMERS C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022
   ERNST P, 2004, DEV CELL, V6, P437
   HARDY RR, 1991, J EXP MED, V173, P1213
   HESS JL, 1997, BLOOD, V90, P1799
   HESS JL, 2004, TRENDS MOL MED, V10, P500, DOI
   10.1016/j.molmed.2004.08.005
   HUGHES CM, 2004, MOL CELL, V13, P587
   JUDE CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019
   KIEL MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   LAWRENCE HJ, 1997, BLOOD, V89, P1922
   LAWRENCE HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003
   LESSARD J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   MCMAHON KA, 2007, CELL STEM CELL, V1, P338, DOI
   10.1016/j.stem.2007.07.002
   MILLER JP, 2003, J IMMUNOL, V171, P2326
   MILNE TA, 2002, MOL CELL, V10, P1107
   PARK IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   RUZANKINA Y, 2007, CELL STEM CELL, V1, P113
   SCACHERI PC, 2006, PLOS GENET, V2, P406, ARTN e51
   SCHNEPP RW, 2006, CANCER RES, V66, P5707, DOI
   10.1158/0008-5472.CAN-05-4518
   SO CW, 2004, BLOOD, V103, P3192
   YAGI H, 1998, BLOOD, V92, P108
   YOKOYAMA A, 2004, MOL CELL BIOL, V24, P5639, DOI
   10.1128/MCB.24.13.5639-5649.2004
   YOKOYAMA A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025
   YU BD, 1995, NATURE, V378, P505
   ZEISIG BB, 2004, MOL CELL BIOL, V24, P617, DOI
   10.1128/MCB.24.2.617-628.2004
NR 32
TC 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 19
PY 2009
VL 113
IS 8
BP 1661
EP 1669
DI 10.1182/blood-2008-01-135012
PG 9
SC Hematology
GA 410GS
UT ISI:000263566100008
ER

PT J
AU Reheman, A
   Yang, H
   Zhu, GH
   Jin, WX
   He, F
   Spring, CM
   Bai, XF
   Gross, PL
   Freedman, J
   Ni, HY
AF Reheman, Adili
   Yang, Hong
   Zhu, Guangheng
   Jin, Wuxun
   He, Feng
   Spring, Christopher M.
   Bai, Xufang
   Gross, Peter L.
   Freedman, John
   Ni, Heyu
TI Plasma fibronectin depletion enhances platelet aggregation and thrombus
   formation in mice lacking fibrinogen and von Willebrand factor
SO BLOOD
LA English
DT Article
ID PROTEIN-DISULFIDE-ISOMERASE; IN-VIVO; MONOCLONAL-ANTIBODY; INJURED
   ARTERIOLES; MURINE MODEL; GAMMA-CHAIN; HEMOSTASIS; INHIBITION;
   COLLAGEN; THROMBOSPONDIN-1
AB We previously showed that platelet aggregation and thrombus formation
   occurred in mice lacking both fibrinogen (Fg) and von Willebrand factor
   (VWF) and that plasma fibronectin (pFn) promoted thrombus growth and
   stability in injured arterioles in wild-type mice. To examine whether
   pFn is required for Fg/VWF-independent thrombosis, we generated
   Fg/VWF/conditional pFn triple-deficient (TKO; Cre(+), Fn(flox/flox),
   Fg/VWF-/-) mice and littermate control (Cre(-), Fn(flox/flox),
   Fg/VWF-/-) mice. Surprisingly, TKO platelet aggregation was not
   abolished, but instead was enhanced in both heparinized platelet-rich
   plasma and gel-filtered platelets. This enhancement was diminished when
   TKO platelets were aggregated in pFn-positive control platelet-poor
   plasma (PPP), whereas aggregation was enhanced when control platelets
   were aggregated in pFn-depleted TKO PPP. The TKO platelet aggregation
   can be completely inhibited by our newly developed mouse anti-mouse
   beta(3) integrin antibodies but was not affected by anti-mouse GPIb
   alpha antibodies. Enhanced platelet aggregation was also observed when
   heparinized TKO blood was perfused in collagen-coated perfusion
   chambers. Using intravital microscopy, we further showed that
   thrombogenesis in TKO mice was enhanced in both FeCl3-injured
   mesenteric arterioles and laser-injured cremaster arterioles. Our data
   indicate that pFn is not essential for Fg/VWF-independent thrombosis
   and that soluble pFn is probably an important inhibitory factor for
   platelet aggregation. (Blood. 2009; 113: 1809-1817)
C1 [Ni, Heyu] Univ Toronto, Canadian Blood Serv, Toronto, ON M5B 1W8, Canada.
   [Reheman, Adili; Yang, Hong; Freedman, John; Ni, Heyu] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5B 1W8, Canada.
   [Reheman, Adili; Yang, Hong; Zhu, Guangheng; Jin, Wuxun; He, Feng; Spring, Christopher M.; Bai, Xufang; Gross, Peter L.; Freedman, John; Ni, Heyu] St Michaels Hosp, Toronto Platelet Immunobiol Grp, Toronto, ON M5B 1W8, Canada.
   [Reheman, Adili; Yang, Hong; Zhu, Guangheng; Jin, Wuxun; He, Feng; Spring, Christopher M.; Bai, Xufang; Gross, Peter L.; Freedman, John; Ni, Heyu] St Michaels Hosp, Dept Lab Med, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
   [Bai, Xufang; Gross, Peter L.] McMaster Univ, Dept Med, Henderson Res Ctr, Hamilton, ON, Canada.
   [Freedman, John; Ni, Heyu] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada.
   [Ni, Heyu] Univ Toronto, Dept Physiol, Toronto, ON M5B 1W8, Canada.
RP Ni, HY, Univ Toronto, Canadian Blood Serv, 30 Bond St,Room 2-006,Bond
   Wing, Toronto, ON M5B 1W8, Canada.
EM nih@smh.toronto.on.ca
FU Heart and Stroke Foundation of Canada (Ontario) ; Canadian Blood
   Services and Canadian Institutes of Health Research ; St Michael's
   Hospital ; Canadian Blood Services ; Canada Foundation for Innovation ;
   Heart and Stroke/Richard Lewar Excellence Award ; Canadian Blood
   Services postdoctoral fellowship award 
FX We thank Drs Reinhard Farssler, Jay L. Degen, Denisa D. Wagner, and
   Cecile V. Denis for their earlier work preparing pFn conditional
   knockout mice, Fg and VWF gene-deficient mice. We thank Dr Pingguo Chen
   for his assistance with genotyping and backcrossing GPIb
   alpha<SUP>-/-</SUP> and beta 3<SUP>-/-</SUP> mice onto BALB/c
   background and Michelle Lee Webster and Sean Lang for assistance with
   preparation of the manuscript.
   This work was supported by the Heart and Stroke Foundation of Canada
   (Ontario), Canadian Blood Services and Canadian Institutes of Health
   Research, and by equipment funds from St Michael's Hospital, Canadian
   Blood Services, and Canada Foundation for Innovation. H. Y. is a
   recipient of the Heart and Stroke/Richard Lewar Excellence Award and a
   Canadian Blood Services postdoctoral fellowship award.
CR ANDRE P, 2002, NAT MED, V8, P247
   ARNESON MA, 1980, JAMA-J AM MED ASSOC, V244, P144
   BERGMEIER W, 2002, CYTOMETRY, V48, P80
   BONNEFOY A, 2001, J BIOL CHEM, V276, P5605
   CHAUHAN AK, 2008, ARTERIOSCL THROM VAS, V28, P296, DOI
   10.1161/ATVBAHA.107.149146
   CHEN VM, 2006, J THROMB HAEMOST, V4, P2533
   CHO J, 2005, J BIOL CHEM, V280, P35490, DOI 10.1074/jbc.M506289200
   CHO J, 2006, J THROMB HAEMOST, V4, P1461
   CHO J, 2006, J THROMB HAEMOST, V4, P943
   CHO J, 2008, J CLIN INVEST, V118, P1123, DOI 10.1172/JCI34134
   CHO JH, 2006, BLOOD, V107, P3555, DOI 10.1182/blood-2005-10-4168
   CHO JH, 2006, BLOOD, V108, P2229, DOI 10.1182/blood-2006-02-002063
   DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3844
   FALATI S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782
   HODIVALADILKE KM, 1999, J CLIN INVEST, V103, P229
   HOFFMEISTER KM, 2003, CELL, V112, P87
   HYNES RO, 1990, FIBRONECTINS, P546
   ISENBERG JS, 2008, BLOOD, V111, P613, DOI 10.1182/blood-2007-06-098392
   JACKSON SP, 2007, BLOOD, V109, P5087, DOI 10.1182/blood-2007-02-027696
   JONES KL, 2001, BLOOD, V98, P1456
   LANGENBACH KJ, 1999, J BIOL CHEM, V274, P7032
   MATUSKOVA J, 2006, ARTERIOSCL THROM VAS, V26, P1391, DOI
   10.1161/01.ATV.0000216282.58291.c6
   MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531
   MOON DG, 1986, BLOOD, V67, P450
   MOON DG, 1994, THROMB RES, V76, P343
   MOSHER DF, 2006, ARTERIOSCL THROM VAS, V26, P1193, DOI
   10.1161/01.ATV.0000223342.15969.7a
   NI H, 2001, BLOOD, V98, P368
   NI H, 2006, J THROMB HAEMOST, V4, P940
   NI HY, 2000, J CLIN INVEST, V106, P385
   NI HY, 2003, BLOOD, V102, P3609, DOI 10.1182/blood-2003-03-0850
   NI HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI
   10.1073/pnas.2628067100
   NI HY, 2003, TRANSFUS APHER SCI, V28, P257, DOI
   10.1016/S1473-0502(03)00044-2
   NI HY, 2006, BLOOD, V107, P2976, DOI 10.1182/blood-2005-06-2562
   OLORUNDARE OE, 2001, BLOOD, V98, P117
   OREM C, 2002, THROMB RES, V105, P37
   OREM C, 2003, CORONARY ARTERY DIS, V14, P219, DOI
   10.1097/01.mca.0000066454.28270.fb
   PECHENIUK NM, 2008, THROMB HAEMOSTASIS, V100, P224, DOI
   10.1160/TH08-02-0078
   PLOW EF, 2001, THROMB HAEMOSTASIS, V86, P34
   REHEMAN A, 2005, J THROMB HAEMOST, V3, P875
   RUGGERI ZM, 1997, THROMB HAEMOSTASIS, V78, P611
   RUGGERI ZM, 2002, NAT MED, V8, P1227
   SACHS UJH, 2007, CIRC RES, V100, P979, DOI
   10.1161/01.RES.0000261936.85776.5f
   SAKAI T, 2001, NAT MED, V7, P324
   SANTORO SA, 1983, BIOCHEM BIOPH RES CO, V116, P135
   SONG KS, 2001, ATHEROSCLEROSIS, V154, P449
   SUH TT, 1995, GENE DEV, V9, P2020
   WARE J, 2000, P NATL ACAD SCI USA, V97, P2803
   WU YP, 2004, BLOOD, V104, P1034, DOI 10.1182/blood-2003-12-4293
   YANG H, 2006, J THROMB HAEMOST, V4, P2230
   ZHAI Z, 2007, J THROMB HAEMOST, V5, P1740
   ZHU G, 2007, BLOOD, V118, A627
NR 51
TC 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 19
PY 2009
VL 113
IS 8
BP 1809
EP 1817
DI 10.1182/blood-2008-04-148361
PG 9
SC Hematology
GA 410GS
UT ISI:000263566100025
ER

PT J
AU Cui, X
   Xu, SM
   Mu, DS
   Yang, ZM
AF Cui, Xiao
   Xu, Si Min
   Mu, Dao Shuai
   Yang, Zhi Min
TI Genomic analysis of rice microRNA promoters and clusters
SO GENE
LA English
DT Article
DE miRNA gene; Rice; Promoter; miRNA cluster
ID COMPUTATIONAL IDENTIFICATION; MOLECULAR EVOLUTION; NUCLEAR EXPORT; CORE
   PROMOTERS; SMALL RNAS; ARABIDOPSIS; EXPRESSION; TARGETS; GENES;
   BIOGENESIS
AB MicroRNAs (miRNAs) are endogenous single-stranded non-coding small RNAs
   with a length of about 21 nt, that negatively regulate development and
   stresses. Rice miRNAs are representative of the monocot miRNAs, and
   many of them are non-conserved in Arabidopsis and the other plant
   species. Previous studies have shown that a majority of plant miRNAs
   are expressed from independent transcription units, whereas some others
   are transcribed with their host genes. Despite of the fact that a
   growing number of rice miRNAs are discovered, little is known about the
   transcriptional regulation of miRNA genes. In this study, we performed
   genomic analysis of rice miRNA transcripts surrounding the regions of
   promoter/transcription start site (TSS) and TATA-box, and organization
   of miRNA clusters. We detected 249 promoters for 212 rice pre-miRNA
   sequences via bioinformatics approach and found that the conserved rice
   miRNA genes have a greater proportion of promoters than the
   non-conserved miRNA genes. We further globally analyzed the genomic
   organization of pri-miRNAs and found that 52 rice miRNA genes appear in
   18 clusters. Alignment of the miRNA sequences in these clusters shows a
   number of miRNA paralogs within the cluster. The data obtained may aid
   our understanding of the specific sequences upstream of pre-miRNAs and
   the functional implications of miRNA clusters in rice plants. (C) 2008
   Elsevier B.V. All rights reserved.
C1 [Cui, Xiao; Xu, Si Min; Mu, Dao Shuai; Yang, Zhi Min] Nanjing Agr Univ, Coll Life Sci, Dept Biochem & Mol Biol, Nanjiang 210095, Peoples R China.
RP Yang, ZM, Nanjing Agr Univ, Coll Life Sci, Dept Biochem & Mol Biol,
   Nanjiang 210095, Peoples R China.
EM zmyang@njau.edu.cn
FU National Natural Science Foundation of China [30671249]; Natural
   Science Foundation of Jiang Su, China [BK2006137]; NAU 
FX This research was supported by the National Natural Science Foundation
   of China (30671249) and the Natural Science Foundation of Jiang Su,
   China (BK2006137), as well as the Student Research Training program
   from NAU.
CR ALLEN E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004
   ALTUVIA Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567
   BARTEL DP, 2004, CELL, V116, P281
   CHEN K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   CHEN XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060
   GRIFFITHSJONES S, 2006, DATABASE ISSUE, V34, D140
   GUDDETI S, 2005, CELL RES, V15, P631
   GUO HS, 2005, PLANT CELL, V17, P1376, DOI 10.1105/tpc.105.030841
   JONESRHOADES MW, 2004, MOL CELL, V14, P787
   KURIHARA Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI
   10.1073/pnas.0403115101
   LAUFS P, 2004, DEVELOPMENT, V131, P4311, DOI 10.1242/dev.01320
   LEE RC, 2001, SCIENCE, V294, P862
   LEE Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   LEWIS SE, 2002, GENOME BIOL, V3, UNSP RESEARCH0082.1-0082.14
   LIU K, 2008, MICROSYST TECHNOL, V14, P1, DOI 10.1007/s00542-007-0392-3
   LU C, 2008, P NATL ACAD SCI USA, V105, P4951, DOI
   10.1073/pnas.0708743105
   LUND E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   MEGRAW M, 2006, RNA, V12, P1612, DOI 10.1261/rna.130506
   OHLER U, 2001, BIOINFORMATICS S1, V17, S199
   OUYANG S, 2007, NUCLEIC ACIDS RES, V35, D883, DOI 10.1093/nar/gkl976
   PALATNIK JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958
   PARK MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI
   10.1073/pnas.0405570102
   QIU CX, 2007, GENE, V395, P49, DOI 10.1016/j.gene.2007.01.034
   SAINI HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI
   10.1073/pnas.0703890104
   SHAHMURADOV IA, 2005, NUCLEIC ACIDS RES, V33, P1069, DOI
   10.1093/nar/gki247
   SMALE ST, 2001, GENE DEV, V15, P2503
   SUNKAR R, 2004, PLANT CELL, V16, P2001, DOI 10.1105/tpc.104.022830
   SUNKAR R, 2005, PLANT CELL, V17, P1397, DOI 10.1105/tpc.105.031682
   TANG GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103
   TANZER A, 2004, J MOL BIOL, V339, P327, DOI 10.1016/j.jmb.2004.03.065
   VOLINIA S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI
   10.1073/pnas.0510565103
   WANG JF, 2004, NUCLEIC ACIDS RES, V32, P1688, DOI 10.1093/nar/gkh332
   WANG S, 2007, FEBS LETT, V581, P4789, DOI 10.1016/j.febslet.2007.09.002
   WANG Y, 2006, BIOINFORMATICS, V22, P2585, DOI
   10.1093/bioinformatics/btl437
   WEAVER RF, 2001, MOL BIOL, P279
   XIE FL, 2007, FEBS LETT, V581, P1464, DOI 10.1016/j.febslet.2007.02.074
   XIE ZX, 2005, PLANT PHYSIOL, V138, P2145, DOI 10.1104/pp.105.062943
   YI R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   YIN ZJ, 2008, GENE, V414, P60
   YU J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI
   10.1016/j.bbrc.2006.07.207
   ZHOU XF, 2007, PLOS COMPUT BIOL, V3, P412, ARTN e37
   ZHOU ZS, 2008, BIOCHEM BIOPH RES CO, V374, P538, DOI
   10.1016/j.bbrc.2008.07.083
NR 42
TC 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD FEB 15
PY 2009
VL 431
IS 1-2
BP 61
EP 66
DI 10.1016/j.gene.2008.11.016
PG 6
SC Genetics & Heredity
GA 407XG
UT ISI:000263397000009
ER

PT J
AU Zhao, Q
   Yam, R
   Zhang, BQ
   Yang, YK
   Cheng, XJ
   Li, R
AF Zhao, Qiang
   Yam, Richard C. M.
   Zhang, Baoqing
   Yang, Yingkui
   Cheng, Xinjian
   Li, Robert K. Y.
TI Novel all-cellulose ecocomposites prepared in ionic liquids
SO CELLULOSE
LA English
DT Article
DE Cellulose; Rice husk (RH); Ionic liquid (IL); Ecocomposite
ID SELF-REINFORCED COMPOSITES; RICE HUSK; POLYMER COMPOSITES; POROUS
   CARBON; FIBER; DISSOLUTION; SILICA; NANOCOMPOSITE; DERIVATIVES; SOLVENT
AB In this study, a kind of novel all-cellulose ecocomposites based on
   cellulose and rice husk (RH) has been prepared by using green solvent,
   ionic liquid (IL), as processing medium. Due to the presence of the RH,
   these ecocomposites also contain an inorganic component, silica. The
   content and distribution of the silica in the ecocomposite have been
   investigated by energy dispersive X-ray (EDX) and X-ray photoelectron
   spectroscopy (XPS) analyses. The mechanical properties of these
   ecocomposites, including both static and dynamic, have been determined
   by using tensile test and dynamic mechanical analysis (DMA),
   respectively. The effect of processing conditions on the interfacial
   bonding and therefore the mechanical performance of the final
   ecocomposites has been investigated further. Results show that the
   incorporation of the RH can provide stiffening effect for cellulose
   matrix, and the pretreatment of RH fillers by IL can enhance the
   filler/matrix interfacial bonding, thus further improving the
   mechanical performance of the ecocomposite. By selecting suitable
   composition ratios and processing conditions optimal mechanical
   performance with the balance among stiffness, strength and elongation
   at break can be obtained.
C1 [Zhao, Qiang; Zhang, Baoqing; Yang, Yingkui; Cheng, Xinjian; Li, Robert K. Y.] City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon, Hong Kong, Peoples R China.
   [Zhao, Qiang; Yam, Richard C. M.; Zhang, Baoqing] City Univ Hong Kong, Dept Mfg Engn & Engn Management, Kowloon, Hong Kong, Peoples R China.
RP Li, R, City Univ Hong Kong, Dept Phys & Mat Sci, Tat Chee Ave, Kowloon,
   Hong Kong, Peoples R China.
EM aprkyl@cityu.edu.hk
FU City University of Hong Kong [ARG 9667009]
FX This work was supported by a grant from the City University of Hong
   Kong (Project No. ARG 9667009).
CR BANSAL V, 2006, J AM CHEM SOC, V128, P14059, DOI 10.1021/ja062113+
   BHARDWAJ R, 2006, BIOMACROMOLECULES, V7, P2044, DOI 10.1021/bm050897y
   EGUSA S, 2007, ANGEW CHEM INT EDIT, V46, P2063, DOI
   10.1002/anie.200603981
   ELSEOUD OA, 2007, BIOMACROMOLECULES, V8, P2629, DOI 10.1021/bm070062i
   GANDINI A, 2005, POLYMER, V46, P10611, DOI 10.1016/j.polymer.2005.09.004
   GINDL W, 2005, POLYMER, V46, P10221, DOI 10.1016/j.polymer.2005.08.040
   GINDL W, 2006, COMPOS SCI TECHNOL, V66, P2639, DOI
   10.1016/j.compscitech.2006.03.020
   GINDL W, 2007, J APPL POLYM SCI, V103, P2703
   GUO YP, 2002, MATER CHEM PHYS, V74, P320
   HEINZE T, 2000, MACROMOL CHEM PHYSIC, V201, P627
   HEINZE T, 2005, MACROMOL BIOSCI, V5, P520, DOI 10.1002/mabi.200500039
   JACOBIAN V, 1980, CELLUL CHEM TECHNOL, V14, P37
   JULIANO BO, 1985, RICE CHEM TECHNOLOGY
   KENNEDY LJ, 2004, IND ENG CHEM RES, V43, P1832, DOI 10.1021/ie034093f
   KILPELAINEN I, 2007, J AGR FOOD CHEM, V55, P9142
   KIM HS, 2004, J THERM ANAL CALORIM, V76, P395
   KIM HS, 2005, J APPL POLYM SCI, V97, P1513, DOI 10.1002/app.21905
   KLEMM D, 1998, COMPREHENSIVE CELLUL, V1, P1
   KOHLER S, 2007, MACROMOL BIOSCI, V7, P307, DOI 10.1002/mabi.200600197
   LIOU TH, 2004, MAT SCI ENG A-STRUCT, V364, P313, DOI
   10.1016/j.msea.2003.08.045
   LIU CF, 2007, J AGR FOOD CHEM, V55, P2399, DOI 10.1021/jf062876g
   LU X, 2002, POLYM COMPOSITE, V23, P624
   LU X, 2004, COMPOS SCI TECHNOL, V64, P1301, DOI
   10.1016/j.compscitech.2003.10.013
   MOULTHROP JS, 2005, CHEM COMMUN, P1557, DOI 10.1039/b417745b
   NELSON ML, 1964, J APPL POLYM SCI, V8, P1325
   NISHINO T, 2004, MACROMOLECULES, V37, P7683, DOI 10.1021/ma049300h
   NISHINO T, 2007, BIOMACROMOLECULES, V8, P2712, DOI 10.1021/bm0703416
   PARK BD, 2003, BIOMASS BIOENERG, V25, P319, DOI
   10.1016/S0961-9534(03)00014-X
   RYU AE, 1997, J MATER SCI, V32, P6639, DOI 10.1023/A:1018600403263
   SAHEB DN, 1999, ADV POLYM TECH, V18, P351
   SEAVEY KC, 2001, CELLULOSE, V8, P149
   SUN LY, 2001, IND ENG CHEM RES, V40, P5861
   SWATLOSKI RP, 2002, J AM CHEM SOC, V124, P4974
   TURBAK A, 1981, 4302252, US
   TURI EA, 1997, THERMAL CHARACTERIZA
   WU QJ, 2007, BIOMACROMOLECULES, V8, P3687, DOI 10.1021/bm701061t
   ZHANG H, 2005, MACROMOLECULES, V38, P8272, DOI 10.1021/ma0505676
   ZHANG LN, 2001, IND ENG CHEM RES, V40, P5923
   ZHAO Q, 2008, POLYM DEGRAD STABIL, V93, P1571, DOI
   10.1016/j.polymdegradstab.2008.05.002
   ZHU SD, 2006, GREEN CHEM, V8, P325, DOI 10.1039/b601395c
NR 40
TC 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-0239
J9 CELLULOSE
JI Cellulose
PD APR
PY 2009
VL 16
IS 2
BP 217
EP 226
DI 10.1007/s10570-008-9251-3
PG 10
SC Materials Science, Paper & Wood; Materials Science, Textiles; Polymer
   Science
GA 407GZ
UT ISI:000263352900007
ER

PT J
AU Chiu, HY
   Tsao, LY
   Yang, RC
AF Chiu, Han-Yao
   Tsao, Lon-Yen
   Yang, Rei-Cheng
TI Heat-shock response protects peripheral blood mononuclear cells (PBMCs)
   from hydrogen peroxide-induced mitochondrial disturbance
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Heat-shock response; Rat; Superoxide; Oxidative stress; Mitochondrion
ID OXIDATIVE STRESS; CYTOCHROME-C; SEPTIC LIVER; DNA-DAMAGE; DEATH;
   PRETREATMENT; APOPTOSIS; EXERCISE; DYSFUNCTION; ACTIVATION
AB The present study was designed to investigate ex vivo the protective
   mechanisms of heat-shock response against H2O2-induced oxidative stress
   in peripheral blood mononuclear cells (PBMCs) of rats. Twenty-four
   hours later, heat-shock treatment was executed in vivo; rat PBMCs were
   collected and treated with H2O2. The accumulation of reactive oxygen
   species and the mitochondrial membrane potential were evaluated by
   intracellular fluorescent dHE and JC-1 dye staining, respectively, and
   expression of HSP72 and cytochrome c was detected by Western blot
   analysis. Cellular apoptosis was assayed by TUNEL staining and double
   staining of Annexin V and PI. The results showed that H2O2-induced
   oxidative stress leads to intracellular superoxide accumulation and
   collapse of the mitochondrial membrane potential in rat PBMCs.
   Moreover, cellular apoptosis was detected after H2O2 treatment, and the
   release of mitochondrial cytochrome c from mitochondria to cytosol was
   significantly enhanced. Heat-shock pretreatment decreases the
   accumulation of intracellular superoxide in PBMCs during H2O2-induced
   oxidative stress. Moreover, heat-shock treatment prevents the collapse
   of the mitochondrial membrane potential and cytochrome c release from
   mitochondria during H2O2-induced oxidative stress. In conclusion,
   mitochondria are critical organelles of the protective effects of
   heat-shock treatment. Cellular apoptosis during H2O2-induced oxidative
   stress is decreased by heat-shock treatment through a decrease in
   superoxide induction and preservation of the mitochondrial membrane
   potential.
C1 [Yang, Rei-Cheng] Kaohsiung Med Univ, Coll Med, Dept Pediat, Kaohsiung, Taiwan.
   [Chiu, Han-Yao; Tsao, Lon-Yen] Changhua Christian Hosp, Dept Pediat, Changhua, Taiwan.
   [Chiu, Han-Yao; Tsao, Lon-Yen] Chang Jung Christian Univ, Dept Resp Care, Tainan, Taiwan.
RP Yang, RC, Kaohsiung Med Univ, Coll Med, Dept Pediat, 100 Shih Chuan 1st
   Rd, Kaohsiung, Taiwan.
EM rechya@kmu.edu.tw
CR ANDREYEV AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200
   ARYA R, 2007, J BIOSCIENCES, V32, P595
   ASLAN M, 2006, MUTAT RES-FUND MOL M, V601, P144, DOI
   10.1016/j.mrfmmm.2006.06.013
   BEERE HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JC126471
   CASES N, 2006, EUR J APPL PHYSIOL, V98, P263, DOI
   10.1007/s00421-006-0273-y
   CHEN HW, 2000, CELL STRESS CHAPERON, V5, P188
   CHEN HW, 2003, SHOCK, V20, P274, DOI 10.1097/01.shk.0000079425.52617.db
   CHEN HW, 2004, INT J EXP PATHOL, V85, P249
   CHEN HW, 2005, SHOCK, V24, P232, DOI 10.1097/01.shk.0000174020.87439.f2
   CHOI S, 2005, J BIOCHEM MOL BIOL, V38, P111
   CLARKSON PM, 2000, AM J CLIN NUTR, V72, P637
   CSISZAR A, 2007, ACTA PHYSIOL HUNG, V94, P107, DOI
   10.1556/APhysiol.94.2007.1-2.10
   FATOKUN AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   FEDELI D, 2007, J APPL TOXICOL, V27, P561, DOI 10.1002/jat.1236
   GOGVADZE V, 2007, J BIOENERG BIOMEMBR, V39, P23, DOI
   10.1007/s10863-006-9054-x
   GUO SH, 2007, CELL STRESS CHAPERON, V12, P245
   HANSEN JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI
   10.1146/annurev.pharmtox.46.120604.141122
   JI LL, 1999, P SOC EXP BIOL MED, V222, P283
   JIANG BM, 2005, CELL STRESS CHAPERON, V10, P252
   KAKKAR P, 2007, MOL CELL BIOCHEM, V305, P235, DOI
   10.1007/s11010-007-9520-8
   KWON JH, 2007, BIOCHEM BIOPH RES CO, V363, P399, DOI
   10.1016/j.bbrc.2007.09.001
   LIU XS, 1996, CELL, V86, P147
   NARULA J, 2006, NAT CLIN PRACT CARD, V3, P681, DOI 10.1038/ncpcardio0710
   NICOLLS MR, 2007, ANTIOXID REDOX SIGN, V9, P879, DOI
   10.1089/ars.2007.1631
   OHTSUKA K, 2005, INT J HYPERTHER, V21, P703, DOI
   10.1080/02656730500384248
   ONYANGO IG, 2006, CURR ALZHEIMER RES, V3, P339
   PANDEY P, 2000, ONCOGENE, V19, P1975
   SAKAGUCHI S, 2006, FEMS IMMUNOL MED MIC, V47, P167, DOI
   10.1111/J.574-695X.2006.00072.x
   SALEH A, 2000, NAT CELL BIOL, V2, P476
   SONG HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI
   10.1124/jpet.104.074401
   SOTI C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/sj.bjp.0706396
   SUREDA A, 2005, FREE RADICAL RES, V39, P1317, DOI
   10.1080/10715760500177500
   WARDLE EN, 2005, AM J NEPHROL, V25, P13
   ZALATA A, 2007, MUTAT RES-GEN TOX EN, V629, P140, DOI
   10.1016/j.mrgentox.2007.02.001
   ZHENG KC, 2007, J OCCUP HEALTH, V49, P32
NR 35
TC 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
J9 CELL STRESS CHAPERONES
JI Cell Stress Chaperones
PD MAR
PY 2009
VL 14
IS 2
BP 207
EP 217
DI 10.1007/s12192-008-0075-8
PG 11
SC Cell Biology
GA 407GY
UT ISI:000263352800011
ER

PT J
AU Li, CL
   Yang, Y
   Gu, JJ
   Ma, Y
   Jin, Y
AF Li, Chunliang
   Yang, Ying
   Gu, Junjie
   Ma, Yu
   Jin, Ying
TI Derivation and transcriptional profiling analysis of pluripotent stem
   cell lines from rat blastocysts
SO CELL RESEARCH
LA English
DT Article
DE embryonic stem cells; blastocysts; primitive endoderm; teratomas
ID SELF-RENEWAL; EFFICIENT DERIVATION; PRIMITIVE ENDODERM; FACTOR OCT-4;
   MOUSE; DIFFERENTIATION; ESTABLISHMENT; CULTURE; GROWTH; FGF
AB Embryonic stem (ES) cells are derived from blastocyst-stage embryos.
   Their unique properties of self-renewal and pluripotency make them an
   attractive tool for basic research and a potential cell resource for
   therapy. ES cells of mouse and human have been successfully generated
   and applied in a wide range of research. However, no genuine ES cell
   lines have been obtained from rat to date. In this study, we identified
   pluripotent cells in early rat embryos using specific antibodies
   against markers of pluripotent stem cells. Subsequently, by modifying
   the culture medium for rat blastocysts, we derived pluripotent rat
   ES-like cell lines, which expressed pluripotency markers and formed
   embryoid bodies (EBs) in vitro. Importantly, these rat ES-like cells
   were able to produce teratomas. Both EBs and teratomas contained
   tissues from all three embryonic germ layers. In addition, from the rat
   ES-like cells, we derived a rat primitive endoderm (PrE) cell line.
   Furthermore, we conducted transcriptional profiling of the rat ES-like
   cells and identified the unique molecular signature of the rat
   pluripotent stem cells. Our analysis demonstrates that multiple
   signaling pathways, including the BMP, Activin and mTOR pathways, may
   be involved in keeping the rat ES-like cells in an undifferentiated
   state. The cell lines and information obtained in this study will
   accelerate our understanding of the molecular regulation underlying
   pluripotency and guide us in the appropriate manipulation of ES cells
   from a particular species.
C1 [Li, Chunliang; Yang, Ying; Gu, Junjie; Ma, Yu; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci,Key Lab Stem Cell Biol, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200025, Peoples R China.
   [Gu, Junjie; Ma, Yu; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Shanghai Stem Cell Inst, Shanghai 200025, Peoples R China.
   [Gu, Junjie; Ma, Yu; Jin, Ying] Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Shanghai 200025, Peoples R China.
   [Li, Chunliang; Yang, Ying] Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China.
RP Jin, Y, Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci,Key Lab Stem
   Cell Biol, Shanghai Inst Biol Sci,Inst Hlth Sci, 225 S Chongqing Rd,
   Shanghai 200025, Peoples R China.
EM yjin@sibs.ac.cn
FU Shanghai Science & Technology Developmental Foundations [06dj14001];
   National High Technology Research and Development Program of China
   [2006AA02Z197, 2006CB943901, 2007CB947904, 2007CB948004]; Shanghai
   JiaoTong University School of Medicine and Shanghai Institutes for
   Biological Sciences, CAS 
FX Authors express appreciation to Erbo Xu (Boston College) for his help
   in preparation of this manuscript and to Yuan Guan (Institute of Health
   Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy
   of Sciences) for his help in subretinal injection. The study was
   supported by the financial support of the Grants from the Shanghai
   Science & Technology Developmental Foundations (Grant number:
   06dj14001), the National High Technology Research and Development
   Program of China (2006AA02Z197, 2006CB943901, 2007CB947904, and
   2007CB948004), Shanghai JiaoTong University School of Medicine and
   Shanghai Institutes for Biological Sciences, CAS.
CR AUSTIN CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921
   BECK S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890
   BENDALL SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027
   BRONS IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950
   BROOK FA, 1997, P NATL ACAD SCI USA, V94, P5709
   BUEHR M, 2003, BIOL REPROD, V68, P222, DOI 10.1095/biolreprod.102.006197
   CHAMBERS I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930
   COLE MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408
   DEMERS SP, 2007, CLONING STEM CELLS, V9, P512, DOI 10.1089/clo.2007.0029
   DRAVID G, 2005, STEM CELLS, V23, P1489
   DVORAK P, 2005, STEM CELLS, V23, P1200, DOI 10.1634/stemcells.2005-0303
   EVANS M, 2002, CR BIOL, V325, P1003
   EVANS MJ, 1981, NATURE, V292, P154
   FANDRICH F, 2002, NAT MED, V8, P171
   GANGLOFF YG, 2004, MOL CELL BIOL, V24, P9508, DOI
   10.1128/MCB.24.21.9508-9516.2004
   HAMAZAKI T, 2004, J CELL SCI, V117, P5681, DOI 10.1242/jcs.01489
   JIANG JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698
   KAJI K, 2007, DEVELOPMENT, V134, P1123, DOI 10.1242/dev.02802
   LI TQ, 2005, STEM CELLS, V23, P1192, DOI 10.1634/stemcells.2005-0286
   MATSUDA T, 1999, EMBO J, V18, P4261
   NARISAWA S, 1994, DEV DYNAM, V201, P227
   NICHOLS J, 1998, REPROD FERT DEVELOP, V10, P517
   OUHIBI N, 1995, MOL REPROD DEV, V40, P311
   PALMIERI SL, 1994, DEV BIOL, V166, P259
   QI XX, 2004, P NATL ACAD SCI USA, V101, P6027
   RUHNKE M, 2003, STEM CELLS, V21, P428
   RULA ME, 2007, GENESIS, V45, P327, DOI 10.1002/dvg.20298
   SATO N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   THOMSON JA, 1998, SCIENCE, V282, P1147
   UEDA S, 2008, PLOS ONE, V3, ARTN e2800
   UMEHARA H, 2007, STEM CELLS, V25, P2705, DOI 10.1634/stemcells.2007-0086
   VALLIER L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553
   VASSILIEVA S, 2000, EXP CELL RES, V258, P361
   XU CH, 2001, NAT BIOTECHNOL, V19, P971
   XU HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200
   XU RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744
   YING QL, 2003, CELL, V115, P281
   ZHANG ZH, 2007, FASEB J, V21, P3042, DOI 10.1096/fj.06-6914com
NR 38
TC 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD FEB
PY 2009
VL 19
IS 2
BP 173
EP 186
DI 10.1038/cr.2008.301
PG 14
SC Cell Biology
GA 406IF
UT ISI:000263287500004
ER

PT J
AU Guo, W
   Zhang, KM
   Tu, K
   Li, YX
   Zhu, L
   Xiao, HS
   Yang, Y
   Wu, JR
AF Guo, Wei
   Zhang, Kun-Ming
   Tu, Kang
   Li, Yi-Xue
   Zhu, Li
   Xiao, Hua-Sheng
   Yang, Ying
   Wu, Jia-Rui
TI Adipogenesis licensing and execution are disparately linked to cell
   proliferation
SO CELL RESEARCH
LA English
DT Article
DE adipogenesis; proliferation; contact inhibition; DNA methylation; C/EBP
   alpha
ID MITOTIC CLONAL EXPANSION; 3T3-L1 PREADIPOCYTE DIFFERENTIATION;
   ADIPOCYTE DIFFERENTIATION; LEUKEMIC-CELLS; GROWTH ARREST; STEM-CELL;
   RECEPTOR; CYCLE; INHIBITION; PHASE
AB Coordination of cell differentiation and proliferation is a key issue
   in the development process of multi-cellular organisms and stem cells.
   Here we provide evidence that the establishment of adipocyte
   differentiation of 3T3-L1 cells requires two processes: the licensing
   of an adipogenesis gene-expression program within a particular
   growth-arrest stage, i.e., the contact-inhibition stage, and then the
   execution of this program in a cell-cycle-independent manner, by which
   the licensed progenitors are differentiated into adipocytes in the
   presence of inducing factors. Our results showed that differentiation
   licensing of 3T3-L1 cells during the contact-inhibition stage involved
   epigenetic modifications such as DNA methylation and histone
   modifications, whereas disturbing these epigenetic modifications by DNA
   methylation inhibitors or RNAi during the contact-inhibition stage
   significantly reduced adipogenesis efficiency. More importantly, when
   these licensed 3T3-L1 cells were re-cultured under non-differentiating
   conditions or treated only with insulin, this adipogenesis commitment
   could be maintained from one cell generation to the next, whereby the
   licensed program could be activated in a cell-cycle-independent manner
   once these cells were subjected to adipogenesis-inducing conditions.
   This result suggests that differentiation licensing and differentiation
   execution can be uncoupled and disparately linked to cell
   proliferation. Our findings deliver a new concept that cell-fate
   decision can be subdivided into at least two stages, licensing and
   execution, which might have different regulatory relationships with
   cell proliferation. In addition, this new concept may provide a clue
   for developing new strategies against obesity.
C1 [Guo, Wei; Zhang, Kun-Ming; Tu, Kang; Li, Yi-Xue; Zhu, Li; Xiao, Hua-Sheng; Yang, Ying; Wu, Jia-Rui] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai 200031, Peoples R China.
   [Guo, Wei; Zhang, Kun-Ming; Yang, Ying; Wu, Jia-Rui] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.
   [Xiao, Hua-Sheng] Natl Engn Ctr Biochip Shanghai, Shanghai 201203, Peoples R China.
   [Wu, Jia-Rui] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Peoples R China.
   [Wu, Jia-Rui] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China.
RP Wu, JR, Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell
   Biol, Key Lab Syst Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R
   China.
EM wujr@sibs.ac.cn
FU National Natural Science Foundation of China [2006CB503900, 30230110,
   30521005]; Chinese Academy of Sciences [KSCX1-YW-02]
FX We thank DS Li (Chinese Academy of Scienses, China) for critically
   reading this article. This work was supported by the "973 Program" No.
   2006CB503900, grants from the National Natural Science Foundation of
   China No. 30230110 and No. 30521005, and a grant from the Knowledge
   Innovation Program of the Chinese Academy of Sciences KSCX1-YW-02 to
   JRW.
CR ANDANG M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488
   ARNEY KL, 2004, J CELL SCI, V117, P4355, DOI 10.1242/jcs.01390
   BATT DB, 1998, J BIOL CHEM, V273, P3408
   BEAUJEAN N, 2004, BIOL REPROD, V71, P185, DOI
   10.1095/biolreprod.103.026559
   BROWN G, 2002, EXP CELL RES, V281, P28, DOI 10.1006/excr.2002.5654
   BROWN G, 2003, EXP CELL RES, V291, P282, DOI
   10.1016/S0014-4827(03)00393-8
   COLLER HA, 2006, PLOS BIOL, V4, UNSP 0329-0349
   FUJITO T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090
   GREGOIRE FM, 1998, PHYSIOL REV, V78, P783
   HUO HR, 2003, J BIOL CHEM, V278, P11561, DOI 10.1074/jbc.M211785200
   KONDO T, 2006, CURR OPIN GENET DEV, V16, P502, DOI
   10.1016/j.gde.2006.07.001
   LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757
   MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345
   MAIONE R, 1997, BBA-REV CANCER, V1332, M19
   MATUSHANSKY I, 2000, P NATL ACAD SCI USA, V97, P14317
   MATUSHANSKY I, 2003, ONCOGENE, V22, P4143, DOI 10.1038/sj.onc.1206484
   MCNAIRN AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305
   NG RK, 2008, NAT CELL BIOL, V10, P102, DOI 10.1038/ncb1674
   OTTO TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI
   10.1080/10409230591008189
   PARDEE AB, 1989, SCIENCE, V246, P603
   PATEL YM, 2000, J BIOL CHEM, V275, P17653
   QIU ZL, 2001, J BIOL CHEM, V276, P11988
   SCOTT RE, 1982, J CELL BIOL, V94, P400
   SCOTT RE, 1982, P NATL ACAD SCI USA, V79, P845
   SKAPEK SX, 1995, SCIENCE, V267, P1022
   TADA Y, 2006, J NATL CANCER I, V98, P396
   TANG QQ, 2003, P NATL ACAD SCI USA, V100, P44
   VALENTINIS B, 1999, J BIOL CHEM, V274, P12423
   ZHU L, 2001, CURR OPIN GENET DEV, V11, P91
NR 29
TC 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD FEB
PY 2009
VL 19
IS 2
BP 216
EP 223
DI 10.1038/cr.2008.319
PG 8
SC Cell Biology
GA 406IF
UT ISI:000263287500008
ER

PT J
AU Zhu, CY
   Li, CY
   Li, Y
   Zhan, YQ
   Li, YH
   Xu, CW
   Xu, WX
   Sun, HB
   Yang, XM
AF Zhu, C-Y
   Li, C-Y
   Li, Y.
   Zhan, Y-Q
   Li, Y-H
   Xu, C-W
   Xu, W-X
   Sun, H. B.
   Yang, X-M
TI Cell growth suppression by thanatos-associated protein 11(THAP11) is
   mediated by transcriptional downregulation of c-Myc
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE THAP11; c-Myc; growth suppression; transcriptional repressor
ID ORNITHINE-DECARBOXYLASE GENE; EMBRYONIC STEM-CELLS; CYCLIN D1; HISTONE
   ACETYLATION; BINDING PROTEIN; TARGET GENES; THAP DOMAIN; P2 PROMOTER;
   REPRESSION; PROLIFERATION
AB Thanatos-associated proteins (THAPs) are zinc-dependent,
   sequence-specific DNA-binding factors involved in cell proliferation,
   apoptosis, cell cycle, chromatin modification and transcriptional
   regulation. THAP11 is the most recently described member of this human
   protein family. In this study, we show that THAP11 is ubiquitously
   expressed in normal tissues and frequently downregulated in several
   human tumor tissues. Overexpression of THAP11 markedly inhibits growth
   of a number of different cells, including cancer cells and
   non-transformed cells. Silencing of THAP11 by RNA interference in HepG2
   cells results in loss of cell growth repression. These results suggest
   that human THAP11 may be an endogenous physiologic regulator of cell
   proliferation. We also provide evidence that the function of THAP11 is
   mediated by its ability to repress transcription of c-Myc. Promoter
   reporter assays indicate a DNA binding-dependent c-Myc transcriptional
   repression. Chromatin immunoprecipitations and EMSA assay suggest that
   THAP11 directly binds to the c-Myc promoter. The findings that
   expression of c-Myc rescues significantly cells from THAP11-mediated
   cell growth suppression and that THAP11 expression only slightly
   inhibits c-Myc null fibroblasts cells growth reveal that THAP11
   inhibits cell growth through downregulation of c-Myc expression. Taken
   together, these suggest that THAP11 functions as a cell growth
   suppressor by negatively regulating the expression of c-Myc.
C1 [Yang, X-M] Beijing Inst Radiat Med, Dept Biochem & Mol Biol, Beijing 100850, Peoples R China.
   [Li, C-Y; Zhan, Y-Q; Xu, W-X] Key Lab Prote & Geom, Beijing, Peoples R China.
   [Li, Y.] Anhui Med Univ, Dept Pathophysiol, Hefei, Peoples R China.
   [Li, Y-H; Sun, H. B.] Mt Sinai Sch Med, New York, NY USA.
RP Yang, XM, Beijing Inst Radiat Med, Dept Biochem & Mol Biol, 27 Taiping
   Rd, Beijing 100850, Peoples R China.
EM xmyang2@nic.bmi.ac.cn
FU Special Funds for Major State Basic Research of China [2006CB910802];
   Chinese National Natural Science Fund for the Popularization of Science
   [30321003]; Chinese National Nature Foundation Key Program Project
   [30630035]; Chinese National Natural Science Foundation project
   [30480659, 30870958]; Beijing National Natural Science Foundation
   project 
FX We are grateful to Dr. Ken Kinzler and Bert Vogelstein (The Sidney
   Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
   Medicine) for providing c-Myc promoter luciferase reporter, and
   appreciate Dr. Tong- Chuan He for advice. This work was partially
   supported by the Special Funds for Major State Basic Research of China
   (2006CB910802), Chinese National Natural Science Fund for the
   Popularization of Science (30321003), Chinese National Nature
   Foundation Key Program Project (30630035), Chinese National Natural
   Science Foundation project (30480659, 30870958), and Beijing National
   Natural Science Foundation project.
CR ALBERT T, 2001, J BIOL CHEM, V276, P20482
   AUVINEN M, 2003, INT J BIOCHEM CELL B, V35, P496
   BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804
   BHASKAR V, 2000, J BIOL CHEM, V275, P4033
   BOUCHARD C, 1998, TRENDS CELL BIOL, V8, P202
   BOXEM M, 2002, CURR BIOL, V12, P906
   CARBONE CJ, 2007, CANCER RES, V67, P4130, DOI
   10.1158/0008-5472.CAN-07-0499
   CARTWRIGHT P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670
   CAYROL C, 2007, BLOOD, V109, P584, DOI 10.1182/blood-2006-03-012013
   CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438
   CLAASSEN GF, 2000, P NATL ACAD SCI USA, V97, P9498
   CLOUAIRE T, 2005, P NATL ACAD SCI USA, V102, P6907
   COLLER HA, 2000, P NATL ACAD SCI USA, V97, P3260
   DAKSIS JI, 1994, ONCOGENE, V9, P3635
   DEISS LP, 1995, GENE DEV, V9, P15
   DEJOSEZ M, 2008, CELL, V133, P1162, DOI 10.1016/j.cell.2008.05.047
   EBERHARDY SR, 2000, J BIOL CHEM, V275, P33798
   FAY DS, 2002, GENE DEV, V16, P503
   FILIPPOVA GN, 1996, MOL CELL BIOL, V16, P2802
   FILIPPOVA GN, 1998, GENE CHROMOSOME CANC, V22, P26
   FONG LYY, 2003, CANCER RES, V63, P4244
   GALE M, 1998, MOL CELL BIOL, V18, P859
   GARTEL AL, 1996, P SOC EXP BIOL MED, V213, P138
   GINISTY H, 1999, J CELL SCI, V112, P761
   GREASLEY PJ, 2000, NUCLEIC ACIDS RES, V28, P446
   IZZO MW, 1999, J BIOL CHEM, V274, P19498
   LAN L, 2000, CANCER RES, V60, P5696
   LATIL A, 1997, CANCER RES, V57, P1058
   LIN Y, 1997, SCIENCE, V276, P596
   MACFARLAN T, 2005, J BIOL CHEM, V280, P7346, DOI 10.1074/jbc.M411675200
   MACFARLAN T, 2006, MOL ENDOCRINOL, V20, P335, DOI 10.1210/me.2005-0248
   MARCHONG MN, 2004, MOL CANCER RES, V2, P495
   MATEYAK MK, 1997, CELL GROWTH DIFFER, V8, P1039
   PANDEY N, 2004, J HUM GENET, V49, P596, DOI 10.1007/s10038-004-0194-8
   REDDY KC, 2004, CELL, V118, P439
   ROUSSIGNE M, 2003, ONCOGENE, V22, P2432, DOI 10.1038/sj/onc.1206271
   ROUSSIGNE M, 2003, TRENDS BIOCHEM SCI, V28, P66
   ROY PG, 2006, BREAST, V15, P718
   SPENCER CA, 1991, ADV CANCER RES, V56, P1
   SUMI T, 2007, ONCOGENE, V26, P5564, DOI 10.1038/sj.onc.1210353
   TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791
   WATSON JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200
   WU KJ, 1999, NAT GENET, V21, P220
   YANG W, 2001, ONCOGENE, V20, P1688
NR 44
TC 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFERENTIATION
JI Cell Death Differ.
PD MAR
PY 2009
VL 16
IS 3
SI Sp. Iss. SI
BP 395
EP 405
DI 10.1038/cdd.2008.160
PG 11
SC Biochemistry & Molecular Biology; Cell Biology
GA 407JT
UT ISI:000263360100006
ER

PT J
AU Ye, J
   Li, JZ
   Liu, Y
   Li, XH
   Yang, TS
   Ma, XD
   Li, Q
   Yao, ZM
   Li, P
AF Ye, Jing
   Li, John Zhong
   Liu, Yang
   Li, Xuanhe
   Yang, Tianshu
   Ma, Xiaodong
   Li, Qing
   Yao, Zemin
   Li, Peng
TI Cideb, an ER- and Lipid Droplet-Associated Protein, Mediates VLDL
   Lipidation and Maturation by Interacting with Apolipoprotein B
SO CELL METABOLISM
LA English
DT Article
ID LOW-DENSITY LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; DIET-INDUCED
   OBESITY; ENDOPLASMIC-RETICULUM; PROTEASOMAL DEGRADATION; INSULIN
   SENSITIVITY; GOLGI-APPARATUS; MOUSE-LIVER; MICE; SECRETION
AB Secretion of triacylglycerol-enriched very-low-density lipoproteins
   (VLDLs) from the liver is vital for maintaining plasma lipid
   homeostasis. However, the process of VLDL assembly and lipidation is
   not well characterized. Here, we observed that liver of Cideb null mice
   had higher levels of triacylglycerols accompanied by low level of VLDL
   secretion. Furthermore, VLDL particles secreted from hepatocytes of
   Cideb null mice have low levels of triacylglycerols but normal levels
   of apoB. We also observed that Cideb is localized to endoplasmic
   reticulum and lipid droplets. Importantly, we have identified apoB as a
   Cideb-inter-acting protein. By infecting adenoviruses expressing
   various Cideb truncations into hepatocytes of Cideb null mice, we found
   that Cideb requires both its apoB-binding and lipid droplet association
   domains to restore the secretion of triacyl glycerol-enriched VLDL
   particles. Our data suggest that Cideb promotes the formation of
   triacylglycerol-enriched VLDL particles and provides a molecular
   insight into VLDL lipidation and maturation in hepatocytes.
C1 [Ye, Jing; Li, John Zhong; Liu, Yang; Li, Xuanhe; Yang, Tianshu; Ma, Xiaodong; Li, Peng] Tsinghua Univ, Dept Biol Sci & Biotechnol, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China.
   [Ye, Jing; Li, Qing] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China.
   [Yao, Zemin] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
RP Li, P, Tsinghua Univ, Dept Biol Sci & Biotechnol, Minist Educ, Prot Sci
   Lab, Beijing 100084, Peoples R China.
EM li-peng@mail.tsinghua.edu.cn
FU National Natural Science Foundation of China [30429001, 30530350,
   30700268]; Ministry of Education of China [704002]; National Basic
   Research Program of China [2006CB5039009, 2007CB914404]; Ministry of
   Science and Technology of China ; Canadian Institute of Health Research
   [MT-15486]
FX We thank members of Peng Li's laboratory at Tsinghua University for
   technical assistance and helpful discussion and Doctor S.C. Lin for
   critical editing of the manuscript. This work was supported by grants
   from the National Natural Science Foundation of China (30429001 and
   30530350 to P.L. and 30700268 to J.Y.), the Ministry of Education of
   China (704002 to P.L.), the National Basic Research Program of China
   (2006CB5039009 and 2007CB914404), the Ministry of Science and
   Technology of China, and the Canadian Institute of Health Research
   (MT-15486 to Z.Y.). We are grateful to the technical help provided by
   Mr. Mingxi Li at Tsinghua University and Ms. Shumei Zhong at University
   of Ottawa. This work was also supported by the Program for Changjiang
   Scholars and Innovative Research Team in University from the Ministry
   of Education in China. We thank Doctor Wanjin Hong at the Institute of
   Molecular and Cell Biology in Singapore for providing GS28 antibody and
   Doctor Senfang Sui at Tsinghua University for help with EM analysis.
CR BORENSZTAJN J, 1976, BIOCHEM J, V156, P539
   BUHMAN KK, 2000, NAT MED, V6, P1341
   CARTWRIGHT IJ, 2000, J LIPID RES, V41, P1728
   CHEN ZM, 2000, J BIOL CHEM, V275, P22619
   CHOU PY, 1978, ADV ENZYMOL, V47, P45
   CROZE EM, 1984, J CELL PHYSIOL, V119, P46
   FISHER EA, 2002, J BIOL CHEM, V277, P17377
   GIBBONS GF, 2004, BIOCHEM SOC T 1, V32, P59
   GORDON DA, 1997, CURR OPIN LIPIDOL, V8, P131
   GUSAROVA V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345
   INOHARA N, 1998, EMBO J, V17, P2526
   JUMP DB, 2005, J NUTR, V135, P2503
   KELLER P, 2008, J BIOL CHEM, V283, P14355, DOI 10.1074/jbc.M708323200
   KHALIL MB, 2008, J LIPID RES, V3, P47
   KLAUNIG JE, 1981, IN VITRO, V17, P913
   KOONEN DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907
   LI JZ, 2007, DIABETES, V56, P2523, DOI 10.2337/db07-0040
   LIANG JS, 2000, J BIOL CHEM, V275, P32003
   NEWBERRY EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200
   OLOFSSON SO, 2000, TRENDS CARDIOVAS MED, V10, P338
   PAN MH, 2008, P NATL ACAD SCI USA, V105, P5862, DOI
   10.1073/pnas.0707460104
   PURI V, 2008, P NATL ACAD SCI USA, V105, P7833, DOI
   10.1073/pnas.0802063105
   RAABE M, 1999, J CLIN INVEST, V103, P1287
   ROSEMAN MA, 1988, J MOL BIOL, V200, P513
   SAKATA N, 1999, J BIOL CHEM, V274, P17068
   STILLEMARKBILLTON P, 2005, J LIPID RES, V46, P104, DOI
   10.1194/jlr.M400296-JLR200
   TACHIBANA S, 2005, BBA-MOL CELL BIOL L, V1737, P36, DOI
   10.1016/j.bbalip.2005.09.001
   TOH SY, 2008, PLOS ONE, V3, ARTN e2890
   VALYINAGY K, 2002, LIPIDS, V37, P879
   YAMAZAKI T, 2005, J BIOL CHEM, V280, P21506, DOI 10.1047/jbc.M412989200
   ZHOU ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225
NR 32
TC 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD FEB 4
PY 2009
VL 9
IS 2
BP 177
EP 190
DI 10.1016/j.cmet.2008.12.013
PG 14
SC Cell Biology; Endocrinology & Metabolism
GA 406BG
UT ISI:000263269400009
ER

PT J
AU Koto, K
   Horie, N
   Kimura, S
   Murata, H
   Sakabe, T
   Matsui, T
   Watanabe, M
   Adachi, S
   Maekawa, T
   Fushiki, S
   Kubo, T
AF Koto, Kazutaka
   Horie, Naoyuki
   Kimura, Shinya
   Murata, Hiroaki
   Sakabe, Tomoya
   Matsui, Takaaki
   Watanabe, Motonobu
   Adachi, Souichi
   Maekawa, Taira
   Fushiki, Shinji
   Kubo, Toshikazu
TI Clinically relevant dose of zoledronic acid inhibits spontaneous lung
   metastasis in a murine osteosarcoma model
SO CANCER LETTERS
LA English
DT Article
DE Zoledronic acid; Osteosarcoma; Metastasis; Neovascularization
ID NITROGEN-CONTAINING BISPHOSPHONATES; CANCER-CELL GROWTH; 3RD-GENERATION
   BISPHOSPHONATE; IN-VITRO; PROSTATE-CANCER; BONE METASTASES; ANTICANCER
   AGENTS; BLADDER-CANCER; VIVO; APOPTOSIS
AB Clinically obtainable concentrations of zoledronic acid (ZOL) inhibited
   the production of vascular endothelial growth factor and reduced the
   migration, adhesion, and invasiveness of osteosarcoma (OS) cells in
   vitro. The in vivo effects of ZOL were investigated by using a murine
   model of spontaneous lung metastasis. The higher dose of ZOL (80 mu
   g/kg three times/week) inhibited the growth of OS at the primary site,
   accompanied by inhibition of neovascularization in the tumor.
   Interestingly, while the lower dose of ZOL (80 mu g/kg once a week)
   could not inhibit the growth of CS at the primary site, it
   significantly prevented lung metastasis. (C) 2008 Elsevier Ireland Ltd.
   All rights reserved.
C1 [Kimura, Shinya; Maekawa, Taira] Kyoto Univ Hosp, Dept Transfus Med & Cell Therapy, Sakyo Ku, Kyoto 6068507, Japan.
   [Koto, Kazutaka; Horie, Naoyuki; Murata, Hiroaki; Sakabe, Tomoya; Matsui, Takaaki; Kubo, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthoped, Kamigyo Ku, Kyoto 6028566, Japan.
   [Horie, Naoyuki; Fushiki, Shinji] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pathol & Appl Neurobiol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Watanabe, Motonobu; Adachi, Souichi] Kyoto Univ Hosp, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan.
RP Kimura, S, Kyoto Univ Hosp, Dept Transfus Med & Cell Therapy, Sakyo Ku,
   Kyoto 6068507, Japan.
EM shkimu@kuhp.kyoto-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [15790796, 18591056]
FX We are grateful to Dr. Jonathan Green (Novartis Pharma AG, Basel,
   Switzerland) for critically reading the manuscript and to Ms. Yoko
   Nakagawa for her excellent technical support. This study is partially
   supported by Grants-inAid for Scientific Research from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (15790796
   to H.M. and 18591056 to S.K.).
CR ARNDT CAS, 1999, NEW ENGL J MED, V341, P342
   ASAI T, 1998, INT J CANCER, V76, P418
   BACCI G, 2001, EUR J CANCER, V37, P32
   BAUSS F, 2002, J RHEUMATOL, V29, P990
   BUDMAN DR, 2006, ONCOLOGY-BASEL, V70, P147, DOI 10.1159/000093006
   CHEN TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI
   10.1177/0091270002238765
   COLEMAN RE, 2002, SEMIN ONCOL S21, V29, P43, DOI 10.1053/sonc.2002.37415
   DAUBINE F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   DUNFORD JE, 2001, J PHARMACOL EXP THER, V296, P235
   DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101
   FIDLER IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   FOURNIER P, 2002, CANCER RES, V62, P6538
   GREEN JR, 2004, ONCOLOGIST S4, V9, P3
   GREEN JR, 2005, ACTA ONCOL, V44, P282, DOI 10.1080/02841860510029644
   HACKER U, 1998, GENE DEV, V12, P274
   HIRAGA T, 2004, CLIN CANCER RES, V10, P4559
   HORIE N, 2006, CANCER LETT, V238, P111, DOI 10.1016/j.canlet.2005.06.041
   HORIE N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   KEMPFBIELACK B, 2005, J CLIN ONCOL, V23, P559, DOI
   10.1200/JCO.2005.04.063
   KIM KJ, 1993, NATURE, V362, P841
   KIMURA S, 1995, CANCER RES, V55, P1379
   KURODA J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305
   MATSUMOTO S, 2005, LUNG CANCER-J IASLC, V47, P31, DOI
   10.1016/j.lungcan.2004.06.003
   MITSIADES CS, 2006, ANTICANCER RES, V26, P3693
   MONKKONEN H, 2006, BRIT J PHARMACOL, V147, P437, DOI
   10.1038/sj.bjp.0706628
   MYSTAKIDOU K, 2005, MED ONCOL, V22, P195
   NAM JS, 2002, JPN J CANCER RES, V93, P1020
   NOGAWA M, 2005, CANCER LETT, V217, P243, DOI
   10.1016/j.canlet.2004.07.010
   NOGAWA M, 2005, J CLIN INVEST, V115, P978
   NOGAWA M, 2005, ONCOL RES, V15, P1
   ORY B, 2005, CANCER, V104, P2522, DOI 10.1002/cncr.21530
   ROELOFS AJ, 2006, CLIN CANCER RES S 2, V12, S6222, DOI
   10.1158/1078-0432.CCR-06-0843
   SANTINI D, 2003, CLIN CANCER RES, V9, P2893
   SATO K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   SATO K, 2006, BRIT J CANCER, V95, P1354, DOI 10.1038/sj.bjc.6603423
   TAKESHITA H, 1998, ANTICANCER RES, V18, P739
   UEDA T, 2002, J CLIN PATHOL, V55, P853
   UNNI K, 1996, DAHLINS BONE TUMORS
   UNNI KK, 1998, J ORTHOP SCI, V3, P287
   VANBEEK ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   WOODWARD JKL, 2005, ANTI-CANCER DRUG, V16, P11
   YANG J, 2004, CELL, V117, P927
   YUASA T, 2005, CLIN CANCER RES, V11, P853
NR 43
TC 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD FEB 18
PY 2009
VL 274
IS 2
BP 271
EP 278
DI 10.1016/j.canlet.2008.09.026
PG 8
SC Oncology
GA 405ER
UT ISI:000263206100014
ER

PT J
AU Luo, XM
   Maarschalk, E
   O'Connell, RM
   Wang, P
   Yang, L
   Baltimore, D
AF Luo, Xin M.
   Maarschalk, Emily
   O'Connell, Ryan M.
   Wang, Pin
   Yang, Lili
   Baltimore, David
TI Engineering human hematopoietic stem/progenitor cells to produce a
   broadly neutralizing anti-HIV antibody after in vitro maturation to
   human B lymphocytes
SO BLOOD
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODY; PBL-SCID MICE; IMMUNODEFICIENCY-VIRUS;
   STEM-CELLS; TRANSGENE EXPRESSION; PASSIVE-IMMUNIZATION; LENTIVIRAL
   VECTORS; RETROVIRAL VECTOR; SECRETING CELLS; AIDS VACCINE
AB Broadly neutralizing anti-HIV antibodies are rare and have proved hard
   to elicit with any immunogen. We have tested in vitro the notion that
   such antibodies or other antiviral proteins could be made by
   lentivirus-mediated gene transfer into human hematopoietic
   stem/progenitor cells (HSPCs), followed by differentiation of the
   transduced cells into B cells, the most potent antibody-producing
   cells. To do this, we have developed a highly efficient system for in
   vitro maturation of secreting B lymphocytes and plasma cells from
   CD34(+) HSPCs. It is a 3-stage, in vitro culture system that supports
   normal human B-lineage development from HSPCs to antibody-secreting
   plasmablasts (similar to 36%) and plasma cells (similar to 20%). By
   transducing human cord blood CD34(+) cells with lentiviral vectors
   encoding a secretory monoclonal anti-HIV antibody, b12 (IgG(1)), we
   were able to program human B cells to produce in vitro up to 1.5 mu
   g/mL of this broadly neutralizing antibody. Our results suggest that an
   HIV vaccine might be delivered by autologous transplantation of in
   vitro-programmed HSPCs, which would develop into antibody-secreting B
   cells in vivo and provide a continuous supply of anti-HIV neutralizing
   antibodies. ( Blood. 2009; 113: 1422-1431)
C1 [Luo, Xin M.; Maarschalk, Emily; O'Connell, Ryan M.; Yang, Lili; Baltimore, David] CALTECH, Div Biol, Pasadena, CA 91125 USA.
   [Wang, Pin] Univ So Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA USA.
RP Baltimore, D, CALTECH, Div Biol, M-C 147-75,1200 E Calif Blvd,
   Pasadena, CA 91125 USA.
EM liyang@caltech.edu
   baltimo@caltech.edu
FU Bill and Melinda Gates Foundation 
FX This study was supported by the Bill and Melinda Gates Foundation (
   Seattle, WA) through the Grand Challenges in Global Health Initiative (
   D. B.).
CR ARCE S, 2004, J LEUKOCYTE BIOL, V75, P1022, DOI 10.1189/jlb.0603279
   BARBAS CF, 1993, J MOL BIOL, V230, P812
   BINLEY JA, 2004, J VIROL, V78, P13232, DOI
   10.1128/JVI.78.23.13232-13252.2004
   BRUSSEL A, 2005, METHOD MOL BIOL, V304, P139
   BURTON DR, 1994, SCIENCE, V266, P1024
   BURTON DR, 2005, P NATL ACAD SCI USA, V102, P14943
   BUTLER SL, 2001, NAT MED, V7, P631
   CHEN J, 1993, CURR OPIN IMMUNOL, V5, P194
   DOUEK DC, 2006, CELL, V124, P677
   FLUCKIGER AC, 1998, BLOOD, V92, P4509
   GAUDUIN MC, 1997, NAT MED, V3, P1389
   GRANDE A, 1999, BLOOD, V93, P3276
   GRASSINGER J, 2006, EUR J HAEMATOL, V77, P134, DOI
   10.1111/j.1600-0609.2006.00673.x
   HAO QL, 1995, BLOOD, V86, P3745
   HEDESTAM GBK, 2008, NAT REV MICROBIOL, V6, P143, DOI 10.1038/nrmicro1819
   HIRAYAMA F, 1995, BLOOD, V85, P1762
   HUGGINS J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441
   IWASAKI H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004
   KEHRY MR, 1996, J IMMUNOL, V156, P2345
   KESSLER JA, 1997, AIDS RES HUM RETROV, V13, P575
   LANE HC, 1983, NEW ENGL J MED, V309, P453
   LANZAVECCHIA A, 2006, IMMUNOL REV, V211, P303
   LAZAR GA, 2006, P NATL ACAD SCI USA, V103, P4005
   LENS SMA, 1996, J IMMUNOL, V156, P507
   LETVIN NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   LIN KI, 2002, MOL CELL BIOL, V22, P4771
   LOIS C, 2002, SCIENCE, V295, P868
   MARODON G, 2003, BLOOD, V101, P3416, DOI 10.1182/blood-2002-02-0578
   MESSNER HA, 1995, STEM CELLS S3, V13, P13
   MIZUMA H, 1987, CLIN EXP IMMUNOL, V68, P5
   NISHIMURA Y, 2003, P NATL ACAD SCI USA, V100, P15131, DOI
   10.1073/pnas.2436476100
   OHKAWARA JI, 1998, LEUKEMIA, V12, P764
   PANTOPHLET R, 2003, J VIROL, V77, P642, DOI
   10.1128/JVI.77.1.642-658.2003
   PANTOPHLET R, 2006, ANNU REV IMMUNOL, V24, P739, DOI
   10.1146/annurev.immunol.24.021605.090557
   PARREN PWHI, 1995, AIDS, V9, F1
   PARREN PWHI, 2001, J VIROL, V75, P8340
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392
   PITISUTTITHUM P, 2006, J INFECT DIS, V194, P1661
   SAELAND S, 1991, BLOOD, V78, P2229
   SELVARAJAH S, 2005, J VIROL, V79, P12148, DOI
   10.1128/JVI.79.19.12148-12163.2005
   SZYMCZAK AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957
   VANDEWINKEL JGJ, 1997, IMMUNOL TODAY, V18, P562
   VEAZEY RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   WATKINS DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   WERNER M, 2004, GENE THER, V11, P992, DOI 10.1038/sj.gt.3302255
   WYATT R, 1998, SCIENCE, V280, P1884
   YANG L, 2005, P NATL ACAD SCI USA, V102, P4518, DOI
   10.1073/pnas.0500600102
   ZWICK MB, 2001, J VIROL, V75, P12198
NR 48
TC 15
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 12
PY 2009
VL 113
IS 7
BP 1422
EP 1431
DI 10.1182/blood-2008-09-177139
PG 10
SC Hematology
GA 406SY
UT ISI:000263316400007
ER

PT J
AU Hao, DC
   Yang, L
   Huang, BL
AF Hao, Da Cheng
   Yang, Ling
   Huang, Beili
TI Molecular evolution of paclitaxel biosynthetic genes TS and DBAT of
   Taxus species
SO GENETICA
LA English
DT Article
DE Adaptive evolution; 10-Deacetylbaccatin III-10
   beta-O-acetyltransferase; Paclitaxel; Positive selection; Taxadiene
   synthase; Taxus
ID AMINO-ACID SITES; TAXOL BIOSYNTHESIS; TAXADIENE SYNTHASE; SELECTION
   PRESSURE; ESCHERICHIA-COLI; COMMITTED STEP; NUCLEOTIDE; MODELS;
   SUBSTITUTIONS; CYCLIZATION
AB Evolutionary patterns of sequence divergence were analyzed in genes
   from the conifer genus Taxus (yew), encoding paclitaxel biosynthetic
   enzymes taxadiene synthase (TS) and 10-deacetylbaccatin III-10
   beta-O-acetyltransferase (DBAT). N-terminal fragments of TS,
   full-length DBAT and internal transcribed spacer (ITS) were amplified
   from 15 closely related Taxus species and sequenced. Premature stop
   codons were not found in TS and DBAT sequences. Codon usage bias was
   not found, suggesting that synonymous mutations are selectively
   neutral. TS and DBAT gene trees are not consistent with the ITS tree,
   where species formed monophyletic clades. In fact, for both genes,
   alleles were sometimes shared across species and parallel amino acid
   substitutions were identified. While both TS and DBAT are, overall,
   under purifying selection, we identified a number of amino acids of TS
   under positive selection based on inference using maximum likelihood
   models. Positively selected amino acids in the N-terminal region of TS
   suggest that this region might be more important for enzyme function
   than previously thought. Moreover, we identify lineages with
   significantly elevated rates of amino acid substitution using a genetic
   algorithm. These findings demonstrate that the pattern of adaptive
   paclitaxel biosynthetic enzyme evolution can be documented between
   closely related Taxus species, where species-specific taxane metabolism
   has evolved recently.
C1 [Yang, Ling] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian, Peoples R China.
RP Yang, L, Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut
   Resource Discovery, Dalian, Peoples R China.
EM haodc@126.com
   yling@dicp.ac.cn
FU Ministry of Science & Technology of China [2007CB707802]
FX We thank the following experts for providing plant materials: YunFen
   Geng (YunNan Academy of Forestry, KunMing, China), YinKe Zhang
   (HangZhou Botanical Garden, China), Ron Determann (Atlanta Botanical
   Garden, GA, USA), Richard W. Spjut (World Botanical Associates, CA,
   USA), Robert G. Nicolson (Smith College, USA), Stephane Bailleul
   (Montreal Botanical Garden, Canada), Eric La Fountaine (University of
   British Columbia Botanical Garden, Canada), and James Stevenson
   (University of Oxford Botanic Garden, UK). We are grateful to Sergei L.
   Kosakovsky Pond and Leslie M. Turner (University of California, San
   Diego, USA) for suggestions in genetic algorithm and parallel amino
   acid substitutions, respectively, and to two anonymous reviewers for
   their critical comments. This study is supported by the National 973
   Project (2007CB707802) of the Ministry of Science & Technology of China.
CR ANISIMOVA M, 2003, GENETICS, V164, P1229
   BISHOP JG, 2005, MOL BIOL EVOL, V22, P1531, DOI 10.1093/molbev/msi146
   CHENG YC, 2000, MOL PHYLOGENET EVOL, V14, P353
   DORONFAIGENBOIM A, 2007, MOL BIOL EVOL, V24, P388, DOI
   10.1093/molbev/msl175
   GRANTHAM R, 1974, SCIENCE, V185, P862
   HARTMANN T, 2005, PHYTOCHEMISTRY, V66, P1198, DOI
   10.1016/j.phytochem.2005.04.021
   KOEPP AE, 1995, J BIOL CHEM, V270, P8686
   KRESS WJ, 2005, P NATL ACAD SCI USA, V102, P8369, DOI
   10.1073/pnas.0503123102
   LI J, 2001, HARVARD PAP BOT, V6, P267
   LI WH, 1984, J MOL EVOL, V21, P58
   LIU ZY, 2005, MOL BIOL EVOL, V22, P659, DOI 10.1093/molbev/msi049
   MORTON BR, 1993, J MOL EVOL, V37, P273
   NIELSEN R, 2005, PLOS BIOL, V3, P976, ARTN e170
   POND SLK, 2005, BIOINFORMATICS, V21, P2531, DOI
   10.1093/bioinformatics/bti320
   POND SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   POND SLK, 2005, MOL BIOL EVOL, V22, P478, DOI 10.1093/molbev/msi031
   POSADA D, 2006, NUCLEIC ACIDS RES, V34, W700, DOI 10.1093/nar/gkl042
   RONQUIST F, 2003, BIOINFORMATICS, V19, P1572, DOI
   10.1093/bioinformatics/btg180
   ROZAS J, 2003, BIOINFORMATICS, V19, P2496, DOI
   10.1093/bioinformatics/btg359
   SHARP PM, 1991, J MOL EVOL, V33, P23
   SPJUT RW, 2007, J BOT RES INST TEX, V23, P203
   SPJUT RW, 2007, J BOT RES INST TEX, V23, P291
   SWANSON WJ, 2001, P NATL ACAD SCI USA, V98, P2509
   SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN
   TRAPP SC, 2001, GENETICS, V158, P811
   VANROZENDAAL ELM, 2000, PHYTOCHEMISTRY, V53, P383
   WALKER K, 2000, P NATL ACAD SCI USA, V97, P583
   WALKER K, 2001, PHYTOCHEMISTRY, V58, P1
   WILDUNG MR, 1996, J BIOL CHEM, V271, P9201
   WILLIAMS DC, 2000, ARCH BIOCHEM BIOPHYS, V379, P137
   WRIGHT F, 1990, GENE, V87, P23
   YANG ZH, 1995, GENETICS, V141, P1641
   YANG ZH, 2000, GENETICS, V155, P431
   YANG ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088
   ZHANG JZ, 2003, MOL BIOL EVOL, V20, P1310, DOI 10.1093/molbev/msg143
   ZWICKL DJ, 2006, THESIS U TEXAS AUSTI
NR 36
TC 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
J9 GENETICA
JI Genetica
PD MAR
PY 2009
VL 135
IS 2
BP 123
EP 135
DI 10.1007/s10709-008-9257-7
PG 13
SC Genetics & Heredity
GA 403CE
UT ISI:000263058600001
ER

PT J
AU Sun, BL
   Zheng, CB
   Yang, MF
   Yuan, H
   Zhang, SM
   Wang, LX
AF Sun, Bao-Liang
   Zheng, Cheng-Bi
   Yang, Ming-Feng
   Yuan, Hui
   Zhang, Su-Ming
   Wang, Le-Xin
TI Dynamic Alterations of Cerebral Pial Microcirculation During
   Experimental Subarachnoid Hemorrhage
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Subarachnoid hemorrhage; Secondary cerebral ischemia; Microcirculation;
   Rat
ID NITRIC-OXIDE DONOR; BLOOD-FLOW; VASOSPASM; RATS; DYSFUNCTION;
   ENDOTHELIN; NIMODIPINE; ISCHEMIA; ARTERIES; RABBITS
AB The study aimed to investigate the involvement of cerebral
   microcirculation turbulence after subarachnoid hemorrhage (SAH). Wistar
   rats were divided into non-SAH and SAH groups. Autologous arterial
   hemolysate was injected into rat's cisterna magna to induce SAH.
   Changes of pial microcirculation within 2 h were observed. It was found
   that there were no obvious changes of the diameters, flow velocity, and
   fluid state of microvessels in non-SAH group. With the exception of
   rare linear-granular flow in A4 arteriole, linear flow was observed in
   most of the arterioles. There was no blood agglutination in any of the
   arterioles. After SAH, abnormal cerebral pial microcirculation was
   found. Spasm of microvessels, decreased blood flow, and agglutination
   of red blood cells occurred. Five minutes following the induction of
   SAH, the diameters of the arterioles and venules significantly
   decreased. The decreased diameters persisted for 2 h after cisternal
   injection. Decreased flow velocity of venules was found from 5 to 90
   min after induction of SAH. Spasm of the basilar artery and increased
   brain malondialdehyde were also found after SAH. We concluded that
   cerebral microcirculation turbulence plays an important role in the
   development of secondary cerebral ischemia following SAH.
C1 [Sun, Bao-Liang; Yuan, Hui] Taishan Med Coll, Affiliated Hosp, Dept Neurol, Tai An 271000, Shandong, Peoples R China.
   [Sun, Bao-Liang; Yuan, Hui] Taishan Med Coll, Affiliated Hosp, Inst Microcirculat, Tai An 271000, Shandong, Peoples R China.
   [Zhang, Su-Ming] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurol, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Wang, Le-Xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia.
RP Sun, BL, Taishan Med Coll, Affiliated Hosp, Dept Neurol, 706 Taishan
   Ave, Tai An 271000, Shandong, Peoples R China.
EM blsun@tsmc.edu.cn
   lwang@csu.edu.au
FU National Natural Science Foundation of China [30570651, 30670724];
   Natural Medicine Research Foundation of Shandong, China [2005-231]
FX This work was supported by the National Natural Science Foundation of
   China ( No. 30570651, 30670724) and the Natural Medicine Research
   Foundation of Shandong, China (2005-231).
CR ASANO T, 1999, CRIT REV NEUROSURG, V9, P303
   BARISKANER H, 2003, PHARMACOLOGY, V68, P162, DOI 10.1159/000070174
   DREIER JP, 2002, NEUROSURGERY, V51, P1457, DOI
   10.1227/01.NEU.000003638.90415.04
   FARRUGIA A, 1992, MED J AUSTRALIA, V157, P716
   GERMANO A, 2000, ACTA NEUROCHIR, V142, P575
   GRASSO G, 2004, BRAIN RES REV, V44, P49, DOI
   10.1016/j.brainresrev.2003.10.003
   GRUBB RL, 1977, J NEUROSURG, V46, P446
   HINO A, 1989, STROKE, V20, P1504
   ISHIKAWA M, 1998, MICROVASC RES, V56, P166
   JUVELA S, 2002, J NEUROSURG, V97, P1287
   MANNO EM, 2004, NEUROL CLIN, V22, P347, DOI 10.1016/j.ncl.2003.12.002
   MEGYESI JF, 2000, NEUROSURGERY, V46, P448
   NICHOLLS MD, 1989, LANCET, V1, P71
   NIHEI H, 1991, STROKE, V22, P1419
   PARK KW, 2001, ANESTH ANALG, V92, P990
   PRADILLA G, 2004, NEUROSURGERY, V55, P1393, DOI
   10.1227/01.NEU.0000143615.26102.1A
   SATOMURA Y, 2004, CLIN HEMORHEOL MICRO, V31, P31
   SEHBA FA, 2005, J NEUROSURG, V102, P1094
   SUN BL, 2000, CLIN HEMORHEOL MICRO, V23, P139
   SUN BL, 2003, CLIN HEMORHEOL MICRO, V29, P337
   UEDA Y, 2003, J NEUROSURG, V99, P899
   UHL E, 2003, NEUROSURGERY, V52, P1307, DOI
   10.1227/01.NEU.0000065154.04824.9E
   VEELKEN JA, 1995, STROKE, V26, P1279
   WOLF EW, 1998, J NEUROSURG, V89, P279
   YUNDT KD, 1998, J CEREBR BLOOD F MET, V18, P419
   ZIMMERMANN M, 1998, NEUROSURGERY, V43, P863
NR 26
TC 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD MAR
PY 2009
VL 29
IS 2
BP 235
EP 241
DI 10.1007/s10571-008-9316-8
PG 7
SC Cell Biology; Neurosciences
GA 403XB
UT ISI:000263114200010
ER

PT J
AU Wiederschain, D
   Wee, S
   Chen, L
   Loo, A
   Yang, GZ
   Huang, A
   Chen, Y
   Caponigro, G
   Yao, YM
   Lengauer, C
   Sellers, WR
   Benson, JD
AF Wiederschain, Dmitri
   Wee, Susan
   Chen, Lin
   Loo, Alice
   Yang, Guizhi
   Huang, Alan
   Chen, Yan
   Caponigro, Giordano
   Yao, Yung-mae
   Lengauer, Christoph
   Sellers, William R.
   Benson, John D.
TI Single-vector inducible lentiviral RNAi system for oncology target
   validation
SO CELL CYCLE
LA English
DT Article
DE inducible; single-vector; shRNA; xenograft; cancer; Bmi-1; Mel-18
ID SHRNA EXPRESSION; INTERFERENCE; PROMOTER; CANCER; GENES
AB The use of RNA interference (RNAi) has enabled loss-of-function studies
   in mammalian cancer cells and has hence become critical for identifying
   and validating cancer drug targets. Current transient siRNA and stable
   shRNA systems, however, have limited utility in accurately assessing
   the cancer dependency due to their short-lived effects and limited in
   vivo utility, respectively. In this study, a single-vector lentiviral,
   Tet-inducible shRNA system (pLKO-Tet-On) was generated to allow for the
   rapid generation of multiple stable cell lines with regulatable shRNA
   expression. We demonstrate the advantages and versatility of this
   system by targeting two polycomb group proteins, Bmi-1 and Mel-18, in a
   number of cancer cell lines. Our data show that pLKO-Tet-On-mediated
   knockdown is tightly regulated by the inducer tetracycline and its
   derivative, doxycycline, in a concentration-and time-dependent manner.
   Furthermore, target gene expression is fully restored upon withdrawal
   of the inducing agent. An additional, 17 distinct gene products have
   been targeted by inducible shRNAs with robust regulation in all cases.
   Importantly, we functionally validate the ability of the pLKO-Tet-On
   vector to reversibly silence targeted transcripts in vivo. The
   versatile and robust inducible lentiviral RNAi system reported herein
   can therefore serve as a powerful tool to rapidly reveal tumor cell
   dependence.
C1 [Wiederschain, Dmitri; Wee, Susan; Chen, Lin; Loo, Alice; Yang, Guizhi; Huang, Alan; Chen, Yan; Caponigro, Giordano; Yao, Yung-mae; Lengauer, Christoph; Sellers, William R.; Benson, John D.] Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
RP Wiederschain, D, Novartis Inst Biomed Res, 250 Massachusetts Ave,
   Cambridge, MA 02139 USA.
EM dmitri.wiederschain@novartis.com
CR AMAR L, 2006, NUCLEIC ACIDS RES, V34, ARTN 037
   BENSON EE, 2006, FOCUS BIOTECHNOL, V6, P441
   CZAUDERNA F, 2003, NUCLEIC ACIDS RES, V31, P127
   GIL J, 2005, DNA CELL BIOL, V24, P117
   HENRIKSEN JR, 2007, NUCLEIC ACIDS RES, V35, P67
   HOEFLICH KP, 2006, CANCER RES, V66, P999
   KAPPEL S, 2007, NAT PROTOC, V2, P3257, DOI 10.1038/nprot.2007.458
   LI LM, 2006, CLIN CANCER RES, V12, P4747, DOI
   10.1158/1078-0432.CCR-05-2842
   LIN XY, 2004, FEBS LETT, V577, P376, DOI 10.1016/j.febslet.2004.10.033
   MCMURRAY HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973
   MOFFAT J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   SILVA J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176
   SZULC J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846
   WEE S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI
   10.1073/pnas.0802655105
   WIEDERSCHAIN D, 2007, MOL CELL BIOL, V27, P4968, DOI
   10.1128/MCB.02244-06
   WIZNEROWICZ M, 2006, NAT METHODS, V3, P682, DOI 10.1038/NMETH914
NR 16
TC 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD FEB 1
PY 2009
VL 8
IS 3
BP 498
EP 504
PG 7
SC Cell Biology
GA 402GS
UT ISI:000263002800026
ER

PT J
AU Yan, Y
   Zhang, J
   Guo, JL
   Huang, W
   Yang, YZ
AF Yan, Yuan
   Zhang, Jie
   Guo, Jian-Li
   Huang, Wei
   Yang, Yu-Zhen
TI Multiple shRNA-mediated knockdown of TACE reduces the malignancy of
   HeLa cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE shRNA; TACE; HeLa cell; Malignancy
ID NECROSIS-FACTOR-ALPHA; CONVERTING-ENZYME; BREAST-CANCER; EXPRESSION;
   ADAM17; DISINTEGRIN; RECEPTOR; EGFR; RNA; INTERFERENCE
AB Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) is a
   key enzyme involved in the proteolytic shedding of the ectodomain of
   several membrane- bound growth factors, cytokines and receptors. Here,
   we constructed a multiple short hairpin RNA (shRNA) expression vector
   containing four shRNAs against TACE. We found that in HeLa cells our
   multiple shRNAs vector produced a higher level of TACE knockdown than
   any single shRNA vector containing only one TACE shRNA. Silencing TACE
   expression in HeLa cells decreased their malignancy by decreasing the
   proliferation, adhesion and migration, as well as inducing apoptosis in
   these cells. Furthermore, our data suggest that the effects of TACE on
   the malignancy of HeLa cells may be mediated via activation of the EGFR
   (epidermal growth factor receptor) signaling pathway. Our findings
   suggest that using a combination of shRNAs within one vector to silence
   the expression of TACE might be a potential therapeutic strategy for
   tumors. (C) 2008 Published by Elsevier Ltd on behalf of International
   Federation for Cell Biology.
C1 [Yan, Yuan; Zhang, Jie; Guo, Jian-Li; Yang, Yu-Zhen] Huazhong Univ Sci & Technol, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Huang, Wei] Inst Med Sci, Wuhan 430014, Peoples R China.
RP Yang, YZ, Huazhong Univ Sci & Technol, Dept Biochem & Mol Biol, Tongji
   Med Coll, Wuhan 430030, Peoples R China.
EM yangyz@mails.tjmu.edu.cn
FU The Natural Science Foundation of China [30500085]
FX We sincerely thank Dr. Xiao-ou Li, Dr. Guishen Zhao and Dr. Wenfang
   Feng for their excellent technical assistance. This work was supported
   by a grant from The Natural Science Foundation of China (No. 30500085).
CR BAX DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200
   BLACK RA, 1997, NATURE, V385, P729
   BORRELLPAGES M, 2003, EMBO J, V22, P1114
   BUXBAUM JD, 1998, J BIOL CHEM, V273, P27765
   CHUNG J, 2008, MICROSC RES TECHNIQ, V71, P380, DOI 10.1002/jemt.20566
   CONDON TP, 2001, ANTISENSE NUCLEIC A, V11, P107
   DOEDENS JR, 2000, J BIOL CHEM, V275, P14598
   DOGGRELL SA, 2002, EXPERT OPIN INV DRUG, V11, P1003
   FIRE A, 1998, NATURE, V391, P806
   GARTON KJ, 2001, J BIOL CHEM, V276, P37993
   GARTON KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200
   GOU DM, 2007, J GENE MED, V9, P751, DOI 10.1002/jgm.1080
   HENRY SD, 2006, MOL THER, V14, P485, DOI 10.1016/j.ymthe.2006.04.012
   IBA K, 1999, AM J PATHOL, V154, P1489
   KARAN D, 2003, INT J ONCOL, V23, P1365
   KENNY PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518
   LENDECKEL U, 2005, J CANCER RES CLIN, V131, P41, DOI
   10.1007/s00432-004-0619-y
   LOVERING F, 2005, CURR DRUG TARGETS CN, V4, P161
   MATTHEWS V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200
   MCMANUS MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   RAO BG, 2005, CURR PHARM DESIGN, V11, P295
   REISS K, 2006, PHARMACOL THERAPEUT, V111, P985, DOI
   10.1016/j.pharmthera.2006.02.009
   ROEMER A, 2004, ONCOL REP, V11, P529
   SAHIN U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137
   SCHLESSINGER J, 2000, CELL, V103, P211
   SIOUD M, 2004, TRENDS PHARMACOL SCI, V25, P22, DOI
   10.1016/j.tips.2003.11.006
   SUNNARBORG SW, 2002, J BIOL CHEM, V277, P12838
   TER BO, 2006, MOL THER, V14, P883
   TUCKER GC, 2006, CURR ONCOL REP, V8, P96
   TUSCHL T, 2002, NAT BIOTECHNOL, V12, P735
NR 30
TC 2
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD FEB
PY 2009
VL 33
IS 2
BP 158
EP 164
DI 10.1016/j.cellbi.2008.10.008
PG 7
SC Cell Biology
GA 401YO
UT ISI:000262980300004
ER

PT J
AU Li, Y
   Song, JL
   Yang, P
   Zou, R
   Fan, XF
   Zhao, ZH
AF Li, Yu
   Song, Jinlin
   Yang, Pu
   Zou, Rui
   Fan, Xiaofeng
   Zhao, Zhihe
TI Establishment of a three-dimensional culture and mechanical loading
   system for skeletal myoblasts
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE PLGA; Scaffolds; Myoblast; 3-D culture; Mechanical loading; Device;
   Cytomechanics
ID PERIODONTAL-LIGAMENT CELLS; SMOOTH-MUSCLE-CELLS; SCAFFOLDS; STRETCH;
   STRESS; STRAIN; GROWTH; EXPRESSION; DIFFERENTIATION; PROLIFERATION
AB Establishment of a three-dimensional (3-D) culture and mechanical
   loading system which simulates the in vivo environment is critical in
   cytomechanical studies. The present article attempts to do this by
   integrating porous PLGA scaffolds with a four-point bending strain
   unit. Three types of PLGA scaffolds with three average pore sizes were
   synthesized, i.e., type I (60-88 mm), type II (88-100 mm) and type III
   (100-125 mm). To establish the 3-D mechanical loading system, PLGA
   membrane was integrated with conventional force-loading plates and the
   third passage skeletal myoblasts from neonatal Sprague-Dawley (SD) rats
   were seeded. Small PLGA membranes were put in 24-well plates followed
   by cell implantation and MTT assay was performed on days 1, 2, 4, 6 and
   8 to compare biocompatibility of the three types of scaffolds. After 3
   days' culture, many more cells had grown in type II than in type I or
   type III under fluorescence microscopy. In the MTT assay, OD of type II
   was significantly higher (P < 0.05) than the other two, especially at
   the early stage. As type II proved to be the best among the three, it
   was used as the scaffold in the preliminary mechanical loading study
   and 4000 mu strain cyclic uniaxial strain was imposed. The system
   worked well and it was found that short to median time of stretching
   enhances while prolonged time of stretching inhibits cell proliferative
   activity of the 3-D cultured skeletal myoblasts(P < 0.05). It is
   concluded that the combination of PLGA scaffolds with a four-point
   bending strain unit provides a satisfactory 3-D mechanical loading
   system. (C) 2008 International Federation for Cell Biology. Published
   by Elsevier Ltd. All rights reserved.
C1 [Li, Yu; Yang, Pu; Zou, Rui; Fan, Xiaofeng; Zhao, Zhihe] Sichuan Univ, W China Stomatol Hosp, Dept Orthodont, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Song, Jinlin] Chongqing Med Univ, Dept Orthodont, Coll Stomatol, Chongqing 400015, Peoples R China.
   [Zou, Rui] Xi An Jiao Tong Univ, Dept Orthodont, Stomatol Hosp, Xian 710004, Shanxi, Peoples R China.
RP Zhao, ZH, Sichuan Univ, W China Stomatol Hosp, Dept Orthodont, State
   Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
EM zhaozhihe1963@yahoo.com.cn
FU National Nature Science Foundation of China [10472138]
FX We owe our thanks to Chengdu Institute of Organic Chemistry, the
   Chinese Academy of Sciences, for the synthesis of PLGA membrane. This
   work was supported by the National Nature Science Foundation of China
   (No. 10472138).
CR BUTTERFIELD TA, 2005, J APPL PHYSIOL, V99, P593, DOI
   10.1152/japplphysiol.01128.2004
   CARSON JA, 1998, AM J PHYSIOL-CELL PH, V275, C1438
   DEARAUJO RMS, 2007, J PERIODONTAL RES, V42, P15, DOI
   10.1111/j.1600-0765.2006.00906.x
   DELAPORTE C, 1984, J NEUROL SCI, V64, P149
   DISCHER DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   FERMOR B, 1998, BONE, V22, P637
   FRENETTE J, 1998, AM J PHYSIOL-CELL PH, V275, C818
   GOLDSPINK DF, 1991, J CARDIAC SURG, V6, P218
   GOLDSPINK DF, 1995, AM J PHYSIOL-ENDOC M, V268, E288
   ISHAUG SL, 1997, J BIOMED MATER RES, V36, P17
   ISHAUGRILEY SL, 1999, BIOMATERIALS, V20, P2245
   JACQUOT J, 1994, J CELL PHYSIOL, V161, P407
   KANDA K, 1993, ASAIO J, V39, M686
   KARAGEORGIOU V, 2005, BIOMATERIALS, V26, P5474, DOI
   10.1016/j.biomaterials.2005.02.002
   KIM JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI
   10.1016/j.semcancer.2005.05.002
   LEE JW, 2004, YONSEI MED J S, V45, P41
   LI H, 2007, ZHONGHUA KOU QIANG Y, V42, P529
   LI J, 2007, MOL CELL BIOCHEM, V304, P45, DOI 10.1007/s11010-007-9484-8
   LIU J, 2006, BIOCHEM BIOPH RES CO, V348, P1167, DOI
   10.1016/j.bbrc.2006.07.175
   LIU L, 2006, J DENT RES, V85, P757
   NAKANISHI Y, 2003, J PEDIATR SURG, V38, P1781, DOI
   10.1016/S0022-3468(03)00632-8
   OKANO T, 1998, CELL TRANSPLANT, V7, P71
   OWAN I, 1997, AM J PHYSIOL-CELL PH, V273, C810
   PANKOV R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152
   PASZEK MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   POWELL CA, 2002, AM J PHYSIOL-CELL PH, V283, C1557, DOI
   10.1152/ajpcell.00595.2001
   SEGUROLA RJ, 1998, IN VITRO CELL DEV-AN, V34, P609
   SONG JL, 2006, HUA XI KOU QIANG YI, V24, P397
   SONG JL, 2007, HUA XI KOU QIANG YI, V25, P289
   SUNG HJ, 2004, BIOMATERIALS, V25, P5735, DOI
   10.1016/j.biomaterials.2004.01.066
   VANDENBURGH HH, 1990, AM J PHYSIOL, V259, C232
   WEN SJ, 2005, ZHONGHUA YI XUE ZA Z, V85, P816
   WOZNIAK MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010
   WU XP, 2008, MOL CELL BIOCHEM, V311, P51, DOI 10.1007/s11010-007-9693-1
   WU YC, 2006, BIOMATERIALS, V27, P896, DOI
   10.1016/j.biomaterials.2005.07.002
   YAMADA KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   ZHU YB, 2005, J BIOMED MATER RES B, V75, P193
NR 37
TC 4
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1065-6995
J9 CELL BIOL INT
JI Cell Biol. Int.
PD FEB
PY 2009
VL 33
IS 2
BP 192
EP 198
DI 10.1016/j.cellbi.2008.11.002
PG 7
SC Cell Biology
GA 401YO
UT ISI:000262980300009
ER

PT J
AU Nicklin, P
   Bergman, P
   Zhang, BL
   Triantafellow, E
   Wang, H
   Nyfeler, B
   Yang, HD
   Hild, M
   Kung, C
   Wilson, C
   Myer, VE
   MacKeigan, JP
   Porter, JA
   Wang, YK
   Cantley, LC
   Finan, PM
   Murphy, LO
AF Nicklin, Paul
   Bergman, Philip
   Zhang, Bailin
   Triantafellow, Ellen
   Wang, Henry
   Nyfeler, Beat
   Yang, Haidi
   Hild, Marc
   Kung, Charles
   Wilson, Christopher
   Myer, Vic E.
   MacKeigan, Jeffrey P.
   Porter, Jeffrey A.
   Wang, Y. Karen
   Cantley, Lewis C.
   Finan, Peter M.
   Murphy, Leon O.
TI Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
SO CELL
LA English
DT Article
ID P70 S6 KINASE; CELL-GROWTH; FUNCTIONAL-CHARACTERIZATION;
   GLUTAMINE-METABOLISM; MAMMALIAN-CELLS; GENE-EXPRESSION; RAG GTPASES;
   SYSTEM L; TOR; PROTEIN
AB Amino acids are required for activation of the mammalian target of
   rapamycin ( mTOR) kinase which regulates protein translation, cell
   growth, and autophagy. Cell surface transporters that allow amino acids
   to enter the cell and signal to mTOR are unknown. We show that cellular
   uptake of L-glutamine and its subsequent rapid efflux in the presence
   of essential amino acids (EAA) is the rate-limiting step that activates
   mTOR. L-glutamine uptake is regulated by SLC1A5 and loss of SLC1A5
   function inhibits cell growth and activates autophagy. The molecular
   basis for L-glutamine sensitivity is due to SLC7A5/SLC3A2, a
   bidirectional transporter that regulates the simultaneous efflux of
   L-glutamine out of cells and transport of L-leucine/EAA into cells.
   Certain tumor cell lines with high basal cellular levels of L-glutamine
   bypass the need for L-glutamine uptake and are primed for mTOR
   activation. Thus, L-glutamine flux regulates mTOR, translation and
   autophagy to coordinate cell growth and proliferation.
C1 Novartis Inst BioMed Res, Dev & Mol Pathways, Cambridge, MA 02139 USA.
   [Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   [Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA.
   [Zhang, Bailin; Wang, Y. Karen] Novartis Inst BioMed Res, Analyt Sci, Cambridge, MA 02139 USA.
RP Murphy, LO, Novartis Inst BioMed Res, Dev & Mol Pathways, 250
   Massachusetts Ave, Cambridge, MA 02139 USA.
EM leon.murphy@novartis.com
FU Novartis Pharmaceuticals 
FX We would like to thank Stephen Helliwell, Dan Garza, Dmitri
   Wiederschain, Greg Michaud, Alex Huang, Leslie Pond, and John Westwick
   for support, comments, and advice; and to Alan Abrams for help with
   graphics; and Akos Szilvasi for help with confocal imaging. All authors
   ( except L. C. C.) are employees of Novartis Pharmaceuticals.
CR ANJUM R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509
   ARSHAM AM, 2006, CURR OPIN CELL BIOL, V18, P589, DOI
   10.1016/j.ceb.2006.09.005
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320
   BOADO RJ, 1999, P NATL ACAD SCI USA, V96, P12079
   BODINE SC, 2001, NAT CELL BIOL, V3, P1014
   CARDENAS ME, 1999, GENE DEV, V13, P3271
   CHRISTA L, 1994, GASTROENTEROLOGY, V106, P1312
   COLOMBANI J, 2003, CELL, V114, P739
   CRESPO JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI
   10.1128/MMBR.66.4.579-591.2002
   CRINO PB, 2006, NEW ENGL J MED, V355, P1345
   DANN SG, 2006, FEBS LETT, V580, P2821, DOI 10.1016/j.febslet.2006.04.068
   DEBERARDINIS RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI
   10.1073/pnas.0709747104
   DECHELOTTE P, 1991, AM J PHYSIOL, V260, G677
   EAGLE H, 1956, J BIOL CHEM, V218, P607
   EDINGER AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584
   ESSLINGER CS, 2005, BIOORGAN MED CHEM, V13, P1111, DOI
   10.1016/j.bmc.2004.11.028
   FINGAR DC, 2002, GENE DEV, V16, P1472
   FUCHS BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI
   10.1016/j.semcancer.2005.04.005
   FUCHS BC, 2006, J SURG RES, V131, P26, DOI 10.1016/j.jss.2005.07.013
   GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267
   GEBHARDT R, 1995, CARCINOGENESIS, V16, P1673
   GINGRAS AC, 2004, CURR TOP MICROBIOL I, V279, P169
   HARA K, 1998, J BIOL CHEM, V273, P14484
   HARDWICK JS, 1999, P NATL ACAD SCI USA, V96, P14866
   HOLECEK M, 2002, NUTRITION, V18, P130
   HOLZ MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024
   HUANG J, 2008, BIOCHEM J 2, V412, P179, DOI 10.1042/BJ20080281
   JACINTO E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   JACINTO E, 2008, BIOCHEM J 1, V410, P19, DOI 10.1042/BJ20071518
   KANAI Y, 1998, J BIOL CHEM, V273, P23629
   KIM DH, 2002, CELL, V110, P163
   KIM E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753
   KIMURA S, 2007, AUTOPHAGY, V3, P452
   KOVACEVIC Z, 1972, CANCER RES, V32, P326
   LIU XM, 2004, FASEB J, V18, P768
   MA XM, 2008, CELL, V133, P303
   MARTIN JF, 2000, MECH DEVELOP, V92, P155
   MARTIN KA, 2002, ADV CANCER RES, V86, P1
   MASTROBERARDINO L, 1998, NATURE, V395, P288
   MCGIVAN JD, 2007, FRONT BIOSCI, V12, P874
   MEIER C, 2002, EMBO J, V21, P580
   MITTENDORFER B, 2001, AM J PHYSIOL-ENDOC M, V280, E323
   MIZUSHIMA N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   NII T, 2001, BIOCHEM J 3, V358, P693
   OHANNA M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231
   REITZER LJ, 1979, J BIOL CHEM, V254, P2669
   SANCAK Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   SARBASSOV DD, 2004, CURR BIOL, V14, P1296
   SARBASSOV DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI
   10.1016/j.ceb.2005.09.009
   SEGAWA H, 1999, J BIOL CHEM, V274, P19745
   SHAW RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   SMITH EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200
   TAKESHIGE K, 1992, J CELL BIOL, V119, P301
   UTSUNOMIYATATE N, 1996, J BIOL CHEM, V271, P14883
   VERREY F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI
   10.1007/S00424-002-0973-Z
   WANG XM, 1998, BIOCHEM J 1, V334, P261
   WOLF DA, 1996, CANCER RES, V56, P5012
   WULLSCHLEGER S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   YANAGIDA O, 2001, BBA-BIOMEMBRANES, V1514, P291
NR 59
TC 85
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 6
PY 2009
VL 136
IS 3
BP 521
EP 534
DI 10.1016/j.cell.2008.11.044
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 403ZN
UT ISI:000263120600021
ER

PT J
AU Chauhan, SC
   Vannatta, K
   Ebeling, MC
   Vinayek, N
   Watanabe, A
   Pandey, KK
   Bell, MC
   Koch, MD
   Aburatani, H
   Lio, YL
   Jaggi, M
AF Chauhan, Subhash C.
   Vannatta, Kelley
   Ebeling, Mara C.
   Vinayek, Namita
   Watanabe, Akira
   Pandey, Krishan K.
   Bell, Maria C.
   Koch, Michael D.
   Aburatani, Hiroyuki
   Lio, Yuhlong
   Jaggi, Meena
TI Expression and Functions of Transmembrane Mucin MUC13 in Ovarian Cancer
SO CANCER RESEARCH
LA English
DT Article
ID CELL-SURFACE MUCIN; GENE-EXPRESSION; PANCREATIC ADENOCARCINOMA;
   DIAGNOSTIC-SIGNIFICANCE; EPISIALIN MUC1; OVEREXPRESSION; ADHESION;
   P21-ACTIVATED-KINASE-1; MOTILITY; KINASE
AB MUC13, a transmembrane mucin, is normally expressed in gastrointestinal
   and airway epithelium. Its aberrant expression has been correlated with
   gastric colon and cancer. However, the expression and functions of
   MUC13 in ovarian cancer are unknown. In the present study, the
   expression profile and functions of MUC13 were analyzed to elucidate
   its potential role in ovarian cancer diagnosis and pathogenesis. A
   recently generated monoclonal antibody (clone PPZ0020) was used to
   determine the expression profile of MUC13 by immunohistochemistry using
   ovarian cancer tissue micro-arrays and 56 additional epithelial ovarian
   cancer (EOC) samples. The expression of MUC13 was significantly (P <
   0.005) higher in cancer samples compared with the normal ovary/benign
   tissues. Among all ovarian cancer types, MUC13 expression was
   specifically present in EOC. For the functional analyses, a full-length
   MUC13 gene cloned in pcDNA3.1 was expressed in a MUC13 null ovarian
   cancer cell line, SKOV-3. Here, we show that the exogenous MUC13
   expression induced morphologic changes, including scattering of cells.
   These changes were abrogated through c-Jun NH2 kinase (JNK) chemical
   inhibitor (SP600125) or JNK2 siRNA. Additionally, a marked reduction in
   cell-cell adhesion and significant (P < 0.05) increases in cell
   motility, proliferation, and tumorigenesis in a xenograft mouse model
   system were observed upon exogenous MUC13 expression. These cellular
   characteristics were correlated with up-regulation of HER2,
   p21-activated kinase 1, and p38 protein expression. Our findings show
   the aberrant expression of MUC13 in ovarian cancer and that its
   expression alters the cellular characteristics of SKOV-3 cells. This
   implies a significant role of MUC13 in ovarian cancer. [Cancer Res
   2009;69(3):765-74]
C1 [Chauhan, Subhash C.] Univ S Dakota, Sanford Res Univ S Dakota, Canc Biol Res Ctr, Sanford Sch Med,Dept Obstet & Gynecol, Sioux Falls, SD 57105 USA.
   [Koch, Michael D.] Sanford Sch Med, Lab Med & Pathol, Sioux Falls, SD USA.
   [Watanabe, Akira; Aburatani, Hiroyuki] Univ Tokyo, Tokyo, Japan.
   [Lio, Yuhlong] Univ S Dakota, Dept Math Sci, Vermillion, SD 57069 USA.
   [Pandey, Krishan K.] St Louis Univ, Inst Mol Virol, St Louis, MO 63103 USA.
RP Chauhan, SC, Univ S Dakota, Sanford Res Univ S Dakota, Canc Biol Res
   Ctr, Sanford Sch Med,Dept Obstet & Gynecol, 1400 W 22nd St, Sioux
   Falls, SD 57105 USA.
EM subhash.chauhan@usd.edu
FU Sanford Research/University of South Dakota ; Sanford School of
   Medicine research ; NFAT ; NEDO, Japan ; NIH NCRR [P20 RR17662]
FX Grant support: Sanford Research/University of South Dakota grant,
   Sanford School of Medicine research grant. (S.C. Chauhan). and NFAT
   project (H. Aburatani) from NEDO, Japan. Confocal microscopy studies
   were conducted at the Sanford Research/University of South Dakota
   Imaging Core. This core facility is supported by NIH NCRR grant P20
   RR17662 to A. Martin Gerdes.
   The costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be hereby marked
   advertisement in accordance with 18 U.S.C. Section 1734 solely to
   indicate this fact.
   We thank Cathy Christopherson for editorial assistance and Dr. Keith
   Miskimins (director of Cancer Biology Research Center) for his
   constructive suggestions.
CR ADAM L, 1998, J BIOL CHEM, V273, P28238
   ALEXANDERSEFRE F, 2002, HOSP MED, V63, P210
   ANDRIANIFAHANANA M, 2001, CLIN CANCER RES, V7, P4033
   AUERSPERG N, 1998, SEMIN ONCOL, V25, P281
   AUERSPERG N, 2001, ENDOCR REV, V22, P255
   BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953
   BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088
   BENNETT BL, 2001, P NATL ACAD SCI USA, V98, P13681
   CHAUHAN SC, 2006, MODERN PATHOL, V19, P1386, DOI
   10.1038/modpathol.3800646
   CHAUHAN SC, 2007, J HISTOCHEM CYTOCHEM, V55, P867, DOI
   10.1369/jhc.7A7213.2007
   DONG Y, 1997, J PATHOL, V183, P311
   FELDNER JC, 2002, EXP CELL RES, V272, P93
   GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607
   GIUNTOLI RL, 1998, CANCER RES, V58, P5546
   GROTHEY A, 2000, ONCOGENE, V19, P4864
   HOLLINGSWORTH MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251
   JAGGI M, 2005, CANCER RES, V65, P483
   JEMAL A, 2006, CA-CANCER J CLIN, V56, P106
   KOMATSU M, 1997, J BIOL CHEM, V272, P33245
   KOMATSU M, 2002, BIOCHEM J 1, V368, P41, DOI 10.1042/BJ20020862
   KONDO K, 1998, CANCER RES, V58, P2014
   MENON U, 2002, BEST PRACT RES CL OB, V16, P469, DOI
   10.1053/beog.2002.0297
   MONIAUX N, 2001, FRONT BIOSCI, V6, D1192
   OZOLS RF, 2002, CANCER J S1, V8, S22
   PACKER LM, 2004, INT J ONCOL, V25, P1119
   PARRY S, 2001, BIOCHEM BIOPH RES CO, V283, P715
   REDFIELD A, 1997, J CELL BIOL, V138, P1323
   SHIMAMURA T, 2005, CANCER SCI, V96, P265, DOI
   10.1111/j.1349-7006.2005.00043.x
   SINGH AP, 2004, CANCER RES, V64, P622
   SINGH AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764
   VADLAMUDI RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838
   VADLAMUDI RK, 2005, MOL CELL BIOL, V25, P3726, DOI
   10.1128/MCB.25.9.3726-3736.2005
   WALSH MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020
   WESSELING J, 1995, J CELL BIOL, V129, P255
   WESSELING J, 1996, MOL BIOL CELL, V7, P565
   WILLIAMS SJ, 2001, J BIOL CHEM, V276, P18327
   YU DH, 2000, ONCOGENE, V19, P6115
NR 37
TC 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2009
VL 69
IS 3
BP 765
EP 774
DI 10.1158/0008-5472.CAN-08-0587
PG 10
SC Oncology
GA 402YJ
UT ISI:000263048700009
ER

PT J
AU Watanabe, T
   Kobunai, T
   Sakamoto, E
   Yamamoto, Y
   Konishi, T
   Horiuchi, A
   Shimada, R
   Oka, T
   Nagawa, H
AF Watanabe, Toshiaki
   Kobunai, Takashi
   Sakamoto, Etsuko
   Yamamoto, Yoko
   Konishi, Tsuyoshi
   Horiuchi, Atsushi
   Shimada, Ryu
   Oka, Toshinori
   Nagawa, Hirokazu
TI Gene Expression Signature for Recurrence in Stage III Colorectal Cancers
SO CANCER
LA English
DT Article
DE colorectal cancer; recurrence; lymph node metastasis; stage III;
   microarray; prediction; copy number; CABIN1; Duke stage C; tailored
   therapy
ID MICROARRAY ANALYSIS; DNA MICROARRAY; HYBRIDIZATION; POLYMORPHISM;
   PREDICTION; MUTATIONS; PROFILES; SURVIVAL
AB BACKGROUND: Colorectal cancer patients with lymph node metastases
   (stage III) show poorer prognosis than those without. Predicting
   development of recurrence may guide the need for intensive follow-up
   and/or adjuvant chemotherapy in such patients. The authors' objective
   was to identify a set of discriminating genes that could predict
   recurrence in stage III colorectal cancer. METHODS: Thirty-six stage
   III colorectal cancer patients were studied. Tumor samples were
   obtained from surgically resected specimens. Thirteen patients
   developed recurrence, whereas 23 patients did not. Gene expression
   profiles were determined using human HG-U133 Plus 2.0 Gene Chip
   (Affymetrix, Santa Clara, Calif). RESULTS: The authors identified 45
   discriminating genes between patients with and without recurrence. By
   using this gene set, they established a new model to predict recurrence
   with an accuracy of 90.9%. The discriminating genes included
   calcineurin-binding protein 1 (CABIN1), whose expression differed
   remarkably between patients with and without recurrence (P = .0073).
   The authors further examined the DNA copy number of CABIN1 and were
   able to show a significant relation with recurrence (P < .012).
   Patients having CABIN1 gene loss demonstrated a higher risk of
   recurrence (odds ratio, 18.8). DNA copy number of CABIN1 alone could
   predict recurrence with an accuracy of 80.0%. CONCLUSIONS: The results
   of the current study demonstrated that gene expression profiling is
   useful in predicting recurrence in stage III colorectal cancer. The
   authors identified CABIN1 among discriminating genes that may play a
   key role in the development of recurrence. These results may help to
   establish an individualized therapy for stage III colorectal cancer.
   Cancer 2009;115:28392. (C) 2009 American Cancer Society.
C1 [Watanabe, Toshiaki] Teikyo Univ, Sch Med, Dept Surg, Itabashi Ku, Tokyo 1738605, Japan.
   [Sakamoto, Etsuko; Oka, Toshinori] Taiho Pharmaceut Co Ltd, Tokushima Res Ctr, Personalized Med Res Lab, Tokushima, Japan.
   [Konishi, Tsuyoshi; Nagawa, Hirokazu] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan.
RP Watanabe, T, Teikyo Univ, Sch Med, Dept Surg, Itabashi Ku, 2-11-1 Kaga,
   Tokyo 1738605, Japan.
EM toshwatanabe@yahoo.co.jp
FU Ministry of Education, Culture, sports, Science, and Technology of
   Japan ; Ministry of Health, Labor and Welfare of Japan 
FX This study was supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Culture, sports, Science, and Technology of
   Japan and a grant from the Ministry of Health, Labor and Welfare of
   Japan.
CR ARANGO D, 2005, GASTROENTEROLOGY, V129, P874, DOI
   10.1053/j.gastro.2005.06.066
   BELL SM, 1993, GASTROENTEROLOGY, V104, P57
   BENHATTAR J, 1993, GASTROENTEROLOGY, V104, P1044
   BUCKLEY PG, 2005, HUM MUTAT, V26, P540, DOI 10.1002/humu.20255
   CHIN KV, 2002, PHARM RES-DORD, V19, P1773
   CLARKE PA, 2001, BIOCHEM PHARMACOL, V62, P1311
   COVER TM, 1967, IEEE T INFORM THEORY, V13, P21
   GOH HS, 1995, CANCER RES, V55, P5217
   LANDI S, 2000, MUTAT RES-REV MUTAT, V463, P247
   PAULETTI G, 1996, ONCOGENE, V13, P63
   PEMBLE S, 1994, BIOCHEM J 1, V300, P271
   PINKEL D, 2005, NAT GENET S, V37, S11, DOI 10.1038/ng1569
   WANG TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI
   10.1073/pnas.202610899
   WATANABE T, 2001, NEW ENGL J MED, V344, P1196
   WATANABE T, 2006, CANCER RES, V66, P3370, DOI
   10.1158/0008-5472.CAN-05-3834
   WATANABE T, 2006, CANCER RES, V66, P9804, DOI
   10.1158/0008-5472.CAN-06-1163
   WATANABE T, 2007, CLIN CANCER RES 1, V13, P415, DOI
   10.1158/1078-0432.CCR-06-0753
   YOUN HD, 2000, IMMUNITY, V13, P85
   ZHANG H, 1999, INT J CANCER, V84, P135
   ZHAO XJ, 2004, CANCER RES, V64, P3060
NR 20
TC 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER
JI Cancer
PD JAN 15
PY 2009
VL 115
IS 2
BP 283
EP 292
DI 10.1002/cncr.24023
PG 10
SC Oncology
GA 401LJ
UT ISI:000262941900008
ER

PT J
AU Patel, N
   Gonsalves, CS
   Yang, MY
   Malik, P
   Kalra, VK
AF Patel, Nitin
   Gonsalves, Caryn S.
   Yang, Minyang
   Malik, Punam
   Kalra, Vijay K.
TI Placenta growth factor induces 5-lipoxygenase-activating protein to
   increase leukotriene formation in sickle cell disease
SO BLOOD
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR; ACUTE CHEST SYNDROME; PHOSPHOLIPASE A(2)
   LEVELS; VEIN ENDOTHELIAL-CELLS; LUNG-FUNCTION; SIGNAL-TRANSDUCTION;
   THP-1 CELLS; PULMONARY-HYPERTENSION; ADVERSE OUTCOMES; GENE-EXPRESSION
AB Individuals with sickle cell disease (SCD) have increased inflammation,
   a high incidence of airway hyperreactivity (AH), and increased
   circulating leukotrienes (LT). We show that expression of
   5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), key
   catalytic molecules in the LT pathway, were significantly increased in
   peripheral blood mononuclear cells (MNCs) in patients with SCD,
   compared with healthy controls. Placenta growth factor (PlGF),
   elaborated from erythroid cells, activated MNC and THP-1 monocytic
   cells to induce LT production. PlGF-mediated increased FLAP mRNA
   expression occurred via activation of phosphoinositide-3 (PI-3) kinase,
   nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and
   hypoxia inducible factor-1 alpha (HIF-1 alpha). HIF-1 alpha small
   interfering RNA (siRNA) reduced PlGF-induced FLAP expression. FLAP
   promoter-driven luciferase constructs demonstrated that PlGF-mediated
   luciferase induction was abrogated upon mutation of HIF-1 alpha
   response element (HRE), but not the nuclear factor-kappa B (NF-kappa B)
   site in the FLAP promoter; a finding confirmed by chromatin
   immunoprecipitation (ChIP) analysis. PlGF also increased HIF-1 alpha
   binding to the HRE in the FLAP promoter. Therefore, it is likely that
   the intrinsically elevated levels of PlGF in SCD subjects contribute to
   increased LT, which in turn, mediate both inflammation and AH. Herein,
   we identify a mechanism of increased LT in SCD and show HIF-1 alpha as
   a hypoxia-independent target of PlGF. These studies provide new avenues
   to ameliorate these complications. (Blood. 2009;113:1129-1138)
C1 [Patel, Nitin; Gonsalves, Caryn S.; Kalra, Vijay K.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Yang, Minyang; Malik, Punam] Cincinnati Childrens Hosp, Med Ctr, Div Hematol, Cincinnati, OH USA.
RP Kalra, VK, Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, HMR
   611, Los Angeles, CA 90033 USA.
EM Punam.Malik@cchmc.org
   vkalra@usc.edu
FU Institutional Core of USC Research Center for Liver Disease for the use
   of the spectrofluorometer and sequence detection instrument [NIH-P30-DK
   048522]; National Institutes of Health (NIH) [HL-070595, R01-HL-079916]
FX We thank Dr Timothy Bigby (VA Hospital San Diego, La Jolla, CA) for
   kindly providing FLAP promoter constructs. We thank Institutional Core
   of USC Research Center for Liver Disease for the use of the
   spectrofluorometer and sequence detection instrument (NIH-P30-DK
   048522).
   This work was supported by National Institutes of Health (NIH) grant
   HL-070595 (CSCC) and R01-HL-079916.
CR BALLAS SK, 2006, HEMOGLOBIN, V30, P165, DOI 10.1080/03630260600642260
   BELCHER JD, 2000, BLOOD, V96, P2451
   BERCHNERPFANNSCHMIDT U, 2007, J BIOL CHEM, V282, P1788, DOI
   10.1074/M607065200
   BOYD JH, 2006, BLOOD, V108, P2923, DOI 10.1182/blood-2006-01-011072
   BRADY HR, 1992, BIOCHEM BIOPH RES CO, V186, P1307
   BRYANT R, 2005, J PEDIATR HEALTH CAR, V19, P157
   CASTRO O, 2005, HEMATOL ONCOL CLIN N, V19, P881, DOI
   10.1016/j.hoc.2005.07.007
   CHU SJ, 2000, J IMMUNOL, V165, P4640
   CIANFARANI F, 2006, AM J PATHOL, V169, P1167, DOI
   10.2353/ajpath.2006.051314
   CROIZAT H, 1999, AM J HEMATOL, V60, P105
   DATTA YH, 1995, CIRCULATION, V92, P3304
   DESAI J, 1999, BIOL REPROD, V60, P887
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475
   DUBE LM, 1999, CLIN REV ALLERG IMMU, V17, P213
   FEISST C, 2005, MOL PHARMACOL, V67, P1751, DOI 10.1124/mol.105.011007
   GAO P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004
   GIRI RK, 2003, J IMMUNOL, V170, P5281
   GLADWIN MT, 2004, NEW ENGL J MED, V350, P886
   HANZE J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI
   10.1016/j.bbrc.2003.10.153
   HATTORI K, 2002, NAT MED, V8, P841
   HAUSER S, 1993, GROWTH FACTORS, V9, P259
   HAYNES J, 2004, BLOOD, V103, P3945, DOI 10.1182/blood-2003-08-2969
   HOFSTRA TC, 1996, BLOOD, V87, P4440
   HUANG LE, 1998, P NATL ACAD SCI USA, V95, P7987
   IBE BO, 1994, EUR J CLIN INVEST, V24, P57
   JENNINGS JE, 2008, AM J HEMATOL, V83, P640, DOI 10.1002/ajh.21199
   KAELIN WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006
   KAUL DK, 2004, AM J PHYSIOL-HEART C, V287, H293, DOI
   10.1152/ajpheart.01150.2003
   KENNEDY BP, 1991, J BIOL CHEM, V266, P8511
   KIM KS, 2006, J IMMUNOL, V177, P7211
   KOUMBOURLIS AC, 1997, PEDIATR PULM, V24, P277
   KOUMBOURLIS AC, 2001, J PEDIATR, V138, P188
   LEONG MA, 1997, J PEDIATR, V131, P278
   LUTTUN A, 2002, NAT MED, V8, P831
   MCMAHON S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200
   MILLER GJ, 1978, THORAX, V33, P85
   MILLER ST, 2000, NEW ENGL J MED, V342, P83
   MINTER KR, 2001, AM J RESP CRIT CARE, V164, P2016
   NANDEDKAR SD, 2008, BLOOD, V112, P2529, DOI 10.1182/blood-2008-01-132506
   NOLFO R, 1990, PROSTAGLANDINS, V39, P157
   OURA H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   PATEL N, 2008, BLOOD, V112, P856, DOI 10.1182/blood-2007-12-130567
   PERELMAN N, 2003, BLOOD, V102, P1506, DOI 10.1182/blood-2002-11-3422
   PERSICO MG, 1999, CURR TOP MICROBIOL, V237, P31
   PETASIS NA, 2005, PROSTAG LEUKOTR ESS, V73, P301, DOI
   10.1016/j.plefa.2005.05.020
   PFAFFL MW, 2001, NUCLEIC ACIDS RES, V29, ARTN e45
   PLATT OS, 1994, NEW ENGL J MED, V330, P1639
   PLATT OS, 2000, J CLIN INVEST, V106, P337
   QUINN CT, 2008, BLOOD, V111, P544, DOI 10.1182/blood-2007-07-100719
   REDDY KV, 2003, J BIOL CHEM, V278, P13810, DOI 10.1074/jbc.M211102200
   RICHARD DE, 2000, J BIOL CHEM, V275, P26765
   SAMUELSSON B, 1987, SCIENCE, V237, P1171
   SELVARAJ SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   SERIO KJ, 2005, AM J PHYSIOL-CELL PH, V288, C1125, DOI
   10.1152/ajpcell.00296.2004
   SETTY BNY, 2002, J LAB CLIN MED, V139, P80
   SOBERMAN RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338
   SOLOVEY A, 1999, BLOOD, V93, P3824
   STYLES LA, 1996, BLOOD, V87, P2573
   SUNDARESAN M, 1995, SCIENCE, V270, P296
   SYLVESTER KP, 2006, J PEDIATR, V149, P17, DOI 10.1016/j.peds.2005.12.059
   SZETO SSW, 2007, J BIOL CHEM, V282, P27518, DOI 10.1074/jbc.M700601200
   TCHAIKOVSKI V, 2008, ARTERIOSCL THROM VAS, V28, P322, DOI
   10.1161/ATVBAHA.107.158022
   TORDJMAN R, 2001, BLOOD, V97, P1968
   TURHAN A, 2002, P NATL ACAD SCI USA, V99, P3047
   WALL MA, 1979, AM REV RESPIR DIS, V120, P210
   WERZ O, 2002, BLOOD, V99, P1044
NR 66
TC 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JAN 29
PY 2009
VL 113
IS 5
BP 1129
EP 1138
DI 10.1182/blood-2008-07-169821
PG 10
SC Hematology
GA 400RD
UT ISI:000262885300021
ER

PT J
AU Be'er, A
   Zhang, HP
   Florin, EL
   Payne, SM
   Ben-Jacob, E
   Swinney, HL
AF Be'er, Avraham
   Zhang, H. P.
   Florin, E. -L.
   Payne, Shelley M.
   Ben-Jacob, Eshel
   Swinney, Harry L.
TI Deadly competition between sibling bacterial colonies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bacterial competition; bacterial growth; growth inhibition;
   Paenibacillus dendritiformis
ID COOPERATIVE ORGANIZATION; MULTICELLULAR ORGANISMS; SELF-ORGANIZATION;
   BACILLUS-SUBTILIS; ADAPTIVE MUTATION; ESCHERICHIA-COLI; GROWTH;
   COMMUNICATION; CANNIBALISM; PATTERNS
AB Bacteria can secrete a wide array of antibacterial compounds when
   competing with other bacteria for the same resources. Some of these
   compounds, such as bacteriocins, can affect bacteria of similar or
   closely related strains. In some cases, these secretions have been
   found to kill sibling cells that belong to the same colony. Here, we
   present experimental observations of competition between 2 sibling
   colonies of Paenibacillus dendritiformis grown on a low-nutrient agar
   gel. We find that neighboring colonies (growing from droplet
   inoculation) mutually inhibit growth through secretions that become
   lethal if the level exceeds a well-defined threshold. In contrast,
   within a single colony developing from a droplet inoculation, no growth
   inhibition is observed. However, growth inhibition and cell death are
   observed if material extracted from the agar between 2 growing colonies
   is introduced outside a growing single colony. To interpret the
   observations, we devised a simple mathematical model for the secretion
   of an antibacterial compound. Simulations of this model illustrate how
   secretions from neighboring colonies can be deadly, whereas secretions
   from a single colony growing from a droplet are not.
C1 [Be'er, Avraham; Zhang, H. P.; Florin, E. -L.; Swinney, Harry L.] Univ Texas Austin, Ctr Nonlinear Dynam, Austin, TX 78712 USA.
   [Be'er, Avraham; Zhang, H. P.; Florin, E. -L.; Swinney, Harry L.] Univ Texas Austin, Dept Phys, Austin, TX 78712 USA.
   [Payne, Shelley M.] Univ Texas Austin, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.
   [Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel.
RP Be'er, A, Univ Texas Austin, Ctr Nonlinear Dynam, Austin, TX 78712 USA.
EM abeer@chaos.utexas.edu
   eshelbj@gmail.com
   swinney@chaos.utexas.edu
FU Robert A. Welch Foundation ; Tauber Funds ; Maguy-Glass chair in
   Physics of Complex Systems ; Sid W. Richardson Foundation 
FX We thank Inna Brainis for providing the bacterial strain and the growth
   protocol; Gil Ariel for illuminating discussions about the modeling and
   boundary conditions; and Efrat Hagai, Dalit Roth, and Oren Kalisman for
   their help. E.-L. F. acknowledges support by the Robert A. Welch
   Foundation, E. B.-J. acknowledges support by the Tauber Funds and the
   Maguy-Glass chair in Physics of Complex Systems, and H. L. S.
   acknowledges support by the Sid W. Richardson Foundation.
CR AHMED H, 2004, PRINCIPLES REACTIONS
   BASSLER BL, 2002, CELL, V109, P421
   BASSLER BL, 2006, CELL, V125, P237, DOI 10.1016/j.cell.2006.04.001
   BENJACOB E, 1994, NATURE, V368, P46
   BENJACOB E, 1995, NATURE, V373, P566
   BENJACOB E, 1998, ANNU REV MICROBIOL, V52, P779
   BENJACOB E, 2000, ADV PHYS, V49, P395
   BENJACOB E, 2000, PHYSICA A, V282, P247
   BENJACOB E, 2003, PHILOS T ROY SOC A, V361, P1283, DOI
   10.1098/rsta.2003.1199
   BENJACOB E, 2004, TRENDS MICROBIOL, V12, P366, DOI
   10.1016/j.tim.2004.06.006
   BENJACOB E, 2006, J R SOC INTERFACE, V3, P197, DOI
   10.1098/rsif.2005.0089
   BUDRENE EO, 1991, NATURE, V349, P630
   CLAVERYS JP, 2007, NAT REV MICROBIOL, V5, P219, DOI 10.1038/nrmicro1613
   CZARAN TL, 2002, P NATL ACAD SCI USA, V99, P786
   DANIELS R, 2006, P NATL ACAD SCI USA, V103, P14965, DOI
   10.1073/pnas.0511037103
   DIFRANCO C, 2002, BMC MICROBIOL, V2, P33
   DWORKIN M, 1999, BIOESSAYS, V21, P590
   EIJSINK VGH, 2002, ANTON LEEUW INT J G, V81, P639
   ELLERMEIER CD, 2006, CELL, V124, P549
   FUJIKAWA H, 1991, J PHYS SOC JPN, V60, P88
   FUQUA C, 1999, CELL CELL SIGNALING, P211
   FUQUA WC, 1996, ANNU REV MICROBIOL, V50, P727
   GALITSKI T, 1995, SCIENCE, V268, P421
   GOLDING I, 1998, PHYSICA A, V260, P510
   GOLDING I, 2001, LECT NOTES PHYS, V567
   GONZALEZPASTOR JE, 2003, SCIENCE, V301, P510, DOI
   10.1126/science.1086462
   GUIRAL S, 2005, P NATL ACAD SCI USA, V102, P8710
   HARSHEY RM, 1994, MOL MICROBIOL, V13, P389
   HAVARSTEIN LS, 2006, MOL MICROBIOL, V59, P1297, DOI
   10.1111/j.1365-2005.05021.x
   HSIEH FC, 2004, CURR MICROBIOL, V49, P186, DOI 10.1007/s00284-004-4314-7
   INGHAM CJ, 2008, BMC MICROBIOL, V8, ARTN 36
   KAISER D, 1993, CELL, V73, P873
   KAISER D, 1996, SCIENCE, V272, P1598
   MATSUYAMA T, 1992, J BACTERIOL, V174, P1769
   MATSUYAMA T, 1993, FRACTALS, V1, P302
   MENDELSON NH, 1978, P NATL ACAD SCI USA, V75, P2478
   MILLER MB, 2002, CELL, V110, P303
   MILLER RV, 1998, SCI AM, V278, P66
   MOK KC, 2003, EMBO J, V22, P870
   MOSS T, 2001, DNA PROTEIN INTERACT
   PTASHNE M, 2002, GENES SIGNALS
   RADICELLA JP, 1995, SCIENCE, V268, P418
   SEARLS DB, 2002, NATURE, V420, P211, DOI 10.1038/nature01255
   SHAPIRO JA, 1988, SCI AM, V258, P82
   SHAPIRO JA, 1998, ANNU REV MICROBIOL, V52, P81
   WIRTH R, 1996, TRENDS MICROBIOL, V4, P96
   XAVIER KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI
   10.1016/S1369-5274(03)00028-6
NR 47
TC 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 PROC NAT ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 13
PY 2009
VL 106
IS 2
BP 428
EP 433
DI 10.1073/pnas.0811816106
PG 6
SC Multidisciplinary Sciences
GA 399MM
UT ISI:000262804000015
ER

PT J
AU Kessler, JD
   Hasegawa, H
   Brun, SN
   Emmenegger, BA
   Yang, ZJ
   Dutton, JW
   Wang, F
   Wechsler-Reya, RJ
AF Kessler, Jessica D.
   Hasegawa, Hiroshi
   Brun, Sonja N.
   Emmenegger, Brian A.
   Yang, Zeng-Jie
   Dutton, John W.
   Wang, Fan
   Wechsler-Reya, Robert J.
TI N-myc alters the fate of preneoplastic cells in a mouse model of
   medulloblastoma
SO GENES & DEVELOPMENT
LA English
DT Article
DE Medulloblastoma; brain tumor; preneoplastic; hedgehog; patched
ID GRANULE NEURON PRECURSORS; SONIC HEDGEHOG; STEM-CELLS; BRAIN-TUMORS;
   CEREBELLAR DEVELOPMENT; GENETIC ALTERATIONS; PANCREATIC-CANCER;
   NERVOUS-SYSTEM; IN-SITU; K-RAS
AB Studying the early stages of cancer can provide important insight into
   the molecular basis of the disease. We identified a preneoplastic stage
   in the patched (ptc) mutant mouse, a model for the brain tumor
   medulloblastoma. Preneoplastic cells (PNCs) are found in most ptc
   mutants during early adulthood, but only 15% of these animals develop
   tumors. Although PNCs are found in mice that develop tumors, the
   ability of PNCs to give rise to tumors has never been demonstrated
   directly, and the fate of cells that do not form tumors remains
   unknown. Using genetic fate mapping and orthotopic transplantation, we
   provide definitive evidence that PNCs give rise to tumors, and show
   that the predominant fate of PNCs that do not form tumors is
   differentiation. Moreover, we show that N-myc, a gene commonly
   amplified in medulloblastoma, can dramatically alter the fate of PNCs,
   preventing differentiation and driving progression to tumors.
   Importantly, N-myc allows PNCs to grow independently of hedgehog
   signaling, making the resulting tumors resistant to hedgehog
   antagonists. These studies provide the first direct evidence that PNCs
   can give rise to tumors, and demonstrate that identification of genetic
   changes that promote tumor progression is critical for designing
   effective therapies for cancer.
C1 [Kessler, Jessica D.; Brun, Sonja N.; Emmenegger, Brian A.; Yang, Zeng-Jie; Dutton, John W.; Wechsler-Reya, Robert J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   [Hasegawa, Hiroshi; Wang, Fan] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
RP Wechsler-Reya, RJ, Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol,
   Durham, NC 27710 USA.
EM rw.reya@duke.edu
FU National Cancer Center ; NIDCR [DE016550]; Whitehall Foundation ;
   McKnight Endowment Fund for Neuroscience ; Japanese Society for the
   Promotion of Science ; Children's Brain Tumor Foundation ; McDonnell
   Foundation ; Pediatric Brain Tumor Foundation of the US ; NINDS
   [NS-052323-01]
FX We thank Sam Johnson and the Duke Light Microscopy Core Facility for
   assistance with microscopy, Bob Weinberg for helpful advice and
   insight, Simon Gregory for use of the Laser Capture Microdissection
   system, and Tracy-Ann Read for assistance with transplantation. This
   work was supported by funding from the National Cancer Center (J.D.K.),
   NIDCR grant #DE016550 ( F. W), the Whitehall Foundation ( F. W), the
   McKnight Endowment Fund for Neuroscience ( F. W), the Japanese Society
   for the Promotion of Science ( H. H), the Children's Brain Tumor
   Foundation ( R. W. R.), the McDonnell Foundation ( R. W. R.), the
   Pediatric Brain Tumor Foundation of the US ( R. W. R.), and NINDS grant
   #NS-052323-01 ( R. W. R.).
CR ADAMS NC, 2002, DEVELOPMENT, V129, P965
   ALDOSARI N, 2002, ARCH PATHOL LAB MED, V126, P540
   BELL E, 2007, CELL CYCLE, V6, P1249
   BENARIE N, 2000, DEVELOPMENT, V127, P1039
   BERMAN DM, 2002, SCIENCE, V297, P1559
   BOXER RB, 2004, CANCER CELL, V6, P577
   BROWD SR, 2006, CANCER RES, V66, P2666, DOI
   10.1158/0008-5472.CAN-05-2198
   CIEMERYCH MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602
   DAHMANE N, 1999, DEVELOPMENT, V126, P3089
   DELLOVADE T, 2006, ANNU REV NEUROSCI, V29, P539, DOI
   10.1146/annurev.neuro.29.051605.112858
   EBERHART CG, 2002, BRAIN PATHOL, V12, P36
   EPSTEIN EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503
   FLEMING JB, 2005, MOL CANCER RES, V3, P413
   FOGARTY MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166
   FOGARTY MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI
   10.1073/pnas.0605770104
   FRAPPART PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703
   GOODRICH LV, 1997, SCIENCE, V277, P1109
   HALLAHAN AR, 2004, CANCER RES, V64, P7794
   HANAHAN D, 2000, CELL, V100, P57
   HEMMATI HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI
   10.1073/pnas.2036535100
   JAIN M, 2002, SCIENCE, V297, P102
   JASS JR, 2001, BEST PRACT RES CL GA, V15, P175
   JIA J, 2006, CELL MOL LIFE SCI, V63, P1249, DOI
   10.1007/s00018-005-5519-z
   KENNEY AM, 2000, MOL CELL BIOL, V20, P9055
   KENNEY AM, 2003, DEVELOPMENT, V130, P15
   KERJAN G, 2005, NAT NEUROSCI, V8, P1516, DOI 10.1038/nn1555
   KIM JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2
   KIM MJ, 2002, CANCER RES, V62, P2999
   KLEIN C, 2005, DEVELOPMENT, V132, P4497
   KNOEPFLER PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202
   LEE A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473
   LEE Y, 2003, CANCER RES, V63, P5428
   LEIGHTON PA, 2001, NATURE, V410, P174
   LEVINE JS, 2006, NEW ENGL J MED, V355, P2551
   LI L, 2003, CANCER RES, V63, P2733
   LUM L, 2004, SCIENCE, V304, P1755
   LUMPKIN EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI
   10.1016/S1567-133X(03)00089-9
   MACHOLD R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028
   MAGLIONE JE, 2001, CANCER RES, V61, P8298
   MARTINS CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007
   MESSER A, 1984, J NEUROGENET, V1, P239
   MIYAZAWA K, 2000, J NEUROSCI, V20, P5756
   MOKBEL K, 2006, LANCET ONCOL, V7, P756
   MONTIRONI R, 2007, NAT CLIN PRACT UROL, V4, P321, DOI 10.1038/ncpuro0815
   NAKAMURA M, 2003, CELL DEATH DIFFER, V10, P230, DOI
   10.1038/sj.cdd.4401125
   NICOT A, 2002, J NEUROSCI, V22, P9244
   OLIVER TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI
   10.1073/pnas.0832317100
   OLIVER TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793
   POMEROY SL, 2002, NATURE, V415, P436
   ROHATGI R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435
   ROMER J, 2005, CANCER RES, V65, P4975
   SANCHEZ P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002
   SASAI K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505
   SHAKHOVA O, 2006, CANCER RES, V66, P5190, DOI
   10.1158/0008-5472.CAN-05-3545
   SHARMA SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   SINGH M, 2007, PANCREATOLOGY, V7, P9, DOI 10.1159/000101873
   SINGH SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   SRINIVAS S, 2001, BMC DEV BIOL, V1, P4
   THOMPSON MC, 2006, J CLIN ONCOL, V24, P1924, DOI
   10.1200/JCO.2005.04.4974
   TRAN PT, 2008, PLOS ONE, V3, ARTN e2125
   UZIEL T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605
   WALLACE VA, 1999, CURR BIOL, V9, P445
   WECHSLERREYA RJ, 1999, NEURON, V22, P103
   WETMORE C, 2000, CANCER RES, V60, P2239
   WIENCKENBARGER AE, 2007, GLIA, V55, P675, DOI 10.1002/glia.20484
   YAN CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI
   10.1073/pnas.0601938103
   YANG ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003
   ZHAO H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408
   ZINDY F, 2006, P NATL ACAD SCI USA, V103, P11579, DOI
   10.1073/pnas.0604727103
   ZINDY F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418
NR 70
TC 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0890-9369
J9 GENE DEVELOP
JI Genes Dev.
PD JAN 15
PY 2009
VL 23
IS 2
BP 157
EP 170
DI 10.1101/gad.1759909
PG 14
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 399JR
UT ISI:000262796700005
ER

PT J
AU Yang, XH
   Zou, L
AF Yang, Xiaohong H.
   Zou, Lee
TI Dual functions of DNA replication forks in checkpoint signaling and
   PCNA ubiquitination
SO CELL CYCLE
LA English
DT Article
DE DNA damage; checkpoint; replication fork; PCNA; ATR; Chk1;
   ubiquitination
ID S-PHASE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; MONOUBIQUITINATED PCNA;
   INTERACTING PROTEIN; MAMMALIAN-CELLS; STRANDED-DNA; MRC1; PROGRESSION;
   POLYMERASE; COMPLEX
AB During cell proliferation, DNA damage inflicted by intrinsic or
   extrinsic genotoxic stresses impose a thereat to DNA replication. The
   stability of the DNA replication forks that encounter DNA damage is
   crucial for genomic integrity. Both the ATR-regulated checkpoint
   pathway and the translesion DNA synthesis mediated by the ubiquitinated
   PCNA are important for continuous replication of damaged DNA. We have
   recently shown that Chk1, a key effector kinase of ATR in checkpoint
   response, is required for efficient PCNA ubiquitination after DNA
   damage. Surprisingly, the ubiquitination of PCNA is independent of ATR,
   but regulated by Claspin, a replication protein that mediates the
   activation of Chk1 by ATR. Like Claspin, Timeless and Rad17, two other
   Chk1 regulators at stressed replication forks, are also implicated in
   PCNA ubiquitination. These findings suggest that while ATR signaling
   and PCNA ubiquitination are two independent processes, they are
   mediated by a common group of proteins including Chk1 and it regulators
   at replication forks. Furthermore, these data raise the possibility
   that Chk1 and its regulators may constitute a functional module at
   replication forks to enable multiple stress responses.
C1 [Yang, Xiaohong H.; Zou, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA.
   [Zou, Lee] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Zou, L, Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Bldg
   149-7404,13th St, Charlestown, MA 02129 USA.
EM zou.lee@mgh.harvard.edu
FU NIH [GM076388]; Ellison Medical Foundation ; Susan G. Komen for the
   Cure 
FX The Zou laboratory is supported by grants from the NIH (GM076388),
   Susan G. Komen for the Cure, and the Ellison Medical Foundation.
CR BI XH, 2006, MOL CELL BIOL, V26, P3527, DOI
   10.1128/MCB.26.9.3517-3540.2006
   BYUN TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205
   CALZADA A, 2005, GENE DEV, V19, P1905, DOI 10.1101/gad.337205
   CHANG DJ, 2006, J BIOL CHEM, V281, P32081, DOI 10.1074/jbc.M606799200
   CHINI C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447
   CHOU DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI
   10.1073/pnas.0609251103
   CIMPRICH KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450
   DAVIS SL, 2008, J BURN CARE RES, V29, P36, DOI
   10.1097/BCR.0b013e31815f2b63
   FRAMPTON J, 2006, MOL BIOL CELL, V17, P2976
   FU Y, 2008, CELL, V133, P601, DOI 10.1016/j.cell.2008.02.050
   GARG P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI
   10.1073/pnas.0505949102
   GOTTER AL, 2007, J MOL BIOL, V366, P36, DOI 10.1016/j.jmb.2006.10.097
   HODGSON B, 2007, MOL BIOL CELL, V18, P3894, DOI 10.1091/mbc.E07-05-0500
   HUANG TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378
   KANNOUCHE PL, 2004, MOL CELL, V14, P491
   KATOU Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900
   KUMAGAI A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041
   LEACH CA, 2005, J CELL BIOL, V171, P947, DOI 10.1083/jcb.200508100
   LEHMANN AR, 2006, EXP CELL RES, V312, P2673, DOI
   10.1016/j.yexcr.2006.06.010
   LOPES M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015
   LOU HQ, 2008, MOL CELL, V32, P106, DOI 10.1016/j.molcel.2008.08.020
   MOHANTY BK, 2006, P NATL ACAD SCI USA, V103, P897
   NAMIKI Y, 2006, P NATL ACAD SCI USA, V103, P580, DOI
   10.1073/pnas.0510223103
   NIIMI A, 2008, P NATL ACAD SCI USA, V105, P16125, DOI
   10.1073/pnas.0802727105
   OSBORN AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303
   PETERMANN E, 2006, MOL CELL BIOL, V26, P3319, DOI
   10.1128/MCB.26.8.3319-3326.2006
   PETERMANN E, 2008, MOL BIOL CELL, V19, P2373, DOI
   10.1091/mbc.E07-10-1035
   SCORAH J, 2008, J BIOL CHEM, V283, P17250, DOI 10.1074/jbc.M800369200
   SOGO JM, 2002, SCIENCE, V297, P599
   SZYJKA SJ, 2005, MOL CELL, V19, P691, DOI 10.1016/j.molcel.2005.06.037
   TONG AHY, 2004, SCIENCE, V303, P808
   TOURRIERE H, 2005, MOL CELL, V19, P699, DOI 10.1016/j.molcel.2005.07.028
   TSUJI Y, 2008, GENES CELLS, V13, P343, DOI
   10.1111/j.1365-2443.2008.01176.x
   UNSALKACMAZ K, 2007, MOL CELL BIOL, V27, P3131, DOI 10.1128/MCB.02190-06
   WANG X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022
   WATANABE K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383
   XU H, 2004, MOL CELL BIOL, V24, P7082, DOI
   10.1128/MCB.24.16.7082-7090.2004
   YANG XH, 2008, GENE DEV, V22, P1147, DOI 10.1101/gad.1632808
   YOSHIZAWASUGATA N, 2007, J BIOL CHEM, V282, P2729, DOI
   10.1074/jbc.M605596200
   ZOU L, 2002, GENE DEV, V16, P198
   ZOU L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI
   10.1073/pnas.2336100100
   ZOU L, 2003, SCIENCE, V300, P1542
   ZOU L, 2007, GENE DEV, V21, P879, DOI 10.1101/gad.1550307
NR 43
TC 7
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JAN 15
PY 2009
VL 8
IS 2
BP 191
EP 194
PG 4
SC Cell Biology
GA 396WT
UT ISI:000262622800005
ER

PT J
AU Zhang, YX
   Yan, LB
   Zhou, Z
   Yang, PG
   Tian, E
   Zhang, K
   Zhao, Y
   Li, ZP
   Song, B
   Han, JH
   Miao, L
   Zhang, H
AF Zhang, Yuxia
   Yan, Libo
   Zhou, Zhi
   Yang, Peiguo
   Tian, E.
   Zhang, Kai
   Zhao, Yu
   Li, Zhipeng
   Song, Bing
   Han, Jinghua
   Miao, Long
   Zhang, Hong
TI SEPA-1 Mediates the Specific Recognition and Degradation of P Granule
   Components by Autophagy in C. elegans
SO CELL
LA English
DT Article
ID CAENORHABDITIS-ELEGANS; GERM GRANULES; MOLECULAR MACHINERY;
   SELF-DIGESTION; MECHANISMS; MICE; NEURODEGENERATION; PROTEINS; DISEASE;
   P62
AB How autophagy, an evolutionarily conserved intracellular catabolic
   system for bulk degradation, selectively degrades protein aggregates is
   poorly understood. Here, we show that several maternally derived germ P
   granule components are selectively eliminated by autophagy in somatic
   cells during C. elegans embryogenesis. The activity of sepa-1 is
   required for the degradation of these P granule components and for
   their accumulation into aggregates, termed PGL granules, in autophagy
   mutants. SEPA-1 forms protein aggregates and is also a preferential
   target of autophagy. SEPA-1 directly binds to the P granule component
   PGL-3 and also to the autophagy protein LGG-1/Atg8. SEPA-1 aggregates
   consistently colocalize with PGL granules and with LGG-1 puncta. Thus,
   SEPA-1 functions as a bridging molecule in mediating the specific
   recognition and degradation of P granule components by autophagy. Our
   study reveals a mechanism for preferential degradation of protein
   aggregates by autophagy and emphasizes the physiological significance
   of selective autophagy during animal development.
C1 [Zhang, Yuxia; Yan, Libo; Zhou, Zhi; Yang, Peiguo; Tian, E.; Zhao, Yu; Li, Zhipeng; Song, Bing; Han, Jinghua; Zhang, Hong] Natl Inst Biol Sci, Beijing 102206, Peoples R China.
   [Yan, Libo] Chinese Acad Med Sci, Grad Program, Beijing 100730, Peoples R China.
   [Yan, Libo] Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Zhang, Kai; Miao, Long] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
RP Zhang, H, Natl Inst Biol Sci, Beijing 102206, Peoples R China.
EM zhanghong@nibs.ac.cn
FU National High Technology Projects 863 [2005AA210910]
FX We thank Drs. Susan Strome and Xiaodong Wang for their helpful comments
   on the manuscript, Dr. David Hall for his advice on immuno EM, and Dr.
   Isabel Hanson for editing the manuscript. This work was supported by
   the National High Technology Projects 863 (2005AA210910).
CR BJORKOY G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   DERENZO C, 2003, NATURE, V424, P685, DOI 10.1038/nature01887
   HARA T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   HIRD SN, 1996, DEVELOPMENT, V122, P1303
   KAWASAKI I, 1998, CELL, V94, P635
   KAWASAKI L, 2004, GENETICS, V167, P645
   KLIONSKY DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   KOMATSU M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   KOMATSU M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   LEVINE B, 2004, DEV CELL, V6, P463
   MELENDEZ A, 2003, SCIENCE, V301, P1387
   MIZUSHIMA N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   NEZIS IP, 2008, J CELL BIOL, V180, P1065
   PANKIV S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   ROWLAND AM, 2006, J NEUROSCI, V26, P1711, DOI
   10.1523/JNEUROSCI.2279-05.2006
   RUBINSZTEIN DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   SHINTANI T, 2002, DEV CELL, V3, P825
   STROME S, 2007, SCIENCE, V316, P392, DOI 10.1126/science.1140846
   SUZUKI K, 2007, FEBS LETT, V581, P2156, DOI
   10.1016/j.febslet.2007.01.096
   VANDERVAART A, 2008, TRAFFIC, V9, P281, DOI
   10.1111/j.1600-0854.2007.00674.x
NR 20
TC 30
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JAN 23
PY 2009
VL 136
IS 2
BP 308
EP 321
DI 10.1016/j.cell.2008.12.022
PG 14
SC Biochemistry & Molecular Biology; Cell Biology
GA 397FR
UT ISI:000262648800019
ER

PT J
AU Das, J
   Ho, M
   Zikherman, J
   Govern, C
   Yang, M
   Weiss, A
   Chakraborty, AK
   Roose, JP
AF Das, Jayajit
   Ho, Mary
   Zikherman, Julie
   Govern, Christopher
   Yang, Ming
   Weiss, Arthur
   Chakraborty, Arup K.
   Roose, Jeroen P.
TI Digital Signaling and Hysteresis Characterize Ras Activation in
   Lymphoid Cells
SO CELL
LA English
DT Article
ID NUCLEOTIDE EXCHANGE FACTOR; T-CELLS; POSITIVE FEEDBACK; DENDRITIC
   CELLS; SOS; SEVENLESS; GENE; TRANSDUCTION; REQUIREMENT; LYMPHOCYTES
AB Activation of Ras proteins underlies functional decisions in diverse
   cell types. Two molecules, RasGRP and SOS, catalyze Ras activation in
   lymphocytes. Binding of active Ras to SOS' allosteric pocket markedly
   increases SOS' activity establishing a positive feedback loop for
   SOS-mediated Ras activation. Integrating in silico and in vitro
   studies, we demonstrate that digital signaling in lymphocytes (cells
   are "on'' or "off'') is predicated upon feedback regulation of SOS.
   SOS' feedback loop leads to hysteresis in the dose-response curve,
   which can enable a capacity to sustain Ras activation as stimuli are
   withdrawn and exhibit "memory'' of past encounters with antigen. Ras
   activation via RasGRP alone is analog (graded increase in amplitude
   with stimulus). We describe how complementary analog (RasGRP) and
   digital (SOS) pathways act on Ras to efficiently convert analog input
   to digital output. Numerous predictions regarding the impact of our
   findings on lymphocyte function and development are noted.
C1 [Zikherman, Julie; Weiss, Arthur] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94143 USA.
   [Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.
   [Ho, Mary; Roose, Jeroen P.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   [Das, Jayajit; Govern, Christopher; Yang, Ming; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Chakraborty, Arup K.] MIT, Dept Chem, Cambridge, MA 02139 USA.
   [Chakraborty, Arup K.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
RP Weiss, A, Univ Calif San Francisco, Dept Med, Div Rheumatol, 513
   Parnassus Ave, San Francisco, CA 94143 USA.
EM aweiss@medicine.ucsf.edu
   arupc@mit.edu
   jeroen.roose@ucsf.edu
FU NIH Director's Pioneer [1PO1/AI071195/01]; Rosalind Russell Medical
   Research Center for Arthritis ; NCI [K01CA113367]; Arthritis Foundation
   ; Sandler Foundation 
FX We thank Dr. Kurosaki for DT40 lines and Dr. Dafna Bar-sagi for the
   H-RasG59E38 plasmid. We are grateful to Dr. DeFranco and members of the
   Weiss, Chakraborty, and Roose labs for critical reading of the
   manuscript. We apologize to colleagues we could not cite due to space
   constraints. Financial support: NIH Director's Pioneer Award and
   1PO1/AI071195/01 (A. K. C.), the Howard Hughes Medical Institute as
   well as the Rosalind Russell Medical Research Center for Arthritis (A.
   W.), and the NCI (K01CA113367), Arthritis Foundation, and Sandler
   Foundation (J.P.R.).
CR ALTANBONNET G, 2005, PLOS BIOL, V3, P1925, ARTN e356
   BARKAI N, 2000, NATURE, V403, P267
   BHALLA US, 1999, SCIENCE, V283, P381
   BORTZ AB, 1975, J COMPUT PHYS, V17, P10
   BOYKEVISCH S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033
   CAMPBELL SL, 1998, ONCOGENE, V17, P1395
   CORBALANGARCIA S, 1998, MOL CELL BIOL, V18, P880
   DANIELS MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269
   DOWER NA, 2000, NAT IMMUNOL, V1, P317
   EBINU JO, 2000, BLOOD, V95, P3199
   ELF J, 2004, SYST BIOL, V1, P230
   FERRELL JE, 2002, CURR OPIN CELL BIOL, V14, P140
   FREEDMAN TS, 2006, P NATL ACAD SCI USA, V103, P16692, DOI
   10.1073/pnas.0608127103
   GENOT E, 2000, CURR OPIN IMMUNOL, V12, P289
   GIDEON P, 1992, MOL CELL BIOL, V12, P2050
   GILBERT JJ, 1996, J IMMUNOL, V156, P2054
   GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340
   GUREASKO J, 2008, NAT STRUCT MOL BIOL, V15, P452, DOI 10.1038/nsmb.1418
   HARTIGAN JA, 1985, ANN STAT, V13, P70
   HENRICKSON SE, 2008, NAT IMMUNOL, V9, P282, DOI 10.1038/ni1559
   HOUTMAN JC, 2006, NAT STRUCT MOL BIOL, V13, P798
   KHOLODENKO BN, 2002, P NATL ACAD SCI USA, V99, P12841, DOI
   10.1073/pnas.192442699
   KUSSELL E, 2005, GENETICS, V169, P1807, DOI
   10.1534/genetics.2=104.035352
   MARGARIT SM, 2003, CELL, V112, P685
   MCADAMS HH, 1997, P NATL ACAD SCI USA, V94, P814
   MOR A, 2006, ANNU REV IMMUNOL, V24, P771, DOI
   10.1146/annurev.immunol.24.021605.090723
   OHHORA M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547
   PRASAD A, 2009, P NATL ACAD SCI USA, V106, P528, DOI
   10.1073/pnas.0805981105
   ROOSE JP, 2005, MOL CELL BIOL, V25, P4426, DOI
   10.1128/MCB.25.11.4426-4441.2005
   ROOSE JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06
   RUIZ S, 2007, MOL CELL BIOL, V27, P8127, DOI 10.1128/MCB.00912-07
   SKOKOS D, 2007, NAT IMMUNOL, V8, P835, DOI 10.1038/ni1490
   SONDERMANN H, 2004, CELL, V119, P393
   STARR TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI
   10.1146/annurev.immunol.21.120601.141107
   TIAN TH, 2007, NAT CELL BIOL, V9, P905
   TRAHEY M, 1987, SCIENCE, V238, P542
   VANKAMPEN NG, 1992, STOCHASTIC PROCESSES
   WANG DZM, 1997, GENE DEV, V11, P309
   WEISS A, 1987, J IMMUNOL, V138, P2169
NR 39
TC 44
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JAN 23
PY 2009
VL 136
IS 2
BP 337
EP 351
DI 10.1016/j.cell.2008.11.051
PG 15
SC Biochemistry & Molecular Biology; Cell Biology
GA 397FR
UT ISI:000262648800021
ER

PT J
AU Aihara, T
   Takatsuka, Y
   Osumi, S
   Aogi, K
   Hozumi, Y
   Imoto, S
   Mukai, H
   Iwata, H
   Watanabe, T
   Shimizu, C
   Nakagami, K
   Tamura, M
   Ito, T
   Masuda, N
   Ogino, N
   Hisamatsu, K
   Mitsuyama, S
   Abe, H
   Yamaguchi, T
   Ohashi, Y
AF Aihara, T.
   Takatsuka, Y.
   Osumi, S.
   Aogi, K.
   Hozumi, Y.
   Imoto, S.
   Mukai, H.
   Iwata, H.
   Watanabe, T.
   Shimizu, C.
   Nakagami, K.
   Tamura, M.
   Ito, T.
   Masuda, N.
   Ogino, N.
   Hisamatsu, K.
   Mitsuyama, S.
   Abe, H.
   Yamaguchi, T.
   Ohashi, Y.
TI Phase III randomized adjuvant study of tamoxifen alone versus
   sequential tamoxifen and anastrozole in postmenopausal women with
   hormone-responsive breast cancer: N-SAS BC03 study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 31st Annual San Antonio Breast Cancer Symposium
CY DEC 10-14, 2008
CL San Antonio, TX
C1 Aihara Hosp, Osaka, Japan.
   Kansai Rosai Hosp, Hyogo, Japan.
   Shikoku Canc Hosp, Ehime, Japan.
   Jichi Med Univ, Tochigi, Japan.
   Natl Canc Ctr Hosp E, Chiba, Japan.
   Aichi Canc Ctr Hosp, Aichi, Japan.
   Natl Canc Ctr, Tokyo, Japan.
   Shizuoka Prefectural Gen Hosp, Shizuoka, Japan.
   Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan.
   Rinku Gen Med Ctr, Osaka, Japan.
   Osaka Natl Hosp, Osaka, Japan.
   Tondabayashi Hosp, Osaka, Japan.
   Hiroshima City Asa Hosp, Hiroshima, Japan.
   Kitakyushu Municipal Med Ctr, Fukuoka, Japan.
   Shiga Univ Med Sci, Shiga, Japan.
   Univ Tokyo, Tokyo, Japan.
NR 0
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2009
VL 69
IS 2
SU Suppl. S
BP 148S
EP 148S
PG 1
SC Oncology
GA 396HQ
UT ISI:000262583200268
ER

PT J
AU Duchnowska, R
   Jassem, J
   Shen, C
   Thorat, M
   Li, L
   Morimiya, A
   Zhao, Q
   Biernat, W
   Mandat, T
   Staszkiewicz, R
   Och, W
   Szostak, W
   Gugala, K
   Trojanowski, T
   Czartoryska-Arlukowicz, B
   Szczylik, C
   Nakshatri, H
   Steeg, P
   Sledge, G
   Badve, S
AF Duchnowska, R.
   Jassem, J.
   Shen, C.
   Thorat, M.
   Li, L.
   Morimiya, A.
   Zhao, Q.
   Biernat, W.
   Mandat, T.
   Staszkiewicz, R.
   Och, W.
   Szostak, W.
   Gugala, K.
   Trojanowski, T.
   Czartoryska-Arlukowicz, B.
   Szczylik, C.
   Nakshatri, H.
   Steeg, P.
   Sledge, G.
   Badve, S.
TI Molecular characteristics of matched brain metastasis (BM) versus the
   primary breast cancer (PBC).
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 31st Annual San Antonio Breast Cancer Symposium
CY DEC 10-14, 2008
CL San Antonio, TX
C1 Mil Inst Med, Warsaw, Poland.
   Med Univ, Gdansk, Poland.
   Indiana Univ, Indianapolis, IN 46204 USA.
   Gen Hosp, Olsztyn, Poland.
   Med Univ, Lublin, Poland.
   Reg Canc Ctr, Bialystok, Poland.
   NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2009
VL 69
IS 2
SU Suppl. S
BP 164S
EP 164S
PG 1
SC Oncology
GA 396HQ
UT ISI:000262583200319
ER

PT J
AU Ando, N
   Iwamitsu, Y
   Kuranami, M
   Okazaki, S
   Wada, M
   Yamamoto, K
   Watanabe, M
   Miyaoka, H
AF Ando, N.
   Iwamitsu, Y.
   Kuranami, M.
   Okazaki, S.
   Wada, M.
   Yamamoto, K.
   Watanabe, M.
   Miyaoka, H.
TI Analysis of factors associated with increased psychological distress in
   new outpatients at the breast clinic
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 31st Annual San Antonio Breast Cancer Symposium
CY DEC 10-14, 2008
CL San Antonio, TX
C1 Kitasato Univ, Grad Sch Med Sci, Kanagawa, Japan.
   Kitasato Univ, Sch Med, Kanagawa, Japan.
NR 0
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2009
VL 69
IS 2
SU Suppl. S
BP 235S
EP 235S
PG 1
SC Oncology
GA 396HQ
UT ISI:000262583201129
ER

PT J
AU Watanabe, T
   Kuranami, M
   Inoue, K
   Masuda, N
   Aogi, K
   Oono, S
   Iwata, H
   Mukai, H
   Tanaka, S
   Yamaguchi, T
   Ohashi, Y
AF Watanabe, T.
   Kuranami, M.
   Inoue, K.
   Masuda, N.
   Aogi, K.
   Oono, S.
   Iwata, H.
   Mukai, H.
   Tanaka, S.
   Yamaguchi, T.
   Ohashi, Y.
TI Phase III two by two factorial comparison of doxorubicin and
   cyclophosphamide followed by a taxan vs. a taxan alone, and paclitaxel
   vs. docetaxel in operable node positive breast cancer-results of the
   first interim analysis of NSASBC02 trial.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 31st Annual San Antonio Breast Cancer Symposium
CY DEC 10-14, 2008
CL San Antonio, TX
C1 Hamamatsu Oncol Ctr, Hamamatsu, Shizuoka, Japan.
   Kitasato Univ Hosp, Sagamihara, Kanagawa, Japan.
   Saitama Canc Ctr, Ina, Saitama, Japan.
   Osaaka Med Ctr, Osaka, Japan.
   Shikoku Canc Ctr, Matsuyama, Ehime, Japan.
   Kyushu Canc Ctr, Fukuoka, Japan.
   Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
   Natl Canc Ctr E, Kashiwa, Chiba, Japan.
   Kyoto Univ, Kyoto, Japan.
   Univ Tokyo, Tokyo, Japan.
NR 0
TC 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2009
VL 69
IS 2
SU Suppl. S
BP 281S
EP 281S
PG 1
SC Oncology
GA 396HQ
UT ISI:000262583201271
ER

PT J
AU Liu, J
   Hong, DF
   Lu, W
   Liu, PW
   He, QB
   Yang, GS
AF Liu, Jun
   Hong, Dengfeng
   Lu, Wei
   Liu, Pingwu
   He, Qingbiao
   Yang, Guangsheng
TI Genetic Analysis and Molecular Mapping of Gene Associated with Dominant
   Genic Male Sterility in Rapeseed (Brassica napus L.)
SO GENES & GENOMICS
LA English
DT Article
DE Brassica napus (rapeseed); dominant genic male sterility (DGMS);
   inheritance model; molecular mapping; marker-assisted selection (MAS)
ID SCAR MARKERS; IDENTIFICATION; AFLP; MS
AB Rs1046AB is a dominant genic male sterility (DGMS) line derived from a
   spontaneous mutant in Brassica napus. The sterility of this mutant was
   previously regarded as to be conditioned by the interaction of a
   dominant male sterility gene Ms and its non-allelic dominant restorer
   gene Mf (or Rf in previous reports). Recent genetic analyses, however,
   indicated that Ms and Mf may be allelic. In this research, we confirmed
   that a multiple allele model should be more appropriate to elucidate
   the heredity of DGMS line Rs1046AB. Based on this result, the present
   study emphasized on identifying DNA markers linked to Ms/Mf an F-2
   population constructed by crossing Rs1046A with a double haploid (DH)
   restorer line (19514A). Twenty amplified fragment length polymorphism
   (AFLP) markers linked to the Ms/Mf locus were identified by combination
   of bulked segregant analysis (BSA) with AFLP technique. The target
   locus was detected to be co-segregating with the marker S05T05 and
   bracketed by two nearest markers, E14M01 and E01M02, with a genetic
   distance of 0.1 cM and 1.2 cM respectively. Furthermore, we
   successfully converted two AFLP markers into sequence characterized
   amplified region (SCAR) markers. These findings provided direct
   molecular marker proofs on the inheritance model of this DGMS line, and
   the high density molecular markers linkage map around the Ms/Mf locus
   will be more informative for both marker-assisted selection MAS) of
   elite male sterile lines and isolation of the Ms/Mf genes by positional
   cloning in future.
C1 [Liu, Jun; Hong, Dengfeng; Lu, Wei; Liu, Pingwu; He, Qingbiao; Yang, Guangsheng] Huazhong Agr Univ, Natl Ctr Rapeseed Improvement Wuhan, Coll Plant Sci & Technol, Natl Key Lab Crop Genet Improvement, Wuhan 430070, Peoples R China.
RP Yang, GS, Huazhong Agr Univ, Natl Ctr Rapeseed Improvement Wuhan, Coll
   Plant Sci & Technol, Natl Key Lab Crop Genet Improvement, Wuhan 430070,
   Peoples R China.
EM gsyang@mail.hzau.edu.cn
FU National Natural Science Foundation of China [30570999]; Doctoral
   Educational Program of the Minstry Education [20050504008]; National
   "973" project [2007CB109006]
FX The authors thank Dr Fan ZX and Dr Wu JY for critically reading this
   manuscript. This research was supported by National Natural Science
   Foundation of China (No. 30570999), Doctoral Educational Program of the
   Minstry Education (No. 20050504008) and National "973" project (No.
   2007CB109006).
CR DENG JY, 1980, ACTA AGRON SIN, V6, P85
   DONG ZS, 1998, ACTA AGRON SIN, V24, P187
   DONG ZS, 1999, ACTA AGRON SIN, V25, P193
   DOYLE JJ, 1987, PHYTOCHEMISTRY B, V19, P11
   FANG ZY, 1997, EUPHYTICA, V97, P265
   HONG DF, 2006, EUPHYTICA, V151, P401, DOI 10.1007/s10681-006-9162-z
   HU SW, 2004, J NW SCI TECH U AGR, V32, P18
   HU SW, 2004, J NW SCI TECH U AGR, V32, P9
   KE LP, 2004, EUPHYTICA, V138, P163
   KOSAMBI DD, 1944, ANN EUGEN, V12, P172
   LANDER ES, 1987, GENOMICS, V1, P174
   LI SG, 1999, CHINESE SCI BULL, V44, P955
   LI SL, 1985, ACTA AGR SHANGHAI, V1, P1
   LI SL, 1988, CAN J PLANT SCI, V68, P1115
   LI SL, 1990, CROP RES, V4, P5
   LIU DF, 1992, HEREDITAS, V14, P1
   LIU RH, 2003, HEREDITAS BEIJING, V25, P317
   LU GY, 2001, J HUAZHONG AGR U, V20, P413
   LU GY, 2004, PLANT BREEDING, V123, P262
   MATHIAS R, 1985, Z PFLANZENZUCHT, V94, P170
   MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828
   SONG LQ, 2005, ACTA AGRON SIN, V31, P896
   SONG LQ, 2006, SCI AGR SINICA, V39, P456
   SONG LQ, 2006, THEOR APPL GENET, V113, P55, DOI
   10.1007/s00122-006-0271-9
   STEVE R, 2000, BIOINFORMATICS METHO, P365
   WANG DJ, 2003, ACTA BOT BOREAL OCCI, V23, P1556
   WANG XW, 1998, ACTA HORT SINICA, V25, P197
   WANG XW, 2000, ACTA HORTIC SIN, V27, P143
   XU M, 2003, EUPHYTICA, V132, P227
   YI B, 2006, THEOR APPL GENET, V113, P643, DOI 10.1007/s00122-006-0328-9
   ZHANG SF, 1990, ACTA HORTIC SIN, V17, P117
   ZHOU YM, 1994, PLANT BREEDING, V113, P222
   ZHOU YM, 1995, J HUAZHONG AGR U, V14, P26
NR 33
TC 0
PU KOREAN SOC GENETICS
PI SEOUL
PA KOREAN SCIENCE & TECHNOLOGY CENTER, RM 1002, 635-4 YEOKSAM-DONG,
   KANGNAM, SEOUL, 135-703, SOUTH KOREA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD DEC
PY 2008
VL 30
IS 6
BP 523
EP 532
PG 10
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 396JK
UT ISI:000262587800004
ER

PT J
AU Yamashita, K
   Watanabe, M
AF Yamashita, Keishi
   Watanabe, Masahiko
TI Clinical significance of tumor markers and an emerging perspective on
   colorectal cancer
SO CANCER SCIENCE
LA English
DT Review
ID FECAL-OCCULT-BLOOD; KIRSTEN RAS MUTATIONS; COLON-CANCER; DNA-PLOIDY;
   PROGNOSTIC INDICATOR; PREDICT RECURRENCE; EARLY-STAGE; CEA; EXPRESSION;
   LEVEL
AB Serum carcinoembryonic antigen (CEA) and CA19-9, a carbohydrate antigen
   recognized by the monoclonal antibody NS19-9, are commonly used as
   classical tumor markers in colorectal cancer (CRC) clinics. The roles
   of tumor markers include: (1) diagnostic screening (diagnostic
   markers); (2) prediction of prognosis after treatment (prognostic
   markers); and (3) judgment tools for treatment effect (surveillance
   markers). Tumor markers can be evaluated in serum, stools, or even in
   tissues depending on the clinical purpose. The American Society for
   Clinical Oncology recommends that CEA is the only marker of choice for
   monitoring the response of metastatic disease to systemic therapy at
   present. In the present paper, we are the first to review the clinical
   significance of the classical tumor markers CEA and CA19-9 in serum,
   allowing for our original data, and present our view on the newly
   emerging biomarkers in CRC. Novel promising biomarkers for diagnostic,
   prognostic, and surveillance purposes are reviewed and considered, some
   of which are anticipated for further validation. For diagnostic
   markers, urine or serum might replace fecal samples in the near future.
   On the other hand, prognostic or predictive markers for treatment
   sensitivity may be identified from the molecular profiles of primary
   cancer tissues. Selection of patients who are sensitive to chemotherapy
   will reduce the number of patients who undergo harmful chemotherapy
   with no effectiveness. The optimal tumor markers would be generalized,
   easy to assess, and accurate, and such markers are eagerly anticipated
   to enable personalized tailored therapy for CRC patients. (Cancer Sci
   2009; 100: 195-199).
C1 [Yamashita, Keishi; Watanabe, Masahiko] Kitasato Univ Hosp, Dept Surg, Kanagawa 2288555, Japan.
RP Yamashita, K, Kitasato Univ Hosp, Dept Surg, Kitasato 1-15-1, Kanagawa
   2288555, Japan.
EM gekaw@med.kitasato-u.ac.jp
CR ANDRE T, 2004, NEW ENGL J MED, V350, P2343
   ANDREYEV HJN, 1998, J NATL CANCER I, V90, P675
   ANDREYEV HJN, 2001, BRIT J CANCER, V85, P692
   ARAUJO SEA, 2007, DIS COLON RECTUM, V50, P1800, DOI
   10.1007/s10350-007-9013-6
   BENVENUTI S, 2007, CANCER RES, V67, P2643, DOI
   10.1158/0008-5472.CAN-06-4158
   BRANCH P, 1993, NATURE, V362, P652
   CHEN CC, 2005, J SURG RES, V124, P169, DOI 10.1016/j.jss.2004.08.013
   CONRADS TP, 2004, MOL DIAGN, V8, P77
   GORG A, 1997, ELECTROPHORESIS, V18, P328
   HABERMANN JK, 2006, GASTROENTEROLOGY, V131, P1020, DOI
   10.1053/j.gastro.2006.07.011
   HARDCASTLE JD, 1996, LANCET, V348, P1472
   HARRISON LE, 1997, J AM COLL SURGEONS, V185, P55
   HIRAMATSU K, 2005, CLIN CANCER RES, V11, P2986
   KATOH H, 2008, ANTICANCER RES, V28, P1933
   KATOH H, 2008, WORLD J SURG, V32, P1130, DOI 10.1007/s00268-008-9535-7
   KHAMBATAFORD S, 2007, J CLIN ONCOL, V25, P3230, DOI
   10.1200/JCO.2006.10.5437
   KRONBORG O, 1996, LANCET, V348, P1467
   LANZA G, 1998, CANCER, V82, P49
   LOCKER GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644
   MANDEL JS, 1993, NEW ENGL J MED, V328, P1365
   MANDEL JS, 1999, J NATL CANCER I, V91, P434
   MARCHENA J, 2003, HEPATO-GASTROENTEROL, V50, P1017
   MELLE C, 2005, GASTROENTEROLOGY, V129, P66, DOI
   10.1053/j.gastro.2005.05.014
   NORI D, 1995, J SURG ONCOL, V59, P239
   OCONNELL JB, 2004, J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   RIBIC CM, 2003, NEW ENGL J MED, V349, P247
   ROSETH AG, 1993, SCAND J GASTROENTERO, V28, P1073
   SCHENA M, 1995, SCIENCE, V270, P467
   SCOTT NA, 1987, ARCH SURG-CHICAGO, V122, P1375
   SONNENBERG A, 2000, ANN INTERN MED, V133, P573
   TRAVERSO G, 2002, NEW ENGL J MED, V346, P311
   TRILLETLENOIR V, 2004, CLIN ONCOL-UK, V16, P196, DOI
   10.1016/j.clon.203.11.005
   UNLU M, 1997, ELECTROPHORESIS, V18, P2071
   VEENSTRA TD, 2004, DRUG DISCOV TODAY, V9, P889
   WANEBO HJ, 1978, NEW ENGL J MED, V299, P448
   WANG WS, 2002, HEPATO-GASTROENTEROL, V49, P160
   WANG YX, 2004, J CLIN ONCOL, V22, P1564
   WEISSENBERGER C, 2005, ANTICANCER RES, V25, P1787
   WIGGERS T, 1988, DIS COLON RECTUM, V31, P33
   YU JK, 2004, WORLD J GASTROENTERO, V10, P3127
   ZHOU W, 2002, LANCET, V359, P219
NR 41
TC 7
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2009
VL 100
IS 2
BP 195
EP 199
DI 10.1111/j.1349-7006.2008.01022.x
PG 5
SC Oncology
GA 395FG
UT ISI:000262509400001
ER

PT J
AU Kanda, J
   Matsuo, K
   Suzuki, T
   Kawase, T
   Hiraki, A
   Watanabe, M
   Mizuno, N
   Sawaki, A
   Yamao, K
   Tajima, K
   Tanaka, H
AF Kanda, Junya
   Matsuo, Keitaro
   Suzuki, Takeshi
   Kawase, Takakazu
   Hiraki, Akio
   Watanabe, Miki
   Mizuno, Nobumasa
   Sawaki, Akira
   Yamao, Kenji
   Tajima, Kazuo
   Tanaka, Hideo
TI Impact of alcohol consumption with polymorphisms in
   alcohol-metabolizing enzymes on pancreatic cancer risk in Japanese
SO CANCER SCIENCE
LA English
DT Article
ID GENETIC-POLYMORPHISM; POPULATION; DEHYDROGENASE; ALLELE; COFFEE;
   EPIDEMIOLOGY; TOBACCO; CARCINOGENESIS; GENOTYPES; SMOKING
AB The putative impact of alcohol on pancreatic cancer (PC) risk remains
   controversial. Here, we conducted a case-control study in Japanese to
   assess the impact of alcohol in conjunction with polymorphisms in
   alcohol-metabolizing enzymes. Cases were 160 patients with pancreatic
   cancer at Aichi Cancer Center, Nagoya, Japan. Two control groups of 800
   age- and sex-matched non-cancer subjects each were independently
   selected. The impact of alcohol and polymorphisms in aldehyde
   dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B
   His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate
   analysis adjusted for potential confounders to estimate odds ratios
   (ORs) and 95% confidence intervals (CIs). Results showed no independent
   impact of alcohol or genotype on PC risk except former drinking. To
   avoid reverse causation, former drinkers were excluded in further
   analyses. In the analysis of the combined effects of alcohol
   consumption and genotype, significant impact of alcohol was seen for
   those subjects with ALDH2 Lys+ allele, ADH1B His/His, or ADH1C Arg/Arg
   (trend P = 0.077, 0.003, or 0.020, respectively), each of which is
   associated with a high concentration or rapid production of
   acetaldehyde. Analysis of genotype combinations showed that 'ever
   drinking' with both ADH1B His/His and ALDH2 Lys + was the most potent
   risk factor for PC relative to 'never drinkers' with both ADH1B His/His
   and ALDH2 Glu/Glu [OR (95% CI); 4.09 (1.30-12.85)]. These results
   indicate that alcohol has an impact on PC risk when the effects of
   alcohol consumption and metabolism are combined. Acetaldehyde may be
   involved in the mechanisms underlying PC development. (Cancer Sci 2009;
   100: 296-302).
C1 [Kanda, Junya; Matsuo, Keitaro; Suzuki, Takeshi; Kawase, Takakazu; Hiraki, Akio; Watanabe, Miki; Tajima, Kazuo; Tanaka, Hideo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Mizuno, Nobumasa; Sawaki, Akira; Yamao, Kenji] Aichi Canc Ctr, Cent Hosp, Dept Gastroenterol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Matsuo, Keitaro; Tajima, Kazuo] Nagoya Univ, Grad Sch Med, Dept Epidemiol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Kanda, Junya] Kyoto Univ, Grad Sch Med, Dept Hematol Oncol, Sakyo Ku, Kyoto 6068507, Japan.
RP Matsuo, K, Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Chikusa
   Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
EM kmatsuo@aichi-cc.jp
FU Ministry of Education, Science, Sports, Culture and Technology of Japan
   ; Ministry of Health, Labour and Welfare of Japan ; Uehara Memorial
   Foundation 
FX This study was supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Science, Sports, Culture and Technology of
   Japan, by a Grant-in-Aid for Cancer Research from the Ministry of
   Health, Labour and Welfare of Japan, by a Grant-in-Aid for the Third
   Term Comprehensive 10-Year Strategy for Cancer Control from the
   Ministry of Health, Labour and Welfare of Japan and by a research grant
   from the Uehara Memorial Foundation.
   The authors are grateful to the doctors, nurses, technical staff, and
   hospital administration staff at Aichi Cancer Center Hospital for the
   daily administration of the HERPACC study.
CR BORRAS E, 2000, HEPATOLOGY, V31, P984
   BOSRON WF, 1986, HEPATOLOGY, V6, P502
   BRENNAN P, 2004, AM J EPIDEMIOL, V159, P1
   BROOKS PJ, 2005, ALCOHOL, V35, P187, DOI 10.1016/j.alcohol.2005.03.009
   CHEN AM, 2001, BIODRUGS, V15, P833
   CRABB DW, 1989, J CLIN INVEST, V83, P314
   HAMAJIMA N, 1995, J EPIDEMIOL, V5, P99
   HAMAJIMA N, 2001, ASIAN PACIFIC J CANC, V2, P99
   HAMAJIMA N, 2002, ASIAN PACIFIC J CANC, V3, P197
   HARNACK LJ, 1997, CANCER EPIDEM BIOMAR, V6, P1081
   HASHIBE M, 2008, NAT GENET, V40, P707, DOI 10.1038/ng.151
   HEUCH I, 1983, BRIT J CANCER, V48, P637
   INOUE M, 1997, J CLIN EPIDEMIOL, V50, P69
   INOUE M, 2003, INT J EPIDEMIOL, V32, P257, DOI 10.1093/ije/dyg062
   LARSSON SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535
   LIN YS, 2007, INT J CANCER, V120, P2665, DOI 10.1002/ijc.22614
   LIVAK KJ, 1999, GENET ANAL-BIOMOL E, V14, P143
   LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433
   LOWENFELS AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI
   10.1016/j.bpg.2005.10.001
   MARUYAMA K, 2008, J GASTROEN HEPATO S1, V23, S69, DOI
   10.1111/j.1440-1746.2007.05288.x
   MATSUO K, 2007, HUM MUTAT, V28, P506, DOI 10.1002/humu.20477
   MICHAUD DS, 2001, CANCER EPIDEM BIOMAR, V10, P429
   MIYASAKA K, 2005, PANCREAS, V30, P95
   OOTA H, 2004, ANN HUM GENET 2, V68, P93
   OSIER M, 1999, AM J HUM GENET, V64, P1147
   PARTANEN TJ, 1997, CANCER LETT, V116, P27
   PENG GS, 2007, PHARMACOGENET GENOM, V17, P845
   QIU DM, 2005, J EPIDEMIOL S2, V15, S157
   SEITZ HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191
   SHIMOSEGAWA T, 2008, J GASTROEN HEPATO S1, V23, S82, DOI
   10.1111/j.1440-1746.2007.05291.x
   TSUKUMA H, 2006, JPN J CLIN ONCOL, V36, P602, DOI 10.1093/jjco/hyl068
   VILLENEUVE PJ, 2000, EUR J CANCER PREV, V9, P49
   YANG CX, 2003, EUR J CANCER PREV, V12, P109, DOI
   10.1097/01.cej.0000062798.86004.d1
   YE W, 2002, GUT, V51, P236
   YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255
   YOSHIMURA K, 2003, J HUM GENET, V48, P654, DOI 10.1007/s10038-003-0096-1
NR 36
TC 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2009
VL 100
IS 2
BP 296
EP 302
DI 10.1111/j.1349-7006.2008.01044.x
PG 7
SC Oncology
GA 395FG
UT ISI:000262509400015
ER

PT J
AU Matsuo, J
   Tsukumo, Y
   Sakurai, J
   Tsukahara, S
   Park, HR
   Shin-ya, K
   Watanabe, T
   Tsuruo, T
   Tomida, A
AF Matsuo, Junichi
   Tsukumo, Yoshinori
   Sakurai, Junko
   Tsukahara, Satomi
   Park, Hae-Ryong
   Shin-ya, Kazuo
   Watanabe, Toshiki
   Tsuruo, Takashi
   Tomida, Akihiro
TI Preventing the unfolded protein response via aberrant activation of
   4E-binding protein 1 by versipelostatin
SO CANCER SCIENCE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; INDUCED GENE-EXPRESSION; RENAL-CELL
   CARCINOMA; TRANSLATION INITIATION; TUMOR-DEVELOPMENT; CANCER-THERAPY;
   ER STRESS; SURVIVAL; HYPOXIA; GROWTH
AB We recently isolated a macrocyclic compound, versipelostatin (VST),
   that exerts in vivo antitumor activity. VST shows unique, selective
   cytotoxicity to glucose-deprived tumor cells by preventing the unfolded
   protein response (UPR). Here we show that eukaryotic initiation factor
   4E-binding protein 1 (4E-BP1), a negative regulator of eukaryotic
   initiation factor 4E-mediated protein translation, plays a role in the
   UPR-inhibitory action of VST. Indeed, 4E-BP1 is aberrantly activated by
   VST. This activation occurs specifically during glucose deprivation and
   results in profound translation repression and prevents induction of
   the typical UPR markers glucose-regulated protein (GRP) 78 and
   activating transcription factor (ATF) 4. Our overexpression and
   knockdown experiments showed that 4E-BP1 can regulate GRP78 and ATF4
   expression. These mechanisms appear to be specific for VST. By
   contrast, rapamycin, which activates 4E-BP1 regardless of cellular
   glucose availability, has only marginal effects on the expression of
   GRP78 and ATF4. Our present findings demonstrate that aberrant 4E-BP1
   activation can contribute to UPR preventing by VST, possibly through a
   mechanism that does not operate in rapamycin-treated cells. (Cancer Sci
   2009; 100: 327-333).
C1 [Matsuo, Junichi; Tsukumo, Yoshinori; Sakurai, Junko; Tsukahara, Satomi; Tsuruo, Takashi; Tomida, Akihiro] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, Tokyo 1358550, Japan.
   [Matsuo, Junichi; Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Tumor Cell Biol Lab,Minato Ku, Tokyo 1088639, Japan.
   [Park, Hae-Ryong] Kyungnam Univ, Dept Food Sci & Biotechnol, Masan 631701, South Korea.
   [Shin-ya, Kazuo] Natl Inst Adv Ind Sci & Technol, Biomed Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan.
RP Tomida, A, Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku,
   3-10-6 Ariake, Tokyo 1358550, Japan.
EM akihiro.tomida@jfcr.or.jp
FU Ministry of Health, Labor, and Welfare ; Ministry of Education,
   Culture, Sport, Science, and Technology of Japan 
FX This work was supported in part by a Grant-in-Aid for Cancer Research
   (15-2) from the Ministry of Health, Labor, and Welfare (to A.T.), and a
   Grant-in-Aid for scientific research on priority areas for cancer from
   the Ministry of Education, Culture, Sport, Science, and Technology of
   Japan (to T.T.).
CR ARSHAM AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200
   BI MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777
   BROWN JM, 1998, CANCER RES, V58, P1408
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271
   DEVER TE, 2002, CELL, V108, P545
   DONG DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950
   FELS DR, 2006, CANCER BIOL THER, V5, P723
   GINGRAS AC, 1999, GENE DEV, V13, P1422
   GINGRAS AC, 2001, GENE DEV, V15, P807
   GRAFF JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635
   GRIDELLI C, 2007, ONCOLOGIST, V13, P139
   HARDING HP, 1999, NATURE, V397, P271
   HARDING HP, 2000, MOL CELL, V5, P897
   HARDING HP, 2000, MOL CELL, V6, P1099
   HORIE K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917
   HUDES G, 2007, NEW ENGL J MED, V356, P2271
   KOJIMA E, 2003, FASEB J, V17, P1573
   KORITZINSKY M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998
   LEE AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   LEE E, 2007, CANCER RES, V66, P7849
   MA YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200
   MA YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   MARCINIAK SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   MARCINIAK SJ, 2006, PHYSIOL REV, V86, P1133, DOI
   10.1152/physrev.00015.2006
   MOTZER RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   NOVOA I, 2003, EMBO J, V22, P1180
   PARK HR, 2004, J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243
   POLUNOVSKY VA, 2000, J BIOL CHEM, V275, P24776
   POLUNOVSKY VA, 2006, RNA BIOL, V3, P10
   PYRKO P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   RON D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   SCRIVEN P, 2007, J MOL MED-JMM, V85, P331, DOI 10.1007/s00109-006-0150-5
   TSUKUMO Y, 2007, J BIOL CHEM, V282, P29264, DOI 10.1074/jbc.M705038200
   YAMAGUCHI S, 2008, CELL METAB, V7, P269, DOI 10.1016/j.cmet.2008.01.008
   ZHAO L, 2006, CURR OPIN CELL BIOL, V18, P1
NR 35
TC 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2009
VL 100
IS 2
BP 327
EP 333
DI 10.1111/j.1349-7006.2008.01036.x
PG 7
SC Oncology
GA 395FG
UT ISI:000262509400020
ER

PT J
AU Iwasaki, R
   Ito, K
   Ishida, T
   Hamanoue, M
   Adachi, S
   Watanabe, T
   Sato, Y
AF Iwasaki, Reo
   Ito, Kinji
   Ishida, Takaomi
   Hamanoue, Makoto
   Adachi, Souichi
   Watanabe, Toshiki
   Sato, Yuko
TI Catechin, green tea component, causes caspase-independent necrosis-like
   cell death in chronic myelogenous leukemia
SO CANCER SCIENCE
LA English
DT Article
ID SERINE-PROTEASE ACTIVITY; NECROTIC TUMOR-CELLS; EPIGALLOCATECHIN
   GALLATE; CANCER-CELLS; IN-VITRO; POLYPHENOL
   (-)-EPIGALLOCATECHIN-3-GALLATE; MEDIATED APOPTOSIS; SIGNALING PATHWAYS;
   CARCINOMA-CELLS; CYCLE ARREST
AB Management strategies of chronic phase chronic myelogenous leukemia
   (CML) have been revolutionized due to the discovery of a selective
   tyrosine kinase inhibitor, imatinib (Gleevec, STI571), which is
   substantially improving median survival. However, emergence of
   imatinib-resistance has put up a serious problem that requires novel
   treatment methods. Catechins, polyphenolic compounds in green tea, are
   gathering much attention due to their potential antitumor effects. So
   far (-)-epigallocatechin-3-gallate (EGCG), the most abundant component
   of catechin, has been shown to cause typical apoptosis in several tumor
   cell lines in most cases through activation of caspases. In this study,
   we showed that EGCG predominantly caused necrosis-like cell death via a
   caspase-independent mechanism in CML cells, K562 and C2F8, whereas
   imatinib induced the typical apoptotic cell death. Moreover, this
   caspase-independent cell death partially mediated the release of
   apoptosis-inducing factor, AIF, and serine protease, HtrA2/Omi, from
   the mitochondria to cytosol. In addition, EGCG enhanced the
   imatinib-induced cell death (P < 0.01) resulting in additive cell death
   in K562 cells and EGCG alone, effectively reduced the viability of
   imatinib-resistant K562 cells (P < 0.01). Catechin is a possible
   candidate for an antitumor agent that causes cell death in CML cells
   via a caspase-independent mechanism. (Cancer Sci 2009; 100: 349-356).
C1 [Iwasaki, Reo; Sato, Yuko] Int Med Ctr Japan, Dept Pathol, Div Ultrafine Struct, Shinjuku Ku, Tokyo 1628655, Japan.
   [Iwasaki, Reo; Ishida, Takaomi; Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Tumor Cell Biol Lab,Minato Ku, Tokyo 1088649, Japan.
   [Hamanoue, Makoto] Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1430015, Japan.
   [Hamanoue, Makoto] Toho Univ, Sch Med, Dept Physiol, Ohta Ku, Tokyo 1430015, Japan.
   [Adachi, Souichi] Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan.
RP Sato, Y, Int Med Ctr Japan, Dept Pathol, Div Ultrafine Struct, Shinjuku
   Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.
EM ysato@ri.imcj.go.jp
FU Japan Foundation for Promotion of International Medical Research
   Co-operation (JF-PIMRC) 
FX This work was supported by the Japan Foundation for Promotion of
   International Medical Research Co-operation (JF-PIMRC).
CR AHMAD N, 1997, J NATL CANCER I, V89, P1881
   AHMAD N, 2000, BIOCHEM BIOPH RES CO, V275, P328
   ANTONSSON B, 2004, MOL CELL BIOCHEM, V256, P141
   BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3
   BETTUZZI S, 2006, CANCER RES, V66, P1234, DOI
   10.1158/0008-5472.CAN-05-1145
   BLAGOSKLONNY MV, 2000, LEUKEMIA, V14, P1502
   CHEN LS, 1997, DRUG METAB DISPOS, V25, P1045
   DAN S, 1998, CELL DEATH DIFFER, V5, P710
   DAUGAS E, 2000, FASEB J, V14, P729
   DECAUDIN D, 1998, INT J ONCOL, V12, P141
   EDDY SF, 2007, CANCER RES, V67, P9018, DOI 10.1158/0008-5472.CAN-07-1691
   ERMAKOVA SP, 2006, CANCER RES, V66, P9260, DOI
   10.1158/0008-5472.CAN-06-1586
   FESTJENS N, 2004, ACTA HAEMATOL, V111, P7
   FRIESEN C, 1999, LEUKEMIA, V13, P1854
   GARG AK, 2005, ANTIOXID REDOX SIGN, V7, P1630
   GUPTA S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177
   HAMAHATA K, 2005, EUR J PHARMACOL, V516, P187, DOI
   10.1016/j.ejphar.2005.04.018
   HAYAKAWA S, 2001, BIOCHEM BIOPH RES CO, V285, P1102
   HUH SW, 2004, GYNECOL ONCOL, V94, P760, DOI 10.1016/j.ygyno.2004.05.031
   IGNEY FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   ISBRUCKER RA, 2006, FOOD CHEM TOXICOL, V44, P626, DOI
   10.1016/j.fct.2005.07.005
   ISLAM S, 2000, BIOCHEM BIOPH RES CO, V270, P793
   KHAN N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   KITANAKA C, 1999, CELL DEATH DIFFER, V6, P508
   KOHRI T, 2001, J AGR FOOD CHEM, V49, P1042
   LANDISPIWOWAR KR, 2007, CANCER RES, V67, P4303, DOI
   10.1158/0008-5472.CAN-06-4699
   LEIST M, 1997, J EXP MED, V185, P1481
   LEIST M, 2001, NAT REV MOL CELL BIO, V2, P589
   MARZO I, 2001, BIOCHEM J 3, V359, P537
   NAASANI I, 1998, BIOCHEM BIOPH RES CO, V249, P391
   NAASANI I, 2003, CANCER RES, V63, P824
   NAKAZATO T, 2005, HAEMATOLOGICA, V90, P317
   OBEID M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   OKADA M, 2004, BLOOD, V103, P2299
   PAN MH, 2000, J AGR FOOD CHEM, V48, P6337
   RAVAGNAN L, 2002, J CELL PHYSIOL, V192, P131
   REITER I, 1999, J IMMUNOL, V163, P1730
   SAEKI K, 2002, BIOCHEM J 3, V368, P705, DOI 10.1042/BJ20020101
   SAUTER B, 2000, J EXP MED, V191, P423
   SHAMMAS MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814
   SIDDIQUI IA, 2008, ONCOGENE, V27, P2055, DOI 10.1038/sj.onc.1210840
   SOMERSEDGAR TJ, 2008, INT J CANCER, V122, P1966, DOI 10.1002/ijc.23328
   TACHIBANA H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   THOMPSON CB, 1995, SCIENCE, V267, P1456
   UMEDA D, 2008, J BIOL CHEM, V283, P3050, DOI 10.1074/jbc.M707892200
   VAIDYANATHAN JB, 2003, J PHARMACOL EXP THER, V307, P745, DOI
   10.1124/jpet.103.054296
   VANGURP M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI
   10.1016/S0006-291X(03)00621-1
   VERHAGEN AM, 2002, J BIOL CHEM, V277, P445
   YANG SH, 2006, EXP MOL MED, V38, P435
   ZONG WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 50
TC 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2009
VL 100
IS 2
BP 349
EP 356
DI 10.1111/j.1349-7006.2008.01046.x
PG 8
SC Oncology
GA 395FG
UT ISI:000262509400023
ER

PT J
AU Lin, M
   Wu, JR
   Yang, LY
   Chen, H
   Wang, PP
   Wang, Q
   Zheng, L
AF Lin, Min
   Wu, Jiao-Ren
   Yang, Li-Ye
   Chen, Hui
   Wang, Peng-Peng
   Wang, Qian
   Zheng, Lei
TI Hb G-Waimanalo: occurrence in combination with alpha-thalassemia-1
   Southeast Asian deletion
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Letter
ID HEMOGLOBIN-G-WAIMANALO; JAPANESE; ASP->ASN; FAMILY
C1 [Lin, Min; Wu, Jiao-Ren; Yang, Li-Ye; Chen, Hui; Wang, Peng-Peng] Chaozhou Cent Hosp, Chaozhou 521021, Guangdong, Peoples R China.
   [Wang, Qian; Zheng, Lei] Nanfang Med Univ, Nanfang Hosp, Dept Clin Lab, Guangzhou 510515, Peoples R China.
RP Yang, LY, Chaozhou Cent Hosp, Chaozhou 521021, Guangdong, Peoples R
   China.
EM yangleeyee@sina.com
CR BAINE RM, 1979, HEMOGLOBIN, V3, P293
   BLACKWELL RQ, 1973, BIOCHIM BIOPHYS ACTA, V322, P27
   ENRICA F, 1996, HAEMATOLOGICA, V81, P387
   HARANO T, 1981, HEMOGLOBIN, V5, P591
   LANDIN B, 1994, HEMOGLOBIN, V18, P71
   LIN M, 2008, BLOOD CELLS MOL DIS, V22
   MANCA L, 1994, HEMOGLOBIN, V18, P53
   PERUTZ MF, 1968, NATURE, V219, P902
   SUGIHARA J, 1984, HEMOGLOBIN, V8, P79
   SUN JQ, 1987, CHINESE J MED GENET, V4, P97
NR 10
TC 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELLS MOLECULES DIS
JI Blood Cells Mol. Dis.
PD JAN-FEB
PY 2009
VL 42
IS 1
BP 36
EP 37
DI 10.1016/j.bcmd.2008.09.005
PG 2
SC Hematology
GA 393CG
UT ISI:000262347900007
ER

PT J
AU Payne, JL
   Boyer, AG
   Brown, JH
   Finnegan, S
   Kowalewski, M
   Krause, RA
   Lyons, SK
   McClain, CR
   McShea, DW
   Novack-Gottshall, PM
   Smith, FA
   Stempien, JA
   Wang, SC
AF Payne, Jonathan L.
   Boyer, Alison G.
   Brown, James H.
   Finnegan, Seth
   Kowalewski, Michal
   Krause, Richard A., Jr.
   Lyons, S. Kathleen
   McClain, Craig R.
   McShea, Daniel W.
   Novack-Gottshall, Philip M.
   Smith, Felisa A.
   Stempien, Jennifer A.
   Wang, Steve C.
TI Two-phase increase in the maximum size of life over 3.5 billion years
   reflects biological innovation and environmental opportunity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE body size; Cambrian; oxygen; Precambrian; trend
ID BODY-SIZE; COPES RULE; ATMOSPHERIC OXYGEN; EVOLUTION; EUKARYOTES;
   OXIDATION; ANIMALS; FOSSILS; TRENDS; OCEANS
AB The maximum size of organisms has increased enormously since the
   initial appearance of life > 3.5 billion years ago (Gya), but the
   pattern and timing of this size increase is poorly known. Consequently,
   controls underlying the size spectrum of the global biota have been
   difficult to evaluate. Our period-level compilation of the largest
   known fossil organisms demonstrates that maximum size increased by 16
   orders of magnitude since life first appeared in the fossil record. The
   great majority of the increase is accounted for by 2 discrete steps of
   approximately equal magnitude: the first in the middle of the
   Paleoproterozoic Era (approximate to 1.9 Gya) and the second during the
   late Neoproterozoic and early Paleozoic eras (0.6-0.45 Gya). Each size
   step required a major innovation in organismal complexity-first the
   eukaryotic cell and later eukaryotic multicellularity. These size steps
   coincide with, or slightly postdate, increases in the concentration of
   atmospheric oxygen, suggesting latent evolutionary potential was
   realized soon after environmental limitations were removed.
C1 [Payne, Jonathan L.; Finnegan, Seth] Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA.
   [Boyer, Alison G.; Brown, James H.; Smith, Felisa A.] Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.
   [Kowalewski, Michal] Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA.
   [Krause, Richard A., Jr.] Humboldt Univ, Museum Naturkunde, D-10115 Berlin, Germany.
   [Lyons, S. Kathleen] Smithsonian Inst, Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20560 USA.
   [McClain, Craig R.] Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.
   [McShea, Daniel W.] Duke Univ, Dept Biol, Durham, NC 27708 USA.
   [Novack-Gottshall, Philip M.] Univ W Georgia, Dept Geosci, Carrollton, GA 30118 USA.
   [Stempien, Jennifer A.] Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA.
   [Wang, Steve C.] Swarthmore Coll, Dept Math & Stat, Swarthmore, PA 19081 USA.
RP Payne, JL, Stanford Univ, Dept Geol & Environm Sci, 450 Serra Mall,Bldg
   320, Stanford, CA 94305 USA.
EM jlpayne@stanford.edu
FU National Evolutionary Synthesis Center (NESCent) ; National Science
   Foundation [EF-0423641]
FX This study is a product of the working group on body size evolution (
   principal investigators: J.L.P., J.A.S., and M. K.) funded by the
   National Evolutionary Synthesis Center (NESCent), National Science
   Foundation Grant EF-0423641. We thank N. Butterfield, M, Carrano, W.
   DiMichele, L. Dong, R. Feldmann, P. Gensel, J. Huntley, P. Janvier, A.
   Logan, S. Low, S. Lucas, R. Lupia, W. Manger, K. Niklas, W. Ou, S.
   Porter, C. Schweitzer, H. Steur, R. Taggert, B. Tiffney, S. Truebe, S.
   Wing, and S. Xiao for advice and assistance in data compilation; J.
   Denton and especially S. Porter for comments on previous drafts of the
   manuscript; and G. Hunt and 2 anonymous reviewers for constructive and
   thoughtful suggestions.
CR ACQUISTI C, 2007, NATURE, V445, P47, DOI 10.1038/nature05450
   ALROY J, 1998, SCIENCE, V280, P731
   BENGTSON S, 2007, PALEOBIOLOGY, V33, P351
   BERNER RA, 2003, ANNU REV EARTH PL SC, V31, P105, DOI
   10.1146/annurev.earth.31.100901.141329
   BONNER JT, 1988, EVOLUTION COMPLEXITY
   BONNER JT, 2006, WHY SIZE MATTERS BAC
   BROCKS JJ, 1999, SCIENCE, V285, P1033
   BROWN JH, 1991, AM NAT, V138, P1478
   BROWN JH, 1995, MACROECOLOGY
   BUTTERFIELD NJ, 2000, PALEOBIOLOGY, V26, P386
   CALDER WA, 1984, SIZE FUNCTION LIFE H
   CANFIELD DE, 2005, ANNU REV EARTH PL SC, V33, P1, DOI
   10.1146/annurev.earth.33.092203.122711
   CANFIELD DE, 2007, SCIENCE, V315, P92, DOI 10.1126/science.1135013
   CHAPELLE G, 1999, NATURE, V399, P114
   CHAPMAN DJ, 1983, EARTHS EARLIEST BIOS, P302
   CLOUD P, 1972, AM J SCI, V272, P537
   DROSER ML, 1993, ANNU REV EARTH PL SC, V21, P205
   DUTKIEWICZ A, 2006, GEOLOGY, V34, P437, DOI 10.1130/G22360.1
   FIKE DA, 2006, NATURE, V444, P744, DOI 10.1038/nature05345
   FISCHER WW, 2007, GEOBIOLOGY, V5, P19, DOI
   10.1111/j.1472-4669.2007.00096.x
   GEIGENBERGER P, 2003, CURR OPIN PLANT BIOL, V6, P247, DOI
   10.1016/S1369-5266(03)00038-4
   GOULD SJ, 1988, J PALEONTOL, V62, P319
   HAN TM, 1992, SCIENCE, V257, P232
   HOLLAND HD, 2006, PHILOS T R SOC B, V361, P903, DOI
   10.1098/rstb.2006.1838
   HUNT G, 2006, P NATL ACAD SCI USA, V103, P1347, DOI
   10.1073/pnas.0510550103
   HUNTLEY JW, 2006, PRECAMBRIAN RES, V144, P53
   JABLONSKI D, 1996, EVOLUTIONARY PALEOBI, P256
   JABLONSKI D, 1997, NATURE, V385, P250
   KAIHO K, 1998, GEOLOGY, V26, P491
   KNOLL AH, 1995, EFFECTS PAST GLOBAL, P21
   KNOLL AH, 2006, PHILOS T R SOC B, V361, P1023, DOI
   10.1098/rstb.2006.1843
   KUMAR S, 1995, PRECAMBRIAN RES, V72, P171
   LAMB DM, 2007, PRECAMBRIAN RES, V154, P236, DOI
   10.1016/j.precamres.2006.12.012
   MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087
   MCCLAIN CR, 2001, MAR BIOL, V139, P681
   MCFADDEN KA, 2008, P NATL ACAD SCI USA, V105, P3197, DOI
   10.1073/pnas.0708336105
   MCSHEA DW, 1994, EVOLUTION, V48, P1747
   MCSHEA DW, 2001, PALEOBIOLOGY, V27, P405
   NIKLAS KJ, 2001, P NATL ACAD SCI USA, V98, P2922
   NOVACKGOTTSHALL PM, 2008, P NATL ACAD SCI USA, V105, P5430, DOI
   10.1073/pnas.0709645105
   NOVACKGOTTSHALL PM, 2008, PALAIOS, V23, P163, DOI
   10.2110/palo.2007.p07-017r
   PAPINEAU D, 2007, EARTH PLANET SC LETT, V255, P188, DOI
   10.1016/j.epsl.2006.12.015
   PAYNE JL, 2005, PALEOBIOLOGY, V31, P269
   PETERS RH, 1983, ECOLOGICAL IMPLICATI
   RAFF RA, 1970, NATURE, V228, P1003
   RASMUSSEN B, 2008, NATURE, V455, P1101, DOI 10.1038/nature07381
   RAYMOND J, 2004, GEOBIOLOGY, V2, P199
   RUNNEGAR B, 1982, ALCHERINGA, V6, P223
   RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395
   RUNNEGAR B, 1991, PALAEOGEOGR PALAEOCL, V97, P97
   SAMUELSSON J, 2001, PRECAMBRIAN RES, V107, P235
   SCHMIDTNIELSEN K, 1984, SCALING WHY IS ANIMA
   SCHULZ HN, 2001, ANNU REV MICROBIOL, V55, P105
   SCOTT C, 2008, NATURE, V452, P456, DOI 10.1038/nature06811
   SEILACHER A, 1998, SCIENCE, V282, P80
   SHEN YN, 2008, P NATL ACAD SCI USA, V105, P7376, DOI
   10.1073/pnas.0802168105
   SMITH FA, 2004, AM NAT, V163, P672
   STANLEY SM, 1973, EVOLUTION, V27, P1
   STEVENS GR, 1988, CEPHALOPODS PRESENT, P141
   XIAO S, 2006, NEOPROTEROZOIC GEOBI, P57
NR 60
TC 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 PROC NAT ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 6
PY 2009
VL 106
IS 1
BP 24
EP 27
DI 10.1073/pnas.0806314106
PG 4
SC Multidisciplinary Sciences
GA 391WC
UT ISI:000262263900008
ER

PT J
AU Yang, SH
   Cheng, PH
   Sullivan, RT
   Thomas, JW
   Chan, AWS
AF Yang, Shang-Hsun
   Cheng, Pei-Hsun
   Sullivan, Robert T.
   Thomas, James W.
   Chan, Anthony W. S.
TI Lentiviral Integration Preferences in Transgenic Mice
SO GENESIS
LA English
DT Article
DE lentiviral vector; transgenesis; integration; preference genome; mouse
   zygote
ID IMMUNODEFICIENCY-VIRUS TYPE-1; OVINE PULMONARY ADENOCARCINOMA;
   PSEUDOTYPED RETROVIRAL VECTORS; GENE-TRANSFER; HUMAN GENOME;
   CHROMOSOMAL POSITION; SITE SELECTION; HIGH-TITER; GERM LINE; IN-VITRO
AB Lentiviral gene transfer has a significant impact on the development of
   biomedical research. One of the most important features of lentiviruses
   is the capability to infect both dividing and nondividing cells.
   However, little is known whether integration preference exists,
   specifically in early embryos. An in-depth genome analysis on 112
   independent lentiviral integration sites from 43 transgenic founder
   mice was performed to determine if there are preferable sites for
   lentiviral integration in early embryonic genome. Our results
   demonstrated that lentiviruses were biased in integrating within
   intragenic regions, especially in the introns. However, no integration
   preference was found associated with specific chromosomes, repetitive
   elements, or CpG islands, nor was there any preference for integrating
   at close proximity to transcription start sites. Our findings suggested
   that lentiviruses were biased to integrate into the intragenic regions
   of early embryonic genome of mouse. genesis 46:711-718, 2008. (C) 2008
   Wiley-Liss, Inc.
C1 [Yang, Shang-Hsun; Cheng, Pei-Hsun; Chan, Anthony W. S.] Emory Univ, Yerkes Natl Primate Res Ctr, Div Neurosci, Atlanta, GA 30329 USA.
   [Yang, Shang-Hsun; Thomas, James W.; Chan, Anthony W. S.] Emory Univ, Genet & Mol Biol Program, Atlanta, GA 30329 USA.
   [Yang, Shang-Hsun; Cheng, Pei-Hsun; Sullivan, Robert T.; Thomas, James W.; Chan, Anthony W. S.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30329 USA.
RP Chan, AWS, Emory Univ, Yerkes Natl Primate Res Ctr, Div Neurosci, Rm
   2212,Neurosci Res Bldg,954 Gatewood Rd,NE, Atlanta, GA 30329 USA.
EM achan@genetics.emory.eclu
FU NIH (Yerkes National Primate Research Center) [RR-00165]; NCRR/NIH
   [RR018827-04]
FX Contract grant sponsor: NIH (Yerkes National Primate Research Center),
   Contract grant number: RR-00165. Contract grant sponsor: NCRR/NIH,
   Contract grant number: RR018827-04.
CR BARR SD, 2006, MOL THER, V14, P218, DOI 10.1016/j.ymthe.2006.03.012
   BRYDA EC, 2006, BIOTECHNIQUES, V41, P715, DOI 10.2144/000112289
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033
   CABOT RA, 2001, ANIM BIOTECHNOL, V12, P205
   CHAN AWS, 1998, P NATL ACAD SCI USA, V95, P14028
   CHAN AWS, 2001, SCIENCE, V291, P309
   CIUFFI A, 2006, MOL THER, V13, P366, DOI 10.1016/j.ymthe.2005.10.009
   CLARK AJ, 1994, REPROD FERT DEVELOP, V6, P589
   COUSENS C, 2004, J VIROL, V78, P8506, DOI
   10.1128/JVI.78.16.8506-8512.2004
   HOGAN B, 1994, MANIPULATING MOUSE E, P497
   JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260
   JAENISCH R, 1981, CELL, V24, P519
   JAENISCH R, 1983, CIBA F S, V98, P44
   KANG YB, 2006, J VIROL, V80, P8820, DOI 10.1128/JVI.00719-06
   KAROLCHIK D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129
   KENT WJ, 2002, GENOME RES, V12, P656
   LEWINSKI MK, 2006, PLOS PATHOG, V2, UNSP 0611-0622
   LIU HB, 2006, J VIROL, V80, P7765, DOI 10.1128/JVI.00542-06
   LOIS C, 2002, SCIENCE, V295, P868
   MACNEIL A, 2006, J VIROL, V80, P7316, DOI 10.1128/JVI.00604-06
   MILUTINOVIC S, 2002, J BIOL CHEM, V277, P20974
   MITCHELL RS, 2004, PLOS BIOL, V2, P1127, ARTN e234
   NAREZKINA A, 2004, J VIROL, V78, P11656, DOI
   10.1128/JVI.78.21.11656-11663.2004
   NOWROUZI A, 2006, J GEN VIROL 5, V87, P1339, DOI 10.1099/vir.0.81554-0
   PERLETTI G, 2004, J CELL MOL MED, V8, P142
   PHILBEY AW, 2006, VIRUS RES, V117, P254, DOI
   10.1016/j.virusres.2005.10.020
   ROMANO G, 2005, DRUG NEWS PERSPECT, V18, P128, DOI
   10.1358/dnp.2005.18.2.886481
   SAXONOV S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI
   10.1073/pnas.0510310103
   SCHRODER ARW, 2002, CELL, V110, P521
   SHIMOTOHNO K, 1981, CELL, V26, P67
   STEVENS SW, 1994, P NATL ACAD SCI USA, V91, P5557
   STEVENS SW, 1996, J VIROL, V70, P6459
   TEMIN HM, 1990, HUM GENE THER, V1, P111
   TROBRIDGE GD, 2006, P NATL ACAD SCI USA, V103, P1498, DOI
   10.1073/pnas.0510046103
   WATERSTON RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   WU XL, 2003, SCIENCE, V300, P1749
   YANG SH, 2007, GENESIS, V45, P177, DOI 10.1002/dvg.20289
   YANG SH, 2008, NATURE, V453, P921, DOI 10.1038/nature06975
   YEE JK, 1994, METHOD CELL BIOL, V43, P99
   ZUFFEREY R, 1998, J VIROL, V72, P9873
NR 40
TC 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1526-954X
J9 GENESIS
JI Genesis
PD DEC
PY 2008
VL 46
IS 12
BP 711
EP 718
DI 10.1002/dvg.20435
PG 8
SC Developmental Biology; Genetics & Heredity
GA 390HW
UT ISI:000262155900001
ER

PT J
AU Sun, WJ
   Yu, Y
   Dotti, G
   Shen, T
   Tan, XJ
   Savoldo, B
   Pass, AK
   Chu, MJ
   Zhang, DK
   Lu, XB
   Fu, SB
   Lin, X
   Yang, JH
AF Sun, Wenjing
   Yu, Yang
   Dotti, Gianpietro
   Shen, Tao
   Tan, Xiaojie
   Savoldo, Barbara
   Pass, Amy K.
   Chu, Meijin
   Zhang, Dekai
   Lu, Xiongbin
   Fu, Songbin
   Lin, Xia
   Yang, Jianhua
TI PPM1A and PPM1B act as IKK beta phosphatases to terminate TNF
   alpha-induced IKK beta-NF-kappa B activation
SO CELLULAR SIGNALLING
LA English
DT Article
DE Tumor necrosis factor; Kinase; Phosphatase; I kappa B kinase; NF-kappa
   B; Signal transduction
ID KINASE COMPLEX; SIGNALING PATHWAY; PROTEIN-KINASE; PHOSPHORYLATION;
   SUBUNIT; 2C; ASSOCIATION; MECHANISM; CLONING; MAPK
AB IKK beta serves as a central intermediate signaling molecule in the
   activation of the NF-kappa B pathway. However, the precise mechanism
   for the termination of IKK beta activity is still not fully understood.
   Using a functional genomic approach, we have identified two protein
   serine/threonine phosphatases, PPM1A and PPM1B, as IKK beta
   phosphatases. Overexpression of PPM1A or PPM1B results in
   dephosphorylation of IKK beta at Ser177 and Ser181 and termination of
   IKK beta-induced NF-kappa B activation. PPM1A and PPM1B associate with
   the phosphorylated form of IKK beta, and the interaction between
   PPM1A/PPM1B and IKK beta is induced by TNF alpha in a transient fashion
   in the cells. Furthermore, knockdown of PPM1A and PPM1B expression
   enhances TNF alpha-induced IKK beta phosphorylation, NF-kappa B nuclear
   translocation and NF-kappa B-dependent gene expression. These data
   suggest that PPM1A and PPM1B play an important role in the termination
   of TNF alpha-mediated NF-kappa B activation through dephosphorylating
   and inactivating IKK beta. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Sun, Wenjing; Yu, Yang; Tan, Xiaojie; Pass, Amy K.; Yang, Jianhua] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Dotti, Gianpietro; Savoldo, Barbara] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
   [Shen, Tao; Chu, Meijin; Lin, Xia] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Zhang, Dekai] Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.
   [Lu, Xiongbin] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
   [Fu, Songbin] Harbin Med Coll, Med Genet Lab, Harbin 150081, Peoples R China.
RP Yang, JH, Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Dan L
   Duncan Canc Ctr, Houston, TX 77030 USA.
EM jianhuay@bcm.tmc.edu
FU National Institutes of Health [1R21CA106513-01A2]; American Cancer
   Society [RSG-06-070-01-TBE]; NIH/NCI T32 [1T32CA115303-01A1]
FX We thank Susan Burlingame for technical assistance. We are very
   grateful to Dr. Paul Chiao, Dr. Sergei Nekhai, Dr. Larry Donehower and
   Dr. Xiaofan Wang for providing IKK beta, PPP1, PPM1D and PPP5C
   expression plasmids, respectively. This work was supported by National
   Institutes of Health Grant 1R21CA106513-01A2 and American Cancer
   Society grant RSG-06-070-01-TBE (to J. Y.). A.K.P. was supported by the
   NIH/NCI T32 training grant 1T32CA115303-01A1.
CR BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P649
   BEG AA, 1993, GENE DEV, V7, P2064
   BEG AA, 1993, MOL CELL BIOL, V13, P3301
   CHENG AY, 1999, GENE DEV, V13, P2946
   COHEN P, 2003, METHOD ENZYMOL, V255, R45
   CRAIG R, 2000, J BIOL CHEM, V275, P23814
   DELHASE M, 1999, SCIENCE, V284, P309
   DIDONATO JA, 1997, NATURE, V388, P548
   GALLEGO M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI
   10.1016/j.ceb.2005.01.002
   GHOSH S, 2002, CELL S, V109, S81
   HANADA M, 1998, FEBS LETT, V437, P172
   HANADA M, 2001, J BIOL CHEM, V276, P5753
   HAYDEN MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   KARIN M, 2000, ANNU REV IMMUNOL, V18, P621
   KRAY AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200
   LI HY, 2008, NAT IMMUNOL, V9, P533, DOI 10.1038/ni.1600
   LI ZW, 1999, J EXP MED, V189, P1839
   MAY MJ, 1998, IMMUNOL TODAY, V19, P80
   MERCURIO F, 1997, SCIENCE, V278, P860
   MOORE F, 1991, EUR J BIOCHEM, V199, P691
   PRAJAPATI S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200
   REGNIER CH, 1997, CELL, V90, P373
   ROTHWARF DM, 1998, NATURE, V395, P297
   SINGHIRUNNUSORN P, 2005, J BIOL CHEM, V280, P7359, DOI
   10.1074/jbc.M407537200
   TAKEKAWA M, 1998, EMBO J, V17, P4744
   TANAKA M, 1999, IMMUNITY, V10, P421
   VERMA IM, 1995, GENE DEV, V9, P2723
   WENK J, 1992, FEBS LETT, V297, P135
   WORONICZ JD, 1997, SCIENCE, V278, P866
   YAMAOKA S, 1998, CELL, V93, P1231
   YANG JH, 2001, NAT IMMUNOL, V2, P620
   ZANDI E, 1997, CELL, V91, P243
   ZANDI E, 1998, SCIENCE, V281, P1360
   ZANDI E, 1999, MOL CELL BIOL, V19, P4547
NR 34
TC 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JAN
PY 2009
VL 21
IS 1
BP 95
EP 102
DI 10.1016/j.cellsig.2008.09.012
PG 8
SC Cell Biology
GA 389AB
UT ISI:000262060900012
ER

PT J
AU Han, J
   Pedersen, JS
   Kwon, SC
   Belair, CD
   Kim, YK
   Yeom, KH
   Yang, WY
   Haussler, D
   Blelloch, R
   Kim, VN
AF Han, Jinju
   Pedersen, Jakob S.
   Kwon, S. Chul
   Belair, Cassandra D.
   Kim, Young-Kook
   Yeom, Kyu-Hyeon
   Yang, Woo-Young
   Haussler, David
   Blelloch, Robert
   Kim, V. Narry
TI Posttranscriptional Crossregulation between Drosha and DGCR8
SO CELL
LA English
DT Article
ID MICROPROCESSOR COMPLEX; MICRORNA BIOGENESIS; ALZHEIMERS-DISEASE; RNA
   INTERFERENCE; EXPRESSION; PROLIFERATION; DROSOPHILA; MIR-222; PATHWAY;
   CELLS
AB The Drosha-DGCR8 complex, also known as Microprocessor, is essential
   for microRNA (miRNA) maturation. Drosha functions as the catalytic
   subunit, while DGCR8 (also known as Pasha) recognizes the RNA
   substrate. Although the action mechanism of this complex has been
   intensively studied, it remains unclear how Drosha and DGCR8 are
   regulated and if these proteins have any additional role(s) apart from
   miRNA processing. Here, we report that Drosha and DGCR8 regulate each
   other posttranscriptionally. The Drosha-DGCR8 complex cleaves the
   hairpin structures embedded in the DGCR8 mRNA and thereby destabilizes
   the mRNA. We further find that DGCR8 stabilizes the Drosha protein via
   protein-protein interaction. This crossregulation between Drosha and
   DGCR8 may contribute to the homeostatic control of miRNA biogenesis.
   Furthermore, microarray analyses suggest that a number of mRNAs may be
   downregulated in a Microprocessor-dependent, miRNA-independent manner.
   Our study reveals a previously unsuspected function of Microprocessor
   in mRNA stability control.
C1 [Han, Jinju; Kwon, S. Chul; Kim, Young-Kook; Yeom, Kyu-Hyeon; Yang, Woo-Young; Kim, V. Narry] Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.
   [Pedersen, Jakob S.] Univ Copenhagen, Dept Biol, Bioinformat Ctr, DK-2200 Copenhagen, Denmark.
   [Belair, Cassandra D.; Blelloch, Robert] Univ Calif San Francisco, Inst Regenerat Med, Ctr Reprod Sci, San Francisco, CA 94143 USA.
   [Belair, Cassandra D.; Blelloch, Robert] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
   [Haussler, David] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
RP Kim, VN, Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.
EM narrykim@snu.ac.kr
FU Creative Research Initiatives Program [R16-2007-073-01000-0]; BK21
   Research Fellowships ; Ministry of Education, Science, and Technology
   of Korea ; Danish Medical Research Council [271-06-0711]; University of
   California, San Francisco, Urology Developmental Award ; Prostate
   Cancer Foundation ; National Institutes of Health [K08 NS48118, RO1
   NS057221]; Stem Cell Research Foundation 
FX We are grateful to Dr. Seogang Hyun for help with S2 transfection, to
   Dr. Chirlmin Joo for critical reading of this manuscript, and to
   members of our laboratory for helpful discussion. We also thank Dr.
   Young-Joon Kim for kindly providing S2 cell. This work was supported by
   the Creative Research Initiatives Program (R16-2007-073-01000-0)
   (V.N.K.) and the BK21 Research Fellowships (J.H. and S.C.K.) from the
   Ministry of Education, Science, and Technology of Korea. J.S.P. was
   supported by the Danish Medical Research Council (271-06-0711). C.B.
   was supported through a University of California, San Francisco,
   Urology Developmental Award and the Prostate Cancer Foundation. R.B. is
   a Pew Scholar and was supported by National Institutes of Health grants
   (K08 NS48118, RO1 NS057221), the Prostate Cancer Foundation, and Stem
   Cell Research Foundation. J.H., S.C.K., Y.K.K., K.H.Y., and W.Y.Y.
   performed the experiments and analyzed the data. C.B. and R.B. carried
   out experiments with Dgcr8 KO mES cells, generated Dgcr8 KO MEF, and
   helped with manuscript preparation. J.S.P. performed bioinformatics
   analyses with D.H. and helped with editing of paper. J.H. and V.N.K.
   designed the study and wrote the paper.
CR AMBROS V, 2003, RNA, V9, P277
   BABIARZ JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308
   BUSHATI N, 2007, ANNU REV CELL DEV BI, V23, P175
   DENLI AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049
   ELBASHIR SM, 2001, GENE DEV, V15, P188
   FALLER M, 2007, NAT STRUCT MOL BIOL, V14, P23, DOI 10.1038/nsmb1182
   FILIPOWICZ W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   FRIEDLANDER MR, 2008, NAT BIOTECHNOL, V26, P407, DOI 10.1038/nbt1394
   GALARDI S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   GREGORY RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   HAN JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   HAN JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043
   HEBERT SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI
   10.1073/pnas.0710263105
   JONESRHOADES MW, 2006, ANNU REV PLANT BIOL, V57, P19
   KIM HK, 2006, J CELL BIOL, V174, P677
   KIM YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   KROL J, 2007, MOL CELL, V25, P575, DOI 10.1016/j.molcel.2007.01.031
   LANDTHALER M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001
   LEE RC, 1993, CELL, V75, P843
   LEE Y, 2002, EMBO J, V21, P4663
   LEE Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   LEE Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942
   LESAGE C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   LIU QH, 2003, SCIENCE, V301, P1921
   LIU X, 2008, BRAIN PATHOL, V18, P113, DOI
   10.1111/j.1750-3639.2007.00121.x
   LU J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   MACRAE IJ, 2007, CURR OPIN STRUC BIOL, V17, P138, DOI
   10.1016/j.sbi.2006.12.002
   MORIN RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508
   OKAMURA K, 2007, CELL, V130, P89, DOI 10.1016/j.cell.2007.06.028
   PEDERSEN JS, 2006, PLOS COMPUT BIOL, V2, P251, ARTN e33
   RODRIGUEZ A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   RUBY JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983
   SHIOHAMA A, 2007, EXP CELL RES, V313, P4196, DOI
   10.1016/j.yexcr.2007.07.020
   STARK KL, 2008, NAT GENET, V40, P751, DOI 10.1038/ng.138
   THOMSON JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.144406
   VISONE R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129
   WANG WX, 2008, J NEUROSCI, V28, P1213, DOI
   10.1523/JNEUROSCI.5065-07.2008
   WANG Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250
   WANG YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969
   YEOM KH, 2006, NUCLEIC ACIDS RES, V34, P4622, DOI 10.1093/nar/gkl458
   ZENG Y, 2002, RNA, V8, P855
NR 41
TC 47
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JAN 9
PY 2009
VL 136
IS 1
BP 75
EP 84
DI 10.1016/j.cell.2008.10.053
PG 10
SC Biochemistry & Molecular Biology; Cell Biology
GA 392QX
UT ISI:000262318400016
ER

PT J
AU Maeshima, AM
   Taniguchi, H
   Nomoto, J
   Maruyama, D
   Kim, SW
   Watanabe, T
   Kobayashi, Y
   Tobinai, K
   Matsuno, Y
AF Maeshima, Akiko Miyagi
   Taniguchi, Hirokazu
   Nomoto, Junko
   Maruyama, Dai
   Kim, Sung-Won
   Watanabe, Takashi
   Kobayashi, Yukio
   Tobinai, Kensei
   Matsuno, Yoshihiro
TI Histological and immunophenotypic changes in 59 cases of B-cell
   non-Hodgkin's lymphoma after rituximab therapy
SO CANCER SCIENCE
LA English
DT Article
ID ANTI-CD20 ANTIBODY RITUXIMAB; CHRONIC LYMPHOCYTIC-LEUKEMIA; FOLLICULAR
   LYMPHOMA; PLASMACYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODY; CD20;
   EXPRESSION; TRANSFORMATION; DISEASE; LINES
AB Rituximab is a chimeric monoclonal antibody that recognizes the CD20
   antigen. It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL),
   but recently rituximab resistance has been a cause for concern. We
   examined histological and immunohistochemical changes in 59 patients
   with B-NHL after rituximab therapy. The patients comprised 32 men and
   27 women with a median age of 59 years. Pre-rituximab specimens
   comprised 34 follicular lymphomas (FL), 11 diffuse large B-cell
   lymphomas (DLBCL), 10 mantle cell lymphomas, two marginal zone B-cell
   lymphomas (MZBCL), and two chronic lymphocytic leukemias (CLL). CD20
   expression in lymphoma cells was evaluated by immunohistochemistry or
   flow cytometry. Post-rituximab materials were taken a median of 6
   months (4 days to 59 months) after rituximab therapy. Sixteen cases
   (27%) showed loss of CD20 expression with four histological patterns:
   pattern 1, no remarkable histological change (FL, 5; DLBCL, 3; and CLL,
   2); pattern 2, proliferation of plasmacytoid cells (FL, 2; DLBCL, 1;
   and MZBCL, 1); pattern 3, transformation to classical Hodgkin's
   lymphoma (FL, 1); and pattern 4, transformation to anaplastic large
   cell lymphoma-like undifferentiated lymphoma (FL, 1). Loss of CD20 was
   unrelated to the interval of biopsies, treatment regimen, clinical
   response, and frequency of rituximab administration. Loss of CD20
   within 1 month of rituximab therapy (3/14, 21%) and regain of CD20
   (2/7, 29%) were not frequent. CD20-positive relapse with transformation
   occurred most frequently in cases of early relapse. In conclusion,
   B-NHL showed various histological and immunophenotypic changes after
   rituximab therapy, including not only CD20 loss but also proliferation
   of plasmacytoid cells or transformation to special subtypes of
   lymphoma. (Cancer Sci 2009; 100: 54-61).
C1 [Maeshima, Akiko Miyagi; Taniguchi, Hirokazu] Natl Canc Ctr, Clin Lab, Tokyo, Japan.
   [Nomoto, Junko; Maruyama, Dai; Kim, Sung-Won; Watanabe, Takashi; Kobayashi, Yukio; Tobinai, Kensei] Natl Canc Ctr, Div Hematol, Tokyo, Japan.
   [Nomoto, Junko; Maruyama, Dai; Kim, Sung-Won; Watanabe, Takashi; Kobayashi, Yukio; Tobinai, Kensei] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan.
   [Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan.
RP Maeshima, AM, Natl Canc Ctr, Clin Lab, 1-1 Tsukiji 5 chome, Tokyo,
   Japan.
EM akmaeshi@ncc.go.jp
CR ALOVARONARANJO TA, 2003, ANN HEMATOL, V82, P585
   BRAUNINGER A, 1999, NEW ENGL J MED, V340, P1239
   CARDARELLI PM, 2002, CANCER IMMUNOL IMMUN, V51, P15
   CHU PG, 2002, LEUKEMIA LYMPHOMA, V43, P2335, DOI
   10.1080/1042819021000040044
   COHEN Y, 2002, EUR J HAEMATOL, V68, P80
   CRAGG MS, 2004, BLOOD, V103, P3989
   CZUCZMAN MS, 2008, CLIN CANCER RES, V14, P1561, DOI
   10.1158/1078-0432.CCR-07-1254
   DAVIS TA, 1999, CLIN CANCER RES, V5, P611
   DEMIDEM A, 1997, CANCER BIOTHER RADIO, V12, P177
   FORAN JM, 2001, BRIT J HAEMATOL, V114, P881
   GOTERI G, 2006, INT J IMMUNOPATH PH, V19, P421
   JAFFE ES, 2001, WHO CLASSIFICATION T
   JAZIREHI AR, 2007, CANCER RES, V67, P1270, DOI
   10.1158/0008-5472.CAN-06-2184
   JILANI I, 2003, BLOOD, V102, P3514, DOI 10.1182/blood-2003-01-0055
   KEITH TA, 1985, AM J CLIN PATHOL, V84, P283
   KENNEDY GA, 2002, BRIT J HAEMATOL, V119, P412
   KINOSHITA T, 1998, J CLIN ONCOL, V16, P3916
   LENZ G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133
   MAESHIMA AM, 2008, CANCER SCI, V99, P1760, DOI
   10.1111/j.1349-7006.2008.00873.x
   MARAFIOTI T, 1999, J CLIN ONCOL, V17, P3804
   MEEKER T, 1985, NEW ENGL J MED, V312, P1658
   MICALLEF INM, 1999, BLOOD, V93, P2427
   PIJUAN L, 2005, AM J SURG PATHOL, V29, P1399
   RAWAL YB, 2005, J CUTAN PATHOL, V32, P616
   REFF ME, 1994, BLOOD, V83, P435
   SCARAMUCCI L, 2007, LEUKEMIA LYMPHOMA, V48, P1878, DOI
   10.1080/10428190701509814
   SCHMITZ K, 1999, BRIT J HAEMATOL, V106, P571
   SEKIGUCHI N, 2005, CANCER SCI, V96, P77
   SELIEM RM, 2006, APPL IMMUNOHISTO M M, V14, P18
   SHAN D, 1998, BLOOD, V91, P1644
   TAKEI K, 2006, LEUKEMIA RES, V30, P625, DOI
   10.1016/j.leukres.2005.09.008
   TETREAULT S, 1998, J CLIN ONCOL, V16, P1635
   TOMITA A, 2007, INT J HEMATOL, V86, P49, DOI 10.1532/IJH97.07028
   VAGO JF, 1985, AM J SURG PATHOL, V9, P764
   WOEHRER S, 2005, LEUKEMIA LYMPHOMA, V46, P1645, DOI
   10.1080/10428190500178399
NR 35
TC 7
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2009
VL 100
IS 1
BP 54
EP 61
DI 10.1111/j.1349-7006.2008.01005.x
PG 8
SC Oncology
GA 390FN
UT ISI:000262149800009
ER

PT J
AU Tobinai, K
   Watanabe, T
   Ogura, M
   Morishima, Y
   Hotta, T
   Ishizawa, K
   Itoh, K
   Okamoto, S
   Taniwaki, M
   Tsukamoto, N
   Okumura, H
   Terauchi, T
   Nawano, S
   Matsusako, M
   Matsuno, Y
   Nakamura, S
   Mori, S
   Ohashi, Y
   Hayashi, M
   Endo, K
AF Tobinai, Kensei
   Watanabe, Takashi
   Ogura, Michinori
   Morishima, Yasuo
   Hotta, Tomomitsu
   Ishizawa, Kenichi
   Itoh, Kuniaki
   Okamoto, Shin-ichiro
   Taniwaki, Masafumi
   Tsukamoto, Norifumi
   Okumura, Hirokazu
   Terauchi, Takashi
   Nawano, Shigeru
   Matsusako, Masaki
   Matsuno, Yoshihiro
   Nakamura, Shigeo
   Mori, Shigeo
   Ohashi, Yasuo
   Hayashi, Masaki
   Endo, Keigo
TI Japanese phase II study of Y-90-ibritumomab tiuxetan in patients with
   relapsed or refractory indolent B-cell lymphoma
SO CANCER SCIENCE
LA English
DT Article
ID NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODY THERAPY; Y-90 IBRITUMOMAB
   TIUXETAN; FOLLICULAR LYMPHOMA; LOW-GRADE; CHOP CHEMOTHERAPY; FOLLOW-UP;
   RESPONSE CRITERIA; ONCOLOGY-GROUP; STAGE-I
AB There is no data about the efficacy and safety of radioimmunotherapy
   with Y-90-ibritumomab tiuxetan in patients with relapsed or refractory
   indolent B-cell lymphoma pretreated with rituximab-containing
   chemotherapy. We focused on this in a Japanese phase II study.
   Radioimmunotherapy with Y-90-ibritumomab tiuxetan (11.1 and 14.8 MBq)
   was evaluated in patients with 100-149 x 10(9) and > 150 x 10(9)
   platelets/L, respectively. The primary endpoint was the overall
   response rate. Forty patients were treated with Y-90-ibritumomab
   tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five
   patients (88%) had been pretreated with rituximab, including 27 (68%)
   pretreated with rituximab-containing chemotherapy. The overall response
   rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete
   response rate was 68% (27/40; 95% confidence interval, 51-81%). The
   overall response rates in patients pretreated with rituximab-containing
   chemotherapy and rituximab plus cyclophosphamide, doxorubicin,
   vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18),
   respectively. The median progression-free survival time of the 40
   patients who received Y-90-ibritumomab tiuxetan was 9.6 months.
   Toxicity was primarily hematological and mostly transient. No grade 4
   non-hematological toxicity was observed. In conclusion,
   radioimmunotherapy with Y-90-ibritumomab tiuxetan is safe and highly
   effective in patients with relapsed or refractory indolent B-cell
   lymphoma, including those pretreated with rituximab-containing
   chemotherapy. (ClinicalTrials.gov number NCT00220285) (Cancer Sci 2009;
   100: 158-164).
C1 [Tobinai, Kensei; Watanabe, Takashi] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Chuo Ku, Tokyo 1040045, Japan.
   [Matsuno, Yoshihiro] Natl Canc Ctr, Clin Lab Div, Chuo Ku, Tokyo 1040045, Japan.
   [Ogura, Michinori; Morishima, Yasuo] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Hotta, Tomomitsu] Tokai Univ, Sch Med, Dept Hematol & Oncol, Kanagawa 2591193, Japan.
   [Ishizawa, Kenichi] Tohoku Univ Hosp, Dept Rheumatol & Hematol, Aoba Ku, Sendai, Miyagi 9808574, Japan.
   [Nawano, Shigeru] Natl Canc Ctr Hosp E, Diagnost Radiol Div, Chiba 2778577, Japan.
   [Itoh, Kuniaki] Natl Canc Ctr Hosp E, Div Hematol Oncol, Chiba 2778577, Japan.
   [Okamoto, Shin-ichiro] Keio Univ, Sch Med, Div Hematol Infect Dis Rheumatol, Shinjuku Ku, Tokyo 1608582, Japan.
   [Taniwaki, Masafumi] Kyoto Prefectural Univ Med, Dept Hematol & Oncol, Kamikyo Ku, Hirokoji Noboru, Japan.
   [Endo, Keigo] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Maebashi, Gumma 3718511, Japan.
   [Tsukamoto, Norifumi] Gunma Univ, Grad Sch Med, Dept Med & Clin Sci, Maebashi, Gumma 3718511, Japan.
   [Okumura, Hirokazu] Kanazawa Univ, Grad Sch Med Sci, Dept Cellular Transplantat Biol, Kanazawa, Ishikawa 9208641, Japan.
   [Terauchi, Takashi] Natl Canc Ctr, Canc Screening Div, Res Ctr Canc Prevent & Screening, Chuo Ku, Tokyo 1040045, Japan.
   [Matsusako, Masaki] St Lukes Int Hosp, Dept Radiol, Chuo Ku, Tokyo 1048560, Japan.
   [Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol, Showa Ku, Nagoya, Aichi 4668560, Japan.
   [Mori, Shigeo] Teikyo Univ, Sch Med, Dept Pathol, Itabashi Ku, Tokyo 1738606, Japan.
   [Ohashi, Yasuo] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Bunkyo Ku, Tokyo 1138655, Japan.
   [Hayashi, Masaki] Bayer HealthCare, Dept Clin Dev, Yodogawa Ku, Osaka 5328577, Japan.
RP Tobinai, K, Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Chuo
   Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM ktobinai@ncc.go.jp
CR CHESON BD, 1999, J CLIN ONCOL, V17, P1244
   CONTI PS, 2005, J NUCL MED, V46, P1812
   CZUCZMAN MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020
   CZUCZMAN MS, 2005, J CLIN ONCOL, V23, P694, DOI 10.1200/JCO.2005.02.172
   DAVIS TA, 2000, J CLIN ONCOL, V18, P3135
   HARRIS NL, 1999, J CLIN ONCOL, V17, P3835
   HIDDEMANN W, 2005, BLOOD, V106, P3725
   IGARASHI T, 2001, INT J HEMATOL, V73, P213
   IGARASHI T, 2002, ANN ONCOL, V13, P928
   KAMINSKI MS, 2005, NEW ENGL J MED, V352, P441
   LEONARD JP, 2005, J CLIN ONCOL, V23, P5696, DOI 10.1200/JCO.2005.14.803
   MACMANUS MP, 1996, J CLIN ONCOL, V14, P1282
   MARCUS R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175
   MCLAUGHLIN P, 1998, J CLIN ONCOL, V16, P2825
   MORSCHHAUSER F, 2007, BLOOD, V110, P54, DOI 10.1182/blood-2007-01-068056
   OGURA M, 2006, CANCER SCI, V97, P305, DOI
   10.1111/j.1349-7006.2006.00173.x
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649
   PRESS OW, 2006, J CLIN ONCOL, V24, P4143, DOI 10.1200/JCO.2006.05.8198
   REDDY S, 1989, INT J RADIAT ONCOL, V16, P687
   ROSENBERG SA, 1982, CANCER, V49, P2112
   SOLALCELIGNY P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434
   TOBINAI K, 2006, J CLIN ONCOL, V24, P174, DOI 10.1200/JCO.2005.03.9313
   WATANABE T, 2005, CANCER SCI, V96, P903, DOI
   10.1111/j.1349-7006.2005.00120.x
   WISEMAN GA, 2002, BLOOD, V99, P4336
   WISEMAN GA, 2002, CANCER S, V94, P1349
   WITZIG TE, 2002, J CLIN ONCOL, V20, P2453
   WITZIG TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017
   WITZIG TE, 2003, J CLIN ONCOL, V21, P1263, DOI 10.1200/JCO.2003.08.043
NR 28
TC 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2009
VL 100
IS 1
BP 158
EP 164
DI 10.1111/j.1349-7006.2008.00999.x
PG 7
SC Oncology
GA 390FN
UT ISI:000262149800023
ER

EF